PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Lull, N; Noe, E; Lull, JJ; Garcia-Panach, J; Chirivella, J; Ferri, J; Lopez-Aznar, D; Sopena, P; Robles, M				Lull, Nuria; Noe, Enrique; Jose Lull, Juan; Garcia-Panach, Javier; Chirivella, Javier; Ferri, Joan; Lopez-Aznar, Diego; Sopena, Pablo; Robles, Montse			Voxel-based statistical analysis of thalamic glucose metabolism in traumatic brain injury: Relationship with consciousness and cognition	BRAIN INJURY			English	Article						Voxel-based analysis; positron emission tomography; consciousness; PET-FDG; prognosis; thalamus; traumatic brain injury	DIFFUSE AXONAL INJURY; REGIONAL CEREBRAL METABOLISM; PERSISTENT VEGETATIVE STATE; SEVERE HEAD-INJURY; POSTTRAUMATIC AMNESIA; MRI; CONNECTIVITY; MODERATE; PET; CONSEQUENCES	Objective: To study the relationship between thalamic glucose metabolism and neurological outcome after severe traumatic brain injury (TBI). Methods: Forty-nine patients with severe and closed TBI and 10 healthy control subjects with F-18-FDG PET were studied. Patients were divided into three groups: MCS&VS group (n = 17), patients in a vegetative or a minimally conscious state; In-PTA group (n = 12), patients in a state of post-traumatic amnesia (PTA); and Out-PTA group (n = 20), patients who had emerged from PTA. SPM5 software implemented in MATLAB 7 was used to determine the quantitative differences between patients and controls. FDG-PET images were spatially normalized and an automated thalamic ROI mask was generated. Group differences were analysed with two sample voxel-wise t-tests. Results: Thalamic hypometabolism was the most prominent in patients with low consciousness (MCS&VS group) and the thalamic hypometabolism in the In-PTA group was more prominent than that in the Out-PTA group. Healthy control subjects showed the greatest thalamic metabolism. These differences in metabolism were more pronounced in the internal regions of the thalamus. Conclusions: The results confirm the vulnerability of the thalamus to suffer the effect of the dynamic forces generated during a TBI. Patients with thalamic hypometabolism could represent a sub-set of subjects that are highly vulnerable to neurological disability after TBI.	[Lull, Nuria; Jose Lull, Juan; Garcia-Panach, Javier; Robles, Montse] Univ Politecn Valencia, Grp Informat Biomed, Inst Aplicac Tecnol Informac & Comunicac Avanzada, E-46071 Valencia, Spain; [Lull, Nuria] Univ CEU Cardenal Herrera, Valencia, Spain; [Noe, Enrique; Garcia-Panach, Javier; Chirivella, Javier; Ferri, Joan] FIVAN, Serv Dano Cerebral, Hosp NISA, Valencia, Spain; [Lopez-Aznar, Diego; Sopena, Pablo] Hosp 9 Octubre, Serv PET Med Nucl, Valencia, Spain	Noe, E (corresponding author), Hosp Valencia Mar, Serv Dano Cerebral, Hosp NISA, C Rio Tajo 1, Valencia 46011, Spain.	enoe@comv.es	Sopena-Novales, Pablo/AAA-4427-2019; Lull, Juan Jose/AAB-5154-2019; Robles, Montserrat/A-6722-2016	Sopena-Novales, Pablo/0000-0002-0560-0051; Lull, Juan Jose/0000-0002-4399-950X; Noe Sebastian, Enrique/0000-0002-2547-8727; Robles, Montserrat/0000-0002-7705-1389			Ahmed S, 2000, BRAIN INJURY, V14, P765; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gispert JD, 2003, NEUROIMAGE, V19, P601, DOI 10.1016/S1053-8119(03)00072-7; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Guye M, 2008, CURR OPIN NEUROL, V21, P393, DOI 10.1097/WCO.0b013e3283065cfb; ICHISE M, 1994, J NUCL MED, V35, P217; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mitelman SA, 2006, BRAIN RES, V1114, P125, DOI 10.1016/j.brainres.2006.07.043; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; OLEARY DDM, 1994, ANNU REV NEUROSCI, V17, P419, DOI 10.1146/annurev.ne.17.030194.002223; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	47	18	19	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	9					1098	1107		10.3109/02699052.2010.494592			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636RH	WOS:000280756700006	20597637	Green Published			2021-06-18	
J	Mrakovcic, L; Wildburger, R; Jaganjac, M; Cindric, M; Cipak, A; Sunjic, SB; Waeg, G; Milankovic, AM; Zarkovic, N				Mrakovcic, Lidija; Wildburger, Renate; Jaganjac, Morana; Cindric, Marina; Cipak, Ana; Sunjic, Suzana Borovic; Waeg, Georg; Milankovic, Andrea M.; Zarkovic, Neven			Lipid peroxidation product 4-hydroxynonenal as factor of oxidative homeostasis supporting bone regeneration with bioactive glasses	ACTA BIOCHIMICA POLONICA			English	Article; Proceedings Paper	Open Workshop on Natural and Synthetic Antioxidants	SEP 25-26, 2009	Rzeszow, POLAND	COST B 35 WG 4		bone regeneration; bioactive glass; lipid peroxidation; 4-hydroxynonenal; oxidative homeostasis	TRAUMATIC BRAIN INJURY; IN-VITRO; GROWTH; CELLS; DIFFERENTIATION; SCAFFOLDS; OSTEOBLASTS; ACTIVATION; CERAMICS	Bone regeneration is a process of vital importance since fractures of long bones and large joints have a highly deleterious impact on both, individuals and society. Numerous attempts have been undertaken to alleviate this severe medical and social problem by development of novel bioactive materials, among which bioactive glass is the most attractive because of its osteoconductive and osteostimulative properties. Since lipid peroxidation is an important component of systematic stress response in patients with traumatic brain injuries and bone fractures, studies have been undertaken of the molecular mechanisms of the involvement of 4-hydroxynonenal (HNE), an end product of lipid peroxidation, in cellular growth regulation. We found that HNE generated in bone cells grown in vitro on the surfaces of bioactive glasses 4555 and 13-93. This raises an interesting possibility of combined action of HNE and ionic bioglass dissolution products in enhanced osteogenesis probably through a mitogen-activated protein kinase (MAPK) pathway. While the proposed mechanism still has to be elucidated, the finding of HNE generation on bioglass offers a new interpretation of the osteoinducting mechanisms of bioglass and suggests the possibility of tissue engineering based on manipulations of oxidative homeostasis.	[Mrakovcic, Lidija; Jaganjac, Morana; Cipak, Ana; Sunjic, Suzana Borovic; Zarkovic, Neven] Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia; [Wildburger, Renate] Med Univ, LKH Clin Traumatol, Graz, Austria; [Cindric, Marina] Clin Hosp Ctr Zagreb, Fac Med, Dept Pathol, Zagreb, Croatia; [Waeg, Georg] Karl Franzens Univ Graz, Inst Mol Biosci, Graz, Austria; [Milankovic, Andrea M.] Rudjer Boskovic Inst, NMR Ctr, Zagreb, Croatia	Zarkovic, N (corresponding author), Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia.	zarkovic@irb.hr	Zarkovic, Neven/AAG-5836-2019; Milkovic, Lidija/F-5097-2019; Jaganjac, Morana/AAX-2526-2020	Zarkovic, Neven/0000-0001-5032-0369; Milkovic, Lidija/0000-0002-4484-039X; Jaganjac, Morana/0000-0001-5051-1843			Awasthi YC, 2005, METHOD ENZYMOL, V401, P379, DOI 10.1016/S0076-6879(05)01024-4; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BOROVIC S, 2007, PROGR CELL GROWTH PR, P187; BOROVIC SS, 2005, BIOFACTORS, V24, P141; Borovic S, 2007, REDOX REP, V12, P50, DOI 10.1179/135100007X162194; Borovic S, 2006, FREE RADICAL RES, V40, P809, DOI 10.1080/10715760600693422; Brown RF, 2008, ACTA BIOMATER, V4, P387, DOI 10.1016/j.actbio.2007.07.006; Buckwalter J A, 1996, Instr Course Lect, V45, P387; Buckwalter J A, 1996, Instr Course Lect, V45, P371; Chen KCW, 2007, MOL VIS, V13, P374; Chen ZH, 2005, J BIOL CHEM, V280, P41921, DOI 10.1074/jbc.M508556200; Colnot C, 2005, CLIN ORTHOP RELAT R, P69, DOI 10.1097/01.blo.0000167251.26164.37; Day RM, 2004, BIOMATERIALS, V25, P5857, DOI 10.1016/j.biomaterials.2004.01.043; Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002; Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fu Q, 2008, ACTA BIOMATER, V4, P1854, DOI 10.1016/j.actbio.2008.04.019; Hench L.L., 1971, J BIOMED MATER RES, V5, P117, DOI [DOI 10.1002/JBM.820050611, 10.1002/jbm.820050611]; Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063-4584(03)00150-X; Kakishita H, 2001, LIFE SCI, V69, P689, DOI 10.1016/S0024-3205(01)01166-3; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KITSUGI T, 1987, J BIOMED MATER RES, V21, P1255, DOI 10.1002/jbm.820211008; Leonarduzzi G, 2004, FREE RADICAL BIO MED, V37, P1694, DOI 10.1016/j.freeradbiomed.2004.08.027; Mattson MP, 2000, J MOL NEUROSCI, V14, P175, DOI 10.1385/JMN:14:3:175; Niki E, 2009, FREE RADICAL BIO MED, V47, P469, DOI 10.1016/j.freeradbiomed.2009.05.032; Ohgushi H, 1996, J BIOMED MATER RES, V32, P341, DOI 10.1002/(SICI)1097-4636(199611)32:3<341::AID-JBM6>3.0.CO;2-S; Ramana KV, 2006, J BIOL CHEM, V281, P17652, DOI 10.1074/jbc.M600270200; Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; Wildburger R, 2000, WIEN KLIN WOCHENSCHR, V112, P798; WILDBURGER R, 1997, BIOFACTORS, V6, P292; Wildburger R, 2009, TURK KLIN TIP BILIM, V29, P189; Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503; Yan J, 2006, J PHARMACOL EXP THER, V319, P613, DOI 10.1124/jpet.106.109850; Zarkovic K, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P146; ZARKOVIC N, 2009, P EUR SOC FREE RAD R, P37; Zarkovic Neven, 2003, Molecular Aspects of Medicine, V24, P281, DOI 10.1016/S0098-2997(03)00023-2	41	18	19	0	3	ACTA BIOCHIMICA POLONICA	WARSAW	PASTEURA 3, 02-093 WARSAW, POLAND	0001-527X			ACTA BIOCHIM POL	Acta Biochim. Pol.		2010	57	2					173	178					6	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	619GJ	WOS:000279416900007	20512168				2021-06-18	
J	Penna, S; Novack, TA; Carlson, N; Grote, M; Corrigan, JD; Hart, T				Penna, Suzanne; Novack, Thomas A.; Carlson, Nichole; Grote, Miranda; Corrigan, John D.; Hart, Tessa			Residence Following Traumatic Brain Injury: A Longitudinal Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; household composition; longitudinal study; traumatic brain injury	COMMUNITY; COMA; PREDICTORS; SCALE	Objective: To examine change in residence following traumatic brain injury (TBI) as a function of preinjury residential status, demographic factors, and injury-related characteristics. Design: Prospective, observational study. Setting: Inpatient, comprehensive rehabilitation programs for persons with TBI. Participants: A total of 7925 patients with moderate or severe TBI receiving acute rehabilitation, and enrolled in the TBI Model Systems National Database. Main Measures: Preinjury and discharge residential status determined during rehabilitation, and at 1, 2, and 5 years postinjury by telephone interview. Variables contributing to residential status included Injury severity, demographic information, and functional status. Results: There was significant change in residence across 5 years characterized by discharge to a less independent residence following injury, with a return to a more independent residence over time. The most significant transition took place in the first year after injury. Residence prior to injury was the strongest predictor of residence after injury. Age and race were significantly associated with residence following TBI, with increasing age related to more independent residence, and whites more likely to live independently than are African Americans. Severity of injury had little impact, although functional status at rehabilitation discharge was associated with residence, with higher functional status associated with a more independent residence. Conclusion: Among persons who received acute rehabilitation for TBI, 35.4% were discharged from rehabilitation to a setting different from the one in which they resided before injury. The degree of change varied on the basis of preinjury residence. Overall, the results indicate that while many patients are discharged to a different residential setting than prior to their injury, some patients recover to the point where they are able to return to their premorbid residential setting. The most substantial change was for those living alone at the time of injury, and within the first year of injury.	[Penna, Suzanne] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; [Novack, Thomas A.] Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; [Carlson, Nichole; Grote, Miranda] Univ Colorado, Dept Biostat & Informat, Denver, CO 80202 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA	Penna, S (corresponding author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.	suzanne.penna@emoryhealthcare.com	Corrigan, John D./E-2921-2011		National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133A970032, H133AO7039]	This study was supported by The National Institute on Disability and Rehabilitation Research, US Department of Education (grants H133A970032 and H133AO7039).	Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Blicher Jakob Udby, 2007, Ugeskr Laeger, V169, P228; Brzuzy S, 1996, J HEAD TRAUMA REHAB, V11, P74, DOI 10.1097/00001199-199606000-00011; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KARPMAN T, 1985, J APPL REHABIL COUNS, V78, P1321; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kleinbaum D., 1998, APPL REGRESSION ANAL; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McColl MA, 1999, BRAIN INJURY, V13, P311, DOI 10.1080/026990599121511; Molenberghs G., 2005, MODELS DISCRETE LONG; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561	23	18	18	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					52	60		10.1097/HTR.0b013e3181c29952			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800007	20051896				2021-06-18	
J	Smith, MM; Arnett, PA				Smith, Megan M.; Arnett, Peter A.			Awareness of executive functioning deficits in multiple sclerosis: Self versus informant ratings of impairment	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Multiple sclerosis; Awareness; Cognition; Caregivers; Questionnaire; Neuropsychology	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; DYSEXECUTIVE SYNDROME; WORKING-MEMORY; DEPRESSION; DYSFUNCTION; MS; QUESTIONNAIRE; PERFORMANCE; METAMEMORY	This study investigates the accuracy of self and informant ratings of executive dysfunction in a multiple sclerosis (MS) and control sample. Participants completed a neuropsychological battery. Participants and informants completed depression measures and the Dysexecutive Questionnaire (DEX). MS participants rated themselves more impaired than controls, while informants' ratings were not statistically different. MS participants' performance on executive tasks was more highly correlated with self than informant DEX ratings. Discrepancies between informant DEX ratings and executive performance were related to executive functioning for the MS participants only. Overall, results indicate that MS patients were able to accurately rate their executive functioning.	[Smith, Megan M.; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA	Smith, MM (corresponding author), Univ Iowa, Dept Psychiat, 1-308 MEB, Iowa City, IA 52242 USA.	megan-m-smith@uiowa.edu					Alderman N, 2001, NEUROPSYCHOL REHABIL, V11, P529, DOI 10.1080/09602010042000231; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Arnett PA, 2001, J INT NEUROPSYCH SOC, V7, P665, DOI 10.1017/S1355617701766027; Basso MR, 2008, J CLIN EXP NEUROPSYC, V30, P920, DOI 10.1080/13803390801888733; BEATTY WW, 1991, J CLIN EXP NEUROPSYC, V13, P309, DOI 10.1080/01688639108401046; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benedict RHB, 2004, MULT SCLER J, V10, P675, DOI 10.1191/1352458504ms1098oa; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bruce JM, 2004, J CLIN EXP NEUROPSYC, V26, P200, DOI 10.1076/jcen.26.2.200.28081; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Christodoulou C, 2005, J INT NEUROPSYCH SOC, V11, P614, DOI 10.1017/S1355617705050733; Daneman M, 1996, PSYCHON B REV, V3, P422, DOI 10.3758/BF03214546; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gold SM, 2001, MULT SCLER J, V7, P119, DOI 10.1177/135245850100700208; Heffernan Thomas, 2004, Irish Journal of Psychological Medicine, V21, P122, DOI 10.1017/S0790966700008545; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; Kujala P, 1996, ACTA NEUROL SCAND, V93, P329; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Malloy P. F., 1998, CLIN NEUROPSYCHOLOGY, P573; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Maor Y, 2001, MULT SCLER, V7, P131, DOI 10.1177/135245850100700209; Marrie RA, 2005, MULT SCLER J, V11, P69, DOI 10.1191/1352458505ms1110oa; Matotek K, 2001, Appl Neuropsychol, V8, P204, DOI 10.1207/S15324826AN0804_2; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Middleton LS, 2006, ARCH CLIN NEUROPSYCH, V21, P487, DOI 10.1016/j.acn.2006.06.008; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Podewils LJ, 2003, PSYCHOSOMATICS, V44, P461, DOI 10.1176/appi.psy.44.6.461; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; RANDOLPH JJ, 2003, ARCH CLIN NEUROPSYCH, V619, P1; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Robertson I. H., 1994, TEST EVERYDAY ATTENT; TAYLOR R, 1990, BRIT J CLIN PSYCHOL, V29, P251, DOI 10.1111/j.2044-8260.1990.tb00882.x; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zachary R., 1986, SHIPLEY I LIVING SCA	47	18	18	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	7					780	787	PII 919993334	10.1080/13803390903540307			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	631WB	WOS:000280380200012	20306356				2021-06-18	
J	Wrona, RM				Wrona, Ronald M.			Disability and return to work outcomes after traumatic brain injury: Results from the Washington State Industrial Insurance Fund	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; workers' compensation administrative data; disability outcomes; return to work outcomes	MODEL	Introduction. This article contains a description of community traumatic brain injury (TBI) treatment patterns and outcomes based solely on workers' compensation administrative records for Washington State. Methods. Administrative records available from the Washington State Department of Labor and Industries data warehouse of administrative records are used to describe medical rehabilitation services and return to work (RTW) referrals for cases of TBI between 1 January 1998 and 31 December 2002. These data represent official records for disability determination and referral for vocational rehabilitation (VR) services. Results. At total of 797 cases were identified all of which had identifiable treatment trajectories. No disability was the outcome in 9.0% of cases; temporary disability in 53.5% of cases, permanent disability in 31.1% of cases. Only 48% of surviving cases include a medical rehabilitation phase. This phase included only inpatient services in 26.5% of referred cases, only ambulatory services in 59.6% and both inpatient and ambulatory services in 13.9%. Only about half of surviving cases were referred for RTW services. Employment rates were similar to those published from other state rehabilitation programs. Conclusions. State/community treatment and disability outcome patterns are more diverse than the expected sequence of acute treatment, medical rehabilitation and VR. Employment rates after referral for VR were 65%.	Western Kentucky Univ, Dept Publ Hlth, Owensboro, KY 42303 USA	Wrona, RM (corresponding author), Western Kentucky Univ, Dept Publ Hlth, 4441 Greenacre Dr, Owensboro, KY 42303 USA.	ronwrona@roadrunner.com	Wrona, Ronald/W-9319-2019		National Institute for Occupational Safety and HealthUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [5U01OH07292-01]; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [U01OH007292] Funding Source: NIH RePORTER	This publication was supported by Grant/Cooperative Agreement 5U01OH07292-01 from the National Institute for Occupational Safety and Health, while the author was employed by the state of Washington. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the National Institute for Occupational Safety and Health.	Brown AW, 2004, NEUROREHABILITATION, V19, P37; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; Pransky G, 2005, J OCCUP REHABIL, V15, P453, DOI 10.1007/s10926-005-8027-y; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008; Wyman DO, 1999, AM FAM PHYSICIAN, V59, P844	10	18	18	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2010	32	8					650	655		10.3109/09638280903186327			6	Rehabilitation	Rehabilitation	575WI	WOS:000276100100006	20205578				2021-06-18	
J	Shum, D; Gill, H; Banks, M; Maujean, A; Griffin, J; Ward, H				Shum, David; Gill, Hannah; Banks, Miranda; Maujean, Annick; Griffin, Janelle; Ward, Heather			Planning Ability Following Moderate to Severe Traumatic Brain Injury: Performance on a 4-Disk Version of the Tower of London	BRAIN IMPAIRMENT			English	Article						planning; Tower of London; adults; TBI	CLOSED-HEAD INJURY; TASK; CHILDREN	This study aimed to assess planning ability in adults with traumatic brain injury (TBI) using a 4-disk version of the Tower of London (TOL). Thirty three individuals with TBI were compared with equivalent numbers of matched controls. Overall, the TOL4 was shown to be sensitive to the effects of brain injury, with the TBI group performing significantly more poorly on this version of the planning test than the matched controls. More specifically, group differences were found to be related to the complexity of the planning problems, particularly among a TBI subgroup with localised prefrontal damage. Results of the study provide support for the adverse effects of TBI on planning ability, and the important role of the prefrontal cortex in planning.	[Shum, David] Griffith Univ, Griffith Inst Hlth & Med Res, Brisbane, Qld 4111, Australia; [Shum, David; Banks, Miranda; Maujean, Annick] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Gill, Hannah] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Griffin, Janelle] Princess Alexandra Hosp, Occupat Therapy Dept, Brain Injury Rehabil Unit, Brisbane, Qld 4102, Australia; [Ward, Heather] Albany Creek Specialists Ctr, Brisbane, Qld, Australia	Shum, D (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus,176 Messines Ridge Rd, Mt Gravatt, Qld 4122, Australia.	d.shum@griffith.edu.au	Shum, David/A-3914-2008; Gullo, Hannah/C-5011-2008	Shum, David/0000-0002-4810-9262; Maujean, Annick/0000-0002-9623-1369; GULLO, Hannah/0000-0003-4238-4033			Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Baker K, 2001, CLIN NEUROPSYCHOL, V15, P309; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; Jefferson AL, 2006, ARCH CLIN NEUROPSYCH, V21, P311, DOI 10.1016/j.acn.2006.03.007; Kaller CP, 2004, COGNITIVE BRAIN RES, V20, P462, DOI 10.1016/j.cogbrainres.2004.04.002; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rasmussen IA, 2006, ACTA NEUROPSYCHIATR, V18, P216, DOI 10.1111/j.1601-5215.2006.00145.x; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shum D, 2000, BRAIN COGNITION, V44, P59; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; TEASDALE G, 1974, LANCET, V2, P81; TUNSTALL J, 1999, IMPROVING UTIL UNPUB	17	18	20	0	5	AUSTRALIAN ACAD PRESS	BOWEN HILLS	32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA	1443-9646			BRAIN IMPAIR	Brain Impair.	DEC	2009	10	3					320	324		10.1375/brim.10.3.320			5	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	548OG	WOS:000273972400005		Green Published			2021-06-18	
J	Tian, HL; Guo, Y; Hu, J; Rong, BY; Wang, G; Gao, WW; Chen, SW; Chen, H				Tian, Heng-Li; Guo, Yan; Hu, Jin; Rong, Bo-Ying; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Chen, Hao			Clinical Characterization of Comatose Patients With Cervical Spine Injury and Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Cervical spine injury; Cervical stability; Skull fracture; Traumatic brain injury	CORD-INJURY; HEAD	Background: Reports on the risk factors for combined craniocervical spine injury in comatose patients are rare. The incidence of concomitant cervical injury in comatose patients with traumatic brain injury (TBI) was determined herein. Methods: One thousand twenty-six comatose patients with TBI were examined. The clinical characteristics of combined craniocervical trauma were documented, including type and location of cervical injury, occurrence of hypotension, and dyspnea. Results: Seventy-one patients (6.92%) sustained cervical spine injury. The most common injury region included the upper cervical segments, demonstrated in 37 (52.11%) of 71 patients. Of the 71 patients who sustained combined craniocervical spine injury, 42 (59.15%) had hypotension, including 26 (36.62%) with dyspnea. With regard to the association between the severity of TBI and the incidence of the cervical injury, a significant difference was apparent between patients with an initial Glasgow Coma Scale (GCS) score of 3-5 and those with an initial GCS score of 9-12 (11.62% compared with 4.03%, p < 0.01). Regarding the relationship between the mechanism of injury and the occurrence of cervical spine injury, cervical spine injury was associated at a significantly higher incidence with motorcycle accident-related head trauma as compared with nonmotorcycle accident-related trauma (10.32% vs. 4.68%, p < 0.01). Conclusion: Patients who Sustained TBI as a result of motorcycle accidents and those exhibiting a lower GCS score are at the highest risk for concomitant cervical spine injury.	[Tian, Heng-Li; Guo, Yan; Hu, Jin; Rong, Bo-Ying; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Chen, Hao] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai People Hosp 6, Shanghai 200030, Peoples R China	Chen, H (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai People Hosp 6, Shanghai 200030, Peoples R China.	chenhao_316@yahoo.com.cn		Chen, Hao/0000-0002-9943-9237	Shanghai Council for Nature and Science [03ZR14059]	Supported in part by a grant from the Shanghai Council for Nature and Science (Grant no. 03ZR14059).	Ayas N T, 1999, J Spinal Cord Med, V22, P97; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; Cooper D J, 2005, Crit Care Resusc, V7, P181; Drainer EK, 2003, INJURY, V34, P330, DOI 10.1016/S0020-1383(02)00260-7; Hadley Mark N, 2002, Clin Neurosurg, V49, P407; Harrahill M, 1997, J Emerg Nurs, V23, P282, DOI 10.1016/S0099-1767(97)90032-5; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; KACH K, 1993, HELV CHIR ACTA, V59, P655; Lu K, 2000, SPINE, V25, P1332, DOI 10.1097/00007632-200006010-00003; Mathias CJ, 2006, PROG BRAIN RES, V152, P231, DOI 10.1016/S0079-6123(05)52015-6; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; OLLER DW, 1992, ACCIDENT ANAL PREV, V24, P187, DOI 10.1016/0001-4575(92)90036-I; Piatt JH, 2006, J NEUROSURG-SPINE, V5, P210, DOI 10.3171/spi.2006.5.3.210; Swartz EE, 2005, J ATHL TRAINING, V40, P155; Vinit S, 2006, J NEUROTRAUM, V23, P1137, DOI 10.1089/neu.2006.23.1137	16	18	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2009	67	6					1305	1310		10.1097/TA.0b013e31819db57c			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	531IL	WOS:000272658100037	20009682				2021-06-18	
J	Yadon, CA; Bugg, JM; Kisley, MA; Davalos, DB				Yadon, Carly A.; Bugg, Julie M.; Kisley, Michael A.; Davalos, Deana B.			P50 sensory gating is related to performance on select tasks of cognitive inhibition	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; EVOKED POTENTIAL P50; HIPPOCAMPAL VOLUME; PREFRONTAL CORTEX; ATTENTION-DEFICIT; VISUAL-ATTENTION; PERCEPTUAL LOAD; SCHIZOPHRENIA; INTERFERENCE; SUPPRESSION	P50 suppression deficits have been documented in clinical and nonclinical populations, but the behavioral correlates of impaired auditory sensory gating remain poorly understood. In the present study, we examined the relationship between P50 gating and healthy adults' performance on cognitive inhibition tasks. On the basis of load theory (Lavie, Hirst, de Fockert, & Viding, 2004), we predicted that a high perceptual load, a possible consequence of poor auditory P50 sensory gating, would have differential (i.e., positive vs. negative) effects on performance of cognitive inhibition tasks. A dissociation was observed such that P50 gating was negatively related to interference resolution on a Stroop task and positively related to response inhibition on a go/no-go task. Our findings support the idea that a high perceptual load may be beneficial to Stroop performance because of the reduced processing of distractors but detrimental to performance on the go/no-go task because of interference with stimulus discrimination.	[Yadon, Carly A.; Davalos, Deana B.] Colorado State Univ, Ft Collins, CO 80523 USA; [Bugg, Julie M.] Washington Univ, St Louis, MO USA; [Kisley, Michael A.] Univ Colorado, Colorado Springs, CO 80907 USA	Yadon, CA (corresponding author), Colorado State Univ, Ft Collins, CO 80523 USA.	cyadon@lamar.colostate.edu	Kisley, Michael/AAZ-3102-2020		National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5T32AG00030]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000030] Funding Source: NIH RePORTER	The authors thank Aubrey Anthony, Kathleen Kelsey, Lauren Shirley, and Becky Tucker for assistance with data collection and analysis. J.M.B. was supported by National Institute on Aging Grant 5T32AG00030 during writing of the manuscript. Correspondence concerning this article should be addressed to C. A. Yadon, 1876 Campus Delivery, Department of Psychology, Colorado State University, Ft. Collins, CO 80521 (e-mail: cyadon@lamancolostate.edu).	ADLER LE, 1985, BIOL PSYCHIAT, V20, P1284, DOI 10.1016/0006-3223(85)90113-1; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Arnfred SM, 2001, PSYCHIAT RES, V101, P221, DOI 10.1016/S0165-1781(01)00226-8; Barch DM, 1999, SCHIZOPHRENIA BULL, V25, P749, DOI 10.1093/oxfordjournals.schbul.a033416; Barnhardt J, 2008, NEUROPSYCHOLOGIA, V46, P2071, DOI 10.1016/j.neuropsychologia.2008.02.007; BICKFORDWIMER PC, 1990, BIOL PSYCHIAT, V27, P183, DOI 10.1016/0006-3223(90)90648-L; Braver T, 2007, VARIATION WORKING ME, P76, DOI [10.1093/acprof:oso/9780195168648.003.0004, DOI 10.1093/ACPROF:OSO/9780195168648.003.0004]; Brink JM, 1999, J GERONTOL B-PSYCHOL, V54, pP30, DOI 10.1093/geronb/54B.1.P30; Brumback CR, 2004, NEUROREPORT, V15, P373, DOI 10.1097/00001756-200402090-00032; Clementz BA, 1998, AM J PSYCHIAT, V155, P1691, DOI 10.1176/ajp.155.12.1691; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; Croft RJ, 2001, BIOL PSYCHIAT, V50, P441, DOI 10.1016/S0006-3223(01)01082-4; CULLUM CM, 1993, SCHIZOPHR RES, V10, P131, DOI 10.1016/0920-9964(93)90048-N; Wilde OM, 2007, SCHIZOPHR RES, V97, P137, DOI 10.1016/j.schres.2007.04.028; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Donders F. C., 1868, ATTENTION PERFORM, P412; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Erwin RJ, 1998, SCHIZOPHR RES, V33, P157, DOI 10.1016/S0920-9964(98)00075-9; EVERETT J, 1989, J NERV MENT DIS, V177, P735, DOI 10.1097/00005053-198912000-00004; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Fuerst DR, 2007, PSYCHOPHYSIOLOGY, V44, P620, DOI 10.1111/j.1469-8986.2007.00524.x; Ghisolfi ES, 2006, J PSYCHIATR RES, V40, P535, DOI 10.1016/j.jpsychires.2006.02.006; Gooding DC, 2006, SCHIZOPHR RES, V88, P169, DOI 10.1016/j.schres.2006.07.009; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Grunwald T, 2003, BIOL PSYCHIAT, V53, P511, DOI 10.1016/S0006-3223(02)01673-6; GUTERMAN Y, 1994, INT J PSYCHOPHYSIOL, V18, P1, DOI 10.1016/0167-8760(84)90010-2; GUTERMAN Y, 1992, INT J PSYCHOPHYSIOL, V12, P197, DOI 10.1016/0167-8760(92)90011-Y; HEAL L, 1970, INT REV MENTAL RETAR, P107; Healey MK, 2008, PROG BRAIN RES, V169, P353, DOI 10.1016/S0079-6123(07)00022-2; JERGER K, 1992, BIOL PSYCHIAT, V31, P365, DOI 10.1016/0006-3223(92)90230-W; Jessen F, 2001, AM J PSYCHIAT, V158, P1319, DOI 10.1176/appi.ajp.158.8.1319; Kisley MA, 2004, PSYCHOPHYSIOLOGY, V41, P604, DOI 10.1111/j.1469-8986.2004.00191.x; Knight RT, 1999, ACTA PSYCHOL, V101, P159, DOI 10.1016/S0001-6918(99)00004-9; Korzyukov O, 2007, NEUROIMAGE, V35, P814, DOI 10.1016/j.neuroimage.2006.12.011; KRAMER AF, 1994, PSYCHOL AGING, V9, P491, DOI 10.1037/0882-7974.9.4.491; Kurthen M, 2007, PSYCHIAT RES-NEUROIM, V155, P121, DOI 10.1016/j.pscychresns.2006.10.003; LADAVAS E, 1990, CORTEX, V26, P307, DOI 10.1016/S0010-9452(13)80083-4; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; Lavie N, 2004, J EXP PSYCHOL GEN, V133, P339, DOI 10.1037/0096-3445.133.3.339; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Lustig C., 2007, INHIBITION COGNITION, P145, DOI [10.1037/11587-008, DOI 10.1037/11587-008]; Luu P., 2005, DETERMINATION GEODES; MACLEOD CM, 1988, J EXP PSYCHOL LEARN, V14, P126, DOI 10.1037/0278-7393.14.1.126; MARLOWOCONNER MA, 2005, DISS ABSTR INT, V66, P3417; MCGHIE A, 1961, BRIT J MED PSYCHOL, V34, P103, DOI 10.1111/j.2044-8341.1961.tb00936.x; Nagamoto HT, 1996, BIOL PSYCHIAT, V40, P181, DOI 10.1016/0006-3223(95)00371-1; NAGAMOTO HT, 1991, SCHIZOPHR RES, V4, P31, DOI 10.1016/0920-9964(91)90007-E; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; NEILL WT, 1977, J EXP PSYCHOL HUMAN, V3, P444, DOI 10.1037/0096-1523.3.3.444; Olincy A, 2000, BIOL PSYCHIAT, V47, P969, DOI 10.1016/S0006-3223(00)00239-0; Patterson JV, 2008, PSYCHIAT RES, V158, P226, DOI 10.1016/j.psychres.2007.02.009; PERSONS JB, 1986, AM PSYCHOL, V41, P1252, DOI 10.1037/0003-066X.41.11.1252; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Potter D, 2006, SCHIZOPHRENIA BULL, V32, P692, DOI 10.1093/schbul/sbj050; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schwartz S, 2005, CEREB CORTEX, V15, P770, DOI 10.1093/cercor/bhh178; SMITH DA, 1994, PSYCHOPHYSIOLOGY, V31, P495, DOI 10.1111/j.1469-8986.1994.tb01053.x; Steel C, 2001, NEUROREPORT, V12, P3619, DOI 10.1097/00001756-200111160-00049; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TALAYONGAN A, 2000, INT J DISABIL DEV ED, V47, P201, DOI DOI 10.1080/713671112; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P571, DOI 10.1080/14640748508400920; Tregellas JR, 2007, SCHIZOPHR RES, V92, P262, DOI 10.1016/j.schres.2006.12.033; Uc EY, 2003, J NEUROL SCI, V212, P1, DOI 10.1016/S0022-510X(03)00082-0; VENABLES P H, 1964, Prog Exp Pers Res, V72, P1; WALDO MC, 1994, SCHIZOPHR RES, V12, P93, DOI 10.1016/0920-9964(94)90067-1; Weisbrod M, 2000, BIOL PSYCHIAT, V47, P51, DOI 10.1016/S0006-3223(99)00218-8; Weisser R, 2001, NEUROREPORT, V12, P3303, DOI 10.1097/00001756-200110290-00031; Wright CI, 2006, NEUROIMAGE, V30, P983, DOI 10.1016/j.neuroimage.2005.10.015	73	18	18	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	DEC	2009	9	4					448	458		10.3758/CABN.9.4.448			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	525ZF	WOS:000272256100009	19897797	Green Accepted, Bronze			2021-06-18	
J	Liao, ZB; Jiang, GY; Tang, ZH; Zhi, XG; Sun, XC; Tang, WY; Wu, MJ				Liao, Z. B.; Jiang, G. Y.; Tang, Z. H.; Zhi, X. G.; Sun, X. C.; Tang, W. Y.; Wu, M. J.			Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats	NEUROLOGY INDIA			English	Article						Bax; cell death; rhEPO; traumatic brain injury	ALTERNATIVE COMPLEMENT PATHWAY; CLOSED-HEAD INJURY; NEURONAL DEATH; APOPTOSIS; ACTIVATION; ISCHEMIA; NEUROPROTECTION; EXPRESSION; MODULATION; MECHANISMS	Background: Traumatic brain injury (TBI) is an important cause of adult mortality and morbidity. Erythropoietin (Epo) has been shown to promote the viability of cerebral cells by upregulating Bcl-2 gene; however, Epo may exert its antiapoptotic effect via the differential regulation of the expression of genes involved in the apoptotic process. Aim: The present study examined the neuroprotective effect of Epo as a survival factor through the regulation of the Bax. Materials and Methods: Wistar rats were randomly divided into three groups: Recombinant human EPO treated (rhEPO) TBI, vehicle-treated TBI, and sham-operated. Traumatic brain injury was induced by the Feeney free-falling model. Rats were killed 5, 12, 24, 72, 120, or 168 h after TBI. Regulation of Bcl-2 was detected by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and immunofluorescence. Results: Bax mRNA and protein levels were lower in the rhEPO)-treated rat brains than in the vehicle-treated rat brains. Induction of Bax expression peaked at 24 h and remained stable for 72-120 h in vehicle-treated rat brains, whereas induction of Bax expression was only slightly elevated in rhEPO-treated rat brains. The number of TdT-mediated dUTP Nick-End Labeling(TUNEL)-positive cells in the rhEPO-treated rat brains was far fewer than in the vehicle-treated rat brains. Conclusions: Epo exerts neuroprotective effect against traumatic brain injury via reducing Bax gene expression involved in inhibiting TBI-induced neuronal cell death.	[Liao, Z. B.; Jiang, G. Y.; Tang, Z. H.; Zhi, X. G.; Sun, X. C.; Tang, W. Y.] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Wu, M. J.] Chongqing Med Univ, Dept Lab Med, Chongqing 400016, Peoples R China	Liao, ZB (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	stonebu8@yahoo.com.cn		sun, xiao chuan/0000-0001-6992-332X	National Natural Science Funds of ChinaNational Natural Science Foundation of China (NSFC) [30801182]	This research was supported by the National Natural Science Funds of China (30801182).	Alexander JJ, 2005, J IMMUNOL, V175, P8312, DOI 10.4049/jimmunol.175.12.8312; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Golarai G, 2001, J NEUROSCI, V21, P8523; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Nataf S, 2000, J IMMUNOL, V165, P5867, DOI 10.4049/jimmunol.165.10.5867; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohlsson M, 2006, NEUROSCI LETT, V394, P179, DOI 10.1016/j.neulet.2005.10.037; Ohlsson M, 2003, J NEUROTRAUM, V20, P895, DOI 10.1089/089771503322385827; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Thurman JM, 2005, KIDNEY INT, V67, P524, DOI 10.1111/j.1523-1755.2005.67109.x; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	48	18	23	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	NOV-DEC	2009	57	6					722	728		10.4103/0028-3886.59466			7	Neurosciences	Neurosciences & Neurology	561XR	WOS:000275013900006	20139499				2021-06-18	
J	Shear, DA; Williams, AJ; Sharrow, K; Lu, XCM; Tortella, FC				Shear, Deborah A.; Williams, Anthony J.; Sharrow, Keith; Lu, Xi-Chun M.; Tortella, Frank C.			Neuroprotective profile of dextromethorphan in an experimental model of penetrating ballistic-like brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Penetrating ballistic-like brain injury; PBBI; Traumatic brain injury; TBI; Dextromethorphan; DM; Motor; Cognitive; Novel object recognition; NOR	D-ASPARTATE ANTAGONIST; PREFRONTAL CORTEX; MEDIATED NEUROPROTECTION; CORTICAL-NEURONS; SIGMA-RECEPTORS; RAT MODEL; CALCIUM; DEXTRORPHAN; ATTENTION; ISCHEMIA	Dextromethorphan (DM) has been well-characterized as a neuroprotective agent in experimental models of CNS injury. The goal of this study was to determine the neuroprotective profile of DM in a military-relevant model of penetrating ballistic-like brain injury (PBBI). In an acute (3 day) dose-response study, anesthetized male Sprague-Dawley rats were exposed to a unilateral frontal PBBI with DM (0.156-10 mg/kg) or vehicle delivered as an i.v. bolus from 30 min to 48 h post-injury. In a follow-up (7 day) experiment, the 10-mg/kg bolus injections of DM were administered in conjunction with a 6-h infusion (5 mg/kg/h). DM bolus injections alone produced a dose-dependent improvement in motor recovery on a balance beam task at 3 days post-injury. However, more rapid recovery (24 h) was observed on this task when the bolus injections were combined with the 6-h infusion. Moreover, the DM bolus/infusion treatment regimen resulted in a significant (76%) improvement in cognitive performance in a novel object recognition (NOR) task at 7 days post-injury. Although post-injury administration of DM (all doses) failed to reduce core lesion size, the maximum dose of DM (10 mg/kg) was effective in reducing silver-stained axonal fiber degeneration in the cortical regions adjacent to the injury. Published by Elsevier Inc.	[Shear, Deborah A.; Williams, Anthony J.; Sharrow, Keith; Lu, Xi-Chun M.; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 21045 USA	Shear, DA (corresponding author), Walter Reed Army Inst Res, MRMC UWI C,Bldg 503-2W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Shear, Deborah/B-3607-2011				BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BELL RS, 2009, TRAUMA, V65, pS104; CARPENTER CL, 1988, BRAIN RES, V439, P372, DOI 10.1016/0006-8993(88)91497-7; CHOI DW, 1987, BRAIN RES, V403, P333, DOI 10.1016/0006-8993(87)90070-9; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; D'Esposito M, 1999, NEUROPSYCHOLOGIA, V37, P1303, DOI 10.1016/S0028-3932(99)00021-4; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; DECOSTER MA, 1995, BRAIN RES, V671, P45, DOI 10.1016/0006-8993(94)01294-R; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; Godefroy O, 1997, NEUROLOGY, V49, P695, DOI 10.1212/WNL.49.3.695; GOLDBERG MP, 1987, NEUROSCI LETT, V80, P11, DOI 10.1016/0304-3940(87)90486-1; Katnik C, 2006, J PHARMACOL EXP THER, V319, P1355, DOI 10.1124/jpet.106.107557; Klette KL, 1997, BRAIN RES, V756, P231, DOI 10.1016/S0006-8993(97)00142-X; Klette KL, 1995, BRAIN RES, V704, P31, DOI 10.1016/0006-8993(95)01103-X; LU XC, 2009, J NEUROTRAUMA; MATSUMOTO RR, 1990, PHARMACOL BIOCHEM BE, V36, P151, DOI 10.1016/0091-3057(90)90141-4; Maurice T, 2001, BRAIN RES REV, V37, P116, DOI 10.1016/S0165-0173(01)00112-6; SCHADEL M, 1995, J CLIN PSYCHOPHARM, V15, P263, DOI 10.1097/00004714-199508000-00005; Senda T, 1996, EUR J PHARMACOL, V315, P1, DOI 10.1016/S0014-2999(96)00572-9; Steinberg GK, 1996, J NEUROSURG, V84, P860, DOI 10.3171/jns.1996.84.5.0860; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; TORTELLA FC, 1989, TRENDS PHARMACOL SCI, V10, P501, DOI 10.1016/0165-6147(89)90050-3; WALKER FO, 1989, CLIN NEUROPHARMACOL, V12, P322, DOI 10.1097/00002826-198908000-00010; WALKER JM, 1990, PHARMACOL REV, V42, P355; Werling LL, 2007, NEUROLOGIST, V13, P272, DOI 10.1097/NRL.0b013e3180f60bd8; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang HL, 2002, J NEUROPHYSIOL, V87, P2867, DOI 10.1152/jn.2002.87.6.2867; ZHOU GZ, 1991, EUR J PHARM-MOLEC PH, V206, P261, DOI 10.1016/0922-4106(91)90108-T	33	18	18	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	NOV	2009	94	1					56	62		10.1016/j.pbb.2009.07.006			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	513ZH	WOS:000271362300009	19619574				2021-06-18	
J	Roberts, DJ; Goralski, KB; Renton, KW; Julien, LC; Webber, AM; Sleno, L; Volmer, DA; Hall, RI				Roberts, Derek J.; Goralski, Kerry B.; Renton, Kenneth W.; Julien, Lisa C.; Webber, Adam M.; Sleno, Lekha; Volmer, Dietrich A.; Hall, Richard I.			Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3-and 6-glucuronide in the human brain	CRITICAL CARE MEDICINE			English	Article						blood-brain barrier; inflammation; morphine; morphine-3-glucuronide; morphine-6-glucuronide; P-glycoprotein; multidrug resistance protein	P-GLYCOPROTEIN EXPRESSION; NECROSIS-FACTOR-ALPHA; BARRIER TRANSPORT; MEDIATED TRANSPORT; MORPHINE-6-GLUCURONIDE; MORPHINE-3-GLUCURONIDE; PHARMACOKINETICS; MICRODIALYSIS; MICE; RAT	Objective: In animals, central nervous system inflammation increases drug accumulation in the brain partly due to a loss of central nervous system drug efflux transporter function at the blood-brain barrier. To determine whether a similar loss of active drug efflux occurs in humans after acute inflammatory brain injury. Design: Observational human pharmacokinetic study. Setting: Medical-surgical-neurosurgical intensive care unit at a university-affiliated, Canadian tertiary care center. Patients: Patients with acute inflammatory brain injury, including subarachnoid hemorrhage (n = 10), intracerebral and/or intraventricular hemorrhage (n = 4), or closed head trauma (n = 2) who received morphine intravenously after being fitted with cerebrospinal fluid ventriculostomy and peripheral arterial catheters. Interventions: We correlated the cerebrospinal fluid distribution of morphine, morphine-3-glucuronide, and morphine-6-glucuronide with the cerebrospinal fluid and plasma concentration of the proinflammatory cytokine interleukin-6 and the passive marker of blood-brain barrier permeability, albumin. Measurements and Main Results: Acute brain injury produced a robust inflammatory response in the central nervous system as reflected by the elevated concentration of interleukin-6 in cerebrospinal fluid. Penetration of morphine metabolites into the central nervous system increased in proportion to the neuroinflammatory response as demonstrated by the positive correlation between cerebrospinal fluid interleukin-6 exposure and the area under the curve cerebrospinal fluid/plasma ratio for morphine-3-glucuronide (r = .49, p < .001) and morphine-6-glucuronide (r = .51, p < .001). In contrast, distribution of morphine into the brain was not linked with cerebrospinal fluid interleukin-6 exposure (r = .073, p = .54). Albumin concentrations in plasma and cerebrospinal fluid were consistently in the normal range, indicating that the physical integrity of the blood-brain barrier was likely undisturbed. Conclusions: Our results suggest that central nervous system inflammation following acute brain injury may selectively inhibit the activity of specific drug efflux transporters within the blood-brain barrier. This finding may have significant implications for patients with neuroinflammatory conditions when administered centrally acting drugs normally excluded from the brain by such transporters. (Crit Care Med 2009; 37:2767-2774)	[Roberts, Derek J.; Julien, Lisa C.; Webber, Adam M.; Hall, Richard I.] Dalhousie Univ, Div Crit Care Med, Halifax, NS, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Dalhousie Univ, Dept Anesthesia, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Dalhousie Univ, Fac Med, Halifax, NS, Canada; [Roberts, Derek J.; Goralski, Kerry B.; Renton, Kenneth W.; Hall, Richard I.] Dalhousie Univ, Dept Pharmacol, Fac Med, Halifax, NS B3H 4H7, Canada; [Goralski, Kerry B.] Dalhousie Univ, Coll Pharm, Fac Hlth Profess, Halifax, NS B3H 3J5, Canada; [Sleno, Lekha] Univ Quebec, Dept Chem, Montreal, PQ H3C 3P8, Canada; [Volmer, Dietrich A.] MRC, Elsie Widdowson Lab, Cambridge, England	Hall, RI (corresponding author), Dalhousie Univ, Div Crit Care Med, Halifax, NS, Canada.	RIHall@Dal.Ca	Volmer, Dietrich/G-7900-2012; Roberts, Derek J./L-6229-2019	Volmer, Dietrich/0000-0003-2820-1480; Roberts, Derek J./0000-0001-6111-6291; Goralski, Kerry/0000-0003-0040-5879	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Dalhousie Medical Research Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105960396] Funding Source: researchfish	Support for this investigation was afforded, in part, by the Canadian Institutes of Health Research and the Dalhousie Medical Research Foundation.	BARTLETT SE, 1994, LIFE SCI, V54, P687, DOI 10.1016/0024-3205(94)00552-4; Bauer B, 2007, MOL PHARMACOL, V71, P667, DOI 10.1124/mol.106.029512; Bourasset F, 2003, J NEUROCHEM, V86, P1564, DOI 10.1046/j.1471-4159.2003.01990.x; Bouw MR, 2001, BRIT J PHARMACOL, V134, P1796, DOI 10.1038/sj.bjp.0704406; Bouw R, 2001, ACTA ANAESTH SCAND, V45, P390, DOI 10.1034/j.1399-6576.2001.045003390.x; DeVries HE, 1997, PHARMACOL REV, V49, P143; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Goralski KB, 2003, BRIT J PHARMACOL, V139, P35, DOI 10.1038/sj.bjp.0705227; Hamabe W, 2007, J PHARMACOL SCI, V105, P353, DOI 10.1254/jphs.FP0071287; Hartz AMS, 2006, MOL PHARMACOL, V69, P462, DOI 10.1124/mol.105.017954; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Huwyler J, 1996, BRIT J PHARMACOL, V118, P1879, DOI 10.1111/j.1476-5381.1996.tb15619.x; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; LABELLA FS, 1979, BRAIN RES, V174, P263, DOI 10.1016/0006-8993(79)90849-7; Letrent SP, 1998, PHARMACEUT RES, V15, P599, DOI 10.1023/A:1011938112599; Lotsch J, 2000, LIFE SCI, V66, P2393, DOI 10.1016/S0024-3205(00)00569-5; Lotsch J, 2002, J NEUROCHEM, V83, P241, DOI 10.1046/j.1471-4159.2002.01177.x; Meineke I, 2002, BRIT J CLIN PHARMACO, V54, P592, DOI 10.1046/j.1365-2125.2002.t01-1-01689.x; Nies AT, 2004, NEUROSCIENCE, V129, P349, DOI 10.1016/j.neuroscience.2004.07.051; Ohtsuki S, 2007, PHARM RES-DORDR, V24, P1745, DOI 10.1007/s11095-007-9374-5; Osuka K, 1998, ACTA NEUROCHIR, V140, P943, DOI 10.1007/s007010050197; Roberts DJ, 2008, EXPERT OPIN DRUG MET, V4, P1245, DOI [10.1517/17425255.4.10.1245, 10.1517/17425255.4.10.1245 ]; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Skarke C, 2004, ANESTHESIOLOGY, V101, P1394; Theron D, 2003, BIOCHEM PHARMACOL, V66, P579, DOI 10.1016/S0006-2952(03)00340-X; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; van de Wetering K, 2007, MOL PHARMACOL, V72, P387, DOI 10.1124/mol.107.035592; Welsh P, 2008, STROKE, V39, P2226, DOI 10.1161/STROKEAHA.107.504498; Xie RJ, 2000, BRIT J PHARMACOL, V131, P1784, DOI 10.1038/sj.bjp.0703759	32	18	18	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2009	37	10					2767	2774		10.1097/CCM.0b013e3181b755d5			8	Critical Care Medicine	General & Internal Medicine	499OU	WOS:000270234700013	19865006				2021-06-18	
J	Singh, GD; Maher, GJ; Padilla, RR				Singh, G. Dave; Maher, Gerald J.; Padilla, Ray R.			Customized mandibular orthotics in the prevention of concussion/mild traumatic brain injury in football players: a preliminary study	DENTAL TRAUMATOLOGY			English	Article							PROFESSIONAL FOOTBALL; HIGH-SCHOOL; NECK INJURIES; MOUTHGUARDS; HEAD; STRENGTH; IMPACTS; SPORTS; BITE	Background/Aim: It is accepted that sports mouthguards decrease the incidence of dental injuries in athletes, but the value of oral orthotics in the prevention of concussion/mild traumatic brain injuries in footballers remains contentious. However, previous investigations have primarily studied non-customized mouthguards without dental/temporo-mandibular joint examinations of the subjects. Therefore, the aim of this study is to determine whether the use of a customized mandibular orthotic after temporo-mandibular joint assessment reduces the incidence of concussion/mild traumatic brain injuries in high-school football players. Materials and methods: Using a longitudinal, retrospective design, data were collected from a cohort of football players (n = 28) over three seasons using a questionnaire. The mean age of the sample prior to the use of the customized mandibular orthotic was 17.3 years +/- 1.9. Prior to deployment, dental records and temporo-mandibular joint evaluations were undertaken, as well as neurocognitive assessment, including history of concussion/mild traumatic brain injuries. After establishing optimal jaw position, a customized mandibular orthotic was fabricated to the new spatial relations. Results: The mean age of the sample after three seasons was 19.7 years +/- 2.0. Prior to the use of the customized mandibular orthotic, the mean self-reported incidence of concussion/mild traumatic brain injuries was 2.1 +/- 1.4 concussive events. After the deployment of the customized mandibular orthotic the number of concussive events fell to 0.11 +/- 0.3 with an odds ratio of 38.33 (95% CI 8.2-178.6), P < 0.05. Conclusion: The preliminary results of this study suggest that a customized mandibular orthotic may decrease the incidence of concussion/mild traumatic brain injuries in high- school football athletes, but a comprehensive study is required to confirm these initial findings. Furthermore, additional research is necessary to indicate the possible mode(s) of action of a customized mandibular orthotic in the prevention of concussion/mild traumatic brain injuries.	[Singh, G. Dave] SMILE Fdn, Chatsworth, CA 91311 USA; [Maher, Gerald J.] Mahercor Labs LLC, S Weymouth, MA USA; [Padilla, Ray R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA	Singh, GD (corresponding author), SMILE Fdn, 9129 Lurline Ave, Chatsworth, CA 91311 USA.	drsingh@smilefoundation.org					Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Barth J T, 2000, Dent Clin North Am, V44, P67; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Chapman P., 1985, AUST J SCI MED SPORT, V17, P25; Cohenca N, 2007, J AM DENT ASSOC, V138, P1420, DOI 10.14219/jada.archive.2007.0065; dela Cruz GG, 2008, DENT TRAUMATOL, V24, P86, DOI 10.1111/j.1600-9657.2006.00500.x; Dimitroulis G, 1998, BMJ-BRIT MED J, V317, P190, DOI 10.1136/bmj.317.7152.190; FORGIONE AG, 1992, CRANIO, V10, P13, DOI 10.1080/08869634.1992.11677886; FORGIONE AG, 1991, CRANIO, V9, P305, DOI 10.1080/08869634.1991.11678377; Francis K T, 1991, Br J Sports Med, V25, P227; Gelb H, 1996, CRANIO, V14, P320, DOI 10.1080/08869634.1996.11745984; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gusenbauer Albert, 2002, Dent Today, V21, P74; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, J ATHL TRAINING, V34, P277; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Sgan-Cohen HD, 2008, DENT TRAUMATOL, V24, P458, DOI 10.1111/j.1600-9657.2008.00601.x; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey K F, 1999, Gen Dent, V47, P64; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	33	18	19	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	OCT	2009	25	5					515	521		10.1111/j.1600-9657.2009.00808.x			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	492ZB	WOS:000269700900012	19614931				2021-06-18	
J	Sookplung, P; Vavilala, MS				Sookplung, Pimwan; Vavilala, Monica S.			What is new in pediatric traumatic brain injury?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						biomarkers; head injury; hyperglycemia; hypothermia; outcomes; pediatric	INTENSIVE-CARE-UNIT; NERVE GROWTH-FACTOR; CEREBRAL AUTOREGULATION; CLINICAL-TRIAL; THERAPEUTIC HYPOTHERMIA; AIRWAY MANAGEMENT; INSULIN THERAPY; CHILDREN; DEXMEDETOMIDINE; HYPERGLYCEMIA	Purpose of review Pediatric traumatic brain injury (TBI) is associated with significant morbidity and mortality. The purpose of this review is to discuss emerging concepts and to provide an update on the clinical evaluation, management, and predictors of outcome after pediatric TBI. Recent findings We review the epidemiology, patterns of injury, and pathophysiology of pediatric TBI and focus on selective 'hot topics' such as biomarkers, glucose control, and the potential benefits of hypothermia after pediatric TBI. Summary As TBI is the leading cause of death in children, research in this area is needed to advance our knowledge of the sequelae after and improve outcomes of children with TBI.	[Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Sookplung, Pimwan] Univ Washington, Dept Anesthesiol, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Dept Anesthesiol Pediat & Neurol Surg Adj, Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS56; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; *AM COLL SURG COMM, 1993, PED TRAUM ADV TRAUM, P261; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bullock M Ross, 2006, Neurosurgery, V58, pS7; CARNEY NA, 2003, PEDIAT CRIT CARE M S, V4, pS75; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Crosby ET, 2006, ANESTHESIOLOGY, V104, P1293, DOI 10.1097/00000542-200606000-00026; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Klein GW, 2008, J PEDIATR-US, V153, P379, DOI 10.1016/j.jpeds.2008.04.012; Lipshutz AKM, 2009, ANESTHESIOLOGY, V110, P408, DOI 10.1097/ALN.0b013e3181948a80; Marion DW, 2006, NEUROSURGERY, V58, P655; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nishisaki A, 2008, PEDIATR EMERG CARE, V24, P749, DOI 10.1097/PEC.0b013e31818c2665; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Ogawa Y, 2008, ANESTHESIOLOGY, V109, P642, DOI 10.1097/ALN.0b013e3181862a33; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Sharma D, 2009, ANESTH ANALG, V108, P81, DOI 10.1213/ane.0b013e31818a6f32; SYDENHAM E, 2009, COCHRANE DATABASE SY; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Tuggle DW, 2008, AM SURGEON, V74, P195; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P233, DOI 10.1097/00008506-200107000-00009	37	18	18	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2009	22	5					572	578		10.1097/ACO.0b013e3283303884			7	Anesthesiology	Anesthesiology	497ID	WOS:000270051500005	19620860				2021-06-18	
J	Gunter, TD; Philibert, R; Hollenbeck, N				Gunter, Tracy D.; Philibert, Robert; Hollenbeck, Nancy			Medical and Psychiatric Problems among Men and Women in a Community Corrections Residential Setting	BEHAVIORAL SCIENCES & THE LAW			English	Article							EPIDEMIOLOGIC CATCHMENT-AREA; TRAUMATIC BRAIN-INJURY; HIV RISK BEHAVIORS; PRISON HEALTH; UNITED-STATES; DRUG-USE; DSM-IV; PREVALENCE; DEPENDENCE; DISORDERS	Though the medical and mental health morbidity of incarcerated offenders has been discussed in a number of recent reports, very few data have been published concerning medical and mental health problems facing those on community corrections supervision. In this study of community corrections offenders utilizing residential facilities, we found that frequencies of substance use disorders, other mental health disorders, and medical problems exceeded frequencies found in the community and, in some cases, were higher than frequencies found in incarcerated individuals. Of particular concern were the high frequencies of substance use disorders, traumatic brain injury, anxiety states, suicidal ideation, and prior self-harm. While the level of self-reported medical and mental health service utilization was higher than expected, it appeared low relative to the disease burden reported by this special population. We conclude that concurrent evaluation and treatment of medical and psychiatric problems during the process of community supervision is indicated in this population. Copyright (C) 2009 John Wiley & Sons, Ltd.	[Gunter, Tracy D.; Philibert, Robert] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA	Gunter, TD (corresponding author), St Louis Univ, Sch Med, Div Forens Psychiat, Dept Neurol & Psychiat, 1438 S Grand Blvd, St Louis, MO 63104 USA.		Gunter, Tracy/ABD-1754-2020	Gunter, Tracy/0000-0003-2122-8816; Philibert, Robert/0000-0001-7822-4977			Achenbach T. M., 2003, MANUAL ASEBA ADULT F; ALLEN JP, 2000, ASSESSING ALCOHOL PR; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Awofeso N, 2008, INT J PRISON HEALTH, V4, P175, DOI 10.1080/17449200802473081; Baillargeon J, 2007, ANN EPIDEMIOL, V17, P808, DOI 10.1016/j.annepidem.2007.04.005; Belenko S, 2004, AIDS EDUC PREV, V16, P367, DOI 10.1521/aeap.16.4.367.40394; Breslau N, 2001, ARCH GEN PSYCHIAT, V58, P810, DOI 10.1001/archpsyc.58.9.810; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Carcedo RJ, 2008, INT J OFFENDER THER, V52, P641, DOI 10.1177/0306624X07311596; Cashin A, 2008, INT J PRISON HEALTH, V4, P208, DOI 10.1080/17449200802473131; CONDON L, 2006, J COMMUNITY PRACTICE, V79, P19; Condon L, 2007, J CLIN NURS, V16, P1201, DOI 10.1111/j.1365-2702.2007.01799.x; de Viggiani N, 2007, SOCIOL HEALTH ILL, V29, P115, DOI 10.1111/j.1467-9566.2007.00474.x; DeVol R, 2007, UNHEALTHY AM EC BURD; Dyer O, 2008, BRIT MED J, V336, P1210, DOI 10.1136/bmj.39590.660174.DB; FRIESTAD C, 2008, NORD J PSYCH, P1; GLAZE LE, 2008, PROB PAR US 2007 STA; Goodwin RD, 2005, AM J PUBLIC HEALTH, V95, P717, DOI 10.2105/AJPH.2003.019109; Grant BF, 1996, J SUBST ABUSE, V8, P195, DOI 10.1016/S0899-3289(96)90249-7; Grant BF, 1996, AM J PUBLIC HEALTH, V86, P1450, DOI 10.2105/AJPH.86.10.1450; Grant BF, 1996, ALCOHOL CLIN EXP RES, V20, P1481, DOI 10.1111/j.1530-0277.1996.tb01152.x; Gunter TD, 2008, J AM ACAD PSYCHIATRY, V36, P27; HANSER RD, 2009, COMMUNITY CORRECTION; Havens Jennifer R, 2007, J Opioid Manag, V3, P107; Hesselbrock M, 1999, ADDICTION, V94, P1361, DOI 10.1046/j.1360-0443.1999.94913618.x; James DJ., 2006, MENTAL HLTH PROBLEMS; Kanato M, 2008, CURR OPIN PSYCHIATR, V21, P252, DOI 10.1097/YCO.0b013e3282fc985c; KARBERG JC, 2006, SUBSTANCE DEPENDENCE; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; MARUSCHAK L, 2006, MED PROBLEMS JAIL IN; Maruschak LM, 2008, MED PROBLEMS PRISONE; Massoglia M, 2008, J HEALTH SOC BEHAV, V49, P56, DOI 10.1177/002214650804900105; MCLOUGHLIN M, 2006, J COMMUNITY PRACTICE, V79, P178; Messina N, 2006, AM J PUBLIC HEALTH, V96, P1842, DOI 10.2105/AJPH.2005.082016; Metraux S, 2008, PSYCHIAT SERV, V59, P800, DOI 10.1176/appi.ps.59.7.800; MOORE A, 2007, J HEALTH SERV RES PO, V117, P26; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; Mumola C., 1999, SUBSTANCE ABUSE TREA; Oser CB, 2006, AIDS CARE, V18, P339, DOI 10.1080/02652040500200491; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Shepherd J, 2004, J PUBLIC HEALTH, V26, P347, DOI 10.1093/pubmed/fdh169; Shepherd J, 2002, J ROY SOC MED, V95, P539, DOI 10.1258/jrsm.95.11.539; SHEPHERD J, 2004, J PUBLIC HLTH OXFORD, V27, P312; SHEPHERD JP, 2009, J PUBLIC HLTH OXFORD; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Skeem JL, 2006, PSYCHIAT SERV, V57, P333, DOI 10.1176/appi.ps.57.3.333; Skogstad Philip, 2006, Crim Behav Ment Health, V16, P43, DOI 10.1002/cbm.54; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Steel J, 2007, BRIT J PSYCHIAT, V190, P373, DOI 10.1192/bjp.bp.106.031294; US Department of Health and Human Services, 1999, MENT HLTH REP SURG G; Watson R, 2007, J CLIN NURS, V16, P1195, DOI 10.1111/j.1365-2702.2007.01848.x; Way BB, 2007, J FORENSIC SCI, V52, P965, DOI 10.1111/j.1556-4029.2007.00472.x; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U; Wunsch MJ, 2007, J ADDICT DIS, V26, P15, DOI 10.1300/J069v26n04_03	55	18	18	0	10	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0735-3936			BEHAV SCI LAW	Behav. Sci. Law	SEP-OCT	2009	27	5					695	711		10.1002/bsl.887			17	Psychology, Applied; Law	Psychology; Government & Law	511BX	WOS:000271140000004	19743513				2021-06-18	
J	Majernicek, M; Dungl, P; Kolman, J; Malkus, T; Vaculik, J				Majernicek, M.; Dungl, P.; Kolman, J.; Malkus, T.; Vaculik, J.			Osteosynthesis of Intracapsular Femoral Neck Fractures by Dynamic Hip Screw (DHS) Fixation	ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA			Czech	Article						DHS; intra-capsular fracture of the femoral head	AVASCULAR NECROSIS; SUBCAPITAL FRACTURES; INTERNAL-FIXATION; RADIOGRAPHS; HEAD	PURPOSE OF THE STUDY The treatment of femoral neck fractures shows a relatively high number of poor outcomes, usually due to late complications, such as avascular necrosis of the femoral head or pseudoarthrosis. The latter may develop when the osteosynthesis of osteoporotic bone fails. The aim of this retrospective study was to evaluate a group of patients treated by osteosynthesis for intra-capsular femoral neck fractures at our department, and to verify indication criteria and identify the therapeutic procedures that are best suited to our conditions. MATERIAL In the 1997-2001 period, a total of 81 patients with intra-capsular femoral neck fractures were operated on. Of these, 64 treated by dynamic hip screw (DHS) fixation were followed up for at least 5 years. There were 33 women and 31 men; the average age was 21.5 years (range, 21 to 74 years). METHODS The Garden classification was used to evaluate the displacement of femoral neck fractures. Preferably, osteosynthesis was carried out by closed reduction; only exceptionally was an extension device for the operating table used. A 135-degree sliding hip screw, with a short thread, directed to the head centre and a two-hole side plate were used most often. The average follow-up was 6.9 years. Evaluated were: the occurrence of late complications in relation to the length of time between injury and surgery, quality of fracture reduction, use of an anti-rotation screw and necessity of repeat surgery. RESULTS Garden I or II fractures were diagnosed in 13 patients, 51 had Garden III or Garden IV fractures. Bone union without complications was achieved in 73.4% of the patients within 12 months of surgery. Late complications were found in 26.6%; of these, only one had Garden I fracture and the rest were Garden III and IV fractures. An anti-rotation screw was used in 39 patients (60.9%) and its use had no effect on the development of late complications. Of the seven patients who developed pseudoarthrosis, the screw was used in four (57.1%); out of the nine patients with avascular necrosis, it was used in six (66.7%). In the whole group, an unsatisfactory outcome of post-operative reduction was recorded in 29.7%. in the patients with late complications this was found in 52.9%, which was a statistically significant difference. Of the 17 patients with poor outcomes, 14 underwent total hip arthroplasty; in the patients with necrosis, arthroplasty was carried out at an average of 26 months post-operatively, in those with pseudoarthrosis it was at 7 months post-operatively. DISCUSSION For the treatment of intra-capsular fractures of the femoral neck, surgery is the most frequent approach, but there are controversial views on various relevant issues. An important factor affecting the treatment outcome is the patient's bone quality. CONCLUSIONS Our results show a direct relationship between the extent of fracture displacement and late complications, i.e., avascular necrosis and non-union. The quality of fracture reduction had a greater effect on fracture non-union than on the development of femoral head necrosis. The length of time between injury and surgery played a lesser role than it is believed. The use of an anti-rotation screw was not significantly related to the occurrence of late complications. The DHS method is economical and available, and provided sufficient results whose comparisons with the literature data show that this therapeutic approach is correct.	[Majernicek, M.; Dungl, P.; Kolman, J.; Malkus, T.; Vaculik, J.] FN Bulovce, IPVZ & LF UK 1, Ortoped Klin, Prague 18081, Czech Republic	Majernicek, M (corresponding author), FN Bulovce, IPVZ & LF UK 1, Ortoped Klin, Budinova 2, Prague 18081, Czech Republic.	m.majernicek@toscali.cz	Dungl, Pavel/J-4115-2017; Vacullik, Jan/J-3999-2017	Dungl, Pavel/0000-0001-6018-7362; Vacullik, Jan/0000-0003-4850-9490; Majernicek, Marek/0000-0003-4783-1488			ALBERTS KA, 1999, CLIN ORTHOP RELAT R, V257, P129; BARNES R, 1976, J BONE JOINT SURG BR, V58, P2; BECK M, 2004, CLIN ORTHOP RELAT R, V424, P149; Bonnaire FA, 2002, INJURY, V33, pS33; Bonnaire FA, 2002, INJURY, V33, pS24; Cho MR, 2007, J ORTHOP TRAUMA, V21, P158, DOI 10.1097/BOT.0b013e31803773ae; GARDEN RS, 1961, J BONE JOINT SURG BR, V43, P647; GARDEN RS, 1964, J BONE JOINT SURG BR, V46, P630; Heetveld MJ, 2005, ARCH ORTHOP TRAUM SU, V125, P160, DOI 10.1007/s00402-004-0780-4; Itadera Eichi, 2003, J Orthop Sci, V8, P155, DOI 10.1007/s007760300026; Jakob M, 1999, Swiss Surg, V5, P257, DOI 10.1024/1023-9332.5.6.257; Kunesova M, 2006, Acta Chir Orthop Traumatol Cech, V73, P380; Lee KBL, 2004, ANN ACAD MED SINGAP, V33, P248; LUYAO GL, 1994, J BONE JOINT SURG AM, V76A, P15, DOI 10.2106/00004623-199401000-00003; Nikolopoulos KE, 2003, INJURY, V34, P525, DOI 10.1016/S0020-1383(02)00367-4; Parker MJ, 2007, CLIN ORTHOP RELAT R, P175, DOI 10.1097/BLO.0b013e3180325a42; Parker MJ, 2002, J BONE JOINT SURG BR, V84B, P1150, DOI 10.1302/0301-620X.84B8.13522; Perren SM, 2008, ACTA CHIR ORTHOP TR, V75, P241; RAAYMAKERS ELFB, 1991, J BONE JOINT SURG BR, V73, P950; Raaymakers ELFB, 2002, INJURY, V33, pS8; Raaymakers Ernst L F B, 2006, Acta Chir Orthop Traumatol Cech, V73, P45; SINGH M, 1970, J BONE JOINT SURG AM, VA 52, P457, DOI 10.2106/00004623-197052030-00005; Skala-Rosenbaum J, 2005, Rozhl Chir, V84, P291; Toh EM, 2004, INJURY, V35, P125, DOI 10.1016/S0020-1383(02)00422-9; Totterman A, 2007, ARCH ORTHOP TRAUM SU, V127, P185, DOI 10.1007/s00402-006-0276-5; Visna P, 2007, ACTA CHIR ORTHOP TR, V74, P37; Watanabe Y, 2007, J ORTHOP TRAUMA, V21, P456, DOI 10.1097/BOT.0b013e318126bb56; Yih-Shiunn L, 2007, INT ORTHOP, V31, P677, DOI 10.1007/s00264-006-0243-3; Zofka P, 2007, ACTA CHIR ORTHOP TR, V74, P99	29	18	26	0	1	GALEN SRO	PRAGUE 5	NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC	0001-5415			ACTA CHIR ORTHOP TR	Acta Chir. Orthop. Traumatol. Cechoslov.	AUG	2009	76	4					319	325					7	Orthopedics	Orthopedics	492VV	WOS:000269691300009	19755057				2021-06-18	
J	Puccio, AM; Hoffman, LA; Bayir, H; Zullo, TG; Fischer, M; Darby, J; Alexander, S; Dixon, CE; Okonkwo, DO; Kochanek, PM				Puccio, Ava M.; Hoffman, Leslie A.; Bayir, Huelya; Zullo, Thomas G.; Fischer, Michael; Darby, Joseph; Alexander, Sheila; Dixon, C. Edward; Okonkwo, David O.; Kochanek, Patrick M.			Effect of Short Periods of Normobaric Hyperoxia on Local Brain Tissue Oxygenation and Cerebrospinal Fluid Oxidative Stress Markers in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						antioxidant reserve; normobaric hyperoxia; oxidative stress; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL METABOLISM; IMPROVEMENT	Preliminary evidence suggests local brain tissue oxygenation (PbtO(2)) values of <= 15 mm Hg following severe traumatic brain injury (TBI) represent brain tissue hypoxia. Accordingly, many neurotrauma units attempt to maintain PbtO(2) >= 20 mm Hg to avoid hypoxia. This study tested the impact of a short (2 h) trial of normobaric hyperoxia on measures of oxidative stress. We hypothesized this treatment would positively affect cerebral oxygenation but negatively affect the cellular environment via oxidative stress mechanisms. Cerebrospinal fluid (CSF) was serially assessed in 11 adults (9 male, 2 female), aged 26 +/- 1.8 years with severe TBI (Glasgow Coma Scale score, 6 +/- 1.4) before, during, and after a FiO(2) = 1.0 challenge for markers of oxidative stress, including lipid peroxidation (F-2-isoprostane [ELISA]), protein oxidation (protein sulfhydryl [fluorescence]), and antioxidant defenses (total antioxidant reserve (AOR) [chemiluminescence] and glutathione [fluorescence]). Physiological parameters [PbtO(2), arterial oxygen content (PaO2), intracranial pressure (ICP), mean arterial pressure (MAP), and cerebral perfusion pressure (CPP)] were assessed at the same time points. Mean (+/- SD) PbtO(2) and PaO2 levels significantly changed for each time point. Oxidative stress markers, antioxidant reserve defenses, and ICP, MAP, and CPP did not significantly change for any time period. These preliminary findings suggest that brief periods of normobaric hyperoxia do not produce oxidative stress and/or change antioxidant reserves in CSF. Additional studies are required to examine extended periods of normobaric hyperoxia in a larger sample.	[Puccio, Ava M.; Fischer, Michael; Dixon, C. Edward; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Hoffman, Leslie A.; Zullo, Thomas G.; Alexander, Sheila] Univ Pittsburgh, Dept Acute Tertiary Care, Sch Nursing, Pittsburgh, PA 15213 USA; [Darby, Joseph] Univ Pittsburgh, Dept Pediat & Crit Care Med, Med Ctr, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kochanek, Patrick M.] Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Puccio, Ava M.; Dixon, C. Edward; Okonkwo, David O.] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Puccio, AM (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,B-400 PUH, Pittsburgh, PA 15213 USA.	puccioam@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	University of Pittsburgh Brain Trauma Research CenterUniversity of Pittsburgh; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ProNS30318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER	This research was supported in part by the University of Pittsburgh Brain Trauma Research Center (NIH ProNS30318 to C. E. D.), Walter Copeland Research Award, and Leslie A. Hoffman Research Award. We thank Keri Feldman-Janesco and Ashley L. Glumac for technical assistance; the nurses and residents at the University of Pittsburgh Medical Center for excellent patient care, and Dr. Valerian Kagan for helpful discussions.	Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Kaindl AM, 2006, CELL DEATH DIFFER, V13, P1097, DOI 10.1038/sj.cdd.4401796; Langmuir VK, 1996, INT J RADIAT ONCOL, V34, P79, DOI 10.1016/0360-3016(95)02077-2; Longhi Luca, 2004, Curr Opin Crit Care, V10, P105, DOI 10.1097/00075198-200404000-00005; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; TYURINA YY, 1995, TOXICOL APPL PHARM, V131, P277, DOI 10.1006/taap.1995.1070; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Zenri H, 2004, CRIT CARE MED, V32, P1155, DOI 10.1097/01.CCM.0000126264.00551.C8	18	18	21	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1241	1249		10.1089/neu.2008.0624			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900007	19505175	Green Published			2021-06-18	
J	Larson, MJ; Kaufman, DAS; Kellison, IL; Schmalfuss, IM; Perlstein, WM				Larson, Michael J.; Kaufman, David A. S.; Kellison, Ida L.; Schmalfuss, Ilona M.; Perlstein, William M.			Double Jeopardy! The Additive Consequences of Negative Affect on Performance-Monitoring Decrements Following Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						depression; anxiety; cognitive control; executive function; error monitoring	ANTERIOR CINGULATE CORTEX; ERROR-RELATED-NEGATIVITY; MAJOR DEPRESSIVE DISORDER; EVENT-RELATED POTENTIALS; CLOSED-HEAD INJURY; COGNITIVE CONTROL; SEVERE TBI; FUNCTIONAL-SIGNIFICANCE; ANTISACCADE TASK; MOOD DISORDERS	Survivors of severe traumatic brain injury (TBI) are at increased risk for emotional sequelae. The current study utilized the error-related negativity (ERN) and posterror positivity (Pe) components of the event-related potential (ERP) to test the hypothesis that negative affect disproportionately impairs performance-monitoring following severe TBI. High-density ERPs were acquired while 20 survivors of severe TBI and 20 demographically matched controls performed a single-trial Stroop task. Response-locked ERPs were separately averaged for correct and error trials. Negative affect was measured as the single latent factor of measures of depression and anxiety. Groups did not differ on overall level of negative affect. Control and TBI participants did not differ on error rates as a function of negative affect, but differed in response times. ERP results revealed disproportionately smaller ERN amplitudes in participants with TBI relative to controls as a function of negative affect. Pe amplitude did not differ between groups. Negative affect inversely correlated with ERN amplitude in TBI but not control participants. Overall, results support a "double jeopardy" hypothesis of disproportionate impairments in performance monitoring when negative affect is overlaid on severe TBI.	[Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Kaufman, David A. S.; Kellison, Ida L.; Perlstein, William M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA; [Schmalfuss, Ilona M.] N Florida S Georgia Vet Adm Hosp, Dept Radiol, Gainesville, FL USA; [Schmalfuss, Ilona M.] Univ Florida, Dept Med, Gainesville, FL 32611 USA; [Perlstein, William M.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Perlstein, William M.] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS053335, K01 MH01857, R21 MH073076]; Evelyn F. McKnight Brain Research Grant Program; Florida Brain and Spinal Cord Injury Research Trust Fund; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS053335] Funding Source: NIH RePORTER	This original research has not been published elsewhere and was supported by a predoctoral National Institute of Health (NIH) Fellowship F31 NS053335 to Michael J. Larson and grants front the Evelyn F. McKnight Brain Research Grant Program., the Florida Brain and Spinal Cord Injury Research Trust Fund, and NIH to William M. Perlstein (K01 MH01857; R21 MH073076). We extend our appreciation to Ashley Carroll, Cortney Mauer, Megan McIntyre, Drew Nagle, Floris Singletary, Allen Sirizi, and Raechel Steckicy for their assistance in participant recruitment and data collection.	Alain C, 2002, CEREB CORTEX, V12, P840, DOI 10.1093/cercor/12.8.840; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; BURLE B, J COGNITIVE IN PRESS; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CACIOPPO JT, 1990, AM PSYCHOL, V45, P177; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; CLARK DA, 1994, J ABNORM PSYCHOL, V103, P645, DOI 10.1037/0021-843X.103.4.645; Clark H. J., 1924, AM J PHYSL OPTICS, V5, P269; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Compton RJ, 2007, BRAIN COGNITION, V64, P247, DOI 10.1016/j.bandc.2007.03.006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Dux MC, 2008, J INT NEUROPSYCH SOC, V14, P327, DOI 10.1017/S1355617708080363; Emerson CS, 2005, ARCH CLIN NEUROPSYCH, V20, P539, DOI 10.1016/j.acn.2004.10.003; Emerson CS, 2001, NEUROPSY NEUROPSY BE, V14, P130; Endrass T, 2007, EUR J NEUROSCI, V26, P1714, DOI 10.1111/j.1460-9568.2007.05785.x; Falkenstein M, 2005, J PSYCHOPHYSIOL, V19, P305, DOI 10.1027/0269-8803.19.4.305; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; FELDMAN LA, 1993, J CONSULT CLIN PSYCH, V61, P631, DOI 10.1037/0022-006X.61.4.631; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hajcak G, 2004, BRAIN COGNITION, V56, P189, DOI 10.1016/j.bandc.2003.11.001; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hajcak G, 2002, PSYCHIAT RES, V110, P63, DOI 10.1016/S0165-1781(02)00034-3; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hirsh AT, 2006, J PAIN, V7, P592, DOI 10.1016/j.jpain.2006.02.006; Holroyd CB, 2005, J EXP PSYCHOL GEN, V134, P163, DOI 10.1037/0096-3445.134.2.163; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kessler RC, 1996, BRIT J PSYCHIAT, V168, P17, DOI 10.1192/S0007125000298371; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2006, NEUROREPORT, V17, P329, DOI 10.1097/01.wnr.0000199461.01542.db; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Luu P, 2000, J EXP PSYCHOL GEN, V129, P43, DOI [10.1037/0096-3445.129.1.43, 10.1037//0096-3445.129.1.43]; MacCallum RC, 2002, PSYCHOL METHODS, V7, P19, DOI 10.1037//1082-989X.7.1.19; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mathalon DH, 2003, NEUROBIOL AGING, V24, P675, DOI 10.1016/S0197-4580(02)00154-9; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; Neter J., 1985, APPL LINEAR STAT MOD; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Reza MF, 2007, NEUROPSYCHOL REHABIL, V17, P723, DOI 10.1080/09602010601082441; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Shenal BV, 2003, NEUROPSYCHOL REV, V13, P33, DOI 10.1023/A:1022300622902; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SPEILBERGER CD, 1983, MANUAL STATE TRAIT A; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; TEASDALE G, 1974, LANCET, V2, P81; TRICHARD C, 1995, PSYCHOL MED, V25, P79, DOI 10.1017/S0033291700028105; Tucker DM, 2003, J ABNORM PSYCHOL, V112, P667, DOI 10.1037/0021-843X.112.4.667; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; WETZLER S, 1989, J PSYCHIATR RES, V23, P1, DOI 10.1016/0022-3956(89)90013-7; Wilson RS, 2003, AM J EPIDEMIOL, V158, P827, DOI 10.1093/aje/kwg224; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x	91	18	19	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2009	23	4					433	444		10.1037/a0015723			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	472IA	WOS:000268122600003	19586208				2021-06-18	
J	Farhadi, MR; Becker, M; Stippich, C; Unterberg, AW; Kiening, KL				Farhadi, M. R.; Becker, M.; Stippich, C.; Unterberg, A. W.; Kiening, K. L.			Transorbital penetrating head injury by a toilet brush handle	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Foreign body; Intraoperative CT		Transorbital penetrating brain injuries are rare lesions without defined therapy standards. A male patient presented at our institution with a toilet brush handle in the right cerebral hemisphere. CT imaging identified the object entering the right orbit and having crossed the right hemisphere in the ventricular plane. After performing a medium-sized craniotomy, the object was removed step-by-step under monitoring with an intraoperative CT scan to ensure no involving major hemorrhage. Transorbital penetrating brain injuries are treated best by utilizing all up-to-date technical developments such as intraoperative CT-scanning to increase the safety in the management of such exceptional lesions with increased risk of immediate life-threatening intracranial bleeding.	[Farhadi, M. R.; Unterberg, A. W.; Kiening, K. L.] Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; [Becker, M.] Univ Heidelberg Hosp, Dept Ophthalmol, Heidelberg, Germany; [Stippich, C.] Univ Heidelberg Hosp, Dept Neuroradiol, Heidelberg, Germany	Farhadi, MR (corresponding author), Univ Heidelberg, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	mohammad.farhadi@med.uni-heidelberg.de	Farhadi, Mohammad Reza/AAN-9612-2021	Farhadi, Mohammad Reza/0000-0001-5333-5355			Heininger AD, 2004, ANAESTHESIST, V53, P830, DOI 10.1007/s00101-004-0729-6; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lin Hung-Lin, 2007, J Chin Med Assoc, V70, P36; Matsuyama T, 2001, NEUROL MED-CHIR, V41, P345, DOI 10.2176/nmc.41.345	4	18	20	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUN	2009	151	6					685	687		10.1007/s00701-009-0221-9			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	456AZ	WOS:000266811700019	19255713				2021-06-18	
J	Hosalkar, HS; Greenbaum, JN; Flynn, JM; Cameron, DB; Dormans, JP; Drummond, DS				Hosalkar, H. S.; Greenbaum, J. N.; Flynn, J. M.; Cameron, D. B.; Dormans, J. P.; Drummond, D. S.			Fractures of the odontoid in children with an open basilar synchondrosis	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							CERVICAL-SPINE INJURIES; YOUNG-CHILDREN; DISLOCATIONS; ADOLESCENTS; AXIS	Fractures of the odontoid in children with an open basilar synchondrosis differ from those which occur in older children and adults. We have reviewed the morphology of these fractures and present a classification system for them. There were four distinct patterns of fracture (types IA to IC and type II) which were distinguished by the site of the fracture, the degree of displacement and the presence or absence of atlantoaxial dislocation. Children with a closed synchondrosis were classified using the system devised by Anderson and D'Alonzo. Those with an open synchondrosis had a comparatively lower incidence of traumatic brain injury, a higher rate of missed diagnosis and a shorter mean stay in hospital. Certain subtypes ( type IA and type II) are likely to be missed on plain radiographs and therefore more advanced imaging is recommended. We suggest staged treatment with initial stabilisation in a Halo body jacket and early fusion for those with unstable injuries, severe displacement or neurological involvement.	[Flynn, J. M.; Cameron, D. B.; Dormans, J. P.] Childrens Hosp Philadelphia, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	Hosalkar, HS (corresponding author), Univ Penn, Sch Med, 2nd Floor Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	Harish.hosalkar@uphs.upenn.edu					ALP MS, 1990, BMJ-BRIT MED J, V300, P319, DOI 10.1136/bmj.300.6720.319; AMYES EW, 1956, ARCH SURG-CHICAGO, V72, P377, DOI 10.1001/archsurg.1956.01270210007002; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; [Anonymous], INT CLASSIFICATION D, V3rd; APPLE JS, 1987, PEDIATR RADIOL, V17, P45, DOI 10.1007/BF02386594; BOHN D, 1990, J TRAUMA, V30, P463, DOI 10.1097/00005373-199030040-00017; CONNOLLY B, 1995, PEDIATR RADIOL, V25, P129; Copley L A, 1998, J Am Acad Orthop Surg, V6, P204; EVANS DL, 1989, J PEDIATR ORTHOPED, V9, P563, DOI 10.1097/01241398-198909010-00011; FIELDING JW, 1974, J BONE JOINT SURG AM, VA 56, P187, DOI 10.2106/00004623-197456010-00023; FLYNN J, 2001, SPINE, V14, P249; FREIBERGER RH, 1965, J BONE JOINT SURG AM, VA 47, P1231, DOI 10.2106/00004623-196547060-00013; FUJII E, 1988, SPINE, V13, P604; Godard J, 1997, CHILD NERV SYST, V13, P105, DOI 10.1007/s003810050054; GRIFFITHS SC, 1972, J PEDIATR SURG, V7, P680, DOI 10.1016/0022-3468(72)90279-5; GROPPER P, 1975, J BONE JOINT SUR B S, V33, P434; Lui TN, 1996, J TRAUMA, V40, P408, DOI 10.1097/00005373-199603000-00014; MANDABACH M, 1993, PEDIATR NEUROSURG, V19, P225, DOI 10.1159/000120737; MAZUR JM, 2002, SPINE, V27, P197; MCGRORY BJ, 1994, J BONE JOINT SURG AM, V76A, P1606, DOI 10.2106/00004623-199411000-00003; Odent T, 1999, J PEDIATR ORTHOPED, V19, P51, DOI 10.1097/00004694-199901000-00012; Schippers N, 1996, ACTA NEUROCHIR, V138, P524, DOI 10.1007/BF01411172; SEIMON LP, 1977, J BONE JOINT SURG AM, V59, P943, DOI 10.2106/00004623-197759070-00019; SHERK HH, 1978, J BONE JOINT SURG AM, V60, P921, DOI 10.2106/00004623-197860070-00008; UEMARA K, 1996, NEUROL MED CHIR TOKY, V36, P175; VINING DJ, 1992, J NEUROSURG, V77, P795, DOI 10.3171/jns.1992.77.5.0795; GLASGOW COMA SCORE	27	18	22	0	1	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X			J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	JUN	2009	91B	6					789	796		10.1302/0301-620X.91B6.22173			8	Orthopedics; Surgery	Orthopedics; Surgery	458PF	WOS:000267035300015	19483234	Bronze			2021-06-18	
J	Mauritz, W; Leitgeb, J; Wilbacher, I; Majdan, M; Janciak, I; Brazinova, A; Rusnak, M				Mauritz, Walter; Leitgeb, Johannes; Wilbacher, Ingrid; Majdan, Marek; Janciak, Ivan; Brazinova, Alexandra; Rusnak, Martin			Outcome of brain trauma patients who have a Glasgow Coma Scale score of 3 and bilateral fixed and dilated pupils in the field	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						brain injury; fixed and dilated; Glasgow Coma Scale; Glasgow Outcome Scale; pupils; traumatic	INJURY; MANAGEMENT; REACTIVITY; IMPACT; CARE	Objective To investigate the outcome of brain trauma patients who had a Glasgow Coma Scale score (GCS) of 3 and bilateral fixed and dilated pupils (BFDP) in the field. Methods Between January 2001 and December 2005, 13 European centres enrolled patients with severe brain trauma. Data sets of all patients who had a GCS of 3 as well as BFDP were analysed. Patients were classified according to the Glasgow Outcome Scale, 12 months after trauma as 'good' (Glasgow Outcome Scale of 5 or 4) or 'poor' functional recovery; relevant data for these two groups were compared. Variables that showed differences in univariate analyses (chi(2) and Wilcoxon-Mann-Whitney tests) were then used as covariates in logistic regression models. A P value of less than 0.05 was considered significant. Results Ninety-two (78%) of 1172 patients had a GCS of 3 and BFDP; eight had 'good', 84 had 'poor' recovery. We found no significant differences in sex (79% male), age (median 32 years), and trauma mechanisms. Trauma was significantly less severe, probability of survival significantly higher (0.48 vs. 0.23) in the 'good' group. Only one of 39 patients who had closed basal cisterns on the first computed tomography scan, and none of the patients with midline shift greater than 15 mm had good outcomes. Logistic regression revealed that age, trauma severity, and status of basal cisterns on the first computed tomography scan were the factors determining outcomes. Conclusion Patients with a GCS of 3 and BFDP in the field should be resuscitated aggressively, especially if the trauma seems to be not too severe. European Journal of Emergency Medicine 16:153-158 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Mauritz, Walter; Leitgeb, Johannes; Wilbacher, Ingrid; Janciak, Ivan; Brazinova, Alexandra; Rusnak, Martin] INRO, A-1080 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Buehler, Dept Anaesthesiol & Intens Care Med, Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Trauma Surg, Vienna, Austria; [Majdan, Marek; Brazinova, Alexandra; Rusnak, Martin] Trnava Univ, Fac Hlth & Social Serv, Dept Publ Hlth, Trnava, Slovakia	Mauritz, W (corresponding author), INRO, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CLUSMANN H, 2001, J NEUROL NEUROSURG P, V71; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Sousa J, 2002, NEUROL INDIA, V50, P430; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4	18	18	18	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0969-9546			EUR J EMERG MED	Eur. J. Emerg. Med.	JUN	2009	16	3					153	158		10.1097/MEJ.0b013e32832a0864			6	Emergency Medicine	Emergency Medicine	444GC	WOS:000265967700011	19282759				2021-06-18	
J	Scott, LK; Green, R; McCarthy, PJ; Conrad, SA				Scott, L. Keith; Green, Rebecca; McCarthy, Paul J.; Conrad, Steven A.			Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						traumatic brain injury; agitation; aggression; ziprasidone; Riker Sedation-Agitation Scale	ANTIPSYCHOTICS; ADOLESCENTS; EFFICACY; CHILDREN	Object. Agitation and aggression are common after traumatic brain injury (TBI) and can hamper recovery and rehabilitative efforts. To date. there is no consensus on pharmaceutical intervention for these conditions after TBI. Ziprasidone has been reported efficacious in this Population but the evidence is limited. The authors report their experience of using ziprasidone to treat posttraumatic brain injury agitation in 20 consecutive pediatric patients. A secondary objective of this case series was to attempt to establish an age-specific dosage and identify possible side effects of this medication. Methods. This case series Study was performed at a university hospital and pediatric trauma center. Over an 18-month period, all patients who presented to the pediatric intensive care unit with TBI and later developed agitation and/or aggression were treated with ziprasidone as the sole intervention. Pre- and posttreatment scored; on the Riker Scclation-A-itation Scale (SAS) were recorded along with demographic data. Results. Twenty children received ziprasidone for agitation and/or aggression during the immediate recovery period from TBI. The median patient age was 8 years (range 9 months-17 years). Children were stratified into 4 age groups: < 2 years old (Group 1). 2-6 years old (Group 2), 7-12 years old (Group 3), and >= 13 years old (Group 4). The SAS score, before and 24 hours after the initiation of ziprasidone, demonstrated a significant reduction after initiation of the medication (p < 0.001). The initial dose for Groups 1-4 was 1.7, 0.9, 0.7, and 0.6 mg/kg, respectively, with final doses of 1.8, 1.5, 1.7, and 0.07 mg/kg. respectively. The duration of therapy for Groups 1-4 was 5, 8 6, and 3 clays, respectively. All patients received continuous cardiac and blood-pressure monitoring. No adverse events were reported in any of the age groups. Conclusions. Based oil this limited patient series. ziprasidone appears to be safe and effective in pediatric patients with closed head injuries who develop agitation and/or aggression in the immediate postinjury period. Ziprasidone consistently lowered SAS scores and did so in all age groups. There were minimal dose adjustments and the duration of therapy was relatively brief. No adverse events were reported. A prospective trial of ziprasidone in this Population appears warranted. (DOI: 10.3171/2009.2.PEDS08292)	[Scott, L. Keith; McCarthy, Paul J.; Conrad, Steven A.] Louisiana State Univ, Hlth Sci Ctr, Dept Med, Shreveport, LA 71130 USA; [Scott, L. Keith; Green, Rebecca; Conrad, Steven A.] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Shreveport, LA 71130 USA; [Scott, L. Keith; McCarthy, Paul J.; Conrad, Steven A.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Shreveport, LA 71130 USA	Scott, LK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, 1541 Kings Highway, Shreveport, LA 71130 USA.	lscott2@lsuhsc.edu	Conrad, Steven/F-3257-2015	Conrad, Steven/0000-0002-4014-969X			Biederman J, 2007, BIPOLAR DISORD, V9, P888, DOI 10.1111/j.1399-5618.2007.00450.x; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; FLEMINGER S, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003299; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Lescot T, 2007, NEUROCRIT CARE, V7, P124, DOI 10.1007/s12028-007-0051-7; Maryniak O, 2001, BRAIN INJURY, V15, P167, DOI 10.1080/026990501458399; Noe E, 2007, BEHAV NEUROL, V18, P7, DOI 10.1155/2007/529076; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Pachet A, 2003, BRAIN INJURY, V17, P715, DOI 10.1080/0269905031000110445; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Rosati DL, 2002, AM J PHYS MED REHAB, V81, P90, DOI 10.1097/00002060-200202000-00003; Sallee FR, 2003, J AM ACAD CHILD PSY, V42, P902, DOI 10.1097/01.CHI.0000046897.27264.46; Serretti A, 2004, CURR MED CHEM, V11, P343, DOI 10.2174/0929867043456043; Sprouse JS, 1999, NEUROPSYCHOPHARMACOL, V21, P622, DOI 10.1016/S0893-133X(99)00057-3; Teng CJ, 2001, BRAIN INJURY, V15, P463, DOI 10.1080/02699050010005931	17	18	18	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2009	3	6					484	487		10.3171/2009.2.PEDS08292			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	451HK	WOS:000266461100009	19485732				2021-06-18	
J	McCluggage, LK; Voils, SA; Bullock, MR				McCluggage, Lauren K.; Voils, Stacy A.; Bullock, Malcolm Ross			Phenytoin Toxicity Due to Genetic Polymorphism	NEUROCRITICAL CARE			English	Article						Phenytoin; Case report; Phenytoin toxicity; Polymorphism; Traumatic brain injury	INTOXICATION	Patients with traumatic brain injury commonly receive phenytoin for seizure prophylaxis. Due to the non-linear pharmacokinetics of phenytoin and narrow therapeutic window, phenytoin concentrations are monitored to ensure efficacy and prevent toxicity. Because phenytoin is hepatically metabolized, polymorphisms within cytochrome P450 enzymes can affect phenytoin concentrations. We report a case of a 53-year-old Asian female admitted to the neuroscience intensive care unit after suffering a traumatic brain injury. Phenytoin was subsequently administered for seizure prophylaxis. Four days after being initiated on phenytoin, the patient remained lethargic, and phenytoin toxicity was suspected. Lab values revealed a free phenytoin concentration of 4.4 mg/l, and phenytoin was discontinued. Upon further investigation, it was found that the patient was a cytochrome P450 2C9 poor metabolizer. Causes of the patient's toxic phenytoin concentration such as drug interactions, decreased albumin, and lab error were excluded. The cause of her elevated phenytoin concentration was determined to be hepatic polymorphism. This case reveals the clinical significance of genetic polymorphisms and the effect on phenytoin dosage requirements. Because pharmacogenomic testing is expensive and not readily available, routine monitoring of phenytoin concentrations is warranted. Further, established polymorphisms should be documented to prevent toxicity of drugs metabolized by similar pathways.	[Voils, Stacy A.] Virginia Commonwealth Univ Hlth Syst, Dept Pharm Serv, Richmond, VA 23298 USA; [McCluggage, Lauren K.] Univ Sci Philadelphia, Dept Pharm Practice, Philadelphia, PA USA; [McCluggage, Lauren K.] Univ Sci Philadelphia, Pharm Adm, Philadelphia, PA USA; [Bullock, Malcolm Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA	Voils, SA (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Pharm Serv, POB 980042, Richmond, VA 23298 USA.	svoils@mcvh-vcu.edu					Citerio G, 2003, NEUROLOGY, V60, P1395, DOI 10.1212/01.WNL.0000058756.61277.17; Hung CC, 2004, THER DRUG MONIT, V26, P534, DOI 10.1097/00007691-200410000-00012; Lardizabal DV, 2004, NEUROLOGY, V62, P161; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; Ninomiya H, 2000, THER DRUG MONIT, V22, P230, DOI 10.1097/00007691-200004000-00016; Schwarz UI, 2003, EUR J CLIN INVEST, V33, P23, DOI 10.1046/j.1365-2362.33.s2.6.x; van der Weide J, 2001, PHARMACOGENETICS, V11, P287, DOI 10.1097/00008571-200106000-00002; WINTER ME, 1994, BASIC CLIN PHARMACOK, P312	8	18	18	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2009	10	2					222	224		10.1007/s12028-008-9165-9			3	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	414XP	WOS:000263898800012	19030785				2021-06-18	
J	Mercer, J; Erickson-Owens, D; Skovgaard, R				Mercer, J.; Erickson-Owens, D.; Skovgaard, R.			Cardiac asystole at birth: Is hypovolemic shock the cause?	MEDICAL HYPOTHESES			English	Article							UMBILICAL BLOOD-FLOW; TIGHT NUCHAL CORD; SHOULDER DYSTOCIA; CARDIOCEREBRAL RESUSCITATION; NEWBORN-INFANTS; FETAL BLOOD; VOLUME; EXPRESSION; MANAGEMENT; CELLS	A birth involving shoulder dystocia can rapidly deteriorate-from a fetus with a reassuring tracing in the minutes before birth, to a neonate needing aggressive resuscitation. Infants experiencing a traumatic birth involving shoulder dystocia may be severely compromised, even when the preceding labor was uncomplicated. This paper presents two cases in which infants had normal heart beats recorded 510 min before birth and were born with cardiac asystole following shoulder dystocia. Often, in cases of shoulder dystocia, infants shift blood to the placenta due to the tight compressive squeeze of the body in the birth canal (along with cord compression) and thereby may be born hypovolemic. Our hypothesis is that the occurrence of sudden cardiac asystole at birth is due to extreme hypovolemic shock secondary to the loss of blood. At birth, the sudden release of pressure on the infant's body results in hypoperfusion resulting in low central circulation and blood pressure. Severe hypovolemic shock from these effects leads to sudden cardiac arrest. Immediate cord clamping maintains the hypovolemic state by preventing the physiologic and readily available placental blood from returning to the infant. Loss of this blood initiates an inflammatory response leading to seizures, hypoxic-ischemic encephalopathy, and brain damage or death. Animal studies have shown that human umbilical stem cells injected into a rat's abdomen after induced brain damage, can protect the rat's brain from developing permanent injury. To prevent damage to newborns, the infant must receive the blood volume and stem cells lost at the time of descent and immediate cord clamping. Recommended countermeasures for research include: (1) resuscitation at the perineum with intact cord: or (2) milking the cord before clamping; or (3) autologous transfusion of placenta blood after the birth; or (4) rapid transfusion of 0 negative blood after birth and before seizures begin. (C) 2008 Elsevier Ltd. All rights reserved.	[Mercer, J.; Erickson-Owens, D.] Univ Rhode Isl, Coll Nursing, Kingston, RI 02881 USA; [Mercer, J.; Erickson-Owens, D.] Brown Univ, Providence, RI 02912 USA; [Skovgaard, R.] Highland Hosp, Univ Rochester, Dept Obstet & Gynecol, Rochester, NY USA	Mercer, J (corresponding author), 76 Woodbury Rd, Cranston, RI 02905 USA.	jmercer@uri.edu					[Anonymous], 2003, INT J GYNECOL OBSTET, V80, P87; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; BALL RH, 1992, AM J OBSTET GYNECOL, V166, P1683, DOI 10.1016/0002-9378(92)91557-Q; BALLIN A, 1995, ARCH DIS CHILD-FETAL, V73, pF181, DOI 10.1136/fn.73.3.F181; BARKOVICH AJ, 1990, PEDIAT NEUROIMAGING, V1, P355; BLACKBURN S, 2003, MATERNAL FETAL NEONA, P781; CASHORE WJ, 1973, PEDIATR RES, V7, P399; COLOZZI AE, 1954, NEW ENGL J MED, V250, P629, DOI 10.1056/NEJM195404152501502; COPSTEAD LC, 2000, PATHOPHYSIOLOGY BIOL; Dhar K K, 1995, J Indian Med Assoc, V93, P451; Dildy GA, 2000, CLIN OBSTET GYNECOL, V43, P265, DOI 10.1097/00003081-200006000-00005; Ewy GA, 2006, AM J MED, V119, P6, DOI 10.1016/j.amjmed.2005.06.067; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; FAXELIUS G, 1977, J PEDIATR-US, V90, P273, DOI 10.1016/S0022-3476(77)80650-1; GUYTON AC, 2006, TXB MED PHYSL, V1, P1116; Hensleigh PA, 2002, BJOG-INT J OBSTET GY, V109, P1377, DOI 10.1016/S1470-0328(02)02997-X; Hope P, 1998, BRIT J OBSTET GYNAEC, V105, P1256, DOI 10.1111/j.1471-0528.1998.tb10003.x; Hosono S, 2008, ARCH DIS CHILD-FETAL, V93, pF14, DOI 10.1136/adc.2006.108902; Iffy L, 2001, Med Law, V20, P627; Iffy L, 2006, MED LAW, V25, P553; Iffy L, 1994, Med Law, V13, P323; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jevitt CM, 2005, J MIDWIFERY WOM HEAL, V50, P485, DOI 10.1016/j.jmwh.2005.07.005; JONES JG, 1990, BRIT J HAEMATOL, V76, P288, DOI 10.1111/j.1365-2141.1990.tb07886.x; Kattwinkel J, 2006, TXB NEONATAL RESUSCI; LANZKOWSKY P, 1960, BMJ-BRIT MED J, V5215, P1777; McCAUSLAND A M, 1949, Calif Med, V71, P190; Meier C, 2006, PEDIATR RES, V59, P244, DOI 10.1203/01.pdr.0000197309.08852.f5; MERCER J, 2004, NORMA CHILDBIRTH EVI; Mercer JS, 2005, J MIDWIFERY WOM HEAL, V50, P373, DOI 10.1016/j.jmwh.2005.04.023; Mercer JS, 2002, J PERINAT NEONAT NUR, V15, P56, DOI 10.1097/00005237-200203000-00007; Miller LMJ, 2006, ANIM REPROD SCI, V94, P54, DOI 10.1016/j.anireprosci.2006.03.072; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; Nodwell A, 2005, OBSTET GYNECOL, V105, P129, DOI 10.1097/01.AOG.0000146635.51033.9d; Osak R, 1997, EARLY HUM DEV, V49, P193, DOI 10.1016/S0378-3782(97)00030-3; Perlman JM, 2006, CLIN THER, V28, P1353, DOI 10.1016/j.clinthera.2006.09.005; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; Rajnik M, 2002, SHOCK, V17, P322, DOI 10.1097/00024382-200204000-00015; Rogers J, 1998, LANCET, V351, P693, DOI 10.1016/S0140-6736(97)09409-9; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHEPHERD AJ, 1985, AM J DIS CHILD, V139, P71, DOI 10.1001/archpedi.1985.02140030073033; SIDDALL RS, 1952, AM J OBSTET GYNECOL, V63, P1059, DOI 10.1016/0002-9378(52)90546-2; SIDDALL RS, 1953, OBSTET GYNECOL, V1, P230; STEMBERA ZK, 1965, AM J OBSTET GYNECOL, V91, P568, DOI 10.1016/0002-9378(65)90130-4; STEMBERA ZK, 1968, AM J OBSTET GYNECOL, V101, P546, DOI 10.1016/0002-9378(68)90568-1; Strauss RG, 2003, TRANSFUSION, V43, P1168, DOI 10.1046/j.1537-2995.2003.00454.x; USHER R, 1963, ACTA PAEDIATR, V52, P497, DOI 10.1111/j.1651-2227.1963.tb03809.x; VANHAESEBROUCK P, 1987, ARCH DIS CHILD, V62, P1276, DOI 10.1136/adc.62.12.1276; VOLPE JJ, 2001, NEUROLOGY NEWBORN, P912; WALSH SZ, 1969, BRIT HEART J, V31, P122; WHIPPLE GA, 1957, OBSTET GYNECOL, V10, P603, DOI 10.1097/00006250-195712000-00002; YAO AC, 1969, LANCET, V2, P871; Yao BD, 2002, APPL PHYS LETT, V81, P757, DOI 10.1063/1.1495878	53	18	18	1	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	APR	2009	72	4					458	463		10.1016/j.mehy.2008.11.019			6	Medicine, Research & Experimental	Research & Experimental Medicine	425EM	WOS:000264619800025	19121560				2021-06-18	
J	Bigler, ED; Brooks, M				Bigler, Erin D.; Brooks, Michael			Traumatic Brain Injury and Forensic Neuropsychology	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						forensic neuropsychology; practice standards; research standards; traumatic brain injury	ASSOCIATION PRACTICE SURVEY; UNITED-STATES; CLINICAL NEUROPSYCHOLOGY; MILD; CONTROVERSIES; ACADEMY; OUTCOMES; ISSUES; NATIONAL-ACADEMY-OF-NEUROPSYCHOLOGY/DIVISION-40; CONCUSSION	As part of a special issue of The Journal of Head Trauma Rehabilitation, forensic neuropsychology is reviewed as it applies to traumatic brain injury (TBI) and other types of acquired brain Injury in which clinical neuropsychologists and rehabilitation psychologists may be asked to render professional opinions about the neurobehavioral effects and outcome of a brain injury. The article introduces and overviews the topic focusing on the process of forensic neuropsychological consultation and practice as it applies to patients with TBI or other types of acquired brain injury. The emphasis is on the application of scientist-practitioner standards as they apply to legal questions about the status of a TBI patient and how best that may be achieved. This article introduces each topic area covered in this special edition.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Brooks, Michael] Brigham Young Univ, Univ Accessibil Ctr, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Brain Inst Utah, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					*AM PSYCH ASS, 2007, COMM PSYCH TESTS ASS; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Baker DB, 2000, AM PSYCHOL, V55, P241, DOI 10.1037/0003-066X.55.2.241; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BIGLER ED, 2006, BRAIN INJURY PROFESS, V3, P8; Bigler ED, 2006, ARCH CLIN NEUROPSYCH, V21, P503, DOI 10.1016/j.acn.2006.03.008; Bigler ED, 2008, ARCH CLIN NEUROPSYCH, V23, P755, DOI 10.1016/j.acn.2008.09.003; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Boone, 2007, ASSESSMENT FEIGNED C; Bryan A, 1999, BLACKS LAW DICT; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Buchanan A, 2006, J AM ACAD PSYCHIATRY, V34, P14; Burt RA, 2006, CRIT CARE MED, V34, pS348, DOI 10.1097/01.CCM.0000237270.55658.34; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P997, DOI 10.1016/j.acn.2005.06.003; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cain DM, 2008, JAMA-J AM MED ASSOC, V299, P2893, DOI 10.1001/jama.299.24.2893; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Coyle PK, 2007, NEUROLOGY, V68, pS3, DOI 10.1212/01.wnl.0000277702.74115.9b; CYNKAR A, 2007, APA MONIT PSYCHOL, V38, P52; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DeAngelis CD, 2008, JAMA-J AM MED ASSOC, V299, P1833, DOI 10.1001/jama.299.15.1833; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; EDLUND W, 2005, AM ACAD NEUROLOGY CL; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Farmer A, 2008, BRIT J PSYCHIAT, V192, P351, DOI 10.1192/bjp.bp.107.038380; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2009, J HEAD TRAUMA REHAB, V24, P105, DOI 10.1097/HTR.0b013e31819b1210; Genovese Elizabeth, 2004, Clin Occup Environ Med, V4, P361; Gorwood P, 2008, AM J PSYCHIAT, V165, P731, DOI 10.1176/appi.ajp.2008.07040574; Griffin GAE, 1996, J CONSULT CLIN PSYCH, V64, P1425, DOI 10.1037/0022-006X.64.6.1425; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Heilbronner RL, 2004, CLIN NEUROPSYCHOL, V18, P312, DOI 10.1080/13854040490501574; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Holloway RG, 2008, NEUROLOGY, V71, P57, DOI 10.1212/01.wnl.0000316319.19159.c3; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kendler KS, 2008, AM J PSYCHIAT, V165, P695, DOI 10.1176/appi.ajp.2008.07071061; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2008, ARCH CLIN NEUROPSYCH, V23, P763, DOI 10.1016/j.acn.2008.09.004; Larriviere D, 2008, JAMA-J AM MED ASSOC, V299, P1667, DOI 10.1001/jama.299.14.1667-a; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; LoPiccolo CJ, 1999, ANN MED, V31, P166, DOI 10.3109/07853899909115975; Lundin KA, 1999, CLIN NEUROPSYCHOL, V13, P433, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT433; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Martelli MF, 2002, PAIN MANAGEMENT PRAC, P895; Michaels D, 2008, DOUBT IS THEIR PRODU; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NARAYAN R, 1996, J NEUROTRAUMA; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1813, DOI 10.1001/jama.299.15.1813; Quill TE, 2005, NEW ENGL J MED, V352, P1630, DOI 10.1056/NEJMp058062; Racette BA, 2006, NEUROLOGY, V67, P2124, DOI 10.1212/01.wnl.0000249306.85048.86; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Ross JS, 2008, JAMA-J AM MED ASSOC, V299, P1800, DOI 10.1001/jama.299.15.1800; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sagsveen MG, 2004, NEUROLOGY, V63, P1555, DOI 10.1212/01.WNL.0000146627.92573.8D; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schwarz L, 2009, J HEAD TRAUMA REHAB, V24, P100, DOI 10.1097/HTR.0b013e31819b0504; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Silver JM, 2005, TXB TRAUMATIC BRAIN; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; STERN BH, 2007, LITIGATING BRAIN INJ; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Sweet JJ, 2003, ARCH CLIN NEUROPSYCH, V18, P557, DOI 10.1016/S0887-6177(02)00215-9; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P109, DOI 10.1076/clin.16.2.109.13237; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; VOISS DV, 1995, NEUROL CLIN, V13, P431; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams MA, 2006, NEUROLOGY, V66, P13, DOI 10.1212/01.wnl.0000190568.69950.11; Wood RL, 2009, J HEAD TRAUMA REHAB, V24, P88, DOI 10.1097/HTR.0b013e31819b118a; Zasler N, 2007, BRAIN INJURY MED PRI	85	18	18	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2009	24	2					76	87		10.1097/HTR.0b013e31819c2190			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427WF	WOS:000264809100002	19333063				2021-06-18	
J	Zadik, Y; Levin, L				Zadik, Yehuda; Levin, Liran			Does a free-of-charge distribution of boil-and-bite mouthguards to young adult amateur sportsmen affect oral and facial trauma?	DENTAL TRAUMATOLOGY			English	Article							FITTED MOUTHGUARDS; DENTAL TRAUMA; PROTECTION; INJURIES; PREVENTION; CONCUSSION; ISRAEL	The purpose of this retrospective study was to evaluate the compliance effectiveness of free-of-charge distribution of boil-and-bite mouthguards to amateur sportsmen who exercise and play without a formal team, a coach, or regulations. Several infantry units in the Israel Defense Forces distributed maxillary boil-and-bite mouthguards to their recruits. Target companies from these battalions and from similar battalions (comparison group -mouthguards not supplied), were selected. Soldiers were interviewed using a structured questionnaire. Of the 630 male participants, 272 received a mouthguard and 358 served as the comparison group. No differences were found between groups regarding demographic parameters or overall trauma cases. When compliance to a free-of-charge distributed boil-and-bite mouthguard was assessed, 93 (34.2%) participants reported using the mouthguard during sport activities. Compliance was high for martial arts, but low for other sports. Although the number of self-reported sport-related oral/dental trauma cases was similar between mouthguard users and non-users, the users group showed less severe injuries. However, free distribution to young amateur sportsmen does not affect oral and dental trauma unless accompanied by education and motivation.	[Levin, Liran] Tel Aviv Univ, Sch Dent Med, Dept Oral Rehabil, IL-69978 Tel Aviv, Israel; [Levin, Liran] Rambam Med Ctr, Dept Oral & Dent Sci, Unit Periodontol, Haifa, Israel; [Zadik, Yehuda] Israel Def Forces Med Corps, Zrifin Cent Dent Clin, Jerusalem, Israel; [Zadik, Yehuda] Israel Def Forces Med Corps, Ctr Hlth Promot & Prevent Med, Jerusalem, Israel	Levin, L (corresponding author), Tel Aviv Univ, Sch Dent Med, Dept Oral Rehabil, IL-69978 Tel Aviv, Israel.	liranl@post.tau.ac.il	Zadik, Yehuda/H-7242-2019				Bastone EB, 2000, AUST DENT J, V45, P2, DOI 10.1111/j.1834-7819.2000.tb00234.x; Bechor R, 2008, DENT TRAUMATOL, V24, P550, DOI 10.1111/j.1600-9657.2007.00545.x; Cohenca N, 2007, J AM DENT ASSOC, V138, P1121, DOI 10.14219/jada.archive.2007.0326; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Gardiner D M, 2000, Dent Clin North Am, V44, P53; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; Holmes C, 2000, BRIT DENT J, V188, P473, DOI 10.1038/sj.bdj.4800514a; KATZ RV, 1979, COMMUNITY DENT ORAL, V7, P30, DOI 10.1111/j.1600-0528.1979.tb01182.x; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Levin L, 2003, DENT TRAUMATOL, V19, P237, DOI 10.1034/j.1600-9657.2003.00196.x; Levin L, 2007, DENT TRAUMATOL, V23, P356, DOI 10.1111/j.1600-9657.2006.00473.x; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; Patrick DG, 2005, BRIT J SPORT MED, V39, P278, DOI 10.1136/bjsm.2004.012658; PERSSON LG, 1994, SCAND J DENT RES, V102, P367; Ranalli D N, 2000, Dent Clin North Am, V44, P35; RANALLI DN, 1993, J PUBLIC HEALTH DENT, V53, P96, DOI 10.1111/j.1752-7325.1993.tb02682.x; Winters JE, 2001, J ATHL TRAINING, V36, P339	17	18	19	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2009	25	1					69	72		10.1111/j.1600-9657.2008.00708.x			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	397CN	WOS:000262639700014	19208013				2021-06-18	
J	Chaudhuri, K; Malham, GM; Rosenfeld, JV				Chaudhuri, Krishanu; Malham, Gregory M.; Rosenfeld, Jeffrey V.			Survival of trauma patients with coma and bilateral fixed dilated pupils	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Glasgow Coma Score; Pupillary status; Traumatic brain injury; Pre-hospital; Outcome	SEVERE HEAD-INJURY; BRAIN-INJURY; SCALE SCORE; GLASGOW; ASSOCIATION; REACTIVITY; HEMATOMA; FIELD	Background: Survival of patients with severe trauma presenting with Glasgow Coma Score (GCS) 3 and bilateral fixed dilated pupils is uncertain. Pre-hospital management of these patients affects the true measurement of the GCS and other factors may affect pupillary status. Patients and methods: A retrospective review was undertaken of all patients who were classified GCS 3 and had bilateral fixed dilated pupils on admission to a Level I Adult Trauma Centre between July 2001 and March 2005. Pre-hospital assessment, hospital interventions and outcomes were determined. Results: Ninety-three patients fulfilled the criteria for inclusion into the study. There were 6 survivors who were all less than 28 years of age, had at least one GCS score above 3 in the pre-hospital phase and were more likely to have had an evacuable mass lesion on CT brain scan and undergo craniotomy. Of the 6 surviving patients, none had significant thoracoabdominal injuries. Four of the survivors had Glasgow Outcome Score (COS) of 4 or 5. Time to hospital, mechanism of injury and pre-hospital haemodynamic parameters had no significant effect on Survival. Of the 57 patients who were GCS 3 at the scene of the accident, post-basic resuscitation and on admission, none survived. Conclusion: Pre-hospital GCS scores, prior to the effects of intubation, sedation and paralysis should be given more attention when assessing prognosis in patients who are GCS 3 on admission. Trauma patients with GCS 3 persisting from the scene with bilaterally fixed dilated pupils have no appreciable chance of Survival. Further interventions such as ICU admission and surgery may not be warranted. Physicians may need to consider stopping treatment and discussing organ donation. (C) 2008 Elsevier Ltd. All rights reserved.	[Chaudhuri, Krishanu; Malham, Gregory M.; Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Malham, Gregory M.; Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3004, Australia	Rosenfeld, JV (corresponding author), Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia.	j.rosenfeld@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011				Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Cheung PSY, 2007, INJURY, V38, P76, DOI 10.1016/j.injury.2006.08.059; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; GOETTING MG, 1991, ANN EMERG MED, V20, P55, DOI 10.1016/S0196-0644(05)81119-9; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; He DM, 2007, J ORAL MAXIL SURG, V65, P713, DOI 10.1016/j.joms.2006.09.006; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; RITTER AM, 2002, NEUROSURGERY, V51, P848; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Sousa J, 2002, NEUROL INDIA, V50, P430; Stein SC, 2004, J TRAUMA, V56, P457, DOI 10.1097/01.TA.0000112354.87333.F3; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON D, 2000, DRUG DELIV TECHNOL, V2, P34; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4	25	18	18	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2009	40	1					28	32		10.1016/j.injury.2008.09.004			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	407TA	WOS:000263386000004	19070839				2021-06-18	
J	Czarnik, T; Gawda, R; Kolodziej, W; Latka, D; Sznajd-Weron, K; Weron, R				Czarnik, Tomasz; Gawda, Ryszard; Kolodziej, Waldemar; Latka, Dariusz; Sznajd-Weron, Katarzyna; Weron, Rafal			Associations between intracranial pressure, intraocular pressure and mean arterial pressure in patients with traumatic and non-traumatic brain injuries	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Intracranial pressure; Intraocular pressure; Mean arterial pressure; Ocular tonometry; Correlation; Brain injury	CEREBRAL VASOMOTOR REACTIVITY; NONINVASIVE MEASUREMENT; PERFUSION-PRESSURE; CODMAN MICROSENSOR; SUCCINYLCHOLINE	Introduction: Anatomical proximity of the eye and the intracranial space is a fact but the existence of physiological and pathophysiological relationships between them is elusive. The objective of this study was to explore anatomical and pathophysiological interactions between the eye and the intracranial space and to assess clinical Utility Of intraocular pressure measurement in estimation of intracranial pressure in patients with brain injuries and to discover how haemodynamic instability could influence these interactions. Controversy surrounds the recent literature concerning this problem and the Consensus has not been achieved. Materials and methods: We evaluated the correlation between intracranial pressure and intraocular pressure, intracranial pressure and mean arterial pressure, intraccular pressure and mean arterial pressure in 40 patients with brain injuries initially comatose, admitted to our hospital. All patients required the intracranial pressure monitoring on clinical grounds. Simultaneous recordings of intracranial pressure, intraocular pressure and mean arterial pressure were performed. Results: We calculated both the linear correlation coefficient and the Spearman rank-order correlation coefficient for all three relations, We found significant correlation between intraocular pressure and mean arterial pressure in 63%, of the tested population. When the power of the test was increased, by considering only patients with 11 or more observations, this ratio increased to 76%. However, the correlation between intraocular pressure and intracranial pressure, as well as, between intracranial pressure and mean arterial pressure was not significant. Conclusions: There is no anatomical and pathophysiological basis for the statement that intraocular pressure can be used as an indirect estimator of intracranial pressure. (C) 2008 Elsevier Ltd. All rights reserved.	[Czarnik, Tomasz; Gawda, Ryszard] St Francis Reg Med Ctr, Dept Anaesthesia & Crit Care, PL-45418 Opole, Poland; [Kolodziej, Waldemar; Latka, Dariusz] St Francis Reg Med Ctr, Dept Neurosurg, PL-45418 Opole, Poland; [Sznajd-Weron, Katarzyna] Univ Wroclaw, Inst Theoret Phys, Complex Syst & Nonlinear Dynam Div, PL-50204 Wroclaw, Poland; [Weron, Rafal] Wroclaw Univ Technol, Inst Math & Comp Sci, Hugo Steinhaus Ctr Stochast Methods, PL-50372 Wroclaw, Poland	Czarnik, T (corresponding author), St Francis Reg Med Ctr, Dept Anaesthesia & Crit Care, Aleja Witosa 26, PL-45418 Opole, Poland.	antocz@mp.pl	Czarnik, Tomasz/W-5602-2019; Weron, Rafal/D-8778-2013; Kolodziej, Waldemar/M-6369-2019; Latka, Dariusz/X-2332-2018; Gawda, Ryszard/K-2941-2017	Czarnik, Tomasz/0000-0002-6734-978X; Kolodziej, Waldemar/0000-0001-6381-152X; Latka, Dariusz/0000-0003-3958-2477; Gawda, Ryszard/0000-0001-6060-0751; Weron, Rafal/0000-0003-1619-5239; Sznajd-Weron, Katarzyna/0000-0002-1851-8508			Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BESSMAN ES, 2004, EMERGENCY MED COMPRE, P132; Carter K, 1999, J GLAUCOMA, V8, P204; Casati A, 1999, J CLIN ANESTH, V11, P216, DOI 10.1016/S0952-8180(99)00029-X; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czarnik T, 2007, J TRAUMA, V62, P207, DOI 10.1097/01.ta.0000219128.29515.d5; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Firsching R, 1998, LANCET, V351, P523, DOI 10.1016/S0140-6736(05)78717-1; Hayreh SS, 1998, LANCET, V351, P524, DOI 10.1016/S0140-6736(05)78719-5; Hirlinger W K, 1986, Anasth Intensivther Notfallmed, V21, P324, DOI 10.1055/s-2007-1002491; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; *JOINT VENT BRAIN, 2007, GUID MAN SEV TRAUM B; KELLY RE, 1993, ANESTHESIOLOGY, V79, P948, DOI 10.1097/00000542-199311000-00012; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LAMB K, 1992, BRIT J ANAESTH, V69, P143, DOI 10.1093/bja/69.2.143; Lane PL, 2000, CAN J SURG, V43, P442; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; LAYON AJ, 2004, TXB NEUROINTENSIVE C, P709; LEHMAN RAW, 1972, J NEUROSURG, V36, P60, DOI 10.3171/jns.1972.36.1.0060; Lirng JF, 2003, AM J NEURORADIOL, V24, P700; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Mickey R.M., 2004, APPL STAT ANAL VARIA; Moeini HA, 2006, EUR J ANAESTH, V23, P739, DOI 10.1017/S0265021506000536; Motschmann M, 2001, Strabismus, V9, P13, DOI 10.1076/stra.9.1.13.711; Nagdeve NG, 2006, J PEDIAT OPHTH STRAB, V43, P219, DOI 10.3928/01913913-20060701-03; Ng HP, 2000, BRIT J ANAESTH, V85, P785, DOI 10.1093/bja/85.5.785; Querfurth HW, 2004, NEUROCRIT CARE, V1, P183, DOI 10.1385/NCC:1:2:183; Ravi R, 2003, CURR ANAESTH CRIT CA, V14, P229, DOI DOI 10.1016/J.CACC.2003.09.003; Reitsamer HA, 2003, INVEST OPHTH VIS SCI, V44, P3967, DOI 10.1167/iovs.03-0088; Reitsamer HA, 2002, INVEST OPHTH VIS SCI, V43, P3728; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Ross N., 2005, CURR ANAESTH CRIT CA, V16, P255; Salman MS, 1997, LANCET, V350, P1367, DOI 10.1016/S0140-6736(05)65138-0; Sheeran P, 2000, LANCET, V355, P899, DOI 10.1016/S0140-6736(99)02768-3; Shimbles S, 2005, ACTA NEUROCHIR SUPPL, V95, P197; Signorini DF, 1998, BRIT J NEUROSURG, V12, P223; STOVER JF, 2005, EUR J TRAUMA, V31, P308; TEBA L, 1993, CRIT CARE MED, V21, P867, DOI 10.1097/00003246-199306000-00014	40	18	19	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2009	40	1					33	39		10.1016/j.injury.2008.10.010			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	407TA	WOS:000263386000005	19135194				2021-06-18	
J	DeFina, P; Fellus, J; Polito, MZ; Thompson, JWG; Moser, RS; DeLuca, J				DeFina, Philip; Fellus, Jonathan; Polito, Mary Zemyan; Thompson, James W. G.; Moser, Rosemarie Scolaro; DeLuca, John			THE NEW NEUROSCIENCE FRONTIER: PROMOTING NEUROPLASTICITY AND BRAIN REPAIR IN TRAUMATIC BRAIN INJURY	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuroplasticity; Neuromarkers; Neuromodulation	TRANSCRANIAL MAGNETIC STIMULATION; PLASTICITY	Increased awareness of traumatic brain injury (TBI) in the military, a persistent call for evidence-based treatment, and recent government funding have revealed new research opportunities in neuroscience. This paper describes a relatively new frontier for research: that of the facilitation or enhancement of neuroplasticity and brain repair in TBI using novel treatment protocols. Such protocols, algorithmically introduced, may be tailored to the individual through the matching of neuromarkers with specific interventions. Examples of neuromarkers and interventions employed for the purpose of neuromodulation are reported. Problems with lack of controlled studies and inferring causation in correlational research are noted. Healthy skepticism and open-minded creativity are needed so that we can think in unorthodox ways, create partnerships, harness available knowledge and expertise, and ultimately develop effective treatments.	[DeFina, Philip; Polito, Mary Zemyan; Thompson, James W. G.] IBRF, Edison, NJ 08837 USA; [Fellus, Jonathan] Kessler Inst Rehabil, W Orange, NJ USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Lawrenceville, NJ USA; [DeLuca, John] Kessler Fdn Res Ctr, W Orange, NJ USA	Thompson, JWG (corresponding author), IBRF, 100 Menlo Pk,Suite 412, Edison, NJ 08837 USA.	JThompson@IBRFinc.org					Bacskai BJ, 2002, J CEREBR BLOOD F MET, V22, P1035, DOI 10.1097/00004647-200209000-00001; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; COLE M, 1979, MAKING MIND PERSONAL; COOPER E, 2008, RIGHT MEDIAN N UNPUB; *DEP DEF, 2009, NEW ER RESP FUND HIG; DINGFELDER SF, 2009, MONITOR PSYCHOL  MAR, P40; Gevensleben H, 2009, J CHILD PSYCHOL PSYC, V50, P780, DOI 10.1111/j.1469-7610.2008.02033.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOODMAN A, 2008, NEUROLOGY TODAY; Gordon E, 2007, PERS MED, V4, P201, DOI 10.2217/17410541.4.2.201; HALTER JA, 1995, J NEUROPHYSIOL, V73, P867; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hermens DF, 2005, PEDIATR NEUROL, V32, P248, DOI 10.1016/j.pediatrneurol.2004.11.009; Hess G, 1996, J NEUROPHYSIOL, V75, P1765; HYER R, 2006, MEDSCAPE MED NE 0327; Ilgin N, 1998, Q J NUCL MED, V42, P179; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KUBE C, 2009, SUICIDES CONTINUE AL; Liepert J, 2005, ACT NEUR S, V93, P71; Liepert J, 2003, SUPPL CLIN NEUROPHYS, V56, P368; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pascrell WJ, 2009, CLIN NEUROPSYCHOL, V23, P1281, DOI 10.1080/13854040902939319; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; *ROYAL SOC, 2005, PERS MED HOP REAL; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; *ST JOS REG MED CT, 2008, INT C TRAUM BRAIN IN; Tinius T. P., 2000, J NEUROTHERAPY, V4, P27, DOI [10.1300/J184v04n02_05, DOI 10.1300/J184V04N02_05]; Toni N, 1999, NATURE, V402, P421; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Zielinski K, 2006, ACTA NEUROBIOL EXP, V66, P75	36	18	20	1	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	8					1391	1399		10.1080/13854040903058978			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	524KF	WOS:000272141500009	19882477				2021-06-18	
J	Ellis, C; Peach, RK				Ellis, Charles; Peach, Richard K.			Sentence planning following traumatic brain injury	NEUROREHABILITATION			English	Article						Language; cognition; confusion; pauses; Rancho Levels; verbal initiation	DISCOURSE ABILITIES; ADULTS; DEFICITS; CHILDREN; MEMORY	Background: Current descriptions of the language problems following traumatic brain injury (TBI) generally emphasize evaluating discourse production and explaining the observed outcomes in terms of disruptions to executive processes. The notion of sentence production impairments at the sentence level has generally been ignored. To respond to this issue, we examined patterns of intrasentential pausing and sentence planning during sentences produced by normal and TBI speakers. Methods: Seven individuals with TBI functioning at Rancho Level V-VI and seven age-matched controls participated in this pilot experiment. Group performances were compared for pause time and verbal initiation time during the production of sentences varying in syntactic complexity under two conditions (reading and repetition). Results: Significant group differences were observed in pausing during both conditions. Pausing patterns of the participants with TBI were strongly correlated with the syntactic complexity of sentences. No significant group differences were observed on verbal initiation time of repeated sentences, although increased initiation times were present among the TBI participants. Conclusions: These findings of this pilot project suggest that the deficits in language production following TBI may include specific impairments to sentence planning. This evidence suggests that the language profile of TBI may be one of both microlinguistic and macrolinguistic impairments.	[Ellis, Charles] Med Univ S Carolina, Coll Hlth Profess, Dept Rehabil Sci, Charleston, SC 29425 USA; [Peach, Richard K.] Rush Univ, Med Ctr, Chicago, IL 60612 USA	Ellis, C (corresponding author), Med Univ S Carolina, Coll Hlth Profess, Dept Rehabil Sci, 151-B Rutledge Ave,POB 250965, Charleston, SC 29425 USA.	ellisc@musc.edu					Brown-Schmidt S, 2006, J MEM LANG, V54, P592, DOI 10.1016/j.jml.2005.12.008; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Caplan D., 1987, NEUROLINGUISTICS LIN; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho C. A., 2007, BRAIN INJURY MED, P895; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COELHO CA, 1994, DISCOURSE ANAL APPL; Copland DA, 2000, J MED SPEECH-LANG PA, V8, P1; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Ferreira F, 2002, J MEM LANG, V46, P57, DOI 10.1006/jmla.2001.2797; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; FORD M, 1978, COGNITION, V6, P35, DOI 10.1016/0010-0277(78)90008-2; GARRETT MF, 1982, NORMALITY PATHOLOGY; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goldman-Eisler F., 1968, PSYCHOLINGUISTICS EX; HAGEN C, 1984, LANGUAGE DISORDERS A; HAGEN C, 1979, ANN CONV AM SPEECH L; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Holmes V. M., 1988, LANG COGNITIVE PROC, V3, P323; HOLMES VM, 1984, LANG SPEECH, V27, P115, DOI 10.1177/002383098402700202; Hough MS, 2003, APHASIOLOGY, V17, P183, DOI 10.1080/02687030244000608; Kertesz A., 1982, W APHASIA BATTERY; Kircher TTJ, 2004, NEUROIMAGE, V21, P84, DOI 10.1016/j.neuroimage.2003.09.041; KIRSNER K, 2002, P 9 INT SPEECH SCI T; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; LEVELT WJM, 1983, COGNITION, V14, P41, DOI 10.1016/0010-0277(83)90026-4; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, COMMUNICATION DISORD; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Peach R. K., 1990, ANN CONV AM SPEECH L; Peach R. K., 1986, ANN CONV AM SPEECH L; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; *SIL INT, SPEECH TOOLS 2 0 SPE; Smith M, 1999, COGNITION, V73, P205, DOI 10.1016/S0010-0277(99)00053-0; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	44	18	18	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	3					255	266		10.3233/NRE-2009-0476			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	452ZR	WOS:000266580200008	19458433				2021-06-18	
J	Guerreiro, DF; Navarro, R; Silva, M; Carvalho, M; Gois, C				Guerreiro, D. F.; Navarro, R.; Silva, M.; Carvalho, M.; Gois, C.			Psychosis secondary to traumatic brain injury	BRAIN INJURY			English	Article						Head injury; neurobehavioural; neuropsychiatric; psychiatry; psychopharmacology; traumatic brain injury	HEAD TRAUMA; FOLLOW-UP; DISORDERS	Background: Traumatic brain injury (TBI) can result in serious and disabling neuropsychiatric disorders. Method: The authors report a case of a 51-year old male, admitted to the psychiatric ward for acute psychosis and suicidal ideation, probably associated with TBI. After a temporal head trauma he initiated auditory/verbal hallucinations and subsequently developed paranoid delusions. The electroencephalography showed slow bilateral temporal activity and the neuropsychological testing showed several impairments. The patient improved with olanzapine at a dosage of 20 mg daily. Results: This case shows the difficulty of differential diagnosis between schizophrenia and psychotic disorder due to traumatic brain injury. Conclusions: The authors conducted a revision of literature about the diagnosis, epidemiology, clinical aspects, laboratory and structural investigations and the treatment of this condition. Based on this revision work, the authors sketch some recommendations about the work-up that should be done when faced with this diagnostic hypothesis.	[Guerreiro, D. F.; Navarro, R.; Silva, M.; Carvalho, M.; Gois, C.] Hosp Santa Maria, Dept Psychiat, P-1649035 Lisbon, Portugal	Guerreiro, DF (corresponding author), Hosp Santa Maria, Dept Psychiat, Ave Prof Egas Moniz, P-1649035 Lisbon, Portugal.	dfguerreiro@gmail.com	de Carvalho, Mamede/I-6295-2019	de Carvalho, Mamede/0000-0001-7556-0158; Guerreiro, Diogo/0000-0003-3701-9509; Gois, Carlos/0000-0003-4346-4844; Silva, Manuela/0000-0003-1275-0338			ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BURG JS, 1996, J CLIN PSYCHOL MED S, V3, P245; DAVISON K, 1983, PSYCHIAT DEV, V1, P1; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; HILLBOM E, 1960, Acta Psychiatr Scand Suppl, V35, P1; KOUFEN H, 1987, EUR ARCH PSY CLIN N, V237, P2, DOI 10.1007/BF00385660; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; REICHENBERG A, 2008, SCHIZOPHRENIA B; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Stewart B, 2005, J NEUROPSYCH CLIN N, V17, P243, DOI 10.1176/appi.neuropsych.17.2.243; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; Violon A, 1988, Acta Neurochir Suppl (Wien), V44, P67; WILL RG, 1988, BRIT J PSYCHIAT, V152, P410, DOI 10.1192/bjp.152.3.410	19	18	20	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	4					358	361	PII 909310751	10.1080/02699050902800918			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000011	19274520				2021-06-18	
J	Kirk, D; Rainey, T; Vail, A; Childs, C				Kirk, Danielle; Rainey, Timothy; Vail, Andy; Childs, Charmaine			Infra-red thermometry: the reliability of tympanic and temporal artery readings for predicting brain temperature after severe traumatic brain injury	CRITICAL CARE			English	Article							CEREBRAL-BLOOD-FLOW; CARE; HYPERTHERMIA; SCORE	Introduction Temperature measurement is important during routine neurocritical care especially as differences between brain and systemic temperatures have been observed. The purpose of the study was to determine if infra-red temporal artery thermometry provides a better estimate of brain temperature than tympanic membrane temperature for patients with severe traumatic brain injury. Methods Brain parenchyma, tympanic membrane and temporal artery temperatures were recorded every 15-30 min for five hours during the first seven days after admission. Results Twenty patients aged 17-76 years were recruited. Brain and tympanic membrane temperature differences ranged from -0.8 degrees C to 2.5 degrees C (mean 0.9 degrees C). Brain and temporal artery temperature differences ranged from-0.7 degrees C to 1.5 degrees C (mean 0.3 degrees C). Tympanic membrane temperature differed from brain temperature by an average of 0.58 degrees C more than temporal artery temperature measurements (95% CI 0.31 degrees C to 0.85 degrees C, P < 0.0001). Conclusions At temperatures within the normal to febrile range, temporal artery temperature is closer to brain temperature than is tympanic membrane temperature.	[Kirk, Danielle; Rainey, Timothy; Childs, Charmaine] Univ Manchester, Salford Royal Fdn Trust, Brain Injury Res Grp, Sch Translat Med, Salford M6 8HD, Lancs, England; [Vail, Andy] Univ Manchester, Biostat Grp, Salford Royal Fdn Trust, Salford M6 8HD, Lancs, England	Childs, C (corresponding author), Univ Manchester, Salford Royal Fdn Trust, Brain Injury Res Grp, Sch Translat Med, Stott Lane, Salford M6 8HD, Lancs, England.	charmaine.childs@manchester.ac.uk	Childs, Charmaine/G-9928-2012	Vail, Andy/0000-0001-8274-2726	Salford Royal Foundation Trust	The authors would like to thank all the staff of the intensive care unit of the Salford Royal Foundation Trust for their support during the study.	Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGERSEN TK, 1993, ACTA PHYSIOL SCAND, V147, P195, DOI 10.1111/j.1748-1716.1993.tb09489.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; BROGAN P, 1993, LANCET, V342, P1364, DOI 10.1016/0140-6736(93)92275-X; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Childs C, 1999, ARCH DIS CHILD, V80, P262, DOI 10.1136/adc.80.3.262; Childs C, 2008, BRIT J NEUROSURG, V22, P486, DOI 10.1080/02688690802245541; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Craig JV, 2002, LANCET, V360, P603, DOI 10.1016/S0140-6736(02)09783-0; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; DUCHARME M, 1994, 6 INT C ENV ERG ERG, V2530, P146; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HOOKER EA, 1993, SOUTHERN MED J, V86, P855, DOI 10.1097/00007611-199308000-00001; Johnston NJ, 2006, RESUSCITATION, V70, P254, DOI 10.1016/j.resuscitation.2006.02.010; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; POMPEI F, 2004, P SOC PHOTO-OPT INS, V5404, P61; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Suleman MI, 2002, ANESTH ANALG, V95, P67, DOI 10.1097/00000539-200207000-00012	26	18	19	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	3							R81	10.1186/cc7898			8	Critical Care Medicine	General & Internal Medicine	487XN	WOS:000269311700020	19473522	DOAJ Gold, Green Published			2021-06-18	
J	Salim, A; Hannon, M; Brown, C; Hadjizacharia, P; Backhus, L; Teixeira, PGR; Chan, LS; Ford, H				Salim, Ali; Hannon, Matthew; Brown, Carlos; Hadjizacharia, Pantelis; Backhus, Leah; Teixeira, Pedro G. R.; Chan, Linda S.; Ford, Henri			Intracranial Pressure Monitoring in Severe Isolated Pediatric Blunt Head Trauma	AMERICAN SURGEON			English	Article; Proceedings Paper	18th Annual Meeting of the Southern California Chapter of the American-College-of-Surgeons	JAN 19-21, 2007	Santa Barbara, CA	Amer Coll Surg, So Calif Chapter			BRAIN-INJURY; MANAGEMENT; CHILDREN	Very little research regarding standard treatments for pediatric traumatic brain injury (PTBI) exists. The objective of this study was to examine the use of intracranial pressure (ICP) monitoring devices in PTBI and to determine if its use was associated with any outcome benefit. Data were collected from the Trauma Registry over an 11-year period (1996-2006) on all blunt trauma pediatric patients (age < 14 years) with an initial Glasgow Coma Scale score <= 8. Data collected included: demographics, admission Glasgow Coma Scale score, mechanism of injury, Injury Severity Score, Abbreviated Injury Score, and use of an ICP monitor. Outcome measures included: mortality, complications, discharge location, and capacity. Thirty-three (25%) of 129 blunt PTBI patients had ICP monitors placed. Patients with monitors were more severely injured overall (Injury Severity Score: 25 vs 18, P = 0.001) and had more severe head injury (81% head Abbreviated Injury Score > 3 vs 55%, P = 0.01) than patients without monitors. However, there was no difference in mortality (28% vs 35%, P = 0.52), discharge location (P = 0.10), and discharge capacity (P = 0.84). After multivariable analysis to adjust for the differences between the two study groups, the use of ICP monitor provided no survival benefit (adjusted odds ratio: 1.1; 95% confidence interval [CI]: 0.3-4.1; adjusted P value = 0.85). The use of ICP monitor was, however, independently associated with a higher risk of developing extracranial complications (adjusted odds ratio: 4.3; 95% Cl: 1.2-16.4; adjusted P value = 0.025). In conclusion, the use of ICP monitors in pediatric patients with severe isolated head injury provided no survival benefit and was associated with an increased risk of complications.	[Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hannon, Matthew; Hadjizacharia, Pantelis; Backhus, Leah; Teixeira, Pedro G. R.; Chan, Linda S.] Los Angeles Cty Univ So Calif, Med Ctr, Los Angeles, CA USA; [Brown, Carlos] Brackenridge Hosp, Div Trauma, Austin, TX USA; [Ford, Henri] Childrens Hosp Los Angeles, Dept Surg, Los Angeles, CA 90027 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Teixeira, Pedro/H-2239-2011	Teixeira, Pedro/0000-0002-7258-7977; Hannon, Matthew/0000-0002-1631-232X			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037	13	18	18	0	3	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	NOV	2008	74	11					1088	1093					6	Surgery	Surgery	373WX	WOS:000261005300010	19062667				2021-06-18	
J	Wertheimer, JC; Hanks, RA; Hasenau, DL				Wertheimer, Jeffrey C.; Hanks, Robin A.; Hasenau, Deborah L.			Comparing Functional Status and Community Integration in Severe Penetrating and Motor Vehicle-Related Brain Injuries	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries, penetrating; Health status; Rehabilitation; Wounds, gunshot	CIVILIAN GUNSHOT WOUNDS; GLASGOW-COMA-SCALE; OUTCOME PREDICTION; MODEL SYSTEMS; HEAD-INJURY; MANAGEMENT; PROGNOSIS; POPULATION	Objective: To examine the functional status of persons surviving a severe penetrating traumatic brain injury (TBI) resulting from a gunshot wound who require inpatient rehabilitation. Design: Data were collected prospectively at 4 different time periods: rehabilitation admission and discharge and year I and year 2 postinjury. Setting: Rehabilitation hospital within a Traumatic Brain Injury Model System. Participants: Forty-five persons with severe penetrating brain injury and 45 persons involved in a motor vehicle crash (MVC). Interventions: Not applicable. Main Outcome Measures: Disability Rating Scale (DRS), FIM instrument, and Community Integration Questionnaire (CIQ). Results: Results indicated functional improvements for both the penetrating and motor vehicle severe TBI groups on the DRS and the FIM from rehabilitation admission to discharge. Follow-up data at I and 2 years postinjury revealed continued improvements on the DRS and FIM measures for both groups, with the greatest improvement in recovery during the first year. In addition, improved community reintegration emerged between I and 2 years postinjury for both groups, as measured by the CIQ. There was a small significant difference on the outcome measures between the 2 groups in the course of their recovery. Conclusions: Persons who survive severe penetrating brain injuries and who require inpatient rehabilitation may show continuing improvement in functioning over time. For persons receiving inpatient rehabilitation services, initial improvement is most likely to occur during the hospital stay and continue postinjury, with the largest improvement in the first year after injury. Community reintegration can also be expected over time. One can expect similar outcomes for individuals who sustain a severe penetrating brain injury and a severe brain injury ensuing from an MVC.	[Wertheimer, Jeffrey C.] Brooks Rehabil Ctr, Dept Behav Med, Jacksonville, FL 32216 USA; [Wertheimer, Jeffrey C.; Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Wertheimer, Jeffrey C.; Hanks, Robin A.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA; [Hasenau, Deborah L.] William Beaumont Hosp, Dept Urol Res, Royal Oak, MI 48072 USA	Wertheimer, JC (corresponding author), Brooks Rehabil Ctr, Dept Behav Med, 3901 Univ Blvd S, Jacksonville, FL 32216 USA.	jeffrey.wertheimer@brookshealth.org			National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Ansari SA, 1998, BRIT J NEUROSURG, V12, P340; Aryan HE, 2005, BRAIN INJURY, V19, P505, DOI 10.1080/02699050400005143; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Carey ME, 2000, NEUROSURG QUART, V10, P1; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; Kim TW, 2007, J TRAUMA, V62, P1446, DOI 10.1097/01.ta.0000222909.31666.db; Kuhne CA, 2007, UNFALLCHIRURG, V110, P341, DOI 10.1007/s00113-007-1244-4; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; LINDGREN BR, 1993, PEDIATR PULM, V16, P336, DOI 10.1002/ppul.1950160603; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Minino AM, 2006, NATL VITAL STAT REP, V54, P1; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; TEASDALE G, 1974, LANCET, V2, P81; Tsuei Yuang-Seng, 2005, J Chin Med Assoc, V68, P126, DOI 10.1016/S1726-4901(09)70233-3; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370	32	18	18	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2008	89	10					1983	1990		10.1016/j.apmr.2008.04.010			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	366LY	WOS:000260484200019	18929027				2021-06-18	
J	Aoyama, N; Lee, SM; Moro, N; Hovda, DA; Sutton, RL				Aoyama, Naoki; Lee, Stefan M.; Moro, Nobuhiro; Hovda, David A.; Sutton, Richard L.			Duration of ATP reduction affects extent of CA1 cell death in rat models of fluid percussion injury combined with secondary ischemia	BRAIN RESEARCH			English	Article						adenosine triphosphate; cell death; hippocampus; rat; secondary ischemia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; ENERGY PHOSPHATE-METABOLISM; PERMEABILITY TRANSITION; GLUCOSE-UTILIZATION; HEAD-INJURY; MITOCHONDRIAL DYSFUNCTION; HEMORRHAGIC HYPOTENSION; FOREBRAIN ISCHEMIA; PROGNOSTIC VALUE	Secondary ischemia (SI) following traumatic brain injury (TBI) increases damage to the brain in both animals and humans. The current study determined if SI after TBI alters the extent or duration of reduced energy production within the first 24 h post-injury and hippocampal cell loss at one week post-injury. Adult male rats were subjected to sham injury, lateral (LFPI) or central fluid percussion injury (CFPI) only, or to combined LFPI or CFPI with SI. The SI was 8 min of bilateral forebrain ischemia combined with hemorrhagic hypotension, applied at 1 h following FPI. After LFPI alone adenosine triphosphate (ATP) levels within the ipsilateral CA1 were reduced at 2 h (p < 0.05) and subsequently recovered. After LFPI+SI the ATP reductions in CA1 ipsilateral to FP persisted for 24 h (p<0.01). ATP levels in the contralateral CA1 were not affected by LFPI alone or LFPI+SI. After CFPI alone CA1 ATP levels were depressed bilaterally only at 2 h (p<0.05). Similar to the LFPI paradigm, CFPI+SI reduced ATP levels for 24 h (p < 0.01), with bilateral ATP reductions seen after CFPI+SI. Cell counts in the CA1 region at 7 days post-injury revealed no significant neuronal cell loss after LFPI or CFPI alone. Significant neuronal cell loss was present only within the ipsilateral (p<0.001) CA1 after LFPI+SI, but cell loss was bilateral (p<0.001) after CFPI+SI. Thus, SI prolongs ATP reductions induced by LFPI and CFPI within the CA1 region and this SI-induced energy reduction appears to adversely affect regional neuronal viability. (C) 2008 Elsevier B.V. All rights reserved.	[Aoyama, Naoki; Lee, Stefan M.; Moro, Nobuhiro; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Aoyama, Naoki; Lee, Stefan M.; Moro, Nobuhiro; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Sutton, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 10833 Le Conte Ave,Box 957039, Los Angeles, CA 90095 USA.	rsutton@mednet.ucla.edu			UCLA Brain Injury Research Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS27544, NS37363]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037363, R01NS027544] Funding Source: NIH RePORTER	We wish to thank Monica D. Wong and Sima S. Ghavim for their superb technical assistance. This research was supported by the UCLA Brain Injury Research Center and NIH grants NS27544 and NS37363. The authors have no conflicts of interest to declare.	ARAI H, 1986, METAB BRAIN DIS, V1, P263, DOI 10.1007/BF00999356; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Bedell EA, 2004, J NEUROTRAUM, V21, P1212; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis KL, 1998, J NEUROTRAUM, V15, P615, DOI 10.1089/neu.1998.15.615; DeWitt D S, 1995, New Horiz, V3, P376; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Geeraerts T, 2008, INTENS CARE MED, V34, P551, DOI 10.1007/s00134-007-0863-0; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Hata R, 2000, J CEREBR BLOOD F MET, V20, P937, DOI 10.1097/00004647-200006000-00006; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Katayama Y, 1997, BRAIN RES, V746, P126, DOI 10.1016/S0006-8993(96)01218-8; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOGURE K, 1978, BRAIN RES, V154, P273, DOI 10.1016/0006-8993(78)90700-X; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MIES G, 1990, J CEREBR BLOOD F MET, V10, P638, DOI 10.1038/jcbfm.1990.116; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MIES G, 1999, J CEREB BLOOD FLOW M, V11, P753; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	64	18	20	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 16	2008	1230						310	319		10.1016/j.brainres.2008.07.006			10	Neurosciences	Neurosciences & Neurology	359BW	WOS:000259962200033	18657524	Green Accepted			2021-06-18	
J	Dalgic, A; Okay, HO; Gezici, AR; Daglioglu, E; Akdag, R; Ergungor, MF				Dalgic, A.; Okay, H. O.; Gezici, A. R.; Daglioglu, E.; Akdag, R.; Ergungor, M. F.			An effective and less invasive treatment of post-traumatic cerebrospinal fluid fistula: Closed lumbar drainage system	MINIMALLY INVASIVE NEUROSURGERY			English	Article						trauma; cerebrospinal fluid fistula; closed lumbar drainage system; meningitis; treatment	SKULL BASE; SUBARACHNOID CATHETER; MANAGEMENT; PREVENTION; RHINORRHEA; FRACTURES; DIAGNOSIS; LEAK	Cerebrospinal fluid (CSF) leakage may develop when a defect is formed in dural layers by traumatic or iatrogenic processes. Traumatic CSF leakage was encountered in 2 % of head injuries. CSF leakage is an associated feature of 12-30 % of skull base fractures. Numerous treatment modalities are proposed for the management of CSF leaks. A closed lumbar drainage system (CLDS) is recommended as an alternative method to surgery for preventing complications related to leakage. In the present study, we report the clinical details of 46 patients who suffered from rhinorrhea/otorrhea (R/O), three of whom were urgently operated due to other causes like subdural hematoma and tension pneumocephalus. Leakage spontaneously ceased in 26 (60.4%) patients whereas CLDS insertion was found to be necessary in 17 patients. A prophylactic antibiotic regimen was started in the CLDS group and these patients were followed with daily CSF cell counts. Fifteen patients (88.2 %) were successfully treated by CLDS, however meningitis developed in 2 patients (11.7 %). Severe complications like meningitis could be avoided by a simple daily microbiological analysis of CSF.	[Dalgic, A.; Okay, H. O.; Daglioglu, E.; Akdag, R.; Ergungor, M. F.] Ankara Numune Training & Res Hosp, Neurosurg Clin 2, Ankara, Turkey; [Gezici, A. R.] Abant Izzet Baysal Univ, Izzet Baysal Fac Med, Dept Neurosurg, Bolu, Turkey	Dalgic, A (corresponding author), Yenicag Mah Serdar Sok 77-3, TR-06170 Ankara, Turkey.	dalgica@superonline.com		DALGIC, Ali/0000-0003-1000-2811			Acikbas SC, 2002, ACTA NEUROCHIR, V144, P475, DOI 10.1007/s007010200068; Basauri LT, 1999, CRIT REV NEUROSURG, V9, P21, DOI 10.1007/s003290050104; FRIEDMAN AJ, 2000, NEUROSURG FOCUS, V9, P1; Kerr JT, 2005, OTOLARYNG CLIN N AM, V38, P597, DOI 10.1016/j.otc.2005.03.011; Lee TJ, 2004, LARYNGOSCOPE, V114, P1475, DOI 10.1097/00005537-200408000-00029; PIEK J, 2000, NEUROSURG FOCUS, V9, P1; Puzzilli F, 1998, NEUROSURG REV, V21, P237, DOI 10.1007/BF01105778; Raine C, 2005, OTOLARYNG CLIN N AM, V38, P583, DOI 10.1016/j.otc.2005.03.009; Selesnick SH, 2004, OTOL NEUROTOL, V25, P580, DOI 10.1097/00129492-200407000-00027; SHAPIRO SA, 1992, NEUROSURGERY, V30, P241, DOI 10.1227/00006123-199202000-00015; SHEKAR L, 1991, NEUROSURGERY, V28, P882; SNOW RB, 1991, NEUROSURGERY, V28, P880, DOI 10.1227/00006123-199106000-00016; Trotter MI, 2002, ANN ROY COLL SURG, V84, P64; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666; VOURCH G, 1963, BRIT J ANAESTH, V35, P118, DOI 10.1093/bja/35.2.118; Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3	16	18	22	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0946-7211			MINIM INVAS NEUROSUR	Minim. Invasive Neurosurg.	JUN	2008	51	3					154	157		10.1055/s-2008-1042437			4	Clinical Neurology; Neuroimaging; Surgery	Neurosciences & Neurology; Surgery	318UD	WOS:000257117400005	18521786				2021-06-18	
J	Saltapidas, H; Ponsford, J				Saltapidas, Helen; Ponsford, Jennie			The influence of cultural background on experiences and beliefs about traumatic brain injury and their association with outcome	BRAIN IMPAIRMENT			English	Article						traumatic brain injury; culture; beliefs; emotions; outcome	VOCATIONAL-REHABILITATION CLIENTS; MINOR HEAD-INJURY; PERCEPTION QUESTIONNAIRE; SYMPTOM EXPECTATION; PREDICTORS; ILLNESS; SAMPLE; AGE; PARTICIPATION; ACCULTURATION	The aim of the study was to compare beliefs and experiences of traumatic brain injury (TBI) in patients with TBI from the dominant English-speaking culture in Australia versus those from minority culturally and linguistically diverse (CALD) backgrounds and examine the relative influence of beliefs, acculturation, along with demographic and injury-related variables on outcome. The primary measures included the Illness Perception Questionnaire-Revised (IPQ-R), and the Craig Handicap Assessment and Reporting Technique (CHART). Participants were 70 individuals with mild to severe TBI, including 38 of English-speaking background (ESB) and 32 from CALD backgrounds. Although similar to the ESB participants in education, preinjury employment status, injury severity and experience of TBI, the CALD participants differed significantly from ESB participants on acculturation variables. CALD participants also experienced greater negative emotions and were less likely to have internal locus of control causal beliefs than ESB participants. Regression analyses indicated that describing one's value system as other than Australian, poorer understanding of TBI and greater negative emotional reactions, along with fewer years of education were associated with poorer outcomes on the CHART. Thus, in treating patients from different cultural backgrounds it is important for health professionals to understand beliefs about and responses to TBI, as they could potentially impact on coping, emotional adjustment and long-term outcome.	[Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Saltapidas, Helen] Monash Univ, Clayton, Vic 3800, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Epworth Rehabil Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au					Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Banja JD, 1996, DISABIL REHABIL, V18, P279, DOI 10.3109/09638289609165881; BATES MS, 1994, SOC SCI MED, V39, P629, DOI 10.1016/0277-9536(94)90020-5; Berry J.W., 1980, ACCULTURATION THEORY, P9, DOI DOI 10.1525/AE.1981.8.4.02A00200; Berry JW, 1997, APPL PSYCHOL-INT REV, V46, P5, DOI 10.1080/026999497378467; Blackmer J, 1999, BRAIN INJURY, V13, P627; BROWN PJ, 1994, HUMAN BEHAV INTRO ME, P84; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Chu C, 1998, Ethn Health, V3, P125; Daniel A. E., 1983, POWER PRIVILEGE PRES; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; FITZGERALD MH, 1992, J REHABIL        APR, P38; Gallaher CK, 2001, REHABIL PSYCHOL, V46, P312, DOI 10.1037/0090-5550.46.3.312; Harley D. A., 1996, J APPL REHABILITATIO, V27, P59; HASLAM C, 1995, NEUROPSYCHOLOGY, V9, P599, DOI 10.1037/0894-4105.9.4.599; Heijmans M, 1998, J BEHAV MED, V21, P485, DOI 10.1023/A:1018788427100; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Man DWK, 2001, BRAIN INJURY, V15, P961, DOI 10.1080/02699050110065664; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE AD, 1991, NEUROPSYCHOL REHABIL, V1, P185, DOI DOI 10.1080/09602019108520164; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Paniagua F. A., 1998, ASSESSING TREATING C; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; Sastry J, 1998, SOC PSYCHOL QUART, V61, P101, DOI 10.2307/2787064; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Skeel RL, 2003, REHABIL PSYCHOL, V48, P145, DOI 10.1037/0090-5550.48.3.145; Smart JF, 1997, J REHABIL, V63, P9; Snead SL, 2002, BRAIN INJURY, V16, P947, DOI 10.1080/02699050210147211; Stanhope V, 2002, PSYCHIATR REHABIL J, V25, P273, DOI 10.1037/h0095015; Sue D. W., 1990, COUNSELING CULTURALL; SUINN RM, 1992, EDUC PSYCHOL MEAS, V52, P1041, DOI 10.1177/0013164492052004028; Tabachnick BG, 2013, USING MULTIVARIATE S; Victor M., 2001, ADAMS VICTORS PRINCI; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Wallace CA, 2000, BRAIN INJURY, V14, P549; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	49	18	18	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	MAY	2008	9	1					1	13		10.1375/brim.9.1.1			13	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	325OP	WOS:000257598500001					2021-06-18	
J	Huttemann, M; Lee, I; Kreipke, CW; Petrov, T				Huttemann, M.; Lee, I.; Kreipke, C. W.; Petrov, T.			Suppression of the inducible form of nitric oxide synthase prior to traumatic brain injury improves cytochrome c oxidase activity and normalizes cellular energy levels	NEUROSCIENCE			English	Article						trauma; mitochondria; iNOS; cytochrome c oxidase; nitric oxide; ATP	EXPRESSION; ENDOTHELIN-1; CALCIUM; OXYGEN; PHOSPHORYLATION; HYPOPERFUSION; RESPIRATION; DYSFUNCTION; METABOLISM; MODEL	We have previously shown that the observed immediate increase in nitric oxide (NO) plays a significant role in the control of the cerebral microcirculation following traumatic brain injury (TBI). However, a second consequence of increased NO production after TBI may be impaired mitochondrial function, due to the fact that NO is a well-known inhibitor of cytochrome c oxidase (CcO). CcO is a key enzyme of the mitochondrial oxidative phosphorylation (OxPhos) machinery, which creates cellular energy in the form of ATP. NO competes with oxygen at the heme a(3)-Cu-B reaction center of CcO. We thus hypothesized that TBI triggers inhibition of CcO, which would in turn lead to a decreased energy production by OxPhos at a time of an elevated energy demand for tissue remodeling. Here we show that TBI as induced by an acceleration weight drop model of diffuse brain injury in rats leads to CcO inhibition and dramatically decreased ATP levels in brain cortex. CcO inhibition can be partially restored by application of iNOS antisense oligonucleotides prior to TBI, which leads to a normalization of ATP levels similar to the controls. We propose that a lack of energy after TBI caused by inhibition of CcO is an important aspect of trauma pathology. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Huttemann, M.; Lee, I.] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; [Kreipke, C. W.; Petrov, T.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Huttemann, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, 540 E Canfield Ave, Detroit, MI 48201 USA.	mhuttema@med.wayne.edu; tpetrov@med.wayne.edu		Huttemann, Maik/0000-0001-6310-7081	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		Assreuy Jamil, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P165; Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cuzzocrea S, 2006, CURR PHARM DESIGN, V12, P3551, DOI 10.2174/138161206778343082; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; GORREN AC, 2006, BIOCHIM BIOPHYS ACTA, V1770, P432; Hopper RK, 2006, BIOCHEMISTRY-US, V45, P2524, DOI 10.1021/bi052475e; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Kadenbach B, 2004, BBA-BIOENERGETICS, V1655, P400, DOI 10.1016/j.bbabio.2003.06.005; Lee I, 2005, J BIOL CHEM, V280, P6094, DOI 10.1074/jbc.M411335200; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Napiwotzki J, 1997, BIOL CHEM, V378, P1013, DOI 10.1515/bchm.1997.378.9.1013; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Rafols D, 2004, NEUROSCI LETT, V362, P154, DOI 10.1016/j.neulet.2004.03.021; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stepp DW, 2006, CLIN EXP PHARMACOL P, V33, P407, DOI 10.1111/j.1440-1681.2006.04381.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	30	18	19	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 2	2008	151	1					148	154		10.1016/j.neuroscience.2007.09.029			7	Neurosciences	Neurosciences & Neurology	254SR	WOS:000252608800015	18037245				2021-06-18	
J	Dolce, G; Riganello, F; Quintieri, M; Candelieri, A; Conforti, D				Dolce, G.; Riganello, F.; Quintieri, M.; Candelieri, A.; Conforti, D.			Personal Interaction in the Vegetative State A Data-Mining Study	JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						vegetative state; autonomic response; mother's voice; heart rate variability; machine-learning procedures	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; OWN NAME; MOTHERS VOICE; CONSCIOUSNESS; RECOGNITION; RESPONSES; HRV	Background and purpose: Brain processing at varying levels of functional complexity and emotional reactions to relatives are anecdotally reported by the caregivers of patients in a vegetative state. In this study, computer-assisted machine-learning procedures were applied to identify heart rate variability changes or galvanic skin responses to a relative's presence. Methods: The skin conductance (galvanic skin response) and heart beats were continuously recorded in 12 patients in a vegetative state, at rest (baseline) and while approached by a relative (usually the mother; test condition) or by a nonfamiliar person (control condition). The cardiotachogram (the series of consecutive intervals between heart beats) was analyzed in the time and frequency domains by computing the parametric and nonparametric frequency spectra. A machine-learning algorithm was applied to sort out the significant spectral parameter(s). For all patients, each condition (baseline, test, control) was characterized by the values of its spectral parameters, and the association between spectral parameters values and experimental condition was tested (WEKA machine-learning software). Results and comments: A galvanic skin response was obtained in two patients. The machine-learning procedure independently selected the nu_LF spectral parameter and attributed each nu_LF measure to any of the three experimental conditions. 69.4% of attributions were correct (baseline: 58%; test condition: 75%; control. 75%). In seven patients, attribution changed when the subject was approached by the test person; specifically, sequential shifts from baseline to test condition ("the Mom effect") to control condition were identified in four patients (30.0%); the change from test to control was attributed correctly in seven patients (58%). The observation of heart rate changes tentatively attributable to emotional reaction in a vegetative state suggest residual rudimentary personal interaction, consistent with functioning limbic and paralimbic systems after massive brain damage. Machine-learning proved applicable to sort significant measure(s) out of large samples and to control for statistical alpha inflation.	[Dolce, G.; Riganello, F.; Quintieri, M.] S Anna Inst, Intens Care Unit, I-88900 Crotone, Italy	Dolce, G (corresponding author), S Anna Inst, Intens Care Unit, Via Siris 11, I-88900 Crotone, Italy.	giulianodolce@libero.it	Riganello, Francesco/AAC-3976-2020; Riganello, Francesco/N-2615-2014; Conforti, Domenico/D-2734-2011; /AAI-7627-2021	Riganello, Francesco/0000-0003-0678-9252; Riganello, Francesco/0000-0003-0678-9252; Conforti, Domenico/0000-0002-4816-4333; /0000-0003-1431-576X	S. Anna Institute, Crotone; Italian Ministry of University and ResearchMinistry of Education, Universities and Research (MIUR)	This research has been supported by the S. Anna Institute, Crotone, and the University of Calabria under the special project "MIMERICA," funded by the Italian Ministry of University and Research ( 2004-2007). Thanks are due to Professors Leon Sazbon, MD ( University of Tel Aviv, Israel) and Walter G. Sannita, MD ( University of Genova, Genova, Italy, and State University of New York, Stony Brook, NY, USA) for continuing support and valuable advice.	ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; APPELHANS BM, 2007, BIOL PSYCHOL, V12; Appelhans BM, 2006, REV GEN PSYCHOL, V10, P229, DOI 10.1037/1089-2680.10.3.229; Barbieri R, 2002, AM J PHYSIOL-REG I, V283, pR1210, DOI 10.1152/ajpregu.00127.2002; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Chambers AS, 2002, PSYCHOPHYSIOLOGY, V39, P861, DOI 10.1111/1469-8986.3960861; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Critchley HD, 2005, NEUROIMAGE, V24, P751, DOI 10.1016/j.neuroimage.2004.10.013; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; DOLCE G, 1973, ELECTROEN CLIN NEURO, V34, P647, DOI 10.1016/0013-4694(73)90010-2; Dolce G., 2002; Eibe F., 2004, MACHINE LEARNING WEK; Frazier TW, 2004, PSYCHOPHYSIOLOGY, V41, P75, DOI 10.1046/j.1469-8986.2003.00131.x; Han J., 2006, DATA MINING CONCEPTS; Hildebrandt H, 1998, EUR ARCH PSY CLIN N, V248, P46, DOI 10.1007/s004060050016; HOLTE RC, 1993, MACH LEARN, V11, P63, DOI 10.1023/A:1022631118932; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 2002, VEGETATIVE STATE; JOHN ER, 2008, LANCET IN PRESS; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King ML, 1997, BRAIN INJURY, V11, P445; Kotchoubey B, 2006, J NEUROL, V253, P1374, DOI 10.1007/s00415-006-0221-0; LAFRANCHI PA, 2003, AM J PHYSIOL-REG I, V283, pR815; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Lehrer PM, 2003, PSYCHOSOM MED, V65, P796, DOI 10.1097/01.PSY.0000089200.81962.19; Levy DA, 2003, PSYCHOPHYSIOLOGY, V40, P291, DOI 10.1111/1469-8986.00031; Luecken LJ, 2005, PSYCHOSOM MED, V67, P514, DOI 10.1097/01.psy.0000160466.10397.18; Machado C, 2007, CLIN EEG NEUROSCI, V38, P124, DOI 10.1177/155005940703800306; Malpas SC, 2002, AM J PHYSIOL-HEART C, V282, pH6; Mashin VA, 2000, HUMAN PHYSL, V26, P420, DOI [10.1007/BF02760270, DOI 10.1007/BF02760270]; MEHLER J, 1978, PERCEPTION, V7, P491, DOI 10.1068/p070491; Mizuno K, 2004, ACTA PAEDIATR, V93, P1640, DOI 10.1080/08035250410023115; Nikki S.R., 2004, PSYCHOL MUSIC, V32, P371; Niskanen JP, 2004, COMPUT METH PROG BIO, V76, P73, DOI 10.1016/j.cmpb.2004.03.004; OWEN A, 2006, SCIENCE, V8, P402; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Purhonen M, 2005, COGNITIVE BRAIN RES, V24, P627, DOI 10.1016/j.cogbrainres.2005.03.012; Qiu J, 2007, LANCET NEUROL, V6, P946, DOI 10.1016/S1474-4422(07)70255-7; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; REITERO N, 2002, AM J PHYSIOL-REG I, V283, pR1327; RIGANELLO F, 2008, J PSYCHOPHY IN PRESS; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schwarz G, 1987, Funct Neurol, V2, P149; SOSNOWSKI T, 1991, PSYCHOPHYSIOLOGY, V28, P665, DOI 10.1111/j.1469-8986.1991.tb01011.x; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; Sztajzel J, 2004, SWISS MED WKLY, V134, P514; Urakawa K, 2005, TOHOKU J EXP MED, V206, P213, DOI 10.1620/tjem.206.213; van Bemmel J.H., 1997, HDB MED INFORM; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Witten IH, 2005, DATA MINING PRACTICA; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011	56	18	18	0	3	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	MERKELSTR 3, D-37085 GOTTINGEN, GERMANY	0269-8803	2151-2124		J PSYCHOPHYSIOL	J. Psychophysiol.		2008	22	3					150	156		10.1027/0269-8803.22.3.150			7	Psychology, Biological; Neurosciences	Psychology; Neurosciences & Neurology	468TB	WOS:000267843400005					2021-06-18	
J	MacLennan, DL; MacLennan, DC				MacLennan, Don L.; MacLennan, Diane C.			Assessing readiness for post-secondary education after traumatic brain injury using a simulated college experience	NEUROREHABILITATION			English	Article						Traumatic brain injury; rehabilitation; vocational rehabilitation; career counseling; higher education; treatment outcomes	STUDENTS	Approximately 1.4 million Americans sustain a traumatic brain injury (TBI) each year with approximately two-thirds of these injuries affecting people between the ages of 15 and 24 years. Consequently, many adults with brain injury sustain their injuries during a time when they are making important decisions regarding future vocational activities, including return to school. Cognitive impairments resulting from TBI present as a significant barrier to return to school and it is difficult to predict those persons who will succeed in school after a TBI and those who will not. This article presents a college simulation experience currently used in a rehabilitation setting. It involves lectures and examinations that test an individual's ability to learn new material. Lecture content focuses on the nature and effects of brain injury and on study skills. In addition, compensatory strategies commonly used in university settings (note takers, extended time for exams, taped lectures) may be used to assess potential benefit of these services. The simulated college experience provides a realistic appraisal of the individual's ability to learn information in a lecture-oriented class setting. It also provides information regarding the benefits of specific study skills and compensatory strategies. Case studies of three individuals with severe TBI are presented.	[MacLennan, Don L.] Minneapolis VA Med Ctr, Polytrauma Transit Rehabil Program, Minneapolis, MN 55417 USA; [MacLennan, Diane C.] Minneapolis VA Med Ctr, Polytrauma Network Site, Minneapolis, MN 55417 USA	MacLennan, DL (corresponding author), Minneapolis VA Med Ctr, Polytrauma Transit Rehabil Program, 1Veterans Dr 4K TBI, Minneapolis, MN 55417 USA.	donald.maclennan@va.gov					BRIEL LW, 2007, BRAIN INJURY PROFESS, P24; BURSUCK WD, 1989, EXCEPT CHILDREN, V56, P236, DOI 10.1177/001440298905600309; *CDC, TRAUM BRAIN INJ; COOK J, 1991, J HEAD TRAUMA REHAB, V6, P64; Damasio A. R., 1994, DESCARTESERROR; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; ELLIS D, 2007, BECOMING MASTER STUD; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; KAY T, 1990, TRAUMATIC BRAIN INJU, P21; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Savage R. C., 1994, ED DIMENSIONS ACQUIR, P3; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg McKay Moore, 2000, Seminars in Speech and Language, V21, P135; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; Ward NS, 2006, NEUROREHAB NEURAL RE, V20, P398, DOI 10.1177/1545968306286322; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P35	22	18	18	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2008	23	6					521	528					8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200008	19127005				2021-06-18	
J	McMahon, CG; Kenny, R; Bennett, K; Kirkman, E				McMahon, C. Geraldine; Kenny, RoseAnne; Bennett, Kathleen; Kirkman, Emrys			Modification of acute cardiovascular homeostatic responses to hemorrhage following mild to moderate traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injuries; trauma; hemorrhagic shock; homeostasis	AFFERENT NERVE-STIMULATION; SEVERE HEAD-INJURY; BRADYCARDIA; MODELS; BAROREFLEX; SHOCK; RESUSCITATION; ISCHEMIA; SURVIVAL; MORPHINE	Objectives. The cardiovascular homeostatic responses to hemorrhage are coordinated in the central nervous system. Coincidental brain injury, which is present in 64% of trauma patients, could impair these responses. Our objective was to test the hypothesis that mild to moderate traumatic brain injury alters cardiovascular reflex responses to acute hemorrhage. Design: Experimental prospective, randomized study in terminally anesthetized rats. Setting: Experimental laboratory of university. Subjects. Twenty-four male Wistar rats weighing 240-260 g. Interventions., Brain injury was induced using the lateral fluid percussion injury model in anesthetized rats. The fluid percussion device delivered an applied cortical pressure of 1.2 atm and 1.8 atm, producing mild and moderate injury, respectively. Control animals underwent identical surgical procedures but with no applied cortical pressure. Hemorrhage was carried out 10 mins after brain injury, at a rate of 2% of blood volume per minute until 40% blood volume was withdrawn. Measurements and Main Results: The effects of acute traumatic brain injury on the biphasic heart rate and mean arterial blood pressure response to hemorrhage were studied. Traumatic brain injury attenuated the normal bradycardic response and delayed the hypotensive response to hemorrhage. This effect was graded according to the severity of brain injury. In mild injury, the depressor phase was delayed, but the biphasic pattern of heart rate response was maintained. No mortality was observed in this group. Following moderate brain injury, marked attenuation of the biphasic heart rate and mean arterial blood pressure response (p < .001 and p = .0007) was observed. Fifty percent of this group died within 90 mins of hemorrhage completion. Significant differences in the biphasic response were observed between survivors and nonsurvivors (p = .013, p = .001, respectively). In nonsurvivors, the biphasic response was abolished. Conclusions: Acute mild and moderate traumatic brain injury disrupts cardiovascular homeostatic responses to extracranial hemorrhage; this disruption is graded according to the severity of traumatic brain injury. Severe disruption is associated with an increase in early mortality.	[McMahon, C. Geraldine; Kenny, RoseAnne] Trinity Coll Dublin, Inst Neurosci, Dublin, Ireland; [Bennett, Kathleen] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland	McMahon, CG (corresponding author), Trinity Coll Dublin, Inst Neurosci, Dublin, Ireland.	gmcmahon@stjames.le	McMahon, C Geraldine/M-8684-2019	McMahon, C Geraldine/0000-0002-9870-3104			ANDERSON ID, 1990, BRIT J SURG, V77, P1338, DOI 10.1002/bjs.1800771207; ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; ANDERSON ID, 1990, J TRAUMA, V30, P974, DOI 10.1097/00005373-199008000-00005; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Barcroft H, 1944, LANCET, V1, P489; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; DRONEN SC, 1993, AM J EMERG MED, V11, P331, DOI 10.1016/0735-6757(93)90162-5; ELEBUTE EA, 1978, CLIN SCI MOL MED, V54, P431, DOI 10.1042/cs0540431; EVANS RG, 1992, CLIN EXP PHARMACOL P, V19, P657, DOI 10.1111/j.1440-1681.1992.tb00518.x; FEUERSTEIN G, 1986, CIRC SHOCK, V19, P293; Foex BA, 2004, CRIT CARE MED, V32, P740, DOI 10.1097/01.CCM.0000117320.69308.E5; GERMARELLI TA, 1983, ACTA NEUROCHIR SUPP, V32, P1; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Kongo M, 1999, EXP PHYSIOL, V84, P47, DOI 10.1111/j.1469-445X.1999.tb00071.x; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LITTLE RA, 1989, Q J EXP PHYSIOL CMS, V74, P825, DOI 10.1113/expphysiol.1989.sp003352; LITTLE RA, 1984, Q J EXP PHYSIOL CMS, V69, P753, DOI 10.1113/expphysiol.1984.sp002866; Ludbrook J, 1996, AM J PHYSIOL-HEART C, V270, pH1538; Mackway-Jones K, 1999, J TRAUMA, V47, P481, DOI 10.1097/00005373-199909000-00008; Majde JA, 2003, J TRAUMA, V54, pS100, DOI 10.1097/01.TA.0000064503.24416.F4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; OBERG B, 1970, Acta Physiologica Scandinavica, V80, P395, DOI 10.1111/j.1748-1716.1970.tb04803.x; Ohnishi M, 1997, BRAIN RES, V763, P39, DOI 10.1016/S0006-8993(97)00379-X; OVERMAN RR, 1947, AM J PHYSIOL, V148, P289; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Ryan KL, 2006, RESUSCITATION, V70, P133, DOI 10.1016/j.resuscitation.2005.11.008; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SECHER NH, 1985, CLIN PHYSIOL, V5, P315, DOI 10.1111/j.1475-097X.1985.tb00752.x; SECHER NH, 1984, CIRC SHOCK, V14, P267; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TIMMS RJ, 1981, PFLUG ARCH EUR J PHY, V391, P49, DOI 10.1007/BF00580694; TOMLINSON BE, 1970, J CLIN PATH S4, V23, P178; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; TURNBULL AV, 1993, J PHYSIOL-LONDON, V468, P529, DOI 10.1113/jphysiol.1993.sp019786; *US NAT I HLTH, 1996, GUID CAR US LAB AN; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	43	18	20	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					216	224		10.1097/01.CCM.0000295425.41831.85			9	Critical Care Medicine	General & Internal Medicine	291YA	WOS:000255232100031	18090349				2021-06-18	
J	Mossberg, KA; Orlander, EE; Norcross, JL				Mossberg, Kurt A.; Orlander, Evelyne E.; Norcross, Julie L.			Cardiorespiratory capacity after weight-supported treadmill training in patients with traumatic brain injury	PHYSICAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Physical-Therapy-Association	JUN 22, 2006	Orlando, FL	Amer Phys Therapy Assoc			SPINAL-CORD-INJURY; OXYGEN-CONSUMPTION; WALKING; REHABILITATION; STROKE; GAIT; INDIVIDUALS; RELIABILITY; RESPONSES; EXERCISE	Background and Purpose The primary goal of body-weight-supported treadmill training (BWSTI) has been to improve the temporal and spatial characteristics of unsupported overground walking; however, little attention has been given to cardiorespiratory adaptations. The purpose of this case report is to describe the effects of BWSTT on cardiorespiratory fitness in 2 patients recovering from severe traumatic brain injury (TBI). Case Description Both patients were involved in motor vehicle accidents and were studied after admission to a postacute residential treatment program. Patient 1 was a 25-year-old man (initial Glasgow Coma Scale [GCS] score=3) who began observation and treatment 3 months after the injury. Patient 2 was an 18-year-old woman (initial GCS=6) who began observation and treatment 1 year after the injury. Outcomes Each patient received 2 to 3 sessions of BWSTT per week. Aerobic capacity was measured while they ambulated on a treadmill without body-weight support before and after BWSTT. Both patients' submaximal and peak responses improved. For patient 1 and patient 2, total treadmill work performed increased 134% and 53%, respectively. Peak oxygen uptake increased 24% for patient 1 and 16% for patient 2. Estimated cardiac stroke volume (oxygen pulse) increased 32% and 26% for patient 1 and patient 2, respectively. Discussion The observations made on these 2 patients suggest that BWSTT has the potential to favorably change cardiorespiratory capacity after TBI.	[Mossberg, Kurt A.; Orlander, Evelyne E.; Norcross, Julie L.] Univ Texas Galveston, Med Branch, Sch Allied Hlth Sci, Dept Phys Therapy, Galveston, TX 77555 USA	Mossberg, KA (corresponding author), Univ Texas Galveston, Med Branch, Sch Allied Hlth Sci, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046570] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046570] Funding Source: NIH RePORTER		Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Carvalho DCL, 2005, SPINAL CORD, V43, P400, DOI 10.1038/sj.sc.3101730; Danielsson A, 2000, ARCH PHYS MED REHAB, V81, P953, DOI 10.1053/apmr.2000.6283; David D, 2006, ARCH PHYS MED REHAB, V87, P482, DOI 10.1016/j.apmr.2005.11.034; Ditor DS, 2005, SPINAL CORD, V43, P664, DOI 10.1038/sj.sc.3101785; Ditor DS, 2005, J APPL PHYSIOL, V98, P1519, DOI 10.1152/japplphysiol.01004.2004; Dobkin BH, 2003, NEUROREHAB NEURAL RE, V17, P153, DOI 10.1177/0888439003255508; FINCH L, 1986, Physiotherapy Canada, V38, P36; Gazzani F, 1999, SPINAL CORD, V37, P336, DOI 10.1038/sj.sc.3100821; GOLIGHTLY LK, 1985, DRUG INTEL CLIN PHAR, V19, P302; Hesse Stefan, 2003, Adv Neurol, V92, P423; Israel JF, 2006, PHYS THER, V86, P1466, DOI 10.2522/ptj.20050266; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; MOSSBERG KA, 2003, BRAIN INJURY, V17, P266; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Nash MS, 2004, J SPINAL CORD MED, V27, P78, DOI 10.1080/10790268.2004.11753734; Noonan V, 2000, PHYS THER REHABIL J, V80, P782, DOI 10.1093/ptj/80.8.782; Pollock ML, 1990, EXERCISE HLTH DIS; Seif-Naraghi AH, 1999, J HEAD TRAUMA REHAB, V14, P146, DOI 10.1097/00001199-199904000-00005; Silver KHC, 2000, NEUROREHAB NEURAL RE, V14, P65, DOI 10.1177/154596830001400108; SVEDENHAG J, 1984, ACTA PHYSIOL SCAND, V120, P77, DOI 10.1111/j.1748-1716.1984.tb07376.x; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Whaley MH, 2006, ACSMS GUIDELINES EXE; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922; Wolman RL, 1994, CLIN REHABIL, V8, P253	30	18	18	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	JAN	2008	88	1					77	87		10.2522/ptj.20070022			11	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	253RP	WOS:000252535600011	17940106	Bronze			2021-06-18	
J	Sturzenegger, M; Radanov, BP; Winter, P; Simko, M; Farra, AD; Di Stefano, G				Sturzenegger, M.; Radanov, B. P.; Winter, P.; Simko, M.; Farra, A. D.; Di Stefano, G.			MRI-based brain volumetry in chronic whiplash patients: no evidence for traumatic brain injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cognitive complaints; mild traumatic brain injury; VBR; whiplash injury	DIFFUSE AXONAL INJURY; COMMON WHIPLASH; FOLLOW-UP; ATTENTION; DISORDERS; MEMORY	Introduction Cognitive complaints, such as poor concentration and memory deficits, are frequent after whiplash injury and play an important role in disability. The origin of these complaints is discussed controversially. Some authors postulate brain lesions as a consequence of whiplash injuries. Potential diffuse axonal injury (DAI) with subsequent atrophy of the brain and ventricular expansion is of particular interest as focal brain lesions have not been documented so far in whiplash injury. Objective To investigate whether traumatic brain injury can be identified using a magnetic resonance (MR)-based quantitative analysis of normalized ventricle-brain ratios (VBR) in chronic whiplash patients with subjective cognitive impairment that cannot be objectively confirmed by neuropsychological testing. Materials and methods MR examination was performed in 21 patients with whiplash injury and symptom persistence for 9 months on average and in 18 matched healthy controls. Conventional MR imaging (MRI) was used to assess the volumes of grey and white matter and of ventricles. The normalized VBR was calculated. Results The values of normalized VBR did not differ in whiplash patients when compared with that in healthy controls (F = 0.216, P = 0.645). Conclusions This study does not support loss of brain tissue following whiplash injury as measured by VBR. On this basis, traumatic brain injury with subsequent DAI does not seem to be the underlying mechanism for persistent concentration and memory deficits that are subjectively reported but not objectively verifiable as neuropsychological deficits.	[Sturzenegger, M.] Univ Hosp Bern, Dept Neurol, CH-3010 Bern, Switzerland; [Radanov, B. P.] Pain Management & Ctr Medico Legal Affairs, Klin Wilhelm Schulthess, CH-8008 Zurich, Switzerland; [Winter, P.] Univ Bern, Dept Psychol, Bern, Switzerland; [Simko, M.] Lindenhof Spital, Dept Radiol, Bern, Switzerland; [Farra, A. D.] Clin Epilepsy & Neurorehabil, Klin Bethesda, Tschugg, Switzerland; [Di Stefano, G.] Univ Hosp Bern, Dept Psychiat, CH-3010 Bern, Switzerland	Radanov, BP (corresponding author), Pain Management & Ctr Medico Legal Affairs, Klin Wilhelm Schulthess, Lengghalda 2, CH-8008 Zurich, Switzerland.	bogdan.radanov@kws.ch					Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Blokhorst M, 2002, J CLIN EXP NEUROPSYC, V24, P471, DOI 10.1076/jcen.24.4.471.1042; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borchgrevink G, 1997, INJURY, V28, P331, DOI 10.1016/S0020-1383(97)00027-2; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HODGE JR, 1971, PSYCHOSOMATICS, V12, P245; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Regard M, 1981, THESIS U VICTORIA CA; Robinson JP, 2007, ARCH PHYS MED REHAB, V88, P774, DOI 10.1016/j.apmr.2007.03.004; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; SPITZER WO, 1995, SPINE, V20, pS1; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Zimmermann P., 1993, DEV ASSESSMENT REHAB, P3	24	18	18	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JAN	2008	117	1					49	54		10.1111/j.1600-0404.2007.00939.x			6	Clinical Neurology	Neurosciences & Neurology	240JN	WOS:000251584000007	17949454				2021-06-18	
J	Yao, XL; Liu, J; McCabe, JT				Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.			Ubiquitin and ubiquitin-conjugated protein expression in the rat cerebral cortex and hippocampus following traumatic brain injury (TBI)	BRAIN RESEARCH			English	Article						ubiquitin; free ubiquitin; ubiquitin-conjugated protein; cerebral cortex; hippocampus; protein degradation; Q-PCR; traumatic brain injury	GENE-EXPRESSION; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-PROTEINS; ISCHEMIA; IMMUNOREACTIVITY; NEURONS; FUSION; AGGREGATION; PROTEASOME	Regulation of protein turnover is essential to the survival of eukaryotic cells. This important cellular process is partly regulated by the ubiquitin-proteasome system through posttranslational modification by the conjugation of ubiquitin chains to proteins targeted for degradation by proteasomes. The present study examined ubiquitin mRNA and protein expression in the CNS of rats that sustained traumatic brain injury (TBI). Quantitative real-time polymerase chain reaction results indicated that mRNA levels of ubA52, ubB and ubC in the ipsilateral cerebral cortex were significantly decreased on Day I post-TBI, that UbC mRNA levels also were significantly lower than control on Day 3 post-TBI,but that by Day 7 post-TBI, ubA52, ubB and ubC mRNA levels had all returned to control levels. In the ipsilateral hippocampus, ubA52 mRNA levels were significantly lower on Days 1-7 post-TBI, while ubB and ubC mRNA levels were less only on Day I post-TBI. Western blotting found that free ubiquitin protein levels were significantly reduced in both ipsilateral cerebral cortex and hippocampus on Days 1-7 post-TBI, while there was markedly increased ubiquitin-conjugated protein in ipsilateral cerebral cortex on Day 7 and in hippocampus on Days 3-7 post-TBI. Our study suggests that altered ubiquitin system function in the CNS contributes to the pathological outcomes of TBI. (C) 2007 Elsevier B.V. All rights reserved.	[Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Yao, XL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	XYao@usuhs.mil; JLiu@usuhs.mil; JMcCabe@usuhs.mil					Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; Ceremuga TE, 2003, NEUROSCI RES, V45, P305, DOI 10.1016/S0168-0102(02)00228-6; Ceremuga TE, 2001, ENDOCR RES, V27, P433, DOI 10.1081/ERC-100107867; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V215, P682, DOI 10.1006/bbrc.1995.2518; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groothuis TAM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-21; HAYASHI T, 1994, BBA-GENE STRUCT EXPR, V1218, P232, DOI 10.1016/0167-4781(94)90020-5; HAYASHI T, 1991, MOL CHEM NEUROPATHOL, V15, P75, DOI 10.1007/BF03161057; HAYASHI T, 1993, BRAIN RES, V620, P171, DOI 10.1016/0006-8993(93)90288-X; HAYASHI T, 1992, J NEUROSCI RES, V31, P561, DOI 10.1002/jnr.490310321; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Ide T, 1999, J CEREBR BLOOD F MET, V19, P750, DOI 10.1097/00004647-199907000-00004; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; KANAYAMA H, 1991, CANCER RES, V51, P6677; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Liu C, 2005, NEUROSCIENCE, V134, P69, DOI 10.1016/j.neuroscience.2005.03.036; LUND PK, 1985, J BIOL CHEM, V260, P7609; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Mizukami K, 2002, ACTA NEUROPATHOL, V103, P453, DOI 10.1007/s00401-001-0489-1; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORI H, 1996, RECENT ADV GASTROENT, V1, P249; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Tan ZQ, 2001, MOL BRAIN RES, V91, P179, DOI 10.1016/S0169-328X(01)00117-6; Vannucci SJ, 1998, J CEREBR BLOOD F MET, V18, P376, DOI 10.1097/00004647-199804000-00005; Weih M, 2001, J CEREBR BLOOD F MET, V21, P1090, DOI 10.1097/00004647-200109000-00006; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	36	18	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 28	2007	1182						116	122		10.1016/j.brainres.2007.08.076			7	Neurosciences	Neurosciences & Neurology	242CS	WOS:000251702700012	17936732				2021-06-18	
J	Ozisik, PA; Oruckaptan, H; Geyik, PO; Misirlioglu, M; Sargon, MF; Kilinc, K; Ozgen, T				Ozisik, Pinar Akdemir; Oruckaptan, Hakan; Geyik, Pinar Ozdemir; Misirlioglu, Muge; Sargon, Mustafa F.; Kilinc, Kamer; Ozgen, Tuncalp			Effect of erythropoietin on brain tissue after experimental head trauma in rats	SURGICAL NEUROLOGY			English	Article						brain injury; methylprednisolone; erythropoietin; apoptosis; bcl-2; survivin; electron microscopy; lipid peroxidation	LIPID-PEROXIDATION; TRANSGENIC MICE; INJURY; METHYLPREDNISOLONE; BCL-2; APOPTOSIS; SURVIVIN; EDEMA; BCL-2-DEFICIENT; EXPRESSION	Background: The purpose of this study was to investigate the effect of EPO on LPO, on ultrastructural findings, and on antiapoptotic bcl-2 and survivin gene expressions after TBI. The authors also compared the activity of EPO with that of MPSS. Methods: Wistar rats were divided into 6 groups: sham-operated, control, moderate TBI-alone (300 g/cm), TBI + EPO-treated (1000 IU/kg), TBI + MPSS-treated (30 mg/kg), and TBI + vehicle-treated (0.4 mL albumin solution) groups. Results: Compared with the levels in control and sham-operated animals, LPO was significantly elevated in rats in the trauma-alone group. The administration of EPO and MPSS significantly decreased the LPO levels (P < .05). Trauma also increases the antiapoptotic bcl-2 gene expression significantly at 24 hours postinjury (P < .05), but it has no effect on survivin expression. The EPO and MPSS treatments caused significant elevation in both gene expressions (P < .05). It is also showed that MPSS has more protective effect than EPO on brain ultrastructure, especially on the structure of small- (P < .05) and medium-sized myelinated axons, after TBI. Conclusions: EPO has protective effects after moderate TBI, and this effect seems better than MPSS on antiapoptotic gene expression and LPO. The protection of cerebral subcellular organelles after traumatic injury is more prominent in MPSS-treated animals than EPO-treated animals quantitatively. This experimental study indicates that the benefits of EPO in the management of TBI have promising results and prompts further studies on the difference between EPO and MPSS in histopathological findings at the subcellular level. (C) 2007 Elsevier Inc. All rights reserved.	Hacettepe Univ, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biostat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Anat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, TR-06100 Ankara, Turkey	Ozisik, PA (corresponding author), Hacettepe Univ, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey.	pozisik@hacettepe.edu.tr; oruckaptan@hacettepe.edu.tr; pozdemir@hacettepe.edu.tr; msargon@hacettepe.edu.tr; kkilinc@hacettepe.edu.tr; tozgen@hacettepe.edu.tr		Sargon, Mustafa Fevzi/0000-0001-6360-6008; OZISIK, PINAR/0000-0001-5183-8100			Adida C, 1998, AM J PATHOL, V152, P43; ANDERSON DK, 1994, BRAIN RES, V637, P119, DOI 10.1016/0006-8993(94)91224-6; Aoki Y, 2001, J PHARMACOL EXP THER, V296, P306; BanyMohammed FM, 1996, PEDIATR RES, V40, P381, DOI 10.1203/00006450-199609000-00003; BOURKE RS, 1979, NEURAL TRAUMA, P95; Braughler J M, 1986, Cent Nerv Syst Trauma, V3, P153; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Cheung NS, 2000, J NEUROCHEM, V74, P1613, DOI 10.1046/j.1471-4159.2000.0741613.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; EID T, 2002, CLIN BREAST CANCER, V3, P109, DOI DOI 10.3816/CBC.2002.S.021; FUJIMOTO S, 1984, SURG NEUROL, V22, P449, DOI 10.1016/0090-3019(84)90301-X; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Ildan F, 1995, SURG NEUROL, V44, P573; JELKMANN W, 1992, PHYSIOL REV, V72, P672; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kalinina O, 1997, NUCLEIC ACIDS RES, V25, P1999, DOI 10.1093/nar/25.10.1999; KIRKALI Z, 1995, J UROLOGY, V154, P1939, DOI 10.1016/S0022-5347(01)66830-7; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; KLEINDIENST A, 13 INT S BRAIN ED C; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Koc PK, 1999, RES EXP MED, V199, P21, DOI 10.1007/s004330050129; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsuo Y, 2001, STROKE, V32, P2143, DOI 10.1161/hs0901.94259; MEYER JS, 1971, LANCET, V2, P933; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MUCHMORE SW, 1999, MOL CELL, V6, P213; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003; Ozisik K, 2004, AM J TRANSPLANT, V4, P900, DOI 10.1111/j.1600-6143.2004.00448.x; Paydas S, 2003, ANN ONCOL, V14, P1045, DOI 10.1093/annonc/mdg277; Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Simonati A, 1999, MICROSC RES TECHNIQ, V45, P341, DOI 10.1002/(SICI)1097-0029(19990615)45:6<341::AID-JEMT2>3.0.CO;2-U; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; TRON VA, 1995, AM J PATHOL, V146, P643; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Yamada Y, 2002, NEUROSCIENCE, V114, P165, DOI 10.1016/S0306-4522(02)00210-5	45	18	18	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	NOV	2007	68	5					547	555		10.1016/j.surneu.2007.01.030			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	231QV	WOS:000250965000017	17586022				2021-06-18	
J	Armstead, WM; Vavilala, MS				Armstead, William M.; Vavilala, Monica S.			Adrenomedullin reduces gender-dependent loss of hypotensive cerebrovasodilation after newborn brain injury through activation of ATP-dependent K channels	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						autoregulation; brain injury; cerebral circulation; newborn; signal transduction	CEREBROSPINAL-FLUID; POTASSIUM CHANNELS; UNITED-STATES; CHILDREN; VASODILATION; ARTERIOLES; DILATION; INFANTS; PIGLETS; NO	Cerebrovascular dysregulation during hypotension occurs after fluid percussion brain injury (FPI) in the newborn pig owing to impaired K channel function. This study was designed to ( 1) determine the role of gender and K channel activation in adrenomedullin (ADM) cerebrovasodilation, ( 2) characterize the role of gender in the loss of hypotensive cerebrovasodilation after FPI, and ( 3) determine the role of gender in the ability of exogenous ADM to modulate hypotensive dysregulation after FPI. Lateral FPI ( 2 atm) was induced in newborn male and female newborn pigs ( 1 to 5 days old) equipped with a closed cranial window, n = 6 for each protocol. Adrenomedullin-induced pial artery dilation was significantly greater in female than male piglets and blocked by the KATP channel antagonist glibenclamide, but not by the K-ca channel antagonist iberiotoxin. Cerebrospinal fluid ADM was increased from 3.8 +/- 0.7 to 14.6 +/- 3.0 fmol/ mL after FPI in female but was unchanged in male piglets. Hypotensive pial artery dilation was blunted to a significantly greater degree in male versus female piglets after FPI. Topical pretreatment with a subthreshold vascular concentration of ADM ( 10(-10) mol/ L) before FPI reduced the loss of hypotensive pial artery dilation in both genders, but protection was significantly greater in male versus female piglets. These data show that hypotensive pial artery dilation is impaired after FPI in a gender- dependent manner. By unmasking a genderdependent endogenous protectant, these data suggest novel gender- dependent approaches for clinical intervention in the treatment of perinatal traumatic brain injury.	Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu					Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Armstead WM, 1998, AM J PHYSIOL-HEART C, V274, pH1674; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1999, BRAIN RES, V816, P158, DOI 10.1016/S0006-8993(98)01146-9; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faraci FM, 1998, PHYSIOL REV, V78, P53; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Kanu A, 2006, AM J PHYSIOL-HEART C, V291, pH2409, DOI 10.1152/ajpheart.01368.2005; Lang MG, 1997, STROKE, V28, P181, DOI 10.1161/01.STR.28.1.181; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON MT, 1993, TRENDS CARDIOVAS MED, V3, P54, DOI 10.1016/1050-1738(93)90037-7; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Robertson CL, 2001, J NEUROTRAUM, V18, P861, DOI 10.1089/089771501750451785; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Sakai K, 1998, EUR J PHARMACOL, V359, P151, DOI 10.1016/S0014-2999(98)00641-4; Terata K, 2000, AM J PHYSIOL-HEART C, V279, pH2620; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Willis AP, 1999, AM J PHYSIOL-HEART C, V277, pH299; Willis AP, 2001, AM J PHYSIOL-HEART C, V281, pH2366; Xi Q, 2004, AM J PHYSIOL-HEART C, V286, pH610, DOI 10.1152/ajpheart.00782.2003; Zuckerman SL, 1996, AM J PHYSIOL-HEART C, V271, pH535	31	18	19	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2007	27	10					1702	1709		10.1038/sj.jcbfm.9600473			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	212GV	WOS:000249583200006	17377515	Bronze			2021-06-18	
J	Halabchi, F; Ziaee, V; Lotfian, S				Halabchi, Farzin; Ziaee, Vahid; Lotfian, Sarah			Injury profile in women Shotokan karate championships in Iran (2004-2005)	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						karate; martial arts; athletic injuries; risk factors; safety; sports	MARTIAL ARTS; COMPETITIONS	The aims of this paper were to record injury rates among Iranian women competitive Shotokan karate athletes and propose possible predisposing factors. A prospective recording of the injuries resulting from all matches in 6 consecutive women national Shotokan Karate Championships in all age groups in Iran (season 2004-2005) was performed. Data recorded included demographic characteristics (Age and Weight), athletic background (rank, years of experience, time spent training and previous injuries), type, location and reason for the injury, and the result of the match. Results indicate 186 recorded injuries from a total of 1139 bouts involving 1019 athletes, therefore there were 0.163 injury per bout [C.I. 95%: 0.142-0.184] and 183 injuries per 1000 athletes [C.I. 95%: 159-205]. Injuries were most commonly located in the head and neck (55.4%) followed by the lower limb (21%), upper limb (12.9%) and trunk (10.8%). Punches (48.4%) were associated with more injuries than kicks (33.3%). The injuries consisted of muscle strain and contusion (81, 43.6%), hematoma and epistaxis (49, 26.3%), lacerations and abrasions (28, 15.1%), concussion (13, 7%), tooth avulsion or subluxation (3, 1.6%), joint dislocation (3, 1.6%) and fractures (3, 1.6%). In conclusion, as the majority of injuries are minor, and severe or longstanding injuries are uncommon, it can be argued that shotokan karate is a relatively safe for females, despite its image as a combat sport, where ostensibly the aim appears to injure your opponent. Further research is needed to evaluate the effective strategies to minimize the risk of injuries.	Univ Tehran Med Sci, Sports Med Res Ctr, Tehran, Iran	Ziaee, V (corresponding author), Univ Tehran Med Sci, Sports Med Res Ctr, POB 143950578, Tehran, Iran.	fhalabchi@sina.tums.ac.ir; ziaee@tums.ac.ir	Halabchi, Farzin/A-3191-2019; Ziaee, Vahid/E-2786-2014	Ziaee, Vahid/0000-0003-4648-3573			Arriaza R, 2005, KNEE SURG SPORT TR A, V13, P603, DOI 10.1007/s00167-004-0593-6; ARRIAZA R, 1990, Journal of Sports Traumatology and Related Research, V12, P255; BIRRER RB, 1988, AM J SPORT MED, V16, P408, DOI 10.1177/036354658801600418; BIRRER RB, 1996, AM J SPORTS MED, V24, P72; Buschbacher R M, 1999, Phys Med Rehabil Clin N Am, V10, P35; Critchley GR, 1999, BRIT J SPORT MED, V33, P174, DOI 10.1136/bjsm.33.3.174; Daniels K, 1992, Br J Sports Med, V26, P118; Daniels K, 1990, J SPORT SCI, V8, P95, DOI 10.1080/02640419008732137; Destombe C, 2006, JOINT BONE SPINE, V73, P182, DOI 10.1016/j.jbspin.2005.02.003; Fetto JF, 1994, SPORTS INJURIES MECH, P455; FREDERIC L, 1995, DICT MARTIAL ARTS; Johannsen H V, 1988, Br J Sports Med, V22, P113; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; LAYTON C, 1993, PERCEPT MOTOR SKILL, V76, P1001, DOI 10.2466/pms.1993.76.3.1001; Macan J, 2006, BRIT J SPORT MED, V40, P326, DOI 10.1136/bjsm.2005.022459; McLatchie G, 1981, Br J Sports Med, V15, P84; McLatchie G R, 1977, Br J Sports Med, V11, P78; MCLATCHIE GR, 1976, INJURY, V8, P132, DOI 10.1016/0020-1383(76)90049-8; Muller-Rath R, 2000, SPORTVERLETZ SPORTSC, V14, P20, DOI 10.1055/s-2000-3818; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Ortu M, 2006, BRIT J SPORT MED, V40, P730, DOI 10.1136/bjsm.2006.026500; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Plancher KD, 1996, CLIN SPORT MED, V15, P207; STRICEVIC MV, 1983, AM J SPORT MED, V11, P320, DOI 10.1177/036354658301100507; TENVERGERT EM, 1992, J SPORT MED PHYS FIT, V32, P214; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; Violan MA, 1997, PEDIATR EXERC SCI, V9, P55, DOI 10.1123/pes.9.1.55; Zetaruk MN, 2005, BRIT J SPORT MED, V39, P29, DOI 10.1136/bjsm.2003.010322; Zetaruk MN, 2000, CLIN J SPORT MED, V10, P117, DOI 10.1097/00042752-200004000-00006; Zetaruk MN, 2000, ACCIDENT ANAL PREV, V32, P421, DOI 10.1016/S0001-4575(99)00120-7	30	18	18	1	4	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	OCT	2007	6				2		52	57					6	Sport Sciences	Sport Sciences	215DS	WOS:000249789100010	24198704	DOAJ Gold			2021-06-18	
J	Sussmann, PS; Zumstein, M; Hahn, F; Dora, C				Sussmann, Patrick S.; Zumstein, Matthias; Hahn, Frederik; Dora, Claudio			The risk of vascular injury to the femoral head when using the posterolateral arthroscopy portal: Cadaveric investigation	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						arthroscopy; avascular necrosis; blood supply; complication; hip; portal	HIP ARTHROSCOPY; COMPLICATIONS; ANATOMY	Purpose: The aim was to clarify the relationship between the posterolateral arthroscopy portal to the hip joint and the deep branch of the medial femoral circumflex artery (MFCA) and its terminal divisions. Methods: In 7 fresh fixated human cadavers, the deep femoral arteries were injected with latex. In all specimens, the standard anterior, anterolateral, and posterolateral arthroscopy portals to the central compartment of the hip were established in a standardized procedure as done in our operating room. Subsequently, all specimens underwent surgical dissection to identify the tract of the posterolateral portal, the course of the deep branch of the MFCA, and its terminal divisions. The distance between the portal tract and the deep branch of the MFCA was measured at its shortest point. Results: None of the specimens revealed injury to the deep branch of the MFCA and its terminal divisions; however, I specimen did not reveal filling of the MFCA, and did not allow for accurate measurement. For the remaining 6 specimens, the mean distance of the portal tract to the vessels at the closest point was 10.16 rum (standard deviation, 4.4 mm; range, 5 to 15 mm). In all specimens, the greater trochanter seemed to prevent closer contact between the vessel and the portal tract. Conclusions: As long as the shape of the posterior aspect of the greater trochanter has not been changed by previous surgery, the posterolateral portal to the hip joint can be performed safely with respect to the vital blood supply to the femoral head, because the MFCA is protected by the overhang of the posterior aspect of the greater trochanter, giving a minimum of 3 rum and an average 10 rum of clearance. Clinical Relevance: At the level of the piriformis muscle, the posterolateral portal has a minimum of 3 mm and an average of 10 mm of clearance to the deep branch of the MFCA. As long as the shape of the posterior aspect of the greater trochanter has not been changed, and the skin penetration remains close to this bony margin with direction of the portal toward the joint space, this portal can be performed safely with respect to the vital blood supply to the femoral head.	Univ Zurich, Dept Orthopaed, CH-8008 Zurich, Switzerland; Inselspital Bern, Dept Orthopaed & tRAUMATOL, CH-3010 Bern, Switzerland	Sussmann, PS (corresponding author), Univ Zurich, Dept Orthopaed, Forchstr 340, CH-8008 Zurich, Switzerland.	sussmannp@gmx.net	Zumstein, Matthias/AAV-3268-2020				BYRD JWT, 1995, ARTHROSCOPY, V11, P418, DOI 10.1016/0749-8063(95)90193-0; Byrd JWT, 2000, ARTHROSCOPY, V16, P770, DOI 10.1053/jars.2000.7686; Byrd JWT, 2006, ORTHOPADE, V35, P41, DOI 10.1007/s00132-005-0892-8; Clarke MT, 2003, CLIN ORTHOP RELAT R, P84, DOI 10.1097/01.blo.0000043048.84315.af; Dienst M, 2005, ARTHROSCOPY, V21, P1510, DOI 10.1016/j.arthro.2005.09.014; ERIKSSON E, 1982, ORTHOP CLIN N AM, V13, P293; Funke EL, 1996, ARTHROSCOPY, V12, P156, DOI 10.1016/S0749-8063(96)90004-3; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; Griffin DR, 1999, J BONE JOINT SURG BR, V81B, P604, DOI 10.1302/0301-620X.81B4.9102; Guanche CA, 2006, ARTHROSCOPY, V22, P95, DOI 10.1016/j.arthro.2005.10.018; Kelly BT, 2003, AM J SPORT MED, V31, P1020, DOI 10.1177/03635465030310060701; MCCARTHY JC, 1995, ORTHOPEDICS, V18, P753; SEVITT S, 1965, J Bone Joint Surg Br, V47, P560; Thiel W, 2002, ANN ANAT, V184, P267, DOI 10.1016/S0940-9602(02)80121-2	14	18	20	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063			ARTHROSCOPY	Arthroscopy	OCT	2007	23	10					1112	1115		10.1016/j.arthro.2007.05.014			4	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	225DY	WOS:000250498500013	17916478				2021-06-18	
J	Shah, MK; Carayannopoulos, AG; Burke, DT; Al-Adawi, S				Shah, Mrugeshkumar K.; Carayannopoulos, Alexios G.; Burke, David T.; Al-Adawi, Samir			A comparison of functional outcomes in hypoxia and traumatic brain injury: A pilot study	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	39th Annual Meeting of the Association-of-Academic-Physiatrists	MAR 26-30, 2003	Ft Lauderdale, FL	Assoc Acad Physiatrists		rehabilitation; anoxia; brain injury; traumatic brain injury; functional prognosis	CARDIAC-ARREST SURVIVORS; ANOXIC ENCEPHALOPATHY; NEUROLOGICAL REHABILITATION; INPATIENT REHABILITATION; CEREBRAL HYPOXIA; ADULT SURVIVORS; OLDER-ADULTS; FOLLOW-UP	We present our experience with 30 patients on functional outcomes of patients with anoxic brain injury (ABI, n=15) due to cardiac etiologies from freestanding inpatient rehabilitation hospital. A convenience sample of patient with traumatic brain injury (TBI, n=15) with similar demographic characteristic to ABI was used for comparison on indices of activity of daily living, cognition, mobility as well as other indices of functional prognosis such as hospital length of stay, cost and discharge predisposition. No statistical significant differences were found between the two groups on the presently employed outcome measures. This investigation supports the positive impact of inpatient rehabilitation for individuals with hypoxia of cardiac etiology. Future research comparing outcomes of ABI to TBI with larger, controlled trials is warranted. (C) 2007 Elsevier B.V. All rights reserved.	Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Med, Al Khoud 123, Oman; Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Med, Muscat, Oman	Al-Adawi, S (corresponding author), Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Med, POB 35, Al Khoud 123, Oman.	adawi@squ.edu.om	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			Burke DT, 2005, BRAIN INJURY, V19, P675, DOI 10.1080/02699050400024953; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; Campos JF, 2006, NEUROLOGIA, V21, P318; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goldberg KB, 1997, BRAIN INJURY, V11, P743, DOI 10.1080/026990597123115; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; *I HLTH STUD, 1988, 9 REV CLIN MOD ANN E; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Wilson BA, 1996, BRAIN INJURY, V10, P863, DOI 10.1080/026990596123846; Wilson FC, 2003, NEUROREHABILITATION, V18, P291; 1995, GUIDE UNIFORM DATA S	20	18	18	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	SEP 15	2007	260	1-2					95	99		10.1016/j.jns.2007.04.012			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	208JG	WOS:000249315000015	17537457				2021-06-18	
J	Berg, P; Westerling, R				Berg, Peter; Westerling, Ragnar			A decrease in both mild and severe bicycle-related head injuries in helmet wearing ages - trend analyses in Sweden	HEALTH PROMOTION INTERNATIONAL			English	Article						bicycle helmet; head injuries; head protection; bicycle-related accidents	TRAUMA CENTER; LEGISLATION; CHILDREN; STRATEGIES; EFFICACY; LAWS	Several international studies point at the efficacy of bicycle helmets in reducing head injuries. In Sweden, observational studies show that from 1988 to 1996 helmet use increased in all categories of cyclists. The objectives of this study were to analyse the trends of bicycle-related head injuries based on their main diagnosis and external cause of injury by different age groups. Our study area was the whole population of Sweden from 1987 to 1996. Outcome evaluation was based on data from the Swedish National Hospital Discharge Register concerning all bicycle-related injuries from 1987 to 1996, which presented 49 758 reported in-patient care. The trends in incidence rates (IRs) were studied with regression analyses. The results show that children under 15 years had the highest IRs. For these children, the IR decreased by 46%. The head injuries in children decreased both in collisions with motor vehicles and in other accidents. Similarly, the IR of concussion and skull fracture decreased. For nonhead injuries, there were no significant changes for children. On the other hand, the incidence of both head and other injuries for adults aged 16-50 years increased. Ages above that showed no significant changes. Our conclusions are that the decrease in IR for bicycle-related head injuries refers to children in ages for whom bicycle helmet use during the period increased. This could not be explained by any general decrease in bicycle-related accidents or by any changes in the distribution of injuries after collision with motor vehicles. The increasing helmet use among younger schoolchildren probably contributed to the decrease in head injuries.	Dept Publ Hlth & Caring Sci & Social Med, SE-75185 Uppsala, Sweden	Berg, P (corresponding author), Dept Publ Hlth & Caring Sci & Social Med, Uppsala Sci Pk, SE-75185 Uppsala, Sweden.	peter.berg@pubcare.uu.se					Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Berg P, 2001, Inj Prev, V7, P218, DOI 10.1136/ip.7.3.218; Bostrom L, 2001, J TRAUMA, V50, P900, DOI 10.1097/00005373-200105000-00021; *CENTR ORG TRAFF S, LIIKENNETURVA; Cook A, 2000, BRIT MED J, V321, P1055, DOI 10.1136/bmj.321.7268.1055; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P667, DOI 10.2105/AJPH.83.5.667; Ekman R, 2001, PUBLIC HEALTH, V115, P38, DOI 10.1038/sj.ph.1900713; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; LeBlanc JC, 2002, CAN MED ASSOC J, V166, P592; Lee BHY, 2005, ACCIDENT ANAL PREV, V37, P93, DOI 10.1016/j.aap.2004.07.001; Linn S, 1998, Inj Prev, V4, P122; MACKNIN ML, 1994, ARCH PEDIAT ADOL MED, V148, P255, DOI 10.1001/archpedi.1994.02170030025005; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; MOCK CN, 1995, J TRAUMA, V39, P29, DOI 10.1097/00005373-199507000-00004; NILSSON G, 2003, EVALUATION GOVT 11 P; Nolen S, 2005, HEALTH PROMOT INT, V20, P33, DOI 10.1093/heapro/dah505; Rivara F P, 1999, Inj Prev, V5, P194; Rivara FP, 2000, BRIT MED J, V321, P1035, DOI 10.1136/bmj.321.7268.1035; Robinson DL, 1996, ACCIDENT ANAL PREV, V28, P463, DOI 10.1016/0001-4575(96)00016-4; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; WELANDER G, 2001, J TRAFFIC MED, V29, P20	23	18	18	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0957-4824			HEALTH PROMOT INT	Health Promot. Int.	SEP	2007	22	3					191	197		10.1093/heapro/dam020			7	Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	218IJ	WOS:000250008900003	17728326	Bronze			2021-06-18	
J	Ellis, T; McNames, J; Aboy, M				Ellis, Tim; McNames, James; Aboy, Mateo			Pulse morphology visualization and analysis with applications in cardiovascular pressure signals	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						terms-Arterial blood pressure (ABP); hemodynamics intracranial pressure (ICP); point process; pulse contour analysis; pulse morphology; pulse pressure; traumatic brain injury (TBI)	WAVE-FORM ANALYSIS; CONTINUOUS CARDIAC-OUTPUT; CONTOUR ANALYSIS; ARTERIAL COMPLIANCE; SYSTEMS-ANALYSIS; TRANSMISSION; ALGORITHM; AGE	We present a new analysis and visualization method for studying the functional relationship between the pulse morphology of pressure signals and time or signal metrics such as heart rate, pulse pressure, and means of pressure signals, such as arterial blood pressure and central venous pressure. The pulse morphology is known to contain potentially useful clinical information, but it is difficult to study in the time domain without the aid of a tool such as the method we present here. The primary components of the method are established signal processing techniques, nonparametric regression, and an automatic beat detection algorithm. Some of the insights that can be gained from this are demonstrated through the analysis of intracranial pressure signals acquired from patients with traumatic brain injuries. The analysis indicates the point of transition from low-pressure morphology consisting of three distinct peaks to a high-pressure morphology consisting of a single peak. In addition, we demonstrate how the analysis can reveal distinctions in the relationship between morphology and several signal metrics for different patients.	Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, Portland, OR 97201 USA; Oregon Inst Technol, Elect Engn Technol Dept, Portland, OR 97229 USA; Univ London, London WC1E 7HU, England	Ellis, T (corresponding author), Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, 1900 SW 4th Ave, Portland, OR 97201 USA.	taellis@pdx.edu; mcnames@pdx.edu	Aboy, Mateo/K-4060-2019	Aboy, Mateo/0000-0002-5168-4321			Aboy M, 2005, BLOOD PRESS MONIT, V10, P111, DOI 10.1097/00126097-200506000-00001; Aboy M, 2004, IEEE T BIO-MED ENG, V51, P2198, DOI 10.1109/TBME.2004.834295; Adelson PD, 2003, CRIT CARE MED, V31, pS418, DOI 10.1097/00003246-200306006-00002; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Balestreri L, 2004, HORIZ CANC RES, V2, P1; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Chaney JC, 2002, CRIT CARE MED, V30, P2338, DOI 10.1097/00003246-200210000-00025; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; COHN D, 1995, NEW LITERARY HIST, V26, P3, DOI 10.1353/nlh.1995.0004; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; Dubin MJ, 1998, NEUROL RES, V20, P533; ELLIS T, 2005, P 27 ANN INT C IEEE, P2880; FOLTZ E L, 1990, Neurological Research, V12, P67; Godje O, 2002, CRIT CARE MED, V30, P52; Godje O, 1999, ANN THORAC SURG, V68, P1532, DOI 10.1016/S0003-4975(99)00956-X; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Linton NWF, 2001, BRIT J ANAESTH, V86, P486, DOI 10.1093/bja/86.4.486; Luerssen T G, 1997, Semin Pediatr Neurol, V4, P146, DOI 10.1016/S1071-9091(97)80033-2; Lundberg N, 1960, ACTA PSYCHIAT NEUR S, V36, P149; McNames J, 2006, IEEE SIGNAL PROC MAG, V23, P82, DOI 10.1109/MSP.2006.1593340; McVeigh GE, 1999, HYPERTENSION, V33, P1392, DOI 10.1161/01.HYP.33.6.1392; McVeigh GE, 2002, CLIN SCI, V102, P51, DOI 10.1042/CS20010191; NORTH B, 1997, HEAD INJURY, P209; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Resnick LM, 2000, AM J HYPERTENS, V13, P1243, DOI 10.1016/S0895-7061(00)01219-X; Rodig G, 1999, BRIT J ANAESTH, V82, P525; van Lieshout JJ, 2001, BRIT J ANAESTH, V86, P467, DOI 10.1093/bja/86.4.467; Wesseling K H, 1976, Acta Anaesthesiol Belg, V27 suppl, P327	35	18	18	0	7	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	SEP	2007	54	9					1552	1559		10.1109/TBME.2007.892918			8	Engineering, Biomedical	Engineering	204TW	WOS:000249067900002	17867347				2021-06-18	
J	Kirchhoff, C; Stegmaier, J; Krotz, M; Muetzel, E; Mutschler, W; Kanz, KG; Heindl, B				Kirchhoff, Chlodwig; Stegmaier, Julia; Krotz, Michael; Muetzel, Elisabeth; Mutschler, Wolf; Kanz, Karl-Georg; Heindl, Bernhard			Celiac dissection after blunt abdominal trauma complicated by acute hepatic failure: Case report and review of literature	JOURNAL OF VASCULAR SURGERY			English	Article							SUPERIOR MESENTERIC-ARTERY; ROW CT ANGIOGRAPHY; SURGICAL-MANAGEMENT; COMPUTED-TOMOGRAPHY; MULTIDETECTOR CT; INJURY; AXIS; LIVER; AORTA; CIRCULATION	Injuries of the abdominal visceral vessels are uncommon but devastating entities resulting in extremely high rates of mortality. The most common cause of abdominal vascular injuries is penetrating trauma, accounting for 90% to 95% of these injuries. In contrast, blunt trauma accounts for 5% to 10% of all abdominal vascular lesions. Although traumatic injury to the celiac artery is among the rarest of all vascular injuries, mortality can be as high as 75%. We report a 66-year-old patient who sustained multiple injuries in a motor vehicle crash. The initial whole-body computed tomography (CT) scan revealed a combination of severe brain injury and bilateral thoracic lesions. On day 6 after the accident, the patient's clinical situation deteriorated rapidly. At this time, the abdominal arterial CT scan showed a dissection of the celiac artery. Therapeutic anticoagulation was not feasible because of the intracranial hemorrhage. Also the patient's clinical situation worsened so rapidly that interventional therapy, including surgical and endovascular treatment, could not be performed. Finally, the patient died of fulminant hepatic failure, therefore not surviving a potentially treatable injury. The diagnosis of celiac artery dissection in this patient was significantly delayed because the initial trauma CT protocol did not include an arterial phase of the abdominal vessels.	Univ Munich, Dept Traumat & Orthopaed Surg, D-80686 Munich, Germany; Univ Munich, Dept Clin Radiol, D-80686 Munich, Germany; Univ Munich, Dept Anesthesiol, D-80686 Munich, Germany; Univ Munich, Inst Forens Med, D-80686 Munich, Germany	Kirchhoff, C (corresponding author), Univ Munich, Dept Surg, Campus Innenstadt,Nussbaumstr 20, D-80686 Munich, Germany.	Chlodwig.Kirchhoff@med.uni-muenchen.de					Asensio JA, 2005, SOUTH MED J, V98, P462, DOI 10.1097/01.SMJ.0000136239.16913.C2; BENGMARK S, 1970, AM J SURG, V119, P620, DOI 10.1016/0002-9610(70)90228-X; Berthet JP, 2003, J VASC SURG, V38, P997, DOI 10.1016/S0741-5214(03)00613-X; Brofman N, 2006, RADIOGRAPHICS, V26, P1119, DOI 10.1148/rg.264055144; Brown DB, 1998, J VASC INTERV RADIOL, V9, P783, DOI 10.1016/S1051-0443(98)70392-6; BUSUTTIL RW, 1980, ANN SURG, V191, P641, DOI 10.1097/00000658-198005000-00017; Chaillou P, 1997, ANN VASC SURG, V11, P413, DOI 10.1007/s100169900070; CORBETTI F, 1989, J COMPUT ASSIST TOMO, V13, P965, DOI 10.1097/00004728-198911000-00006; Davis TP, 2001, AM SURGEON, V67, P565; Edwards MS, 2003, ANN VASC SURG, V17, P72, DOI 10.1007/s10016-001-0329-8; Francque S, 2004, EUR J GASTROEN HEPAT, V16, P411, DOI 10.1097/00042737-200404000-00008; Fujisawa Y, 2005, ANN VASC SURG, V19, P553, DOI 10.1007/s10016-005-5022-2; Graham DD, 1997, AM SURGEON, V63, P327; GUTHRIE W, 1972, J PATHOL, V108, P219, DOI 10.1002/path.1711080308; Hashimoto M, 1998, CLIN RADIOL, V53, P913, DOI 10.1016/S0009-9260(98)80220-1; HUET PM, 1986, SEMIN LIVER DIS, V6, P277, DOI 10.1055/s-2008-1040610; Johnson JW, 2002, J TRAUMA, V52, P1102, DOI 10.1097/00005373-200206000-00013; JURKOVICH GJ, 1995, J TRAUMA, V39, P426; Killeen KL, 2001, J TRAUMA, V51, P26, DOI 10.1097/00005373-200107000-00005; Kock MCJM, 2005, RADIOLOGY, V237, P727, DOI 10.1148/radiol.2372040616; Lalancette M, 2006, ANN VASC SURG, V20, P681, DOI 10.1007/s10016-006-9058-3; LINDNER HH, 1971, ARCH SURG-CHICAGO, V103, P600; Linsenmaier U, 2002, EUR RADIOL, V12, P1728, DOI 10.1007/s00330-001-1225-x; Linuma Y, 2006, J TRAUMA, V61, P451, DOI 10.1097/01.ta.0000229960.31334.ca; Martin ML, 2003, AM J ROENTGENOL, V180, P1085, DOI 10.2214/ajr.180.4.1801085; MILLER MA, 1989, J TRAUMA, V29, P1571, DOI 10.1097/00005373-198911000-00019; Peytel E, 2001, INTENS CARE MED, V27, P1756, DOI 10.1007/s00134-001-1119-z; PLENGVAN.U, 1972, ANN SURG, V175, P105, DOI 10.1097/00000658-197201000-00016; Poletti PA, 2004, J TRAUMA, V57, P1072, DOI 10.1097/01.TA.0000092680.73274.E1; Ray B, 2006, CARDIOVASC INTER RAD, V29, P886, DOI 10.1007/s00270-004-0113-6; Sachdev U, 2006, J VASC SURG, V44, P718, DOI 10.1016/j.jvs.2006.06.027; So YH, 2003, J VASC INTERV RADIOL, V14, P493, DOI 10.1097/01.RVI.0000064855.87207.C5; Starnes Benjamin W, 2006, Perspect Vasc Surg Endovasc Ther, V18, P114, DOI 10.1177/1531003506293418; STONEY RJ, 1966, ANN SURG, V164, P714, DOI 10.1097/00000658-196610000-00016; Tian JL, 2006, WORLD J GASTROENTERO, V12, P3265, DOI 10.3748/wjg.v12.i20.2000; Willmann JK, 2003, RADIOLOGY, V226, P798, DOI 10.1148/radiol.2271020014	36	18	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	SEP	2007	46	3					576	580		10.1016/j.jvs.2007.04.041			5	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	208JL	WOS:000249315500034	17826250				2021-06-18	
J	Gottshall, KR; Gray, NL; Drake, AI; Tejidor, R; Hoffer, ME; McDonald, EC				Gottshall, Kim R.; Gray, Nicola L.; Drake, Angela I.; Tejidor, Raechel; Hoffer, Michael E.; McDonald, Eric C.			To investigate the influence of acute vestibular impairment following mild traumatic brain injury on subsequent ability to remain on activity duty 12 months later	MILITARY MEDICINE			English	Article							DYNAMIC VISUAL-ACUITY; HEAD-INJURY; MENTAL-DISORDERS; OUTCOME MEASURES; US MILITARY; RETURN; WORK; PERFORMANCE; CONCUSSION; TESTS	The objective of this study was to investigate the relationship between acute vestibular dysfunction as measured by the Dizziness Handicap Inventory and the Dynamic Visual Acuity Test and the ability to remain on active duty status in the U.S. military 1 year after mild traumatic brain injury. This longitudinal prospective study was conducted by the Defense and Veterans Brain Injury Clinic at Marine Corp Base, Camp Pendleton, California. Participants (n = 47, controls = 44) were referrals to the clinic who had sustained a mild traumatic brain injury and were initially seen within 6 days of injury, then weekly for 1 month, and for follow-up 12 months later. The results demonstrated that those on active duty at 12 months were older in age, had more years of service, and had no history of psychiatric illness or apparent secondary gain issues. Acute vestibular dysfunction and demographic and injury variables were not significantly correlated or predictive of work status at 12 months.	Naval Med Ctr, Spatial Orientat Ctr, Dept Otolaryngol, San Diego, CA 92134 USA; Naval Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurosci, San Diego, CA 92134 USA; Naval Med Ctr, Emergency Dept, San Diego, CA 92134 USA	Gottshall, KR (corresponding author), Naval Med Ctr, Spatial Orientat Ctr, Dept Otolaryngol, 34800 Bob Wilson Dr,Suite 200, San Diego, CA 92134 USA.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; *CDCP, 2003, REPORT C MILD TRAUM; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cigrang JA, 1998, MIL MED, V163, P834; Clendaniel RA, 2000, OTOLARYNG CLIN N AM, V33, P519, DOI 10.1016/S0030-6665(05)70225-5; Demer JL, 2001, ANN NY ACAD SCI, V942, P428; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; *DVA, 1991, USERS MANUAL RES, P1; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman SJ, 2001, ARCH OTOLARYNGOL, V127, P1205, DOI 10.1001/archotol.127.10.1205; Herdman SJ, 1998, AM J OTOL, V19, P790; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Hoge CW, 2002, AM J PSYCHIAT, V159, P1576, DOI 10.1176/appi.ajp.159.9.1576; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JONTZ S, 2006, TBI WARTIME AFGHAN I; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; KIRTANE MV, 1982, J LARYNGOL OTOL, V96, P521, DOI 10.1017/S0022215100092793; Kisilevski V, 2001, Int Tinnitus J, V7, P118; Lee MH, 1997, AVIAT SPACE ENVIR MD, V68, P111; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nyabenda A., 2004, Annales de Readaptation et de Medecine Physique, V47, P105; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sylvia FR, 2001, MIL MED, V166, P918; *TBI STAT DEM GRAN, 2000, J HEAD TRAUMA REHAB, V15, P750; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Whitney SL, 2004, OTOL NEUROTOL, V25, P139, DOI 10.1097/00129492-200403000-00010	39	18	18	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2007	172	8					852	857		10.7205/MILMED.172.8.852			6	Medicine, General & Internal	General & Internal Medicine	201JW	WOS:000248828400012	17803077	Other Gold			2021-06-18	
J	West, SL; Luck, RS; Capps, CF				West, Steven L.; Luck, Richard S.; Capps, C. Fred			Physical inaccessibility negatively impacts the treatment participation of persons with disabilities	ADDICTIVE BEHAVIORS			English	Article						persons with disabilities; treatment access; physical accessibility	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSE; MISUSE	This research assessed the impact that physical inaccessibility of provider locations has on the substance abuse treatment participation of two groups of persons with disabilities. A random sample of treatment providers in the Mid-Atlantic region were surveyed and asked if they had declined services to persons with spinal cord (SCI) or traumatic brain (TBI) injuries due to the inaccessibility of their practices. Over half of those who had been approached by persons with SCI and nearly half of those approached by persons with TBI were unable to provide services due to physical barriers. The inability to serve such individuals was not related to practice affiliation (public or private) or practice type (hospital based, non-medical residential, or outpatient). These findings support earlier research indicating the treatment participation of persons with disabilities is negatively affected by physical accessibility concerns. (C) 2007 Published by Elsevier Ltd.	Virginia Commonwealth Univ, Dept Rehabil Counseling, Richmond, VA 23298 USA	West, SL (corresponding author), Virginia Commonwealth Univ, Dept Rehabil Counseling, POB 980330, Richmond, VA 23298 USA.	slwest2@vcu.edu					Burgard JF, 2000, J PSYCHOACTIVE DRUGS, V32, P293, DOI 10.1080/02791072.2000.10400452; Cherry L., 1993, SUBSTANCE ABUSE PHYS, P181; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; MOORE D, 1991, INT J ADDICT, V26, P65, DOI 10.3109/10826089109056240; Nelipovich M, 1998, J VISUAL IMPAIR BLIN, V92, P567, DOI 10.1177/0145482X9809200805; RADNITZ CL, 1995, INT J ADDICT, V30, P1117, DOI 10.3109/10826089509055831; Schaschl S., 1993, SUBSTANCE ABUSE PHYS, P165; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Voss C. P., 2002, TOPICS SPINAL CORD I, V7, P47; Waldrop J., 2003, DISABILITY STATUS 20; West S. L., 2005, 5 ANN NAT COUNC REH; WEST SL, IN PRESS J SUBSTANCE; Westermeyer J, 1996, AM J ADDICTION, V5, P23	15	18	18	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4603			ADDICT BEHAV	Addict. Behav.	JUL	2007	32	7					1494	1497		10.1016/j.addbeh.2006.10.009			4	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	171JL	WOS:000246732000017	17258869				2021-06-18	
J	Keris, V; Lavendelis, E; Macane, I				Keris, Valdis; Lavendelis, Egils; Macane, Inta			Association between implementation of clinical practice guidelines and outcome for traumatic brain injury	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; NEUROSURGICAL TRAUMA; MANAGEMENT	Background Traumatic brain injury (TBI) is the leading cause of death in the population under 40 years of age in Western countries, and the same was true for Latvia in 1999. This indicated a strong need to improve the management of TBI. The Latvian Society of Neurosurgeons in collaboration with related societies created a dedicated working group, and the Guidelines for Medical Management of TBI in Latvia (Guidelines) were developed in 2001. This study aimed to assess the association between implementation of the Guidelines and the outcome of TBI patients. Methods The Guidelines were printed and distributed to relevant clinical units and teaching institutions. To assess the impact of the Guidelines on the outcome of TBI, Latvian medical statistics were researched. All patients admitted to emergency departments and registered as either discharged or dead with a diagnosis of head trauma from 1998 to 2004 were included in a retrospective survey. The primary endpoint accepted for analysis was the hospital case fatality rate (HCFR). Results The survey included 73,062 consecutive cases. The annual incidence rate of TBI admissions was stable during the period 1998 to 2004 (range 41.5-46.0/10,000), and the incidence of moderate and severe TBI (range 7.2-8.7/10,000) showed no significant trends. There was a reduction of HCFR from 3.7% during 1998-2000 to 2.6% during 2002-2004 (relative risk 0.72; 95% confidence interval 0.67-0.76; p = 0.03). Conclusion Implementation of the Guidelines was associated with a statistically significant decrease of HCFR in TBI patients.	Riga Stradins Univ, Clin Hosp Gailezers, Dept Neurosurg, LV-1038 Riga, Latvia; State Hlth Stat & Med Technol Agcy, Riga, Latvia; Riga Stradins Univ, Dept Sci, Riga, Latvia	Keris, V (corresponding author), Riga Stradins Univ, Clin Hosp Gailezers, Dept Neurosurg, 2 Hipokrata Str, LV-1038 Riga, Latvia.	valker@delfi.lv					Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Basso A, 2001, WORLD J SURG, V25, P1174; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; FORSYTH R, 2003, COCHRANE DATABASE SY, V1; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Kelly DF, 2001, WORLD J SURG, V25, P1179; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; *NIH, 1998, NIH CONSENSUS STATE, V16, P1; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004	11	18	18	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2007	31	6					1352	1355		10.1007/s00268-007-9002-x			4	Surgery	Surgery	171UB	WOS:000246759800035	17464541				2021-06-18	
J	Testerman, GM; Dacks, LM				Testerman, George M.; Dacks, Laura M.			Multiple self-inflicted nail gun head injury	SOUTHERN MEDICAL JOURNAL			English	Article						brain trauma; penetrating brain injury; self-inflicted injury; nail gun	TRAUMATIC ANEURYSMS; SUICIDE; MANAGEMENT	Penetrating brain injury resulting from nail-gun use is a well-characterized entity, one that is increasing in frequency as nail guns become more powerful and more readily available to the public. We present a case and offer management strategies for a 50-year-old male with two intracranial penetrating nail gun injuries. Nail gun brain injuries are commonly intentionally self-inflicted. Suicide should be considered when straight nails cause wounds to the chest, head, or abdomen. The primary preoperative concern is formation of a traumatic pseudoaneurism, which prompts both preoperative and follow-up cerebral angiography. Surgery for combined intracranial and extracranial injury may require the collaborative expertise of colleagues from the fields of ophthalmology, otolaryngology, and oral maxillofacial surgery. A rational management strategy should permit these patients to be discharged with no additional injury.	E Tennessee State Univ, Coll Med, Wellmont Holston Valley Med Ctr, Dept Surg, Kingsport, TN 37660 USA	Testerman, GM (corresponding author), E Tennessee State Univ, Coll Med, Wellmont Holston Valley Med Ctr, Dept Surg, 134 W Pk Dr, Kingsport, TN 37660 USA.	gmt0@charter.net					AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; Beaver AC, 1999, AM SURGEON, V65, P1113; GAUL JS, 1987, J HAND SURG-AM, V12A, P966, DOI 10.1016/S0363-5023(87)80266-6; HARRIS T, NAIL GUNS WORK; KENNY N, 1993, J TRAUMA, V35, P943, DOI 10.1097/00005373-199312000-00023; Litvack ZN, 2006, J NEUROSURG, V104, P828, DOI 10.3171/jns.2006.104.5.828; MCCORKELL SJ, 1986, AM J FOREN MED PATH, V7, P192, DOI 10.1097/00000433-198607030-00004; Panourias IG, 2006, CLIN NEUROL NEUROSUR, V108, P490, DOI 10.1016/j.clineuro.2005.01.007; Sahjpaul RL, 2000, CAN J NEUROL SCI, V27, pS55, DOI 10.1017/S0317167100000676; VISWANATHAN R, 1994, SCOT MED J, V39, P83, DOI 10.1177/003693309403900310; Wu W Q, 1975, Surg Neurol, V3, P83	12	18	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	JUN	2007	100	6					608	610		10.1097/SMJ.0b013e3180398e47			3	Medicine, General & Internal	General & Internal Medicine	177PZ	WOS:000247166300013	17591316				2021-06-18	
J	Hayden, MG; Jandial, R; Duenas, HA; Mahajan, R; Levy, M				Hayden, M. G.; Jandial, R.; Duenas, H. A.; Mahajan, R.; Levy, M.			Pediatric concussions in sports; a simple and rapid assessment tool for concussive injury in children and adults	CHILDS NERVOUS SYSTEM			English	Article						brain concussion; pediatrics; athletic injuries; clinical protocol; prevention and control		We established a routine protocol for concussion evaluation in athletes for nonmedical personnel. The evaluation, management guidelines, and return-to-play recommendations were summarized with a memorable mnemonic on a convenient handheld card. The ability to remember the return-to-play mnemonic and effectively apply it to corresponding guidelines was evaluated in 194 sports personnel without medical training. The participants were given three clinical scenarios, each including age, pertinent history, sporting event, description of an injury, symptoms, signs, and a brief neurological exam. Subsequently, the subject's ability to recall the return-to-play mnemonic and the Standard Assessment of Concussion, to describe the corresponding guidelines, and to advise return-to-play was evaluated. Our "return-to-play" mnemonic was found to be simple and memorable, allowing for a high recall percentage and accurate evaluation of concussion cases. High intersubject agreement suggests that this method has both standardization and generalization potential.	Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA; Childrens Specialists San Diego, Childrens Hosp San Diego, San Diego, CA 92123 USA	Jandial, R (corresponding author), Univ Calif San Diego, Div Neurosurg, Mailcode 8893200,W Arbor Dr, San Diego, CA 92103 USA.	rahuljandial@hotmail.com					Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lazar L, 1997, J PEDIATR SURG, V32, P88, DOI 10.1016/S0022-3468(97)90102-0; Poirier MP, 2000, PEDIATR EMERG CARE, V16, P278, DOI 10.1097/00006565-200008000-00018; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Skokan EG, 2003, AM J EMERG MED, V21, P95, DOI 10.1053/ajem.2003.50032	6	18	18	0	11	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2007	23	4					431	435		10.1007/s00381-006-0277-2			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	143UH	WOS:000244750900012	17219233				2021-06-18	
J	Ruocco, AC; Swirsky-Sacchetti, T				Ruocco, Anthony C.; Swirsky-Sacchetti, Thomas			Personality disorder symptomatology and neuropsychological functioning in closed head injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; AXIS-I	Despite an emerging literature characterizing the neuropsychological profiles of borderline, antisocial, and schizotypal personality disorders, relations between personality disorder traits and neurocognitive domains remain unknown. The authors examined associations among Millon Clinical Multiaxial Inventory-III personality disorder scales and eight neuropsychological domains in 161 patients referred for neuropsychological evaluation following closed head injury. Most personality disorder scales were associated with some decrement in cognitive function, particularly speeded processing, executive function, and language, while histrionic and narcissistic scales had positive relations with neuropsychological functioning. Results suggest that many personality disorder traits are related to neurocognitive function, particularly those functions subserved by frontal and temporal regions.	Drexel Univ, Dept Psychol, Neuropsychol Program, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA	Ruocco, AC (corresponding author), Drexel Univ, Dept Psychol, Neuropsychol Program, 245 N 15th St,Mail Stop 626, Philadelphia, PA 19102 USA.	acr32@drexel.edu	Ruocco, Anthony C./B-4915-2010; Ruocco, Anthony Charles/AAM-4794-2021	Ruocco, Anthony C./0000-0002-1942-7181; 			Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Burton LA, 1999, SEIZURE-EUR J EPILEP, V8, P116, DOI 10.1053/seiz.1999.0271; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Castano Monsalve B, 2005, Actas Esp Psiquiatr, V33, P96; Choca J, 1996, J PERS DISORD, V10, P377, DOI 10.1521/pedi.1996.10.4.377; Choca J.P., 2004, INTERPRETIVE GUIDE M, V3rd; Costa Jr. P. T., 1994, PERSONALITY DISORDER; Delis DC, 1987, CALIFORNIA VERBAL LE; Dickinson KA, 2003, J PERS DISORD, V17, P188, DOI 10.1521/pedi.17.3.188.22146; Golden C., 1978, STROOP COLOUR WORD T; GOLOMB M, 1995, AM J PSYCHIAT, V152, P579; GRAHAM JR, 1999, MMMP2 ASSESSING PERS; IRANI F, IN PRESS CLIN NEUROP; Kaplan E, 1978, BOSTON NAMING TEST; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leyton M, 2001, AM J PSYCHIAT, V158, P775, DOI 10.1176/appi.ajp.158.5.775; Lysaker PH, 2004, SCHIZOPHR RES, V68, P87, DOI 10.1016/S0920-9964(03)00195-6; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Millon T., 1997, MCMI 3 MANUAL; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422; Ruocco AC, 2005, J CLIN PSYCHOL, V61, P1509, DOI 10.1002/jclp.20205; Ruocco AC, 2003, ARCH CLIN NEUROPSYCH, V18, P737; RUOCCO AC, IN PRESS PSYCHIAT RE; Sherry A, 2005, J PERS ASSESS, V84, P37, DOI 10.1207/s15327752jpa8401_09; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Skodol AE, 1999, DEPRESS ANXIETY, V10, P175, DOI 10.1002/(SICI)1520-6394(1999)10:4<175::AID-DA6>3.3.CO;2-U; Soloff PH, 2000, BIOL PSYCHIAT, V47, P540, DOI 10.1016/S0006-3223(99)00202-4; STONG C, 2004, NEUROL REV, P53; SWIRSKYSACCHETTI T, 1993, J CLIN PSYCHOL, V49, P385, DOI 10.1002/1097-4679(199305)49:3<385::AID-JCLP2270490313>3.0.CO;2-4; Tombaugh TN, 1996, TEST MEMORY MALINGER; TROBST KK, 1999, 4 ANN INTR SCI RETR; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Voglmaier MM, 2005, SCHIZOPHR RES, V74, P43, DOI 10.1016/j.schres.2004.09.013; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yovel I, 2005, PSYCHOL SCI, V16, P123, DOI 10.1111/j.0956-7976.2005.00792.x; Zillmer E. A., 2001, PRINCIPLES NEUROPSYC	39	18	18	0	17	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FEB	2007	19	1					27	35		10.1176/appi.neuropsych.19.1.27			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	137KA	WOS:000244290300004	17308224				2021-06-18	
J	Donat, CK; Schuhmann, MU; Voigt, C; Nieber, K; Schliebs, R; Brust, P				Donat, Cornelius Kurt; Schuhmann, Martin Ulrich; Voigt, Cornelia; Nieber, Karen; Schliebs, Reinhard; Brust, Peter			Alterations of acetylcholinesterase activity after traumatic brain injury in rats	BRAIN INJURY			English	Article						traumatic brain injury; acetylcholinesterase; cholinergic system; controlled cortical impact; histochemistry; rat	CONTROLLED CORTICAL IMPACT; REDUCED EVOKED RELEASE; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; CHOLINERGIC NEURONS; GENE-EXPRESSION; MOLECULAR-FORMS; DEFICITS; MEMORY; INHIBITION	Objective: The cholinergic system is highly vulnerable to traumatic brain injury (TBI). However, limited information is available to what extent the degrading enzyme acetylcholinesterase (AChE) is involved. The present study addresses this question. Method: Thirty-six anaesthetized Sprague-Dawley rats were subjected to sham operation or to TBI using controlled cortical impact (CCI). The AChE activity was histochemically determined in frozen brain slices at 2,24 and 72 hours after TBI. Results: High enzyme activity was observed in regions rich in cholinergic innervation such as the olfactory tubercle, basal forebrain, putamen and superior colliculi. Low activity was found in the cortex, cerebellum and particularly in the white matter. A decrease of AchE activity (20 - 35%) was found in the hippocampus and hypothalamus already at 2 hours after TBI. An increase of similar to 30% was found in the basal forebrain at 2 and 24 hours. No changes occurred at 72 hours. Conclusion: The findings are consistent with impairment of the cholinergic neurotransmission after TBI and suggest the involvement of the AChE in short-term regulatory mechanisms.	Inst Interdisciplinary Isotope Res, D-04318 Leipzig, Germany; Univ Leipzig, Dept Neurosurg, Leipzig, Germany; Univ Tubingen, Dept Neurosurg, D-72074 Tubingen, Germany; Univ Leipzig, Inst Pharm, Leipzig, Germany; Univ Leipzig, Paul Flechsig Inst Brain Res, Leipzig, Germany	Donat, CK (corresponding author), Inst Interdisciplinary Isotope Res, Permoserstr 15, D-04318 Leipzig, Germany.	donat@iif-leipzig.de		, Peter/0000-0001-5555-7058			ANDRA J, 1986, HISTOCHEMISTRY, V84, P575, DOI 10.1007/BF00482994; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; ATACK JR, 1986, J NEUROCHEM, V47, P263; Beeri R, 1997, J NEUROCHEM, V69, P2441; Bohnen NI, 2005, NEUROSCI LETT, V380, P127, DOI 10.1016/j.neulet.2005.01.031; Bohnen NI, 2005, J NEUROL NEUROSUR PS, V76, P315, DOI 10.1136/jnnp.2004.038729; Chen Y, 1998, BRAIN RES, V784, P18, DOI 10.1016/S0006-8993(97)00982-7; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fu AL, 2005, BRAIN RES, V1066, P10, DOI 10.1016/j.brainres.2005.09.063; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Hammond PI, 1996, ANAL BIOCHEM, V241, P82, DOI 10.1006/abio.1996.0381; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kar S, 2004, J PSYCHIATR NEUROSCI, V29, P427; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, CHEM-BIOL INTERACT, V119, P349, DOI 10.1016/S0009-2797(99)00046-0; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Ma TG, 2001, ANAL BIOCHEM, V296, P18, DOI 10.1006/abio.2001.5208; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Noppens R, 2004, EXP TOXICOL PATHOL, V56, P113, DOI 10.1016/j.etp.2004.04.005; Perrier NA, 2005, J NEUROCHEM, V94, P629, DOI 10.1111/j.1471-4159.2005.03140.x; Perrier NA, 2006, J MOL NEUROSCI, V30, P75, DOI 10.1385/JMN:30:1:75; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Scremin OU, 2006, BRAIN RES, V1124, P155, DOI 10.1016/j.brainres.2006.09.062; Shinotoh H, 2004, CURR PHARM DESIGN, V10, P1505, DOI 10.2174/1381612043384763; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8	53	18	19	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1031	1037		10.1080/02699050701630359			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600005	17891565				2021-06-18	
B	Mahone, EM; Slomine, BS		Hunter, SJ; Donders, J		Mahone, E. Mark; Slomine, Beth S.			Managing dysexecutive disorders	PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE			English	Article; Book Chapter							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; WORKING-MEMORY; YOUNG-CHILDREN; TOURETTE-SYNDROME; PHARMACOLOGICAL-TREATMENT; PRESCHOOL-CHILDREN; HEAD-INJURY		[Mahone, E. Mark; Slomine, Beth S.] Johns Hopkins Univ, Med Ctr, Dept Neuropsychol, Kennedy Krieger Inst, Baltimore, MD 21218 USA	Mahone, EM (corresponding author), Johns Hopkins Univ, Med Ctr, Dept Neuropsychol, Kennedy Krieger Inst, Baltimore, MD 21218 USA.						Anderson V, 1997, Pediatr Rehabil, V1, P63; Barkley RA, 2000, J AM ACAD CHILD PSY, V39, P1064, DOI 10.1097/00004583-200008000-00025; Barnett R, 2001, PSYCHOL MED, V31, P1107, DOI 10.1017/S0033291701004172; Beebe DW, 2004, J INT NEUROPSYCH SOC, V10, P962, DOI 10.1017/S135561770410708X; Beebe DW, 2000, J CLIN EXP NEUROPSYC, V22, P779, DOI 10.1076/jcen.22.6.779.950; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; BERNSTEIN J, 1990, NEUROMETHODS NEUROPS, P311, DOI DOI 10.1385/0-89603-133-0:311; Bernstein J. H., 1996, ISSUES PSYCHOEDUCATI; Bernstein JH, 2000, SCI PRACT NEUROPSYCH, P405; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Burmeister R, 2005, CHILD NEUROPSYCHOL, V11, P265, DOI 10.1080/092970490911324; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Canfield RL, 2004, DEV NEUROPSYCHOL, V26, P513, DOI 10.1207/s15326942dn2601_8; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Chronis AM, 2001, COGN BEHAV PRACT, V8, P346, DOI 10.1016/S1077-7229(01)80008-0; Chronis AM, 2006, CLIN PSYCHOL REV, V26, P486, DOI 10.1016/j.cpr.2006.01.002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CROWLEY JA, 1991, J PEDIATR PSYCHOL, V16, P611, DOI 10.1093/jpepsy/16.5.611; Cummings DD, 2002, CLIN NEUROPHARMACOL, V25, P325, DOI 10.1097/00002826-200211000-00009; DAWSON P, 2004, EXECUTIVE SKILLS CHI; Delis DC, 2001, DELISKAPLAN EXECUTIV; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; Dodrill CB, 1999, CLIN NEUROPSYCHOL, V13, P562, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT562; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Espy KA, 2002, CHILD NEUROPSYCHOL, V8, P83, DOI 10.1076/chin.8.2.83.8723; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P379, DOI 10.1207/s15326942dn2601_1; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Gassio R, 2005, DEV MED CHILD NEUROL, V47, P443, DOI 10.1017/S0012162205000861; Gioia G.A., 2000, BEHAV RATING INVENTO; Goldberg MC, 2005, J AUTISM DEV DISORD, V35, P279, DOI 10.1007/s10803-005-3291-4; Griffith EM, 1999, CHILD DEV, V70, P817, DOI 10.1111/1467-8624.00059; Gureasko-Moore S, 2006, BEHAV MODIF, V30, P159, DOI 10.1177/0145445503259387; Habboushe DF, 2001, COGN BEHAV PRACT, V8, P123, DOI 10.1016/S1077-7229(01)80018-3; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; Heilman K. M., 1994, NIH C ATT MEM EX FUN; HEILMAN KM, 1991, J CHILD NEUROL, V6, pS76, DOI 10.1177/0883073891006001S09; Heilman KM., 1993, INT J CLIN NEUROPSYC, V3, P279; Holmbeck GN, 2003, EVIDENCE-BASED PSYCHOTHERAPIES FOR CHILDREN AND ADOLESCENTS, P21; HOLMES JM, 1987, HDB COGNITIVE SOCIAL, P303; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Jung RE, 2000, CLIN NEUROPSYCHOL, V14, P535, DOI 10.1076/clin.14.4.535.7198; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Krause KH, 2000, NEUROSCI LETT, V285, P107, DOI 10.1016/S0304-3940(00)01040-5; Mahone E. M., TXB CLIN NE IN PRESS; Mahone E. M., 2001, INSIGHTS SPINA BIFID, V7, p1A; Mahone EM, 2005, DEV NEUROPSYCHOL, V27, P11, DOI 10.1207/s15326942dn2701_2; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P52, DOI 10.1076/chin.8.1.52.8719; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mahone EM, 2001, J INT NEUROPSYCH SOC, V7, P102, DOI 10.1017/S1355617701711101; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; Mash E. J., 1998, TREATMENT CHILDHOOD, P3; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; MCEVOY RE, 1993, J CHILD PSYCHOL PSYC, V34, P563, DOI 10.1111/j.1469-7610.1993.tb01036.x; Michel JA, 2005, CHILD NEUROPSYCHOL, V11, P295, DOI 10.1080/092970490911270; Mostofsky SH, 2003, PERCEPT MOTOR SKILL, V97, P1315, DOI 10.2466/PMS.97.7.1315-1331; Nyden A, 2000, EUR CHILD ADOLES PSY, V9, P180, DOI 10.1007/s007870070041; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; O'Driscoll GA, 2005, BIOL PSYCHIAT, V57, P1452, DOI 10.1016/j.biopsych.2005.02.029; Ozonoff S, 1999, J AUTISM DEV DISORD, V29, P171, DOI 10.1023/A:1023052913110; Pelham W. E., 2004, PSYCHOSOCIAL TREATME, P311; Pelham WE, 2000, J ABNORM CHILD PSYCH, V28, P507, DOI 10.1023/A:1005127030251; Rapport MD, 2001, J CLIN CHILD PSYCHOL, V30, P48, DOI 10.1207/S15374424JCCP3001_6; Reiter A, 2005, DYSLEXIA, V11, P116, DOI 10.1002/dys.289; Riva D, 2005, NEUROL SCI, V26, P263, DOI 10.1007/s10072-005-0469-7; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; RUDEL RG, 1981, B ORTON SOC, V31, P89; Russell EW, 2001, CLIN NEUROPSYCHOL, V15, P423, DOI 10.1076/clin.15.3.423.10267; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Slusarek M, 2001, J AM ACAD CHILD PSY, V40, P355, DOI 10.1097/00004583-200103000-00016; Snyder MC, 1997, J LEARN DISABIL, V30, P534, DOI 10.1177/002221949703000509; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Thompson PM, 2005, INT REV NEUROBIOL, V67, P285, DOI 10.1016/S0074-7742(05)67009-2; Turner GR, 2004, SCI PRACT NEUROPSYCH, P224; Vance ALA, 2003, AUST NZ J PSYCHIAT, V37, P570, DOI 10.1046/j.1440-1614.2003.01238.x; Vygotsky L. S., 1962, THOUGHT LANGUAGE; Weber P, 2002, PEDIATR NEUROL, V26, P261, DOI 10.1016/S0887-8994(01)00408-8; Willcutt EG, 2005, DEV NEUROPSYCHOL, V27, P35, DOI 10.1207/s15326942dn2701_3; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wodka E. L., 2007, J CLIN EXPT NEUROPSY, DOI [10.1080/13803390600678056, DOI 10.1080/13803390600678056]; Wodka E. L., 2007, J INT NEUROPSYCH SOC, V12, P40; Wong G, 2001, WORKING TIME IN COMPARATIVE PERSPECTIVE, VOL I, P1, DOI 10.1079/9780851994567.0001; Yerys BE, 2003, J PEDIAT HEMATOL ONC, V25, P495, DOI 10.1097/00043426-200306000-00014; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159; ZABEL TA, 2004, CEREBROSPINAL FLUID, V1, pS57; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	96	18	18	0	2	CAMBRIDGE UNIV PRESS	CAMBRIDGE	THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND			978-0-521-87550-9				2007							287	313					27	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	BXM34	WOS:000296371600014					2021-06-18	
J	Parish, L; Oddy, M				Parish, Liz; Oddy, Michael			Efficacy of rehabilitation for functional skills more than 10 years after extremely severe brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; FOLLOW-UP; MEMORY; ADULTS; RECOVERY	Purpose: To determine whether gains in personal independence can be achieved in individuals 10 or more years after very severe acquired brain injury. Method: Four individuals in a continuing (slow stream) rehabilitation centre were assessed by an occupational therapist (OT) and programmes were designed to help the individual enhance personal independence. Support staff were trained to implement these programmes under the guidance of the OT. Methods described by Giles, Ridley, Dill, and Frye (1997) were used. Pre- and post-training measures were taken as well as follow up measures to assess the durability of such changes. Results: The results demonstrate that it is possible to achieve clinically significant improvements in personal independence many years after very severe acquired brain injury. Conclusions: The findings of this study suggest that personally and clinically significant goals can be achieved 10 or more years after brain injury and there should be continuing effort to improve the circumstances of individuals with acquired brain injury. Such gains can be achieved through consistent application of such programmes by support workers working under the supervision of an occupational therapist.	Brain Injury Rehabil Trust, Burgess Hill RH15 9NP, W Sussex, England	Oddy, M (corresponding author), Brain Injury Rehabil Trust, 32 Market Pl, Burgess Hill RH15 9NP, W Sussex, England.	michael.oddy@birt.co.uk					Baddeley A.D., 1992, SPEED CAPACITY LANGU; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1073, DOI 10.1016/j.apmr.2005.01.003; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Giles GM, 1997, AM J OCCUP THER, V51, P256, DOI 10.5014/ajot.51.4.256; GILES GM, 1999, REHABILITATION SEVER; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3187; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; McMillan TM, 2004, CLIN REHABIL, V18, P132, DOI 10.1191/0269215504cr712oa; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Thomsen IV, 1990, NEUROPSYCHOLOGY, V4, P1; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Warrington EK., 1984, RECOGNITION MEMORY T; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	27	18	19	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	2					230	243		10.1080/09602010600750675			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IP	WOS:000246298400006	17454695				2021-06-18	
S	Park, E; Ai, JL; Baker, AJ		Weber, JT; Maas, AIR		Park, Eugene; Ai, Jinglu; Baker, Andrew J.			Cerebellar injury: clinical relevance and potential in traumatic brain injury research	NEUROTRAUMA: NEW INSIGHTS INTO PATHOLOGY AND TREATMENT	PROGRESS IN BRAIN RESEARCH		English	Article; Proceedings Paper	8th International Neurotrauma Symposium	MAY 21-25, 2006	Rotterdam, NETHERLANDS			animal models; cerebellum; electrophysiology; FPI; TAI; TBI	LURCHER MUTANT MICE; PENETRATING CRANIOCEREBRAL INJURIES; PURKINJE-CELL VULNERABILITY; PARALLEL FIBER STIMULATION; BERGMANN GLIAL-CELLS; SEVERE HEAD-INJURY; FLUID-PERCUSSION; GUNSHOT INJURIES; AXONAL INJURY; TIME-COURSE	A treatment for traumatic brain injury (TBI) remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. Numerous animal models have been developed to address the wide spectrum of mechanisms involved in the progression of secondary injury after TBI. Evidence from well-established models such as the fluid percussion injury (FPI) device, cortical impact model, and the impact acceleration model has demonstrated diffuse pathophysiological mechanisms throughout various brain structures. More specifically, we have recently extended characterization of the FPI model to include pathophysiological changes in the cerebellum following unilateral fluid percussion. Data suggest that the cerebellum is susceptible to selective Purkinje cell loss as well as white matter dysfunction. Despite the cerebellum's low profile in TBI research, there is evidence to warrant further study of the cerebellum to examine mechanisms of neuronal death and traumatic axonal injury. Furthermore, evidence from clinical literature and basic science suggests that some components of TBI pathophysiology have a basis in cerebellar dysfunction. This review highlights some of the recent findings in cerebellar trauma and builds an argument for including the cerebellum as a model to assess mechanisms of secondary injury and its potential contribution to the pathology of TBI.	[Park, Eugene; Ai, Jinglu; Baker, Andrew J.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada	Baker, AJ (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Alavi A, 1997, J NUCL MED, V38, P1717; ANDERSON JR, 1973, J NEUROL NEUROSUR PS, V36, P826, DOI 10.1136/jnnp.36.5.826; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Bellamy TC, 2005, GLIA, V52, P325, DOI 10.1002/glia.20248; Bellamy TC, 2006, CEREBELLUM, V5, P116, DOI 10.1080/14734220600724569; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; BHATIA KP, 1995, BRAIN, V118, P1087, DOI 10.1093/brain/118.5.1087; Bostrom K, 1992, Acta Neurochir Suppl (Wien), V55, P25; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHESTER CS, 1987, ANN NEUROL, V22, P77; Clark BA, 1997, J PHYSIOL-LONDON, V502, P335, DOI 10.1111/j.1469-7793.1997.335bk.x; D'Avella D, 2001, J Neurosurg Sci, V45, P29; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FOX CA, 1957, J ANAT, V91, P299; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Glickstein M, 2000, TRENDS NEUROSCI, V23, P613, DOI 10.1016/S0166-2236(00)01681-7; Gordon N, 1996, EUR J DISORDER COMM, V31, P359; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HECKROTH JA, 1994, J COMP NEUROL, V343, P173, DOI 10.1002/cne.903430113; HECKROTH JA, 1991, J COMP NEUROL, V312, P641, DOI 10.1002/cne.903120413; HECKROTH JA, 1992, J COMP NEUROL, V315, P85, DOI 10.1002/cne.903150107; Herrup K, 1997, ANNU REV NEUROSCI, V20, P61, DOI 10.1146/annurev.neuro.20.1.61; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mariotti C, 2005, J NEUROL, V252, P511, DOI 10.1007/s00415-005-0814-z; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathoo N, 2002, SURG NEUROL, V58, P225, DOI 10.1016/S0090-3019(02)00828-5; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; OHearn E, 1997, J NEUROSCI, V17, P8828; PARK E, 2006, IN PRESS EXP FLUIDS; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Ramnani N, 2006, NAT REV NEUROSCI, V7, P511, DOI 10.1038/nrn1953; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shamoto H, 1997, J CHILD NEUROL, V12, P407, DOI 10.1177/088307389701200701; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Sillitoe RV, 2002, J HISTOCHEM CYTOCHEM, V50, P235, DOI 10.1177/002215540205000211; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Strata P, 1998, TRENDS NEUROSCI, V21, P407, DOI 10.1016/S0166-2236(98)01305-8; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Voogd J, 1998, TRENDS NEUROSCI, V21, P370, DOI 10.1016/S0166-2236(98)01318-6; Welsh JP, 2002, ADV NEUROL, V89, P331; Zanjani HS, 1998, J NEUROSCI, V18, P319, DOI 10.1523/jneurosci.18-01-00319.1998; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	69	18	18	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0079-6123		978-0-444-53017-2	PROG BRAIN RES			2007	161						327	338		10.1016/S0079-6123(06)61023-6			12	Medicine, General & Internal; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	BGY20	WOS:000251295200023	17618988				2021-06-18	
J	Crespo, ART; Da Rocha, AB; Jotz, GP; Schneider, RF; Grivicich, I; Pinheiro, K; Zanoni, C; Regner, A				Proenca Crespo, Antonio Rogerio Tavares; Da Rocha, Adriana Brondani; Jotz, Geraldo Pereira; Schneider, Rogerio Fett; Grivicich, Ivana; Pinheiro, Kleiner; Zanoni, Caroline; Regner, Andrea			Increased serum sFas and TNF alpha following isolated severe head injury in males	BRAIN INJURY			English	Article						traumatic brain injury; sFas; TNF alpha; apoptosis; humans; biomarkers	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; CELL-DEATH; ANTIINFLAMMATORY MEDIATORS; UP-REGULATION; FAS LIGAND; APOPTOSIS	Objectives: Severe traumatic brain injury ( TBI) is associated with a 30 - 70% mortality rate. Nevertheless, controversy has been raised concerning the prognostic value of biomarkers following severe TBI. Therefore, our aim was to determine whether sFas or TNF alpha serum levels correlate with primary outcome following isolated severe TBI. Methods: Seventeen consecutive male patients, victims of isolated severe TBI ( Glasgow Coma Scale score 3 - 8) and a control group consisting of 6 healthy male volunteers were enrolled in this prospective study. Clinical outcome variables of severe TBI comprised: survival, time for intensive care unit (ICU) discharge, and neurological assessment by Glasgow Outcome Scale at ICU discharge. Venous blood samples were taken at admission in the ICU. Serum sFas and TNF alpha concentrations were measured by ELISA assays. Results: At admission in the ICU ( mean time 10.2 h after injury), mean sFas and TNF alpha concentrations were significantly increased in the TBI ( 0.105 and 24.275 rho g/l, respectively) compared with the control group ( 0.047 and 15.475 rho g/l, respectively). However, no significant correlation was found between higher serum sFas or TNF alpha concentrations and fatal outcome. Conclusions: Increased serum sFas and TNF alpha levels following isolated severe TBI did not predict fatal outcome.	Univ Luterana Brasil, Ctr Pesquisa Ciencias Med, Lab Marcadores Estresse Celular, BR-92425900 Canoas, RS, Brazil; Hosp Municipal Pronto Socorro, SAMU, Porto Alegre, RS, Brazil; Hosp Municipal Pronto Socorro, Serv Cirurgia, Porto Alegre, RS, Brazil; Fdn Fac Fed Ciencias Med, Curso Med, Porto Alegre, RS, Brazil; Hosp Mae Deus, Serv Cirurgia Trauma, Porto Alegre, RS, Brazil	Regner, A (corresponding author), Univ Luterana Brasil, Ctr Pesquisa Ciencias Med, Lab Marcadores Estresse Celular, Ave Farroupilha 8001,Predio 22,5 Andar,Bairrao Sa, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	JOTZ, GERALDO P/G-2664-2014; Regner, Andrea/M-2596-2014; Grivicich, Ivana/A-6777-2013	JOTZ, GERALDO P/0000-0001-6289-7827; Regner, Andrea/0000-0002-6657-7991; Grivicich, Ivana/0000-0001-9820-5730			ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BEER R, 2000, J CEREBRAL BLOOD FLO, V20, P429; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Duff D, 2003, AXONE, V23, P18; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kanduc D, 2002, INT J ONCOL, V21, P165; KRAUS JF, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Qiu JH, 2002, J NEUROSCI, V22, P3504; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	59	18	21	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					441	447		10.1080/02699050701311125			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600010	17487642				2021-06-18	
J	Schonberger, M; Humle, F; Teasdale, TW				Schoenberger, Michael; Humle, Frank; Teasdale, Thomas W.			The relationship between clients' cognitive functioning and the therapeutic working alliance in post-acute brain injury rehabilitation	BRAIN INJURY			English	Article						therapeutic working alliance; acquired brain injury; rehabilitation; cognitive functioning; neuropsychological tests; process research	PATIENT COMPLIANCE; HEAD-INJURY; PSYCHOTHERAPY; AWARENESS	Objective: To examine the impact of brain-injured patients' cognitive abilities on their working alliance (WA) with their therapist in post-acute rehabilitation. Design: Cognitive tests were administered to brain-injured individuals at the beginning of post-acute, holistic brain-injury rehabilitation. Clients as well as their primary therapists rated their mutual WA at four time points throughout a 14-week rehabilitation programme. Subjects consisted of 86 clients as well as their primary therapists. Clients had suffered a traumatic brain injury (n=27), a cerebrovascular accident (n = 49) or another neurological insult (n = 10). Measures: (1) Neuropsychological tests of attention, memory and higher cognitive functions; ( 2) the Working Alliance Inventory, client and therapist short form. Results: Overall, the relationships between cognitive tests and WA ratings were weak. The tests of attention, memory and higher cortical functions were differentially related to clients' and therapists' view of their mutual WA at the different stages of their collaborative work. Discussion and conclusion: Clients' cognitive profile affects clients' and therapists' view of their WA in different ways. The weakness of the correlations between cognitive tests and WA ratings may indicate that a good WA is achievable also with clients with severe cognitive difficulties.	Univ Copenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; Univ Copenhagen, Dept Psychol, Copenhagen, Denmark; Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	michael_schonberger@web.de					Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; Brickenkamp R., 1981, AUFMERKSAMKEITS BELA; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; Christensen AL, 1998, J HEAD TRAUMA REHAB, V13, P79, DOI 10.1097/00001199-199810000-00009; Christensen AL, 1996, NEUROPSYCHOL REHABIL, V6, P279, DOI 10.1080/713755511; CHRISTENSEN AL, 1975, NEUROPSYKOLOGISKE UN, P50; Constantino M.J., 2002, COUNSELING BASED PRO, P81; Davis LW, 2004, J NERV MENT DIS, V192, P508, DOI 10.1097/01.nmd.0000131919.60151.a7; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Herman S.M., 1998, J PSYCHOTHERAPY PRAC, V7, P56; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Judd D, 2005, BRAIN INJURY, V19, P437, DOI 10.1080/02699050400010994; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lambert M.J., 2002, PSYCHOTHERAPY RELATI, P17; Lewis L., 1991, AWARENESS DEFICIT BR, P223; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP., 1988, J HEAD TRAUMA REHAB, V3, P45; Raven J., 1998, MANUAL RAVENS ADV PR; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; SPREEN O, 1968, NEUROSENSORY CTR COM; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Tracey T. J., 1989, PSYCHOL ASSESS, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	35	18	18	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	8					825	836		10.1080/02699050701499433			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202YZ	WOS:000248942400004	17676440				2021-06-18	
J	Schroeter, ML; Ettrich, B; Schwier, C; Scheid, R; Guthke, T; von Cramon, DY				Schroeter, Matthias L.; Ettrich, Barbara; Schwier, Christiane; Scheid, Rainer; Guthke, Thomas; von Cramon, D. Yves			Diffuse axonal injury due to traumatic brain injury alters inhibition of imitative response tendencies	NEUROPSYCHOLOGIA			English	Article						diffuse axonal injury; executive functions; inhibition; imitation; stroop; traumatic brain injury	NEAR-INFRARED SPECTROSCOPY; MATCHING STROOP TASK; CLOSED-HEAD INJURY; NEUROPSYCHIATRIC INVENTORY; EXECUTIVE DYSFUNCTION; EMOTION RECOGNITION; MIND; INTERFERENCE; NEUROPRAGMATICS; COMMUNICATION	It is well known that traumatic brain injury particularly affects the frontal lobes. Consequently, patients often suffer from executive dysfunction and behavioral disturbances. Accordingly, our study aimed at investigating patients after traumatic brain injury with two tasks involving different functional processes and structural networks supported by the frontal lobes. Two paradigms were applied: the Stroop color-word task and a task in which subjects had to inhibit imitative response tendencies. We selected a patient group solely with diffuse axonal injury, as this type of injury is homogenous and is correlated with cognitive dysfunction more than focal contusions. To evaluate long-term effects most relevant for rehabilitation, we selected a patient group whose brain injuries dated back several years. Our results show that patients with diffuse axonal injury inhibited imitative responses more successfully than control subjects, whereas executive processes examined with the Stroop task were unaltered. Interestingly, impairments were tightly correlated both with the length of the post-traumatic amnesia predicting outcome in traumatic brain injury and with behavioral disturbances. Impairments in the imitation-inhibition task may indicate alterations in an anterior frontomedian neural network even years after traumatic brain injury. (C) 2007 Elsevier Ltd. All rights reserved.	Max Planck Inst Human Cognit & Brain Sci, D-04103 Leipzig, Germany; Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; Tech Univ Chemnitz, Inst Psychol, D-09120 Chemnitz, Germany	Schroeter, ML (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04103 Leipzig, Germany.	schroet@cbs.mpg.de					Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Beringer J., 1995, EXPT RUN TIME SYSTEM; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brass M, 2005, NEUROPSYCHOLOGIA, V43, P89, DOI 10.1016/j.neuropsychologia.2004.06.018; Brass M, 2005, TRENDS COGN SCI, V9, P314, DOI 10.1016/j.tics.2005.05.001; Brass M, 2003, NEUROPSYCHOLOGY, V17, P265, DOI 10.1037/0894-4105.17.2.265; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DELIS D, 1987, CALIFORNIA VERBAL LE; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Goethals I, 2004, J NEUROTRAUM, V21, P1059, DOI 10.1089/0897715041651051; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; HAERTING C, 2000, WMS R DTSCH ADAPTATI; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; LUCAS JA, 1999, CLIN NEUROPSYCHOLOGY, P243; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MacDonald SWS, 2006, TRENDS NEUROSCI, V29, P474, DOI 10.1016/j.tins.2006.06.011; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Okamoto T, 2007, EUR J NEUROL, V14, P540, DOI 10.1111/j.1468-1331.2007.01742.x; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schroeter ML, 2004, NEUROIMAGE, V22, P341, DOI 10.1016/j.neuroimage.2003.12.041; Schroeter ML, 2004, NEUROIMAGE, V23, P1317, DOI 10.1016/j.neuroimage.2004.08.001; Schroeter ML, 2002, HUM BRAIN MAPP, V17, P61, DOI 10.1002/hbm.10052; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson JTL, 2005, ACTA NEUROCHIR SUPPL, V93, P75; WOLFRAM H, 1986, PSYCHOL LEISTUNGSTES; Zimmermann P, 1993, TESTBATTERIE AUFMERK; Zysset S, 2001, NEUROIMAGE, V13, P29, DOI 10.1006/nimg.2000.0665	47	18	19	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2007	45	14					3149	3156		10.1016/j.neuropsychologia.2007.07.004			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	230DG	WOS:000250855400002	17727901				2021-06-18	
J	Lubsch, L; Habersang, R; Haase, M; Luedtke, S				Lubsch, Lisa; Habersang, Rolf; Haase, Mark; Luedtke, Sherry			Oral baclofen and clonidine for treatment of spasticity in children	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	12th Annual Meeting of the Pediatric-Pharmacy-Advocacy-Group	OCT, 2002	St Petersburg, FL	Pediat Pharm Advocacy Grp			CEREBRAL-PALSY; TRIAL; PHARMACOTHERAPY	Few data exist in the literature to support the use of high dosages of oral baclofen and clonidine that are frequently required to treat children with spasticity. This study was a retrospective chart review of baclofen and clonidine dosages used in children diagnosed with cerebral palsy or traumatic brain injury. The primary objective was to calculate the mean dosages of baclofen and clonidine based on the duration of spasticity postinjury. Secondary objectives included determining correlations between dosage and age, injury type, location of spasticity, comorbid seizures, or concomitant antispasticity medications. Eighty-seven children receiving baclofen and/or clonidine were included in this study. Mean dosages of 40 mg/day (n = 86) and 0.4 mg/day (n = 31) were required for baclofen and clonidine, respectively. The maximum dosage was 240 mg/day for baclofen and 3.6 mg/day for clonidine. Duration postinjury, age, and concomitant antispasticity medications were the most predictive variables for baclofen dosage as a model (r = .522; P = .000). Duration postinjury and location of spasticity were the most predictive variables for clonidine dosage as a model (r = .523; P = .000). The average dosages of baclofen and clonidine used in this population of children with cerebral palsy or traumatic brain injury were similar to those reported in the literature, with higher maximum dosages found in this investigation.	So Illinois Univ, Sch Pharm, Dept Pharm Practice, Edwardsville, IL 62026 USA; Texas Tech Hlth Sci Ctr, Sch Pharm, Dept Pediat, Amarillo, TX USA; Texas Tech Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Amarillo, TX USA	Lubsch, L (corresponding author), So Illinois Univ, Sch Pharm, Dept Pharm Practice, Campus Box 2000, Edwardsville, IL 62026 USA.	llubsch@siue.edu					Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; ASHWORTH B, 1964, PRACTITIONER, V192, P540; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; Goldstein EM, 2001, J CHILD NEUROL, V16, P16, DOI 10.1177/088307380101600104; Krach LE, 2001, J CHILD NEUROL, V16, P31, DOI 10.1177/088307380101600106; MILLA PJ, 1977, J INT MED RES, V5, P398; PARZIALE JR, 1993, ORHTOPEDICS, V16, P901; Rapp CE, 2000, ARCH FAM MED, V9, P466, DOI 10.1001/archfami.9.5.466; ROCCHINI AP, 1984, PEDIATR CLIN N AM, V31, P1259; Tilton AH, 2001, J CHILD NEUROL, V16, P66, DOI 10.1177/088307380101600112; WILENS TE, 1994, J AM ACAD CHILD PSY, V33, P424, DOI 10.1097/00004583-199403000-00018; YOUNG RR, 1994, NEUROLOGY, V44, P12	12	18	18	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	DEC	2006	21	12					1090	1092		10.1177/7010.2006.00134			3	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	122DX	WOS:000243207000020	17156708				2021-06-18	
J	Ulug, T; Ulubil, SA				Ulug, Tuncay; Ulubil, S. Arif			Contralateral labyrinthine concussion in temporal bone fractures	JOURNAL OF OTOLARYNGOLOGY			English	Article						hearing loss; labyrinthine concussion; temporal bone trauma	FACIAL-NERVE PARALYSIS	In this case presentation, three cases of labyrinthine concussion in the opposite ears of patients who had unilateral traumatic temporal bone fractures with facial paralysis are reported. The first patient was a 30-year-old male who had a right-sided longitudinal temporal bone fracture and labyrinthine concussion showing pure sensorineural hearing loss with a characteristic notch of 60 dB at 4000 Hz on the left side. The second patient was a 42-year-old male who had a right-sided traumatic facial paralysis owing to a mixed-type temporal bone fracture and labyrinthine concussion, demonstrating pure sensorineural hearing loss reaching its peak of 50 dB at 4000 Hz on the left. The third patient was a 19-year-old male who had a left-sided mixed-type temporal bone fracture and a right labyrinthine concussion exhibiting pure sensorineural hearing loss reaching 60 dB at 4000 Hz. For their facial paralyses, all three patients underwent middle cranial fossa or combined approach operations. The labyrinthine concussion in these patients was managed expectantly. At their 1-year follow-up, it was observed that the hearing loss owing to labyrinthine concussion persisted. Although labyrinthine concussion is not a rare complication of head injuries, it has rarely been reported in the medical literature. The main symptoms of labyrinthine concussion are hearing loss, tinnitus, and dizziness. The diagnosis mainly relies on audiometric tests, which reveal characteristic tracings reminiscent of acoustic trauma.	Univ Istanbul, Dept Otolaryngol, Fac Med, Istanbul, Turkey; Univ Miami, Dept Otolaryngol, Miami, FL 33152 USA	Ulug, T (corresponding author), Akdogan Sokak 30-11 Besiktas, Istanbul, Turkey.	tuncayu@superonline.com					AGUILAR EA, 1987, HEAD NECK-J SCI SPEC, V9, P162, DOI 10.1002/hed.2890090306; CANALIS RF, 1999, EAR COMPREHENSIVE OT, P795; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; KHAN AA, 1985, OTOLARYNG HEAD NECK, V93, P177, DOI 10.1177/019459988509300210; Lancaster JL, 1999, J ROY COLL SURG EDIN, V44, P87; Quaranta A, 2001, ACTA OTO-LARYNGOL, V121, P652, DOI 10.1080/000164801316878999; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; Scott A M, 1999, Am J Audiol, V8, P101, DOI 10.1044/1059-0889(1999/020); Segal S, 2002, OTOL NEUROTOL, V23, P312, DOI 10.1097/00129492-200205000-00014; Ulrich K., 1926, ACTA OTO-LARYNGOL, V6, P1	11	18	19	0	4	B C DECKER INC	HAMILTON	50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA	0381-6605			J OTOLARYNGOL	J. Otolaryngol.	DEC	2006	35	6					380	383		10.2310/7070.2006.0069			4	Otorhinolaryngology	Otorhinolaryngology	122TE	WOS:000243249000005	17380831				2021-06-18	
J	Zhang, J; Zhang, L; Ye, YL; Fang, SH; Zhou, Y; Zhang, WP; Lu, YB; Wei, EQ				Zhang, Jun; Zhang, Lei; Ye, Yi-Lu; Fang, San-Hua; Zhou, Yu; Zhang, Wei-Ping; Lu, Yun-Bi; Wei, Er-Qing			Cysteinyl leukotriene receptors CysLT(1) and CysLT(2) are upregulated in acute neuronal injury after focal cerebral ischemia in mice	ACTA PHARMACOLOGICA SINICA			English	Article						cysteinyl leukotriene receptor; cerebral ischemia; neuronal injury; mRNA expression	TRAUMATIC BRAIN-INJURY; MOLECULAR-CLONING; ARACHIDONIC-ACID; CELL-DEATH; RATS; ANTAGONIST; EXPRESSION; TUMORS; IDENTIFICATION; PROTECTS	Aim: To determine whether cysteinyl leukotriene receptors (CysLT(1) and CysLT(2)) are upregulated in acute neuronal injury after focal cerebral ischemia in mice, and to confirm CysL(T)1 receptor localization. Methods: After permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO), neurological deficits and neuron loss were determined at various time points within 48 h. The mRNA expressions of CysLT(1) and CysLT(2) receptors in the brain were analyzed by RT-PCR. CysLT(1) receptor localization was detected by double immunofluorescence. Results: Neurological deficits and neuron loss were found 6, 24 and 48 h after MCAO. The mRNA expressions of both CysLT(1) and CysLT(2) receptors were upregulated in the ischemic hemisphere 1, 24, and 48 h after MCAO with peaks at 24 h. The CysLT(1) receptor was selectively localized in neurons 24 h after MCAO. Conclusion: CysLT(1) and CysLT(2) receptors are upregulated in acute neuronal injury after focal cerebral ischemia, and the CysLT(1) receptor is localized in neurons after ischemia.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310058, Peoples R China; Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310009, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310058, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; CHU LS, 2003, ACTA PHARM SIN, V27, P282; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; Mazzetti L, 2003, BRIT J PHARMACOL, V138, P707, DOI 10.1038/sj.bjp.0705087; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Sarau HM, 1999, MOL PHARMACOL, V56, P657; Sheng WW, 2006, BIOCHEM BIOPH RES CO, V346, P19, DOI 10.1016/j.bbrc.2006.05.023; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; ZENG LH, 2001, ACTA PHARMACOL SINIC, V36, P148; Zhang LH, 2003, ACTA PHARMACOL SIN, V24, P1241; Zhang RL, 2003, EXP NEUROL, V184, P746, DOI 10.1016/S0014-4886(03)00296-6; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	31	18	22	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1671-4083			ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	DEC	2006	27	12					1553	1560		10.1111/j.1745-7254.2006.00458.x			8	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	108DU	WOS:000242221300005	17112408	Bronze			2021-06-18	
J	Carlile, MC; Yablon, SA; Mysiw, WJ; Frol, AB; Lo, D; Diaz-Arrastia, R				Carlile, Mary C.; Yablon, Stuart A.; Mysiw, W. Jerry; Frol, Alan B.; Lo, David; Diaz-Arrastia, Ramon			Deep venous thrombosis management following traumatic brain injury - A practice survey of the traumatic brain injury model systems	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						deep venous thrombosis; prophylaxis; pulmonary embolism; traumatic brain injury; venous thromboembolism	VEIN THROMBOSIS; THROMBOEMBOLIC DISEASE; PULMONARY-EMBOLISM; REHABILITATION; PROPHYLAXIS; PREVENTION; PREVALENCE; GUIDELINES; DIAGNOSIS; THERAPY	Objective: To determine national patterns of screening, prophylaxis, and treatment of deep venous thrombosis (DVT) following traumatic brain injury (TBI) within the Traumatic Brain Injury Model Systems (TBIMS). Design: e-mail survey instrument. Setting: Multicenter Regional TBIMS. Results: Fifteen of the 16 rehabilitation centers within the TBIMS responded to the survey (94% response rate). Approximately half of these centers routinely screen to detect subclinical DVTs (56% venous duplex ultrasonography, 12% plasma D-dimer) on admission to inpatient rehabilitation. Fifty-six percent of respondents use anticoagulation prophylactically, while 69% use mechanical means for DVT prophylaxis. Eighty fatal pulmonary emboli were reported for TBI patients in 189 practice-years, corresponding to 0.42 fatalities per year of practice. Conclusions: No consensus exists regarding the optimal methods for screening, prevention, or treatment of DVT in TBI patients in the acute rehabilitation setting of the TBIMS. The number of fatal pulmonary emboli reported among these centers emphasizes the need to develop evidence-based clinical practice guidelines for the prevention and treatment of venous thromboembolism in this patient population.	Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX 75246 USA; Univ Mississippi, Sch Med, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Sch Med, Dept Neurosurg, Jackson, MS 39216 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA	Carlile, MC (corresponding author), Baylor Inst Rehabil, Dept Phys Med & Rehabil, 3505 Gaston Ave, Dallas, TX 75246 USA.	MaryCar@BaylorHealth.edu	Mysiw, Walter/E-3724-2011	Diaz-Arrastia, Ramon/0000-0001-6051-3594			Bates SM, 2004, NEW ENGL J MED, V351, P268, DOI 10.1056/NEJMcp031676; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Burke DT, 1999, J HEAD TRAUMA REHAB, V14, P515, DOI 10.1097/00001199-199910000-00015; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; Hammond FM, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199802000-00007; Hirsh J, 2004, CHEST, V126, p172S, DOI 10.1378/chest.126.3_suppl.172S; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; LAGERSTEDT CI, 1985, LANCET, V2, P515; Lai JM, 1997, BRAIN INJURY, V11, P331, DOI 10.1080/026990597123485; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Sharpe RP, 2002, J TRAUMA, V53, P1048, DOI 10.1097/00005373-200212000-00003; STEIN PD, 1995, CHEST, V108, P978, DOI 10.1378/chest.108.4.978; WRIGHT DJ, 1990, J VASC SURG, V11, P675, DOI 10.1067/mva.1990.18519; Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F; Yablon SA, 2000, AM J PHYS MED REHABI, V79, P204	21	18	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					483	490		10.1097/00001199-200611000-00003			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400003	17122679				2021-06-18	
J	Zhang, YH; Zhang, HJ; Wu, F; Chen, YH; Ma, XQ; Du, JQ; Zhou, ZL; Li, JY; Nan, FJ; Li, J				Zhang, Ya-Hui; Zhang, Hua-Jie; Wu, Fang; Chen, Yi-Hua; Ma, Xue-Qin; Du, Jun-Qin; Zhou, Zhong-Liang; Li, Jing-Ya; Nan, Fa-Jun; Li, Jia			Isoquinoline-1,3,4-trione and its derivatives attenuate beta-amyloid-induced apoptosis of neuronal cells	FEBS JOURNAL			English	Article						attenuate apoptosis; beta-amyloid; caspase-3 inhibitor; irreversible; neuronal cell	TRAUMATIC BRAIN-INJURY; CASPASE INHIBITOR; PRECURSOR PROTEIN; PEPTIDE; ACTIVATION; CLEAVAGE; POTENT; INVOLVEMENT; SURVIVAL; DISEASE	Caspase-3 is a programmed cell death protease involved in neuronal apoptosis during physiological development and under pathological conditions. It is a promising therapeutic target for treatment of neurodegenerative diseases. We reported previously that isoquinoline-1,3,4-trione and its derivatives inhibit caspase-3. In this report, we validate isoquinoline-1,3,4-trione and its derivatives as potent, selective, irreversible, slow-binding and pan-caspase inhibitors. Furthermore, we show that these inhibitors attenuated apoptosis induced by beta-amyloid(25-35) in PC12 cells and primary neuronal cells.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Beijing 100864, Peoples R China; E China Normal Univ, Acad Life Sci, Shanghai 200062, Peoples R China	Nan, FJ (corresponding author), 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.	fjnan@mail.shcnc.ac.cn; jli@mail.shcnc.ac.cn	Chen, Yihua/A-4323-2013; Du, Junqing/B-7803-2016; Li, Jia/F-9116-2011; Chen, Yihua/O-2743-2019	Chen, Yihua/0000-0003-1733-7980; Du, Junqing/0000-0001-7449-1170; Chen, Yihua/0000-0003-1733-7980			Ayala-Grosso C, 2002, BRAIN PATHOL, V12, P430; Chapman JG, 2002, EUR J PHARMACOL, V456, P59, DOI 10.1016/S0014-2999(02)02484-6; Chen YH, 2006, J MED CHEM, V49, P1613, DOI 10.1021/jm050896o; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EARNSHAW WC, 2003, J PHARMACOL EXP THER, V304, P433; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Erhardt J, 1999, MOL BIOL CELL, V10, p328A; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Guo ZM, 2001, BIOORGAN MED CHEM, V9, P99, DOI 10.1016/S0968-0896(00)00222-4; Hoglen NC, 2004, J PHARMACOL EXP THER, V309, P634, DOI 10.1124/jpet.103.062034; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Kim R, 2001, INT J ONCOL, V18, P1227; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Krakauer T, 2004, CLIN DIAGN LAB IMMUN, V11, P621, DOI 10.1128/CDLI.11.3.621-624.2004; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Misiti F, 2005, NEUROCHEM INT, V46, P575, DOI 10.1016/j.neuint.2005.01.001; Natori S, 2003, LIVER TRANSPLANT, V9, P278, DOI 10.1053/jlts.2003.50019; Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; ROBERT AC, 2004, DRUG DISCOVERY GUIDE, P125; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van de Craen M, 1999, FEBS LETT, V445, P149, DOI 10.1016/S0014-5793(99)00108-8; Velez-Pardo C, 2002, NEUROTOXICOLOGY, V23, P351, DOI 10.1016/S0161-813X(02)00081-5; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang W, 2003, BRIT J PHARMACOL, V140, P402, DOI 10.1038/sj.bjp.0705450	36	18	18	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	NOV	2006	273	21					4842	4852		10.1111/j.1742-4658.2006.05483.x			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	095YJ	WOS:000241343900004	17032354				2021-06-18	
J	Anderson, V; Anderson, D; Anderson, P				Anderson, Vicki; Anderson, Dianne; Anderson, Peter			Comparing attentional skills in children with acquired and developmental central nervous system disorders	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						sustained attention; children; CNS; ADHD; TBI; variability	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; PEDIATRIC HEAD-INJURY; ACUTE LYMPHOBLASTIC-LEUKEMIA; CONTINUOUS PERFORMANCE-TEST; SELECTIVE ATTENTION; NEUROPSYCHOLOGICAL EVALUATION; CRANIAL IRRADIATION; SUSTAINED ATTENTION; EVERYDAY ATTENTION	Attentional impairments in children occur in the context of both developmental and acquired disorders involving the central nervous system (CNS) and may have implications for ongoing development, potentially impeding cognitive, educational, and behavioral functions. Using a continuous performance paradigm (CPT), this study compared attentional profiles of children with developmental and acquired conditions impacting on the CNS: (i) attention deficit-hyperactivity disorder (ADHD: n = 27); (ii) moderate traumatic brain injury (TBI: n = 41); (iii) acute lymphoblastic leukemia (n = 3 1); and (iv) insulin-dependent diabetes mellitus (n = 39). A healthy control group (n = 46) was also examined. Groups were compared on measures of sustained attention, selective attention, and response inhibition. In addition, measures of performance variability and deterioration and processing speed were examined. Results showed that children with ADHD exhibited global and severe attentional impairments in contrast to all other groups. Children with moderate TBI displayed mild attentional difficulties, restricted to selective and sustained attention domains. In conclusion, although CPT parameters differentiated the ADHD group from all others, a disorder-specific profile was not observed.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Dept Psychol, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Anderson, Peter J/B-6839-2015; Anderson, Peter John/O-5302-2019	Anderson, Peter J/0000-0001-7430-868X; Anderson, Peter John/0000-0001-7430-868X			Aman CJ, 1998, DEV PSYCHOL, V34, P956, DOI 10.1037/0012-1649.34.5.956; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2004, J CLIN EXP NEUROPSYC, V26, P684, DOI 10.1080/13803390490504344; Anderson VA, 2000, BRIT J CANCER, V82, P255; Aronson M, 1997, DEV MED CHILD NEUROL, V39, P583; AUGUST GJ, 1990, J ABNORM CHILD PSYCH, V18, P29, DOI 10.1007/BF00919454; Barkley R.A., 1999, HDB DISRUPTIVE BEHAV, P295; BARONCOHEN S, 1995, MOVEMENT ALLIED DISO, P306; BROUWERS P, 1985, J PEDIATR-US, V106, P723, DOI 10.1016/S0022-3476(85)80343-7; CASEY BJ, 1993, J CLIN EXP NEUROPSYC, V15, P933, DOI 10.1080/01688639308402609; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; Cowan N., 1997, ATTENTION MEMORY; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; GOFF JR, 1980, DEV BEH PEDIAT, V1, P153; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; HAGEN JW, 1990, CHILD DEV, V61, P1714, DOI 10.2307/1130833; Heaton SC, 2001, CHILD NEUROPSYCHOL, V7, P251, DOI 10.1076/chin.7.4.251.8736; HOLMES CS, 1990, NEUROPSYCHOLOGICAL B, P122; HOOKS K, 1994, J CLIN CHILD PSYCHOL, V23, P69, DOI 10.1207/s15374424jccp2301_9; James W., 1890, PRINCIPLES PSYCHOL; Johannes S, 2001, ACTA NEUROL SCAND, V104, P36, DOI 10.1034/j.1600-0404.2001.00308.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINGMA A, 1993, AM J PEDIAT HEMATOL, V15, P231; KLIN A, 1995, SYNDROME NONVERBAL L, P93; Konrad KN, 2000, BRAIN INJURY, V14, P859; Lajoie G., 2005, BRAIN IMPAIR, V6, P21, DOI DOI 10.1375/BRIM.6.1.21.65479; LANE DM, 1982, MERRILL PALMER QUART, V28, P317; LANE DM, 1978, J EXPT CHILD PSYCHOL, V28, P16; Levy F, 1997, J PAEDIATR CHILD H, V33, P384; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEA CH TEST EVERYDAY; MCCALL AL, 1997, DIABETES SPECTRUM, V10, P25; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; Northam EA, 1998, DIABETES CARE, V21, P379, DOI 10.2337/diacare.21.3.379; Northam EA, 2001, DIABETES CARE, V24, P1541, DOI 10.2337/diacare.24.9.1541; PAAKKO E, 1992, CANCER, V70, P2728, DOI 10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 1997, J INT NEUROPSYCH SOC, V3, P225; POSNER M, 1984, NEUROBIOLOGY LEARNIN; Posner MI., 1978, CHRONOMETRIC EXPLORA; REBOK G, 1997, CHILD NEUROPSYCHOL, V3, P47; Reeve WV, 2001, ADOLESCENCE, V36, P749; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; ROWE JK, 1995, ROWE BEHAV RATING IN; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; Ruff HA, 1996, ATTENTION EARLY DEV; Sattler J.M., 1988, ASSESSMENT CHILDRENS, V3rd; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SEIDEL WT, 1990, J ABNORM CHILD PSYCH, V18, P217, DOI 10.1007/BF00910732; Semrud-Clikeman M, 2000, J AM ACAD CHILD PSY, V39, P477, DOI 10.1097/00004583-200004000-00017; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; SHEPP BE, 1987, J EXP CHILD PSYCHOL, V43, P159, DOI 10.1016/0022-0965(87)90057-9; Shiffrin R. M., 1988, STEVENS HDB EXPT PSY, V2, P739; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; TALLROTH G, 1992, METABOLISM, V41, P717, DOI 10.1016/0026-0495(92)90310-7; TAYLOR HM, 1993, PHLEBOLOGY S, V1, P22; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P627, DOI 10.1007/BF00913474; Villella S., 2001, CLIN NEUROPSYCHOL, V21, P1; WAINWRIGHTSHARP JA, 1993, J AUTISM DEV DISORD, V23, P1, DOI 10.1007/BF01066415; WATERS KD, 1992, MED PAEDIAT ONCOLOGY, V20; Wechsler D., 1991, MANUAL WECHSLER INTE; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5; Wu KK, 2002, DEV NEUROPSYCHOL, V22, P501, DOI 10.1207/S15326942DN2202_5; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 1994, NEUROPSYCHOLOGY, V8, P65, DOI 10.1037/0894-4105.8.1.65	83	18	19	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2006	12	4					519	531		10.1017/S135561770606067X			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	063DU	WOS:000238997300009	16981604				2021-06-18	
J	Israelsson, C; Lewen, A; Kylberg, A; Usoskin, D; Althini, S; Lindeberg, J; Deng, CX; Fukuda, T; Wang, Y; Kaartinen, V; Mishina, Y; Hillered, L; Ebendal, T				Israelsson, Charlotte; Lewen, Anders; Kylberg, Annika; Usoskin, Dmitry; Althini, Susanna; Lindeberg, Jonas; Deng, Chu-Xia; Fukuda, Tomokazu; Wang, Yun; Kaartinen, Vesa; Mishina, Yuji; Hillered, Lars; Ebendal, Ted			Genetically modified bone morphogenetic protein signalling alters traumatic brain injury-induced gene expression responses in the adult mouse	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						TBI; activin receptor-1; Smad4; CaMKII-Cre; glial fibrillary acidic protein	CENTRAL-NERVOUS-SYSTEM; SERINE/THREONINE KINASE RECEPTORS; MICROTUBULE-ASSOCIATED PROTEIN-2; MESSENGER-RNA; TISSUE INHIBITOR; DENDRITIC GROWTH; MICE; BMP; HIPPOCAMPUS; ISCHEMIA	Three genetic mouse models were examined to define effects of bone morphogenetic protein (BMP) signalling on gene expression in normal and injured adult brain. CaMKII-Cre eliminated the BMP receptor Acvr1 (Alk2) and the common TGF beta superfamily signal mediator Smad4 or activated a constitutively active Acvr1 in postnatal forebrain neurons. All mutants followed mendelian ratios, with no overt phenotypic changes. In situ hybridization demonstrated normal patterns of the dendritic marker MAP2 (Mtap2) throughout cortex despite neuron-specific losses of Acvr1 or Smad4. However, strong up-regulation of Mtap2 transcript in these mice was found by quantitative RT-PCR (qRT-PCR), indicating that Mtap2 is normally suppressed by BMR Traumatic brain injury (TBI) resulted in increases of histone-associated DNA fragments in both control and Smad4-deficient cortex. Several cell-type-specific transcripts known to be involved in injury-related responses were measured by qRT-PCR. Gfap mRNA was strongly upregulated in controls as well as in the loss-of-BMP-signalling mutants. Notably, activated Acvr1 signalling gave significantly lower TBI-induced up-regulations of Gfap and Phox2a mRNA levels, indicating reductions in astroglial and neuronal reactions to injury. Strong impairment in injury-induced Timp1 transcript up-regulation was also seen in these mice. In contrast, osteopontin (Spp1) transcript levels in activated microglia were not reduced by Acvr1 signalling. Altogether, the data suggest that BMP signalling is dispensable in adult cortical neurons but that augmented BMP signalling affects molecular changes associated with neuronal lesions. (c) 2006 Wiley-Liss, Inc.	Uppsala Univ, Dept Neurosci, Biomed Ctr, SE-75123 Uppsala, Sweden; Univ Uppsala Hosp, Uppsala, Sweden; NIDDK, Mammalian Genet Sect, NIH, Bethesda, MD USA; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; NIDA, NIH, Neurol Protect & Regenerat Sect, Baltimore, MD 21224 USA; Univ So Calif, Childrens Hosp, Dev Biol Program, Los Angeles, CA 90027 USA	Ebendal, T (corresponding author), Uppsala Univ, Dept Neurosci, Biomed Ctr, Box 587, SE-75123 Uppsala, Sweden.	ted.ebendal@neuro.uu.se	Lewen, Anders/A-5156-2013; deng, chuxia/N-6713-2016; Fukuda, Tomokazu/O-1257-2018	Lewen, Anders/0000-0003-4925-1348; Fukuda, Tomokazu/0000-0001-8456-0483; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL074862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE013085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [Z01DK056012, ZIADK056001, Z01DK056001, ZIADK056012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES071003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000443, ZIADA000461, Z01DA000443, Z01DA000461] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL074862] Funding Source: Medline; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE013085] Funding Source: Medline		Althini S, 2004, MOL CELL NEUROSCI, V25, P345, DOI 10.1016/j.mcn.2003.10.015; Angley C, 2003, J NEUROSCI, V23, P260; Bengtsson H, 1995, NEUROREPORT, V7, P113, DOI 10.1097/00001756-199512000-00027; Bengtsson H, 1998, J NEUROSCI RES, V53, P559, DOI 10.1002/(SICI)1097-4547(19980901)53:5<559::AID-JNR6>3.0.CO;2-8; Chang CF, 2002, NEUROPHARMACOLOGY, V43, P418, DOI 10.1016/S0028-3908(02)00092-8; Crocker SJ, 2004, J NEUROSCI RES, V75, P1, DOI 10.1002/jnr.10836; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dudas M, 2004, MECH DEVELOP, V121, P173, DOI 10.1016/j.mod.2003.12.003; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FUKUDA T, IN PRESS GENESIS; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Gu ZY, 1999, DEVELOPMENT, V126, P2551; Guha U, 2004, DEVELOPMENT, V131, P1175, DOI 10.1242/dev.01013; Hall AK, 2004, J NEUROSCI RES, V76, P1, DOI 10.1002/jnr.20019; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Kaartinen V, 2001, GENESIS, V31, P126, DOI 10.1002/gene.10015; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lein PJ, 2002, J NEUROSCI, V22, P10377; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; Liu YT, 2001, BRAIN RES, V905, P81, DOI 10.1016/S0006-8993(01)02502-1; Lonn P, 2005, NEUROCHEM RES, V30, P753, DOI 10.1007/s11064-005-6868-6; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Mishina Y, 1999, DEV BIOL, V213, P314, DOI 10.1006/dbio.1999.9378; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soderstrom S, 1999, J NEUROSCI RES, V56, P482; Soderstrom S, 1996, CELL TISSUE RES, V286, P269, DOI 10.1007/s004410050697; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Withers GS, 2000, EUR J NEUROSCI, V12, P106, DOI 10.1046/j.1460-9568.2000.00889.x; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang YQ, 2004, J APPL PHYS, V95, P3667, DOI 10.1063/1.1652250; Zhou YX, 2003, J BIOL CHEM, V278, P42313, DOI 10.1074/jbc.M308287200	51	18	18	0	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL	2006	84	1					47	57		10.1002/jnr.20856			11	Neurosciences	Neurosciences & Neurology	061UD	WOS:000238897400005	16583403				2021-06-18	
J	Hoffmann, B; Karbe, H; Krusch, C; Muller, B; Pause, M; Prosiegel, M; Puschendorf, W; Schleep, J; Spranger, M; Steube, D; Voss, A				Hoffmann, B.; Karbe, H.; Krusch, C.; Mueller, B.; Pause, M.; Prosiegel, M.; Puschendorf, W.; Schleep, J.; Spranger, M.; Steube, D.; Voss, A.			Early rehabilitation in neurology and neurosurgery: a multicenter study to describe typical impairments and complications define patient characteristics	AKTUELLE NEUROLOGIE			German	Article							SCALE	In nine centers for neurological in-patient rehabilitation in different states within the Federal Republic of Germany, every patient who was admitted and treated in the phase of early rehabilitation was prospectively documented. The aim of this documentation was a general description of the Phase-B-patient group in Germany with demographic and medical data. 1280 patients were included in the study. They were predominantly of male gender (62%) and the median of the age was 65 years. The largest number of these patients were transferred from neurological and/or neurosurgical departments where they were treated for 27 days on average before their discharge and transfer to the rehabilitation centre. On admission to the rehabilitation hospital, 17% of all patients were dependent on artificial respiration. The average patient was rated by the Glasgow Coma Scale (GCS) as being in a light or middle coma status at this time. Patients remained in the rehabilitation center for 57 days on average. During this time recovery depended on diagnosis: Those with a favourable diagnosis e.g. traumatic brain injury (TBI) recovered rather quickly compared to those who where diagnosed with brain hypoxia, who did not show measurable amendments. A discharge from early rehabilitation Phase B to home care was documented in 24.3% of all patients, 33.1% were transferred to further rehabilitation treatment and 23.1% to a nursing home. 6.4% of all documented patients died during the documented study period. For a great number of patients the outcome, as defined by the Glasgow Outcome Scale was estimated as "upper severe diasability" or "lower moderate disability", therefore it is concluded, that the early rehabilitation Phase B is a very effective treatment.	Klinikum Staffelstein, D-96231 Bad Staffelstein, Germany; Clemenshosp, Munster, Germany; Neurol Rehabil Zentrum Godeshohe, Bad Godesberg, Germany; Asklepios Schlossberg Klin, Bad Konig, Germany; Klin Bavaria, Kreischa, Germany; Neurol Krankenhaus, Munich, Germany; Neurol Klin Westend, Bad Wildungen, Germany; Friedehorst Neurol Rehabil Zentrum, Bremen, Germany; Neurol Clin, Bad Neustadt an der Saale, Germany	Pause, M (corresponding author), Klinikum Staffelstein, Kurpk 11, D-96231 Bad Staffelstein, Germany.	Mpause@Schoen-Kliniken.de					Bundesarbeitsgemeinschaft fur Rehabilitation (BAR), 1999, EMPF NEUR REH PAT SC; Chesnut RM, 1998, EVIDENCE REPORT REHA; *FACHPR STAT VERS, 1982, HEUR BAY STAATSM ARB; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; MAHONEY F I, 1965, Md State Med J, V14, P61; Schonle P W, 2001, Rehabilitation (Stuttg), V40, P123; Schonle P W, 1995, Rehabilitation (Stuttg), V34, P69; Stier-Jarmer M, 2002, PHYS MED REHAB KUROR, V12, P260, DOI 10.1055/s-2002-35154; TEASDALE G, 1974, LANCET, V2, P81; Voss A, 1993, SPECTRUM NEUROREHABI, P112; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zieger A, 1998, J ANASTHESIE INTENSI, V1, P220	12	18	18	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0302-4350			AKTUEL NEUROL	Aktuelle Neurol.	JUN	2006	33	5					287	296		10.1055/s-2005-915348			10	Clinical Neurology	Neurosciences & Neurology	061BH	WOS:000238845700006					2021-06-18	
J	Cunningham, MG; Goldstein, M; Katz, D; O'Neil, SQ; Joseph, A; Price, B				Cunningham, MG; Goldstein, M; Katz, D; O'Neil, SQ; Joseph, A; Price, B			Coalescence of psychiatry, neurology, and neuropsychology: From theory to practice	HARVARD REVIEW OF PSYCHIATRY			English	Article; Proceedings Paper	16th Annual Meeting of the American-Neuropsychiatry-Association	FEB-MAR -, 2005	Bal Harbour, FL	Amer Neuropsychiat Assoc		collaboration; cross-training; multidisciplinary; neurology; neuropsychiatry; psychiatry	TRAUMATIC BRAIN-INJURY; BORDERLINE PERSONALITY-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; MAJOR DEPRESSION; FUNCTIONAL NEUROANATOMY; INTELLECTUAL FRAMEWORK; HIPPOCAMPAL-NEURONS; CINGULATE CORTEX; METABOLIC-RATE; SCHIZOPHRENIA	In a climate of renewed interest in the synergy between neurology and psychiatry, practitioners are increasingly recognizing the importance of exchange and collaboration between these two disciplines. However, there are few working models of interdisciplinary teams that freely share expertise in real time, while providing clinical and academic training to future physicians who specialize in the central nervous system. Over the past 11 years, the McLean Hospital Neuropsychiatry and Behavioral Neurology service has provided proof-of-principle for such collaboration, demonstrating that a team comprising psychiatrists, neurologists, and neuropsychologists can function effectively as a unit while maintaining the autonomy of these three disciplines and also synthesizing their combined knowledge. In addition to delivering enhanced patient care and promoting medical research, this clinical service has provided enriched cross-specialty training for fellows, residents, and medical students. The practical functioning of the team is described, and case vignettes are presented to illustrate the team's collaborative synergism in practice.	McLean Hosp, Belmont, MA 02478 USA; Harvard Univ, Med Sch, Dept Psychiat, Cambridge, MA 02138 USA; Harvard Univ, Med Sch, Dept Neurol, Cambridge, MA 02138 USA; Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Univ British Columbia, Dept Psychol, Vancouver, BC, Canada; Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA	Cunningham, MG (corresponding author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA.	mcunningham@mclean.harvard.edu					Adachi N, 2002, EPILEPSIA, V43, P1574, DOI 10.1046/j.1528-1157.2002.22402.x; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Benes FM, 2001, BIOL PSYCHIAT, V50, P395, DOI 10.1016/S0006-3223(01)01084-8; BENES FM, 1992, CEREB CORTEX, V2, P503, DOI 10.1093/cercor/2.6.503; BRAGG TA, 1990, MCLEAN HOSP J, V15, P1; BRAUN AR, 1995, NEUROPSYCHOPHARMACOL, V13, P151, DOI 10.1038/sj.npp.1380284; Chapman C B, 1974, Daedalus, V103, P105; Coyle JT, 1996, MOL PSYCHIATR, V1, P5; Cummings J. L., 1995, NEUROPSYCHIATRY BEHA; Detre T, 1997, ARCH GEN PSYCHIAT, V54, P201; Drevets WC, 2000, NUCL MED BIOL, V27, P499, DOI 10.1016/S0969-8051(00)00119-0; Driessen M, 2000, ARCH GEN PSYCHIAT, V57, P1115, DOI 10.1001/archpsyc.57.12.1115; EISENBURG L, 2002, NEUROL TODAY, V12, P4; Filley CM, 2002, J NEUROPSYCH CLIN N, V14, P344, DOI 10.1176/appi.neuropsych.14.3.344; GORMAN J, 2001, CNS SPECTRUMS, V6, P740; Gorman J M, 2001, CNS Spectr, V6, P947; Gorman Jack M, 2002, CNS Spectr, V7, P261; Haase CG, 2003, BEHAV NEUROL, V14, P39, DOI 10.1155/2003/843760; Haznedar MM, 1997, AM J PSYCHIAT, V154, P682; Heckers S, 2002, J NEURAL TRANSM, V109, P891, DOI 10.1007/s007020200073; Herpertz SC, 2001, BIOL PSYCHIAT, V50, P292, DOI 10.1016/S0006-3223(01)01075-7; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kandel ER, 1998, AM J PSYCHIAT, V155, P457, DOI 10.1176/ajp.155.4.457; Kandel ER, 1999, AM J PSYCHIAT, V156, P505; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leroi I, 2002, AM J PSYCHIAT, V159, P1306, DOI 10.1176/appi.ajp.159.8.1306; Martin JB, 2002, AM J PSYCHIAT, V159, P695, DOI 10.1176/appi.ajp.159.5.695; MAYBERG HS, 1994, J NUCL MED, V35, P929; MCCULLOUGH D, 2001, TOUCHSTONE; McHenry L.C., 1969, GARRISONS HIST NEURO; Mitterschiffthaler MT, 2003, NEUROREPORT, V14, P177, DOI 10.1097/00001756-200302100-00003; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Paquette V, 2003, NEUROIMAGE, V18, P401, DOI 10.1016/S1053-8119(02)00030-7; PATERSON A, 1946, BRAIN, V69, P58, DOI 10.1093/brain/69.1.58; Posse S, 2003, NEUROIMAGE, V18, P760, DOI 10.1016/S1053-8119(03)00004-1; PRICE B, 2002, PSYCHIAT UPDATE; PRICE BH, 1999, HOSP NEUROLOGY, P619; Price BK, 2000, NEUROLOGY, V54, P8, DOI 10.1212/WNL.54.1.8; SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60; Saxena S, 2003, AM J PSYCHIAT, V160, P522, DOI 10.1176/appi.ajp.160.3.522; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; Soderstrom H, 2002, PSYCHIAT RES-NEUROIM, V114, P81, DOI 10.1016/S0925-4927(02)00006-9; Tiihonen J, 1997, AM J PSYCHIAT, V154, P239; van Praag H, 1999, NAT NEUROSCI, V2, P266; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WATSON RI, 1953, PSYCHOL BULL, V50, P321, DOI 10.1037/h0062847	48	18	20	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1067-3229			HARVARD REV PSYCHIAT	Harv. Rev. Psychiatr.	MAY-JUN	2006	14	3					127	140		10.1080/10673220600748536			14	Psychiatry	Psychiatry	058XH	WOS:000238697400001	16787885				2021-06-18	
J	Brandstack, N; Kurki, T; Tenovuo, O; Isoniemi, H				Brandstack, Nina; Kurki, Timo; Tenovuo, Olli; Isoniemi, Heli			MR imaging of head trauma: Visibility of contusions and other intraparenchymal injuries in early and late stage	BRAIN INJURY			English	Article						head trauma; magnetic resonance imaging; contusion; diffuse axonal injury	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; COMA SCALE SCORE; BRAIN-INJURY; CORPUS-CALLOSUM; COMPUTERIZED-TOMOGRAPHY; QUANTITATIVE-ANALYSIS; DEGENERATIVE CHANGES; CT FINDINGS; MILD	The aim of this study was to investigate the visibility of traumatic brain lesions on conventional magnetic resonance images (MRI) in early and late phase. Thirty-six patients were studied 1 week and 1 year after a traumatic brain injury. A similar MRI technique was used in both studies; T-2-weighted fast or turbo spin echo images, fluid attenuated inversion recovery ( FLAIR) images and T-1-weighted images were used for analysis. The number and extent of contusions and semi-quantitative score of other traumatic intraparenchymal lesions were compared in the early and late phase. Contusions were seen in 18 patients both in acute and 1 year MRI; the number and extent of visible contusions was significantly decreased at 1 year. Other traumatic intraparenchymal lesions were detected in 12 patients in early MRI and in 10 patients in late MRI. The number of visible lesions and the semi-quantitative scores were significantly lower at 1 year. There is a significant decrease in the visibility of both cortical contusions and other intraparenchymal injuries in late MRI studies compared with studies in acute stage using conventional imaging techniques. Thus, early phase MRI is essential for the detection of brain injury at least using conventional imaging techniques.	Turku Univ Hosp, Dept Radiol, FIN-20521 Turku, Finland; Turku Univ Hosp, Dept Neurol, FIN-20521 Turku, Finland	Kurki, T (corresponding author), Turku Univ Hosp, Dept Radiol, Pl 52, FIN-20521 Turku, Finland.	timoji.kurki@pp.inet.fi		Kurki, Timo/0000-0001-5532-3534			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, ACT NEUR S, V70, P115; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Fiser SM, 1998, AM SURGEON, V64, P1088; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; FUMEYA H, 1990, ACT NEUR S, V51, P283; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; ICHISE M, 1994, J NUCL MED, V35, P217; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marmarou A, 2000, ACT NEUR S, V76, P349; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; PRAYER L, 1993, ACTA RADIOL, V34, P593; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Sinson G, 2001, AM J NEURORADIOL, V22, P143; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Stamatakis EA, 2002, J NUCL MED, V43, P476; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Voller B, 2001, BRAIN INJURY, V15, P107, DOI 10.1080/026990501458344; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wilson JTL, 1990, NEUROPSYCHOLOGY, V4, P261, DOI 10.1037/0894-4105.4.4.261; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	85	18	19	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2006	20	4					409	416		10.1080/02699050500487951			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700005	16716986				2021-06-18	
J	Skarbek-Borowska, S; Amanullah, S; Mello, MJ; Linakis, JG				Skarbek-Borowska, S; Amanullah, S; Mello, MJ; Linakis, JG			Emergency department visits for sledding injuries in children in the United States in 2001/2002	ACADEMIC EMERGENCY MEDICINE			English	Article						sledding; injuries; children	ACCIDENTS; ONTARIO; RISK	Objectives: To describe the characteristics of nonfatal sledding-related injuries in U.S. children resulting in emergency department (ED) visits in 2001/2002 and to explore the implications of these findings for injury prevention efforts. Methods: A stratified probability sample of U.S. hospitals providing emergency services in the National Electronic Injury Surveillance System-All Injury Program was utilized for 2001/2002. ED visits resulting from injuries involving sleds, snow discs, snow tubes, and toboggans were analyzed for patients 19 years of age or younger. Results: In 2001/2002, there were an estimated 57,866 ED visits for sledding-related injuries in the United States for all age groups. Of these, 41,272 (71%) occurred in patients 19 years of age or younger, 58% of whom were male. The highest number of injuries occurred in children between five and 14 years of age (74%), and the injuries were most often caused by falls or collisions (75%). The head or neck was the most frequently injured body region among those 0-9 years of age, while the extremities were injured most commonly among those 10-19 years of age. Head and neck injuries occurred in 56% (95% confidence interval [CI] = 32% to 81%) of children 0-4 years of age versus 19% (95%, CI = 9% to 29%) of patients 15-19 years of age. Nine percent (95% Cl = 6% to 12%) of patients sustained a traumatic brain injury. Three percent (95% CI = 1% to 5%) of patients required admission to the hospital. Conclusions: Sledding injuries resulting in ED visits predominantly affect children and are a source of measurable morbidity in this population. An increase in injury prevention efforts for this activity is warranted.	Brown Med Sch, Dept Emergency Med, Providence, RI USA; Brown Med Sch, Dept Pediat, Providence, RI USA; Hasbro Childrens Hosp, Rhode Isl Hosp, Injury Prevent Ctr, Providence, RI USA	Linakis, JG (corresponding author), Hasbro Childrens Hosp, 159 Potter Bldg,593 Eddy St, Providence, RI 02903 USA.	james_linakis_phd@brown.edu					Bernardo L M, 1998, J Trauma Nurs, V5, P34; BJORNSTIG U, 1986, SCAND J SOC MED, V14, P83; DERSHEWITZ R, 1990, AM J DIS CHILD, V144, P1071; Federiuk CS, 2002, WILD ENVIRON MED, V13, P245, DOI 10.1580/1080-6032(2002)013[0245:SSASII]2.0.CO;2; Hackam DJ, 1999, J PEDIATR SURG, V34, P65, DOI 10.1016/S0022-3468(99)90230-0; HEDGES JR, 1980, ANN EMERG MED, V9, P131, DOI 10.1016/S0196-0644(80)80267-8; HERKOWITZ HN, 1978, J TRAUMA, V18, P806, DOI 10.1097/00005373-197812000-00004; KIM PCW, 1995, J PEDIATR SURG, V30, P1135, DOI 10.1016/0022-3468(95)90005-5; Landsman I S, 1987, Pediatr Emerg Care, V3, P277, DOI 10.1097/00006565-198712000-00015; Lee F, 1999, Inj Prev, V5, P198; Major CP, 1999, SOUTHERN MED J, V92, P193, DOI 10.1097/00007611-199902000-00006; MANARY MJ, 1993, PEDIATR EMERG CARE, V9, P155, DOI 10.1097/00006565-199306000-00011; ODOM JA, 1976, J BONE JOINT SURG AM, V58, P733; ROWE BH, 1994, CAN FAM PHYSICIAN, V40, P68; Shorter NA, 1999, AM J EMERG MED, V17, P32, DOI 10.1016/S0735-6757(99)90010-4; SHUGERMAN RP, 1992, PEDIATR EMERG CARE, V8, P283, DOI 10.1097/00006565-199210000-00009; *US DEP HHS, 2003, ICPSR VERS; *US DEP HHS, 2004, ICPSR VERS; Verrees M, 2004, PEDIATR NEUROSURG, V40, P2, DOI 10.1159/000076570; Voaklander DC, 2001, ACAD EMERG MED, V8, P629, DOI 10.1111/j.1553-2712.2001.tb00176.x; WYNNE AD, 1994, J TRAUMA, V37, P820, DOI 10.1097/00005373-199411000-00019	21	18	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	FEB	2006	13	2					181	185	PII 1069-6563583	10.1197/j.aem.2005.09.009			5	Emergency Medicine	Emergency Medicine	010HW	WOS:000235179500010	16436798				2021-06-18	
J	Warren, MW; Kobeissy, FH; Liu, MC; Svetlov, SI; Hayes, RL; Gold, MS; Wang, KKW				Warren, Matthew W.; Kobeissy, Firas H.; Liu, Ming Cheng; Svetlov, Stanislav I.; Hayes, Ronald L.; Gold, Mark S.; Wang, Kevin K. W.			Ecstasy toxicity: A comparison to methamphetamine and traumatic brain injury	JOURNAL OF ADDICTIVE DISEASES			English	Article						ecstasy; neurotoxicity; methamphetamine; MDMA; hepatocytes	RAT-BRAIN; NEURONAL APOPTOSIS; II-SPECTRIN; CALPAIN; CASPASE; CELLS; EXPRESSION; TAU	Ecstasy use is a growing problem in the United States. Techniques to demonstrate and characterize the toxicity associated with its use have been limited and employed infrequently. In this study, we compare the deleterious effects of ecstasy use in rats with that of methamphetamine and traumatic brain injury. Specifically, we investigate the degradation of structural proteins alpha II-spectrin and tau by the pro-necrotic calpain and pro-apoptotic caspase systems. Ecstasy-induced neurotoxicity is shown after 24 hours, although to a much lesser extent than that of methamphetamine or traumatic brain injury. Neurotoxicity is still evident after 72 hours. Furthermore, apoptosis of the liver is seen 72 hours after ecstasy use. Use of protease inhibitors may be useful in preventing ecstasy-induced toxicity.	Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	Gold, MS (corresponding author), Univ Florida, Coll Med, Dept Psychiat, POB 100183, Gainesville, FL 32610 USA.	msgold@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; *DAWN, 2003, DAWN SER; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Larsen KE, 2002, J NEUROSCI, V22, P8951; Montiel-Duarte C, 2002, BBA-MOL BASIS DIS, V1588, P26, DOI 10.1016/S0925-4439(02)00112-6; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLSON W, 1997, TRENDS BIOCHEM SCI, V22, P299; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Ricaurte George A., 2003, Science (Washington D C), V301, P1479; Stephenson CP, 1999, NEUROSCIENCE, V92, P1011, DOI 10.1016/S0306-4522(99)00049-4; Stumm G, 1999, FASEB J, V13, P1065; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; Yuen Po-Wai, 1998, Drugs of the Future, V23, P741, DOI 10.1358/dof.1998.023.07.858362	19	18	18	0	1	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2006	25	4					115	123		10.1300/J069v25n04_11			9	Substance Abuse	Substance Abuse	116YN	WOS:000242839800011	17088231				2021-06-18	
J	Taguchi, A; Kurz, A				Taguchi, Akiko; Kurz, Andrea			Thermal management of the patient: where does the patient lose and/or gain temperature?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						heat redistribution; perioperative hypothermia; shivering threshold; therapeutic hypothermia; vasoconstriction	TRAUMATIC BRAIN-INJURY; PERIOPERATIVE NORMOTHERMIA; TRANSFUSION REQUIREMENTS; SHIVERING THRESHOLD; CORE-TEMPERATURE; WARMING BLANKETS; WOUND-INFECTION; BLOOD-LOSS; HEAT-FLOW; HYPOTHERMIA	Purpose of review Anesthesia inhibits normal thermoregulatory control, leading to perioperative hypothermia or allowing therapeutic hypothermia. During the last decade many studies have shown the effects of anesthesia on thermoregulation. As a consequence many active warming and cooling devices are available to manipulate patients' core temperature. This review focuses on new findings in the field of temperature management. Recent findings Thermal management of patients has improved tremendously in recent years. Many outcome studies have shown adverse effects of perioperative hypothermia, as well as beneficial effects of therapeutic hypothermia after out-of-hospital cardiac arrest and brain trauma. However, inducing hypothermia is limited by physiologic thermoregulatory responses. Small reductions in core temperature lead to vasoconstriction and shivering, effectively hindering hypothermia. Thus prevention of vasoconstriction and shivering have become major goals during induction of therapeutic hypothermia. All anesthetics, opioids and sedatives lower the vasoconstriction and shivering threshold, thus allowing hypothermia. However, these drugs have side effects, such as respiratory depression, sedation and nausea. Several drugs, alone or in combination, lower the shivering threshold while causing minimal or no side effects. Summary Anesthesia affects thermoregulatory control and leads to perioperative hypothermia. The prevention of perioperative hypothermia improves patient's outcome. Therapeutic hypothermia can be induced and also improves outcome in certain conditions.	[Taguchi, Akiko] Tokyo Womens Med Univ, Dept Anesthesiol, Tokyo, Japan; [Kurz, Andrea] Univ Bern, Dept Anesthesiol, Bern, Switzerland; [Kurz, Andrea] Univ Louisville, Ooucomes Res Inst, Louisville, KY 40292 USA	Kurz, A (corresponding author), Univ Bern, Dept Anesthesiol, Bern, Switzerland.	andrea.kurz@insel.ch					Alfonsi P, 2004, ANESTHESIOLOGY, V100, P37, DOI 10.1097/00000542-200401000-00010; Bar-Yosef S, 2004, ANESTH ANALG, V99, P641, DOI 10.1213/01.ANE.0000130354.90659.63; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brauer A, 2004, BRIT J ANAESTH, V92, P836, DOI 10.1093/bja/aeh156; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CRINO MH, 1968, ANESTHESIOLOGY, V29, P149, DOI 10.1097/00000542-196801000-00038; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Grocott HP, 2004, ANESTH ANALG, V98, P298, DOI 10.1213/01.ANE.0000096212.06561.C0; Guest James D, 2004, Spine J, V4, P130, DOI 10.1016/j.spinee.2003.08.027; Hofer CK, 2005, J THORAC CARDIOV SUR, V129, P838, DOI 10.1016/j.jtcvs.2004.07.002; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; Janicki PK, 2001, ANESTHESIOLOGY, V95, P868, DOI 10.1097/00000542-200110000-00014; Keller E, 2003, INTENS CARE MED, V29, P939, DOI 10.1007/s00134-003-1685-3; Kimme P, 2004, BRIT J ANAESTH, V93, P343, DOI 10.1093/bja/aeh206; KOKATE JY, 1995, ARCH PHYS MED REHAB, V76, P666, DOI 10.1016/S0003-9993(95)80637-7; Komatsu R, 2005, ANESTH ANAL IN PRESS; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1993, ANESTH ANALG, V77, P89; Lenhardt Rainer, 2003, Best Pract Res Clin Anaesthesiol, V17, P569, DOI 10.1016/S1521-6896(03)00048-X; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; Macario A, 2002, ANESTH ANALG, V94, P215, DOI 10.1097/00000539-200201000-00042; Maglinger PE, 2005, ANESTH ANALG, V100, P738, DOI 10.1213/01.ANE.0000143954.98285.63; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; MATSUKAWA T, 1995, ANESTHESIOLOGY, V83, P961, DOI 10.1097/00000542-199511000-00008; Matsuzaki Y, 2003, BRIT J ANAESTH, V90, P689, DOI 10.1093/bja/aeg106; Melling AC, 2001, LANCET, V358, P876, DOI 10.1016/S0140-6736(01)06071-8; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; MORRIS RH, 1972, ANESTHESIOLOGY, V36, P408, DOI 10.1097/00000542-197204000-00020; MORRIS RH, 1971, ARCH SURG-CHICAGO, V102, P95; Nathan HJ, 2004, J THORAC CARDIOV SUR, V127, P1270, DOI 10.1016/j.jtcvs.2003.07.018; Negishi C, 2003, ANESTH ANALG, V96, P1683, DOI 10.1213/01.ANE.0000062770.73862.B7; Nesher N, 2003, ANESTH ANALG, V96, P328, DOI 10.1097/00000539-200302000-00007; Nesher N, 2001, ANN THORAC SURG, V72, pS1069, DOI 10.1016/S0003-4975(01)02943-5; Passard A, 2004, AM SOC ANESTHESIOL, V101, pA; Playford H, 2004, ANESTH ANALG, P98; Polderman KH, 2004, INTENS CARE MED, V30, P1860, DOI 10.1007/s00134-004-2383-5; Ratnaraj J, 2004, AM SOC ANESTHESIOL, V101; Rohrer K, 2004, AM SOC ANESTHESIOL, V101, pA; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; SESSLER DI, 1995, ANESTHESIOLOGY, V82, P674, DOI 10.1097/00000542-199503000-00009; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P875, DOI 10.1097/00000542-199105000-00012; SESSLER DI, 1993, ANESTH ANALG, V77, P73; SESSLER DI, 1990, ANESTHESIOLOGY, V73, P218, DOI 10.1097/00000542-199008000-00005; Stanley TO, 2003, ANN THORAC SURG, V75, P1140, DOI 10.1016/S0003-4975(02)04545-9; Stanley TO, 2005, ANN THORAC IN PRESS; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Taguchi A, 2004, ANESTHESIOLOGY, V100, P1058, DOI 10.1097/00000542-200405000-00005; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Wadhwa A, 2005, BRIT J ANAESTH, V94, P756, DOI 10.1093/bja/aei105; Woo Y Joseph, 2005, Asian Cardiovasc Thorac Ann, V13, P157; Yamakage M, 2004, AM SOC ANESTHESIOL, V101, pA; Yamakage Michiaki, 2004, Masui, V53, P10; Zweifler R.M., 1997, J STROKE CEREBROVASC, V6, P100	58	18	20	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	DEC	2005	18	6					632	639		10.1097/01.aco.0000191890.36691.cc			8	Anesthesiology	Anesthesiology	V40ZS	WOS:000209517100008	16534304				2021-06-18	
J	Coimbra, R; Hoyt, DB; Anjaria, DJ; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P				Coimbra, R; Hoyt, DB; Anjaria, DJ; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P			Reversal of anticoagulation in trauma: A North American survey on clinical practices among trauma surgeons	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		trauma; anticoagulation; warfarin; reversal of anticoagulation; fresh frozen plasma; severe head injury; abdominal trauma; chest trauma; survey; anticoagulation; complications; mortality; outcomes	PREINJURY WARFARIN USE; ATRIAL-FIBRILLATION; ELDERLY-PATIENTS; HEAD-INJURY; ANTITHROMBOTIC THERAPY; COMPLICATIONS; RISK; PATIENT; STROKE; IMPACT	Background: Recent studies addressing reversal of anticoagulation in trauma have reported conflicting results. We hypothesized that current clinical practice is variable throughout North America. Methods: We surveyed 100 trauma surgeons to obtain information regarding variability in current clinical practice. Results: Seventy-five of 100 trauma surgeons surveyed responded, and the majority (98.7%) agreed that preinjury anticoagulation poses problems in trauma management that include bleeding, increased complications, and mortality. Nine participants (12.2%) had a protocol addressing reversal of anticoagulation in their institution. Most use fresh frozen plasma based on the type and location of injury, initial international normalized ratio (INR), and targeted INR value. Fresh frozen plasma was consistently used in patients with positive head computed tomographic scans, hemothorax, nonoperative solid organ injury management, pelvic and long bone fractures, and any operative intervention. Practice inconsistencies were found in patients with loss of consciousness and normal head computed tomographic scan, facial and rib fractures, and pulmonary contusion. Significant variability was found in the reversal INR target. One third of participants agreed that anticoagulation could be restarted 5 to 7 days after craniotomy; one sixth would do so within 72 hours and one third would wait 10 or more days. Most agreed that anticoagulation could be restarted 3 days after chest, abdominal, and orthopedic operations. Significant inconsistencies were also observed regarding when to restart anticoagulation in closed head injury patients treated nonoperatively. Conclusion: On the basis of the discrepancies observed in this survey, a clinical trial addressing specific injury location and patterns, INR thresholds, and type of strategy to achieve reversal is warranted, and most would agree to participate.	Univ Calif San Diego, Sch Med, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Sch Med, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr,Suite 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Man-Son-Hing M, 2003, ARCH INTERN MED, V163, P1580, DOI 10.1001/archinte.163.13.1580; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; White RH, 1996, ARCH INTERN MED, V156, P1197, DOI 10.1001/archinte.156.11.1197; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	18	18	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2005	59	2					374	381		10.1097/01.ta.000174728.46883.a4			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	014BX	WOS:000235454800025	16294078				2021-06-18	
J	Kim, J; Whyte, J; Hart, T; Vaccaro, M; Polansky, M; Coslett, HB				Kim, J; Whyte, J; Hart, T; Vaccaro, M; Polansky, M; Coslett, HB			Executive function as a predictor of inattentive behavior after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain injuries; attention; neuropsychological tests; cognition; predictive value of tests; ecological validity	FRONTAL-LOBE; HEAD-INJURY; WORKING-MEMORY; PREFRONTAL CORTEX; VISUAL-ATTENTION; METHYLPHENIDATE; DEFICITS; TESTS; REHABILITATION; FLUENCY	Emerging evidence from recent studies using laboratory and naturalistic attention tasks suggests that individuals with traumatic brain injury (TBI) may have a deficit mainly in strategic control of attention. In the present study, we tested the hypothesis that inattentive behavior after TBI could be predicted by performance on psychometric measures of executive function. A group of 37 individuals with moderate to severe TBI were assessed with previously validated naturalistic measures of attention. A battery of neuropsychological tests was also administered to assess various aspects of executive function. Seven measures of executive function and 10 variables reflecting inattentive behavior were combined to form 1 executive and 3 inattentive behavior (TB) composite scores. Three predictors (executive composite, current disability scores, and age) were associated, at the univariate level, with one of the IB composites reflecting frequency and duration of off-task episodes. A stepwise multiple regression procedure indicated that the executive composite was the only significant predictor of the IB composite. Additional post-hoc regression analyses suggested that the relationship was not likely to be mediated by processing speed. The current study supports the hypothesis that executive function, measured by commonly used neuropsychological tests, significantly predicts certain aspects of inattentive behavior in real-world tasks after TBT.	Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Drexel Univ, Dept Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd,Suite 213, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu	Kim, Junghoon John/I-6702-2019; Kim, Junghoon/A-6669-2012	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Benton AL, 1983, MULTILINGUAL APHASIA; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Downing PE, 2000, PSYCHOL SCI, V11, P467, DOI 10.1111/1467-9280.00290; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Heaton R., 1993, WISCONSIN CARD SORTI; KERNS KA, 1996, ECOLOGICAL VALIDITY, P147; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Miller E, 1970, Cortex, V6, P121; Miller EK, 2000, NEUROIMAGE, V11, P447, DOI 10.1006/nimg.2000.0574; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Posner M. I., 1986, CHRONOMETRIC EXPLORA; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Pratt J, 2003, J EXP PSYCHOL HUMAN, V29, P835, DOI 10.1037/0096-1523.29.5.835; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reitan RM., 1985, HALSTEAD REITAN NEUR; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Whyte J, 1998, REHABILITATION MED P, P1191; WHYTE J, 1998, INT PERSPECTIVES TRA, P154; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; Yantis S, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P73; Zasler ND, 1996, MED REHABILITATION T, P133	77	18	18	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					434	445		10.1017/S1355617705050563			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400011	16209424				2021-06-18	
J	Morris, PG; Wilson, JTL; Dunn, LT; Teasdale, GM				Morris, PG; Wilson, JTL; Dunn, LT; Teasdale, GM			Premorbid intelligence and brain injury	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CONTEXTUAL-READING-TEST; HEAD-INJURY; DEMOGRAPHIC-VARIABLES; ALZHEIMERS-DISEASE; OLDER PERSONS; ABILITY; DEMENTIA; EQUATION; IQ	Objectives. To determine whether NART scores are associated with severity of brain injury and therefore presumably affected by brain injury. In addition, to compare the Cambridge Contextual Reading Test (CCRT) with injury severity in head-injured individuals. Design and methods. Participants were 55 survivors of traumatic head injury, who completed the NART and the CCRT. The scores on these premorbid measures were then compared with indices of injury severity from their initial neurosurgical admission. Results. The NART was significantly correlated with Glasgow coma scale, with greater severity of injury associated with poorer performance. Poorer NART performance was also significantly more likely amongst those whose injury resulted in coma. The CCRT was preferred by patients, though it was also significantly associated with Glasgow coma scale and presence of coma. Conclusions. The data suggest that performance on both the NART and the CCRT are affected by brain injury severity and thus may underestimate true premorbid ability in these individuals. Similar findings would be likely with the conceptually identical WTAR measure. These measures should be used with appropriate caution and may be usefully supplemented by predictions based on demographic information.	Royal Edinburgh & Associated Hosp, Sect Clin & Hlth Psychol, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Glasgow, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland	Morris, PG (corresponding author), Royal Edinburgh & Associated Hosp, Sect Clin & Hlth Psychol, Kennedy Tower, Edinburgh EH10 5HF, Midlothian, Scotland.	p.g.morris@ed.ac.uk	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Morris, Paul/0000-0001-8467-1669; Dunn, Laurence/0000-0002-8990-4334			Beardsall L, 1998, BRIT J CLIN PSYCHOL, V37, P229, DOI 10.1111/j.2044-8260.1998.tb01297.x; BEARDSALL L, 1994, J CLIN EXP NEUROPSYC, V16, P232, DOI 10.1080/01688639408402634; Conway SC, 1997, BRIT J CLIN PSYCHOL, V36, P623, DOI 10.1111/j.2044-8260.1997.tb01267.x; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P97, DOI 10.1348/014466501163517; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P435, DOI 10.1111/j.2044-8260.1990.tb00908.x; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NEBES RD, 1994, J CLIN EXP NEUROPSYC, V16, P489, DOI 10.1080/01688639408402660; Nebes RD, 1996, BRAIN LANG, V54, P233, DOI 10.1006/brln.1996.0073; Nelson H., 1991, REVISED NATL ADULT R; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; OCarroll R, 1995, NEUROCASE, V1, P83, DOI 10.1080/13554799508402350; Patterson K. E., 1994, NEUROPSYCHOLOGY, V8, DOI [DOI 10.1037/0894-4105.8.3.395, 10.1037/0894-4105.8.3.395]; TEASDALE G, 1985, HDB CLIN NEUROLOGY C, P185; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474	18	18	19	0	6	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	JUN	2005	44		2				209	214		10.1348/014466505X34174			6	Psychology, Clinical	Psychology	937FO	WOS:000229910200005	16004655				2021-06-18	
J	Sample, PL; Langlois, JA				Sample, PL; Langlois, JA			Linking people with traumatic brain injury to services - Successes and challenges in Colorado	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; services	SILENT EPIDEMIC; NEEDS; PERCEPTIONS; TBI	People with traumatic brain injury (TBI)-related disability often need services and other types of support to return to productive lives; thus, improving access to available TBI services is a priority for a variety of states' agencies, such as Human Services and Public Health. Although infrastructure and resources vary from state to state, each can benefit by learning about how other states link people with TBI to services. In this report, we summarize Colorado's experience in exploring and developing better ways to link state residents with TBI to services. Recommendations for improving the system of linking people to services in Colorado included the following: (1) expanding the population targeted for linkage to services beyond those who are hospitalized; (2) improving access to information about available services; and (3) increasing the availability of services.	Colorado State Univ, Dept Occupat Therapy, Ft Collins, CO 80523 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Sample, PL (corresponding author), Colorado State Univ, Dept Occupat Therapy, 211 Occupat Therapy Bldg, Ft Collins, CO 80523 USA.	psample@cabs.colostate.edu					Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; *CDCP, 2003, HEADS BRAIN INJ YOUR; CONNORS S, 2003, GUIDE STATE GOVT BRA; Connors SH, 2001, RESOURCE FACILITATIO; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Darragh AR, 2001, AM J OCCUP THER, V55, P191, DOI 10.5014/ajot.55.2.191; *GEN ACC OFF, 1998, PUBL GAO HEHS; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; RICH CJ, 1998, THESIS COLORADO STAT; Sample P L, 1995, Occup Ther Health Care, V9, P45, DOI 10.1080/J003v09n01_05; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; SAMPLE PL, IN PRESS SUBST USE M; Stuart M, 2004, J HEAD TRAUMA REHAB, V19, P329, DOI 10.1097/00001199-200407000-00007; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOMTER H, 2001, THESIS COLORADO STAT; WETHERELL W, 2001, THESIS COLORADO STAT; Whiteneck G, 2001, COLORADO TRAUMATIC B; Zimmerman DE, 2003, J HEALTH PSYCHOL, V8, P119, DOI 10.1177/1359105303008001448	21	18	18	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					270	278		10.1097/00001199-200505000-00009			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500009	15908826				2021-06-18	
J	Baker, KA; Hagg, T				Baker, KA; Hagg, T			An adult rat spinal cord contusion model of sensory axon degeneration: The estrus cycle or a preconditioning lesion do not affect outcome	JOURNAL OF NEUROTRAUMA			English	Article						anterograde tracing; axonal protection; gracile nucleus; sex hormones; spinal cord injury	DORSAL-ROOT GANGLION; GLOBAL CEREBRAL-ISCHEMIA; ESTROGEN-RECEPTOR-ALPHA; PRIMARY AFFERENT-FIBERS; TRAUMATIC BRAIN-INJURY; TOXIN B-SUBUNIT; NEUROTROPHIC FACTOR; FUNCTIONAL RECOVERY; CHOLERA-TOXIN; WHITE-MATTER	A therapeutic strategy for acute spinal cord injury would be to reduce the progressive degeneration and disconnection of axons from their targets. Here, we describe a model to evaluate degeneration of the ascending sensory projections to the nuclei in the medulla following graded spinal cord contusions in adult female Sprague-Dawley rats. Cholera toxin B (CTB) labeling from the sciatic nerve of naive rats revealed effective labeling of the terminal fibers in the gracile nucleus at 3 days post-injection and a subpopulation of rapidly transporting fibers after 1 day. Seven days after contusions using the Infinite Horizon impactor the area of CTB-labeled terminal fibers had a negative correlation with increasing impact force. Moderate spinal contusions of around 150 kilodyne (kdyn or 0.15 x 10(-3) newton) caused a reduction to 40% in the fiber area which will enable the identification of protective as well as detrimental drugs and post-injury mechanisms. A preconditioning injury of the sciatic nerve reportedly can enhance growth of sensory axons but did not affect the terminal fiber area in the gracile nucleus. Estrogen and progesterone are protective in various systems and could therefore influence experimental outcomes when using females. However, the phase of the estrus cycle at the time of contusion or during the post-injury time did not affect the outcome of the contusion, indicating that female rats may be used without consideration of the estrus cycle. This model can readily be used to evaluate pharmacological agents for protection of sensory axons and pathophysiological mechanisms of their degeneration.	Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	Hagg, T (corresponding author), Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, MDR Bldg 616,511 S Floyd St, Louisville, KY 40292 USA.	theo.hagg@louisville.edu					Agrawal SK, 1997, J NEUROSCI, V17, P1055; BASKIN DS, 1987, NEUROSURGERY, V20, P871, DOI 10.1227/00006123-198706000-00009; Bouyer LJG, 2003, J NEUROPHYSIOL, V90, P3640, DOI 10.1152/jn.00497.2003; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cafferty WBJ, 2004, J NEUROSCI, V24, P4432, DOI 10.1523/JNEUROSCI.2245-02.2004; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Freeman Marc E., 1994, P613; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GIUFFRIDA R, 1992, J COMP NEUROL, V316, P206, DOI 10.1002/cne.903160206; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall E D, 1987, Cent Nerv Syst Trauma, V4, P15; HARRY GJ, 1987, J NEUROCHEM, V48, P1529, DOI 10.1111/j.1471-4159.1987.tb05696.x; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Inserte J, 2004, CARDIOVASC RES, V64, P105, DOI 10.1016/j.cardiores.2004.06.001; Jones LL, 2003, J NEUROSCI, V23, P9276; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Li WP, 1999, NEUROSCI LETT, V260, P49, DOI 10.1016/S0304-3940(98)00958-6; LITERSKY JM, 1995, J NEUROCHEM, V65, P903; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MASLANY S, 1991, BRAIN RES, V564, P56, DOI 10.1016/0006-8993(91)91351-Z; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MUIR GD, 1995, J NEUROPHYSIOL, V74, P358; MURPHY PG, 1995, J NEUROSCI, V15, P5130; Murphy PG, 2000, EUR J NEUROSCI, V12, P1891, DOI 10.1046/j.1460-9568.2000.00074.x; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; Oudega M, 2000, NEUROSCIENCE, V100, P873, DOI 10.1016/S0306-4522(00)00350-X; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; OUDEGA M, 1994, EXP NEUROL, V129, P194, DOI 10.1006/exnr.1994.1161; Oudega M, 1996, EXP NEUROL, V140, P218, DOI 10.1006/exnr.1996.0131; Papka RE, 2002, NEUROSCI LETT, V319, P71, DOI 10.1016/S0304-3940(01)02562-9; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; PATTERSON JT, 1992, PAIN, V49, P117, DOI 10.1016/0304-3959(92)90197-J; PATTERSON JT, 1989, J COMP NEUROL, V290, P384, DOI 10.1002/cne.902900307; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Rau SW, 2003, J NEUROSCI, V23, P11420; RICHARDSON PM, 1987, BRAIN RES, V411, P406, DOI 10.1016/0006-8993(87)91096-1; RICHARDSON PM, 1984, NATURE, V309, P791, DOI 10.1038/309791a0; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Sayer FT, 2002, EXP NEUROL, V175, P282, DOI 10.1006/exnr.2002.7901; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shehab SAS, 2003, BRAIN RES, V964, P218, DOI 10.1016/S0006-8993(02)04001-5; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; Suzer T, 1999, SPINAL CORD, V37, P480, DOI 10.1038/sj.sc.3100874; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; SWETT JE, 1985, J COMP NEUROL, V231, P66, DOI 10.1002/cne.902310106; Taleghany N, 1999, J NEUROSCI RES, V57, P603, DOI 10.1002/(SICI)1097-4547(19990901)57:5<603::AID-JNR3>3.3.CO;2-I; Teng YD, 1997, J NEUROSCI, V17, P4359; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tong YG, 1999, J COMP NEUROL, V404, P143; van der Want JJL, 1997, BRAIN RES PROTOC, V1, P269, DOI 10.1016/S1385-299X(96)00042-6; VANHEYNI.WE, 1974, NATURE, V249, P415, DOI 10.1038/249415a0; VANHEYNINGEN S, 1974, SCIENCE, V183, P656, DOI 10.1126/science.183.4125.656; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; YOUNG WF, 1994, J NEUROSURG ANESTH, V6, P122; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhou XF, 1999, NEUROSCIENCE, V92, P841, DOI 10.1016/S0306-4522(99)00027-5	79	18	18	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					415	428		10.1089/neu.2005.22.415			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400001	15853460				2021-06-18	
J	Bell, MDD				Bell, MDD			Non-heartbeating organ donation: clinical process and fundamental issues	BRITISH JOURNAL OF ANAESTHESIA			English	Article						complications, death; organ donation, consent; organ donation, futility; organ donation, legal problems	DEATH; TRANSPLANTATION; DONORS	This case report outlines the clinical process whereby a patient with severe traumatic brain injury became a non-heartbeating organ donor after a withdrawal-of-care decision. This process raises a series of ethical questions regarding decision-making on grounds of futility, the role of the next of kin, informed consent, the accommodation of manoeuvres directed towards organ retrieval at maximal viability, and the timing and determination of death. Although many aspects of the process can be accommodated within fundamental ethical principles and a broad interpretation of the concept of the 'best interests', the variance with established law requires authoritative clarification if a need for transplantable organs is to be responded to without compromising the reputation of practitioners involved in this area of care. Therefore, this recruitment strategy warrants wide public and professional debate to achieve longer-term sustainability and ensure the protection of all parties.	Gen Infirm Leeds, Leeds LS1 3EX, W Yorkshire, England	Bell, MDD (corresponding author), Gen Infirm Leeds, Great George St, Leeds LS1 3EX, W Yorkshire, England.	dominic.bell@leedsth.nhs.uk					[Anonymous], 1968, JAMA, V205, P337; Beauchamp T, 1994, PRINCIPLES BIOMEDICA; Bell D, 2004, CRIT CARE MED, V32, P1241, DOI 10.1097/01.CCM.0000124856.92699.25; Bell John C., 2003, Cancer Cell, V4, P7, DOI 10.1016/S1535-6108(03)00170-3; Bell MDD, 2003, J MED ETHICS, V29, P176, DOI 10.1136/jme.29.3.176; BELL MDD, 2004, CARE CRITICALLY ILL, V20, P1; *BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; *BRIT MED ASS, 1993, B MED ETHICS, V3, P8; *DEP HLTH, 2001, 2001023 HSC DEP HLTH; *DEP HLTH, 2001023 HSC DEP HLTH; *DEP HLTH, 2003, IS REP; *DEP HLTH, 2003, SAV LIV VAL DON TRAN; *DEP HLTH GREAT BR, 1983, CAD ORG TRANSPL COD; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P113; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; General Medical Council, 2002, WITHH WITHDR LIF PRO; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; *HOUS LORD SEL COM, 1993, 211 HL SEL COMM MED; KENNEDY I, 2000, MED LAW; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; McConnell JR, 1999, J MED ETHICS, V25, P322, DOI 10.1136/jme.25.4.322; *NAT HLTH SERV, 2001, MOR TRANSPL NEW LIV; *NAT HLTH SERV, 2003, UK TRANSPL POT DON A; *NAT HLTH SERV, UK TRANSPL; *NAT HLTH SERV AC, 1994, 9441 NHS EX HSG AC S; PALLIS C, 1982, BRIT MED J, V285, P1409, DOI 10.1136/bmj.285.6352.1409; Re F, 1990, AC, V2, P1; RUERS TJM, 1986, TRANSPLANT P, V18, P408; Steen S, 2001, LANCET, V357, P825, DOI 10.1016/S0140-6736(00)04195-7; Truog RD, 2003, CRIT CARE MED, V31, P2391, DOI 10.1097/01.CCM.0000090869.19410.3C; Weber M, 2002, NEW ENGL J MED, V347, P248, DOI 10.1056/NEJMoa020274; WILLIAMS M, 2003, BJA CEPD REV, V3, P163	32	18	18	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	APR	2005	94	4					474	478		10.1093/bja/aei048			5	Anesthesiology	Anesthesiology	905JJ	WOS:000227564100012	15591330	Bronze			2021-06-18	
J	Barth, A; Nguyen, LB; Barth, L; Newell, DW				Barth, A; Nguyen, LB; Barth, L; Newell, DW			Glycine-induced neurotoxicity in organotypic hippocampal slice cultures	EXPERIMENTAL BRAIN RESEARCH			English	Article						glycine; NMDA receptor; excitatory amino acid; excitotoxicity; organotypic hippocampal culture	NMDA RECEPTOR CHANNEL; TRANSIENT GLOBAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; RECOGNITION SITE; ASPARTATE; RAT; STROKE	The role of the neutral amino acid glycine in excitotoxic neuronal injury is unclear. Glycine coactivates glutamate N-methyl-D-aspartate (NMDA) receptors by binding to a distinct recognition site on the NR1 subunit. Purely excitatory glycine receptors composed of NR1 and NR3/NR4 NMDA receptor subunits have recently been described, raising the possibility of excitotoxic effects mediated by glycine alone. We have previously shown that exposure to high concentrations of glycine causes extensive neurotoxicity in organotypic hippocampal slice cultures by activation of NMDA receptors. In the present study, we investigated further properties of in vitro glycine-mediated toxicity. Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures, whereas competitive blockade of the glycine site by 7-chlorokynurenic acid was neuroprotective. Stimulation (taurine, beta-alanine) or inhibition (strychnine) of the inhibitory strychnine-sensitive glycine receptors did not produce any neurotoxicity. The toxic effects of high-dose glycine were comparable in extent to those produced by the excitatory amino acid glutamate in our model. When combined with sublethal hypoxia/hypoglycemia, the threshold of glycine toxicity was decreased to less than 1 mM, which corresponds to the range of concentrations of excitatory amino acids measured during in vivo cerebral ischemia. Taken together, these results further support the assumption of an active role of glycine in excitotoxic neuronal injury.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland	Barth, A (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA.	alain.barth@insel.ch	mo, qin/O-7877-2014				Albers GW, 1999, STROKE, V30, P508, DOI 10.1161/01.STR.30.3.508; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Dingledine R, 1999, PHARMACOL REV, V51, P7; FADDA E, 1988, NEUROPHARMACOLOGY, V27, P1183, DOI 10.1016/0028-3908(88)90015-9; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Foucaud B, 2003, J BIOL CHEM, V278, P24011, DOI 10.1074/jbc.M300219200; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOOD WF, 1990, J NEUROCHEM, V54, P1040, DOI 10.1111/j.1471-4159.1990.tb02355.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KAPLITA PV, 1990, EUR J PHARM-MOLEC PH, V188, P175, DOI 10.1016/0922-4106(90)90053-Z; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LARSON AA, 1988, J NEUROSCI, V8, P3822; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MADDEN K, 2002, CURR MED RES OPIN S2, V18, P27; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; MCNAMARA D, 1990, J NEUROSCI, V10, P3970; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAHAN JB, 1990, MOL PHARMACOL, V37, P780; Newell DW, 1997, EXP NEUROL, V145, P235, DOI 10.1006/exnr.1997.6463; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWELL DW, 1995, BRAIN RES, V675, P38, DOI 10.1016/0006-8993(95)00039-S; Obrenovitch TP, 1997, BRAIN RES, V746, P190, DOI 10.1016/S0006-8993(96)01197-3; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; PACE JR, 1992, NEUROSCI LETT, V141, P97, DOI 10.1016/0304-3940(92)90343-6; PATEL J, 1990, J NEUROCHEM, V54, P849, DOI 10.1111/j.1471-4159.1990.tb02329.x; PERRY TL, 1981, NEUROLOGY, V31, P872, DOI 10.1212/WNL.31.7.872; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Saransaari P, 2001, NEUROCHEM RES, V26, P845, DOI 10.1023/A:1011624421505; SHALABY I, 1989, EUR J PHARMACOL, V160, P309, DOI 10.1016/0014-2999(89)90506-2; Shoham S, 2001, BIOL PSYCHIAT, V49, P876, DOI 10.1016/S0006-3223(00)01046-5; Sierra-Paredes G, 2001, BRAIN RES, V888, P19, DOI 10.1016/S0006-8993(00)02974-7; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; THOMSON AM, 1990, PROG NEUROBIOL, V35, P53, DOI 10.1016/0301-0082(90)90040-N; vonEssen C, 1996, J NEUROCHEM, V67, P260; Wallis Roi Ann, 1995, Brain Research, V685, P225, DOI 10.1016/0006-8993(95)00465-3; Waziri R, 1999, SCHIZOPHR RES, V37, P205, DOI 10.1016/S0920-9964(98)00169-8	49	18	19	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	MAR	2005	161	3					351	357		10.1007/s00221-004-2079-7			7	Neurosciences	Neurosciences & Neurology	900TJ	WOS:000227236900011	15490133	Green Published			2021-06-18	
J	Dharap, SB; Khandkar, AA; Pandey, A; Sharma, AK				Dharap, SB; Khandkar, AA; Pandey, A; Sharma, AK			Repeat CT scan in closed head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						CT scan; serial CT scan; repeat CT scan; head injury; economics	SERIAL COMPUTED-TOMOGRAPHY; EPIDURAL HEMATOMA; MANAGEMENT; UTILITY; TRAUMA	Background: Cranial CT scans are often repeated to observe the progress of an intracranial injury. This prospective observational study analyses the effect of repeat CT scans with the aim of formulating a guideline for their use. Methods: One hundred and seventy-five patients with blunt head injury presenting to the trauma unit and undergoing CT scan were included. Unstable patients with polytrauma were excluded. There was no standard protocol for ordering the repeat cranial. CT scans. This decision was purely based on the discretion of neurosurgeons. Results: CT scan was repeated in 53 (30%) patients. The clinical indications for the repeat CT scan could be grouped into three: (i) clinical deterioration, (ii) failure of improvement, and (iii) as a follow-up scan. Nine underwent surgical intervention based on the repeat CT scan findings. They were associated with clinical deterioration and had a better survival after surgery. In others the repeat CT scan findings did not alter the management. Conclusion: When a head injured patient shows clinical deterioration, it is necessary to repeat the CT scan to pick up a surgically treatable lesion; which is likely in a significant number of patients. Repeat CT scan as a matter of "routine" follow-up when the patient is clinically status-quo or improving, is unlikely to yield any further information necessitating change in treatment. This guideline may be useful in settings where CT scan facility is not easily available or expenditure is an issue. (c) 2004 Elsevier Ltd. All rights reserved.	LTM Med Coll, Dept Surg, Bombay 400022, Maharashtra, India; LTM Med Coll, Dept Neurosurg, Bombay 400022, Maharashtra, India	Dharap, SB (corresponding author), 905 Hrishikesh Apartments,Veer Savarkar Marg, Bombay 400028, Maharashtra, India.	drdharap@hotmail.com	Dharap, Satish/AAE-8565-2020	Dharap, Satish/0000-0002-9304-9617			ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Gentleman D, 1989, Br J Neurosurg, V3, P367, DOI 10.3109/02688698909002817; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; Mandavia DP, 2001, PEDIATR EMERG CARE, V17, P193, DOI 10.1097/00006565-200106000-00011; Muszynski CA, 1999, NEURORADIOLOGY, V41, P875, DOI 10.1007/s002340050859; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; POON WS, 1992, NEUROSURGERY, V30, P681; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Sinson G, 2001, J TRAUMA, V51, P875; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	18	18	18	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAR	2005	36	3					412	416		10.1016/j.injury.2004.06.020			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	905XP	WOS:000227605000010	15710159				2021-06-18	
J	De Monte, VE; Geffen, GM; May, CR; McFarland, K; Heath, P; Neralic, M				De Monte, VE; Geffen, GM; May, CR; McFarland, K; Heath, P; Neralic, M			The acute effects of mild traumatic brain injury on finger tapping with and without word repetition	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; NEUROPSYCHOLOGICAL DEFICITS; STANDARDIZED ASSESSMENT; RAPID SCREEN; SEQUELAE; TASK; TOMOGRAPHY; CONCUSSION; RECOVERY; LESIONS	This study aimed to investigate the acute effects of mild Traumatic Brain Injury (mTBI) on the performance of a finger tapping and word repetition dual task in order to determine working memory impairment in mTBI Sixty-four (50 male, 14 female) right-handed cases of mTBI and 26 (18 male and 8 female) right-handed cases of orthopaedic injuries were tested within 24 hours of injury. Patients with mTBI completed fewer correct taps in 10 seconds than patients with orthopaedic injuries, and female mTBI cases repeated fewer words. The size of the dual task decrement did not vary between groups. When added to a test battery including the Rapid Screen of Concussion (RSC; Comerford, Geffen, May, Medland & Geffen, 2002) and the Digit Symbol Substitution Test,finger tapping speed accounted for 1% of between groups variance and did not improve classification rates of male participants. While the addition of tapping rate did not improve the sensitivity and specificity of the RSC and DSST to mTBI in males, univariate analysis of motor performance in females indicated. that dual task performance might be diagnostic. An increase in female sample Size is warranted. These results confirm the view that there is a generalized slowing of processing ability following mTBI.	Univ Queensland, Sch Med, Cognit Psychophysiol Lab, Brisbane, Qld 4006, Australia; Royal Brisbane Hosp, Dept Emergency Med, Brisbane, Qld 4029, Australia; Univ Queensland, Sch Psychol, Brisbane, Qld, Australia	De Monte, VE (corresponding author), Univ Queensland, Sch Med, Cognit Psychophysiol Lab, Edith Cavell Bldg,Herston Rd, Brisbane, Qld 4006, Australia.	comerf@psy.uq.edu.au					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS RD, 1993, PRINCIPLES NEUROLOGY; ALLEN JW, 1996, MJM, V2, P40; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Arnsten AFT, 1997, J PSYCHOPHARMACOL, V11, P151, DOI 10.1177/026988119701100208; BADCOCK KA, 1988, COMMUNITY HEALTH ST, V12, P428; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bradshaw J.L., 2001, DEV DISORDERS FRONTO; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Cudmore LJ, 2000, BRAIN COGNITION, V44, P86; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; DEMONTE VE, 2003, UNPUB SELECTION APPR; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUCKETT S, 1993, MINOR HEAD TRAUMA, P5; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; GABELLA B, 1997, MMWR            0110, P8; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hillier SL, 1997, BRAIN INJURY, V11, P649; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; JENKINS A, 1986, LANCET, V2, P445; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; KRAUS JF, 1989, MILD HEAD INJURY, P8; LANGFITT TW, 1987, NEUROBEHAVIOURAL REC, P31; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCFARLAND K, 1982, NEUROPSYCHOLOGIA, V20, P383, DOI 10.1016/0028-3932(82)90038-0; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Prigatano GP, 2003, J INT NEUROPSYCH SOC, V9, P128, DOI 10.1017/S1355617703000134; Ruff RM, 1995, RUFF 2 7 SELECTIVE A; SCHNIDER A, 1999, SCI PRACT NEUROPSYCH, P487; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; TRONCOSO JC, 1996, HEAD INJURY POSTCONC, P46; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANZOMEREN AH, 1989, MILD HEAD INJURY, P398; VENDRELL P, 1995, NEUROPSYCHOLOGIA, V33, P341, DOI 10.1016/0028-3932(94)00116-7; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Whitall J, 1996, RES Q EXERCISE SPORT, V67, P349, DOI 10.1080/02701367.1996.10607963; WHITE N, 1995, BRAIN COGNITION, V28, P59, DOI 10.1006/brcg.1995.1033; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	72	18	18	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2005	27	2					224	239		10.1080/13803390490515766			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	908NP	WOS:000227794000006	15903152				2021-06-18	
J	Munoz-Sanchez, M; Murillo-Cabezas, F; Cayuela, A; Flores-Cordero, J; Rincon-Ferrari, M; Amaya-Villar, R; Fornelino, A				Munoz-Sanchez, M; Murillo-Cabezas, F; Cayuela, A; Flores-Cordero, J; Rincon-Ferrari, M; Amaya-Villar, R; Fornelino, A			The significance of skull fracture in mild head trauma differs between children and adults	CHILDS NERVOUS SYSTEM			English	Article						pediatric mild head injury; adult mild head injury; skull fracture; Glasgow Coma Scale; abbreviated injury score	COMA-SCALE SCORE; INJURY; CONSCIOUSNESS; EMERGENCY; MANAGEMENT; DIAGNOSIS; CARE	Objective: The objective was to determine whether the age of patients with mild head injury and skull fracture influences the level of risk for acute intracranial injuries. Method: A study was conducted of 156 patients with skull fracture, 60 children (aged <14 years) and 96 adults, detected among 5,097 consecutive patients with mild head injury (Glasgow Coma Scale [GCS] score of 15-14 points) arriving at the Emergency Department of a Level I University Hospital Trauma Center during 1998. Acute intracranial injuries were defined as traumatic brain injuries identified by cranial computed tomography scan, excluding pneumocephalus. Results: Compared with the children, this risk of intracranial injury was 13 times greater in the adults aged 14-54 years and 16 times greater in the over-54-year-olds. Besides age over 14 years (p<0.0001), compound skull fracture (p<0.001), and a GCS score of 14 (p<0.001) were factors significantly associated with intracranial injury in the logistic regression analysis. Conclusions: Skull fracture in mild head injury implies a greater risk of intracranial injury in adults than in children.	Hosp Univ Virgen del Rocio, Dept Crit Care & Emergency, Res Unit, Seville 41013, Spain	Munoz-Sanchez, M (corresponding author), Hosp Univ Virgen del Rocio, Dept Crit Care & Emergency, Res Unit, Avda Manuel Siurot S-N, Seville 41013, Spain.	angeles.munoz.sspa@juntadeandalucia.es	IBIS, NEUROCRITICOS/C-1805-2016; Cayuela, Aurelio/AAZ-1294-2020; Murillo-Cabezas, Francisco/AAO-3348-2021; Cayuela, Aurelio/C-6698-2012	Cayuela, Aurelio/0000-0002-4936-9402			*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRUCE S, 2001, J TRAUMA, V51, P231; CULLOTA VP, 1996, NEUROSURGERY, V38, P245; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Lavelle JM, 1998, ARCH PEDIAT ADOL MED, V152, P1220; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Mandera M, 2000, CHILD NERV SYST, V16, P156, DOI 10.1007/s003810050484; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Phillips S, 1996, PEDIATR EMERG CARE, V12, P394, DOI 10.1097/00006565-199612000-00002; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014	20	18	18	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2005	21	2					128	132		10.1007/s00381-004-1036-x			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	894NQ	WOS:000226799000010	15338178				2021-06-18	
J	Unden, J; Bellner, J; Astrand, R; Romner, B				Unden, J; Bellner, J; Astrand, R; Romner, B			Serum S100B levels in patients with epidural haematomas	BRITISH JOURNAL OF NEUROSURGERY			English	Article						epidural/intracranial haematoma/haematoma; head/brain injury; S100B/S100/S-100	S-100B PROTEIN; BRAIN-DAMAGE; HEAD-INJURY; MANAGEMENT	Protein S100B is today the most promising biomarker for cerebral injury. A welcomed area for the use of such a marker is in the early stages of head trauma and diagnosis of brain injury, in particular epidural haematomas. We report five consecutive cases of epidural haematoma where serum samples for S100B were drawn at admission. Three of the patients showed low levels of S100B (<= 0.2 mu g/l). One patient with a large epidural haematoma with radiological signs of cerebral herniation displayed normal levels (0.14 mu g/l) of S100B 3.5 h after the initial head trauma. Normal S100B levels in serum do not predict normal intracranial findings. S100B may be unreliable as a marker for epidural haematomas after closed head injury.	Univ Lund Hosp, Dept Neurosurg, Neurointens care Unit NIVA, S-22185 Lund, Sweden	Romner, B (corresponding author), Univ Lund Hosp, Dept Neurosurg, Neurointens care Unit NIVA, S-22185 Lund, Sweden.	bertil.romner@skane.se					Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bottiger BW, 2001, CIRCULATION, V103, P2694; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JENNETT B, 1996, J NEUROL NEUROSUR PS, V60, P101; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KRAUS JF, 1993, HEAD INJURY; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Unden J, 2004, BRIT J NEUROSURG, V18, P277, DOI 10.1080/02688690410001732742; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; Wiesmann M, 1998, CLIN CHEM, V44, P1056	15	18	19	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	FEB	2005	19	1					43	45		10.1080/02688690500089381			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	933IO	WOS:000229622300007	16147582				2021-06-18	
J	Tamimi, A; Abu-Elrub, M; Shudifat, A; Saleh, Q; Kharazi, K; Tamimi, I				Tamimi, A; Abu-Elrub, M; Shudifat, A; Saleh, Q; Kharazi, K; Tamimi, I			Superior sagittal sinus thrombosis associated with raised intracranial pressure in closed head injury with depressed skull fracture	PEDIATRIC NEUROSURGERY			English	Article						superior sagittal sinus; thrombosis; acetazolamide; lumbar puncture		A case of delayed signs of intracranial hypertension following closed head injury with a depressed cranial fracture and superior sagittal sinus thrombosis is reported. Conservative treatment of intracranial hypertension, including just repeated lumbar puncture and oral acetazolamide, was performed. Spontaneous recanalization of the superior sagittal sinus was observed. Pathogenesis and different modalities of treatment are discussed. Copyright (c) 2005 S. Karger AG, Basel.	Univ Jordan, Fac Med, Amman 11942, Jordan; Hosp Univ Jordan, Dept Neurosurg, Amman, Jordan	Tamimi, A (corresponding author), Univ Jordan, Fac Med, POB 13349, Amman 11942, Jordan.	aftamimi@hotmail.com	Alsabbagh, Qussay/ABB-8281-2020	Alsabbagh, Qussay/0000-0003-3981-6712; Tamimi Marino, Iskandar/0000-0003-4196-5151			BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BELLER AJ, 1964, J NEUROL NEUROSUR PS, V27, P149, DOI 10.1136/jnnp.27.2.149; CARRIE AW, 1954, J NEUROSURG, V11, P173, DOI 10.3171/jns.1954.11.2.0173; D'Alise MD, 1998, SURG NEUROL, V49, P430, DOI 10.1016/S0090-3019(97)00182-1; DUPLESSIS JJ, 1993, J TRAUMA, V34, P290, DOI 10.1097/00005373-199302000-00021; GETTELFINGER DM, 1997, ARCH NEUROL-CHICAGO, V34, P2; Gudeman S. K., 1989, TXB HEAD INJURY, P138; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; KINAL ME, 1959, NEUROLOGICAL SURG, V2, P178; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; Kumar GSS, 2004, NEUROL INDIA, V52, P123; LeFeuvre D, 2004, SURG NEUROL, V62, P121, DOI 10.1016/j.surneu.2003.10.048; Muthukumar N, 2005, CHILD NERV SYST, V21, P86, DOI 10.1007/s00381-004-0926-2; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; Uzan M, 1998, J NEUROSURG, V88, P598, DOI 10.3171/jns.1998.88.3.0598; vandenBrink WA, 1996, NEUROSURGERY, V38, P1044, DOI 10.1097/00006123-199605000-00039; VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357	18	18	19	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2005	41	5					237	240		10.1159/000087480			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	970FN	WOS:000232290700003	16195674				2021-06-18	
J	Wittebole, X; Hantson, P; Laterre, PF; Galvez, R; Duprez, T; Dejonghe, D; Renkin, J; Gerber, BL; Brohet, CR				Wittebole, X; Hantson, P; Laterre, PF; Galvez, R; Duprez, T; Dejonghe, D; Renkin, J; Gerber, BL; Brohet, CR			Electrocardiographic changes after head trauma	JOURNAL OF ELECTROCARDIOLOGY			English	Article						head trauma; diffuse axonal injury; ECG changes	SUBARACHNOID HEMORRHAGE; INJURY	We report the case of a patient who developed, a few days after a closed head injury, marked electrocardiographic changes mimicking an acute coronary event, in the absence of actual cardiac damage. The electrocardiographic changes were fully reversible, paralleling the neurologic status. Neuro-imaging examinations excluded subarachnoid hemorrhage or space-occupying hematoma, but demonstrated diffuse axonal injury using susceptibility-weighted magnetic resonance techniques. This kind of traumatic brain injury thus may be responsible for a pseudo-acute myocardial ischemic syndrome. (C) 2005 Elsevier Inc. All rights reserved.	Catholic Univ Louvain, Hosp St Luc, Dept Intens Care, B-1200 Brussels, Belgium; Univ Catholique Louvain, Hosp St Luc, Dept Radiol & Med Imaging, B-1200 Brussels, Belgium; Catholic Univ Louvain, Hosp St Luc, Dept Internal Med, Div Cardiol, B-1200 Brussels, Belgium	Brohet, CR (corresponding author), Clin Univ St Luc, B-1200 Brussels, Belgium.	brohet@card.ucl.ac.be	Gerber, Bernhard L/H-5838-2011	Gerber, Bernhard/0000-0003-1708-8558; Duprez, Thierry/0000-0002-1579-0100			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CARRUTH JE, 1980, CHEST, V78, P886, DOI 10.1378/chest.78.6.886; DAVIS TP, 1993, PROG CARDIOVASC DIS, V36, P245, DOI 10.1016/0033-0620(93)90017-8; GREENSPAHN BR, 1978, CHEST, V74, P468, DOI 10.1378/chest.74.4.468; HERSCH C, 1961, CIRCULATION, V23, P853, DOI 10.1161/01.CIR.23.6.853; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; NATELSON BH, 1985, ARCH NEUROL-CHICAGO, V42, P178, DOI 10.1001/archneur.1985.04060020096022; REICHENBACH DD, 1968, ARCH PATHOL, V85, P189; Sakr YL, 2002, PROG CARDIOVASC DIS, V45, P67, DOI 10.1053/pcad.2002.124633; SCOTT I, 1988, MED J AUSTRALIA, V148, P94, DOI 10.5694/j.1326-5377.1988.tb104520.x; Sharkey SW, 1998, CHEST, V114, P98, DOI 10.1378/chest.114.1.98; SURAWICZ B, 2001, CHOUS ELECTROCARDIOG, P534; SURAWICZ B, 1989, COMPREHENSIVE ELECTR, P538	14	18	18	0	2	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	0022-0736	1532-8430		J ELECTROCARDIOL	J. Electrocardiol.	JAN	2005	38	1					77	81		10.1016/j.jelectrocard.2004.09.004			5	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	896UE	WOS:000226958500013	15660352				2021-06-18	
J	Gilchrist, MD				Gilchrist, MD			Experimental device for simulating traumatic brain injury resulting from linear accelerations	STRAIN			English	Article						experimental device; impact biomechanics; linear acceleration; tissue damage; traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; DIFFUSE AXONAL INJURY; HEAD-INJURY; PRESSURE CHANGES; CONTUSION; BIOMECHANICS; CONCUSSION; RATS; RECONSTRUCTION	Various methods are used to model and analyse traumatic brain injuries (TBI) in human beings. These include volunteer and cadaver experiments, anthropomorphic dummies, physical models, computational models and mathematical models. The pathophysiological response to mechanical impact of the human central nervous system and of in vivo neural tissue, is most realistically analysed using animal models, which provide the best surrogate for the human brain. During non-fatal impacts, a mechanical insult may trigger a cascade of physiological processes, many mediated by neurochemicals within the neural tissue which will, in turn, control the depth and extent of the brain injury. This paper reports the development of a novel experimental device which can apply different linear acceleration impacts directly to in vivo neural tissue in a manner which permits the experimental analysis of non-fatal TBI of varying severity.	Univ Coll Dublin, Dept Mech Engn, Dublin 2, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Dept Mech Engn, Dublin 2, Ireland.		Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ANDERSON TE, 1982, J NEUROSCI METH, V6, P327, DOI 10.1016/0165-0270(82)90033-4; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BECKMAN DL, 1969, P SOC EXP BIOL MED, V130, P5; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GOLDSMITH W, 1970, BIOMECHANICS ITS FDN, P585; GURDJIAN ES, 1975, SURG GYNECOL OBSTET, V140, P845; HARRIS GF, 1993, J BIOMED ENG, V15, P67, DOI 10.1016/0141-5425(93)90096-H; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; KING AI, 1995, BIOMEDICAL ENG HDB; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Krantz K P, 1986, Acta Neurochir Suppl (Wien), V36, P47; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MURAI II, 1991, P 1 INT NEUROTRAUMA; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; SMYTH A, 2003, P 33 ANN NEUROSCI M; SMYTH A, 2004, P 34 ANN NEUROSCI M; Stalhammar D, 1986, Acta Neurochir Suppl (Wien), V36, P33; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VIANO D, 1988, 881706 SAE, P1070; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	58	18	18	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0039-2103	1475-1305		STRAIN	Strain	NOV	2004	40	4					180	192		10.1111/j.1475-1305.2004.00168.x			13	Materials Science, Characterization & Testing	Materials Science	880AM	WOS:000225760700005					2021-06-18	
J	Brodhun, M; Bauer, R; Patt, S				Brodhun, M; Bauer, R; Patt, S			Potential stem cell therapy and application in neurotrauma	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	4th International Congress of Pathophysiology	JUN 29-JUL 05, 2002	BUDAPEST, HUNGARY			stem cells; neurotrauma; spinal cord injury	EPIDERMAL-GROWTH-FACTOR; MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; BONE-MARROW; SPINAL-CORD; PRECURSOR CELLS; ADULT RATS; IN-VITRO; INTRASTRIATAL TRANSPLANTATION; REPLACEMENT STRATEGIES	Traumatic brain injury results from a sudden and external physical insult to the head, which is often accompanied by motor and cognitive impairment. Neurotrauma is characterized not only by focal abnormalities, but rather by multifocal, or even global structural and functional disturbances of the brain network. The impact initially causes necrotic cell death in the underlying tissue, followed by apoptotic cell death in the surrounding tissue due to multiple subsequent events, such as ischemia. excitotoxicity and altered gene expression. These pathological conditions are associated with high morbidity and mortality. Despite the high medical and economical relevance of neurotrauma there are currently no sufficient treatments. Supplementary therapeutic strategies have to be established. Many types of stem cells have the ability to engraft diffusely and become integral members of structures throughout the host CNS. Intrinsic factors appear to derive spontaneously from stem cells and seem to be capable of neuroprotective and/or neuroregenerative functions. Furthermore stem cells can be readily engineered to express specific genes. Such observations suggest that stem cells might participate in reconstructing the molecular and cellular milieu of traumatized brains. In this paper, the state of stem cell research is reviewed and its possible application in neurotrauma will be discussed. (C) 2004 Elsevier GmbH. All rights reserved.	Univ Jena, Inst Pathol, D-07740 Jena, Germany; Univ Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany	Brodhun, M (corresponding author), Univ Jena, Inst Pathol, Bachstr 18, D-07740 Jena, Germany.	michael.brodhun@med.uni-jena.de					Armstrong RJE, 2001, LANCET, V358, P1174, DOI 10.1016/S0140-6736(01)06260-2; Bjorklund A, 2000, NATURE, V405, P892, DOI 10.1038/35016175; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Bonilla S, 2001, INT J DEV BIOL, V45, pS67; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Castro RF, 2003, SCIENCE, V299; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; del Rio JA, 2002, EUR J NEUROSCI, V15, P1881, DOI 10.1046/j.1460-9568.2002.02027.x; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Ducray A, 2002, EUR J NEUROSCI, V15, P1907, DOI 10.1046/j.1460-9568.2002.02044.x; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Fung KM, 1997, BRAIN RES, V761, P347, DOI 10.1016/S0006-8993(97)00467-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, NATURE, V392, P18; Gerlach M, 2002, J NEUROL S3, V249, piii33, DOI DOI 10.1007/S00415-002-1307-Y; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P198; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hagell P, 1999, BRAIN, V122, P1121, DOI 10.1093/brain/122.6.1121; Hagell P, 2001, J NEUROPATH EXP NEUR, V60, P741, DOI 10.1093/jnen/60.8.741; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hynes M, 2000, NEURON, V28, P11, DOI 10.1016/S0896-6273(00)00079-9; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2002, J NEUROSCI, V22, P5365; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kruger GM, 2002, CELL, V110, P399, DOI 10.1016/S0092-8674(02)00899-1; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Legrier ME, 2001, CELL GROWTH DIFFER, V12, P591; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindvall O, 2001, CLIN CHEM LAB MED, V39, P356, DOI 10.1515/CCLM.2001.056; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu K, 2002, SPINE, V27, P887, DOI 10.1097/00007632-200204150-00021; Magavi SS, 2000, NATURE, V405, P951; McDonald JW, 2000, NAT MED, V6, P358, DOI 10.1038/74759; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Modo M, 2002, BRAIN RES, V958, P70, DOI 10.1016/S0006-8993(02)03463-7; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nishino H, 2000, Prog Brain Res, V127, P461; Ohta Y, 2000, ORL-J OTO-RHIN-LARYN, V62, P20, DOI 10.1159/000027710; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parent JM, 2002, PROG BRAIN RES, V135, P121; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Park KI, 2002, GENE THER, V9, P613, DOI 10.1038/sj.gt.3301721; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prestoz L, 2001, MOL CELL NEUROSCI, V18, P473, DOI 10.1006/mcne.2001.1037; Rathjen J, 2002, DEVELOPMENT, V129, P2649; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; ROMERORAMOS M, 2002, J NEUROSCI RES, V15, P3999; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; Senior K, 2000, LANCET, V355, P1890, DOI 10.1016/S0140-6736(05)73336-5; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Tamaki S, 2002, J NEUROSCI RES, V69, P976, DOI 10.1002/jnr.10412; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanapat P, 2001, J COMP NEUROL, V437, P496, DOI 10.1002/cne.1297; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tatton WG, 1997, J NEURAL TRANSM-SUPP, P245; TERSKIKH A, 2000, HUNTING HEMATOPOIETI, V1, P33; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Whittemore SR, 1999, J NEUROTRAUM, V16, P667, DOI 10.1089/neu.1999.16.667; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	102	18	23	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0940-2993	1618-1433		EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	OCT	2004	56	1-2					103	112		10.1016/j.etp.2004.04.004			10	Pathology; Toxicology	Pathology; Toxicology	872QF	WOS:000225221900013	15581281				2021-06-18	
J	Curry, DJ; Wright, DA; Lee, RC; Kang, UL; Frim, DM				Curry, DJ; Wright, DA; Lee, RC; Kang, UL; Frim, DM			Poloxamer 188 volumetrically decreases neuronal loss in the rat in a time-dependent manner	NEUROSURGERY			English	Article						excitoxicity; Poloxamer 188; surfactant; time course	MITOCHONDRIAL PERMEABILITY TRANSITION; ACUTE MYOCARDIAL-INFARCTION; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTOR; NERVE GROWTH-FACTOR; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; CELL-DEATH; APOPTOSIS; NECROSIS	OBJECTIVE: Excitotoxicity is a multistep process that results in either necrosis or apoptosis. It has been associated with neuronal death in trauma, ischemia, and neurodegeneration. The final step in necrotic cell death is the rupture of a cell's plasma membrane; repair of this membrane rupture is a potentially powerful technique of neuroprotection. Poloxamer 188 (P-188) is a synthetic surfactant that seals experimentally porated membranes. This study investigated the usefulness and time dependence of intrathecal P-188 in protecting neurons in an in vivo model of excitotoxicity in the rat. METHODS: Twenty-eight Sprague-Dawley rats underwent striatal infusion of quinolinic acid to produce a spherical excitotoxic lesion. Each animal then received either vehicle or P-188 at 10 minutes, 4 hours, or both time points after surgery by direct cisterna magna injection. Animals were killed at 1 week, and brains were stained immunohistochemically for the neuronal marker Neu-N. Volumes of neuronal loss were calculated and compared between groups by analysis of variance. RESULTS: All animals were found to have spherical, stereotyped lesions. The animals that received intrathecal poloxamer at the early injection time had statistically smaller lesions (8.16 +/- 6.12 mm(3); n = 5; P = 0.0015) than controls (18.25 +/- 11.42 mm(3); n = 11). Those animals that received poloxamer at both injection times also had statistically smaller lesions (10.57 +/- 9.00 mm(3); n = 7; P = 0.0095). The group that received poloxamer at the late injection time only did not have significantly decreased lesion size (14.86 +/- 7.95 mm(3); n = 5). CONCLUSION: Intrathecal P-188 reduces neuronal loss after excitotoxic injury in the rat only when delivered immediately after the toxin. This observation confirms the potential of surfactant molecules as neuroprotectants but predicts that their usefulness is best realized by early and potentially ongoing treatment.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	Frim, DM (corresponding author), Univ Chicago Hosp, Sect Pediat Neurosurg, MC-4066,5841 S Maryland Ave, Chicago, IL 60637 USA.	dfrimn@peds.bsd.uchicago.edu	Wright, David/K-7898-2012	Wright, David/0000-0002-2785-0254; Kang, Un/0000-0002-5970-6839			AdamsGraves P, 1997, BLOOD, V90, P2041, DOI 10.1182/blood.V90.5.2041; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARMSTRONG JK, 1995, THROMB RES, V79, P437, DOI 10.1016/0049-3848(95)00134-D; *BASF WYAND CORP, 1975, PLUR POL TOX IRR STU; BATRAKOVA EV, 1999, PHARM RES, V16, P1317; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COLBASSANI HJ, 1989, STROKE, V20, P1241, DOI 10.1161/01.STR.20.9.1241; Curry DJ, 2004, J NEUROSURG, V101, P91, DOI 10.3171/ped.2004.101.2.0091; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; FARBER JL, 1981, AM J PATHOL, V102, P271; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FERRER I, 1995, ACTA NEUROPATHOL, V90, P504; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; HUNTER RL, 1995, ANTIMICROB AGENTS CH, V39, P435, DOI 10.1128/AAC.39.2.435; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; KNIZE DM, 1969, SURG GYNECOL OBSTETR, V129, P1019; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MAY LE, 1958, J AM GERIATR SOC, V6, P814, DOI 10.1111/j.1532-5415.1958.tb00788.x; Maynard C, 1998, AM HEART J, V135, P797, DOI 10.1016/S0002-8703(98)70037-7; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; MEZROW CK, 1992, J THORAC CARDIOV SUR, V103, P1143; Moghimi SM, 1996, J NATL CANCER I, V88, P766, DOI 10.1093/jnci/88.11.766; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OKeefe JH, 1996, AM J CARDIOL, V78, P747, DOI 10.1016/S0002-9149(96)00414-6; Parnaud G, 2001, BRIT J CANCER, V84, P90, DOI 10.1054/bjoc.2000.1540; PATON BC, 1968, ORGAN PERFUSION PRES, P105; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PETITO CK, 1984, J NEUROPATH EXP NEUR, V43, P141, DOI 10.1097/00005072-198403000-00004; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Rapoport N, 2000, ARCH BIOCHEM BIOPHYS, V384, P100, DOI 10.1006/abbi.2000.2104; RODEHEAVER GT, 1980, ANN EMERG MED, V9, P572, DOI 10.1016/S0196-0644(80)80228-9; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SIESJO BK, 1989, ANN NY ACAD SCI, V568, P234; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; UHLER TA, 1994, NEUROSURGERY, V34, P122; Urushitani M, 2001, J NEUROSCI RES, V63, P377, DOI 10.1002/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#; WADDELL WR, 1957, METABOLISM, V6, P815; Wang MY, 2001, NEUROSURGERY, V49, P962; Ward MW, 2000, J NEUROSCI, V20, P7208; WEATHERL.RC, 1969, SURGERY, V66, P208; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	64	18	19	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					943	948		10.1227/01.NEU.0000137890.29862.2C			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100048	15458603				2021-06-18	
J	Al-Adawi, S; Dorvlo, ASS; Burke, DT; Huynh, CC; Jacob, L; Knight, R; Shah, MK; Al-Hussaini, AA				Al-Adawi, S; Dorvlo, ASS; Burke, DT; Huynh, CC; Jacob, L; Knight, R; Shah, MK; Al-Hussaini, AA			Apathy and depression in cross-cultural survivors of traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							INTERNATIONAL DIAGNOSTIC INTERVIEW; CLOSED HEAD-INJURY; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; SCALE; OMAN; PREVALENCE; SYMPTOMS; MOOD; INDIVIDUALS	The disturbance of motivation and its relationship to depression continues to spark contradictory findings among European and North American populations. Could a cross-cultural study shed some light on the situation? This study aims to detect the prevalence of apathy and to test whether the Apathy Evaluation Scale (AES) can spot the presence or absence of depression in survivors of traumatic brain injury (TBI) in Oman. Eighty subjects who sustained a TBI were given an Arabic version of the AES and were also interviewed with the semistructured Composite International Diagnostic Interview (CIDI). The authors found that the incidence of apathy and depression among Omani people who sustained TBI is similar to that reported elsewhere. The AES has poor discriminatory power in identifying cases of depression. These findings emphasize the importance of developing assessment tools that are culturally sensitive hi light of the rising incidence of TBI in developing countries such as Oman.	Sultan Qaboos Univ, Coll Med, Dept Behav Med, Muscat, Oman; Harvard Univ, Sch Med, Spaulding Hosp, Dept Phys Med & Rehabil, Boston, MA 02115 USA; Sultan Qaboos Univ, Coll Sci, Dept Math & Stat, Muscat, Oman	Al-Adawi, S (corresponding author), Sultan Qaboos Univ, Coll Med, Dept Behav Med, POB 35,Al Khoudh 123, Muscat, Oman.	adawi@squ.edu.om	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			Abou-Saleh MT, 2001, SOC PSYCH PSYCH EPID, V36, P20, DOI 10.1007/s001270050286; Al-Adawi S, 2001, EPILEPSIA, V42, P1476, DOI 10.1046/j.1528-1157.2001.05599.x; Al-Adawi S, 2000, MED HYPOTHESES, V54, P523, DOI 10.1054/mehy.1999.0890; Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Al-Marshudi AS, 2001, WATER INT, V26, P259, DOI 10.1080/02508060108686912; ALADAWI S, 2001, SULTAN QABOOS U J SC, V3, P35; ALLAWATIA J, 2000, SULTAN QABOOS U J SC, V2, P105; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Beck A. T., 1996, BECK DEPRESSION INVE, VII; COREY MR, 1987, COGNITIVE REHABILITA, V5, P28; Deen JL, 1999, B WORLD HEALTH ORGAN, V77, P518; Galynker I, 1997, J NERV MENT DIS, V185, P616, DOI 10.1097/00005053-199710000-00004; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; GRINSTEAD P, 1997, HOSP DOCTOR     0220, P36; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; *INF PUBL CTR, 2001, STAT YB SULT OM MIN; Isella V, 2002, MOVEMENT DISORD, V17, P366, DOI 10.1002/mds.10041; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lampe IK, 2001, J GERIATR PSYCH NEUR, V14, P11, DOI 10.1177/089198870101400104; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; Lesser IM, 1997, J PSYCHOPATHOL BEHAV, V19, P149, DOI 10.1007/BF02229040; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; MARIN RS, 1996, AMER P PR R, V15, P205; McPherson S, 2002, J INT NEUROPSYCH SOC, V8, P373, DOI 10.1017/S1355617702813182; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; Pang FC, 2002, INT J GERIATR PSYCH, V17, P29, DOI 10.1002/gps.510; Patel V, 2001, BRIT MED BULL, V57, P33, DOI 10.1093/bmb/57.1.33; Ramirez SM, 2001, PSYCHOL REP, V88, P189, DOI 10.2466/PR0.88.1.189-200; Resnick B, 1998, Rehabil Nurs, V23, P141; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; SILVER JM, 1994, J HEAD TRAUMA REHAB, V9, P61, DOI 10.1097/00001199-199409000-00006; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; *SPSS, 1999, SPSS 9 0 WIND; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; Sulaiman AJM, 2001, J TROP PEDIATRICS, V47, P1; TEASDALE G, 1974, LANCET, V2, P81; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; USTUN TB, 2002, HDB PSYCHIAT CARE, P25; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Viguier D, 2001, BRAIN INJURY, V15, P263; WITTCHEN HU, 1991, BRIT J PSYCHIAT, V159, P645, DOI 10.1192/bjp.159.5.645; World Health Organization, 1993, COMP INT DIAGN INT C, V1.1; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; Zaidan ZAJ, 2002, TROP MED INT HEALTH, V7, P549, DOI 10.1046/j.1365-3156.2002.00887.x	57	18	19	0	6	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2004	16	4					435	442		10.1176/appi.neuropsych.16.4.435			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	881VN	WOS:000225897600005	15616169				2021-06-18	
J	Bombardier, CH; Stroud, MW; Esselman, PC; Rimmele, CT				Bombardier, CH; Stroud, MW; Esselman, PC; Rimmele, CT			Do preinjury alcohol problems predict poorer rehabilitation progress in persons with spinal cord injury?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcohol-related disorders; health services research; rehabilitation; spinal cord injuries	FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN INJURY; SUBSTANCE-ABUSE; READINESS	Objective: To determine whether a history of alcohol-related problems is associated with inpatient rehabilitation progress. Design: Cross-sectional cohort survey. Setting: Acute inpatient rehabilitation program in a level I trauma center. Participants: Seventy-six of 104 consecutive patients with spinal cord injury (SCI) who met inclusion criteria and had completed interviews and functional outcome data. Participants were on average 38 years old; 84% were white, and 86% were men. Forty-two percent had tetraplegia and 39% had a history of problem drinking. Interventions: Not applicable. Main Outcome Measures: FIM instrument admission, discharge, and efficiency scores as well as rehabilitation length of stay (LOS). Results: The group with a history of problem drinking had significantly lower FIM admission, discharge, and efficiency scores and longer rehabilitation LOS. After controlling for potential confounding factors, a history of problem drinking accounted for a significant proportion of the variance in FIM efficiency scores. Conclusions: A history of problem drinking may be a risk factor for poorer rehabilitation progress among patients with SCI. They may be more costly to rehabilitate and may be discharged before attaining an adequate level of independence. Despite this, the current rehabilitation prospective payment system does not recognize this common comorbid condition.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle VA Puget Sound Hlth Care Syst, Seattle, WA USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chh@u.washington.edu					BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; CARTER GM, DRU2309J RAND, P210; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Elliott TR, 2002, REHABIL PSYCHOL, V47, P278, DOI 10.1037//0090-5550.47.3.278; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; HALT PS, 1992, ARCH NEUROL-CHICAGO, V49, P1178, DOI 10.1001/archneur.1992.00530350096025; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1988, ALCOHOL CLIN EXP RES, V12, P815, DOI 10.1111/j.1530-0277.1988.tb01352.x; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; Kiwerski J E, 1992, Int J Rehabil Res, V15, P240, DOI 10.1097/00004356-199209000-00008; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; Miller WR, 1997, AM PSYCHOL, V52, P1269, DOI 10.1037/0003-066X.52.12.1269; Mulder RT, 2002, AUST NZ J PSYCHIAT, V36, P44, DOI 10.1046/j.1440-1614.2002.00958.x; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	26	18	19	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1488	1492		10.1016/j.apmr.2003.10.010			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	852DW	WOS:000223736400017	15375822				2021-06-18	
J	Bush, BA; Novack, TA; Schneider, JJ; Madan, A				Bush, BA; Novack, TA; Schneider, JJ; Madan, A			Depression following traumatic brain injury: The validity of the CES-D as a brief screening device	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS			English	Article						depression; traumatic brain injury; assessment; CES-D	GENDER-DIFFERENCES; SCALE; POSTSTROKE; INVENTORY; ADULTS; MOOD	The validity, reliability, and factor structure of the Center for Epidemiological Studies-Depression Scale (CES-D) was examined with 253 patients seen for neuropsychological evaluation following traumatic brain injury (TBI). All patients completed the CES-D; 31 also completed the Beck Depression Inventory (BDI) and 17 completed the Minnesota Multiphasic Personality Inventory-II (MMPI-II). The CES-D demonstrated good concurrent, construct validity, significantly correlating with the BDI (r=.673, p<.0001) and the MMPI-II ( Depression Scale T scorer=.536, p=.027). The CES-D also demonstrated good internal consistency (coefficient alpha=.8195) and split-half reliability (Spearman-Brown r=.8284). Principal components factor analysis with varimax rotation resulted in a four-factor solution that accounted for 56.01% of the variance. The factor structure differed from the originally reported factor structure, and indicated that somatic difficulties were strongly associated with dysphoric affect in TBI patients. The CES-D is a valid and reliable screening instrument for use with TBI patients.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Bush, BA (corresponding author), Univ Alabama, Dept Psychiat & Behav Neurobiol, 1530 3rd Ave S,C253, Birmingham, AL 35294 USA.	babush@uab.edu					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beals J., 1991, PSYCHOL ASSESSMENT, V3, P623, DOI [10.1037/1040-3590.3.4.623, DOI 10.1037/1040-3590.3.4.623]; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Bush BA, 1999, ARCH CLIN NEUROPSYCH, V14, P123, DOI 10.1093/arclin/14.1.123; CALLAHAN CM, 1994, MED CARE, V32, P341, DOI 10.1097/00005650-199404000-00003; Devins GM., 1988, PSYCHOL HLTH, V2, P139, DOI [10.1080/08870448808400349, DOI 10.1080/08870448808400349]; GARCIA M, 1989, PSYCHIAT RES, V27, P137, DOI 10.1016/0165-1781(89)90129-7; GUARNACCIA PJ, 1989, SOC SCI MED, V29, P85, DOI 10.1016/0277-9536(89)90131-7; HATHAWAY SR, 1989, MINNESOTA MULTIPHASI, V2; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; Paradiso S, 1998, J NEUROPSYCH CLIN N, V10, P41, DOI 10.1176/jnp.10.1.41; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROSS CE, 1984, AM J EPIDEMIOL, V119, P997, DOI 10.1093/oxfordjournals.aje.a113819; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; STOMMEL M, 1993, PSYCHIAT RES, V49, P239, DOI 10.1016/0165-1781(93)90064-N	20	18	18	0	3	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9583			J CLIN PSYCHOL MED S	J. Clin. Psychol. Med. Settings	SEP	2004	11	3					195	201		10.1023/B:JOCS.0000037613.69367.d4			7	Psychology, Clinical	Psychology	845GO	WOS:000223230500006					2021-06-18	
J	Adembri, C; Bechi, A; Meli, E; Gramigni, E; Venturi, L; Moroni, F; De Gaudio, AR; Pellegrini-Giampietro, DE				Adembri, C; Bechi, A; Meli, E; Gramigni, E; Venturi, L; Moroni, F; De Gaudio, AR; Pellegrini-Giampietro, DE			Erythropoietin attenuates post-traumatic injury in organotypic hippocampal slices	JOURNAL OF NEUROTRAUMA			English	Article						erythropoietin; neuroprotection; organotypic hippocampal slices; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; IN-VITRO; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; NITRIC-OXIDE; CELL-DEATH; BRAIN; PROTECTS; CULTURES; RECEPTOR	Recent experimental evidence indicates that erythropoietin (Epo), in addition to its hormonal role in regulating red cell production, operates as a neuroprotective agent. So far, the neuroprotective effect of human recombinant Epo (rhEpo) has been mainly demonstrated in models of cerebral ischemia/hypoxia and in selected in vivo studies of traumatic neuronal injury. To further investigate the potential role of this multifunctional trophic factor in post-traumatic cell death, we examined the protective effects of rhEpo in a newly developed model of mechanical trauma in organotypic hippocampal slices. Organotypic rat hippocampal slices were subjected to traumatic injury by allowing a stylus to impact on the CA1 area with an energy of 6 muJ. Hippocampal damage was identified and measured 24 and 48 h later with the fluorescent dye propidium iodide (PI). In untreated slices, the impact induced a significant increase in the mean hippocampal PI fluorescence, co-localized with the area of impact at 24 h (primary post-traumatic injury) and progressively spread to the whole slice between 24 and 48 h (secondary post-traumatic injury). Addition of rhEpo (1-100 UI/mL) or of the NMDA antagonist MK-801 (30 muM) immediately after the traumatic injury reduced hippocampal damage by approximately 30% when observed 24 h later. At 48 h after trauma, the protective effect of rhEpo was greater (by about 47%) and significantly more pronounced than that of MK-801 (28%). Our results suggest that the neuroprotective activity of rhEpo is particularly effective against delayed, secondary post-traumatic damage. This well tolerated agent could provide a therapeutic benefit in pathologies involving post-traumatic neurodegeneration.	Univ Florence, Dipartimento Area Crit Med Chirurg, Sez Anestesiol & Terapia Intens, I-50134 Florence, Italy; Univ Florence, Dipartimento Farmacol Preclin & Clin, Florence, Italy	Adembri, C (corresponding author), Univ Florence, Dipartimento Area Crit Med Chirurg, Sez Anestesiol & Terapia Intens, Viale Morgagni,85, I-50134 Florence, Italy.	chiara.adembri@unifi.it		Pellegrini-Giampietro, Domenico E./0000-0002-3920-2297			AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2002, CRIT CARE MED, V30, pA13, DOI 10.1097/00003246-200212001-00047; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Allen JW, 1999, FASEB J, V13, P1875; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fisher JW, 2003, EXP BIOL MED, V228, P1; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Lahtinen H, 2001, NEUROSCIENCE, V105, P131, DOI 10.1016/S0306-4522(01)00168-3; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sinor AD, 2000, NEUROSCI LETT, V290, P213, DOI 10.1016/S0304-3940(00)01361-6; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TASKER RC, 1992, J NEUROSCI, V12, P4298; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Yu XB, 2001, BLOOD, V98, P475, DOI 10.1182/blood.V98.2.475	39	18	20	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2004	21	8					1103	1112		10.1089/0897715041651079			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	846AK	WOS:000223286800012	15319009				2021-06-18	
J	Dodson, KM; Bridges, MA; Reiter, ER				Dodson, KM; Bridges, MA; Reiter, ER			Endoscopic transnasal management of intracranial foreign bodies	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							SPHENOID SINUS FOREIGN; PEN INJURY; BRAIN; BODY	Foreign bodies may be introduced into the paranasal sinuses or cranium through a variety of traumatic or iatrogenic events. A variety of open and, more recently, endoscopic approaches have been used for the removal of sinonasal foreign bodies. Intracranial foreign bodies, however, typically require retrieval via a craniotomy approach, which continues to carry significant perioperative risks. We describe the first reported case of an intracranial foreign body removed using the transnasal endoscopic approach with intraoperative image guidance. We discuss the preoperative evaluation required for this approach to be applied safely and successfully in properly selected cases.	Virginia Commonwealth Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Richmond, VA 23298 USA	Reiter, ER (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Box 980146, Richmond, VA 23298 USA.	ejreiter@comcast.net					Alsarraf R, 1998, ARCH OTOLARYNGOL, V124, P1018, DOI 10.1001/archotol.124.9.1018; Bhattacharyya N, 1998, OTOLARYNG HEAD NECK, V118, P687, DOI 10.1177/019459989811800523; CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184; Davis GA, 2000, J CLIN NEUROSCI, V7, P545, DOI 10.1054/jocn.2000.0692; FOY P, 1980, LANCET, V2, P662; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; LaFrentz JR, 2000, ANN OTO RHINOL LARYN, V109, P119, DOI 10.1177/000348940010900201; LOES DJ, 1987, PEDIATR NEUROL, V3, P44, DOI 10.1016/0887-8994(87)90055-5; Madei W, 1998, DEUT MED WOCHENSCHR, V123, P1139, DOI 10.1055/s-2007-1024136; Mohanty A, 2002, PEDIATR NEUROSURG, V37, P52, DOI 10.1159/000065104; Mori S, 1999, ORL J OTO-RHINO-LARY, V61, P165, DOI 10.1159/000027664; Pagella F, 1999, LARYNGOSCOPE, V109, P339, DOI 10.1097/00005537-199902000-00030; Sharif S, 2000, BRIT J NEUROSURG, V14, P159; Thaler ER, 1999, AM J RHINOL, V13, P303, DOI 10.2500/105065899782102827; Thomas RF, 2002, OTOLARYNG HEAD NECK, V127, P409, DOI 10.1067/mhn.2002.129821	15	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0886-4470	1538-361X		ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	AUG	2004	130	8					985	988		10.1001/archotol.130.8.985			4	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	844DY	WOS:000223138800013	15313871				2021-06-18	
J	Ratanalert, S; Phuenpathom, N; Saeheng, S; Oearsakul, T; Sripairojkul, B; Hirunpat, S				Ratanalert, S; Phuenpathom, N; Saeheng, S; Oearsakul, T; Sripairojkul, B; Hirunpat, S			ICP threshold in CPP management of severe head injury patients	SURGICAL NEUROLOGY			English	Article						intracranial pressure (ICP); threshold; head injury; cerebral perfusion pressure (CPP)	TRAUMATIC BRAIN-INJURY; PRESSURE; ISCHEMIA	BACKGROUND Elevated intracranial pressure (ICP) is significantly associated with high mortality rate in severe head injury (SHI) patients. However, there is no absolute agreement regarding the level at which ICP must be treated. The objective of this study was to compare the outcomes of severe head injury patients treated by setting the ICP threshold at greater than or equal to20 mm Hg or greater than or equal to25 mm Hg. METHODS Treatment protocol in this study consisted of therapeutic maneuvers designed to maximize cerebral profusion pressure (CPP) and control ICP. Twenty-seven patients with severe head injury and intracranial hypertension (ICP greater than or equal to20 mm Hg) were enrolled and fourteen cases were allocated to the group of ICP threshold greater than or equal to25 mm Hg. Six-month clinical outcomes were evaluated using the Glasgow Outcome Score (GOS). RESULTS There were no statistically significant differences in clinical parameters between the groups. Logistic regression identified the presence of basal cisterns on the initial computed tomography (CT) scan as a significant predictor of good outcome. ICP threshold did not influence outcome. CONCLUSIONS This study supported a recommended ICP threshold of 20 to 25 mm Hg in SHI management. However, in cases with an absence of basal cisterns on initial CT scan, the probability of good outcome may be higher using an ICP threshold of greater than or equal to20 mm Hg. (C) 2004 Elsevier Inc. All rights reserved.	Prince Songkla Univ, Fac Med, Dept Surg, Hat Yai 90110, Thailand; Prince Songkla Univ, Fac Med, Dept Radiol, Hat Yai 90110, Thailand	Ratanalert, S (corresponding author), Prince Songkla Univ, Fac Med, Dept Surg, Hat Yai 90110, Thailand.						ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P559; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JENNETT B, 1975, LANCET, V1, P480; Klein D G, 1999, Crit Care Nurs Clin North Am, V11, P209; LEVIN HS, 1990, HEAD INJURY, P367; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; MAPSTONE TB, 1996, CONT NEUROSURG, V18, P1; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1990, ADV BRAIN RESUSCITAT, P315; Ratanalert S, 2002, BRIT J NEUROSURG, V16, P487, DOI 10.1080/0268869021000030311; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498	24	18	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAY	2004	61	5					429	435		10.1016/S0090-3019(03)00579-2			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	818GO	WOS:000221233800007	15120212				2021-06-18	
J	Haug, E; Miner, J; Dannehy, M; Seigel, T; Biros, M				Haug, E; Miner, J; Dannehy, M; Seigel, T; Biros, M			Bispectral electroencephalographic analysis of head-injured patients in the emergency department	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting	MAY, 2002	ST LOUIS, MO	SAEM		trauma; head injury; bispectral analysis; emergency department	BRAIN INJURY; SEDATION; PROPOFOL; INDEX; PREDICTION; ALFENTANIL; LEVEL	Objectives: Bispectral analysis of single-lead electroencephalographs (BIS) has proven valuable in assessing the level of awareness in sedated patients. In this study, the authors sought to determine if BIS values had a predictive value in patients with traumatic brain injuries (TBIs). Therefore, the objective was to determine in emergency department (ED) patients presenting with head trauma whether BIS and Glasgow Coma Scale score (GCS) prior to sedation would be sensitive and specific in predicting TBI. Methods: A convenience sample of patients with known or suspected head trauma presenting between June and August of both 2001 and 2002 were entered into the study by having a BIS monitor placed immediately on presentation to the ED. BIS and GCS scores were collected every 2 minutes. Head computed tomography (CT) results and discharge dictations were then evaluated to determine the presence of TBI. Results: Fifty-two patients were entered into the study; 13 were excluded due to receiving sedatives prior to enrollment. Of the remaining 39 patients, 14 had intracranial hemorrhage on initial head CT. Of these 14, two had BIS scores over 95. Both of these were neurologically intact at discharge. Eleven of the 12 remaining patients died or left the hospital neurologically impaired. Of the patients with no abnormalities on initial head CT, 19 of 25 had initial BIS scores >95 and all left the hospital neurologically intact. Of the patients with normal initial head CT and initial BIS scores <95, four of six died or were neurologically impaired at discharge. Twenty of 39 patients presented with an initial GCS of 15; four of 20 had an initial BIS score <95, three of whom were neurologically impaired at discharge. The 16 of 20 with BIS >95 left the hospital neurologically intact. All patients with a GCS of 14 had BIS scores >95 and left the hospital neurologically intact. All patients with a GCS of 13 had initial BIS scores <95 and were neurologically impaired at discharge. One patient with a GCS of 11 and a BIS score of 67 left the hospital neurologically intact; all other patients with a GCS <12 had a BIS <95 and left the hospital with a neurologic deficit. Conclusions: BIS scores obtained prior to sedative medicines in the face of trauma are predictive of TBI and neurologic outcome at discharge.	Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA	Miner, J (corresponding author), Hennepin Cty Med Ctr, Dept Emergency Med, 701 Pk Ave S, Minneapolis, MN 55415 USA.	jimminer@hotmail.com	Miner, James/AAI-4801-2020				AVRAMOV MN, 1995, CRIT CARE CLIN, V11, P803; Bloom MJ, 1996, ANESTHESIOLOGY, V85, pA461; De Deyne C, 1998, INTENS CARE MED, V24, P1294, DOI 10.1007/s001340050765; Gill M, 2003, ACAD EMERG MED, V10, P175, DOI 10.1197/aemj.10.2.175; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Iselin-Chaves IA, 2000, ANESTHESIOLOGY, V92, P1300, DOI 10.1097/00000542-200005000-00018; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; ROSOW C, 1998, ANESTHESIOL CLIN N A, V2, P89; Sandler N A, 2000, Anesth Prog, V47, P72	13	18	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	APR	2004	11	4					349	352		10.1197/j.aem.2003.12.015			4	Emergency Medicine	Emergency Medicine	809TO	WOS:000220659200005	15064207	Bronze			2021-06-18	
J	O'Neill, JH; Zuger, RR; Fields, A; Fraser, R; Pruce, T				O'Neill, JH; Zuger, RR; Fields, A; Fraser, R; Pruce, T			The program without walls: Innovative approach to state agency vocational rehabilitation of persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; community health services; rehabilitation; vocational	QUALITY-OF-LIFE; COMMUNITY; WORK	Objective: To describe the Program Without Walls (PWW), a person-centered, community-based approach for state rehabilitation counselors to provide vocational rehabilitation (VR) services to people with traumatic brain injury (TBI). Design: Nonrandomized posttest only matched control group design using existing state VR data. Setting: Community-based within 2 district offices of the state-federal VR program in New York State. Participants: VR consumers with TBI (N = 42); 21 received PWW services, and 21 matched controls received traditional VR services. Intervention: All participants experienced the initial VR process: eligibility determination and the development of an individualized employment plan. Participants receiving the traditional approach were referred to various organizations for services and monitored by their state VR counselor. Those receiving PWW services were never "handed off" to outside agencies. Instead, they received person-centered, community-based services from a team of freelance consultants who were recruited, trained, and supervised by the state VR counselor overseeing the PWW team. Main Outcome Measures: Data were gathered from VR central files for all consumers with a primary or secondary disability of TBI. Outcome variables were case status at closure, weekly earnings at closure, hours working at closure, and cost of case services. Results: The PWW successfully placed more consumers who worked a greater number of hours per week and earned more per week than those who received traditional VR services without increasing the cost of case services. Conclusions: The PWW showed promise as a systems change effort to improve VR services for people with TBI.	CUNY Hunter Coll, Dept Educ Fdn & Counseling Programs, New York, NY 10021 USA; Mt Sinai Sch Med, New York, NY USA; New York State Off Vocat & Educ Sci Individuals D, New York, NY USA; Univ Washington, Seattle, WA 98195 USA	O'Neill, JH (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling Programs, 695 Pk Ave, New York, NY 10021 USA.	joneil@hunter.cuny.edu					BENNETT P, 1990, NAT HEAD INJ ASS 9 A; BERGMAN A, 2002, STAT OF THE SCI C CO; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; FRASER RT, 1994, NEUROL REHABIL, V5, P39; Gordon W. A., 2003, REH SERV ADM WORK GR; Hayward B., 2002, STAT OF THE SCI C CO; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	15	18	18	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S68	S72		10.1016/j.apmr.2003.08.114			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300009	15083424				2021-06-18	
J	Wassenberg, R; Max, JE; Koele, SL; Firme, K				Wassenberg, R; Max, JE; Koele, SL; Firme, K			Classifying psychiatric disorders after traumatic brain injury and orthopaedic injury in children: adequacy of K-SADS versus CBCL	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; BEHAVIOR PROBLEM SYNDROMES; ADOLESCENTS; DIAGNOSES; OUTCOMES; LIFETIME; TERM; MILD; PSYCHOPATHOLOGY; COMORBIDITY	Primary objective : To evaluate the convergence between the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) for the diagnosis of psychiatric disorders and the Child Behavior Checklist (CBCL). Research design : Cross-sectional psychiatric study of 72 children with traumatic brain injuries or orthopaedic injuries aged 5-14. Methods and procedures : Sensitivity, specificity, total predictive value and odds ratio were calculated to evaluate the association between CBCL summary scores and K-SADS diagnosis of at least one psychiatric disorder (K-SADS-1), and of CBCL subscales and K-SADS diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). Lowered cut-off scores of t greater than or equal to 60 were used. Main outcomes and results : Convergence between the CBCL total problem scale and K-SADS-1 was poor. Convergence between 'at least one elevated CBCL subscale' and K-SADS-1, and between CBCL attention problems and social problems scales and K-SADS diagnosis of ADHD was excellent. Conclusions : Caution is needed when using the total problem scale of CBCL in predicting global psychological impairment because underestimation of problems is likely. The attention and social problems scales of CBCL can be used to estimate ADHD.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Hosp Maastricht, Maastricht, Netherlands; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08 MH 01800] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; EDELBROCK C, 1988, J ABNORM CHILD PSYCH, V16, P219, DOI 10.1007/BF00913597; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; GOULD MS, 1993, J ABNORM CHILD PSYCH, V21, P287, DOI 10.1007/BF00917536; Green ML, 1998, J PEDIATR PSYCHOL, V23, P289, DOI 10.1093/jpepsy/23.5.289; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; JENSEN PS, 1993, J AM ACAD CHILD PSY, V32, P397, DOI 10.1097/00004583-199303000-00022; Kasius MC, 1997, J CHILD PSYCHOL PSYC, V38, P625, DOI 10.1111/j.1469-7610.1997.tb01689.x; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LACHAR D, 1986, ASSESSMENT CHILD ADO; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McGuire RJ, 2000, EUR CHILD ADOLES PSY, V9, P263, DOI 10.1007/s007870070029; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Reich W., 1988, REVISED VERSION DIAG; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sparrow S., 1984, VINELAND ADAPTIVE BE; STEINGARD R, 1992, J AM ACAD CHILD PSY, V31, P449, DOI 10.1097/00004583-199205000-00010; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; WIRT RD, 1977, MULTIDIMENSIONAL DES; YEATES KO, 2001, JINS, V3, P617	52	18	18	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2004	18	4					377	390		10.1080/02699050310001617325			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	765VB	WOS:000188304100004	14742151				2021-06-18	
J	Betts, R; Anagli, J				Betts, R; Anagli, J			The beta- and gamma-CH2 of B27-WT's Leu(11) and Ile(18) side chains play a direct role in calpain inhibitions	BIOCHEMISTRY			English	Article							TERMINAL CONSERVED REGION; CALMODULIN-LIKE DOMAIN; HUMAN CALPASTATIN; FUNCTIONAL DOMAIN; CALCIUM; PROTEASE; PEPTIDE; LOCALIZATION; DEGRADATION; PROTEINASE	Uncontrolled activation of calpain has been linked to tissue damage after neuronal and cardiac ischemias, traumatic spine and brain injuries, and multiple sclerosis and Alzheimer's disease. In vivo, the activity of calpain is regulated by its endogenous inhibitor calpastatin. The pathological role of calpain has been attributed to an imbalance between the activities of the protease and its inhibitor. Thus, it is possible that by reimposing functional control on the protease, the progression of calpain-mediated diseases could be slowed or eliminated. B27-WT is a 27-residue peptide (DPMSSTYIEELGKREVTIPPKYRELLA) derived from calpastatin that was previously shown to be a potent inhibitor of mu- and m-calpain. Recently, we identified two hot spots (Leu(11)-Gly(12) and Thr(17)-Ile(18)-Pro(19)) within which the amino acid residues that are key to B27-WT's bioactivity are clustered. In the work described here, the most critical residues of B27-WT, Leu(11) and Ile(18), were further probed to determine the nature of their interaction with calpain. Our results demonstrate that the side chains of both residues interact with hydrophobic pockets in calpain and that each of these interactions is indispensable for effective inhibition of calpain. Direct interactions involving the beta- and gamma-CH2- of the Leu(11) and Ile(18) side chains, respectively, rather than the degree of side chain branching or hydrophobicity, seemed to play a significant role in the peptide's ability to inhibit calpain. Furthermore, the minimum peptide sequence that still retained the calpain-inhibitory potency of B27-WT was found to be MSSTYIEELGKREVTIPPKYRELL.	Henry Ford Hlth Sci Ctr, Dept Pathol, Detroit, MI 48202 USA; Karmanos Canc Inst, Protease Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Anagli, J (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, 1 Ford Pl 5D, Detroit, MI 48202 USA.	janagli1@hfhs.org			NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P60 AR20557] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39075] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039075] Funding Source: NIH RePORTER		Anagli J, 1996, EUR J BIOCHEM, V241, P948, DOI 10.1111/j.1432-1033.1996.00948.x; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Barrett AJ., 1986, PROTEINASE INHIBITOR, P23; Betts R, 2003, J BIOL CHEM, V278, P7800, DOI 10.1074/jbc.M208350200; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; De Tullio R, 1999, BIOCHEM J, V343, P467; Hao LY, 2000, BIOCHEM BIOPH RES CO, V279, P756, DOI 10.1006/bbrc.2000.4040; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; ISHIMA R, 1991, FEBS LETT, V294, P64, DOI 10.1016/0014-5793(91)81344-8; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Lokuta MA, 2003, P NATL ACAD SCI USA, V100, P4006, DOI 10.1073/pnas.0636533100; MA H, 1994, J BIOL CHEM, V269, P24430; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P1787; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Pinton P, 2001, DRUG DEVELOP RES, V52, P558, DOI 10.1002/ddr.1159.abs; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Todd B, 2003, J MOL BIOL, V328, P131, DOI 10.1016/S0022-2836(03)00274-2; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L	29	18	18	0	2	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0006-2960			BIOCHEMISTRY-US	Biochemistry	MAR 9	2004	43	9					2596	2604		10.1021/bi0359832			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	800QB	WOS:000220041700025	14992597				2021-06-18	
J	Petridou, E; Kedikoglou, S; Belechri, M; Ntouvelis, E; Dessypris, N; Trichopoulos, D				Petridou, E; Kedikoglou, S; Belechri, M; Ntouvelis, E; Dessypris, N; Trichopoulos, D			The mosaic of equestrian-related injuries in Greece	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	6th World Conference on Injury Prevention and Control	MAY 12-15, 2002	MONTREAL, CANADA			horse racing; equestrian sport; farm; horse injury; severity; helmet protective devices; injury prevention	TRAUMA; DIAGNOSIS; ANIMALS; HORSES	Background: This study ainis to estimate the burden and describe the profile of equestrian injuries in Greece, where horses, donkeys, and mules are still used in agriculture and where horse riding is a popular leisure activity. Methods: Prospectively collected information on 140,823 injuries reported in the national Emergency Department Injury Surveillance System was examined and 244 equestrian-related injuries that occurred during farming, equestrian sports, or horse racing were analyzed. Results: The estimated countrywide injury incidence for farming and equestrian sports combined was 21 per 100,000 person-years, but it was 160 times higher for horse-racing personnel. Men had higher rates of racing injuries and women had higher rates of equestrian sport injuries. Fractures accounted for 39.0% of injuries in horse racing and 30.5% in farming; head injuries accounted for approximately 50% of injuries among farmers. Farming injuries were more serious, with 25% requiring hospitalization. Analysis through the Barell matrix pointed to the role of spurs in the causation of ankle fractures and dislocations and the likely contribution of helmets in preventing traumatic brain injuries. conclusion: Equestrian-related injuries are a serious but underappreciated health problem and merit targeted prevention efforts for each category affected.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Petridou, E (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 Mikras Asias, GR-11527 Athens, Greece.	epetrid@rned.uoa.gr		PETRIDOU, ELENI/0000-0003-3695-3439			[Anonymous], 1996, EUR HOM LEIS SURV SY; Ball DJ, 1998, SPORTS EXERC INJURY, V4, P3; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Dessypris N, 2002, J Cancer Epidemiol Prev, V7, P123; Frankel HL, 1998, AM SURGEON, V64, P151; Griffen M, 2002, SOUTHERN MED J, V95, P441, DOI 10.1097/00007611-200204000-00013; GROSSMAN JAI, 1978, JAMA-J AM MED ASSOC, V240, P1881, DOI 10.1001/jama.240.17.1881; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lloyd R G, 1987, Br J Sports Med, V21, P22; McGhee C N, 1987, Br J Neurosurg, V1, P131, DOI 10.3109/02688698709034348; McLatchie G R, 1979, Br J Sports Med, V13, P29; Norwood S, 2000, J TRAUMA, V48, P740, DOI 10.1097/00005373-200004000-00025; ORNEHULT L, 1989, ACCIDENT ANAL PREV, V21, P377, DOI 10.1016/0001-4575(89)90029-8; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; Temes RT, 1997, J TRAUMA, V43, P492, DOI 10.1097/00005373-199709000-00017; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005; Whitlock MR, 1999, BRIT J SPORT MED, V33, P212, DOI 10.1136/bjsm.33.3.212	24	18	18	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					643	647		10.1097/01.TA.0000053470.38129.F4			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	808CM	WOS:000220547200035	15128138				2021-06-18	
J	Mezey, E				Mezey, E			On bone marrow stem cells and openmindedness	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN INJURY; RAT SPINAL-CORD; STROMAL CELLS; FUNCTIONAL RECOVERY; IN-VIVO; TRANSPLANTATION; DIFFERENTIATION; LIVER; EXPRESSION; FUSION	Several lines of evidence support the concept that pluripotent stem cells reside in the hematopoietic system of adults, but each has been questioned for valid reasons. Thus, the results reported to date after infusion of bone marrow stem cells, may be due to cell fusion, non-physiological de-differentiation and subsequent differentiation to lineages directed by the culture environment, microchimerism, or transdifferentiation. Several authors have suggested complex ways of investigating each of these possibilities, but in no case are any of the suggested protocols complete, nor will they rule out other possible causes of the results observed to date. Determining the nature, origin, and characteristics of adult cells is important and interesting, but the important question at this time is not what happens physiologically, but what we can do with these cells therapeutically. Research addressing therapeutic endpoints now takes a pivotal position in studies of nonembryonic stem cells.	NINDS, NIH, Bethesda, MD 20892 USA	Mezey, E (corresponding author), NINDS, NIH, Bldg 36,Rm 3D-10,9000 Rockville Pike, Bethesda, MD 20892 USA.	mezeye@ninds.nih.gov	Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [ZIADE000714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [Z01DE000714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002996] Funding Source: NIH RePORTER		AHKONG QF, 1973, NATURE-NEW BIOL, V242, P215; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; ANTONOV PA, 1990, BIOCHIM BIOPHYS ACTA, V1051, P279, DOI 10.1016/0167-4889(90)90134-Y; Bateman A, 2000, CANCER RES, V60, P1492; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Gasser A, 1999, INFECT IMMUN, V67, P395, DOI 10.1128/IAI.67.1.395-402.1999; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mezey E, 2003, SCIENCE, V299; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; OHNOSHOSAKU T, 1984, BIOCHEM BIOPH RES CO, V120, P138, DOI 10.1016/0006-291X(84)91424-4; Okamoto R, 2003, TRENDS MOL MED, V9, P286, DOI 10.1016/S1471-4914(03)00110-2; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; REH TA, 1995, SEMIN CELL BIOL, V6, P137, DOI 10.1006/scel.1995.0019; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tran SD, 2003, LANCET, V361, P1084, DOI 10.1016/S0140-6736(03)12894-2; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	36	18	18	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	FEB	2004	13	1					147	152		10.1089/154732804773099344			6	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	843CR	WOS:000223053700014	15068702				2021-06-18	
J	Ryan, JP; Atkinson, TM; Dunham, KT				Ryan, JP; Atkinson, TM; Dunham, KT			Sports-related and gender differences on neuropsychological measures of frontal lobe functioning	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						perceptual-motor speed; verbal fluency; sports; gender	SEX-DIFFERENCES; PERFORMANCE; ABILITIES; EXPERTISE; WOMEN	Objective: To determine similarities and differences in the performance of female and male athletes on neuropsychological measures of frontal lobe functioning. Design: A cross-sectional study of male and female college-aged athletes involved in one of the following sports: hockey, basketball, softball, lacrosse, soccer, swimming, and track. Setting: Division III college. Participants: A total of 262 athletes (male, n = 157; female, n 105) participated in the study. Main Outcome Measures: Controlled Oral Word Association (letters F, A, S), Cognitive Assessment System (Planned Codes, Planned Connections, Number Detection), and WAIS-R-NI Vocabulary were administered to all athletes. Results: MANCOVA was performed with gender and sport as fixed factors. Female athletes displayed faster and more accurate performance on perceptual-motor tasks (P < 0.01) and on one condition of a verbal fluency task (P < 0.01) compared with male athletes. Male hockey athletes showed superior perceptual-motor speed and accuracy (P < 0.01) compared with male athletes in the track/swimming group. Evaluators were naive to athletes' gender and sport. Conclusion: Gender- and sport-specific performances on perceptual-motor and verbal fluency tasks were found. Adding cognitive components to base functions eliminates gender- and sports-related distinctions, suggesting that existing differences are related to basic, fundamental skills, which are inherent and practiced within the respective sport. Understanding the differences and similarities across sports and gender on various neurocognitive measures is relevant for determining group differences in studies examining the consequences of mild traumatic brain injury among athletes.	SUNY Coll Plattsburgh, Dept Psychol, Plattsburgh, NY 12901 USA; Univ Virginia, Dept Psychol, Charlottesville, VA 22903 USA	Ryan, JP (corresponding author), SUNY Coll Plattsburgh, Dept Psychol, 101 Broad St, Plattsburgh, NY 12901 USA.	Jeanne.Ryan@Plattsburgh.edu					Adam JJ, 1992, J SPORT SCI, V10, P261, DOI 10.1080/02640419208729925; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bird S, 2001, J SPORT SCI, V19, P243, DOI 10.1080/026404101750158295; CAPLAN PJ, 1997, GENDER DIFFERENCES H; CHANCE JE, 1971, PERCEPT PSYCHOPHYS, V9, P33, DOI 10.3758/BF03213024; CHATTERJEE S, 1995, SOC BIOL, V42, P124; CONNOR JM, 1977, DEV PSYCHOL, V13, P293, DOI 10.1037/0012-1649.13.3.293; COX JS, 1984, AM J SPORT MED, V12, P241, DOI 10.1177/036354658401200315; Dabbs JM, 1998, EVOL HUM BEHAV, V19, P89, DOI 10.1016/S1090-5138(97)00107-4; Das JP, 1997, COGNITIVE ASSESSMENT; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GARLAND DJ, 1990, PERCEPT MOTOR SKILL, V70, P1299, DOI 10.2466/PMS.70.4.1299-1314; Halpern D. F., 2000, SEX DIFFERENCES COGN; KIMURA D, 1983, CAN J PSYCHOL, V37, P19, DOI 10.1037/h0080696; Kimura D, 1999, SEX COGNITION; Kioumourtzoglou E, 1998, PERCEPT MOTOR SKILL, V86, P899, DOI 10.2466/pms.1998.86.3.899; LEWIS DA, 1986, SPORTS MED, V3, P357, DOI 10.2165/00007256-198603050-00005; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Lidor R, 1998, PERCEPT MOTOR SKILL, V86, P279, DOI 10.2466/pms.1998.86.1.279; MAJERES RL, 1988, INTELLIGENCE, V12, P149, DOI 10.1016/0160-2896(88)90013-X; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; MCKEEVER WF, 1995, LEARN INDIVID DIFFER, V7, P323, DOI 10.1016/1041-6080(95)90005-5; MCPHERSON SL, 1990, RES Q EXERCISE SPORT, V70, P369; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Ripoll H, 1997, J SPORT SCI, V15, P573, DOI 10.1080/026404197367001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Thein LA, 1996, J ORTHOP SPORT PHYS, V23, P134, DOI 10.2519/jospt.1996.23.2.134; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEISS EM, 2002, SCIENCE DIRECT   DEC, P15; Wilmore J H, 1979, Can J Appl Sport Sci, V4, P103	31	18	19	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2004	14	1					18	24		10.1097/00042752-200401000-00004			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BM	WOS:000230326800004	14712162				2021-06-18	
J	Statler, KD; Janesko, KL; Melick, JA; Clark, RSB; Jenkins, LW; Kochanek, PM				Statler, KD; Janesko, KL; Melick, JA; Clark, RSB; Jenkins, LW; Kochanek, PM			Hyperglycolysis is exacerbated after traumatic brain injury with fentanyl vs. isoflurane anesthesia in rats	BRAIN RESEARCH			English	Article						head injury; excitotoxicity; sedation; narcotics; metabolism	CEREBRAL BLOOD-FLOW; TOXICITY IN-VIVO; GLUCOSE-UTILIZATION; INTRACRANIAL-PRESSURE; PENTOBARBITAL REDUCE; AEROBIC GLYCOLYSIS; FOREBRAIN ISCHEMIA; INDUCED SEIZURES; AMINO-ACIDS; HIPPOCAMPAL	Despite common use of narcotics in the clinical management of severe traumatic brain injury (TBI), in experimental models rats treated with fentanyl have exhibited worse functional outcome and more CA1 hippocampal death than rats treated with standard isoflurane anesthesia. We hypothesized that greater post-traumatic excitotoxicity, reflected by cerebral glucose utilization (CMRglu), may account for detrimental effects of fentanyl vs. isoflurane. Rats were anesthetized with either isoflurane (1% by inhalation) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h infusion). C-14-deoxyglucose autoradiography was performed 45 min after controlled cortical impact (CCI) to left parietal cortex (n = 4 per anesthetic group) or in uninjured rats after 45 min of anesthesia (n = 3 per anesthetic group). Uninjured rats treated with fentanyl vs. isoflurane showed 35-45% higher CMRglu in all brain structures (p < 0.05) except CA3. After TBI in rats treated with isoflurane, CMRglu increased significantly only in ipsilateral CA1 and ipsilateral parietal cortex (p<0.05 vs. isoflurane uninjured). Conversely, after TBI in rats treated with fentanyl, CMRglu increased markedly and bilaterally in CA1 and CA3 (p < 0.05 vs. fentanyl uninjured), but not ipsilateral parietal cortex. In contralateral CA1, CMRglu was nearly two times greater after TBI in fentanyl vs. isoflurane treated rats (p < 0.05). Hyperglycolysis was exacerbated in CA1 and CA3 hippocampus after TBI in rats treated with fentanyl vs. isoflurane anesthesia. This post-traumatic hyperglycolysis suggests greater excitotoxicity and concurs with reports of worse functional outcome and more CA1 hippocampal death after TBI with fentanyl vs. isoflurane anesthesia. (C) 2003 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40686] Funding Source: Medline		*AANS BRAIN TRAUM, 2000, J NEUROTRAUM, V17, P463; ARCHER DP, 1990, J CEREBR BLOOD F MET, V10, P624, DOI 10.1038/jcbfm.1990.114; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; Harada H, 1999, ANESTH ANALG, V89, P1442, DOI 10.1097/00000539-199912000-00022; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Izumi Y, 2002, J CLIN NEUROSCI, V9, P289, DOI 10.1054/jocn.2001.0966; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; Nellgard B, 2000, ANESTH ANALG, V91, P145, DOI 10.1097/00000539-200007000-00027; NEUMAIER JF, 1998, J PHARMACOL EXP THER, V244, P564; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Smolders I, 1997, EUR J PHARMACOL, V319, P21, DOI 10.1016/S0014-2999(96)00830-8; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2000, CRIT CARE MED, V28, pA53; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; TOMMASINO C, 1984, ANESTHESIOLOGY, V60, P283, DOI 10.1097/00000542-198404000-00003; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	18	18	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 19	2003	994	1					37	43		10.1016/j.brainres.2003.09.042			7	Neurosciences	Neurosciences & Neurology	753UT	WOS:000187249500004	14642446				2021-06-18	
J	Peasley, MA; Shi, RY				Peasley, MA; Shi, RY			Ischemic insult exacerbates acrolein-induced conduction loss and axonal membrane disruption in guinea pig spinal cord white matter	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						neurotrauma; oxygen-glucose deprivation; reperfusion; membrane; metabolism	AORTIC-ANEURYSM REPAIR; POLYETHYLENE-GLYCOL; LIPID-PEROXIDATION; INJURY; MODEL; GLUTATHIONE; PROTEINS; BRAIN; RAT	Cellular destruction following ischemic insult may be due to secondary injury mechanisms, not the oxygen-glucose deprivation itself We have examined the effect of acrolein, an aldehyde product of lipid peroxidation (LPO) and oxidative stress, on the axons in isolated guinea pig spinal cord white matter following ischemic insult. We have found that acrolein at 50 muM, which is unharmful to spinal cord when applied alone, causes action potential conduction failure and membrane disruption following I to 2 h of exposure when applied during the reperfusion period. Ischemic insult also exacerbates the effect of acrolein at 200 [M. which does inflict functional and anatomical damage when applied alone. Unlike metabolic poisoning, acrolein-mediated damage is not a function of axonal size and does not affect the refractoriness in response to dual and multiple stimuli. These results indicate that spinal cord axons, in addition to experiencing elevated free radicals, are more vulnerable to acrolein attack when the level of oxygen and glucose is low. We conclude that free radicals and lipid peroxidation in general, and acrolein in specific, may play a critical role in cellular destruction and functional loss in such injury. (C) 2003 Elsevier B.V. All rights reserved.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA.						ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P187, DOI 10.1016/0891-5849(93)90058-3; ALLEN BT, 1995, VASCULAR SURG THEORY, P1402; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Coselli JS, 1997, ANN THORAC SURG, V63, P28, DOI 10.1016/S0003-4975(96)01029-6; DENNIS KJ, 1990, LIPIDS, V25, P460, DOI 10.1007/BF02538089; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Hall ED, 1996, ADV NEUROL, V71, P247; HALLIWELL B, 1999, FREE RADICALS BIOL M; Kanellopoulos GK, 1997, STROKE, V28, P2532, DOI 10.1161/01.STR.28.12.2532; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; Lang-Lazdunski L, 2000, EUR J CARDIO-THORAC, V18, P174, DOI 10.1016/S1010-7940(00)00430-9; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo J, 2002, SPINAL CORD, V40, P656, DOI 10.1038/sj.sc.3101363; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Safi HJ, 1998, ANN THORAC SURG, V66, P1204, DOI 10.1016/S0003-4975(98)00781-4; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; YOUNG W, 1993, RES P ARNMD, V71, P191	31	18	20	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	DEC 15	2003	216	1					23	32		10.1016/S0022-510X(03)00201-6			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	748DH	WOS:000186846600004	14607299				2021-06-18	
J	Muller, K; Waterloo, K; Romner, B; Wester, K; Ingebrigtsen, T				Muller, K; Waterloo, K; Romner, B; Wester, K; Ingebrigtsen, T			Mild head injuries: Impact of a national strategy for implementation of management guidelines	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; management; guidelines; implementation; guideline compliance	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; HOSPITALS	Background. A national survey in 1996 showed insufficient routines for management of patients with mild head injuries in Norwegian hospitals. Since then, the Scandinavian Guidelines for Management of Mild Head Injuries have been published. Methods. A cross-sectional questionnaire survey of management practice was performed in all 59 hospitals in 2002. We compared the results with figures from 1996 and evaluated guideline compliance. Results. The proportion of noncompliant hospitals was reduced (p = 0.02) from 52% to 31%. The proportion assessing the patient's level of consciousness according to the Glasgow Coma Scale increased (p = 0.001) from 49% to 80%. The proportion requiring a normal computed tomographic scan if a patient with a history of loss of consciousness was to be sent home from the accident and emergency department increased (p < 0.001) from 1 (2%) to 13 (19%). Conclusion. The Scandinavian Guidelines for Management of Mild Head Injuries have had a significant impact on management practice in Norwegian hospitals.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Univ Hosp N Norway, Dept Neurol, N-9038 Tromso, Norway; Univ Bergen, Inst Surg Sci, Bergen, Norway; Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Ingebrigtsen, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	tor.ingebrigtsen@unn.no		Ingebrigtsen, Tor/0000-0001-5966-9786			Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; INBEBRIGTSEN T, 2000, TIDSSKR NOR LAEGEFOR, V120, P1985; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; NARAYAN RK, 1995, J NEUROTRAUM, V12, P907, DOI 10.1089/neu.1995.12.907; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Stiell IG, 2000, NEW ENGL J MED, V343, P1570; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	18	18	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1029	1034		10.1097/01.TA.0000100371.49160.2A			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200005	14676646				2021-06-18	
J	Power, PW; Hershenson, DB				Power, PW; Hershenson, DB			Work adjustment and readjustment of persons with mid-career onset traumatic brain injury	BRAIN INJURY			English	Article							RETURN; EMPLOYMENT; REHABILITATION; DISABILITY	This study investigated the effects of mid-career onset traumatic brain injury on work adjustment, as well as examining the utility of Hershenson's model of work adjustment. Ten clients in a head injury rehabilitation programme were intensively interviewed and completed questionnaires concerning the effect of their mid-career onset disability on their work adjustment. Information about post-traumatic work adjustment and coping was identified, collated and summarized. Results indicated that for this population work adjustment assumes a special meaning and career development becomes a redevelopment and planning process, rather than an unbroken, linear process. Results also suggested the utility of the Hershenson model for structuring studies on this specific topic and further emphasized that work adjustment development must be studied in the context of personal, family and social development.	Univ Maryland, Coll Educ, Dept Counseling & Personnel Serv, College Pk, MD 20742 USA	Power, PW (corresponding author), Univ Maryland, Coll Educ, Dept Counseling & Personnel Serv, College Pk, MD 20742 USA.	pp21@umail.umd.edu					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; CORTHELL DW, 1985, REHABILITATION TRAUM; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FABIANO RJ, 1995, J APPL REHABILITATIO, V26, P17; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HACKETT G, 1981, J VOCAT BEHAV, V18, P326, DOI 10.1016/0001-8791(81)90019-1; HERSHENSON DB, 1981, REHABIL COUNS BULL, V25, P91; Hershenson DB, 1996, REHABIL COUNS BULL, V40, P2; HOWELL L, 1978, DISABILITY REHABILIT, P67; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KOSCIULEK JF, 1991, VOCATIONAL EVALUATIO, V24, P137; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Marshall C., 1995, DESIGNING QUALITATIV; Moore R.L., 1990, J APPL REHABILITATIO, V21, P3; PARKER RS, 1987, EAP DIGEST, V7, P55; Possl O, 2001, BRAIN INJURY, V15, P15; ROCCHIO C, 2001, BRAIN INJURY SOURCE, V5, P44; Super D.E., 1990, J VOCAT BEHAV, V2nd ed., P197; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	27	18	18	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2003	17	12					1021	1034		10.1080/0269905031000110526			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731WR	WOS:000185909900002	14555362				2021-06-18	
J	Schootman, M; Buchman, TG; Lewis, LM				Schootman, M; Buchman, TG; Lewis, LM			National estimates of hospitalization charges for the acute care of traumatic brain injuries	BRAIN INJURY			English	Article							UNITED-STATES; SYSTEM; COSTS	Primary objective: To estimate hospitalization charges for the acute care of traumatic brain injuries ( TBIs) in the US and to identify factors associated with increased charges. Research design: Population-based descriptive study. Methods: The 1996 National Inpatient Sample was used, which contains all-payer data on hospital inpatient stays from 906 hospitals in 19 states. Multivariate linear regression with the log (mean+1) charges as the dependent variable was used to identify factors associated with increased charges. Results: An estimated 254 500 TBIs required hospitalization in 1996 in the US, with $5.4 billion charged to treat these injuries during acute hospitalization. Patient age ( up to 34 years), increasing severity of injury and urban teaching hospitals were associated with higher mean charges in multivariate analysis. Conclusions: Based on hospitalization rates, mean and total charges, segments of the population were identified that are likely candidates for injury prevention interventions.	Washington Univ, Sch Med, Dept Pediat, Div Hlth Behav ARes, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Med, Div Hlth Behav ARes, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Emergency Med, St Louis, MO USA	Schootman, M (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Hlth Behav ARes, 4444 Forest Pk Pkwy,Box 8504, St Louis, MO 63108 USA.		Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824; Buchman, Timothy/0000-0001-7350-5921			*AG HLTH CAR POL R, 1999, COMP AN HCUP NHDS S, V13; *AG HLTH CAR POL R, 1999, TECHN SUPPL HCUP 3 N; ANNEST JL, 1998, STATES ARE COLLECTIN; [Anonymous], 1998, REH PERS TRAUM BRAIN, P1; Bass RR, 1999, J TRAUMA, V47, pS15, DOI 10.1097/00005373-199909001-00005; *BUR LAB STAT, 2003, CONS PRIC IND CONV F; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; EASTMAN AB, 1994, J TRAUMA, V36, P835, DOI 10.1097/00005373-199406000-00014; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; LEWIN ICF, 1992, COST DISORDERS BRAIN; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Rogers FB, 1997, J TRAUMA, V43, P65, DOI 10.1097/00005373-199707000-00016; Rutledge R, 1996, J TRAUMA, V40, P1002, DOI 10.1097/00005373-199606000-00025; Schootman M, 2000, BRAIN INJURY, V14, P373; SCHOOTMAN M, 1998, FRONTIERS HEAD NECK; SCHOOTMAN M, 2000, J TRAUMA, V13, P995; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA	23	18	18	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2003	17	11					983	990		10.1080/0269905031000110427			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725GE	WOS:000185534800005	14514449				2021-06-18	
J	Babin, PR				Babin, PR			Diagnosing depression in persons with brain injuries: a look at theories, the DSM-IV and depression measures	BRAIN INJURY			English	Article							MOOD DISORDERS; HEAD-INJURIES; SCALE; INVENTORY; INDIVIDUALS; SEQUELAE; DISEASE; MILD	There have been numerous articles published on the incidence of depression after brain injury. Unfortunately, the studies have shown the incidence of depression varies widely depending on multiple factors: definition of 'depression', time of assessment post-injury and type of measure used. It is well known that traumatic brain injury (TBI) sequelae and depressive symptoms overlap, contributing further to measurement error and ultimately epidemiologic report of depression. This paper reviews different theories of depression, the DSM-IV depression diagnoses, the overlap in depression and TBI symptoms and depression measures and how they contribute to possible diagnostic error. This paper also discusses evaluation and treatment considerations when assessing depression in a person with a TBI.	Charlotte Inst Rehabil, Charlotte, NC 28203 USA	Babin, PR (corresponding author), Charlotte Inst Rehabil, 1100 Blythe Blvd, Charlotte, NC 28203 USA.						AKISKAL HS, 1995, COMPREHENSIVE TXB PS, V6, P1067; ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A. T., 1967, DEPRESSION CLIN EXPT; BIELIAUSKAS LA, 1993, J CLIN EXP NEUROPSYC, V15, P421, DOI 10.1080/01688639308407232; Bremner JD, 2002, BIOL PSYCHIAT, V51, P273, DOI 10.1016/S0006-3223(01)01336-1; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUTCHER JN, 1994, MINNESOTA MULTIPHASI; COYNE JC, 1986, ESSENTIAL PAPERS DEP; CUMMINGS JL, 1994, PSYCHIAT ANN, V24, P25; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M., 1995, STRUCTURED CLIN INTE; *GAL GROUP INC, 2002, GAL ENC PSYCH EM, P1; GASPARRINI WG, 1978, J NEUROL NEUROSUR PS, V41, P470, DOI 10.1136/jnnp.41.5.470; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; KRAMER T, 2002, MEDSCAPE PSYCHOPHARM, P1; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOGSDON RG, 1995, J AM GERIATR SOC, V43, P150, DOI 10.1111/j.1532-5415.1995.tb06380.x; Miguel-Hidalgo JJ, 2002, CNS DRUGS, V16, P361, DOI 10.2165/00023210-200216060-00001; PARKER R, 1990, TRAUMATIC BRAIN INJU; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Ressler KJ, 1999, BIOL PSYCHIAT, V46, P1219, DOI 10.1016/S0006-3223(99)00127-4; ROBIN L, 1991, PSYCHIAT DISORDERS A; ROBINSON RG, 1986, HOSP PRACT, V21, P83; ROSENBAUM J, 2001, 154 ANN M AM PSYCH A, P1; Rosenstein LD, 1998, NEUROPSYCHOL REV, V8, P109, DOI 10.1023/A:1025628925796; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; SADEK N, 2000, MEDSCAPE PSYCHIAT ME, P1; SCHILDKRAUT JJ, 1989, COMPREHENSIVE TXB PS, P868; SELIGMAN ME, 1975, HELOPLESSNESS; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SNAITH RP, 1986, BRIT MED J, V292; STARRATT C, 1998, CLIN NEUROPSYCHOLOGY, P613; STEIN DG, 1994, CLIN NEUROPSYCHOLOGY, P9; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	46	18	18	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2003	17	10					889	900		10.1080/0269905031000088595			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500007	12963555				2021-06-18	
J	Danielsen, ER; Christensen, PB; Arlien-Soborg, P; Thomsen, C				Danielsen, ER; Christensen, PB; Arlien-Soborg, P; Thomsen, C			Axonal recovery after severe traumatic brain injury demonstrated in vivo by 1H MR spectroscopy	NEURORADIOLOGY			English	Article						diffuse axonal injury; magnetic resonance spectroscopy; N-acetylaspartate	MAGNETIC-RESONANCE SPECTROSCOPY	Proton magnetic resonance spectroscopy (MRS) suggested almost complete axonal recovery 21 months after trauma in a patient with severe diffuse axonal injury. MRS while the patient was comatose showed evidence of severe diffuse axonal injury in occipitoparietal white matter, but occipital grey matter was relatively spared. At 21 months N-acetylaspartate was normal. At 33 months examination showed a Functional Independence Measure of 83 and a Rancho Los Amigos Scale of Cognitive Function of 7-8, a remarkable improvement considering all the initial findings, except those of MRS.	Rigshosp, Dept Neuroradiol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Neurol, Hammel Neuroctr, DK-8000 Aarhus, Denmark; Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark	Danielsen, ER (corresponding author), Rigshosp, Dept Neuroradiol, Sect 3023,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	erdanielsen@rh.dk		Christensen, Peter Broegger/0000-0002-0046-5727			Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHRISTIANSEN P, 1994, ACTA RADIOL, V35, P117; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; EVANS SJJ, 1999, MRI, P1347; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Takanashi J, 1997, J NEUROL SCI, V149, P99, DOI 10.1016/S0022-510X(97)05401-4	13	18	22	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	OCT	2003	45	10					722	724		10.1007/s00234-003-1068-z			3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	732AD	WOS:000185917900009	12942218				2021-06-18	
J	Hawley, CA; Maden, A				Hawley, CA; Maden, A			Mentally disordered offenders with a history of previous head injury: are they more difficult to discharge ?	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; FOLLOW-UP; SCHIZOPHRENIA; RELATIVES	Primary objectives : To identify the incidence of head injury (HI) amongst mentally disordered offenders (MDOs) in UK medium secure units (MSUs) and test the hypothesis that patients with a history of HI are more difficult to discharge than patients without HI. Design, methods and procedures : One hundred and thirteen MDOs being discharged to community settings from five MSUs in England were recruited consecutively between 1 April 1999 and 31 December 2000. Data on previous HI, offending history and discharge planning were collected from clinical casenotes, structured questionnaires and interviews with clinical staff. Main outcomes and results : More patients with HI (57.4%) than patients without HI (47%) had a violent index offence. Risk assessments carried out prior to discharge showed patients with HI to be at greater risk of violence to others and of self-harm than patients without HI ( p less than or equal to 0.05). All but two patients in the HI group were difficult to discharge (43, 95.6%), compared to 52 (82.5%) in the non-HI group. Conclusions : Information on previous HI should be collected on admission to MSUs and considered when planning for discharge.	Univ Warwick, Warwick Business Sch, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; Univ London Imperial Coll Sci Technol & Med, Acad Ctr, Southall, Middx, England	Hawley, CA (corresponding author), Univ Warwick, Warwick Business Sch, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.		Hawley, Carol/AAG-3830-2019; Lorente, Rosa/AAL-5850-2021				Ahmed II, 1998, SEMIN CLIN NEUROPSYC, V3, P23; BACHYRITA G, 1974, AM J PSYCHIAT, V131, P1015; Bond M. R., 1990, REHABILITATION ADULT, P179; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; GIBBENS TCN, 1959, J MENT SCI, V105, P108; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hawley C., 1998, NATL TRAUMATIC BRAIN; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; *HOM OFF DEP HLTH, 1975, CMND6244; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P584; MADEN A, 2001, PATHWAYS OUT MEDIUM; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Matthews H., 1997, ADV PSYCHIAT TREATME, V3, P154; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; MILLER JD, 1990, REHABILITATION ADULT, P236; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128	25	18	18	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2003	17	9					743	758		10.1080/0269905031000089341			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000002	12850941				2021-06-18	
J	Muellner, A; Benz, M; Kloss, CUA; Mautes, A; Burggraf, D; Hamann, GF				Muellner, A; Benz, M; Kloss, CUA; Mautes, A; Burggraf, D; Hamann, GF			Microvascular basal lamina antigen loss after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						basal lamina; cerebral microvasculature; collagen type IV; fluid percussion injury; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; BARRIER DISRUPTION; CELLULAR EDEMA; BLOOD-FLOW; METABOLISM; MICROCIRCULATION; REPERFUSION; ACTIVATION; SEQUELAE	The loss of microvascular basal lamina antigen is known to be a consequence of cerebral ischemia, but little information is available on its role in traumatic brain injury (TBI). The aim of our study was (1) to test the hypothesis that there is damage to the basal lamina of brain microvasculature after TBI, (2) to localize microvascular damage, and (3) to compare this loss with that in ischemia. Rats (n = 14) were either sham operated (n = 5) or subjected to fluid percussion injury (n = 9; TBI = 1.5 atm) and killed after 0 (n = 5, sham), 12 (n = 4), or 24 h (n = 5). Collagen-type-IV immunoreactivity and a digital image-processing system were used to localize and quantify the number of stained vascular elements and the total collagen stained area. Western blot was used to compare collagen-type-IV content on the traumatic and nontraumatic brain side. The cortex of animals subjected to TBI and killed after 24 h showed a reduction in the area of stained collagen amounting to 19 +/- 4% (p < 0.009) and a reduction in the total number of microvessels identified by collagen stain (29 +/- 6 %; p < 0.02). The Western blot revealed a 31 +/- 6 % (p < 0.03) reduction of collagen, compared to the mirror cortical area after 24 h. No significant reduction was found in the group that survived 12 h or in basal ganglia in both groups. TBI causes microvascular basal lamina damage. Whereas TBI affected only cortical areas, cerebral ischemia also induced microvascular basal lamina damage in the basal ganglia. After 24 h, the extent of severe basal lamina damage due, to TBI was less severe than in ischemia.	Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany; Univ Saarland, Sch Med, Neurosurg Res Lab, D-66421 Homburg, Germany	Hamann, GF (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.	hamann@brain.nefo.med.uni-muenchen.de	Hamann, Gerhard F./J-6300-2014				Armao D, 1997, BRAIN RES, V767, P259, DOI 10.1016/S0006-8993(97)00567-2; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P119; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; del Zoppo GJ, 1998, J NEUROL NEUROSUR PS, V65, P1, DOI 10.1136/jnnp.65.1.1; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Franko J, 1999, LIFE SCI, V65, P1963, DOI 10.1016/S0024-3205(99)00456-7; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Grammas P, 2000, NEUROBIOL AGING, V21, P199, DOI 10.1016/S0197-4580(00)00102-0; Hamann Gerhard F., 1999, Thrombosis and Haemostasis, V82, P92; Hamann GF, 1996, J CEREBR BLOOD F MET, V16, P1373, DOI 10.1097/00004647-199611000-00036; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; Hamann GF, 2002, J CEREBR BLOOD F MET, V22, P526, DOI 10.1097/00004647-200205000-00004; HARPER SL, 1984, AM J PHYSIOL, V246, pH17; JAFFE EA, 1987, HUM PATHOL, V18, P234, DOI 10.1016/S0046-8177(87)80005-9; Kloss CUA, 2002, NEUROL RES, V24, P713, DOI 10.1179/016164102101200636; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lijnen HR, 1997, PROG CARDIOVASC DIS, V39, P343, DOI 10.1016/S0033-0620(97)80032-1; Lijnen HR, 1999, THROMB HAEMOSTASIS, V81, P799; Lijnen HR, 1998, THROMB HAEMOSTASIS, V79, P1171; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Marchal G, 1999, J CEREBR BLOOD F MET, V19, P467, DOI 10.1097/00004647-199905000-00001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; MAXWELL WL, 1994, ACTA NEUROCHIR, P465; Nobles M, 1998, EUR J PHARMACOL, V361, P119, DOI 10.1016/S0014-2999(98)00671-2; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pfefferkorn T, 2000, J CEREBR BLOOD F MET, V20, P337, DOI 10.1097/00004647-200002000-00015; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Risau W, 1998, PATHOL BIOL, V46, P171; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; Rosenberg GA, 1999, PROG CARDIOVASC DIS, V42, P209, DOI 10.1016/S0033-0620(99)70003-4; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SAITO N, 1990, ACT NEUR S, V51, P186; Sharma HS, 1997, ACT NEUR S, V70, P269; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TOUZANI O, 1995, STROKE, V26, P2112, DOI 10.1161/01.STR.26.11.2112; Touzani O, 1997, BRAIN RES, V767, P17, DOI 10.1016/S0006-8993(97)00515-5; WANG W, 1996, AM J PHYSIOL, V271, P973; Weinzierl MR, 2002, J MOL NEUROSCI, V18, P247, DOI 10.1385/JMN:18:3:247; Wiedermann D, 2001, MAGN RESON MATER PHY, V13, P118, DOI 10.1016/S1352-8661(01)00136-3; YURCHENCO PD, 1990, FASEB J, V4, P1577	68	18	18	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					745	754		10.1089/089771503767869971			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000005	12965053				2021-06-18	
J	Cooper, MT; McGee, KM; Anderson, DG				Cooper, MT; McGee, KM; Anderson, DG			Epidemiology of athletic head and neck injuries	CLINICS IN SPORTS MEDICINE			English	Article							CERVICAL-SPINE INJURIES; TRAUMATIC BRAIN-INJURY; SOCCER INJURIES; SAFETY HELMETS; CORD-INJURY; ICE HOCKEY; CONCUSSION; SPORTS; PREVENTION; ACCIDENTS	In this article, we review the available data on sporting injuries to the head and neck and discuss sport-specific injury risk and prevention strategies, as well as the costs of head and neck injuries.	Univ Virginia, Sch Med, Dept Orthopaed Surg, Charlottesville, VA 22908 USA	Anderson, DG (corresponding author), Univ Virginia, Sch Med, Dept Orthopaed Surg, POB 800159, Charlottesville, VA 22908 USA.	dga3k@virginia.edu		Cooper, Minton/0000-0002-8860-2166			Albrand O W, 1975, Surg Neurol, V4, P461; ALBRIGHT JP, 1976, JAMA-J AM MED ASSOC, V236, P1243, DOI 10.1001/jama.236.11.1243; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; *C NEUR SURG INC, 1966, CLIN NEUROSURG, V14, P424; CAINE D, 1989, AM J SPORT MED, V17, P811, DOI 10.1177/036354658901700616; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1997, MED SCI SPORT EXER, V29, pS233; Cantu RC, 2000, SEMIN NEUROL, V20, P173, DOI 10.1055/s-2000-9825; CANTU RC, 1995, CLIN SPORT MED, V14, P517; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; *CONS PROD SAF COM, 2001, TRAMPL SAF AL; *CONS PROD SAF COM, 1999, WHATS NEW BIC HELM; *CONS PROD SAF COM, 1996, CPSC URG BIC WEAR HE; *CONS PROD SAF COM, 1995, GUID MOV SOCC GOAL S; *CONS PROD SAF COM, 2001, PUB CPSC, V93; *CONS PROD SAF COM, 2002, PUB CPSC, V329; *CONS PROD SAF COM, 1990, 5044 CPSC; d'Hemecourt PA, 2000, CLIN SPORT MED, V19, P663, DOI 10.1016/S0278-5919(05)70231-3; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; Ferrera PC, 1999, AM J EMERG MED, V17, P575, DOI 10.1016/S0735-6757(99)90199-7; *FIFA, 2001, FIFA SURV APPR 250 M; Frankel HL, 1998, AM SURGEON, V64, P151; Furnival RA, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e57; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; GROSSMAN JAI, 1978, JAMA-J AM MED ASSOC, V240, P1881, DOI 10.1001/jama.240.17.1881; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hobbs Gregory D., 1994, Journal of Emergency Medicine, V12, P143, DOI 10.1016/0736-4679(94)90690-4; HOFF GL, 1986, AM J SPORT MED, V14, P231, DOI 10.1177/036354658601400309; Hunter RE, 1999, AM J SPORT MED, V27, P381, DOI 10.1177/03635465990270032101; Katoh S, 1996, SPINAL CORD, V34, P416, DOI 10.1038/sc.1996.74; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kuhlman GS, 1999, AM FAM PHYSICIAN, V60, P2035; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Marsan MA, 2000, J SYST ARCHITECT, V46, P105, DOI 10.1016/S1383-7621(98)00064-2; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; Mueller F O, 2001, N C Med J, V62, P368; *NCCSIR, 2000, 18 ANN REP FALL 1982; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; *NSCISC, 2001, SPIN CORD INJ INF NE; PALEY D, 1986, AM J SPORT MED, V14, P92, DOI 10.1177/036354658601400117; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Prall JA, 1995, J TRAUMA, V39, P1115, DOI 10.1097/00005373-199512000-00018; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; RODGERS GC, 2002, CONSUMER PRODUCT SAF; Rubin BD, 1999, CLIN SPORT MED, V18, P293, DOI 10.1016/S0278-5919(05)70145-9; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Schenke K, 1998, BRIT TELECOMMUN ENG, V17, P1; SCHER AT, 1991, AM J SPORT MED, V19, P485, DOI 10.1177/036354659101900511; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; Schmitt H, 2001, CLIN J SPORT MED, V11, P17, DOI 10.1097/00042752-200101000-00004; TALL RL, 1993, CLIN SPORT MED, V12, P441; Tapper E M, 1978, Am J Sports Med, V6, P114, DOI 10.1177/036354657800600304; Tarazi F, 1999, AM J SPORT MED, V27, P177, DOI 10.1177/03635465990270021101; TATOR CH, 1993, PARAPLEGIA, V31, P700, DOI 10.1038/sc.1993.112; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; WU WQ, 1985, SURG NEUROL, V23, P143, DOI 10.1016/0090-3019(85)90332-5	77	18	18	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					427	+		10.1016/S0278-5919(02)00110-2			18	Sport Sciences	Sport Sciences	692LT	WOS:000183663100003	12852678				2021-06-18	
J	Cross, KM; Serenelli, C				Cross, KM; Serenelli, C			Training and equipment to prevent athletic head and neck injuries	CLINICS IN SPORTS MEDICINE			English	Article							CERVICAL-SPINE; FOOTBALL; HYPEREXTENSION; MOUTHGUARDS; STRENGTH; FORCES	Due to the likelihood of poor outcomes from neurotraumas, it is very important that coaches and athletes comply with preventive measures. Strength training, sporting techniques, and equipment are the fundamental means of addressing this issue. Cervical spine injuries may be best addressed by cervical stabilization exercises and the use of proper sporting techniques. Concussions, however, are best addressed by proper use and fitting of sports equipment and sporting techniques.	Univ Virginia Sports Med, McCue Ctr, Charlottesville, VA 22904 USA	Cross, KM (corresponding author), Univ Virginia Sports Med, McCue Ctr, POB 400834,Emmet St & Massie Rd, Charlottesville, VA 22904 USA.	kmc7e@virginia.edu					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Andrish J T, 1977, Am J Sports Med, V5, P89, DOI 10.1177/036354657700500207; ARHEIM DD, 1997, PRINCIPLES ATHLETIC, P116; BAILES J, 1991, NEURO, V29; BLYTH C, 1978, AM FOOTB COACH ASS D; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P1; CARTER DR, 1980, AM J SPORT MED, V8, P302, DOI 10.1177/036354658000800502; Caswell SV, 2002, J ATHL TRAINING, V37, P164; Clancy W G Jr, 1977, Am J Sports Med, V5, P209, DOI 10.1177/036354657700500508; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; FISHER SV, 1978, ARCH PHYS MED REHAB, V59, P505; Grimmer K, 1994, Aust J Physiother, V40, P251, DOI 10.1016/S0004-9514(14)60461-X; Grimmer Karen, 1998, Aust J Physiother, V44, P201; HERTLING D, 1996, CERVICAL SPINE MANAG, P544; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; HOVIS WD, 1994, MED SCI SPORT EXER, V26, P872; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; KENDALL FP, 1993, MUSCLES TESTING FUNC, P334; Kettler A, 2002, J BIOMECH, V35, P339, DOI 10.1016/S0021-9290(01)00206-8; KISNER C, 1996, THERAPEUTIC EXERCISE, P551; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; MARKEY K, 1993, AM J SPORTS MED, V21, P1993; *NAT COLL ATHL ASS, 2001, SPORTS MED HDB NCAA; *NAT OP COMM STAND, 2000, NOCSAE MAN; Nightingale RW, 1996, J BONE JOINT SURG AM, V78A, P412, DOI 10.2106/00004623-199603000-00013; POLLOCK ML, 1993, ARCH PHYS MED REHAB, V74, P1080, DOI 10.1016/0003-9993(93)90065-I; ROAF R, 1960, J BONE JOINT SURG BR, V42, P810; SALIBA E, 1996, ATHLETIC INJURIES RE, P899; SPEER KP, 1990, AM J SPORT MED, V18, P591, DOI 10.1177/036354659001800606; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; Weinstein SM, 1998, CLIN SPORT MED, V17, P127, DOI 10.1016/S0278-5919(05)70067-3; Winkelstein BA, 1997, MED SCI SPORT EXER, V29, pS246, DOI 10.1097/00005768-199707001-00007; 2001, BR J SPORTS MED, V35, P81; 2002, NCCA NEWS FEATU 0805	35	18	18	1	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					639	+		10.1016/S0278-5919(02)00099-6			30	Sport Sciences	Sport Sciences	692LT	WOS:000183663100017	12852692				2021-06-18	
J	Sherer, M; Nick, TG; Millis, SR; Novack, TA				Sherer, M; Nick, TG; Millis, SR; Novack, TA			Use of the WCST and the WCST-64 in the assessment of traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CARD SORTING TEST; DISABILITY RATING-SCALE; HEAD-INJURY; SHORT-FORM; WISCONSIN; PERFORMANCE; RECOVERY; UTILITY	The Wisconsin Card Sorting Test (WCST) has been found to be valid in characterizing cognitive dysfunction in a variety of neurological disorders including traumatic brain injury (TBI). However, the test has been criticized as being too lengthy and frustrating for severely impaired patients. As a result, shortened versions of the WCST have been proposed. The utility of one of these shortened versions, the Wisconsin Card Sorting Test-64 (WCST-64), was examined in 106 persons with TBI. Findings showed strong associations between scores derived from the two tests. WCST scores were predicted from WCST-64 scores with sufficient accuracy for research purposes with adjusted R-squared values ranging from .74 to .87. Using the standard cutpoint of <40T to indicate impairment or normal performance for perseverative responses from each of the two tests, 91 (86%) of 106 subjects received the same classification showing substantial agreement (Kappa statistic 0.71; 95% CI 0.58-0.84). The WCST and the WCST-64 also performed comparably in predicting functional status at discharge from inpatient rehabilitation using the first score from a principal components analysis as a summary measure (both significant with p=.0002). These findings support the use of the WCST-64 in early evaluations of persons with moderate and severe TBI.	Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, W Orange, NJ 07052 USA; Spain Rehabil Ctr, Birmingham, AL USA; Univ Alabama Birmingham, Birmingham, AL USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodwrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A011403, H133A980035, H133A980010] Funding Source: Medline		ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Axelrod BN, 1997, ASSESSMENT, V4, P41, DOI 10.1177/107319119700400105; Axelrod Bradley N, 1992, Clin Neuropsychol, V6, P143, DOI 10.1080/13854049208401851; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DREWE E A, 1974, Cortex, V10, P159; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graham DI, 1996, NEUROTRAUMA, P43; Greve KW, 2001, CLIN NEUROPSYCHOL, V15, P228, DOI 10.1076/clin.15.2.228.1901; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hannay HJ, 1996, NEUROTRAUMA, P723; Heaton R., 1993, WISCONSIN CARD SORTI; IVERSON GL, 2001, APPL NEUROPSYCHOLOGY, V7, P247; Kongs S.K., 2000, WCST 64 WISCONSIN CA; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Milner B, 1964, FRONTAL GRANULAR COR, P313; Paolo AM, 1996, J CLIN EXP NEUROPSYC, V18, P892, DOI 10.1080/01688639608408310; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Robinson L J, 1991, Arch Clin Neuropsychol, V6, P27, DOI 10.1016/0887-6177(91)90019-6; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Smith-Seemiller L, 1997, CLIN NEUROPSYCHOL, V11, P421, DOI 10.1080/13854049708400472; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267	30	18	20	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2003	25	4					512	520		10.1076/jcen.25.4.512.13877			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	683GY	WOS:000183141300007	12911105				2021-06-18	
J	Swartz, CM; Acosta, D; Bashir, A				Swartz, CM; Acosta, D; Bashir, A			Diminished ECT response in catatonia due to chronic neurologic condition	JOURNAL OF ECT			English	Article						delirium; catatonia; neurologic disease; traumatic brain injury; dementia	SYSTEMIC LUPUS-ERYTHEMATOSUS; DEPRESSION	A series of four clinical cases suggests that catatonic disorder due to a chronic neurologic condition does not respond as reliably to electroconvulsive therapy (ECT) as functional catatonia does. Cases reported in the medical literature show a similar pattern. Presumably this form of catatonia is intrinsically less responsive to ECT, although the possibility remains that a more intense quality of treatment and prophylaxis is needed. Conversely, catatonia resistant to ECT suggests an underlying medical condition.	So Illinois Univ, Sch Med, Dept Psychiat, Springfield, IL 62794 USA; E Carolina Univ, Sch Med, Dept Psychiat, Greenville, NC USA	Swartz, CM (corresponding author), So Illinois Univ, Sch Med, Dept Psychiat, POB 19642, Springfield, IL 62794 USA.						BARNES MP, 1986, J NEUROL NEUROSUR PS, V49, P991, DOI 10.1136/jnnp.49.9.991; BRASIC JR, 2000, GERMAN J PSYCHIAT, V3, P13; DITMORE BG, 1992, CONVULSIVE THER, V8, P33; Folkerts HW, 1998, J ECT, V14, P53; KESSING L, 1994, CONVULSIVE THER, V10, P232; Lance JW, 1998, MOVEMENT DISORD, V13, P835, DOI 10.1002/mds.870130515; Lee J W, 2000, Ann Clin Psychiatry, V12, P89, DOI 10.3109/10401230009147094; MAC DS, 1983, J CLIN PSYCHIAT, V44, P155; Malur C, 2001, J ECT, V17, P55, DOI 10.1097/00124509-200103000-00012; MATTINGLY G, 1992, J NEUROPSYCH CLIN N, V4, P145; ROHLAND BM, 1993, J AFFECT DISORDERS, V29, P255, DOI 10.1016/0165-0327(93)90015-C; Swartz C, 2002, J ECT, V18, P167, DOI 10.1097/00124509-200209000-00012; Swartz CM, 2001, J ECT, V17, P180, DOI 10.1097/00124509-200109000-00006; SWARTZ CM, 1994, NEUROPSYCHOBIOLOGY, V29, P174; TAYLOR MA, 1982, ELECTROCONVULSIVE TH, P7	15	18	18	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1095-0680			J ECT	J. ECT	JUN	2003	19	2					110	114		10.1097/00124509-200306000-00010			5	Behavioral Sciences; Psychiatry	Behavioral Sciences; Psychiatry	687FB	WOS:000183364500010	12792461				2021-06-18	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			The influence of litigation on maintenance of posttraumatic stress disorder	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; ACCIDENTS; INTERVIEW; PTSD		Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			[Anonymous], 1990, ABBR INJ SCAL; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blanchard EB, 1998, J TRAUMA STRESS, V11, P337, DOI 10.1023/A:1024407321677; BROOKS N, 1992, J TRAUMA STRESS, V5, P527, DOI 10.1002/jts.2490050403; Bryant R.A., 2000, ACUTE STRESS DISORDE; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1002/jts.2490090303; GREEN RL, 1991, MMPI 2MMPI INTERPRET; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KELLY R, 1981, J ROY SOC MED, V74, P275; MAYOU R, 1995, J PSYCHOSOM RES, V39, P789, DOI 10.1016/0022-3999(95)00031-D; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Napier M, 1991, Med Leg J, V59 ( Pt 3), P157; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Stone A A, 1993, Bull Am Acad Psychiatry Law, V21, P23; THOMPSON GN, 1965, AM J PSYCHIAT, V121, P1043, DOI 10.1176/ajp.121.11.1043	24	18	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	MAR	2003	191	3					191	193		10.1097/00005053-200303000-00009			3	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	655LD	WOS:000181553000008	12637846				2021-06-18	
J	Redell, JB; Moore, AN; Dash, PK				Redell, JB; Moore, AN; Dash, PK			Expression of the prodynorphin gene after experimental brain injury and its role in behavioral dysfunction	EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						dynorphin; behavior; hippocampus; brain trauma; kappa receptor	CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY; ENDOGENOUS DYNORPHINS; HIPPOCAMPAL-LESIONS; CEREBRAL-ISCHEMIA; RECEPTOR AGONIST; AXONAL INJURY; RATS; DEFICITS; ANTAGONISTS	Traumatic brain injury (TBI) causes excess release of neurotransmitters, such as glutamate, and increases intracellular calcium levels. Elevated levels of calcium, and perhaps other intracellular second messengers, as a result of TBI can alter the expression of many genes. The protein products of some of these genes may be signals for TBI-associated memory dysfunction. Therefore, identification of genes whose expression is altered after TBI in the hippocampus, a structure in the medial temporal lobe that plays a critical role in memory formation and storage, and elucidation of the role(s) of their protein products may shed light on the molecular mechanisms underlying TBI-elicited memory dysfunction. The prodynorphin gene is expressed in hippocampal granule cells, and its expression has been reported to be enhanced as a result of elevated intracellular calcium. The prodynorphin protein is proteolytically cleaved to generate multiple dynorphin peptides, which can modulate neurotransmitter release through the activation of presynaptic kappa opioid receptors. In this study, we report that 1) TBI transiently increases prodynorphin mRNA in the hippocampus, 2) dynorphin peptide immunoreactivity is enhanced for up to 24 hr after TBI and 3) intracerebroventricular infusion of the K receptor antagonist nor-binaltorphimine (nor-BNI) impairs subsequent performance in a spatial memory task. These results suggest that dynorphin action may serve a beneficial role after TBI.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, P50NS3327] Funding Source: Medline		Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; BIRCH PJ, 1991, BRIT J PHARMACOL, V103, P1819, DOI 10.1111/j.1476-5381.1991.tb09869.x; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen ACH, 2002, AM J MED GENET, V114, P429, DOI 10.1002/ajmg.10362; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig TA, 2002, J BIOL CHEM, V277, P10955, DOI 10.1074/jbc.M109660200; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Ghosh S, 1997, BRAIN RES, V745, P152, DOI 10.1016/S0006-8993(96)01144-4; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lukoyanov NV, 2000, NEUROSCI LETT, V285, P139, DOI 10.1016/S0304-3940(00)01053-3; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; McIntosh T K, 1986, NIDA Res Monogr, V75, P527; MCINTOSH TK, 1994, AM J PHYSIOL, V267, pR665; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OHNO M, 1991, EUR J PHARMACOL, V193, P357, DOI 10.1016/0014-2999(91)90151-F; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; RUEGG H, 1994, BRAIN RES, V635, P203, DOI 10.1016/0006-8993(94)91440-0; Sandin J, 1998, NEUROSCIENCE, V85, P375, DOI 10.1016/S0306-4522(97)00605-2; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Scoville WB, 2000, J NEUROPSYCH CLIN N, V12, P103; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; VINK R, 1991, AM J PHYSIOL, V261, pR1527; WAGNER JJ, 1991, J NEUROCHEM, V57, P333, DOI 10.1111/j.1471-4159.1991.tb02132.x; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WEISSKOPF MG, 1993, NATURE, V365, P188, DOI 10.1038/365188a0; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	43	18	19	0	1	SOC EXPERIMENTAL BIOLOGY MEDICINE	MAYWOOD	195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA	1535-3702			EXP BIOL MED	Exp. Biol. Med.	MAR	2003	228	3					261	269					9	Medicine, Research & Experimental	Research & Experimental Medicine	654FF	WOS:000181483000004	12626770				2021-06-18	
J	Tinius, TP				Tinius, TP			The Intermediate Visual and Auditory Continuous Performance Test as a neuropsychological measure	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neuropsychology; CPT; mTBI; ADHD	CLOSED-HEAD-INJURY; REACTION-TIME; SUSTAINED ATTENTION	The Intermediate Visual and Auditory (IVA) Continuous Performance Test (CPT) and Neuropsychological Impairment Scale (NIS) were completed with adults diagnosed with mild traumatic brain injury (mTBI), adults diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), and controls. On the IVACPT, the mTBI and ADHD groups performed significantly lower on the full and secondary scales for attention and response accuracy. For individual scales, the mTBI and ADHD groups showed lower performance on measures of reaction time, inattention, impulsivity, and variability of RT. The mTBI and ADHD groups showed similar patterns of performance on the IVA. On the NIS, the mTBI and ADHD groups reported more neuropsychological symptoms than the control group and the mTBI group reported more neuropsychological symptoms than the ADHD group. The results are discussed in regard to changes in cognitive processing and sustained attention in individuals diagnosed with mTBI and ADHD. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	St Cloud State Univ, Dept Psychol, St Cloud, MN 56301 USA	Tinius, TP (corresponding author), St Cloud State Univ, Dept Psychol, 420 7th Ave S, St Cloud, MN 56301 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Beck A. T., 1967, DEPRESSION CLIN EXPT; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Conners C.K., 1999, CONNERS ADULT ADHD R; ERRICO AL, 1990, J CONSULT CLIN PSYCH, V1, P45; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gordon M, 1988, INSTRUCTION MANUAL G; Gronwall D, 1989, MILD HEAD INJURY, P153; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; LARRABEE GJ, 1996, ECOLOGICAL VALIDITY, P225; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Miller E, 1970, Cortex, V6, P121; NORMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236; O'Donnell W., 1994, NEUROPSYCHOLOGICAL I; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Rimel R. W., 1981, NEUROSURGERY, V9, P35; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Sandford J, 1995, MANUAL INTERMEDIATE; SOLHBERG MM, 1989, INTRO COGNITIVE REHA; Spielberger CD, 1970, TEST MANUAL STATE TR; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Van Zomeren A. H., 1990, NEUROBEHAVIORAL RECO, P225; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wechsler D., 1981, WAIS R MANUAL WECHSL; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7	31	18	22	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2003	18	2					199	214	PII S0887-6177(01)00196-2	10.1016/S0887-6177(01)00196-2			16	Psychology, Clinical; Psychology	Psychology	648LC	WOS:000181152000009	14591471				2021-06-18	
J	Ungerstedt, JS; Grenander, A; Bredbacka, S; Blomback, M				Ungerstedt, JS; Grenander, A; Bredbacka, S; Blomback, M			Clotting onset time may be a predictor of outcome in human brain injury: A pilot study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain injury; antithrombin; blood rheology; coagulation activation; bedside monitoring	ANTITHROMBIN-III; SOLUBLE FIBRIN; HEAD-INJURY; TRAUMA; ASSAY; PLASMA	In this study we assess the clotting onset time (COT) in samples from a population of traumatic brain injury patients. The patients were randomized to standard treatment plus high dose antithrombin (AT group) or standard treatment, alone (nonAT group), during the first 16 hours after hospital admission. Our aim was to study the two patient groups during the first 5 days after injury, to assess COT as a coagulation monitoring method compared to routine parameters (thrombin-antithrombin complex (TAT), b-dimer, and soluble fibrin), and to correlate COT to clinical parameters and outcome. Clotting onset time measurements are carried out using free oscillating rheometry, where the endpoint of coagulation onset is determined by a deviation from initial viscoelastic properties of an oscillating sample. Both patient groups initially showed hypercoagulation. In the AT group, a significant increase of COT (i.e., decrease in hypercoagulation), was already seen 16 hours after hospital admission, but not until day 3 in the non AT group. Routine coagulation tests were not able to discriminate AT patients from nonAT patients. Clotting onset time correlated significantly to soluble fibrin, D-dimer, TAT, and leukocyte count. Additionally, COT levels at hospital admission correlated to outcomes measured with the Glasgow Outcome Scale (GOS) after 3 months. These results indicate that COT may be a clinically relevant variable with prognostic value, able to monitor the degree of hypercoagulation over time.	Karolinska Sjukhuset, Div Blood Coagulat Res, S-17176 Stockholm, Sweden; Karolinska Sjukhuset, Karolinska Inst, Dept Surg Sci, Div Anesthesia & Intens Care, S-17176 Stockholm, Sweden	Ungerstedt, JS (corresponding author), Karolinska Sjukhuset, Div Blood Coagulat Res, Clin Chem Bldg L2-05, S-17176 Stockholm, Sweden.		Ungerstedt, Johanna/C-7004-2014				ABILDGAARD U, 1977, THROMB RES, V11, P549, DOI 10.1016/0049-3848(77)90208-0; BLAUHUT B, 1985, THROMB RES, V39, P81, DOI 10.1016/0049-3848(85)90123-9; BOHLIN L, 1994, INT PATENT COOPERATI; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; ERIKSSON BI, 1995, THROMB HAEMOSTASIS, V73, P398; Grenander A, 2001, J NEUROSURG ANESTH, V13, P49, DOI 10.1097/00008506-200101000-00010; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Okajima K, 1998, SEMIN THROMB HEMOST, V24, P27, DOI 10.1055/s-2007-995820; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PELZER H, 1988, THROMB HAEMOSTASIS, V59, P101; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE G, 1974, LANCET, V2, P81; Ungerstedt JS, 2002, SCAND J CLIN LAB INV, V62, P135; WIMAN B, 1986, THROMB HAEMOSTASIS, V55, P189	20	18	22	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2003	15	1					13	18		10.1097/00008506-200301000-00003			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	629UZ	WOS:000180070800003	12499977				2021-06-18	
J	de Freitas, MS; Spohr, TCLS; Benedito, AB; Caetano, MS; Margulis, B; Lopes, UG; Moura-Neto, V				de Freitas, MS; Spohr, TCLS; Benedito, AB; Caetano, MS; Margulis, B; Lopes, UG; Moura-Neto, V			Neurite outgrowth is impaired on HSP70-positive astrocytes through a mechanism that requires NF-kappa B activation	BRAIN RESEARCH			English	Article						astrocyte; GFAP; HSP70; NF-kappa B; TNF-alpha; stress response; neurite outgrowth; reactive astrocyte	TUMOR-NECROSIS-FACTOR; HEAT-SHOCK-PROTEIN; FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; FACTOR-ALPHA; CEREBELLAR ASTROCYTES; TRANSCRIPTION FACTOR; MESSENGER-RNA; BRAIN; INDUCTION	In the adult central nervous system (CNS), prominent reactive astrocytosis is seen in acute traumatic brain injury, neurodegenerative diseases and a variety of viral infections, Reactive astrocytes synthesize a number of factors that could play different roles in neuronal regeneration. In this study, the effects of thermal stress were evaluated on nuclear factor-kappaB (NF-kappaB) activation and proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) secretion in primary astrocytic cultures. The ability of HSP70-positive astrocytes to support or inhibit neurite outgrowth was investigated in neuron-astrocyte cocultures. Cultured astrocytes from cerebral cortex of rats were exposed to transient hyperthermia (42 degreesC/30 min) and incubated at 37 degreesC for different periods of recovery. During HSP70 accumulation. astrocytes extended large and thick processes associated to rearrangement of glial fibrillary acidic protein (GFAP) filaments and an increase in protein synthesis and GFAP. suggesting an astrogliosis event, A delay of NF-kappaB activation appeared closely related to TNF-alpha secretion by HSP70-positive astrocytes. These cells demonstrated a functional shift from neurite growth-promoting to non-permissive substrate. We also found that gliotoxin, a specific NF-kappaB inhibitor, partially abrogated the inhibitory ability of reactive astrocytes. These findings may suggest a involvement of NF-kappaB and TNF-alpha in modulating the failure of HSP70-positive astrocytes to provide functional support to neuritic outgrowth. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Anat, BR-21949900 Rio De Janeiro, Brazil; Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, BR-20551030 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949900 Rio De Janeiro, Brazil; Russian Acad Sci, Inst Cytol, Dept Cell Cultures, St Petersburg 194064, Russia	Moura-Neto, V (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Anat, Ilha Fundao, BR-21949900 Rio De Janeiro, Brazil.		Lopes, Ulisses/N-4416-2013; de Freitas, Marta Sampaio/AAE-8422-2021; Moura-Neto, VIVALDO/V-9913-2019; Lopes, Ulisses Gazos/T-6634-2019; Spohr, Tania/I-4299-2015	Moura-Neto, VIVALDO/0000-0002-6266-043X; Spohr, Tania/0000-0001-8691-5962			BACUERLE PA, 1996, CELL, V87, P13; BOLOVENTA P, 1992, PROG BRAIN RES, V94, P367; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; Canning DR, 1996, INT J DEV NEUROSCI, V14, P153, DOI 10.1016/0736-5748(96)00004-4; Coelho ALJ, 1999, EXP CELL RES, V251, P379, DOI 10.1006/excr.1999.4583; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ENG LF, 1996, NEUROCHEM RES, V21, P521; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Froes MM, 1999, P NATL ACAD SCI USA, V96, P7541, DOI 10.1073/pnas.96.13.7541; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; Garcia-Abreu J, 2000, GLIA, V29, P260, DOI 10.1002/(SICI)1098-1136(20000201)29:3<260::AID-GLIA7>3.0.CO;2-I; GARCIAABREU J, 1995, J NEUROSCI RES, V40, P471, DOI 10.1002/jnr.490400406; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Gilbert C D, 1993, Curr Opin Neurobiol, V3, P100, DOI 10.1016/0959-4388(93)90042-W; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; Gomes FCA, 1999, GLIA, V26, P97; Gomes FCA, 1999, GLIA, V25, P247, DOI 10.1002/(SICI)1098-1136(19990201)25:3<247::AID-GLIA5>3.3.CO;2-U; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lima FRS, 1998, INT J DEV NEUROSCI, V16, P19, DOI 10.1016/S0736-5748(98)00002-1; MA KC, 1994, J NEUROL SCI, V126, P184, DOI 10.1016/0022-510X(94)90271-2; McNaught KSP, 2000, NEUROSCI LETT, V285, P61, DOI 10.1016/S0304-3940(00)00982-4; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Miyagishi R, 1997, J NEUROIMMUNOL, V77, P17, DOI 10.1016/S0165-5728(97)00040-4; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Nishimura RN, 1996, MOL BRAIN RES, V36, P227, DOI 10.1016/0169-328X(95)00261-P; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; OTANO IP, 1996, GLIA, V16, P304; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SATOH J, 1992, BRAIN RES, V573, P37, DOI 10.1016/0006-8993(92)90111-L; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Shafer RA, 1997, GLIA, V21, P370, DOI 10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7; SHARP FR, 1991, J CEREBR BLOOD F MET, V11, P621, DOI 10.1038/jcbfm.1991.113; Stasiolek M, 2000, J BIOL CHEM, V275, P24847, DOI 10.1074/jbc.M910284199; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Trentin AG, 2001, AM J PHYSIOL-ENDOC M, V281, pE1088; Trillo-Pazos G, 2000, BRAIN RES, V864, P315, DOI 10.1016/S0006-8993(00)02213-7; UNEY JB, 1988, FEBS LETT, V235, P215, DOI 10.1016/0014-5793(88)81265-1; Wu VW, 1998, J NEUROCHEM, V71, P749; Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3	59	18	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 27	2002	958	2					359	370	PII S0006-8993(02)03682-X	10.1016/S0006-8993(02)03682-X			12	Neurosciences	Neurosciences & Neurology	630BH	WOS:000180087300016	12470872				2021-06-18	
J	Borgaro, SR; Prigatano, GP				Borgaro, SR; Prigatano, GP			Early cognitive and affective sequelae of traumatic brain injury: A study using the BNI Screen for Higher Cerebral Functions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute rehabilitation; cognitive and affective disturbances; TBI	SEVERE HEAD-INJURY; REHABILITATION; 1-YEAR	Objective: To demonstrate that the Barrow Neurological Institute (BNI) Screen for Higher Cerebral Functions (BNIS) can be used to briefly assess cognitive and affective disturbances during the acute stages after traumatic brain injury (TBI). Design and Outcome Measures: People with TBI were administered the BNIS during the first 60 days after injury and their performance compared to a convenience sample of control subjects used in the standardization of the BNIS. Setting: Inpatient units of a neurological institute and medical center. Subjects: Forty-two individuals with moderate-to-severe TBI and 21 control subjects. Results: Compared to patients with TBI, control subjects performed significantly better on the BNIS total and all subtest scores. TBI patients were best classified by poor performance on measures of affect disturbance and impaired awareness. Stepwise discriminant analysis identified disturbances in memory; awareness, and affect as contributing most to the classification of an individual as having TBI. Conclusions: Both cognitive and affective disturbances can be directly assessed during the early stages after significant TBI. The BNIS can be used for this purpose and help document that TBI specifically affects memory awareness, and affect during its early stages and should be addressed in rehabilitation.	St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; Ctr Med, Phoenix, AZ USA; St Josephs Hosp, Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	gprigat@chw.edu					Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CHAPMAN LF, 1959, ARCH NEUROL-CHICAGO, V1, P357, DOI 10.1001/archneur.1959.03840040001001; Clair JS, 1998, J CLIN EXP NEUROPSYC, V20, P320; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Evans D A, 1993, Ann Epidemiol, V3, P71; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; JENNETT B, 1974, MANAGEMENT HEAD INJU; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Prigatano G., 2002, CLIN NEUROPSYCHOLOGY; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1993, BNI Q, V9, P2; Prigatano GP, 1995, ADM SCORING MANUAL B; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Rosenstein LD, 1997, NEUROPSY NEUROPSY BE, V10, P113; Rosenstein LD, 1992, BNI Q, V8, P24; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SHERER M, 2001, IN PRESS ARCH PHYS M; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; WAAS P, 1997, THESIS U WINDSOR ONT; 1975, CIBA FDN S, V34	37	18	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					526	534		10.1097/00001199-200212000-00004			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900004	12802243				2021-06-18	
J	Cato, MA; Brewster, J; Ryan, T; Giuliano, AJ				Cato, MA; Brewster, J; Ryan, T; Giuliano, AJ			Coaching and the ability to simulate mild traumatic brain injury symptoms	CLINICAL NEUROPSYCHOLOGIST			English	Article							FORCED-CHOICE METHOD; MEMORY IMPAIRMENT; BELIEVABLE DEFICITS; PERFORMANCE; TASK	This study assessed the ability of normal controls to simulate mild traumatic brain injury with or without the aid of general simulation strategies. An additional purpose was to evaluate the relative ability of four tests of performance motivation or malingering to discriminate among the five groups in this study. Twenty-one patients with documented mild traumatic brain injury (TBI) and 112 undergraduate students were administered the measures of symptom validity in randomized order with instructions either to perform to the best of their ability or to fake believable deficits. Students asked to malinger were either given instructions to do so with no guidance (No Strategies group or NS), a minimal level of guidance (Only Strategies group or OS) or a moderate level of guidance (Strategies and Example or SE). Students given simulation strategies (OS and SE groups) were able to match performance of the TBI group in only those instances when TBI performance was similar to the normal comparison group. When TBI performance fell considerably below the normal comparison group, naive simulators (NS group) best approximated TBI performance. The degree of variability in the classification success of the four tests underscored the necessity of combining detection methods, as well as the need to develop new tests more resistant to attempts to feign brain injury.	Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; James Madison Univ, Sch Psychol, Harrisonburg, VA 22807 USA; Univ Virginia, Dept Psychiat Med, Charlottesville, VA USA; Univ Hartford, Dept Psychol, Hartford, CT USA	Cato, MA (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, 1600 SW Archer Rd,Box 100165, Gainesville, FL 32610 USA.						BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; FAUST D, 1990, J CONSULT CLIN PSYCH, V58, P248, DOI 10.1037/0022-006X.58.2.248; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; Faust D, 1988, Arch Clin Neuropsychol, V3, P145, DOI 10.1016/0887-6177(88)90060-1; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Larrabee G. J., 1992, NEUROPSYCHOLOGY, V6, DOI https://doi.org/10.1037/0894-4105.6.1.23; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LORING DW, 1995, ANN M AM AC NEUR SEA; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; Pankratz L., 1997, CLIN ASSESSMENT MALI; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROGERS R, 1988, CLIN ASSESSMENT MALI; Warrington EK., 1984, RECOGNITION MEMORY T; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P1182; ZIELINSKI JJ, 1994, CLIN PSYCHOL-SCI PR, V1, P169, DOI 10.1111/j.1468-2850.1994.tb00018.x	23	18	18	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2002	16	4					524	535		10.1076/clin.16.4.524.13901			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	681AY	WOS:000183015300010	12822060				2021-06-18	
J	Slewa-Younan, S; Green, AM; Baguley, IJ; Felmingham, KL; Haig, AR; Gordon, E				Slewa-Younan, S; Green, AM; Baguley, IJ; Felmingham, KL; Haig, AR; Gordon, E			Is 'gamma' (40 Hz) synchronous activity disturbed in patients with traumatic brain injury?	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; gamma (40 Hz) synchrony; speed of information processing; electroencephalogram	SEVERE HEAD-INJURY; FUNCTIONAL-SIGNIFICANCE; REACTION-TIME; VALIDATION; POTENTIALS; COMPONENT; PARADIGM; TASK	Objectives: The objective of this work is to determine whether Gamma (40 Hz) synchronous activity has disturbed patients with severe traumatic brain injury (TBI). Methods: Using a conventional auditory oddball paradigm, the extent of Gamma synchrony across multiple scalp sites in specific frequency bands as a function of time was examined in 15 patients with severe TBI and 15 age- and sex-matched controls. Averaged Gamma synchrony was analyzed using within and between group multiple analyses of variance with region (left versus right hemisphere, anterior versus posterior region) as the within factor. Results: Compared to controls, subjects with TBI displayed significantly delayed early Gamma latency (from -150 to 150 ms) (F-(1,F-28)=10.28, P<0.003) across All sites in addition to other specific regional disturbances. For late Gamma synchrony, subjects with TBI displayed delayed Gamma latency at the left hemisphere (from 200 to 450 ms) (F-(1,F-28)=8.71, P<0.006) and posterior region (F-(1,F-28)=9.18, P<0.006) in comparison to controls. Conclusions: Impaired integration of spatially distributed brain activity ('40 Hz' electroencephalogram rhythms) may be an important marker of deficits of cortical network binding postulated to be abnormal in people who have survived TBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; Westmead Hosp, Brain Dynam Ctr, Wentworthville, NSW 2145, Australia; Univ Sydney, Dept Psychol Med, Sydney, NSW 2006, Australia	Slewa-Younan, S (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; BasarEroglu C, 1996, INT J PSYCHOPHYSIOL, V24, P101, DOI 10.1016/S0167-8760(96)00051-7; BLOM JL, 1982, ELECTROEN CLIN NEURO, V54, P591, DOI 10.1016/0013-4694(82)90046-3; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Fisher N.I., 1993, STAT ANAL CIRCULAR D; Gordon E, 1999, AUST NZ J PSYCHIAT, V33, P187, DOI 10.1046/j.1440-1614.1999.00557.x; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Haig AR, 1999, CLIN NEUROPHYSIOL, V110, P158, DOI 10.1016/S0013-4694(98)00112-6; Haig AR, 2000, NEUROREPORT, V11, P669, DOI 10.1097/00001756-200003200-00004; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; JENNETT B, 1977, LANCET, V1, P878; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; KRIEGER D, 1987, ELECTROEN CLIN NEURO, V67, P222, DOI 10.1016/0013-4694(87)90020-4; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Phillips WA, 1997, BEHAV BRAIN SCI, V20, P657, DOI 10.1017/S0140525X9700160X; PRESS WH, 1992, FOURIER SPECTRAL APP; Revonsuo A, 1997, NEUROREPORT, V8, P3867, DOI 10.1097/00001756-199712220-00006; Sauve K, 1999, CONSCIOUS COGN, V8, P213, DOI 10.1006/ccog.1999.0383; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Smith A., 1973, SYMBOL DIGIT MODALIT; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN A, 1994, CLIN NEUROPSYCHOLOGY, P179; Viggiano MP, 1996, J CLIN EXP NEUROPSYC, V18, P631, DOI 10.1080/01688639608408288; Williams LM, 2000, INT J NEUROSCI, V105, P37, DOI 10.3109/00207450009003264	30	18	18	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	OCT	2002	113	10					1640	1646	PII S1388-2457(02)00239-0	10.1016/S1388-2457(02)00239-0			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	607GH	WOS:000178783400015	12350441				2021-06-18	
J	Zhang, FY; Sprague, SM; Farrokhi, F; Henry, MN; Son, MG; Vollmer, DG				Zhang, FY; Sprague, SM; Farrokhi, F; Henry, MN; Son, MG; Vollmer, DG			Reversal of attenuation of cerebrovascular reactivity to hypercapnia by a nitric oxide donor after controlled cortical impact in a rat model of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						nitric oxide; controlled cortical impact; hypercapnia; cortical spreading depression; rat	CEREBRAL BLOOD-FLOW; CEREBELLAR FASTIGIAL NUCLEUS; FLUID-PERCUSSION INJURY; SEVERE HEAD-INJURY; SPREADING DEPRESSION; AUTO-REGULATION; L-ARGININE; CO2; RESPONSES; REDUCTION	Object. Traumatic brain injury (TBI) attenuates the cerebral vasodilation to hypercapnia. Cortical spreading depression (CSD) also transiently reduces hypercapnic vasodilation. The authors sought to determine whether the CSD elicited by a controlled cortical impact (CCI) injury masks the true effect of TBI on hypercapnic vasodilation, and whether a nitric oxide (NO) donor can reverse the attenuation of hypercapnic vasodilation following CCI Methods, Anesthetized rats underwent moderate CCL Cerebral blood flow was monitored with laser Doppler flowmetry and the response to hypercapnia was determined for injured and sham-injured animals. The effect of the NO donor, S-nitroso-Al-acetylpenicillamine (SNAP), on this response was also assessed. At an uninjured cortical site ipsilateral to the CCI, a single wave of CSD was recorded and the CO2 response at this location was significantly attenuated for up to 30 minutes (seven rats, p < 0.05). At the injured cortex, hypercapnic vasodilation continued to be attenuated for 7 hours. The cerebral vasodilation to CO2 was 37 +/- 5% in injured rats (six) compared with 84 +/- 10%, in the sham-injured group (five rats, p < 0.05). After 30 minutes of topical supetfusion with SNAP, hypercapnic vasodilation was restored to 74 7% (nine rats, p > 0.1 compared with that in the sham-injured group). In contrast, papaverine, an NO-independent vasodilator, failed to reverse the attenuation of the CO2 response to CCI. Conclusions. The authors conclude that CSD elicited by CCI can mask the true effect of TBI on hypercapnic vasodilation for at least 30 minutes. Exogenous NO, but not papaverine, can reverse the attenuation of cerebrovascular reactivity to CO2 caused by TBI. This result supports the hypothesis that NO production is reduced after TBI and that the NO donor has a potential beneficial role in the clinical management of head injury.	Univ Texas, Hlth Sci Ctr, Div Neurosurg, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Div Crit Care, Dept Pediat, San Antonio, TX 78229 USA	Zhang, FY (corresponding author), Univ Texas, Hlth Sci Ctr, Div Neurosurg, Dept Surg, Mail Code 7843,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	fangyizhang@hotmail.com					Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; Colonna DM, 1997, AM J PHYSIOL-HEART C, V272, pH1315; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FABRICIUS M, 1995, AM J PHYSIOL-HEART C, V269, pH23; FABRICIUS M, 1993, BRAIN RES, V602, P350, DOI 10.1016/0006-8993(93)90701-N; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Gahm C, 2000, NEUROSURGERY, V46, P169; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GORJI A, 1907, BRAIN RES BRAIN RES, V38, P33; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; IADECOLA C, 1990, J CEREBR BLOOD F MET, V10, P608, DOI 10.1038/jcbfm.1990.112; IADECOLA C, 1994, AM J PHYSIOL, V267, pR228; IADECOLA C, 1992, AM J PHYSIOL, V263, pR1156; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LACOMBE P, 1992, EXP NEUROL, V117, P278, DOI 10.1016/0014-4886(92)90137-F; LADECOLA C, 1992, P NATL ACAD SCI USA, V89, P3913; LAURITZEN M, 1984, J CEREBR BLOOD F MET, V4, P546, DOI 10.1038/jcbfm.1984.79; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Mayevsky A, 1998, ACT NEUR S, V71, P78; Mayevsky A, 1999, ACT NEUR S, V75, P63; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Read SJ, 1998, NEUROSCI LETT, V250, P115, DOI 10.1016/S0304-3940(98)00442-X; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SOMJEN GG, 1992, CAN J PHYSIOL PHARM, V70, pS248, DOI 10.1139/y92-268; Sonn J, 2000, BRAIN RES, V882, P212, DOI 10.1016/S0006-8993(00)02827-4; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZHANG F, 1995, NEUROSCIENCE, V69, P1195, DOI 10.1016/0306-4522(95)00302-Y; ZHANG ZG, 1994, J CEREBR BLOOD F MET, V14, P939, DOI 10.1038/jcbfm.1994.125	52	18	18	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2002	97	4					963	969		10.3171/jns.2002.97.4.0963			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	604MY	WOS:000178626400037	12405388				2021-06-18	
J	Buczek, M; Alvarez, J; Azhar, J; Zhou, Y; Lust, WD; Selman, WR; Ratcheson, RA				Buczek, M; Alvarez, J; Azhar, J; Zhou, Y; Lust, WD; Selman, WR; Ratcheson, RA			Delayed changes in regional brain energy metabolism following cerebral concussion in rats	METABOLIC BRAIN DISEASE			English	Article						head injury; concussion; brain energy metabolism; glucose consumption	FLUID-PERCUSSION MODEL; CLOSED-HEAD INJURY; GLUCOSE-UTILIZATION; MAGNETIC-RESONANCE; BLOOD-FLOW; MECHANISMS; ISCHEMIA; EDEMA; EXPRESSION; OXIDASE	Traumatic brain injury (TBI) results in an acute altered metabolic profile of brain tissue which resolves within hours of initial insult and yet some of the functional deficits and cellular perturbations persist for days. It is hypothesized that a delayed change in energy status does occur and is a factor in the neural tissue's ability to survive and regain function. Regional metabolic profile and glucose consumption were determined at either 1 or 3 days following two different intensities of parasagittal fluid-percussion (F-P). A significant decrease in both 1CMR(g)luc and levels of ATP and P-creatine was evident in the hemisphere ipsilateral to the trauma at 1 day after the insult. The effect was greater in the cortical than the subcortical regions and was more pronounced at the higher trauma intensity. Normalization of glucose consumption and energy levels was essentially complete by 3 days. It would appear that the delayed metabolic changes at 1 day postinsult cannot be explained by a secondary ischemia since the changes in the metabolite profile do not elicit an increase in the consumption of glucose. These changes in energy metabolites may account for and contribute to the chronic neurological deficits following TBI.	Case Western Reserve Univ, Univ Hosp Cleveland, Res Inst, Lab Expt Neurol Surg,Dept Neurol Surg, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurol Surg, Cleveland, OH USA	Lust, WD (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Res Inst, Lab Expt Neurol Surg,Dept Neurol Surg, Biomed Res Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.						ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BUCZEK M, 1991, J CEREBR BLOOD F MET, V11, P845, DOI 10.1038/jcbfm.1991.144; DEMEDIUK P, 1988, Journal of Neurotrauma, V5, P105, DOI 10.1089/neu.1988.5.105; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LUST WD, 1981, ANAL BIOCHEM, V110, P258, DOI 10.1016/0003-2697(81)90144-5; LUST WD, IN PRESS METAB BRAIN; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, J NEUROTRAUMA S1, V9, P201; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; Passonneau JV., 1972, FLEXIBLE SYSTEM ENZY; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PONTEN U, 1973, J NEUROCHEM, V21, P1121, DOI 10.1111/j.1471-4159.1973.tb07566.x; PRASAD MR, 1994, J NEUROCHEM, V63, P1094; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	46	18	18	0	4	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490			METAB BRAIN DIS	Metab. Brain Dis.	SEP	2002	17	3					153	167	UNSP 0885-7490/02/0900-0153/0	10.1023/A:1019973921217			15	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	587FM	WOS:000177629900005	12322786				2021-06-18	
J	Peasley, MA; Shi, RY				Peasley, MA; Shi, RY			Resistance of isolated mammalian spinal cord white matter to oxygen-glucose deprivation	AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY			English	Article						axons; neurotrauma; reperfusion; mitochondria; membrane	CNS MYELINATED AXONS; AORTIC-ANEURYSM REPAIR; NERVOUS-SYSTEM; ANOXIC INJURY; BRAIN; MECHANISMS; TRANSPORT; GLUTAMATE; ISCHEMIA; CALCIUM	We found that isolated guinea pig spinal cord white matter is resistant to acute oxygen-glucose deprivation. Sixty minutes of oxygen-glucose deprivation resulted in a 60% reduction of compound action potential (CAP) conductance, and there was a near complete recovery after 60 min reperfusion. Corresponding horseradish peroxidase-exclusion assay showed little axonal membrane damage. To further deprive the axons of metabolic substrate, we added 2 mM sodium cyanide or 2 mM sodium azide, both mitochondrial suppressors, to the ischemic medium, which completely abolished CAP and resulted in a 15 to similar to30% recovery postreperfusion. Both compounds preferentially reduced the conductance of large diameter axons. We suggest the residual ATP in our ischemic model can protect anatomic integrity and physiological functioning of spinal axons following ischemic insult. This further suggests that oxygen-glucose deprivation alone cannot be solely responsible for short-term functional and anatomic damage. The damaging effects of ischemia in vivo may be mediated by factors originating from the gray matter of the cord or other systemic factors; both were largely eliminated in our in vitro white matter preparation.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Med Sci, W Lafayette, IN 47907 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27073] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027073, R56NS027073] Funding Source: NIH RePORTER		ALLEN BT, 1995, VASCULAR SURG THEORY, P1402; AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; ASANO T, 1995, J NEUROTRAUM, V12, P993; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Coselli JS, 1997, ANN THORAC SURG, V63, P28, DOI 10.1016/S0003-4975(96)01029-6; ERECINSKA M, 1994, PROG NEUROBIOL, V43, P37, DOI 10.1016/0301-0082(94)90015-9; GARRETT RH, 1999, BIOCHEMISTRY-US, P268; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kanellopoulos GK, 1997, STROKE, V28, P2532, DOI 10.1161/01.STR.28.12.2532; Lang-Lazdunski L, 2000, EUR J CARDIO-THORAC, V18, P174, DOI 10.1016/S1010-7940(00)00430-9; Leppanen L, 1997, J NEUROPHYSIOL, V78, P2095; RANSOM BR, 1990, STROKE, V21, P52; RANSOM BR, 1993, RES P ARNMD, V71, P121; Rose CR, 1998, J NEUROSCI, V18, P3554; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Safi HJ, 1998, ANN THORAC SURG, V66, P1204, DOI 10.1016/S0003-4975(98)00781-4; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; SATRAN R, 1988, Stroke, V19, P529; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2001, J NEUROTRAUM, V18, P1130; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Siegel G.J., 1999, BASIC NEUROCHEMISTRY; Stys PK, 1996, ANN NY ACAD SCI, V779, P366, DOI 10.1111/j.1749-6632.1996.tb44808.x; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; Stys PK, 1998, NEUROREPORT, V9, P447, DOI 10.1097/00001756-199802160-00017; Stys PK, 1998, NEUROSCIENCE, V82, P21; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; YOUNG W, 1993, RES P ARNMD, V71, P191	36	18	18	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6143			AM J PHYSIOL-CELL PH	Am. J. Physiol.-Cell Physiol.	SEP	2002	283	3					C980	C989		10.1152/ajpcell.00591.2001			10	Cell Biology; Physiology	Cell Biology; Physiology	586FG	WOS:000177573500032	12176754				2021-06-18	
J	Ter Minassian, A; Dube, L; Guilleux, AM; Wehrmann, N; Ursino, M; Beydon, L				Ter Minassian, A; Dube, L; Guilleux, AM; Wehrmann, N; Ursino, M; Beydon, L			Changes in intracranial pressure and cerebral autoregulation in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; cerebral autoregulation; intracranial pressure; cerebral perfusion pressure; cerebral blood flow velocity	SEVERE HEAD-INJURY; CARBON-DIOXIDE REACTIVITY; BLOOD-FLOW; TRANSCRANIAL DOPPLER; MATHEMATICAL-MODEL; PERFUSION-PRESSURE; VOLUME; HYPERTENSION; HUMANS; HYPEREMIA	Background. Impaired cerebral autoregulation is frequent after severe traumatic head injury. This could result in intracranial pressure fluctuating passively with the mean arterial pressure. Objective: This study examines the influence of autoregulation on the amplitude and direction of changes in intracranial pressure in patients with severe head injuries during the management of cerebral perfusion pressure. Design: Prospective study. Setting: Neurosurgical intensive care unit Patients: A total of 42 patients with severe head injuries. Interventions. Continuous recording of cerebral blood flow velocity, intracranial pressure, and mean arterial pressure during the start or change of continuous norepinephrine infusion. Measurements and Main Results. Cerebrovascular resistance was calculated from the cerebral perfusion pressure and middle cerebral artery blood flow velocity. The strength of autoregulation index was calculated as the ratio of the percentage of change in cerebrovascular resistance by the percentage of change in cerebral perfusion pressure before and after 121 changes in mean arterial pressure at constant ventilation between day 1 and day 18 after trauma. The strength of autoregulation index varied widely, indicating either preserved or severely perturbed autoregulation during hypotensive or hypertensive challenge in patients with or without intracranial hypertension at the basal state (strength of autoregulation index, 0.51 +/- 0.32 to 0.71 +/- 0.25). The change in intracranial pressure varied linearly with the strength of autoregulation index. There was a clinically significant change in intracranial pressure (greater than or equal to 5 mm Hg) in the same direction as the change in mean arterial pressure in five tracings of three patients. This was caused by the mean arterial pressure dropping below the identified lower limit of autoregulation in three tracings for two patients. It seemed to be caused by a loss of cerebral autoregulation in the remaining two tracings for one patient. Conclusion: Cerebral perfusion pressure-oriented therapy can be a safe way to reduce intracranial pressure, whatever the status of autoregulation, in almost all patients with severe head injuries.	CHU Angers, Dept Anesthesie Reanimat, Angers, France; Univ Studi Bologna, Dipartimento Elettron Systemist & Math, Bologna, Italy	Ter Minassian, A (corresponding author), CHU Angers, Dept Anesthesie Reanimat, Angers, France.			Ursino, Mauro/0000-0002-0911-0308			AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AUER LM, 1984, CEREBRAL VENOUS SYST, P169; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P243; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; G. Mchedlishvili, 1986, ARTERIAL BEHAV BLOOD, P42; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; HANDA Y, 1992, J NEUROSURG, V76, P493, DOI 10.3171/jns.1992.76.3.0493; HARDEBO JE, 1990, FERNS FOUND SERIES, V14, P41; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; KOSTELJANETZ M, 1986, NEUROSURGERY, V18, P17, DOI 10.1227/00006123-198601000-00004; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; LINDEGAARD KF, 1988, ACTA NEUROCHIR SUPP, V42, P80; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A., 1996, NEUROTRAUMA, P413; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OLESEN J, 1972, NEUROLOGY, V22, P978, DOI 10.1212/WNL.22.9.978; PAULSON OB, 1972, NEUROLOGY, V22, P286, DOI 10.1212/WNL.22.3.286; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P342; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Ursino M, 2000, AM J PHYSIOL-HEART C, V279, pH2439; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459	41	18	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2002	30	7					1616	1622		10.1097/00003246-200207000-00036			7	Critical Care Medicine	General & Internal Medicine	573PY	WOS:000176841100036	12130988				2021-06-18	
J	Hanten, G; Zhang, LF; Levin, HS				Hanten, G; Zhang, LF; Levin, HS			Selective learning in children after traumatic brain injury: A preliminary study	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ORBITOFRONTAL CORTEX; VERBAL REHEARSAL; WORKING-MEMORY; WHITE-MATTER; DAMAGE; METACOGNITION; ORGANIZATION; INCENTIVES; RETRIEVAL	Selective learning (SL) is the ability to select items to learn from among other items. it requires the use of the executive processes of metacognitive control and working memory, which are considered to be mediated by the frontal cortex and its circuitry. We studied the efficiency with which verbal items of greater value are selectively learned from among items varying in value in 14 children ages 8-15 years who had sustained severe traumatic brain injury (TBI) and in 39 typically developing age-matched children. We hypothesized that children with TBI would be disproportionately compromised in selective learning efficiency in contrast to memory span when compared to normally developing children. The results supported our hypothesis, as children with TBI performed significantly worse than controls on a measure of selective learning efficiency, but the two groups performed similarly on a measure of word recall within the same task. Furthermore, the effect of TBI on performance was demonstrated to take place at the time of encoding, rather than at retrieval.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin,Suite 1144, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2000, BRAIN INJURY, V14, P679; APPEL LF, 1972, CHILD DEV, V43, P1365, DOI 10.2307/1127522; Baddeley A. D., 1986, WORKING MEMORY; BAUER RH, 1990, J GEN PSYCHOL, V117, P447, DOI 10.1080/00221309.1990.9921150; BAYLIS LL, 1991, EXP BRAIN RES, V86, P617; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BJORK RA, 1998, INTENTIONAL FORGETTI; BUTTER CM, 1969, PHYSIOL BEHAV, V4, P163, DOI 10.1016/0031-9384(69)90075-4; BUTTER CM, 1970, J COMP PHYSIOL PSYCH, V72, P132, DOI 10.1037/h0029303; CHAPMAN S, IN PRESS DEV NEUROPS; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1905, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; DUFRESNE A, 1989, J EXP CHILD PSYCHOL, V47, P274, DOI 10.1016/0022-0965(89)90033-7; DUSEK JB, 1978, DEV PSYCHOL, V14, P115, DOI 10.1037/0012-1649.14.1.115; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; EPSTEIN W, 1969, J EXP PSYCHOL, V82, P168, DOI 10.1037/h0028045; EYSENCK MW, 1982, Q J EXP PSYCHOL-A, V34, P489, DOI 10.1080/14640748208400832; FLAVELL JH, 1966, CHILD DEV, V37, P283, DOI 10.1111/j.1467-8624.1966.tb05387.x; Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003; Fuster JM, 1997, ANATOMY PHYSL NEUROP; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GARRITY LI, 1975, DEV PSYCHOL, V11, P274, DOI 10.1037/h0076563; HAMILTON P, 1974, COGNITIVE PSYCHOL, V6, P61, DOI 10.1016/0010-0285(74)90004-8; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; HANTEN G, 2000, SELECTIVE LEARNING D; HANTEN G, 1996, UNPUB SELECTIVE REME; HARLEY WF, 1965, PSYCHON SCI, V2, P377, DOI 10.3758/BF03343506; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; JONES B, 1972, EXP NEUROL, V36, P362, DOI 10.1016/0014-4886(72)90030-1; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KENNEDY BA, 1976, CHILD DEV, V47, P566, DOI 10.2307/1128824; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Konrad KN, 2000, BRAIN INJURY, V14, P859; Koriat A, 1996, PSYCHOL REV, V103, P490, DOI 10.1037/0033-295X.103.3.490; KUNZINGER EL, 1984, J GENET PSYCHOL, V144, P19; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LOFTUS GR, 1970, J EXP PSYCHOL, V85, P141, DOI 10.1037/h0029537; Mazzoni G, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, pIX; Metcalfe J, 1994, METACOGNITION KNOWIN; MILLER PH, 1991, J EXP CHILD PSYCHOL, V52, P149, DOI 10.1016/0022-0965(91)90057-Y; OSULLIVAN JT, 1993, J EXP CHILD PSYCHOL, V55, P396, DOI 10.1006/jecp.1993.1022; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rogoff B., 1974, CHILD DEV, V44, P238; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rolls ET, 1999, BRAIN EMOTION; RYDBERG JN, 1994, RADIOLOGY, V193, P173, DOI 10.1148/radiology.193.1.8090888; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; SECHLER E, 1985, THESIS RICE U HOUSTO; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Siegler R. S., 1978, CHILDRENS THINKING W, P3; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	73	18	18	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JUN	2002	8	2					107	120		10.1076/chin.8.2.107.8729			14	Clinical Neurology	Neurosciences & Neurology	651BB	WOS:000181299300005	12638064				2021-06-18	
J	Andermahr, J; Greb, A; Hensler, T; Helling, HJ; Bouillon, B; Sauerland, S; Rehm, KE; Neugebauer, E				Andermahr, J; Greb, A; Hensler, T; Helling, HJ; Bouillon, B; Sauerland, S; Rehm, KE; Neugebauer, E			Pneumonia in multiple injured patients: a prospective controlled trial on early prediction using clinical and immunological parameters	INFLAMMATION RESEARCH			English	Article						pneumonia; multiple trauma; interleukin; TNF receptors; procalcitonin	RISK-FACTORS; INFLAMMATORY MEDIATORS; NOSOCOMIAL PNEUMONIA; ORGAN FAILURE; PLASMA-LEVELS; TRAUMA; SEPSIS; SEVERITY; PROCALCITONIN; INTERLEUKIN-10	Objective and design: In a prospective trial 266 multiple injured patients were included to evaluate clinical risk factors and immune parameters related to pneumonia. Methods: Clinical and humoral parameters were assessed and multivariate analysis performed. Results: The multivariate analysis (odds ratio with 95% confidence interval (Cl)) revealed male gender (3.65), traumatic brain injury (TBI) (2.52), thorax trauma (AIS(thorax) greater than or equal to 3) (2.05), antibiotic prophylaxis (1.30), injury severity score (ISS) (1.03 per ISS point) and the age (1.02 per year) as risk factors for pneumonia. The main pathogens were Acinetobacter Baumannii (40 %) and Staphylococcus aureus (25 %). A tendency towards higher Procalcitonin (PCT) and Interleukin (IL)-6 levels two days after trauma was observed for pneumonia patients. Conclusion: The immune parameters (PCT, IL-6, IL-10, soluble tumor necrosis factor p-55 and p-75) could not confirm the diagnosis of pneumonia earlier than the clinical parameters.	Univ Cologne, Clin Trauma Hand & Reconstruct Surg, DE-50924 Cologne, Germany; Univ Cologne, Dept Surg 2, Biochem & Expt Div, DE-51109 Cologne, Germany; Univ Cologne, Dept Surg 2, Surg Clin, DE-51109 Cologne, Germany	Andermahr, J (corresponding author), Univ Cologne, Clin Trauma Hand & Reconstruct Surg, Joseph Stelzmannstr 9, DE-50924 Cologne, Germany.	JAndermahr@t-online.de		Sauerland, Stefan/0000-0003-1048-796X			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Aufmkolk M, 1998, UNFALLCHIRURG, V101, P433, DOI 10.1007/s001130050292; BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BRUNBUISSON C, 1995, CURR OPIN CRIT CARE, V1, P341; Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHAMPION HR, 1983, WORLD J SURG, V7, P4, DOI 10.1007/BF01655906; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; DALISE MD, 1994, J TRAUMA, V37, P171, DOI 10.1097/00005373-199408000-00002; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; FAIST E, 1992, SURGERY, V112, P562; Gendrel D, 1997, INFECTION, V25, P133, DOI 10.1007/BF02113598; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Kahlke V, 2000, CYTOKINE, V12, P69, DOI 10.1006/cyto.1999.0511; KRAGSBJERG P, 1995, EUR J SURG, V161, P17; KRAGSBJERG P, 1995, THORAX, V50, P1253, DOI 10.1136/thx.50.12.1253; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; TOEWS GB, 1986, AM J MED SCI, V291, P355, DOI 10.1097/00000441-198605000-00013; TRINKLE JK, 1975, ANN THORAC SURG, V19, P355, DOI 10.1016/S0003-4975(10)64034-9; WALKER WE, 1985, ANN SURG, V201, P752, DOI 10.1097/00000658-198506000-00012; Wanner GA, 2000, CRIT CARE MED, V28, P950, DOI 10.1097/00003246-200004000-00007; WAYDHAS C, 1992, ARCH SURG-CHICAGO, V127, P460; Weber DJ, 1999, CHEST, V115, p34S, DOI 10.1378/chest.115.suppl_1.34S; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114	36	18	22	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	MAY	2002	51	5					265	272		10.1007/PL00000303			8	Cell Biology; Immunology	Cell Biology; Immunology	556BG	WOS:000175827100008	12056515				2021-06-18	
J	Boswell, JE; McErlean, M; Verdile, VP				Boswell, JE; McErlean, M; Verdile, VP			Prevalence of traumatic brain injury in an ED population	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						traumatic brain injury; injury prevention; emergency medical services; population prevalence	CLOSED-HEAD INJURY; POSTCONCUSSION SYNDROME; MILD; CHILDREN; ADMISSION; TRENDS; COUNTY; DEATH	The objective of this study was to determine prevalence of traumatic brain injury (TBI) in an emergency department (ED) population. Questionnaires were administered to patients in an urban, university, trauma center ED. All respondents provided demographics; patients reporting TBI were asked age at injury, if they experienced loss of consciousness (LOC), mechanism, or if medical attention was sought. Five hundred one patients completed the survey. Forty-one percent reported TBI; 23% had TBI with LOC. Mean age at injury was 21.5 years. Mechanism was evenly distributed among sports, assaults, falls, and motor vehicle crashes (MVC). Medical attention was sought for 61% of injuries. Men were more likely to report TBI (P < .001). Medical attention was more likely if MVC or LOC and less likely in sports-injured patients (all P < .01). Twenty-five percent of patients with TBI sustained repeat injury by the same mechanism. Prevalence of TBI in this population is high. Many occur by mechanisms that potentially are preventable. (Am J Emerg Med 2002;20: 177-180. Copyright 2002, Elsevier Science (USA). All rights reserved.)	Albany Med Coll, Dept Emergency Med MC139, Albany, NY 12208 USA	McErlean, M (corresponding author), Albany Med Coll, Dept Emergency Med MC139, 47 New Scotland Ave, Albany, NY 12208 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Buss T F, 1995, Violence Vict, V10, P183; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; EVANS RW, 1992, NEUROL CLIN, V10, P815; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gutentag SS, 1998, ASSESSMENT, V5, P263, DOI 10.1177/107319119800500306; HEDGES BE, 1995, AM J PUBLIC HEALTH, V85, P1008, DOI 10.2105/AJPH.85.7.1008; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; Kraus Jess F., 1994, P3; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; MacKenzie E J, 1989, Md Med J, V38, P725; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Robertson LS, 1996, AM J PUBLIC HEALTH, V86, P31, DOI 10.2105/AJPH.86.1.31; Skelton CE, 1997, SCOT MED J, V42, P40, DOI 10.1177/003693309704200204; SmithSeemiller L, 1997, BRAIN INJURY, V11, P735; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Teasdale TW, 1997, BRIT MED J, V315, P569; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1997, MMWR MORB MORTAL WKL, V46, P8	36	18	18	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2002	20	3					177	180		10.1053/ajem.2002.32641			4	Emergency Medicine	Emergency Medicine	549WK	WOS:000175469600008	11992336				2021-06-18	
J	Brooke, SM; McLaughlin, JR; Cortopassi, KM; Sapolsky, RM				Brooke, SM; McLaughlin, JR; Cortopassi, KM; Sapolsky, RM			Effect of GP120 on glutathione peroxidase activity in cortical cultures and the interaction with steroid hormones	JOURNAL OF NEUROCHEMISTRY			English	Article						estrogen; glucocorticoids; glutathione peroxidase; gp120; neurotoxicity; reactive oxygen species	CENTRAL-NERVOUS-SYSTEM; PNEUMOCYSTIS-CARINII PNEUMONIA; MANGANESE SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYME-ACTIVITIES; TRAUMATIC BRAIN INJURY; SIMPLEX VIRUS VECTORS; AIDS DEMENTIA COMPLEX; OXIDATIVE STRESS; HIV-1 INFECTION; FOCAL ISCHEMIA	GP120 (the protein component of the HIV viral coat) is neurotoxic and may contribute to the cell loss associated with AIDS-related dementia Previously, it has been shown in rat cortical mixed cultures that gp120 increased the accumulation of hydrogen peroxide and superoxide, two reactive oxygen species (ROS). We new demonstrate that gp120 increased activity of the key antioxidant glutathione peroxidase (GSPx), presumably as a defensive mechanism against the increased ROS load. Both estrogen and glucocorticoids (GCs), the adrenal steroid released during stress, blunted this gp120 effect on GSPx activity. The similar effects of estrogen and of GCs are superficially surprising, given prior demonstrations that GCs exacerbated and estrogens protected against gp120 neurotoxicity. We find that these similar effects of estrogen and GCs on GSPx regulation arose, in fact, from very different routes, which are commensurate with these prior reports. Specifically, estrogen has demonstrated antioxidant properties that may prevent the ROS increase (therefore acting as a neuroprotective agent) and rendered unnecessary the compensatory GSPx increased activity. To verify this we have added H2O2 to estrogen + gp120-treated cells, and GSPx activity was increased. However, with addition of H2O2 to GCs + gp-120-treated cells there was no increase in activity. GCs appeared to decrease enzyme production and or activity and therefore under insult conditions ROS levels rose in the cell resulting in increased neurotoxicity. Overexpression of GSPx enzyme via herpes vector system reversed the GCs-induced loss of enzyme and eliminated the GCs exacerbation of gp120 neurotoxicity.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Brooke, SM (corresponding author), Stanford Univ, Dept Biol Sci, Gilbert Bldg,Rm432, Stanford, CA 94305 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00563] Funding Source: Medline		Adamson DC, 1999, MOL MED, V5, P98, DOI 10.1007/BF03402144; Ahlbom E, 2000, P NATL ACAD SCI USA, V97, P14726, DOI 10.1073/pnas.260501697; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bagetta G, 1996, NEUROREPORT, V7, P1722, DOI 10.1097/00001756-199607290-00005; Barks JDE, 1997, NEUROSCIENCE, V76, P397, DOI 10.1016/S0306-4522(96)00373-9; Binienda Z, 1998, NEUROSCI LETT, V251, P173, DOI 10.1016/S0304-3940(98)00539-4; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Brooke S, 1997, P NATL ACAD SCI USA, V94, P9457, DOI 10.1073/pnas.94.17.9457; Brooke SM, 2000, BIOL PSYCHIAT, V48, P881, DOI 10.1016/S0006-3223(00)00922-7; Brooke SM, 1999, NEUROSCI LETT, V267, P21, DOI 10.1016/S0304-3940(99)00315-8; Brooke SM, 1998, J NEUROCHEM, V71, P1187, DOI 10.1046/j.1471-4159.1998.71031187.x; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; Corasaniti MT, 1998, BIOCHEM BIOPH RES CO, V246, P686, DOI 10.1006/bbrc.1998.8687; Foga IO, 1997, J ACQ IMMUN DEF SYND, V16, P223, DOI 10.1097/00042560-199712010-00001; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389; Gonenc S, 2000, NEUROSCI LETT, V289, P107, DOI 10.1016/S0304-3940(00)01272-6; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hansen JM, 2001, FREE RADICAL BIO MED, V30, P1078, DOI 10.1016/S0891-5849(01)00502-0; HO DY, 1995, J NEUROSCI METH, V57, P205, DOI 10.1016/0165-0270(94)00150-F; HO DY, 1994, METHOD CELL BIOL, V43, P191; Howard SA, 1999, EXP NEUROL, V158, P164, DOI 10.1006/exnr.1999.7080; Howard SA, 2001, EXP NEUROL, V168, P385, DOI 10.1006/exnr.2000.7619; LAWRENCE MS, 1995, P NATL ACAD SCI USA, V92, P7247, DOI 10.1073/pnas.92.16.7247; Lee BR, 1999, EXP CELL RES, V248, P430, DOI 10.1006/excr.1999.4409; Lipton SA, 1998, ANNU REV PHARMACOL, V38, P159, DOI 10.1146/annurev.pharmtox.38.1.159; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MATSUYAMA T, 1994, STROKE, V25, P1417, DOI 10.1161/01.STR.25.7.1417; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; McIntosh LJ, 1998, BRAIN RES, V791, P215, DOI 10.1016/S0006-8993(98)00104-8; Michaels J, 1988, Immunodefic Rev, V1, P71; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; Pajovic SB, 1999, GEN PHYSIOL BIOPHYS, V18, P35; Pareja JG, 1998, CHEST, V113, P1215, DOI 10.1378/chest.113.5.1215; Perl A, 2000, ANTIOXID REDOX SIGN, V2, P551, DOI 10.1089/15230860050192323; Pippenger C E, 1998, Methods Mol Biol, V108, P299; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rohrdanz E, 2001, ARCH TOXICOL, V75, P150, DOI 10.1007/s002040000206; Roy M, 2001, BRAIN RES, V901, P12, DOI 10.1016/S0006-8993(01)02034-0; Saksena NK, 1998, B I PASTEUR, V96, P171, DOI 10.1016/S0020-2452(98)80012-2; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; Sapolsky RM, 1999, NEUROLOGY, V53, P1922, DOI 10.1212/WNL.53.9.1922; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Sokolova T, 2001, NEUROSCI LETT, V297, P129, DOI 10.1016/S0304-3940(00)01689-X; Tabatabaie T, 1996, BIOCHEM BIOPH RES CO, V221, P386, DOI 10.1006/bbrc.1996.0605; Toyoda T, 1997, NEUROREPORT, V8, P847, DOI 10.1097/00001756-199703030-00008; Toyoda T, 1997, NEUROSCI LETT, V235, P29, DOI 10.1016/S0304-3940(97)00707-6; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x	53	18	18	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	APR	2002	81	2					277	284		10.1046/j.1471-4159.2002.00825.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	542TE	WOS:000175059800007	12064474				2021-06-18	
J	Muller, SV; von Schweder, AJ; Frank, B; Dengler, R; Munte, TF; Johannes, S				Muller, SV; von Schweder, AJ; Frank, B; Dengler, R; Munte, TF; Johannes, S			The effects of proprioceptive stimulation on cognitive processes in patients after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cognition; event-related potentials; P300; muscles; rehabilitation	MUSCLE VIBRATION; EVOKED-POTENTIALS; DISORDERS; CORTEX; INDEX	Objective: To investigate the hypothesis that proprioceptive stimulation may be effective in the treatment of brain injury, using neurophysiologic and neuropsychologic measures. Design: Cohort analytic study. Setting: Patients recovering from traumatic brain injury (TBI) in a neurologic rehabilitation hospital were examined. Participants: Eleven patients with TBI (Glasgow Coma Scale score > 3) and 11 healthy control subjects matched for age and education. Interventions: Subjects were examined with the event-related potential (ERP) technique during a computerized choice-reaction-time task, in which they had to discriminate between even and odd digits. There were experimental runs with and without vibratory stimuli applied to the left forearm serving a as proprioceptive stimulation. In addition, ERPs were recorded to vibratory stimuli without any additional task. Main Outcome Measures: Outcome measures included latencies and amplitudes of the P300 ERP component and of the late negative component. Results: In the passive vibration condition, both groups showed the same ERP distribution. In the choice-reaction-time task, latencies and amplitudes of the P300 differed between the 2 groups. The patient group showed longer P300 latencies, which were shortened by vibratory stimuli. In contrast, the control subjects were not affected by vibratory stimuli. Conclusion: Our findings support the hypothesis that pathologic cognitive processes after TBI can be improved by proprioceptive stimulation. Muscle vibration has positive effects on pathologically slowed cognitive processes but not in healthy subjects.	Otto Von Guericke Univ, Dept Neuropsychol, D-39016 Magdeburg, Germany; Hannover Med Sch, Dept Neurol, D-3000 Hannover, Germany; Rehabil Hosp Leezen 3, Leezen, Germany	Muller, SV (corresponding author), Otto Von Guericke Univ, Dept Neuropsychol, Box 4120, D-39016 Magdeburg, Germany.	sandra.mueller@nat.uni-magdeburg.de	Munte, Thomas/C-2077-2014				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; COHEN LG, 1985, NEUROLOGY, V35, P691, DOI 10.1212/WNL.35.5.691; DINSE HR, 1997, ADV NEUROL, V73, P229; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Elbert T, 1987, J PSYCHOPHYSIOL, V1, P317; ELEK JM, 1991, ELECTROEN CLIN NEURO, V81, P279, DOI 10.1016/0168-5597(91)90014-O; GOETZ CG, 1992, NEUROL CLIN, V10, P907; GOLDEN CJ, 1976, J CLIN PSYCHOL, V32, P654, DOI 10.1002/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; JANKOVIC J, 1994, NEUROLOGY, V44, P2006, DOI 10.1212/WNL.44.11.2006; JENSEN AR, 1986, ACTA PSYCHOL, V25, P36; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Karnath HO, 1996, EXP BRAIN RES, V109, P333; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Khudados E, 1999, J NEUROL NEUROSUR PS, V67, P504, DOI 10.1136/jnnp.67.4.504; King JH, 1998, J CLIN EXP NEUROPSYC, V20, P603, DOI 10.1076/jcen.20.5.603.1124; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; Kossev A, 1999, MUSCLE NERVE, V22, P946, DOI 10.1002/(SICI)1097-4598(199907)22:7<946::AID-MUS22>3.0.CO;2-O; LEZAK MD, 1998, NEUROPSYCHOLOGICAL A; Maldjian JA, 1999, BRAIN RES, V824, P291, DOI 10.1016/S0006-8993(99)01126-9; MATTHEWS PBC, 1982, ANNU REV NEUROSCI, V5, P189, DOI 10.1146/annurev.ne.05.030182.001201; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Munte TF, 1996, NEUROSCI LETT, V216, P163, DOI 10.1016/0304-3940(96)13036-6; Munte TF, 1997, J COGNITIVE NEUROSCI, V9, P318, DOI 10.1162/jocn.1997.9.3.318; PECK EA, 1990, J CLIN EXP NEUROPSYC, V12, P34; RIXECKER H, 1980, J CLIN PSYCHOL, V36, P465, DOI 10.1002/jclp.6120360213; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; SCHOTT GD, 1996, LANCET, V348, P712; Siggelkow S, 1999, MUSCLE NERVE, V22, P1544, DOI 10.1002/(SICI)1097-4598(199911)22:11<1544::AID-MUS9>3.3.CO;2-#; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Strupp M, 1998, BRAIN, V121, P677, DOI 10.1093/brain/121.4.677; STURM W, 1984, THESIS U AACHEN AACH; SWARTZ JR, 1999, SCI PRACT NEUROPSYCH, P159; SWETS JA, 1973, SCIENCE, V182, P990, DOI 10.1126/science.182.4116.990; VALLAR G, 1995, NEUROPSYCHOLOGIA, V33, P73, DOI 10.1016/0028-3932(94)00088-7; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; ZIMMERMANN P, 1995, TESTBATTERIE AUFMERK	39	18	18	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2002	83	1					115	121		10.1053/apmr.2002.27472			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	509JU	WOS:000173145300018	11782841				2021-06-18	
J	Ma, JJ; Novikov, LN; Karlsson, K; Kellerth, JO; Wiberg, M				Ma, JJ; Novikov, LN; Karlsson, K; Kellerth, JO; Wiberg, M			Plexus avulsion and spinal cord injury increase the serum concentration of S-100 protein: An experimental study in rats	SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND SURGERY			English	Article						S-100 protein; plexus avulsion; spinal cord injury	NEURON-SPECIFIC ENOLASE; ISCHEMIC STROKE; BRAIN-DAMAGE; SERIAL S-100; HEAD-INJURY; BLOOD; MOTONEURONS; INFARCTION; SURVIVAL; SURGERY	The possibility of using the presence of the glial-cell-derived protein S-100 in serum as a marker for neuronal damage caused by spinal cord injury and plexus avulsion injury was investigated in 144 adult rats. After a spinal cord injury had been induced at the thoracic level or a plexus avulsion injury at the lumbar level, blood samples were taken and analysed for S-100 protein by a monoclonal two-site immunno-luminometric assay. The two types of neurotrauma changed the kinetics of serum S-100 in different ways. After spinal cord injury it rapidly increased and within 72 hours had reached a concentration about 5 times that of the control animals. Three peak concentrations occurred at 3, 12, and 72 hours, respectively, and differed significantly from those of the control group (p < 0.05). After six days the values had returned to normal. After lumbar plexus injury alone there was no significant increase in the concentration of S-100. These results suggest that the concentration of S-100 protein in serum may be used as an early diagnostic tool for detecting neuronal damage caused by spinal cord injury or plexus avulsion associated with damage to the root entry zone.	Univ Umea Hosp, Dept Hand & Plast Surg, SE-90185 Umea, Sweden; Umea Univ, Sect Anat, Dept Integrat Med Biol, Umea, Sweden; Univ Umea Hosp, Dept Clin Chem, S-90185 Umea, Sweden	Wiberg, M (corresponding author), Univ Umea Hosp, Dept Hand & Plast Surg, SE-90185 Umea, Sweden.		Novikov, Lev/I-1983-2012	Novikov, Lev/0000-0001-5520-3890			Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; Birch R, 1998, SURG DISORDERS PERIP, P157; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; USUI A, 1989, CLIN CHEM, V35, P1942; van Dongen EP, 1998, J VASC SURG, V27, P344, DOI 10.1016/S0741-5214(98)70365-9; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	16	18	19	0	0	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0284-4311			SCAND J PLAST RECONS	Scand. J. Plast. Reconstr. Surg. Hand Surg.	DEC	2001	35	4					355	359					5	Surgery	Surgery	509PE	WOS:000173155800003	11878171				2021-06-18	
J	Horn, P; Vajkoczy, P; Thome, C; Muench, E; Schilling, L; Schmiedek, P				Horn, P; Vajkoczy, P; Thome, C; Muench, E; Schilling, L; Schmiedek, P			Xenon-induced flow activation in patients with cerebral insult who undergo xenon-enhanced CT blood flow studies	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	5th International Conference on Xenon/CT CBF	SEP, 1999	TOKYO, JAPAN				TRAUMATIC BRAIN INJURY; STABLE XENON; ISOFLURANE; ENDOTHELIUM; INHALATION; HALOTHANE; STIMULATION; TOMOGRAPHY; ANESTHESIA; RELAXATION	BACKGROUND AND PURPOSE: Stable xenon-enhanced CT (Xe-s/CT) has gained wide acceptance in the assessment of regional cerebral blood flow (rCBF) in patients with intracranial abnormalities. The aim of this study was to test whether the contrast medium (ie, Xe-s) itself directly induces relevant changes in rCBF, thereby distorting any valid determination of cerebral perfusion by using Xe-s/CT. METHODS: To characterize the degree and temporal dynamics of Xe-s-induced flow activation, a thermal diffusion (TD)-based microprobe was placed subcortically into the frontal lobe on either hemisphere to assess rCBF (TD-rCBF) continuously in 23 patients (mean age, 55 +/- 18 years) with severe intracranial insult who were undergoing Xe-s/CT. RESULTS: In 35, the Xe-s/CT studies TD-rCBF rose from 25 +/- 17 mL/100 g per minute (range, 5-42 mL/100 g per minute) before Xe-s administration to 28 +/- 21 mL/100 g per minute (range, 6-46 mL/100 g per minute) after arterial Xe-s saturation was reached. Analysis of the flow activation curve showed a logarithmic shape with an increase in TD-rCBF between 3% and 7% within the first 76 seconds of Xe-s wash-in (12% after 190 seconds) and showed no further augmentation until the end of the blood flow study. CONCLUSION: The observed Xe-s-induced rCBF activation, which showed significant interand intraindividual variability, might lead to overestimation of rCBF in patients with severe intracranial insult. The obtained How activation curve provides essential information that may allow subsequent refinement of the methodology, aiming to further minimize the influence of Xe-s-induced rCBF activation on rCBF calculations when using Xe-s/CT technology.	Heidelberg Univ, Dept Neurosurg, Univ Hosp, Fac Clin Med, D-68167 Mannheim, Germany; Heidelberg Univ, Fac Clin Med, Univ Hosp, Dept Anesthesiol & Intens Care, D-6800 Mannheim, Germany	Horn, P (corresponding author), Heidelberg Univ, Dept Neurosurg, Univ Hosp, Fac Clin Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.						ASHWAL S, 1990, J PEDIATR-US, V117, P523, DOI 10.1016/S0022-3476(05)80683-3; BECK T, 1987, AM J PHYSIOL, V252, pH504; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOOMSMA F, 1990, ANAESTHESIA, V45, P273, DOI 10.1111/j.1365-2044.1990.tb14731.x; BROICH K, 1992, CEREBRAL BLOOD FLOW MEASUREMENT WITH STABLE XENON-ENHANCED COMPUTED TOMOGRAPHY, P292; CHRISTENSEN MS, 1967, BRIT J ANAESTH, V39, P927, DOI 10.1093/bja/39.12.927; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CUCCHIARA RF, 1974, ANESTHESIOLOGY, V40, P571, DOI 10.1097/00000542-197406000-00011; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; DETTMERS C, 1987, ADV NEUROSURG, V15, P67; FLYNN NM, 1992, ANESTHESIOLOGY, V76, P461, DOI 10.1097/00000542-199203000-00021; GELMAN S, 1984, ANESTH ANALG, V63, P557; GILLER CA, 1990, AM J NEURORADIOL, V11, P177; GUR D, 1985, STROKE, V16, P871, DOI 10.1161/01.STR.16.5.871; Hamberg LM, 1996, AM J NEURORADIOL, V17, P639; HARTMANN A, 1991, STROKE, V22, P182, DOI 10.1161/01.STR.22.2.182; HARTMANN A, 1987, STROKE, V18, P643, DOI 10.1161/01.STR.18.3.643; HOLL K, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P41; Horn Peter, 2000, Keio Journal of Medicine, V49, pA161; JENSEN NF, 1992, ANESTHESIOLOGY, V76, P624, DOI 10.1097/00000542-199204000-00021; JUNCK L, 1985, J CEREBR BLOOD F MET, V5, P126, DOI 10.1038/jcbfm.1985.16; Klar E, 1999, MICROVASC RES, V58, P156, DOI 10.1006/mvre.1999.2166; LACHMANN B, 1989, NARKOSEBEATMUNG LOW, P125; LINDER J, 1982, ACTA PHYSIOL SCAND, V114, P379, DOI 10.1111/j.1748-1716.1982.tb06998.x; LOVE JT, 1992, CEREBRAL BLOOD FLOW MEASUREMENT WITH STABLE XENON-ENHANCED COMPUTED TOMOGRAPHY, P282; Marion DW, 1999, CRIT CARE MED, V27, P2063, DOI 10.1097/00003246-199909000-00077; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; MOORE LE, 1994, ANESTHESIOLOGY, V80, P1328, DOI 10.1097/00000542-199406000-00021; Nakamura N, 2000, MAGN RESON IMAGING, V18, P397, DOI 10.1016/S0730-725X(00)00129-6; Obrist WD, 1998, J CEREBR BLOOD F MET, V18, P1192, DOI 10.1097/00004647-199811000-00005; OBRIST WD, 1992, STROKE, V23, P464; OBRIST WD, 1985, J CEREB BLOOD FLOW M, V5, P557; Stippich C, 1999, NEUROSCI LETT, V277, P25, DOI 10.1016/S0304-3940(99)00835-6; TEASDALE G, 1974, LANCET, V2, P81; THOME C, 1999, J CEREB BLOOD FLOW M, V19, pS623; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UELTZEN J, 1992, HIRNDURCHBLUTUNG CER, P35; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; WITT JP, 1991, AM J NEURORADIOL, V12, P973; YONAS H, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P1; YOSHIDA K, 1992, ANESTHESIOLOGY, V76, P440, DOI 10.1097/00000542-199203000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	42	18	24	0	3	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	SEP	2001	22	8					1543	1549					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	474QZ	WOS:000171119500016	11559502				2021-06-18	
J	Shapira, MY; Chelouche, M; Yanai, R; Kaner, C; Szold, A				Shapira, MY; Chelouche, M; Yanai, R; Kaner, C; Szold, A			Tai Chi Chuan practice as a tool for rehabilitation of severe head trauma: 3 case reports	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						art therapy; brain injuries; case report; martial arts; physical therapy; rehabilitation; Tai Chi; therapy	BALANCE; STRENGTH	Rehabilitation after severe head trauma is a complex process that can be long and frustrating, New, more holistic methods for rehabilitation are constantly sought. We present the cases of 3 patients who had severe head injury and whose rehabilitation was facilitated by Tai Chi Chuan (TCC) therapy. TCC therapy should be taught only by a qualified TCC therapist and under close medical supervision.	Hebrew Univ Jerusalem, Dept Bone Marrow Transplant, Hadassah Univ Hosp, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Shalvata Psychiat Hosp, Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Surg, Tel Aviv, Israel; Israeli Thai Chi Ctr, Tel Aviv, Israel	Shapira, MY (corresponding author), Hebrew Univ Jerusalem, Dept Bone Marrow Transplant, Hadassah Univ Hosp, Hadassah Med Sch, POB 12000, IL-91120 Jerusalem, Israel.		Szold, Amir/AAS-7223-2020	Szold, Amir/0000-0002-2238-8670			BROWN DR, 1995, MED SCI SPORT EXER, V27, P765; CHANNER KS, 1996, POSTGRAD MED J, V72, P347; Hong YL, 2000, BRIT J SPORT MED, V34, P29, DOI 10.1136/bjsm.34.1.29; Jacobson BH, 1997, PERCEPT MOTOR SKILL, V84, P27, DOI 10.2466/pms.1997.84.1.27; JIN PT, 1992, J PSYCHOSOM RES, V36, P361, DOI 10.1016/0022-3999(92)90072-A; KOH TC, 1982, AM J CHINESE MED, V10, P59, DOI 10.1142/S0192415X82000105; Wolf SL, 1997, PHYS THER, V77, P371, DOI 10.1093/ptj/77.4.371; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	9	18	18	1	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2001	82	9					1283	1285		10.1053/apmr.2001.25152			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	470LR	WOS:000170873900023	11552205				2021-06-18	
J	Haley, SM; Dumas, HM; Ludlow, LH				Haley, SM; Dumas, HM; Ludlow, LH			Variation by diagnostic and practice pattern groups in the mobility outcomes of inpatient rehabilitation programs for children and youth	PHYSICAL THERAPY			English	Article						disability; functional limitations; functional mobility assessment; outcomes; pediatrics; physical therapy; rehabilitation	TRAUMATIC BRAIN INJURY; RECOVERY	Background and Purpose. The purpose Of this study was to describe variation in functional mobility outcomes among children and youth with different diagnoses and belonging to groups with different practice patterns from an inpatient pediatric rehabilitation hospital setting. Subjects. A sample of 138 individuals between the ages of I and 22 years ((X) over bar =9.4, SD=5.3) was enrolled. Methods. Physical therapists administered the "Mobility" domain of the Pediatric Evaluation of Disability Inventory at the time of admission and at the time of discharge. Mobility level (combined admission and discharge scores) and amount of change between and within 4 diagnostic groups (traumatic brain injury, non-traumatic brain injury, orthopedic, and neurological) and 5 neuromuscular and musculoskeletal practice pattern groups were calculated, and post hoc analyses were done for specific contrast comparisons. Results. Mobility scores between admission and discharge for all subgroups were different. Practice pattern groups were useful for identifying variations in level of motor performance. Diagnostic groups best described differences in mobility change during inpatient rehabilitation. Discussion and Conclusion. The use of practice patterns as grouping categories may enhance our understanding of variation in clinical outcomes of children during inpatient rehabilitation.	Boston Univ, Sargent Coll Hlth & Rehabil Sci, Ctr Rehabil Effect, Boston, MA 02215 USA; Franciscan Childrens Hosp & Res Ctr, Ctr Excellence Children Special Hlth Care Needs, Boston, MA USA; Boston Coll, Lynch Sch Educ, Chestnut Hill, MA 02167 USA	Haley, SM (corresponding author), Boston Univ, Sargent Coll Hlth & Rehabil Sci, Ctr Rehabil Effect, 635 Commonwealth Ave, Boston, MA 02215 USA.						Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Butler C, 1999, DEV MED CHILD NEUROL, V41, P55, DOI 10.1017/S0012162299000110; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Dobrzykowski EA, 1997, J REHABILITATION OUT, V1, P8; DUDGEON BJ, 1994, ARCH PHYS MED REHAB, V75, P46; Engelbert R H, 1997, Pediatrics, V99, pE3, DOI 10.1542/peds.99.2.e3; Engelbert RHH, 1997, PEDIAT PHYS THER, V9, P18; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; GLASS GV, 1994, STAT METHODS ED PSYC; Haley S. M., 1993, PHYS MED REH CLIN N, V4, P529; HALEY SM, 1997, J REHABILITATION OUT, V1, P61; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; HALEY SM, MOVEMENT DISORDERS C, V199, P278; HALEY SM, 1992, PEDIAT PHYS THERAPY, V4, P24; HALEY SM, 1992, PEDIAT EVALUATION DI; HALEY SM, 1991, PEDIATRIC PHYSICAL T, V3, P177; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KANE RL, 1994, PHYS THER, V74, P425, DOI 10.1093/ptj/74.5.425; Massey B, 2001, PHYS THER, V81, P9; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; NAGI SZ, 1991, DISABILITY AM NATL A; *NCMRR, 1992, REP PLAN MED REH RES; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; PALISANO RJ, 2000, PHYSICAL THERAPY CHI, P198; PHILIP PA, 1994, ARCH PHYS MED REHAB, V75, P36; POPE AM, 1991, DISABILITY AM NATL A; Reid DT, 1993, PHYSICAL OCCUPATIONA, V13, P57, DOI [DOI 10.1080/J006V13N04_04, 10.1080/J006v13n0404]; SCHYVE PM, 1996, JOINT COMMISSION J Q, V11, pS54; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; WHO, 1977, MAN INT STAT CLASS D; WILKINS D, 1997, ANN ARBOR NEWS   JAN, P1; WRIGHT BD, 1978, BEST TEST DESIGN	35	18	18	0	2	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023			PHYS THER	Phys. Ther.	AUG	2001	81	8					1425	1436		10.1093/ptj/81.8.1425			12	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	458VQ	WOS:000170216500004	11509072	Bronze			2021-06-18	
J	[Anonymous]				[Anonymous]			Vascular complications of penetrating brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CRANIOCEREBRAL GUNSHOT WOUNDS; MISSILE HEAD WOUNDS; TRAUMATIC ANEURYSMS; ANGIOGRAPHY; MANAGEMENT									AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; HADDAD FS, 1997, NEUROSURGERY, V28, P1; JINKINS JR, 1992, AM J ROENTGENOL, V159, P365, DOI 10.2214/ajr.159.2.1632358; Kordestani RK, 1997, NEUROSURGERY, V41, P351, DOI 10.1097/00006123-199708000-00003; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3	10	18	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2001	51	2		S			S26	S28					3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	464LR	WOS:000170534500006	11505196				2021-06-18	
J	Basso, D; Bisiacchi, PS; Cotelli, M; Farinello, C				Basso, D; Bisiacchi, PS; Cotelli, M; Farinello, C			Planning times during traveling salesman's problem: Differences between closed head injury and normal subjects	BRAIN AND COGNITION			English	Article; Proceedings Paper	11th Annual Meeting on Theoretical and Experimental Neuropsychology	JUN 15-17, 2000	MONTREAL, CANADA	Univ Quebec, Montreal, Minist Rech, Sci & Technol, Quebec, Med Res Council, Ottawa			SPATIAL DECISIONS; PERFORMANCE	We studied planning behavior in a group of normal subjects and a group of closed head injury patients (CHI). A computerized version of the traveling salesman's problem was used as a visuospatial planning ability task. The program collected measurements of partial times, number of moves, and number of skipped subgoals. These measures allow us to calculate a "planning index" of subjects' planning ability. Results show that CHI patients present limitations in thr planning process due to the lack of ongoing planning, (C) 2001 Academic Press.	Univ Padua, Dept Gen Psychol, Padua, Italy; Spedali Civili Brescia, I-25125 Brescia, Italy; Opsed Civile San Bortolo, Vicenza, Italy	Basso, D (corresponding author), Univ Padua, Dept Gen Psychol, Padua, Italy.		Cotelli, Maria/K-1355-2016; Basso, Demis/Q-4782-2017; BISIACCHI, PATRIZIA/B-8976-2008	Cotelli, Maria/0000-0003-3208-3798; Basso, Demis/0000-0002-4595-3513; BISIACCHI, PATRIZIA/0000-0003-2760-8000			BASSO D, 1999, C NAZ SEZ PSIC SPER; Bisiacchi PS, 1998, BRAIN COGNITION, V37, P113; BISIACCHI PS, 1999, RES PERCEPTION, P179; CADWALLADER M, 1975, ECON GEOGR, V51, P339, DOI 10.2307/142918; Cohen G, 1989, MEMORY REAL WORLD; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; GARLING T, 1994, EUR J COGN PSYCHOL, V6, P399, DOI 10.1080/09541449408406522; GARLING T, 1989, J ENVIRON PSYCHOL, V9, P269, DOI 10.1016/S0272-4944(89)80009-X; HAYES-ROTH B, 1979, Cognitive Science, V3, P275, DOI 10.1016/S0364-0213(79)80010-5; HIRTLE SC, 1992, GEOFORUM, V23, P227, DOI 10.1016/0016-7185(92)90019-Z; MacGregor JN, 1996, PERCEPT PSYCHOPHYS, V58, P527, DOI 10.3758/BF03213088; VILKKI J, 1991, CORTEX, V27, P203, DOI 10.1016/S0010-9452(13)80124-4	12	18	18	0	5	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	JUN-JUL	2001	46	1-2					38	42		10.1016/S0278-2626(01)80029-4			5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	436JT	WOS:000168933300027	11527359				2021-06-18	
J	Nakayama, Y; Aoki, Y; Niitsu, H				Nakayama, Y; Aoki, Y; Niitsu, H			Studies on the mechanisms responsible for the formation of focal swellings on neuronal processes using a novel in vitro model of axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						axon reaction; cell culture; cytoskeleton; head injuries; closed; PC12 cells; transmission electron microscopy	PC12 CELLS; CYTOSKELETAL CHANGES; BRAIN INJURY; HEAD-INJURY; NEUROPATHOLOGY; PROTEOLYSIS; STRETCH	A novel in vitro model of axonal injury using PC12 cells was designed to introduce traumatic alterations on neuronal precesses and to identify mechanisms responsible for the formation of focal swellings by observation with phase-contrast and transmission electron microscopes. The injury on the processes was produced by one-dimensional, horizontal oscillation. The fluid shear stress applied by the oscillation did not exceed 380 dyne/cm(2). The injured processes showed two forms, One involved an increase in the terminal diameter of the processes and the other entailed beading along the injured portions, Long-term observation of cellular responses to the mechanical insult disclosed that the terminal swelling coincided with the detachment of growth cones from the culture plate. The finding suggests that the detachment of the growth cone destroys the cytoskeletal network, which determines and maintains the cell shape, resulting in spherical deformation of the processes. When the cytoskeletal destruction occurred at non-terminal sites along the processes, spherical deformations developed slowly, and these appeared as beads. The beading also caused the detachment of the growth cones, As the most proximal bead grew, they absorbed the distal segment and their growth cones were pulled proximally with the spreading cytoskeletal destruction. The processes with terminal swellings as well as the bead segments showed regeneration with time evidence of and growth cone formation.	Iwate Med Univ, Sch Med, Dept Legal Med, Morioka, Iwate 0208505, Japan	Nakayama, Y (corresponding author), Iwate Med Univ, Sch Med, Dept Legal Med, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.	yumin@iwate-med.ac.jp					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hotani H, 1990, Adv Biophys, V26, P135, DOI 10.1016/0065-227X(90)90010-Q; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; LANGUI D, 1990, ACTA NEUROPATHOL, V80, P649, DOI 10.1007/BF00307634; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITCHISON T, 1994, MOL BIOL CELL, P787; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; NAKAYAMA Y, 1998, 6 IND PAC C LEG MED, P991; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037; Ochs S, 1996, NEUROSCIENCE, V70, P1081, DOI 10.1016/0306-4522(95)00390-8; OCHS S, 1994, NEUROSCIENCE, V61, P361, DOI 10.1016/0306-4522(94)90237-2; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Schweitzer ES, 1996, J NEUROSCI RES, V46, P519; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1999, J NEUROSCI, V19, P4263; TAHIR SK, 1992, BIOCHEM CELL BIOL, V70, P1159, DOI 10.1139/o92-162	32	18	19	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					545	554		10.1089/089771501300227341			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000007	11393257				2021-06-18	
J	Choi, SC; Bullock, R				Choi, SC; Bullock, R			Design and statistical issues in multicenter trials of severe head injury	NEUROLOGICAL RESEARCH			English	Article						head injury; randomised clinical trials; Glasgow coma scale; therapy	CLINICAL-TRIALS	Multicenter clinical trials are the most powerful agent to evaluate new therapies in medicine, but have failed to impact traumatic brain injury, in which at least 20 such trials have been performed, without a positive result. Such trials need to be carefully planned, with a run-in period to ensure center compliance. Stratification, careful monitoring, adequate sample size, interim analysis and adequate numbers of patients per center are all vital requirements for a useful outcome in such trials.	Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA.						BRACKEN MB, 2001, IN PRESS NEUROSURGER; Choi S C, 1998, J Biopharm Stat, V8, P367, DOI 10.1080/10543409808835246; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; EDERER P, 1975, AM J EPIDEMIOL, V102, P111; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SYLVESTER RJ, 1981, NEW ENGL J MED, V305, P852, DOI 10.1056/NEJM198110083051503; WHITEHEAD J, 1983, BIOMETRICS, V39, P227, DOI 10.2307/2530822	8	18	19	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					190	192		10.1179/016164101101198325			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200011	11320598				2021-06-18	
J	Kemmeter, PR; Hoedema, RE; Foote, JA; Scholten, DJ				Kemmeter, PR; Hoedema, RE; Foote, JA; Scholten, DJ			Concomitant blunt enteric injuries with injuries of the liver and spleen: A dilemma for trauma surgeons	AMERICAN SURGEON			English	Article; Proceedings Paper	43rd Annual Meeting of the Midwest-Surgical-Association	AUG 13-16, 2000	MACKINAC ISL, MI	Midwest Surg Assoc			DIAGNOSTIC PERITONEAL-LAVAGE; SMALL-BOWEL INJURY; COMPUTED-TOMOGRAPHY; ABDOMINAL-TRAUMA; MORBIDITY; MORTALITY	Prompt identification of enteric injuries after blunt trauma remains problematic. With the increased utilization of nonoperative management of blunt abdominal trauma gastrointestinal disruptions may escape timely detection and repair, The purpose of this study was to evaluate blunt enteric injuries requiring operative repair in adult patients and the association of concomitant hepatic and/or splenic injuries, Over a 10-year period (January 1990 through December 1999) 1648 patients suffered blunt liver, spleen, and/or enteric injuries, with 87 (5.3%) of these requiring operative repairs of the enteric injury. These patients had enteric injury only (EI) (60.9%; 53 of 87), concomitant enteric/splenic injury (ESI) (10.3%; 9 of 87), concomitant enteric/hepatic injury (EHI) (13.8%; 12 of 87), and enteric/hepatic/splenic injury (EHSI) 14.9% (13 of 87). A delay in treatment of >8 hours from presentation of EI compared with either EHI or ESI was not significantly different between the two groups. EHSI had exploratory laparotomy more expeditiously related to hemodynamic instability. Mortality rates were higher with EHI related to hemorrhagic shock and/or severe traumatic brain injury. Morbidity was not related to a delay in diagnosis until the period of delay was greater than 24 hours. The nonoperative management of blunt solid organ injury does not delay the detection and treatment of concomitant bowel injuries compared with isolated blunt enteric injuries. Occult enteric injury with solid organ injury has a low incidence and represents a continuing challenge to the clinical acumen of the trauma surgeon.	Michigan State Univ, Spectrum Hlth, Grand Rapids, MI USA	Scholten, DJ (corresponding author), 1000 E Paris SE,Suite 150, Grand Rapids, MI 49546 USA.						Allen GS, 1998, J TRAUMA, V45, P69, DOI 10.1097/00005373-199807000-00014; Brownstein MR, 2000, J TRAUMA, V48, P402, DOI 10.1097/00005373-200003000-00006; BUCKMAN RF, 1988, J TRAUMA, V28, P1317, DOI 10.1097/00005373-198809000-00004; CARMONA RH, 1982, AM J SURG, V144, P88, DOI 10.1016/0002-9610(82)90607-9; DAUTERIVE AH, 1985, ANN SURG, V201, P198, DOI 10.1097/00000658-198502000-00011; Fakhry SM, 2000, J TRAUMA, V48, P408, DOI 10.1097/00005373-200003000-00007; FLAHERTY L, 1991, J TRAUMA, V31, P1618, DOI 10.1097/00005373-199112000-00009; HAGIWARA A, 1995, J TRAUMA, V38, P630, DOI 10.1097/00005373-199504000-00029; HUNTER RA, 1984, AUST NZ J SURG, V54, P129, DOI 10.1111/j.1445-2197.1984.tb06703.x; Kafie F, 1997, AM SURGEON, V63, P889; Kern SJ, 1997, AM SURGEON, V63, P669; McKenney MG, 1996, J TRAUMA, V40, P607, DOI 10.1097/00005373-199604000-00015; MEYER DM, 1989, J TRAUMA, V29, P1168, DOI 10.1097/00005373-198908000-00017; Otomo Y, 1998, J TRAUMA, V44, P991, DOI 10.1097/00005373-199806000-00010; Richards JR, 1999, RADIOLOGY, V211, P399, DOI 10.1148/radiology.211.2.r99ma54399; ROBBS JV, 1980, J TRAUMA, V20, P308; ROOT HD, 1967, ARCH SURG-CHICAGO, V95, P531; ROZYCKI GS, 1995, J TRAUMA, V39, P492; Sartorelli KH, 2000, J TRAUMA, V49, P56, DOI 10.1097/00005373-200007000-00008; SHERCK J, 1994, AM J SURG, V168, P670, DOI 10.1016/S0002-9610(05)80142-4; TRAUB AC, 1981, J TRAUMA, V21, P840, DOI 10.1097/00005373-198110000-00003	21	18	20	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	MAR	2001	67	3					221	225					5	Surgery	Surgery	409UE	WOS:000167403400006	11270878				2021-06-18	
J	Perron, AD; Brady, WJ; Huff, JS				Perron, AD; Brady, WJ; Huff, JS			Concussive convulsions: Emergency department assessment and management of a frequently misunderstood entity	ACADEMIC EMERGENCY MEDICINE			English	Article						concussion; concussive convulsion; brain injury; head injury; posttraumatic epilepsy	TRAUMATIC BRAIN INJURY; POSTTRAUMATIC SEIZURES; HEAD-INJURY; POPULATION; EPILEPSY; SPORT	Immediate concussive convulsions are an unusual but dramatic sequela to head injuries. Previously believed to be an epileptic phenomenon, they are now thought to be a brief traumatic functional decerebration that results from loss of cortical inhibition. With concussive convulsions generally occurring within seconds of head impact and lasting up to several minutes, patients are initially in a tonic phase, followed by a clonic convulsion. A postictal phase is generally brief if it occurs at all with these episodes. Patients with isolated concussive convulsions have no evidence of structural brain injury as assessed with neuroimaging studies or physical examination. Neuropsychological testing often demonstrates transient cortical dysfunction consistent with the concussive episode. The long-term outcome for patients with isolated concussive convulsion is universally good, with no long-term neurologic sequelae and no increased incidence of early or late posttraumatic epilepsy. Emergency department management should focus on evaluation of the associated concussive injury. The concussive convulsion requires no specific therapy, and antiepileptic medication is not indicated.	Univ Virginia Hlth Syst, Dept Emergency Med, Charlottesville, VA 22908 USA	Perron, AD (corresponding author), Univ Virginia Hlth Syst, Dept Emergency Med, Box 800699, Charlottesville, VA 22908 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BINDER LM, 1988, J CLIN EXP NEUROPSYC, V8, P23; Biros MH., 1998, EMERGENCY MED CONCEP, P416; BORCZUK P, 1990, EMERG MED CLIN N AM, P563; Chadwick D, 2000, LANCET, V355, P334, DOI 10.1016/S0140-6736(99)00452-3; Chadwick D, 1997, BRIT MED J, V314, P1283; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; DALY CC, 1986, RES VET SCI, V41, P353, DOI 10.1016/S0034-5288(18)30629-5; DALY CC, 1987, BRIT VET J, V143, P574, DOI 10.1016/0007-1935(87)90049-2; EVANS RW, 1992, NEUROL CLIN, V10, P815; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GASTAUT H, 1957, LANCET, V2, P1018; GRANDIN T, 1980, INT J STUD ANIM PROB, V1, P242; GRANDIN T, 1994, J AM VET MED ASSOC, V204, P1354; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SASAKI M, 1987, Brain and Nerve (Tokyo), V39, P983; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEPHENSON JBP, 1990, FITS FAINTS, P112; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WOLFDIETER R, 1989, METAB BRAIN DIS, V4, P3, DOI 10.1007/BF00999487	29	18	18	0	2	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	MAR	2001	8	3					296	298		10.1111/j.1553-2712.2001.tb01312.x			3	Emergency Medicine	Emergency Medicine	408UA	WOS:000167345000017	11229957	Bronze			2021-06-18	
J	Poloyac, SM; Perez, A; Scheff, S; Blouin, RA				Poloyac, SM; Perez, A; Scheff, S; Blouin, RA			Tissue-specific alterations in the 6-hydroxylation of chlorzoxazone following traumatic brain injury in the rat	DRUG METABOLISM AND DISPOSITION			English	Article							ACUTE-PHASE RESPONSE; CYTOCHROME-P450; NEUROTRAUMA; EXPRESSION; PHARMACOKINETICS; METABOLISM; PHENYTOIN; ENZYMES	Interest in the non-neuronal alterations following traumatic brain injury (TBI) has led to research evaluating hepatic metabolism following injury. Several models of injury demonstrate tissue-specific alterations in cytochrome P450 activity. This study examined tissue-specific alterations in cytochrome P450-mediated hydroxylation in the rat model of TBI. Male Sprague-Dawley rats received anesthesia alone, craniotomy, or craniotomy plus TBI. Rats were sacrificed at 24 and 48 h. Liver, kidney, and brain cortex microsomes were isolated. Total liver P450 content, 6-hydroxychlorzoxazone formation rate, and CYP2E1 protein were evaluated. In liver microsomes, spectral P450 was decreased to 86 +/- 5% (p < 0.05) of control at 24 h following injury, and 6-hydroxychlorzoxazone formation rate decreased to 74 +/- 18% of control (p < 0.05) at 48 h following injury. In kidney microsomes, 6-hydroxychlorzoxazone formation rate was increased to 154% of control (p < 0.01) 24 h following injury. 6-Hydroxychlorzoxazone formation rate was unaffected by TBI in brain cortical microsomes. The CYP2E1 inhibitor, 4-methylpyrazole, inhibited the formation of 6-hydroxychlorzoxazone in brain, kidney, and liver microsomes. These data demonstrate that tissue-specific alterations in 6-hydroxychlorzoxazone formation rate occur following TBI.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Puerto Rico, Sch Pharm, San Juan, PR 00936 USA	Poloyac, SM (corresponding author), Univ Pittsburgh, Dept Pharmaceut Sci, 1014 Salk Hall,3500 Terrace St, Pittsburgh, PA 15261 USA.		Perez, Alex/AAX-5145-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER		Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; GRIFFETH LK, 1984, DRUG METAB DISPOS, V12, P588; Hanioka N, 1997, ARCH TOXICOL, V72, P9, DOI 10.1007/s002040050462; HEINEMEYER G, 1986, THER DRUG MONIT, V8, P145, DOI 10.1097/00007691-198606000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; OMARA NB, 1995, CRIT CARE MED, V23, P1418, DOI 10.1097/00003246-199508000-00017; OMURA T, 1964, J BIOL CHEM, V239, P2379; Renton KW, 2000, J PHARMACOL EXP THER, V294, P524; Rockich K, 1999, DRUG METAB DISPOS, V27, P1074; Sewer MB, 1996, DRUG METAB DISPOS, V24, P401; Sewer MB, 1997, J PHARMACOL EXP THER, V280, P1445; Tindberg N, 1996, J NEUROCHEM, V67, P2066, DOI 10.1046/j.1471-4159.1996.67052066.x; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064	15	18	18	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0090-9556			DRUG METAB DISPOS	Drug Metab. Dispos.	MAR	2001	29	3					296	298					3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	402KC	WOS:000166985300014	11181498				2021-06-18	
J	Von Wild, K; Terwey, S				Von Wild, K; Terwey, S			Diagnostic confusion in mild traumatic brain injury (MTBI). Lessons from clinical practice and EFNS - Inquiry	BRAIN INJURY			English	Article								A 1997 inquiry of 130 neurosurgeons throughout Germany, dealing with diagnosis and therapy of patients with mild traumatic brain injury showed a mainly inhomogeneous picture. The European Federation of Neurological Societies inquiry form 'Management of Patients with Mild Head Injury' was sent on behalf of the German Society of Neurological Surgeons to every leading neurosurgeon in Germany, of whom only 74 (57%) answered. The diagnosis 'mild brain injury' is used by 63%, `commotio cerebri' by 49%, and 'brain concussion' by 4% of the institutions. GCS is used for classification by 60%, PTA 48%, retrograde amnesia by 50%, and LOC by 63% of institutions. Guidelines are used in 78%. Diagnostic x-ray of the skull is used in 77%, cervical spine in 62%, CT in 66%, MRT in 7%; and routine EEG in 35%. Fourteen per cent of the patients are not admitted; home observation is used in 45% of institutions, full bedrest in 19%, working pause in 48%, pain medication in 27%, control in 51%. Seperate guidelines for children in 54% of those departments.	Univ Munster, Dept Neurosurg, Clemenshosp, Teaching Hosp, D-48153 Munster, Germany; Univ Munster, Div Early Neurotraumatol Rehabil, Clemenshosp, Teaching Hosp, D-48153 Munster, Germany	Von Wild, K (corresponding author), Univ Munster, Dept Neurosurg, Clemenshosp, Teaching Hosp, Duesbergweg 124, D-48153 Munster, Germany.						Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; JACOBIC G, 1966, EUROPEAN J PAEDIAT, V55, P673; KIBBY MY, 1996, BRAIN INJURY, V10, P156; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; ROZENTHAL M, 1993, ANN EMERG MED, V22, P1048; SNOEK JW, 1989, MILD HEAD INJURY, P102; TORNEI G, 1996, J NEUROSURGERY SCI, V40, P11	7	18	18	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2001	15	3					273	277					5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100007	11260775				2021-06-18	
J	Zwienenberg, M; Muizelaar, JP				Zwienenberg, M; Muizelaar, JP			Cerebral perfusion and blood flow in neurotrauma	NEUROLOGICAL RESEARCH			English	Article						cerebral blood flow; cerebral blood volume; cerebral metabolism; ischemia; autoregulation; CO2-reactivity	SEVERE HEAD-INJURY; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; ENDOTHELIN-RECEPTOR-ANTAGONIST; TRAUMATIC BRAIN INJURY; INTRACRANIAL-PRESSURE; ISCHEMIC BRAIN; PROLONGED HYPERVENTILATION; AGGRESSIVE TREATMENT; COMATOSE PATIENTS; AUTO-REGULATION	Post-traumatic cerebral ischemia is associated with a poor prognosis. Optimization of cerebral perfusion and blood flow thus plays a key role in contemporary head injury management However, understanding of the pathophysiology of severe head injury is required for optimal patient management. This article explains the relationships between cerebral blood flow and metabolism and summarizes the current understanding of how these parameters can be helpful in the treatment of patients with severe head injuries.	Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA	Muizelaar, JP (corresponding author), Univ Calif Davis, Dept Neurol Surg, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	j.paul.muizelaar@ucdmc.ucdavis.edu					ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; BOUMA G, 1993, THESIS U AMSTERDAM; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Caner HH, 1996, J NEUROSURG, V85, P917, DOI 10.3171/jns.1996.85.5.0917; Chesnut R M, 1991, Neurosurg Clin N Am, V2, P267; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; EKSTEDT J, 1978, J NEUROL NEUROSUR PS, V41, P345, DOI 10.1136/jnnp.41.4.345; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HIROSE H, 1995, EUR J PHARMACOL, V277, P77, DOI 10.1016/0014-2999(95)00070-2; HIROSE H, 1995, EUR J PHARMACOL, V284, P335, DOI 10.1016/0014-2999(95)00446-R; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; KORITOS HA, 1978, AM J PHYSIOL, V234, pH371; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Monro Alexander, 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pierre LN, 1999, STROKE, V30, P638, DOI 10.1161/01.STR.30.3.638; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROUX S, 1995, NEUROSURGERY, V37, P78, DOI 10.1227/00006123-199507000-00012; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Sobey CG, 1998, CLIN EXP PHARMACOL P, V25, P867, DOI 10.1111/j.1440-1681.1998.tb02337.x; TEASDALE G, 1974, LANCET, V2, P81; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Zimmermann M, 1997, J Neurosurg Sci, V41, P139; Zimmermann M, 1996, NEUROSURGERY, V38, P115, DOI 10.1097/00006123-199601000-00028; Zimmermann M, 1996, ZBL NEUROCHIR, V57, P143; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083; ZUCCARELLO M, 1995, AM J PHYSIOL-HEART C, V269, pH1009	64	18	19	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					167	174		10.1179/016164101101198505			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200008	11320595				2021-06-18	
J	Allain, P; Etcharry-Bouyx, F; Le Gall, D				Allain, P; Etcharry-Bouyx, F; Le Gall, D			A case study of selective impairment of the central executive component of working memory after a focal frontal lobe damage	BRAIN AND COGNITION			English	Article; Proceedings Paper	19th Annual Mid-Year Meeting of the International-Neuropsychological-Society	JUN 19-22, 1996	VELDHOVEN, NETHERLANDS	Int Neuropsychol Soc			SORTING TEST-PERFORMANCE; UTILIZATION BEHAVIOR; PREFRONTAL CORTEX; SCRIPTS; LESIONS; TASKS; REPRESENTATION; DEMENTIA; DISEASE; SYSTEM	RC is a 36-year-old man who sustained a closed head injury with bilateral frontal lobe hypometabolism in 1978. In 1994, after a lobectomy of a large part of the left frontal lobe, he presented no behavioral disruption and normal performances on most of intelligence, longterm memory, and executive tests. However, he showed deficits in tasks that implicate short-term storage (i.e.. span tasks). These deficits in working memory were explored with regard to Baddeley's model using computerized tasks. On these tasks RC showed normal functioning of the articulatory loops and dysfunction of the central executive component in dual tasks. These results confirm those reported in another single case study by Van Der Linden, Coyette, and Seron (1993) and indicate that dual-task performance may assess one separable feature of executive functions. (C) 2001 Academic Press.	CHU Angers, Dept Neurol, Unite Neuropsychol, Psychol Lab, F-49033 Angers 01, France; Univ Angers, Psychol Lab, Angers, France	Allain, P (corresponding author), CHU Angers, Dept Neurol, Unite Neuropsychol, Psychol Lab, 4 Rue Larrey,EA 2646, F-49033 Angers 01, France.			ALLAIN, Philiooe/0000-0003-0668-0986			ABBOTT V, 1985, J MEM LANG, V24, P179, DOI 10.1016/0749-596X(85)90023-3; Agniel A, 1987, PROTOCOLE EVALUATION; Allain P, 1999, J CLIN EXP NEUROPSYC, V21, P643, DOI 10.1076/jcen.21.5.643.871; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Aubin G, 1997, REV NEUROPSYCHOL, V7, P411; AUBIN G, 1994, REV NEUROPSYCHOL, V4, P437; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; BADDELEY A, 1992, Q J EXP PSYCHOL-A, V44, P1, DOI 10.1080/14640749208401281; Baddeley A, 1990, HUMAN MEMORY THEORY; Baddeley A., 1974, PSYCHOL LEARNING MOT, V8; Baddeley A. D., 1986, WORKING MEMORY; Baddeley A. D., 1997, METHODOLOGY FRONTAL, P61; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BADDELEY AD, 1997, NEUROPSYCHOLOGY, V2, P187; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BELLEVILLE S, 1992, BRAIN LANG, V43, P713, DOI 10.1016/0093-934X(92)90092-S; Belleville S, 1992, BATTERIE EVALUATION; BRAZZELLI M, 1994, CORTEX, V30, P27, DOI 10.1016/S0010-9452(13)80323-1; Brooks DN, 1994, EVALUATION TRAUMATIS; BURGESS PW, 1994, REV NEUROPSYCHOL, V4, P345; Cowey CM, 1996, MEMORY, V4, P19, DOI 10.1080/741940668; CREPEAU F, 1997, NEUROPSYCHOLOGICAL R, V2, P147; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; Damasio H., 1989, LESION ANAL NEUROPSY; DeRenzi E, 1996, J NEUROL NEUROSUR PS, V61, P396, DOI 10.1136/jnnp.61.4.396; DEROUESNE C, 1994, REV NEUROPSYCHOL, V3, P273; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DUBOIS B, 1994, NEUROPSYCHOLOGIE HUM, P453; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FASOTTI L, 1992, ARITHMETICAL WORD PR; FASOTTI L, 1999, NEUROPSYCHOLOGIE LOB, P255; Fasotti L., 1992, NEUROPSYCHOL REHABIL, V2, P3, DOI DOI 10.1080/09602019208401392; FASOTTI L, 1994, J CLIN EXPT NEUROPSY, V5, P723; FRISK V, 1990, NEUROPSYCHOLOGIA, V28, P121, DOI 10.1016/0028-3932(90)90095-6; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; Grafman J., 1989, INTEGRATING THEORY P, P93; GRAFMAN J, 1994, HDB NEUROPSYCHOLOGY, V9; GRAFMAN J, 1994, NEUROPSYCHOLOGY HDB, V15; HANLEY JR, 1991, Q J EXP PSYCHOL-A, V43, P101, DOI 10.1080/14640749108401001; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Heaton R., 1993, WISCONSIN CARD SORTI; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; JOANETTE Y, 1989, PENO PROTOCOLE EVALU; LEGALL D, 1993, REV NEUROPSYCHOL, V1, P87; LEGALL D, 1993, TETRALOGIQUES, V8, P64; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; LHERMITTE F, 1986, ANN NEUROL, V19, P335, DOI 10.1002/ana.410190405; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; LHERMITTE F, 1972, REV NEUROL-FRANCE, V127, P415; Luria A. R., 1966, HIGHER CORTICAL FUNC; LURIA AR, 1967, TROUBLES RESOLUTION; Mayer N., 1990, NEUROPSYCHOLOGY EVER, P259; MAZAUX JM, 1981, BOSTON DIAGNOSTIC AP; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MORRIS RG, 1984, COGNITIVE NEUROPSYCH, V1, P143, DOI 10.1080/02643298408252019; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; RAVEN JC, 1982, PROGR MATRICES COU A; RAVEN JC, 1982, PROGR MATRICES COU C; RAVEN JC, 1982, PROGR MATRICES COU D; RAVEN JC, 1982, PROGR MATRICES COU B; RAVEN JC, 1982, PROGR MATRICES COU E; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REY A, 1968, EPREUVES MNESIQUES A; Rey A., 1958, LEXAMEN CLINIQUE PSY; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Schank R., 1977, SCRIPTS PLANS GOALS; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sirigu A, 1996, CORTEX, V32, P297, DOI 10.1016/S0010-9452(96)80052-9; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TRUELLE JL, 1995, NEUROPSY NEUROPSY BE, V8, P14; VALLAR G, 1984, J VERB LEARN VERB BE, V23, P151, DOI 10.1016/S0022-5371(84)90104-X; Vallar G, 1997, NEUROPSYCHOLOGIA, V35, P795, DOI 10.1016/S0028-3932(96)00127-3; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; WATERS GS, 1991, COGNITIVE NEUROPSYCH, V8, P82; WECHSLER D, 1991, ECHELLE CLIN MEMOIRE; Wechsler D, 1989, ECHELLE INTELLIGENCE; Wilson B.A., 1997, METHODOLOGY FRONTAL, P239; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1996, BEHAV ASSESSMENT DYS	97	18	18	0	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	FEB	2001	45	1					21	43		10.1006/brcg.2000.1249			23	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	403UF	WOS:000167060300003	11161360				2021-06-18	
J	Brors, M; Schafers, M; Schick, B; Dazert, S; Draf, W; Kahle, G				Brors, M; Schafers, M; Schick, B; Dazert, S; Draf, W; Kahle, G			Sigmoid and transverse sinus thrombosis after closed head injury presenting with unilateral hearing loss	NEURORADIOLOGY			English	Article; Proceedings Paper	4th European-Skull-Base-Society Congress	MAY 19-22, 1999	NURNBERG, GERMANY	European Skull Base Soc		Sigmoid sinus thrombosis; head injury; magnetic resonance imaging; magnetic resonance angiography		Sinus thrombosis has rarely been associated with closed head injury; more often, thrombosis of the sigmoid or transverse sinus is caused by otogenic inflammations or tumours, or occurs during pregnancy. Symptoms are frequently vague, while untreated thrombus progression may be fatal due to venous congestion and infarction. We report a 32-year-old man presenting with right hearing loss, tinnitus and headache 2 days after a closed head injury. Neurological examination showed no additional abnormality. The EEG showed focal bifrontal slowing. CT revealed a fracture of the occipital bone. MRI and MRA demonstrated complete thrombosis of the right sigmoid and transverse sinuses. After 2 weeks of intravenous heparin therapy followed by warfarin, the patient's hearing improved and MRI and MRA showed complete recanalisation of the sigmoid and transverse sinuses. Venous sinus thrombosis can be an undetected sequel to head injury. Appropriate imaging studies should be carried out to enable therapy to be started as soon as possible.	Univ Hosp Wurzburg, Dept Otorhinolaryngol Head & Neck Surg, D-97080 Wurzburg, Germany; Klinikum Fulda, Dept Ear Nose & Throat Dis Head Neck & Facial Pla, Fulda, Germany; Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany; Univ Hosp Wurzburg, Dept Otorhinolaryngol Head & Neck Surg, Wurzburg, Germany; Hosp Fulda, Dept Radiol, Fulda, Germany	Brors, M (corresponding author), Univ Hosp Wurzburg, Dept Otorhinolaryngol Head & Neck Surg, Josef-Schneider Str 12, D-97080 Wurzburg, Germany.	dominik.brors@mail.uni-wuerzburg.de					BJORNEBRINK J, 1976, ANGIOLOGY, V27, P688, DOI 10.1177/000331977602701203; DAVELLA D, 1984, J NEUROSURG, V61, P1129, DOI 10.3171/jns.1984.61.6.1129; HULCELLE PJ, 1989, NEURORADIOLOGY, V31, P217, DOI 10.1007/BF00344346; KAPP J, 1985, NEUROSURGERY, P1300; KINAL M, 1967, J NEUROSURG, V27, P215; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; LENZ RP, 1984, LARYNGOSCOPE, V94, P1451; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; MAS JL, 1990, STROKE, V21, P1350, DOI 10.1161/01.STR.21.9.1350; NISSEN A J, 1980, American Journal of Otology, V2, P164; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; SCOTT JA, 1988, J NEUROSURG, V68, P284, DOI 10.3171/jns.1988.68.2.0284; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; TSURUDA JS, 1991, AM J NEURORADIOL, V12, P481; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494	15	18	20	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	FEB	2001	43	2					144	146		10.1007/PL00006045			3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	401CY	WOS:000166910600006	11326560				2021-06-18	
J	Sinha, M; Kennedy, CS; Ramundo, ML				Sinha, M; Kennedy, CS; Ramundo, ML			Artificial neural network predicts CT scan abnormalities in pediatric patients with closed head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	National Congress on Childhood Emergencies	MAR, 2000	BALTIMORE, MARYLAND			artificial neural networks; closed head injury; clinical prediction; predictive models	ACUTE MYOCARDIAL-INFARCTION; COMPUTED-TOMOGRAPHY; BRAIN INJURY; CHILDREN; TRAUMA; IDENTIFY	Background: Artificial neural networks (ANNs) use nonlinear statistical modeling techniques to explore relationships in complex clinical situations. This study compared predictive ability of a trained ANN model to that of physician prediction of cranial computed tomographic (CT) scan abnormalities in children with head injury, Methods: A prospective cohort of 351 patients who presented with head trauma and underwent CT scans were studied. All pertinent data on historical and demographic information, and clinical features were recorded, Emergency department physicians used clinical judgment to record pretest probability of abnormal CT scans for all patients prospectively, Similar data front a retrospective chart review of 382 patients with head injury in the immediate preceding year were collected and used to train the ANN, Data from the prospective study was used to validate the ANN, construct a logistic regression model, and compare physician prediction. Results: Forty-five (12.9%) of 351 patients had abnormal CT scans. In predicting CT scan abnormality, the ANN model was more sensitive (82.2%) compared with physician prediction (62.2%). Conclusion: ANNs may serve as a useful aid for decision support for emergency physicians in predicting intracranial abnormalities in closed head injury.	Childrens Hosp, Med Ctr, Div Pediat Emergency Med, Akron, OH 44308 USA	Sinha, M (corresponding author), 30 Chittaranjan Pk, New Delhi 110019, India.						BAXT WG, 1992, ANN EMERG MED, V21, P1439, DOI 10.1016/S0196-0644(05)80056-3; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; Baxt WG, 1996, LANCET, V347, P12, DOI 10.1016/S0140-6736(96)91555-X; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; Bottaci L, 1997, LANCET, V350, P469, DOI 10.1016/S0140-6736(96)11196-X; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Heden B, 1997, CIRCULATION, V96, P1798, DOI 10.1161/01.CIR.96.6.1798; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; PATIL S, 1993, CHEST, V104, P1685, DOI 10.1378/chest.104.6.1685; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; RIVARA F, 1987, PEDIATRICS, V80, P579; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; THORNBURY JR, 1984, AM J ROENTGENOL, V143, P661	19	18	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2001	50	2					308	312		10.1097/00005373-200102000-00018			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	404WL	WOS:000167125000028	11242297				2021-06-18	
J	Solomon, NP; McKee, AS; Garcia-Barry, S				Solomon, NP; McKee, AS; Garcia-Barry, S			Intensive voice treatment and respiration treatment for hypokinetic-spastic dysarthria after traumatic brain injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article; Proceedings Paper	1998 Annual Convention of the American-Speech-Language-Hearing-Association	NOV, 1998	SAN ANTONIO, TX	Amer Speech Language Hearing Assoc		LSVT; TBI; dysarthria; breathing; voice; physical therapy; treatment efficacy	LARYNGEAL AIRWAY-RESISTANCE; PARKINSONS-DISEASE; PALLIDOTOMY SURGERY; SPEECH PRODUCTION; VOWEL PRODUCTION; CHEST WALL; RIB CAGE; ABDOMEN; AGE	The short-term efficacy of the Lee Silverman Voice Treatment (LSVT) and the short- and long-term efficacy of LSVT exercises combined with respiration treatment and physical therapy (Combination Treatment) were examined for a young man diagnosed with mixed hypokinetic-spastic dysarthria 20 months after sustaining a traumatic brain injury (TBI). The efficacy of the LSVT, an intensive 4-week program that focuses on increased vocal effort, is well documented for idiopathic Parkinson's disease. This is the first known published account of the use of LSVT with TBI. Breathing and speech function were assessed by spirometry, respiratory kinematics, intelligibility, and other selected acoustic and auditory-perceptual measures. Improvements generally were minor and inconsistent after LSVT, although sound pressure level (SPL) and loudness increased notably. After an additional 6 weeks of intensive Combination Treatment, gains were documented for resting and speech breathing. Moreover, SPL increased further and sentence intelligibility improved substantially. The gains were maintained to varying degrees after 10 weekly sessions of Combination Treatment. Although several measures returned to baseline 3 months after treatment ceased, some improvements in resting and speech breathing remained. Most important clinically, improvements in vocal SPL and sentence intelligibility persisted.	Univ Minnesota, Minneapolis, MN 55455 USA; Courage Ctr, Minneapolis, MN USA	Solomon, NP (corresponding author), Univ Minnesota, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.			Solomon, Nancy/0000-0002-5018-7569			BROWN RG, 1988, BRAIN, V111, P323, DOI 10.1093/brain/111.2.323; Burke D, 1988, Adv Neurol, V47, P401; Countryman S., 1993, J MED SPEECH-LANG PA, V1, P233; Countryman S, 1994, J MED SPEECH-LANG PA, V2, P211; Duffy J. R., 2020, MOTOR SPEECH DISORDE; DWORKIN JP, 1991, MOTOR SPEECH DISORDE; Fairbanks G., 1960, VOICE ARTICULATION D, V, 2nd ed; Hagen C, 1979, REHABILITATION HEAD; HIXON TJ, 1976, J SPEECH HEAR RES, V19, P297, DOI 10.1044/jshr.1902.297; HIXON TJ, 1973, J SPEECH HEAR RES, V16, P78, DOI 10.1044/jshr.1601.78; HOIT JD, 1987, J SPEECH HEAR RES, V30, P351, DOI 10.1044/jshr.3003.351; McHenry MA, 1998, NEUROMOTOR SPEECH DISORDERS, P167; MELCON MC, 1989, J SPEECH HEAR DISORD, V54, P282, DOI 10.1044/jshd.5402.282; Ramig L., 1994, J MED SPEECH LANG PA, V2, P191; Ramig LO, 1996, NEUROLOGY, V47, P1496, DOI 10.1212/WNL.47.6.1496; RAMIG LO, 1995, J SPEECH HEAR RES, V38, P1232, DOI 10.1044/jshr.3806.1232; Schulz GM, 1999, J SPEECH LANG HEAR R, V42, P1176, DOI 10.1044/jslhr.4205.1176; SMITHERAN JR, 1981, J SPEECH HEAR DISORD, V46, P138, DOI 10.1044/jshd.4602.138; TEASDALE G, 1974, LANCET, V2, P81; Theodoros DG, 1999, J MED SPEECH-LANG PA, V7, P157; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; VERDOLINI K, 1997, ASHA, V39, P34; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; WILSON BA, 1995, HDB MEMORY DISORDERS, P451; Woodcock R. W., 1989, WOODCOCK JOHNSON PSY; Yorkston K. M., 1984, ASSESSMENT INTELLIGI	26	18	18	0	13	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	FEB	2001	10	1					51	64		10.1044/1058-0360(2001/008)			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	405KF	WOS:000167158000009					2021-06-18	
J	Bowen, A; Tennant, A; Neumann, V; Chamberlain, MA				Bowen, A; Tennant, A; Neumann, V; Chamberlain, MA			Neuropsychological rehabilitation for traumatic brain injury: do carers benefit?	BRAIN INJURY			English	Article							HEAD-INJURY	This study evaluated the effectiveness of a new rehabilitation service, compared with existing services, for carers of people with traumatic brain injury (TBI). Subjects were 96 adult carers of people consecutively admitted to two local hospitals. They were assigned to one of three groups: Early new service (pre-discharge); Late new service (post-discharge); or a Control condition (existing services only). Individual randomization was not possible and randomization by hospital site was rejected because of demographic and clinical differences between sites. Group assignment was determined by a pre-specified timetable which alternated between hospitals. Two outcomes were compared at 6 months post-injury: carers' emotional distress and how well-informed they felt about TBI and available resources. Analyses adjusting for potential confounding factors confirmed a clinically plausible superior outcome for both intervention groups compared to the control group. However, these differences did not obtain statistical significance (p greater than or equal to 0.01). Several reasons for these findings are discussed, including the novelty of the new service and methodological issues such as statistical power. Longer term follow-up studies are required as psychological sequelae and, therefore, the need for intervention is known to increase with time and may not be most apparent during the first 6 months.	Univ Leeds, Rheumatol & Rehabil Res Unit, Leeds, W Yorkshire, England	Bowen, A (corresponding author), Hope Hosp, Stroke Assoc, Therapy Res Unit, 1st Floor Clin Sci Bldg,Eccles Old Rd, Salford M6 8HD, Lancs, England.		Bowen, Audrey/K-5544-2012	Bowen, Audrey/0000-0003-4075-1215			Bowen A, 1999, NEUROREHABILITATION, V13, P147; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; MCMORDIE W R, 1991, Brain Injury, V5, P43, DOI 10.3109/02699059108998510; *MED DIS SOC WORK, 1988, MAN TRAUM BRAIN INJ	9	18	20	0	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2001	15	1					29	38		10.1080/02699050150209101			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	384UF	WOS:000165963600003	11201312				2021-06-18	
J	Ratzliff, ADH; Soltesz, I				Ratzliff, ADH; Soltesz, I			Differential immunoreactivity for alpha-actinin-2, an N-methyl-D-aspartate-receptor/actin binding protein, in hippocampal interneurons	NEUROSCIENCE			English	Article						dentate gyrus; cytoskeleton; development; hippocampus; NPY; trauma	RAT DENTATE GYRUS; TRAUMATIC BRAIN INJURY; LONG-TERM POTENTIATION; POSTNATAL MURINE HIPPOCAMPUS; MESSENGER-RNA EXPRESSION; NEUROPEPTIDE-Y; ALPHA-ACTININ; NMDA RECEPTOR; GRANULE CELLS; AMPA RECEPTORS	Recent studies have demonstrated that hippocampal interneurons possess distinct cytoskeletal and cell-signaling proteins in comparison to hippocampal principal cells; however, little is known about the differences in the actin cytoskeleton between these two populations. This study examined the immunoreactivity of alpha -actinin-2, an actin binding/N-methyl-D-aspartate-receptor linking protein, in the rat hippocampal formation using double-labelling immunofluorescence. Alpha-actinin-2 immunoreactivity is seen throughout the hippocampus with heavy labeling observed in the dendrites of granule cells, in CA2 pyramidal cells and in presumed interneuronal somata throughout the dentate gyrus and CA1. All the cells with heavy somatic a-actinin-2 immunoreactivity in the dentate gyrus and CA1 were GABAergic interneurons labeled by glutamate decarboxylase (99%). Examination of the neurochemical marker content of the alpha -actinin-2 immunoreactive interneurons revealed that the majority of this population was neuropeptide-Y-positive and a minority was positive for calretinin. Fluid percussion head trauma did not result in significant alterations of alpha -actinin-2 immunoreactivity in hippocampal interneurons. The developmental profile of alpha -actinin-2 immunoreactivity showed the presence of alpha -actinin-2 in the hippocampus at P1, labeling of interneurons by P7 and the adult staining pattern seen by P21. This study demonstrates that principal cells and interneurons are differentially immunoreactive for alpha -actinin-2, and that alpha -actinin-2 staining is restricted to a subpopulation of interneurons. Each of the three classes of cytoskeletal elements have been shown to be differentially expressed in hippocampal interneurons and principal cells, suggesting that the cytoskeleton is a defining feature of neuronal populations. Additionally, the limited expression of alpha -actinin-2 could have important functional implications in N-methyl-D-aspartate receptor localization and modulation. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Ratzliff, ADH (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	adehaasj@uci.edu		Ratzliff, Anna/0000-0002-6654-8007	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS035915, R01NS035915, R29NS035915] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08620] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35915] Funding Source: Medline		Acsady L, 1997, J COMP NEUROL, V378, P320; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; Allison DW, 1998, J NEUROSCI, V18, P2423; BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BUCHAN AMJ, 1988, PEPTIDES, V9, P333, DOI 10.1016/0196-9781(88)90269-0; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289; Charton JP, 1999, BRAIN RES, V816, P609, DOI 10.1016/S0006-8993(98)01243-8; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; DELLER T, 1990, J COMP NEUROL, V300, P433, DOI 10.1002/cne.903000312; DEQUIDT ME, 1986, NEUROSCIENCE, V18, P545, DOI 10.1016/0306-4522(86)90057-6; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dupuy ST, 1996, J NEUROSCI, V16, P6919; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; GULYAS AI, 1992, NEUROSCIENCE, V48, P1, DOI 10.1016/0306-4522(92)90334-X; Gulyas AI, 1996, J NEUROSCI, V16, P3397; GULYAS AI, 1990, NEUROSCIENCE, V37, P31, DOI 10.1016/0306-4522(90)90189-B; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; Hollrigel GS, 1998, J NEUROPHYSIOL, V80, P2340; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; Kim CH, 1999, J NEUROSCI, V19, P4314; Klapstein GJ, 1997, J NEUROPHYSIOL, V78, P1651; KOHLER C, 1987, NEUROSCI LETT, V78, P1, DOI 10.1016/0304-3940(87)90551-9; KOHLER C, 1986, J COMP NEUROL, V244, P384, DOI 10.1002/cne.902440310; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; LERANTH C, 1992, EPILEPSY RES, P49; Liu XB, 1997, NEUROREPORT, V8, P1475, DOI 10.1097/00001756-199704140-00030; Liu XB, 1996, P NATL ACAD SCI USA, V93, P7332, DOI 10.1073/pnas.93.14.7332; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUBBERS K, 1985, NEUROSCI LETT, V62, P317, DOI 10.1016/0304-3940(85)90568-3; LUBBERS K, 1988, ANAT EMBRYOL, V178, P119, DOI 10.1007/BF02463645; MACCAFERRI G, 1995, NEURON, V15, P137, DOI 10.1016/0896-6273(95)90071-3; Martinez A, 1999, J COMP NEUROL, V404, P438, DOI 10.1002/(SICI)1096-9861(19990222)404:4<438::AID-CNE2>3.0.CO;2-K; Matus A, 1999, CURR OPIN NEUROBIOL, V9, P561, DOI 10.1016/S0959-4388(99)00018-5; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McBain CJ, 1997, CAN J PHYSIOL PHARM, V75, P488, DOI 10.1139/cjpp-75-5-488; McBain CJ, 1999, TRENDS NEUROSCI, V22, P228, DOI 10.1016/S0166-2236(98)01347-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MORRISETT RA, 1990, DEV BRAIN RES, V56, P257, DOI 10.1016/0165-3806(90)90090-L; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; Petralia RS, 1999, NAT NEUROSCI, V2, P31; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Pinkstaff JK, 1998, MOL BRAIN RES, V55, P265, DOI 10.1016/S0169-328X(98)00007-2; Qian J, 1997, J NEUROSCI, V17, P8169; Rao A, 1998, J NEUROSCI, V18, P1217; Ratzliff AD, 2000, HIPPOCAMPUS, V10, P162; Redrobe JP, 1999, BRAIN RES, V848, P153, DOI 10.1016/S0006-8993(99)02119-8; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; Schwarzer C, 1996, BRAIN RES REV, V22, P27; SERESS L, 1993, NEUROSCIENCE, V55, P775, DOI 10.1016/0306-4522(93)90441-H; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SORIANO E, 1989, J COMP NEUROL, V281, P603, DOI 10.1002/cne.902810409; SORIANO E, 1994, J COMP NEUROL, V342, P571, DOI 10.1002/cne.903420406; SPERK G, 1992, NEUROSCIENCE, V50, P831, DOI 10.1016/0306-4522(92)90207-I; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; Tamamaki N, 1999, J COMP NEUROL, V411, P257; Toth Z, 1997, J NEUROSCI, V17, P8106; van Rossum D, 1999, TRENDS NEUROSCI, V22, P290, DOI 10.1016/S0166-2236(99)01404-6; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Whittaker E, 1999, BRAIN RES, V827, P229, DOI 10.1016/S0006-8993(99)01302-5; WINSKY L, 1989, P NATL ACAD SCI USA, V86, P10139, DOI 10.1073/pnas.86.24.10139; Wintergerst ES, 1996, NEUROSCI LETT, V209, P173, DOI 10.1016/0304-3940(96)12643-4; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; ZAFIROV S, 1994, J COMP NEUROL, V345, P472, DOI 10.1002/cne.903450312; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhang WD, 1999, J NEUROSCI, V19, P96	85	18	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	103	2					337	349		10.1016/S0306-4522(01)00013-6			13	Neurosciences	Neurosciences & Neurology	414ZD	WOS:000167695300005	11246149				2021-06-18	
J	Stover, JF; Beyer, TF; Unterberg, AW				Stover, JF; Beyer, TF; Unterberg, AW			Riluzole reduces brain swelling and contusion volume in rats following controlled cortical impact injury	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; cell swelling; cerebrospinal fluid; glutamate; hypoxanthine; taurine; traumatic brain injury	NEUROPROTECTIVE AGENT RILUZOLE; FOCAL CEREBRAL-ISCHEMIA; EXTRACELLULAR GLUTAMATE; TAURINE; RELEASE; EDEMA; NMDA; ACCUMULATION; HIPPOCAMPUS; ANTAGONISM	Modulation of the glutamatergic and excitotoxic pathway may attenuate secondary damage following traumatic brain injury by reducing presynaptic glutamate release and blocking sodium channels in their inactivated state. The aim of the present study was to investigate the neuroprotective potential of riluzole in traumatic brain-injured rats. A left temporoparietal contusion was induced in 70 male Sprague-Dawley rats (controlled cortical impact injury). Riluzole (8 mg/kg body weight) was given 30 min, and 6, 24, and 30 h after trauma, while control rats received physiological saline. Experiments were performed at two different degrees of trauma severity as defined by penetration depth of the impactor rod (1 vs. 1.5 mm) with the aim of investigating impact of severity of tissue damage on the neuroprotective potential of riluzole. At 48 h after trauma, brains were removed to determine hemispheric swelling and water content and to assess cortical contusion volume. Before brain removal cisternal cerebrospinal fluid (CSF) was collected in all rats to determine the effects of riluzole on substances associated with edema formation. For this, the excitatory transmitter glutamate, the volume-regulatory amino acid taurine, and the ATP-degradation product hypoxanthine were analyzed by high-performance liquid chromatography. Overall, the degree of tissue damage seems to influence the neuroprotective potential of riluzole. In rats with a less severe trauma (l-mm penetration depth), hemispheric swelling, cerebral water content of the traumatized hemisphere and cortical contusion volume were significantly reduced under riluzole compared to controls (p < 0.05). In rats with a more severe trauma (1.5-mm penetration depth), the neuroprotective effect of riluzole failed to reach statistical significance. Following trauma, CSF glutamate, taurine, and hypoxanthine levels were significantly increased compared to nontraumatized rats (p < 0.001). However, these neurochemical parameters as measured in cisternal CSF failed to reflect trauma-dependent increases in severity of tissue damage and did not reveal riluzole-mediated neuroprotection. Under the present study design, riluzole significantly reduced brain edema formation and contusion volume in rats subjected to a mild focal cortical contusion.	Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany	Stover, JF (corresponding author), Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 01, D-13353 Berlin, Germany.	john.stover@charite.de					Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; Bezard E, 1998, EUR J PHARMACOL, V356, P101, DOI 10.1016/S0014-2999(98)00537-8; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; Bryson HM, 1996, DRUGS, V52, P549, DOI 10.2165/00003495-199652040-00010; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Centonze D, 1998, NEUROPHARMACOLOGY, V37, P1063, DOI 10.1016/S0028-3908(98)00081-1; CHERAMY A, 1992, NEUROSCI LETT, V147, P209, DOI 10.1016/0304-3940(92)90597-Z; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; Doble A., 1997, REV CONTEMP PHARMACO, V8, P213; Guyot MC, 1997, NEUROSCIENCE, V81, P141, DOI 10.1016/S0306-4522(97)00192-9; HAGBERG H, 1986, NEUROSCI LETT, V68, P311, DOI 10.1016/0304-3940(86)90508-2; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; HUBERT JP, 1994, BRIT J PHARMACOL, V113, P261, DOI 10.1111/j.1476-5381.1994.tb16203.x; Kanthasamy AG, 1999, J PHARMACOL EXP THER, V288, P1340; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kwon JY, 1998, ANESTH ANALG, V86, P128, DOI 10.1097/00000539-199801000-00026; MAGNUSSON KR, 1991, BRAIN RES, V549, P1, DOI 10.1016/0006-8993(91)90592-J; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1996, LAB INVEST, V74, P315; MENENDEZ N, 1989, NEUROSCI LETT, V102, P64, DOI 10.1016/0304-3940(89)90308-X; Mottet I, 1997, MAGN RESON MATER PHY, V5, P185, DOI 10.1007/BF02594581; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; ONeill MJ, 1997, EUR J PHARMACOL, V332, P121, DOI 10.1016/S0014-2999(97)01074-1; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PASANTESMORALES H, 1990, GLIA, V3, P427, DOI 10.1002/glia.440030514; Pratt J, 1999, NEUROSCI LETT, V272, P143, DOI 10.1016/S0304-3940(99)00005-1; Rao VLR, 1998, J NEUROCHEM, V70, P2020; SAMUEL D, 1992, FUND CLIN PHARMACOL, V6, P177, DOI 10.1111/j.1472-8206.1992.tb00109.x; SARANSAARI P, 1991, NEUROSCIENCE, V45, P451, DOI 10.1016/0306-4522(91)90240-O; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; TABER KH, 1986, BRAIN RES, V386, P113, DOI 10.1016/0006-8993(86)90147-2; Unterberg AW, 1997, ACT NEUR S, V70, P106; Urenjak J, 1996, PHARMACOL REV, V48, P21; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zona C, 1998, NEUROSCIENCE, V85, P931, DOI 10.1016/S0306-4522(97)00604-0	47	18	21	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1171	1178		10.1089/neu.2000.17.1171			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900005	11186230				2021-06-18	
J	Stowe, CD; Lee, KR; Storgion, SA; Phelps, SJ				Stowe, CD; Lee, KR; Storgion, SA; Phelps, SJ			Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article							ACUTE-PHASE RESPONSE; MICHAELIS-MENTEN PHARMACOKINETICS; OXIDATIVE DRUG-METABOLISM; DIETARY-PROTEIN; CYTOCHROME-P-450 ENZYMES; THEOPHYLLINE METABOLISM; PEDIATRIC-PATIENTS; HUMAN HEPATOCYTES; PRIMARY CULTURE; CARBOHYDRATE	The purpose of this study was to determine if phenytoin protein binding and metabolism rt ere altered in prepubescent pediatric patients within the first 10 days following severe, acute traumatic brain injury. Patients (n = 10) received phenytoin loading doses (15-20 mg/kg) follow ed by a maintenance regimen (7 mg/kg/day) initiated within 12 hours of the loading dose. Phenytoin serum concentrations were measured serially on days 1, 2, 3, 5, 7 9, and 10 at 1, 6, and 12 hours. Time-invariant and time-variant Michaelis-Menten pharmacokinetic models were fit to the unbound phenytoin concentration-time data (ADAPT II(TM)). Albumin concentrations significantly decreased over time (p < 0.001) and were predictive of the phenytoin binding ratio (r(2) = 0.373, p < 0.0001). The time-variant model provided a superior fit of th e data in 7 patients with no difference between models in 3 pa tien ts. Rapid inhibition of metabolism (Vmax(baseline) = 2.82 +/- 2.35 mg/kg/day) was observed initially following injury. This was followed by induction of metabolism as reflected by a Vmax(induced) of 20.79 +/- 13.71 mg/kg/day, which was approximately twofold higher than reported values for nonstressed children. Children with severe, acute neurotrauma were found to have markedly altered protein binding and phenytoin metabolism. (C)2000 the American College of Clinical Pharmacology.	Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Univ Tennessee, Memphis, TN USA	Stowe, CD (corresponding author), PharmD,800 Marshall St,Mailslot 304, Little Rock, AR 72202 USA.						ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ANDERSON KE, 1979, CLIN PHARMACOL THER, V26, P493, DOI 10.1002/cpt1979264493; ANDERSON KE, 1984, J CLIN ENDOCR METAB, V59, P103, DOI 10.1210/jcem-59-1-103; BAHALOMARA N, 1995, CRIT CARE MED, V23, P1418; BAUER LA, 1983, CLIN PHARMACOKINET, V8, P545, DOI 10.2165/00003088-198308060-00006; BEAL SL, 1983, J PHARMACOKINET BIOP, V11, P641, DOI 10.1007/BF01059062; BOUCHER BA, 1988, CLIN PHARMACOL THER, V44, P675, DOI 10.1038/clpt.1988.211; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; BOUCHER BA, 1987, CLIN PHARMACY, V6, P881; CHIBA K, 1980, J PEDIATR-US, V96, P479; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; FAGAN TC, 1987, CLIN PHARMACOL THER, V41, P402, DOI 10.1038/clpt.1987.48; FELDMAN CH, 1980, PEDIATRICS, V66, P956; GRIEBEL ML, 1990, CRIT CARE MED, V18, P385, DOI 10.1097/00003246-199004000-00007; GRIFFETH LK, 1983, DRUG METAB DISPOS, V11, P517; GRIFFETH LK, 1984, DRUG METAB DISPOS, V12, P582; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; KAPPAS A, 1976, CLIN PHARMACOL THER, V20, P643; KRISHNASWAMY K, 1984, BRIT J CLIN PHARMACO, V17, P139, DOI 10.1111/j.1365-2125.1984.tb02328.x; LACKNER TE, 1991, PHARMACOTHERAPY, V11, P344; LANDAW EM, 1984, AM J PHYSIOL, V246, pR665; Markowsky SJ, 1996, ANN PHARMACOTHER, V30, P443, DOI 10.1177/106002809603000501; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; PANTUCK EJ, 1984, ANESTHESIOLOGY, V60, P534, DOI 10.1097/00000542-198406000-00002; Taketomo CK., 1999, PEDIAT DOSAGE HDB, V6; THOMPSON PJ, 1983, BRIT J CLIN PHARMACO, V16, P267, DOI 10.1111/j.1365-2125.1983.tb02160.x; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; YOSHIDA N, 1993, CRIT CARE MED, V21, P1514, DOI 10.1097/00003246-199310000-00020; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	31	18	18	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	DEC	2000	40	12	2				1452	1461					10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	374MZ	WOS:000165350100006	11185666				2021-06-18	
J	Banik, NL; Matzelle, D; Terry, E; Gantt-Wilford, G; Hogan, EL				Banik, NL; Matzelle, D; Terry, E; Gantt-Wilford, G; Hogan, EL			Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin	NEUROCHEMICAL RESEARCH			English	Article						calpain; cyclooxygenase; free radicals; inhibitor; anti-inflammatory	SPINAL-CORD INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYTOSKELETAL PROTEIN-DEGRADATION; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; CALPAIN-I; NEUROFILAMENT PROTEINS; CATHEPSIN-D; RAT-BRAIN; ACTIVATION	The effect of indomethacin, a non-steroidal anti-inflammatory drug upon purified calpain has been studied. Also, its effects upon Ca2+-mediated degradation of cytoskeletal proteins (neurofilament) in spinal cord homogenate has been investigated. A dose-dependent inhibition of purified calpain activity was observed. A 50% inhibition of C-14-caseinolytic activity was obtained with less than 1.1 mM of indomethacin while the activity was completely inhibited at 3.3 mM concentration. The inhibitory effect of ketorlac, another non-steroidal anti-inflammatory drug, upon calpain was weaker than that of indomethacin. The degradation of myelin basic protein (MBP) by cathepsin B, a lysosomal cysteine protease, was significantly inhibited by indomethacin. It also inhibited the Ca2+-mediated degradation of neurofilament protein (NFP) in spinal cord homogenate. The extent of NFP degradation was analyzed by SDS-PAGE and the inhibition shown by indomethacin was weaker than that observed with leupeptin and the calpain inhibitor E64-d. The inhibitory effect of indomethacin on the activity of multicatalytic proteinase complex was negligible. These results suggest that indomethacin, a non-steroidal anti-inflammatory drug and cyclooxygenase inhibitor also inhibits proteinases, including cathepsin B and calpain.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038146, R01NS031622] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-31622, NS-38146] Funding Source: Medline		BANAYSCHWARTZ M, 1987, NEUROCHEM RES, V12, P361, DOI 10.1007/BF00993246; Banik Naren L., 1992, P571; Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1999, NEUR M MIAM BEACH FL; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Beasley TC, 1998, DEV BRAIN RES, V105, P125, DOI 10.1016/S0165-3806(97)00179-X; BRACKEN MB, 1990, NEW ENGL J MED, V67, P1575; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; CHAN PH, 1985, PROG BRAIN RES, V63, P227; CHOU CHJ, 1978, J NEUROCHEM, V30, P745, DOI 10.1111/j.1471-4159.1978.tb10780.x; COMPSTON A, 1988, ARCH NEUROL-CHICAGO, V45, P669, DOI 10.1001/archneur.1988.00520300089025; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS J, 1992, NEUROCHEM RES, V17, P1261, DOI 10.1007/BF00968410; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pasinetti GM, 1998, J NEUROSCI RES, V54, P1; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Shields DC, 1998, EXP EYE RES, V67, P403, DOI 10.1006/exer.1998.0537; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; Singh IN, 1997, NEUROSCI LETT, V222, P5, DOI 10.1016/S0304-3940(97)13327-4; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STRACHER A, 1978, SCIENCE, V200, P50, DOI 10.1126/science.635570; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X	41	18	19	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2000	25	11					1509	1515		10.1023/A:1007684311023			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	369DF	WOS:000090156000008	11071371				2021-06-18	
J	Puig, N; Davalos, A; Adan, J; Piulats, J; Martinez, JM; Castillo, J				Puig, N; Davalos, A; Adan, J; Piulats, J; Martinez, JM; Castillo, J			Serum amino acid levels after permanent middle cerebral artery occlusion in the rat	CEREBROVASCULAR DISEASES			English	Article						excitotoxicity; glutamate; glycine; ischemia; cerebral; amino acids	TRANSIENT GLOBAL-ISCHEMIA; GAMMA-AMINOBUTYRIC-ACID; TRAUMATIC BRAIN INJURY; INVIVO MICRODIALYSIS; EXTRACELLULAR CONCENTRATIONS; GERBIL HIPPOCAMPUS; IN-VIVO; INTRACEREBRAL MICRODIALYSIS; GLUTAMATE NEUROTOXICITY; SYNAPTIC TRANSMISSION	Background and Purpose: High levels of glutamate in plasma and cerebrospinal fluid (CSF) have been demonstrated in patients with acute ischemic stroke. Whereas this glutamate increase in CSF is only evidenced during the first 6 h in stable ischemic stroke, it is sustained for 24 h in progressing stroke. The aim of this investigation was to study the evolution of serum glutamate levels after stroke in a rat model of permanent cerebral artery occlusion. Methods: Glutamate, glycine, aspartate, taurine and tryptophan were measured by high-performance liquid chromatography from serum samples taken before and at different times after permanent middle cerebral artery occlusion (MCAO) and from sham-operated rats. Results:After MCAO, a 3-fold increase in glutamate and a 2-fold increase in glycine and aspartate were observed in rat serum. The onset of this amino acid increase began 4-6 h after ischemic induction, reached peak values at 8-24 h and returned to preischemic values by 48-72 h. Serum concentrations of taurine and tryptophan were not modified after MCAO. Sham-operated rats did not exhibit changes of basal amino acid concentrations in serum. Conclusions: The serum excitatory amino acid profile in this experimental model confirms that the early detection of increased concentrations of glutamate and glycine at systemic circulation observed in patients with acute stroke is a consequence of the cerebral ischemic process. Copyright (C) 2000 S. Karger AG. Basel.	Univ Santiago Compostela, Hosp Clin Univ Santiago, Dept Neurol, E-15705 Santiago De Compostela, Spain; Merck Farma & Quim SA, Dept Pharmacol, Lab Bioinvestigat, Barcelona, Spain; Hosp Doctor Josep Trueta, Neurol Sect, Girona, Spain	Puig, N (corresponding author), Univ Santiago Compostela, Hosp Clin Univ Santiago, Dept Neurol, E-15705 Santiago De Compostela, Spain.			Castillo, Jose/0000-0002-6685-3001; Puig Calvo, Nuria/0000-0001-8235-4934			BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; Berger C, 1999, STROKE, V30, P460, DOI 10.1161/01.STR.30.2.460; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOI KT, 1994, BRAIN RES, V642, P104; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Davson H., 1967, PHYSL CEREBROSPINAL; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; GEMBA T, 1992, NEUROSCI LETT, V135, P184, DOI 10.1016/0304-3940(92)90432-7; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GLOBUS MYT, 1990, STROKE, V21, P43; GORDON KE, 1991, STROKE, V22, P928, DOI 10.1161/01.STR.22.7.928; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; Herz RCG, 1996, BRAIN RES, V715, P163, DOI 10.1016/0006-8993(95)01572-8; HOSSMANN KA, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P239; Kahn RA, 1997, ANESTH ANALG, V84, P997, DOI 10.1097/00000539-199705000-00009; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; MARTINEZ F, 1993, HEADACHE, V33, P324, DOI 10.1111/j.1526-4610.1993.hed3306324.x; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MATSUMOTO K, 1991, BRAIN RES, V543, P236, DOI 10.1016/0006-8993(91)90033-R; MITANI A, 1990, BRAIN RES BULL, V25, P319, DOI 10.1016/0361-9230(90)90077-D; MITANI A, 1994, J NEUROCHEM, V63, P2152; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MIYASHITA K, 1994, NEUROREPORT, V5, P945, DOI 10.1097/00001756-199404000-00023; MONTALBETTI L, 1995, NEUROSCI LETT, V192, P153, DOI 10.1016/0304-3940(95)11632-7; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MYSEROS R, 1995, ANN NY ACAD SCI, V765, P262; NAKATA N, 1994, BRAIN RES BULL, V35, P247, DOI 10.1016/0361-9230(94)90130-9; NAKATA N, 1993, STROKE, V24, P458, DOI 10.1161/01.STR.24.3.458; OJA SS, 1978, TAURINE NEUROLOGICAL, P181; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; Owen AJ, 1997, BRAIN RES, V770, P115, DOI 10.1016/S0006-8993(97)00789-0; PHILLIS JW, 1978, TAURINE NEUROLOGICAL, P289; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1985, J NEUROPHYSIOL, V54, P701; SHIBANOKI S, 1993, J NEUROCHEM, V61, P1698, DOI 10.1111/j.1471-4159.1993.tb09806.x; SHIROTANI T, 1995, STROKE, V26, P878, DOI 10.1161/01.STR.26.5.878; SILVERSTEIN FS, 1991, PEDIATR RES, V30, P587, DOI 10.1203/00006450-199112000-00021; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TURNELL DC, 1982, CLIN CHEM, V28, P527; UCHIYAMATSUYUKI Y, 1994, J NEUROCHEM, V62, P1074; VONLUBITZ DKJE, 1992, EUR J PHARMACOL, V219, P153, DOI 10.1016/0014-2999(92)90594-T; WAHL F, 1994, J NEUROCHEM, V63, P1003; YOUNG RSK, 1992, EXP NEUROL, V117, P204, DOI 10.1016/0014-4886(92)90128-D	55	18	22	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-9770	1421-9786		CEREBROVASC DIS	Cerebrovasc. Dis.	NOV-DEC	2000	10	6					449	454		10.1159/000016106			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	373ND	WOS:000165294800006	11070375				2021-06-18	
J	Golding, EM; Steenberg, ML; Johnson, TD; Bryan, RM				Golding, EM; Steenberg, ML; Johnson, TD; Bryan, RM			The effects of potassium on the rat middle cerebral artery	BRAIN RESEARCH			English	Article						cerebral arteries; inward rectifier K+ channels; nitric oxide; osmolality	EXTRACELLULAR POTASSIUM; SMOOTH-MUSCLE; ASTROCYTE ENDFEET; BRAIN INJURY; BLOOD-FLOW; CIRCULATION; K+; CALCIUM; ENDOTHELIUM; ARTERIOLES	After traumatic brain injury, extracellular K+ in brain can dramatically increase. We studied the effects of increased K+ on the isolated pressurized rat middle cerebral artery (MCA). MCAs (200-250 mum OD) were isolated, cannulated with glass micropipettes, and pressurized. K+ was increased in the extraluminal bath using three paradigms: (1) isotonic K+ (Ki,,) where increases in Kt were offset by decreases in Na+, (2) hypertonic K+ (K-hyper) where K+ was increased without a concomitant adjustment of Na+, and (3) K-suc, a solution using K-iso but with the addition of sucrose to obtain a hypertonic solution. Increases in K+ in the extraluminal bath produced significant dilations (approximately 20%) at 21 mM K+ in all three groups (K-iso, K-hyper, and K-suc). With the K-hyper and K-suc groups, the magnitude of the dilation diminished with further increases in K+. L-NAME (10(-5) M), an inhibitor of nitric oxide synthase, had no effect on the response of the K-hyper and K-suc groups at 21 mM but significantly enhanced constrictions of the MCAs above 40 mM K+ compared to the control. The K-iso group was not affected by L-NAME at any K+ concentration and showed profound constrictions above 40 mM K+. We conclude that changes in the K+ concentration and osmolality of the extracellular fluid may have profound effects on the cerebral vasculature. (C) 2000 Elsevier Science B.V. All rights reserved.	Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Golding, EM (corresponding author), Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; AYDIN F, 1991, STROKE, V22, P1592, DOI 10.1161/01.STR.22.12.1592; Beny JL, 1999, NEWS PHYSIOL SCI, V14, P68; BETZ E, 1976, IONIC ACTIONS VASCUL, P75; Bryan RM, 1996, ANESTHESIOLOGY, V85, P82, DOI 10.1097/00000542-199607000-00012; BRYAN RM, 1995, AM J PHYSIOL-HEART C, V269, pH1171; BUSIJA DW, 1984, REV PHYSIOL BIOCH P, V101, P161, DOI 10.1007/BFb0027696; DAHL E, 1973, Z ZELLFORSCH MIK ANA, V145, P577, DOI 10.1007/BF00306725; Dora KA, 1997, P NATL ACAD SCI USA, V94, P6529, DOI 10.1073/pnas.94.12.6529; EDWARDS FR, 1988, J PHYSIOL-LONDON, V404, P455, DOI 10.1113/jphysiol.1988.sp017299; FARACI FM, 1992, PHARMACOL THERAPEUT, V56, P1, DOI 10.1016/0163-7258(92)90035-X; FARACI FM, 1993, NEUROSURGERY, V33, P648, DOI 10.1227/00006123-199310000-00014; HANSEN AJ, 1978, ACTA PHYSIOL SCAND, V102, P324, DOI 10.1111/j.1748-1716.1978.tb06079.x; HOGESTATT ED, 1984, J PHARMACOL EXP THER, V228, P187; HOGESTATT ED, 1983, ACTA PHYSIOL SCAND, V117, P49, DOI 10.1111/j.1748-1716.1983.tb07178.x; HOSSMANN KA, 1977, BRAIN HEART INFARCT, P107; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Johnson TD, 1998, AM J PHYSIOL-REG I, V274, pR541; Katayama Y, 1998, ACT NEUR S, V71, P289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KNABE U, 1972, VASCULAR SMOOTH MUSC, P83; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KUFFER SW, 1984, NEURON BRAIN SINAUER; KUSCHINSKY W, 1972, CIRC RES, V31, P240, DOI 10.1161/01.RES.31.2.240; LITTLE TL, 1995, AM J PHYSIOL-HEART C, V268, pH729; LITTLE TL, 1995, CIRC RES, V76, P498, DOI 10.1161/01.RES.76.3.498; Marrelli SP, 1998, STROKE, V29, P1469, DOI 10.1161/01.STR.29.7.1469; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902; MCCULLOCH J, 1982, PFLUG ARCH EUR J PHY, V393, P95, DOI 10.1007/BF00582399; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; NEWMAN EA, 1986, SCIENCE, V233, P453, DOI 10.1126/science.3726539; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OSOL G, 1991, CIRC RES, V68, P359, DOI 10.1161/01.RES.68.2.359; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363; RYMAN T, 1989, ACTA PHYSIOL SCAND, V136, P151, DOI 10.1111/j.1748-1716.1989.tb08647.x; SPAGNOLI LG, 1982, EXPERIENTIA, V38, P124, DOI 10.1007/BF01944566; SYKOVA E, 1983, PROG BIOPHYS MOL BIO, V42, P135, DOI 10.1016/0079-6107(83)90006-8; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TODA N, 1974, AM J PHYSIOL, V227, P1206; VARON S S, 1979, Neurosciences Research Program Bulletin, V17, P1; VINALL PE, 1987, STROKE, V18, P92, DOI 10.1161/01.STR.18.1.92; VINALL PE, 1987, BLOOD VESSELS, V24, P51; YONAS H, 1984, J COMPUT ASSIST TOMO, V8, P990, DOI 10.1097/00004728-198410000-00038; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	45	18	18	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 13	2000	880	1-2					159	166		10.1016/S0006-8993(00)02793-1			8	Neurosciences	Neurosciences & Neurology	365MT	WOS:000089955600017	11033000				2021-06-18	
J	Kowalske, K; Plenger, PM; Lusby, B; Hayden, ME				Kowalske, K; Plenger, PM; Lusby, B; Hayden, ME			Vocational reentry following TBI: An enablement model	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						ecological validity; employment; rehabilitation	TRAUMATIC BRAIN INJURY; INTEGRATION; PREDICTORS; WORK	Objective: To illustrate the importance of environmental factors for optimizing return to work following traumatic brain injury (TBI) using illustrative case examples. Design and Participants: Three case studies are presented that were selected from an overall sample of 57 TBI survivors. Setting: Postacute, outpatient TBI rehabilitation program. Main Outcome Measures: Outcome was essentially descriptive and focused on factors associated with successful return to work. Results and Conclusions: These case examples point out the necessity of specialized treatment that not only focuses on the specific strengths and weakness of the individual, but also on extant environmental factors, including degree of structure or distractions that either reinforce or preclude optimal performance.	Univ Texas, SW Med Ctr, Dallas, TX USA; Pate Rehabil, Vocat Programs, Dallas, TX USA	Kowalske, K (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX USA.						Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART T, 1986, CLIN NEUROPSYCHOLOGY; Hayden ME, 2000, J HEAD TRAUMA REHAB, V15, P1000, DOI 10.1097/00001199-200008000-00004; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; 1998, NATL I HLTH CONS DEV, V16, P1	12	18	18	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2000	15	4					989	999		10.1097/00001199-200008000-00003			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	340DK	WOS:000088517700003	10876171				2021-06-18	
J	Cornish, R; Blumbergs, PC; Manavis, J; Scott, G; Jones, NR; Reilly, PL				Cornish, R; Blumbergs, PC; Manavis, J; Scott, G; Jones, NR; Reilly, PL			Topography and severity of axonal injury in human spinal cord trauma using amyloid precursor protein as a marker of axonal injury	SPINE			English	Article						amyloid precursor protein (APP); axonal injury; quantitation; spinal cord trauma	CLOSED-HEAD INJURY; BETA-APP; DAMAGE; BRAIN; RAT; IMMUNOREACTIVITY; PATHOPHYSIOLOGY; UBIQUITIN; DISEASE; MILD	Study Design. Axonal injury was examined in 18 human cases of acute spinal cord compression using amyloid precursor protein as a marker of Al. Objectives. To topographically map and semiquantitate axonal injury in spinal cord compression of sufficient severity to produce para- or quadriplegia. Summary of Background Data, Amyloid precursor protein is carried along the axon by fast axoplasmic transport and has been extensively used as a marker of traumatic axonal injury. Methods. The study group comprised 18 cases of spinal cord compression (17 due to fracture dislocation of the vertebral column and 1 iatrogenic compression from Harrington rods) and two normal control. All the cords were examined according to a standard protocol, and at least 10 segmental levels were immunostained using a monoclonal antibody to amyloid precursor protein and immunopositive Al was semiquantited using a grading system to provide the axonal injury severity score (AISS). The focal injury at the site of cord compression (haemorrhage, haemorrhagic necrosis, ischaemic necrosis) was also semiquantitated to provide the focal injury area score (FIAS). Al occurring around the site of focal compression (focal axonal injury severity score or FAISS) was distinguished from Al distant to the focal injury (nonfocal axonal injury severity score or NFAISS). Results. All 18 cases showed widespread amyloid precursor protein immunoreactive axonal injury and the AISS ranged from 28 to 60%. In all cases, the FAISS was greater than the NFAISS and there was a statistically significant relationship between the AISS and the FIAS. Conclusion. Acute spinal cord compression of sufficient severity to produce permanent paralysis causes widespread axonal damage that is maximal at the site of compression but also present throughout the length of the cord in segments far distant from the site of the focal injury.	Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA 5000, Australia; Univ Adelaide, Adelaide, SA, Australia	Blumbergs, PC (corresponding author), Inst Med & Vet Sci, Neuropathol Lab, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.						AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; Blumbergs PC, 1998, J CLIN NEUROSCI, V5, P123, DOI 10.1016/S0967-5868(98)90026-1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BUNGE RP, 1993, ADV NEUROL, V59, P75; COCHRAN E, 1991, AM J PATHOL, V139, P485; Croul S E, 1997, Adv Neurol, V72, P317; FERREIRA A, 1993, J NEUROSCI, V13, P3112; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; KAKULAS B, 1985, RECENT ACHIEVEMENTS, V1, P163; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; KAKULAS BA, 1992, HDB CLIN NEUROLOGY, V17, P21; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRAUS JF, 1985, CENTRAL NERVOUS SYST, P313; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Olsson Y, 1996, NEUROPATH APPL NEURO, V22, P518, DOI 10.1111/j.1365-2990.1996.tb01129.x; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V15, P49; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; WALSH J, 1987, QUADCARE, V1, P1; YEO JD, 1994, MOD MED AUST, V37, P36	32	18	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	MAY 15	2000	25	10					1227	1233		10.1097/00007632-200005150-00005			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	316AY	WOS:000087146200004	10806498				2021-06-18	
J	Masson, F				Masson, F			Epidemiology of severe brain injuries.	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						head trauma	GLASGOW-COMA-SCALE; MOTORCYCLE-HELMET-USE; SEVERE HEAD-INJURIES; PREVENTION STRATEGIES; TRAUMA CENTERS; POPULATION; MORTALITY; CALIFORNIA; DEATH; DISABILITY	Head injuries (HI) are one of the most common causes of death, morbidity and disabilities in young adults. Epidemiological studies allow a quantitative estimation in terms of incidence and a qualitative estimate for the identification of risk factors in specific populations. These estimates may enable appropriate prevention programs. Estimates of annual incidence rates depend on territories, periods and methodological tools. Annual rates for hospitalized patients are found between 150 and 300/100000 inhabitants. Severity of HI can be assessed by the Glasgow Coma Scale (GCS), the Abbreviated Injury Scale (AIS) or the Post-Traumatic Amnesia duration. Annual incidences of severe HI will depend on the selected score: around 25/100000 inhabitants for cerebral trauma with intracranial injuries, around 9/100000 for the most severe Hi, with an AIS maximum of 5 with coma. The male: female ratio increases with degree of severity. Traffic accidents were the most frequent cause of HI. Many patients have associated injuries, worsening the outcome. Some risk factors are considered. Preventive measures are mainly conducted for traffic accidents, and include speed limit and regulations on helmet or seat belt use. Results of these mesures are analysed. (C) 2000 Editions scientifiques et medicales Elsevier SAS.	Hop Pellegrin, Dept Anesthesie Reanimat 1, F-33076 Bordeaux, France	Masson, F (corresponding author), Hop Pellegrin, Dept Anesthesie Reanimat 1, Pl Amelie Raba Leon, F-33076 Bordeaux, France.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; CAYTEN C G, 1982, Critical Care Quarterly, V5, P79; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; *COMM INJ SCAL, 1990, ABBR INJ SCAL AIS; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Engberg Aase, 1995, Acta Neurologica Scandinavica, V92, P1; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; JAGGER J, 1987, NEUROSURGERY, V20, P815, DOI 10.1227/00006123-198705000-00028; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; KRAUS JF, 1995, J NEUROTRAUM, V12, P873, DOI 10.1089/neu.1995.12.873; LAVECCHIA C, 1994, SOZ PRAVENTIV MED, V39, P150, DOI 10.1007/BF01299659; Lenfant F, 1997, ANN FR ANESTH, V16, P239, DOI 10.1016/S0750-7658(97)86408-8; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MASSON F, 1998, ANN FR ANESTH, V17, P921; MCKENZIE EJ, 1989, MARYLAND MED J, V38, P725; MCKENZIE EJ, 1988, J TRAUMA, V28, P281; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; MOCK CN, 1995, J TRAUMA, V39, P29, DOI 10.1097/00005373-199507000-00004; MORRIS K, 1993, INJURY, V24, P369, DOI 10.1016/0020-1383(93)90097-P; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; ROSS SE, 1992, ACCIDENT ANAL PREV, V24, P181, DOI 10.1016/0001-4575(92)90035-H; Rowland J, 1996, AM J PUBLIC HEALTH, V86, P41, DOI 10.2105/AJPH.86.1.41; RUNE V, 1970, ACTA PAEDIATR SC   S, V209, P1; SALMI R, 1989, ACCIDENT ANAL PREV, V6, P589; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; VIANO DC, 1995, J TRAUMA, V38, P538, DOI 10.1097/00005373-199504000-00013; WALTERS KA, 1992, ARCH EMERG MED, V10, P29; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	48	18	18	0	2	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS CEDEX 15	23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	APR	2000	19	4					261	269					9	Anesthesiology	Anesthesiology	313GX	WOS:000086992900008	10836112				2021-06-18	
J	Bhatt, M; Desai, J; Mankodi, A; Elias, M; Wadia, N				Bhatt, M; Desai, J; Mankodi, A; Elias, M; Wadia, N			Posttraumatic akinetic-rigid syndrome resembling Parkinson's disease: A report on three patients	MOVEMENT DISORDERS			English	Article						parkinsonism; trauma; imaging; MRI	POSITRON EMISSION TOMOGRAPHY; HEAD TRAUMA; MOVEMENT-DISORDERS; BRAIN; PAIRS; TWINS	We describe three patients who developed a rapidly evolving posttraumatic akinetic-rigid syndrome (ARS), the clinical manifestations of which were similar to Parkinson's disease, including response to levodopa. Despite initial imaging studies showing traumatic damage to the substantia nigra, the ARS appeared after a delay of 1-5 months after the injury. We stress the importance of magnetic resonance imaging to illustrate nigral damage in all patients in whom head trauma precedes an ARS.	Jaslok Hosp & Res Ctr, Movement Disorders Clin, Dept Neurol, Bombay 400026, Maharashtra, India	Bhatt, M (corresponding author), Jaslok Hosp & Res Ctr, Movement Disorders Clin, Dept Neurol, 15 G Deshmukh Marg, Bombay 400026, Maharashtra, India.						BenShlomo Y, 1996, J NEUROL NEUROSUR PS, V61, P4, DOI 10.1136/jnnp.61.1.4; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; BHATT MH, 1993, NEUROLOGY, V43, P314, DOI 10.1212/WNL.43.2.314; BURN DJ, 1992, NEUROLOGY, V42, P1894, DOI 10.1212/WNL.42.10.1894; CALNE DB, 1985, NATURE, V317, P246, DOI 10.1038/317246a0; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; GOETZ CG, 1992, NEUROL CLIN, V10, P907; GOETZ CG, 1991, ANN NEUROL, V29, P191, DOI 10.1002/ana.410290213; HORNYKIE.O, 1973, FED PROC, V32, P183; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; KRAUSS JK, 1992, MOVEMENT DISORD, V7, P263, DOI 10.1002/mds.870070313; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; SAINTHILAIRE MH, 1991, NEUROLOGY, V41, P216; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; YOUDIM MBH, 1989, ACTA NEUROL SCAND, V80, P47, DOI 10.1111/j.1600-0404.1989.tb01782.x	20	18	19	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	MAR	2000	15	2					313	317		10.1002/1531-8257(200003)15:2<313::AID-MDS1017>3.0.CO;2-P			5	Clinical Neurology	Neurosciences & Neurology	293WT	WOS:000085878500017	10752583				2021-06-18	
J	Georgievski, AB				Georgievski, AB			Rehabilitation in the community	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article								The Project applied rehabilitation in community (RIC) in Zagreb, Croatia as a model of care with the aim of maximizing physical and mental abilities in a persons' own life environment as well as social integration. From September 96 to June 98, 785 patients with primary physical disablement were admitted: 80% with musculoskeletal conditions, and 20% with traumatic brain or spinal injury, stroke, multiple sclerosis, amputation or rheumatoid arthritis. They were residents of Trnje community (55%), Zagreb area (40%) and Croatia area (5%). Mean age was 44 years (men 39, women 48, range 7-76); 52% of patients were women and 17% were recent war wounded. The RIC programme focused on training for physical condition, activities of daily living, preservation of energy and instructions on self-rehabilitation measures, application of aids, and psychosocial consultation. Patients' families were actively involved. Educational activities involved 1100 participants and RIC was promoted by 182 health and social care agencies, humanitarian organizations, the Church, Red Cross, the University and public. The Project demonstrated that primary health care nurse, social worker, and peer counsellor joined to rehabilitation professionals were able to develop interdisciplinary teamwork and to confirm their roles as CBR workers.	Univ Zagreb, Sveti Duh Gen Hosp, HR-10002 Zagreb, Croatia	Georgievski, AB (corresponding author), Univ Zagreb, Sveti Duh Gen Hosp, 64 Sveti Duh St, HR-10002 Zagreb, Croatia.						AITKEN C, 1987, INT DISABILITY STUDI, V9, P55; Clarke A K, 1987, Int Disabil Stud, V9, P18; *DIS MAN INF SYST, 1995, MIDT REP INF SYST WO; Eldar R, 1997, DISABIL REHABIL, V19, P547, DOI 10.3109/09638289709166048; ELDAR R, 2000, IN PRESS DISABILITY; Eldar Reuben, 1993, Croatian Medical Journal, V34, P21; FINDLEY TW, 1987, MED CARE, V25, P753, DOI 10.1097/00005650-198708000-00008; GRANGER CV, 1973, PHYSICAL MED REHABIL, V4, P596; Hermanova H, 1987, Int Disabil Stud, V9, P61; Heruti RJ, 1995, AM J PHYS MED REHAB, V74, P466, DOI 10.1097/00002060-199511000-00017; Kosuta D, 1996, Acta Med Croatica, V50, P53; PEAT M, 1991, CLIN REHABIL, V5, P161; PEAT M, 1997, COMMUNITY BASED REHA; ROKSANDICTOMEK S, 1996, SOME HLTH STAT RELAT; Symington D C, 1994, Int J Rehabil Res, V17, P1, DOI 10.1097/00004356-199403000-00001; *WHO EURO CONS STA, 1992, WHO EURO CONS STAT R	16	18	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	2000	23	1					1	6					6	Rehabilitation	Rehabilitation	305HJ	WOS:000086533100001	10826120				2021-06-18	
J	Van den Heuvel, C; Blumbergs, P; Finnie, J; Manavis, J; Lewis, S; Jones, N; Reilly, P; Pereira, R				Van den Heuvel, C; Blumbergs, P; Finnie, J; Manavis, J; Lewis, S; Jones, N; Reilly, P; Pereira, R			Upregulation of amyloid precursor protein and its mRNA in an experimental model of paediatric head injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						amyloid precursor protein; paediatric head injury model; lambs; neuronal cell body; messenger RNA; immunocytochemistry; in-situ hybridisation	EXPERIMENTAL BRAIN INJURY; AXONAL INJURY; TRANSCRIPTIONAL ACTIVATION; ALZHEIMERS-DISEASE; IMPACT MODEL; RAT-BRAIN; GENE; NEURONS; EXPRESSION; IMMATURE	Amyloid precursor protein (APP), a membrane spanning glycoprotein which plays an important role in neuronal growth and synaptic plasticity, is increased after traumatic brain injury (TBI) and has been used as a sensitive marker of neuronal damage in an adult sheep head impact model. We hypothesised that APP expression would similarly be increased in lambs, suggesting that in the immature injured brain APP is also upregulated as an acute phase response to trauma. Ten anaesthetised and Ventilated 4-5 week old Merino lambs sustained a left temporal head impact from a humane stunner. At 2 h after impact, there was widespread and intense neuronal cell body APP immunoreactivity which was more widely distributed than axonal APP. APP messenger RNA (mRNA) expression was also markedly increased with a distribution similar to that of APP antigen. These results demonstrate that APP antigen and mRNA are sensitive early indicators of TBI in paediatric cases. (C) 2000 Harcourt Publishers Ltd.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Vet Div, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Neurosurg, Adelaide, SA, Australia; Inst Med & Vet Sci, Infect Dis Lab, Adelaide, SA 5000, Australia	Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA, Australia.						AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ARTHUR J, 1993, J GEN VIROL, V74, P1363, DOI 10.1099/0022-1317-74-7-1363; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; Dewji NN, 1996, MOL BRAIN RES, V35, P325, DOI 10.1016/0169-328X(95)00214-D; DOBBING J, 1981, SCI FDN PAEDIAT, P747; FARBER SA, 1995, J NEUROSCI, V15, P7442; Fearnside MR, 1997, HEAD INJURY PATHOPHY, P3; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; PEREIRA RA, 1994, J EXP MED, V180, P841, DOI 10.1084/jem.180.3.841; Pierce JES, 1996, J NEUROSCI, V16, P1083; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMITH ML, 1995, J NEUROTRAUM, V12, P143; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Ward JD, 1996, NEUROTRAUMA, P859; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	42	18	18	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2000	7	2					140	145					6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	301LX	WOS:000086312600013	10844801				2021-06-18	
J	Newman, SJ; Bond, B; Crook, B; Darker, J; Edge, C; Maycox, PR				Newman, SJ; Bond, B; Crook, B; Darker, J; Edge, C; Maycox, PR			Neuron-specific localisation of the TR3 death receptor in Alzheimer's disease	BRAIN RESEARCH			English	Article						death receptor; Alzheimer's disease; TR3; lymphocyte; apoptosis; antibody	DOMAIN-CONTAINING RECEPTOR; ISCHEMIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; TNF RECEPTOR; CEREBRAL-ISCHEMIA; CELL-DEATH; APOPTOSIS; PROTEIN; LOCALIZATION	Death receptors are associated with the homeostatic and pathologic induction of cell death. TR3 is a recently characterised member of the death receptor family that is expressed in the adult brain, In order to establish the role of TR3 in acute CNS disease and chronic neurodegeneration, we analysed brain regions from Alzheimer's disease (AD), stroke and neurotrauma patients, using a novel anti-peptide antibody generated to an exposed epitope in the extracellular domain of the receptor. We show a statistically significant increase in TR3 protein levels in AD brain samples but not in stroke, neurotrauma or control samples. The increase observed for TR3 was specific to neurons in regions associated with AD pathology. This is the first report describing the neuron-specific regulation of a death receptor in chronic disease and may indicate that a TR3 receptor-mediated signalling pathway is involved in AD-associated neuronal loss. (C) 2000 Elsevier Science B.V. All rights reserved.	SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Analyt Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Computat & Struct Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Stat Sci, Harlow CM19 5AW, Essex, England	Maycox, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Neurosci Res, 3rd Ave, Harlow CM19 5AW, Essex, England.						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; BRAAK H, 1990, J NEUROPATH EXP NEUR, V49, P215, DOI 10.1097/00005072-199005000-00003; BRAAK H, 1992, NEUROSCI RES, V15, P6, DOI 10.1016/0168-0102(92)90014-4; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chen J, 1998, J NEUROSCI, V18, P4914; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CONLON I, 1999, SIZE CONTROL ANIMAL, V96, P235; CUEVAS EC, 1994, J CLIN PATHOL, V47, P448, DOI 10.1136/jcp.47.5.448; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; HARRISON DC, IN PRESS TR3 DEATH R; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LINNIK MD, 1995, MOL BRAIN RES, V32, P116, DOI 10.1016/0169-328X(95)00069-5; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Namura S, 1998, J NEUROSCI, V18, P3659; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pitti RM, 1998, NATURE, V396, P699; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Siegel S., 1956, NONPARAMETRIC STAT B; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOOD JA, 1993, BRAIN RES, V629, P245, DOI 10.1016/0006-8993(93)91327-O; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; 0869179	47	18	19	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 28	2000	857	1-2					131	140		10.1016/S0006-8993(99)02417-8			10	Neurosciences	Neurosciences & Neurology	290BV	WOS:000085657200014	10700560				2021-06-18	
J	Savitsky, EA; Votey, SR				Savitsky, EA; Votey, SR			Current controversies in the management of minor pediatric head injuries	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						pediatric; minor head injury; management; head trauma; cranial computed tomography	TRAUMATIC BRAIN INJURY; COMPUTED TOMOGRAPHIC SCANS; DEPRESSED SKULL FRACTURES; ACUTE SUBDURAL-HEMATOMA; POSTTRAUMATIC SEIZURES; NEUROLOGIC EXAMINATION; INTRACRANIAL HEMATOMA; EXTRADURAL HEMATOMA; CLINICAL PREDICTORS; CHILDREN	Each year hundreds of thousands of children receive care in emergency departments after head injury. Minor head injuries account for a majority of these injuries. The prevalence, morbidity, and costs associated with pediatric minor head injuries make it an important topic. We review the management of pediatric minor head injury, emphasizing current areas of controversy, including criteria for neuroimaging, indications for hospitalization, the role of anticonvulsant therapy, and the long-term neurobehavioral sequelae of pediatric minor head injury. Copyright (C) 2000 by W.B. Saunders Company.	Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA	Savitsky, EA (corresponding author), Univ Calif Los Angeles, Sch Med, 924 Westwood Blvd,Suite 300, Los Angeles, CA 90024 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CEVIKER N, 1995, ACTA NEUROCHIR, V133, P116, DOI 10.1007/BF01420061; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; DUHAIME AC, 1992, PEDIATRICS, V90, P179; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; GROVEDAHL DL, 1995, PEDIATR EMERG CARE, V95, P345; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HENDRICK E, 1963, CLIN NEUROSURG, V11, P46; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; LENDE RA, 1961, J NEUROSURG, V18, P479, DOI 10.3171/jns.1961.18.4.0479; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Miller J D, 1988, Brain Inj, V2, P83, DOI 10.3109/02699058809150934; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1969, LANCET, P991; MISES J, 1970, EPILEPSIA, V11, P37, DOI 10.1111/j.1528-1157.1970.tb03864.x; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; MUHONEN MG, 1995, SURG NEUROL, V43, P367, DOI 10.1016/0090-3019(95)80066-P; NAIMURRAHMAN, 1994, BRIT J NEUROSURG, V8, P667, DOI 10.3109/02688699409101180; PATERNITI S, 1994, ACTA NEUROCHIR, V131, P207, DOI 10.1007/BF01808614; PIETRZAK M, 1991, AM J EMERG MED, V9, P153, DOI 10.1016/0735-6757(91)90179-N; PITTS L, 1991, ANN EMERG MED, V20, P1386; POHMANNEDEN B, 1997, ACTA NEUROL SCAND, V95, P257; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; RIVARA F, 1987, PEDIATRICS, V80, P579; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; Saab M, 1996, J ACCID EMERG MED, V13, P208; SAINSBURY CPQ, 1984, ARCH DIS CHILD, V59, P858; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEINBOK P, 1987, J NEUROSURG, V66, P506, DOI 10.3171/jns.1987.66.4.0506; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186; Wheeler DS, 1997, PEDIATRICS, V100, P1033, DOI 10.1542/peds.100.6.1033	73	18	18	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	JAN	2000	18	1					96	101		10.1016/S0735-6757(00)90060-3			6	Emergency Medicine	Emergency Medicine	278QB	WOS:000084999500023	10674544				2021-06-18	
J	Kant, R; Coffey, CE; Bogyi, AM				Kant, R; Coffey, CE; Bogyi, AM			Safety and efficacy of ECT in patients with head injury: A case series	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ELECTROCONVULSIVE-THERAPY; DISEASE; DEPRESSION; SCALE	Electroconvulsive therapy (ECT) is a safe and effective treatment for certain psychiatric disorders. Eleven patients who had sustained a closed head injury were treated with ECT for their psychiatric symptoms. Eight patients responded to an index course of ECT: 2 were partial responders and became responders during continuation ECT (cECT); 1 patient was 17 nonresponder. Post-ECT Neurobehavioral Cognitive Status Examination and Mini-Mental State Examination scores showed no significant decline (P>0.70 and P>0.89, respectively) from baseline. Eight patients received cECT, without any lasting cognitive side effects. These findings indicate that ECT can be used effectively in patients with a history of closed head injury without adverse effects on cognitive functioning.	Head Injury Clin, Pittsburgh, PA 15224 USA; Henry Ford Hosp, Dept Psychiat, Detroit, MI 48202 USA; St Elizabeth Hlth Ctr, Dept Psychiat, Youngstown, OH USA	Kant, R (corresponding author), Head Injury Clin, 4608 Penn Ave, Pittsburgh, PA 15224 USA.						American Psychiatric Association, 1990, PRACT ECT REC TREATM; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; COFFEY CE, 1995, BIOL PSYCHIAT, V37, P777, DOI 10.1016/0006-3223(95)00053-J; COFFEY CE, 1995, BIOL PSYCHIAT, V37, P713, DOI 10.1016/0006-3223(95)00262-F; DUBOVSKY SL, 1986, HOSP COMMUNITY PSYCH, V37, P819; Epstein Richard S., 1994, P285; FOLSTEIN MF, 1975, J PSYCHIAT RES, P189; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HSIAO JK, 1987, CONVULSIVE THER, V3, P121; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KANT R, 1995, CONVULSIVE THER, V11, P45; Kant R, 1996, BRAIN INJURY, V10, P55; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mulsant B H, 1991, J Geriatr Psychiatry Neurol, V4, P3, DOI 10.1177/089198879100400102; *NO CA NEUR GROUP, 1991, MAN NEUR COGN STAT E; OSHANICK GJ, 1988, PSYCHIATRY, P1; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; PRICE TRP, 1989, CONVULSIVE THER, V5, P61; RANEN NG, 1994, J NEUROPSYCH CLIN N, V6, P154; RIMEL RW, 1981, NEUROSURGERY, V9, P274; RUEDRICH SL, 1983, AM J PSYCHIAT, V140, P928; SCHNUR DB, 1989, CONVULSIVE THER, V5, P353; SILVERMAN M, 1964, BRIT J PSYCHIAT, P648; STOUDEMIRE A, 1995, J NEUROPSYCH CLIN N, V7, P31; Taylor Craig A., 1994, P81; TEASDALE G, 1974, LANCET, V2, P81; ZWIL AS, 1994, INT J PSYCHIAT MED, V24, P1; ZWIL AS, 1992, CONVULSIVE THER, V8, P103	28	18	18	0	1	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1999	11	1					32	37		10.1176/jnp.11.1.32			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	162PC	WOS:000078354800005	9990553				2021-06-18	
J	Meyer, P; Legros, C; Orliaguet, G				Meyer, P; Legros, C; Orliaguet, G			Critical care management of neurotrauma in children: new trends and perspectives	CHILDS NERVOUS SYSTEM			English	Article; Proceedings Paper	World Conference on Pediatric Neurosurgery, 2000 AD	NOV 27-DEC 04, 1999	MARTINIQUE			pediatrics; head injury; cerebral monitoring; critical care; therapeutic hyperventilation; cerebral metabolic rate of oxygen	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; PEDIATRIC TRAUMA; ENDOTRACHEAL INTUBATION; HYPERVENTILATION; HYPERTENSION; HYPOTENSION; OXYGENATION	Secondary brain lesions resulting from cerebral metabolic and hemodynamic reactions can be prevented by neurocritical care management. It must be initiated as soon as possible, ideally in a prehospital setting. Tracheal intubation, controlled ventilation and hemodynamic stabilization are the prerequisites. Beside intracranial and cerebral perfusion pressure, monitoring must evaluate the coupling between cerebral metabolic demand and blood flow. Jugular bulb oximetry is the most reliable approach to global cerebral coupling. Transcranial Doppler evaluates cerebral blood flow indirectly and noninvasively. Technological developments have led to local metabolic evaluation that does not yet have any clinical relevance. Therapeutic developments are more a new approach to the use of old drugs. Controlled hyperventilation, mannitol and, more recently, hypertonic saline solutions, used for restoring cerebral metabolic coupling, are the foundations of treatment. Thiopental, revisited as a vasoconstrictive agent, the "Lund" vasoconstrictive approach with anti-hypertensive drugs and cerebral vasoconstrictors, must be further evaluated in children, as must therapeutic hypothermia. Finally, what we probably need for the immediate future is a noninvasive and easily reproducible method of monitoring cerebral metabolic coupling that will allow precise therapeutic adaptation of multimodal therapy to the individual needs of the child.	Hop Necker Enfants Malad, Dept Anesthesie Reanimat Pediat, F-75743 Paris 15, France	Meyer, P (corresponding author), Hop Necker Enfants Malad, Dept Anesthesie Reanimat Pediat, 149 Rue Sevres, F-75743 Paris 15, France.	philippe.meyer@nck.ap-hop-paris.fr	Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; Orliaguet, Gilles/0000-0003-0930-2251			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BLANOT S, 1995, BRIT J ANAESTH, V74, pA334; Boswell W C, 1995, Air Med J, V14, P125, DOI 10.1016/1067-991X(95)90513-8; Brownstein D, 1996, ANN EMERG MED, V28, P34, DOI 10.1016/S0196-0644(96)70136-1; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; CZONIKA M, 1997, NEUROSURGERY, V41, P11; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Furnival RA, 1996, PEDIATRICS, V98, P56; Giroux JD, 1993, REAN SOINS INTENS ME, V9, P35; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MEYER P, 1994, JEUR, V4, P193; Meyer PG, 1999, PAEDIATR ANAESTH, V9, P373, DOI 10.1046/j.1460-9592.1999.00391.x; MEYER PG, 1994, INT ANESTHESIOL CLIN, V32, P149; MEYER PG, 1999, IN PRESS PAEDIAT ANA; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MOESCHLER O, 1995, ANN FR ANESTH, V14, P114, DOI 10.1016/S0750-7658(05)80159-5; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; NAKAYAMA DK, 1992, ANN SURG, V216, P205, DOI 10.1097/00000658-199208000-00011; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Orliaguet GA, 1997, ANESTH ANALG, V85, P1218; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; PFENNINGER J, 1993, INTENS CARE MED, V19, P243, DOI 10.1007/BF01690543; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SANKER P, 1991, CHILD NERV SYST, V7, P391, DOI 10.1007/BF00304204; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIMMA B, 1998, CRIT CARE MED, V8, P1161; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Suominen P, 1998, J PEDIATR SURG, V33, P1388, DOI 10.1016/S0022-3468(98)90014-8; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	42	18	18	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	NOV	1999	15	11-12					732	739		10.1007/s003810050462			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	258WM	WOS:000083862700014	10603014				2021-06-18	
J	Spitzfaden, AC; Jimenez, DF; Tobias, JD				Spitzfaden, AC; Jimenez, DF; Tobias, JD			Propofol for sedation and control of intracranial pressure in children	PEDIATRIC NEUROSURGERY			English	Article						propofol; intracranial pressure; traumatic brain injury	INTENSIVE-CARE UNIT; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; INTRAVENOUS ANESTHETICS; PROLONGED SEDATION; METABOLIC-ACIDOSIS; INFUSION; MIDAZOLAM; PATIENT	Following central nervous system insults, control of intracranial pressure may lessen the incidence of morbidity and mortality. Therapies to control intracranial pressure include osmolar agents, prevention of and control of seizures, drainage of cerebrospinal fluid, hypothermia, and barbiturates. Control of agitation and excessive patient movement are additional components in the management of ICP. Although opioids and benzodiazepines are generally effective, in a small subset of patients, alternative agents may be necessary. The authors present 2 children with increased ICP in whom propofol was used to provide sedation and control ICP. The use of propofol in this setting and its possible applications in the children with increased ICP are discussed. Copyright (C) 2000 S. Karger AG, Basel.	Univ Missouri, Dept Child Hlth Anesthesiol, Columbia, MO 65211 USA; Univ Missouri, Dept Neurosurg, Columbia, MO 65211 USA	Tobias, JD (corresponding author), Univ Missouri, Dept Child Hlth, Hlth Sci Ctr M658, 1 Hosp Dr, Columbia, MO 65212 USA.	Joseph_Tobias@muccmail.missouri.edu					BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BELLER JP, 1988, BRIT J ANAESTH, V61, P583, DOI 10.1093/bja/61.5.583; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; BULLOCK R, 1993, ACTA NEUROCHIR, P113; EGAN TD, 1991, ANESTH ANALG, V73, P818; FARLING PA, 1989, ANAESTHESIA, V44, P222, DOI 10.1111/j.1365-2044.1989.tb11228.x; FINLEY GA, 1993, CAN J ANAESTH, V40, P863, DOI 10.1007/BF03009258; GOTTARDIS M, 1989, BRIT J ANAESTH, V62, P393, DOI 10.1093/bja/62.4.393; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HARRIS CE, 1990, ANAESTHESIA, V45, P366, DOI 10.1111/j.1365-2044.1990.tb14777.x; Herregods L, 1988, Anaesthesia, V43 Suppl, P107, DOI 10.1111/j.1365-2044.1988.tb09089.x; Hertzog JH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e30; LAXENAIRE MC, 1992, ANESTHESIOLOGY, V77, P275, DOI 10.1097/00000542-199208000-00009; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Mangez J F, 1987, Ann Fr Anesth Reanim, V6, P336, DOI 10.1016/S0750-7658(87)80055-2; Marion DW, 1997, J INTENSIVE CARE MED, V12, P239, DOI 10.1177/088506669701200504; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MERGAERT C, 1991, EUR J ANAESTH, V8, P324; Nimkoff L, 1997, J CRIT CARE, V12, P132, DOI 10.1016/S0883-9441(97)90042-3; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; PINAUD M, 1990, ANESTHESIOLOGY, V73, P404, DOI 10.1097/00000542-199009000-00007; RAVUSSIN P, 1988, ANAESTHESIA S, V43, P107; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SLADEN RN, 1995, CRIT CARE MED, V23, P423, DOI 10.1097/00003246-199503000-00001; SOSIS MB, 1993, ANESTH ANALG, V77, P766; STEWART L, 1994, ACTA NEUROCHIR, P544; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; TOBIAS JD, IN PRESS CRIT CARE M; TROTTER C, 1992, ANAESTHESIA, V47, P340, DOI 10.1111/j.1365-2044.1992.tb02178.x; VALENTE JF, 1994, CRIT CARE MED, V22, P710, DOI 10.1097/00003246-199404000-00030; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; Watts ADJ, 1998, ANESTH ANALG, V87, P564, DOI 10.1097/00000539-199809000-00012; WEIGHTMAN WM, 1992, ANAESTHESIA, V47, P500, DOI 10.1111/j.1365-2044.1992.tb02275.x; Yamaguchi S, 1999, CAN J ANAESTH, V46, P593, DOI 10.1007/BF03013553; 1990, MMWR, V39, P426	38	18	18	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	OCT	1999	31	4					194	200		10.1159/000028861			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	280QF	WOS:000085112900006	10705929				2021-06-18	
J	Vajramani, GV; Chandramouli, BA; Jayakumar, PN; Kolluri, S				Vajramani, GV; Chandramouli, BA; Jayakumar, PN; Kolluri, S			Evaluation of posttraumatic vasospasm, hyperaemia, and autoregulation by transcranial colour-coded duplex sonography	BRITISH JOURNAL OF NEUROSURGERY			English	Article						autroregulation; posttraumatic hyperaemia; posttraumatic vasospasm; severe head injury; transcranial Doppler	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; DOPPLER ULTRASOUND; INTRACRANIAL HYPERTENSION; ANGIOGRAPHIC FINDINGS; PERFUSION-PRESSURE; VELOCITY; HYPEREMIA; ULTRASONOGRAPHY	Serial transcranial colour-coded duplex sonography (TCCS) was performed on 24: adult patients with severe head injury (GCS 8 or less). Flow velocities were obtained from the middle cerebral artery (MCA) and extracranial internal carotid artery (EICA). An autoregulation study was done using the transient hyperaemic response test, evidence of vasospasm (V-MCA greater than 100 cm/s and Lindegaard ratio more than 3) was found in nine patients (37%). Two of these developed non-contusion-related infarction and two others contusion-related infarction. This was significant (p < 0.05). Vasospasm started around day 2, reaching maximum around day 4 and persisting until the second week. Vasospasm was significantly associated with a poor outcome (p < 0.05). There was no correlation between the extent of SAH as seen on CT and vasospasm. Evidence of hyperaemia were observed in two patients (8%) and impaired autoregulation in seven patients (29%). Impaired autoregulation was significantly associated with development of hyperaemia (p < 0.05). TCCS studies permit a non-invasive evaluation of cerebral haemodynamics that will help in the management of head injured patients.	Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 29, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Neuroradiol, Bangalore 29, Karnataka, India	Chandramouli, BA (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 29, Karnataka, India.		VAJRAMANI, Girish/AAP-6731-2021				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1992, NEUROSURGERY, V30, P697; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P249, DOI 10.1111/j.1399-6576.1978.tb01299.x; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; CZOSNYKA M, 1993, ACTA NEUROCHIR, V121, P159, DOI 10.1007/BF01809269; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; GORAJ B, 1993, RADIOLOGY, V188, P137, DOI 10.1148/radiology.188.1.8511287; ITO U, 1986, ACTA NEUROCHIR, V79, P120, DOI 10.1007/BF01407455; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; NEWELL DW, 1995, NEUROSONOLOGY, P189; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; PAULSON OB, 1972, NEUROLOGY, V22, P286, DOI 10.1212/WNL.22.3.286; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Smielewski P, 1996, STROKE, V27, P2197, DOI 10.1161/01.STR.27.12.2197; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; ZANE CJ, 1992, J NEUROSURG, V76, pA399; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P33, DOI 10.1016/0022-510X(95)00172-9	42	18	18	0	0	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	1999	13	5					468	473		10.1080/02688699908540620			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	242VC	WOS:000082961500006	10627777				2021-06-18	
J	Hormuth, D; Cefali, D; Rouse, T; Cutshaw, J; Turner, W; Rodman, G				Hormuth, D; Cefali, D; Rouse, T; Cutshaw, J; Turner, W; Rodman, G			Traumatic disruption of the thoracic aorta in children	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	106th Scientific Session of the Western-Surgical-Association	NOV 16-18, 1998	INDIANAPOLIS, IN	Western Surg Assoc			PRIMARY REPAIR; RUPTURE; DIAGNOSIS; INJURIES	Hypothesis: This study was undertaken to identify mechanisms of injury, diagnostic modalities, surgical management, and outcome in children with traumatic aortic disruptions. Design: Retrospective study. Setting: University-affiliated private hospital. Patients: All patients younger than 17 years listed in the trauma registry. Intervention: Operative repair of thoracic aortic injuries. Main Outcome Measures: There were 8 boys and 3 girls ranging in age from 12 to 17 years (mean, 14.8 years). Seven children were motor vehicle passengers; 3 were pedestrians struck by vehicles; and 1 was thrown from a bull. Aortic injuries were suspected on the basis of the mechanism of injury and abnormal chest x-ray films (mediastinal widening). Aortic injuries were confirmed in 9 patients by arch aortography and in 2 patients by computed tomography. The injuries involved the isthmus of the aorta in 9 patients (complete transections) and the aortic arch in 2 patients (avulsions of the great vessels). Isthmus injuries were repaired by means of left heart bypass with direct cannulation of the distal thoracic aorta in 8 patients and femoral venous to femoral arterial bypass in 1 patient. Arch injuries were repaired during hypothermic circulatory arrest. The injured aortic segments were replaced with interposition grafts. There were no direct complications of anticoagulation. Ten patients (91%) survived. The only death was caused by a severe closed head injury. There were no instances of paraplegia related to aortic repairs. Conclusion: Good outcomes resulted from early diagnosis based on mechanism of injury, prompt aortography, and computed tomography and operative management that included distal aortic perfusion with left heart bypass.	Clarian Methodist Hosp, Sect Cardiothorac Surg, Indianapolis, IN USA; Clarian Methodist Hosp, Pediat Surg Sect, Indianapolis, IN USA; Clarian Methodist Hosp, Sect Trauma Surg, Indianapolis, IN USA	Hormuth, D (corresponding author), 1801 N Senate Blvd,Suite 755, Indianapolis, IN 46202 USA.						ALI IS, 1992, J PEDIATR SURG, V27, P1281, DOI 10.1016/0022-3468(92)90274-B; Beaver B L, 1992, Semin Thorac Cardiovasc Surg, V4, P255; BERGMAN K, 1990, J TRAUMA, V30, P604, DOI 10.1097/00005373-199005000-00013; BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; BROOKS AP, 1989, CLIN RADIOL, V40, P133, DOI 10.1016/S0009-9260(89)80071-6; DART CH, 1976, ARCH SURG-CHICAGO, V111, P697; Defilippi Vincent J., 1995, P65; EDDY AC, 1990, J TRAUMA, V30, P989, DOI 10.1097/00005373-199008000-00007; HALLER JA, 1986, PEDIAT SURG, V1, P143; KIRSH MM, 1976, ANN SURG, V184, P308, DOI 10.1097/00000658-197609000-00008; MATTOX KL, 1989, ANN THORAC SURG, V48, P1, DOI 10.1016/0003-4975(89)90164-1; MCBRIDE LR, 1987, ANN THORAC SURG, V43, P65, DOI 10.1016/S0003-4975(10)60168-3; MELLER JL, 1984, PEDIATRICS, V74, P813; MILLER FB, 1989, SURGERY, V106, P596; MURE A J, 1990, Pediatric Emergency Care, V6, P104, DOI 10.1097/00006565-199006000-00008; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; ORRINGER MB, 1983, ANN THORAC SURG, V35, P672, DOI 10.1016/S0003-4975(10)61083-1; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; ROBERTS SR, 1995, MANAGEMENT PEDIAT TR, P248; SCHMIDT CA, 1989, J TRAUMA, V29, P248, DOI 10.1097/00005373-198902000-00020; SYMBAS PN, 1973, ANN SURG, V178, P6, DOI 10.1097/00000658-197307000-00002; Trachiotis GD, 1996, ANN THORAC SURG, V62, P724, DOI 10.1016/S0003-4975(96)00355-4; WOODRING J H, 1990, Journal of Emergency Medicine, V8, P467	23	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	JUL	1999	134	7					759	763		10.1001/archsurg.134.7.759			5	Surgery	Surgery	212FF	WOS:000081206100025	10401829	Bronze			2021-06-18	
J	Watt, S; Shores, EA; Kinoshita, S				Watt, S; Shores, EA; Kinoshita, S			Effects of reducing attentional resources on implicit and explicit memory after severe traumatic brain injury	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; DIVIDED ATTENTION; PERFORMANCE; TESTS; AMNESIA; WORDS	Implicit and explicit memory were examined in individuals with severe traumatic brain injury (TBI) under conditions of full and divided attention. Participants included 12 individuals with severe TBI and 12 matched controls. In Experiment 1, participants carried out an implicit test of word-stem completion and an explicit test of cued recall. Results demonstrated that TBI participants exhibited impaired explicit memory but preserved implicit memory. In Experiment 2, a significant reduction in the explicit memory performance of both TBI and control participants, as well as a significant decrease in the implicit memory performance of TBI participants, was achieved by reducing attentional resources at encoding. These results indicated that performance on an implicit task of word-stem completion may require the availability of additional attentional resources that are not preserved after severe TBI.	Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	Watt, S (corresponding author), Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia.			Kinoshita, Sachiko/0000-0002-5288-2485; Shores, Edwin A/0000-0003-1553-5131			AURENBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1; Baayen R., 1993, CELEX LEXICAL DATABA; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; CHAPMAN LJ, 1994, DEV REV, V14, P159, DOI 10.1006/drev.1994.1007; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; EICH E, 1984, MEM COGNITION, V12, P105, DOI 10.3758/BF03198423; FELVUS J, 1989, ACER PSYCHOL TEST B, V2, P20; GRABRIELI JDE, 1996, M PSYCH SOC CHIC IL; GRAF P, 1984, J VERB LEARN VERB BE, V23, P553, DOI 10.1016/S0022-5371(84)90346-3; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; JERNIGAN TL, 1993, NEUROPSYCHOLOGY, V7, P14, DOI DOI 10.1037/0894-4105.7.1.14; KING MG, 1986, ACER B PSYCHOL, V39, P3; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1992, NEUROPSYCHOLOGY MEMO, P291; Mulligan NW, 1996, MEM COGNITION, V24, P453, DOI 10.3758/BF03200934; Mulligan NW, 1997, MEM COGNITION, V25, P11, DOI 10.3758/BF03197281; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PARKIN AJ, 1990, EUROPEAN J COGNITIVE, V2, P71, DOI DOI 10.1080/09541449008406198; PARKIN AJ, 1993, NEUROPSYCHOLOGY AMNE; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; RUFF RM, 1988, J CLIN EXPT NEUROPSY, V11, P539; Schacter D., 1988, THOUGHT LANGUAGE, P242; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Shimamura Arthur P., 1993, P265; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SMITH ME, 1990, J EXP PSYCHOL LEARN, V16, P1033, DOI 10.1037/0278-7393.16.6.1033; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Wechsler D., 1981, WAIS R MANUAL WECHSL; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; Winocur G, 1996, NEUROPSYCHOLOGY, V10, P57, DOI 10.1037/0894-4105.10.1.57	46	18	18	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1999	13	3					338	349		10.1037/0894-4105.13.3.338			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	221TH	WOS:000081742100002	10447296				2021-06-18	
J	Horne, LT; Blue, BA				Horne, LT; Blue, BA			Intraarticular heterotopic ossification in the knee following intramedullary nailing of the fractured femur using a retrograde method	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						retrograde intramedullary rod; heterotopic ossification; femur fracture; knee	HIP-ARTHROPLASTY; REPLACEMENT; IBUPROFEN	The cases of a forty-five-year-old woman and a twenty-year-old man who developed severe intraarticular and periarticular heterotopic ossification around the knee following intramedullary nailing of a femur fracture using a retrograde technique. The association of musculoskeletal heterotopic ossification with closed head injuries seems well established and can occur in and around the knee following retrograde intramedullary nailing. This complication may occur more often than has been reported.	Univ S Carolina, Sch Med, Dept Orthopaed Surg, Columbia, SC 29203 USA	Blue, BA (corresponding author), Univ S Carolina, Sch Med, Dept Orthopaed Surg, 2 Richland Med Pk,Suite 404, Columbia, SC 29203 USA.						AHRENGART L, 1994, ACTA ORTHOP SCAND, V65, P139, DOI 10.3109/17453679408995421; BRUMBACK RJ, 1992, J BONE JOINT SURG AM, V74A, P106, DOI 10.2106/00004623-199274010-00013; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; ELMSTEDT E, 1985, ACTA ORTHOP SCAND, V56, P25, DOI 10.3109/17453678508992973; FIROOZBAKHSH K, 1995, J ORTHOP TRAUMA, V9, P152, DOI 10.1097/00005131-199504000-00011; FREEMAN PA, 1973, CLIN ORTHOP RELAT R, P224; Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604; GEBUHR P, 1991, ACTA ORTHOP SCAND, V62, P226, DOI 10.3109/17453679108993597; GOSSELIN RA, 1993, J TRAUMA, V34, P161, DOI 10.1097/00005373-199301000-00033; HARRIS LJ, 1980, J BONE JOINT SURG AM, V62, P1185, DOI 10.2106/00004623-198062070-00021; Letournel E, 1993, FRACTURES ACETABULUM; MARKS PH, 1988, J TRAUMA, V28, P1207, DOI 10.1097/00005373-198808000-00012; MOED BR, 1994, J BONE JOINT SURG BR, V76B, P895; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; NOLLEN AJG, 1993, ACTA ORTHOP SCAND, V64, P185, DOI 10.3109/17453679308994567; PATTERSON BM, 1995, J TRAUMA, V38, P38, DOI 10.1097/00005373-199501000-00012; ROSENDAHL S, 1977, ACTA ORTHOP SCAND, V48, P400, DOI 10.3109/17453677708992016; SANDERS R, 1993, J ORTHOP TRAUMA, V7, P293, DOI 10.1097/00005131-199308000-00001; STEINBERG GG, 1993, J ORTHOP TRAUMA, V7, P536, DOI 10.1097/00005131-199312000-00009; Tornetta P 3rd, 1992, J Orthop Trauma, V6, P113; WLODARSKI KH, 1991, CLIN ORTHOP RELAT R, P8	21	18	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	JUN-JUL	1999	13	5					385	388		10.1097/00005131-199906000-00013			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	207LQ	WOS:000080938700013	10406709				2021-06-18	
J	Curtiss, S; de Bode, S				Curtiss, S; de Bode, S			Age and etiology as predictors of language outcome following hemispherectomy	DEVELOPMENTAL NEUROSCIENCE			English	Article						hemispherectomy; language; language development; plasticity; linguistic outcomes	CLOSED HEAD-INJURY; INFANTILE HEMIPLEGICS; NARRATIVE DISCOURSE; BRAIN INJURY; CHILDREN; HEMIDECORTICATION; COMPREHENSION; EPILEPSY; MEMORY; SPEECH	We report on the effects of etiology and age on the linguistic outcomes in a large pediatric hemispherectomy population. Four populations were considered separately: cortical dysplasia (multilobar involvement), Rasmussen's encephalitis, infarction as a primary etiology and, fourth, children who failed to develop language, regardless of etiology. We argue against the 'the-earlier-the-better' hypothesis and propose our own hypothesis that weds maturational factors to etiological factors to predict language outcomes following pervasive brain insult. The implications of our 'critical impact point' hypothesis are discussed. Copyright (C) 1999 S.Karger AG, Basel.	Univ Calif Los Angeles, Dept Linguist, Neurolinguist Lab, Los Angeles, CA 90095 USA	Curtiss, S (corresponding author), Univ Calif Los Angeles, Dept Linguist, Neurolinguist Lab, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	scurtiss@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS028383, P50NS028383] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28383] Funding Source: Medline		Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ARAM D, 1992, DEV NEUROPSYCHOL, V8, P171; BATES E, 1992, HDB NEUROPSYCHOLOGY, V6; CAPLAN R, 1989, J AM ACAD CHILD ADOL, V28, P208; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COHEN M, 1992, BRAIN COGNITION, V20, P315, DOI 10.1016/0278-2626(92)90024-G; CURTISS S, 1999, UNPUB BRAIN LANG; CURTISS S, 1997, 4 ANN SOC COGN NEUR; CURTISS S, 1997, P 21 ANN BOST U C LA, P103; CURTISS S, 1998, BOST U C LANG DEV BO; DAY P, 1979, BRAIN LANG, V10, P287; DEBODE S, 1999, P 23 BOST U C LANG D; DEBODE S, 1998, P 22 BOST U C LANG D, V1, P150; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1980, BRAIN LANG, V10, P287, DOI 10.1016/0093-934X(80)90058-9; DENNIS M, 1975, BRAIN LANG, V2, P472, DOI 10.1016/S0093-934X(75)80084-8; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DENNIS M, 1980, BIOL STUDIES MENTAL, P159; Duchowny M, 1996, ANN NEUROL, V40, P31, DOI 10.1002/ana.410400108; FENSON L, 1990, MACARTHUR COMMUNICAT; GALLAGHER T, 1996, 3 D ULTRASONIC FETAL; GORDON N, 1996, DEV MED CHILD NEUROL, V38, P133; HELMSTAEDTER C, 1994, BRAIN, V117, P729, DOI 10.1093/brain/117.4.729; HEMPHILL L, 1994, J COMMUN DISORD, V27, P107, DOI 10.1016/0021-9924(94)90037-X; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KINSBOURNE M, 1974, HEMISPHERIC DISCONNE, P34; Kolb B, 1998, ANNU REV PSYCHOL, V49, P43, DOI 10.1146/annurev.psych.49.1.43; KOLB B, 1990, CEREBRAL CORTEX RAT, P537; LECOURS A, 1985, NEONATE COGNITION; Locke JL, 1997, BRAIN LANG, V58, P265, DOI 10.1006/brln.1997.1791; Mills Debra L., 1994, P427; MOLFESE D, 1988, BRAIN LATERALIZATION; Ogden JA, 1996, NEUROPSYCHOLOGIA, V34, P905, DOI 10.1016/0028-3932(96)00005-X; OLEARY DS, 1983, J NERV MENT DIS, V171, P624, DOI 10.1097/00005053-198310000-00006; Peacock WJ, 1996, CHILD NERV SYST, V12, P376, DOI 10.1007/BF00395089; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; ROSSI PG, 1996, DYSPLASIAS CEREBRAL; Stark RE, 1997, BRAIN LANG, V60, P222, DOI 10.1006/brln.1997.1800; Stark RE, 1995, BRAIN LANG, V51, P406, DOI 10.1006/brln.1995.1068; STILES J, 1993, HUMAN BEHAV DEV BRAI, P643; STRAUSS E, 1983, BRAIN LANG, V20, P1, DOI 10.1016/0093-934X(83)90027-5; THAL DJ, 1991, BRAIN LANG, V40, P491, DOI 10.1016/0093-934X(91)90145-Q; VarghaKhadem F, 1997, BRAIN, V120, P159, DOI 10.1093/brain/120.1.159; VARGHAKHADEM F, 1992, ADV EXP MED BIOL, V325, P137; VARGHAKHADEM F, 1991, BRAIN, V114, P473, DOI 10.1093/brain/114.1.473; WITELSON S, 1985, LANGUAGE FUNCTION BR	47	18	19	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.	MAY-OCT	1999	21	3-5					174	181		10.1159/000017396			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	262GM	WOS:000084057600003	10575240				2021-06-18	
J	Lafuente, JV; Cervos-Navarro, J				Lafuente, JV; Cervos-Navarro, J			Craniocerebral trauma induces hemorheological disturbances	JOURNAL OF NEUROTRAUMA			English	Article						fibrinolysis; hemorheology; microthrombi; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; HEAD-INJURY; ENDOTHELIAL-CELLS; BRAIN; MICROTHROMBI; ADHESION; ISCHEMIA; INVIVO; MODELS	Several mechanisms are involved in the development of secondary ischemic brain damage, including microthrombi formation, which is thought to play a prominent role. Ninety-four autopsy cases were macro- and microscopically examined by specific staining for fibrin, 74 of which showed cortical contusion after a craniocerebral trauma, Twenty cases with no neurological pathology were used as controls, Traumatic cases comprised 52 males and 22 females, with a mean age of 48 years; most cases died in the first 48 h, The total number of fibrinous microthrombi in a slice of each hemisphere was determined. The mean number of microthrombi found in contused hemisphere was 152 (37-283), with 88 in the contralateral hemisphere (21-139) as compared to 13 (0-27) in control cases, Differences were statistically significant. Globular microthrombi or "shock bodies" (2-60 mu diameter) were present in five cases. Enhanced presence of microthrombi in contused brain areas, higher incidence in young people, an increase in the amount of microthrombi up to the 9th day after injury and involvement of the contralateral hemisphere free of contusion foci were all demonstrated, Microthrombi would therefore seem to be one of the central secondary events after brain trauma to bear in mind when designing treatment strategies.	Univ Int Catalunya, Inst Neurol & Gerontol Sci, Barcelona 08017, Spain; Univ Basque Country, Dept Neurosci, Leioa, Spain	Cervos-Navarro, J (corresponding author), Univ Int Catalunya, Inst Neurol & Gerontol Sci, C Inmaculada 22, Barcelona 08017, Spain.		Lafuente, Jose-Vicente/O-6395-2014	Lafuente, Jose-Vicente/0000-0001-7246-0987			ANDERSON M L, 1990, Neurological Research, V12, P195; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; HALLENBECK JM, 1994, ACTA NEUROCHIR, P233; Heye N, 1996, STROKE, V27, P431, DOI 10.1161/01.STR.27.3.431; HEYE N, 1992, ACTA NEUROL SCAND, V86, P450, DOI 10.1111/j.1600-0404.1992.tb05122.x; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; LADEWIG P, 1938, Z MIKROSKOP TECHNIK, V55, P215; Lafuente JV, 1998, REV NEUROLOGIA, V26, P224, DOI 10.33588/rn.26150.981062; Lafuente JV, 1999, NEUROPATHOLOGY, V19, P28, DOI 10.1046/j.1440-1789.1999.00204.x; LEESTMA JE, 1988, FORENSIC NEUROPATHOL, P157; Maeda T, 1997, ACT NEUR S, V70, P102; MANLOW A, 1992, J NEUROPATH EXP NEUR, V51, P298, DOI 10.1097/00005072-199205000-00008; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mendoza L, 1998, J CELL PHYSIOL, V174, P322; MENTER DG, 1987, CLIN EXP METASTAS, V5, P65, DOI 10.1007/BF00116627; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003	25	18	18	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					425	430		10.1089/neu.1999.16.425			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200008	10369562				2021-06-18	
J	Zasler, ND				Zasler, ND			Posttraumatic tension pneumocephalus	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; headache; pneumocephalus		This case presentation will review tension pneumocephalus as a rare etiology of delayed posttraumatic headache (PTHA). It demonstrates that clinicians must be aware of even the uncommon causes of PTHA if appropriate diagnostic assessment and treatment are to be rendered. The case involves a 26-year-old right-handed white male who was 4 years post severe traumatic brain injury with facial fractures and an initial Glasgow Coma Scale score of 5. The patient's main postinjury functional impairments were cognitive-behavioral dysfunction, dysmetria, left hemiparesis, and posttraumatic epilepsy. Approximately 3 years post injury, the patient started to have complaints of right unilateral frontal headache. This complaint was addressed conservatively by several treating physicians. Due to the progressive nature of the patient's complaints, a second opinion was obtained with the author. On assessment, the patient complained of unilateral right headache and described the pain as making him feel as if his head was going to "bust open." A computed tomography (CT) scan showed findings consistent with a tension pneumocephalus. The patient was referred to neurosurgery, at which time the tension pneumocephalus was evacuated and a dural leak, felt to be responsible for the condition, patched. The patient's headache complaints reserved postoperatively. Clinicians should be aware of uncommon conditions that may be present in patients presenting with late PTHA, particularly conditions such as tension pneumocephalus which may have a significant clinical morbidity.	Concuss Care Ctr Virginia, Glen Allen, VA 23060 USA; Tree Life, Glen Allen, VA USA	Zasler, ND (corresponding author), Concuss Care Ctr Virginia, 10120 W Broad St,Suite G, Glen Allen, VA 23060 USA.						Ferrante L, 1988, Br J Neurosurg, V2, P269, DOI 10.3109/02688698808992679; FLEMING M S, 1988, Journal of Computed Tomography, V12, P86, DOI 10.1016/0149-936X(88)90039-2; ISHIWATA Y, 1988, J NEUROSURG, V68, P58, DOI 10.3171/jns.1988.68.1.0058; KAWAKAMI Y, 1985, Neurological Surgery, V13, P833; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; MARKHAM JW, 1976, HDB CLIN NEUROLOGY I, P24; Marras LC, 1998, CAN J NEUROL SCI, V25, P79, DOI 10.1017/S0317167100033540; MATSUBA HM, 1986, AM J OTOL, V7, P208; MCCORMACK B, 1996, NEUROTRAUMA; NORTH JB, 1971, BRIT J SURG, V58, P826, DOI 10.1002/bjs.1800581106; RAM Z, 1992, CHILD NERV SYST, V8, P351, DOI 10.1007/BF00296568; STEUDEL WI, 1986, ACTA NEUROCHIR, V80, P93, DOI 10.1007/BF01812281	12	18	20	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					81	84		10.1097/00001199-199902000-00009			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100009	9949248				2021-06-18	
J	Shreiber, DI; Smith, DH; Meaney, DF				Shreiber, DI; Smith, DH; Meaney, DF			Immediate in vivo response of the cortex and the blood-brain barrier following dynamic cortical deformation in the rat	NEUROSCIENCE LETTERS			English	Article						blood-brain barrier; cerebral contusion; brain injury; biomechanics	FLUID-PERCUSSION MODEL; IMPACT HEAD-INJURY; PERMEABILITY; DISRUPTION	Although it is known that the brain can be injured by mechanical forces initiated at the moment of impact during trauma, it is not clear how the physical response of the brain dictates the injury patterns that occur in experimental models of traumatic brain injury. In this study, we investigated the mechanical response of the brain to a technique that creates a focal injury in the rat brain. Using a transient vacuum pulse applied to the exposed cortical surface, we found that the displacement of the cortex and the extent of in vivo blood-brain barrier breakdown were related significantly to the vacuum pressure level. The relationship between the response of the cortex and injury pattern points towards a new opportunity for control of the distribution and extent of injury patterns in animal models through a precise understanding of the model biomechanics, as well as potential improvements in means of preventing traumatic brain injury. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 120 Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007	Shreiber, David/0000-0001-8248-419X; Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR312712, R01 35712] Funding Source: Medline		CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MOOS T, 1993, NEUROPATH APPL NEURO, V19, P120, DOI 10.1111/j.1365-2990.1993.tb00416.x; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Schreiber DI, 1997, 41 STAPP CAR CRASH C, P277; Smith D.C., 1996, NEW DIRECTIONS TEACH, V1996, P5, DOI [10.1002/tl.37219966604, DOI 10.1002/TL.37219966604]; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STEINWALL O, 1996, J NEUROPATHOL EXP NE, V25, P542; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Ward C. C., 1980, P 24 STAPP CAR CRASH, P347	19	18	18	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 4	1999	259	1					5	8		10.1016/S0304-3940(98)00853-2			4	Neurosciences	Neurosciences & Neurology	160RC	WOS:000078243900002	10027542				2021-06-18	
J	Emond, SD; Tayoun, P; Bedolla, JP; Camargo, CA				Emond, SD; Tayoun, P; Bedolla, JP; Camargo, CA			Injuries in a 1-day recreational cycling tour: Bike New York	ANNALS OF EMERGENCY MEDICINE			English	Article							BICYCLE SAFETY HELMETS; ACCIDENTS; PREVENTION; TRAUMA; CARE	Study objective: To describe injuries during a 1-day urban cycling tour. Methods: During the May 1996 "Bike New York" tour, we monitored EMS calls to identify injuries in a cohort of helmeted cyclists shielded from traffic. We collected demographic information from entry records, injury data from ambulance call reports, and follow-up on transported patients from telephone interviews with emergency physicians. Data were summarized using proportions, relative risks (RRs), 95% confidence intervals (Cls), and chi(2) test. Results: Approximately 28,000 cyclists participated, of which 23,502 (84%) were officially registered. Sixty-eight percent of registered bicyclists were male, and 92% were between 18 and 55 years old. Of the 140 EMS calls made during the tour, 136 (97%) involved participants; this yielded an injury incidence of 5 per 1,000 riders, or 12 to 13 per 100,000 person-miles. Injury was more common among younger cyclists (RR=1.4 for age less than or equal to 35 years versus age >35 years; 95% CI, 1.0 to 2.0; P<.05), and possibly women (RR=1.3; 95% CI, .9 to 1.8, P=.11). Injuries were mostly minor, but there were 7 concussions and 6 clavicle fractures; none of the 140 injuries was fatal. Thirty-eight calls resulted in ED transport, and 5 of these patients were admitted. Although EMS units were evenly distributed along the route, most EMS calls occurred in only 3 of the 7 zones (P<.001). Conclusion: Injuries during the largest 1-day US cycling tour were uncommon, More data are needed to determine the relative importance of injury risk factors. Data collection during mass events may help guide distribution of EMS personnel.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Emergency Med, New York, NY 10025 USA	Emond, SD (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Emergency Med, New York, NY 10025 USA.		Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-03533] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K14HL003533] Funding Source: NIH RePORTER		AULT MJ, 1996, YOUR PATIENT FITNESS, V10, P23; BALLHAM A, 1985, INJURY, V16, P405, DOI 10.1016/0020-1383(85)90057-9; Dannenberg AL, 1996, AM J SPORT MED, V24, P747, DOI 10.1177/036354659602400608; FRANK E, 1995, ACAD EMERG MED, V2, P200, DOI 10.1111/j.1553-2712.1995.tb03198.x; Friedman LJ, 1998, ANN EMERG MED, V31, P219, DOI 10.1016/S0196-0644(98)70310-5; HEMS TEJ, 1992, J TRAUMA, V32, P683, DOI 10.1097/00005373-199206000-00002; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; KULUND D, 1978, PHYSICIAN SPORTSMED, V6, P75; LOFTHOUSE GA, 1994, CLIN SPORT MED, V13, P113; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MONTALTO NJ, 1994, CLIN SPORT MED, V13, P249; Nyberg P, 1996, SCAND J SOC MED, V24, P293, DOI 10.1177/140349489602400410; Rivara F P, 1997, Inj Prev, V3, P110, DOI 10.1136/ip.3.2.110; RIVARA FP, 1989, JAMA-J AM MED ASSOC, V261, P566, DOI 10.1001/jama.261.4.566; SANDERS AB, 1986, ANN EMERG MED, V15, P515, DOI 10.1016/S0196-0644(86)80984-2; SIMPSON AHRW, 1992, INJURY, V23, P171, DOI 10.1016/S0020-1383(05)80038-5; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1388, DOI 10.2105/AJPH.80.11.1388; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TINSWORTH DK, 1994, BICYCLE USE HAZARD P; TUCCI JJ, 1988, AM J SPORT MED, V16, P181, DOI 10.1177/036354658801600216; WEISS BD, 1985, AM J SPORT MED, V13, P187, DOI 10.1177/036354658501300308; YELON JA, 1995, AM SURGEON, V61, P202	24	18	18	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	1999	33	1					56	61		10.1016/S0196-0644(99)70417-8			6	Emergency Medicine	Emergency Medicine	154RC	WOS:000077901700010	9867887				2021-06-18	
J	Parente, R; Stapleton, M				Parente, R; Stapleton, M			Development of a Cognitive strategies group for vocational training after traumatic brain injury	NEUROREHABILITATION			English	Article						cognitive rehabilitation; group therapy; memory training		This study evaluated the effectiveness of a group cognitive skills training model. Thirty-three clients with traumatic brain injury participated in the group over a one year period. Their vocational rehabilitation rate was compared to that of a baseline condition of 64 matched clients who receive similar services but who did not participate in the group. The results indicated a 76% rehabilitation rate for those clients who participated in the group. Fifty-eight percent of the baseline clients returned to work. A description of the group activities is presented that can be implemented by virtually any facility.	Towson State Univ, Dept Psychol, Towson, MD 21204 USA; Maryland Rehabil Ctr, Baltimore, MD 21218 USA	Parente, R (corresponding author), Towson State Univ, Dept Psychol, Townson, MD 21286 USA.		Parente, Frederick/W-2570-2019	Parente, Frederick/0000-0002-2784-3433			BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; HART T, 1986, CLIN NEUROPSYCHOLOGY; Parente R, 1994, NeuroRehabilitation, V4, P25, DOI 10.3233/NRE-1994-4105; Parente R., 1996, RETRAINING COGNITION; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; PARENTE R, 1999, COGNITIVE TECHNOLOGY, V4, P57; PEPPING M, 1998, BRAIN INJURY SOURCE, V2; PRIGATANO G, 1996, NEUROPSYCHOLOGICAL R, P96; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P67; WILSON B, 1986, CLIN MANAGEMENT MEMO, P171	10	18	18	0	5	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		1999	13	1					13	20					8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	244UT	WOS:000083069700003					2021-06-18	
J	Slaughter, J; Bobo, W; Childers, MK				Slaughter, J; Bobo, W; Childers, MK			Selective serotonin reuptake inhibitor treatment of post-traumatic Kluver-Bucy syndrome	BRAIN INJURY			English	Article							DISORDERS; PATIENT	Two cases of Kluver-Bucy syndrome following severe traumatic brain injury (TBI), are described during the period of recovery from acute TBI. These patients posed significant management problems, until successfully managed with selective serotonin reuptake inhibitors (SSRIs). These cases support the benefit of SSRIs in treating associated Kluver-Bucy syndrome.	Univ Missouri, Dept Psychiat & Neurol, Columbia, MO 65212 USA; Univ Missouri, Sch Med, Columbia, MO 65212 USA	Slaughter, J (corresponding author), Univ Missouri, Dept Psychiat & Neurol, 1 Hosp Dr, Columbia, MO 65212 USA.			Childers, Martin/0000-0003-4754-0883			CLARKE DJ, 1990, BRIT J PSYCHIAT, V157, P439, DOI 10.1192/bjp.157.3.439; FORMISANO R, 1995, ACTA NEUROL SCAND, V91, P54; GERSTENBRAND F, 1983, NEUROSCI BIOBEHAV R, V7, P413, DOI 10.1016/0149-7634(83)90047-7; HOOSHMAND H, 1974, JAMA-J AM MED ASSOC, V229, P1782, DOI 10.1001/jama.229.13.1782; JACOME DE, 1991, AM J EEG TECHNOL, V31, P267; LILLY R, 1983, NEUROLOGY, V33, P1141, DOI 10.1212/WNL.33.9.1141; LOPEZ OL, 1995, NEUROPSY NEUROPSY BE, V8, P215; OTT BR, 1995, CLIN NEUROPHARMACOL, V18, P443, DOI 10.1097/00002826-199510000-00007; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STEWART JT, 1985, J CLIN PSYCHIAT, V46, P496; VANPRAAG HM, 1987, BIOL PSYCHIAT, V22, P205, DOI 10.1016/0006-3223(87)90232-0	11	18	19	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1999	13	1					59	62		10.1080/026990599121890			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	158TA	WOS:000078131200008	9972444				2021-06-18	
J	Santos, ME; Castro-Caldas, A; De Sousa, L				Santos, ME; Castro-Caldas, A; De Sousa, L			Spontaneous complaints of long-term traumatic brain injured subjects and their close relatives	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY	Long-term consequences of head injury for patients and families are not well known, given the complexity of variables that have to be studied. Subject's self-experience is one of these less studied aspects. The purpose of this study is to examine the spontaneous complaints of long-term brain injured adult subjects to be compared to the impression of their relatives. A total of 18 chronic head trauma subjects were studied more than 6 years after injury together with a relative, usually a mother or wife. At the beginning of the interview the participants were asked to freely refer their present complaints. In general, relatives referred more complaints about the injured subjects than the injured subjects referred about themselves. This occurred in several domains: somatic, physical, cognitive and behavioural. Memory problems were highly reported by both groups. Somatic complaints were more frequently reported by patients and behavioural problems were more often reported by relatives. Mothers and wives had different profiles of responses. Mothers' opinions were identical to those of their TBI sons in all domains. These different results must be taken into consideration so that the real needs of patients and relatives can be addressed.	Hosp Santa Maria, Ctr Estudos Egas Moniz, Lab Estud Linguagem, P-1600 Lisboa, Portugal; Univ Porto, ICBAS, Porto, Portugal	Santos, ME (corresponding author), Hosp Santa Maria, Ctr Estudos Egas Moniz, Lab Estud Linguagem, P-1600 Lisboa, Portugal.		de Sousa, Liliana/K-9756-2014; Castro-Caldas, Alexandre/M-4156-2013	de Sousa, Liliana/0000-0001-6656-4595; Castro-Caldas, Alexandre/0000-0002-9148-3719; Santos, Maria Emilia/0000-0002-7575-4435			Brooks DN, 1994, EVALUATION TRAUMATIS; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kay Thomas, 1994, P533; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	14	18	19	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					759	767		10.1080/026990598122151			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500004	9755367				2021-06-18	
J	Smith, SL; Hall, ED				Smith, SL; Hall, ED			Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome	JOURNAL OF NEUROTRAUMA			English	Article						cortical degeneration; cortical hemorrhaging; riluzole; shaken baby syndrome; tirilazad mesylate	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; NONGLUCOCORTICOID 21-AMINOSTEROID U74006F; TRAUMA-INDUCED NEURODEGENERATION; EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; BRAIN INJURY; LIPID-PEROXIDATION; BARRIER DISRUPTION; HEAD-INJURY	Our infant rat model of traumatic subarchnoid hemorrhage combines violent shaking and hypoxia to produce subdural hemorrhaging and progressive cortical degeneration similar to that seen in victims of the shaken baby syndrome. Anesthetized, 6-day-old male rats were subjected to one episode of shaking under hypoxic conditions. Brain histologies revealed moderate-to-severe cortical hemorrhaging at 48 h postinjury and progressive cortical degeneration, as indicated by a 15.3% and 20.2% reduction in cortical wet weight, at 7 and 14 days postinjury, respectively. The purpose of the present study was to assess the effects of two antioxidant lipid peroxidation inhibitors (tirilazad mesylate and PNU-101033E), and the glutamate release inhibitor (riluzole), upon the brain pathology seen in this model. A significant, 54.3-75.3%, reduction in cortical hemorrhaging was observed in rats that were treated with a total of three doses of tirilazad (10 mg/kg, i.p.): 10 min before or 5-30 min after injury, and again at 2 and 24 h postinjury (p < 0.01 vs. vehicle). However, treatment with tirilazad or the more potent, brain-penetrating pyrrolopyrimidine, PNU-101033E (10 min before plus 2, 24, 48, and 72 h after), did not attenuate the progressive cortical degeneration typically seen at 14 days postinjury. These results suggest that free radicals play an important role in the pathophysiology of secondary brain hemorrhaging due to shaking + hypoxia, but may not be critical in the mediation of the subsequent neurodegeneration. Rather, glutamate neurotoxicity may be a key factor here. This is suggested by our observation that the glutamate release inhibitor, riluzole, significantly reduced cortical degeneration when it was administered up to 1 h postinjury in the present model. Specifically, the cortical wet weights of rats treated with 8 mg/kg riluzole (i.p.) 10 min before or 1 h after shaking + hypoxia (and again at 24 h postinjury) were 95.3% and 97.4% of noninjured controls, respectively, at 14 days postinjury (p < 0.02 vs. vehicle). Riluzole treatment beyond 1 h (e.g., 2 or 4 h postinjury) did not reduce the neurodegeneration. Lastly, we attempted to demonstrate that the therapeutic window for riluzole-induced attenuation of cortical degeneration could be extended beyond 1 h through the use of combination therapy. In this experiment, rat pups were treated with 10 mg/kg tirilazad (i.p.) at 30 min postinjury followed by 8 mg/kg riluzole (i.p.) at 4 and 24 h postinjury. At 14 days postinjury, the cortical wet weights of these rats were 94.5% of noninjured controls, thus demonstrating significant neuroprotection (p < 0.05 vs, vehicle) and a widening of the therapeutic window from 1 to 4 h in length. These results suggest that early attenuation of free radical-induced lipid peroxidation may slow down the biochemical cascade of events related to glutamate-induced excitotoxicity and, in doing so, prolong the time during which a glutamate release inhibitor, such as riluzole, is effective.	Pharmacia & Upjohn Inc, CNS Dis Res, Kalamazoo, MI 49001 USA	Smith, SL (corresponding author), Pharmacia & Upjohn Inc, CNS Dis Res, 301 Henrietta St 7251-209-4, Kalamazoo, MI 49001 USA.		Hall, Edward D/F-8930-2013				Bagenholm R, 1996, PEDIATR RES, V40, P399, DOI 10.1203/00006450-199609000-00006; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DIETRICH WD, 1992, ACTA NEUROPATHOL, V84, P621, DOI 10.1007/BF00227739; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; Du C, 1996, J NEUROTRAUM, V13, P215, DOI 10.1089/neu.1996.13.215; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1996, NEUROLOGICAL SURG CO, V3, P1777; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLECK TJ, 1995, J NEUROTRAUM, V12, P968; GILLAND E, 1994, DEV BRAIN RES, V83, P79, DOI 10.1016/0165-3806(94)90181-3; GRAFE MR, 1994, BRAIN RES, V653, P161, DOI 10.1016/0006-8993(94)90385-9; HAGBERG H, 1994, BIOL NEONATE, V66, P205; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; Hall ED, 1996, ACT NEUR S, V66, P107; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1988, BRAIN RES, V451, P350, DOI 10.1016/0006-8993(88)90782-2; Hall ED, 1996, EUR J ANAESTH, V13, P279, DOI 10.1046/j.1365-2346.1996.00980.x; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1997, HDB SYNTHETIC ANTIOX, P261; Hall ED, 1993, IRON CENTRAL NERVOUS, P173; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MUNNS PL, 1995, FREE RADICAL BIO MED, V18, P467, DOI 10.1016/0891-5849(94)00163-E; NAKAGOMI T, 1987, J NEUROSURG, V66, P915, DOI 10.3171/jns.1987.66.6.0915; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Povlishock John T., 1993, P185; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; ROHN TT, 1993, BIOCHEM PHARMACOL, V46, P525, DOI 10.1016/0006-2952(93)90530-A; SASAKI T, 1986, NEUROSURGERY, V19, P177, DOI 10.1227/00006123-198608000-00002; SASAKI T, 1985, J NEUROSURG, V63, P433, DOI 10.3171/jns.1985.63.3.0433; SCHMIDT I, 1987, CAN J PHYSIOL PHARM, V65, P1355, DOI 10.1139/y87-214; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; Taylor BM, 1996, J PHARMACOL EXP THER, V276, P1224; VOLLMER DG, 1989, SURG NEUROL, V31, P190, DOI 10.1016/0090-3019(89)90115-8; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; WAHL F, 1996, J NEUROTRAUM, V13, P627; YANG GY, 1994, NEUROSURGERY, V34, P339, DOI 10.1097/00006123-199402000-00018; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367	54	18	20	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					707	719		10.1089/neu.1998.15.707			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400006	9753218				2021-06-18	
J	Yamaki, T; Murakami, N; Iwamoto, Y; Sakakibara, T; Kobori, N; Ueda, S; Uwahodo, Y; Kikuchi, T				Yamaki, T; Murakami, N; Iwamoto, Y; Sakakibara, T; Kobori, N; Ueda, S; Uwahodo, Y; Kikuchi, T			Cognitive dysfunction and histological findings in rats with chronic-stage contusion and diffuse axonal injury	BRAIN RESEARCH PROTOCOLS			English	Article						behavioral neurobiology; traumatic brain injury; cortical contusion; diffuse axonal injury; Morris water maze	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; DEFICITS; LESION; MODEL	The Morris water maze (MWM) technique is well known as a prominent method of evaluating learning acquisition and memory retention impairments in rats. We previously reported on a modified fluid percussion device that is able to consistently produce experimental cortical contusion (CC) and diffuse axonal injury (DAI) in separate groups of rats. The purpose of the present protocol is to evaluate the differences in learning acquisition and memory retention impairments between these two types of injured rats in the chronic stage using the MWM technique. CC and DAT rats are respectively induced by lateral and midline fluid percussion. We also compare the histological differences between these two different types of traumatic brain injury. The results show statistically significant differences in learning acquisition impairment between the sham and CC rats and between the sham and DAI rats. However, a difference in memory retention impairment was expected to be seen only between the sham and DAI rats. Histologically, the loss of CA3 pyramidal cells in the hippocampus was observed ipsilaterally in the CC and bilaterally in DAI. Neuronal cell loss was observed in bilaterally in layer II of the entorhinal cortex in DAI, but not in CC. (C) 1998 Elsevier Science B.V. All rights reserved.	Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kyoto 602, Japan; Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, Tokushima 77101, Japan	Yamaki, T (corresponding author), Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kyoto 602, Japan.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; IWAMOTO Y, IN PRESS NEUROSURGER; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; PELLEGRINO LJ, 1975, STEREOTAXIC ATLAS RA; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2	19	18	18	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	SEP	1998	3	1					100	106		10.1016/S1385-299X(98)00030-0			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	134TU	WOS:000076760200015	9767137				2021-06-18	
J	Ferland, MB; Ramsay, J; Engeland, C; O'Hara, P				Ferland, MB; Ramsay, J; Engeland, C; O'Hara, P			Comparison of the performance of normal individuals and survivors of traumatic brain injury on repeat administrations of the Wisconsin Card Sorting Test	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; AGE; SEX	Repeat administrations of the Wisconsin Card Sorting Test (WCST) are a common clinical practice to assess changes in cognitive functions of individuals recovering from traumatic brain injury (TBI). Yet, little is even known about the performance of healthy individuals on repeat administrations of the test. The present study compared the effects of repeat administration of the WCST in normal individuals and survivors of traumatic brain injury. Normal participants were administered the WCST twice, with a 5-month interval between testings and the findings were compared to the data from patients with TBI tested twice. Normal controls only modestly improved their performance on repeat testing. In constrast, using a reliability of change (RC) index, TBI survivors demonstrated clinically meaningful gains in performance.	Sisters Charity Ottawa Hlth Serv, Dept Res, Ottawa, ON K1R 7A5, Canada; Univ Toronto, Dept Human Dev & Appl Psychol, Toronto, ON, Canada; Royal Ottawa Hosp, Neurophysiol Res Lab, Ottawa, ON K1Z 7K4, Canada	Ferland, MB (corresponding author), Sisters Charity Ottawa Hlth Serv, Dept Res, St Vincent Pavil,60 Cambridge St N, Ottawa, ON K1R 7A5, Canada.	mferland@scohs.on.ca					ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BOONE KB, 1993, J CLIN PSYCHOL, V49, P54, DOI 10.1002/1097-4679(199301)49:1<54::AID-JCLP2270490108>3.0.CO;2-6; DREWE E A, 1974, Cortex, V10, P159; Esposito G, 1996, J NUCL MED, V37, P559; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; YEUDALL LT, 1986, J CLIN PSYCHOL, V42, P918, DOI 10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y	19	18	19	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1998	20	4					473	482		10.1076/jcen.20.4.473.1475			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	153JY	WOS:000077831000005	9892051				2021-06-18	
J	Johnstone, B; Childers, MK; Hoerner, J				Johnstone, B; Childers, MK; Hoerner, J			The effects of normal ageing on neuropsychological functioning following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA; ONSET	Increasing age is associated with greater absolute neuropsychological impairment (e.g. slower processing speed, diminished memory), although it is unclear if older individuals with traumatic brain injury (TBI) show greater relative impairment than younger individuals with TBI. The current study evaluated the effects of normal ageing on TBI by using age-based normative data to calculate indices of relative decline from pre-morbid levels (expressed as z-deficit scores) for different age groups (20-39 years, 40-59 years, 60+ years). The sample included 279 individuals with TBI between the ages of 20 and 65 who were assessed in a department of rehabilitation neuropsychology laboratory over a 4-year period. Spearman correlations and ANOVAs did not show age-related differences in relative memory, attention or speed of processing abilities, although results did indicate that increasing age is associated with relatively less impairment in intelligence. The results suggest that the greater neuropsychological impairment noted in older individuals with TBI is most likely related to normal ageing. The importance of considering both absolute and relative degrees of impairment is discussed.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, 1 Hosp Dr, Columbia, MO 65212 USA.			Childers, Martin/0000-0003-4754-0883; Johnstone, Brick/0000-0001-8845-9649			ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; ALEXANDER MP, 1928, PSYCHIAT ASPECTS NEU, V2, P219; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; COFFEY E, 1992, BRIT NEUR ASS ANN M; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; FOGEL, 1994, NEUROPSYCHIATRY TRAU, P413; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HORTON AM, 1992, PERCEPT MOTOR SKILL, V75, P257, DOI 10.2466/PMS.75.4.257-258; Hung C C, 1991, J Formos Med Assoc, V90, P1227; JASTAK S, 1984, WRAT R WIDE RANGE AC; Johnstone B, 1996, J Int Neuropsychol Soc, V2, P282; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MEIER U, 1991, ZBL CHIR, V116, P845; Miller JR, 1989, MILD MODERATE HEAD I, P125; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MOULTON RJ, 1992, CAN J SURG, V35, P35; NEE LE, 1987, NEUROLOGY, V37, P359, DOI 10.1212/WNL.37.3.359; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RAKIER A, 1995, BRAIN INJURY, V9, P187, DOI 10.3109/02699059509008191; Reitan RM., 1985, HALSTEAD REITAN NEUR; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; TEASDALE TW, 1982, HEAD INJURY BASIC CL, P213; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC	30	18	19	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					569	576		10.1080/026990598122331			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200003	9653520				2021-06-18	
J	Klapdor, K; Van der Staay, FJ				Klapdor, K; Van der Staay, FJ			Repeated acquisition of a spatial navigation task in mice: Effects of spacing of trials and of unilateral middle cerebral artery occlusion	PHYSIOLOGY & BEHAVIOR			English	Article						repeated acquisition; Morris maze; working memory; spatial navigation; middle cerebral artery occlusion; MCA-O; C57BL mouse	TRAUMATIC BRAIN INJURY; WATER-ESCAPE BEHAVIOR; MEDIAL SEPTAL AREA; LEARNING-SET; RATS; MEMORY; MAZE; ISCHEMIA; AGE; PERFORMANCE	The working memory version of the Morris water escape task, the repeated acquisition task, consists of trial pairs in which an animal is started twice from the same start position. Animals have mastered this task when they need less time to find the platform in the second of the two trials. In this study, study, male C57BL mice were trained on this task with massed, spaced, or spaced delay trials in which there was a 90-min delay between the first and second trials of a pair. The mice trained with spaced trials learned the repeated acquisition task, whereas the mice trained with massed or spaced delay trials were not consistently able to do so. When the mice had reached a stable baseline performance, the middle cerebral artery (MCA) was occluded or the mice were sham-operated. Then, the effects of the MCA occlusion (MCA-O) on the performance in the repeated acquisition tasks were studied. MCA occlusion hardly affected the performance in this task, irrespective of the spacing condition of the trials, although surgery per se seemed to have a transient disruptive effect. (C) 1998 Elsevier Science Inc.	Bayer, CNS Res, D-51063 Cologne, Germany	Van der Staay, FJ (corresponding author), Bayer, CNS Res, Neurather Ring 1, D-51063 Cologne, Germany.			van der Staay, F. Josef/0000-0002-8704-3366			AITKEN DH, 1989, NEUROBIOL AGING, V10, P273, DOI 10.1016/0197-4580(89)90062-6; AUER RN, 1989, J NEUROSCI, V9, P1641; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; CHIAMULERA C, 1993, BRAIN RES, V606, P251, DOI 10.1016/0006-8993(93)90992-V; Cohn J, 1996, COGNITIVE BRAIN RES, V3, P183, DOI 10.1016/0926-6410(96)00005-5; DENENBERG VH, 1991, BRAIN RES, V562, P98, DOI 10.1016/0006-8993(91)91192-4; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HARA H, 1991, EUR J PHARMACOL, V197, P72; HIMORI N, 1990, J PHARMACOL METHOD, V23, P311; Klapdor K, 1996, PHYSIOL BEHAV, V60, P1247, DOI 10.1016/S0031-9384(96)00224-7; KOLB B, 1987, BEHAV BRAIN RES, V23, P127, DOI 10.1016/0166-4328(87)90050-7; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kumon Y, 1996, NEUROSCI LETT, V206, P141; LAMBERTY Y, 1991, BEHAV NEURAL BIOL, V56, P89, DOI 10.1016/0163-1047(91)90315-H; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MEMEZAWA H, 1993, THESIS U LUND SWEDEN; MHARZI M, 1987, PHYSIOL BEHAV, V40, P181, DOI 10.1016/0031-9384(87)90205-8; MORRIS RGM, 1984, J NEUROSCI METH, V1, P47; MUNDY WR, 1990, BRAIN RES, V512, P221, DOI 10.1016/0006-8993(90)90629-P; NAGAHARA AH, 1992, BRAIN RES, V591, P54, DOI 10.1016/0006-8993(92)90977-H; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PARK CK, 1994, BRAIN RES, V645, P157; PAYLOR R, 1990, BEHAV BRAIN RES, V36, P79, DOI 10.1016/0166-4328(90)90162-8; Petrie BF, 1995, PSYCHOL REP, V77, P1339, DOI 10.2466/pr0.1995.77.3f.1339; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PITSIKAS N, 1993, NEUROBIOL AGING, V14, P561, DOI 10.1016/0197-4580(93)90039-E; RashidyPour A, 1996, BRAIN RES, V709, P131, DOI 10.1016/0006-8993(95)01323-7; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Shinoda M, 1996, EUR J PHARMACOL, V305, P31, DOI 10.1016/0014-2999(96)00173-2; ShukittHale B, 1996, PHYSIOL BEHAV, V59, P867, DOI 10.1016/0031-9384(95)02107-8; SWEENEY JE, 1988, PHARMACOL BIOCHEM BE, V31, P141, DOI 10.1016/0091-3057(88)90325-5; TAMURA A, 1985, J CEREB BLOOD FLOW M, V5, P379; VANDERSTAAY FJ, 1993, BEHAV NEURAL BIOL, V60, P33, DOI 10.1016/0163-1047(93)90690-J; vanderStaay FJ, 1996, BRAIN RES, V715, P180, DOI 10.1016/0006-8993(95)01581-7; VANDERSTAAY FJ, 1992, NEUROSCI RES COMMUN, V11, P11; VINCENT GP, 1992, BRAIN RES, V597, P264, DOI 10.1016/0006-8993(92)91483-U; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WELSH FA, 1987, J NEUROCHEM, V49, P846, DOI 10.1111/j.1471-4159.1987.tb00971.x; WHISHAW IQ, 1995, PHYSIOL BEHAV, V58, P687, DOI 10.1016/0031-9384(95)00110-5; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P59, DOI 10.1016/0166-4328(87)90036-2; Winer BJ., 1971, STAT PRINCIPLES EXPT; YAMAMOTO M, 1991, EUR J PHARMACOL, V197, P117; YOUNGBLOOD BD, 1997, PHYSIOL BEHAV, V61, P239	47	18	18	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	MAR	1998	63	5					903	909		10.1016/S0031-9384(98)00003-1			7	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	ZN303	WOS:000073632400023	9618015				2021-06-18	
J	Jukkala-Partio, K; Partio, EK; Hirvensalo, E; Rokkanen, P				Jukkala-Partio, K; Partio, EK; Hirvensalo, E; Rokkanen, P			Absorbable fixation of femoral head fractures - A prospective study of six cases	ANNALES CHIRURGIAE ET GYNAECOLOGIAE			English	Article						bioabsorbable implants; fracture; femoral	DISLOCATION; HIP	Background and Aims: Fracture of the femoral head associated with a traumatic dislocation of the hip is a rare but severe injury. The methods of the recommended treatment have varied from primary closed or open reduction without fixation to excision of fragments or internal fixation. In our department we have treated other kinds of intra-articular fractures successfully with totally absorbable polyglycolide and poly-L-lactide implants. The aim of this study was to investigate the value of totally absorbable rods and screws in the fixation of the femoral head fractures. Material and Methods: Six femoral head fractures associated with a posterior traumatic dislocation of the hip were treated by open reduction and internal fixation using self-reinforced absorbable polyglycolide (SR-PGA) or poly-L-lactide (SR-PLLA) rods and screws. The follow-up time was 38 months in average (range 6 weeks to 77 months). Results: In three patients the end results were excellent and in one fair. One patient died six weeks after the accident from the consequences of the cerebral injury. In one 61-year-old patient an arthroplasty was performed one year after the primary osteosynthesis, because of avascular necrosis of the femoral head. Conclusions: Self-reinforced polyglycolide and polylactide implants can be used safely to fix femoral head fractures without the need of implant removal.	Univ Helsinki, Cent Hosp, Dept Orthopaed & Traumatol, FIN-00260 Helsinki, Finland	Jukkala-Partio, K (corresponding author), Univ Helsinki, Cent Hosp, Dept Orthopaed & Traumatol, Topeliuksenkatu 5, FIN-00260 Helsinki, Finland.						BOSTMAN O, 1987, J BONE JOINT SURG BR, V69, P615; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; GUIRAL J, 1992, INJURY, V23, P417, DOI 10.1016/0020-1383(92)90022-K; HIRVENSALO E, 1990, ARCH ORTHOP TRAUM SU, V109, P258, DOI 10.1007/BF00419939; HOUGAARD K, 1988, J BONE JOINT SURG AM, V70A, P233, DOI 10.2106/00004623-198870020-00011; HUANG X, 1995, CHINESE J ORTHOP, V15, P758; JAKOB JR, 1987, CLIN ORTHOPAEDICS, V214, P249; KELLY RP, 1971, J TRAUM, V11, P97, DOI 10.1097/00005373-197102000-00001; KUHN DA, 1987, J TRAUMA, V27, P442, DOI 10.1097/00005373-198704000-00019; LANGSTEVENSON A, 1987, INJURY, V18, P264, DOI 10.1016/0020-1383(87)90011-8; MOWERY C, 1986, J TRAUMA, V26, P1041, DOI 10.1097/00005373-198611000-00014; MURRAY P, 1988, INJURY, V19, P220, DOI 10.1016/0020-1383(88)90023-X; Partio E K, 1992, J Orthop Trauma, V6, P209, DOI 10.1097/00005131-199206000-00013; PIPKIN G, 1957, J BONE JOINT SURG AM, V39, P1027, DOI 10.2106/00004623-195739050-00004; ROEDER LF, 1980, CLIN ORTHOP RELAT R, P121; Ruf W, 1990, Unfallchirurgie, V16, P202, DOI 10.1007/BF02588776; SIMMERT JB, 1993, J ORTHOP TRAUMA, V7, P567, DOI 10.1097/00005131-199312000-00014; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; VERMEIREN JAM, 1991, J TRAUMA, V31, P579, DOI 10.1097/00005373-199104000-00020; Warren P J, 1991, J Orthop Trauma, V5, P504, DOI 10.1097/00005131-199112000-00020	24	18	19	0	0	FINNISH SURGICAL SOC	HELSINKI	MAKELANKATU 2, SF-00550 HELSINKI, FINLAND	0355-9521			ANN CHIR GYNAECOL FE	Ann. Chir. Gynaecol.		1998	87	1					44	48					5	Obstetrics & Gynecology; Surgery	Obstetrics & Gynecology; Surgery	ZL668	WOS:000073458500012	9598230				2021-06-18	
J	Stover, JF; Lenzlinger, PM; Stocker, R; Morganti-Kossmann, MC; Imhof, HG; Trentz, O; Kossmann, T				Stover, JF; Lenzlinger, PM; Stocker, R; Morganti-Kossmann, MC; Imhof, HG; Trentz, O; Kossmann, T			Thiopental in CSF and serum correlates with prolonged loss of cortical activity	EUROPEAN NEUROLOGY			English	Article						thiopental; traumatic brain injury; drug kinetics; drug monitoring; barbiturate coma; electroencephalogram	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; PHARMACOKINETICS	Barbiturate coma is initiated in brain-injured patients whenever elevated intracranial pressure remains unresponsive to other therapeutical strategies. However, barbiturates alter cortical activity resulting in difficulties in clinical evaluation. Therefore, we investigated the impact of long-term thiopental administration on responsiveness to exteroceptive stimuli in relation to pharmacokinetics of thiopental in CSF and serum. Long-term infusion increases thiopental levels which remain elevated for 6 and 9 days in CSF and serum, respectively, after termination of its administration. Prolonged unresponsiveness to exteroceptive stimuli correlates with persisting thiopental in CSF and serum. Thus, quantitative analysis of thiopental in serum becomes indispensable in predicting the length of drug-induced neurological impairment and in avoiding misinterpretation of the neurological status.	Univ Zurich, Div Trauma Surg, Dept Surg, Sch Med, CH-8091 Zurich, Switzerland; Univ Zurich, Div Surg Res, Dept Surg, Sch Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Sch Med, Dept Neurosurg, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Univ Zurich, Div Trauma Surg, Dept Surg, Sch Med, Ramistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			AIREY IL, 1982, ANAESTHESIA, V37, P328, DOI 10.1111/j.1365-2044.1982.tb01110.x; ALTMAYER P, 1987, METHOD FIND EXP CLIN, V9, P817; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; BRODIE BB, 1952, FED PROC, V11, P632; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRUHL H, 1984, J CLIN CHEM CLIN BIO, V22, P385; HUDSON RJ, 1983, ANESTHESIOLOGY, V59, P215; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LUNDAR T, 1983, CRIT CARE MED, V11, P559, DOI 10.1097/00003246-198307000-00017; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MILLER JD, 1971, BRAIN RES, V34, P411; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; PRICE HL, 1960, ANESTHESIOLOGY, V21, P40, DOI 10.1097/00000542-196001000-00008; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; SELMAN WR, 1981, SURG NEUROL, V15, P9, DOI 10.1016/S0090-3019(81)80081-X; SHERWIN AL, 1988, EPILEPSY RES, V2, P281, DOI 10.1016/0920-1211(88)90035-6; STANSKI DR, 1980, ANESTHESIOLOGY, V53, P169, DOI 10.1097/00000542-198008000-00012; STOCKER R, 1995, INTEGRATED APPROACH, P196; SUTTON LN, 1987, J NEUROSURG, V67, P381, DOI 10.3171/jns.1987.67.3.0381; TURCANT A, 1985, ANESTHESIOLOGY, V63, P50, DOI 10.1097/00000542-198507000-00007; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; WOOD M, 1990, DRUGS ANESTHESIA PHA, P178	26	18	19	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022			EUR NEUROL	Eur. Neurol.		1998	39	4					223	228		10.1159/000007938			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZR376	WOS:000073968500006	9635473	Green Accepted			2021-06-18	
J	Casselman, JW; Bensimon, JL				Casselman, JW; Bensimon, JL			Imaging of the inner ear	RADIOLOGE			German	Article						inner ear; CT; MRT; malformation; trauma; tumor; inflammation	TEMPORAL BONE; HEARING-LOSS; SPIN-ECHO; MR; MALFORMATIONS; ENHANCEMENT; VERTIGO; CT	New computed tomography (CT) and magnetic resonance (MR) techniques allow more detailed anatomic studies of the inner ear. CT is still the best technique to study patients with fractures, congenital malformations and otodystrophies involving the inner ear. During recent years MR imaging has emerged as an excellent method to detect pathology in the internal auditory canal, membranous labyrinth and bony labyrinth and to characterize petrous apex lesions. MR has even proved its value in patients with fractures and congenital malformations making the diagnosis of, for instance, labyrinthine concussion and absence of the vestibulocochlear nerve possible. The diagnosis of acute/chronic labyrinthitis and intralabyrinthine tumors has also became possible. However, MR and CT are often complementary, as is the case in patients with mixed hearing loss, congenital malformations and petrous apex lesions.	AZ St Jan Brugge, Dept Radiol, B-8000 Brugge, Belgium; Imagerie ORL & Gen, Paris, France	Casselman, JW (corresponding author), AZ St Jan Brugge, Dept Radiol, Ruddershove 10, B-8000 Brugge, Belgium.						Brandt T, 1993, J Vestib Res, V3, P373; CASSELMAN JW, 1993, AM J NEURORADIOL, V14, P59; Casselman JW, 1996, NEURORADIOLOGY, V38, P278; Casselman JW, 1997, RADIOLOGY, V202, P773, DOI 10.1148/radiology.202.3.9051033; Casselman JW, 1996, NEUROIMAG CLIN N AM, V6, P265; CASSELMAN JW, 1993, AM J NEURORADIOL, V14, P47; CASSELMAN JW, 1994, AM J NEURORADIOL, V15, P131; HARNSBERGER HR, 1987, RADIOLOGY, V164, P53, DOI 10.1148/radiology.164.1.3108956; JACKLER RK, 1987, LARYNGOSCOPE, V97, P2; LO WWM, 1991, HEAD NECK IMAGING, P1046; Mafee M F, 1994, Neuroimaging Clin N Am, V4, P561; MARK AS, 1993, AM J NEURORADIOL, V14, P991; MARK AS, 1992, ANN OTO RHINOL LARYN, V101, P459, DOI 10.1177/000348949210100601; RAMSEY KL, 1993, AM J OTOL, V14, P605; SCHMALBROCK P, 1993, JMRI-J MAGN RESON IM, V3, P451, DOI 10.1002/jmri.1880030304; SCHUKNECHT HF, 1993, PATHOLOGY EAR, P105; SWARTZ JD, 1986, IMAGING TEMPORAL BON, P161; TANIOKA H, 1991, RADIOLOGY, V178, P141, DOI 10.1148/radiology.178.1.1984292; TIEN RD, 1992, AM J ROENTGENOL, V159, P395, DOI 10.2214/ajr.159.2.1632364; TIEN RD, 1993, MAGN RESON IMAGING, V11, P429, DOI 10.1016/0730-725X(93)90077-Q; TORIZUKA T, 1992, RADIOLOGY, V184, P109, DOI 10.1148/radiology.184.1.1609065	21	18	18	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0033-832X			RADIOLOGE	Radiologe	DEC	1997	37	12					954	963		10.1007/s001170050307			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	YP395	WOS:000071272600004	9498245				2021-06-18	
J	Bogner, JA; Corrigan, JD; Spafford, DE; LambHart, GL				Bogner, JA; Corrigan, JD; Spafford, DE; LambHart, GL			Integrating substance abuse treatment and vocational rehabilitation after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Objective: To describe and evaluate a resource and service coordination model for integrating substance abuse treatment and vocational rehabilitation following brain injury. Design: Retrospective study, consecutive sample. Setting: Community-based treatment. Subjects: Seventy-two clients who received services from the TBI Network. Only subjects that had received a comprehensive assessment, agreed to a treatment plan, and had been monitored fcr at least 1 year after initiation of the plan were included in the sample. Main Outcome Measures: Substance use and productivity, as measured by the Quantity-Frequency-Variability Index, General Health;md History Questionnaire, Addiction Severity Index, and the Employability Rating Scale. Results: Pre-and postcomparisons showed significantly better vocational status and greater Likelihood of abstinence from alcohol and other drugs after the intervention. Investigation of a priori hypotheses regarding mediating variables was limited by sample size and selection biases. Time after injury was not associated with positive outcomes, though a trend was evident for decreased substance use among those referred within 3 months after injury. The engagement of a community team was associated with decreased substance use but not greater productivity. Results are discussed in terms of possible ingredients for replication of this approach in other settings.	TBI NETWORK,COLUMBUS,OH; OHIO STATE UNIV,OHIO VALLEY CTR BRAIN INJURY PREVENT & REHABIL,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210			Corrigan, John D./E-2921-2011				Ashery R S, 1994, J Case Manag, V3, P179; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; CALLAHAN D, 1968, Q J STUD ALCOHOL, V29, P130; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; KAY T, 1993, COMMUNITY BASED EMPL, P29; Kreutzer J., 1987, GEN HLTH HIST QUESTI; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; LANGLEY MJ, 1992, NEUROREHABILITATION, V2, P52; LANGLEY MJ, 1991, ADV BRAIN INJURY REH; MCLELLAN AT, 1990, ADDICTION SEVERITY I; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT HEAD INJ F, 1988, SUBST AB TASK FORC W; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Ridgely M S, 1994, J Case Manag, V3, P132; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; SPARADEO FR, 1993, STAFF DEV CLIN INTER; Willenbring M L, 1994, J Case Manag, V3, P150	25	18	18	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1997	12	5					57	71		10.1097/00001199-199710000-00006			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YA515	WOS:A1997YA51500006					2021-06-18	
J	Zink, BJ; Maio, RF; Chen, B				Zink, BJ; Maio, RF; Chen, B			Alcohol, central nervous system injury, and time to death in fatal motor vehicle crashes	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						alcohol; brain injury; motor vehicle crashes; trauma	TRAUMATIC BRAIN INJURY; HOSPITAL COURSE; ETHANOL; INTOXICATION; ABUSE	Objectives: Motor vehicle crash (MVC) studies have found that alcohol (ALC) is associated with increased mortality and decreased time to death (TTD). Clinical and experimental data suggest that ALC potentiates central nervous system injury (CNSI). We hypothesize that ALC-intoxicated, MVC fatalities with CNSI are more likely to die in the immediate postinjury period than are sober victims with CNSI. Methods: Design-A retrospective cohort of 401 MVC fatalities from four Michigan counties for the time period 1985 to 1991 was studied. Measurements-Medical examiner records were reviewed to determine age, blood alcohol concentration (BAC), and TTD. Injury severity was calculated with the Abbreviated Injury Scale (1985 version). Anatomical profile scores and G scores were also calculated and used to identify CNSI subjects. Analysis-chi(2) and Student's t test were used, and odds ratios with 0.95 confidence intervals (CIs) were calculated. Results: ALC(+) cases (BAC greater than or equal to 100 mg/dl) (n = 99) were significantly younger and more frequently had TTD < 1 hr than ALC(-) cases (n = 233): odds ratio 1.62 [0.95 CI (1.02 to 2.56)]. Overall, CNSI cases (n = 297) were significantly younger and had fewer thoracic injuries, but did not have significantly shorter TTD, compared with non-CNSI cases. However, ALC(+) CNSI cases (n = 77) were over twice as likely to have TTD < 1 hr {odds ratio 2.04 [0.95 CI (1.13 to 3.70)]}. For ALC(+) isolated CNSI cases, the odds ratio for TTD < 1 hr, compared with nonisolated CNSI cases was 8.25 (0.95; CI 0.66 to 102.5). Injury Severity Score, anatomical profile, and G scores were not significantly different for ALC(+) CNSI cases, compared with ALC(-) CNSI cases, whether isolated or nonisolated. Conclusions: These data suggest that alcohol intoxication is associated with increased frequency of early death in MVC victims with CNSI, despite there being no detectable difference in anatomical injury scoring.		Zink, BJ (corresponding author), UNIV MICHIGAN,DEPT SURG,SECT EMERGENCY MED,TC B1354,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.						ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; Becker DP, 1989, TXB HEAD INJURY, P1; CHEN B, 1995, J TRAUMA, V38, P228, DOI 10.1097/00005373-199502000-00014; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FELL JC, 1990, 34 ANN P ASS ADV AUT, P69; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALT PS, 1992, ARCH NEUROL-CHICAGO, V49, P1178, DOI 10.1001/archneur.1992.00530350096025; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MILLER JD, 1991, J NEUROL SCI, V103, pS33; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SELIGMAN ML, 1978, LIPIDS, V12, P946; SHANLEY BC, 1993, RES MONOGRAPH US DEP, V22, P299; STEWART JR, 1988, 32 ANN P ASS ADV AUT, P319; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Zink B J, 1994, Acad Emerg Med, V1, P171; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; 1992, MMWR-MORBID MORTAL W, V41, P893	28	18	18	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0145-6008			ALCOHOL CLIN EXP RES	Alcoholism (NY)	DEC	1996	20	9					1518	1522		10.1111/j.1530-0277.1996.tb01693.x			5	Substance Abuse	Substance Abuse	VZ863	WOS:A1996VZ86300004	8986197	Green Published			2021-06-18	
J	Shum, DKY; Chau, CH				Shum, DKY; Chau, CH			Changes in glycosaminoglycans during regeneration of post-crush sciatic nerves of adult guinea pigs	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neural glycosaminoglycans; post-crush sciatic nerve; regeneration	CHONDROITIN-SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; GOLDFISH OPTIC-NERVE; NEURITE OUTGROWTH; SCHWANN-CELLS; EXTRACELLULAR-MATRIX; HYALURONIC-ACID; AXONAL-TRANSPORT; BRAIN; RAT	The glycosaminoglycans of sciatic nerves recovering from crush-injury were studied in adult guinea pigs and compared with those of non-injured mature neural tissues, The glycosaminoglycans were recovered from the 1,900 g supernatant and pellet of the tissue homogenates and assayed for hexuronate contents and susceptibilities to hyaluronidase, chondroitinase ABC, and nitrous acid, In the normal brain and central nerve tracts, the glycosoaminoglycans were distributed both in the supernatant and pellet fractions; the brain showed a predominance of chondroitin sulphates but the tracts showed a predominance of heparan sulphates, Twice as much glycosaminoglycans were found in normal sciatic nerves, only in the pellet fraction and with heparan sulphate predominant, In the 2 weeks post-crush, progressive increase in hexuronate was observed, due mainly to additional chondroitin sulphate forms in the supernatant; the pellet fraction in the same period was however similar to the untreated controls in relative abundance of glycosaminoglycan classes and hexuronate content, At 4 weeks post-crush, although the total hexuronate returned to the control level, a significant proportion of glycosaminoglycans remained in the supernatant fraction, Evidence is thus provided for the need to modulate the glycosaminoglycan expression pattern in adult neural tissue to allow post-traumatic tissue remodelling and axonal regrowth. (C) 1996 Wiley-Liss, Inc.		Shum, DKY (corresponding author), UNIV HONG KONG,DEPT BIOCHEM,FAC MED,5 SASSOON RD,HONG KONG,HONG KONG.		Chau, Chi Ho/C-4221-2009; Shum, Daisy/C-4393-2009				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; BERTOLOTTO A, 1991, J NEUROSCI RES, V29, P225, DOI 10.1002/jnr.490290213; BICKNESE AR, 1994, J NEUROSCI, V14, P3500; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P804; BRITTIS PA, 1994, P NATL ACAD SCI USA, V91, P7539, DOI 10.1073/pnas.91.16.7539; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; CAREY DJ, 1986, J BIOL CHEM, V261, P7518; CAREY DJ, 1993, EXP CELL RES, V208, P10, DOI 10.1006/excr.1993.1217; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; COUGHLIN C, 1989, BRAIN RES, V493, P326, DOI 10.1016/0006-8993(89)91167-0; Dou CL, 1995, J NEUROSCI, V15, P8053; DOW KE, 1994, EXP NEUROL, V126, P129, DOI 10.1006/exnr.1994.1049; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUXE K, 1994, BRAIN RES, V636, P131, DOI 10.1016/0006-8993(94)90187-2; GHIRNIKAR RS, 1995, GLIA, V14, P145, DOI 10.1002/glia.440140209; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HANEMANN CO, 1993, J HISTOCHEM CYTOCHEM, V41, P1383, DOI 10.1177/41.9.8354878; Hennig A., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P585; IIJIMA N, 1991, J NEUROCHEM, V56, P706, DOI 10.1111/j.1471-4159.1991.tb08207.x; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEE YC, 1961, ARCH BIOCHEM BIOPHYS, V93, P292, DOI 10.1016/0003-9861(61)90265-X; LEVINE JM, 1994, J NEUROSCI, V14, P4716; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; NEWTON DJ, 1974, ANAL BIOCHEM, V62, P268, DOI 10.1016/0003-2697(74)90386-8; OOHIRA A, 1991, J NEUROSCI, V11, P822; PERIDES G, 1990, BRAIN RES, V512, P309, DOI 10.1016/0006-8993(90)90642-O; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; RAULO E, 1994, J BIOL CHEM, V269, P12999; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; SAITO H, 1968, J BIOL CHEM, V243, P1536; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; Schachner M., 1990, SEMIN NEUROSCI, V2, P497; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SILBERT JE, 1993, BIOCHEM J, V296, P119, DOI 10.1042/bj2960119; SNOW DM, 1992, J NEUROBIOL, V23, P322, DOI 10.1002/neu.480230311; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TONA A, 1993, J HISTOCHEM CYTOCHEM, V41, P593, DOI 10.1177/41.4.8450198	45	18	19	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	NOV 15	1996	46	4					465	476		10.1002/(SICI)1097-4547(19961115)46:4<465::AID-JNR8>3.0.CO;2-E			12	Neurosciences	Neurosciences & Neurology	VV519	WOS:A1996VV51900008	8950706				2021-06-18	
J	Kehle, TJ; Clark, E; Jenson, WR				Kehle, TJ; Clark, E; Jenson, WR			Interventions for students with traumatic brain injury: Managing behavioral disturbances	JOURNAL OF LEARNING DISABILITIES			English	Article							CLOSED HEAD-INJURY; CHILDREN; SEQUELAE; ADOLESCENTS; MORBIDITY; MILD	The present article provides information about the behavioral sequelae that are commonly seen in children and adolescents following a traumatic brain injury (TBI) and ways that educators can begin to address these problems. Because, for the most part, behavioral interventions have not been empirically validated for use with TBI populations, this article focuses on the unique needs of these students and the factors that should be considered in designing intervention strategies. Emphasis is placed on the cognitive sequelae of TBI that can cause further behavioral problems and interfere with interventions (e.g., impaired attention, executive function, reasoning and problem solving, and learning and memory).	UNIV UTAH,SCH PSYCHOL PROGRAM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT EDUC PSYCHOL,SALT LAKE CITY,UT 84112							ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BANDURA A, 1986, SOCIAL F THOUGHT ACT; BEGALI V, 1992, HEAD INJURY CHILDREN; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bond M. R., 1990, REHABILITATION ADULT, P179; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CASEY R, 1986, PEDIATRICS, V78, P497; Clarke E, 1990, SCHOOL PSYCHOL INT, V11, P227; COPE DN, 1987, J HEAD TRAUMA REHABI, V2, P2; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Deaton A, 1994, ED DIMENSIONS ACQUIR, P257; DEMPSTER FN, 1988, AM PSYCHOL, V43, P627, DOI 10.1037/0003-066X.43.8.627; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FOXX RM, 1978, J APPL BEHAV ANAL, V11, P125, DOI 10.1901/jaba.1978.11-125; FRANZEN MD, 1987, PSYCHIAT ANN, V17, P389, DOI 10.3928/0048-5713-19870601-10; GLENN MB, 1987, J HEAD TRAUMA REHAB, V2, P71; GLENN MB, 1987, J HEAD TRAUMA REHABI, V2, P80; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; HELLER MS, 1975, J EDUC PSYCHOL, V67, P769; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KEHLE TJ, 1986, SCHOOL PSYCHOL REV, V15, P289; KEHLE TJ, 1994, ANN M NAT ASS SCH PS; KEHLE TJ, 1991, PRACTICAL GUIDE VIDE, P221; KEHLE TJ, 1992, SCHOOL PSYCHOL INT, V13, P307; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1987, HEAD INJURY; MALEC J, 1984, BEHAVIORAL ASSESSMEN, P121; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P522; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Reavis H. K., 1993, UTAHS BEST PROJECT B; Rhode G., 1993, TOUGH KID BOOK PRACT; ROSE MJ, 1988, J HEAD TRAUMA REHAB, V3, P7; SHUTTE RC, 1970, J APPL BEHAV ANAL, V3, P117; SIASSI I, 1982, J CLIN PSYCHIAT, V45, P482; SILVER JM, 1987, PSYCHIAT ANN, V17, P367, DOI 10.3928/0048-5713-19870601-06; THOMAS DR, 1968, J APPL BEHAV ANAL, V1, P35, DOI 10.1901/jaba.1968.1-35; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; VANHOUTEN R, 1982, J APPL BEHAV ANAL, V15, P65, DOI 10.1901/jaba.1982.15-65; VANHOUTEN R, 1983, EFFECTS PUNISHMENT H, P45; WHITE MA, 1975, J APPL BEHAV ANAL, V8, P367, DOI 10.1901/jaba.1975.8-367; Wood R. L., 1987, BRAIN INJURY REHABIL; YUDOFSKY SC, 1987, PSYCHIAT ANN, V17, P397, DOI 10.3928/0048-5713-19870601-11	50	18	18	0	4	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					633	642		10.1177/002221949602900607			10	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400007	8942307				2021-06-18	
J	Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Millis, SR; Black, KL				Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Millis, SR; Black, KL			Revised trauma score - An additive predictor of disability following traumatic brain injury?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						revised trauma score; trauma scores; trauma; head injury; outcome; disability; hypoxic-ischemic injury	SEVERE HEAD-INJURY; RATING-SCALE; COMA; RECOVERY; INSULTS	Recent studies have clarified the role of hypoxic-ischemic damage as a secondary factor in traumatic brain injury (TBI). Many trauma centers are now consistently using the Revised Trauma Score (Glasgow Coma Scale, systolic blood pressure, and respiratory rate) to assist with triage of multitrauma patients. This study investigated the predictive power of the Revised Trauma Score (RTS) instead of the Glasgow Coma Scale (GCS) in determination of disability as measured by the Disability Rating Scale (DRS). Data were obtained as part of the National institute for Disability and Rehabilitation Research TBI Model Systems database on 501 patients receiving acute medical care and inpatient rehabilitation within a coordinated neurotrauma program for treatment of TBI. initial RTS and GCS were obtained on admission to the emergency department, along with the lowest CCS measured in the first 24 h. Analysis of initial RTS and GCS demonstrated modest, but statistically significant Pearson's correlations with DRS at rehabilitation admission (-0.18 and -0.25, respectively) and discharge (-0.22 and -0.24, respectively). Lowest GCS within the first 24 h postinjury also failed to show a strong relationship with DRS at rehabilitation admission (-0.28) and discharge (-0.24). Multiple regression analysis performed on RTS subsets for systolic blood pressure and respiratory rate did not reveal an added predictive value. Although RTS may be important in emergency triage For its ability to predict mortality, this study indicates its limited usefulness in prediction of disability.	WAYNE STATE UNIV,SCH MED,DETROIT,MI	Zafonte, RD (corresponding author), REHABIL INST MICHIGAN,SERV PHYS,261 MACK AVE,DETROIT,MI 48201, USA.						BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; MACIVER IN, 1958, LANCET, V1, P390; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBERTSON C, 1973, ACTA NEUROCHIR WIEN, V59, pS98; TEASDALE G, 1974, LANCET, V2, P81	19	18	18	1	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1996	75	6					456	460		10.1097/00002060-199611000-00011			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WA783	WOS:A1996WA78300009	8985110				2021-06-18	
J	Dall, JT; Harmon, RL; Quinn, CM				Dall, JT; Harmon, RL; Quinn, CM			Use of clonidine for treatment of spasticity arising from various forms of brain injury: A case series	BRAIN INJURY			English	Article							SPINAL SPASTICITY; CORD	Spasticity may occur as a result of different types of brain injury. The experience with six patients, aged 17-73 years, treated with clonidine for spasticity due to brain injuries of various causes is presented. These cases include a patient with traumatic brain injury, three patients with intracranial haemorrhage, a patient with a right basal ganglia stroke 3 years prior to a left subdural haematoma associated with a fall, and a patient with cerebral palsy. To varying degrees for each patient, clonidine was effective in reducing extremity hypertonicity. A possible mechanism of action is discussed. These case findings suggest clonidine may be useful in the management of spasticity associated with various forms of brain injury, and that formal studies of clonidine for this application appear warranted.	MED COLL OHIO,DEPT PHYS MED & REHABIL,TOLEDO,OH 43699							BOYESON MG, 1994, ARCH NEUROL-CHICAGO, V51, P405, DOI 10.1001/archneur.1994.00540160107014; Dall J T, 1995, J Stroke Cerebrovasc Dis, V5, P78, DOI 10.1016/S1052-3057(10)80350-7; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; GLENN MB, 1990, PRCTICAL MANAGEMENT, P296; Glenn MB, 1986, J HEAD TRAUMA REHAB, V1, P71; GOLDSTEIN LB, 1990, STROKE, V21, P179; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1990, J NEURO REHAB, V4, P137; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; MAYNARD FM, 1986, PARAPLEGIA, V24, P175, DOI 10.1038/sc.1986.24; MILANOV IG, 1992, ACTA NEUROL SCAND, V85, P305; NAFTCHI NE, 1982, SCIENCE, V217, P1042, DOI 10.1126/science.6126002; NANCE PW, 1989, PARAPLEGIA, V27, P296, DOI 10.1038/sc.1989.44; Robinson K. M., 1990, PRACTICAL MANAGEMENT, P201; SANDFORD PR, 1992, AM J PHYS MED REHAB, V71, P301, DOI 10.1097/00002060-199210000-00010; STEVENS J, 1986, ARCH PHYSICAL MED RE, V67, P666; TREMBLAY LE, 1986, NEUROPHARMACOLOGY, V25, P41, DOI 10.1016/0028-3908(86)90056-0; TUCKMAN J, 1982, SPINAL CORD INJURY, P133; UNNERSTALL JR, 1984, BRAIN RES REV, V319, P69; YABLON SA, 1993, AM J PHYS MED REHAB, V72, P154, DOI 10.1097/00002060-199306000-00009	21	18	19	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1996	10	6					453	458					6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UR327	WOS:A1996UR32700005	8816098				2021-06-18	
J	Di, X; Harpold, T; Watson, JC; Bullock, MR				Di, X; Harpold, T; Watson, JC; Bullock, MR			Excitotoxic damage in neurotrauma: Fact or fiction	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						secondary brain injury; excitatory amino acid; glutamate antagonist; ischemia; extracellular fluid	ACUTE SUBDURAL-HEMATOMA; TRAUMATIC BRAIN INJURY; COMPETITIVE NMDA ANTAGONIST; FOCAL CEREBRAL-ISCHEMIA; CORTICAL CELL-CULTURE; GLUTAMATE NEUROTOXICITY; HEAD-INJURY; RECEPTOR; CAT; RAT	Secondary brain injury is a well-demonstrated contributor to the morbidity and mortality of severe head injury. At least ten new compounds which antagonize the effects of glutamate in the brain are currently undergoing clinical evaluation as putative protectants against this secondary injury. None have yet shown clear benefit in humans. It is accepted that excitatory amino acids, glutamate in particular, have 'neurotoxic' effects on the brain, especially when present in excessive amounts. Whether or not this excitatory amino acid toxicity represents the major pathway for secondary damage is disputed. In the laboratory, over 300 studies have now demonstrated the ability of glutamate antagonist drugs of various types to prevent ischemic and post-traumatic acute brain damage. The magnitude and consistency of protection afforded by this group of compounds exceeds that which has ever been shown with any other mechanisms. Laboratory studies using in vitro neuronal models have implicated glutamate as a promoter of ionic flux and calcium entry across the cell membrane, which may then initiate astrocytic swelling and neuronal necrosis. In vivo animal models of brain trauma and ischemia have demonstrated glutamate release and potassium efflux into the extracellular fluid (ECF). Outcome in these models is improved, as assessed by both histopathology and behavioral studies, when glutamate antagonists are used. Additionally, presynaptic glutamate blockade in animal models such as middle cerebral artery (MCA) occlusion and subdural hematoma, creates reduction in lesion size which is paralleled by reduced glutamate production. In bridging the gap between the laboratory and the patient care setting, human microdialysis studies have shown massive release of excitatory amino acids into the ECF after severe head injury. Early studies with N-methyl-D-aspartate (NMDA) antagonists in head injured humans have demonstrated a reduction of intracranial pressure and an improvement in cerebral perfusion. Future studies are needed to examine further the value of protection from excitatory amino acid induced injury.		Di, X (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT NEUROSURG, BOX 631, MCV STN, RICHMOND, VA 23298 USA.						ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BULLOCK MR, 1995, INTRACRANIAL PRESURE, V10, P64; BULLOCK MR, 1994, INTRACRANIAL PRESSUR, V9, P238; BULLOCK MR, 1994, INTRACRANIAL PRESSUR, V9, P264; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1994, J CEREBR BLOOD F MET, V14, P466, DOI 10.1038/jcbfm.1994.57; BULLOCK R, 1990, J CEREBR BLOOD F MET, V10, P668, DOI 10.1038/jcbfm.1990.120; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUJISAWA H, 1993, BRAIN RES, V629, P73, DOI 10.1016/0006-8993(93)90483-4; GARTHWAITE G, 1989, NEUROSCI LETT, V99, P113, DOI 10.1016/0304-3940(89)90274-7; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; GROTTA J, 1995, STROKE, V26, P602, DOI 10.1161/01.STR.26.4.602; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOSSMAN KA, 1992, BRAIN PATHOL, V4, P23; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1992, J NEUROTRAUMA; HUMPHREYS RP, 1990, CHILD NERV SYST, V6, P139, DOI 10.1007/BF00308490; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; Kakarieka A., 1995, Journal of Neurotrauma, V12, P375; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; KOTAPA M, 1992, J NEUROL NEUROSURG P; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1991, NEUROREHABILITATION, P50; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MAXWELL WL, 1994, ACTA NEUROCHIR WIEN, V60, P122; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86	55	18	18	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	JUN	1996	9	4					231	241					11	Neurosciences	Neurosciences & Neurology	UU331	WOS:A1996UU33100007	21551912				2021-06-18	
J	Goshen, E; Zwas, ST; Shahar, E; Tadmor, R				Goshen, E; Zwas, ST; Shahar, E; Tadmor, R			The role of Tc-99(m)-HMPAO brain SPET in paediatric traumatic brain injury	NUCLEAR MEDICINE COMMUNICATIONS			English	Article							HM-PAO-SPECT; HEAD-INJURY; CT; DISORDERS; CHILDREN; MR	Twenty-eight paediatric patients suffering from chronic sequelae of traumatic brain injury (TBI) were examined by EEG, radionuclide imaging with Tc-99(m)-hexamethylpropyleneamine oxime (Tc-99(m)-HMPAO), computed tomography (CT) and,when available, magnetic resonance imaging (MRI), the results of which were evaluated retrospectively Our findings indicate that neuro-SPET (single photon emission tomography) with Tc-99(m)-HMPAO is more sensitive than morphological or electrophysiological tests in detecting functional lesions. In our group, 15 of 32 CT scans were normal, compared with 3 of 35 SPET studies. SPET identified approximately 2.5 times more lesions than CT (86 vs 34). SPET was found to be particularly sensitive in detecting organic abnormalities in the basal ganglia and cerebellar regions, with a 3.6:1 detection rate in the basal ganglia and a 5:1 detection rate in the cerebellum compared with CT. In conclusion, neuro-SPET appears to be very useful when evaluating paediatric post-TBI patients in whom other modalities are not successful.		Goshen, E (corresponding author), CHAIM SHEBA MED CTR,DEPT NUCL MED,IL-52621 RAMAT GAN,ISRAEL.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS C, 1992, PEDIATR NEUROL, V8, P97, DOI 10.1016/0887-8994(92)90028-W; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P1; Goncalves J M, 1992, Acta Neurochir Suppl (Wien), V55, P11; GRAY B, 1992, J NUCL MED, V35, P52; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEGIDO A, 1993, J CHILD NEUROL, V8, P227, DOI 10.1177/088307389300800304; OTUAMA LA, 1993, SEMIN NUCL MED, V23, P255, DOI 10.1016/S0001-2998(05)80106-0; PRAYER L, 1993, ACTA RADIOL, V34, P593; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; SHAHAR E, 1990, ARCH NEUROL-CHICAGO, V47, P578, DOI 10.1001/archneur.1990.00530050102019; TIKOFSKY RS, 1994, J NUCL MED, V35, P947	14	18	19	0	0	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	MAY	1996	17	5					418	422		10.1097/00006231-199605000-00011			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	UL550	WOS:A1996UL55000011	8736519				2021-06-18	
J	Wiley, JL; Compton, AD; Pike, BR; Temple, MD; McElderry, JW; Hamm, RJ				Wiley, JL; Compton, AD; Pike, BR; Temple, MD; McElderry, JW; Hamm, RJ			Reduced sensorimotor reactivity following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						startle; reflex function; sensory system; traumatic brain injury	ACOUSTIC STARTLE; PREPULSE INHIBITION; SEQUELAE; LESIONS; REFLEX	The present study examined sensorimotor reactivity in rats following traumatic brain injury (TBI). Moderate injury was induced with midline fluid percussion in some of the rats. Others received identical surgery, but were not injured (sham-injured rats), or received neither surgery nor injury (naive rats). All rats were evaluated in acoustic and/or tactile startle procedures. At 8 days post-injury, the sensorimotor reactivity of TBI rats to acoustic stimuli was severely reduced compared to that of sham-injured rats. This TBI-induced deficit was enduring (> 30 days). In a separate experiment, greater sensorimotor reactivity was observed with tactile (vs. acoustic) stimulation in both TBI and naive rats, although startle amplitudes for the TBI rats were lower than control levels for both types of stimuli. These results suggest that sensorimotor reactivity is altered by TBI and that the startle procedure is a promising method for investigation of information processing alterations following TBI.	UNIV RICHMOND, DEPT PSYCHOL, RICHMOND, VA 23173 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PSYCHOL, RICHMOND, VA 23298 USA	Wiley, JL (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, POB 980613, RICHMOND, VA 23298 USA.			Wiley, Jenny/0000-0001-8489-2947	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline		BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; CAINE SB, 1992, PHARMACOL BIOCHEM BE, V43, P1201, DOI 10.1016/0091-3057(92)90503-8; COOVER GD, 1971, PHYSIOL BEHAV, V7, P727, DOI 10.1016/0031-9384(71)90140-5; DAVIS M, 1977, J COMP PHYSIOL PSYCH, V91, P549, DOI 10.1037/h0077345; DAVIS M, 1982, J NEUROSCI, V2, P791; DAVIS M, 1980, NEUROSCI BIOBEHAV R, V4, P241, DOI 10.1016/0149-7634(80)90016-0; Davis M., 1984, P287; DEWITT DS, 1989, J CEREB BLOOD FLO S1, V9, pS93; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GEYER MA, 1990, BRAIN RES BULL, V25, P485, DOI 10.1016/0361-9230(90)90241-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1995, CENTRAL NERVOUS SYST, P307; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; HAMMOND GR, 1973, PHYSIOL BEHAV, V10, P239, DOI 10.1016/0031-9384(73)90304-1; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOFFMAN HS, 1980, PSYCHOL REV, V87, P175, DOI 10.1037/0033-295X.87.2.175; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KODSI MH, 1994, BRAIN RES, V643, P59, DOI 10.1016/0006-8993(94)90008-6; LINGENHOHL K, 1994, J NEUROSCI, V14, P1176; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; SWERDLOW NR, 1993, BEHAV NEUROSCI, V107, P104, DOI 10.1037/0735-7044.107.1.104; TAYLOR BK, 1991, PHYSIOL BEHAV, V49, P527, DOI 10.1016/0031-9384(91)90275-S; WHYTE J, 1994, AM J PHYS MED REHAB, V73, P2; WILEY JL, 1995, J NEUROTRAUM, V12, P992	29	18	19	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	1996	716	1-2					47	52		10.1016/0006-8993(96)00045-5			6	Neurosciences	Neurosciences & Neurology	UM083	WOS:A1996UM08300006	8738219				2021-06-18	
J	Porter, MD; Fricker, PA				Porter, MD; Fricker, PA			Controlled prospective neuropsychological assessment of active experienced amateur boxers	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						active; amateur boxing; chronic traumatic encephalopathy; neuropsychological tests; prospective; screening	CHRONIC BRAIN-DAMAGE; MINOR HEAD-INJURY; BOXING LEAD	Objective: To use a practical battery of eight neuropsychological tests for the detection of an association between amateur boxing and chronic traumatic encephalopathy. Design: A controlled prospective neuropsychological study over a 15-18-month period. Setting: Dublin, Ireland. March 1992 to September 1993. Participants: Twenty experienced actively competing amateur boxers and 20 controls matched for age and socioeconomic status. Interventions: Participation in competitive amateur boxing and training. Main outcome measures: Absolute scores, and changes in scores, in the neuropsychological tests. Results: At the end of the study period, the boxers performed significantly better then the controls in both the Trail-Making Tests A and B (TMT-A, TMT-B), whereas the control group's scores for the Finger Tapping Tests (FTT) were significantly higher than those of the boxers. The boxer's scores for the dominant-hand FTT showed a significant deterioration, but there was no association between this change and boxing exposure. Conclusions: There was no evidence of neuropsychological impairment in the boxers as compared with socioeconomically, educationally and age-matched controls, and there was no association between boxing exposure and performances in any of the neuropsychological tests used. There is accumulating evidence that amateur boxing is not associated with chronic traumatic encephalopathy but longer term prospective studies are needed.		Porter, MD (corresponding author), AUSTRALIAN INST SPORT,DEPT SPORTS MED,POB 176,BELCONNEN,ACT 2616,AUSTRALIA.						ADAMS JH, 1992, AIBA J, V25, P26; *BRIT MED ASS, 1984 BRIT MED ASS BO; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ATHLETIC INJURIES HE; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HARVEY PKP, 1974, LANCET, V19, P928; INGLIS J, 1959, BRAIN, P440; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1988, J NATL MED ASSOC, V80, P407; KASTE M, 1982, LANCET, V2, P1186; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lewis RF., 1979, MANUAL REPEATABLE CO; MALISZEWSKI M, 1990, SPORT PSYCHOL, V4, P55; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; PORTER MD, 1993, THESIS DUBLIN U; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SCHMIDTOLSEN S, 1990, AM J SPORT MED, V18, P98, DOI 10.1177/036354659001800117; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; Sironi V A, 1982, J Neurosurg Sci, V26, P165; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEWART WF, 1994, IABA MAGAZINE    APR, P3; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; WECHSLER D, 1971, WECHSLER ADULT INTEL	38	18	18	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	APR	1996	6	2					90	96		10.1097/00042752-199604000-00005			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	UC180	WOS:A1996UC18000005	8673582				2021-06-18	
J	Golding, EM; Dobson, GP; Golding, RM				Golding, EM; Dobson, GP; Golding, RM			A critical assessment of noise-induced errors in P-31 MRS: Application to the measurement of free intracellular magnesium in vivo	MAGNETIC RESONANCE IN MEDICINE			English	Article						phosphorus magnetic resonance spectroscopy; magnesium; fluid percussion brain injury	TRAUMATIC BRAIN INJURY; FREE MG-2+; RATS; NMR; RECOVERY; INVIVO; ATP	Phosphorus magnetic resonance spectroscopy (P-31 MRS) is a noninvasive technique that has been used to estimate free intracellular magnesium concentration (free [Mg2+]). Free [Mg2+] is computed from the chemical shift separation between the alpha- and beta-phosphate resonances of ATP. The current study was undertaken to critically assess the influence of noise effects in estimating free [Mg2+] in rat brain subjected to moderate parasagittal fluid percussion-induced injury. We show that contrary to published data, free [Mg2+] does not significantly change for up to 4 h after moderate trauma in different rat strains and using different surface coils, Before injury, free [Mg2+] = 0.56 +/- 0.11 (mean +/- SD, n = 36) and 4 h post-trauma, free [Mg2+] = 0.56 +/- 0.28. Our results suggest that explanations for this discrepancy comprise errors of chemical shift assignments accompanying low signal-to-noise ratios and the method of analysis employed, Indeed, the authors propose that spectra of beta-ATP signal-to-noise ratio less than 5:1 will produce significant noise-induced errors. We conclude that without knowledge of the inherent errors in P-31 MRS spectroscopy and appropriate statistical analysis, caution should be exercised in calculating free [Mg2+] and using these changes as a basis for proposing pharmacotherapeutic interventions.		Golding, EM (corresponding author), JAMES COOK UNIV N QUEENSLAND,SCH MOLEC SCI,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA.						Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; COHN M, 1962, J BIOL CHEM, V237, P176; DOBSON GP, 1992, NMR BIOMED, V5, P20, DOI 10.1002/nbm.1940050105; EMERSON CS, 1992, NEUROREPORT, V11; FITTS RH, 1994, PHYSIOL REV, V74, P49; GADIAN DG, 1982, NUCLEAR MAGNETIC RES; Galland L, 1991, Magnes Trace Elem, V10, P287; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALVORSON HR, 1992, NMR BIOMED, V5, P53, DOI 10.1002/nbm.1940050202; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WHITE JR, 1993, ANN PHARMACOTHER, V27, P775, DOI 10.1177/106002809302700619; WILLIAMS GD, 1995, MAGNET RESON MED, V33, P853, DOI 10.1002/mrm.1910330618	23	18	18	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0740-3194			MAGNET RESON MED	Magn.Reson.Med.	FEB	1996	35	2					174	185		10.1002/mrm.1910350208			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	TT422	WOS:A1996TT42200007	8622581				2021-06-18	
J	Iwamoto, Y; Yang, K; Clifton, GL; Hayes, RL				Iwamoto, Y; Yang, K; Clifton, GL; Hayes, RL			Liposome-mediated BDNF cDNA transfer in intact and injured rat brain	NEUROREPORT			English	Article						gene transfer; liposome; BDNF; cDNA; traumatic brain injury; in vivo; rat	INVIVO GENE-TRANSFER; VECTOR; CELLS; MODEL; RNA	WE examined the temporal profile of the expression of brain-derived neurotrophic factor (BDNF) cDNA containing a viral promoter following the injection of liposome cDNA complexes into the intact and traumatically injured rat brain. In situ hybridization and PCR confirmed the presence of injected BDNF cDNA for at least 6 days after injection. A similar profile of BDNF cDNA was observed when it was injected following cortical impact injury. mRNA was also localized around the injection areas. These results suggest that liposome-mediated delivery of neurotrophin cDNA may be a practical gene transfer method for treating traumatic brain injury.	UNIV TEXAS, HLTH SCI CTR, DEPT NEUROSURG, HOUSTON, TX 77030 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER		BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BARINAGA M, 1994, SCIENCE, V264, P773; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINK DJ, 1992, HUM GENE THER, V3, P11, DOI 10.1089/hum.1992.3.1-11; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; GIORDANO T, 1992, MOL BRAIN RES, V16, P239, DOI 10.1016/0169-328X(92)90231-Y; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATO K, 1994, MOL BRAIN RES, V25, P359, DOI 10.1016/0169-328X(94)90173-2; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; NAKAO N, 1995, EXP NEUROL, V131, P1, DOI 10.1016/0014-4886(95)90002-0; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; WHITSON JS, 1995, IN PRESS BRAIN RES; YANG K, 1994, NEUROSCI LETT, V182, P287, DOI 10.1016/0304-3940(94)90818-4; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, 1994, NEUROSCI LETT, V182, P291, DOI 10.1016/0304-3940(94)90819-2; YANG K, 1995, IN PRESS J NEUROSCI	25	18	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JAN 31	1996	7	2					609	612		10.1097/00001756-199601310-00056			4	Neurosciences	Neurosciences & Neurology	UC299	WOS:A1996UC29900056	8730841				2021-06-18	
J	PERSINGER, MA				PERSINGER, MA			NEUROPSYCHOLOGICA PRINCIPIA BREVITA - AN APPLICATION TO TRAUMATIC (ACQUIRED) BRAIN INJURY	PSYCHOLOGICAL REPORTS			English	Article							HEAD-INJURY; RECEPTORS; SCHIZOPHRENIA; INTERNEURONS; EPILEPSY	The concepts and discoveries of modern neuroscience now challenge many of the presumptions that influence diagnostic decisions within neurology, psychiatry, and clinical neuropsychology. Many of these presumptions are derived from archaic bivariate models such as the mind-body argument, organic-functional dichotomy, and single lesion-single behavior causality. Thirteen basic principles which may be useful for inferring more reliable and accurate relationships between microstructural function and clinical manifestations are developed.		PERSINGER, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,RAMSEY LAKE RD,SUDBURY,ON P3E 2C6,CANADA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSEN AR, 1990, COMPREHENSIVE EPILEP, P375; ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; ARDILA A, 1988, INT J NEUROSCI, V39, P235, DOI 10.3109/00207458808985710; ARNSTEN AFT, 1985, SCIENCE, V230, P1273, DOI 10.1126/science.2999977; BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIZIERE K, 1985, NEURAL MODULATION IM, P81; Carmichael L, 1926, PSYCHOL REV, V33, P51, DOI 10.1037/h0074309; CHUGANI HT, 1986, SCIENCE, V237, P840; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; Delorey Timothy M., 1994, P389; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOLDSTEIN JA, 1993, CHRONIC FATIGUE SYND; JARVIS PE, 1984, HALSTEAD REITAN TEST; JIBIKI I, 1994, NEUROSCI BIOBEHAV R, V18, P281, DOI 10.1016/0149-7634(94)90030-2; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P318; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; Miller L., 1993, PSYCHOTHERAPY BRAIN; MOORE RY, 1993, NEUROSCI LETT, V150, P112, DOI 10.1016/0304-3940(93)90120-A; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARKER R, 1990, TRAUMATIC BRAIN INJU; Pawlik G, 1989, NEUROPSYCHOLOGICAL F, P65; PERSINGER MA, 1994, PHYSIOL BEHAV, V56, P225, DOI 10.1016/0031-9384(94)90188-0; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; PERSINGER MA, 1971, THESIS U MANITOBA; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; POKRAS RS, 1994, MED HYPOTHESES, V42, P253, DOI 10.1016/0306-9877(94)90126-0; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; REILA AR, 1990, COMPREHENSIVE EPILEP, P359; REIMAN EM, 1984, NATURE, V316, P683; ROBERTS GW, 1990, NEUROPATH APPL NEURO, V16, P3, DOI 10.1111/j.1365-2990.1990.tb00927.x; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; TERRY RD, 1988, AGING BRAIN, P109; WEILAND NG, 1990, ENDOCRINOLOGY, V126, P2392, DOI 10.1210/endo-126-5-2392	41	18	18	0	1	PSYCHOLOGICAL REPORTS	MISSOULA	P O BOX 9229, MISSOULA, MT 59807	0033-2941			PSYCHOL REP	Psychol. Rep.	DEC	1995	77	3	1				707	724		10.2466/pr0.1995.77.3.707			18	Psychology, Multidisciplinary	Psychology	TJ037	WOS:A1995TJ03700001	8559908				2021-06-18	
J	MURR, R; SCHURER, L				MURR, R; SCHURER, L			CORRELATION OF JUGULAR VENOUS OXYGEN-SATURATION TO SPONTANEOUS FLUCTUATIONS OF CEREBRAL PERFUSION-PRESSURE IN PATIENTS WITH SEVERE HEAD-INJURY	NEUROLOGICAL RESEARCH			English	Article						AUTOREGULATION; CEREBRAL PERFUSION PRESSURE; JUGULAR VENOUS OXYGEN SATURATION; OXIMETRY; TRAUMATIC BRAIN INJURY	BLOOD-FLOW; BRAIN INJURY; INTRACRANIAL HYPERTENSION; AUTO-REGULATION; METABOLISM; AUTOREGULATION; CIRCULATION; MANNITOL	Continuous measurements of mean arterial pressure (MAP), ICP, and jugular venous oxygen saturation (SjO(2)) were performed in 11 patients with severe head injury (GCS 3-7) to assess the dependence of SjO(2) from the cerebral perfusion pressure (CPP) trying to establish an indirect measure of cerebrovascular autoregulation. Changes in CPP resulting from spontaneous fluctuations in MAP or ICP induced highly significant alterations in SjO(2) in the range of 0.14-0.56% SjO(2) mmHg(-1) CPP in all patients and all periods after trauma. The analysis of the distribution of the SjO(2):CPP-ratios showed the highest frequency of values in the range of 0.0-0.25% SjO(2) mmHg(-1) CPP in 9 of the 11 patients. Within the first 2 days after trauma, a more pronounced dependency of SjO(2) from changes in CPP was found, but this was not statistically significant. No predictable relationship of the SjO(2):CPP-ratio to the level of ICP could be demonstrated in the patients. Because changes in SjO(2) induced by alterations in CPP were found in all patients and throughout the acute phase of severe head injury, these changes more probably reflect physiological alterations in CBF with varying perfusion pressure rather than impaired autoregulation after head trauma. Although assessment of cerebral autoregulation by estimation of the SjO(2):CPP-ratio offers new possibilities for monitoring of these patients, the high frequency of erroneous readings or irregular fluctuations of the SjO(2)-signal from the fibreoptic catheter limits the usefulness of the SjO(2)-dependency from CPP for practical use in the intensive care unit.	UNIV HEIDELBERG,KLINIKUM MANNHEIM,DEPT NEUROSURG,MANNHEIM,GERMANY	MURR, R (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,INST ANAESTHESIOL,MARCHIONINISTR 15,D-81366 MUNICH,GERMANY.						AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AOYAGI M, 1975, J NEUROSURG, V43, P689, DOI 10.3171/jns.1975.43.6.0689; BAUMBACH GL, 1985, AM J PHYSIOL, V249, pH629; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1993, NEUROSURGERY, V32, P547; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; HERNANDEZPEREZ MJ, 1976, AM J PHYSIOL, V231, P929; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JAMES IM, 1969, CIRC RES, V25, P77, DOI 10.1161/01.RES.25.1.77; LASSEN NA, 1959, PHYSIOL REV, V39, P183; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MURR R, 1993, J NEUROTRAUMA S1, V10, pS2555; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PRICE DJ, 1993, INTRACRANIAL PRESSUR, V8, P61; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; STRANDGAARD S, 1976, STROKE, V7, P287, DOI 10.1161/01.STR.7.3.287; THEODORSSONNORH.E, 1986, COMPUT METH PROG BIO, V23, P57	20	18	20	0	0	FOREFRONT PUBL GROUP	LONDON	MONOMARK HOUSE 27 OLD GLOUCESTER STREET, LONDON, ENGLAND WC1N 3XX	0161-6412			NEUROL RES	Neurol. Res.	OCT	1995	17	5					329	333		10.1080/01616412.1995.11740338			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TA934	WOS:A1995TA93400002	8584122				2021-06-18	
J	MILDERS, MV; BERG, IJ; DEELMAN, BG				MILDERS, MV; BERG, IJ; DEELMAN, BG			4-YEAR FOLLOW-UP OF A CONTROLLED MEMORY TRAINING STUDY IN CLOSED-HEAD INJURED PATIENTS	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; COGNITIVE REHABILITATION; REMEDIATION; STRATEGIES	In a controlled group study Berg, Koning-Haanstra, and Deelman (1991) compared the effects of memory strategy training with the effects of drill and practice training and no treatment in severely head injured patients. Four months after training the group in the strategy condition performed significantly better on three memory tests than the patient groups in the other two conditions. Four years following this last evaluation, 31 of the 38 patients from the original training study were retested on the same memory tests. Thirteen normal subjects, who had already served as normal controls in the training study, were also retested. In contrast to the results four years earlier, memory performance was the same for all three patient groups. The level of performance of the patients was still well below the level of the normal controls. One reason for the disappearance of the advantage of the strategy group over the other two patient groups, was the drop-out of patients with relatively poor memory scores on the previous evaluation. A second reason was the improvement in memory performance relative to the previous evaluation found in the drill and practice and the no-treatment groups.	UNIV GRONINGEN,DEPT NEUROPSYCHOL,9713 EZ GRONINGEN,NETHERLANDS							BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DEELMAN BG, 1990, TRAUMATIC BRAIN INJU; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; GODFREY HPD, 1985, J CONSULT CLIN PSYCH, V53, P555, DOI 10.1037/0022-006X.53.4.555; GODLSTEIN G, 1988, CLIN NEUROPSYCHOLOGI, V2, P251; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; MILLER E, 1992, BRIT J PSYCHIAT, V160, P1, DOI 10.1192/bjp.160.1.1; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; ROBERTSON IH, 1993, CURR OPIN NEUROL, V6, P756, DOI 10.1097/00019052-199310000-00013; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]	21	18	18	0	2	LAWRENCE ERLBAUM ASSOC LTD	HOVE	27 PALMEIRA MANSIONS CHURCH RD, HOVE, E SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	SEP	1995	5	3					223	238		10.1080/09602019508401468			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	RG859	WOS:A1995RG85900002					2021-06-18	
J	LEHMANN, U; REIF, W; HOBBENSIEFKEN, G; SEEKAMP, A; REGEL, G; STURM, JA; DWENGER, A; SCHWEITZER, G; MANN, D; ELLERBECK, M; TSCHERNE, H				LEHMANN, U; REIF, W; HOBBENSIEFKEN, G; SEEKAMP, A; REGEL, G; STURM, JA; DWENGER, A; SCHWEITZER, G; MANN, D; ELLERBECK, M; TSCHERNE, H			THE INFLUENCE OF PRIMARY FRACTURE STABILIZATION ON BRAIN INJURY IN MULTIPLE TRAUMA - A SHEEP MODEL	UNFALLCHIRURG			English	Article								Severe head trauma (BI) associated with long bone fractures is present in about 60% of polytraumatized patients admitted to hospital. However, there is no consensus regarding early fracture stabilization in such patients. In an experimental sheep study, the influence of intramedullary nailing of the femur (IMNF) on a cold-induced, vasogenic brain edema (method of Klatzo) in combination with traumatic hemorrhagic shock (THS) was investigated. Three animal groups (n=6) were explored: group A, only BI; group B, BI and THS; group C, BI, THS and IMNF. The animals remained intubated, on controlled ventilation, sedated and received analgesia during the whole experiment. For a period of 6 h after the cold-induced brain injury the hemodynamic changes were measured and the intracranial pressure (ICP) was recorded in the left and the right hemisphere continuously. The hemorrhagic shock (MAP = 60 mm Hg) was maintained over 1.5 h. At the end of the reperfusion period (2 h) the nailing of the femur was performed. The animals were killed and the percentage water content of the brain was determined and compared with the brain water content of a control group (n = 6). There were no significant differences in ICP between groups A, B and C before or after IMNF, but in group C the ICP increased significantly after nailing. Brain water content in group C was significantly higher than in the control group and slightly significantly higher than in groups A and B. Brain edema and ICP are increased by IMNF. Primary nailing of the femur in patients with severe brain injury should be considered carefully. Alternatively, another technique for stabilization could be used.		LEHMANN, U (corresponding author), HANNOVER MED SCH,UNFALLCHIRURG KLIN,KONSTANTY GUTSCHOW STR 8,D-30625 HANNOVER,GERMANY.		Seekamp, Andreas/E-3252-2010					0	18	18	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	AUG	1995	98	8					437	441					5	Emergency Medicine; Surgery	Emergency Medicine; Surgery	RR060	WOS:A1995RR06000006	7570037				2021-06-18	
J	MAIER, DL; KALB, RG; STELZNER, DJ				MAIER, DL; KALB, RG; STELZNER, DJ			NMDA ANTAGONISM DURING DEVELOPMENT EXTENDS SPARING OF HINDLIMB FUNCTION TO OLDER SPINALLY TRANSECTED RATS	DEVELOPMENTAL BRAIN RESEARCH			English	Article						NMDA RECEPTOR; MK-801; SPINAL CORD; DEVELOPMENTAL PLASTICITY; CRITICAL PERIOD; RECOVERY OF FUNCTION	EXCITATORY AMINO-ACIDS; ACTIVITY-DEPENDENT DEVELOPMENT; TRAUMATIC BRAIN INJURY; LONG-TERM POTENTIATION; POSTNATAL-DEVELOPMENT; CORTICOSPINAL TRACT; CORD TRANSECTION; MOTOR NEURONS; RECEPTORS; GROWTH	Hindlimb weight support and bipedal stepping occur after spinal cord transection in neonatal rats (birth to 12 days of age) while the same lesion in 15-day and older animals results in permanent loss of these responses. Some compensatory change in lumbar spinal circuitry must occur after spinal transection in young animals subserving these hindlimb behaviors. In contrast, animals just a few days older are incapable of such compensatory responses. We have examined the hypothesis that neural activity leads to the postnatal loss of plasticity in spinal circuitry. We find that antagonism of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor with MK-801 in young animals extends the sparing of hindlimb function after spinal transection to older animals. This effect is not due to a non-specific depression of all exciatory drive to motor neurons since Ia to motor neuron synaptic transmission through non-NMDA receptors is preserved during MK-801 treatment. Acute administration of MK-801 at the time of spinal transection or chronic administration of MK-801 after postnatal day 17 has no effect on recovery of hindlimb function after spinal transection. These results highlight the importance of NMDA receptor activation in spinal circuit maturation.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,SYRACUSE,NY 13210; YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029837, R01NS014096, F32NS009235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32NS09235, NS29837, NS14096] Funding Source: Medline		ALTMAN J, 1975, ANIM BEHAV, V23, P896, DOI 10.1016/0003-3472(75)90114-1; CARONI P, 1992, J NEUROSCI, V12, P3849; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COMMISSIONG JW, 1989, EXP BRAIN RES, V78, P597; CUMMINGS JP, 1984, EXP NEUROL, V83, P155, DOI 10.1016/0014-4886(84)90054-2; CURFS MHJM, 1993, DEVELOPMENT, V117, P535; DONATELLE JM, 1977, J COMP NEUROL, V175, P207, DOI 10.1002/cne.901750205; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GILBERT M, 1979, J COMP NEUROL, V184, P821, DOI 10.1002/cne.901840413; GOLDBERGER ME, 1986, DEV PLASTICITY MAMMA, P363; GRIDNAU AAM, 1986, ANAT EMBRYOL, V175, P101; JAHR CE, 1986, J PHYSIOL-LONDON, V370, P515, DOI 10.1113/jphysiol.1986.sp015948; KALB RG, 1994, DEV BIOL, V162, P539, DOI 10.1006/dbio.1994.1107; KALB RG, 1992, P NATL ACAD SCI USA, V89, P8502, DOI 10.1073/pnas.89.18.8502; KALB RG, 1992, BRAIN RES REV, V17, P283, DOI 10.1016/0165-0173(92)90020-M; KALB RG, 1988, J NEUROSCI, V8, P2350; KALB RG, 1990, SCIENCE, V250, P294, DOI 10.1126/science.2145629; Kimura J., 1983, ELECTRODIAGNOSIS DIS; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KUANG RZ, 1990, J COMP NEUROL, V292, P585, DOI 10.1002/cne.902920408; LEONG SK, 1984, J COMP NEUROL, V228, P18; MAIER DL, 1993, SOC NEUR ABSTR; MAIER DL, 1993, SEC INT BEHAV NEUROS; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; RAUSCHECKER JP, 1987, NATURE, V326, P183, DOI 10.1038/326183a0; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; SCHREYER DJ, 1982, NEUROSCIENCE, V7, P1837, DOI 10.1016/0306-4522(82)90001-X; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STANFIELD BB, 1992, PROG NEUROBIOL, V38, P169, DOI 10.1016/0301-0082(92)90039-H; STELZNER DJ, 1971, EXP NEUROL, V31, P337, DOI 10.1016/0014-4886(71)90237-8; STELZNER DJ, 1991, RES NEUROL, V5, P419; STELZNER DJ, 1988, CURRENT ISSUES NEURA, P343; STELZNER DJ, 1986, DEV PLASTICITY MAMMA, P81; STELZNER DJ, 1986, DEV NEUROPSYCHOBIOLO, P241; THORNE B, 1980, INTRO STATISTICS PSY; TINCO M, 1993, J NEUROPHYSIOL, V70, P403; WEBER ED, 1980, BRAIN RES, V185, P17, DOI 10.1016/0006-8993(80)90667-8; WEBER ED, 1977, BRAIN RES, V125, P241, DOI 10.1016/0006-8993(77)90618-7	44	18	19	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	JUL 14	1995	87	2					135	144		10.1016/0165-3806(95)00065-L			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	RL550	WOS:A1995RL55000005	7586495				2021-06-18	
J	BATES, L; REDMAN, S; BROWN, W; HANCOCK, L				BATES, L; REDMAN, S; BROWN, W; HANCOCK, L			DOMESTIC VIOLENCE EXPERIENCED BY WOMEN ATTENDING AN ACCIDENT AND EMERGENCY DEPARTMENT	AUSTRALIAN JOURNAL OF PUBLIC HEALTH			English	Article							VICTIMS	The aim of the study was to establish the extent and severity of domestic violence experienced by women attending the accident and emergency department of a large teaching hospital in Newcastle. The data were collected over a five-week period in 1992. All women between 17 and 80 years, attending the emergency or ambulatory areas between 8 a.m. and midnight, were asked to complete a confidential structured interview. A total of 401 women participated in the study, representing 82 per cent of eligible women approached. Each participant was asked if she had ever been physically hurt by someone close to her. Questions were asked to determine the relationship to the perpetrator, the type and cause of injury, treatment necessary and help sought Seven (1.7 per cent, 95 per cent confidence interval (CI) 0.46 to 3.02) of the women surveyed were attending the hospital as a direct result of an incident of domestic violence, and 100 women (25 per cent, CI 21 to 29) had experienced domestic violence at some time. Bruising, fractures and cuts were the most common forms of injury, with the most common locations being the head, face and chest. Weapons, such as guns and knives, were used in 20 per cent of the incidents. A considerable number of the women (68 per cent) did not seek help at the time of their injuries. As a substantial proportion of women have experienced domestic violence in their lives, accident and emergency workers should receive training in recognising and assisting victims of domestic violence.	HUNTER CTR HLTH ADVANCEMENT,NEWCASTLE,NSW,AUSTRALIA			Parkinson, Lynne/C-1949-2008; Brown, Wendy J/A-1553-2016	Parkinson, Lynne/0000-0001-9433-9555; Brown, Wendy J/0000-0001-9093-4509			*CANB PUBL POL RES, 1988, DOM VIOL ATT SURV; CUTHBERT M, 1991, AUSTR VIOL CONT PERS; DEVERY C, 1992, EOMSTIC VIOLENCE NSW; Dobash R.E., 1979, VIOLENCE WIVES CASE; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; MATKA E, 1991, CRIME JUSTICE B, V12; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; Mugford J., 1989, VIOLENCE TODAY; MULLEN PE, 1988, LANCET          0416, P841; National Committee on Violence against Women, 1992, NAT STRAT VIOL WOM; *NSW BUR CRIM STAT, 1987, CRIM JUST B, V5; *NSW DOM VIOL COMM, 1991, NSW DOM VIOL STRAT P; *QUEENSL DOM VIOL, 1988, THES WALLS, P117; RANDALL T, 1990, JAMA-J AM MED ASSOC, V264, P940, DOI 10.1001/jama.264.8.940; ROBERTS G, 1989, VIOLENCE TODAY; ROBERTS GL, 1993, MED J AUSTRALIA, V159, P307, DOI 10.5694/j.1326-5377.1993.tb137866.x; SCUTT J, 1990, CONNEXIONS, V10, P7; WIDOM CS, 1992, 2ND NAT C VIOL CANB	18	18	18	0	1	PUBLIC HEALTH ASSOC	CANBERRA	GPO BOX 2204 ATTN:FIONA BRAY, CANBERRA 2601, AUSTRALIA	1035-7319			AUST J PUBLIC HEALTH	Aust. J. Public Health	JUN	1995	19	3					293	299					7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	RH041	WOS:A1995RH04100016	7626680				2021-06-18	
J	MITCHELL, HL; FRISELLA, WA; BROOKER, RW; YOON, KW				MITCHELL, HL; FRISELLA, WA; BROOKER, RW; YOON, KW			ATTENUATION OF TRAUMATIC CELL-DEATH BY AN ADENOSINE A(1) AGONIST IN RAT HIPPOCAMPAL CELLS	NEUROSURGERY			English	Article						ADENOSINE; CELL DEATH; GLUTAMATE; ISCHEMIA; TRAUMA	SYNAPTIC TRANSMISSION; NEURONAL INJURY; BRAIN INJURY; AMINO-ACIDS; RECEPTORS; CURRENTS; INVITRO	IN A RAT hippocampal cell culture, we studied the mechanism of adenosine-mediated neuroprotection in traumatic injury to neurons. When the processes and bodies of cells in culture were mechanically disrupted, neurons that were located at a distance from the damage site died. This secondary neuronal death is at least partially mediated by glutamate, because MK801, a specific N-methyl-D-aspartate glutamate channel blocker, diminished the toxic effect. Furthermore, cyclopentyl adenosine, a specific A(1) adenosine receptor agonist that specifically attenuates synaptic release at the excitatory terminal, also blocked this trauma-mediated cell death. The dissemination of neurotoxicity from cell injury implies a release of a toxin by the dying cells. Consistent with this hypothesis, we found that neurotoxicity could be transferred to an uninjured neuronal culture by applying extracellular solution of the damaged culture to the healthy undamaged culture, as long as the fluid was transferred within 5 minutes. However, the glutamate concentrations in this medium were never higher than 20 nmol/L, suggesting that glutamate is not mediating the soluble and transferable toxicity. Consistent with this observation, the transferable neurotoxicity was not blocked by MK801 but was effectively blocked by cyclopentyl adenosine. Our observations suggest that traumatic cell death in culture is mediated by multiple mechanisms, including glutamate excitotoxicity.	ST LOUIS UNIV,DEPT PHARMACOL & PHYSIOL SCI,DIV NEUROSURG,ST LOUIS,MO 63131; ST LOUIS UNIV,INST SURG RES,DEPT SURG,ST LOUIS,MO 63131					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS01547] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001547] Funding Source: NIH RePORTER		BOWMER CJ, 1989, TRENDS PHARMACOL SCI, V10, P339, DOI 10.1016/0165-6147(89)90001-1; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; Kurbat J. M., 1993, Society for Neuroscience Abstracts, V19, P1661; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MILLER LP, 1992, J NEUROTRAUM, V9, pS563; PARK TS, 1991, DEV BRAIN RES, V61, P73, DOI 10.1016/0165-3806(91)90115-Y; PARK TS, 1987, J CEREBR BLOOD F MET, V7, P178, DOI 10.1038/jcbfm.1987.41; PHILLIS JW, 1991, J NEUROCHEM, V56, P644, DOI 10.1111/j.1471-4159.1991.tb08198.x; PINARD E, 1989, BRAIN RES, V481, P124, DOI 10.1016/0006-8993(89)90492-7; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SHOEMAKER JD, 1991, J CHROMATOGR-BIOMED, V562, P125, DOI 10.1016/0378-4347(91)80571-S; STRATTON KR, 1989, BRAIN RES, V494, P359, DOI 10.1016/0006-8993(89)90604-5; STURM CD, 1993, J NEUROSURG, V79, P111, DOI 10.3171/jns.1993.79.1.0111; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P347, DOI 10.1113/jphysiol.1992.sp019168; TRUSSELL LO, 1985, P NATL ACAD SCI USA, V82, P4857, DOI 10.1073/pnas.82.14.4857; YAMADA KA, 1989, J NEUROSCI, V9, P3230; YOON KW, 1991, J NEUROSCI, V11, P1375	23	18	18	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1995	36	5					1003	1007		10.1227/00006123-199505000-00017			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QV351	WOS:A1995QV35100057	7791963				2021-06-18	
J	ALQURAINY, IA				ALQURAINY, IA			CONVERGENCE INSUFFICIENCY AND FAILURE OF ACCOMMODATION FOLLOWING MIDFACIAL TRAUMA	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Article								A prospective evaluation of patients who had sustained midfacial trauma was carried out in order to determine the prevalence of impaired convergence and accommodation and to establish the risk factors for such defects. Of 52 patients in this study, 11 suffered accommodation and/or convergence disturbances. They included 6 males (17% of the male population) and 5 females (29% of the female population). Nine of these 11 patients sustained their injuries due to alleged assaults (24.3% of all assaulted patients) and 2 following simple falls (25% of all fall victims). Five patients complained of double vision for near (5/11=45.5%) and another 4 had blurred vision and/or difficulty with reading (4/11=36.4%). The remaining two were asymptomatic. Six patients were randomly selected to receive orthoptic exercises/treatment while the other five were monitored for signs of spontaneous recovery. Within six months of injury/surgery, 83% of the treated patients (n=5) and 80% of the non-treated patients (n=4) recovered to within the normal values of accommodation and convergence. No significant statistical relationship was found between the incidence of accommodation and/or convergence failure, and the cause or the type of fracture sustained. It may, however, be related to the severity of both the impact and the associated closed head trauma.		ALQURAINY, IA (corresponding author), ROYAL EYE INFIRM,ASPLEY RD,PLYMOUTH PL4 6PL,DEVON,ENGLAND.						ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P291; BRINKLEY JR, 1983, ANN OPHTHALMOL, V15, P826; CANDLER RG, 1945, T OPHTHAL SOC UK, V65, P57; COOPER J, 1978, J AM OPTOM ASSOC, V49, P673; Cross AG, 1945, T OPHTHAL SOC UK, V65, P20; DAVIES C E, 1956, Am Orthopt J, V6, P124; DODEN W, 1965, KLIN MBL AUGENHEILK, V146, P845; Duane A., 1922, AM J OPHTHALMOL, V5, P865, DOI [DOI 10.1016/S0002-9394(22)90793-7, 10.1016/S0002-9394(22)90793-7]; DUKEELDER S, 1972, SYSTEM OPHTHALMOLO 1, V14, P710; Franceschetti A, 1943, SCHWEIZ ARCH NEUROL, V50, P267; HENDERSON D, 1973, UNPUB CLASSIFICATION; JAMPOLSKY A, 1971, T AM OPHTHAL SOC, V68, P730; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; Matsuzaki H, 1964, Nippon Ganka Gakkai Zasshi, V68, P569; MEIN J, 1986, DIAGNOSIS MANAGEMENT, P119; RASKIND R H, 1976, American Orthoptic Journal, V26, P53; VANNOORDEN GK, 1985, BINOCULAR VISION OCU, P380	17	18	18	0	5	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, MIDLOTHIAN, SCOTLAND EH1 3AF	0266-4356			BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	APR	1995	33	2					71	75		10.1016/0266-4356(95)90203-1			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	QR213	WOS:A1995QR21300002	7772590				2021-06-18	
J	HERNANDEZ, TD; WARNER, LA				HERNANDEZ, TD; WARNER, LA			KINDLED SEIZURES DURING A CRITICAL POSTLESION PERIOD EXERT A LASTING IMPACT ON BEHAVIORAL RECOVERY	BRAIN RESEARCH			English	Article						AMYGDALA KINDLING; ANTEROMEDIAL CORTEX LESION; SOMATOSENSORY ASYMMETRY; RECOVERY OF FUNCTION; KINDLED SEIZURE STAGE; NEUROLOGICAL MODEL	MORRIS WATER MAZE; POSTTRAUMATIC SEIZURES; TRAUMATIC EPILEPSY; GLUCOSE-UTILIZATION; CORTICAL INJURY; SPATIAL MEMORY; BRAIN-DAMAGE; HEAD-INJURY; RATS; PHENYTOIN	The present study was undertaken to assess the effects of amygdala kindling on behavioral recovery following unilateral frontal cortex damage in rats. Daily electrical stimulation of the amygdala began 48 h after lesion and continued until all animals had a single Stage 5 seizure. When amygdala kindled seizure activity ratable as Stage 0 occurred within the first 6 days after lesion, animals recovered from somatosensory asymmetries in approximately 3 weeks. In contrast, kindled animals that experienced Stage 1 seizure activity within the first 6 days after lesion failed to recover from somatosensory deficits in 4 months of testing. Differences in rate of recovery could not be accounted for by lesion size or placement. These data support the notion that not only is there a 'critical period' after brain damage during which the recovery process is vulnerable to seizure activity, but the type of kindled seizure that is experienced during that time ultimately determines how recovery is affected.		HERNANDEZ, TD (corresponding author), UNIV COLORADO,DEPT PSYCHOL,CAMPUS BOX 345,BOULDER,CO 80309, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30595] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS030595] Funding Source: NIH RePORTER		ACKERMANN RF, 1989, EXP NEUROL, V104, P73, DOI 10.1016/0014-4886(89)90011-3; ADLER MW, 1969, EPILEPSIA, V10, P263, DOI 10.1111/j.1528-1157.1969.tb03847.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BECKER A, 1992, BEHAV NEURAL BIOL, V57, P37, DOI 10.1016/0163-1047(92)90735-M; BELDHUIS HJA, 1992, HIPPOCAMPUS, V2, P397, DOI 10.1002/hipo.450020407; BOYESON MG, 1985, EXP NEUROL, V89, P479, DOI 10.1016/0014-4886(85)90107-4; BRAILOWSKI S, 1986, BRAIN RES, V363, P322; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COOPER RM, 1984, EXP NEUROL, V86, P261, DOI 10.1016/0014-4886(84)90185-7; CORCORAN ME, 1976, KINDLING, P215; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DAUTH GW, 1985, ANN NEUROL, V17, P431, DOI 10.1002/ana.410170503; Dietz M A, 1991, J Stroke Cerebrovasc Dis, V1, P37, DOI 10.1016/S1052-3057(11)80018-2; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DUELL RM, 1984, ANN NEUROL, V15, P521; ENGEL J, 1978, ANN NEUROL, V3, P538, DOI 10.1002/ana.410030615; FEASEYTRUGER KJ, 1993, NEUROSCI LETT, V151, P25, DOI 10.1016/0304-3940(93)90036-K; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; GILMAN S, 1987, ANN NEUROL, V22, P370, DOI 10.1002/ana.410220314; GLASSMAN RB, 1976, BEHAV BIOL, V17, P333, DOI 10.1016/S0091-6773(76)90688-X; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDSTEIN IB, 1991, J NEUROL REHAB, V5, P129; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Guidice M A, 1987, Brain Inj, V1, P61; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Hernandez T D, 1990, Restor Neurol Neurosci, V1, P323, DOI 10.3233/RNN-1990-1503; HERNANDEZ TD, 1989, BRAIN RES, V487, P89, DOI 10.1016/0006-8993(89)90943-8; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HERNANDEZ TD, 1989, CEREBROVASC DIS, P327; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; JENNETT B, 1973, LANCET, V2, P652; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; JENNETT WB, 1969, LANCET, V1, P1023; KEMPINSKY WH, 1958, ARCH NEURO PSYCHIATR, V79, P376, DOI 10.1001/archneurpsyc.1958.02340040020002; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; KNOWLTON BJ, 1989, BEHAV NEUROSCI, V103, P1144, DOI 10.1037/0735-7044.103.5.1144; KUHL DA, 1990, DICP ANN PHARMAC, V24, P277, DOI 10.1177/106002809002400314; MASON CR, 1972, EPILEPSIA, V13, P663, DOI 10.1111/j.1528-1157.1972.tb04401.x; MCINTYRE DC, 1979, PHYSIOL BEHAV, V23, P855, DOI 10.1016/0031-9384(79)90190-2; MCNAMARA RK, 1992, BEHAV BRAIN RES, V50, P167, DOI 10.1016/S0166-4328(05)80298-0; MCNAMARA RK, 1993, HIPPOCAMPUS, V3, P149, DOI 10.1002/hipo.450030207; MEYER JS, 1970, ARCH NEUROL-CHICAGO, V23, P241, DOI 10.1001/archneur.1970.00480270051007; NAMBA H, 1989, BRAIN RES, V486, P221, DOI 10.1016/0006-8993(89)90508-8; PAPPIUS HM, 1989, PROG NEURO-PSYCHOPH, V13, P353, DOI 10.1016/0278-5846(89)90124-3; PARENTI ML, 1980, ITAL J NEUROL SCI, V4, P225; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PEELE DB, 1992, BEHAV BRAIN RES, V48, P65, DOI 10.1016/S0166-4328(05)80140-8; PETERSON SL, 1982, PROG NEUROBIOL, V19, P237, DOI 10.1016/0301-0082(82)90008-9; RACINE R, 1979, BRAIN RES BULL, V4, P1, DOI 10.1016/0361-9230(79)90050-9; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHWARTZ AS, 1979, BRAIN, V102, P669, DOI 10.1093/brain/102.4.669; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P487; VONMONAKOW C, 1969, MOODS STATES MIND, P27; Ward Arthur A., 1942, YALE JOUR BIOL AND MED, V15, P189; WATSON CW, 1945, J NEUROPHYSIOL, V8, P221; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	71	18	18	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 6	1995	673	2					208	216		10.1016/0006-8993(94)01415-E			9	Neurosciences	Neurosciences & Neurology	QK714	WOS:A1995QK71400005	7606434				2021-06-18	
J	FRASER, RT; WEHMAN, P				FRASER, RT; WEHMAN, P			TRAUMATIC BRAIN INJURY REHABILITATION - ISSUES IN VOCATIONAL OUTCOME	NEUROREHABILITATION			English	Article						TRAUMATIC BRAIN INJURY; VOCATIONAL REHABILITATION OUTCOME	CLOSED-HEAD-INJURY; WORK; RETURN	Since the population with a traumatic brain injury is principally young with many years of potential future earning capacity, understanding the issues affecting the vocational outlook for this group is critical. This article overviews the research to date on vocational outcome, emphasizing newly developed multivariate prediction models and encouraging a focus on actually examining the effects of different vocational interventions. The reasons for the variability in current study findings are reviewed with a framework proposed for more meaningful future research on the vocational rehabilitation process for this disability group. It is only through utilization of more standard intake and outcome variables and manipulation of interventions within this more standardized context that efficient and effective vocational rehabilitation for these survivors will be understood.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT REHABIL MED,SEATTLE,WA 98104; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23284; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SPECIAL EDUC,RICHMOND,VA 23284	FRASER, RT (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,ZA-05,SEATTLE,WA 98104, USA.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BENNETT P, 1990, 9TH ANN S NAT HEAD I; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ELLERD DA, 1990, VOCATIONAL REHABILIT, P105; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; FRASER R, 1990, SUMMARY NIDRR STUDIE; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; HAFFEY W, 1989, REHAB PSYCHOL, V2, P147; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KAY T, 1984, PUBLICATION, V1851; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MEYERSON L, 1979, REHAB PSYCHOL, V26, P228; NOVACK AT, 1988, 65TH ANN C AM C REH; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Rosenthal R., 1994, METAANALYTIC PROCEDU; SCHWAB K, 1993, NEUROLOGY, V43, P96; STAPLETON M, 1989, COGNITIVE REHABILITA, V7, P18; U.S. Department of Labor, 1991, DICT OCC TITL; WEHMAN P, 1995, IN PRESS J HEAD TRAU; WEHMAN P, 1992, ADA MANDATE SOCIAL C	27	18	18	0	5	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	FEB	1995	5	1					39	48		10.1016/1053-8135(94)00103-2			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ879	WOS:A1995RJ87900004	24525458				2021-06-18	
J	NIDA, TY; BIROS, MH; PHELEY, AM; BERGMAN, TA; ROCKSWOLD, GL				NIDA, TY; BIROS, MH; PHELEY, AM; BERGMAN, TA; ROCKSWOLD, GL			EFFECT OF HYPOXIA OR HYPERBARIC-OXYGEN ON CEREBRAL EDEMA FOLLOWING MODERATE FLUID PERCUSSION OR CORTICAL IMPACT INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; INTRACRANIAL-PRESSURE; MODEL	This study was designed to evaluate the production of cerebral edema [as measured by tissue specific gravity (SpG)] following moderate fluid percussion (FP) and cortical impact (CI) injury in rodents. To determine the effects of a secondary systemic insult, hypoxia (13% oxygen for 30 min) was added to some experimental groups immediately after head injury. To determine the effects of hyperbaric oxygen (HBO) on injured cortical tissue, additional animal groups were exposed to HBO (1.5 atm, for 60 min), beginning 4 h after head trauma. Both injury models produced equal amounts of tissue edema at the site of injury (mean SpG +/- SEM = 1.035 +/- 0.001), when measured 6 h posttrauma. There was no significant edema at the tissue sites immediately adjacent to the trauma sites. The addition of hypoxia to either injury system did not increase edema formation beyond that produced by injury alone. HBO reduced the water content of the trauma site in animals that had received FP, but not in animals receiving CI. We conclude that with the injury parameters used in this protocol, both FP and CI appear to produce focal cerebral edema at the site of trauma. Hypoxia does not worsen edema. HBO appears to reduce edema produced by FP, but not by CI.	HENNEPIN CTY MED CTR,DEPT EMERGENCY MED,MINNEAPOLIS,MN 55415; UNIV MINNESOTA HOSP & CLIN,DEPT NEUROSURG,MINNEAPOLIS,MN; HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55415; HENNEPIN CTY MED CTR,DEPT SURG,DIV NEUROSURG,MINNEAPOLIS,MN 55415					ONROffice of Naval Research [P2ONS30322-01] Funding Source: Medline		BIROS MH, 1990, ANN EMERG MED, V19, P201; BIROS MH, 1991, ANN EMERG MED, V20, P194; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYAKAWA T, 1971, NEUROL NEUROSURG PSY, V34, P580; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; KAWAMURA S, 1990, J HYPERBARIC MED, V5, P111; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1970, J NEUROSURG, V33, P287, DOI 10.3171/jns.1970.33.3.0287; NODA Y, 1983, J NEUROCHEM, V40, P1329, DOI 10.1111/j.1471-4159.1983.tb13574.x; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; REITAN JA, 1990, STROKE, V21, P119, DOI 10.1161/01.STR.21.1.119; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; ZALESKA MM, 1985, NEUROCHEM RES, V10, P397, DOI 10.1007/BF00964608	27	18	22	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1995	12	1					77	85		10.1089/neu.1995.12.77			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QN638	WOS:A1995QN63800006	7783234				2021-06-18	
J	BOHNEN, NJ; WIJNEN, G; TWIJNSTRA, A; VANZUTPHEN, W; JOLLES, J				BOHNEN, NJ; WIJNEN, G; TWIJNSTRA, A; VANZUTPHEN, W; JOLLES, J			THE CONSTELLATION OF LATE POSTTRAUMATIC SYMPTOMS OF MILD HEAD-INJURY PATIENTS	JOURNAL OF NEUROLOGIC REHABILITATION			English	Article						MILD HEAD INJURY; POSTCONCUSSIVE COMPLAINTS	POSTCONCUSSIONAL SYMPTOMS; CONCUSSION	A questionnaire based investigation was carried out in patients with mild head injury (MHI) one to five years after the injury. A heterogeneous item pool was used in order to study the interrelationships between traditional postconcussive complaints and more emotional and vegetative complaints. A three-factor model of residual subjective and psycho logical complaints was identified in the patient population (N = 231). This model contained a dysthymic factor, a vegetative/bodily complaints factor, and a cognitive performance factor. A factor analysis in a matched non-concussed population (N = 231) revealed a rather different pattern. Although symptoms in both the patient and control group were non-specific in nature, patients reported significantly more severe symptoms compared with control persons.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT GEN PRACTICE MED,6200 MD MAASTRICHT,NETHERLANDS							Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1995, IN PRESS BRAIN INJUR; BOHNEN N, 1992, INT J NEUROSCI, V64, P95; CAVENESS WF, 1966, HEAD INJURY C P, P209; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1974, LANCET, V2, P605; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P211; VERHAGE R, 1964, THESIS ASSEN NETHERL; 1985, SAS USERS GUIDE STAT	21	18	19	0	0	DEMOS PUBLICATIONS	NEW YORK	386 PARK AVE S STE 201, NEW YORK, NY 10016-8804	0888-4390			J NEUROL REHABIL	J. Neurol. Rehabil.		1995	9	1					33	39					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TF487	WOS:A1995TF48700005					2021-06-18	
J	WOOD, DMG; BIGLER, ED				WOOD, DMG; BIGLER, ED			DIENCEPHALIC CHANGES IN TRAUMATIC BRAIN INJURY - RELATIONSHIP TO SENSORY PERCEPTUAL FUNCTION	BRAIN RESEARCH BULLETIN			English	Article						DIENCEPHALON; SENSORY-PERCEPTUAL ABILITY; 3RD-VENTRICLE; INTERNAL CAPSULE; TRAUMATIC BRAIN INJURY	MIDDLE CEREBRAL-ARTERY; CLOSED HEAD-INJURY; DEGENERATION; ATROPHY; NEURONS; NUCLEUS; INFARCTION; THALAMUS; ISCHEMIA; RATS	Magnetic resonance (MR) imaging scans of 33 traumatically brain-injured (TBI) patients were compared quantitatively to MR scans of controls matched for age and gender. Quantitative estimates of thalamic, internal capsule, and third ventricle morphology were obtained in each TBI patient. Comparisons were made to normal control subjects and revealed significant reduction in thalamic volume with corresponding increase in third ventricle. Measurements of internal capsule reflected nonsignificant changes. Significant correlations were observed between sensory-perceptual functioning, as measured by the Reitan-Klove Sensory-Perceptual Exam, and thalamic volume in TBI patients. A decrease in thalamic volume was associated with an increase in sensory-perceptual errors.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143							ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Bigler E D, 1987, Arch Clin Neuropsychol, V2, P293, DOI 10.1016/0887-6177(87)90017-5; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BIGLER ED, 1992, BRAIN INJURY, V7, P125; BLATTER DD, AJNR, V16, P241; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; DUVERNOY HM, 1991, HUMAN BRAIN SURFACE; EAGLESON KL, 1992, EXP NEUROL, V116, P156, DOI 10.1016/0014-4886(92)90163-K; FUJIE W, 1990, STROKE, V21, P1485, DOI 10.1161/01.STR.21.10.1485; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gean A, 1994, IMAGING HEAD TRAUMA; Gilman S., 1992, CLIN NEUROANATOMY NE; GONZALES CF, 1993, MINOR HEAD TRAUMA AS, P33; Halstead WC, 1985, HALSTEAD REITAN NEUR; HANYU H, 1991, Brain and Nerve (Tokyo), V43, P255; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Jones E.G., 1985, THALAMUS; KUCHARCZYK J, 1994, MAGNETIC RESONANCE N; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RASBAND W, 1993, IMAGE 1 52 COMPUTER; REIDERGROSWASSE.I, 1992, AJR, V160, P147; ROBB RA, 1990, NATO ASI SER, P333; Roberts M, 1970, ATLAS HUMAN BRAIN SE; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; ROSS DT, 1989, BRAIN RES, V501, P129, DOI 10.1016/0006-8993(89)91034-2; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; STEWART MG, 1992, QUANTITATIVE METHODS; TAGUOHI J, 1989, Brain and Nerve (Tokyo), V41, P813; TAMURA A, 1991, STROKE, V22, P615, DOI 10.1161/01.STR.22.5.615; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMADA K, 1992, Neurological Research, V14, P267	40	18	18	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0361-9230			BRAIN RES BULL	Brain Res. Bull.		1995	38	6					545	549		10.1016/0361-9230(95)02026-0			5	Neurosciences	Neurosciences & Neurology	TF570	WOS:A1995TF57000005	8590076				2021-06-18	
J	THEODOROS, DG; MURDOCH, BE				THEODOROS, DG; MURDOCH, BE			LARYNGEAL DYSFUNCTION IN DYSARTHRIC SPEAKERS FOLLOWING SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							VOICE QUALITY; DYSPHONIA; APHONIA; SPEECH	The laryngeal function of 19 severely closed head-injured subjects with a perceptible dysarthria was assessed using electrolaryngography and a computerized airflow/air pressure analysis system (Aerophone II). Variables measured included parameters of the Lx waveform (Fo, duty cycle and closing time) as well as aerodynamic parameters such as subglottal pressure, glottal resistance, average phonatory sound pressure level, phonatory flow rate and ad/abduction rate. Values were compared to those recorded from a non-neurologically impaired control group matched for age and sex, and correlated with the findings of a perceptual speech analysis. The findings are discussed in relation to the effects of a severe closed-head injury on laryngeal function. The clinical implications of the findings for the assessment and treatment of vocal dysfunction in head-injured subjects are also discussed.	UNIV QUEENSLAND,DEPT SPEECH & HEARING,MOTOR SPEECH RES UNIT,ST LUCIA,QLD 4072,AUSTRALIA			Theodoros, Deborah/F-1362-2010; Murdoch, Bruce E/C-1397-2012				ARONSON AE, 1968, J SPEECH HEAR DISORD, V33, P203, DOI 10.1044/jshd.3303.203; Aronson AE., 1980, CLIN VOICE DISORDERS; Baken R., 1987, CLIN MEASUREMENT SPE, P197; BASSICH CJ, 1986, J SPEECH HEAR DISORD, V51, P125, DOI 10.1044/jshd.5102.125; BLAUSTEIN S, 1983, J COMMUN DISORD, V16, P157, DOI 10.1016/0021-9924(83)90046-1; Boone D., 1977, VOICE VOICE THERAPY; COLTON RH, 1991, J VOICE, V4, P10; Darley F., 1975, MOTOR SPEECH DISORDE; FEX S, 1992, J VOICE, V6, P155, DOI 10.1016/S0892-1997(05)80130-4; FROKJAERJENSEN B, 1989, C INT ASS LOG PHON P; GREENE MCL, 1972, VOICE ITS DISORDERS; HANSON DG, 1983, ANN OTO RHINOL LARYN, V92, P413, DOI 10.1177/000348948309200501; HANSON DG, 1991, OTOLARYNGOLOGIC CLIN, P1035; HARTMAN DE, 1984, ANN OTO RHINOL LARYN, V93, P57, DOI 10.1177/000348948409300114; HARTMANN E, 1984, J COMMUN DISORD, V17, P425, DOI 10.1016/0021-9924(84)90004-2; HILLMAN RE, 1989, J SPEECH HEAR RES, V32, P373, DOI 10.1044/jshr.3202.373; Holmberg E, 1980, J ACOUST SOC AM, V68, pS101; HOLMBERG E B, 1989, Journal of Voice, V3, P294, DOI 10.1016/S0892-1997(89)80051-7; HOLMBERG EB, 1988, J ACOUST SOC AM, V84, P511, DOI 10.1121/1.396829; HOODIN RB, 1989, FOLIA PHONIATR, V41, P249, DOI 10.1159/000265976; IISSHIKI N, 1965, FOLIA PHONIATR, V17, P92; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KENT RD, 1982, BRAIN LANG, V15, P259, DOI 10.1016/0093-934X(82)90060-8; KITZING P, 1982, FOLIA PHONIATR, V34, P216, DOI 10.1159/000265653; LABLANCE G R, 1991, Ear Nose and Throat Journal, V70, P691; Ludlow C., 1983, CLIN DYSARTHRIA, P121; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; Murdoch Bruce E., 1990, AUSTR J HUMAN COMMUN, V18, P83; ORLIKOFF R F, 1992, Seminars in Speech and Language, V13, P25, DOI 10.1055/s-2008-1064184; Prater RJ, 1984, MANUAL VOICE THERAPY; Ramig L. O., 1992, INTELLIGIBILITY SPEE, DOI [10.1075/sspcl.1.05ram, DOI 10.1075/SSPCL.1.05RAM]; SAPIR S, 1985, BRIT J DISORD COMMUN, V20, P289; SCHOLEFIELD JA, 1987, BRIT J DISORD COMMUN, V22, P167; Schutte H K, 1986, Acta Otorhinolaryngol Belg, V40, P344; SCHUTTE HK, 1980, EFFICIENCY VOICE; SMITHERAN JR, 1981, J SPEECH HEAR DISORD, V46, P138, DOI 10.1044/jshd.4602.138; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; VOGEL M, 1982, FOLIA PHONIATR, V34, P150, DOI 10.1159/000265644; VONCRAMON D, 1981, NEUROPSYCHOLOGIA, V19, P801, DOI 10.1016/0028-3932(81)90092-0; VONLEDEN H, 1968, ANN NY ACAD SCI, V155, P56; ZYSKI JB, 1987, J COMMUN DISORD, V204, P367	41	18	18	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1994	8	8					667	684		10.3109/02699059409151021			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PT049	WOS:A1994PT04900003	7849686				2021-06-18	
J	TAKEHARA, S; TANAKA, T; UEMURA, K; SHINOHARA, Y; YAMAMOTO, T; TOKUYAMA, T; SATOH, A				TAKEHARA, S; TANAKA, T; UEMURA, K; SHINOHARA, Y; YAMAMOTO, T; TOKUYAMA, T; SATOH, A			OPTIC-NERVE INJURY DEMONSTRATED BY MRI WITH STIR SEQUENCES	NEURORADIOLOGY			English	Article						OPTIC NERVE INJURY; MAGNETIC RESONANCE IMAGING; SHORT INVERSION TIME INVERSION RECOVERY SEQUENCE		We studied nine patients with optic nerve injury associated with closed head trauma by magnetic resonance imaging (MRI) with short inversion time inversion recovery (STIR) sequences on 11 occasions from 4 days to 14 years after the injury: three studies were within 17 days and eight over 4 months to 14 years. MRI revealed abnormal high signal in 10 of the 11 injured nerves. MRI 4 days after the injury showed no abnormality.	HAMAMATSU UNIV SCH MED, DEPT NEUROSURG, SHIZUOKA, JAPAN; SHIDA GEN HOSP FUJIEDA, DEPT NEUROSURG, SHIZUOKA, JAPAN; FUJINOMIYA CITY GEN HOSP, DEPT NEUROSURG, SHIZUOKA, JAPAN	TAKEHARA, S (corresponding author), YAIZU MUNICIPAL HOSP, DEPT NEUROSURG, 100 DOUBARA, YAIZU SHIZUOKA 425, JAPAN.						ATLAS SW, 1988, AM J NEURORADIOL, V9, P969; BYDDER GM, 1985, J COMPUT ASSIST TOMO, V9, P659, DOI 10.1097/00004728-198507010-00002; DANIELS DL, 1986, AM J NEURORADIOL, V7, P249; JOHNSON G, 1987, NEURORADIOLOGY, V29, P238, DOI 10.1007/BF00451760; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; Kojima S, 1990, No To Shinkei, V42, P1191; MILLER DH, 1988, NEUROLOGY, V38, P175, DOI 10.1212/WNL.38.2.175; SIMON J, 1988, AM J NEURORADIOL, V9, P961; TAKEHARA S, 1992, PROG COMPUT IMAG, V14, P56	9	18	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	OCT	1994	36	7					512	514		10.1007/BF00593510			3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	PL580	WOS:A1994PL58000004	7845573				2021-06-18	
J	JANECZKO, K				JANECZKO, K			AGE-DEPENDENT CHANGES IN THE PROLIFERATIVE RESPONSE OF S-100 PROTEIN-POSITIVE GLIAL-CELLS TO INJURY IN THE RAT-BRAIN	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						BRAIN INJURY; ASTROCYTE PROLIFERATION; BRAIN DEVELOPMENT; AUTORADIOGRAPHY; S-100 PROTEIN IMMUNOCYTOCHEMISTRY	FIBRILLARY ACIDIC PROTEIN; NEURON-RICH REGIONS; NEONATAL RAT; CEREBRAL-CORTEX; ADULT-RAT; IMMUNOHISTOCHEMICAL OBSERVATIONS; POSTNATAL-DEVELOPMENT; GLUTAMINE-SYNTHETASE; GROWTH-FACTOR; ASTROCYTES	A mechanical injury was inflicted to the left cerebral hemisphere in rats of four age groups: newborns, 6, 14 and 30 days old. The injury was followed by [H-3]thymidine injections at different time intervals. Brain sections were immunostained for S-100 protein and subjected to autoradiography. During microscopic observations of the injury region, locations and numbers of the autoradiographically labeled astrocytes expressing S-100 protein were recorded. On the basis of the observations, injury-induced changes in the total number of proliferating astrocytes, as well as in their distribution, were analysed quantitatively. In rats injured neonatally, as well as those injured on postnatal days 6 and 14, the reactive increase in the number of proliferating astrocytes began on the first post-traumatic day. In 30-day-old rats the increase was slower and appeared on day 2. The maximal increase in the astrocyte proliferative activity occurred in 6-day-old rats as early as day 1 after injury and was about eight times higher than that recorded in newborns, and nearly twice as high as that recorded in brains of 30-day-old rats. The results suggest that the intensity of astrocyte proliferative response to injury cannot be regarded as simply being proportional to the developmental progress of the brain tissue. Rather, these results indicate that changes in glial proliferative responses to injury follow a developmental time course, with a peak around the end of the first postnatal week.		JANECZKO, K (corresponding author), JAGIELLONIAN UNIV,INST ZOOL,DEPT NEUROANAT,PL-30060 KRAKOW,POLAND.			Janeczko, Krzysztof/0000-0002-9544-918X			Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; CHAN CLH, 1990, DEV BRAIN RES, V55, P275, DOI 10.1016/0165-3806(90)90209-H; COCCHIA D, 1981, CELL TISSUE RES, V214, P529; DAHL D, 1986, ASTROCYTES, V3, P1; FERRER I, 1992, PROG NEUROBIOL, V39, P1, DOI 10.1016/0301-0082(92)90029-E; GHANDOUR MS, 1981, DEV NEUROSCI-BASEL, V4, P66, DOI 10.1159/000112742; GIULIAN D, 1988, J NEUROSCI, V8, P709; GOMEZ LA, 1990, INT J DEV NEUROSCI, V8, P55; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; JACOBSON M, 1991, DEV NEUROBIOLOGY; JANAS MS, 1991, ANAT EMBRYOL, V184, P549, DOI 10.1007/BF00942577; JANAS MS, 1991, ANAT EMBRYOL, V184, P559, DOI 10.1007/BF00942578; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; KONDO H, 1984, CELL TISSUE RES, V238, P503; LEGRAND C, 1981, NEUROPATH APPL NEURO, V7, P299, DOI 10.1111/j.1365-2990.1981.tb00101.x; LUDWIN SK, 1976, J COMP NEUROL, V165, P197, DOI 10.1002/cne.901650206; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MIYAKE T, 1989, BRAIN RES, V493, P376, DOI 10.1016/0006-8993(89)91174-8; MOORE BW, 1977, NEUROCHEM RES, V2, P549, DOI 10.1007/BF00966014; MOORE IE, 1987, NEUROPATH APPL NEURO, V13, P219, DOI 10.1111/j.1365-2990.1987.tb00185.x; NAGANO N, 1993, GLIA, V8, P71, DOI 10.1002/glia.440080202; PFEIFFER B, 1992, HISTOCHEMISTRY, V97, P405, DOI 10.1007/BF00270387; RAPPORT MM, 1974, T AM SOC NEUROCHEM, V5, P58; SARNAT HB, 1992, J NEUROPATH EXP NEUR, V51, P58, DOI 10.1097/00005072-199201000-00008; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; TANAKA H, 1992, EXP NEUROL, V116, P264, DOI 10.1016/0014-4886(92)90006-C; TANAKA H, 1991, ACTA HISTOCHEM CYTOC, V24, P11, DOI 10.1267/ahc.24.11	32	18	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	AUG	1994	12	5					431	440		10.1016/0736-5748(94)90027-2			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	PF198	WOS:A1994PF19800007	7817786				2021-06-18	
J	SILVER, JK; LUX, WE				SILVER, JK; LUX, WE			EARLY-ONSET DYSTONIA FOLLOWING TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEMIDYSTONIA; THERAPY		NATL REHABIL HOSP,BRAIN INJURY PROGRAM,102 IRVING ST NW,WASHINGTON,DC 20010			Silver, Julie K/AAE-7163-2019	Silver, Julie K./0000-0001-9711-0713			ANDREW J, 1983, BRAIN, V106, P981, DOI 10.1093/brain/106.4.981; Brin M F, 1988, Adv Neurol, V50, P599; DEMIERRE B, 1983, J NEUROL NEUROSUR PS, V46, P404, DOI 10.1136/jnnp.46.5.404; Elston J S, 1988, Adv Neurol, V50, P579; FAHN S, 1984, NEUROL CLIN, V2, P541, DOI 10.1016/S0733-8619(18)31090-9; Fahn S, 1976, Adv Neurol, V14, P1; FAHN S, 1984, NEUROL CLIN, V2, P555, DOI 10.1016/S0733-8619(18)31091-0; FAHN S, 1983, NEUROLOGY, V33, P1255, DOI 10.1212/WNL.33.10.1255; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HUANG G-S, 1992, Kaohsiung Journal of Medical Sciences, V8, P108; JABBARI B, 1992, MOVEMENT DISORD, V7, P78, DOI 10.1002/mds.870070116; KRUASS JK, 1992, MOV DIS, V7, P263; Marsden C D, 1976, Adv Neurol, V14, P259; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; MAURO AJ, 1980, TRANSCRIPTS AM NEURO, P229; PETTIGREW LC, 1985, J NEUROL NEUROSUR PS, V48, P650, DOI 10.1136/jnnp.48.7.650; Tanner C M, 1988, Adv Neurol, V50, P557; Teravainen H, 1988, Adv Neurol, V50, P571; YOSHIMURA DM, 1992, NEUROLOGY, V42, P627, DOI 10.1212/WNL.42.3.627	19	18	19	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1994	75	8					885	888		10.1016/0003-9993(94)90113-9			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PB621	WOS:A1994PB62100008	8053795				2021-06-18	
J	LEVIN, BE; PAN, SJ; DUNNMEYNELL, A				LEVIN, BE; PAN, SJ; DUNNMEYNELL, A			CHRONIC ALTERATIONS IN RAT-BRAIN ALPHA-ADRENOCEPTORS FOLLOWING TRAUMATIC BRAIN INJURY	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						BRAIN INJURY; HEAD TRAUMA; NOREPINEPHRINE; RECOVERY OF FUNCTION; PLASTICITY	SENSORIMOTOR CORTEX INJURY; CENTRAL NORADRENERGIC NEURONS; LOCUS COERULEUS NEURONS; MOTOR RECOVERY; BEAM-WALKING; CEREBELLAR NOREPINEPHRINE; FACILITATE RECOVERY; FUNCTIONAL RECOVERY; AXONAL INJURY; LESION SIZE	Norepinephrine (NE) has been implicated in cerebral plasticity and recovery of function after brain injury. To examine the status of noradrenergic mechanisms in the brain following traumatic brain injury (TBI), male Sprague-Dawley rats underwent right sensorimotor cortex contusions and were observed for the next 30 days for recovery of motor function by measurement of the time taken to perform a modified beam walking task. At 30 days, their brains were assayed by receptor autoradiography for alpha(1)- and alpha(2)-adrenoceptor binding with 1 nM [H-3]prazosin and 1 nM [H-3]paraminoclonidine, respectively. One day after contusion, TBI rats took 60% longer to run the beam than sham-lesioned controls. Run times were directly proportional (r = 0.784; P = 0.012) to lesion volume determined at 30 days. The motor deficit persisted for 8 days, after which TBI and control rats had similar run times, largely due to increased run times in sham rats. At 30 days, TBI rats had a generalized, bilateral decrease in [3H]prazosin binding across all brain areas read (F[1,13] = 9.23; P = 0.009) with specific 12%-21% decreases in the cortex contralateral to the lesion and bilaterally in the dorsomedial hypothalamic and three thalamic nuclei. On the other hand, [H-3]paraminoclonidine binding did not differ from sham lesion controls in any brain area of TBI rats. Thus, unilateral TBI is followed by widespread, bilateral changes in alpha(1)-adrenoceptor binding which would leave the animal vulnerable to any factors which reduced the access of NE to its postsynaptic adrenoceptors. This is compatible with the observation that alpha(1)-antagonists and alpha(2)-agonists can transiently reinstate the motor deficit after recovery has occurred.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	LEVIN, BE (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,385 TREMONT AVE,E ORANGE,NJ 07018, USA.						ABERCROMBIE ED, 1989, J NEUROSCI, V9, P4062; ACHESON AL, 1981, J NEUROSCI, V1, P493; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, PHARMACOL BIOCHEM BE, V43, P771, DOI 10.1016/0091-3057(92)90407-7; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; CURET O, 1987, J PHARMACOL EXP THER, V240, P327; Dunn-Meynell A., 1993, Society for Neuroscience Abstracts, V19, P1882; DUNNMEYNELL AA, 1993, BRAIN RES, V623, P25, DOI 10.1016/0006-8993(93)90005-8; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILE AM, 1978, BEHAV BIOL, V22, P417, DOI 10.1016/S0091-6773(78)92547-6; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GRABOWSKI M, 1991, BRAIN RES, V547, P249, DOI 10.1016/0006-8993(91)90968-2; GUSTAFSON I, 1992, J NEUROL SCI, V113, P165, DOI 10.1016/0022-510X(92)90244-F; LEVIN BE, 1988, BRAIN RES, V443, P261, DOI 10.1016/0006-8993(88)91620-4; LEVIN BE, 1993, MOL BRAIN RES, V18, P59, DOI 10.1016/0169-328X(93)90173-M; LEVIN BE, 1985, BRAIN RES, V359, P215, DOI 10.1016/0006-8993(85)91431-3; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1991, EXP NEUROL, V113, P237, DOI 10.1016/0014-4886(91)90180-K; OLTMANS GA, 1981, BRAIN RES, V222, P411, DOI 10.1016/0006-8993(81)91046-5; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROBINSON RG, 1980, BRAIN RES, V188, P63, DOI 10.1016/0006-8993(80)90557-0; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Ungerstedt U, 1971, ACTA PHYSIOL SC S367, V82, P1; WILMOT CA, 1988, BRAIN RES, V453, P157, DOI 10.1016/0006-8993(88)90154-0	35	18	19	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	JUL	1994	7	1					5	12					8	Neurosciences	Neurosciences & Neurology	PD027	WOS:A1994PD02700002	21551766				2021-06-18	
J	PRIOER, M; KINSELLA, G; SAWYER, M; BRYAN, D; ANDERSON, V				PRIOER, M; KINSELLA, G; SAWYER, M; BRYAN, D; ANDERSON, V			COGNITIVE AND PSYCHOSOCIAL OUTCOME AFTER HEAD-INJURY IN CHILDREN	AUSTRALIAN PSYCHOLOGIST			English	Article							EMOTIONAL-PROBLEMS; COMMUNITY; BEHAVIOR; ADOLESCENTS; ADJUSTMENT; SEQUELAE; TRAUMA	Neuropsychological and psychosocial assessment of 58 Victorian and South Australian school-aged children who sustained a closed head injury was carried out immediately postinjury and at 6 months follow-up. For those children whose head injury was defined as mild (length of coma less than 1 hour) outcome on all variables was good at both time points. Children with moderate to severe injury (length of coma greater than 1 hour) had lower WISC-R IQ scores at both time points and were particularly poor on reading and spelling measures. There was no improvement over time on the academic measures. Family and parental functioning was in the normative range and, although some children showed a clinical level of behaviour problems, there was no consistency in their clinical status over time nor across parent and teacher informants. Our results suggest that there are no particular concerns for the long-term outcome of mildly head-injured children but that cognitive and school learning problems for moderate to severely head-injured children puts them at continuing risk.	ADELAIDE CHILDRENS HOSP INC,ADELAIDE,SA 5006,AUSTRALIA	PRIOER, M (corresponding author), LA TROBE UNIV,DEPT PSYCHOL,BUNDOORA,VIC 3083,AUSTRALIA.		Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			ACHANBACH TM, 1986, MANUAL TEAHCERS REPO; ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; Bond M R, 1975, Ciba Found Symp, P141; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Brooks N., 1984, CLOSED HEAD INJURY P; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BURNS S, 1990, THESIS LA TROBE U; BURVILL PW, 1983, AUST NZ J PSYCHIAT, V17, P237, DOI 10.3109/00048678309161279; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FORRESTER G, 1990, CLIN NEUROPSYCHOLOGI, V5, P345; HENSLEY VR, 1988, AUST PSYCHOL, V23, P371, DOI 10.1080/00050068808255619; JOHNSTON C, 1984, DEV MED CHILD NEUROL, V26, P588; JONES D, 1987, THESIS LA TROBE U; KYRIOS M, 1988, THESIS LA TROBE U; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MORSE S, 1987, P AUSTR SOC BRAIN IM, P46; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; PRIOR M, 1993, J AM ACAD CHILD PSY, V32, P291, DOI 10.1097/00004583-199303000-00009; PRIOR M, 1985, HYPERACTIVITY DIAGNO; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SAWYER MG, 1988, J MARITAL FAM THER, V14, P287, DOI 10.1111/j.1752-0606.1988.tb00748.x; SAWYER MG, 1992, J CHILD PSYCHOL PSYC, V33, P441, DOI 10.1111/j.1469-7610.1992.tb00878.x; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; VERHULST FC, 1989, J CHILD PSYCHOL PSYC, V30, P123, DOI 10.1111/j.1469-7610.1989.tb00772.x; WERNER E, 1982, VULNERABLE BUT INVIN; WILLSHIRE D, 1992, THESIS LA TROBE U	34	18	18	0	3	AUSTRALIAN PSYCHOLOGICAL SOC	CARLTON	1 GRATTAN STREET, CARLTON VICTORIA 3053, AUSTRALIA	0005-0067			AUST PSYCHOL	Aust. Psychol.	JUL	1994	29	2					116	123		10.1080/00050069408257334			8	Psychology, Multidisciplinary	Psychology	PK594	WOS:A1994PK59400007					2021-06-18	
J	WEHMAN, P; KREGEL, J; WEST, M; CIFU, D				WEHMAN, P; KREGEL, J; WEST, M; CIFU, D			RETURN TO WORK FOR PATIENTS WITH TRAUMATIC BRAIN INJURY - ANALYSIS OF COSTS	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article								This brief report describes staff time commitment and program cost outcomes for a return to work program of supported employment for persons with brain injuries. The mean cost of providing services was $10,198 for the first year of service (median, $6,942). Clients achieved job stabilization after an average of 18 wk of time-limited job coaching services, during which they received mean intervention time of 245.7 h (median, 219) at a cost of $7,789. A mean of 2.24 h/wk of extended services intervention was required to maintain clients in employment for the remainder of the first year of service, at a mean weekly cost of $71.01. Results are compared with findings reported in a previous study using a smaller sample.		WEHMAN, P (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CTR REHABIL RES & TRAINING,1314 W MAIN ST,BOX 2011,RICHMOND,VA 23298, USA.			Cifu, David/0000-0003-1600-9387			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; KAY T, 1986, ANNOTATED BIBL RES V; Kregel J, 1994, NeuroRehabilitation, V4, P1, DOI 10.3233/NRE-1994-4103; WEHMAN P, 1992, SUPPORTED EMPLOYMENT; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127	8	18	18	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1994	73	4					280	282		10.1097/00002060-199407000-00010			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PB254	WOS:A1994PB25400010	8043251				2021-06-18	
J	GOODMAN, JC				GOODMAN, JC			PATHOLOGICAL-CHANGES IN MILD HEAD-INJURY	SEMINARS IN NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN INJURY; DAMAGE; IMPACT; MODEL; HEMATOMA; ASSAULT; COMA; RAT	Physical injury of the brain constitutes a major cause of loss of life and productivity. Populations at highest risk for such injuries include children, men in late adolescence and early adult life, and the elderly. Head injuries most commonly result from assaults, vehicular accidents, and falls. The neuropathology of severe injury has been described extensively and constitutes much of the lore of clinical neurosurgery, forensic neuropathology, and critical care neurology.1 The neuropathology of mild head injury is much less well explored, reflecting the low mortality of these injuries. Experimental head injury models originally developed to facilitate research in severe trauma have proven valuable in understanding the neurobiologic basis of the numerous and debilitating symptoms that follow mild head injury and have focused attention on diffuse axonal injury (DAI) as the primary neuropathologic mechanism underlying these symptoms.2 This review sequentially covers experimental models of head injury, neuropathology of human head trauma, with a detailed discussion of DAI, and ends with a discussion of the regenerative response to head injury and possible role of neuroplasticity in the genesis of post-traumatic symptomatology.	BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA	GOODMAN, JC (corresponding author), BAYLOR COLL MED, DEPT PATHOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; AMMONS AM, 1990, NURS CLIN N AM, V25, P23; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P407, DOI 10.1111/j.1365-2990.1991.tb00740.x; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ERB DE, 1991, EXP BRAIN RES, V83, P253; Gennarelli T A, 1993, Acta Neurochir Suppl (Wien), V57, P49; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; IMAJO T, 1992, AM J FOREN MED PATH, V13, P169; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; KIRKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; KOBAYASHI S, 1989, Neurosurgical Review, V12, P451, DOI 10.1007/BF01790690; LEESTMA JE, 1988, FORENSIC NEUROPATHOL, P184; LEESTMA JE, 1988, FORENSIC NEUROPATHOL, P1; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1989, MILD HEAD INJURY, P1; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LUCAS JH, 1992, J NEUROTRAUM, V9, P117, DOI 10.1089/neu.1992.9.117; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; NAKAZAWA S, 1989, Neurological Surgery, V17, P247; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Onaya M, 1991, No To Shinkei, V43, P283; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER JR, 1990, ANN CLIN LAB SCI, V20, P220; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POTAPOV AA, 1990, ZH VOPR NEIROKHIR, V2, P3; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; RODDA RA, 1987, CLIN NEUROPATHOL, V6, P179; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SGANZERLA EP, 1989, CHILD NERV SYST, V5, P168, DOI 10.1007/BF00272121; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P37; SHIGEMORI M, 1991, NEUROL MED CHIR TOKY, V314, P390; SHIMURA T, 1988, Neurological Surgery, V16, P647; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TOMINAGA I, 1991, REV NEUROL-FRANCE, V147, P658; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, P7; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAKI T, 1992, ACTA NEUROCHIR, V119, P153, DOI 10.1007/BF01541800; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	64	18	18	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					19	24		10.1055/s-2008-1041054			6	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100005	8029556				2021-06-18	
J	MURSHID, WR				MURSHID, WR			ROLE OF SKULL RADIOGRAPHY IN THE INITIAL EVALUATION OF MINOR HEAD-INJURY - A RETROSPECTIVE STUDY	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; SKULL FRACTURE; SKULL RADIOGRAPHY	TRAUMA; ADMISSION	The use of skull radiography in the initial evaluation of minor head injured patients is controversial. In an attempt to evaluate its benefits, a retrospective study of 566 cases subjected to skull radiography following close minor head trauma (Glasgow Coma Scale 13-15), is presented. A skull fracture (linear vault, depressed or base of skull) was present in 64 (11 %) cases. Only three (5 %) who were found to have a skull fracture on skull radiography developed an intracranial injury which required surgery. Intracranial injuries developed in 19 (3 %) cases and were followed by surgery in six (32 %). All, except for one case, had a decreased level of consciousness and a Glasgow Coma Scale less than 15, few had focal neurological deficits. Management had not been altered by the results of skull radiography in any of the cases. We concluded that skull radiographs are unnecessary for the decision process in closed minor head injury because management decisions are based primarily on a careful neurological examination, When intracranial injuries are a concern, a CT scan should be obtained.		MURSHID, WR (corresponding author), KING SAUD UNIV, KING KHALID UNIV HOSP, DEPT SURG 37, DIV NEUROSURG, POB 7805, RIYADH 11472, SAUDI ARABIA.						BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BRIGGS M, 1984, BRIT MED J, V288, P983; COOPER PR, 1983, NEUROSURGERY, V13, P136, DOI 10.1227/00006123-198308000-00005; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; JENNETT B, 1980, CLIN RADIOL, V31, P463, DOI 10.1016/S0009-9260(80)80195-4; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; PHILLIPS LA, 1979, NEUROSURGERY, V4, P580, DOI 10.1227/00006123-197906000-00017; ROBERTS CJ, 1983, LANCET, V1, P115; ROBERTS CJ, 1981, LANCET, V2, P791; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	14	18	19	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994	129	1-2					11	14		10.1007/BF01400866			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NY476	WOS:A1994NY47600003	7998489				2021-06-18	
J	LEVIN, HS				LEVIN, HS			HEAD TRAUMA	CURRENT OPINION IN NEUROLOGY			English	Article							BRAIN INJURY; BLOOD-FLOW; SEVERITY; CHILDREN; DEFICITS; SPECT; MILD	Progress in research includes studies concerning the pathophysiology and outcome of pediatric head injury, the pathology of the hippocampus in fatal injury, and the use of multivariate statistics to predict outcome in survivors. Recent research has confirmed and extended findings regarding the differential effects of closed head injury, depending on the age of the individual. These studies indicate that the consequences of head injury are more severe in older adults and in children younger than 2 years. Neuroimaging findings include evidence for delayed brain injury as a major cause of mortality and disability. Functional brain imaging provides evidence for cerebral dysfunction that is not appreciated by structural brain imaging techniques and may have a stronger relationship to neurobehavioral sequelae. The neurobehavioral sequelae frequently implicate frontal dysfunction, even in the absence of structural findings on computed tomography or magnetic resonance imaging. Studies of mild head injury have expanded our knowledge concerning the pathogenesis of postconcussional symptoms, including a preinjury vulnerability based on recent life events. Persistent postconcussional symptoms after mild head injury are frequently associated with emotional disturbance of clinical proportions.		LEVIN, HS (corresponding author), UNIV MARYLAND,DIV NEUROSURG,ROOM N12E27,22 S GREENE ST,BALTIMORE,MD 21201, USA.						ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DUHAIME AC, 1992, PEDIATRICS, V90, P179; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135	26	18	18	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1993	6	6					841	846		10.1097/00019052-199312000-00003			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	MJ016	WOS:A1993MJ01600003	8293157				2021-06-18	
J	ROSENTHAL, M				ROSENTHAL, M			MILD TRAUMATIC BRAIN INJURY SYNDROME	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		TRAUMA; BRAIN INJURY		The mild post-traumatic brain injury syndrome has continued to pose clinical management problems for medical specialists from the emergency physician to the family practitioner. The contribution of preinjury medical and psychosocial factors, along with the concomitant risk of litigation, complicates the diagnostic task. This review examines selected aspects of this problem, including definition and classification, pathophysiology, symptom constellation, medicolegal pitfalls, diagnostic procedures, and treatment recommendations. Practitioners need to be particularly alert to the optimal strategies for emergency department management to prevent ''mild'' injuries from becoming major disabilities.		ROSENTHAL, M (corresponding author), REHABIL INST MICHIGAN,261 MACK BLVD,DETROIT,MI 48201, USA.							0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					1048	1051		10.1016/S0196-0644(05)82749-0			4	Emergency Medicine	Emergency Medicine	LE338	WOS:A1993LE33800015	8503524				2021-06-18	
J	PHILLIS, JW; PERKINS, LM; OREGAN, MH				PHILLIS, JW; PERKINS, LM; OREGAN, MH			POTASSIUM-EVOKED EFFLUX OF TRANSMITTER AMINO-ACIDS AND PURINES FROM RAT CEREBRAL-CORTEX	BRAIN RESEARCH BULLETIN			English	Article						GLUTAMATE; ASPARTATE; GABA; ADENOSINE; INOSINE; CORTEX; RELEASE; POTASSIUM	GAMMA-AMINOBUTYRIC ACID; INHIBITORY SYNAPTIC TRANSMISSION; HIPPOCAMPAL SLICES; BRAIN SYNAPTOSOMES; GLUTAMATE RELEASE; ISCHEMIC BRAIN; INVIVO RELEASE; ADENOSINE; ASPARTATE; HYPOXIA	Repeated applications of elevated K+ (50 or 75 mM) in cerebral cortical cup superfusates was used to evoke an efflux of gamma-aminobutyric acid (GABA), glutamate, aspartate, glycine, adenosine. and inosine from the in vivo rat cerebral cortex. K+ (50 mM) significantly elevated GABA levels in cup superfusates but had little effect on the efflux of glutamate, aspartate, glycine, adenosine, or inosine. K+ (75 mM) significantly enhanced the efflux of GABA, aspartate, adenosine, and inosine and caused nonsignificant increases in glutamate and glycine efflux. The adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA), applied in cup superfusates at a concentration of 10(-10) M had no effect on either basal or K+-evoked release of any of the amino acids or purines measured. At 10(-6) M CPA significantly enhanced aspartate release, and depressed GABA efflux. The selective A2 adenosine receptor agonist 2-p(2-carboxyethyl) phenethylamino-5'-N-ethyl-carboxamidoadenosine (CGS 21680) (10(-8) M) was without effect on either basal, or K+-evoked, efflux of amino acids or purines. The enhancement of aspartate (an excitotoxic amino acid) efflux by higher concentrations of CPA is likely due to activation of adenosine A2b receptors. This observation may be of relevance when selecting adenosinergic agents to treat ischemic or traumatic brain injuries. Overall, the results suggest that effects of adenosine receptor agonists on K+-evoked efflux of transmitter amino acids from the in vivo rat cerebral cortex may not be comparable to those observed with in vitro preparations.		PHILLIS, JW (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT PHYSIOL, 540 E CANFIELD, DETROIT, MI 48201 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26912] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026912] Funding Source: NIH RePORTER		ANDINE P, 1991, J NEUROCHEM, V57, P222, DOI 10.1111/j.1471-4159.1991.tb02119.x; ARVIN B, 1989, BRIT J PHARMACOL, V98, P225, DOI 10.1111/j.1476-5381.1989.tb16886.x; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BURKE SP, 1988, J NEUROCHEM, V51, P1541, DOI 10.1111/j.1471-4159.1988.tb01123.x; CLARK RM, 1976, J PHYSIOL-LONDON, V262, P383, DOI 10.1113/jphysiol.1976.sp011600; CORRADETTI R, 1984, EUR J PHARMACOL, V104, P19, DOI 10.1016/0014-2999(84)90364-9; DOLPHIN AC, 1983, NEUROSCI LETT, V43, P49, DOI 10.1016/0304-3940(83)90127-1; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FASTBOM J, 1985, ACTA PHYSIOL SCAND, V125, P121, DOI 10.1111/j.1748-1716.1985.tb07698.x; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GARRITSEN A, 1989, BIOCHEM PHARMACOL, V38, P693, DOI 10.1016/0006-2952(89)90218-9; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GONCALVES ML, 1991, J NEUROCHEM, V56, P1769; GRIFFITH NC, 1991, EPILEPSIA, V32, P767, DOI 10.1111/j.1528-1157.1991.tb05532.x; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HOLLINS C, 1980, BRIT J PHARMACOL, V69, P107, DOI 10.1111/j.1476-5381.1980.tb10888.x; JHAMANDAS K, 1980, CAN J PHYSIOL PHARM, V58, P1262, DOI 10.1139/y80-193; KAMIYA H, 1991, SYNAPSE, V8, P229, DOI 10.1002/syn.890080309; LAMBERT NA, 1991, NEUROSCI LETT, V122, P50, DOI 10.1016/0304-3940(91)90190-5; LEHMANN A, 1985, BRAIN RES, V359, P147, DOI 10.1016/0006-8993(85)91422-2; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MICHAELIS ML, 1988, BRAIN RES, V473, P249, DOI 10.1016/0006-8993(88)90854-2; MORONI F, 1981, N-S ARCH PHARMACOL, V316, P235, DOI 10.1007/BF00505655; NICHOLLS DG, 1989, J NEUROCHEM, V52, P331, DOI 10.1111/j.1471-4159.1989.tb09126.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OREGAN MH, 1992, NEUROSCI LETT, V138, P169, DOI 10.1016/0304-3940(92)90498-V; OREGAN MH, 1992, BRAIN RES, V582, P22, DOI 10.1016/0006-8993(92)90312-W; PHILLIS JW, 1989, BRAIN RES, V504, P121, DOI 10.1016/0006-8993(89)91606-5; PHILLIS JW, 1988, J CEREBR BLOOD F MET, V8, P733, DOI 10.1038/jcbfm.1988.121; PHILLIS JW, 1991, J NEUROCHEM, V56, P644, DOI 10.1111/j.1471-4159.1991.tb08198.x; PHILLIS JW, 1987, J CEREBR BLOOD F MET, V7, P679, DOI 10.1038/jcbfm.1987.122; PHILLIS JW, 1989, NEUROSCI LETT, V106, P147, DOI 10.1016/0304-3940(89)90217-6; PHILLIS JW, 1991, INT J PURINE PYRIMID, V2, P41; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SHINOZUKA K, 1985, EUR J PHARMACOL, V113, P417, DOI 10.1016/0014-2999(85)90090-1; SIMPSON RE, 1992, J NEUROCHEM, V58, P1683, DOI 10.1111/j.1471-4159.1992.tb10041.x; TERRIAN DM, 1989, J NEUROCHEM, V53, P1390, DOI 10.1111/j.1471-4159.1989.tb08529.x; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VONLUBITZ DKEJ, 1989, NEUROSCIENCE, V30, P451, DOI 10.1016/0306-4522(89)90265-0; YOON KW, 1991, J NEUROSCI, V11, P1375	42	18	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.		1993	31	5					547	552		10.1016/0361-9230(93)90122-R			6	Neurosciences	Neurosciences & Neurology	KX863	WOS:A1993KX86300016	8098653				2021-06-18	
J	RATHBONE, D; JOHNSON, G; LETTS, M				RATHBONE, D; JOHNSON, G; LETTS, M			SPINAL-CORD CONCUSSION IN PEDIATRIC ATHLETES	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						SPINAL CORD CONCUSSION; SPINAL STENOSIS; TRANSIENT QUADRAPARESIS		Children with a narrowed canal secondary to spinal stenosis or congenital malformation may be predisposed to spinal cord concussion when the canal is further narrowed in hyperflexion or hyperextension. Review of the medical records of the Winnipeg and Ottawa Children's Hospitals disclosed 12 children who had been treated for transient sensory or motor loss after a spinal injury. Measurements of the spinal canal were compared with standard normal measurements, and the spinal canal width was expressed as a percentage of the vertebral width (the Torg ratio). This study shows that narrowing of the spinal canal is an inconsistent predisposing factor to spinal cord concussion in children. A poor correlation between the Torg ratio and comparison with a series of normal control canal widths was noted.	CHILDRENS HOSP EASTERN ONTARIO,DEPT SURG,401 SMYTH RD,OTTAWA K1H 8L1,ONTARIO,CANADA								0	18	18	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	SEP-OCT	1992	12	5					616	620					5	Orthopedics; Pediatrics	Orthopedics; Pediatrics	JJ224	WOS:A1992JJ22400010	1517422				2021-06-18	
J	CRUZ, J; GENNARELLI, TA; ALVES, WM				CRUZ, J; GENNARELLI, TA; ALVES, WM			CONTINUOUS MONITORING OF CEREBRAL OXYGENATION IN ACUTE BRAIN INJURY - MULTIVARIATE ASSESSMENT OF SEVERE INTRACRANIAL PLATEAU WAVE - CASE-REPORT	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEAD-INJURY; PRESSURE; MANNITOL	A case of acute closed brain trauma is presented in which, for the first time, a full spectrum of multivariate physiologic abnormalities was clearly documented in association with a severe posttraumatic intracranial "plateau" wave and clinical signs of tentorial herniation. Prompt therapeutic measures proved effective, ultimately contributing to a favorable outcome.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR HEAD INJURY,PHILADELPHIA,PA 19104							BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1984, Society for Neuroscience Abstracts, V10, P542; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1983, INTRACRANIAL PRESSUR, P45; TEASDALE G, 1974, LANCET, V2, P81	13	18	18	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1992	32	3					401	403		10.1097/00005373-199203000-00020			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	HM904	WOS:A1992HM90400020	1548731				2021-06-18	
J	LAM, CS; PRIDDY, DA; JOHNSON, P				LAM, CS; PRIDDY, DA; JOHNSON, P			NEUROPSYCHOLOGICAL INDICATORS OF EMPLOYABILITY FOLLOWING TRAUMATIC BRAIN INJURY	REHABILITATION COUNSELING BULLETIN			English	Article									INST PHYS MED & REHABIL,PEORIA,IL; NEW MEDICO REHABIL CTR WISCONSIN,WATERFORD,WI	LAM, CS (corresponding author), IIT,DEPT PSYCHOL,CHICAGO,IL 60616, USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS N, 1987, BRAIN INJURY, V5, P5; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; MORRIS J, 1982, AM PSYCHOL ASS WASH; NEWMAN OS, 1978, BRAIN INJURY, V46, P635; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239	11	18	18	0	0	AMER COUNSELING ASSOC	ALEXANDRIA	5999 STEVENSON AVE, ALEXANDRIA, VA 22304-3300	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	SEP	1991	35	1					68	74					7	Rehabilitation	Rehabilitation	GB357	WOS:A1991GB35700005					2021-06-18	
J	SPEED, WG				SPEED, WG			CLOSED HEAD-INJURY SEQUELAE - CHANGING CONCEPTS	HEADACHE			English	Article									JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205							BECKER RF, 1945, FED PROC, V4, P6; COOMBE A, 1831, OBSERVATIONS MENTAL; COURVILLE CB, 1953, COMMOTIO CEREBRI; de Morsier G, 1943, SCHWEIZ ARCH NEUROL, V50, P161; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; Holbourn AHS, 1943, LANCET, V2, P438; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; KELLY R, 1981, J ROY SOC MED, V74, P275; Kelly R., 1972, PAHLAVI MED J, V3, P530; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; VEITH I, HYSTERIA HIST DISEAS; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210	19	18	20	0	0	AMER ASSOC STUDY HEADACHE	WOODBURY	875 KINGS HIGHWAY, STE 200, WOODBURY, NJ 08096	0017-8748			HEADACHE	Headache	NOV	1989	29	10					643	647		10.1111/j.1526-4610.1989.hed2910643.x			5	Clinical Neurology	Neurosciences & Neurology	CG305	WOS:A1989CG30500004	2693407				2021-06-18	
J	HARIRI, RJ; GHAJAR, JBG; POMERANTZ, KB; HAJJAR, DP; GIANNUZZI, RF; TOMICH, E; ANDREWS, DW; PATTERSON, RH				HARIRI, RJ; GHAJAR, JBG; POMERANTZ, KB; HAJJAR, DP; GIANNUZZI, RF; TOMICH, E; ANDREWS, DW; PATTERSON, RH			HUMAN GLIAL-CELL PRODUCTION OF LIPOXYGENASE-GENERATED EICOSANOIDS - A POTENTIAL ROLE IN THE PATHO-PHYSIOLOGY OF VASCULAR CHANGES FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article									CORNELL UNIV, MED CTR, DEPT SURG, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, DEPT PATHOL, VAC BIOL LAB, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, DIV NEUROSURG, AITKEN NEUROSURG LAB, NEW YORK, NY 10021 USA				Pomerantz, Kenneth/0000-0001-9443-5301			BACH MK, 1982, ANNU REV MICROBIOL, V36, P371, DOI 10.1146/annurev.mi.36.100182.002103; BLACK KL, 1985, ANN NEUROL, V18, P349, DOI 10.1002/ana.410180313; BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; DEMBINSKAKIEC A, 1984, EUR J PHARMACOL, V99, P57, DOI 10.1016/0014-2999(84)90431-X; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; FEINMARK SJ, 1988, ANN NY ACAD SCI, V524, P122; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; KENNEDY PGE, 1986, BRAIN, V109, P1261, DOI 10.1093/brain/109.6.1261; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; PIOMELLI D, 1987, J PHARMACOL EXP THER, V241, P763; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; POWELL WS, 1982, METHOD ENZYMOL, V86, P467; TAGARI P, 1983, PROSTA LEUKOTR MED, V11, P281, DOI 10.1016/0262-1746(83)90041-0; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x	18	18	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1989	29	9					1203	1210		10.1097/00005373-198909000-00003			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AQ652	WOS:A1989AQ65200003	2504938				2021-06-18	
J	TREXLER, LE; ZAPPALA, G				TREXLER, LE; ZAPPALA, G			NEUROPATHOLOGICAL DETERMINANTS OF ACQUIRED ATTENTION DISORDERS IN TRAUMATIC BRAIN INJURY	BRAIN AND COGNITION			English	Article									CTR NEUROPSYCHOL REHABIL,INDIANAPOLIS,IN							ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GROSS Y, 1982, COGNITIVE REHABILITA, P99; Jennett B, 1981, MANAGEMENT HEAD INJU; KAPLAN E, 1978, UNPUB BOSTON VERSION; KAPLAN E, 1980, UNPUB BOSTON VISUAL; LEVIN HS, 1985, STATUS REPORT CENTRA, P281; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; PAPANICOLAOU AC, 1985, P EUROPEAN M INT NEU; SARA SJ, 1985, MEMORY DYSFUNCTIONS, V44; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1983, LOCALIZATION NEUROPS, P429; TREXLER LE, UNPUB COMPUTER TASKS; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WALSH K, 1978, NEUROPSYCHOLOGY CLIN	22	18	19	0	2	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	1988	8	3					291	302		10.1016/0278-2626(88)90056-5			12	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	R4757	WOS:A1988R475700002	3214587				2021-06-18	
J	MARTIN, DA				MARTIN, DA			CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY - IMPACT ON THE FAMILY	JOURNAL OF LEARNING DISABILITIES			English	Article									UNIV TEXAS,SCH NURSING,AUSTIN,TX 78712							BLACHER J, 1984, SEVERELY HANDICAPPED; BLAZYCK S, 1983, SOCIAL WORK HLTH CAR, V80, P55; BOND MR, 1983, REHABILITATION HEAD, P209; Bristol MM, 1984, SEVERELY HANDICAPPED, V91-141; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P69; DARLING RB, 1982, CHILDREN ARE DIFFERE; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DEMYER M, 1983, AUTISM ADOLESCENTS A, P75; DROTAR D, 1975, PEDIATRICS, V56, P710; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Elkins T E, 1986, Issues Law Med, V1, P419; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; FEATHERSTONE MA, 1980, DIFFERENCE FAMILY; FISHER JM, 1985, SEMIN NEUROL, V5, P197, DOI 10.1055/s-2008-1041516; FRANKOWSKI RF, 1985, INJURED CHILD, P20; Gallagher J, 1981, J DIVISION EARLY CHI, V3, P3; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Hill R., 1949, FAMILIES STRESS ADJU; Hills R., 1958, SOCIAL CASEWORK, V49, P139; HOLADAY B, 1984, NURS CLIN N AM, V19, P361; Klaus M.H., 1982, PARENT INFANT BONDIN, V2nd Edn; LIEBERMAN M, 1979, SELF HELP GROUPS COP; MCCUBBIN H, 1979, J MARRIAGE FAMILY, V42, P237; McCubbin H.I., 1983, STRESS FAMILY, P5; McCubbin H.I., 1982, FAMILY STRESS COPING; McCubbin M, 1984, West J Nurs Res, V6, P407, DOI 10.1177/019394598400600404; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; *NAT HEAD INJ FDN, 1985, ED MAN WHAT ED NEED; NEVIN RS, 1979, NATIONAL COUNCIL FAM; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSHANKY S, 1970, COUNSELING PARENTS M; Panting A., 1972, REHABILITATION, V38, P33; PATTERSON JM, 1985, FAM RELAT, V34, P79, DOI 10.2307/583760; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Pueschel S M, 1986, Issues Law Med, V2, P171; ROSENTHAL M, 1986, NEUROPSYCHOLOGY HDB, P325; SIMEONSSON RJ, 1981, CHILD CARE HLTH DEV, V7, P153, DOI 10.1111/j.1365-2214.1981.tb00833.x; SOLNIT AJ, 1961, PSYCHOANAL STUD CHIL, V16, P523; Turk D. C., 1985, HLTH ILLNESS FAMILIE, P1	39	18	18	0	1	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	OCT	1988	21	8					464	470		10.1177/002221948802100803			7	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	Q4889	WOS:A1988Q488900011	3053950				2021-06-18	
J	RICHARDSON, JTE; SNAPE, W				RICHARDSON, JTE; SNAPE, W			THE EFFECTS OF CLOSED HEAD-INJURY UPON HUMAN-MEMORY - AN EXPERIMENTAL-ANALYSIS	COGNITIVE NEUROPSYCHOLOGY			English	Article										RICHARDSON, JTE (corresponding author), BRUNEL UNIV, DEPT PSYCHOL, UXBRIDGE UB8 3PH, MIDDX, ENGLAND.			Richardson, John/0000-0002-6267-0603			Anderson J.R., 1973, HUMAN ASS MEMORY; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS DN, 1974, CORTEX, V11, P224; CLARK HH, 1973, J VERB LEARN VERB BE, V12, P335, DOI 10.1016/S0022-5371(73)80014-3; CONKEY RC, 1938, ARCH PSYCHOL, V33; DUNN J, 1974, RES NEUROLOGY NEUROS, V2, P1497; Eyseck MW, 1979, J RES PERS, V13, P365; Eysenck Michael W., 1982, ATTENTION AROUSAL CO; GALBRAITH RC, 1973, MEM COGNITION, V1, P56, DOI 10.3758/BF03198068; Goldstein K., 1948, LANGUAGE LANGUAGE DI; JAMIESON KG, 1971, HEAD INJURIES; JONES DM, 1979, APPLIED PROBLEMS MEM; Kucera H, 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MORRIS LW, 1977, STRESS ANXIETY, V4; MUELLER JH, 1979, PERS SOC PSYCHOL B, V5, P288, DOI 10.1177/014616727900500303; OMMAYA AK, 1976, HEAD INJURIES; PAIVIO A, 1968, J EXPT PSYCHOL MON 2, V76; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; Richardson J. T., 1980, J MENTAL IMAGERY, V4; Richardson J. T. E., 1980, MENTAL IMAGERY HUMAN; RICHARDSON JT, 1974, J VERB LEARN VERB BE, V13, P709, DOI 10.1016/S0022-5371(74)80057-5; RICHARDSON JTE, 1979, BRIT J SOC CLIN PSYC, V18, P319, DOI 10.1111/j.2044-8260.1979.tb00342.x; RICHARDSON JTE, 1975, BRIT J MATH STAT PSY, V28, P235; RICHARDSON JTE, 1984, UNPUB EFFECTS MINOR; ROGERS JL, 1972, J EXP PSYCHOL, V92, P373, DOI 10.1037/h0032273; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Spielberger C.D., 1972, ANXIETY CURRENT TREN, V1; SPIELBERGER CD, 1966, ANXIETY BEHAVIOR; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; Thorndike EL., 1944, TEACHERS WORD BOOK 3	38	18	18	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0264-3294			COGN NEUROPSYCHOL	Cogn. Neuropsychol.		1984	1	3					217	231		10.1080/02643298408252023			15	Psychology; Psychology, Experimental	Psychology	TM318	WOS:A1984TM31800001					2021-06-18	
J	LINDSAY, JR; ZAJTCHUK, J				LINDSAY, JR; ZAJTCHUK, J			FOWLER, E.P. MEMORIAL LECTURE - CONCUSSION OF INNER EAR	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article																BRUNNER H, 1928, HDB NEUROLOGIE OHR 1, V2, P305; Fischer J, 1943, INNER EAR; KIMURA R, 1956, Ann Otol Rhinol Laryngol, V65, P620; Koch J, 1933, ARCH OHREN NASEN KEH, V137, P105; LINDSAY JR, UNPUBLISHED MATERIAL; Manasse P, 1924, BEITR Z ANAT PHYSIOL, V21, P230; NAGER FR, 1907, Z OHRENHEILK, V101, P217; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; Stenger P, 1909, ARCH OHRENH, V79, P43; STEURER O, HNDB SPEZ PATH ANAT, V12, P451; Theodore E, 1910, Z OHRENHEILKD, V61, P299; VOS O, 1933, ARCH OHRRN NASEN KEH, P137; Wittmaack K, 1932, ARCH OHREN NASEN KEH, V131, P59; WITTMAACK K, HNDB SPEZ PATH ANAT, V12, pC290	14	18	18	0	0	ANNALS PUBL CO	ST LOUIS	4507 LACLEDE AVE, ST LOUIS, MO 63108	0003-4894			ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.		1970	79	4					699	&		10.1177/000348947007900403			0	Otorhinolaryngology	Otorhinolaryngology	H1275	WOS:A1970H127500002	5316676				2021-06-18	
J	Hassin, GB				Hassin, GB			Concussion of the spinal cord - A case with the clinical picture of amyotrophic lateral sclerosis	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article									Illinois State Psychopath Inst, Chicago, IL USA							ASTWAZATUOW M, 1911, DTSCH Z NERVENH, V42, P352; BICKELES, 1895, OBERSTEINER ARB, V3, P102; BICKELES G, 1895, I WIENER U, V3, P102; BING R, 1905, ARCH PSYCHIAT, V39, P75; BRUCE A, 1897, M S J, V1, P41; CLAUDE H, 1915, B MEM SOC MED HOP P, V39, P680; CLAUDE H, 1915, ANN MED, V2, P479; DUMENIL L, 1885, ARCH NEUROL-CHICAGO, V9, P1; ERB W, 1897, DTSCH Z NERVENH, V1, P122; ERB W, 1912, DTSCH Z NERVENH, V45, P1; ERB W, 1910, DTSCH Z NERVENH, V38, P261; ERICHSEN JE, 1883, CONCUSSION SPINE, P5; FICKLER, 1905, DTSCH Z NERVENHEILK, V29, P1; Finkelnburg R, 1914, DEUT MED WOCHENSCHR, V40, P2057, DOI 10.1055/s-0029-1190830; Giese O, 1904, DEUT MED WOCHENSCHR, V30, P1348; GOLDBERG L, 1898, BERLIN KLIN WCHNSCHR, V35, P263; GUSSENBAUER C, 1893, PRAGER MED WOCHENSCH, V18, P496; GUSSENBAUER C, 1893, PRAG MED WCHNSCHR, V18, P485; HARTMANN F, 1900, JB PSYCHIAT NEUROL, V19, P380; Hassin GB, 1922, ARCH NEURO PSYCHIATR, V7, P613, DOI 10.1001/archneurpsyc.1922.02190110064007; HASSIN GB, 1917, MED REC, V91, P228; HELLBACH H, 1909, DTSCH Z NERVENH, V37, P321; HENNEBERG, 1915, BERLIN KLIN WCHNSCHR, V52, P859; HOLMES G, 1909, REV NEUROL PSYCHIAT, V7, P693; JACOB, 1912, NISSL ALZHEIMER ARB, V5, P182; JACOB A, 1919, Z NEUROL PSYCHIAT, V51, P247; JACOB A, 1912, NISSL ALZHEIMERS ARB, V5, P1; JOFFROY A, 1890, ARCH MED EXP ANAT PA, V2, P434; KIENBOCK R, 1899, WIEN MED PRESSE, V40, P1926; Kirchgasser G., 1897, DTSCH Z NERVENH, V11, P406; Kocher T, 1896, MITT GRENZGEB MED CH, V1, P481; LHERMITTE J, 1917, ANN MED, V4, P295; LHERMITTE J, 1915, B MEM SOC MED HOP P, V39, P680; Licen E, 1917, MON PSYCHIATR NEUROL, V42, P86; MARIE P, 1893, SEMAINE MED, V13, P533; MARIE P, 1894, SEMAINE MED, V14, P17; MOTT F, 1888, BRAIN, V10, P478; OBERSTEINER H, 1879, WIEN MED JB; REDLICH E, 1917, JB PSYCHIAT NEUROL, V38, P103; ROUSSY, 1917, ANN MED, V4, P458; ROUSSY G, 1920, ANN MED, V8, P335; SARBO A, 1913, DTSCH Z NERVENH, V46, P43; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P326; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; SEIFFER W, 1902, CHARITE ANN, V27, P542; Thorburn W, 1887, BRAIN, V9, P510; WESTPHAL, 1896, ARCH PSYCHIAT, V28, P554	47	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0096-6754			ARCH NEURO PSYCHIATR		AUG	1923	10	2					194	211		10.1001/archneurpsyc.1923.02190260055004			18	Psychiatry	Psychiatry	V23SJ	WOS:000201602500004					2021-06-18	
J	James, SL; Lucchesi, LR; Bisignano, C; Castle, CD; Dingels, ZV; Fox, JT; Hamilton, EB; Liu, ZC; McCracken, D; Nixon, MR; Sylte, DO; Roberts, NLS; Adebayo, OM; Aghamolaei, T; Alghnam, SA; Aljunid, SM; Almasi-Hashiani, A; Badawi, A; Behzadifar, M; Behzadifar, M; Bekru, ET; Bennett, DA; Chapman, JR; Deribe, K; Adema, BD; Fatahi, Y; Gelaw, BK; Getahun, EA; Hendrie, D; Henok, A; de Hidru, H; Hosseinzadeh, M; Hu, GQ; Jahani, MA; Jakovljevic, M; Jalilian, F; Joseph, N; Karami, M; Kelbore, AG; Khan, MN; Kim, YJ; Koul, PA; La Vecchia, C; Linn, S; Majdzadeh, R; Mehndiratta, MM; Memiah, PTN; Mengesha, MM; Merie, HE; Miller, TR; Mirzaei-Alavijeh, M; Darwesh, AM; Mezerji, NMG; Mohammadibakhsh, R; Moodley, Y; Moradi-Lakeh, M; Musa, KI; Nascimento, BR; Nikbakhsh, R; Nyasulu, PS; Bali, AO; Onwujekwe, OE; Pati, S; Kalhori, RP; Salehi, F; Shahabi, S; Shallo, SA; Shamsizadeh, M; Sharafi, Z; Shukla, SR; Sobhiyeh, MR; Soriano, JB; Sykes, BL; Tabares-Seisdedos, R; Tadesse, DBB; Tefera, YM; Tehrani-Banihashemi, A; Tlou, B; Topor-Madry, R; Wiangkham, T; Yaseri, M; Yaya, S; Yenesew, MA; Younis, MZ; Ziapour, A; Zodpey, S; Pigott, DM; Reiner, RC; Hay, SI; Lopez, AD; Mokdad, AH				James, Spencer L.; Lucchesi, Lydia R.; Bisignano, Catherine; Castle, Chris D.; Dingels, Zachary, V; Fox, Jack T.; Hamilton, Erin B.; Liu, Zichen; McCracken, Darrah; Nixon, Molly R.; Sylte, Dillon O.; Roberts, Nicholas L. S.; Adebayo, Oladimeji M.; Aghamolaei, Teamur; Alghnam, Suliman A.; Aljunid, Syed Mohamed; Almasi-Hashiani, Amir; Badawi, Alaa; Behzadifar, Masoud; Behzadifar, Meysam; Bekru, Eyasu Tamru; Bennett, Derrick A.; Chapman, Jens Robert; Deribe, Kebede; Adema, Bereket Duko; Fatahi, Yousef; Gelaw, Belayneh K.; Getahun, Eskezyiaw Agedew; Hendrie, Delia; Henok, Andualem; de Hidru, Hagos; Hosseinzadeh, Mehdi; Hu, Guoqing; Jahani, Mohammad Ali; Jakovljevic, Mihajlo; Jalilian, Farzad; Joseph, Nitin; Karami, Manoochehr; Kelbore, Abraham Getachew; Khan, Md Nuruzzaman; Kim, Yun Jin; Koul, Parvaiz A.; La Vecchia, Carlo; Linn, Shai; Majdzadeh, Reza; Mehndiratta, Man Mohan; Memiah, Peter T. N.; Mengesha, Melkamu Merid; Merie, Hayimro Edemealem; Miller, Ted R.; Mirzaei-Alavijeh, Mehdi; Darwesh, Aso Mohammad; Mezerji, Naser Mohammad Gholi; Mohammadibakhsh, Roghayeh; Moodley, Yoshan; Moradi-Lakeh, Maziar; Musa, Kamarul Imran; Nascimento, Bruno Ramos; Nikbakhsh, Rajan; Nyasulu, Peter S.; Bali, Ahmed Omar; Onwujekwe, Obinna E.; Pati, Sanghamitra; Kalhori, Reza Pourmirza; Salehi, Farkhonde; Shahabi, Saeed; Shallo, Seifadin Ahmed; Shamsizadeh, Morteza; Sharafi, Zeinab; Shukla, Sharvari Rahul; Sobhiyeh, Mohammad Reza; Soriano, Joan B.; Sykes, Bryan L.; Tabares-Seisdedos, Rafael; Tadesse, Degena Bahray Bahrey; Tefera, Yonatal Mesfin; Tehrani-Banihashemi, Arash; Tlou, Boikhutso; Topor-Madry, Roman; Wiangkham, Taweewat; Yaseri, Mehdi; Yaya, Sanni; Yenesew, Muluken Azage; Younis, Mustafa Z.; Ziapour, Arash; Zodpey, Sanjay; Pigott, David M.; Reiner, Robert C., Jr.; Hay, Simon, I; Lopez, Alan D.; Mokdad, Ali H.			Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017	INJURY PREVENTION			English	Article						burden of disease; motorcycle; descriptive epidemiology; road traffic accident; road injuries; pedestrian injuries; traumatic brain injury	SEX-SPECIFIC MORTALITY; ADJUSTED LIFE-YEARS; SYSTEMATIC ANALYSIS; 195 COUNTRIES; EPIDEMIOLOGIC TRANSITION; TRAFFIC INJURIES; TERRITORIES; DISABILITY; AGE; POPULATION	Background The global burden of road injuries is known to follow complex geographical, temporal and demographic patterns. While health loss from road injuries is a major topic of global importance, there has been no recent comprehensive assessment that includes estimates for every age group, sex and country over recent years. Methods We used results from the Global Burden of Disease (GBD) 2017 study to report incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years for all locations in the GBD 2017 hierarchy from 1990 to 2017 for road injuries. Second, we measured mortality-to-incidence ratios by location. Third, we assessed the distribution of the natures of injury (eg, traumatic brain injury) that result from each road injury. Results Globally, 1 243 068 (95% uncertainty interval 1 191 889 to 1 276 940) people died from road injuries in 2017 out of 54 192 330 (47 381 583 to 61 645 891) new cases of road injuries. Age-standardised incidence rates of road injuries increased between 1990 and 2017, while mortality rates decreased. Regionally, age-standardised mortality rates decreased in all but two regions, South Asia and Southern Latin America, where rates did not change significantly. Nine of 21 GBD regions experienced significant increases in age-standardised incidence rates, while 10 experienced significant decreases and two experienced no significant change. Conclusions While road injury mortality has improved in recent decades, there are worsening rates of incidence and significant geographical heterogeneity. These findings indicate that more research is needed to better understand how road injuries can be prevented.	[James, Spencer L.; Lucchesi, Lydia R.; Bisignano, Catherine; Castle, Chris D.; Dingels, Zachary, V; Fox, Jack T.; Hamilton, Erin B.; Liu, Zichen; McCracken, Darrah; Nixon, Molly R.; Sylte, Dillon O.; Roberts, Nicholas L. S.; Pigott, David M.; Reiner, Robert C., Jr.; Hay, Simon, I; Lopez, Alan D.; Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA; [Adebayo, Oladimeji M.] Univ Coll Hosp, Coll Med, Ibadan, Nigeria; [Aghamolaei, Teamur] Hormozgan Univ Med Sci, Dept Hlth Educ & Hlth Promot, Bandar Abbas, Iran; [Alghnam, Suliman A.] King Abdullah Int Med Res Ctr, Dept Populat Hlth Res, Riyadh, Saudi Arabia; [Aljunid, Syed Mohamed] Kuwait Univ, Dept Hlth Policy & Management, Safat, Kuwait; [Aljunid, Syed Mohamed] Natl Univ Malaysia, Int Ctr Casemix & Clin Coding, Bandar Tun Razak, Malaysia; [Almasi-Hashiani, Amir] Arak Univ Med Sci, Dept Epidemiol, Arak, Iran; [Badawi, Alaa] Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, Canada; [Badawi, Alaa] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada; [Behzadifar, Masoud] Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, Iran; [Behzadifar, Meysam] Lorestan Univ Med Sci, Hepatitis Res Ctr, Khorramabad, Iran; [Bekru, Eyasu Tamru] Wolaita Sodo Univ, Coll Hlth Sci & Med, Sodo, Ethiopia; [Bennett, Derrick A.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Chapman, Jens Robert] Swedish Brain & Spine Specialists, Swedish Neurosci Inst, Seattle, WA USA; [Deribe, Kebede] Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, England; [Deribe, Kebede] Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, Ethiopia; [Adema, Bereket Duko] Hawassa Univ, Dept Publ Hlth, Hawassa, Ethiopia; [Fatahi, Yousef] Univ Tehran Med Sci, Dept Pharmaceut Nanotechnol, Tehran, Iran; [Gelaw, Belayneh K.] Debre Tabor Univ, Sch Pharm, Ambo, Ethiopia; [Getahun, Eskezyiaw Agedew] Arba Minch Univ, Dept Publ Hlth, Arba Minch City, Ethiopia; [Hendrie, Delia; Miller, Ted R.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia; [Henok, Andualem] Mizan Tepi Univ, Dept Publ Hlth, Teppi, Ethiopia; [de Hidru, Hagos] Adigrat Univ, Dept Biostat & Epidemiol, Adigrat, Ethiopia; [Hosseinzadeh, Mehdi] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran; [Hosseinzadeh, Mehdi] Univ Human Dev, Comp Sci Dept, Sulaimaniyah, Iraq; [Hu, Guoqing] Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Peoples R China; [Jahani, Mohammad Ali] Babol Univ Med Sci, Fac Med, Babol, Iran; [Jakovljevic, Mihajlo] IM Sechenov First Moscow State Med Univ, NA Semashko Dept Publ Hlth & Healthcare, Sechenov Univ, Moscow, Russia; [Jalilian, Farzad; Mirzaei-Alavijeh, Mehdi] Kermanshah Univ Med Sci, Social Dev & Hlth Promot Res Ctr, Kermanshah, Iran; [Joseph, Nitin] Manipal Univ, Kasturba Med Coll, Dept Community Med, Mangalore, India; [Karami, Manoochehr] Hamadan Univ Med Sci, Dept Epidemiol, Hamadan, Hamadan, Iran; [Kelbore, Abraham Getachew] Wolaita Sodo Univ, Dept Dermatol, Wolaita Sodo, Ethiopia; [Khan, Md Nuruzzaman] Jatiya Kabi Kazi Nazrul Islam Univ, Dept Populat Sci, Mymensingh, Bangladesh; [Khan, Md Nuruzzaman] Univ Newcastle, Dept Publ Hlth, Newcastle, NSW, Australia; [Kim, Yun Jin] Xiamen Univ Malaysia, Sch Med, Sepang, Malaysia; [Koul, Parvaiz A.] Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar, India; [La Vecchia, Carlo] Univ Milan, Dept Clin Med & Community Hlth, Milan, Italy; [Linn, Shai] Univ Haifa, Sch Publ Hlth, Haifa, Israel; [Majdzadeh, Reza] Univ Tehran Med Sci, Community Based Participatory Res CBPR Ctr, Tehran, Iran; [Majdzadeh, Reza] Univ Tehran Med Sci, Knowledge Utilizat Res Ctr KURC, Tehran, Iran; [Mehndiratta, Man Mohan] Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, India; [Mehndiratta, Man Mohan] Dept Neurol, New Delhi, India; [Memiah, Peter T. N.] Univ West Florida, Dept Publ Hlth, Pensacola, FL USA; [Mengesha, Melkamu Merid] Haramaya Univ, Dept Epidemiol & Biostat, Harar, Ethiopia; [Merie, Hayimro Edemealem] Debre Markos Univ, Dept Stat, Debre Markos, Ethiopia; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Darwesh, Aso Mohammad] Univ Human Dev, Informat Technol Dept, Sulaimaniyah, Iraq; [Mezerji, Naser Mohammad Gholi] Hamadan Univ Med Sci, Dept Biostat, Hamadan, Hamadan, Iran; [Mohammadibakhsh, Roghayeh] Hamadan Univ Med Sci, Hamadan, Hamadan, Iran; [Moodley, Yoshan] Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South Africa; [Moradi-Lakeh, Maziar; Tehrani-Banihashemi, Arash] Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, Iran; [Musa, Kamarul Imran] Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, Malaysia; [Nascimento, Bruno Ramos] Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, Brazil; [Nikbakhsh, Rajan] Shahid Beheshti Univ Med Sci, Obes Res Ctr, Res Inst Endocrine Sci, Tehran, Iran; [Nyasulu, Peter S.] Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South Africa; [Bali, Ahmed Omar] Univ Human Dev, Dept Diplomacy & Publ Relat, Sulaimaniyah, Iraq; [Onwujekwe, Obinna E.] Univ Nigeria Nsukka, Dept Pharmacol & Therapeut, Enugu, Nigeria; [Pati, Sanghamitra] Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, India; [Kalhori, Reza Pourmirza] Kermanshah Univ Med Sci, Paramed Dept, Kermanshah, Iran; [Salehi, Farkhonde] Kermanshah Univ Med Sci, Taleghani Hosp, Kermanshah, Iran; [Shahabi, Saeed] Shiraz Univ Med Sci, Hlth Policy Res Ctr, Inst Hlth, Shiraz, Iran; [Shallo, Seifadin Ahmed] Ambo Univ, Dept Publ Hlth, Ambo, Ethiopia; [Shamsizadeh, Morteza] Hamadan Univ Med Sci, Chron Dis Home Care Res Ctr, Hamadan, Hamadan, Iran; [Sharafi, Zeinab] Lorestan Univ Med Sci, Razi Herbal Med Res Ctr, Khorramabad, Iran; [Shukla, Sharvari Rahul] Symbiosis Int Univ, Symbiosis Inst Hlth Sci, Pune, Maharashtra, India; [Sobhiyeh, Mohammad Reza] Kermanshah Univ Med Sci, Dept Vasc, Kermanshah, Iran; [Sobhiyeh, Mohammad Reza] Kermanshah Univ Med Sci, Dept Endovasc Surg, Gen Surg, Kermanshah, Iran; [Sobhiyeh, Mohammad Reza] Kermanshah Univ Med Sci, Peripheral Vasc Intervent Dept, Kermanshah, Iran; [Soriano, Joan B.] Autonomous Univ Madrid, Hosp Univ Princesa, Madrid, Spain; [Soriano, Joan B.] Inst Hlth Carlos III, Resp Dis Networking Biomed Res Ctr CIBERES, Madrid, Spain; [Sykes, Bryan L.] Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USA; [Tabares-Seisdedos, Rafael] Univ Valencia, Dept Med, Valencia, Spain; [Tabares-Seisdedos, Rafael] Carlos III Hlth Inst, Biomed Res Networking Ctr Mental Hlth Network Cib, Madrid, Spain; [Tadesse, Degena Bahray Bahrey] Inst Trop Med, Nursing Dept, Aksum, Ethiopia; [Tadesse, Degena Bahray Bahrey] Axum Coll Hlth Sci, Mekelle, Ethiopia; [Tefera, Yonatal Mesfin] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia; [Tefera, Yonatal Mesfin] Wollo Univ, Dept Environm Hlth, Dessie, Ethiopia; [Tehrani-Banihashemi, Arash] Iran Univ Med Sci, Dept Community Med, Tehran, Iran; [Tlou, Boikhutso] Univ KwaZulu Natal, Dept Publ Hlth, Durban, South Africa; [Topor-Madry, Roman] Jagiellonian Univ Med Coll, Fac Hlth Sci, Krakow, Poland; [Topor-Madry, Roman] Agcy Hlth Technol Assessment & Tariff Syst, Warsaw, Poland; [Wiangkham, Taweewat] Naresuan Univ, Fac Allied Hlth Sci, Dept Phys Therapy, Meung Dist, Thailand; [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran; [Yaseri, Mehdi] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran; [Yaya, Sanni] Univ Ottawa, Sch Int Dev & Global Studies, Ottawa, ON, Canada; [Yenesew, Muluken Azage] Bahir Dar Univ, Sch Publ Hlth, Bahir Dar, Ethiopia; [Younis, Mustafa Z.] Jackson State Univ, Hlth Econ & Finance, Jackson, MS USA; [Younis, Mustafa Z.] Tsinghua Univ, Res Ctr Publ Hlth, Beijing, Peoples R China; [Ziapour, Arash] Iran Univ Med Sci, Hlth Promot Res Ctr, Tehran, Iran; [Zodpey, Sanjay] Publ Hlth Fdn India, Indian Inst Publ Hlth, Gurugram, India; [Pigott, David M.; Reiner, Robert C., Jr.; Hay, Simon, I; Mokdad, Ali H.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98121 USA; [Lopez, Alan D.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Qld, Australia	James, SL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.	spencj@uw.edu	shahabi, saeed/AAD-1120-2020; Wiangkham, Taweewat/I-9818-2019; Kamyari, Naser/AAP-1999-2021; Mengesha, Melkamu Merid/ABA-7134-2020; Duko, Bereket/P-8904-2019; Linn, Shai/N-3079-2019; Nacimento, Bruno Ramos/F-8066-2013; Topor-Madry, Roman/ABF-5449-2020; Tadesse, Degena Bahrey/AAW-6490-2020; Roberts, Nicholas/AAL-2040-2021; Jakovljevic, Mihajlo B/B-3002-2014; Hay, Simon I/F-8967-2015; Yaya, Sanni/C-1079-2019; Almasi-Hashiani, Amir/P-3356-2018; Lopez, Alan D/F-1487-2010; Musa, Kamarul Imran/N-3198-2015; Adebayo, Oladimeji/Y-5260-2019; Karami, Manoochehr/E-5030-2012; Aljunid, Syed/J-6009-2014; KIM, YUN JIN/AAE-8281-2019; Mirzaei-Alavijeh, Mehdi/F-7870-2016; Soriano, Joan B/O-1215-2017; Fatahi, Yousef/S-6193-2016; Yaseri, Mehdi/I-1645-2018; Shamsizadeh, Morteza/C-6000-2014	shahabi, saeed/0000-0002-8190-2190; Wiangkham, Taweewat/0000-0003-4115-704X; Kamyari, Naser/0000-0002-5209-8324; Mengesha, Melkamu Merid/0000-0003-4312-0136; Duko, Bereket/0000-0002-4419-0016; Linn, Shai/0000-0002-0867-2958; Nacimento, Bruno Ramos/0000-0002-5586-774X; Tadesse, Degena Bahrey/0000-0003-3451-0837; Roberts, Nicholas/0000-0001-7238-8559; Jakovljevic, Mihajlo B/0000-0002-9160-6846; Hay, Simon I/0000-0002-0611-7272; Yaya, Sanni/0000-0002-4876-6043; Almasi-Hashiani, Amir/0000-0003-4434-561X; Lopez, Alan D/0000-0001-5818-6512; Musa, Kamarul Imran/0000-0002-3708-0628; Adebayo, Oladimeji/0000-0001-7096-4460; Karami, Manoochehr/0000-0002-9026-3757; Aljunid, Syed/0000-0002-0380-1335; KIM, YUN JIN/0000-0001-8853-6587; Miller, Ted/0000-0002-0958-2639; Tabares-Seisdedos, Rafael/0000-0002-1089-2204; Mirzaei-Alavijeh, Mehdi/0000-0003-3695-6971; Soriano, Joan B/0000-0001-9740-2994; Aghamolaei, Teamur/0000-0002-2504-8014; Fatahi, Yousef/0000-0003-0374-2141; Moodley, Yoshan/0000-0002-4119-1734; Meire, Hayimro Edemealem/0000-0003-0301-6895; Yaseri, Mehdi/0000-0002-4066-873X; Shamsizadeh, Morteza/0000-0002-8153-5482; ahmed, seifadin/0000-0001-6415-7515; Deribe, Kebede/0000-0002-8526-6996	Bill AMP; Melinda Gates FoundationCGIAR	This study was funded by the Bill & Melinda Gates Foundation.	Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; [Anonymous], CHIN ZHUH STUD 2006; [Anonymous], BURD DIS INJ IR 2003, DOI DOI 10.1186/1478-7954-7-9; [Anonymous], GLOB STAT REP ROAD S; Clement ND, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-26; Dicker D, 2018, LANCET, V392, P1684, DOI 10.1016/s0140-6736(18)31891-9; Foreman KJ, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0082-4; Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; Gabbe BJ, 2015, ANN SURG, V261, P565, DOI 10.1097/SLA.0000000000000522; GHDx, HLTH REL QUAL LIF BU; GHDx, FUNCT OUTC 2 5 5 9 2; GHDx, 2007, NETH INJ SURV SYST 2; Goniewicz K, 2016, EUR J TRAUMA EMERG S, V42, P433, DOI 10.1007/s00068-015-0544-6; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; James SL, 2019, LANCET NEUROL, V18, P56, DOI 10.1016/S1474-4422(18)30415-0; James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7; Kim Ellen, 2017, Inj Epidemiol, V4, P1, DOI 10.1186/s40621-016-0098-z; Kyu HH, 2018, LANCET, V392, P1859, DOI 10.1016/s0140-6736(18)32335-3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; MCDERMOTT FT, 1979, BRIT J SURG, V66, P518, DOI 10.1002/bjs.1800660721; Murray CJL, 2018, LANCET, V392, P1995, DOI 10.1016/s0140-6736(18)32278-5; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Peden M., 2004, WORLD REPORT ROAD TR; Petridou E, 2000, EUR J EPIDEMIOL, V16, P819, DOI 10.1023/A:1007649804201; Roth GA, 2018, LANCET, V392, P1736, DOI 10.1016/s0140-6736(18)32203-7; Salomon JA, 2002, POPUL DEV REV, V28, P205, DOI 10.1111/j.1728-4457.2002.00205.x; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Shinar D, 2017, TRAFFIC SAFETY AND HUMAN BEHAVIOR, 2ND EDITION, P1; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Suriyawongpaisal Paibul, 2003, Inj Control Saf Promot, V10, P95, DOI 10.1076/icsp.10.1.95.14110; Sustainable Development Goals, SUST DEV KNOWL PLATF; The World Bank, GDP PER CAP CURR US; Traumatic Brain Injury, 2002, FED REG; W.H. Organization, GLOB STAT REP ROAD S; WHO, DEC ACT ROAD SAF 201; WHO, ROAD TRAFF INJ PUBL; World Bank, 2017, HIGH TOLL TRAFF INJ	39	17	17	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2020	26	SUPP_1		1			46	56		10.1136/injuryprev-2019-043302			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	NZ0BU	WOS:000576754700006	31915274	Green Published			2021-06-18	
J	Bhaskar, S; Bradley, S; Chattu, VK; Adisesh, A; Nurtazina, A; Kyrykbayeva, S; Sakhamuri, S; Moguilner, S; Pandya, S; Schroeder, S; Banach, M; Ray, D				Bhaskar, Sonu; Bradley, Sian; Chattu, Vijay Kumar; Adisesh, Anil; Nurtazina, Alma; Kyrykbayeva, Saltanat; Sakhamuri, Sateesh; Moguilner, Sebastian; Pandya, Shawna; Schroeder, Starr; Banach, Maciej; Ray, Daniel			Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2)	FRONTIERS IN PUBLIC HEALTH			English	Article						coronavirus disease 2019; COVID-19; telemedicine; telerehabilitation; telepsychiatry; teleneurology	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; PATIENT SATISFACTION; CHRONIC DISEASES; TELE-MEDICINE; TELEHEALTH; CARE; TELEPSYCHIATRY; IMPROVE; INTERVENTIONS	Technology has acted as a great enabler of patient continuity through remote consultation, ongoing monitoring, and patient education using telephone and videoconferencing in the coronavirus disease 2019 (COVID-19) era. The devastating impact of COVID-19 is bound to prevail beyond its current reign. The vulnerable sections of our community, including the elderly, those from lower socioeconomic backgrounds, those with multiple comorbidities, and immunocompromised patients, endure a relatively higher burden of a pandemic such as COVID-19. The rapid adoption of different technologies across countries, driven by the need to provide continued medical care in the era of social distancing, has catalyzed the penetration of telemedicine. Limiting the exposure of patients, healthcare workers, and systems is critical in controlling the viral spread. Telemedicine offers an opportunity to improve health systems delivery, access, and efficiency. This article critically examines the current telemedicine landscape and challenges in its adoption, toward remote/tele-delivery of care, across various medical specialties. The current consortium provides a roadmap and/or framework, along with recommendations, for telemedicine uptake and implementation in clinical practice during and beyond COVID-19.	[Bhaskar, Sonu; Bradley, Sian; Chattu, Vijay Kumar; Adisesh, Anil; Nurtazina, Alma; Kyrykbayeva, Saltanat; Sakhamuri, Sateesh; Moguilner, Sebastian; Pandya, Shawna; Schroeder, Starr; Banach, Maciej; Ray, Daniel] REPROGRAM Telemed Subcommittee, Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, Sydney, NSW, Australia; [Bhaskar, Sonu] Liverpool Hosp, Dept Neurol, Sydney, NSW, Australia; [Bhaskar, Sonu] South Western Sydney Local Hlth Dist, Sydney, NSW, Australia; [Bhaskar, Sonu] Ingham Inst Appl Med Res, Neurovasc Imaging Lab, Sydney, NSW, Australia; [Bhaskar, Sonu] Ingham Inst Appl Med Res, NSW Brain Clot Bank, Sydney, NSW, Australia; [Bhaskar, Sonu] Univ New South Wales, South Western Sydney Clin Sch, UNSW Med, Sydney, NSW, Australia; [Bradley, Sian] Univ New South Wales UNSW Med Sydney, South West Sydney Clin Sch, Sydney, NSW, Australia; [Chattu, Vijay Kumar; Adisesh, Anil] Univ Toronto, Dept Med, Toronto, ON, Canada; [Chattu, Vijay Kumar; Adisesh, Anil] St Michaels Hosp, Toronto, ON, Canada; [Nurtazina, Alma; Kyrykbayeva, Saltanat] Semey Med Univ, Dept Epidemiol & Biostat, Semey, Kazakhstan; [Sakhamuri, Sateesh] Univ West Indies, Dept Clin Med Sci, St Augustine, Trinidad Tobago; [Moguilner, Sebastian] Trinity Coll Dublin, Global Brain Hlth Inst, Dublin, Ireland; [Pandya, Shawna] Univ Alberta, Alberta Hlth Serv, Edmonton, AB, Canada; [Pandya, Shawna] Univ Alberta, Project PoSSUM, Edmonton, AB, Canada; [Schroeder, Starr] Penn Med Lancaster Gen Hosp, Lancaster, PA USA; [Schroeder, Starr] Project PoSSUM, Lancaster, PA USA; [Banach, Maciej] Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland; [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland; [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland; [Ray, Daniel] Univ Coll London UCL, Farr Inst Hlth Informat, Birmingham, W Midlands, England; [Ray, Daniel] NHS Fdn Trust, Birmingham, W Midlands, England	Bhaskar, S (corresponding author), REPROGRAM Telemed Subcommittee, Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Liverpool Hosp, Dept Neurol, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), South Western Sydney Local Hlth Dist, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Ingham Inst Appl Med Res, Neurovasc Imaging Lab, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Ingham Inst Appl Med Res, NSW Brain Clot Bank, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Univ New South Wales, South Western Sydney Clin Sch, UNSW Med, Sydney, NSW, Australia.	sonu.bhaskar@health.nsw.gov.au	Bhaskar, Sonu Menachem Maimonides/AAU-1402-2020; Chattu, Vijay Kumar/C-2778-2014; Nurtazina, Alma/AAZ-1614-2020; Kyrykbayeva, Saltanat/AAP-2979-2021	Bhaskar, Sonu Menachem Maimonides/0000-0002-9783-3628; Chattu, Vijay Kumar/0000-0001-9840-8335; Kyrykbayeva, Saltanat/0000-0001-6151-6025; Adisesh, Anil/0000-0002-4973-8474			Achey M, 2014, MOVEMENT DISORD, V29, P871, DOI 10.1002/mds.25903; Ambrosino N, 2017, EXPERT REV RESP MED, V11, P893, DOI 10.1080/17476348.2017.1383898; Ambrosino N, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0090-7; Ambrosino N, 2016, BREATHE, V12, P351, DOI 10.1183/20734735.014616; Ambrosino N, 2016, EUR RESPIR J, V48, P648, DOI 10.1183/13993003.01721-2015; American Academy of Neurology (AAn), NTR; [Anonymous], **NON-TRADITIONAL**; Ateriya N, 2018, NATL MED J INDIA, V31, P215, DOI 10.4103/0970-258X.258220; Banach M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104891; Barker-Davies RM, 2020, BRIT J SPORT MED, V54, P949, DOI 10.1136/bjsports-2020-102596; Basiri Keivan, 2015, Adv Biomed Res, V4, P58, DOI 10.4103/2277-9175.151874; Bhaskar S, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00664; Bhaskar S, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00112; Bhatt A, NTR; Blakey JD, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01147-2018; Blanco C, 2020, J GEN INTERN MED, V35, P2757, DOI 10.1007/s11606-020-05955-3; Block VAJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154335; Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105; Booth R, NTR; Brennan JA, 1999, J TELEMED TELECARE, V5, P18, DOI 10.1258/1357633991932342; Brunetti ND, 2020, OPEN HEART, V7, DOI 10.1136/openhrt-2019-001157; Bruyneel M, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0093-2018; Calderon VJ, 2018, INTERV NEUROL, V7, P347, DOI 10.1159/000487334; Capozzo R, 2020, AMYOTROPH LAT SCL FR, V21, P542, DOI 10.1080/21678421.2020.1773502; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2; Chaffin Hally M, 2019, Hawaii J Health Soc Welf, V78, P280; Chahin N, 2008, NEUROLOGY, V70, P1967, DOI 10.1212/01.wnl.0000312510.49768.eb; CHAN S, 2017, CURR PSYCHIAT REP, V0019; Chan S, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0630-9; Chee Ru-Ik, 2018, Curr Ophthalmol Rep, V6, P36, DOI 10.1007/s40135-018-0161-8; Chen Y, 2020, TOP STROKE REHABIL, V27, P81, DOI 10.1080/10749357.2019.1683792; Cheshire WP, 2020, J TELEMED TELECARE, DOI 10.1177/1357633X19899237; Chipps J, 2012, AFR J PSYCHIATRY, V15, P235, DOI [http://dx.doi.org/10.4314/ajpsy.v15i4.30, 10.4314/ajpsy.v15i4.30]; Chuchu N, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013193; Dams-O'Connor K, 2018, J NEUROTRAUM, V35, P1138, DOI 10.1089/neu.2017.5347; de Bustos EM, 2018, TELEMED E-HEALTH, V24, P155, DOI 10.1089/tmj.2017.0035; DeJong SM, 2018, ACAD PSYCHIATR, V42, P800, DOI 10.1007/s40596-018-0947-x; Dharmar M, 2013, CRIT CARE MED, V41, P2388, DOI 10.1097/CCM.0b013e31828e9824; Dharmasaroja PA, 2010, NEUROCRIT CARE, V13, P62, DOI 10.1007/s12028-010-9360-3; Donate-Martinez A, 2016, ARCH GERONTOL GERIAT, V62, P169, DOI 10.1016/j.archger.2015.09.008; Donelan K, 2019, AM J MANAG CARE, V25, P40; Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874; European Commission, NTR; Fisher E, 2017, POPUL HEALTH MANAG, V20, P342, DOI 10.1089/pop.2016.0087; Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2; Freir V, 1999, J TELEMED TELECARE, V5, P157, DOI 10.1258/1357633991933567; Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164; Gabriel KMA, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01676-6; Gandapur Y, 2016, EUR HEART J-QUAL CAR, V2, P237, DOI 10.1093/ehjqcco/qcw018; Gordon HS, 2020, J GEN INTERN MED, V35, P1751, DOI 10.1007/s11606-020-05673-w; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Gurbeta L, 2018, J AM MED INFORM ASSN, V25, P1213, DOI 10.1093/jamia/ocy055; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Harerimana B, 2019, INT J MENT HEALTH NU, V28, P657, DOI 10.1111/inm.12571; HASSAN A, 2019, CUREUS, V0011; Helleman J, 2020, AMYOTROPH LAT SCL FR, V21, P183, DOI 10.1080/21678421.2020.1718712; Helleman J, 2020, AMYOTROPH LAT SCL FR, V21, P167, DOI 10.1080/21678421.2019.1706581; Hernandez C, 2014, BREATHE, V10, P198, DOI 10.1183/20734735.008314; Hobson E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028526; Honyman E., 2014, INTERV CARDIOL, V6, P227, DOI DOI 10.2217/ica.14.4; Huo XQ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018302; Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096; Inglis SC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub3; Jaeger B, 2016, J INHERIT METAB DIS, V39, P559, DOI 10.1007/s10545-016-9924-2; Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503; Katz M, 2020, ANN PALLIAT MED, V9, pS75, DOI 10.21037/apm.2019.11.12; Khader YS, 2014, INT J TELEMED APPL, V2014, DOI 10.1155/2014/819837; Klein BC, 2020, NEUROLOGY, V94, P903, DOI 10.1212/WNL.0000000000009494; Klompas M, 2020, ANN INTERN MED, V172, P619, DOI 10.7326/M20-0751; Kovacevic P, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2494-6; Kuehn BM, 2016, CIRCULATION, V134, P1189, DOI 10.1161/CIRCULATIONAHA.116.025282; Kuipers E, 2019, J MED INTERNET RES, V21, DOI 10.2196/13551; Kuntz JG, 2020, J PAIN SYMPTOM MANAG, V60, pE28, DOI 10.1016/j.jpainsymman.2020.06.001; Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Linschoten M, 2020, EUR HEART J, V41, P1795, DOI 10.1093/eurheartj/ehaa280; Lyerly MJ, 2016, J TELEMED TELECARE, V22, P114, DOI 10.1177/1357633X15589534; Macaraig M, 2018, J PUBLIC HEALTH MAN, V24, P567, DOI 10.1097/PHH.0000000000000627; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; MAJUMDER S, 2019, SENSORS BASEL, V0019; Martin-Lesende I, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-118; Martinez RN, 2017, PM&R, V9, P231, DOI 10.1016/j.pmrj.2016.07.002; Mbuagbaw L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0654-6; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Mehraeen E, 2018, STUD HEALTH TECHNOL, V248, P172, DOI 10.3233/978-1-61499-858-7-172; Michaud TL, 2018, INT J TECHNOL ASSESS, V34, P410, DOI 10.1017/S0266462318000454; Molinari G, 2002, J TELEMED TELECARE, V8, P97, DOI 10.1258/1357633021937541; MOUSTAFA H, 2019, J TELEMED TELEC 0807; Munafo D, 2016, SLEEP BREATH, V20, P777, DOI 10.1007/s11325-015-1298-4; Napi NM, 2019, HEALTH TECHNOL-GER, V9, P679, DOI 10.1007/s12553-019-00357-w; Nemecek R, 2019, WIEN KLIN WOCHENSCHR, V131, P620, DOI 10.1007/s00508-019-01562-3; Ohta Y, 2018, J CLIN NEUROSCI, V56, P74, DOI 10.1016/j.jocn.2018.07.006; Orozco-Beltran D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7677; Paganoni S, 2019, MUSCLE NERVE, V60, P147, DOI 10.1002/mus.26606; Palmieri V, 2011, G ITAL CARDIOL, V12, P829, DOI 10.1714/996.10828; Park LG, 2014, J ADV NURS, V70, P1932, DOI 10.1111/jan.12400; Pepin JL, 2017, RESPIROLOGY, V22, P1508, DOI 10.1111/resp.13183; Pinto A, 2010, J NEUROL NEUROSUR PS, V81, P1238, DOI 10.1136/jnnp.2010.206680; Piotrowicz E, 2020, JAMA CARDIOL, V5, P300, DOI 10.1001/jamacardio.2019.5006; Piotrowicz E, 2019, AM HEART J, V217, P148, DOI 10.1016/j.ahj.2019.08.015; Porritt A, NTR; Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966; Reilly RO, 2007, PSYCHIAT SERV, V58, P836; Ruskin PE, 2004, AM J PSYCHIAT, V161, P1471, DOI 10.1176/appi.ajp.161.8.1471; Sable CA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e3; Salisbury C, 2016, LANCET PSYCHIAT, V3, P515, DOI 10.1016/S2215-0366(16)00083-3; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Satou GM, 2017, CIRCULATION, V135, pE648, DOI 10.1161/CIR.0000000000000478; Sayani S, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319891587; Scalvini S, 2001, Ital Heart J Suppl, V2, P1091; Schwab S, 2007, NEUROLOGY, V69, P898, DOI 10.1212/01.wnl.0000269671.08423.14; Selzler AM, 2018, CHRON RESP DIS, V15, P41, DOI 10.1177/1479972317724570; Serpen G, 2018, PROCEDIA COMPUT SCI, V140, P238, DOI 10.1016/j.procs.2018.10.324; Sharma R, 2017, INT J EMERG MED, V10, DOI 10.1186/s12245-017-0146-7; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141; Siwicki B, HLTHCARE IT NEWS; Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567; Subbaraman R, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001018; Subramanian S, 2020, CRIT CARE MED, V48, P553, DOI 10.1097/CCM.0000000000004190; Swanson MB, 2019, J TELEMED TELECARE, DOI 10.1177/1357633X19877746; Szperka CL, 2020, HEADACHE, V60, P833, DOI 10.1111/head.13810; Tande AJ, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa003; Truelove S, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003144; Turino C, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01128-2016; van Houwelingen CTM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8407; Vatankhah B, 2008, CEREBROVASC DIS, V25, P332, DOI 10.1159/000118378; Vitacca M, 2018, THER ADV RESPIR DIS, V12, DOI 10.1177/1753465818754778; Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607; White C, 2019, BMJ SUPPORT PALLIAT, V9, P202, DOI 10.1136/bmjspcare-2015-000935; Wilcox ME, 2012, CRIT CARE, V16, DOI 10.1186/cc11429; Williams TL, 2001, TELEMED J E-HEALTH, V7, P293, DOI 10.1089/15305620152814700; World Health Organization, NTR; World Health Organization (WHO), 2018, ART INT GOOD GLOB SU; Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9; Yang CP, 2017, PEDIATR EMERG CARE, V33, P474, DOI 10.1097/PEC.0000000000000653; Yeoh CB, 2020, ANESTH ANALG, V131, P16, DOI 10.1213/ANE.0000000000004884; Yue JK, 2020, J NEUROSCI RURAL PRA, V11, P23, DOI 10.1055/s-0039-3402581; Zheng X, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005616; Zimetbaum P, 2010, CIRCULATION, V122, P1629, DOI 10.1161/CIRCULATIONAHA.109.925610	140	17	17	7	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		2296-2565		FRONT PUBLIC HEALTH	Front. Public Health	SEP 7	2020	8								410	10.3389/fpubh.2020.00410			16	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	NW5MT	WOS:000575056700001	33014958	DOAJ Gold, Green Published			2021-06-18	
J	Sharma, R; Kambhampati, SP; Zhang, Z; Sharma, A; Chen, S; Duh, EI; Kannan, S; Tso, MOM; Kannan, RM				Sharma, Rishi; Kambhampati, Siva P.; Zhang, Zhi; Sharma, Anjali; Chen, Samuel; Duh, Erica I.; Kannan, Sujatha; Tso, Mark O. M.; Kannan, Rangaramanujam M.			Dendrimer mediated targeted delivery of sinomenine for the treatment of acute neuroinflammation in traumatic brain injury	JOURNAL OF CONTROLLED RELEASE			English	Article							ACUTE LUNG INJURY; MICROGLIAL ACTIVATION; INFLAMMATION; INVOLVEMENT; DRUG; CONJUGATE; APOPTOSIS; CYTOKINES; PROTECTS; MICE		[Sharma, Rishi; Kambhampati, Siva P.; Sharma, Anjali; Chen, Samuel; Duh, Erica I.; Kannan, Sujatha; Tso, Mark O. M.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Dept Ophthalmol,Wilmer Eye Inst, Baltimore, MD 21231 USA; [Zhang, Zhi; Kannan, Sujatha; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Chen, Samuel] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Duh, Erica I.] Bryn Mawr Sch, Baltimore, MD 21210 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Zhang, Zhi] Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA	Kannan, RM (corresponding author), Johns Hopkins Sch Med, Ophthalmol, Ctr Nanomed, Wilmer Eye Inst, 400 North Broadway, Baltimore, MD 21231 USA.	krangar1@jhmi.edu		Zhang, Zhi/0000-0001-6256-9516	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD076901]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [RO1 EY025304]; Wilmer core facility and imaging center [P30EY001765]	This study was partly funded by the NICHD grant number R01HD076901 (R.M.K.) and NEI grant number RO1 EY025304 (R.M.K). We also thank the Wilmer core facility and imaging center (core grant: P30EY001765) for confocal microscopy facilities.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Alnasser Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23051025; Bagaev AV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36052-5; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chai XY, 2012, BIOORG MED CHEM LETT, V22, P5849, DOI 10.1016/j.bmcl.2012.07.087; Chandra S, 2011, J MATER CHEM, V21, P5729, DOI 10.1039/c0jm04198j; de Araujo RV, 2018, MOLECULES, V23, DOI 10.3390/molecules23112849; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Gallentine WB, 2017, EPILEPSIA, V58, P1102, DOI 10.1111/epi.13750; Gao TL, 2019, DATA BRIEF, V27, DOI 10.1016/j.dib.2019.104633; Guo Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154437; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; He XB, 2005, IMMUNOL LETT, V98, P91, DOI 10.1016/j.imlet.2004.10.027; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Hernadez-Ontiveros D., 2013, FRONT NEUROL, V4; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Jain KK., 2019, HDB NEUROPROTECTION, P281; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013; Kannan G, 2017, J CONTROL RELEASE, V263, P192, DOI 10.1016/j.jconrel.2017.03.032; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kolhatkar RB, 2007, BIOCONJUGATE CHEM, V18, P2054, DOI 10.1021/bc0603889; Kovesdi E., 2012, FRONT NEUROL, V3; Liu SZ, 2018, BIOMED PHARMACOTHER, V107, P696, DOI 10.1016/j.biopha.2018.08.048; Llorian-Salvador M, 2016, BASIC CLIN PHARMACOL, V119, P32, DOI 10.1111/bcpt.12543; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Miller HA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52622-7; Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044; Nance E, 2015, J CONTROL RELEASE, V214, P112, DOI 10.1016/j.jconrel.2015.07.009; Nemeth CL, 2017, NANOMED-NANOTECHNOL, V13, P2359, DOI 10.1016/j.nano.2017.06.014; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Paulo CSO, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494002; Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038; Price L., 2016, TRANSLATIONAL RES TR; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Schimmel Samantha J, 2017, Brain Circ, V3, P135, DOI 10.4103/bc.bc_18_17; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sevenson S, 2012, ADV DRUG DELIVER REV, V64, P102, DOI 10.1016/j.addr.2012.09.030; Sharma A, 2018, THERANOSTICS, V8, P5529, DOI 10.7150/thno.29039; Sharma R, 2018, BIOENG TRANSL MED, V3, P87, DOI 10.1002/btm2.10094; Sharma R, 2017, BIOCONJUGATE CHEM, V28, P2874, DOI 10.1021/acs.bioconjchem.7b00569; Shi H, 2016, J NEUROIMMUNOL, V299, P28, DOI 10.1016/j.jneuroim.2016.08.010; Shukla SM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-117; Soiberman U, 2017, BIOMATERIALS, V125, P38, DOI 10.1016/j.biomaterials.2017.02.016; Tang J, 2018, MINI-REV MED CHEM, V18, P906, DOI 10.2174/1389557517666171123212557; Tao WW, 2015, INT IMMUNOPHARMACOL, V27, P138, DOI 10.1016/j.intimp.2015.05.005; Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009; Wang AL, 2007, INT IMMUNOPHARMACOL, V7, P1552, DOI 10.1016/j.intimp.2007.07.030; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu WN, 2011, BRIT J PHARMACOL, V164, P1445, DOI 10.1111/j.1476-5381.2011.01487.x; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Xu M, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00220; YAMASAKI H, 1976, ACTA MED OKAYAMA, V30, P1; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Yang Z, 2014, MOL IMMUNOL, V60, P109, DOI 10.1016/j.molimm.2014.03.005; Zhang LL, 2019, NEUROCHEM RES, V44, P763, DOI 10.1007/s11064-018-02706-z; Zhang Z, 2019, J NEUROTRAUM, V36, P74, DOI 10.1089/neu.2017.5450; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701; Zhao ZJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21111520; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu Q, 2014, SCI REP-UK, V4, DOI 10.1038/srep07270; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	17	18	7	23	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	JUL 10	2020	323						361	375		10.1016/j.jconrel.2020.04.036			15	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	LY7FW	WOS:000540694200004	32339548				2021-06-18	
J	Nath, ND; Behzadan, AH; Paal, SG				Nath, Nipun D.; Behzadan, Amir H.; Paal, Stephanie G.			Deep learning for site safety: Real-time detection of personal protective equipment	AUTOMATION IN CONSTRUCTION			English	Article						Personal protective equipment (PPE); Construction safety; Deep learning; Transfer learning; Image dataset; Real-time object detection	CONVOLUTIONAL NEURAL-NETWORKS; CONSTRUCTION; OBJECTS; MODEL	The leading causes of construction fatalities include traumatic brain injuries (resulted from fall and electrocution) and collisions (resulted from struck by objects). As a preventive step, the U.S. Occupational Safety and Health Administration (OSHA) requires that contractors enforce and monitor appropriate usage of personal protective equipment (PPE) of workers (e.g., hard hat and vest) at all times. This paper presents three deep learning (DL) models built on You-Only-Look-Once (YOLO) architecture to verify PPE compliance of workers; i.e., if a worker is wearing hard hat, vest, or both, from image/video in real-time. In the first approach, the algorithm detects workers, hats, and vests and then, a machine learning model (e.g., neural network and decision tree) verifies if each detected worker is properly wearing hat or vest. In the second approach, the algorithm simultaneously detects individual workers and verifies PPE compliance with a single convolutional neural network (CNN) framework. In the third approach, the algorithm first detects only the workers in the input image which are then cropped and classified by CNN-based classifiers (i.e., VGG-16, ResNet-50, and Xception) according to the presence of PPE attire. All models are trained on an in-house image dataset that is created using crowd-sourcing and web-mining. The dataset, named Pictor-v3, contains similar to 1,500 annotated images and similar to 4,700 instances of workers wearing various combinations of PPE components. It is found that the second approach achieves the best performance, i.e., 72.3% mean average precision (mAP), in real-world settings, and can process 11 frames per second (FPS) on a laptop computer which makes it suitable for real-time detection, as well as a good candidate for running on light-weight mobile devices. The closest alternative in terms of performance (67.93% mAP) is the third approach where VGG-16, ResNet-50, and Xception classifiers are assembled in a Bayesian framework. However, the first approach is the fastest among all and can process 13 FPS with 63.1% mAP. The crowed-sourced Pictor-v3 dataset and all trained models are publicly available to support the design and testing of other innovative applications for monitoring safety compliance, and advancing future research in automation in construction.	[Nath, Nipun D.; Paal, Stephanie G.] Texas A&M Univ, Zachry Dept Civil Engn, 3136 TAMU, College Stn, TX 77843 USA; [Behzadan, Amir H.] Texas A&M Univ, Dept Construct Sci, 3137 TAMU, College Stn, TX 77843 USA	Behzadan, AH (corresponding author), Texas A&M Univ, Dept Construct Sci, 3137 TAMU, College Stn, TX 77843 USA.	nipundebnath@tamu.edu; abehzadan@tamu.edu; spaal@tamu.edu			U.S. National Science Foundation (NSF)National Science Foundation (NSF) [CMMI 1800957]	The authors gratefully acknowledge the U.S. National Science Foundation (NSF) for supporting this project through grant CMMI 1800957, as well as Mr. Yalong Pi for assisting in data preparation. Any opinions, findings, conclusions, and recommendations expressed in this paper are those of the authors and do not necessarily represent the views of the NSF or the individual named above.	Akbar-Khanzadeh F, 1998, J Hum Ergol (Tokyo), V27, P70; Barro-Torres S, 2012, COMPUT COMMUN, V36, P42, DOI 10.1016/j.comcom.2012.01.005; Bishop CM., 2006, PATTERN RECOGNITION; Blockeel H., 2000, SIGKDD EXPLOR NEWSL, V2, P1, DOI DOI 10.1145/360402.360406; Bureau of Labor Statistics, IND GLANC CONSTR; Bureau of Labor Statistics, FAT OCC INJ COUNTS R; Castelvecchi D, 2016, NATURE, V537, P20, DOI [10.1038/nature.2016.20491, 10.1038/538020a]; Centers for Disease Control and Prevention, TRAUM BRAIN INJ CONS; Chen X., 2015, ARXIV150400325; Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195; Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848; Ding LY, 2018, AUTOMAT CONSTR, V86, P118, DOI 10.1016/j.autcon.2017.11.002; Everingham M, 2010, INT J COMPUT VISION, V88, P303, DOI 10.1007/s11263-009-0275-4; Fang Q, 2018, AUTOMAT CONSTR, V85, P1, DOI 10.1016/j.autcon.2017.09.018; Fergus R, 2005, IEEE I CONF COMP VIS, P1816; Friedman S, 2001, IND REL RES, P1, DOI 10.1097/00054725-200102000-00001; Girshick R, 2015, IEEE I CONF COMP VIS, P1440, DOI 10.1109/ICCV.2015.169; Girshick R, 2014, PROC CVPR IEEE, P580, DOI 10.1109/CVPR.2014.81; Han S, 2013, AUTOMAT CONSTR, V35, P131, DOI 10.1016/j.autcon.2013.05.001; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; He KM, 2017, IEEE I CONF COMP VIS, P2980, DOI 10.1109/ICCV.2017.322; Hochreiter S, 1997, NEURAL COMPUT, V9, P1735, DOI 10.1162/neco.1997.9.8.1735; Huang XY, 2003, J CONSTR ENG M ASCE, V129, P262, DOI 10.1061/(ASCE)0733-9364(2003)129:3(262); Kelm A, 2013, AUTOMAT CONSTR, V36, P38, DOI 10.1016/j.autcon.2013.08.009; Kingma D., 2014, 14126980 ARXIV; Kolar Z, 2018, AUTOMAT CONSTR, V89, P58, DOI 10.1016/j.autcon.2018.01.003; Krizhevsky A, 2012, NEURAL INFORM PROCES, P1097, DOI DOI 10.1145/3065386; Kyrkou C, 2018, DES AUT TEST EUROPE, P967, DOI 10.23919/DATE.2018.8342149; Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791; Lin TY, 2020, IEEE T PATTERN ANAL, V42, P318, DOI [10.1109/ICCV.2017.324, 10.1109/TPAMI.2018.2858826]; Liu W, 2016, LECT NOTES COMPUT SC, V9905, P21, DOI 10.1007/978-3-319-46448-0_2; Mneymneh BE, 2019, J COMPUT CIVIL ENG, V33, DOI 10.1061/(ASCE)CP.1943-5487.0000813; Murphy KP, 2012, MACHINE LEARNING PRO; Nath N., 2018, P 18 INT C CONSTR AP, P1; Nath ND, 2019, J INF TECHNOL CONSTR, V24, P511, DOI 10.36680/j.itcon.2019.028; Naticchia B, 2013, AUTOMAT CONSTR, V29, P148, DOI 10.1016/j.autcon.2012.09.016; Oquab M, 2014, PROC CVPR IEEE, P1717, DOI 10.1109/CVPR.2014.222; OSHA, TOP 10 MOST FREQ CIT; OSHA, WORK SAF SER CONSTR; OSHA, COMM US STAT; OSHA, CIT STAND CONSTR; OSHA, EMPL PAYM PERS PROT; OSHA, SAF VEST REQ PROT FL; OSHA, SAF HLTH REG CONSTR; Park MW, 2015, J CONSTR ENG M, V141, DOI 10.1061/(ASCE)CO.1943-7862.0000974; Park MW, 2012, AUTOMAT CONSTR, V28, P15, DOI 10.1016/j.autcon.2012.06.001; Perez L., 2017, EFFECTIVENESS DATA A; Redmon J., 2018, ARXIV180402767; Redmon J, 2017, PROC CVPR IEEE, P6517, DOI 10.1109/CVPR.2017.690; Redmon J, 2016, PROC CVPR IEEE, P779, DOI 10.1109/CVPR.2016.91; Ren SQ, 2015, ADV NEUR IN, V28; Russell BC, 2008, INT J COMPUT VISION, V77, P157, DOI 10.1007/s11263-007-0090-8; Seo J, 2015, ADV ENG INFORM, V29, P239, DOI 10.1016/j.aei.2015.02.001; Shan Du, 2011, 2011 3rd International Conference on Computer Research and Development (ICCRD 2011), P25, DOI 10.1109/ICCRD.2011.5763846; Shin HC, 2016, IEEE T MED IMAGING, V35, P1285, DOI 10.1109/TMI.2016.2528162; Shrestha K., 2015, J CONSTRUCTION ENG, V2015, P1; Siddula M, 2016, PROCEDIA ENGINEER, V145, P428, DOI 10.1016/j.proeng.2016.04.010; Simonyan K., 2015, PROC CVPR IEEE; Szegedy C., 2013, PROC C ADV NEURAL IN, P2553; Turpin A., 2006, Proceedings of the Twenty-Ninth Annual International ACM SIGIR Conference on Research and Development in Information Retrieval, P11, DOI 10.1145/1148170.1148176; United States Census Bureau, CONSTR SPEND; Weston J., 1998, CSDTR9804 U LOND DEP; Wu JX, 2019, AUTOMAT CONSTR, V106, DOI 10.1016/j.autcon.2019.102894; Xie ZP, 2018, PR IEEE I C PROGR IN, P430, DOI 10.1109/PIC.2018.8706269; Yuen M. C., 2011, P 3 INT C PRIV SEC R, P766, DOI [10.1109/PASSAT/SocialCom.2011.203, DOI 10.1109/PASSAT/SOCIALCOM.2011.203]; Zeiler MD, 2014, LECT NOTES COMPUT SC, V8689, P818, DOI 10.1007/978-3-319-10590-1_53; Zhang YB, 2011, IEEE T IMAGE PROCESS, V20, P3291, DOI 10.1109/TIP.2011.2158226; Zivkovic Z, 2004, INT C PATT RECOG, P28, DOI 10.1109/ICPR.2004.1333992	68	17	17	7	32	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0926-5805	1872-7891		AUTOMAT CONSTR	Autom. Constr.	APR	2020	112								103085	10.1016/j.autcon.2020.103085			20	Construction & Building Technology; Engineering, Civil	Construction & Building Technology; Engineering	LE5UJ	WOS:000526785600018					2021-06-18	
J	Vlaar, AP; Oczkowski, S; de Bruin, S; Wijnberge, M; Antonelli, M; Aubron, C; Aries, P; Duranteau, J; Juffermans, NP; Meier, J; Murphy, GJ; Abbasciano, R; Muller, M; Shah, A; Perner, A; Rygaard, S; Walsh, TS; Guyatt, G; Dionne, JC; Cecconi, M				Vlaar, Alexander P.; Oczkowski, Simon; de Bruin, Sanne; Wijnberge, Marije; Antonelli, Massimo; Aubron, Cecile; Aries, Philippe; Duranteau, Jacques; Juffermans, Nicole P.; Meier, Jens; Murphy, Gavin J.; Abbasciano, Riccardo; Muller, Marcella; Shah, Akshay; Perner, Anders; Rygaard, Sofie; Walsh, Timothy S.; Guyatt, Gordon; Dionne, J. C.; Cecconi, Maurizio			Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine	INTENSIVE CARE MEDICINE			English	Article						Transfusion; Coagulopathy; Critically ill; Guideline; Intensive care; Plasma; Platelets; Red blood cells; Point of care; EPO	RECOMBINANT-HUMAN-ERYTHROPOIETIN; FRESH-FROZEN PLASMA; BLOOD-CELL TRANSFUSION; EXTRACORPOREAL MEMBRANE-OXYGENATION; PREPROCEDURAL PLATELET TRANSFUSION; NEAR-INFRARED SPECTROSCOPY; PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; RESTRICTIVE TRANSFUSION	Objective To develop evidence-based clinical practice recommendations regarding transfusion practices in non-bleeding, critically ill adults. Design A task force involving 13 international experts and three methodologists used the GRADE approach for guideline development. Methods The task force identified four main topics: red blood cell transfusion thresholds, red blood cell transfusion avoidance strategies, platelet transfusion, and plasma transfusion. The panel developed structured guideline questions using population, intervention, comparison, and outcomes (PICO) format. Results The task force generated 16 clinical practice recommendations (3 strong recommendations, 13 conditional recommendations), and identified five PICOs with insufficient evidence to make any recommendation. Conclusions This clinical practice guideline provides evidence-based recommendations and identifies areas where further research is needed regarding transfusion practices and transfusion avoidance in non-bleeding, critically ill adults.	[Vlaar, Alexander P.; de Bruin, Sanne; Wijnberge, Marije; Juffermans, Nicole P.; Muller, Marcella] Amsterdam UMC, Dept Intens Care Med, Locat AMC, Amsterdam, Netherlands; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] Guidelines Intens Care Dev & Evaluat GUIDE Grp, Hamilton, ON, Canada; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Wijnberge, Marije] Amsterdam UMC, Dept Anaesthesiol, Locat AMC, Amsterdam, Netherlands; [Antonelli, Massimo] Fdn Policlin Univ AGemelli IRCCS, Dept Anaesthesiol & Intens Care Med, Rome, Italy; [Antonelli, Massimo] Univ Cattolica Sacro Cuore, Ist Anaesthesiol & Rianimaz, Rome, Italy; [Aubron, Cecile; Aries, Philippe] Univ Bretagne Occidentale, Ctr Hosp Reg & Univ Brest, Dept Intens Care Med, Site La Cavale Blanche, Brest, France; [Duranteau, Jacques] HUPS, Dept Anaesthesia & Intens Care, Orsay, France; [Meier, Jens] Kepler Univ, Fac Med, Dept Anesthesiol & Crit Care Med, Linz, Austria; [Murphy, Gavin J.; Abbasciano, Riccardo] Univ Leicester, Coll Life Sci, NIHR Leicester Biomed Res Ctr, Cardiovasc,Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England; [Shah, Akshay] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Shah, Akshay] John Radcliffe Hosp, Adult Intens Care Unit, Oxford, England; [Perner, Anders; Rygaard, Sofie] Univ Copenhagen, Rigshosp, Dept Intens Care, Copenhagen, Denmark; [Walsh, Timothy S.] Univ Edinburgh, Anaesthet Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Cecconi, Maurizio] Humanitas Clin & Res Ctr IRCCS, Dept Anaesthesia & Intens Care Med, Milan, Italy; [Cecconi, Maurizio] Humanitas Univ, Via Rita Levi Montalcini, Milan, Italy; [Vlaar, Alexander P.] Univ Amsterdam, Dept Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	Vlaar, AP (corresponding author), Amsterdam UMC, Dept Intens Care Med, Locat AMC, Amsterdam, Netherlands.; Vlaar, AP (corresponding author), Univ Amsterdam, Dept Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.p.vlaar@amsterdamumc.nl	Dionne, Joanna Colleen/X-1720-2018; Abbasciano, Riccardo/AAI-2375-2020; Cecconi, Maurizio/A-6241-2012	Dionne, Joanna Colleen/0000-0002-9401-6868; Abbasciano, Riccardo/0000-0001-6004-8741; Cecconi, Maurizio/0000-0002-4376-6538	British Heart FoundationBritish Heart Foundation [RG/17/9/32812, RG/13/6/29947] Funding Source: Medline; Department of HealthEuropean Commission [DRF-2017-10-094] Funding Source: Medline		Adamczyk S, 2009, ANN FR ANESTH, V28, P522, DOI 10.1016/j.annfar.2009.03.013; Agerstrand CL, 2015, ANN THORAC SURG, V99, P590, DOI 10.1016/j.athoracsur.2014.08.039; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Bafeta A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e813; Bergamin FS, 2017, CRIT CARE MED, V45, P766, DOI 10.1097/CCM.0000000000002283; BOLDT J, 1989, ANAESTHESIST, V38, P353; Bolton-Maggs PHB, 2016, TRANSFUSION MED, V26, P401, DOI 10.1111/tme.12380; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Cahill C, 2016, TRANSFUSION, V56, p32A; Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Chui BK, 2012, J TRAUMA ACUTE CARE, V73, P195, DOI 10.1097/TA.0b013e31824ba1da; Consten ECJ, 1996, J THORAC CARDIOV SUR, V112, P162, DOI 10.1016/S0022-5223(96)70192-7; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2001, CRIT CARE MED, V29, pS201, DOI 10.1097/00003246-200109001-00011; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Curley A, 2019, NEW ENGL J MED, V380, P242, DOI 10.1056/NEJMoa1807320; Dara SI, 2005, CRIT CARE MED, V33, P2667, DOI [10.1097/01.CCM.0000186745.53059.F0, 10.1097/01.CCM.0000151062.00501.60]; de Almeida JP, 2015, ANESTHESIOLOGY, V122, P29, DOI 10.1097/ALN.0000000000000511; de Bruin S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2591-6; DeZern AE, 2016, TRANSFUSION, V56, P1750, DOI 10.1111/trf.13658; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Dolman HS, 2015, SURGERY, V158, P1083, DOI 10.1016/j.surg.2015.05.018; Elabbassi W, 2017, INDIAN HEART J, V69, P762, DOI 10.1016/j.ihj.2017.05.003; Estcourt LJ, 2017, BRIT J HAEMATOL, V176, P365, DOI 10.1111/bjh.14423; Fogagnolo A, 2017, INTENS CARE MED, V5, P41; Garrido-Martin P, 2012, INTERACT CARDIOV TH, V15, P1013, DOI 10.1093/icvts/ivs344; Georgopoulos D, 2005, CRIT CARE, V9, pR508, DOI 10.1186/cc3786; Gobatto ALN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2273-9; Goldman M, 2005, TRANSFUS MED REV, V19, P2, DOI 10.1016/j.tmrv.2004.10.001; Guttendorf J, 2014, AM J CRIT CARE, V23, P365, DOI 10.4037/ajcc2014115; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Harber CR, 2006, ANAESTH INTENS CARE, V34, P434, DOI 10.1177/0310057X0603400414; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Hebert PC, 2001, CHEST, V119, P1850, DOI 10.1378/chest.119.6.1850; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jenq CC, 2018, ARTIF ORGANS, V42, P705, DOI 10.1111/aor.13123; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kasper SM, 2001, ANESTHESIOLOGY, V95, P81, DOI 10.1097/00000542-200107000-00017; Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262; Klein AA, 2016, ANAESTHESIA, V71, P829, DOI 10.1111/anae.13489; Laine A, 2018, J CARDIOTHOR VASC AN, V32, P132, DOI 10.1053/j.jvca.2017.08.039; LENZ C, 2007, TRANSFUS ALTERN TRAN, V9, P265, DOI DOI 10.1111/j.1778-428X.2007.00080.x; Litton E, 2016, INTENS CARE MED, V42, P1715, DOI 10.1007/s00134-016-4465-6; Liu F, 2018, NATL MED J INDIA, V31, P5, DOI 10.4103/0970-258X.243419; Loukas A, 2011, CRIT CARE S1, V15, pP425, DOI [10.1186/cc9845, DOI 10.1186/CC9845]; Luchette FA, 2012, AM J SURG, V203, P508, DOI 10.1016/j.amjsurg.2011.08.006; MacIsaac CM, 2003, ANAESTH INTENS CARE, V31, P653, DOI 10.1177/0310057X0303100607; MacLaren R, 2005, VALUE HEALTH, V8, P105, DOI 10.1111/j.1524-4733.2005.04006.x; Madi-Jebara SN, 2004, J CARDIOTHOR VASC AN, V18, P59, DOI 10.1053/j.jvca.2003.10.012; Mahdy Saad, 2009, Middle East Journal of Anesthesiology, V20, P219; MARTINOWITZ U, 1990, J THORAC CARDIOV SUR, V100, P92; Mazer CD, 2017, NEW ENGL J MED, V377, P2133, DOI 10.1056/NEJMoa1711818; Mazza Bruno Franco, 2015, Rev. bras. ter. intensiva, V27, P36, DOI 10.5935/0103-507X.20150007; McCredie VA, 2017, NEUROCRIT CARE, V26, P247, DOI 10.1007/s12028-016-0310-6; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Meier J, 2016, BRIT J ANAESTH, V116, P255, DOI 10.1093/bja/aev456; Moron NJE, 2003, REV ROL ENF, V26, P591; Muller MCA, 2015, J THROMB HAEMOST, V13, P989, DOI 10.1111/jth.12908; Muller MC, 2015, TRANSFUSION, V55, P26, DOI 10.1111/trf.12750; Muller MCA, 2017, TRANSFUS MED REV, V31, P223, DOI 10.1016/j.tmrv.2017.05.008; Mueller MM, 2019, JAMA-J AM MED ASSOC, V321, P983, DOI 10.1001/jama.2019.0554; Mung'ayi V, 2014, AFR J EMERG MED, V4, P66, DOI 10.1016/j.afjem.2013.06.004; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Muthuchellappan R, 2018, TRANSFUSION MED, V28, P304, DOI 10.1111/tme.12504; Naidech AM, 2010, NEUROCRIT CARE, V13, P313, DOI 10.1007/s12028-010-9424-4; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Navarro JL, 2015, INTENSIVE CARE MED E, V3, pA221, DOI [10.1186/2197-425X-3-S1-A221, DOI 10.1186/2197-425X-3-S1-A221]; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Orlov D, 2009, TRANSFUSION, V49, P682, DOI 10.1111/j.1537-2995.2008.02022.x; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Padhi S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5832; Page C, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-14; Panholzer B, 2017, PERFUSION-UK, V32, P495, DOI 10.1177/0267659117693075; Parimi N, 2018, ANN CLIN LAB SCI, V48, P279; PERUZZI WT, 1993, CRIT CARE MED, V21, P501, DOI 10.1097/00003246-199304000-00007; Peterson J, 2011, NEWCASTLE OTTAWA SCA; Pieracci FM, 2014, CRIT CARE MED, V42, P2048, DOI 10.1097/CCM.0000000000000408; Pieracci FM, 2009, SURG INFECT, V10, P9, DOI 10.1089/sur.2008.043; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Powell M, 2012, APPALACH HERIT, V40, P12, DOI 10.1353/aph.2012.0002; Rasmussen Lone, 2010, Clin Epidemiol, V3, P1, DOI 10.2147/CLEP.S12885; Ratcliffe LEK, 2016, AM J KIDNEY DIS, V67, P548, DOI 10.1053/j.ajkd.2015.11.012; Rezende Ederlon, 2010, Rev. bras. ter. intensiva, V22, P5, DOI 10.1590/S0103-507X2010000100003; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rogers CA, 2017, BRIT J ANAESTH, V119, P384, DOI 10.1093/bja/aex182; Romers LHL, 2016, ANESTHESIOLOGY, V125, P124, DOI 10.1097/ALN.0000000000001156; Salman Salam S, 2007, J Intensive Care Med, V22, P105, DOI 10.1177/0885066606297969; Samarani G, 2015, AM J RESP CRIT CARE, V191; Sanchez-Giron F, 2008, ARCH PATHOL LAB MED, V132, P1916, DOI 10.1043/1543-2165-132.12.1916; Schmidt M, 2013, INTENS CARE MED, V39, P838, DOI 10.1007/s00134-012-2785-8; Schofield WN, 2003, MED J AUSTRALIA, V178, P117, DOI 10.5694/j.1326-5377.2003.tb05101.x; Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x; Sehgal LR, 2001, TRANSFUSION, V41, P591, DOI 10.1046/j.1537-2995.2001.41050591.x; Shehata N, 2012, TRANSFUSION, V52, P91, DOI 10.1111/j.1537-2995.2011.03236.x; Shermock KM, 2005, CRIT CARE MED, V33, P497, DOI 10.1097/01.ccm.0000155988.78188.EE; Silver M, 2006, CRIT CARE MED, V34, P2310, DOI 10.1097/01.CCM.0000233873.17954.42; Simon GI, 2017, LANCET HAEMATOL, V4, pE465, DOI 10.1016/S2352-3026(17)30141-2; SMOLLER BR, 1989, AM J CLIN PATHOL, V91, P701, DOI 10.1093/ajcp/91.6.701; Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772; Stanworth SJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10129; Stanworth SJ, 2011, TRANSFUSION, V51, P62, DOI 10.1111/j.1537-2995.2010.02798.x; Strauss R, 2002, CRIT CARE MED, V30, P1765, DOI 10.1097/00003246-200208000-00015; Surve RM, 2016, TRANSFUSION MED, V26, P343, DOI 10.1111/tme.12332; Swol J, 2018, PERFUSION-UK, V33, P546, DOI 10.1177/0267659118772457; Taha A, 2015, CRIT CARE, V19, P331, DOI [10.1186/cc14411, DOI 10.1186/CC14411]; Tinmouth A, 2013, TRANSFUSION, V53, P2222, DOI 10.1111/trf.12231; Torella F, 2002, SHOCK, V18, P440, DOI 10.1097/00024382-200211000-00009; TRIMBLE AS, 1964, J THORAC CARDIOV SUR, V48, P314, DOI 10.1016/S0022-5223(19)32798-9; Valentine SL, 2018, PEDIATR CRIT CARE ME, V19, P884, DOI 10.1097/PCC.0000000000001613; van Iperen CE, 2000, CRIT CARE MED, V28, P2773, DOI 10.1097/00003246-200008000-00015; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vavricka SR, 2003, ANN HEMATOL, V82, P570, DOI 10.1007/s00277-003-0707-0; Veelo DP, 2012, BLOOD TRANSFUS-ITALY, V10, P213, DOI 10.2450/2012.0086-11; Vincent JL, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2018-9; Vincent JL, 2006, CRIT CARE MED, V34, P1661, DOI 10.1097/01.CCM.0000217919.22155.85; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7; Voelker MT, 2015, ARTIF ORGANS, V39, P374, DOI 10.1111/aor.12385; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Walsh TS, 2010, CRIT CARE MED, V38, P1939, DOI 10.1097/CCM.0b013e3181eb9d2b; Warner MA, 2019, ANESTH ANALG, V128, P288, DOI 10.1213/ANE.0000000000002794; Warner MA, 2017, TRANSFUSION, V57, P890, DOI 10.1111/trf.13996; Watson DM, 2011, TRANSFUSION MED, V21, P124, DOI 10.1111/j.1365-3148.2010.01049.x; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; Weingart C, 2015, ARTIF ORGANS, V39, P765, DOI 10.1111/aor.12464; Wilhelmi M, 2001, EUR J CARDIO-THORAC, V19, P657, DOI 10.1016/S1010-7940(01)00648-0; Woda RP, 1999, J CLIN MONITOR COMP, V15, P215, DOI 10.1023/A:1009936917049; Yang L, 2012, TRANSFUSION, V52, P1673, DOI 10.1111/j.1537-2995.2011.03515.x; Yoo YC, 2011, ANESTHESIOLOGY, V115, P929, DOI 10.1097/ALN.0b013e318232004b; Zeidler K, 2011, TRANSFUSION, V51, P2269, DOI 10.1111/j.1537-2995.2011.03147.x; Zogheib E, 2011, INTENS CARE MED, V37, pS155	143	17	18	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2020	46	4					673	696		10.1007/s00134-019-05884-8			24	Critical Care Medicine	General & Internal Medicine	KY5IV	WOS:000522601500012	31912207	Green Published, Bronze			2021-06-18	
J	Marcos-Contreras, OA; Greineder, CF; Kiseleva, RY; Parhiz, H; Walsh, LR; Zuluaga-Ramirez, V; Myerson, JW; Hood, ED; Villa, CH; Tombacz, I; Pardi, N; Seliga, A; Mui, BL; Tam, YK; Glassman, PM; Shuvaev, VV; Nong, J; Brenner, JS; Khoshnejad, M; Madden, T; Weissmann, D; Persidsky, Y; Muzykantov, VR				Marcos-Contreras, Oscar A.; Greineder, Colin F.; Kiseleva, Raisa Yu; Parhiz, Hamideh; Walsh, Landis R.; Zuluaga-Ramirez, Viviana; Myerson, Jacob W.; Hood, Elizabeth D.; Villa, Carlos H.; Tombacz, Istvan; Pardi, Norbert; Seliga, Alecia; Mui, Barbara L.; Tam, Ying K.; Glassman, Patrick M.; Shuvaev, Vladimir V.; Nong, Jia; Brenner, Jacob S.; Khoshnejad, Makan; Madden, Tom; Weissmann, Drew; Persidsky, Yuri; Muzykantov, Vladimir R.			Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						blood-brain barrier; cerebrovascular drug targeting; drug delivery to brain; mRNA therapy; VCAM-1	SENSITIVE MOLECULAR MRI; ENDOTHELIAL-CELLS; DRUG-DELIVERY; COLLABORATIVE ENHANCEMENT; MAGNETIC-RESONANCE; ADHESION MOLECULES; MOUSE MODEL; EXPRESSION; VCAM-1; NANOCARRIERS	Drug targeting to inflammatory brain pathologies such as stroke and traumatic brain injury remains an elusive goal. Using a mouse model of acute brain inflammation induced by local tumor necrosis factor alpha (TNF alpha), we found that uptake of intravenously injected antibody to vascular cell adhesion molecule 1 (anti-VCAM) in the inflamed brain is >10-fold greater than antibodies to transferrin receptor-1 and intercellular adhesion molecule 1 (TfR-1 and ICAM-1). Furthermore, uptake of anti-VCAM/liposomes exceeded that of anti-TfR and anti-ICAM counterparts by similar to 27- and similar to 8-fold, respectively, achieving brain/blood ratio >300-fold higher than that of immunoglobulin G/liposomes. Single-photon emission computed tomography imaging affirmed specific anti-VCAM/liposome targeting to inflamed brain in mice. Intravital microscopy via cranial window and flow cytometry showed that in the inflamed brain anti-VCAM/liposomes bind to endothelium, not to leukocytes. Anti-VCAM/LNP selectively accumulated in the inflamed brain, providing de novo expression of proteins encoded by cargo messenger RNA (mRNA). Anti-VCAM/LNP-mRNA mediated expression of thrombomodulin (a natural endothelial inhibitor of thrombosis, inflammation, and vascular leakage) and alleviated TNF alpha-induced brain edema. Thus VCAM-directed nanocarriers provide a platform for cerebrovascular targeting to inflamed brain, with the goal of normalizing the integrity of the blood-brain barrier, thus benefiting numerous brain pathologies.	[Marcos-Contreras, Oscar A.; Greineder, Colin F.; Kiseleva, Raisa Yu; Parhiz, Hamideh; Walsh, Landis R.; Myerson, Jacob W.; Hood, Elizabeth D.; Villa, Carlos H.; Glassman, Patrick M.; Shuvaev, Vladimir V.; Nong, Jia; Brenner, Jacob S.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Zuluaga-Ramirez, Viviana; Seliga, Alecia; Persidsky, Yuri] Temple Univ, Dept Pathol, Lewis Katz Sch Med, Philadelphia, PA 19140 USA; [Tombacz, Istvan; Pardi, Norbert; Weissmann, Drew] Univ Penn, Perelman Sch Med, Infect Dis, Philadelphia, PA 19104 USA; [Mui, Barbara L.; Tam, Ying K.; Madden, Tom] Acuitas Therapeut, Vancouver, BC V6L 2A1, Canada; [Brenner, Jacob S.; Muzykantov, Vladimir R.] Univ Penn, Ctr Translat Targeted Therapeut & Nanomed, Philadelphia, PA 19140 USA; [Brenner, Jacob S.] Univ Penn, Perelman Sch Med, Pulm & Crit Care Med, Philadelphia, PA 19104 USA; [Khoshnejad, Makan] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Greineder, Colin F.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Greineder, Colin F.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	Marcos-Contreras, OA; Greineder, CF; Muzykantov, VR (corresponding author), Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.; Muzykantov, VR (corresponding author), Univ Penn, Ctr Translat Targeted Therapeut & Nanomed, Philadelphia, PA 19140 USA.	oscarmar@pennmedicine.upenn.edu; coling@med.umich.edu; muzykant@mail.med.upenn.edu		Glassman, Patrick/0000-0003-3786-0437; Nong, Jia/0000-0002-9210-7707	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HL128398-02, RO1 HL 143806-01, T32 HL 007971, K08 HL130430]; Acuitas (SRA); Cardiovascular Institute of the University of Pennsylvania; American Heart AssociationAmerican Heart Association [19CDA34590001]	V.R.M. received funding from NIH (Grants RO1 HL128398-02 and RO1 HL 143806-01) and Acuitas (SRA), V.R.M. and J.S.B. received funding from the Cardiovascular Institute of the University of Pennsylvania, O.A.M.-C. received funding from the American Heart Association (Grant 19CDA34590001), R.Yu.K. and P.M.G. received funding from NIH (Grant T32 HL 007971), and C.F.G. and L.R.W. received funding from NIH (Grant K08 HL130430). We acknowledge Kathleen LeForte for technical assistance in the preparation of this manuscript and Dr. Silvia Muro (University of Maryland) for the stimulating discussion of the manuscript.	Anraku Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00952-3; Anselmo AC, 2015, J CONTROL RELEASE, V199, P29, DOI 10.1016/j.jconrel.2014.11.027; Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b; Bellavance MA, 2008, AAPS J, V10, P166, DOI 10.1208/s12248-008-9018-7; Boado RJ, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/296151; Bonavia AS, 2006, APPL RADIAT ISOTOPES, V64, P470, DOI 10.1016/j.apradiso.2005.11.004; Brenner JS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05079-7; Brenner Jacob S, 2017, Nanomedicine, V13, P1495, DOI 10.1016/j.nano.2016.12.019; Bruckman MA, 2014, NANO LETT, V14, P1551, DOI 10.1021/nl404816m; BurkeGaffney A, 1996, BRIT J PHARMACOL, V119, P1149, DOI 10.1111/j.1476-5381.1996.tb16017.x; Chacko AM, 2015, ACS NANO, V9, P6785, DOI 10.1021/nn505672x; Danielyan K, 2007, J PHARMACOL EXP THER, V321, P947, DOI 10.1124/jpet.107.120535; Demeule M, 2014, J CLIN INVEST, V124, P1199, DOI 10.1172/JCI70647; Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC; Dogbevia GK, 2017, ANN NEUROL, V82, P93, DOI 10.1002/ana.24981; Fournier AP, 2017, P NATL ACAD SCI USA, V114, P6116, DOI 10.1073/pnas.1619424114; Frechou M, 2013, CONTRAST MEDIA MOL I, V8, P157, DOI 10.1002/cmmi.1512; Gauberti M, 2013, STROKE, V44, P1988, DOI 10.1161/STROKEAHA.111.000544; Greineder CF, 2017, BLOOD ADV, V1, P1452, DOI 10.1182/bloodadvances.2017007229; Greineder CF, 2015, FASEB J, V29, P3483, DOI 10.1096/fj.15-271213; Greineder CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080110; Griffin JH, 2018, BLOOD, V132, P159, DOI 10.1182/blood-2018-02-769026; Hood ED, 2012, J CONTROL RELEASE, V163, P161, DOI 10.1016/j.jconrel.2012.08.031; Howard M, 2014, ACS NANO, V8, P4100, DOI 10.1021/nn500136z; Howard MD, 2014, MOL PHARMACEUT, V11, P2262, DOI 10.1021/mp400677y; Hsu J, 2014, PHARM RES-DORDR, V31, P1855, DOI 10.1007/s11095-013-1289-8; Hu PJ, 2017, AM J PHYSIOL-LUNG C, V313, pL1, DOI 10.1152/ajplung.00485.2016; Huynh GH, 2007, BRAIN RES, V1128, P181, DOI 10.1016/j.brainres.2006.10.041; Irani DN, 1996, J IMMUNOL, V156, P3850; ISHII H, 1986, BLOOD, V67, P362; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Jiang XY, 2018, PROG NEUROBIOL, V163, P144, DOI 10.1016/j.pneurobio.2017.10.001; Johnsen KB, 2016, J CONTROL RELEASE, V222, P32, DOI 10.1016/j.jconrel.2015.11.032; Kanodia JS, 2016, CPT-PHARMACOMET SYST, V5, P283, DOI 10.1002/psp4.12081; Kiseleva R, 2018, DRUG DELIV TRANSL RE, V8, P883, DOI 10.1007/s13346-017-0464-6; Kiseleva RY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20027-7; Klyachko NL, 2017, BIOMATERIALS, V140, P79, DOI 10.1016/j.biomaterials.2017.06.017; Li RR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196976; Liu HL, 2016, THERANOSTICS, V6, P1588, DOI 10.7150/thno.15492; Llovera G, 2017, ACTA NEUROPATHOL, V134, P851, DOI 10.1007/s00401-017-1758-y; Loghmani H, 2018, BLOOD, V132, P148, DOI 10.1182/blood-2017-12-768994; MATTILA P, 1992, SCAND J IMMUNOL, V36, P159, DOI 10.1111/j.1365-3083.1992.tb03087.x; Mead BP, 2017, NANO LETT, V17, P3533, DOI 10.1021/acs.nanolett.7b00616; Montagne A, 2012, NEUROIMAGE, V63, P760, DOI 10.1016/j.neuroimage.2012.07.018; Muller K, 2014, SCI REP-UK, V4, DOI 10.1038/srep04871; Murciano JC, 2003, BLOOD, V101, P3977, DOI 10.1182/blood-2002-09-2853; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Myerson JW, 2018, ADV MATER, V30, DOI 10.1002/adma.201802373; Myerson JW, 2016, ADV DRUG DELIVER REV, V99, P97, DOI 10.1016/j.addr.2015.10.011; Nahrendorf M, 2009, JACC-CARDIOVASC IMAG, V2, P1213, DOI 10.1016/j.jcmg.2009.04.016; National Research Council, 2011, GUIDE CARE USE LAB A; Nicole O, 2001, NAT MED, V7, P59; Papademetriou J, 2014, J CONTROL RELEASE, V188, P87, DOI 10.1016/j.jconrel.2014.06.008; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Patel N, 2015, BIOCONJUGATE CHEM, V26, P1542, DOI 10.1021/acs.bioconjchem.5b00380; Posel C, 2016, JOVE-J VIS EXP, DOI 10.3791/53658; Polfliet MMJ, 2001, J IMMUNOL, V167, P4644, DOI 10.4049/jimmunol.167.8.4644; Rom S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0729-x; Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432; Seo JW, 2015, J CONTROL RELEASE, V220, P51, DOI 10.1016/j.jconrel.2015.09.057; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Shi YJ, 2017, P NATL ACAD SCI USA, V114, pE1243, DOI 10.1073/pnas.1621174114; Shuvaev VV, 2015, J CONTROL RELEASE, V219, P576, DOI 10.1016/j.jconrel.2015.09.055; Sun T, 2017, P NATL ACAD SCI USA, V114, pE10281, DOI 10.1073/pnas.1713328114; Sweeney MD, 2019, PHYSIOL REV, V99, P21, DOI 10.1152/physrev.00050.2017; Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e; Voinea M, 2005, PHARM RES-DORDR, V22, P1906, DOI 10.1007/s11095-005-7247-3; Vuorte J, 1999, J IMMUNOL, V162, P2353; Weissman D, 2015, MOL THER, V23, P1416, DOI 10.1038/mt.2015.138; Wichert S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171205; Yoo D, 2017, ACS NANO, V11, P8600, DOI 10.1021/acsnano.7b03426; Yuan DF, 2017, BIOMATERIALS, V142, P1, DOI 10.1016/j.biomaterials.2017.07.011; Zhang C, 2017, THERANOSTICS, V7, P3260, DOI 10.7150/thno.19979	73	17	17	3	30	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	FEB 18	2020	117	7					3405	3414		10.1073/pnas.1912012117			10	Multidisciplinary Sciences	Science & Technology - Other Topics	KM4JX	WOS:000514096400017	32005712	Bronze, Green Published			2021-06-18	
J	Erlangsen, A; Stenager, E; Conwell, Y; Andersen, PK; Hawton, K; Benros, ME; Nordentoft, M; Stenager, E				Erlangsen, Annette; Stenager, Egon; Conwell, Yeates; Andersen, Per Kragh; Hawton, Keith; Benros, Michael Eriksen; Nordentoft, Merete; Stenager, Elsebeth			Association Between Neurological Disorders and Death by Suicide in Denmark	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; DEPRESSIVE SYMPTOMS; PUBLIC-HEALTH; RISK; NATIONWIDE; DEMENTIA; SCLEROSIS; EPILEPSY; PEOPLE; STROKE	This population epidemiology study uses Danish registry data to examine associations between neurological disorders and higher suicide rates from 1980 through 2016. Question Is there an association between neurological disorders and a higher risk of death by suicide? Findings In this retrospective cohort study that included 7300395 persons in Denmark from 1980 through 2016, there was a significantly higher rate of suicide among those with a diagnosed neurological disorder than all other persons (44.0 per 100000 person-years vs 20.1 per 100000 person-years, adjusted incidence rate ratio, 1.8). Meaning In Denmark, having a diagnosis of a neurological disorder was associated with a small but statistically significant increased risk of death by suicide. Importance Neurological disorders have been linked to suicide, but the risk across a broad spectrum of neurological disorders remains to be assessed. Objectives To examine whether people with neurological disorders die by suicide more often than other people and to assess for temporal associations. Design, Setting, and Participants Nationwide, retrospective cohort study on all persons 15 years or older living in Denmark, from 1980 through 2016 (N = 7300395). Exposures Medical contact for head injury, stroke, epilepsy, polyneuropathy, diseases of myoneural junction, Parkinson disease, multiple sclerosis, central nervous system infections, meningitis, encephalitis, amyotrophic lateral sclerosis, Huntington disease, dementia, intellectual disability, and other brain diseases from 1977 through 2016 (n = 1248252). Main Outcomes and Measures Death by suicide during 1980-2016. Adjusted incidence rate ratio (IRRs) were estimated using Poisson regressions, adjusted for sociodemographics, comorbidity, psychiatric diagnoses, and self-harm. Results Of the more than 7.3 million individuals observed over 161935233 person-years (49.1% males), 35483 died by suicide (median duration of follow-up, 23.6 years; interquartile range, 10.0-37.0 years; mean age, 51.9 years; SD, 17.9 years). Of those, 77.4% were males, and 14.7% (n = 5141) were diagnosed with a neurological disorder, equivalent to a suicide rate of 44.0 per 100000 person-years compared with 20.1 per 100000 person-years among individuals not diagnosed with a neurological disorder. People diagnosed with a neurological disorder had an adjusted IRR of 1.8 (95% CI, 1.7-1.8) compared with those not diagnosed. The excess adjusted IRRs were 4.9 (95% CI, 3.5-6.9) for amyotrophic lateral sclerosis, 4.9 (95% CI, 3.1-7.7) for Huntington disease, 2.2 (95% CI, 1.9-2.6) for multiple sclerosis, 1.7 (95% CI, 1.6-1.7) for head injury, 1.3 (95% CI, 1.2-1.3) for stroke, and 1.7 (95% CI, 1.6-1.8) for epilepsy. The association varied according to time since diagnosis with an adjusted IRR for 1 to 3 months of 3.1 (95% CI, 2.7-3.6) and for 10 or more years, 1.5 (95% CI, 1.4 to 1.6, P < .001). Compared with those who were not diagnosed with a neurological disorder, those with dementia had a lower overall adjusted IRR of 0.8 (95% CI, 0.7-0.9), which was elevated during the first month after diagnosis to 3.0 (95% CI, 1.9-4.6; P < .001). The absolute risk of suicide for people with Huntington disease was 1.6% (95% CI, 1.0%-2.5%). Conclusions and Relevance In Denmark from 1980 through 2016, there was a significantly higher rate of suicide among those with a diagnosed neurological disorder than persons not diagnosed with a neurological disorder. However, the absolute risk difference was small.	[Erlangsen, Annette; Nordentoft, Merete] Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Gentofte Hosp Vej 15,4, DK-2900 Hellerup, Denmark; [Erlangsen, Annette] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Erlangsen, Annette] Univ Hosp Reg Southern Denmark, Dept Psychiat, Focused Res Unit, Aabenraa, Denmark; [Erlangsen, Annette] Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT, Australia; Hosp Southern Jutland, MS Clin Southern Jutland Sonderborg Esbjerg Koldi, Sonderborg, Denmark; Hosp Southern Jutland, Dept Neurol, Sonderborg, Denmark; [Stenager, Egon; Stenager, Elsebeth] Univ Southern Denmark, Dept Reg Hlth Res, Odense, Denmark; Hosp Southern Jutland, Ctr Sonderjylland, Focused Res Unit, Aabenraa, Denmark; [Conwell, Yeates] Univ Rochester, Med Ctr, Ctr Study & Prevent Suicide, Rochester, NY 14642 USA; [Andersen, Per Kragh] Univ Copenhagen, Sect Biostat, Copenhagen, Denmark; [Hawton, Keith] Univ Oxford, Ctr Suicide Res, Oxford, England; [Hawton, Keith] Oxford Hlth NHS Fdn Trust, Warnerford Hosp, Oxford, England; [Benros, Michael Eriksen; Nordentoft, Merete] Mental Hlth Ctr Copenhagen, Copenhagen Res Ctr Mental Hlth, Copenhagen, Denmark; [Nordentoft, Merete] Univ Copenhagen, Inst Clin Med, Copenhagen, Denmark	Erlangsen, A (corresponding author), Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Gentofte Hosp Vej 15,4, DK-2900 Hellerup, Denmark.	annette.erlangsen@regionh.dk	Benros, Michael Eriksen/N-5868-2016; Stenager, Egon/AAU-4463-2020; Erlangsen, Annette/A-7153-2017	Benros, Michael Eriksen/0000-0003-4939-9465; Erlangsen, Annette/0000-0003-3475-0558	Psychiatric Research Foundation; Region of Southern Denmark, Denmark	Supported by a grant from the Psychiatric Research Foundation, Region of Southern Denmark, Denmark.	Andersen PK, 2012, INT J EPIDEMIOL, V41, P861, DOI 10.1093/ije/dyr213; Bronnum-Hansen H, 2005, J NEUROL NEUROSUR PS, V76, P1457, DOI 10.1136/jnnp.2004.056747; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Cukrowicz KC, 2011, PSYCHOL AGING, V26, P331, DOI 10.1037/a0021836; Elman I, 2013, PROG NEUROBIOL, V109, P1, DOI 10.1016/j.pneurobio.2013.06.003; Erlangsen A, 2008, AM J GERIAT PSYCHIAT, V16, P220, DOI 10.1097/JGP.0b013e3181602a12; Erlangsen A, 2015, SOC PSYCH PSYCH EPID, V50, P1427, DOI 10.1007/s00127-015-1051-0; Erlangsen A, 2015, SCAND J PUBLIC HEALT, V43, P333, DOI 10.1177/1403494815575193; Fang F, 2008, BRAIN, V131, P2729, DOI 10.1093/brain/awn161; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X; Fernstrom J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176358; Forsstrom E, 2010, J NEUROPSYCH CLIN N, V22, P182, DOI 10.1176/appi.neuropsych.22.2.182; Fredrikson S, 2003, NEUROEPIDEMIOLOGY, V22, P146, DOI 10.1159/000068746; Haw C, 2009, INT PSYCHOGERIATR, V21, P440, DOI 10.1017/S1041610209009065; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Henson KE, 2019, JAMA PSYCHIAT, V76, P51, DOI 10.1001/jamapsychiatry.2018.3181; Hills M., 2013, STAT MODELS EPIDEMIO; Hubers AAM, 2015, J NEUROENDOCRINOL, V27, P234, DOI 10.1111/jne.12255; Lee T, 2016, PARKINSONISM RELAT D, V32, P102, DOI 10.1016/j.parkreldis.2016.09.006; Lund-Sorensen H, 2016, JAMA PSYCHIAT, V73, P912, DOI 10.1001/jamapsychiatry.2016.1594; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Madsen T, 2018, JAMA-J AM MED ASSOC, V320, P580, DOI 10.1001/jama.2018.10211; Mellion M, 2011, MUSCLE NERVE, V43, P309, DOI 10.1002/mus.21946; Merkies ISJ, 2016, EUR NEUROL, V75, P199, DOI 10.1159/000445347; Nakanishi M, 2014, ALZHEIMERS DEMENT, V10, P468, DOI 10.1016/j.jalz.2013.06.005; Nilsson FM, 2002, J NEUROL NEUROSUR PS, V73, P40, DOI 10.1136/jnnp.73.1.40; Nordentoft M, 2019, SCIENCE, V365, P725, DOI 10.1126/science.aaz1568; Patja K, 2001, ACTA PSYCHIAT SCAND, V103, P307, DOI 10.1034/j.1600-0447.2001.00019.x; Polsky D, 2005, ARCH INTERN MED, V165, P1260, DOI 10.1001/archinte.165.11.1260; Singhal A, 2014, J ROY SOC MED, V107, P194, DOI 10.1177/0141076814522033; Stenager EN, 1996, PSYCHOTHER PSYCHOSOM, V65, P86, DOI 10.1159/000289052; Stenager EN, 1997, DIS PAIN SUICIDAL BE; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teasdale TW, 2001, J EPIDEMIOL COMMUN H, V55, P863, DOI 10.1136/jech.55.12.863; Tian N, 2016, EPILEPSY BEHAV, V61, P210, DOI 10.1016/j.yebeh.2016.05.028; Tollefsen IM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009120; van Heeringen K, 2014, LANCET PSYCHIAT, V1, P63, DOI 10.1016/S2215-0366(14)70220-2; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; Webb RT, 2012, ARCH GEN PSYCHIAT, V69, P256, DOI 10.1001/archgenpsychiatry.2011.1561	40	17	17	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2020	323	5					444	454		10.1001/jama.2019.21834			11	Medicine, General & Internal	General & Internal Medicine	KL0PK	WOS:000513134700014	32016308	Bronze, Green Published			2021-06-18	
J	McCrea, M; Broglio, SP; McAllister, TW; Gill, J; Giza, CC; Huber, DL; Harezlak, J; Cameron, KL; Houston, MN; McGinty, G; Jackson, JC; Guskiewicz, K; Mihalik, J; Brooks, MA; Duma, S; Rowson, S; Nelson, LD; Pasquina, P; Meier, TB; Foroud, T; Katz, BP; Saykin, AJ; Campbell, DE; Svoboda, SJ; Goldman, J; DiFiori, J				McCrea, Michael; Broglio, Steven P.; McAllister, Thomas W.; Gill, Jessica; Giza, Christopher C.; Huber, Daniel L.; Harezlak, Jaroslaw; Cameron, Kenneth L.; Houston, Megan N.; McGinty, Gerald; Jackson, Jonathan C.; Guskiewicz, Kevin; Mihalik, Jason; Brooks, M. Alison; Duma, Stephan; Rowson, Steven; Nelson, Lindsay D.; Pasquina, Paul; Meier, Timothy B.; Foroud, Tatiana; Katz, Barry P.; Saykin, Andrew J.; Campbell, Darren E.; Svoboda, Steven J.; Goldman, Joshua; DiFiori, Jon		CARE Consortium Investigators	Association of Blood Biomarkers With Acute Sport-Related Concussion in Collegiate Athletes Findings From the NCAA and Department of Defense CARE Consortium	JAMA NETWORK OPEN			English	Article							TRAUMATIC BRAIN-INJURY	Question Is sport-related concussion associated with levels of traumatic brain injury biomarkers in collegiate athletes? Findings In this case-control study of 504 collegiate athletes with concussion, contact sport control athletes, and non-contact sport athletes, the athletes with concussion had significant elevations in multiple traumatic brain injury biomarkers compared with preseason baseline and with 2 groups of control athletes without concussion during the acute postinjury period. Meaning These results suggest that blood biomarkers can be used as research tools to inform the underlying pathophysiological mechanism of concussion and provide additional support for future studies to optimize and validate biomarkers for potential clinical use in sport-related concussion. This case-control study examines the association between sport-related concussion and levels of traumatic brain injury biomarkers in collegiate athletes. Importance There is potential scientific and clinical value in validation of objective biomarkers for sport-related concussion (SRC). Objective To investigate the association of acute-phase blood biomarker levels with SRC in collegiate athletes. Design, Setting, and Participants This multicenter, prospective, case-control study was conducted by the National Collegiate Athletic Association (NCAA) and the US Department of Defense Concussion Assessment, Research, and Education (CARE) Consortium from February 20, 2015, to May 31, 2018, at 6 CARE Advanced Research Core sites. A total of 504 collegiate athletes with concussion, contact sport control athletes, and non-contact sport control athletes completed clinical testing and blood collection at preseason baseline, the acute postinjury period, 24 to 48 hours after injury, the point of reporting being asymptomatic, and 7 days after return to play. Data analysis was conducted from March 1 to November 30, 2019. Main Outcomes and Measures Glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), neurofilament light chain, and tau were quantified using the Quanterix Simoa multiplex assay. Clinical outcome measures included the Sport Concussion Assessment Tool-Third Edition (SCAT-3) symptom evaluation, Standardized Assessment of Concussion, Balance Error Scoring System, and Brief Symptom Inventory 18. Results A total of 264 athletes with concussion (mean [SD] age, 19.08 [1.24] years; 211 [79.9%] male), 138 contact sport controls (mean [SD] age, 19.03 [1.27] years; 107 [77.5%] male), and 102 non-contact sport controls (mean [SD] age, 19.39 [1.25] years; 82 [80.4%] male) were included in the study. Athletes with concussion had significant elevation in GFAP (mean difference, 0.430 pg/mL; 95% CI, 0.339-0.521 pg/mL; P < .001), UCH-L1 (mean difference, 0.449 pg/mL; 95% CI, 0.167-0.732 pg/mL; P < .001), and tau levels (mean difference, 0.221 pg/mL; 95% CI, 0.046-0.396 pg/mL; P = .004) at the acute postinjury time point compared with preseason baseline. Longitudinally, a significant interaction (group x visit) was found for GFAP (F-7,F-1507.36 = 16.18, P < .001), UCH-L1 (F-7,F-1153.09 = 5.71, P < .001), and tau (F-7,F-1480.55 = 6.81, P < .001); the interaction for neurofilament light chain was not significant (F-7,F-1506.90 = 1.33, P = .23). The area under the curve for the combination of GFAP and UCH-L1 in differentiating athletes with concussion from contact sport controls at the acute postinjury period was 0.71 (95% CI, 0.64-0.78; P < .001); the acute postinjury area under the curve for all 4 biomarkers combined was 0.72 (95% CI, 0.65-0.79; P < .001). Beyond SCAT-3 symptom score, GFAP at the acute postinjury time point was associated with the classification of athletes with concussion from contact controls (beta = 12.298; 95% CI, 2.776-54.481; P = .001) and non-contact sport controls (beta = 5.438; 95% CI, 1.676-17.645; P = .005). Athletes with concussion with loss of consciousness or posttraumatic amnesia had significantly higher levels of GFAP than athletes with concussion with neither loss of consciousness nor posttraumatic amnesia at the acute postinjury time point (mean difference, 0.583 pg/mL; 95% CI, 0.369-0.797 pg/mL; P < .001). Conclusions and Relevance The results suggest that blood biomarkers can be used as research tools to inform the underlying pathophysiological mechanism of concussion and provide additional support for future studies to optimize and validate biomarkers for potential clinical use in SRC.	[McCrea, Michael; Huber, Daniel L.; Nelson, Lindsay D.; Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Broglio, Steven P.] Univ Michigan, Michigan Concuss Ctr, Ann Arbor, MI 48109 USA; [McAllister, Thomas W.; Foroud, Tatiana; Katz, Barry P.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA; [Giza, Christopher C.; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, UCLA Steve Tisch BrainSPORT Program, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, Dept Pediat, UCLA Steve Tisch BrainSPORT Program, Los Angeles, CA 90024 USA; [Harezlak, Jaroslaw] Indiana Univ, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA; [Cameron, Kenneth L.; Houston, Megan N.; Svoboda, Steven J.] Keller Army Community Hosp, West Point, NY USA; [McGinty, Gerald; Jackson, Jonathan C.; Campbell, Darren E.] US Air Force Acad, Colorado Springs, CO 80840 USA; [Guskiewicz, Kevin; Mihalik, Jason] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA; [Brooks, M. Alison] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped & Rehabil, Madison, WI USA; [Duma, Stephan; Rowson, Steven] Virginia Polytech Inst & State Univ, Dept Biomed Engn, Blacksburg, VA 24061 USA; [Pasquina, Paul] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD USA	McCrea, M (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mmccrea@mcw.edu	Rowson, Steven/B-1270-2012; Harezlak, Jaroslaw/P-8557-2014	Rowson, Steven/0000-0002-3227-0596; Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - NCAA; DODUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This work received support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium funded in part by the NCAA and the DOD andwas supported by award W81XWH-14-2-0151 from the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Dadas A, 2018, NEUROPSYCH DIS TREAT, V14, P2989, DOI 10.2147/NDT.S125620; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Klein AP, 2019, J NEUROTRAUM, V36, P1776, DOI 10.1089/neu.2018.6055; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Lewis LM, 2017, ACAD EMERG MED, V24, P710, DOI 10.1111/acem.13174; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; Meier TB, 2017, J NEUROTRAUM, V34, P3134, DOI 10.1089/neu.2017.5046; Papa L, 2015, BRAIN NEUROTRAUMA MO, DOI [DOI 10.1201/B18126-27, 10.1201/b18126-27]; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014; Wechsler D., 2001, WECHSLER TEST ADULT; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	17	17	17	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	JAN 24	2020	3	1							e1919771	10.1001/jamanetworkopen.2019.19771			16	Medicine, General & Internal	General & Internal Medicine	KF5YS	WOS:000509318000006	31977061	DOAJ Gold, Green Published			2021-06-18	
J	Lumba-Brown, A; Teramoto, M; Bloom, OJ; Brody, D; Chesnutt, J; Clugston, JR; Collins, M; Gioia, G; Kontos, A; Lal, A; Sills, A; Ghajar, J				Lumba-Brown, Angela; Teramoto, Masaru; Bloom, O. Josh; Brody, David; Chesnutt, James; Clugston, James R.; Collins, Michael; Gioia, Gerard; Kontos, Anthony; Lal, Avtar; Sills, Allen; Ghajar, Jamshid			Concussion Guidelines Step 2: Evidence for Subtype Classification	NEUROSURGERY			English	Article						Concussion; subtype; systematic review; meta-analysis; mild traumatic brain injury; head injury; oculomotor; vestibular; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; SYMPTOMS; SLEEP; METAANALYSIS; RECOVERY; SENSITIVITY; DISORDERS; MIGRAINE	BACKGROUND: Concussion is a heterogeneous mild traumatic brain injury (mTBI) characterized by a variety of symptoms, clinical presentations, and recovery trajectories. By thematically classifying the most common concussive clinical presentations into concussion subtypes (cognitive, ocular-motor, headache/migraine, vestibular, and anxiety/mood) and associated conditions (cervical strain and sleep disturbance), we derive useful definitions amenable to future targeted treatments. OBJECTIVE: To use evidence-based methodology to characterize the 5 concussion subtypes and 2 associated conditions and report their prevalence in acute concussion patients as compared to baseline or controls within 3 d of injury. METHODS: A multidisciplinary expert workgroup was established to define the most common concussion subtypes and their associated conditions and select clinical questions related to prevalence and recovery. A literature search was conducted from January 1, 1990 to November 1, 2017. Two experts abstracted study characteristics and results independently for each article selected for inclusion. A third expert adjudicated disagreements. Separate meta-analyses were conducted to do the following: 1) examine the prevalence of each subtype/associated condition in concussion patients using a proportion, 2) assess subtype/associated conditions in concussion compared to baseline/uninjured controls using a prevalence ratio, and 3) compare the differences in symptom scores between concussion subtypes and uninjured/baseline controls using a standardized mean difference (SMD). RESULTS: The most prevalent concussion subtypes for pediatric and adult populations were headache/migraine (0.52; 95% CI = 0.37, 0.67) and cognitive (0.40; 95% CI = 0.25, 0.55), respectively. In pediatric patients, the prevalence of the vestibular subtype was also high (0.50; 95% CI = 0.40, 0.60). Adult patients were 4.4, 2.9, and 1.7 times more likely to demonstrate cognitive, vestibular, and anxiety/mood subtypes, respectively, as compared with their controls (P < .05). Children and adults with concussion showed significantly more cognitive symptoms than their respective controls (SMD = 0.66 and 0.24; P < .001). Furthermore, ocular-motor in adult patients (SMD = 0.72; P < .001) and vestibular symptoms in both pediatric and adult patients (SMD = 0.18 and 0.36; P < .05) were significantly worse in concussion patients than in controls. CONCLUSION: Five concussion subtypes with varying prevalence within 3 d following injury are commonly seen clinically and identifiable upon systematic literature review. Sleep disturbance, a concussion-associated condition, is also common. There was insufficient information available for analysis of cervical strain. A comprehensive acute concussion assessment defines and characterizes the injury and, therefore, should incorporate evaluations of all 5 subtypes and associated conditions.	[Lumba-Brown, Angela] Stanford Univ, Brain Performance Ctr, Dept Emergency Med, Stanford, CA 94305 USA; [Teramoto, Masaru] Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT USA; [Bloom, O. Josh] Carolina Sports Concuss Clin, Cary, NC USA; [Brody, David] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Orthoped & Rehabil, Portland, OR 97201 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Collins, Michael; Kontos, Anthony] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Gioia, Gerard] George Washington Univ, Sch Med, Div Pediat Neuropsychol,Dept Pediat, Safe Concuss Outcome Recovery & Educ Program,Chil, Rockville, MD USA; [Gioia, Gerard] George Washington Univ, Sch Med, Div Pediat Neuropsychol,Dept Psychiat & Behav Sci, Safe Concuss Outcome Recovery & Educ Program,Chil, Rockville, MD USA; [Kontos, Anthony] Univ Pittsburgh, Dept Sports Med & Rehabil, Pittsburgh, PA USA; [Lal, Avtar] Stanford Univ, Concuss & Brain Performance Ctr, Dept Neurosurg, Stanford, CA 94305 USA; [Sills, Allen] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN USA; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Ghajar, Jamshid] Stanford Univ, Brain Performance Ctr, Dept Neurosurg, Stanford, CA 94305 USA	Lumba-Brown, A (corresponding author), 900 Welch Rd 350,MC 5119, Palo Alto, CA 94304 USA.	alumba@stanford.edu		Clugston, James/0000-0002-2103-1039; Lumba-Brown, Angela/0000-0002-9102-8791	US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision [W911 QY-14-C-0086]	This material is based in part upon work supported by (1) the US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision, through a contract awarded to Stanford University (W911 QY-14-C-0086). Any opinions, findings, and conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, or Stanford University. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Borenstein M., 2009, INTRO METAANALYSIS; Bradburn MJ, 2016, METAANALYSIS STATA U, P3; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cheever K, 2016, J ATHL TRAINING, V51, P1037, DOI 10.4085/1062-6050-51.12.15; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Cohen J, 1988, STAT POWER ANAL BEHA; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Craton N, 2014, CLIN J SPORT MED, V24, P93, DOI 10.1097/JSM.0000000000000023; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; de Dhaem OB, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0767-5; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; DoD Clinical Recommendation, 2014, MAN SLEEP DISTR FOLL; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Fu R, 2008, METHODS GUIDE EFFECT; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Harbord RM, 2009, STATA J, V9, P197, DOI 10.1177/1536867X0900900202; Harris RJ, 2016, METAANALYSIS STATA U, P3; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holcomb EM, 2016, J HEAD TRAUMA REHAB, V31, P82, DOI 10.1097/HTR.0000000000000230; Howell DR, 2019, CLIN J SPORT MED, V29, P391, DOI 10.1097/JSM.0000000000000629; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kontos AP, 2017, J ATHL TRAINING, V52, P256, DOI 10.4085/1062-6050-51.11.05; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Lim MM, 2018, SLEEP WAKE DISORDERS; Lumba-Brown A, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.2847; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; Maruta J, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01034; Maruta J, 2017, MIL MED, V182, P120, DOI 10.7205/MILMED-D-16-00093; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Mucha A, 2018, HAND CLINIC, V158, P135, DOI 10.1016/B978-0-444-63954-7.00014-8; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nance ML, 2016, BRAIN INJURY, V30, P184, DOI 10.3109/02699052.2015.1075591; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39; Pac-12, 2019, STUD ATHL HLTH WELL; Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rizzoli P, 2018, AM J MED, V131, P17, DOI 10.1016/j.amjmed.2017.09.005; Saltychev M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008756; Sandel N, 2017, SPORT EXERC PERFORM, V6, P304, DOI 10.1037/spy0000098; Sandsmark DK, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx044; Sateia MJ, 2014, CHEST, V146, P1387, DOI 10.1378/chest.14-0970; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Seifert T, 2018, HAND CLINIC, V158, P119, DOI 10.1016/B978-0-444-63954-7.00012-4; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; St-Onge MP, 2014, INT J OBESITY, V38, P411, DOI 10.1038/ijo.2013.114; Starkey NJ, 2018, BRAIN INJURY, V32, P617, DOI 10.1080/02699052.2018.1439533; Steichen T., 2000, STATA TECHNICAL B, V61, P8; Stone ME, 2015, J TRAUMA ACUTE CARE, V79, P147, DOI 10.1097/TA.0000000000000679; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sufrinko A, 2018, J HEAD TRAUMA REHAB, V33, P7, DOI 10.1097/HTR.0000000000000315; Sufrinko A, 2015, AM J SPORT MED, V43, P830, DOI 10.1177/0363546514566193; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Sutton AJ., 2000, METHODS METAANALYSIS; Thomasy HE, 2019, J NEUROTRAUM, V36, P802, DOI 10.1089/neu.2018.5810; Tobias A., 2001, STATA TECH B, V10; Tobias A., 1999, STATA TECHN B, V47, P15; Wickwire EM, 2016, NEUROTHERAPEUTICS, V13, P403, DOI 10.1007/s13311-016-0429-3; Wiener-Vacher SR, 2013, FRONT INTEGR NEUROSC, V20, P245; Zaremski JL, 2015, CURR SPORT MED REP, V14, P16, DOI 10.1249/JSR.0000000000000121	80	17	17	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2020	86	1					2	13		10.1093/neuros/nyz332			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LS6QI	WOS:000536505700004	31432081	Green Published, Other Gold			2021-06-18	
J	Sims, CA; Holena, D; Kim, P; Pascual, J; Smith, B; Martin, N; Seamon, M; Shiroff, A; Raza, S; Kaplan, L; Grill, E; Zimmerman, N; Mason, C; Abella, B; Reilly, P				Sims, Carrie A.; Holena, Daniel; Kim, Patrick; Pascual, Jose; Smith, Brian; Martin, Neils; Seamon, Mark; Shiroff, Adam; Raza, Shariq; Kaplan, Lewis; Grill, Elena; Zimmerman, Nicole; Mason, Christopher; Abella, Benjamin; Reilly, Patrick			Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial	JAMA SURGERY			English	Article							VENOUS THROMBOEMBOLISM; LIVER TRAUMA; RISK; RESUSCITATION; SURVIVAL; DESMOPRESSIN; ASSOCIATION; MECHANISMS; INJURY; VASODILATION	Key PointsQuestionDoes low-dose arginine vasopressin supplementation decrease the need for blood product transfusions in patients with trauma and hemorrhagic shock? FindingsIn this randomized clinical trial of 100 adult trauma patients in hemorrhagic shock, arginine vasopressin supplementation significantly decreased the volume of blood products given in the first 48 hours by a median of 1.4 L without increasing complications. MeaningIncluding low-dose arginine vasopressin supplementation when resuscitating trauma patients in hemorrhagic shock may safely decrease the need for blood products. This randomized clinical trial assesses whether low-dose supplementation of arginine vasopressin during the resuscitation of hemorrhagic shock decreases the need for transfusions in patients with trauma. ImportanceCurrent therapies for traumatic blood loss focus on hemorrhage control and blood volume replacement. Severe hemorrhagic shock, however, is associated with a state of arginine vasopressin (AVP) deficiency, and supplementation of this hormone may decrease the need for blood products in resuscitation. ObjectiveTo determine whether low-dose supplementation of AVP in patients with trauma (hereinafter referred to as trauma patients) and with hemorrhagic shock decreases their need for transfused blood products during resuscitation. Design, Setting, and ParticipantsThis randomized, double-blind placebo-controlled clinical trial included adult trauma patients (aged 18-65 years) who received at least 6 U of any blood product within 12 hours of injury at a single urban level 1 trauma center from May 1, 2013, through May 31, 2017. Exclusion criteria consisted of prehospital cardiopulmonary resuscitation, emergency department thoracotomy, corticosteroid use, chronic renal insufficiency, coronary artery disease, traumatic brain injury requiring any neurosurgical intervention, pregnancy, prisoner status, or AVP administration before enrollment. Data were analyzed from May 1, 2013, through May 31, 2017, using intention to treat and per protocol. InterventionsAfter administration of an AVP bolus (4 U) or placebo, participants received AVP (<= 0.04 U/min) or placebo for 48 hours to maintain a mean arterial blood pressure of at least 65 mm Hg. Main OutcomesThe primary outcome was total volume of blood product transfused. Secondary end points included total volume of crystalloid transfused, vasopressor requirements, secondary complications, and 30-day mortality. ResultsOne hundred patients underwent randomization (49 to the AVP group and 51 to the placebo group). Patients were primarily young (median age, 27 years [interquartile range {IQR}, 22-25 years]) and male (n=93) with penetrating trauma (n=79). Cohort characteristics before randomization were well balanced. At 48 hours, patients who received AVP required significantly less blood products (median, 1.4 [IQR, 0.5-2.6] vs 2.9 [IQR, 1.1-4.8] L; P=.01) but did not differ in requirements for crystalloids (median, 9.9 [IQR, 7.9-13.0] vs 11.0 [8.9-15.0] L; P=.22) or vasopressors (median, 400 [IQR, 0-5900] vs 1400 [IQR, 200-7600] equivalent units; P=.22). Although the groups had similar rates of mortality (6 of 49 [12%] vs 6 of 51 [12%]; P=.94) and total complications (24 of 44 [55%] vs 30 of 47 [64%]; P=.37), the AVP group had less deep venous thrombosis (5 of 44 [11%] vs 16 of 47 [34%]; P=.02). Conclusions and RelevanceLow-dose AVP during the resuscitation of trauma patients in hemorrhagic shock decreases blood product requirements. Additional research is necessary to determine whether including AVP improves morbidity or mortality. Trial RegistrationClinicalTrials.gov identifier: NCT01611935	[Sims, Carrie A.; Holena, Daniel; Kim, Patrick; Pascual, Jose; Smith, Brian; Martin, Neils; Seamon, Mark; Shiroff, Adam; Raza, Shariq; Kaplan, Lewis; Grill, Elena; Reilly, Patrick] Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 51N 39th St Med Off Bldg Ste120, Philadelphia, PA 19104 USA; [Sims, Carrie A.] Univ Penn, Perelman Sch Med, PARC, Philadelphia, PA 19104 USA; [Holena, Daniel] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Zimmerman, Nicole] Cleveland Clin Fdn, Dept Quantitat Hlth Sci & Outcomes Res, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Mason, Christopher] Univ Penn, Perelman Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA; [Abella, Benjamin] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA	Sims, CA (corresponding author), Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 51N 39th St Med Off Bldg Ste120, Philadelphia, PA 19104 USA.	carrie.sims@uphs.upenn.edu	Seamon, Mark/AAM-4713-2021	Holena, Daniel/0000-0003-3424-5754	National Trauma Institute [NTI-TRA-09-062]; Department of the Army [W81XWH-10-0924]	This study was supported by award NTI-TRA-09-062 from the National Trauma Institute and prime award W81XWH-10-0924 from the Department of the Army (Dr Sims).	Al-Refaie WB, 2012, SURGERY, V152, P344, DOI 10.1016/j.surg.2012.06.008; ALTURA BM, 1980, EXPERIENTIA, V36, P1080, DOI 10.1007/BF01965981; American College of Surgeons, 2018, ADV TRAUM LIF SUPP 1; [Anonymous], 2015, PENNS OUTC PERF IMPR; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Barrett LK, 2007, CRIT CARE MED, V35, P33, DOI 10.1097/01.CCM.0000251127.45385.CD; Bolland K, 2000, STAT MED, V19, P2899, DOI 10.1002/1097-0258(20001115)19:21<2899::AID-SIM597>3.0.CO;2-O; Boutin A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014472; Brown SM, 2013, CHEST, V143, P664, DOI 10.1378/chest.12-1106; Cohn SM, 2013, J TRAUMA ACUTE CARE, V75, P620, DOI 10.1097/TA.0b013e31829eff31; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Collier B, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.05.003; Colucci G, 2014, BLOOD, V123, P1905, DOI 10.1182/blood-2013-04-497123; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dhillon NK, 2018, J SURG RES, V222, P115, DOI 10.1016/j.jss.2017.09.038; Douros A, 2016, BRIT J CLIN PHARMACO, V82, P839, DOI 10.1111/bcp.13019; EDWARDS RM, 1989, AM J PHYSIOL, V256, pF274; ERRINGTON ML, 1972, J PHYSIOL-LONDON, V227, P395, DOI 10.1113/jphysiol.1972.sp010039; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Glance LG, 2011, ANESTHESIOLOGY, V114, P283, DOI 10.1097/ALN.0b013e3182054d06; Goel R, 2018, JAMA SURG, V153, P826, DOI 10.1001/jamasurg.2018.1565; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Heron Melonie, 2018, Natl Vital Stat Rep, V67, P1; Holmes CL, 2004, CRIT CARE, V8, P15, DOI 10.1186/cc2338; Karcutskie CA, 2017, JAMA SURG, V152, P35, DOI 10.1001/jamasurg.2016.3116; Kaufmann JE, 2003, J THROMB HAEMOST, V1, P682, DOI 10.1046/j.1538-7836.2003.00190.x; Landry DW, 1997, CIRCULATION, V95, P1122; Landry DW, 2001, NEW ENGL J MED, V345, P588, DOI 10.1056/NEJMra002709; Landy DW, 1997, CRIT CARE MED, V25, P1279, DOI 10.1097/00003246-199708000-00012; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; MOHRING J, 1980, J CARDIOVASC PHARM, V2, P367; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Oliver JA, 2007, CURR OPIN CRIT CARE, V13, P376, DOI 10.1097/MCC.0b013e3282435e16; Pecci A, 2014, BLOOD, V123, P1779, DOI 10.1182/blood-2014-01-551242; RUDICHENKO VM, 1995, J VASC RES, V32, P100, DOI 10.1159/000159082; Russell JA, 2010, J INNATE IMMUN, V2, P446, DOI 10.1159/000318531; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Sims CA, 2017, AM J SURG, V214, P589, DOI 10.1016/j.amjsurg.2017.06.015; Sims CA, 2013, J TRAUMA ACUTE CARE, V74, P157, DOI 10.1097/TA.0b013e318278908a; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Turan A, 2013, CAN J ANESTH, V60, P761, DOI 10.1007/s12630-013-9937-3; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; WILLIAMS TDM, 1986, CLIN SCI, V71, P173, DOI 10.1042/cs0710173; Xenos ES, 2012, THROMB RES, V129, P568, DOI 10.1016/j.thromres.2011.07.047	49	17	17	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	NOV	2019	154	11					994	1003		10.1001/jamasurg.2019.2884			10	Surgery	Surgery	JT9LP	WOS:000501303100004	31461138	Bronze, Green Published			2021-06-18	
J	Trivedi, B; Kesterke, MJ; Bhattacharjee, R; Weber, W; Mynar, K; Reddy, LV				Trivedi, Bhavin; Kesterke, Matthew J.; Bhattacharjee, Ritesh; Weber, William; Mynar, Karen; Reddy, Likith, V			Craniofacial Injuries Seen With the Introduction of Bicycle-Share Electric Scooters in an Urban Setting	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							BIKE-SHARE; USERS; ROAD	Purpose: Standing electric scooters (e-scooters) are rapidly becoming popular modes of transportation in many urban areas across the United States. However, this increase in popularity has resulted in an increase in traumatic injuries associated with these modes of expedient travel. The purpose of the present study was to determine the types of craniofacial trauma directly related to e-scooter use in a major urban center (Dallas, TX). Materials and Methods: We performed a retrospective case series and examined the medical records of the patients who had presented to the emergency department (ED) for trauma related to e-scooter use. Descriptive statistics were calculated for all variables on patient presentation, including incident notes and patient interviews, demographic information, diagnostic tests, trauma (ie, location, type, severity), treatment (ie, type, admission, outpatient referral, follow-up data), and contributing factors (ie, reported or detected alcohol use, use of protective equipment). Results: A total of 90 patients (56 males, 34 females; mean age, 31.8 years) had presented with scooter-related trauma to the ED during the first 7 months of scooters after their introduction to the metropolitan area. A total of 52 admissions (58% of all admissions) involved injuries of the head and face. The patients had presented with a myriad of craniofacial trauma, ranging from abrasions, lacerations, and concussions to intracranial hemorrhage and Le Fort II and III fractures. Of the 52 craniofacial injuries, 30 (58%) were considered severe (ie, fracture, internal hemorrhage, concussion, loss of consciousness), and 22 (42%) were considered minor (ie, lacerations, contusion, abrasion, dental). Alcohol use had been involved in 18% of all scooter-related trauma admissions, and no rider had reported wearing a helmet. Conclusions: Injuries to the head and face were commonly found with e-scooter admissions in this sample, and the high prevalence of extremity injuries suggested that patients were breaking their fall during the crash. Craniofacial trauma related to e-scooter use could be significantly reduced by the wearing of a protective helmet. Published by Elsevier Inc. on behalf of the American Association of Oral and Maxillofacial Surgeons	[Trivedi, Bhavin; Reddy, Likith, V] Texas A&M Coll Dent, Dept Oral & Maxillofacial Surg, Dallas, TX 75246 USA; [Trivedi, Bhavin] Baylor Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Waco, TX 76798 USA; [Trivedi, Bhavin] US Navy Dent Corps, Dallas, TX USA; [Kesterke, Matthew J.; Bhattacharjee, Ritesh] Texas A&M Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA; [Weber, William; Mynar, Karen] Baylor Univ, Med Ctr, Div Trauma Crit Care & Acute Care Surg, Dallas, TX USA; [Reddy, Likith, V] Texas A&M Coll Dent, Residency Program, Dallas, TX 75246 USA; [Reddy, Likith, V] Baylor Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Dallas, TX USA	Kesterke, MJ (corresponding author), Texas A&M Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA.	kesterke@tamu.edu					Allem JP, 2019, PREV MED REP, V13, P62, DOI 10.1016/j.pmedr.2018.11.013; [Anonymous], 2018, BIC OTH CYCL 2016 DA; Bach T, US NEWS WORLD REPORT; Fishman E, 2016, J SAFETY RES, V56, P41, DOI 10.1016/j.jsr.2015.11.007; Friedman SM, 2016, CAN J EMERG MED, V18, P28, DOI 10.1017/cem.2015.22; Graves JM, 2014, AM J PUBLIC HEALTH, V104, pE106, DOI 10.2105/AJPH.2014.302012; Griffin R, 2008, AMBUL PEDIATR, V8, P379, DOI 10.1016/j.ambp.2008.08.002; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Langford BC, 2015, ACCIDENT ANAL PREV, V82, P220, DOI 10.1016/j.aap.2015.05.016; Papoutsi S, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/850236; Popovich N, 2014, TRAVEL BEHAV SOC, V1, P37, DOI 10.1016/j.tbs.2013.10.006; Rogers M, DOCKLESS VEHICLES PR; Siman-Tov M, 2018, J TRANSP HEALTH, V11, P176, DOI 10.1016/j.jth.2018.10.013; Trivedi TK, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7381; Yao L, 2012, TRANSPORT RES REC, P49, DOI 10.3141/2314-07	15	17	17	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	NOV	2019	77	11					2292	2297		10.1016/j.joms.2019.07.014			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	JH9KD	WOS:000493086000018	31454504	Bronze			2021-06-18	
J	Voormolen, DC; Haagsma, JA; Polinder, S; Maas, AIR; Steyerberg, EW; Vulekovic, P; Sewalt, CA; Gravesteijn, BY; Covic, A; Andelic, N; Plass, AM; von Steinbuechel, N				Voormolen, Daphne C.; Haagsma, Juanita A.; Polinder, Suzanne; Maas, Andrew I. R.; Steyerberg, Ewout W.; Vulekovic, Petar; Sewalt, Charlie A.; Gravesteijn, Benjamin Y.; Covic, Amra; Andelic, Nada; Plass, Anne Marie; von Steinbuechel, Nicole		CTR-TBI Participants Investigators	Post-Concussion Symptoms in Complicated vs. Uncomplicated Mild Traumatic Brain Injury Patients at Three and Six Months Post-Injury: Results from the CENTER-TBI Study	JOURNAL OF CLINICAL MEDICINE			English	Article						complicated mild traumatic brain injury; post-concussion symptoms; post-concussion syndrome; traumatic brain injury	POSTCONCUSSION SYNDROME; HEAD-INJURY; RISK-FACTORS; PREVALENCE; RATES; CARE	The aim of this study was to assess the occurrence of post-concussion symptoms and post-concussion syndrome (PCS) in a large cohort of patients after complicated and uncomplicated mild traumatic brain injury (mTBI) at three and six months post-injury. Patients were included through the prospective cohort study: Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI). Patients enrolled with mTBI (Glasgow Coma Scale 13-15) were further differentiated into complicated and uncomplicated mTBI based on the presence or absence of computed tomography abnormalities, respectively. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) assessed post-concussion symptoms and PCS according to the mapped ICD-10 classification method. The occurrence of post-concussion symptoms and syndrome at both time points was calculated. Chi square tests were used to test for differences between and within groups. Logistic regression was performed to analyse the association between complicated versus uncomplicated mTBI and the prevalence of PCS. Patients after complicated mTBI reported slightly more post-concussion symptoms compared to those after uncomplicated mTBI. A higher percentage of patients after complicated mTBI were classified as having PCS at three (complicated: 46% vs. uncomplicated: 35%) and six months (complicated: 43% vs. uncomplicated 34%). After adjusting for baseline covariates, the effect of complicated versus uncomplicated mTBI at three months appeared minimal: odds ratio 1.25 (95% confidence interval: 0.95-1.66). Although patients after complicated mTBI report slightly more post-concussion symptoms and show higher PCS rates compared to those after uncomplicated mTBI at three and six months, complicated mTBI was only found a weak indicator for these problems.	[Voormolen, Daphne C.; Haagsma, Juanita A.; Polinder, Suzanne; Steyerberg, Ewout W.; Sewalt, Charlie A.; Gravesteijn, Benjamin Y.] Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Haagsma, Juanita A.] Erasmus MC, Dept Emergency Med, Univ Med Ctr Rotterdam, NL-3000 CA Rotterdam, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Dept Neurosurg, B-2000 Edegem, Belgium; [Steyerberg, Ewout W.] Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, NL-2333 ZA Leiden, Netherlands; [Vulekovic, Petar] Clin Ctr Vojvodina, Clin Neurosurg, Novi Sad 21000, Serbia; [Covic, Amra; Plass, Anne Marie; von Steinbuechel, Nicole] UMG, Inst Med Psychol & Med Sociol, D-37075 Gottingen, Germany; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0372 Oslo, Norway; [Andelic, Nada] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, N-0318 Oslo, Norway	Voormolen, DC (corresponding author), Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl; j.haagsma@erasmusmc.nl; s.polinder@erasmusmc.nl; Andrew.Maas@uza.be; e.steyerberg@erasmusmc.nl; pvulekovic@gmail.com; c.sewalt@erasmusmc.nl; b.gravesteijn@erasmusmc.nl; amra.covic@med.uni-goettingen.de; nandelic@online.no; annemarie.plass@med.uni-goettingen.de; nvsteinbuechel@med.uni-goettingen.de	Posti, Jussi P./Y-2908-2019; Gravesteijn, Benjamin/AAN-9524-2020; Maas, Andrew I.R./C-5584-2013	Posti, Jussi P./0000-0002-5925-5193; Plass, Anne Marie/0000-0002-7801-9655; Maas, Andrew I.R./0000-0003-1612-1264	Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); Neurotrauma Sciences (USA); European Union 7th Framework program (EC) [602150]	CENTER-TBI was supported by the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA) and from Neurotrauma Sciences (USA).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gladitz J, 1989, BIOMETRICAL J, V31, P131, DOI DOI 10.1002/bimj.4710310118; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00489; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 2013, BRAIN IMPAIR, V14, P235, DOI 10.1017/BrImp.2013.17; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kondiles BR, 2015, HEALTH PSYCHOL BEHAV, V3, P1, DOI 10.1080/21642850.2014.966717; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Plass AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210138; Polinder S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01113; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Van Buuren S., 2012, FLEXIBLE IMPUTATION; van Buuren S, 2011, J STAT SOFTW, V45, P1; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Voormolen DC, 2019, BRAIN INJURY, V33, P1078, DOI 10.1080/02699052.2019.1607557; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	39	17	17	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2077-0383		J CLIN MED	J. Clin. Med.	NOV	2019	8	11							1921	10.3390/jcm8111921			14	Medicine, General & Internal	General & Internal Medicine	JV3VR	WOS:000502294400164	31717436	DOAJ Gold, Green Published			2021-06-18	
J	Davis, GA; Makdissi, M; Bloomfield, P; Clifton, P; Echemendia, RJ; Falvey, EC; Fuller, GW; Green, G; Harcourt, P; Hill, T; McGuirk, N; Meeuwisse, W; Orchard, J; Raftery, M; Sills, AK; Solomon, GS; Valadka, A; McCrory, P				Davis, Gavin A.; Makdissi, Michael; Bloomfield, Paul; Clifton, Patrick; Echemendia, Ruben J.; Falvey, Eanna Cian; Fuller, Gordon Ward; Green, Gary; Harcourt, Peter; Hill, Thomas; McGuirk, Nathan; Meeuwisse, Willem; Orchard, John; Raftery, Martin; Sills, Allen K.; Solomon, Gary S.; Valadka, Alex; McCrory, Paul			International consensus definitions of video signs of concussion in professional sports	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							HOCKEY LEAGUE NHL; MANAGEMENT	Background The use of video to assist professional sporting bodies with the diagnosis of sport-related concussion (SRC) has been well established; however, there has been little consistency across sporting codes with regards to which video signs should be used, and the definitions of each of these signs. Aim The aims of this study were to develop a consensus for the video signs considered to be most useful in the identification of a possible SRC and to develop a consensus definition for each of these video signs across the sporting codes. Methods A brief questionnaire was used to assess which video signs were considered to be most useful in the identification of a possible concussion. Consensus was defined as >90% agreement by respondents. Existing definitions of these video signs from individual sports were collated, and individual components of the definitions were assessed and ranked. A modified Delphi approach was then used to create a consensus definition for each of the video signs. Results Respondents representing seven sporting bodies (Australian Football League, Cricket Australia, Major League Baseball, NFL, NHL, National Rugby League, World Rugby) reached consensus on eight video signs of concussion. Thirteen representatives from the seven professional sports ranked the definition components. Consolidation and refinement of the video signs and their definitions resulted in consensus definitions for six video signs of possible concussion: lying motionless, motor incoordination, impact seizure, tonic posturing, no protective action-floppy and blank/vacant look. Conclusions These video signs and definitions have reached international consensus, are indicated for use by professional sporting bodies and will form the basis for further collaborative research.	[Davis, Gavin A.; Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia; [Davis, Gavin A.] Cabrini Hosp, Neurosurg, Malvern, Vic, Australia; [Makdissi, Michael] La Trobe Sport & Exercise Med Res Ctr, Melbourne, Vic, Australia; [Bloomfield, Paul; McGuirk, Nathan] NRL, Sydney, NSW, Australia; [Clifton, Patrick; Harcourt, Peter] Australian Football League, Melbourne, Vic, Australia; [Echemendia, Ruben J.] Natl Hockey League, Philadelphia, PA USA; [Falvey, Eanna Cian; Raftery, Martin] World Rugby, Dublin, Ireland; [Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Green, Gary; Valadka, Alex] Major League Baseball, New York, NY USA; [Hill, Thomas] Cricket Australia, Melbourne, Vic, Australia; [Meeuwisse, Willem] Natl Hockey League, Calgary, AB, Canada; [Orchard, John] Cricket Australia, Sydney, NSW, Australia; [Sills, Allen K.; Solomon, Gary S.] Natl Football League, New York, NY USA; [McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Melbourne Brain Ctr, Austin Campus, Heidelberg, Vic, Australia	Davis, GA (corresponding author), Cabrini Malvern, Neurosurg, Suite 53,Wattletree Rd, Malvern, Vic 3144, Australia.	gavin.davis@me.com	Orchard, John W/AAY-7216-2020	Orchard, John W/0000-0003-3530-1711; Echemendia, Ruben/0000-0001-6116-8462; Davis, Gavin/0000-0001-8293-4496; Fuller, Gordon Ward/0000-0001-8532-3500			Bruce JM, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2016-097091; Cross MJ, 2019, BRIT J SPORT MED, V53, P1021, DOI 10.1136/bjsports-2017-097912; Davis GA, 2019, BRIT J SPORT MED, V53, P1298; Davis G, 2016, J SCI MED SPORT, V19, P898, DOI 10.1016/j.jsams.2016.02.005; Echemendia RJ, 2018, BRIT J SPORT MED, V52, P1149, DOI 10.1136/bjsports-2016-097090; Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gardner AJ, 2018, SPORTS MED OPEN, V4; Gardner AJ, 2017, SPORTS MED OPEN, V3; Gardner AJ, 2017, BRAIN INJURY, V31, P1918, DOI 10.1080/02699052.2017.1358399; Gardner AJ, 2017, INT J SPORTS MED, V38, P71, DOI 10.1055/s-0042-116072; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Tucker R, 2017, BRIT J SPORT MED, V51, P1152, DOI 10.1136/bjsports-2017-097895	18	17	17	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2019	53	20					1264	1267		10.1136/bjsports-2019-100628			4	Sport Sciences	Sport Sciences	JG2NR	WOS:000491913000006	30954947	Green Accepted, Bronze			2021-06-18	
J	Lee, EB; Kinch, K; Johnson, VE; Trojanowski, JQ; Smith, DH; Stewart, W				Lee, Edward B.; Kinch, Kevin; Johnson, Victoria E.; Trojanowski, John Q.; Smith, Douglas H.; Stewart, William			Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Traumatic brain injury; Neurodegeneration; Dementia; Alzheimer's disease; Tau	ALZHEIMERS ASSOCIATION GUIDELINES; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; DISEASE; BRAIN; PATHOLOGY; CRITERIA; CONSEQUENCE; CONSORTIUM; DEPOSITION	Chronic traumatic encephalopathy (CTE) is reported at high prevalence in selected autopsy case series of former contact sports athletes. Nevertheless, the contribution of CTE pathology to clinical presentation and its interaction with co-morbid neurodegenerative pathologies remain unclear. To address these issues, we performed comprehensive neuropathology assessments on the brains of former athletes with dementia and considered these findings together with detailed clinical histories to derive an integrated clinicopathological diagnosis for each case. Consecutive, autopsy-acquired brains from former soccer and rugby players with dementia were assessed for neurodegenerative pathologies using established and preliminary consensus protocols. Thereafter, next of kin interviews were conducted to obtain detailed accounts of the patient's clinical presentation and course of disease to inform a final, integrated clinicopathological diagnosis. Neuropathologic change consistent with CTE (CTE-NC) was confirmed in five of seven former soccer and three of four former rugby players' brains, invariably in combination with mixed, often multiple neurodegenerative pathologies. However, in just three cases was the integrated dementia diagnosis consistent with CTE, the remainder having alternate diagnoses, with the most frequent integrated diagnosis Alzheimer's disease (AD) (four cases; one as mixed AD and vascular dementia). This consecutive autopsy series identifies neuropathologic change consistent with preliminary diagnostic criteria for CTE (CTE-NC) in a high proportion of former soccer and rugby players dying with dementia. However, in the majority, CTE-NC appears as a co-morbidity rather than the primary, dementia causing pathology. As such, we suggest that while CTE-NC might be common in former athletes with dementia, in many cases its clinical significance remains uncertain.	[Lee, Edward B.] Univ Penn, Translat Neuropathol Res Lab, Philadelphia, PA 19104 USA; [Kinch, Kevin; Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Inst Aging,Perelman Sch Med, Philadelphia, PA USA; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland	Stewart, W (corresponding author), Queen Elizabeth Univ Hosp, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.; Stewart, W (corresponding author), Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland.	william.stewart@glasgow.ac.uk		Stewart, William/0000-0003-2199-2582	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS038104]; Professional Footballers Association; NHS Research Scotland Career Researcher Fellowship; Football Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS038104, R01NS092398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG017586] Funding Source: NIH RePORTER	This work is supported by funding from: the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R01NS092398, R01NS094003 and R01NS038104; The Football Association and Professional Footballers Association (WS); and an NHS Research Scotland Career Researcher Fellowship (WS).	Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldfinger MH, 2018, ACTA NEUROPATHOL, V136, P973, DOI 10.1007/s00401-018-1926-8; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Josephs KA, 2016, ACTA NEUROPATHOL, V131, P571, DOI 10.1007/s00401-016-1537-1; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P605, DOI 10.1093/jnen/nlx041; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Lee EB, 2018, ACTA NEUROPATHOL, V135, P643, DOI 10.1007/s00401-018-1827-x; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nag S, 2015, ANN NEUROL, V77, P942, DOI 10.1002/ana.24388; OLICHNEY JM, 1995, ARCH NEUROL-CHICAGO, V52, P702, DOI 10.1001/archneur.1995.00540310076019; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Outeiro TF, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0306-8; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Robinson JL, 2018, BRAIN, V141, P2181, DOI 10.1093/brain/awy146; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spires-Jones TL, 2017, ACTA NEUROPATHOL, V134, P187, DOI 10.1007/s00401-017-1709-7; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stewart W, 2019, LANCET NEUROL, V18, P231, DOI 10.1016/S1474-4422(19)30020-1; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Zanier ER, 2018, BRAIN, V141, P2685, DOI 10.1093/brain/awy193	50	17	17	3	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2019	138	3			SI		389	399		10.1007/s00401-019-02030-y			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	IQ2SB	WOS:000480599000004	31152201	Green Published, Other Gold, Green Accepted			2021-06-18	
J	Wu, TT; Alshareef, A; Giudice, JS; Panzer, MB				Wu, Taotao; Alshareef, Ahmed; Giudice, J. Sebastian; Panzer, Matthew B.			Explicit Modeling of White Matter Axonal Fiber Tracts in a Finite Element Brain Model	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Axonal fibers; Brain model; Finite element model validation	MECHANICAL-PROPERTIES; STRAIN RESPONSES; HEAD; TISSUE; BEHAVIOR; VALIDATION; ATLAS	Many human brain finite element (FE) models lack mesoscopic (similar to 1 mm) white matter structures, which may limit their capability in predicting TBI and assessing tissue-based injury metrics such as axonal strain. This study investigated an embedded method to explicitly incorporate white matter axonal fibers into an existing 50th percentile male brain model. The white matter was decomposed into myelinated axon tracts and an isotropic ground substance that had similar material properties to gray matter. The axon tract bundles were derived from a population-based tractography template explicitly modeled using 1-D cable elements. The axonal fibers and ground substance material were implemented using hyper-viscoelastic constitutive models, which were calibrated using white and gray matter brain tissue material testing data available in the literature. Finally, the new axon-based model was extensively validated for brain-skull relative deformation under various loading conditions (n = 17) and showed good biofidelity compared to other brain models. Through these analyses, we demonstrated the applicability of this method for incorporating axonal fiber tracts into an existing FE brain model. The axon-based model will be a useful tool for understanding the mechanisms of TBI, evaluating tissue-based injury metrics, and developing injury mitigation systems.	[Wu, Taotao; Alshareef, Ahmed; Giudice, J. Sebastian; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA	Panzer, MB (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	tw2dx@virginia.edu; aa4kw@virginia.edu; jsg4fd@virginia.edu; mpb2q@virginia.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Giudice, Sebastian/0000-0003-1074-4890; Alshareef, Ahmed/0000-0003-4512-1618	16 NIH Institutes and CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Clinical Center (CC) [1U54MH091657]; McDonnell Center for Systems Neuroscience at Washington University; Football Research, Inc. (FRI)	Diffusion MRI data were provided in part by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The research presented in this paper was made possible in part by a grant from Football Research, Inc. (FRI). The views expressed are solely those of the authors and do not represent those of FRI or any of its affiliates or funding sources.	Alshareef A, 2018, J NEUROTRAUM, V35, P780, DOI 10.1089/neu.2017.5362; Arbogast K. B., 1997, SAE TECHNICAL PAPER; Bermejo M, 2017, SHOCK VIB, V2017, DOI 10.1155/2017/4636381; BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D. W., 1999, SAE TECHNICAL PAPER; Bryan R, 2010, MED ENG PHYS, V32, P57, DOI 10.1016/j.medengphy.2009.10.008; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Davis M. L, 2016, SAE TECHNICAL PAPER; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; FISH J, 1992, COMPUT STRUCT, V43, P539, DOI 10.1016/0045-7949(92)90287-A; Fung Y. C., 2013, BIOMECHANICS MECH PR; Gabler LF, 2018, ANN BIOMED ENG, V46, P972, DOI 10.1007/s10439-018-2015-9; Gabler LF, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4038357; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Ganpule S, 2017, J NEUROTRAUM, V34, P2154, DOI 10.1089/neu.2016.4744; Garimella HT, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2823; Garo A, 2007, BIORHEOLOGY, V44, P51; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gehre C., 2009, OBJECTIVE RATING SIG; Gennarelli T.A., 1972, SAE TECHNICAL PAPER; Giordano C, 2014, SAE TECHNICAL PAPER; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Giudice JS, 2019, ANN BIOMED ENG, V47, P1855, DOI 10.1007/s10439-018-02161-5; Golman A., 2013, P 41 INT WORKSH; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hardy WN., 2001, SAE TECHNICAL PAPER; Holzapfel GA, 2017, J ELASTICITY, V129, P49, DOI 10.1007/s10659-016-9605-2; Holzapfel GA, 2015, EUR J MECH A-SOLID, V49, P561, DOI 10.1016/j.euromechsol.2014.09.005; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jin X., 2006, SAE TECHNICAL PAPER; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Johnson CL, 2013, NEUROIMAGE, V79, P145, DOI 10.1016/j.neuroimage.2013.04.089; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Latorre M, 2016, APPL MATH MODEL, V40, P3938, DOI 10.1016/j.apm.2015.10.045; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Maier-Hein KH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01285-x; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nicolle S., 2004, SAE TECHNICAL PAPER; Nilsson M, 2012, NMR BIOMED, V25, P795, DOI 10.1002/nbm.1795; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Park G, 2017, COMPUT METHOD BIOMEC, V20, P1151, DOI 10.1080/10255842.2017.1340459; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Sahoo D, 2016, ACCIDENT ANAL PREV, V92, P53, DOI 10.1016/j.aap.2016.03.013; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Sanchez EJ, 2019, CLIN BIOMECH, V64, P82, DOI 10.1016/j.clinbiomech.2018.02.019; Sanchez EJ, 2017, J NEUROTRAUM, V34, P2410, DOI 10.1089/neu.2016.4681; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; Tabatabaei SA, 2015, COMPUT STRUCT, V152, P142, DOI 10.1016/j.compstruc.2015.02.014; Takhounts EG, 2008, SAE TECHNICAL PAPER; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yeh FC, 2018, NEUROIMAGE, V178, P57, DOI 10.1016/j.neuroimage.2018.05.027; Zhao W, 2019, J NEUROTRAUM, V36, P250, DOI 10.1089/neu.2018.5634; Zhao W, 2018, J MECH BEHAV BIOMED, V80, P222, DOI 10.1016/j.jmbbm.2018.02.005	66	17	17	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2019	47	9			SI		1908	1922		10.1007/s10439-019-02239-8			15	Engineering, Biomedical	Engineering	JD1MH	WOS:000489738300006	30877404				2021-06-18	
J	Roberts, AL; Pascual-Leone, A; Speizer, FE; Zafonte, RD; Baggish, AL; Taylor, H; Nadler, LM; Connor, A; Grashow, R; Stillman, AM; Marengi, DA; Weisskopf, MG; Courtney, TK				Roberts, Andrea L.; Pascual-Leone, Alvaro; Speizer, Frank E.; Zafonte, Ross D.; Baggish, Aaron L.; Taylor, Herman, Jr.; Nadler, Lee M.; Connor, Ann; Grashow, Rachel; Stillman, Alexandra M.; Marengi, Dean A.; Weisskopf, Marc G.; Courtney, Theodore K.			Exposure to American Football and Neuropsychiatric Health in Former National Football League Players: Findings From the Football Players Health Study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports injuries; postconcussion syndrome; cognitive function; depression; anxiety; football	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; LIFE COGNITIVE IMPAIRMENT; POST-CONCUSSION SYMPTOMS; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; 1ST EXPOSURE; HIGH-SCHOOL; DEPRESSION; PREVALENCE	Background: Former American football players have a higher prevalence of cognitive impairment than that of the US general population. It remains unknown what aspects of playing football are associated with neuropsychiatric outcomes. Hypothesis: It was hypothesized that seasons of professional football, playing position, and experience of concussions were associated with cognition-related quality of life (QOL) and indicators of depression and anxiety. Study Design: Descriptive epidemiology study. Methods: The authors examined whether seasons of professional football, playing position, and experience of concussions, as measured by self-report of 10 symptoms, were associated with cognition-related QOL and indicators of depression and anxiety in a cross-sectional survey conducted 2015 to 2017. Cognition-related QOL was measured by the short form of the Quality of Life in Neurological Disorders: Applied Cognition-General Concerns. The Patient Health Questionnaire-4 measured depression and anxiety symptoms. Of 13,720 eligible men with apparently valid contact information, 3506 players returned a questionnaire at the time of this analysis (response rate = 25.6%). Results: Seasons of professional play (risk ratio [RR] per 5 seasons = 1.19, 95% CI = 1.06-1.34) and playing position were associated with cognition-related QOL. Each 5 seasons of play was associated with 9% increased risk of indicators of depression at borderline statistical significance (P = .05). When compared with former kickers, punters, and quarterbacks, men who played any other position had a higher risk of poor cognition-related QOL, depression, and anxiety. Concussion symptoms were strongly associated with poor cognition-related QOL (highest concussion quartile, RR = 22.3, P < .001), depression (highest quartile, RR = 6.0, P < .0001), and anxiety (highest quartile, RR = 6.4, P < .0001), even 20 years after last professional play. Conclusion: The data suggest that seasons of play and playing position in the NFL are associated with lasting neuropsychiatric health deficits. Additionally, poor cognition-related QOL, depression, and anxiety appear to be associated with concussion in the long term.	[Zafonte, Ross D.; Marengi, Dean A.] Harvard Med Sch, Boston, MA 02115 USA; Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Roberts, Andrea L.; Speizer, Frank E.; Grashow, Rachel; Weisskopf, Marc G.; Courtney, Theodore K.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA; [Pascual-Leone, Alvaro; Connor, Ann; Stillman, Alexandra M.] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Cognit Neurol, Boston, MA 02115 USA; [Speizer, Frank E.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA; [Taylor, Herman, Jr.; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Taylor, Herman, Jr.] Morehouse Univ, Sch Med, Cardiovasc Res Inst, Atlanta, GA USA; [Nadler, Lee M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nadler, Lee M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Roberts, AL (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	aroberts@hsph.harvard.edu	Courtney, Theodore K./P-4829-2019; Pascual-Leone, Alvaro/AAC-5101-2019	Courtney, Theodore K./0000-0001-8139-1565; Pascual-Leone, Alvaro/0000-0001-8975-0382	Sidney R. Baer Jr Foundation; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); Football Players Health Study (FPHS) at Harvard University; Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources/National Institutes of Health) [UL1 RR025758]; Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences/National Institutes of Health) [UL1 RR025758]; National Football League Players Association (NFLPA); American Heart AssociationAmerican Heart Association; American Society of Echocardiography; NFLPA; FPHS at Harvard University - NFLPA	One or more of the authors has declared the following potential conflict of interest or source of funding: A. P.-L. was partly supported by the Sidney R. Baer Jr Foundation, Defense Advanced Research Projects Agency, the Football Players Health Study (FPHS) at Harvard University, and Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences/National Institutes of Health, UL1 RR025758); serves on the scientific advisory boards for Neosync, Neuronix, Starlab Neuroscience, Neuroelectrics, Magstim Inc, Constant Therapy, and Cognito; and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation with electroencephalography and magnetic resonance imaging. A.L.B. has received funding from the National Football League Players Association (NFLPA), the American Heart Association, and the American Society of Echocardiography and receives compensation for his role as team cardiologist from US Soccer, US Rowing, the New England Patriots, the Boston Bruins, the New England Revolution, and Harvard University. R.D.Z. received royalties from Oakstone for authorship of an educational CD and from Demos Publishing for serving as coeditor of Brain Injury Medicine; serves on the scientific advisory boards of Myomo, Oxeia Biopharma, ElMindA, and Biodirection; and evaluates patients in Massachusetts General Hospital's Brain and Body-Trust Program, which is funded by the NFLPA. All other authors are either partially or fully supported by the FPHS at Harvard University, which is in turn sponsored by the NFLPA. Note that the NFLPA had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.	Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Arola HM, 2010, EUR J PAIN, V14, P966, DOI 10.1016/j.ejpain.2010.02.012; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Caplan B, 2016, J HEAD TRAUMA REHAB, V31, P1, DOI 10.1097/HTR.0000000000000211; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cella D, 2012, NEUROLOGY, V78, P1860, DOI 10.1212/WNL.0b013e318258f744; CHOI BCK, 1992, J OCCUP ENVIRON MED, V34, P979; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall EC, 2014, J TRAUMA ACUTE CARE, V76, P859, DOI 10.1097/TA.0000000000000148; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; HealthMeasures, TRANSF HLTH IS MEAS; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005; Pryor James, 2016, J Lifestyle Med, V6, P7, DOI 10.15280/jlm.2016.6.1.7; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Sports Reference LLC, FOOTB REF COM PROF S; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	52	17	17	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2019	47	12					2871	2880	0363546519868989	10.1177/0363546519868989		AUG 2019	10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	JE3YH	WOS:000484623200001	31468987	Green Published, Other Gold			2021-06-18	
J	Chen, YH; Meng, J; Bi, FF; Li, H; Chang, CC; Ji, C; Liu, W				Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Li, Hua; Chang, Cuicui; Ji, Chen; Liu, Wei			EK7 Regulates NLRP3 Inflammasome Activation and Neuroinflammation Post-traumatic Brain Injury	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; NLRP3 inflammasome; NEK7; caspase-1 activation; pyroptosis; potassium efflux; neuroinflammation	INTERLEUKIN-1 RECEPTOR ANTAGONIST; NEK7; INHIBITOR; CASPASES; DEATH; MODEL	As one of the most common causes of mortality and disability, traumatic brain injury (TBI) is a huge psychological and economic burden to patients, families, and societies worldwide. Neuroinflammation reduction may be a favorable option to alleviate secondary brain injuries and ameliorate the outcome of TBI. The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome, has been shown to be involved in TBI. NIMA-related kinase 7 (NEK7)has been verified as an essential mediator of NLRP3 inflammasome activation that is recruited upstream of the formation of inflammasomes in response to NLRP3 activators. However, the underlying mechanism by which NEK7 operates post-TBI remains undefined. In this study, we performed both in vivo and in vitro experiments. Using an in vivo mouse TBI model, mice were administered an intracerebroventricular injection of NEK7-shRNA virus. For the in vitro analysis, primary cortical neurons with NEK7-shRNA were stimulated with lipopolysaccharide (LPS)/ATP or potassium (K+). We evaluated the effects of NEK7 knock-down on neurological deficits, NLRP3 inflammasomes, caspase-1 activation, and neuronal injury. During the 0-168 h post-TBI period in vivo, NEK7 and NLRP3 inflammasome activation increased in what appeared to be a time-dependent manner. As well as pyroptosis-related markers, caspase-1 activation (p20) and interleukin-1 beta (IL-1 beta) activation (p17) were up-regulated. NEK7 down-regulation attenuated neurological deficits, NLRP3 inflammasomes, caspase-1 activation, and neuronal injury. The same phenomena were observed during the in vitro experiments. Furthermore, NEK7 knock-down suppressed NLRP3 inflammasome activation and pyroptosis, which were triggered by K+ efflux, and the LPS + ATP-triggered NEK7-NLRP3 complex was reversed in primary cortical neurons placed in 50 mM K+ medium. Collectively, the data demonstrated that NEK7, as a modulator, regulates NLRP3 inflammasomes and downstream neuroinflammation in response to K+ efflux, through NEK7-NLRP3 assembly, pro-caspase-1 recruitment, caspase-1 activation, and pyroptosis in nerve injuries, post-TBI. NEK7 may be a potential therapeutic target for attenuating neuroinflammation and nerve injury post-TBI.	[Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui; Ji, Chen] Xian Peihua Univ, Dept Cent Lab, Xian, Shaanxi, Peoples R China; [Chen, Yuhua; Liu, Wei] Xian Med Univ, Dept Neurosurg, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China; [Meng, Jiao; Bi, Fangfang; Li, Hua] Shaanxi Fourth Peoples Hosp, Dept Basic Med Sci, Res Ctr, Xian, Shaanxi, Peoples R China	Liu, W (corresponding author), Xian Med Univ, Dept Neurosurg, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.	vincelau@sina.com			Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2018JM7141]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81901270]	This study is supported by the Natural Science Foundation of Shaanxi Province (2018JM7141) and the National Natural Science Foundation of China (No. 81901270).	Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Barlow KM, 2019, J NEUROTRAUM, V36, P523, DOI 10.1089/neu.2018.5752; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YH, 2019, BRAIN RES, V1710, P163, DOI 10.1016/j.brainres.2019.01.005; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Freixo F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04706-7; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Green JP, 2018, P NATL ACAD SCI USA, V115, pE9371, DOI 10.1073/pnas.1812744115; Groslambert M, 2018, J INFLAMM RES, V11, P359, DOI 10.2147/JIR.S141220; Guo QL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01197; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hinojosa AJ, 2018, CELL REP, V24, P1231, DOI 10.1016/j.celrep.2018.06.115; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128; Kuriakose T, 2017, MOL IMMUNOL, V86, P56, DOI 10.1016/j.molimm.2017.01.023; Lazaridis C, 2019, NEUROPHARMACOLOGY, V145, P145, DOI 10.1016/j.neuropharm.2018.06.005; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Ma ZZ, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0192-9; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mamik MK, 2017, BRAIN, V140, P2273, DOI 10.1093/brain/awx133; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Man SM, 2015, CELL RES, V25, P1183, DOI 10.1038/cr.2015.124; Martinez BI, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0145-8; McKenzie BA, 2018, P NATL ACAD SCI USA, V115, pE6065, DOI 10.1073/pnas.1722041115; Minoguchi S, 2003, BIOCHEM BIOPH RES CO, V301, P899, DOI 10.1016/S0006-291X(03)00049-4; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Ross J, 2007, NEUROPHARMACOLOGY, V53, P638, DOI 10.1016/j.neuropharm.2007.07.015; Ruhl S, 2015, EUR J IMMUNOL, V45, P2927, DOI 10.1002/eji.201545772; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schmid-Burgk JL, 2016, J BIOL CHEM, V291, P103, DOI 10.1074/jbc.C115.700492; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Shi HX, 2016, NAT IMMUNOL, V17, P250, DOI 10.1038/ni.3333; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Thelin EP, 2017, AAPS J, V19, P367, DOI 10.1208/s12248-016-0027-7; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Xu J, 2016, ACTA BIOCH BIOPH SIN, V48, P966, DOI 10.1093/abbs/gmw080; Xu KY, 2018, BIOCHEM BIOPH RES CO, V503, P3031, DOI 10.1016/j.bbrc.2018.08.089; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00331; Zhou WY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5702103	52	17	19	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	AUG 29	2019	12								202	10.3389/fnmol.2019.00202			12	Neurosciences	Neurosciences & Neurology	IT7EY	WOS:000483039700001	31555089	DOAJ Gold, Green Published			2021-06-18	
J	Einarsen, CE; Moen, KG; Haberg, AK; Eikenes, L; Kvistad, KA; Xu, J; Moe, HK; Tollefsen, MH; Vik, A; Skandsen, T				Einarsen, Cathrine Elisabeth; Moen, Kent Goran; Haberg, Asta Kristine; Eikenes, Live; Kvistad, Kjell Arne; Xu, Jian; Moe, Hans Kristian; Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril			Patients with Mild Traumatic Brain Injury Recruited from Both Hospital and Primary Care Settings: A Controlled Longitudinal Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; MRI; PCS; prospective study; white matter hyperintensities	WHITE-MATTER HYPERINTENSITIES; POST-CONCUSSION SYMPTOMS; DIFFUSE AXONAL INJURY; SCANDINAVIAN GUIDELINES; OUTCOME PREDICTION; RANDOMIZED-TRIALS; CHRONIC PHASE; FOLLOW-UP; LESIONS; MRI	With an emphasis on traumatic axonal injury (TAI), frequency and evolution of traumatic intracranial lesions on 3T clinical magnetic resonance imaging (MRI) were assessed in a combined hospital and community-based study of patients with mild traumatic brain injury (mTBI). The findings were related to post-concussion symptoms (PCS) at 3 and 12 months. Prospectively, 194 patients (16-60 years of age) were recruited from the emergency departments at a level 1 trauma center and a municipal outpatient clinic into the Trondheim mTBI follow-up study. MRI was acquired within 72 h (n = 194) and at 3 (n = 165) and 12 months (n = 152) in patients and community controls (n = 78). The protocol included T2, diffusion weighted imaging, fluid attenuated inversion recovery (FLAIR), and susceptibility weighted imaging (SWI). PCS was assessed with British Columbia Post Concussion Symptom Inventory in patients and controls. Traumatic lesions were present in 12% on very early MRI, and in 5% when computed tomography (CT) was negative. TAI was found in 6% and persisted for 12 months on SWI, whereas TAI lesions on FLAIR disappeared or became less conspicuous on follow-up. PCS occurred in 33% of patients with lesions on MRI and in 19% in patients without lesions at 3 months (p = 0.12) and in 21% with lesions and 14% without lesions at 12 months (p = 0.49). Very early MRI depicted cases of TAI in patients with mTBI with microbleeds persisting for 12 months. Patients with traumatic lesions may have a more protracted recovery, but the study was underpowered to detect significant differences for PCS because of the low frequency of trauma-related MRI lesions.	[Einarsen, Cathrine Elisabeth; Moen, Kent Goran; Haberg, Asta Kristine; Moe, Hans Kristian; Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway; [Eikenes, Live] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Circulat & Med Imaging, Trondheim, Norway; [Einarsen, Cathrine Elisabeth; Skandsen, Toril] Trondheim Reg & Univ Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, Trondheim, Norway; [Haberg, Asta Kristine; Kvistad, Kjell Arne; Xu, Jian] Trondheim Reg & Univ Hosp, Dept Radiol & Nucl Med, St Olavs Hosp, Trondheim, Norway; [Vik, Anne] Trondheim Reg & Univ Hosp, Dept Neurosurg, St Olavs Hosp, Trondheim, Norway; [Moen, Kent Goran] Nord Trondelag Hosp Trust, Levanger Hosp, Dept Radiol, Levanger, Norway	Skandsen, T (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, N-7491 Trondheim, Norway.	toril.skandsen@ntnu.no		Moe, Hans Kristian/0000-0002-1699-6848	NTNU; Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital; National Norwegian Advisory Unit for functional MRI, St. Olavs Hospital, Trondheim University Hospital; Central Norway Regional Health Authority (RHA); Norwegian University of Science and Technology (NTNU); Liaison Committee	We thank the patients and controls. We also thank the staff of the Trondheim Municipal Emergency Department, the Department of Neurosurgery, the Department of Anesthesiology and Insensitive Care Medicine, and the Department of Radiology and Nuclear Medicine at St. Olavs Hospital, Trondheim University Hospital, for their cooperation during patient recruitment. We also thank the National Norwegian Advisory Unit for functional MRI for collaboration, for use of the MRI machine, and for flexibility in the MRI schedule. Finally, we also thank Stine Bjoralt for coordinating the data collection, and Ingeborg Nakken for her assistance with the MRI procedures. The study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). Cathrine E. Einarsen and Toril Skandsen received separate research grants from the same committee. Kent Goran Moen and Hans Kristian Moe also received a research grant from NTNU during the study period. In addition, the MRI images were funded by the National Norwegian Advisory Unit for functional MRI and Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital.	Ananthaharan A, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0193-2; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chung SW, 2012, J KOREAN NEUROSURG S, V52, P377, DOI 10.3340/jkns.2012.52.4.377; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Haan S, 2017, NEURORADIOLOGY, V59, P963, DOI 10.1007/s00234-017-1898-8; De Simoni S, 2016, BRAIN, V139, P3137, DOI 10.1093/brain/aww241; Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Haberg AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151080; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hutchinson M, 2018, MAGN RESON IMAGING, V48, P138, DOI 10.1016/j.mri.2017.12.022; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Isokuortti H, 2018, J NEUROSURG, V129, P1588, DOI 10.3171/2017.7.JNS17615; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Lasry O, 2017, NEUROLOGY, V89, P2198, DOI 10.1212/WNL.0000000000004671; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moe HK, 2018, J NEUROTRAUM, V35, P975, DOI 10.1089/neu.2017.5252; Moen KG, 2016, J NEUROSCI RES, V94, P623, DOI 10.1002/jnr.23728; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Nyquist PA, 2015, NEUROBIOL AGING, V36, P1653, DOI 10.1016/j.neurobiolaging.2015.01.005; Panenka WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122746; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shetty T, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00836; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Skandsen T, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0495-0; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Strand IH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-62; Suri AK, 2018, HAND CLINIC, V158, P205, DOI 10.1016/B978-0-444-63954-7.00021-5; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Trifan G, 2017, MAGN RESON IMAGING, V37, P243, DOI 10.1016/j.mri.2016.12.009; van den Heuvel DMJ, 2004, NEUROLOGY, V63, P1699, DOI 10.1212/01.WNL.0000143058.40388.44; van den Heuvel TLA, 2016, NEUROIMAGE-CLIN, V12, P241, DOI 10.1016/j.nicl.2016.07.002; van der Horn HJ, 2018, BRAIN IMAGING BEHAV, V12, P912, DOI 10.1007/s11682-017-9743-6; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Wu X, 2016, RADIOLOGY, V279, P693, DOI 10.1148/radiol.16142535; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	57	17	17	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2019	36	22					3172	3182		10.1089/neu.2018.6360		JUL 2019	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JI6MG	WOS:000479784000001	31280698	Green Published, Other Gold			2021-06-18	
J	Golz, C; Kirchhoff, FP; Westerhorstmann, J; Schmidt, M; Hirnet, T; Rune, GM; Bender, RA; Schafert, MKE				Goelz, Christina; Kirchhoff, Florian Paul; Westerhorstmann, Jana; Schmidt, Matthias; Hirnet, Tobias; Rune, Gabriele M.; Bender, Roland A.; Schaefert, Michael K. E.			Sex hormones modulate pathogenic processes in experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						finasteride; letrozole; neuroprotection; neurotrophin; sex steroid hormones; traumatic brain injury	NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; RAT-BRAIN; NEUROPROTECTIVE ACTIONS; AROMATASE INHIBITORS; SYNAPTIC PLASTICITY; ESTROGEN-RECEPTORS; CEREBRAL-ISCHEMIA; MESSENGER-RNA; AXONAL INJURY	Clinical and animal studies have revealed sex-specific differences in histopathological and neurological outcome after traumatic brain injury (TBI). The impact of perioperative administration of sex steroid inhibitors on TBI is still elusive. Here, we subjected male and female C57Bl/6N mice to the controlled cortical impact (CCI) model of TBI and applied pharmacological inhibitors of steroid hormone synthesis, that is, letrozole (LET, inhibiting estradiol synthesis by aromatase) and finasteride (FIN, inhibiting dihydrotestosterone synthesis by 5 alpha-reductase), respectively, starting 72 h prior CCI, and continuing for a further 48 h after CCI. Initial gene expression analyses showed that androgen (Ar) and estrogen receptors (Esr1) were sex-specifically altered 72 h after CCI. When examining brain lesion size, we found larger lesions in male than in female mice, but did not observe effects of FIN or LET treatment. However, LET treatment exacerbated neurological deficits 24 and 72 h after CCI. On the molecular level, FIN administration reduced calpain-dependent spectrin breakdown products, a proxy of excitotoxicity and disturbed Ca2+ homeostasis, specifically in males, whereas LET increased the reactive astrocyte marker glial fibrillary acid protein specifically in females. Examination of neurotrophins (brain-derived neurotrophic factor, neuronal growth factor, NT-3) and their receptors (p75(NTR), TrkA, TrkB, TrkC) revealed CCI-induced down-regulation of TrkB and TrkC protein expression, which was reduced by LET in both sexes. Interestingly, FIN decreased neuronal growth factor mRNA expression and protein levels of its receptor TrkA only in males. Taken together, our data suggest a sex-specific impact on pathogenic processes in the injured brain after TBI. Sex hormones may thus modulate pathogenic processes in experimental TBI.	[Goelz, Christina; Kirchhoff, Florian Paul; Schmidt, Matthias; Hirnet, Tobias; Schaefert, Michael K. E.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Mainz, Germany; [Westerhorstmann, Jana; Rune, Gabriele M.; Bender, Roland A.] Univ Med Ctr, Inst Neuroanat, Hamburg, Germany; [Schaefert, Michael K. E.] Focus Program Translat Neurosci, Mainz, Germany; [Schaefert, Michael K. E.] Res Ctr Immunotherapy FZI, Mainz, Germany	Schafert, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.; Schafert, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci FTN, Langenbeckstr 1, D-55131 Mainz, Germany.	michael.schaefer@unimedizin-mainz.de	Schaefer, Michael K.E./S-1715-2019	Schaefer, Michael K.E./0000-0001-6055-6244	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [Be4107/3-1]; Focus Program Translational Neurosciences (FTN) Mainz	We thank Wiesia Bobkiewicz, Dana Pieter (Department of Anesthesiology, UMC Mainz, Germany) and Christiane Schrooder-Birkner (Institute of Anatomy, UMC Hamburg, Germany) for excellent technical assistance. The authors declare no conflicts of interest. Data presented in this manuscript are part of the doctoral theses of FK, MS, and JW (Faculties of Medicine, Johannes Gutenberg-University Mainz and the University of Hamburg, Germany, respectively). This work was supported by the Deutsche Forschungsgemeinschaft (Be4107/3-1 to RB) and the Focus Program Translational Neurosciences (FTN) Mainz to MS.	Allen KM, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0142-x; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Baudry M, 2013, NEUROSCIENCE, V239, P280, DOI 10.1016/j.neuroscience.2012.10.051; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Lopez-Rodriguez AB, 2016, ENDOCRINOLOGY, V157, P3983, DOI 10.1210/en.2016-1316; Bender RA, 2017, J NEUROSCI, V37, P1532, DOI 10.1523/JNEUROSCI.1532-16.2016; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bhatnagar AS, 2007, BREAST CANCER RES TR, V105, P7, DOI 10.1007/s10549-007-9696-3; Bian C, 2014, J STEROID BIOCHEM, V141, P37, DOI 10.1016/j.jsbmb.2013.12.020; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Bruna B, 2018, BIOCHEM BIOPH RES CO, V505, P201, DOI 10.1016/j.bbrc.2018.09.080; Carbone DL, 2013, NEUROSCIENCE, V239, P295, DOI 10.1016/j.neuroscience.2012.10.073; Castelli MP, 2013, PSYCHONEUROENDOCRINO, V38, P281, DOI 10.1016/j.psyneuen.2012.06.008; Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Chakrabarti M, 2016, REV NEUROSCIENCE, V27, P271, DOI 10.1515/revneuro-2015-0032; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Choi S, 2014, NEUROSCIENCE, V257, P11, DOI 10.1016/j.neuroscience.2013.10.058; Choueiri TK, 2004, CLIN THER, V26, P1199, DOI 10.1016/S0149-2918(04)80017-1; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Cornil CA, 2006, BRAIN RES, V1126, P2, DOI 10.1016/j.brainres.2006.07.098; Dave N, 2013, CANCER CHEMOTH PHARM, V72, P349, DOI 10.1007/s00280-013-2205-y; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Fanaei H, 2014, BRAIN RES, V1558, P74, DOI 10.1016/j.brainres.2014.02.028; Fester L, 2017, J NEUROCHEM, V140, P126, DOI 10.1111/jnc.13889; Finn DA, 2006, CNS DRUG REV, V12, P53, DOI 10.1111/j.1527-3458.2006.00053.x; Fullhase C, 2016, UROL CLIN N AM, V43, P325, DOI 10.1016/j.ucl.2016.04.003; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Hajszan T, 2008, HORM BEHAV, V53, P638, DOI 10.1016/j.yhbeh.2007.12.007; Harden Cynthia, 2005, Expert Rev Neurother, V5, P123, DOI 10.1586/14737175.5.1.123; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hojo Y, 2004, P NATL ACAD SCI USA, V101, P865, DOI 10.1073/pnas.2630225100; Hojo Y, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00183; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Kramer T, 2017, J NEUROCHEM, V143, P523, DOI 10.1111/jnc.14220; Kretz O, 2004, J NEUROSCI, V24, P5913, DOI 10.1523/JNEUROSCI.5186-03.2004; Krishnamurthy K, 2016, TRANSLATIONAL RES TR; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEPHART ED, 1995, NEUROBIOL AGING, V16, P647, DOI 10.1016/0197-4580(95)98115-5; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682, DOI 10.1097/TA.0b013e31829d024f; Li CY, 2018, ARCH PHYS MED REHAB, V99, P1279, DOI 10.1016/j.apmr.2017.12.006; Li L, 2018, CNS NEUROSCI THER, V24, P115, DOI 10.1111/cns.12781; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Lu HH, 2018, J CELL PHYSIOL, V233, P1712, DOI 10.1002/jcp.26083; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Meirelles LD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051082; Menzel L, 2017, GLIA, V65, P278, DOI 10.1002/glia.23091; MIRANDA RC, 1994, HORM BEHAV, V28, P367, DOI 10.1006/hbeh.1994.1033; Mladenovic D, 2014, AM J PHYSIOL-GASTR L, V307, pG931, DOI 10.1152/ajpgi.00463.2013; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; O'Brien EE, 2015, NEUROSCIENCE, V301, P235, DOI 10.1016/j.neuroscience.2015.06.009; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Park SY, 2007, NEUROSCIENCE, V144, P119, DOI 10.1016/j.neuroscience.2006.09.012; Pietranera L, 2010, J NEUROENDOCRINOL, V22, P1082, DOI 10.1111/j.1365-2826.2010.02058.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Prange-Kiel J, 2003, HIPPOCAMPUS, V13, P226, DOI 10.1002/hipo.10075; Prange-Kiel J, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9802086; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saito K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041091; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schafer MKE, 2018, MATRIX BIOL, V68-69, P571, DOI 10.1016/j.matbio.2017.10.002; Schafer M, 2014, CELL TISSUE RES, V357, P395, DOI 10.1007/s00441-014-1807-y; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Sebastiani A, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00678; Sebastiani A, 2016, CRIT CARE MED, V44, pE70, DOI 10.1097/CCM.0000000000001284; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Sethuraman KN, 2014, ACAD EMERG MED, V21, P1386, DOI 10.1111/acem.12536; Siddiqui AN, 2016, CNS NEUROSCI THER, V22, P342, DOI 10.1111/cns.12538; Simpson ER, 2005, ENDOCR REV, V26, P322, DOI 10.1210/er.2004-0020; Singh M, 1999, J NEUROSCI, V19, P1179; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spani CB, 2018, FRONT NEUROENDOCRIN, V50, P52, DOI 10.1016/j.yfrne.2018.03.006; Spencer JL, 2008, NEUROSCIENCE, V155, P1106, DOI 10.1016/j.neuroscience.2008.05.049; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Tabatadze N, 2015, J NEUROSCI, V35, P11252, DOI 10.1523/JNEUROSCI.1067-15.2015; Tanaka M, 2019, TRANSL STROKE RES, V10, P67, DOI 10.1007/s12975-018-0624-0; Uchida M, 2009, J CEREBR BLOOD F MET, V29, P1454, DOI 10.1038/jcbfm.2009.60; VANDERLEE S, 1955, ACTA PHYSIOL PHARM N, V4, P442; Vierk R, 2012, J NEUROSCI, V32, P8116, DOI 10.1523/JNEUROSCI.5319-11.2012; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; WHITTEN WK, 1959, J ENDOCRINOL, V18, P102, DOI 10.1677/joe.0.0180102; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, ACAD EMERG MED, V21, P1414, DOI 10.1111/acem.12532; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zampieri N, 2005, J BIOL CHEM, V280, P14563, DOI 10.1074/jbc.M412957200; Zhang M, 2017, NEUROCRIT CARE, V26, P292, DOI 10.1007/s12028-016-0342-y; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhang WR, 2014, TRANSL STROKE RES, V5, P301, DOI 10.1007/s12975-013-0298-6; Zhang ZL, 2017, BRAIN RES, V1661, P15, DOI 10.1016/j.brainres.2017.02.004; Zhou L, 2010, ENDOCRINOLOGY, V151, P1153, DOI 10.1210/en.2009-0254; Zhu W, 2010, NEUROSCIENCE, V169, P758, DOI 10.1016/j.neuroscience.2010.05.038; Zhu XY, 2017, J NEUROSCI, V37, P10998, DOI 10.1523/JNEUROSCI.3874-16.2017	110	17	17	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2019	150	2					173	187		10.1111/jnc.14678			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	II7WP	WOS:000475402700004	30790293				2021-06-18	
J	Hammond, FM; Corrigan, JD; Ketchum, JM; Malec, JF; Dams-O'Connor, K; Hart, T; Novack, TA; Bogner, J; Dahdah, MN; Whiteneck, GG				Hammond, Flora M.; Corrigan, John D.; Ketchum, Jessica M.; Malec, James F.; Dams-O'Connor, Kristen; Hart, Tessa; Novack, Thomas A.; Bogner, Jennifer; Dahdah, Marie N.; Whiteneck, Gale G.			Prevalence of Medical and Psychiatric Comorbidities Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						comorbidities; medical conditions; outcomes; prevalence; rehabilitation; traumatic brain injury	HEART-RATE-VARIABILITY; OLDER-ADULTS; INPATIENT REHABILITATION; PITUITARY DYSFUNCTION; RISK; OUTCOMES; HEALTH; REHOSPITALIZATION; DYSAUTONOMIA; ASSOCIATION	Objective: To examine the prevalence of selected medical and psychiatric comorbidities that existed prior to or up to 10 years following traumatic brain injury (TBI) requiring acute rehabilitation. Design: Retrospective cohort. Setting: Six TBI Model Systems (TBIMS) centers. Participants: In total, 404 participants in the TBIMS National Database who experienced TBI 10 years prior. Interventions: Not applicable. Main Outcome Measure: Self-reported medical and psychiatric comorbidities and the onset time of each endorsed comorbidity. Results: At 10 years postinjury, the most common comorbidities developing postinjury, in order, were back pain, depression, hypertension, anxiety, fractures, high blood cholesterol, sleep disorders, panic attacks, osteoarthritis, and diabetes. Comparing those 50 years and older to those younger than 50 years, diabetes (odds ratio [OR] = 3.54; P = .0016), high blood cholesterol (OR = 2.04; P = .0092), osteoarthritis (OR = 2.02; P = .0454), and hypertension (OR = 1.84; P = .0175) were significantly more prevalent in the older cohort while panic attacks (OR = 0.33; P = .0022) were significantly more prevalent in the younger cohort. No significant differences in prevalence rates between the older and younger cohorts were found for back pain, depression, anxiety, fractures, or sleep disorders. Conclusions: People with moderate-severe TBI experience other medical and mental health comorbidities during the long-term course of recovery and life after injury. The findings can inform further investigation into comorbidities associated with TBI and the role of medical care, surveillance, prevention, lifestyle, and healthy behaviors in potentially modifying their presence and/or prevalence over the life span.	[Hammond, Flora M.; Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hammond, Flora M.; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Ketchum, Jessica M.; Whiteneck, Gale G.] Craig Hosp, Res Dept, Traumat Brain Injury Model Syst Natl Data & Stat, Englewood, CO USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Dahdah, Marie N.] Baylor Scott & White Inst Rehabil, North Texas TBI Model Syst, Dallas, TX USA; [Dahdah, Marie N.] Baylor Scott White Med Ctr Plano, Plano, TX USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, Phys Med & Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com	Ketchum, Jessica/AAE-8200-2020		National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR): Indiana University School of Medicine/Rehabilitation Hospital of Indiana [90DP0036]; Icahn School of Medicine at Mount Sinai [90DP0038]; Rocky Mountain Regional Brain Injury System [90DP0034]; Ohio State UniversityOhio State University [90DP0040]; University of Alabama at Birmingham [90DP0044]; Traumatic Brain Injury Model Systems National Data and Statistical Center [90DP0013, 90DP0084]; Moss TBI Model System [90DP0037]; North Texas TBI Model System [90DP0045]; National Institutes of Health National Center for Medical Rehabilitation Research (NICHD) [K01HD074651]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	The contents of this publication were developed under grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR): Indiana University School of Medicine/Rehabilitation Hospital of Indiana (grant 90DP0036), Icahn School of Medicine at Mount Sinai (grant 90DP0038), Rocky Mountain Regional Brain Injury System (grant 90DP0034), Ohio State University (grant 90DP0040), University of Alabama at Birmingham (grant 90DP0044), Traumatic Brain Injury Model Systems National Data and Statistical Center (grant 90DP0013 and 90DP0084), Moss TBI Model System (grant 90DP0037), North Texas TBI Model System (grant 90DP0045) and from the National Institutes of Health National Center for Medical Rehabilitation Research (NICHD; K01HD074651). NIDILRR is a center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Center for Disease Control and Prevention, 2017, NAT DIAB STAT REP; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dams-O'Connor K, 2017, J HEAD TRAUMA REHAB, V32, P147, DOI 10.1097/HTR.0000000000000263; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Federal Interagency Forum on Aging-Related Statistics, 2016, OLD AM 2016 KEY IND; Finley EP, 2015, AM J PUBLIC HEALTH, V105, P380, DOI 10.2105/AJPH.2014.301957; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; Goldstein FC., 1998, RECOVERY, V9, P28; Goleburn C., 2001, J CLIN GEROPSYCHOLOG, V7, DOI [https://doi.org/10.1023/A:1011335027445, DOI 10.1023/A:1011335027445]; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS330, DOI 10.1016/j.apmr.2014.09.041; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hart T, 2016, ARCH PHYS MED REHAB, V97, P701, DOI 10.1016/j.apmr.2015.08.436; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Holzman JB, 2017, NEUROSCI BIOBEHAV R, V74, P233, DOI 10.1016/j.neubiorev.2016.12.032; Institute of Medicine, 2009, GULF WAR HLTH, V7; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; Jarczok MN, 2014, J INTERN MED, V276, P667, DOI 10.1111/joim.12295; Jarczok MN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160743; Jarczok MN, 2013, INT J CARDIOL, V167, P855, DOI 10.1016/j.ijcard.2012.02.002; Keller JJ, 2013, NEUROUROL URODYNAM, V32, P354, DOI 10.1002/nau.22309; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kolakowsky-Hayner SA, 2000, NEUROREHABILITATION, V14, P151; Kumar RG, 2018, J HEAD TRAUMA REHAB, V33, P15, DOI 10.1097/HTR.0000000000000273; Liao CC, 2014, MAYO CLIN PROC, V89, P163, DOI 10.1016/j.mayocp.2013.09.019; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; MADDOX GL, 1973, J HEALTH SOC BEHAV, V14, P87, DOI 10.2307/2136940; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Masel BE, 2015, J NEUROTRAUM, V32, P1833, DOI 10.1089/neu.2015.29004.bm; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; MOZAFFARIAN D, 2015, CIRCULATION, V131, pE29, DOI [DOI 10.1161/CIR.0000000000000152, 10.1161/CIR.0000000000000152]; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1884, DOI 10.1016/j.apmr.2012.11.054; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Pasquale MD, 2005, CRIT CARE MED, V33, pA40, DOI 10.1097/00003246-200512002-00148; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Pugh MJV, 2015, J HEAD TRAUMA REHAB, V30, P29, DOI 10.1097/HTR.0000000000000045; Ramirez E, 2015, INT J PSYCHOPHYSIOL, V98, P490, DOI 10.1016/j.ijpsycho.2015.10.007; Schuster AK, 2016, INT J CARDIOL, V203, P728, DOI 10.1016/j.ijcard.2015.11.027; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Stacey A, 2017, J NEUROTRAUM, V34, P1558, DOI 10.1089/neu.2016.4721; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	65	17	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2019	34	4					E1	E10		10.1097/HTR.0000000000000465			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IQ4XH	WOS:000480754400001	30608311	Green Accepted, Green Published			2021-06-18	
J	Sharma, R; Shultz, SR; Robinson, MJ; Belli, A; Hibbs, ML; O'Brien, TJ; Semple, BD				Sharma, Rishabh; Shultz, Sandy R.; Robinson, Marcus J.; Belli, Antonio; Hibbs, Margaret L.; O'Brien, Terence J.; Semple, Bridgette D.			Infections after a traumatic brain injury: The complex interplay between the immune and neurological systems	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Infection; Pneumonia; Brain injury; Neurotrauma; Inflammation; Immune response; Immunosuppression	VENTILATOR-ASSOCIATED PNEUMONIA; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; CRITICALLY-ILL PATIENTS; ACUTE ISCHEMIC-STROKE; DOUBLE-STRANDED-RNA; NOSOCOMIAL INFECTIONS; INPATIENT REHABILITATION; HEAD-INJURY	Traumatic brain injury (TBI) is a serious global health issue, being the leading cause of death and disability for individuals under the age of 45, and one of the largest causes of global neurological disability. In addition to the brain injury itself, it is increasingly appreciated that a TBI may also alter the systemic immune response in a way that renders TBI patients more vulnerable to infections in the acute post-injury period. Such infections pose an additional challenge to the patient, increasing rates of mortality and morbidity, and worsening neurological outcomes. Hospitalization, surgical interventions, and a state of immunosuppression induced by injury to the central nervous system (CNS), may all contribute to the high rate of infections seen in the population with TBI. Ongoing research to better understand the immunomodulators that underlie TBI-induced immunosuppression may aid in the development of effective therapeutic strategies to improve the recovery trajectory for patients. This review first describes the clinical scenario, posing the question of whether TBI patients are more susceptible to infections such as pneumonia, and if so, why? We then consider how cross-talk between the injured brain and the systemic immune system occurs, and further, how the additional immune challenge of an acquired infection can contribute to ongoing neuroinflammation and neurodegeneration after a TBI. Experimental models combining TBI with infection are discussed, as well as current treatment options available for this double-barreled insult. The aims of this review are to summarize current understanding of the bidirectional relationship between the CNS and the immune system when faced with a mechanical trauma combined with a concomitant infection, and to highlight key outstanding questions that remain in the field.	[Sharma, Rishabh; Shultz, Sandy R.; O'Brien, Terence J.; Semple, Bridgette D.] Monash Univ, Dept Neurosci, Cent Clin Sch, Alfred Hosp, Melbourne, Vic, Australia; [Shultz, Sandy R.; O'Brien, Terence J.; Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne Med Sch, Parkville, Vic, Australia; [Robinson, Marcus J.; Hibbs, Margaret L.] Monash Univ, Dept Pathol & Immunol, Cent Clin Sch, Alfred Hosp, Melbourne, Vic, Australia; [Belli, Antonio] Univ Birmingham, Inst Inflammat & Ageing, Coll Med & Dent Sci, Birmingham, W Midlands, England	Semple, BD (corresponding author), Monash Univ, Dept Neurosci, Alfred Ctr, Level 6,99 Commercial Rd, Melbourne, Vic 3004, Australia.	Bridgette.Semple@monash.edu	Belli, Antonio/I-3799-2015	Belli, Antonio/0000-0002-3211-9933; Sharma, Rishabh/0000-0001-6832-9468; O'Brien, Terence/0000-0002-7198-8621; Robinson, Marcus/0000-0001-5677-3078	National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia; Monash UniversityMonash University	The authors gratefully acknowledge Fellowship and Project Grant support from the National Health and Medical Research Council of Australia (NHMRC) and Monash University. They also thank Ms. Bethany Semple, RN (Gold Coast University Hospital, Southport, QLD, Australia) for her critical review of the manuscript draft.	Aarabi B, 2000, NEUROSURG FOCUS, V8, P1, DOI DOI 10.3171/FOC.2000.8.1.155; Acker SN, 2014, J TRAUMA ACUTE CARE, V76, P1082, DOI 10.1097/TA.0000000000000095; Acosta S.A., 2013, PLOS ONE, V8, P1; Ahlers F. S., 2018, EPILEPSIA; Alali AS, 2015, J NEUROSURG-PEDIATR, V16, P523, DOI 10.3171/2015.3.PEDS14507; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Alharfi IM, 2014, J NEUROTRAUM, V31, P452, DOI [10.1089/NEU.2013.2904, 10.1089/neu.2013.2904]; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Alves JC, 2010, SHOCK, V34, P15, DOI 10.1097/SHK.0b013e3181e7e61b; Aly NYA, 2008, MED PRIN PRACT, V17, P373, DOI 10.1159/000141500; Amoo M, 2018, BRIT J NEUROSURG, V32, P585, DOI 10.1080/02688697.2018.1522416; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Andraweera N, 2016, AUST HEALTH REV, V40, P114, DOI 10.1071/AH15062; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Angus DC, 2016, JAMA-J AM MED ASSOC, V315, P1457, DOI 10.1001/jama.2016.2762; [Anonymous], 2018, LANCET, V391, P813, DOI 10.1016/S0140-6736(18)30547-6; Antunes Alessandra Armstrong, 2010, Asian J Neurosurg, V5, P68; Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bang Jin Hyuk, 2015, Korean J Neurotrauma, V11, P81, DOI 10.13004/kjnt.2015.11.2.81; Barald KF, 2018, EXP NEUROL, V301, P92, DOI 10.1016/j.expneurol.2017.10.009; Bassetti M, 2015, INTENS CARE MED, V41, P776, DOI 10.1007/s00134-015-3719-z; Batistaki C, 2008, VASC PHARMACOL, V48, P85, DOI 10.1016/j.vph.2007.12.003; Bhan C, 2016, INFLAMM RES, V65, P853, DOI 10.1007/s00011-016-0970-x; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Bogner J, 2015, ARCH PHYS MED REHAB, V96, pS274, DOI 10.1016/j.apmr.2015.04.020; Borger P, 1998, AM J RESP CELL MOL, V19, P400, DOI 10.1165/ajrcmb.19.3.2765; BRATHWAITE CEM, 1993, J TRAUMA, V34, P586, DOI 10.1097/00005373-199304000-00017; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; Cavaillon JM, 2006, CRIT CARE, V10, DOI 10.1186/cc5055; Cazareth J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-132; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chaudhry R, 2018, J NEUROSURG ANESTH, V30, P251, DOI 10.1097/ANA.0000000000000434; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; CHIU WC, 2014, LIVER TRANSPLANT, V21, P1068, DOI DOI 10.1111/ENE.12317; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cinel I, 2009, CRIT CARE MED, V37, P291, DOI 10.1097/CCM.0b013e31819267fb; Cirulis MM, 2016, PEDIATR CRIT CARE ME, V17, P157, DOI 10.1097/PCC.0000000000000590; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cummings CJ, 1999, J IMMUNOL, V162, P2341; CZLONKOWSKA A, 1979, J NEUROL SCI, V43, P455, DOI 10.1016/0022-510X(79)90024-8; de la Tremblaye PB, 2018, NEUROSCI BIOBEHAV R, V85, P160, DOI 10.1016/j.neubiorev.2017.05.022; DeJong G, 2013, ARCH PHYS MED REHAB, V94, pS87, DOI 10.1016/j.apmr.2012.10.037; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Delaloye J, 2013, CURR VASC PHARMACOL, V11, P123; Delano MJ, 2011, J IMMUNOL, V186, P195, DOI 10.4049/jimmunol.1002104; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Enicker B, 2014, INJURY, V45, P1355, DOI 10.1016/j.injury.2014.04.036; Ernst RK, 2003, J ENDOTOXIN RES, V9, P395, DOI 10.1179/096805103225002764; Eroglu C, 2010, NATURE, V468, P223, DOI 10.1038/nature09612; Esnault P, 2017, NEUROCRIT CARE, V27, P187, DOI 10.1007/s12028-017-0397-4; Fabregas N, 2002, Minerva Anestesiol, V68, P285; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Failli V, 2012, BRAIN, V135, P3238, DOI 10.1093/brain/aws267; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Garcia JM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00244; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gaynes R, 2005, CLIN INFECT DIS, V41, P848, DOI 10.1086/432803; Giamarellos-Bourboulis EJ, 2012, EXPERT REV ANTI-INFE, V10, P369, DOI [10.1586/eri.12.2, 10.1586/ERI.12.2]; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P794, DOI 10.1001/archsurg.2011.41; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Greathouse KM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0469-3; Griffin GD, 2011, MIL MED, V176, P364, DOI 10.7205/MILMED-D-10-00021; Haeusler KG, 2008, CEREBROVASC DIS, V25, P50, DOI 10.1159/000111499; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hamele M, 2016, J NEUROTRAUM, V33, P832, DOI 10.1089/neu.2015.4004; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS330, DOI 10.1016/j.apmr.2014.09.041; Hamza B, 2015, LAB CHIP, V15, P2625, DOI 10.1039/c5lc00245a; Harms H, 2011, CEREBROVASC DIS, V32, P552, DOI 10.1159/000331922; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hauser AR, 2016, CLIN INFECT DIS, V63, P89, DOI 10.1093/cid/ciw200; Hazeldine J, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002338; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hotchkiss RS, 2010, NEW ENGL J MED, V363, P87, DOI 10.1056/NEJMcibr1004371; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Hua R, 2012, WORLD J EMERG MED, V3, P294, DOI [10.5847/wjem.j.issn.1920-8642.2012.04.010, 10.5847/wjem.j.1920-8642.2012.04.010]; Huber-Lang M, 2018, NAT IMMUNOL, V19, P327, DOI 10.1038/s41590-018-0064-8; Hui X, 2013, J SURG RES, V184, P438, DOI 10.1016/j.jss.2013.05.072; Hurley JC., 2018, MICROORGANISMS, V6, pE2, DOI 10.3390/microorganisms6010002; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jovanovic B, 2016, MED PRIN PRACT, V25, P435, DOI 10.1159/000447566; Juengst SB, 2017, PSYCHOL RES BEHAV MA, V10, P175, DOI 10.2147/PRBM.S113264; Kanazawa M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102135; Kasten KR, 2010, BIOCHEM BIOPH RES CO, V393, P28, DOI 10.1016/j.bbrc.2010.01.066; Kenney MJ, 2014, COMPR PHYSIOL, V4, P1177, DOI 10.1002/cphy.c130051; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Khan HA, 2017, ASIAN PAC J TROP BIO, V7, P478, DOI 10.1016/j.apjtb.2017.01.019; Kim ID, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0438-8; Kinoshita D, 2009, PHYSIOL BEHAV, V96, P328, DOI 10.1016/j.physbeh.2008.10.018; Koh AY, 2009, INFECT IMMUN, V77, P5300, DOI 10.1128/IAI.00501-09; Kopp MA, 2017, NEUROLOGY, V88, P892, DOI [10.1212/WNL.0000000000003652, 10.1212/wnl.0000000000003652]; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Kovach MA, 2012, CURR OPIN INFECT DIS, V25, P321, DOI 10.1097/QCO.0b013e3283528c9b; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kuo CF, 2007, ANTIMICROB AGENTS CH, V51, P3122, DOI 10.1128/AAC.01379-06; Lepelletier D, 2010, J NEUROSURG ANESTH, V22, P32, DOI 10.1097/ANA.0b013e3181bdf52f; Li W, 2016, J NEUROL, V263, P1280, DOI 10.1007/s00415-016-8093-4; Liao CC, 2014, MAYO CLIN PROC, V89, P163, DOI 10.1016/j.mayocp.2013.09.019; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lomsadze G. O., 2013, GEORGIAN MED NEWS, V223, P60; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lu Li-quan, 2003, Chin J Traumatol, V6, P302; Lukewich MK, 2014, SEMIN IMMUNOL, V26, P402, DOI 10.1016/j.smim.2014.01.004; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Lustenberger T, 2016, IMMUNOBIOLOGY, V221, P427, DOI 10.1016/j.imbio.2015.11.011; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MacFie J, 2004, BRIT MED BULL, V71, P1, DOI 10.1093/bmb/ldh029; Magnotti Louis J, 2004, Surg Infect (Larchmt), V5, P237, DOI 10.1089/sur.2004.5.237; McClellan N, 2015, ANN PHARMACOTHER, V49, P515, DOI 10.1177/1060028015570466; Medzhitov R, 2010, NAT IMMUNOL, V11, P551, DOI 10.1038/ni0710-551; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mohawk KL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/258185; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Odgaard L, 2018, J NEUROSCI NURS, V50, P149, DOI 10.1097/JNN.0000000000000365; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Pandya A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28189-0; Paradisi F, 2001, CLIN MICROBIOL INFEC, V7, P34, DOI 10.1046/j.1469-0691.2001.00056.x; Park C, 2006, GLIA, V53, P248, DOI 10.1002/glia.20278; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Platzer C, 2000, J NEUROIMMUNOL, V105, P31, DOI 10.1016/S0165-5728(00)00205-8; Pletzer D, 2017, MBIO, V8, DOI 10.1128/mBio.00140-17; Plurad DS, 2013, J SURG RES, V183, P371, DOI 10.1016/j.jss.2013.01.036; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reddy D, 2015, J TROP PEDIATRICS, V61, P182, DOI 10.1093/tropej/fmv017; Restifo NP, 2013, CURR OPIN IMMUNOL, V25, P556, DOI 10.1016/j.coi.2013.09.003; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Russo MV, 2018, J IMMUNOL, V200; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Saletti P. G., 2018, NEUROBIOL DIS; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schimmel Samantha J, 2017, Brain Circ, V3, P135, DOI 10.4103/bc.bc_18_17; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Semple BD, 2017, J NEUROSCI, V37, P7864, DOI 10.1523/JNEUROSCI.0982-17.2017; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shim R, 2018, BRAIN BEHAV IMMUN, V70, P10, DOI 10.1016/j.bbi.2018.03.019; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shuman EK, 2018, INFECT DIS CLIN N AM, V32, P885, DOI 10.1016/j.idc.2018.07.002; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; SMITH CJ, 2004, BMC NEUROL, V4; Smith RS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004120; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stephan F, 2006, ANESTHESIOLOGY, V104, P235, DOI 10.1097/00000542-200602000-00006; Stephan F, 2002, CRIT CARE MED, V30, P315, DOI 10.1097/00003246-200202000-00009; Swearengen James R, 2018, Animal Model Exp Med, V1, P100, DOI 10.1002/ame2.12020; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tamayo E, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.09.001; Tang ME, 2009, MT SINAI J MED, V76, P119, DOI 10.1002/msj.20106; Temkin N R, 1995, New Horiz, V3, P518; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Tran J, 2017, J HEAD TRAUMA REHAB, V32, P264, DOI 10.1097/HTR.0000000000000296; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Ulndreaj A, 2016, EXPERT REV NEUROTHER, V16, P1127, DOI 10.1080/14737175.2016.1207532; Valencic L, 2015, SANAMED, V10, P185, DOI [10.5937/sanamed1503185V, DOI 10.5937/SANAMED1503185V]; Valero J., 2014, FRONT NEUROSCI, V8; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060; Vezzani A, 2016, ACTA NEUROPATHOL, V131, P211, DOI 10.1007/s00401-015-1481-5; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Walsh JT, 2014, J IMMUNOL, V193, P5013, DOI 10.4049/jimmunol.1302401; Walsh S, 2017, NEUROTOXICOLOGY, V61, P64, DOI 10.1016/j.neuro.2016.03.011; Wang CF, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/189785; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woiciechowsky C, 1999, BRAIN RES, V816, P563, DOI 10.1016/S0006-8993(98)01238-4; Woiciechowsky C, 1999, J MOL MED-JMM, V77, P769, DOI 10.1007/s001099900051; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wu Z, 2005, J NEUROIMMUNOL, V167, P90, DOI 10.1016/j.jneuroim.2005.06.025; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu Jing, 2015, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V40, P797, DOI 10.11817/j.issn.1672-7347.2015.07.015; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Yang YW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169267; Zafar SN, 2011, J NEUROTRAUM, V28, P1307, DOI 10.1089/neu.2010.1724; ZHANG XK, 1993, J LEUKOCYTE BIOL, V54, P444; Zhao ZL, 2013, CHINESE MED J-PEKING, V126, P3754, DOI 10.3760/cma.j.issn.0366-6999.20130116; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	233	17	18	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2019	79						63	74		10.1016/j.bbi.2019.04.034			12	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	IH2MH	WOS:000474328400015	31029794				2021-06-18	
J	Romero-Martinez, A; Lila, M; Gracia, E; Moya-Albiol, L				Romero-Martinez, Angel; Lila, Marisol; Gracia, Enrique; Moya-Albiol, Luis			Improving empathy with motivational strategies in batterer intervention programmes: Results of a randomized controlled trial	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						batterer interventions; cognitive flexibility; emotion-decoding abilities; intimate partner violence; neuropsychology	TRAUMATIC BRAIN-INJURY; DOMESTIC VIOLENCE; COGNITIVE FLEXIBILITY; PARTNER; PERPETRATORS; MECHANISMS; MIND; IMPAIRMENTS; VERSION; EYES	ObjectivesEmpathy (i.e., the ability to decode emotions, as well as cognitive and emotional empathy) is involved in moral reasoning, prosocial behaviour, social and emotional adequacy, mood and behaviour regulation. Hence, alterations in these functions could reduce behaviour control and the adoption of specific types of violence such as intimate partner violence (IPV). Although interventions for IPV perpetrators focus on reducing IPV risk factors and increasing protective factors to prevent this kind of violence, the study of the effectiveness of these programmes in promoting changes in empathy (cognitive and emotional) has been neglected. DesignHence, the main aim of this study was to compare the effectiveness of two different modalities of IPV intervention programmes (Standard Batterer Intervention Programs [SBIP] vs. SBIP+Individualized Motivational Plan [IMP]) in promoting empathic improvements after both interventions. MethodParticipants were randomly assigned to receive SBIP (n=40) or SBIP+IMP (n=53). The effectiveness of the intervention in the total sample and the group effects were evaluated with general linear model repeated-measures ANOVA. ResultsResults revealed that only the IPV perpetrators who received the SBIP+IMP were more accurate in decoding emotional facial signals and presented better cognitive empathy (perspective taking) after the intervention programme. ConclusionsOur study reinforces the view that different modalities of IPV intervention might lead to different cognitive outcomes after the intervention. Thus, these results may help professionals to develop specific intervention programmes focused on improving cognitive abilities in order to reduce IPV recidivism. Practitioner points Interventions for batterers' neglected empathic changes after these programmes. Not enough randomized controlled trials for these kinds of interventions. An improvement in the ability to decode emotions after the intervention programme. An improvement in cognitive empathy (perspective taking) after the intervention programme. Different modalities of IPV intervention might lead to different cognitive outcomes after the intervention.	[Romero-Martinez, Angel; Moya-Albiol, Luis] Univ Valencia, Dept Psychobiol, Ave Blasco Ibanez 21, Valencia 46010, Spain; [Lila, Marisol; Gracia, Enrique] Univ Valencia, Dept Social Psychol, Valencia, Spain	Romero-Martinez, A (corresponding author), Univ Valencia, Dept Psychobiol, Ave Blasco Ibanez 21, Valencia 46010, Spain.	Angel.Romero@uv.es	ROMERO-MARTINEZ, ANGEL/L-7316-2018; Gracia, Enrique/B-7105-2008; Lila, Marisol/G-8638-2011	Gracia, Enrique/0000-0003-0514-2983; Lila, Marisol/0000-0002-0522-7461; Romero-Martinez, Angel/0000-0002-5922-0265	Beca Leonardo a Investigadores y Creadores Culturales 2018 de la Fundacion BBVABBVA Foundation; 2018 Leonardo Grant for Researchers and Cultural Creators, BBVA FoundationBBVA Foundation	The implementation of this study has partly been made possible by funding from the Beca Leonardo a Investigadores y Creadores Culturales 2018 de la Fundacion BBVA. Project supported by a 2018 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation. The Foundation accepts no responsibility for the opinions, statements and contents included in the project and/or the results thereof, which are entirely the responsibility of the authors.	Arbach K, 2018, PSYCHOSOC INTERV, V27, P105, DOI 10.5093/pi2018a13; Arias Esther, 2013, Psychosocial Intervention, V22, P153, DOI 10.5093/in2013a18; Babcock JC, 2004, CLIN PSYCHOL REV, V23, P1023, DOI 10.1016/j.cpr.2002.07.001; Balconi M, 2016, COGNITION EMOTION, V30, P210, DOI 10.1080/02699931.2014.993306; Baldner C, 2014, MOTIV EMOTION, V38, P727, DOI 10.1007/s11031-014-9417-2; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Batchelder L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169185; Bowen E., 2011, REHABILITATION PARTN; Burnett EJ, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.08.012; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crane CA, 2013, J COUNS PSYCHOL, V60, P180, DOI 10.1037/a0032178; Cunha O, 2014, REV PSIQ CLIN-BRAZIL, V41, P40, DOI 10.1590/0101-60830000000008; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; De Obeso Orendain A. D. O., 2012, P 11 INT C COGN MOD, P49; Eckhardt C, 2008, VIOLENCE VICTIMS, V23, P446, DOI 10.1891/0886-6708.23.4.446; Eckhardt CI, 2013, PARTN ABUSE, V4, P196, DOI 10.1891/1946-6560.4.2.196; Feder L., 2005, J EXP CRIMINOL, V1, P239, DOI [DOI 10.1007/S11292-005-1179-0, 10.1007/s11292-005-1179-0]; Fernandez-Abascal EG, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-33; Ferrer-Perez VA, 2016, PSYCHOSOC INTERV, V25, P159, DOI 10.1016/j.psi.2016.06.001; Gondolf EW, 2004, AGGRESS VIOLENT BEH, V9, P605, DOI 10.1016/j.avb.2003.06.001; Heinz AJ, 2011, NAT REV NEUROSCI, V12, P400, DOI 10.1038/nrn3042; Huelle JO, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00077; Ingram F, 1999, BRIT J CLIN PSYCHOL, V38, P209, DOI 10.1348/014466599162764; Lopez-Ossorio JJ, 2018, PSYCHOSOC INTERV, V27, P95, DOI 10.5093/pi2018a11; Kistenmacher BR, 2008, VIOLENCE VICTIMS, V23, P558, DOI 10.1891/0886-6708.23.5.558; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; Lila M, 2018, J CONSULT CLIN PSYCH, V86, P309, DOI 10.1037/ccp0000291; Lila M, 2013, EUR J PSYCHOL APPL L, V5, P147, DOI 10.5093/ejpalc2013a4; Lila M, 2012, REV LAT AM PSICOL, V44, P99; Maleki L., 2016, INT J SOCIAL BEHAV E, V9, P3654; Martin-Fernandez M, 2018, PSYCHOSOC INTERV, V27, P133, DOI 10.5093/pi2018a18; Martinez AM, 2017, CURR OPIN PSYCHOL, V17, P27, DOI 10.1016/j.copsyc.2017.06.009; Mestre-Escriva V, 2004, PSICOTHEMA, V16, P255; Murphy C. M., 2017, J INTERPERSONAL VIOL; Musser PH, 2008, VIOLENCE VICTIMS, V23, P539, DOI 10.1891/0886-6708.23.5.539; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Pinto LA, 2010, AGGRESS VIOLENT BEH, V15, P387, DOI 10.1016/j.avb.2010.07.001; Ramsoy TZ, 2015, SOC NEUROSCI-UK, V10, P179, DOI 10.1080/17470919.2014.965341; Richardson JTE, 2011, EDUC RES REV-NETH, V6, P135, DOI 10.1016/j.edurev.2010.12.001; Romero-Martinez A, 2017, PSYCHOSOC INTERV, V26, P165, DOI 10.1016/j.psi.2017.06.002; Romero-Martinez A, 2016, EUR J PSYCHOL APPL L, V8, P57, DOI 10.1016/j.ejpal.2016.01.001; Romero-Martinez A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040394; Romero-Martinez A, 2013, REV NEUROLOGIA, V57, P515, DOI 10.33588/rn.5711.2013141; Romero-Martinez A, 2013, INT J ENV RES PUB HE, V10, P3753, DOI 10.3390/ijerph10083753; Romero-Martinez A, 2013, AGGRESSIVE BEHAV, V39, P355, DOI 10.1002/ab.21490; Santirso FA, 2018, INT J CLIN HLTH PSYC, V18, P152, DOI 10.1016/j.ijchp.2018.02.003; Sato W, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00151; Schipper M, 2013, SOC NEUROSCI-UK, V8, P101, DOI 10.1080/17470919.2012.761650; Stemme A, 2007, J COMPUT NEUROSCI, V23, P313, DOI 10.1007/s10827-007-0034-x; Sun S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01059; Thye MD, 2018, NEUROSCIENCE, V374, P172, DOI 10.1016/j.neuroscience.2018.01.045; van Berkhout ET, 2016, J COUNS PSYCHOL, V63, P32, DOI 10.1037/cou0000093; Zaki J, 2014, PSYCHOL BULL, V140, P1608, DOI 10.1037/a0037679	55	17	17	7	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0144-6657	2044-8260		BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	JUN	2019	58	2					125	139		10.1111/bjc.12204			15	Psychology, Clinical	Psychology	HX1WJ	WOS:000467183500001	30345574				2021-06-18	
J	Tigchelaar, S; Gupta, R; Shannon, CP; Streijger, F; Sinha, S; Flibotte, S; Rizzuto, MA; Street, J; Paquette, S; Ailon, T; Charest-Morin, R; Dea, N; Fisher, C; Dvorak, MF; Dhall, S; Mac-Thiong, JM; Parent, S; Bailey, C; Christie, S; Van Keuren-Jensen, K; Nislow, C; Kwon, BK				Tigchelaar, Seth; Gupta, Rishab; Shannon, Casey P.; Streijger, Femke; Sinha, Sunita; Flibotte, Stephane; Rizzuto, Michael A.; Street, John; Paquette, Scott; Ailon, Tamir; Charest-Morin, Raphaele; Dea, Nicolas; Fisher, Charles; Dvorak, Marcel F.; Dhall, Sanjay; Mac-Thiong, Jean-Marc; Parent, Stefan; Bailey, Christopher; Christie, Sean; Van Keuren-Jensen, Kendall; Nislow, Corey; Kwon, Brian K.			MicroRNA Biomarkers in Cerebrospinal Fluid and Serum Reflect Injury Severity in Human Acute Traumatic Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; microRNA; next-generation sequencing; spinal cord injury	CLINICAL-TRIALS; BRAIN-INJURY; CIRCULATING MICRORNAS; BLOOD BIOMARKERS; PORCINE MODEL; RECOVERY; IDENTIFICATION; PREVALENCE; GENES; ROLES	Spinal cord injury (SCI) is a devastating condition with variability in injury mechanisms and neurologic recovery. Spinal cord impairment after SCI is measured and classified by a widely accepted standard neurological examination. In the very acute stages post-injury, however, this examination is extremely challenging (and often impossible) to conduct and has modest prognostic value in terms of neurological recovery. The lack of objective tools to classify injury severity and predict outcome is a barrier for clinical trials and thwarts development of therapies for those with SCI. Biological markers (biomarkers) represent a promising, complementary approach to these challenges because they represent an unbiased approach to classify injury severity and predict neurological outcome. Identification of a suitable panel of molecular biomarkers would comprise a fundamental shift in how patients with acute SCI are evaluated, stratified, and treated in clinical trials. MicroRNA are attractive biomarker candidates in neurological disorders for several reasons, including their stability in biological fluids, their conservation between humans and model mammals, and their tissue specificity. In this study, we used next-generation sequencing to identify microRNA associated with injury severity within the cerebrospinal fluid (CSF) and serum of human patients with acute SCI. The CSF and serum samples were obtained 1-5 days post-injury from 39 patients with acute SCI (24 American Spinal Injury Association Impairment Scale [AIS] A, 8 AIS B, 7 AIS C) and from five non-SCI controls. We identified a severity-dependent pattern of change in microRNA expression in CSF and identified a set of microRNA that are diagnostic of baseline AIS classification and prognostic of neurological outcome six months post-injury. The data presented here provide a comprehensive description of the CSF and serum microRNA expression changes that occur after acute human SCI. This data set reveals microRNA candidates that warrant further evaluation as biomarkers of injury severity after SCI and as key regulators in other neurological disorders.	[Tigchelaar, Seth; Gupta, Rishab; Streijger, Femke; Rizzuto, Michael A.; Dvorak, Marcel F.; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC, Canada; [Shannon, Casey P.] Prevent Organ Failure Proof Ctr Excellence, Vancouver, BC, Canada; [Sinha, Sunita; Flibotte, Stephane; Nislow, Corey] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Street, John; Charest-Morin, Raphaele; Fisher, Charles; Dvorak, Marcel F.; Kwon, Brian K.] Univ British Columbia, Dept Orthoped, Div Spine, Vancouver, BC, Canada; [Paquette, Scott; Ailon, Tamir; Dea, Nicolas] Univ British Columbia, Div Neurosurg, Vancouver, BC, Canada; [Dhall, Sanjay] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Mac-Thiong, Jean-Marc] Hop Sacre Coeur Montreal, Montreal, PQ, Canada; [Parent, Stefan] Univ Montreal, Dept Surg, Chu St Justine, Montreal, PQ, Canada; [Bailey, Christopher] Victoria Hosp, Div Orthopaed Surg Schulich Med & Dent, London, ON, Canada; [Christie, Sean] Dalhousie Univ, Halifax Infirm, Div Neurosurg, Halifax, NS, Canada; [Van Keuren-Jensen, Kendall] Translat Genom, Phoenix, AZ USA	Kwon, BK (corresponding author), Blusson Spinal Cord Ctr, 6th Floor 818 West 10th Ave, Vancouver, BC V5Z 1M9, Canada.	brian.kwon@ubc.ca	Parent, Stefan/AAO-7492-2020; Bailey, Chris S/L-7522-2015	Parent, Stefan/0000-0002-4854-2816; Bailey, Chris S/0000-0001-5508-8415; Rizzuto, Michael/0000-0001-7743-4454; Christie, Sean/0000-0002-3540-6022; Shannon, Casey/0000-0002-5687-3156; Tigchelaar, Seth/0000-0002-2207-9034; Dvorak, Marcel/0000-0002-9404-8448	Brain Canada Foundation; GenomeBC; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; MITACS; VGH & UBC Hospital Foundation	The authors gratefully acknowledge the grant support of the Brain Canada Foundation, GenomeBC, Michael Smith Foundation for Health Research, MITACS, and the VGH & UBC Hospital Foundation. The authors also acknowledge the assistance of Allan Aludino and Leilani Reichl of the Vancouver Spine Research Program for support of the clinical trial, Daniel Rogers of the Rick Hansen Institute for managing the Canadian Multicentre CSF Monitoring and Biomaker (CAMPER) study, and Sara Assadian for managing the Brain Canada Multi-Investigator Research Initiative (MIRI). MFD is the Paetzold Chair in Spinal Cord Injury Research. BKK is the Canada Research Chair in Spinal Cord Injury and Dvorak Chair in Spine Trauma.	Ahadi R, 2015, SPINE, V40, pE823, DOI 10.1097/BRS.0000000000000654; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Badhiwala JH, 2018, J NEUROTRAUM, V35, P1906, DOI 10.1089/neu.2018.5935; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Baran-Gale J, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00352; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Boon H, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12622; Brennan FH, 2018, CURR OPIN NEUROL, V31, P334, DOI 10.1097/WCO.0000000000000550; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253; Dalkilic T, 2018, J NEUROTRAUM, V35, P435, DOI 10.1089/neu.2017.5357; Elizei SS, 2017, NEURAL REGEN RES, V12, P385, DOI 10.4103/1673-5374.202933; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; Friedlander MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Gong ZM, 2018, BIOCHEM BIOPH RES CO, V501, P501, DOI 10.1016/j.bbrc.2018.05.022; Hachisuka S, 2014, SPINAL CORD, V52, P596, DOI 10.1038/sc.2014.86; He Y., 2018, BIOSCI REP, V38; Jickling GC, 2011, NEUROTHERAPEUTICS, V8, P349, DOI 10.1007/s13311-011-0050-4; Johnson JJ, 2018, JAMA PEDIATR, V172, P65, DOI 10.1001/jamapediatrics.2017.3884; Kim KT, 2018, J KOREAN NEUROSURG S, V61, P539, DOI 10.3340/jkns.2017.0276; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Krueger H, 2013, CHRON DIS INJ CAN, V33, P113; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kwon BK, 2017, J NEUROTRAUM, V34, P567, DOI 10.1089/neu.2016.4435; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lau P, 2008, J NEUROSCI, V28, P11720, DOI 10.1523/JNEUROSCI.1932-08.2008; Lee JHT, 2013, J NEUROTRAUM, V30, P142, DOI 10.1089/neu.2012.2386; Lee RS, 2012, J CLIN NEUROSCI, V19, P1338, DOI 10.1016/j.jocn.2012.02.015; Leshkowitz D, 2013, RNA, V19, P527, DOI 10.1261/rna.036475.112; Li MM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04734; Li P, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1279051; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lubieniecka JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019247; Marincola FM, 2011, J INTERN MED, V270, P123, DOI 10.1111/j.1365-2796.2011.02402.x; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053; Ning B, 2014, INT J BIOL SCI, V10, P997, DOI 10.7150/ijbs.9058; Noonan VK, 2012, NEUROEPIDEMIOLOGY, V38, P219, DOI 10.1159/000336014; Patz S, 2013, J NEUROTRAUM, V30, P1232, DOI 10.1089/neu.2012.2596; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176; Priebe M. M., 2007, ARCH PHYS MED REHA S, V88, pS84; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Shi ZJ, 2017, INT J NEUROSCI, V127, P1104, DOI 10.1080/00207454.2017.1323208; Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889; Squair JW, 2018, ELIFE, V7, DOI 10.7554/eLife.39188; Streijger F, 2017, J NEUROTRAUM, V34, P2054, DOI 10.1089/neu.2016.4879; Strickland ER, 2011, NEUROSCIENCE, V186, P146, DOI 10.1016/j.neuroscience.2011.03.063; Sun ZF, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-423; Tigchelaar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01299-x; Wernersson R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-70; Whiteley W, 2012, STROKE, V43, P86, DOI 10.1161/STROKEAHA.111.634089; Wu YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38718; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yu YM, 2011, EUR J NEUROSCI, V33, P1587, DOI 10.1111/j.1460-9568.2011.07643.x; Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	66	17	18	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 1	2019	36	15					2358	2371		10.1089/neu.2018.6256		MAY 2019	14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IM5VD	WOS:000469288900001	30827169				2021-06-18	
J	Ocak, U; Ocak, PE; Wang, AN; Zhang, JH; Boling, W; Wu, P; Mo, J; Zhang, TY; Huang, L				Ocak, Umut; Ocak, Pinar Eser; Wang, Annie; Zhang, John H.; Boling, Warren; Wu, Pei; Mo, Jun; Zhang, Tongyu; Huang, Lei			Targeting mast cell as a neuroprotective strategy	BRAIN INJURY			English	Article						Mast cell; brain; neuroprotection; neuroinflammation; stroke; trauma; hypoxia	EARLY BRAIN-INJURY; NF-KAPPA-B; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; EXPERIMENTAL ISCHEMIC-STROKE; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; INTRACEREBRAL HEMORRHAGE; SIGNALING PATHWAY; HYPOXIA-ISCHEMIA; C-KIT	Background: Mast cells (MCs) are perivascularly located immune cells of haematopoietic origin. Emerging evidences suggest that the activation of MCs play important roles in the pathogenesis of blood brain barrier disruption, neuroinflammation, and neurodegeneration.Objectives: In this review, we aimed to discuss the detrimental effects of MCs in response to various types of brain injury, as well as the therapeutic potential and neuroprotective effects of targeting the activation and degranulation of MCs, particularly in the management of the acute phase.Methods: An extensive online literature search was conducted through Pubmed/Central on March 2018. Then, we comprehensively summarized the effects of the activation of brain MCs in acute brain injury along with current pharmacological strategies targeting at the activation of MCs.Results: The review of the current literature indicated that the activation and degranulation of brain MCs significantly contribute to the acute pathological process following different types of brain injury including focal and global cerebral ischaemia, intracerebral haemorrhage, subarachnoid haemorrhage, and traumatic brain injury.Conclusions: Brain MCs significantly contribute to the acute pathological processes following brain injury. In that regard, targeting brain MCs may provide a novel strategy for neuroprotection.	[Ocak, Umut; Ocak, Pinar Eser; Boling, Warren; Mo, Jun; Zhang, Tongyu; Huang, Lei] Loma Linda Univ, Sch Med, Dept Basic Sci, Div Physiol, Loma Linda, CA 92354 USA; [Wang, Annie; Zhang, John H.; Boling, Warren] Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Boling, Warren; Wu, Pei; Huang, Lei] Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; [Mo, Jun] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin, Heilongjiang, Peoples R China; [Zhang, Tongyu] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Dept Neurosurg, Yiwu, Zhejiang, Peoples R China	Huang, L (corresponding author), Loma Linda Univ, Sch Med, Dept Basic Sci, Div Physiol, Loma Linda, CA 92354 USA.	lhuang@llu.edu	OCAK, UMUT/O-5167-2018; Eser, Pinar/AAI-2073-2021	OCAK, UMUT/0000-0002-6549-4246; Eser Ocak, Pinar/0000-0003-0132-9927			Ahmad A, 2012, BRAIN RES, V1477, P45, DOI 10.1016/j.brainres.2012.08.006; Akyol GY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15455-w; Aoki T, 2008, CURR NEUROVASC RES, V5, P37, DOI 10.2174/156720208783565663; Aoki T, 2007, CIRCULATION, V116, P2830, DOI 10.1161/CIRCULATIONAHA.107.728303; Aoki T, 2007, STROKE, V38, P162, DOI 10.1161/01.STR.0000252129.18605.c8; Aoki T, 2009, STROKE, V40, P942, DOI 10.1161/STROKEAHA.108.532556; Aoki T, 2009, NEUROSURGERY, V64, P357, DOI 10.1227/01.NEU.0000336764.92606.1D; Arac A, 2014, AM J PATHOL, V184, P2493, DOI 10.1016/j.ajpath.2014.06.003; Arsene D, 2011, ROM J MORPHOL EMBRYO, V52, P29; Arumugam TV, 2008, EXPERT OPIN THER TAR, V12, P19, DOI 10.1517/14728222.12.1.19; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Baba A, 2016, CELL PHYSIOL BIOCHEM, V38, P15, DOI 10.1159/000438605; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Becker KJ, 1998, NEUROSURG CLIN N AM, V9, P435; Berger R, 1999, BRAIN RES REV, V30, P107, DOI 10.1016/S0165-0173(99)00009-0; Beridze M, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-41; Boddaert N, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.137; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Bot I, 2007, CIRCULATION, V115, P2516, DOI 10.1161/CIRCULATIONAHA.106.660472; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Caltagirone C, 2016, TRANSL STROKE RES, V7, P54, DOI 10.1007/s12975-015-0440-8; Chen CH, 2010, NEUROSCIENCE, V169, P402, DOI 10.1016/j.neuroscience.2010.04.043; Chen S, 2015, TRANSL STROKE RES, V6, P4, DOI 10.1007/s12975-014-0384-4; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Chyatte D, 1997, STROKE, V28, P799, DOI 10.1161/01.STR.28.4.799; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; CUTZ E, 1978, NATURE, V275, P661, DOI 10.1038/275661a0; De Filippis D, 2013, CNS NEUROL DISORD-DR, V12, P78, DOI 10.2174/1871527311312010013; De Filippis D, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-3; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Di Girolamo N, 2006, J IMMUNOL, V177, P2638, DOI 10.4049/jimmunol.177.4.2638; DIMITRIADOU V, 1990, NEUROSCIENCE, V39, P209, DOI 10.1016/0306-4522(90)90234-U; Dong HQ, 2014, MED SCI MONIT BASIC, V20, P200, DOI 10.12659/MSMBR.893093; DOYLE MP, 1994, AM J PHYSIOL, V266, pH2042; DROPP JJ, 1976, ACTA ANAT, V94, P1; Dubreuil P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007258; DUX E, 1982, EXP BRAIN RES, V47, P252; EDVINSSON L, 1977, NEUROLOGY, V27, P878, DOI 10.1212/WNL.27.9.878; Erben P, 2014, ANN HEMATOL, V93, P81, DOI 10.1007/s00277-013-1964-1; Esposito E, 2014, PHARMACOL RES, V86, P26, DOI 10.1016/j.phrs.2014.05.009; FALEIRO LCM, 1981, J NEUROSURG, V54, P733, DOI 10.3171/jns.1981.54.6.0733; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Ferriero DM, 2002, DEV NEUROSCI-BASEL, V24, P349, DOI 10.1159/000069048; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Foerch C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054203; Frank BT, 2001, J IMMUNOL, V166, P2783, DOI 10.4049/jimmunol.166.4.2783; Fujii M, 2014, J NEUROL SCI, V342, P101, DOI 10.1016/j.jns.2014.04.034; Fukuda S, 2000, CIRCULATION, V101, P2532, DOI 10.1161/01.CIR.101.21.2532; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Garg P, 2010, NEUROSCIENCE, V166, P252, DOI 10.1016/j.neuroscience.2009.11.069; GOLDSCHMIDT RC, 1984, BRAIN RES, V323, P209, DOI 10.1016/0006-8993(84)90291-9; GOLDSCHMIDT RC, 1985, J NEUROCHEM, V44, P1943, DOI 10.1111/j.1471-4159.1985.tb07191.x; GROSS PM, 1982, AM J PHYSIOL, V243, pH307; Guo ZD, 2016, STROKE, V47, P490, DOI 10.1161/STROKEAHA.115.011223; Hagberg H, 2015, NAT REV NEUROL, V11, P192, DOI 10.1038/nrneurol.2015.13; Hall NC, 2000, CELL MOL BIOL, V46, P673; Hallgren J, 2007, IMMUNOL REV, V217, P8, DOI 10.1111/j.1600-065X.2007.00502.x; He Y, 2015, STROKE, V46, P2277, DOI 10.1161/STROKEAHA.115.010088; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hei ZQ, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-42; Hellings WE, 2008, JAMA-J AM MED ASSOC, V299, P547, DOI 10.1001/jama.299.5.547; Hendrikus E, 2017, NEUROSCI BIOBEHAV R, V83, P774, DOI 10.1016/j.neubiorev.2017.10.030; Hendrix S, 2013, FASEB J, V27, P920, DOI 10.1096/fj.12-204800; Hu WW, 2004, BRAIN RES, V1019, P275, DOI 10.1016/j.brainres.2004.05.109; Huang XP, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00398; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ibrahim MZM, 1996, J NEUROIMMUNOL, V70, P131, DOI 10.1016/S0165-5728(96)00102-6; IBRAHIM MZM, 1985, ACTA ANAT, V124, P149; Ishibashi R, 2010, CURR NEUROVASC RES, V7, P113, DOI 10.2174/156720210791184916; Itoh T, 2009, BIOCHEM BIOPH RES CO, V389, P651, DOI 10.1016/j.bbrc.2009.09.047; Jeong S, 2014, J NEUROIMMUNOL, V276, P112, DOI 10.1016/j.jneuroim.2014.08.626; Jin YX, 2007, DEV NEUROSCI-BASEL, V29, P373, DOI 10.1159/000105478; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Jonsson F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00016; Johnson JL, 1998, ARTERIOSCL THROM VAS, V18, P1707, DOI 10.1161/01.ATV.18.11.1707; Kaptain GJ, 2000, DRUG AGING, V17, P183, DOI 10.2165/00002512-200017030-00003; Kasner SE, 2001, STROKE, V32, P2117, DOI 10.1161/hs0901.095719; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kempuraj D, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00703; Kempuraj D, 2016, NEUROCHEM RES, V41, P1042, DOI 10.1007/s11064-015-1790-z; Khalil M, 2007, BRAIN RES, V1171, P18, DOI 10.1016/j.brainres.2007.07.034; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kim DY, 2010, J IMMUNOL, V185, P273, DOI 10.4049/jimmunol.1000991; King JT, 1997, NEUROIMAG CLIN N AM, V7, P659; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1993, AM J MED SCI, V306, P185, DOI 10.1097/00000441-199309000-00011; Kocic I, 2015, N-S ARCH PHARMACOL, V388, P79, DOI 10.1007/s00210-014-1061-6; Kulka M, 2009, J LEUKOCYTE BIOL, V86, P1217, DOI 10.1189/jlb.0908517; Kusaka G, 2004, J CEREBR BLOOD F MET, V24, P916, DOI 10.1097/01.WCB.0000125886.48838.7E; Kuwabara A, 2017, NEUROSURGERY, V81, P1021, DOI 10.1093/neuros/nyx172; Laine P, 1999, CIRCULATION, V99, P361, DOI 10.1161/01.CIR.99.3.361; Lapchak PA, 2017, TRANSL STROKE RES, V8, P318, DOI 10.1007/s12975-017-0529-3; Lappalainen H, 2004, ARTERIOSCL THROM VAS, V24, P1880, DOI 10.1161/01.ATV.0000140820.51174.8d; Levy D, 2016, CEPHALALGIA, V36, P915, DOI 10.1177/0333102415617412; Li JR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0959-6; Li X, 2018, TRANSL STROKE RES, V9, P549, DOI 10.1007/s12975-018-0664-5; Li XS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00127; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; LISZCZAK TM, 1983, J NEUROSURG, V58, P18, DOI 10.3171/jns.1983.58.1.0018; Liu F, 2015, EXP NEUROL, V272, P120, DOI 10.1016/j.expneurol.2015.04.016; Liu FD, 2013, ACTA PHARMACOL SIN, V34, P1121, DOI 10.1038/aps.2013.89; Liu L, 2018, MOL NEUROBIOL, V55, P8346, DOI 10.1007/s12035-018-1006-z; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; Lok J, 2011, ACTA NEUROCHIR SUPPL, V111, P63, DOI 10.1007/978-3-7091-0693-8_11; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Manaenko A, 2013, CRIT CARE MED, V41, P1266, DOI 10.1097/CCM.0b013e31827711c9; MANNAIONI PF, 1991, INT J TISSUE REACT, V13, P271; Marinkovic I, 2014, J CEREBR BLOOD F MET, V34, P176, DOI 10.1038/jcbfm.2013.189; Mattila OS, 2011, STROKE, V42, P3600, DOI 10.1161/STROKEAHA.111.632224; Medic N, 2010, J NEUROIMMUNOL, V218, P57, DOI 10.1016/j.jneuroim.2009.10.011; Montaner J, 2010, TRANSL STROKE RES, V1, P261, DOI 10.1007/s12975-010-0038-0; Montecucco F, 2010, STROKE, V41, P1394, DOI 10.1161/STROKEAHA.110.578369; Moon TC, 2010, MUCOSAL IMMUNOL, V3, P111, DOI 10.1038/mi.2009.136; Moretti R, 2016, J NEUROSCI RES, V94, P1546, DOI 10.1002/jnr.23911; Moriwaki T, 2006, STROKE, V37, P900, DOI 10.1161/01.STR.0000204028.39783.d9; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Moura DS, 2014, IMMUNOL ALLERGY CLIN, V34, P407, DOI 10.1016/j.iac.2014.02.001; Naghavi M, 2003, CIRCULATION, V108, P1772, DOI 10.1161/01.CIR.0000087481.55887.C9; Nautiyal KM, 2012, EUR J NEUROSCI, V36, P2347, DOI 10.1111/j.1460-9568.2012.08138.x; Nelissen S, 2013, ACTA NEUROPATHOL, V125, P637, DOI 10.1007/s00401-013-1092-y; Nelson KB, 2004, LANCET NEUROL, V3, P150, DOI 10.1016/S1474-4422(04)00679-9; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ollikainen E, 2014, J NEUROPATH EXP NEUR, V73, P855, DOI 10.1097/NEN.0000000000000105; ORR EL, 1984, J NEUROCHEM, V42, P727, DOI 10.1111/j.1471-4159.1984.tb02743.x; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Ottosson A, 1997, CEPHALALGIA, V17, P166, DOI 10.1046/j.1468-2982.1997.1703166.x; Parrella E, 2016, BRAIN RES, V1648, P409, DOI 10.1016/j.brainres.2016.07.014; Patkai J, 2001, PEDIATR RES, V50, P222, DOI 10.1203/00006450-200108000-00010; Peng YC, 2018, NEUROCHEM RES, V43, P785, DOI 10.1007/s11064-018-2480-4; Piette F, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt75; Qiao HM, 2012, NEUROCHEM RES, V37, P2014, DOI 10.1007/s11064-012-0822-1; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Ribatti D, 2008, ANN MED, V40, P606, DOI 10.1080/07853890802186913; RONNBERG AL, 1973, AGENTS ACTIONS, V3, P191; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; Sadamasa N, 2003, STROKE, V34, P2980, DOI 10.1161/01.STR.0000102556.55600.3B; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Shanas U, 1998, J NEUROIMMUNOL, V90, P207, DOI 10.1016/S0165-5728(98)00137-4; Shepherd Rebecca K., 1995, Microcirculation (New York), V2, P363, DOI 10.3109/10739689509148280; Shepherd RK, 1996, CIRC RES, V78, P627, DOI 10.1161/01.RES.78.4.627; Silver R, 1996, TRENDS NEUROSCI, V19, P25, DOI 10.1016/0166-2236(96)81863-7; Silver RB, 2004, P NATL ACAD SCI USA, V101, P13607, DOI 10.1073/pnas.0403208101; Skaper SD, 2017, NEUROSCIENTIST, V23, P478, DOI 10.1177/1073858416687249; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Skaper SD, 2012, FASEB J, V26, P3103, DOI 10.1096/fj.11-197194; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Strbian D, 2007, CIRCULATION, V116, P411, DOI 10.1161/CIRCULATIONAHA.106.655423; Strbian D, 2007, J CEREBR BLOOD F MET, V27, P795, DOI 10.1038/sj.jcbfm.9600387; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Subramanian V, 2008, HUM MOL GENET, V17, P130, DOI 10.1093/hmg/ddm290; Suzuki H, 2018, TRANSL STROKE RES, V9, P1, DOI 10.1007/s12975-017-0546-2; Swindle EJ, 2004, J BIOL CHEM, V279, P48751, DOI 10.1074/jbc.M409738200; Syvaranta S, 2010, ARTERIOSCL THROM VAS, V30, P1220, DOI 10.1161/ATVBAHA.109.198267; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Tashiro M, 2006, BRIT J CLIN PHARMACO, V61, P16, DOI 10.1111/j.1365-2125.2005.02514.x; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; THEOHARIDES TC, 1990, LIFE SCI, V46, P607, DOI 10.1016/0024-3205(90)90129-F; Theoharides TC, 2007, IMMUNOL REV, V217, P65, DOI 10.1111/j.1600-065X.2007.00519.x; Theoharides TC, 2017, EXP DERMATOL, V26, P751, DOI 10.1111/exd.13288; Theoharides TC, 2015, NEW ENGL J MED, V373, P1885, DOI 10.1056/NEJMc1510021; Tore F, 2009, CURR PHARM DESIGN, V15, P3433, DOI 10.2174/138161209789105036; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2000, MAST CELLS BASOPHILS, P497; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vannucci RC, 2000, AM J PERINAT, V17, P113, DOI 10.1055/s-2000-9293; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Volpe JJ, 2001, MENT RETARD DEV D R, V7, P56, DOI 10.1002/1098-2779(200102)7:1<56::AID-MRDD1008>3.0.CO;2-A; von Kummer R, 2001, RADIOLOGY, V219, P95, DOI 10.1148/radiology.219.1.r01ap0695; Woo D, 2002, NEUROSURG CLIN N AM, V13, P265, DOI 10.1016/S1042-3680(02)00011-6; Wu BH, 2011, NEUROCRIT CARE, V14, P109, DOI 10.1007/s12028-010-9372-z; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xie ZY, 2018, BRAIN BEHAV IMMUN, V69, P190, DOI 10.1016/j.bbi.2017.11.012; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yin J, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00096; Yoshida GJ, 2015, NEW ENGL J MED, V373, P1884, DOI 10.1056/NEJMc1510021; ZHANG RL, 1994, J NEUROL SCI, V125, P3, DOI 10.1016/0022-510X(94)90234-8; Zhang X, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0592-9	196	17	17	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY 12	2019	33	6			SI		723	733		10.1080/02699052.2018.1556807			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IG0CN	WOS:000473458900005	30554528				2021-06-18	
J	Yin, B; Li, DD; Huang, H; Gu, CH; Bai, GH; Hu, LX; Zhuang, JF; Zhang, M				Yin, Bo; Li, Dan-Dong; Huang, Huan; Gu, Cheng-Hui; Bai, Guang-Hui; Hu, Liu-Xun; Zhuang, Jin-Fei; Zhang, Ming			Longitudinal Changes in Diffusion Tensor Imaging Following Mild Traumatic Brain Injury and Correlation With Outcome	FRONTIERS IN NEURAL CIRCUITS			English	Article						mild traumatic brain injury; diffusion tensor imaging; longitudinal changes; fractional anisotropy; neuropsychological test	AXONAL INJURY; MULTIPLE-SCLEROSIS; RECOVERY; SEGMENTATION; DAMAGE; MODEL; TIME	The chronic consequences of traumatic brain injury (TBI) may contribute to the increased risk for early cognitive decline and dementia, primarily due to diffusion axonal injury. Previous studies in mild TBI (mTBI) have been controversial in describing the white matter tract integrity changes occurring at acute and subacute post-injury. In this prospective longitudinal study, we aim to investigate the longitudinal changes of white matter (WM) using diffusion tensor imaging (DTI) and their correlations with neuropsychological tests. Thirty-three patients with subacute mTBI and 31 matched healthy controls were studied with an extensive imaging and clinical battery. Neuroimaging was obtained within 7 days post-injury for acute scans and repeated at 1 and 3 months post-injury. Using a region-of-interest-based approach, tract-based spatial statistics was used to conduct voxel-wise analysis on diffusion changes in mTBI and was compared to those of healthy matched controls, scanned during the same time period and rescanned with an interval similar to that of patients. We found decreased fractional anisotropy (FA) values in the left anterior limb of internal capsule (ALIC) and right inferior fronto-occipital fasciculus (IFOF) during the 7 days post-injury, which showed longitudinal evidence of recovery following 1 month post-injury. Increased FA values in these two tracts at 1 month post-injury were positively associated with better performance on cognitive information processing speed at initial assessment. By contrast, there were also some tracts (right anterior corona radiata, forceps major, and body of corpus callosum) exhibiting the continuing loss of integrity sustaining even beyond 3 months, which can predict the persisting post-concussion syndromes. Continuing loss of structural integrity in some tracts may contribute to the persistent post-concussion syndromes in mTBI patients, suggesting certain tracts providing an objective biomarker for tracking the pathological recovery process following mTBI.	[Yin, Bo; Zhang, Ming] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China; [Yin, Bo; Li, Dan-Dong; Gu, Cheng-Hui; Hu, Liu-Xun] Wenzhou Med Univ, Dept Neurosurg, Affiliated Hosp 2, Wenzhou, Peoples R China; [Yin, Bo; Li, Dan-Dong; Huang, Huan; Gu, Cheng-Hui; Bai, Guang-Hui; Hu, Liu-Xun; Zhuang, Jin-Fei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Huang, Huan; Bai, Guang-Hui] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 2, Wenzhou, Peoples R China; [Zhuang, Jin-Fei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Rehabil Med, Wenzhou, Peoples R China	Zhang, M (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China.	zhangming01@mail.xjtu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571640]; Zhejiang Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY15H090016]; Wenzhou Municipal Sci-Tech Bureau [Y20140577]	This research was supported by the National Natural Science Foundation of China under Grant No. 81571640, the Zhejiang Natural Science Foundation (Grant No. LY15H090016), and Wenzhou Municipal Sci-Tech Bureau (Y20140577).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ARNETT JA, 1995, PSYCHOL ASSESSMENT, V7, P220; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baxendale S, 2005, EPILEPSY BEHAV, V6, P207, DOI 10.1016/j.yebeh.2004.12.009; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Harman-Smith YE, 2013, J CLIN EXP NEUROPSYC, V35, P785, DOI 10.1080/13803395.2013.824554; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Khong E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00156; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valverde S, 2015, NEUROIMAGE-CLIN, V9, P640, DOI 10.1016/j.nicl.2015.10.012; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	50	17	17	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5110			FRONT NEURAL CIRCUIT	Front. Neural Circuits	MAY 7	2019	13								28	10.3389/fncir.2019.00028			11	Neurosciences	Neurosciences & Neurology	HW9DP	WOS:000466991200001	31133818	DOAJ Gold, Green Published			2021-06-18	
J	Joseph, JR; Swallow, JS; Wilisey, K; Lapointe, AP; Khalatbari, S; Korley, FK; Oppenlander, ME; Park, P; Szerlip, NJ; Broglio, SP				Joseph, Jacob R.; Swallow, Jennylee S.; Wilisey, Kylene; Lapointe, Andrew P.; Khalatbari, Shokoufeh; Korley, Frederick K.; Oppenlander, Mark E.; Park, Paul; Szerlip, Nicholas J.; Broglio, Steven P.			Elevated markers of brain injury as a result of clinically asymptomatic high-acceleration head impacts in high-school football athletes	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; concussion; subconcussion; biomarker; accelerometry; pediatrics	SERUM NEUROFILAMENT LIGHT; INTRACRANIAL LESIONS; CONCUSSION; MILD; BIOMARKERS; PLAYERS; FLUID; RISK	OBJECTIVE This prospective observational cohort study of high-school football athletes was performed to determine if high-acceleration head impacts (HHIs) that do not result in clinically diagnosed concussion still lead to increases in serum levels of biomarkers indicating traumatic brain injury (TBI) in asymptomatic athletes and to determine the longitudinal profile of these biomarkers over the course of the football season. METHODS Sixteen varsity high-school football athletes underwent baseline neurocognitive testing and blood sampling for the biomarkers tau, ubiquitin C-terminal hydrolase L1 (UCH-L1), neurofilament light protein (NF-L), glial fibrillary acidic protein (GFAP), and spectrin breakdown products (SBDPs). All athletes wore helmet-based accelerometers to measure and record head impact data during all practices and games. At various time points during the season, 6 of these athletes met the criteria for HHI (linear acceleration > 95g and rotational acceleration > 3760 rad/sec(2)); in these athletes a second blood sample was drawn at the end of the athletic event during which the HHI occurred. Five athletes who did not meet the criteria for HHI underwent repeat blood sampling following the final game of the season. In a separate analysis, all athletes who did not receive a diagnosis of concussion during the season (n = 12) underwent repeat neurocognitive testing and blood sampling after the end of the season. RESULTS Total tau levels increased 492.6% +/- 109.8% from baseline to postsession values in athletes who received an HHI, compared with 164% +/- 35% in athletes who did not receive an HHI (p = 0.03). Similarly, UCH-L1 levels increased 738.2% +/- 163.3% in athletes following an HHI, compared with 237.7% +/- 71.9% in athletes in whom there was no HHI (p = 0.03). At the end of the season, researchers found that tau levels had increased 0.6 +/- 0.2 pg/ml (p = 0.003) and UCH-L1 levels had increased 144.3 +/- 56 pg/ml (p = 0.002). No significant elevations in serum NF-L, GFAP, or SBDPs were seen between baseline and end-of-athletic event or end-of-season sampling (for all, p > 0.05). CONCLUSIONS In this pilot study on asymptomatic football athletes, an HHI was associated with increased markers of neuronal (UCH-L1) and axonal (tau) injury when compared with values in control athletes. These same markers were also increased in nonconcussed athletes following the football season.	[Joseph, Jacob R.; Oppenlander, Mark E.; Park, Paul; Szerlip, Nicholas J.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Swallow, Jennylee S.; Lapointe, Andrew P.; Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Wilisey, Kylene] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Khalatbari, Shokoufeh] Univ Michigan, Michigan Inst Clin & Hlth Res, Ann Arbor, MI 48109 USA; [Korley, Frederick K.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA	Joseph, JR (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.	jojacob@med.umich.edu			American Association of Neurological Surgeons (AANS); Congress of Neurological Surgeons (CNS) Joint Section in Neurotrauma & Critical Care Codman Fellowship	This work was supported by the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Joint Section in Neurotrauma & Critical Care Codman Fellowship to Dr. Joseph.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Forbes JA, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12288; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Joseph JR, 2017, WORLD NEUROSURG, V103, P73, DOI 10.1016/j.wneu.2017.03.106; Kawata K, 2017, J NEUROTRAUM, V34, P2254, DOI 10.1089/neu.2016.4786; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Li J, 2015, AM J EMERG MED, V33, P1191, DOI 10.1016/j.ajem.2015.05.023; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945; 2010, AM J EMERG MED, V28, P399, DOI DOI 10.1016/J.AJEM.2008.12.025; 1986, J CELL BIOL, V102, P2088; 2005, NEUROSURGERY, V57, P300, DOI DOI 10.1227/01.NEU.0000166663.98616.E4; 1989, SCIENCE, V246, P670	46	17	17	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2019	130	5					1642	1648		10.3171/2017.12.JNS172386			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HW0VW	WOS:000466401100028	29966462	Bronze			2021-06-18	
J	Nguyen, VT; Zafonte, RD; Chen, JT; Kponee-Shovein, KZ; Paganoni, S; Pascual-Leone, A; Speizer, FE; Baggish, AL; Taylor, HA; Nadler, LM; Courtney, TK; Connor, A; Weisskopf, MG				Nguyen, Vy T.; Zafonte, Ross D.; Chen, Jarvis T.; Kponee-Shovein, Kale Z.; Paganoni, Sabrina; Pascual-Leone, Alvaro; Speizer, Frank E.; Baggish, Aaron L.; Taylor, Herman A., Jr.; Nadler, Lee M.; Courtney, Theodore K.; Connor, Ann; Weisskopf, Marc G.			Mortality Among Professional American-Style Football Players and Professional American Baseball Players	JAMA NETWORK OPEN			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; BODY-MASS INDEX; HEAD-INJURY; ALZHEIMERS-DISEASE; SMOKELESS TOBACCO; SOCCER PLAYERS; LEAGUE PLAYERS; RISK; ASSOCIATION	IMPORTANCE Studies of American-style football players have suggested lower overall mortality rates compared with general populations, but with possibly increased neurodegenerative mortality. However, comparisons with general populations can introduce bias. This study compared mortality between US National Football League (NFL) and US Major League Baseball (MLB) players, a more appropriate comparison group of professional athletes. OBJECTIVE To compare all-cause and cause-specific mortality between NFL and MLB players. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study, the setting was US mortality from January 1, 1979, through December 31, 2013. The dates of analysis were January 2016 to April 2019. Participants were 3419 NFL and 2708 MLB players with at least 5 playing seasons. EXPOSURES Participation in the NFL compared with the MLB. MAIN OUTCOMES AND MEASURES Vital status and causes of death from the National Death Index from 1979 through 2013 were obtained. Cox proportional hazards regression models using age as the timescale were used to calculate hazard ratios (HRs) and 95% CIs to examine all-cause and cause-specific mortality among NFL players compared with MLB players, adjusted for race and decade of birth. RESULTS By the end of follow-up, there were 517 deaths (mean [SD] age, 59.6 [13.2] years) in the NFL cohort and 431 deaths (mean [SD] age, 66.7 [12.3] years) in the MLB cohort. Cardiovascular and neurodegenerative conditions, respectively, were noted as underlying or contributing causes in 498 and 39 deaths in the NFL and 225 and 16 deaths in the MLB. Compared with MLB players, NFL players had significantly elevated rates of all-cause (HR, 1.26; 95% CI, 1.10-1.44), cardiovascular disease (HR, 2.40; 95% CI, 2.03-2.84), and neurodegenerative disease (HR, 2.99; 95% CI, 1.64-5.45) mortality. Comparing hypothetical populations of 1000 NFL and 1000 MLB players followed up to age 75 years, there would be an excess 21 all-cause deaths among NFL players, as well as 77 and 11 more deaths with underlying or contributing causes that included cardiovascular and neurodegenerative conditions, respectively. CONCLUSIONS AND RELEVANCE This study found that NFL players had elevated all-cause, cardiovascular, and neurodegenerative mortality rates compared with MLB players, although the absolute number of excess neurodegenerative deaths was still small. Factors that vary across these sports (eg, body habitus and head trauma) as opposed to those common across sports (eg, physical activity) could underlie the differences.	[Nguyen, Vy T.; Kponee-Shovein, Kale Z.; Speizer, Frank E.; Courtney, Theodore K.; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1-1402, Boston, MA 02115 USA; [Zafonte, Ross D.; Paganoni, Sabrina] Brigham & Womens Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Massachusetts Gen Hosp, 75 Francis St, Boston, MA 02115 USA; [Zafonte, Ross D.; Paganoni, Sabrina; Courtney, Theodore K.] Harvard Med Sch, Boston, MA 02115 USA; [Chen, Jarvis T.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA; [Kponee-Shovein, Kale Z.; Taylor, Herman A., Jr.; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Pascual-Leone, Alvaro; Connor, Ann] Harvard Med Sch, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat, Div Cognit Neurol,Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Speizer, Frank E.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA; [Taylor, Herman A., Jr.] Morehouse Univ, Cardiovasc Res Inst, Sch Med, Atlanta, GA USA; [Nadler, Lee M.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA	Weisskopf, MG (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1-1402, Boston, MA 02115 USA.	mweissko@hsph.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Courtney, Theodore K./P-4829-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Courtney, Theodore K./0000-0001-8139-1565	Spaulding Research Institute; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 ES000002]; National Institute for Occupational Safety and HealthUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42 OH008416]; Football Players Health Study at Harvard University	This work was supported by the Spaulding Research Institute and by grant P30 ES000002 from the National Institutes of Health. Ms Nguyen was supported by grant T42 OH008416 from the National Institute for Occupational Safety and Health. Drs Zafonte, Pascual-Leone, Speizer, Baggish, Taylor, Nadler, and Weisskopf, Mr Courtney, and Ms Connor received support from the Football Players Health Study at Harvard University.	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Abel Ernest L, 2006, Res Sports Med, V14, P239, DOI 10.1080/15438620600985795; Abel Ernest L, 2006, Res Sports Med, V14, P83, DOI 10.1080/15438620500528406; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Blum A, 2005, TOB CONTROL, V14, P1, DOI 10.1136/tc.2004.010728; Chague F, 2015, ARCH CARDIOVASC DIS, V108, P75, DOI 10.1016/j.acvd.2014.10.003; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; Churchill TW, 2018, AM J MED, V131, P1491, DOI 10.1016/j.amjmed.2018.07.042; Cologne J, 2012, EPIDEMIOLOGY, V23, P565, DOI 10.1097/EDE.0b013e318253e418; CONNOLLY GN, 1988, NEW ENGL J MED, V318, P1281, DOI 10.1056/NEJM198805123181918; Conrad Amy K, 2015, J Calif Dent Assoc, V43, P14; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Engber D., NFL PLAYERS DIE YOUN; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Flynn D., WHY EVERYTHING YOU H; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Grashow RG, 2019, ORTHOP J SPORTS MED, V7, DOI 10.1177/2325967119829212; Helzberg JH, 2010, AM J CARDIOL, V106, P664, DOI 10.1016/j.amjcard.2010.04.022; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Imai K, 2016, POLIT ANAL, V24, P263, DOI 10.1093/pan/mpw001; Kim JH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008620; Klein J.P., 2003, SURVIVAL ANAL TECHNI; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lemez S, 2018, SCAND J MED SCI SPOR, V28, P1722, DOI 10.1111/sms.13066; Lemez S, 2015, SPORTS MED-OPEN, V1, DOI 10.1186/s40798-015-0024-x; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Lincoln AE, 2018, MED SCI SPORT EXER, V50, P486, DOI 10.1249/MSS.0000000000001466; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2018, AM J CARDIOL, V122, P1879, DOI 10.1016/j.amjcard.2018.08.030; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; O'Reilly EJ, 2013, AMYOTROPH LAT SCL FR, V14, P205, DOI 10.3109/21678421.2012.735240; Peters TL, 2013, AMYOTROPH LAT SCL FR, V14, P267, DOI 10.3109/21678421.2012.754043; Pupillo E, 2018, AMYOTROPH LAT SCL FR, V19, P118, DOI 10.1080/21678421.2017.1386687; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; STEENLAND K, 1992, AM J EPIDEMIOL, V136, P855, DOI 10.1093/aje/136.7.855; Taioli E, 2007, EUR J PUBLIC HEALTH, V17, P600, DOI 10.1093/eurpub/ckm035; Venkataramani AS, 2018, JAMA-J AM MED ASSOC, V319, P800, DOI 10.1001/jama.2018.0140; Visser AE, 2018, J NEUROL NEUROSUR PS, V89, P797, DOI 10.1136/jnnp-2017-317724; WALSH MM, 1994, ADDICT BEHAV, V19, P411, DOI 10.1016/0306-4603(94)90064-7; Watanabe Y, 2017, EUR J EPIDEMIOL, V32, P867, DOI 10.1007/s10654-017-0327-y	47	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	MAY	2019	2	5							e194223	10.1001/jamanetworkopen.2019.4223			13	Medicine, General & Internal	General & Internal Medicine	IK7XE	WOS:000476806200070	31125098	DOAJ Gold, Green Published			2021-06-18	
J	Voormolen, DC; Polinder, S; von Steinbuechel, N; Vos, PE; Cnossen, MC; Haagsma, JA				Voormolen, Daphne C.; Polinder, Suzanne; von Steinbuechel, Nicole; Vos, Pieter E.; Cnossen, Maryse C.; Haagsma, Juanita A.			The association between post-concussion symptoms and health-related quality of life in patients with mild traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Quality of life; Post-concussion syndrome; Rivermead post-concussion symptoms questionnaire; SF-36	SEVERITY SCORE; PREDICTORS; QUESTIONNAIRE; CONSEQUENCES; MODERATE; ADULTS; IMPACT; DUTCH	A subset of mild traumatic brain injury (mTBI) patients experience post-concussion symptoms. When a cluster of post-concussion symptoms persists for over three months, it is referred to as post-concussion syndrome (PCS). Little is known about the association between PCS and Health-Related Quality of Life (HRQoL) after mTBI. The aims of this study were to assess the implications of PCS on HRQoL six months after mTBI and the relationship between PCS and HRQoL domains. A prospective observational cohort study was conducted among a sample of mTBI patients. Follow-up postal questionnaires at six months after emergency department (ED) admission included socio-demographic information, the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), and HRQoL measured with the 36-item Short-Form Health Survey (SF-36) and the Perceived Quality of Life Scale (PQoL). In total, 731 mTBI patients were included, of whom 38.7% were classified as suffering from PCS. Patients with PCS had significantly lower scores on all SF-36 domains, lower physical and mental component summary scores and lower mean PQoL scores compared to patients without PCS. All items of the RPQ were negatively correlated to all SF-36 domains and PQoL subscale scores, indicating that reporting problems on any of the RPQ symptoms was associated with a decrease on different aspects of an individuals' HRQoL. To conclude, PCS is common following mTBI and patients with PCS have a considerably lower HRQoL. A better understanding of the relationship between PCS and HRQoL and possible mediating factors in this relationship could improve intervention strategies, the recovery process for mTBI patients and benchmarking. (C) 2018 Elsevier Ltd. All rights reserved.	[Voormolen, Daphne C.; Polinder, Suzanne; Cnossen, Maryse C.; Haagsma, Juanita A.] Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [von Steinbuechel, Nicole] Georg August Univ, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, POB 169, NL-7000 AD Doetinchem, Netherlands; [Haagsma, Juanita A.] Erasmus Univ, Med Ctr, Dept Emergency Med, Rotterdam, Netherlands; [von Steinbuechel, Nicole] Univ Med Ctr Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany	Voormolen, DC (corresponding author), Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl; s.polinder@erasmusmc.nl; nvsteinbuechel@med.uni-goettingen.de; p.vos@slingeland.nl; m.c.cnossen@erasmusmc.nl; j.haagsma@erasmusmc.nl			European UnionEuropean Commission [602150]; National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090]	The paper has been written in the context of the CENTER-TBI project. CENTER-TBI has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150. TRACK-TBI has received funding from the National Institutes of Neurologic Disorders and Stroke, grant no U01 NS086090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; American Congress of Rehabilitation Medicine (ACRM), 1993, DEF MILD TRAUM BRAIN; [Anonymous], 2000, AM PSYCH ASS DIAGN S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Cnossen MC, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0641-9; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hiploylee C., 2016, J NEUROTRAUMA; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; King NS, 2013, BRAIN IMPAIR, V14, P235, DOI 10.1017/BrImp.2013.17; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Scholten AC, 2017, POPUL HEALTH METR, V15, DOI 10.1186/s12963-017-0127-3; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; von Steinbuechel N, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/7928014; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware JE, 1994, BOSTON SF 36 PHYS ME; Ware JE, 1993, BOSTON SF 36 HLTH SU; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; 2010, J NEUROTRAUM, V27, P2173, DOI DOI 10.1089/NEU.2010.1353	40	17	17	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2019	50	5					1068	1074		10.1016/j.injury.2018.12.002			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	HX6UG	WOS:000467538200012	30554897				2021-06-18	
J	Posti, JP; Takala, RSK; Lagerstedt, L; Dickens, AM; Hossain, I; Mohammadian, M; Ala-Seppala, H; Frantzen, J; van Gils, M; Hutchinson, PJ; Katila, AJ; Maanpaa, HR; Menon, DK; Newcombe, VF; Tallus, J; Hrusovsky, K; Wilson, DH; Gill, J; Sanchez, JC; Tenovuo, O; Zetterberg, H; Blennow, K				Posti, Jussi P.; Takala, Riikka S. K.; Lagerstedt, Linnea; Dickens, Alex M.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Frantzen, Janek; van Gils, Mark; Hutchinson, Peter J.; Katila, Ari J.; Maanpaeae, Henna-Riikka; Menon, David K.; Newcombe, Virginia F.; Tallus, Jussi; Hrusovsky, Kevin; Wilson, David H.; Gill, Jessica; Sanchez, Jean-Charles; Tenovuo, Olli; Zetterberg, Henrik; Blennow, Kaj			Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; computed tomography; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; SERUM NEUROFILAMENT LIGHT; PLASMA-LEVELS; CT; S100-BETA; INCREASES; DIAGNOSIS; S100B; TAU	The aim of the study was to examine the ability of eight protein biomarkers and their combinations in discriminating computed tomography (CT)-negative and CT-positive patients with traumatic brain injury (TBI), utilizing highly sensitive immunoassays in a well-characterized cohort. Blood samples were obtained from 160 patients with acute TBI within 24 h of admission. Levels of beta-amyloid isoforms 1-40 (A beta 40) and 1-42 (A beta 42), glial fibrillary acidic protein (GFAP), heart fatty-acid binding protein (H-FABP), interleukin 10 (IL-10), neurofilament light (NF-L), S100 calcium-binding protein B (S100B), and tau were measured. Patients were divided into CT-negative (n = 65) and CT-positive (n = 95), and analyses were conducted separately for TBIs of all severities (Glasgow Coma Scale [GCS] score 3-15) and mild TBIs (mTBIs; GCS 13-15). NF-L, GFAP, and tau were the best in discriminating CT-negative and CT-positive patients, both in patients with mTBI and with all severities. In patients with all severities, area under the curve of the receiver operating characteristic (AUC) was 0.822, 0.817, and 0.781 for GFAP, NF-L, and tau, respectively. In patients with mTBI, AUC was 0.720, 0.689, and 0.676, for GFAP, tau, and NF-L, respectively. The best panel of three biomarkers for discriminating CT-negative and CT-positive patients in the group of all severities was a combination of GFAP+H-FABP+IL-10, with a sensitivity of 100% and specificity of 38.5%. In patients with mTBI, the best panel of three biomarkers was H-FABP+S100B+tau, with a sensitivity of 100% and specificity of 46.4%. Panels of biomarkers outperform individual biomarkers in separating CT-negative and CT-positive patients. Panels consisted mainly of different biomarkers than those that performed best as an individual biomarker.	[Posti, Jussi P.; Hossain, Iftakher; Frantzen, Janek; Maanpaeae, Henna-Riikka] Turku Univ Hosp, Dept Neurosurg, POB 52, FI-20521 Turku, Finland; [Posti, Jussi P.; Takala, Riikka S. K.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Katila, Ari J.; Maanpaeae, Henna-Riikka; Tallus, Jussi; Tenovuo, Olli] Turku Univ Hosp, Turku Brain Injury Ctr, Turku, Finland; [Tallus, Jussi] Turku Univ Hosp, Dept Radiol, Turku, Finland; [Posti, Jussi P.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Frantzen, Janek; Maanpaeae, Henna-Riikka; Tallus, Jussi; Tenovuo, Olli] Univ Turku, Dept Neurol, Turku, Finland; [Dickens, Alex M.; Sanchez, Jean-Charles] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Takala, Riikka S. K.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, Turku, Finland; [Lagerstedt, Linnea; Katila, Ari J.] Univ Geneva, Dept Special Internal Med, Geneva, Switzerland; [van Gils, Mark] VTT Tech Res Ctr Finland Ltd, Tampere, Finland; [Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England; [Menon, David K.; Newcombe, Virginia F.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Hrusovsky, Kevin; Wilson, David H.] Quanterix Corp, Lexington, MA USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst UCL, London, England	Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, POB 52, FI-20521 Turku, Finland.	jussi.posti@utu.fi	Posti, Jussi P./Y-2908-2019; Gill, Gill M/Q-2020-2017; Mohammadian, Mehrbod/AAH-1018-2019; Dickens, Alex/F-8566-2013	Posti, Jussi P./0000-0002-5925-5193; Mohammadian, Mehrbod/0000-0002-6851-7511; Ala-Seppala, Henna/0000-0002-1577-3028; Dickens, Alex/0000-0002-3178-8449; Hutchinson, Peter/0000-0002-2796-1835; Newcombe, Virginia/0000-0001-6044-9035; van Gils, Mark/0000-0002-0029-1771	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-270259-TBIcare]; Emil Aaltonen Foundation; Finnish Brain Foundation; Integra EANS Research Grant; University of Turku Graduate School; NIHR Research Professorship; NIHR Cambridge BRC; NIHR Research UK; Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship; Wallenberg Academy Fellowship; Swedish and European Research Councils; Torsten Soderberg Professorship in Medicine - Royal Swedish Academy of Sciences; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Government's Special Financial Transfer tied to academic research in Health Sciences (Finland)	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) (JPP), Emil Aaltonen Foundation (JPP), Finnish Brain Foundation (JPP), Integra EANS Research Grant (IH), University of Turku Graduate School funding (MM), NIHR Research Professorship and the NIHR Cambridge BRC (PJH), NIHR Research UK (through a Senior Investigator Award and the Cambridge Biomedical Research Centre) (DKM), Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship (VFN); Wallenberg Academy Fellowship and grants from the Swedish and European Research Councils (HZ), Torsten Soderberg Professorship in Medicine, award by the Royal Swedish Academy of Sciences, grants from the Swedish Research Council (KB).	Ala-Seppala H., 2016, BRAIN INJURY, P30; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HODGKINSON S, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G104; Isokuortti H, 2014, INJURY, V45, P1340, DOI 10.1016/j.injury.2014.04.012; Kasper C.E., 2015, TRAUMATIC BRAIN INJU; Lagerstedt L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193278; Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Luoto TM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00652; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Missler U, 1999, CLIN CHEM, V45, P138; Ohrt-Nissen S, 2011, EMERG MED J, V28, P941, DOI 10.1136/emj.2010.091363; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Posti J.P., 2016, NEUROSURGERY, P79; Posti J.P., 2017, J NEUROTRAUM, P34; Robin X., 2013, TL PROTEOMICS, V1, P57, DOI [10.1016/j.trprot.2013.04.003, DOI 10.1016/J.TRPROT.2013.04.003]; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sweeney T.E., 2015, WORLD J EMERG SURG, P10; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580	40	17	18	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2019	36	14					2178	2189		10.1089/neu.2018.6254		APR 2019	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IH1NO	WOS:000463593400001	30760178	Green Published			2021-06-18	
J	Maegele, M; Lefering, R; Sakowitz, O; Kopp, MA; Schwab, JM; Steudel, WI; Unterberg, A; Hoffmann, R; Uhl, E; Marzi, I				Maegele, Marc; Lefering, Rolf; Sakowitz, Oliver; Kopp, Marcel A.; Schwab, Jan M.; Steudel, Wolf-Ingo; Unterberg, Andreas; Hoffmann, Reinhard; Uhl, Eberhard; Marzi, Ingo			The Incidence and Management of Moderate to Severe Head Injury A Retrospective Analysis of Data From the Trauma Register of the German Trauma Society	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							BRAIN-INJURY; UNITED-STATES; EPIDEMIOLOGY; PREVENTION; EUROPE	Background: The comprehensive expansion of the Trauma Register of the German Trauma Society (Deutsche Gesellschaft fur Unfallchirurgie; TR-DGU) now enables, for the first time, studies on traumatic brain injury (TBI) with special attention to care processes, clinical course, and outcomes of treatment on discharge or transfer from the acute-care hospital. Methods: Retrospective analysis of patients documented in the TR-DGU in the period 2013-2017 who had moderate to severe head injury as defined by the Abbreviated Injury Scale (AIS). Results: In the period 2013-2017, 41 101 patients with moderate to severe TBI were treated in TR-DGU-associated hospitals in Germany (n = 605 hospitals), corresponding to 8220 cases per year and thus to a population-wide incidence of 10.1 cases per 100 000 persons per year. TBI was present as an isolated injury in 39.1% of cases. The mean age of the patients was 60 years (median; range 0-104 years), and the male-to-female ratio was 2: 1. 97.5% of the patients had blunt trauma. Falls from a low height were the most common cause of TBI (38.7%). 43.6% of the patients were intubated before arriving at the hospital, and more than 95% underwent cranial tomographic imaging within 22 minutes of arrival (standard deviation [SD] = 17 minutes). 18.4% underwent an emergency neurosurgical procedure. The in-hospital mortality was 23.5%, corresponding to a population-wide mortality from TBI of 2.4 per 100 000 persons per year. More than half of the patients recovered well or with only mild disability; 14.9% had persistent severe disability or remained in a vegetative state. Conclusion: Putting these figures in the appropriate international context requires the acquisition of comparable data in multiple countries and is the main task of international TBI consortia.	[Maegele, Marc] Witten Herdecke Univ, Cologne Merheim Med Ctr, Dept Orthopaed Surg Trauma Surg & Sports Med, Cologne, Germany; [Maegele, Marc; Lefering, Rolf] Witten Herdecke Univ, Inst Res Operat Med IFOM, Cologne, Germany; [Sakowitz, Oliver] Heidelberg Univ, Acad Teaching Hosp, RKH Klinikum Ludwigsburg, Neurosurg Ctr Ludwigsburg Heilbronn, Ludwigsburg, Germany; [Kopp, Marcel A.; Schwab, Jan M.] Charite Univ Med Berlin, Dept Neurol Expt Neurol, Berlin, Germany; [Kopp, Marcel A.; Schwab, Jan M.] Berlin Inst Hlth QUEST, BIH Ctr Transforming Biomed Res, Berlin, Germany; [Schwab, Jan M.] Ohio State Univ, Spinal Cord Injury Div, Dept Neurol & Neurosci, Columbus, OH 43210 USA; [Steudel, Wolf-Ingo] Saarland Univ, Med Ctr, Homburg, Germany; [Unterberg, Andreas] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany; [Hoffmann, Reinhard] BG Trauma Ctr Frankfurt Main, Frankfurt, Germany; [Uhl, Eberhard] Univ Giessen Marburg Giessen, Dept Neurosurg Giessen, Giessen, Germany; [Marzi, Ingo] JW Goethe Univ Hosp, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany	Maegele, M (corresponding author), Univ Witten Herdecke Campus Koln Merheim, IFOM, Klin Unfallchirurg Orthopadie & Sporttraumatol, Kliniken Stadt Koln Merheim, Ostmerheimer Str 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de	Kopp, Marcel/AAX-3960-2020	Kopp, Marcel/0000-0001-6832-9599; Schwab, Jan/0000-0001-6784-4919	Kuratorium ZNS-Hannelore Kohl-Stiftung; German Social Accident Insurance (Deutsche Gesetzliche Unfallversicherung, DGUV)	The creation of a nationwide TBI cohort in synchrony with the TR-DGU and international TBI consortia received important initial financial support from the Kuratorium ZNS-Hannelore Kohl-Stiftung and from the German Social Accident Insurance (Deutsche Gesetzliche Unfallversicherung, DGUV).	Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Firsching R, 2017, J NEUROL SURG PART A, V78, P478, DOI 10.1055/s-0037-1599239; Firsching R, 2001, WORLD J SURG, V25, P1221; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Fu TS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145469; Gennarelli A, 2008, ABBREVIATED INJURY S; Gesundheitberichterstattung des Bundes, GES BUND DIAGN KRANK; Hillier SL, 1997, BRAIN INJURY, V11, P649; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; LI M, 2016, GEN MED LOS ANGELES, V4, DOI DOI 10.1186/S13073-016-0341-9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wutzler S, 2009, J AM COLL SURGEONS, V209, P75, DOI 10.1016/j.jamcollsurg.2009.03.015; 2014, INJURY S3, V45, P6, DOI DOI 10.1016/j.injury.2014.08.011	27	17	18	0	1	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	MAR 8	2019	116	10					167	173		10.3238/arztebl.2019.0167			7	Medicine, General & Internal	General & Internal Medicine	HU0OI	WOS:000464969800002	30995953	Green Published			2021-06-18	
J	van Essen, TA; den Boogert, HF; Cnossen, MC; de Ruiter, GCW; Haitsma, I; Polinder, S; Steyerberg, EW; Menon, D; Maas, AIR; Lingsma, HF; Peul, WC; Cecilia, A; Hadie, A; Vanni, A; Judith, A; Krisztina, A; Norberto, A; Nada, A; Lasse, A; Azasevac, A; Audny, A; Anna, A; Hilko, A; Gerard, A; Kaspars, A; Philippe, A; Luisa, AM; Camelia, B; Rafael, B; Ronald, B; Pal, B; Ursula, B; Romuald, B; Ronny, B; Javier, BF; Bo-Michael, B; Antonio, B; Remy, B; Habib, B; Thierry, B; Maurizio, B; Luigi, B; Christopher, B; Federico, B; Harald, B; Erta, B; Morten, B; Hugo, D; Pierre, B; Peter, B; Alexandra, B; Vibeke, B; Joanne, B; Camilla, B; Andras, B; Monika, B; Emiliana, C; Rosa, CM; Peter, C; Guillermo, CL; Marco, C; Elsa, C; Carpenter, K; Ana, CL; Francesco, C; Giorgio, C; Arturo, C; Giuseppe, C; Maryse, C; Mark, C; Jonathan, C; Lizzie, CK; Johnny, C; Jamie, DC; Marta, C; Amra, C; Nicola, C; Endre, C; Marek, C; Claire, DF; Francois, D; Pierre, D; Helen, D; Veronique, D; Francesco, DC; Bart, D; Godard, CWD; Dula, D; Ding, SH; Diederik, D; Abhishek, D; Emma, D; Jens, D; Guy-Loup, D; George, E; Heiko, E; Ari, E; Patrick, E; Erzsebet, E; Martin, F; Valery, LF; Feng, JF; Kelly, F; Francesca, F; Gilles, F; Ulderico, F; Shirin, F; Alex, F; Pablo, G; Damien, G; Dashiell, G; Gao, GY; Karin, G; Pradeep, G; Alexandre, G; Lelde, G; Benoit, G; Ben, G; Jagos, G; Pedro, AG; Francesca, G; Russell, LG; Deepak, G; Juanita, AH; Iain, H; Jed, AH; Raimund, H; Eirik, H; Daniel, H; Astrid, H; Stefan, H; Lindsay, H; Jilske, H; Peter, JH; Kristine, HA; Bram, J; Stefan, J; Mike, J; Bojan, J; Jiang, JY; Kelly, J; Konstantinos, K; Mladen, K; Ari, K; Maija, K; Thomas, K; Riku, K; Angelos, GK; Balint, K; Erwin, K; Ksenija, K; Daniel, K; Lars-Owe, K; Noemi, K; Alfonso, L; Linda, L; Steven, L; Fiona, L; Christian, L; Rolf, L; Valerie, L; Jin, L; Leon, L; Roger, L; Hester, L; Dirk, L; Angels, L; Andrew, IRM; Stephen, M; Marc, M; Marek, M; Sebastian, M; Alex, M; Geoffrey, M; Didier, M; Francisco, ML; Costanza, M; Armando, M; Hugues, M; Alessandro, M; Julia, M; Charles, M; Catherine, M; Bela, M; David, M; Tomas, M; Cristina, MK; Davide, M; Visakh, M; Lynnette, M; Holger, M; Nandesh, N; Ancuta, N; David, N; Virginia, N; Daan, N; Quentin, N; Jozsef, N; Mauro, O; Annemarie, O; Matej, O; Fabrizio, O; Aarno, P; Paul, MP; Adriana, P; Jean-Francois, P; Natascha, P; Vincent, P; Paolo, P; PeulWilco; Anna, PK; Sebastien, PF; Matti, P; Horia, P; Antonia, PM; Suzanne, P; Inigo, P; Jussi, P; Louis, P; Andreea, R; Arminas, R; Rahul, R; Malinka, R; Ruben, R; Veronika, R; Jonathan, R; Samuli, R; Saulius, R; Cecilie, R; Olav, R; Gerwin, R; Jonathan, R; Jeffrey, R; Christina, R; Guy, R; Rolf, R; Sandra, R; Daniel, R; Martin, R; Marco, S; Barbara, S; Juan, S; Oliver, S; Francesca, S; Renan, SP; Janos, S; Edgar, S; Luminita, S; Davide, S; Nadine, S; Inger, S; Barbara, S; Silke, S; Herbert, S; Guus, S; Frederik, SR; Elisabeth, S; Michael, S; Ozcan, S; Toril, S; Lidwien, S; Dirk, S; Peter, S; Abayomi, S; Emmanuel, S; Simon, S; Nicole, S; Ana, S; Robert, S; William, S; Ewout, WS; Nino, S; Nina, S; Anneliese, S; Silvio, TF; Riikka, T; Viktoria, T; Paivi, T; Steven, TM; Braden, TA; Olli, T; Ralph, T; Guido, T; Alice, T; Matt, T; Dick, T; Christos, T; Luaba, TJF; Tony, T; Maria, TC; Peter, V; Shirley, V; Egils, V; Gregory, V; Mathieu, V; Joukje, V; Jeroen, TJMV; Thomas, AV; Wim, V; Caroline, V; Dominique, V; Thijs, VV; Julia, V; Audrey, V; Alessia, V; Emmanuel, V; Kimberley, V; Jan, V; Paul, MV; Anne, V; Rimantas, V; Giacinta, V; Carmen, VL; Victor, V; Daphne, V; Peter, V; Zoltan, V; Derick, W; Kevin, KWW; Lei, W; Lars, W; Eno, W; Guy, W; Lindsay, W; Maren, KLW; Stefan, W; Peter, Y; Alexander, Y; Menashe, Z; Yang, ZH; Agate, Z; Fabrizio, Z				van Essen, Thomas A.; den Boogert, Hugo F.; Cnossen, Maryse C.; de Ruiter, Godard C. W.; Haitsma, Iain; Polinder, Suzanne; Steyerberg, Ewout W.; Menon, David; Maas, Andrew I. R.; Lingsma, Hester F.; Peul, Wilco C.; Cecilia, Ackerlund; Hadie, Adams; Vanni, Agnoletti; Judith, Allanson; Krisztina, Amrein; Norberto, Andaluz; Nada, Andelic; Lasse, Andreassen; Azasevac, Antun; Audny, Anke; Anna, Antoni; Hilko, Ardon; Gerard, Audibert; Kaspars, Auslands; Philippe, Azouvi; Luisa, Azzolini Maria; Camelia, Baciu; Rafael, Badenes; Ronald, Bartels; Pal, Barzo; Ursula, Bauerfeind; Romuald, Beauvais; Ronny, Beer; Francisco Javier, Belda; Bo-Michael, Bellander; Antonio, Belli; Remy, Bellier; Habib, Benali; Thierry, Benard; Maurizio, Berardino; Luigi, Beretta; Christopher, Beynon; Federico, Bilotta; Harald, Binder; Erta, Biqiri; Morten, Blaabjerg; Hugo, den Boogert; Pierre, Bouzat; Peter, Bragge; Alexandra, Brazinova; Vibeke, Brinck; Joanne, Brooker; Camilla, Brorsson; Andras, Buki; Monika, Bullinger; Emiliana, Calappi; Rosa, Calvi Maria; Peter, Cameron; Lozano Guillermo, Carbayo; Marco, Carbonara; Elsa, Carise; Carpenter, K.; Ana M, Castano-Leon; Francesco, Causin; Giorgio, Chevallard; Arturo, Chieregato; Giuseppe, Citerio; Maryse, Cnossen; Mark, Coburn; Jonathan, Coles; Lizzie, Coles-Kemp; Johnny, Collett; Jamie, Cooper D.; Marta, Correia; Amra, Covic; Nicola, Curry; Endre, Czeiter; Marek, Czosnyka; Claire, Dahyot-Fizelier; Francois, Damas; Pierre, Damas; Helen, Dawes; Veronique, De Keyser; Francesco, Della Corte; Bart, Depreitere; Godard, de Ruiter C. W.; Dula, Dilvesi; Ding Shenghao; Diederik, Dippel; Abhishek, Dixit; Emma, Donoghue; Jens, Dreier; Guy-Loup, Duliere; George, Eapen; Heiko, Engemann; Ari, Ercole; Patrick, Esser; Erzsebet, Ezer; Martin, Fabricius; Valery, Feigin L.; Feng Junfeng; Kelly, Foks; Francesca, Fossi; Gilles, Francony; Ulderico, Freo; Shirin, Frisvold; Alex, Furmanov; Pablo, Gagliardo; Damien, Galanaud; Dashiell, Gantner; Gao Guoyi; Karin, Geleijns; Pradeep, George; Alexandre, Ghuysen; Lelde, Giga; Benoit, Giraud; Ben, Glocker; Jagos, Golubovic; Pedro, Gomez A.; Francesca, Grossi; Russell, Gruen L.; Deepak, Gupta; Juanita, Haagsma A.; Iain, Haitsma; Jed, Hartings A.; Raimund, Helbok; Eirik, Helseth; Daniel, Hertle; Astrid, Hoedemaekers; Stefan, Hoefer; Lindsay, Horton; Jilske, Huijben; Peter, Hutchinson J.; Kristine, Haberg Asta; Bram, Jacobs; Stefan, Jankowski; Mike, Jarrett; Bojan, Jelaca; Jiang Ji-yao; Kelly, Jones; Konstantinos, Kamnitsas; Mladen, Karan; Ari, Katila; Maija, Kaukonen; Thomas, Kerforne; Riku, Kivisaari; Angelos, Kolias G.; Balint, Kolumban; Erwin, Kompanje; Ksenija, Kolundzija; Daniel, Kondziella; Lars-Owe, Koskinen; Noemi, Kovacs; Alfonso, Lagares; Linda, Lanyon; Steven, Laureys; Fiona, Lecky; Christian, Ledig; Rolf, Lefering; Valerie, Legrand; Jin, Lei; Leon, Levi; Roger, Lightfoot; Hester, Lingsma; Dirk, Loeckx; Angels, Lozano; Andrew, Maas I. R.; Stephen, MacDonald; Marc, Maegele; Marek, Majdan; Sebastian, Major; Alex, Manara; Geoffrey, Manley; Didier, Martin; Francisco, Martin Leon; Costanza, Martino; Armando, Maruenda; Hugues, Marechal; Alessandro, Masala; Julia, Mattern; Charles, McFadyen; Catherine, McMahon; Bela, Melegh; David, Menon; Tomas, Menovsky; Cristina, Morganti-Kossmann; Davide, Mulazzi; Visakh, Muraleedharan; Lynnette, Murray; Holger, Muehlan; Nandesh, Nair; Ancuta, Negru; David, Nelson; Virginia, Newcombe; Daan, Nieboer; Quentin, Noirhomme; Jozsef, Nyiradi; Mauro, Oddo; Annemarie, Oldenbeuving; Matej, Oresic; Fabrizio, Ortolano; Aarno, Palotie; Paul, Parizel M.; Adriana, Patruno; Jean-Francois, Payen; Natascha, Perera; Vincent, Perlbarg; Paolo, Persona; PeulWilco; Anna, Piippo-Karjalainen; Sebastien, Pili Floury; Matti, Pirinen; Horia, Ples; Maria Antonia, Poca; Suzanne, Polinder; Inigo, Pomposo; Jussi, Posti; Louis, Puybasset; Andreea, Radoi; Arminas, Ragauskas; Rahul, Raj; Malinka, Rambadagalla; Ruben, Real; Veronika, Rehorcikova; Jonathan, Rhodes; Samuli, Ripatti; Saulius, Rocka; Cecilie, Roe; Olav, Roise; Gerwin, Roks; Jonathan, Rosand; Jeffrey, Rosenfeld; Christina, Rosenlund; Guy, Rosenthal; Rolf, Rossaint; Sandra, Rossi; Daniel, Rueckert; Martin, Rusnak; Marco, Sacchi; Barbara, Sahakian; Juan, Sahuquillo; Oliver, Sakowitz; Francesca, Sala; Renan, Sanchez-Porras; Janos, Sandor; Edgar, Santos; Luminita, Sasu; Davide, Savo; Nadine, Schaeffer; Inger, Schipper; Barbara, Schloesser; Silke, Schmidt; Herbert, Schoechl; Guus, Schoonman; Frederik, Schou Rico; Elisabeth, Schwendenwein; Michael, Schoell; Ozcan, Sir; Toril, Skandsen; Lidwien, Smakman; Dirk, Smeets; Peter, Smielewski; Abayomi, Sorinola; Emmanuel, Stamatakis; Simon, Stanworth; Nicole, Steinbuechel; Ana, Stevanovic; Robert, Stevens; William, Stewart; Ewout, Steyerberg W.; Nino, Stocchetti; Nina, Sundstrom; Anneliese, Synnot; Fabio Silvio, Taccone; Riikka, Takala; Viktoria, Tamas; Paivi, Tanskanen; Steven, Taylor Mark; Braden, Te Ao; Olli, Tenovuo; Ralph, Telgmann; Guido, Teodorani; Alice, Theadom; Matt, Thomas; Dick, Tibboel; Christos, Tolias; Luaba, Tshibanda Jean-Flory; Tony, Trapani; Maria, Tudora Cristina; Peter, Vajkoczy; Shirley, Vallance; Egils, Valeinis; Gregory, Van der Steen; Mathieu, Van der Jagt; Joukje, Van der Naalt; Jeroen, van Dijck T. J. M.; Thomas, Van Essen A.; Wim, Van Hecke; Caroline, van Heugten; Dominique, Van Praag; Thijs, Vande Vyvere; Julia, Van Waesberghe; Audrey, Vanhaudenhuyse; Alessia, Vargiolu; Emmanuel, Vega; Kimberley, Velt; Jan, Verheyden; Paul, Vespa M.; Anne, Vik; Rimantas, Vilcinis; Giacinta, Vizzino; Carmen, Vleggeert-Lankamp; Victor, Volovici; Daphne, Voormolen; Peter, Vulekovic; Zoltan, Vamos; Derick, Wade; Kevin, Wang K. W.; Lei, Wang; Lars, Wessels; Eno, Wildschut; Guy, Williams; Lindsay, Wilson; Maren, Winkler K. L.; Stefan, Wolf; Peter, Ylen; Alexander, Younsi; Menashe, Zaaroor; Yang, Zhihui; Agate, Ziverte; Fabrizio, Zumbo		CENTER-TBI Investigators Partici	Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Neurosurgery; Practice variation; Acute subdural hematoma	RANDOMIZED CONTROLLED-TRIALS; ACUTE SUBDURAL HEMATOMAS; SURGICAL-MANAGEMENT; GUIDELINES; MODERATE; OUTCOMES; SURGERY	BackgroundNeurosurgical management of traumatic brain injury (TBI) is challenging, with only low-quality evidence. We aimed to explore differences in neurosurgical strategies for TBI across Europe.MethodsA survey was sent to 68 centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. The questionnaire contained 21 questions, including the decision when to operate (or not) on traumatic acute subdural hematoma (ASDH) and intracerebral hematoma (ICH), and when to perform a decompressive craniectomy (DC) in raised intracranial pressure (ICP).ResultsThe survey was completed by 68 centers (100%). On average, 10 neurosurgeons work in each trauma center. In all centers, a neurosurgeon was available within 30min. Forty percent of responders reported a thickness or volume threshold for evacuation of an ASDH. Most responders (78%) decide on a primary DC in evacuating an ASDH during the operation, when swelling is present. For ICH, 3% would perform an evacuation directly to prevent secondary deterioration and 66% only in case of clinical deterioration. Most respondents (91%) reported to consider a DC for refractory high ICP. The reported cut-off ICP for DC in refractory high ICP, however, differed: 60% uses 25mmHg, 18% 30mmHg, and 17% 20mmHg. Treatment strategies varied substantially between regions, specifically for the threshold for ASDH surgery and DC for refractory raised ICP. Also within center variation was present: 31% reported variation within the hospital for inserting an ICP monitor and 43% for evacuating mass lesions.ConclusionDespite a homogeneous organization, considerable practice variation exists of neurosurgical strategies for TBI in Europe. These results provide an incentive for comparative effectiveness research to determine elements of effective neurosurgical care.	[van Essen, Thomas A.; Peul, Wilco C.] Leiden Univ, UNCH, Dept Neurosurg, Med Ctr, Leiden, Netherlands; [van Essen, Thomas A.; de Ruiter, Godard C. W.; Peul, Wilco C.] UNCH, Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [den Boogert, Hugo F.] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; [Cnossen, Maryse C.; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Menon, David] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge, England; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Cecilia, Ackerlund; Pradeep, George; Linda, Lanyon; Visakh, Muraleedharan; David, Nelson] Karolinska Inst, INCF Int Neuroinformat Coordinating Facil, Stockholm, Sweden; [Hadie, Adams; Angelos, Kolias G.] Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Hadie, Adams; Judith, Allanson; Angelos, Kolias G.] Univ Cambridge, Cambridge, England; [Vanni, Agnoletti; Costanza, Martino; Alessandro, Masala; Fabrizio, Zumbo] Osped Gen Provinciale M Bufalini, Dept Anesthesia & Intens Care, Cesena, Italy; [Judith, Allanson] Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England; [Krisztina, Amrein; Jozsef, Nyiradi] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary; [Norberto, Andaluz; Mladen, Karan] Univ Cincinnati, Cincinnati, OH USA; [Nada, Andelic] Oslo Univ Hosp, Div Surg & Clin Neurosci, Dept Phys Med & Rehabil, Oslo, Norway; [Nada, Andelic] Univ Oslo, Oslo, Norway; [Lasse, Andreassen] Univ Hosp Northern Norway, Dept Neurosurg, Tromso, Norway; [Azasevac, Antun; Dula, Dilvesi; Jagos, Golubovic; Bojan, Jelaca; Peter, Vulekovic] Univ Novi Sad, Fac Med, Dept Neurosurg, Clin Ctr Vojvodina, Novi Sad, Serbia; [Audny, Anke] Univ Hosp Northern Norway, Dept Phys Med & Rehabil, Tromso, Norway; [Anna, Antoni; Harald, Binder; Elisabeth, Schwendenwein] Med Univ Vienna, Trauma Surg, Vienna, Austria; [Hilko, Ardon] Elisabeth Tweesteden Ziekenhuis, Dept Neurosurg, Tilburg, Netherlands; [Gerard, Audibert] Univ Hosp Nancy, Dept Anesthesiol & Intens Care, Nancy, France; [Kaspars, Auslands] Riga Eastern Clin Univ Hosp, Riga, Latvia; [Philippe, Azouvi] Hop Raymond Poincare, AP HP, Paris, France; [Luisa, Azzolini Maria; Luigi, Beretta; Rosa, Calvi Maria] S Raffaele Univ Hosp, Dept Anesthesiol & Intens Care, Milan, Italy; [Camelia, Baciu; Erta, Biqiri; Giorgio, Chevallard; Arturo, Chieregato; Francesca, Fossi; Marco, Sacchi; Giacinta, Vizzino] Osped Niguarda Ca Granda, NeuroIntens Care, Milan, Italy; [Rafael, Badenes; Francisco Javier, Belda; Federico, Bilotta; Angels, Lozano; Armando, Maruenda; Fabio Silvio, Taccone] Hosp Clin Univ Valencia, Dept Anesthesiol & Surg Trauma Intens Care, Valencia, Spain; [Ronald, Bartels; Hugo, den Boogert] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, Nijmegen, Netherlands; [Pal, Barzo] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Ursula, Bauerfeind; Barbara, Schloesser] Witten Herdecke Univ, Inst Transfus Med ITM, Cologne, Germany; [Romuald, Beauvais; Natascha, Perera] ARTTIC, Int Projects Management, Munich, Germany; [Ronny, Beer; Raimund, Helbok] Med Univ Innsbruck, Dept Neurol, Neurol Intens Care Unit, Innsbruck, Austria; [Bo-Michael, Bellander] Karolinska Univ Hosp, Dept Neurosurg & Anesthesia & Intens Care Med, Stockholm, Sweden; [Antonio, Belli] NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Remy, Bellier; Thierry, Benard; Elsa, Carise; Claire, Dahyot-Fizelier; Benoit, Giraud; Thomas, Kerforne] CHU Poitiers, Intens Care Unit, Poitiers, France; [Habib, Benali; Damien, Galanaud; Vincent, Perlbarg; Audrey, Vanhaudenhuyse] AP HP, Anesthesie Reanimat, Paris, France; [Maurizio, Berardino] AOU Citta Salute & Sci Torino, Dept Anesthesia & ICU, Orthoped & Trauma Ctr, Turin, Italy; [Christopher, Beynon; Julia, Mattern; Edgar, Santos; Michael, Schoell; Alexander, Younsi] Univ Hosp Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Morten, Blaabjerg; Daniel, Hertle] Odense Univ Hosp, Dept Neurol, Odense, Denmark; [Pierre, Bouzat; Gilles, Francony; Jean-Francois, Payen] Univ Hosp Grenoble, Dept Anesthesiol & Intens Care, Grenoble, France; [Peter, Bragge] Monash Univ, Monash Sustainabil Inst, BehaviourWorks Australia, Clayton, Vic, Australia; [Alexandra, Brazinova; Marek, Majdan; Veronika, Rehorcikova; Steven, Taylor Mark] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia; [Vibeke, Brinck; Mike, Jarrett; Anneliese, Synnot] Quesgen Syst Inc, Burlingame, CA USA; [Joanne, Brooker] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Camilla, Brorsson; Lars-Owe, Koskinen; Nina, Sundstrom] Umea Univ Hosp, Dept Neurosurg, Umea, Sweden; [Andras, Buki] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Andras, Buki] Univ Pecs, MTA PTE Clin Neurosci MR Res Grp, Hungarian Brain Res Program, Pecs, Hungary; [Andras, Buki] Univ Pecs, Janos Szentagothai Res Ctr, Hungarian Brain Res Program, Pecs, Hungary; [Monika, Bullinger] Univ Klinikum Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany; [Emiliana, Calappi; Marco, Carbonara; Davide, Mulazzi; Fabrizio, Ortolano] IRCCS Ca Granda Osped Maggiore Policlin, Neuro ICU, Milan, Italy; [Peter, Cameron; Emma, Donoghue; Dashiell, Gantner; Lynnette, Murray; Tony, Trapani] Monash Univ, Dept Epidemiol & Prevent Med, ANZIC Res Ctr, Melbourne, Australia; [Lozano Guillermo, Carbayo; Inigo, Pomposo] Hosp Cruces, Dept Neurosurg, Bilbao, Spain; [Carpenter, K.; Karin, Geleijns; Dick, Tibboel; Eno, Wildschut] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Intens Care, Rotterdam, Netherlands; [Carpenter, K.; Karin, Geleijns; Dick, Tibboel; Eno, Wildschut] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat Surg, Rotterdam, Netherlands; [Ana M, Castano-Leon; Pedro, Gomez A.; Alfonso, Lagares; Shirley, Vallance] Hosp Univ 12 Octubre, Dept Neurosurg, Madrid, Spain; [Francesco, Causin] Azienda Osped Univ Padova, Dept Neurosci, Padua, Italy; [Giuseppe, Citerio] ASST Monza, NeuroIntens Care, Monza, Italy; [Giuseppe, Citerio] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Maryse, Cnossen; Juanita, Haagsma A.; Hester, Lingsma; Daan, Nieboer; Suzanne, Polinder; Ewout, Steyerberg W.; Kimberley, Velt; Daphne, Voormolen] Univ Med Ctr, Dept Publ Hlth, Erasmus Med Ctr, Rotterdam, Netherlands; [Mark, Coburn; Rolf, Rossaint; Ana, Stevanovic; Julia, Van Waesberghe] Univ Hosp Aachen, Dept Anaesthesiol, Aachen, Germany; [Jonathan, Coles] Cambridge Univ Hosp NHS Fdn Trust, Dept Anesthesia & Neurointens Care, Cambridge, England; [Lizzie, Coles-Kemp; Johnny, Collett] Oxford Brookes Univ, Oxford Inst Nursing Midwifery & Allied Hlth Res, Movement Sci Grp, Oxford, England; [Jamie, Cooper D.] Monash Univ, Sch Publ Hlth & PM, Melbourne, Vic, Australia; [Jamie, Cooper D.] Alfred Hosp, Melbourne, Vic, Australia; [Marta, Correia] MRC, Cognit & Brain Sci Unit, Radiol MRI Dept, Cambridge, England; [Amra, Covic; Heiko, Engemann; Stefan, Hoefer; Jilske, Huijben; Ruben, Real; Ralph, Telgmann] Univ Med Gottingen, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Nicola, Curry; Simon, Stanworth] Oxford Univ Hosp NHS Trust, Oxford, England; [Endre, Czeiter] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Endre, Czeiter] Univ Pecs, MTA PTE Clin Neurosci MR Res Grp, Hungarian Brain Res Program Grant KTIA 13 NAP A I, Pecs, Hungary; [Endre, Czeiter] Univ Pecs, Janos Szentagothai Res Ctr, Hungarian Brain Res Program Grant KTIA 13 NAP A I, Pecs, Hungary; [Marek, Czosnyka; Peter, Smielewski] Univ Cambridge, Dept Clin Neurosci, Brain Phys Lab, Div Neurosurg,Addenbrookes Hosp, Cambridge, England; [Francois, Damas; Guy-Loup, Duliere; Hugues, Marechal] CHR Citadelle, Intens Care Unit, Liege, Belgium; [Pierre, Damas] CHU, Intens Care Unit, Liege, Belgium; [Helen, Dawes; Patrick, Esser; Caroline, van Heugten; Derick, Wade] Oxford Brookes Univ, Movement Sci Grp, Fac Hlth & Life Sci, Oxford, England; [Veronique, De Keyser; Andrew, Maas I. R.; Tomas, Menovsky; Nandesh, Nair; Gregory, Van der Steen; Dominique, Van Praag] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Veronique, De Keyser; Andrew, Maas I. R.; Tomas, Menovsky; Nandesh, Nair; Gregory, Van der Steen; Dominique, Van Praag] Univ Antwerp, Edegem, Belgium; [Francesco, Della Corte; Francesca, Grossi; Luminita, Sasu] Maggiore Carita Hosp, Dept Anesthesia & Intens Care, Novara, Italy; [Bart, Depreitere] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Godard, de Ruiter C. W.; PeulWilco; Lidwien, Smakman; Jeroen, van Dijck T. J. M.; Thomas, Van Essen A.; Carmen, Vleggeert-Lankamp] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Godard, de Ruiter C. W.; PeulWilco; Lidwien, Smakman; Jeroen, van Dijck T. J. M.; Thomas, Van Essen A.; Carmen, Vleggeert-Lankamp] Med Ctr Haaglanden, Dept Neurosurg, The Hague, Netherlands; [Ding Shenghao; Feng Junfeng; Jin, Lei; Lei, Wang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Diederik, Dippel; Kelly, Foks] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Abhishek, Dixit; Ari, Ercole; Charles, McFadyen; David, Menon; Virginia, Newcombe; Barbara, Sahakian; Emmanuel, Stamatakis; Guy, Williams] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Jens, Dreier; Peter, Vajkoczy] Charite Univ Med Berlin, Neurol Neurochirurg & Psychiat, Berlin, Germany; [George, Eapen; Stefan, Jankowski] Sheffield Teaching Hosp NHS Fdn Trust, Neurointens Care, Sheffield, S Yorkshire, England; [Erzsebet, Ezer; Zoltan, Vamos] Univ Pecs, Dept Anaesthesiol & Intens Therapy, Pecs, Hungary; [Martin, Fabricius; Daniel, Kondziella] Rigshosp, Dept Neurol, Reg Hovedstaden, Copenhagen, Denmark; [Martin, Fabricius; Daniel, Kondziella] Rigshosp, Dept Clin Neurophysiol, Reg Hovedstaden, Copenhagen, Denmark; [Martin, Fabricius; Daniel, Kondziella] Rigshosp, Dept Neuroanesthesiol, Reg Hovedstaden, Copenhagen, Denmark; [Valery, Feigin L.; Braden, Te Ao; Alice, Theadom] Auckland Univ Technol, Fac Hlth & Environm Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Ulderico, Freo] Azienda Osped Univ Padova, Dept Med, Padua, Italy; [Shirin, Frisvold] Univ Hosp Northern Norway, Dept Anesthesiol & Intens care, Tromso, Norway; [Alex, Furmanov; Guy, Rosenthal] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, Jerusalem, Israel; [Pablo, Gagliardo] Fdn Inst Valenciano Neurorrehabil FIVAN, Valencia, Spain; [Gao Guoyi; Jiang Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Alexandre, Ghuysen] CHU, Emergency Dept, Liege, Belgium; [Lelde, Giga; Egils, Valeinis; Agate, Ziverte] Pauls Stradins Clin Univ Hosp, Riga, Latvia; [Ben, Glocker; Konstantinos, Kamnitsas; Christian, Ledig; Daniel, Rueckert] Imperial Coll London, Dept Comp, London, England; [Russell, Gruen L.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Russell, Gruen L.] Monash Univ, Clayton, Vic, Australia; [Deepak, Gupta] All India Inst Med Sci, Dept Neurosurg, Neurosci Ctr, New Delhi 110029, India; [Deepak, Gupta] All India Inst Med Sci, JPN Apex Trauma Ctr, New Delhi 110029, India; [Iain, Haitsma; Victor, Volovici] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Jed, Hartings A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Eirik, Helseth] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Astrid, Hoedemaekers] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, Nijmegen, Netherlands; [Lindsay, Horton; Peter, Hutchinson J.; Lindsay, Wilson] Univ Stirling, Div Psychol, Stirling, Scotland; [Kristine, Haberg Asta] Norwegian Univ Sci & Technol, St Olavs Hosp, Dept Med Imaging, Trondheim, Norway; [Kristine, Haberg Asta] Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway; [Bram, Jacobs; Joukje, Van der Naalt] Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Kelly, Jones] AUT Univ, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Ari, Katila; Jussi, Posti; Riikka, Takala; Olli, Tenovuo] Turku Univ, Cent Hosp, Rehabil & Brain Trauma, Turku, Finland; [Ari, Katila; Jussi, Posti; Riikka, Takala; Olli, Tenovuo] Univ Turku, Turku, Finland; [Maija, Kaukonen; Riku, Kivisaari; Anna, Piippo-Karjalainen; Rahul, Raj; Paivi, Tanskanen] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Balint, Kolumban; Noemi, Kovacs] Univ Pecs, Hungarian Brain Res Program Grant KTIA 13 NAP A I, Pecs, Hungary; [Erwin, Kompanje] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Erwin, Kompanje] Erasmus MC, Dept Eth & Philosophy Med, Rotterdam, Netherlands; [Ksenija, Kolundzija] Univ Novi Sad, Dept Psichiat, Clin Ctr Vojvodina, Fac Med, Novi Sad, Serbia; [Steven, Laureys; Quentin, Noirhomme; Audrey, Vanhaudenhuyse] Univ Liege, Cyclotron Res Ctr, Liege, Belgium; [Fiona, Lecky] Univ Sheffield, Sch Hlth & Related Res ScHARR, Emergency Med Res Sheffield, Hlth Serv Res Sect, Sheffield, S Yorkshire, England; [Rolf, Lefering] Witten Herdecke Univ, Inst Res Operat Med IFOM, Cologne, Germany; [Valerie, Legrand] ICON, VP Global Project Management CNS, Paris, France; [Leon, Levi; Menashe, Zaaroor] Rambam Med Ctr, Dept Neurosurg, Haifa, Israel; [Roger, Lightfoot] Univ Hosp Southhampton NHS Trust, Dept Anesthesiol & Intens Care, Southampton, Hants, England; [Dirk, Loeckx; Francisco, Martin Leon; Dirk, Smeets; Wim, Van Hecke; Thijs, Vande Vyvere; Jan, Verheyden] IcoMetrix NV, Leuven, Belgium; [Stephen, MacDonald] Cambridge Univ Hosp, Cambridge, England; [Marc, Maegele; Nadine, Schaeffer] Witten Herdecke Univ, Dept Traumatol Orthoped Surg & Sportmed, CMMC, Cologne, Germany; [Sebastian, Major; Maren, Winkler K. L.] Charite Univ Med Berlin, Ctr Schlaganfallforsch, Berlin, Germany; [Alex, Manara; Matt, Thomas] Southmead Hosp, Intens Care Unit, Bristol, Avon, England; [Geoffrey, Manley] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Didier, Martin] CHU, Dept Neurosurg, Liege, Belgium; [Catherine, McMahon] Walton Ctr NHS Fdn Trust, Dept Neurosurg, Liverpool, Merseyside, England; [Bela, Melegh] Univ Pecs, Dept Med Genet, Pecs, Hungary; [Cristina, Morganti-Kossmann; Jeffrey, Rosenfeld] Monash Univ, Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Holger, Muehlan; Silke, Schmidt] Ernst Moritz Arndt Univ Greifswald, Dept Hlth & Prevent, Greifswald, Germany; [Ancuta, Negru; Horia, Ples; Maria, Tudora Cristina] Emergency Cty Hosp Timisoara, Dept Neurosurg, Timisoara, Romania; [Mauro, Oddo] CHU Vaudois, Lausanne, Switzerland; [Annemarie, Oldenbeuving] Elisabeth Tweesteden Ziekenhuis, Dept Intens Care, Tilburg, Netherlands; [Matej, Oresic] Steno Diabet Ctr, Dept Syst Med, Gentofte, Denmark; [Aarno, Palotie; Matti, Pirinen; Samuli, Ripatti] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Aarno, Palotie] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Dept Med, Boston, MA 02114 USA; [Aarno, Palotie] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA; [Aarno, Palotie] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Aarno, Palotie] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Aarno, Palotie] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA; [Paul, Parizel M.] Antwerp Univ Hosp, Dept Radiol, Edegem, Belgium; [Paul, Parizel M.] Univ Antwerp, Edegem, Belgium; [Adriana, Patruno; Francesca, Sala; Davide, Savo; Alessia, Vargiolu] ASST Monza, Dept Anesthesia & Intens Care, NeuroIntenisve Care Unit, Monza, Italy; [Paolo, Persona; Sandra, Rossi] Azienda Osped Univ Padova, Dept Anesthesia & Intens Care, Padua, Italy; [Sebastien, Pili Floury] CHRU Besancon, Intens Care Unit, Besancon, France; [Maria Antonia, Poca; Andreea, Radoi; Juan, Sahuquillo] Vall dHebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; [Louis, Puybasset] Pitie Salpetriere Teaching Hosp, AP HP, Dept Anesthesiol & Crit Care, Paris, France; [Louis, Puybasset] Univ Paris 06, Paris, France; [Arminas, Ragauskas; Saulius, Rocka] Kaunas Univ Technol, Dept Neurosurg, Kaunas, Lithuania; [Arminas, Ragauskas; Saulius, Rocka] Vilnius Univ, Kaunas, Lithuania; [Malinka, Rambadagalla] Rezekne Hosp, Rezekne, Latvia; [Jonathan, Rhodes] NHS Lothian, Dept Anesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Jonathan, Rhodes] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Cecilie, Roe] Univ Oslo, Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Olav, Roise] Oslo Univ Hosp, Div Surg & Clin Neurosci, Oslo, Norway; [Gerwin, Roks; Guus, Schoonman] Elisabeth TweeSteden Ziekenhuis, Dept Neurol, Tilburg, Netherlands; [Jonathan, Rosand] Broad Inst, Cambridge, MA USA; [Jonathan, Rosand] Harvard Med Sch, Boston, MA 02115 USA; [Jonathan, Rosand] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Christina, Rosenlund] Odense Univ Hosp, Dept Neurosurg, Odense, Denmark; [Martin, Rusnak] Int Neurotrauma Res Org, Vienna, Austria; [Oliver, Sakowitz; Renan, Sanchez-Porras] Klinikum Ludwigsburg, Klin Neurochirurg, Ludwigsburg, Germany; [Oliver, Sakowitz] Univ Hosp Heidelberg, Heidelberg, Germany; [Janos, Sandor] Univ Debrecen, Div Biostat & Epidemiol, Dept Prevent Med, Debrecen, Hungary; [Inger, Schipper] Leiden Univ, Med Ctr, Dept Traumasurg, Leiden, Netherlands; [Herbert, Schoechl] AUVA Trauma Hosp, Dept Anaesthesiol & Intens Care, Salzburg, Austria; [Frederik, Schou Rico] Odense Univ Hosp, Dept Neuroanesthesia & Neurointens Care, Odense, Denmark; [Ozcan, Sir] Radboud Univ Nijmegen, Med Ctr, Dept Emergency Care Med, Nijmegen, Netherlands; [Toril, Skandsen] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Toril, Skandsen] Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway; [Abayomi, Sorinola; Viktoria, Tamas] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Nicole, Steinbuechel] Univ Med Gottingen, Gottingen, Germany; [Robert, Stevens] Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Baltimore, MD USA; [William, Stewart] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow, Lanark, Scotland; [William, Stewart] Univ Glasgow, Glasgow, Lanark, Scotland; [Ewout, Steyerberg W.] Leiden Univ, Med Ctr, Dept Dept Biomed Data Sci, Leiden, Netherlands; [Nino, Stocchetti] Milan Univ, Dept Pathophysiol & Transplantat, Milan, Italy; [Nino, Stocchetti] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci ICU, Milan, Italy; [Anneliese, Synnot] La Trobe Univ, Cochrane Consumers & Commun Review Grp, Ctr Hlth Commun & Participat, Sch Psychol & Publ Hlth, Melbourne, Vic, Australia; [Guido, Teodorani] Osped Gen Provinciale M Bufalini, Dept Reahabilitat, Cesena, Italy; [Christos, Tolias] Kings Coll London, Dept Neurosurg, London, England; [Luaba, Tshibanda Jean-Flory] CHU, Radiol MRI Dept, Liege, Belgium; [Mathieu, Van der Jagt] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Emmanuel, Vega] Lille Univ Hosp, Dept Anesthesiol Intens Care, Lille, France; [Paul, Vespa M.] Univ Calif Los Angeles, Neurocrit Care, Los Angeles, CA USA; [Anne, Vik] St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Anne, Vik] Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway; [Rimantas, Vilcinis] Kaunas Univ Hlth Sci, Dept Neurosurg, Kaunas, Lithuania; [Kevin, Wang K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Lars, Wessels; Stefan, Wolf] Charite Univ Med Berlin, Interdisciplinary Neuro Intens Care Unit, Berlin, Germany; [Peter, Ylen] VTT Tech Res Ctr, Tampere, Finland; [Yang, Zhihui] Univ Florida, Gainesville, FL USA	van Essen, TA (corresponding author), Leiden Univ, UNCH, Dept Neurosurg, Med Ctr, Leiden, Netherlands.; van Essen, TA (corresponding author), UNCH, Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.	essen@lumc.nl	Raj, Rahul/K-7693-2012; Maas, Andrew IR/C-5584-2013; Posti, Jussi P./Y-2908-2019; Lagares, Alfonso/B-2969-2011; Lanyon, Linda/L-9238-2019; Radoi, Andreea/N-5613-2019; Sacchi, Marco/F-7517-2013; de Ruiter, Godard/ABC-4074-2020; Golubovic, Jagos/AAD-1270-2019; Bartels, R.H.M.A./L-4184-2015; Sahuquillo, Juan/B-3577-2008; Gomez, Pedro/E-2411-2014; Thijs, Vincent/M-9048-2019	Raj, Rahul/0000-0003-4243-9591; Maas, Andrew IR/0000-0003-1612-1264; Posti, Jussi P./0000-0002-5925-5193; Lagares, Alfonso/0000-0003-3996-0554; Lanyon, Linda/0000-0002-0885-1825; Radoi, Andreea/0000-0002-0677-3544; Sacchi, Marco/0000-0003-2386-1156; Golubovic, Jagos/0000-0001-5524-246X; Blaabjerg, Morten/0000-0001-6007-1861; Dippel, Diederik/0000-0002-9234-3515; Bartels, R.H.M.A./0000-0002-8638-4660; Esser, Patrick/0000-0002-3227-0115; Badenes, Rafael/0000-0001-7017-0150; Rossi, Sandra/0000-0002-9963-8121; Sahuquillo, Juan/0000-0003-0713-5875; Gomez, Pedro/0000-0002-4185-5238; Newcombe, Virginia/0000-0001-6044-9035; Castano-Leon, Ana M/0000-0002-7918-5049; , Johnny/0000-0003-4138-2589; Dawes, Helen/0000-0002-2933-5213; Pirinen, Matti/0000-0002-1664-1350; Sanchez-Porras, Renan/0000-0002-9084-8114; Santos, Edgar/0000-0002-8976-5549; Te Ao, Braden/0000-0002-1050-200X; Feigin, Valery L./0000-0002-6372-1740; Thijs, Vincent/0000-0002-6614-8417	European UnionEuropean Commission [602150]; Hersenstichting Nederland (Dutch Brain Foundation) [PS2014-06]	This study was funded by the European Union Seventh Framework Program (grant 602150) for Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) and the Hersenstichting Nederland (Dutch Brain Foundation, grant PS2014-06) for The Dutch Neurotraumatology Quality Registry (Net-QuRe). There is no industry affiliation.	Albuquerque FC, 2013, WORLD NEUROSURG, V79, P598, DOI 10.1016/j.wneu.2013.03.045; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Brattheim BJ, 2012, EUR J VASC ENDOVASC, V44, P267, DOI 10.1016/j.ejvs.2012.04.029; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Carney N, 2016, NEUROSURGERY, V1; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cnossen MC, 2018, CLIN EPIDEMIOL, V10, P841, DOI 10.2147/CLEP.S154500; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2016, NEW ENGL J MED, V375, P2402; Ergina PL, 2009, LANCET, V374, P1097, DOI 10.1016/S0140-6736(09)61086-2; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Gregson BA, 2003, STROKE, V34, P2593, DOI 10.1161/01.STR.0000097491.82104.F3; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Huijben JA, 2017, J NEUROTRAUMA NEU, V2017, P5194; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Macefield RC, 2014, LANGENBECK ARCH SURG, V399, P263, DOI 10.1007/s00423-013-1136-8; Mattei TA, 2013, WORLD NEUROSURG, V79, P602, DOI 10.1016/j.wneu.2013.03.048; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; Mukherjee D, 2013, NEW ENGL J MED, V368, P1748, DOI 10.1056/NEJMc1301076; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Timmons SD, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS1296; van Essen TA, 2019, J NEUROTRAUM, V36, P1184, DOI 10.1089/neu.2018.5869; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495	34	17	17	0	19	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2019	161	3					435	449		10.1007/s00701-018-3761-z			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HO0PZ	WOS:000460607500002	30569224	Green Published, Other Gold			2021-06-18	
J	Wilks, CR; Morland, LA; Dillon, KH; Mackintosh, MA; Blakey, SM; Wagner, HR; Elbogen, EB				Wilks, Chelsey R.; Morland, Leslie A.; Dillon, Kirsten H.; Mackintosh, Margaret-Anne; Blakey, Shannon M.; Wagner, H. Ryan; Elbogen, Eric B.		VA Mid-Atlantic MIRECC Workgrp	Anger, social support, and suicide risk in US military veterans	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Anger; Suicide; Veterans; Social support; PTSD	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; INTERMITTENT EXPLOSIVE DISORDER; CLINICAL-SAMPLE; IDEATION; PREVALENCE; RESILIENCE; DEPRESSION; SYMPTOMS; HEALTH	There have been considerable efforts to understand, predict, and reduce suicide among U.S. military veterans. Studies have shown that posttraumatic stress disorder (PTSD), major depression (MDD), and traumatic brain injury (TBI) increase risk of suicidal behavior in veterans. Limited research has examined anger and social support as factors linked to suicidal ideation, which if demonstrated could lead to new, effective strategies for suicide risk assessment and prevention. Iraq/Afghanistan era veterans (N = 2467) were evaluated in the ongoing Veterans Affairs Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC) multi-site Study of Post-Deployment Mental Health on demographic and psychological variables. Analyses revealed that suicidal ideation in veterans was positively associated with anger and negatively associated with social support. These results remained significant in multivariate logistic regression models controlling for relevant variables including PTSD, MDD, and TBI. Examining interrelationships among these variables, the analyses revealed that the association between PTSD and suicidal ideation was no longer statistically significant once anger was entered in the regression models. Further, it was found that TBI was associated with suicidal ideation in veterans with MDD but not in veterans without MDD. These findings provide preliminary evidence that suicide risk assessment in military veterans should include clinical consideration of the roles of anger and social support in addition to PTSD, MDD, and TBI. Further, the results suggest that suicide prevention may benefit from anger management interventions as well as interventions aimed at bolstering social and family support as treatment adjuncts to lower suicide risk in veterans.	[Wilks, Chelsey R.; Morland, Leslie A.] Vet Affairs Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Morland, Leslie A.] Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Morland, Leslie A.] Natl Ctr PTSD, Pacific Isl Div, 3375 Koapaka St, Honolulu, HI 96819 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Vet Affairs Midatlantic Mental Illness Res Educ &, 3022 Croasdaile Dr, Durham, NC 27705 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Durham Vet Affairs Healthcare Syst, 508 Fulton St, Durham, NC 27705 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Duke Univ, Sch Med, 2424 Erwin Rd, Durham, NC 27705 USA; [Mackintosh, Margaret-Anne] Vet Affairs Palo Alto Healthcare Syst, Natl Ctr PTSD, Disseminat & Training Div, 334795 Willow Rd, Menlo Pk, CA 94025 USA; [Blakey, Shannon M.] Univ N Carolina, Dept Psychol & Neurosci, Davie Hall,CB 3270, Chapel Hill, NC 27599 USA	Wilks, CR (corresponding author), Vet Affairs Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	chelseywilks@fas.harvard.edu		Mackintosh, Margaret-Anne/0000-0002-2725-3177; Blakey, Shannon/0000-0002-9291-3688	VA Mid-Atlantic Mental Illness Research, Education and Clinical Center	Preparation of this report was supported by the VA Mid-Atlantic Mental Illness Research, Education and Clinical Center.	Addis ME, 2008, CLIN PSYCHOL-SCI PR, V15, P153, DOI 10.1111/j.1468-2850.2008.00125.x; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Bertolote, 2015, SUICIDOLOGY, V7, P6, DOI [10.5617/suicidologi.2330, DOI 10.5617/SUICIDOLOGI.2330]; Brancu M, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1570; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Chu C, 2017, J PERS DISORD, V31, P145, DOI 10.1521/pedi_2016_30_241; Conner KR, 2003, AGGRESS VIOLENT BEH, V8, P413, DOI 10.1016/S1359-1789(02)00067-8; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; Department of Veterans Affairs, 2017, VA REL VET SUIC STAT; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Dobscha SK, 2014, J GEN INTERN MED, V29, pS853, DOI 10.1007/s11606-014-3028-1; Doran N., 2018, MILITARY BEHAV HLTH, V6, P215, DOI [10.1080/21635781.2017.1379453, DOI 10.1080/21635781.2017.1379453]; Fanning JR, 2016, COMPR PSYCHIAT, V70, P125, DOI 10.1016/j.comppsych.2016.05.018; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Hawkins KA, 2014, J PSYCHIATR RES, V50, P59, DOI 10.1016/j.jpsychires.2013.12.005; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2015, ANN EPIDEMIOL, V25, P96, DOI 10.1016/j.annepidem.2014.11.020; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kessler RC, 2006, ARCH GEN PSYCHIAT, V63, P669, DOI 10.1001/archpsyc.63.6.669; Kleiman EM, 2012, CRISIS, V33, P273, DOI 10.1027/0227-5910/a000136; Klonsky ED, 2017, CURR OPIN PSYCHIATR, V30, P15, DOI 10.1097/YCO.0000000000000294; Klonsky ED, 2014, SUICIDE LIFE-THREAT, V44, P1, DOI 10.1111/sltb.12068; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Miles SR, 2016, J INTERPERS VIOLENCE, V31, P1795, DOI 10.1177/0886260515570746; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Nock MK, 2015, SUICIDE LIFE-THREAT, V45, P588, DOI 10.1111/sltb.12153; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Nolen-Hoeksema S, 2008, CLIN PSYCHOL-SCI PR, V15, P178, DOI 10.1111/j.1468-2850.2008.00128.x; Reyes VA, 2005, MIL MED, V170, P483, DOI 10.7205/MILMED.170.6.483; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Sher L, 2012, CLEV CLIN J MED, V79, P92, DOI 10.3949/ccjm.79a.11069; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Sippel LM, 2016, PSYCHIAT RES, V243, P421, DOI 10.1016/j.psychres.2016.06.040; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Stanley IH, 2017, J PSYCHIATR RES, V84, P161, DOI 10.1016/j.jpsychires.2016.10.004; Stroebe M, 2005, AM J PSYCHIAT, V162, P2178, DOI 10.1176/appi.ajp.162.11.2178; Teo AR, 2018, J AFFECT DISORDERS, V230, P42, DOI 10.1016/j.jad.2018.01.003; Thompson M., 2006, ENHANCING MENTAL REA; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Youssef NA, 2013, ANN CLIN PSYCHIATRY, V25, P59	48	17	18	2	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	FEB	2019	109						139	144		10.1016/j.jpsychires.2018.11.026			6	Psychiatry	Psychiatry	HI9FR	WOS:000456761200018	30537566				2021-06-18	
J	Yaffe, K; Lwi, SJ; Hoang, TND; Xia, F; Barnes, DE; Maguen, S; Peltz, CB				Yaffe, Kristine; Lwi, Sandy J.; Hoang, Tina D.; Xia, Feng; Barnes, Deborah E.; Maguen, Shira; Peltz, Carrie B.			Military-related risk factors in female veterans and risk of dementia	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; HEALTH; PREVALENCE; DEPRESSION; GENDER; WOMEN; ASSOCIATION	ObjectiveTo determine whether diagnoses of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and depression, alone or in combination, increase dementia risk among older female veterans.MethodsThis cohort study included data from 109,140 female veterans 55 years of age receiving care from Veterans Health Administration medical centers in the United States between October 2004 and September 2015 with at least 1 follow-up visit. TBI, PTSD, depression, and medical conditions at study baseline and incident dementia were determined according to ICD-9-CM codes. Fine-Gray proportional hazards models were used to determine the association between military-related risk factors and dementia diagnosis, accounting for the competing risk of death.ResultsDuring follow-up (mean 4.0 years, SD 2.3), 4% of female veterans (n = 4,125) developed dementia. After adjustment for demographics and medical conditions, women with TBI, PTSD, and depression had a significant increase in risk of developing dementia compared to women without these diagnoses (TBI-adjusted subdistribution hazard ratio [adjusted sHR] 1.49, 95% confidence interval [CI] 1.01-2.20; PTSD adjusted sHR 1.78, 95% CI 1.34-2.36; and depression-adjusted sHR 1.67, 95% CI 1.55-1.80), while women with >1 diagnosis had the highest risk for dementia (adjusted sHR 2.15, 95% CI 1.84-2.51).ConclusionsWe found that women with military-related risk factors had an approximate to 50% to 80% increase in developing dementia relative to women without these diagnoses, while female veterans with multiple risk factors had a >2-fold risk of developing dementia. These findings highlight the need for increased screening of TBI, PTSD, and depression in older women, especially female veterans.	[Yaffe, Kristine; Lwi, Sandy J.; Hoang, Tina D.; Xia, Feng; Barnes, Deborah E.; Maguen, Shira; Peltz, Carrie B.] San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA 94121 USA; [Yaffe, Kristine; Barnes, Deborah E.; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	Yaffe, K (corresponding author), San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA 94121 USA.; Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.	Kristine.yaffe@ucsf.edu			Department of DefenseUnited States Department of Defense [W81XWH-16-1-0507]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG031155]	This research was supported by Department of Defense grant W81XWH-16-1-0507 (principal investigator: Yaffe) and National Institute on Aging grant K24 AG031155 (principal investigator: Yaffe).	Al Hazzouri AZ, 2014, J GERONTOL A-BIOL, V69, P595, DOI 10.1093/gerona/glt139; Amoroso T, 2017, J NERV MENT DIS, V205, P318, DOI 10.1097/NMD.0000000000000621; Armed Forces Health Surveillance Branch, STAND SURV CAS DEF; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bhalerao U, 2013, BRAIN INJURY, V27, P767, DOI 10.3109/02699052.2013.793396; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Butters Meryl A, 2008, Dialogues Clin Neurosci, V10, P345; Byers AL, 2014, ALZHEIMERS DEMENT, V10, pS166, DOI 10.1016/j.jalz.2014.04.007; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Cancelliere C, 2016, ARCH PHYS MED REHAB, V97, pS5, DOI 10.1016/j.apmr.2014.11.028; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Curry JF, 2014, J AFFECT DISORDERS, V152, P434, DOI 10.1016/j.jad.2013.10.012; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Eibner Christine, 2016, Rand Health Q, V5, P13; Engler-Chiurazzi EB, 2017, PROG NEUROBIOL, V157, P188, DOI 10.1016/j.pneurobio.2015.12.008; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; Goveas JS, 2011, J AM GERIATR SOC, V59, P57, DOI 10.1111/j.1532-5415.2010.03233.x; Greenberg MS, 2014, ALZHEIMERS DEMENT, V10, pS155, DOI 10.1016/j.jalz.2014.04.008; Harris DP, 2009, J AM GERIATR SOC, V57, P2209, DOI 10.1111/j.1532-5415.2009.02572.x; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lehavot K, 2018, AM J PREV MED, V54, pE1, DOI 10.1016/j.amepre.2017.09.008; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miller MW, 2018, HARVARD REV PSYCHIAT, V26, P57, DOI 10.1097/HRP.0000000000000167; Mollayeva Tatyana, 2018, Concussion, V3, pCNC51, DOI 10.2217/cnc-2017-0015; Nebel RA, 2018, ALZHEIMERS DEMENT, V14, P1171, DOI 10.1016/j.jalz.2018.04.008; Nordstrom A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002496; Phelan EA, 2012, JAMA-J AM MED ASSOC, V307, P165, DOI 10.1001/jama.2011.1964; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Ramchand R, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0575-z; Ramsey C, 2017, AM J PUBLIC HEALTH, V107, P329, DOI 10.2105/AJPH.2016.303574; RAND, 2008, INVISIBLE WOUNDS WAR; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; US Department of Veterans Affairs (VA) National Center for Veterans Analysis and Statistics, 2017, WOM VET REP PRES FUT; US Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Dementia Steering Committee (DSC), 2016, VHA DEM STEER COMM R; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yan Y, 2018, NEUROBIOL STRESS, V8, P120, DOI 10.1016/j.ynstr.2018.03.002	50	17	17	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 15	2019	92	3					E205	E211		10.1212/WNL.0000000000006778			7	Clinical Neurology	Neurosciences & Neurology	HQ6ZI	WOS:000462568300013	30541865	Green Published			2021-06-18	
J	Clausen, F; Marklund, N; Hillered, L				Clausen, Fredrik; Marklund, Niklas; Hillered, Lars			Acute Inflammatory Biomarker Responses to Diffuse Traumatic Brain Injury in the Rat Monitored by a Novel Microdialysis Technique	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; inflammatory biomarkers; MD; rat; TBI	INTERLEUKIN-1 RECEPTOR ANTAGONIST; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; AXONAL INJURY; EXPRESSION; CYTOKINES; CNS; QUANTIFICATION; ACTIVATION; CHEMOKINES	Neuroinflammation is a major contributor to the progressive brain injury process induced by traumatic brain injury (TBI), and may play an important role in the pathophysiology of axonal injury. The immediate neuroinflammatory cascade cannot be characterized in the human setting. Therefore, we used the midline fluid percussion injury model of diffuse TBI in rats and a novel microdialysis (MD) method providing stable diffusion-driven biomarker sampling. Immediately post-injury, bilateral amphiphilic tri-block polymer coated MD probes (100kDa cut off membrane) were inserted and perfused with Dextran 500kDa-supplemented artificial cerebrospinal fluid (CSF) to optimize protein capture. Six hourly samples were analyzed for 27 inflammatory biomarkers (9 chemokines, 13 cytokines, and 5 growth factors) using a commercial multiplex biomarker kit. TBI (n=6) resulted in a significant increase compared with sham-injured controls (n=6) for five chemokines (eotaxin/CCL11, fractalkine/CX3CL1, LIX/CXCL5, monocyte chemoattractant protein [MCP]1/CCL2, macrophage inflammatory protein [MIP]1 /CCL3), 10 cytokines (interleukin [IL]-1, IL-1, IL-4, IL-6, IL-10, IL-13, IL-17, IL-18, interferon [IFN]-, tumor necrosis factor [TNF]-), and four growth factors (epidermal growth factor [EGF], granulocyte-macrophage colony-stimulating factor [GM-CSF], leptin, vascular endothelial growth factor [VEGF]). Therefore, diffuse TBI was associated with an increased level of 18 of the 27 inflammatory biomarkers at one through six time points, during the observation period whereas the remaining 9 biomarkers were unaltered. The study shows that diffuse TBI induces an acute increase in a number of inflammatory biomarkers. The novel MD technique provides stable MD sampling suitable for further studies on the early neuroinflammatory cascade in TBI.	[Clausen, Fredrik; Marklund, Niklas; Hillered, Lars] Uppsala Univ, Sect Neurosurg, Dept Neurosci, Uppsala, Sweden	Clausen, F (corresponding author), Uppsala Univ, Uppsala Univ Hosp, Dept Neurosci, Sect Neurosurg, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	fredrik.clausen@neuro.uu.se		Clausen, Fredrik/0000-0003-3592-4417	Swedish Research CouncilSwedish Research CouncilEuropean Commission; VINNOVA FoundationVinnova; Selander Foundation; Uppsala University Hospital	The authors thank the CMA division of Harvard Medical Apparatus for donating the microdialysis probes and co-funding the MilliPlex kits for this project; and the Swedish Research Council, VINNOVA Foundation, Uppsala University Hospital, and the Selander Foundation for supporting the work financially.	Abdul-Muneer P.M., 2016, MOL NEUROBIOL; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; CHAO CC, 1993, J IMMUNOL, V151, P1473; Chen WQ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0847-0; Chu JT, 2014, ANAL BIOANAL CHEM, V406, P7601, DOI 10.1007/s00216-014-8192-y; Clausen F, 2014, BRAIN RES, V1588, P37, DOI 10.1016/j.brainres.2014.08.043; Dahlin AP, 2014, ANAL CHEM, V86, P8671, DOI 10.1021/ac501880u; Dahlin AP, 2012, ANAL BIOANAL CHEM, V402, P2057, DOI 10.1007/s00216-011-5614-y; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Ekmark-Lewen S, 2016, EUR J NEUROSCI, V43, P1016, DOI 10.1111/ejn.13190; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gadani SP, 2012, J IMMUNOL, V189, P4213, DOI 10.4049/jimmunol.1202246; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guglielmetti C, 2016, GLIA, V64, P2181, DOI 10.1002/glia.23053; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson P.J., 2015, INTENSIVE CARE MED; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Keeler GD, 2014, EUR J PHARM SCI, V57, P60, DOI 10.1016/j.ejps.2013.11.005; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; Kozai TDY, 2016, BIOMATERIALS, V87, P157, DOI 10.1016/j.biomaterials.2016.02.013; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N., 2009, J NEUROSURG; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Purins K, 2011, CRIT CARE MED, V39, P512, DOI 10.1097/CCM.0b013e318206b824; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Szmydynger-Chodobska J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167677; Tado M, 2014, J NEUROTRAUM, V31, P691, DOI 10.1089/neu.2013.2940; Thelin EP, 2018, J NEUROTRAUM, V35, P341, DOI 10.1089/neu.2017.5155; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Waisman A, 2015, ACTA NEUROPATHOL, V129, P625, DOI 10.1007/s00401-015-1402-7; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00331; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	75	17	18	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2019	36	2					201	211		10.1089/neu.2018.5636			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HM4LJ	WOS:000459444800003	29790398				2021-06-18	
J	Fehr, SD; Nelson, LD; Scharer, KR; Traudt, EA; Veenstra, JM; Tarima, SS; Liu, XC; Walter, KD				Fehr, Shayne D.; Nelson, Lindsay D.; Scharer, Kyle R.; Traudt, Elizabeth A.; Veenstra, Joshua M.; Tarima, Sergey S.; Liu, Xue-Cheng; Walter, Kevin D.			Risk Factors for Prolonged Symptoms of Mild Traumatic Brain Injury: A Pediatric Sports Concussion Clinic Cohort	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild traumatic brain injury; pediatric; child; adolescent; sports medicine; athlete; symptoms; female; loss of consciousness	PREDICT PROTRACTED RECOVERY; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; SEX-DIFFERENCES; HEAD-INJURY; CHILDREN; AGE; EPIDEMIOLOGY; TRAJECTORIES; MANAGEMENT	Objective: To examine predictors of prolonged symptom duration from mild traumatic brain injury (mTBI) in a pediatric sports medicine specialty clinic cohort as these predictors may be distinct in this population. Design: Retrospective chart review. Setting: Outpatient specialty clinic. Patients: Charts of 549 patients (age range: 10-18 years) with concussions were reviewed in an outpatient clinic that predominantly managed sports-related injuries (77.3%). Patients (n = 431) included in the final analysis met the criteria for mTBI and were symptomatic at their first visit. Assessment of Risk Factors: Patient history, injury, and recovery variables were evaluated. Main Outcome Measures: Predictors of prolonged time to reach self-reported symptom recovery were evaluated using Cox proportional hazards. Results: Median time to symptom recovery of the 431 patients who presented to clinic with symptoms was 40 days (full clinic sample median = 34 days). Analyses identified 3 unique predictors of symptom recovery: loss of consciousness (LOC) [hazard ratio (HR) = 0.56, P < 0.0001], female sex (HR = 0.57, P < 0.0001), and concussion symptom score at first clinic visit (HR = 0.76, P < 0.0001). Conclusions: Prolonged duration of mTBI symptoms in patients who present to a pediatric sports-based concussion clinic is related to initial symptom severity, female sex, and LOC.	[Fehr, Shayne D.; Traudt, Elizabeth A.; Veenstra, Joshua M.; Liu, Xue-Cheng; Walter, Kevin D.] Med Coll Wisconsin, Dept Orthopaed Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Fehr, Shayne D.; Scharer, Kyle R.; Liu, Xue-Cheng; Walter, Kevin D.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; [Nelson, Lindsay D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Tarima, Sergey S.] Med Coll Wisconsin, Inst Hlth & Soc, Milwaukee, WI 53226 USA	Fehr, SD (corresponding author), Med Coll Wisconsin, Pediat Orthopaed, 9000 W Wisconsin Ave,POB 1997,Suite C360, Milwaukee, WI 53201 USA.	sfehr@mcw.edu			Department of Orthopaedic Surgery	The authors acknowledge Alexis Visotcky, MS; Ashley Ward, BS; and Heather Zhao, MS for their contributions to the study. Thanks to the Department of Orthopaedic Surgery for funding provided for the study.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	50	17	17	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2019	29	1					11	17		10.1097/JSM.0000000000000494			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	IQ4PZ	WOS:000480734000005	29084034				2021-06-18	
J	Nicola, F; Marques, MR; Odorcyk, F; Petenuzzo, L; Aristimunha, D; Vizuete, A; Sanches, EF; Pereira, DP; Maurmann, N; Goncalves, CA; Pranke, P; Netto, CA				Nicola, Fabricio; Marques, Marilia Rossato; Odorcyk, Felipe; Petenuzzo, Leticia; Aristimunha, Dirceu; Vizuete, Adriana; Sanches, Eduardo Farias; Pereira, Daniela Pavulack; Maurmann, Natasha; Goncalves, Carlos-Alberto; Pranke, Patricia; Netto, Carlos Alexandre			Stem Cells from Human Exfoliated Deciduous Teeth Modulate Early Astrocyte Response after Spinal Cord Contusion	MOLECULAR NEUROBIOLOGY			English	Article						Spinal cord injury; Human dental pulp stem cells; Glial scar formation; Progenitor cells	RECTIFYING POTASSIUM CHANNELS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DENTAL-PULP CELLS; REACTIVE ASTROCYTES; AXONAL REGENERATION; FUNCTIONAL RECOVERY; PROGENITOR CELLS; EXPRESSION; S100B	The transplantation of stem cells from human exfoliated deciduous teeth (SHED) has been studied as a possible treatment strategy for spinal cord injuries (SCIs) due to its potential for promoting tissue protection and functional recovery. The aim of the present study was to investigate the effects of the early transplantation of SHED on glial scar formation and astrocytic reaction after an experimental model of SCI. Wistar rats were spinalized using the NYU Impactor. Animals were randomly distributed into three groups: control (naive) (animal with no manipulation); SCI (receiving laminectomy followed by SCI and treated with vehicle), and SHED (SCI rat treated with intraspinal SHED transplantation, 1h after SCI). In vitro investigation demonstrated that SHED were able to express mesenchymal stem cells, vimentin and S100B markers, related with neural progenitor and glial cells, respectively. The acute SHED transplantation promoted functional recovery, measured as from the first week after spinal cord contusion by Basso, Beattie, and Bresnahan scale. Twenty-four and 48h after lesion, flow cytometry revealed a spinal cord vimentin(+) cells increment in the SHED group. The increase of vimentin(+) cells was confirmed by immunofluorescence. Moreover, the bioavailability of astrocytic proteins such as S100B and Kir4.1 shown to be increased in the spinal cord of SHED group, whereas there was a glial scar reduction, as indicated by ELISA and Western blot techniques. The presented results support that SHED act as a neuroprotector agent after transplantation, probably through paracrine signaling to reduce glial scar formation, inducing tissue plasticity and functional recovery.	[Nicola, Fabricio; Marques, Marilia Rossato; Odorcyk, Felipe] Univ Fed Rio Grande do Sul, Post Grad Program Neurosci, Porto Alegre, RS, Brazil; [Nicola, Fabricio; Marques, Marilia Rossato; Odorcyk, Felipe; Petenuzzo, Leticia; Aristimunha, Dirceu; Vizuete, Adriana; Sanches, Eduardo Farias; Goncalves, Carlos-Alberto; Netto, Carlos Alexandre] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Biochem, R Ramiro Barcelos 2600, BR-90035003 Porto Alegre, RS, Brazil; [Pereira, Daniela Pavulack; Maurmann, Natasha; Pranke, Patricia] Univ Fed Rio Grande do Sul, Hematol & Stem Cell Lab, Porto Alegre, RS, Brazil; [Maurmann, Natasha; Pranke, Patricia] Univ Fed Rio Grande do Sul, Post Grad Program Physiol, Porto Alegre, RS, Brazil; [Pranke, Patricia] Stem Cell Res Inst, Porto Alegre, RS, Brazil	Nicola, F (corresponding author), Univ Fed Rio Grande do Sul, Post Grad Program Neurosci, Porto Alegre, RS, Brazil.; Nicola, F (corresponding author), Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Biochem, R Ramiro Barcelos 2600, BR-90035003 Porto Alegre, RS, Brazil.	fabricionicola@hotmail.com	Maurmann, Natasha/G-3113-2018	Maurmann, Natasha/0000-0001-5103-6394; Netto, Carlos Alexandre/0000-0002-0596-5667; Vizuete, Adriana/0000-0002-9299-7631	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico do Brasil (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Stem Cell Research Institute	This work was supported by funds from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico do Brasil (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Stem Cell Research Institute.	Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Baldwin SA, 1998, J NEUROTRAUM, V15, P1015, DOI 10.1089/neu.1998.15.1015; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Becker D, 2003, NEUROLOGIST, V9, P1, DOI 10.1097/01.nrl.0000038587.58012.05; Bernardi L, 2011, J ENDODONT, V37, P973, DOI 10.1016/j.joen.2011.04.010; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Butt AM, 2006, J CELL MOL MED, V10, P33, DOI 10.1111/j.1582-4934.2006.tb00289.x; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Cerqueira SR, 2013, SMALL, V9, P738, DOI 10.1002/smll.201201888; Chen JQ, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.898190; Cunha JD, 2007, WOUND REPAIR REGEN, V15, P134, DOI 10.1111/j.1524-475X.2006.00194.x; de Almeida FM, 2011, J NEUROTRAUM, V28, P1939, DOI 10.1089/neu.2010.1317; De Berdt P, 2018, CELL MOL LIFE SCI, V75, P2843, DOI 10.1007/s00018-018-2764-5; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Ellis KM, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt419; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Heimfarth L, 2013, NEUROTOXICOLOGY, V34, P175, DOI 10.1016/j.neuro.2012.10.015; Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Lee SJ, 2010, EMERG MED J, V27, P209, DOI 10.1136/emj.2008.063743; Leite MC, 2008, J NEUROSCI METH, V169, P93, DOI 10.1016/j.jneumeth.2007.11.021; Luisi SB, 2007, J ENDODONT, V33, P833, DOI 10.1016/j.joen.2007.04.002; Matsubara K, 2015, J NEUROSCI, V35, P2452, DOI 10.1523/JNEUROSCI.4088-14.2015; Maurmann N, 2017, BIOMED PHYS ENG EXPR, V3, DOI 10.1088/2057-1976/aa6308; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Nesic O, 2010, NEUROSCIENCE, V168, P1019, DOI 10.1016/j.neuroscience.2010.01.037; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nicola FC, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165319; Nicola FD, 2017, BRAIN RES, V1663, P95, DOI 10.1016/j.brainres.2017.03.015; Obermair FJ, 2008, PHYSIOLOGY, V23, P296, DOI 10.1152/physiol.00017.2008; Olsen ML, 2010, BRAIN, V133, P1013, DOI 10.1093/brain/awq049; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Park DY, 2013, GLOB SPINE J, V3, P1, DOI 10.1055/s-0033-1337118; Raponi E, 2007, GLIA, V55, P165, DOI 10.1002/glia.20445; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rodrigues LP, 2012, BRAZ J MED BIOL RES, V45, P49, DOI 10.1590/S0100-879X2011007500162; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Sakai K, 2012, J CLIN INVEST, V122, P80, DOI 10.1172/JCI59251; Seki T, 2007, J COMP NEUROL, V502, P275, DOI 10.1002/cne.21301; Sibille J, 2014, J PHYSIOL-LONDON, V592, P87, DOI 10.1113/jphysiol.2013.261735; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Taghipour Z, 2012, STEM CELLS DEV, V21, P1794, DOI 10.1089/scd.2011.0408; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tramontina F, 2007, J NEUROSCI METH, V162, P282, DOI 10.1016/j.jneumeth.2007.01.001; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Weeks J, 2004, LAB ANIMAL, V33, P35, DOI 10.1038/laban0304-35; Weis SN, 2012, MITOCHONDRION, V12, P271, DOI 10.1016/j.mito.2011.10.002; Wu D, 2017, MOL THER, V25, P2715, DOI 10.1016/j.ymthe.2017.08.011; Acasigua GAX, 2014, CURR STEM CELL RES T, V9, P330, DOI 10.2174/1574888X09666140228123911; Xu C, 2015, EXP NEUROL, V263, P172, DOI 10.1016/j.expneurol.2014.10.013; Yamamoto S, 2001, SPINAL CORD, V127, P115, DOI [10.1006/exnr.2001.7798, DOI 10.1006/EXNR.2001.7798]	60	17	18	2	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2019	56	1					748	760		10.1007/s12035-018-1127-4			13	Neurosciences	Neurosciences & Neurology	HH7VH	WOS:000455938600054	29796991				2021-06-18	
J	Vaca, SD; Kuo, BJ; Vissoci, JRN; Staton, CA; Xu, LW; Muhumuza, M; Ssenyonjo, H; Mukasa, J; Kiryabwire, J; Rice, HE; Grant, GA; Haglund, MM				Vaca, Silvia D.; Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Xu, Linda W.; Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Rice, Henry E.; Grant, Gerald A.; Haglund, Michael M.			Temporal Delays Along the Neurosurgical Care Continuum for Traumatic Brain Injury Patients at a Tertiary Care Hospital in Kampala, Uganda	NEUROSURGERY			English	Article						Global neurosurgery; Traumatic brain injury; Care continuum; Prospective registry; Mulago	SUBDURAL-HEMATOMA; MORTALITY; PROGNOSIS; OUTCOMES; IMPACT	BACKGROUND: Significant care continuum delays between acute traumatic brain injury (TBI) and definitive surgery are associated with poor outcomes. Use of the "3 delays" model to evaluate TBI outcomes in low-and middle-income countries has not been performed. OBJECTIVE: To describe the care continuum, using the 3 delays framework, and its association with TBI patient outcomes in Kampala, Uganda. METHODS: Prospective data were collected for 563 TBI patients presenting to a tertiary hospital in Kampala from 1 June to 30 November 2016. Four time intervals were constructed along 5 time points: injury, hospital arrival, neurosurgical evaluation, computed tomography (CT) results, and definitive surgery. Time interval differences among mild, moderate, and severe TBI and their association with mortality were analyzed. RESULTS: Significant care continuum differences were observed for interval 3 (neurosurgical evaluation to CT result) and 4 (CT result to surgery) between severe TBI patients (7 h for interval 3 and 24 h for interval 4) and mild TBI patients (19 h for interval 3 and 96 h for interval 4). These postarrival delays were associated with mortality for mild (P =.05) and moderate TBI (P=. 03) patients. Significant hospital arrival delays for moderate TBI patients were associated with mortality (P=.04). CONCLUSION: Delays for mild and moderate TBI patients were associated with mortality, suggesting that quality improvement interventions could target current triage practices. Future research should aim to understand the contributors to delays along the care continuum, opportunities for more effective resource allocation, and the need to improve prehospital logistical referral systems.	[Vaca, Silvia D.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Vaca, Silvia D.; Grant, Gerald A.] Stanford Ctr Innovat Global Hlth, Palo Alto, CA USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Haglund, Michael M.] Duke Univ, Div Global Neurosurg & Neurol, Durham, NC USA; [Kuo, Benjamin J.; Haglund, Michael M.] Duke Univ, Global Hlth Inst, Durham, NC USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke NUS Med Sch, Singapore, Singapore; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Med Ctr, Duke Emergency Med, Durham, NC USA; [Xu, Linda W.; Grant, Gerald A.] Stanford Univ, Med Ctr, Dept Neurosurg, Palo Alto, CA 94304 USA; [Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel] Mulago Hosp, Dept Neurosurg, Kampala, Uganda; [Rice, Henry E.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Haglund, Michael M.] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA	Haglund, MM (corresponding author), Duke Univ, Dept Neurol Surg, 4508 Hosp South, Durham, NC 27710 USA.	michael.haglund@dm.duke.edu		Staton, Catherine/0000-0002-6468-2894	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01 TW010000] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01TW010000] Funding Source: NIH RePORTER		Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Ament JD, 2014, J NEUROSURG-SPINE, V20, P436, DOI 10.3171/2014.1.SPINE1228; Bullock M Ross, 2006, Neurosurgery, V58, pS7; BULLOCK MR, 2006, NEUROSURGERY S, V58; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Crandall M, 2013, AM J PUBLIC HEALTH, V103, P1103, DOI 10.2105/AJPH.2013.301223; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Di Saverio S, 2014, LANGENBECK ARCH SURG, V399, P109, DOI 10.1007/s00423-013-1143-9; Emejulu JKC, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.002; Gagne M, 2017, J TRAUMA ACUTE CARE, V82, P374, DOI 10.1097/TA.0000000000001319; Gupta D, 2016, WORLD NEUROSURG, V89, P169, DOI 10.1016/j.wneu.2015.12.097; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Rocha TAH, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0645-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; Jayaraman Sudha, 2009, World J Surg, V33, P2512, DOI 10.1007/s00268-009-0180-6; Jayaraman S, 2011, WORLD J SURG, V35, P505, DOI 10.1007/s00268-010-0871-z; Long C, 2015, SURGERY, V158, P756, DOI 10.1016/j.surg.2015.04.016; Marcoux J, 2016, J NEUROSURG, V125, P642, DOI 10.3171/2015.6.JNS15175; Mowafi H, 2016, WORLD J SURG, V40, P2868, DOI 10.1007/s00268-016-3629-4; Raykar NP, 2015, LANCET, V385, P15, DOI 10.1016/S0140-6736(15)60810-8; Scotter J, 2015, EMERG MED J, V32, P654, DOI 10.1136/emermed-2014-204260; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Sorensen Bjarke Lund, 2011, Afr J Reprod Health, V15, P117; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Uganda Bureau of Statistics, UG NAT HOUS SURV 200; Urgessa F, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-358	30	17	17	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2019	84	1					95	102		10.1093/neuros/nyy004			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HQ7GP	WOS:000462588300059	29490070	Other Gold, Green Published			2021-06-18	
J	Rodriguez, EG; Cardenas, JC; Cox, CS; Kitagawa, RS; Stensballe, J; Holcomb, JB; Johansson, PI; Wade, CE				Rodriguez, Erika Gonzalez; Cardenas, Jessica C.; Cox, Charles S.; Kitagawa, Ryan S.; Stensballe, Jakob; Holcomb, John B.; Johansson, Paer I.; Wade, Charles E.			Traumatic brain injury is associated with increased syndecan-1 shedding in severely injured patients	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Endothelium; Syndecan-1; Traumatic endotheliopathy; Sympathoadrenal activation	FRESH-FROZEN PLASMA; HEMORRHAGIC-SHOCK; ENDOTHELIAL GLYCOCALYX; SYMPATHOADRENAL ACTIVATION; MORTALITY; RESUSCITATION; COAGULOPATHY; INFLAMMATION; TRANSFUSION; MULTICENTER	Introduction: Head injury and exsanguination are the leading causes of death in trauma patients. Hemorrhagic shock triggers systemic endothelial glycocalyx breakdown, potentially leading to traumatic endotheliopathy (EoT). Levels of syndecan-1, a main glycocalyx component, have been used to assess the integrity of the glycocalyx. In TBI patients, it remains unclear whether syndecan-1 shedding occurs and its correlation with outcomes. We aimed to determine the frequency of EoT+, defined as a syndecan-1 level of 40 ng/ml or higher, after TBI in isolated and polytraumatic injury. We also investigated how the presence of EoT+ affected outcomes in TBI patients. Methods: Severely injured trauma patients were enrolled. From blood samples collected upon patients' arrival to the hospital, we measured syndecan-1 (main biomarker of EoT+), soluble thrombomodulin (sTM, endothelial activation) adrenaline and noradrenaline (sympathoadrenal activation), and assessed TBI patients' coagulation capacity. Results: Of the enrolled patients (n = 331), those with TBI and polytrauma (n = 68) had the highest rate of EoT+ compared to isolated TBI (n = 58) and Non-TBI patients (n = 205) (Polytrauma-TBI 55.9% vs. Isolated-TBI 20.0% vs. non-TBI polytrauma 40.0%; p = 0.001). TBI patients with EoT+ exhibited marked increases in sTM, adrenaline and noradrenaline levels, and physiological and coagulation derangements. In isolated TBI patients, increasing syndecan-1 levels (for every 10 ng/ml increase: 0.14; 95% CI: 0.02, 0.26) and hypocoagulability were negatively associated with survival. Conclusions: This study provides evidence of syndecan-1 shedding after TBI supporting the notion that breakdown of the glycocalyx contributes to the physiological derangements after TBI.	[Rodriguez, Erika Gonzalez; Cardenas, Jessica C.; Holcomb, John B.; Johansson, Paer I.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Surg, Ctr Translat Injury Res CeTIR, 6431 Fannin,MSB 5-204, Houston, TX 77030 USA; [Stensballe, Jakob; Johansson, Paer I.] Copenhagen Univ Hosp, Capital Reg Blood Bank, Sect Transfus Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Stensballe, Jakob] Copenhagen Univ Hosp, Ctr Head & Orthoped, Dept Anesthesia, Rigshosp, Copenhagen, Denmark; [Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat Surg, 6431 Fannin,MSB 5-258, Houston, TX 77030 USA; [Kitagawa, Ryan S.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Mischer Neurosci Inst, Dept Neurosurg, 6400 Fannin,Suite 2800, Houston, TX 77030 USA	Rodriguez, EG (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Surg, Ctr Translat Injury Res CeTIR, 6431 Fannin,MSB 5-204, Houston, TX 77030 USA.	Erika.r.gonzalez@uth.tmc.edu		holcomb, john/0000-0001-8312-9157; Johansson, Par Ingemar/0000-0001-9778-5964; Gonzalez Rodriguez, Erika/0000-0003-1401-8925	The Center for Translational Injury Research of The University of Texas Health Science Center; William Stamp Farish Fund; Howell Family Foundation	This study was supported by The Center for Translational Injury Research of The University of Texas Health Science Center and the William Stamp Farish Fund and the Howell Family Foundation.	Alphonsus CS, 2014, ANAESTHESIA, V69, P777, DOI 10.1111/anae.12661; Ban KC, 2015, SHOCK, V44, P452, DOI 10.1097/SHK.0000000000000452; Brettner F, 2017, CURR OPIN ANESTHESIO, V30, P36, DOI 10.1097/ACO.0000000000000434; Chignalia AZ, 2016, SHOCK, V45, P338, DOI 10.1097/SHK.0000000000000513; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Di Battista AP, 2016, SHOCK, V46, P96, DOI 10.1097/SHK.0000000000000642; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Fox EE, 2017, SHOCK, V47, P567, DOI 10.1097/SHK.0000000000000788; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Gonzalez Rodriguez E, 2018, TRAUMATIC BRAIN INJU; Halaweish I, 2016, J TRAUMA ACUTE CARE, V81, P1080, DOI 10.1097/TA.0000000000001204; Halaweish I, 2015, J AM COLL SURGEONS, V220, P809, DOI 10.1016/j.jamcollsurg.2015.01.057; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Johansson PI, 2017, ANN SURG, V265, P597, DOI 10.1097/SLA.0000000000001751; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson P, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1605-5; Kozar RA, 2015, J TRAUMA ACUTE CARE, V78, pS83, DOI 10.1097/TA.0000000000000631; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; McCredie VA, 2016, J TRAUMA ACUTE CARE, V80, P484, DOI 10.1097/TA.0000000000000922; Ostrowski SR, 2017, J TRAUMA ACUTE CARE, V82, P293, DOI 10.1097/TA.0000000000001304; Oyeniyi BT, 2017, INJURY, V48, P5, DOI 10.1016/j.injury.2016.10.037; Pati S, 2016, J TRAUMA ACUTE CARE, V80, P576, DOI 10.1097/TA.0000000000000961; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Rahbar E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0481-5; Rahbar E, 2014, SHOCK, V41, P181, DOI 10.1097/SHK.0000000000000101; Rodriguez EG, 2018, SHOCK, V50, P31, DOI 10.1097/SHK.0000000000001036; Rodriguez EG, 2017, J AM COLL SURGEONS, V225, P419, DOI 10.1016/j.jamcollsurg.2017.05.012; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P12, DOI 10.1097/TA.0b013e3182aaa675; Filho IT, 2013, MICROVASC RES, V85, P128, DOI 10.1016/j.mvr.2012.11.005; Torres IP, 2016, AM J PHYSIOL-HEART C, V310, pH1468, DOI 10.1152/ajpheart.00006.2016; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Wang KW, 2014, ANN CLIN LAB SCI, V44, P145; Wu F, 2017, SHOCK, V48, P340, DOI 10.1097/SHK.0000000000000832	36	17	17	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	NOV 21	2018	26								102	10.1186/s13049-018-0565-3			10	Emergency Medicine	Emergency Medicine	HB3LM	WOS:000450953000001	30463625	DOAJ Gold, Green Published			2021-06-18	
J	Kosari-Nasab, M; Shokouhi, G; Ghorbanihaghjo, A; Abbasi, MM; Salari, AA				Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Abbasi, Mehran Mesgari; Salari, Ali-Akbar			Hesperidin attenuates depression-related symptoms in mice with mild traumatic brain injury	LIFE SCIENCES			English	Article						Natural flavonoids; Antidepressant drugs; Cytokines; Malondialdehyde; Neurotrophins; Hesperidin	OXIDATIVE STRESS; NEUROTROPHIC FACTOR; MOUSE MODEL; REDUCES NEUROINFLAMMATION; HIPPOCAMPAL NEUROGENESIS; COGNITIVE IMPAIRMENT; IMMUNE ACTIVATION; BDNF LEVELS; INFLAMMATION; BEHAVIORS	Aims: There is increasing evidence showing that mild traumatic brain injury (mTBI) is associated with increased depression-related disorders in humans. Recent studies suggest that dietary intake or supplementation of natural flavonoids like hesperidin can be used for therapy of patients with brain injury and depression. However, the exact mechanisms by which hesperidin indicates its neuroprotective effects are not fully understood. The purpose of this study was to explore the influence of hesperidin on depression-related symptoms in a mouse model of mTBI, and that what mechanisms are primarily involved in the antidepressant effects of this bioflavonoid. Main methods: Ten days after mTBI-induction, mice received oral hesperidin treatment (50 mg/kg/14 days), then animals were subjected to different depression tests including sucrose preference test, forced swim test, novelty-suppressed feeding test, and tail suspension test. We also measured levels of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1 beta, malondialdehyde (MDA), and brain-derived-neurotrophic-factor (BDNF) in the hippocampus. Key findings: Our results show that mTBI induction induced depressive-like behaviors in mice by increasing inflammatory cytokines (IL-1 beta and TNF-alpha) and oxidative stress marker (MDA), and reducing BDNF levels in the hippocampus. Interestingly, hesperidin treatment was effective to significantly reduce depression-related symptoms in mTBI-induced mice. In addition, hesperidin decreased the levels of IL-1 beta, TNF-alpha and MDA, and increased BDNF levels in the hippocampus. The major strength of our study is that four behavioral tests gave similar results. Significance: This study suggests that the antidepressant-like effect of hesperidin may be mediated, at least in part, by decreased neuroinflammation and oxidative damage, and enhanced BDNF production in the hippocampus.	[Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Abbasi, Mehran Mesgari; Salari, Ali-Akbar] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Dept Neurosurg, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Ctr Res Neurosci, Tabriz, Iran; [Ghorbanihaghjo, Amir] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran; [Salari, Ali-Akbar] SICBD, Alborz, Iran	Shokouhi, G; Salari, AA (corresponding author), POB 51656-65811, Tabriz, Iran.	shokouhigh@yahoo.com; aa.salari@yahoo.com	Salari, Ali-Akbar/I-7843-2013; Tabrizi, Ghaffar Shokouhi/L-6326-2017	Salari, Ali-Akbar/0000-0002-4970-0337; Tabrizi, Ghaffar Shokouhi/0000-0001-5081-9928; Kosari-Nasab, Morteza/0000-0001-8454-5873; ghorbanihaghjo, amir/0000-0001-6742-0526	Drug Applied Research Center, Tabriz University of Medical Sciences [94/77]	This study was supported by a grant from the Drug Applied Research Center, Tabriz University of Medical Sciences (grant number 94/77).	Antunes MS, 2016, EUR J PHARMACOL, V789, P411, DOI [10.1016/j.ejphar.2016.07.042, 10.1016/j.ejphar.20]; Antunes MS, 2014, NUTRITION, V30, P1415, DOI 10.1016/j.nut.2014.03.024; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Ayatollahi AM, 2017, NEUROL RES, V39, P1056, DOI 10.1080/01616412.2017.1376789; Barker-Collo S, 2015, BRAIN INJURY, V29, P859, DOI 10.3109/02699052.2015.1004759; Belzung C, 2015, CURR OPIN NEUROBIOL, V30, P24, DOI 10.1016/j.conb.2014.08.013; Bombardier CH, 2016, J NEUROTRAUM, V33, P2115, DOI 10.1089/neu.2015.4349; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Chang CY, 2015, NEUROTOXICOLOGY, V50, P157, DOI 10.1016/j.neuro.2015.08.014; Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6; Chen MC, 2010, FOOD CHEM TOXICOL, V48, P2980, DOI 10.1016/j.fct.2010.07.037; Ciftci O, 2015, NEUROCHEM RES, V40, P1111, DOI 10.1007/s11064-015-1571-8; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; Donato F, 2015, J MED FOOD, V18, P818, DOI 10.1089/jmf.2014.0074; Donato F, 2014, BRAIN RES BULL, V104, P19, DOI 10.1016/j.brainresbull.2014.03.004; Duman RS, 2014, DIALOGUES CLIN NEURO, V16, P11; El-Marasy SA, 2014, CAN J PHYSIOL PHARM, V92, P945, DOI 10.1139/cjpp-2014-0281; Filho CB, 2013, EUR J PHARMACOL, V698, P286, DOI 10.1016/j.ejphar.2012.11.003; Gonul AS, 2005, EUR ARCH PSY CLIN N, V255, P381, DOI 10.1007/s00406-005-0578-6; Haghmorad D, 2017, J NEUROIMMUNOL, V302, P23, DOI 10.1016/j.jneuroim.2016.11.009; Jangra A, 2015, BIOL TRACE ELEM RES, V168, P462, DOI 10.1007/s12011-015-0375-7; Javed H, 2015, J NEUROL SCI, V348, P51, DOI 10.1016/j.jns.2014.10.044; Johnson VJ, 2003, NEUROTOXICOLOGY, V24, P261, DOI 10.1016/S0161-813X(02)00194-8; Kosari-Nasab M, 2018, TOXICOL APPL PHARM, V338, P159, DOI 10.1016/j.taap.2017.11.012; Kumar A, 2013, EUR J PHARMACOL, V720, P16, DOI 10.1016/j.ejphar.2013.10.057; Larsen MH, 2010, J PSYCHIATR RES, V44, P808, DOI 10.1016/j.jpsychires.2010.01.005; Lavoie S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00634; Li CY, 2015, BEHAV BRAIN RES, V281, P32, DOI 10.1016/j.bbr.2014.12.012; Li CF, 2016, BRAIN RES BULL, V124, P40, DOI 10.1016/j.brainresbull.2016.03.016; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Loh Kok Poh, 2006, Current Alzheimer Research, V3, P327; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Majidi J, 2016, BRAIN RES BULL, V120, P1, DOI 10.1016/j.brainresbull.2015.10.009; Majidi-Zolbanin J, 2015, NEUROSCIENCE, V294, P69, DOI 10.1016/j.neuroscience.2015.03.016; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mineur YS, 2007, BIOL PSYCHIAT, V61, P250, DOI 10.1016/j.biopsych.2006.04.037; Monteggia LM, 2007, BIOL PSYCHIAT, V61, P187, DOI 10.1016/j.biopsych.2006.03.021; Pinho-Ribeiro FA, 2015, CHEM-BIOL INTERACT, V228, P88, DOI 10.1016/j.cbi.2015.01.011; Polyakova M, 2015, J AFFECT DISORDERS, V174, P432, DOI 10.1016/j.jad.2014.11.044; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Raza SS, 2011, BRAIN RES, V1420, P93, DOI 10.1016/j.brainres.2011.08.047; Rizzetti DA, 2016, NEUROCHEM INT, V101, P30, DOI 10.1016/j.neuint.2016.10.002; Rong Z, 2013, NEUROSCIENCE, V255, P292, DOI 10.1016/j.neuroscience.2013.09.030; Roohbakhsh A, 2015, LIFE SCI, V124, P64, DOI 10.1016/j.lfs.2014.12.030; Roohbakhsh A, 2014, LIFE SCI, V113, P1, DOI 10.1016/j.lfs.2014.07.029; Salari AA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29595-0; Salari AA, 2017, INT J DEV NEUROSCI, V57, P62, DOI 10.1016/j.ijdevneu.2017.01.007; Salari AA, 2015, EUR NEUROPSYCHOPHARM, V25, P1260, DOI 10.1016/j.euroneuro.2015.04.022; Schmidt HD, 2007, BEHAV PHARMACOL, V18, P391, DOI 10.1097/FBP.0b013e3282ee2aa8; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Souza LC, 2013, PROG NEURO-PSYCHOPH, V40, P103, DOI 10.1016/j.pnpbp.2012.09.003; Sulakhiya K, 2014, EUR J PHARMACOL, V744, P124, DOI 10.1016/j.ejphar.2014.09.049; Taliaz D, 2010, MOL PSYCHIATR, V15, P80, DOI 10.1038/mp.2009.67; Thenmozhi AJ, 2017, NUTR NEUROSCI, V20, P360, DOI [10.1080/1028415x.2016.1144846, 10.1080/1028415X.2016.1144846]; Wang DM, 2014, CELL MOL NEUROBIOL, V34, P1209, DOI 10.1007/s10571-014-0098-x; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Youdim KA, 2003, J NEUROCHEM, V85, P180, DOI 10.1046/j.1471-4159.2003.01652.x; Zhang Y, 2010, BRAIN RES, V1366, P141, DOI 10.1016/j.brainres.2010.09.095	60	17	17	2	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	NOV 15	2018	213						198	205		10.1016/j.lfs.2018.10.040			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	GY2ZM	WOS:000448413900025	30352242				2021-06-18	
J	Bernardo-Colon, A; Vest, V; Clark, A; Cooper, ML; Calkins, DJ; Harrison, FE; Rex, TS				Bernardo-Colon, Alexandra; Vest, Victoria; Clark, Adrienne; Cooper, Melissa L.; Calkins, David J.; Harrison, Fiona E.; Rex, Tonia S.			Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma	CELL DEATH & DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; MOUSE MODEL; BETA-HYDROXYBUTYRATE; NLRP3 INFLAMMASOME; KETOGENIC DIET; VITAMIN-C; AXONOPATHY; ASTROCYTES; STRESS; NEUROINFLAMMATION	We investigated the role of oxidative stress and the inflammasome in trauma-induced axon degeneration and vision loss using a mouse model. The left eyes of male mice were exposed to over-pressure air waves. Wild-type C57Bl/6 mice were fed normal, high-vitamin-E (VitE), ketogenic or ketogenic-control diets. Mice lacking the ability to produce vitamin C (VitC) were maintained on a low-VitC diet. Visual evoked potentials (VEPs) and retinal superoxide levels were measured in vivo. Tissue was collected for biochemical and histological analysis. Injury increased retinal superoxide, decreased SOD2, and increased cleaved caspase-1, IL-1 alpha, IL-1 beta, and IL-18 levels. Low-VitC exacerbated the changes and the high-VitE diet mitigated them, suggesting that oxidative stress led to the increase in IL-1 alpha and activation of the inflammasome. The injury caused loss of nearly 50% of optic nerve axons at 2 weeks and astrocyte hypertrophy in mice on normal diet, both of which were prevented by the high-VitE diet. The VEP amplitude was decreased after injury in both control-diet and low-VitC mice, but not in the high-VitE-diet mice. The ketogenic diet also prevented the increase in superoxide levels and IL-1 alpha, but had no effect on IL-1 beta. Despite this, the ketogenic diet preserved optic nerve axons, prevented astrocyte hypertrophy, and preserved the VEP amplitude. These data suggest that oxidative stress induces priming and activation of the inflammasome pathway after neurotrauma of the visual system. Further, blocking the activation of the inflammasome pathway may be an effective post-injury intervention.	[Bernardo-Colon, Alexandra; Vest, Victoria; Clark, Adrienne; Cooper, Melissa L.; Calkins, David J.; Rex, Tonia S.] Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA; [Harrison, Fiona E.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	Rex, TS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA.	tonia.rex@vanderbilt.edu		Cooper, Melissa/0000-0003-4337-8356	NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY022349]; DoDUnited States Department of Defense [W81XWH-15-1-0096, W81XWH-17-2-0055]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 NS094595]; Potocsnak Discovery Grant in Regenerative Medicine; Ayers Foundation Regenerative Visual Neuroscience Pilot Grant; VAUS Department of Veterans Affairs [I01 CX001610-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY024997, P30EY008126]; Glaucoma Research Foundation; Stanley Cohen Innovation Fund; Vanderbilt University Medical Center Cell Imaging Shared Resource core facility (Clinical and Translational Science Award Grant from National Center for Research Resources) [UL1 RR024975]; Training Grant in Vision Research [T32 EY021833]; Research Prevent Blindness, Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY024997, P30EY008126, R01EY022349, T32EY021453, R01EY021833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094595] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001610] Funding Source: NIH RePORTER	We thank Marcus Colyer for valuable input, and Purnima Ghose, John Clifton, Ryan Dahl, and Bohan Kim for their technical assistance. Support was provided by NEI R01 EY022349 (TR), DoD W81XWH-15-1-0096 (TR) and W81XWH-17-2-0055 (TR), NIA R01 NS094595 (TR), Potocsnak Discovery Grant in Regenerative Medicine (TR), Ayers Foundation Regenerative Visual Neuroscience Pilot Grant (TR), VA I01 CX001610-01 (FH), NIH R01EY024997 (DC) and P30EY008126 (DC), the Glaucoma Research Foundation (DC), the Stanley Cohen Innovation Fund (DC), and the Vanderbilt University Medical Center Cell Imaging Shared Resource core facility (Clinical and Translational Science Award Grant UL1 RR024975 from National Center for Research Resources), Training Grant in Vision Research T32 EY021833, Research Prevent Blindness, Inc.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34; Bond WS, 2016, MOL THER, V24, P230, DOI 10.1038/mt.2015.198; Bricker-Anthony C, 2017, OPTOMETRY VISION SCI, V94, P20, DOI 10.1097/OPX.0000000000000898; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Brown AM, 2005, J NEUROSCI RES, V79, P74, DOI 10.1002/jnr.20335; Chapman KM, 1996, J GERONTOL A-BIOL, V51, pB261, DOI 10.1093/gerona/51A.4.B261; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Cooper ML, 2016, EXP EYE RES, V150, P22, DOI 10.1016/j.exer.2015.11.016; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Dapper JD, 2013, NEUROBIOL DIS, V59, P26, DOI 10.1016/j.nbd.2013.07.001; Goldberg EL, 2017, CELL REP, V18, P2077, DOI 10.1016/j.celrep.2017.02.004; Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x; Harrison FE, 2008, J NEUROCHEM, V106, P1198, DOI 10.1111/j.1471-4159.2008.05469.x; Harrison FE, 2012, J ALZHEIMERS DIS, V29, P711, DOI 10.3233/JAD-2012-111853; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Hines-Beard J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0499-5; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Ishaq GM, 2013, J NEUROSCI RURAL PRA, V4, P292, DOI 10.4103/0976-3147.118784; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Langlois K, 2016, HEALTH REP, V27, P3; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Pearson JF, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080831; Perge JA, 2009, J NEUROSCI, V29, P7917, DOI 10.1523/JNEUROSCI.5200-08.2009; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Sarkies N, 2004, EYE, V18, P1122, DOI 10.1038/sj.eye.6701571; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513; Sun D, 2017, J EXP MED, V214, P1411, DOI 10.1084/jem.20160412; Tekkok SB, 2005, J NEUROSCI RES, V81, P644, DOI 10.1002/jnr.20573; Thaler S, 2010, GRAEF ARCH CLIN EXP, V248, P1729, DOI 10.1007/s00417-010-1425-7; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vlasov Anton, 2015, J Trauma Acute Care Surg, V79, pS210, DOI 10.1097/TA.0000000000000666; Wahls T, 2014, NUTR NEUROSCI, V17, P252, DOI 10.1179/1476830513Y.0000000088; Ward NJ, 2014, J NEUROSCI, V34, P3161, DOI 10.1523/JNEUROSCI.4089-13.2014; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Yang XJ, 2016, INVEST OPHTH VIS SCI, V57, P2344, DOI 10.1167/iovs.16-19153; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yu-Wai-Man Patrick, 2015, Taiwan J Ophthalmol, V5, P3; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	47	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	OCT 26	2018	9								1097	10.1038/s41419-018-1061-4			13	Cell Biology	Cell Biology	GZ5PP	WOS:000449477900003	30367086	DOAJ Gold, Green Published			2021-06-18	
J	Wilde, EA; Ware, AL; Li, XQ; Wu, TC; McCauley, SR; Barnes, A; Newsome, MR; Biekman, BD; Hunter, JV; Chu, ZD; Levin, HS				Wilde, Elisabeth A.; Ware, Ashley L.; Li, Xiaoqi; Wu, Trevor C.; McCauley, Stephen R.; Barnes, Amanda; Newsome, Mary R.; Biekman, Brian D.; Hunter, Jill V.; Chu, Zili D.; Levin, Harvey S.			Orthopedic Injured versus Uninjured Comparison Groups for Neuroimaging Research in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						DTI; MRI; mTBI; OI	UNITED-STATES; RISK-FACTORS; POSTTRAUMATIC-STRESS; UNINTENTIONAL INJURY; HEAD IMPACTS; CHILDREN; DIFFUSION; OUTCOMES; SCALE; HOSPITALIZATION	To address controversy surrounding the most appropriate comparison group for mild traumatic brain injury (mTBI) research, mTBI patients 12-30 years of age were compared with an extracranial orthopedic injury (OI) patient group and an uninjured, typically developing (TD) participant group with comparable demographic backgrounds. Injured participants underwent subacute (within 96h) and late (3 months) diffusion tensor imaging (DTI); TD controls underwent DTI once. Group differences in fractional anisotropy (FA) and mean diffusivity (MD) of commonly studied white matter tracts were assessed. For FA, subacute group differences occurred in the bilateral inferior frontal occipital fasciculus (IFOF) and right inferior longitudinal fasciculus (ILF), and for MD, differences were found in the total corpus callosum, right uncinate fasciculus, IFOF, ILF, and bilateral cingulum bundle (CB). In these analyses, differences (lower FA and higher MD) were generally observed between the mTBI and TD groups but not between the mTBI and OI groups. After a 3 month interval, groups significantly differed in left IFOF FA and in right IFOF and CB MD; the TD group had significantly higher FA and lower MD than both injury groups, which did not differ. There was one exception to this pattern, in which the OI group demonstrated significantly lower FA in the left ILF than the TD group, although neither group differed from the mTBI group. The mTBI and OI groups had generally similar longitudinal results. Findings suggest that different conclusions about group-level DTI analyses could be drawn, depending on the selected comparison group, highlighting the need for additional research in this area. Where possible, mTBI studies may benefit from the inclusion of both OI and TD controls.	[Wilde, Elisabeth A.; Newsome, Mary R.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Wilde, Elisabeth A.] George E Wahlen Dept Vet Affairs, Med Ctr, Salt Lake City, UT USA; [Wilde, Elisabeth A.; Ware, Ashley L.; Li, Xiaoqi; Wu, Trevor C.; McCauley, Stephen R.; Newsome, Mary R.; Biekman, Brian D.; Hunter, Jill V.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili D.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Univ Utah, Dept Neurol, 383 Colorow Rd,Suite 302, Salt Lake City, UT 84108 USA; [Ware, Ashley L.; Biekman, Brian D.] Univ Houston, Dept Psychol, Houston, TX USA; [Ware, Ashley L.; Biekman, Brian D.] Univ Houston, TIMES, Houston, TX USA; [Wu, Trevor C.] Mercy Hlth St Marys, Hauenstein Neurosci, Grand Rapids, MI USA; [Barnes, Amanda] Univ Southern Calif, Dept Obstet & Gynecol, Med Ctr, Los Angeles, CA USA; [Hunter, Jill V.; Chu, Zili D.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Wilde, EA (corresponding author), Univ Utah, Dept Neurol, 383 Colorow Rd,Suite 302, Salt Lake City, UT 84108 USA.	elisabeth.wilde@hsc.utah.edu			National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS056202]; US Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [PT13078]; TBI Endpoints Development grant [W81XWH-14-2-0176]	Support for this research was provided by the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) (P01 NS056202, PI: Douglas Smith, M.D.), US Army Medical Research and Materiel Command (USAMRMC) (PT13078, PI: Geoff Manley, M.D.), and TBI Endpoints Development grant W81XWH-14-2-0176 (PI: Geoff Manley, M.D., Ph.D.). We thank the participants and their family members for their participation in this study. We also thank the anonymous reviewers for their helpful comments and suggestions in revising the manuscript.	Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler E.D., 2015, BRAIN NEUROTRAUMA MO; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bodien YG, 2018, J HEAD TRAUMA REHAB, V33, P147, DOI 10.1097/HTR.0000000000000367; Borsook D, 2012, BRAIN, V135, P320, DOI 10.1093/brain/awr271; Bruce B, 2007, PAED CHILD HEALT-CAN, V12, P749, DOI 10.1093/pch/12.9.749; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Collins J G, 1990, Vital Health Stat 10, P1; *COMM INJ SCAL, 1998, ABBR INJ SCAL, DOI DOI 10.3171/2012.9.JNS12815; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; Delaney-Black V, 2002, ARCH PEDIAT ADOL MED, V156, P280, DOI 10.1001/archpedi.156.3.280; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gorman S, 2012, J INT NEUROPSYCH SOC, V18, P29, DOI 10.1017/S1355617711001251; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Heim LR, 2017, J NEUROTRAUM, V34, P2518, DOI 10.1089/neu.2016.4909; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P41, DOI 10.1097/01241398-199501000-00010; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ozer K, 2010, J PEDIATR ORTHOPED, V30, P324, DOI 10.1097/BPO.0b013e3181d8fa8c; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schwebel DC, 2007, J DEV BEHAV PEDIATR, V28, P245, DOI 10.1097/01.DBP.0000268561.80204.2a; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Sollmann N, 2018, NEUROIMAGE-CLIN, V17, P642, DOI 10.1016/j.nicl.2017.11.020; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Sun MJ, 2018, BRAIN BEHAV IMMUN, V69, P618, DOI 10.1016/j.bbi.2018.01.007; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Uslu M, 2007, CLIN ORTHOP RELAT R, P192, DOI 10.1097/BLO.0b013e31805002da; Weckbach S, 2013, J TRAUMA ACUTE CARE, V74, P489, DOI 10.1097/TA.0b013e31827d5f1b; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2016, J NEUROTRAUM, V33, P2000, DOI 10.1089/neu.2015.4212; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wintermark M, 2015, AM J NEURORADIOL, V36, pE12, DOI 10.3174/ajnr.A4254; Xydakis MS, 2015, NEUROLOGY, V84, P1559, DOI 10.1212/WNL.0000000000001475; Yang L, 2016, SCAND J IMMUNOL, V83, P26, DOI 10.1111/sji.12393; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	62	17	17	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2019	36	2					239	249		10.1089/neu.2017.5513		OCT 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HM4LJ	WOS:000447011700001	29786476	Green Published			2021-06-18	
J	Batey, M; Hecht, J; Callahan, C; Wahl, W				Batey, Madelyn; Hecht, Jason; Callahan, Cherise; Wahl, Wendy			Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly	SURGERY			English	Article							PROTHROMBIN COMPLEX CONCENTRATE; ATRIAL-FIBRILLATION; VITAMIN-K; INTRACEREBRAL HEMORRHAGE; PREINJURY WARFARIN; HEAD-INJURY; MORTALITY; REVERSAL; ASSOCIATION; DABIGATRAN	Background: Falls are now the leading cause of trauma and represent the most common type of trauma in the elderly. The use of anticoagulants is increasing in older patients, but there are little data on outcomes after traumatic brain injury while anticoagulated with direct oral anticoagulants compared with warfarin. We hypothesized that anticoagulated patients would have a greater mortality and complications than nonanticoagulated patients, and patients on direct oral anticoagulants would have more fatal outcomes after low-level falls because of lack of reversal agents. Methods: Patients 65 years or older admitted to level 1-3 trauma centers with 24-hour neurosurgical care were identified through the administrative database of 19 Trinity Health hospitals. Patients with International Classification of Diseases, Ninth Revision, codes consistent with low-level fall and traumatic brain injury from May 2013 through October 2015 were included. Preadmission warfarin or direct oral anticoagulant use was extracted from admission reconciliation of medications in the database. Results: A total of 700 patients met inclusion criteria with 177 on anticoagulants before admission. Anticoagulated patients had more cardiac (P < .001), pulmonary (P < .001), and clotting (P < .02) comorbidities. Warfarin patients had the greatest neurosurgical intervention rate at 18% compared with direct oral anticoagulants (2.8%, P < .02) or nonanticoagulation (11%, P < .02). No difference was identified in overall mortality and mortality after neurosurgical intervention between the nonanticoagulated, warfarin, or direct oral anticoagulant groups. Warfarin patients received more plasma (P < .001) and red cell transfusions (P = .035) with greater intensive care unit stays (P < .001) compared with direct oral anticoagulant or nonanticoagulated patients. With logistic regression, only advancing age (P < .05) and a lesser Glasgow Coma Scale score (P < .01) were associated with greater mortality. Conclusion: Older direct oral anticoagulant patients with traumatic brain injury after low-level fall did not have increased morbidity or mortality compared with those treated with warfarin or who were not treated with anticoagulants. Concerns over the use of direct oral anticoagulant agents in this population may be overstated and deserve more scrutiny. (C) 2018 Elsevier Inc. All rights reserved.	[Batey, Madelyn] Univ Michigan Hlth Syst, Dept Pharm, Ann Arbor, MI USA; [Hecht, Jason; Callahan, Cherise; Wahl, Wendy] St Joseph Mercy Ann Arbor, Dept Pharm, Ann Arbor, MI 48106 USA	Wahl, W (corresponding author), St Joseph Mercy Ann Arbor, Trauma & Surg Crit Care, 5301 E Huron River Dr, Ann Arbor, MI 48106 USA.	wendy.wahl@stjoeshealth.org					Ageno W, 2012, CHEST, V141, pE44S, DOI 10.1378/chest.11-2292; Burns ER, 2016, J SAFETY RES, V58, P99, DOI 10.1016/j.jsr.2016.05.001; Centers for Disease Control and Prevention, 2017, IMP FACTS FALL; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410; Dias JD, 2015, ARCH PATHOL LAB MED, V139, P665, DOI 10.5858/arpa.2014-0170-OA; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Feeney JM, 2017, INJURY, V48, P47, DOI 10.1016/j.injury.2016.08.016; Fox BD, 2012, BMJ-BRIT MED J, V345, P1; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Inohara T, 2018, JAMA-J AM MED ASSOC, V319, P463, DOI 10.1001/jama.2017.21917; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Kobayashi L, 2017, J TRAUMA ACUTE CARE, V82, P827, DOI 10.1097/TA.0000000000001414; Marzec LN, 2017, J AM COLL CARDIOL, V69, P2475, DOI 10.1016/j.jacc.2017.03.540; Patel MR, 2010, NEW ENGL J MED, V362, P886, DOI 10.1056/NEJMoa0907272; Pollack CV, N ENGL J MED, V373, P511; Popovsky MA, 2006, TRANSFUS APHER SCI, V34, P243, DOI 10.1016/j.transci.2006.01.005; Riccardi A, 2017, AM J EMERG MED, V35, P1317, DOI 10.1016/j.ajem.2017.03.072; Teddy P, 2012, J CLIN NEUROSCI, V19, P792, DOI 10.1016/j.jocn.2012.01.024; Yasaka M, 2002, THROMB RES, V108, P25, DOI 10.1016/S0049-3848(02)00402-4	25	17	17	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2018	164	4					814	819		10.1016/j.surg.2018.05.060			6	Surgery	Surgery	GW3LI	WOS:000446805100031	30098813				2021-06-18	
J	Raj, R; Bendel, S; Reinikainen, M; Hoppu, S; Laitio, R; Ala-Kokko, T; Curtze, S; Skrifvars, MB				Raj, R.; Bendel, S.; Reinikainen, M.; Hoppu, S.; Laitio, R.; Ala-Kokko, T.; Curtze, S.; Skrifvars, M. B.			Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study	CRITICAL CARE			English	Article						Neurocritical care; neurointensive care; costs; cost-effectiveness; Traumatic brain injury; Intracerebral hemorrhage; Acute ischemic stroke; Subarachnoid hemorrhage; Finland; Outcome	STENT-RETRIEVER THROMBECTOMY; ACUTE ISCHEMIC-STROKE; INTENSIVE-CARE; BED NUMBERS; ENDOVASCULAR TREATMENT; MEDICINE; DISEASE; BURDEN; TRIAL; SCORE	Background: Neurocritical illness is a growing healthcare problem with profound socioeconomic effects. We assessed differences in healthcare costs and long-term outcome for different forms of neurocritical illnesses treated in the intensive care unit (ICU). Methods: We used the prospective Finnish Intensive Care Consortium database to identify all adult patients treated for traumatic brain injury (TBI), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and acute ischemic stroke (AIS) at university hospital ICUs in Finland during 2003-2013. Outcome variables were one-year mortality and permanent disability. Total healthcare costs included the index university hospital costs, rehabilitation hospital costs and social security costs up to one year. All costs were converted to euros based on the 2013 currency rate. Results: In total 7044 patients were included (44% with TBI, 13% with ICH, 27% with SAH, 16% with AIS). In comparison to TBI, ICH was associated with the highest risk of death and permanent disability (OR 2.6, 95% CI 2.1-3.2 and OR 1.7, 95% CI 1.4-2.1), followed by AIS (OR 1.9, 95% CI 15-23 and OR 1.5, 95% CI 1.3-1.8) and SAH (OR 1.8, 95% CI 1.5-2.1 and OR 0. 8, 95% CI 0.6-0.9), after adjusting for severity of illness. SAH was associated with the highest mean total costs ((sic)51,906) followed by ICH ((sic)47,661), TBI ((sic)43,916) and AIS ((sic)39222). Cost per independent survivor was lower for TBI ((sic)58,497) and SAH ((sic)96,369) compared to AIS ((sic)104,374) and ICH ((sic)178,071). Conclusion: Neurocritical illnesses are costly and resource-demanding diseases associated with poor outcomes. Intensive care of patients with TBI or SAH more commonly result in independent survivors and is associated with lower total treatments costs compared to ICH and AIS.	[Raj, R.] Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, Hus Helsinki 00029, Finland; [Raj, R.] Univ Helsinki, Topeliuksenkatu 5,PB 266, Hus Helsinki 00029, Finland; [Bendel, S.] Kuopio Univ Hosp, Dept Intens Care, Kuopio, Finland; [Bendel, S.] Univ Eastern Finland, Kuopio, Finland; [Reinikainen, M.] North Karelia Cent Hosp, Dept Intens Care, Joensuu, Finland; [Hoppu, S.] Tampere Univ Hosp, Dept Intens Care, Tampere, Finland; [Hoppu, S.] Univ Tampere, Tampere, Finland; [Laitio, R.] Turku Univ Hosp, Dept Intens Care, Turku, Finland; [Laitio, R.] Univ Turku, Turku, Finland; [Ala-Kokko, T.] Oulu Univ Hosp, Dept Intens Care, Oulu, Finland; [Ala-Kokko, T.] Univ Oulu, Med Res Ctr, Res Grp Surg Anesthesiol & Intens Care, Oulu, Finland; [Curtze, S.] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland; [Curtze, S.; Skrifvars, M. B.] Univ Helsinki, Helsinki, Finland; [Skrifvars, M. B.] Helsinki Univ Hosp, Dept Anesthesia Intens Care & Pain Med, Helsinki, Finland; [Skrifvars, M. B.] Helsinki Univ Hosp, Dept Emergency Care & Serv, Helsinki, Finland	Raj, R (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, Hus Helsinki 00029, Finland.; Raj, R (corresponding author), Univ Helsinki, Topeliuksenkatu 5,PB 266, Hus Helsinki 00029, Finland.	rahul.raj@hus.fi	Curtze, Sami/AAK-8595-2020; Raj, Rahul/K-7693-2012	Curtze, Sami/0000-0003-1545-8500; Raj, Rahul/0000-0003-4243-9591; Reinikainen, Matti/0000-0001-6878-3740	Helsinki University [H3702 73702705]; Helsinki University Hospital [VTR-TYH2014221]; Svenska Kulturfonden; Medicinska Understodsforeningen Liv and Halsa; Finska Lakaresallskapet; Maud Kuistilan Saatio; Eemil Aaltosen Saatio; Ella and Georg Ehrnroothin Saatio; Suomalais-Norjalainen Laaketieteen Saatio; Suomen Laaketieteen Saatio; Maire Taposen Saatio	This study was funded with grants from Helsinki University (3-year project grant: H3702 73702705) and Helsinki University Hospital (state funding: VTR-TYH2014221). RR has received personal research grants from Svenska Kulturfonden, Medicinska Understodsforeningen Liv and Halsa, Finska Lakaresallskapet, Maud Kuistilan Saatio, Eemil Aaltosen Saatio, Ella and Georg Ehrnroothin Saatio, Suomalais-Norjalainen Laaketieteen Saatio, Suomen Laaketieteen Saatio, and Maire Taposen Saatio. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Achit H, 2017, STROKE, V48, P2843, DOI 10.1161/STROKEAHA.117.017856; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Carr BG, 2010, JAMA-J AM MED ASSOC, V303, P1371, DOI 10.1001/jama.2010.394; Chen A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-76; Davis KL, 2007, J TRAUMA, V62, P622, DOI 10.1097/TA.0b013e318031afe3; Efendijev I, 2016, ACTA ANAESTH SCAND, V60, P1415, DOI 10.1111/aas.12809; Fallenius M, 2017, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-017-0448-z; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4; Fernando SM, 2018, CRIT CARE MED, V1; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; GYLDMARK M, 1995, CRIT CARE MED, V23, P964; Halpern NA, 2004, CRIT CARE MED, V32, P1254, DOI 10.1097/01.CCM.0000128577.31689.4C; Halpern NA, 2016, CRIT CARE MED, V44, P1490, DOI 10.1097/CCM.0000000000001722; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Hemphill JC, 2015, STROKE; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Kapiainen S., 2014, TERVEYDEN JA SOSIAAL; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Korja M, 2016, NEUROLOGY, V87, P1118, DOI 10.1212/WNL.0000000000003091; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Maud A, 2009, J NEUROSURG, V110, P880, DOI 10.3171/2008.8.JNS0858; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Raj R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2151-5; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Reinikainen M, 2007, ACTA ANAESTH SCAND, V51, P522, DOI 10.1111/j.1399-6576.2007.01274.x; Reinikainen M, 2012, ACTA ANAESTH SCAND, V56, P1114, DOI 10.1111/j.1399-6576.2012.02669.x; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Shireman TI, 2017, STROKE, V48, P379, DOI 10.1161/STROKEAHA.116.014735; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wilby MJ, 2003, STROKE, V34, P2508, DOI 10.1161/01.STR.0000089922.94684.13	38	17	17	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 20	2018	22								225	10.1186/s13054-018-2151-5			10	Critical Care Medicine	General & Internal Medicine	GV1LP	WOS:000445839100001	30236140	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, FC; Dong, HP; Lv, T; Jin, K; Jin, YC; Zhang, XH; Jiang, JY				Zhang, Fengchen; Dong, Haiping; Lv, Tao; Jin, Ke; Jin, Yichao; Zhang, Xiaohua; Jiang, Jiyao			Moderate hypothermia inhibits microglia activation after traumatic brain injury by modulating autophagy/apoptosis and the MyD88-dependent TLR4 signaling pathway	JOURNAL OF NEUROINFLAMMATION			English	Article						Apoptosis; Autophagy; Microglial activation; Toll-like receptor; Traumatic brain injury	TOLL-LIKE-RECEPTORS; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY FACTOR-I; INDUCED CELL-DEATH; AUTOPHAGY PATHWAY; RATS; EXPRESSION; DAMAGE; TRANSDUCTION	Background: Complex mechanisms participate in microglial activation after a traumatic brain injury (TBI). TBI can induce autophagy and apoptosis in neurons and glial cells, and moderate hypothermia plays a protective role in the acute phase of TBI. In the present study, we evaluated the effect of TBI and moderate hypothermia on microglial activation and investigated the possible roles of autophagy/apoptosis and toll-like receptor 4 (TLR4). Methods: The TBI model was induced with a fluid percussion TBI device. Moderate hypothermia was achieved under general anesthesia by partial immersion in a water bath for 4 h. All rats were killed 24 h after the TBI. Results: Our results showed downregulation of the microglial activation and autophagy, but upregulation of microglial apoptosis, upon post-TBI hypothermia treatment. The expression of TLR4 and downstream myeloid differentiation primary response 88 (MyD88) was attenuated. Moderate hypothermia reduced neural cell death post-TBI. Conclusions: Moderate hypothermia can reduce the number of activated microglia by inhibiting autophagy and promoting apoptosis, probably through a negative modulation between autophagy and apoptosis. Moderate hypothermia may attenuate the pro-inflammatory function of microglia by inhibiting the MyD88-dependent TLR4 signaling pathway.	[Zhang, Fengchen; Lv, Tao; Jin, Ke; Jin, Yichao; Zhang, Xiaohua; Jiang, Jiyao] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Dong, Haiping] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Anesthesiol, 160 Pujian Rd, Shanghai 200127, Peoples R China	Jin, YC; Zhang, XH (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	honam612@163.com; zxh1969@aliyun.com		Zhang, Xiaohua/0000-0001-9679-2767	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81601061, 81471333]; Shanghai Youth Physician Training Assistance Scheme	This work was supported by grants from the National Natural Science Foundation of China (No. 81601061 to Y. Jin and No. 81471333 to X. Zhang) and the Shanghai Youth Physician Training Assistance Scheme.	Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cui DM, 2017, CNS NEUROSCI THER, V23, P106, DOI 10.1111/cns.12633; Deptala A, 1998, CYTOMETRY, V33, P376, DOI 10.1002/(SICI)1097-0320(19981101)33:3<376::AID-CYTO13>3.0.CO;2-Q; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Flygt J, 2016, J NEUROPATH EXP NEUR, V75, P503, DOI 10.1093/jnen/nlw025; Huang CY, 2017, J NEUROIMMUNOL, V313, P61, DOI 10.1016/j.jneuroim.2017.10.011; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jin YC, 2017, WORLD NEUROSURG, V100, P351, DOI 10.1016/j.wneu.2017.01.033; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Jin YC, 2015, J NEUROTRAUM, V32, P1090, DOI 10.1089/neu.2014.3649; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schwab JM, 2001, J NEUROIMMUNOL, V119, P214, DOI 10.1016/S0165-5728(01)00375-7; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Xue ZL, 2017, BIOCHEM BIOPH RES CO, V486, P589, DOI 10.1016/j.bbrc.2017.03.097; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865; Zhang HB, 2017, BRAIN INJURY, V31, P406, DOI 10.1080/02699052.2016.1225984	36	17	19	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 20	2018	15								273	10.1186/s12974-018-1315-1			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GU4CB	WOS:000445227200002	30236124	DOAJ Gold, Green Published			2021-06-18	
J	He, JC; Liu, H; Zhong, JJ; Guo, ZD; Wu, JC; Zhang, HR; Huang, ZJ; Jiang, L; Li, H; Zhang, ZS; Liu, L; Wu, Y; Qi, LJ; Sun, XC; Cheng, CJ				He, Junchi; Liu, Han; Zhong, Jianjun; Guo, Zongduo; Wu, Jingchuan; Zhang, Hongrong; Huang, Zhijian; Jiang, Li; Li, Hui; Zhang, Zhaosi; Liu, Liu; Wu, Yue; Qi, Lingjun; Sun, Xiaochuan; Cheng, Chongjie			Bexarotene protects against neurotoxicity partially through a PPAR gamma-dependent mechanism in mice following traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Bexarotene; Traumatic brain injury; Neuron; Astrocyte; Microglia; Peroxisome proliferator-activated receptor; gamma	MICROGLIAL ACTIVATION; INFLAMMATION; POLARIZATION; RECOVERY; NEUROPROTECTION; DIFFERENTIATION; IMPAIRMENT; ASTROCYTES; DAMAGE	Traumatic brain injury (TBI) causes a high rate of mortality and disability worldwide, and there exists almost none effective drugs to protect against TBI. Neurotoxicity occurring after TBI can be derived from microglia and astrocytes, and causes neuronal death and synapse loss. Bexarotene has been demonstrated to protect neurons in CNS diseases. In the present study, we aimed to investigate the potential role of bexarotene in protecting against neurotoxicity after TBI, as well as the underlying mechanism. The controlled cortical impact (CCI) model was established on adult C57BL/6 mice, followed by intraperitoneal administration of bexarotene for 14 consecutive days. We found that bexarotene improved sensorimotor function and cognitive recovery in CCI mice. In addition, bexarotene decreased neuronal death and synapse loss, as well as inhibited apoptotic cascade. Moreover, bexarotene treatment reduced M1 microglia polarization, microglia-derived pro-inflammatory cytokines, and the number of A1 astrocytes after CCI. These effects of bexarotene were partially abolished by T0070907, an antagonist of peroxisome proliferator-activated receptor gamma (PPAR gamma). Additionally, bexarotene enhanced nuclear translocation and transcriptional activity of PPAR gamma. These findings show that bexarotene inhibits neurotoxicity in mice after TBI, at least in part through a PPAR gamma-dependent mechanism.	[He, Junchi; Liu, Han; Zhong, Jianjun; Guo, Zongduo; Wu, Jingchuan; Zhang, Hongrong; Huang, Zhijian; Jiang, Li; Li, Hui; Zhang, Zhaosi; Liu, Liu; Wu, Yue; Qi, Lingjun; Sun, Xiaochuan; Cheng, Chongjie] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Youyi Rd, Chongqing, Peoples R China	Sun, XC; Cheng, CJ (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Youyi Rd, Chongqing, Peoples R China.	sunxch1445@qq.com; 358187887@qq.com	He, Junchi/AAD-8482-2019; Wu, Jingchuan/AAV-7799-2020	Wu, Jingchuan/0000-0002-1213-4888; Zhang, Zhaosi/0000-0002-4988-501X; Huang, Zhijian/0000-0002-8241-0761	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371309]; National Natural Science Foundation for Youth of ChinaNational Natural Science Foundation of China (NSFC) [81601072]	This work was supported by the National Natural Science Foundation of China (grant No. 81571159), the National Natural Science Foundation for Youth of China (No. 81601072), and the National Natural Science Foundation of China (No. 81371309).	Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200; Cai W, 2018, PROG NEUROBIOL, V163, P27, DOI 10.1016/j.pneurobio.2017.10.002; Certo M, 2015, PHARMACOL RES, V102, P298, DOI 10.1016/j.phrs.2015.10.009; Chen Chun-Jung, 2017, Collection and Research (Taichung), P1, DOI 10.6693/CAR201712_30(1).0001; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; Drew PD, 2015, ALCOHOL CLIN EXP RES, V39, P445, DOI 10.1111/acer.12639; Ghosal Kaushik, 2016, Alzheimers Dement (N Y), V2, P110, DOI 10.1016/j.trci.2016.06.001; Han LJ, 2015, STROKE, V46, P2628, DOI 10.1161/STROKEAHA.115.010091; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Huang ZJ, 2016, J NEUROCHEM, V136, P1017, DOI 10.1111/jnc.13491; Huuskonen MT, 2016, SCI REP-UK, V6, DOI 10.1038/srep33176; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kincheski GC, 2017, BRAIN BEHAV IMMUN, V64, P140, DOI 10.1016/j.bbi.2017.04.007; le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu XR, 2016, STROKE, V47, P498, DOI 10.1161/STROKEAHA.115.012079; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Marciano DP, 2015, PPAR RES, V2015, DOI 10.1155/2015/254560; Mariani MM, 2017, SCI REP-UK, V7, DOI 10.1038/srep42270; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Pardo L, 2016, GLIA, V64, P853, DOI 10.1002/glia.22969; Perez EJ, 2017, J CLIN INVEST, V127, P3114, DOI 10.1172/JCI92300; Piao C. S., 2017, J CEREB BLOOD FLOW M; Raman P, 2012, J PHARMACOL EXP THER, V342, P816, DOI 10.1124/jpet.112.193003; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Riancho J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00250; Sanz MJ, 2012, J IMMUNOL, V189, P411, DOI 10.4049/jimmunol.1102942; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Savage JC, 2015, J NEUROSCI, V35, P6532, DOI 10.1523/JNEUROSCI.4586-14.2015; Shibata S, 2009, BRAIN RES, V1296, P196, DOI 10.1016/j.brainres.2009.08.015; Teng ZP, 2016, STROKE, V47, P196, DOI 10.1161/STROKEAHA.115.011701; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; Xiong Y, 2012, ANN NY ACAD SCI, V1270, P51, DOI 10.1111/j.1749-6632.2012.06683.x; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Zhang HS, 2016, BRAIN RES, V1643, P130, DOI 10.1016/j.brainres.2016.05.003; Zhao J, 2014, J BIOL CHEM, V289, P11282, DOI 10.1074/jbc.M113.526095; Zhao Z, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00293; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033	43	17	18	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2018	117						114	124		10.1016/j.nbd.2018.06.003			11	Neurosciences	Neurosciences & Neurology	GO8ZO	WOS:000440392100008	29886067				2021-06-18	
J	Nasi, D; Gladi, M; Di Rienzo, A; di Somma, L; Moriconi, E; Iacoangeli, M; Dobran, M				Nasi, Davide; Gladi, Maurizio; Di Rienzo, Alessandro; di Somma, Lucia; Moriconi, Elisa; Iacoangeli, Maurizio; Dobran, Mauro			Risk factors for post-traumatic hydrocephalus following decompressive craniectomy	ACTA NEUROCHIRURGICA			English	Article						Decompressive craniectomy; Post-traumatic hydrocephalus; Traumatic brain injury; Cranioplasty; Ventriculoperitoneal shunt	TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; HYGROMA	Background Post-traumatic hydrocephalus (PTH) is one of the main complications of decompressive craniectomy (DC) after traumatic brain injury (TBI). Then, the recognition of risk factors and subsequent prompt diagnosis and treatment of PTH can improve the outcome of these patients. The purpose of this study was to identify factors associated with the development of PTH requiring surgical treatment in patients undergoing DC for TBI. Methods In this study, we collected the data of 190 patients (149 males and 41 females), who underwent DC for TBI in our Center. Then we analyzed the type of surgical treatment for all patients affected by PTH and the risk factors associated with the development of PTH. Results Post-traumatic hydrocephalus (PTH) developed in 37 patients out of 130 alive 30 days after DC (28.4%). The development of PTH required ventriculoperitoneal shunt (VPS) in 34 patients out of 37 (91.9%), while, in the remaining 3 patients, cerebrospinal fluid hydrodynamic (CSF) disturbances resolved after urgent cranioplasty and temporary external lumbar drain. Multivariate analysis showed that the presence of interhemispheric hygroma (p < 0.001) and delayed cranioplasty (3 months after DC) (p < 0.001) was significantly associated with the need for a VPS or other surgical procedure for PTH. Finally, among the 130 patients alive after 30 days from DC, PTH was associated with unfavorable outcome as measured by the 6-month Glasgow Outcome Scale score (p < 0.0001). Conclusions Our results showed that delayed cranial reconstruction was associated with an increasing rate of PTH after DC. The presence of an interhemispheric hygroma was an independent predictive radiological sign of PTH in decompressed patients for severe TBI.	[Nasi, Davide; Gladi, Maurizio; Di Rienzo, Alessandro; di Somma, Lucia; Moriconi, Elisa; Iacoangeli, Maurizio; Dobran, Mauro] Univ Politecn Marche, Umberto Gen Hosp 1, Dept Neurosurg, Via Conca 71, I-60020 Ancona, Italy	Nasi, D (corresponding author), Univ Politecn Marche, Umberto Gen Hosp 1, Dept Neurosurg, Via Conca 71, I-60020 Ancona, Italy.	davidenasi83@gmail.com		Nasi, Davide/0000-0002-7357-7455			Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Di Rienzo A, 2013, NEUROL MED-CHIR, V53, P329, DOI 10.2176/nmc.53.329; di Somma Lucia, 2016, Surg Neurol Int, V7, pS12, DOI 10.4103/2152-7806.173561; Dobran M, 2017, G CHIR, V38, P124, DOI 10.11138/gchir/2017.38.3.124; Dobran M, 2017, Surg Neurol Int, V8, P212, DOI 10.4103/sni.sni_222_17; Dobran M, 2017, BMJ CASE REP, V2017, P2017; Dobran M, 2016, WORLD NEUROSURG, V96, P152, DOI 10.1016/j.wneu.2016.08.100; Halani SH, 2017, NEUROSURGERY, V81, P204, DOI 10.1093/neuros/nyx054; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7; Nasi D, 2018, WORLD NEUROSURG, V116, pE543, DOI 10.1016/j.wneu.2018.05.028; Nasi D, 2016, WORLD NEUROSURG, V91, DOI 10.1016/j.wneu.2016.04.041; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Vedantam A, 2018, J NEUROSURG, V128, P1547, DOI 10.3171/2017.1.JNS162721; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37	21	17	18	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2018	160	9					1691	1698		10.1007/s00701-018-3639-0			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GQ7JK	WOS:000441915100004	30054725				2021-06-18	
J	Mugon, J; Struk, A; Danckert, J				Mugon, Jhotisha; Struk, Andriy; Danckert, James			A Failure to Launch: Regulatory Modes and Boredom Proneness	FRONTIERS IN PSYCHOLOGY			English	Article						boredom; assessment; locomotion; goal-pursuit; self-regulation	TRAUMATIC BRAIN-INJURY; PSYCHOMETRIC PROPERTIES; SUSTAINED ATTENTION; EXECUTIVE FUNCTIONS; SCALE; EXPERIENCE; LAPSES; CONSEQUENCES; DEPRESSION; CHILDHOOD	Boredom is a ubiquitous human experience characterized as a state of wanting but failing to engage with the world. Individuals prone to the experience of boredom demonstrate lower levels of self-control which may be at the heart of their failures to engage in goal-directed, meaningful behaviors. Here we develop the hypothesis that distinct self-regulatory profiles, which in turn differentially influence modes of goal pursuit, are at the heart of boredom proneness. Two specific regulatory modes are addressed: Locomotion, the desire to 'just do it,' an action oriented mode of goal-pursuit, and Assessment, the desire to 'do the right thing,' an evaluative orientation toward goal pursuit. We present data from a series of seven large samples of undergraduates showing that boredom proneness is negatively correlated with Locomotion, as though getting on with things acts as a prophylactic against boredom. This 'failure to launch' that we suggest is prevalent in the highly boredom prone individual, could be due to an inability to appropriately discriminate value (i.e., everything is tarred with the same gray brush), an unwillingness to put in the required effort to engage, or simply a failure to get started. In contrast, boredom proneness was consistently positively correlated with the Assessment mode of self-regulation. We suggest that this association reflects a kind of rumination that hampers satisfying goal pursuit.	[Mugon, Jhotisha; Struk, Andriy; Danckert, James] Univ Waterloo, Dept Psychol, Waterloo, ON, Canada	Mugon, J (corresponding author), Univ Waterloo, Dept Psychol, Waterloo, ON, Canada.	jmugon@uwaterloo.ca			Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported by Natural Sciences and Engineering Research Council of Canada Discovery Grant to JD.	ABRAMSON EE, 1977, ADDICT BEHAV, V2, P181, DOI 10.1016/0306-4603(77)90015-6; AHMED SMS, 1990, PERCEPT MOTOR SKILL, V71, P963, DOI 10.2466/pms.1990.71.3.963; Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Baumeister RF, 2003, HANDBOOK OF SELF AND IDENTITY, P197; Brankovic S, 2015, PSYCHIAT DANUB, V27, P126; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; DAMRADFRYE R, 1989, J PERS SOC PSYCHOL, V57, P315; Danckert J., 2013, SCI AM MIND, V24, P54, DOI DOI 10.1038/SCIENTIFICAMERICANMIND0713-54; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Eastwood JD, 2012, PERSPECT PSYCHOL SCI, V7, P482, DOI 10.1177/1745691612456044; Fahlman SA, 2013, ASSESSMENT, V20, P68, DOI 10.1177/1073191111421303; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; Ferrari JR, 2000, J SOC BEHAV PERS, V15, P185; Goetz T, 2014, MOTIV EMOTION, V38, P401, DOI 10.1007/s11031-013-9385-y; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberg YK, 2011, J SOC CLIN PSYCHOL, V30, P647, DOI 10.1521/jscp.2011.30.6.647; Hunter A, 2018, EXP BRAIN RES, V236, P2483, DOI 10.1007/s00221-016-4749-7; Isacescu J, 2018, EXP BRAIN RES, V236, P2493, DOI 10.1007/s00221-016-4674-9; Isacescu J, 2017, COGNITION EMOTION, V31, P1741, DOI 10.1080/02699931.2016.1259995; Joireman J, 2003, J PERS SOC PSYCHOL, V84, P1287, DOI 10.1037/0022-3514.84.6.1287; Keating D.P., 2012, ENFANCE, V3, P267, DOI [10.4074/S0013754512003035, DOI 10.4074/S0013754512003035]; Kruglanski AW, 2000, J PERS SOC PSYCHOL, V79, P793, DOI 10.1037/0022-3514.79.5.793; Lee CM, 2007, ADDICT BEHAV, V32, P1384, DOI 10.1016/j.addbeh.2006.09.010; Malkovsky E, 2012, EXP BRAIN RES, V221, P59, DOI 10.1007/s00221-012-3147-z; Massen JJM, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01735; Melton AMA, 2009, J PSYCHOL, V143, P493, DOI 10.3200/JRL.143.5.493-508; Mercer KB., 2010, INT GAMBL STUD, V10, P91, DOI [10.1080/1445979100 3754414, DOI 10.1080/14459791003754414, 10.1080/14459791003754414]; Merrifield C, 2014, EXP BRAIN RES, V232, P481, DOI 10.1007/s00221-013-3755-2; Mor N, 2002, PSYCHOL BULL, V128, P638, DOI 10.1037//0033-2909.128.4.638; Newell SE, 2012, INT J SOC PSYCHIATR, V58, P488, DOI 10.1177/0020764011408655; Nolen-Hoeksema S, 2008, PERSPECT PSYCHOL SCI, V3, P400, DOI 10.1111/j.1745-6924.2008.00088.x; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Ohsuga M, 2001, INT J PSYCHOPHYSIOL, V40, P211, DOI 10.1016/S0167-8760(00)00189-6; Pierro A, 2011, J PERS SOC PSYCHOL, V101, P1317, DOI 10.1037/a0025943; Poletti M, 2009, CLIN NEUROPSYCHIATR, V6, P155; Posner J, 2005, DEV PSYCHOPATHOL, V17, P715, DOI 10.1017/S0954579405050340; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sommers J, 2000, J CLIN PSYCHOL, V56, P149, DOI 10.1002/(SICI)1097-4679(200001)56:1<149::AID-JCLP14>3.0.CO;2-Y; Stickney MI, 1999, INT J EAT DISORDER, V26, P195, DOI 10.1002/(SICI)1098-108X(199909)26:2&lt;195::AID-EAT9&gt;3.0.CO;2-2; Struk AA, 2016, COGNITION EMOTION, V30, P1388, DOI 10.1080/02699931.2015.1064363; Struk AA, 2017, ASSESSMENT, V24, P346, DOI 10.1177/1073191115609996; Tangney JP, 2004, J PERS, V72, P271, DOI 10.1111/j.0022-3506.2004.00263.x; Thackray RI, 1977, VIGILANCE THEORY OPE, P203; Todman M, 2003, PSYCHIATRY, V66, P146, DOI 10.1521/psyc.66.2.146.20623; Vodanovich SJ, 2005, J PERS ASSESS, V85, P295, DOI 10.1207/s15327752jpa8503_05; Vodanovich SJ, 1999, SOC BEHAV PERSONAL, V27, P11, DOI 10.2224/sbp.1999.27.1.11; VODANOVICH SJ, 1990, J PERS ASSESS, V55, P115, DOI 10.1207/s15327752jpa5501&2_11; Westgate E. C., 2017, PSYCHOL REV	51	17	17	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	JUL 17	2018	9								1126	10.3389/fpsyg.2018.01126			7	Psychology, Multidisciplinary	Psychology	GN4JH	WOS:000438987600001	30065675	DOAJ Gold, Green Published			2021-06-18	
J	Lee, DJ; Kearns, JC; Wisco, BE; Green, JD; Gradus, JL; Sloan, DM; Nock, MK; Rosen, RC; Keane, TM; Marx, BP				Lee, Daniel J.; Kearns, Jaclyn C.; Wisco, Blair E.; Green, Jonathan D.; Gradus, Jaimie L.; Sloan, Denise M.; Nock, Matthew K.; Rosen, Raymond C.; Keane, Terence M.; Marx, Brian P.			A longitudinal study of risk factors for suicide attempts among Operation Enduring Freedom and Operation Iraqi Freedom veterans	DEPRESSION AND ANXIETY			English	Article						alcoholism/alcohol use disorders; PTSD/posttraumatic stress disorder; suicide/self harm; trauma; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; COGNITIVE-BEHAVIORAL THERAPY; NATIONAL COMORBIDITY SURVEY; SERVICEMEMBERS ARMY STARRS; DUTY MILITARY PERSONNEL; NONSUICIDAL SELF-INJURY; ACTIVE-DUTY; PRIMARY-CARE	Background: Suicide rates among veterans have increased markedly since the onset of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF; LeardMann etal., 2013). Identification of factors with the greatest contribution to suicide risk among veterans is needed to inform risk assessment and to identify intervention targets. Methods: This study examined predictors of suicide attempts among participants in the Veterans After-Discharge Longitudinal Registry; a nationwide cohort of OEF/OIF veterans enrolled in Department of Veterans Affairs (VA) services. Veterans with and without probable posttraumatic stress disorder (PTSD) were sampled at a 3:1 ratio, and male and female veterans were sampled at a 1:1 ratio. Participants (N=1,649) were assessed at two time points, roughly 2 years apart (M=28.74 months, SD=8.72). Results: Seventy-four participants (4.49%) attempted suicide during the follow-up period. The strongest predictors of suicide attempts among the full sample were suicidal intent, attempt history, suicide ideation, PTSD symptoms, alcohol use disorder (AUD) symptoms, and depression. Veterans with multiple risk factors were particularly vulnerable; of veterans with 0, 1, 2, 3, or 4 of these risk factors, 0%, 7.81%, 10.31%, 18.45%, and 20.51% made a suicide attempt, respectively. Conclusions: This prospective study identified several strong predictors of suicide attempts among OEF/OIF veterans which may be important targets for suicide prevention efforts. Further, co-occurrence of multiple risk factors was associated with markedly greater risk for suicide attempts; veterans with multiple risk factors appear to be at the highest risk among OEF/OIF veterans enrolled in VA care.	[Lee, Daniel J.; Gradus, Jaimie L.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] Natl Ctr PTSD, Boston, MA USA; [Lee, Daniel J.; Kearns, Jaclyn C.; Green, Jonathan D.; Gradus, Jaimie L.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] VA Boston Healthcare Syst, Boston, MA USA; [Lee, Daniel J.; Green, Jonathan D.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kearns, Jaclyn C.] Univ Rochester, Dept Clin & Social Sci Psychol, Rochester, NY USA; [Wisco, Blair E.] Univ North Carolina Greensboro, Dept Psychol, Greensboro, NC USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Rosen, Raymond C.] New England Res Inst Inc, Watertown, MA USA	Marx, BP (corresponding author), 150 South HuntingtonAve 116B-4, Boston, MA 02130 USA.	Brian.Marx@VA.gov	Nock, Matthew/AAE-8330-2019; Marx, Brian/AAK-5072-2020; Keane, Terence/I-8253-2014	Sloan, Denise/0000-0002-0962-478X; Keane, Terence/0000-0002-0482-3149; Kearns, Jaclyn/0000-0001-9246-9057	U.S. Department of DefenseUnited States Department of Defense [W81XWH-08-2-0100/W81XWH-082-0102, W81XWH-12-2-0117/W81XWH-12-20121]	U.S. Department of Defense, Grant/Award Numbers: W81XWH-08-2-0100/W81XWH-082-0102, W81XWH-12-2-0117/W81XWH-12-20121	Benda BB, 2005, SUICIDE LIFE-THREAT, V35, P106, DOI 10.1521/suli.35.1.106.59262; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Borges G, 2010, J CLIN PSYCHIAT, V71, P1617, DOI 10.4088/JCP.08m04967blu; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Bryan CJ, 2016, DEPRESS ANXIETY, V33, P549, DOI 10.1002/da.22456; Bryan CJ, 2015, SUICIDE LIFE-THREAT, V45, P315, DOI 10.1111/sltb.12127; Bryan CJ, 2014, COMPR PSYCHIAT, V55, P534, DOI 10.1016/j.comppsych.2013.10.006; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; de Klerk S, 2011, J AFFECT DISORDERS, V133, P257, DOI 10.1016/j.jad.2011.03.021; Department of the Army, 2010, HLTH PROM RISK RED S; Enders C. K., 2010, APPL MISSING DATA AN; First M., 1995, STRUCTURED CLIN INTE; Franklin JC, 2016, J CONSULT CLIN PSYCH, V84, P544, DOI 10.1037/ccp0000093; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Gradus JL, 2013, SUICIDE LIFE-THREAT, V43, P574, DOI 10.1111/sltb.12040; Gradus JL, 2013, DEPRESS ANXIETY, V30, P1046, DOI 10.1002/da.22117; Gradus JL, 2013, SUICIDE LIFE-THREAT, V43, P39, DOI 10.1111/j.1943-278X.2012.00126.x; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Gysin-Maillart A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001968; HALEY J, 1976, PROBLEM SOLVING THEO; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Ilgen MA, 2012, J CONSULT CLIN PSYCH, V80, P323, DOI 10.1037/a0028266; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 2015, ANN EPIDEMIOL, V25, P96, DOI 10.1016/j.annepidem.2014.11.020; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kaplan MS, 2007, AM J ORTHOPSYCHIAT, V77, P56, DOI 10.1037/0002-9432.77.1.56; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kimbrel NA, 2016, PSYCHIAT RES, V243, P97, DOI 10.1016/j.psychres.2016.06.011; Kimbrel NA, 2015, PSYCHIAT RES, V227, P360, DOI 10.1016/j.psychres.2015.03.026; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Klonsky ED, 2014, SUICIDE LIFE-THREAT, V44, P1, DOI 10.1111/sltb.12068; Kraemer H.C., 1992, EVALUATING MED TESTS; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Maguen S, 2015, J PSYCHIATR RES, V68, P120, DOI 10.1016/j.jpsychires.2015.06.013; Maguen S, 2011, J ANXIETY DISORD, V25, P563, DOI 10.1016/j.janxdis.2011.01.003; May AM, 2016, CLIN PSYCHOL-SCI PR, V23, P5, DOI 10.1111/cpsp.12136; McLean CP, 2017, J AFFECT DISORDERS, V208, P392, DOI 10.1016/j.jad.2016.08.061; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2007, PSYCHOL ASSESSMENT, V19, P309, DOI 10.1037/1040-3590.19.3.309; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; Nock MK, 2016, DEPRESS ANXIETY, V33, P460, DOI 10.1002/da.22528; Nock MK, 2016, CLIN PSYCHOL-SCI PR, V23, P31, DOI 10.1111/cpsp.12133; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Park S, 2012, PSYCHIAT RES, V198, P509, DOI 10.1016/j.psychres.2012.01.028; Pfeiffer PN, 2009, DEPRESS ANXIETY, V26, P752, DOI 10.1002/da.20583; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Ribeiro JD, 2016, PSYCHOL MED, V46, P225, DOI 10.1017/S0033291715001804; Rosen RC, 2012, INT J METH PSYCH RES, V21, P5, DOI 10.1002/mpr.355; Rudd MD, 2015, AM J PSYCHIAT, V172, P441, DOI 10.1176/appi.ajp.2014.14070843; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stein DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010574; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tiet QQ, 2006, PSYCHIAT SERV, V57, P107, DOI 10.1176/appi.ps.57.1.107; Ursano RJ, 2015, DEPRESS ANXIETY, V32, P3, DOI 10.1002/da.22317; Wiborg JF, 2013, PSYCHOSOM MED, V75, P800, DOI 10.1097/PSY.0000000000000013; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	65	17	17	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	JUL	2018	35	7					609	618		10.1002/da.22736			10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	GM0RR	WOS:000437763700003	29637667	Bronze			2021-06-18	
J	Leeper, CM; Neal, MD; Billiar, TR; Sperry, JL; Gaines, BA				Leeper, Christine M.; Neal, Matthew D.; Billiar, Timothy R.; Sperry, Jason L.; Gaines, Barbara A.			Overresuscitation with plasma is associated with sustained fibrinolysis shutdown and death in pediatric traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	31st Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma(EAST)	JAN 09-13, 2018	Lake Buena Vista, FL	Eastern Assoc Surg Trauma		Trauma; pediatric; coagulopathy; traumatic brain injury; fibrinolysis	PRINCIPAL COMPONENT ANALYSIS; ADMISSION RAPID THROMBELASTOGRAPHY; INTERNATIONAL NORMALIZED RATIO; CONVENTIONAL COAGULATION TESTS; HEMORRHAGIC-SHOCK; HEAD TRAUMA; MORTALITY; COAGULOPATHY; CHILDREN; TIME	BACKGROUND Elevated International Normalized Ratio (INR) is a marker of poor outcome but not necessarily bleeding or clinical coagulopathy in injured children. Conversely, children with traumatic brain injury (TBI) tend to be hypercoagulable based on rapid thromboelastography (rTEG) parameters. Many clinicians continue to utilize INR as a treatment target. METHODS Prospective observational study of severely injured children age < 18 with rTEG on arrival and daily thereafter for up to 7 days. Standard rTEG definitions of hyperfibrinolysis (LY30 3), fibrinolysis shutdown (SD) (LY30 0.8), and normal (LY30 = 0.9-2.9) were applied. The first 24-hour blood product transfusion volumes were documented. Abbreviated Injury Scale score 3 defined severe TBI. Sustained SD was defined as two consecutive rTEG with SD and no subsequent normalization. Primary outcomes were death and functional disability, based on functional independence measure score assessed at discharge. RESULTS One hundred one patients were included: median age, 8 years (interquartile range, 4-12 years); Injury Severity Score, 25 (16-30); 72% blunt mechanism; 47% severe TBI; 16% mortality; 45% discharge disability. Neither total volume nor any single product volume transfused (mL/kg; all p > 0.1) differed between TBI and non-TBI groups. On univariate analysis, transfusion of packed red blood cells (p = 0.016), plasma (p < 0.001), and platelets (p = 0.006) were associated with sustained SD; however, in a regression model that included all products (mL/kg) and controlled for severe TBI (head Abbreviated Injury Scale score 3), admission INR, polytrauma, and clinical bleeding, only plasma remained an independent predictor of sustained SD (odds ratio, 1.17; p = 0.031). Patients with both severe TBI and plasma transfusion had 100% sustained SD, 75% mortality, and 100% disability in survivors. Admission INR was elevated in TBI patients, but did not correlate with rTEG activated clotting time (p = NS) and was associated with sustained SD (p = 0.006). CONCLUSION Plasma transfusion is independently associated with sustained fibrinolysis SD. Severe TBI is also associated with sustained SD; the combined effect of plasma transfusion and severe TBI is associated with extremely poor prognosis. Plasma transfusion should not be targeted to INR thresholds but rather to rTEG activated clotting time and clinical bleeding. LEVEL OF EVIDENCE Prognostic and epidemiological study, level III.	[Leeper, Christine M.; Neal, Matthew D.; Billiar, Timothy R.; Sperry, Jason L.] Univ Pittsburgh, Med Ctr, Dept Surg, Div Gen Surg & Trauma, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Div Pediat Gen & Thorac Surg, Pittsburgh, PA USA; [Leeper, Christine M.; Gaines, Barbara A.] UPMC, Childrens Hosp Pittsburgh, 7th Floor,Fac Pavil One Childrens Hosp Dr, Pittsburgh, PA 15224 USA	Leeper, CM (corresponding author), UPMC, Childrens Hosp Pittsburgh, 7th Floor,Fac Pavil One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	leepercm@upmc.edu			University of Pittsburgh Clinical and Translational Science InstituteUniversity of Pittsburgh [UL1 TR000005]; Vascular Medicine Institute; Hemophilia Center of Western Pennsylvania; Institute for Transfusion Medicine; Janssen PharmaceuticalsJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc	This publication was made possible by grant number UL1 TR000005 (University of Pittsburgh Clinical and Translational Science Institute), the Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine. Dr. Neal receives research support from Janssen Pharmaceuticals and is on the consulting and advisory Boards of Janssen Pharmaceuticals, CSL Behring. The remaining authors have no conflicts to declare.	Abdel-Wahab OI, 2006, TRANSFUSION, V46, P1279, DOI 10.1111/j.1537-2995.2006.00891.x; Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; Agren A, 2013, SCAND J CLIN LAB INV, V73, P214, DOI 10.3109/00365513.2013.765960; Ali JT, 2017, AM J EMERG MED, V35, P632, DOI 10.1016/j.ajem.2016.12.061; [Anonymous], 2015, CAUS CHILD MORT 2015; Brown JB, 2015, PREHOSP EMERG CARE, V19, P343, DOI 10.3109/10903127.2014.995851; Centers for Disease Control and Prevention, 2014, 10 LEAD CAUS DEATH A; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Chin TL, 2014, SURGERY, V156, P570, DOI 10.1016/j.surg.2014.04.030; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; Dzik WH, 2009, ROSSIS PRINCIPLES TR, V4; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Hendrickson J E, 2012, J PEDIAT, V160, P204; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Holland LL, 2006, AM J CLIN PATHOL, V126, P133, DOI 10.1309/NQXHUG7HND78LFFK; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Kunitake RC, 2017, J TRAUMA ACUTE CARE, V82, P302, DOI 10.1097/TA.0000000000001313; Kutcher ME, 2013, J TRAUMA ACUTE CARE, V74, P1223, DOI 10.1097/TA.0b013e31828b7fa1; Leeper CM, 2017, ANN SURG, V266, P508, DOI 10.1097/SLA.0000000000002355; Leeper CM, 2017, J TRAUMA ACUTE CARE, V82, P27, DOI 10.1097/TA.0000000000001308; Leeper CM, 2016, J TRAUMA ACUTE CARE, V81, P34, DOI 10.1097/TA.0000000000001002; Leeper CM, 2016, J TRAUMA ACUTE CARE, V80, P711, DOI 10.1097/TA.0000000000000954; Leeper CM, 2017, SURGERY; Liras IN, 2015, SURGERY, V158, P812, DOI 10.1016/j.surg.2015.05.004; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Moore EE, 2014, SHOCK, V41, P35, DOI 10.1097/SHK.0000000000000110; Moore HB, 2017, J SURG RES, V220, P438, DOI 10.1016/j.jss.2017.04.028; Moore HB, 2015, SURGERY, V158, P386, DOI 10.1016/j.surg.2015.04.008; Pape HC, 2014, J TRAUMA ACUTE CARE, V77, P780, DOI 10.1097/TA.0000000000000453; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Rizoli S, 2013, J TRAUMA ACUTE CARE, V74, P1229; Rowell SE, 2014, J TRAUMA ACUTE CARE, V77, P846, DOI 10.1097/TA.0000000000000459; Seheult JN, 2017, TRANSFUSION MED, V27, P30, DOI 10.1111/tme.12372; Soundar EP, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0064-1; Vogel AM, 2013, J PEDIATR SURG, V48, P1371, DOI 10.1016/j.jpedsurg.2013.03.036; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb	37	17	17	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2018	85	1					12	17		10.1097/TA.0000000000001836			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GL8GZ	WOS:000437457000003	29443859				2021-06-18	
J	Reinhart, KM; Shuttleworth, CW				Reinhart, Katelyn M.; Shuttleworth, C. William			Ketamine reduces deleterious consequences of spreading depolarizations	EXPERIMENTAL NEUROLOGY			English	Article						Spreading depression; Brain slice; Excitotoxicity; Metabolic compromise; NMDA receptor; Calcium loading; Neuronal injury; Excitatory postsynaptic potentials	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; IN-VIVO; HIPPOCAMPAL SLICES; NMDA RECEPTOR; DEPRESSION; ACTIVATION; STROKE; RAT; HEMORRHAGE	Recent work has implicated spreading depolarization (SD) as a key contributor the progression of acute brain injuries, however development of interventions selectively targeting SD has lagged behind. Initial clinical intervention efforts have focused on observations that relatively high doses of the sedative agent ketamine can completely suppress SD. However, blocking propagation of SD could theoretically prevent beneficial effects of SD in surrounding brain regions. Selective targeting of deleterious consequences of SD (rather than abolition) could be a useful adjunct approach, and be achieved with lower ketamine concentrations. We utilized a brain slice model to test whether deleterious consequences of SD could be prevented by ketamine, using concentrations that did not prevent the initiation and propagation of SD. Studies were conducted using murine brain slices, with focal KCl as an SD stimulus. Consequences of SD were assessed with electrophysiological and imaging measures of ionic and synaptic recovery. Under control conditions, ketamine (up to 30 mu M) did not prevent SD, but significantly reduced neuronal Ca2+ loading and the duration of associated extracellular potential shifts. Recovery of postsynaptic potentials after SD was also significantly accelerated. When SD was evoked on a background of mild metabolic compromise, neuronal recovery was substantially impaired. Under compromised conditions, the same concentrations of ketamine reduced ionic and metabolic loading during SD, sufficient to preserve functional recovery after repetitive SDs. These results suggest that lower concentrations of ketamine could be utilized to prevent damaging consequences of SD, while not blocking them outright and thereby preserving potentially protective effects of SD.	[Reinhart, Katelyn M.; Shuttleworth, C. William] Univ New Mexico, Dept Neurosci, Sch Med, Albuquerque, NM 87131 USA	Shuttleworth, CW (corresponding author), Univ New Mexico, Dept Neurosci, MSCO8 4740 1, Albuquerque, NM 87131 USA.	bshuttleworth@salud.unm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS051288, P20GM109089, T32 HL007736]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS106901, R01NS051288] Funding Source: NIH RePORTER	This study was supported by NIH grants NS051288, P20GM109089 and T32 HL007736. The authors are grateful to Russell Morton, Ph.D. and Donald Partridge, Ph.D. for helpful discussions and input throughout the course of the study, and for excellent pilot studies contributed by Kisa King.	Abou-Chebl A, 2010, STROKE, V41, P1175, DOI 10.1161/STROKEAHA.109.574129; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; AITKEN PG, 1995, J NEUROSCI METH, V59, P139, DOI 10.1016/0165-0270(94)00204-T; Anderson TR, 2002, J NEUROPHYSIOL, V88, P2713, DOI 10.1152/jn.00321.2002; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Dietz RM, 2008, J NEUROSCI, V28, P8014, DOI 10.1523/JNEUROSCI.0765-08.2008; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Faraguna U, 2010, CEREB CORTEX, V20, P2939, DOI 10.1093/cercor/bhq041; Fayuk D, 2002, J NEUROPHYSIOL, V87, P1924, DOI 10.1152/jn.00231.2001; Footitt DR, 1998, BRAIN RES, V781, P339, DOI 10.1016/S0006-8993(97)01359-0; Frenguelli BG, 2019, NEUROCHEM RES, V44, P661, DOI 10.1007/s11064-017-2386-6; Funke F, 2009, J NEUROPHYSIOL, V101, P2395, DOI 10.1152/jn.91260.2008; Gee JM, 2014, NEURON, V83, P1058, DOI 10.1016/j.neuron.2014.07.024; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hoskison MM, 2006, EXP NEUROL, V202, P302, DOI 10.1016/j.expneurol.2006.06.010; Izumi Y, 2014, NEUROPHARMACOLOGY, V86, P273, DOI 10.1016/j.neuropharm.2014.08.002; Jagt TAV, 2008, J NEUROSCI, V28, P5029, DOI 10.1523/JNEUROSCI.5069-07.2008; Johnson JW, 2015, CURR OPIN PHARMACOL, V20, P54, DOI 10.1016/j.coph.2014.11.006; Khlestova E, 2016, J NEUROSCI, V36, P11151, DOI 10.1523/JNEUROSCI.1203-16.2016; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Lindquist BE, 2017, J CEREBR BLOOD F MET, V37, P1656, DOI 10.1177/0271678X16650696; Lindquist BE, 2014, J CEREBR BLOOD F MET, V34, P1779, DOI 10.1038/jcbfm.2014.146; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Nichols C, 2010, J NEUROINTERV SURG, V2, P67, DOI 10.1136/jnis.2009.001768; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Peltoniemi MA, 2016, CLIN PHARMACOKINET, V55, P1059, DOI 10.1007/s40262-016-0383-6; Petzold GC, 2005, STROKE, V36, P1270, DOI 10.1161/01.STR.0000166023.51307.e0; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Rogers ML, 2017, J CEREBR BLOOD F MET, V37, P1883, DOI 10.1177/0271678X16674486; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Sanchez-Porras R, 2014, NEUROPHARMACOLOGY, V84, P52, DOI 10.1016/j.neuropharm.2014.04.018; Schiefecker AJ, 2015, NEUROCRIT CARE, V22, P293, DOI 10.1007/s12028-014-0050-4; Shohami E, 2014, CNS NEUROL DISORD-DR, V13, P567, DOI 10.2174/18715273113126660196; Shuttleworth CW, 2010, NEUROCHEM INT, V56, P379, DOI 10.1016/j.neuint.2009.12.015; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Tang YT, 2014, J NEUROPHYSIOL, V112, P2572, DOI 10.1152/jn.00205.2014; Urbach A, 2017, J CEREBR BLOOD F MET, V37, P1776, DOI 10.1177/0271678X16643736; Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Wang XJ, 2013, BRAIN RES, V1518, P9, DOI 10.1016/j.brainres.2013.04.042; Yanamoto H, 2004, BRAIN RES, V1019, P178, DOI 10.1016/j.brainres.2004.05.105; Zhang XL, 2015, EXP NEUROL, V273, P312, DOI 10.1016/j.expneurol.2015.07.025	57	17	17	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2018	305						121	128		10.1016/j.expneurol.2018.04.007			8	Neurosciences	Neurosciences & Neurology	GH4TN	WOS:000433397500012	29653188	Bronze, Green Accepted			2021-06-18	
J	Storey, EP; Wiebe, DJ; D'Alonzo, BA; Nixon-Cave, K; Jackson-Coty, J; Goodman, AM; Grady, MF; Master, CL				Storey, Eileen P.; Wiebe, Douglas J.; D'Alonzo, Bernadette A.; Nixon-Cave, Kim; Jackson-Coty, Janet; Goodman, Arlene M.; Grady, Matthew F.; Master, Christina L.			Vestibular Rehabilitation Is Associated With Visuovestibular Improvement in Pediatric Concussion	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						concussion; children; human movement system; vestibular rehabilitation; visuovestibular system	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; HIGH-SCHOOL; FOOTBALL PLAYERS; PROTRACTED RECOVERY; PHYSICAL-THERAPY; NORMATIVE DATA; BALANCE; RELIABILITY	Background and Purpose: Vision and vestibular-related deficits are common after concussion and are associated with prolonged recovery times, substantially impacting the quality of life for children. The utility of targeted vestibular rehabilitation for these deficits in children after concussion is unknown. The purpose of this study was to determine whether active vestibular rehabilitation is associated with an improvement in visuovestibular signs and symptoms in children with concussion. Methods: A retrospective cohort study of children diagnosed with concussion and referred to vestibular rehabilitation between 2012 and 2014 was conducted. Patient-reported symptoms and visuovestibular performance measures were assessed in the medical practice and physical therapy settings. Results: One hundred nine children were included in the study with a mean age of 11.8 (3.4) years. Among this group, 59 (54%) were male and 48 (44%) had a sports-related concussion. Children presented to a pediatric sports medicine office and physical therapy a median of 24 (interquartile range [IQR], 14-42) and 55 (IQR, 39-94) days after injury, respectively. Concussion symptoms decreased from a median of 9 (IQR, 5-13) symptoms at initial evaluation to a median of 0 (IQR, 0-2) symptoms at final assessment. Performance on all visuovestibular tasks improved significantly over the course of therapy except for near point of convergence. For the 45 children who completed the Balance Error Scoring System at both initial and final therapy visits, there was a significant improvement in mean level of performance (P < 0.0001). Characteristics between those who completed a full versus partial course of physical therapy were similar. Discussion and Conclusions: Vestibular rehabilitation in children with concussion is associated with improvement in symptoms as well as visuovestibular performance. This active intervention may benefit children with persistent symptoms after concussion. Future prospective studies are needed to determine the efficacy and optimal postinjury timing of vestibular rehabilitation. Video Abstract available for more insights from the authors (see Supplemental Digital Content 1, available at: http://links.lww.com/JNPT/A208).	[Storey, Eileen P.; Nixon-Cave, Kim; Jackson-Coty, Janet; Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Div Orthopaed, 34th & Civ Ctr Blvd,Wood Bldg,2nd Floor, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Goodman, Arlene M.] St Peters Sports Med Inst, Somerset, NJ USA; [Wiebe, Douglas J.; D'Alonzo, Bernadette A.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Master, CL (corresponding author), Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Div Orthopaed, 34th & Civ Ctr Blvd,Wood Bldg,2nd Floor, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270; D'Alonzo, Bernadette/0000-0002-3760-2158			Aligene K, 2013, NEUROREHABILITATION, V32, P543, DOI 10.3233/NRE-130876; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; *CDCP, 2007, MORTALITY MORBIDITY, V0056; Corwin DJ, 2018, BRAIN INJURY, V32, P794, DOI 10.1080/02699052.2018.1458150; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Cushman D, 2018, BRAIN INJURY, V32, P569, DOI 10.1080/02699052.2018.1432891; Ellis MJ, 2017, J NEUROSURG-PEDIATR, V19, P38, DOI 10.3171/2016.7.PEDS16310; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gaikwad SB, 2018, J NEUROL PHYS THER, V42, P72, DOI 10.1097/NPT.0000000000000216; Gilchrist J, MMWR MORB MORTAL WKL, V60, P1337; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Grabowski P, 2017, PHYS THER SPORT, V23, P22, DOI 10.1016/j.ptsp.2016.06.001; Greenwald BD, 2013, NEUROREHABILITATION, V32, P433, DOI 10.3233/NRE-130865; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Hall CD, 2009, OTOLARYNG CLIN N AM, V42, P161, DOI 10.1016/j.otc.2008.09.006; Han BI, 2011, J CLIN NEUROL, V7, P184, DOI 10.3988/jcn.2011.7.4.184; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kaufman DR, 2014, PHYS THER SPORT, V15, P181, DOI 10.1016/j.ptsp.2013.10.002; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Master CL, 2018, CLIN J SPORT MED, V28, P139, DOI 10.1097/JSM.0000000000000507; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Medeiros IRT, 2005, OTOL NEUROTOL, V26, P699, DOI 10.1097/01.mao.0000169051.69254.85; Moran RN, 2018, AM J SPORT MED, V46, P1475, DOI 10.1177/0363546518756979; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; O'Reilly RC, 2010, OTOL NEUROTOL, V31, P1441, DOI 10.1097/MAO.0b013e3181f20673; Rine RM, 2013, NEUROREHABILITATION, V32, P507, DOI 10.3233/NRE-130873; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Storey EP, 2017, OPTOMETRY VISION SCI, V94, P96, DOI 10.1097/OPX.0000000000000910; Whitney SL, 2011, NEUROREHABILITATION, V29, P157, DOI 10.3233/NRE-2011-0690; Yorke AM, 2017, SPORTS HEALTH, V9, P174, DOI 10.1177/1941738116678411; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	51	17	18	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUL	2018	42	3			SI		134	141		10.1097/NPT.0000000000000228			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GL1OM	WOS:000436873100004	29912034				2021-06-18	
J	Izrael, M; Slutsky, SG; Admoni, T; Cohen, L; Granit, A; Hasson, A; Itskovitz-Eldor, J; Paker, LK; Kuperstein, G; Lavon, N; Ionescu, SY; Solmesky, LJ; Zaguri, R; Zhuravlev, A; Volman, E; Chebath, J; Revel, M				Izrael, Michal; Slutsky, Shalom Guy; Admoni, Tamar; Cohen, Louisa; Granit, Avital; Hasson, Arik; Itskovitz-Eldor, Joseph; Paker, Lena Krush; Kuperstein, Graciela; Lavon, Neta; Ionescu, Shiran Yehezkel; Solmesky, Leonardo Javier; Zaguri, Rachel; Zhuravlev, Alina; Volman, Ella; Chebath, Judith; Revel, Michel			Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models	STEM CELL RESEARCH & THERAPY			English	Article						Amyotrophic lateral sclerosis; Astrocytes; Human embryonic stem cells; Superoxide dismutase 1	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; PHASE-I TRIAL; GLUTAMATE TRANSPORTER GLT-1; MESENCHYMAL STROMAL CELLS; HYPOXIA-RESPONSE ELEMENT; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; DISEASE PROGRESSION; CEREBROSPINAL-FLUID	Background: Amyotrophic lateral sclerosis (ALS) is a motor neuron (MN) disease characterized by the loss of MNs in the central nervous system. As MNs die, patients progressively lose their ability to control voluntary movements, become paralyzed and eventually die from respiratory/deglutition failure. Despite the selective MN death in ALS, there is growing evidence that malfunctional astrocytes play a crucial role in disease progression. Thus, transplantation of healthy astrocytes may compensate for the diseased astrocytes. Methods: We developed a good manufacturing practice-grade protocol for generation of astrocytes from human embryonic stem cells (hESCs). The first stage of our protocol is derivation of astrocyte progenitor cells (APCs) from hESCs. These APCs can be expanded in large quantities and stored frozen as cell banks. Further differentiation of the APCs yields an enriched population of astrocytes with more than 90% GFAP expression (hES-AS). hES-AS were injected intrathecally into hSOD1(G93A) transgenic mice and rats to evaluate their therapeutic potential. The safety and biodistribution of hES-AS were evaluated in a 9-month study conducted in immunodeficient NSG mice under good laboratory practice conditions. Results: In vitro, hES-AS possess the activities of functional healthy astrocytes, including glutamate uptake, promotion of axon outgrowth and protection of MNs from oxidative stress. A secretome analysis shows that these hES-AS also secrete several inhibitors of metalloproteases as well as a variety of neuroprotective factors (e.g. TIMP-1, TIMP-2, OPN, MIF and Midkine). Intrathecal injections of the hES-AS into transgenic hSOD1(G93A) mice and rats significantly delayed disease onset and improved motor performance compared to sham-injected animals. A safety study in immunodeficient mice showed that intrathecal transplantation of hES-AS is safe. Transplanted hES-AS attached to the meninges along the neuroaxis and survived for the entire duration of the study without formation of tumors or teratomas. Cell-injected mice gained similar body weight to the sham-injected group and did not exhibit clinical signs that could be related to the treatment. No differences from the vehicle control were observed in hematological parameters or blood chemistry. Conclusion: Our findings demonstrate the safety and potential therapeutic benefits of intrathecal injection of hES-AS for the treatment of ALS.	[Izrael, Michal; Slutsky, Shalom Guy; Admoni, Tamar; Cohen, Louisa; Granit, Avital; Hasson, Arik; Itskovitz-Eldor, Joseph; Paker, Lena Krush; Kuperstein, Graciela; Lavon, Neta; Ionescu, Shiran Yehezkel; Solmesky, Leonardo Javier; Zaguri, Rachel; Zhuravlev, Alina; Volman, Ella; Chebath, Judith; Revel, Michel] Kadimastem Ltd, Neurodegenerat Dis Dept, Pinchas Sapir 7,Weizmann Sci Pk, Ness Ziona, Israel; [Chebath, Judith; Revel, Michel] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Izrael, M (corresponding author), Kadimastem Ltd, Neurodegenerat Dis Dept, Pinchas Sapir 7,Weizmann Sci Pk, Ness Ziona, Israel.	m.izrael@kadimastem.com			Israel Innovation Authority National Natural [59652]	This work was supported by the Israel Innovation Authority National Natural (grant No. 59652).	Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; Alfei L, 1999, EUR J HISTOCHEM, V43, P29; Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526; Baba H, 1997, DEV NEUROSCI-BASEL, V19, P49, DOI 10.1159/000111185; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bogaert E, 2010, NEUROBIOL AGING, V31, P2185, DOI 10.1016/j.neurobiolaging.2008.12.007; Brambilla L, 2016, HUM MOL GENET, V25, P3080, DOI 10.1093/hmg/ddw161; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Collins MA, 2015, J PROTEOME RES, V14, P4486, DOI 10.1021/acs.jproteome.5b00804; Cordero-Llana O, 2011, CELL DEATH DIFFER, V18, P907, DOI 10.1038/cdd.2010.169; Das MM, 2015, NEUROBIOL AGING, V36, P1130, DOI 10.1016/j.neurobiolaging.2014.09.020; Deepa P, 2011, J NEURAL TRANSM, V118, P531, DOI 10.1007/s00702-010-0520-6; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Di Giorgio FP, 2008, CELL STEM CELL, V3, P637, DOI 10.1016/j.stem.2008.09.017; Do-Ha D, 2018, MOL NEUROBIOL, V55, P1410, DOI 10.1007/s12035-017-0392-y; Endo F, 2015, CELL REP, V11, P592, DOI 10.1016/j.celrep.2015.03.053; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Gao LN, 2014, J NEUROL SCI, V346, P216, DOI 10.1016/j.jns.2014.08.031; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079; Gropp M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045532; Gros-Louis F, 2003, MUSCLE NERVE, V28, P774, DOI 10.1002/mus.10498; Gupta K, 2013, BRIT J CLIN PHARMACO, V75, P907, DOI 10.1111/bcp.12022; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hafner A, 2013, AGING CELL, V12, P604, DOI 10.1111/acel.12093; Haidet-Phillips AM, 2011, NAT BIOTECHNOL, V29, P824, DOI 10.1038/nbt.1957; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P471, DOI 10.1097/00005072-198409000-00002; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Hubbard JA, 2015, ASN NEURO, V7, DOI 10.1177/1759091415605486; Israelson A, 2015, NEURON, V86, P218, DOI 10.1016/j.neuron.2015.02.034; Izrael M, 2018, ASTROCYTES PATHOGENE; Izrael M, 2007, MOL CELL NEUROSCI, V34, P310, DOI 10.1016/j.mcn.2006.11.008; Kaplan A, 2014, NEURON, V81, P333, DOI 10.1016/j.neuron.2013.12.009; Kawahara K, 2002, GLIA, V40, P337, DOI 10.1002/glia.10133; Kondo T, 2014, STEM CELL REP, V3, P242, DOI 10.1016/j.stemcr.2014.05.017; Krakora D, 2013, MOL THER, V21, P1602, DOI 10.1038/mt.2013.108; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Lagier-Tourenne C, 2009, CELL, V136, P1001, DOI 10.1016/j.cell.2009.03.006; Lee AS, 2009, CELL CYCLE, V8, P2608, DOI 10.4161/cc.8.16.9353; Lee J, 2016, EXP NEUROBIOL, V25, P233, DOI 10.5607/en.2016.25.5.233; Li G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005424; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Llado J, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00181; Marchetto MCN, 2008, CELL STEM CELL, V3, P649, DOI 10.1016/j.stem.2008.10.001; Mazzini L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0371-2; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Meyer K, 2014, P NATL ACAD SCI USA, V111, P829, DOI 10.1073/pnas.1314085111; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Mishra PS, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0698-0; Morisaki Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep27354; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Nicaise C, 2015, WORLD J STEM CELLS, V7, P380, DOI 10.4252/wjsc.v7.i2.380; Nizzardo M, 2016, HUM MOL GENET, V25, P3152, DOI 10.1093/hmg/ddw163; Oh KW, 2015, STEM CELL TRANSL MED, V4, P590, DOI 10.5966/sctm.2014-0212; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Papadeas ST, 2011, P NATL ACAD SCI USA, V108, P17803, DOI 10.1073/pnas.1103141108; Petrou P, 2016, JAMA NEUROL, V73, P337, DOI 10.1001/jamaneurol.2015.4321; Petrov D, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00068; Phatnani HP, 2013, P NATL ACAD SCI USA, V110, pE756, DOI 10.1073/pnas.1222361110; Philips T, 2015, CURRENT PROTOCOLS PH, V69; Piao C, 2015, EXP NEUROL, V273, P288, DOI 10.1016/j.expneurol.2015.09.009; Prathalingam N, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt103; Priest CA, 2015, REGEN MED, V10, P939, DOI 10.2217/rme.15.57; Prokhorova TA, 2009, STEM CELLS DEV, V18, P47, DOI 10.1089/scd.2007.0266; Przyborski SA, 2005, STEM CELLS, V23, P1242, DOI 10.1634/stemcells.2005-0014; Ramamohan PY, 2007, AMYOTROPH LATERAL SC, V8, P79, DOI 10.1080/08037060601145489; Ramot Y, 2017, NEUROTOXICOLOGY, V59, P27, DOI 10.1016/j.neuro.2017.01.003; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Re DB, 2014, NEURON, V81, P1001, DOI 10.1016/j.neuron.2014.01.011; Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Rosito M, 2012, J NEUROSCI, V32, P3154, DOI 10.1523/JNEUROSCI.4046-11.2012; Rossi S, 2016, BRAIN PATHOL, V26, P276, DOI 10.1111/bpa.12355; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Roybon L, 2013, CELL REP, V4, P1035, DOI 10.1016/j.celrep.2013.06.021; Sasaki S, 2007, ACTA NEUROPATHOL, V114, P633, DOI 10.1007/s00401-007-0299-1; Scholze AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110668; Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300; Shruthi S, 2017, NEURODEGENER DIS, V17, P44, DOI 10.1159/000447559; Staff NP, 2016, NEUROLOGY, V87, P2230, DOI 10.1212/WNL.0000000000003359; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Straten G, 2009, J ALZHEIMERS DIS, V18, P331, DOI 10.3233/JAD-2009-1146; Tan WZ, 2013, J NEUROSCI, V33, P11588, DOI 10.1523/JNEUROSCI.5385-12.2013; Tannenbaum SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035325; Tarasiuk J, 2012, J NEURAL TRANSM, V119, P747, DOI 10.1007/s00702-012-0806-y; Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053; Tong JB, 2013, EMBO J, V32, P1917, DOI 10.1038/emboj.2013.122; Tripathi P, 2017, STEM CELL REP, V9, P667, DOI 10.1016/j.stemcr.2017.06.008; Tyzack GE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5294; Van Den Bosch L, 2004, NEUROBIOL DIS, V17, P21, DOI 10.1016/j.nbd.2004.06.004; Varghese AM, 2013, CLIN PROTEOM, V10, DOI 10.1186/1559-0275-10-19; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x; Winkler C, 2014, BRIT J PHARMACOL, V171, P905, DOI 10.1111/bph.12462; Wright MC, 2014, J NEUROSCI, V34, P1689, DOI 10.1523/JNEUROSCI.3822-13.2014; Yamanaka K, 2008, P NATL ACAD SCI USA, V105, P7594, DOI 10.1073/pnas.0802556105	99	17	17	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	JUN 6	2018	9								152	10.1186/s13287-018-0890-5			17	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	GJ0BZ	WOS:000434911700001	29871694	DOAJ Gold, Green Published			2021-06-18	
J	Brown, CS; Emmett, SD; Robler, SK; Tucci, DL				Brown, Clifford Scott; Emmett, Susan D.; Robler, Samantha Kleindienst; Tucci, Debara L.			Global Hearing Loss Prevention	OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA			English	Article						Hearing loss; Prevention; Vaccination; Cost effectiveness	TRAUMATIC BRAIN-INJURY; COCHLEAR IMPLANTATION; COST-EFFECTIVENESS; CYTOMEGALOVIRUS-INFECTION; COMMUNICATION DISORDERS; IMMUNIZATION VISION; DEAF EDUCATION; VITAMIN-A; IMPAIRMENT; CHILDREN	Hearing loss is the fourth leading contributor to years lived with a disability worldwide. Most recent estimates indicate that one-half of a billion people suffer from disabling hearing loss worldwide. The social and economic burden is significant. When attributing monetary value to years lived with disability owing to hearing loss, there is greater than $750 billion lost each year globally. There are numerous contributors to hearing loss, including congenital, infectious, noise exposure, age-related, traumatic, and immune-mediated causes. Understanding the pathophysiology of these factors allows for the development of preventative and treatment strategies specific to the underlying cause.	[Brown, Clifford Scott] Duke Univ, Med Ctr, Dept Surg, Div Head & Neck Surg & Commun Sci, 40 Duke Med Circle,M150 Green Zone,DUMC 2824, Durham, NC 27710 USA; [Emmett, Susan D.] Duke Univ, Med Ctr, Dept Surg, Div Head & Neck Surg & Commun Sci,Duke Global Hlt, Box 3805, Durham, NC 27710 USA; [Robler, Samantha Kleindienst] Norton Sound Hlth Corp, Norton Sound Hlth, POB 966, Norton, AK 99762 USA; [Tucci, Debara L.] Duke Univ, Div Head & Neck Surg Commun Sci, Dept Surg, Med Ctr, Box 3805, Durham, NC 27710 USA	Tucci, DL (corresponding author), Duke Univ, Div Head & Neck Surg Commun Sci, Dept Surg, Med Ctr, Box 3805, Durham, NC 27710 USA.	debara.tucci@duke.edu					Abrams H, 2002, J REHABIL RES DEV, V39, P549; Alexander TH, 2013, OTOL NEUROTOL, V34, P1586, DOI 10.1097/MAO.0000000000000222; Alexander TH, 2010, OTOLARYNG CLIN N AM, V43, P965, DOI 10.1016/j.otc.2010.05.001; [Anonymous], 2012, GLOB EST PREV HEAR L; [Anonymous], 1995, WHA489 WHO; Arslan E, 1999, ANN NY ACAD SCI, V884, P1; Baltussen R, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-64; Basner M, 2014, LANCET, V383, P1325, DOI 10.1016/S0140-6736(13)61613-X; Bilous J, 2006, LANCET, V367, P1464, DOI 10.1016/S0140-6736(06)68625-X; BITNUN S, 1986, J LARYNGOL OTOL, V100, P943, DOI 10.1017/S0022215100100362; Bongaarts J, 2009, PHILOS T R SOC B, V364, P2985, DOI 10.1098/rstb.2009.0137; Boothroyd Arthur, 2007, Trends Amplif, V11, P63, DOI 10.1177/1084713807301073; Bortoli R, 2007, CLIN RHEUMATOL, V26, P1809, DOI 10.1007/s10067-007-0662-6; Bovo R, 2009, EUR ARCH OTO-RHINO-L, V266, P37, DOI 10.1007/s00405-008-0801-y; Brouwer MC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub4; Brown ED, 2009, INT J PEDIATR OTORHI, V73, P707, DOI 10.1016/j.ijporl.2009.01.012; Buszman Ewa, 2003, Wiad Lek, V56, P254; Carroll Mark, 2011, Perspect Health Inf Manag, V8, p1d; Castellanos MJ, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121223; Chadambuka A, 2013, Afr Health Sci, V13, P899, DOI 10.4314/ahs.v13i4.6; Chen Y, 2007, HEARING RES, V226, P178, DOI 10.1016/j.heares.2006.05.008; Choudhury V, 2015, AM J CLIN NUTR, V102, P1030, DOI 10.3945/ajcn.115.113084; Cohen BE, 2014, TRENDS HEAR, V18, DOI 10.1177/2331216514541361; Crowson MG, 2017, OTOLARYNG HEAD NECK, V156, P137, DOI 10.1177/0194599816668325; Crowson MG, 2016, AUDIOL NEURO-OTOL, V21, P69, DOI 10.1159/000443629; Curhan SG, 2015, AM J CLIN NUTR, V102, P1167, DOI 10.3945/ajcn.115.109314; De La Sante O., REPORT INFORM CONSUL; Elemraid MA, 2009, ANN TROP PAEDIATR, V29, P85, DOI 10.1179/146532809X440707; Elliott G, 2010, TELEMED J E-HEALTH, V16, P250, DOI 10.1089/tmj.2010.0045; Emmett SD, 2015, OTOL NEUROTOL, V36, P1756, DOI 10.1097/MAO.0000000000000929; Emmett SD, 2018, AM J CLIN NUTR; Emmett SD, 2015, OTOL NEUROTOL, V36, P1357, DOI 10.1097/MAO.0000000000000823; Emmett SD, 2015, OTOL NEUROTOL, V36, P545, DOI 10.1097/MAO.0000000000000562; Emmett SD, 2014, LARYNGOSCOPE, V124, P2176, DOI 10.1002/lary.24746; Emmett SD, 2014, MED HYPOTHESES, V82, P6, DOI 10.1016/j.mehy.2013.09.028; Fechter LD, 2004, J TOXICOL ENV HEAL A, V67, P727, DOI 10.1080/15287390490428206; Galazka AM, 1999, B WORLD HEALTH ORGAN, V77, P3; Gaylor JM, 2013, JAMA OTOLARYNGOL, V139, P265, DOI 10.1001/jamaoto.2013.1744; Goderis J, 2016, J PEDIATR-US, V172, P110, DOI 10.1016/j.jpeds.2016.01.024; Groce NE, 2013, SOCIAL INJUSTICE PUB, P140; Grosse SD, 2008, J CLIN VIROL, V41, P57, DOI 10.1016/j.jcv.2007.09.004; Gurgel RK, 2014, OTOL NEUROTOL, V35, P775, DOI 10.1097/MAO.0000000000000313; HALL R, 1987, ARCH DIS CHILD, V62, P189, DOI 10.1136/adc.62.2.189; Hamamy H, 2012, J COMMUN GENET, V3, P185, DOI 10.1007/s12687-011-0072-y; Hanushek Eric A., 2015, KNOWLEDGE CAPITAL NA; Harrison RV, 2008, PAED CHILD HEALT-CAN, V13, P377, DOI 10.1093/pch/13.5.377; Hassibian M, 2016, RAZAVI INT J MED, V4, DOI [10.17795/rijm38332, DOI 10.17795/RIJM38332]; HENRY KR, 1981, ARCH OTOLARYNGOL, V107, P92; Honeth L, 2015, NOISE HEALTH, V17, P273, DOI 10.4103/1463-1741.165043; Humes LE, 2012, J AM ACAD AUDIOL, V23, P635, DOI 10.3766/jaaa.23.8.5; Jarvelin MR, 1997, BRIT J AUDIOL, V31, P165, DOI 10.3109/03005364000000019; Kemperman MH, 2002, J ROY SOC MED, V95, P171, DOI 10.1258/jrsm.95.4.171; Kennedy CR, 2006, NEW ENGL J MED, V354, P2131, DOI 10.1056/NEJMoa054915; Keppler H, 2010, ARCH OTOLARYNGOL, V136, P538, DOI 10.1001/archoto.2010.84; Kokesh J, 2008, OTOLARYNG HEAD NECK, V139, P87, DOI 10.1016/j.otohns.2008.04.008; Kokesh John, 2004, Int J Circumpolar Health, V63, P387; Kokesh J, 2011, OTOLARYNG CLIN N AM, V44, P1359, DOI 10.1016/j.otc.2011.08.010; Kokesh J, 2010, OTOLARYNG HEAD NECK, V143, P253, DOI 10.1016/j.otohns.2010.04.265; Lantos PM, 2017, J PEDIATR INFECT DIS, V6, pE55, DOI 10.1093/jpids/piw088; Lantos PM, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv143; Lee JY, 2000, CLIN MICROBIOL REV, V13, P571, DOI 10.1128/CMR.13.4.571-587.2000; Lin FR, 2013, JAMA INTERN MED, V173, P293, DOI 10.1001/jamainternmed.2013.1868; Lin FR, 2011, ARCH INTERN MED, V171, P1851, DOI 10.1001/archinternmed.2011.506; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; Low WK, 2005, ANN ACAD MED SINGAP, V34, P301; Mamun K Z, 2006, Mymensingh Med J, V15, P81; Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12; Martinez-Vega R, 2015, FASEB J, V29, P418, DOI 10.1096/fj.14-259283; Melse-Boonstra A, 2013, NUTR RES REV, V26, P110, DOI 10.1017/S0954422413000061; Mueller JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052464; Mulwafu W, 2016, TROP MED INT HEALTH, V21, P158, DOI 10.1111/tmi.12640; Nance WE, 2000, LANCET, V356, P500, DOI 10.1016/S0140-6736(00)02565-4; National Academies of Sciences Engineering and Medicine, 2016, HEAR HLTH CAR AD PRI; National Conference of State Legislatures, NEWB HEAR SCREEN STA; Nayak CS, 2003, ANN OTO RHINOL LARYN, V112, P817, DOI 10.1177/000348940311200913; Nelson DI, 2005, AM J IND MED, V48, P400, DOI 10.1002/ajim.20211; *NZHTA, 1998, SCREEN PROGR DET OT; Olusanya BO, 2006, JAMA-J AM MED ASSOC, V296, P441, DOI 10.1001/jama.296.4.441; Olusanya BO, 2014, B WORLD HEALTH ORGAN, V92, P367, DOI 10.2471/BLT.13.128728; Olusanya BO, 2012, ARCH DIS CHILD, V97, P654, DOI 10.1136/archdischild-2012-301786; Bolajoko BO, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-14; PAPARELLA MM, 1991, OTOLARYNGOLOGY, V2, P1571; Patricoski C, 2003, TELEMED J E-HEALTH, V9, P331, DOI 10.1089/153056203772744653; Robertson Susan E., 2003, Rev Panam Salud Publica, V14, P306, DOI 10.1590/S1020-49892003001000005; Ruben RJ, 2000, LARYNGOSCOPE, V110, P241, DOI 10.1097/00005537-200002010-00010; Saunders JE, 2015, OTOL NEUROTOL, V36, P1349, DOI 10.1097/MAO.0000000000000809; Saunders JE, 2009, OTOLARYNG HEAD NECK, V140, P103, DOI 10.1016/j.otohns.2008.09.027; Schmitz J, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d7962; Shangkuan WC, 2017, LARYNGOSCOPE, V127, P2627, DOI 10.1002/lary.26567; Simons E, 2012, LANCET, V379, P2173, DOI 10.1016/S0140-6736(12)60522-4; SMITH A, 2003, INT C SERIES, V1240, P183; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; Southall K, 2010, INT J AUDIOL, V49, P804, DOI 10.3109/14992027.2010.498447; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; Stevens G, 2013, EUR J PUBLIC HEALTH, V23, P146, DOI 10.1093/eurpub/ckr176; Swanepoel D, 2017, AM J AUDIOL, V26, P426, DOI 10.1044/2017_AJA-16-0117; Tucci DL, 2010, OTOL NEUROTOL, V31, P31, DOI 10.1097/MAO.0b013e3181c0eaec; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; White KR, 2006, J AM ACAD AUDIOL, V17, P295, DOI 10.3766/jaaa.17.4.8; *WHO, DEAFN HEAR IMP; Wilson BS, 2008, HEARING RES, V242, P3, DOI 10.1016/j.heares.2008.06.005; Wilson BS, 2017, LANCET, V390, P2503, DOI 10.1016/S0140-6736(17)31073-5; Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096; Wong BYK, 2000, ADV OTO-RHINO-LARYNG, V57, P377; World Health Organization, NEWB INF HEAR SCREEN; World Health Organization, GRAD HEAR IMP; World Health Organization, 2017, GLOB COSTS UN HEAR L; World Health Organization, 2010, REP 2 GLOB SURV EHEA; Zietsch BP, 2011, AM NAT, V177, P605, DOI 10.1086/659629	109	17	17	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0030-6665	1557-8259		OTOLARYNG CLIN N AM	Otolaryngol. Clin. N. Am.	JUN	2018	51	3					575	+		10.1016/j.otc.2018.01.006			19	Otorhinolaryngology	Otorhinolaryngology	GJ5OV	WOS:000435431700009	29525388				2021-06-18	
J	Dimitriadis, SI; Lopez, ME; Bruna, R; Cuesta, P; Marcos, A; Maestu, F; Pereda, E				Dimitriadis, Stavros I.; Lopez, Maria E.; Bruna, Ricardo; Cuesta, Pablo; Marcos, Alberto; Maestu, Fernando; Pereda, Ernesto			How to Build a Functional Connectomic Biomarker for Mild Cognitive Impairment From Source Reconstructed MEG Resting-State Activity: The Combination of ROI Representation and Connectivity Estimator Matters	FRONTIERS IN NEUROSCIENCE			English; English	Article						connectomic biomarker; magnetoencephalography; mild cognitive impairment; virtual source activity; connectome data analysis; multiplexity; cross-frequency-coupling; intrinsic coupling modes	ALZHEIMERS ASSOCIATION WORKGROUPS; POSTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; SYNCHRONIZATION LIKELIHOOD; DIAGNOSTIC GUIDELINES; OSCILLATORY ACTIVITY; EEG SYNCHRONIZATION; NATIONAL INSTITUTE; FMRI CONNECTIVITY; DISEASE	Our work aimed to demonstrate the combination of machine learning and graph theory for the designing of a connectomic biomarker for mild cognitive impairment (MCI) subjects using eyes-closed neuromagnetic recordings. The whole analysis based on source-reconstructed neuromagnetic activity. As ROI representation, we employed the principal component analysis (PCA) and centroid approaches. As representative bi-variate connectivity estimators for the estimation of intra and cross-frequency interactions, we adopted the phase locking value (PLV), the imaginary part (iPLV) and the correlation of the envelope (CorrEnv). Both intra and cross-frequency interactions (CFC) have been estimated with the three connectivity estimators within the seven frequency bands (intra-frequency) and in pairs (CFC), correspondingly. We demonstrated how different versions of functional connectivity graphs single-layer (SL-FCG) and multi-layer (ML-FCG) can give us a different view of the functional interactions across the brain areas. Finally, we applied machine learning techniques with main scope to build a reliable connectomic biomarker by analyzing both SL-FCG and ML-FCG in two different options: as a whole unit using a tensorial extraction algorithm and as single pair-wise coupling estimations. We concluded that edge-weighed feature selection strategy outperformed the tensorial treatment of SL-FCG and ML-FCG. The highest classification performance was obtained with the centroid ROI representation and edge-weighted analysis of the SL-FCG reaching the 98% for the CorrEnv in a l :012 and 94% for the iPLV in alpha(2). Classification performance based on the multi-layer participation coefficient, a multiplexity index reached 52% for iPLV and 52% for CorrEnv. Selected functional connections that build the multivariate connectomic biomarker in the edge-weighted scenario are located in default-mode, fronto-parietal, and cingulo-opercular network. Our analysis supports the notion of analyzing FCG simultaneously in intra and cross-frequency whole brain interactions with various connectivity estimators in beamformed recordings.	[Dimitriadis, Stavros I.] Cardiff Univ, Sch Med, Div Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr, Neuroinformat Grp, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Cardiff, S Glam, Wales; [Lopez, Maria E.; Bruna, Ricardo; Maestu, Fernando] Univ Complutense Madrid, Dept Basic Psychol 2, Madrid, Spain; [Lopez, Maria E.; Bruna, Ricardo; Cuesta, Pablo; Maestu, Fernando; Pereda, Ernesto] Ctr Biomed Technol, Lab Cognit & Comp Neurosci, Madrid, Spain; [Lopez, Maria E.; Bruna, Ricardo; Maestu, Fernando] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Zaragoza, Spain; [Cuesta, Pablo; Pereda, Ernesto] Univ La Laguna, Dept Ind Engn, Elect Engn & Bioengn Grp, Tenerife, Spain; [Cuesta, Pablo; Pereda, Ernesto] Univ La Laguna, IUNE, Tenerife, Spain; [Marcos, Alberto] San Carlos Univ Hosp, Dept Neurol, Madrid, Spain	Dimitriadis, SI (corresponding author), Cardiff Univ, Sch Med, Div Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales.; Dimitriadis, SI (corresponding author), Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr, Cardiff, S Glam, Wales.; Dimitriadis, SI (corresponding author), Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales.; Dimitriadis, SI (corresponding author), Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr, Neuroinformat Grp, Cardiff, S Glam, Wales.; Dimitriadis, SI (corresponding author), Cardiff Univ, Neurosci & Mental Hlth Res Inst, Cardiff, S Glam, Wales.	stidimitriadis@gmail.com	Lopez, Maria Eugenia/M-4579-2018; maestu, fernando/M-7480-2019; DIMITRIADIS, STAVROS I/AAN-8992-2020; Bruna, Ricardo/ABF-5708-2020; Lopez, Maria Eugenia/E-9311-2016; Pereda, Ernesto/K-5185-2014; Fernandez, Ricardo Bruna/F-8066-2016; De Pablo, Ernesto Pereda/AAB-7440-2021; Lopez, Maria Eugenia/AAC-3233-2019	maestu, fernando/0000-0002-3195-0071; DIMITRIADIS, STAVROS I/0000-0002-0000-5392; Bruna, Ricardo/0000-0003-1007-900X; Lopez, Maria Eugenia/0000-0002-3928-2629; Pereda, Ernesto/0000-0001-5965-164X; Fernandez, Ricardo Bruna/0000-0003-1007-900X; De Pablo, Ernesto Pereda/0000-0001-5965-164X; Lopez, Maria Eugenia/0000-0002-3928-2629; Cuesta Prieto, Pablo/0000-0002-8459-3354	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/K004360/1]; MARIE-CURIE COFUND EU-UK Research Fellowship; Spanish Ministry of Economy and Competitiveness [FIS2013-41057-P]; University Complutense of Madrid; Spanish MINECO [TEC2016-80063-C3-2-R]; Cardiff RCUK funding; MINECO [PSI-2015-68793-C3-1-R]; Spanish Ministry of EducationSpanish Government [FPU13/06009]	SD was supported by a MRC grant MR/K004360/1 (Behavioural and Neurophysiological Effects of Schizophrenia Risk Genes: A Multi-locus, Pathway Based Approach). SD is also supported by a MARIE-CURIE COFUND EU-UK Research Fellowship.; FM and ML were supported by the Spanish Ministry of Economy and Competitiveness under Project FIS2013-41057-P and (ML) a postdoctoral grant of the University Complutense of Madrid. Finally, EP acknowledges the financial support of Spanish MINECO under grant TEC2016-80063-C3-2-R. We would like to acknowledge Cardiff RCUK funding scheme for covering the publication fee. FM is supported by a grant PSI-2015-68793-C3-1-R from MINECO. RB is supported by a grant FPU13/06009 from the Spanish Ministry of Education. We would like to thank the reviewers for their valuable comments.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Pineda-Pardo JA, 2014, BRAIN CONNECT, V4, P312, DOI 10.1089/brain.2013.0208; Antonakakis M, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00416; Antonakakis M, 2017, NEUROSCIENCE, V356, P275, DOI 10.1016/j.neuroscience.2017.05.032; Antonakakis M, 2016, INT J PSYCHOPHYSIOL, V102, P1, DOI 10.1016/j.ijpsycho.2016.02.002; Arendt T, 2009, ACTA NEUROPATHOL, V118, P167, DOI 10.1007/s00401-009-0536-x; Aru J, 2015, CURR OPIN NEUROBIOL, V31, P51, DOI 10.1016/j.conb.2014.08.002; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Battiston F, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.032804; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brookes MJ, 2012, NEUROIMAGE, V63, P910, DOI 10.1016/j.neuroimage.2012.03.048; Brookes MJ, 2016, NEUROIMAGE, V132, P425, DOI 10.1016/j.neuroimage.2016.02.045; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Bruna R, 2017, PHASE LOCKING VALUE; Buldu JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019584; Buzsaki Gyorgy, 2012, Dialogues Clin Neurosci, V14, P345; Cai D., 2010, KDD, P333; Canolty RT, 2010, TRENDS COGN SCI, V14, P506, DOI 10.1016/j.tics.2010.09.001; Canuet L, 2015, J NEUROSCI, V35, P10325, DOI 10.1523/JNEUROSCI.0704-15.2015; Cohen MX, 2009, J COGNITIVE NEUROSCI, V21, P390, DOI 10.1162/jocn.2008.21020; Cole MW, 2014, NEUROSCIENTIST, V20, P652, DOI 10.1177/1073858414525995; Cuesta P, 2015, J ALZHEIMERS DIS, V44, P493, DOI 10.3233/JAD-141872; de Hemptinne C, 2013, P NATL ACAD SCI USA, V110, P4780, DOI 10.1073/pnas.1214546110; Delbeuck X, 2003, NEUROPSYCHOL REV, V13, P79, DOI 10.1023/A:1023832305702; Dhanjal NS, 2014, ANN NEUROL, V76, P241, DOI 10.1002/ana.24199; Dimitriadis S. I., 2013, 35 ANN INT C IEEE EM; Dimitriadis S. I., 2016, FRONT NEUR C NEUR 20, DOI [10.3389/conf.fninf.2016.20.00006, DOI 10.3389/CONF.FNINF.2016.20.00006]; Dimitriadis S. I., 2016, INT C BIOM BIOMAG 20; Dimitriadis S, 2016, IEEE T NEUR SYS REH, V24, P1017, DOI 10.1109/TNSRE.2016.2516107; Dimitriadis SI, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00694; Dimitriadis SI, 2017, BRAIN CONNECT, V7, P661, DOI 10.1089/brain.2017.0512; Dimitriadis Stavros I, 2016, Alzheimers Dement (N Y), V2, P241, DOI 10.1016/j.trci.2016.08.004; Dimitriadis SI, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00423; Dimitriadis SI, 2017, FRONT NEUROINFORM, V11, DOI 10.3389/fninf.2017.00028; Dimitriadis SI, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00454; Dimitriadis SI, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00163; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Dimitriadis SI, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00350; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Durschmid S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00635; Lopez ME, 2016, J ALZHEIMERS DIS, V52, P133, DOI 10.3233/JAD-151034; Lopez ME, 2014, J NEUROSCI, V34, P14551, DOI 10.1523/JNEUROSCI.0964-14.2014; Lopez ME, 2014, AGE, V36, P1389, DOI 10.1007/s11357-014-9643-2; Farias ST, 2005, INT J GERIATR PSYCH, V20, P827, DOI 10.1002/gps.1367; FitzGerald THB, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00084; Florin E, 2015, NEUROIMAGE, V111, P26, DOI 10.1016/j.neuroimage.2015.01.054; Alonso JF, 2011, ANN BIOMED ENG, V39, P524, DOI 10.1007/s10439-010-0155-7; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Garces P, 2014, NEUROIMAGE-CLIN, V6, P214, DOI 10.1016/j.nicl.2014.09.004; Gomez C, 2009, IEEE T BIO-MED ENG, V56, P1683, DOI 10.1109/TBME.2009.2018454; Guillon J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07846-w; He X., 2005, ADV NEURAL INFORM PR, V18; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; Ito J, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00001; Jeong JS, 2004, CLIN NEUROPHYSIOL, V115, P1490, DOI 10.1016/j.clinph.2004.01.001; Jirsa V, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00078; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Koelewijn L, 2017, CLIN NEUROPHYSIOL, V128, P2347, DOI 10.1016/j.clinph.2017.04.018; Koenig T, 2005, NEUROBIOL AGING, V26, P165, DOI 10.1016/j.neurobiolaging.2004.03.008; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Lakatos P, 2005, J NEUROPHYSIOL, V94, P1904, DOI 10.1152/jn.00263.2005; Lizier JT, 2011, J COMPUT NEUROSCI, V30, P85, DOI 10.1007/s10827-010-0271-2; Lu HP, 2008, IEEE T NEURAL NETWOR, V19, P18, DOI 10.1109/TNN.2007.901277; Maestu F, 2006, NEUROBIOL AGING, V27, P32, DOI 10.1016/j.neurobiolaging.2005.01.005; Maestu F, 2015, NEUROIMAGE-CLIN, V9, P103, DOI 10.1016/j.nicl.2015.07.011; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Moretti DV, 2008, J ALZHEIMERS DIS, V14, P285; Mormann F, 2000, PHYSICA D, V144, P358, DOI 10.1016/S0167-2789(00)00087-7; Nakatani C, 2014, J COGNITIVE NEUROSCI, V26, P1168, DOI 10.1162/jocn_a_00540; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nolte G, 2003, PHYS MED BIOL, V48, P3637, DOI 10.1088/0031-9155/48/22/002; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Palva JM, 2018, NEUROIMAGE, V173, P632, DOI 10.1016/j.neuroimage.2018.02.032; Palva JM, 2011, PROG BRAIN RES, V193, P335, DOI 10.1016/B978-0-444-53839-0.00022-3; Papma JM, 2017, EUR RADIOL, V27, P3716, DOI 10.1007/s00330-017-4768-1; Parra MA, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-76; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Pijnenburg YAL, 2004, CLIN NEUROPHYSIOL, V115, P1332, DOI 10.1016/j.clinph.2003.12.029; Pollonini L, 2010, IEEE ENG MED BIO, P1730, DOI 10.1109/IEMBS.2010.5626702; Richiardi J, 2011, NEUROIMAGE, V56, P616, DOI 10.1016/j.neuroimage.2010.05.081; Roffo G, 2017, ARXIV170707538; Roffo G., 2016, ARXIV160701327; Roffo G., 2017, RANKING TO LEARN; Shah Y, 2000, GERIATRICS, V55, P62; Sheffield JM, 2015, NEUROPSYCHOLOGIA, V73, P82, DOI 10.1016/j.neuropsychologia.2015.05.006; Shen X, 2010, NEUROIMAGE, V50, P1027, DOI 10.1016/j.neuroimage.2009.12.119; Song M, 2008, NEUROIMAGE, V41, P1168, DOI 10.1016/j.neuroimage.2008.02.036; Sotero RC, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005180; Sotero RC, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00454; Spaak E, 2012, CURR BIOL, V22, P2313, DOI 10.1016/j.cub.2012.10.020; Stam CJ, 2006, NEUROIMAGE, V32, P1335, DOI 10.1016/j.neuroimage.2006.05.033; Stam CJ, 2002, PHYSICA D, V163, P236, DOI 10.1016/S0167-2789(01)00386-4; Szczepanski SM, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001936; Takahashi RH, 2010, NEUROBIOL AGING, V31, P1145, DOI 10.1016/j.neurobiolaging.2008.07.021; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Tewarie P, 2015, NEUROIMAGE, V104, P177, DOI 10.1016/j.neuroimage.2014.10.015; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Wang JH, 2013, BIOL PSYCHIAT, V73, P472, DOI 10.1016/j.biopsych.2012.03.026; Wang SH, 2018, NEUROIMAGE, V173, P610, DOI 10.1016/j.neuroimage.2018.01.056; Yu EY, 2017, CURR ALZHEIMER RES, V14, P628, DOI 10.2174/1567205013666161201201000; Yu MC, 2017, BRAIN, V140, P1466, DOI 10.1093/brain/awx050	106	17	17	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JUN 1	2018	12								306	10.3389/fnins.2018.00306			21	Neurosciences	Neurosciences & Neurology	GH8DC	WOS:000433896200001	29910704	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Sarnaik, A; Ferguson, NM; O'Meara, AMI; Agrawal, S; Deep, A; Buttram, S; Bell, MJ; Wisniewski, SR; Luther, JF; Hartman, AL; Vavilala, MS				Sarnaik, Ajit; Ferguson, Nikki Miller; O'Meara, A. M. Iqbal; Agrawal, Shruti; Deep, Akash; Buttram, Sandra; Bell, Michael J.; Wisniewski, Stephen R.; Luther, James F.; Hartman, Adam L.; Vavilala, Monica S.		ADAPT Trial	Age and Mortality in Pediatric Severe Traumatic Brain Injury: Results from an International Study	NEUROCRITICAL CARE			English	Article						Pediatric traumatic brain injury; Age; Comparative effectiveness research; Pediatric neurocritical care; Secondary injuries	SEVERE HEAD-INJURY; YOUNG-CHILDREN; PREDICTIVE FACTORS; LESIONS; HYPOTHERMIA; PLASTICITY; RECOVERY; RATS; VULNERABILITY; MECHANISMS	Although small series have suggested that younger age is associated with less favorable outcome after severe traumatic brain injury (TBI), confounders and biases have limited our understanding of this relationship. We hypothesized that there would be an association between age and mortality in children within an ongoing observational, cohort study. The first 200 subjects from the Approaches and Decisions for Acute Pediatric TBI trial were eligible for this analysis (inclusion criteria: severe TBI (Glasgow Coma Scale [GCS] score ae<currency> 8], age 18 years, and intracranial pressure (ICP) monitor placed; exclusion: pregnancy). Children with suspected abusive head trauma (AHT) were excluded to avoid bias related to the association between AHT and mortality. Demographics, and prehospital and resuscitation events were collected/analyzed, and children were stratified based on age at time of injury (< 5, 5-< 11, 11-18 years) and presented as mean +/- standard error of the mean (SEM). Analyses of variance were used to test the equality of the means across the group for continuous variable, and Chi-square tests were used to compare percentages for discrete variables (post hoc comparisons were made using t test and Bonferroni corrections, as needed). Kaplan-Meier curves were generated for each age subgroup describing the time of death, and log-rank was used to compare the curves. Cox proportional hazards regression models were used to assess the effect of age on time to death while controlling for covariates. In the final cohort (n = 155, 45 excluded for AHT), overall age was 9.2 years +/- 0.4 and GCS was 5.3 +/- 0.1. Mortality was similar between strata (14.0, 20.0, 20.9%, respectively, p = 0.58). Motor vehicle accidents were the most common mechanism across all strata, while falls tended to be more common in the youngest stratum (p = 0.08). The youngest stratum demonstrated increased incidence of spontaneous hypothermia at presentation and decreased hemoglobin concentrations and coagulopathies, while the oldest demonstrated lower platelet counts. In contrast to previous reports, we failed to detect mortality differences across age strata in children with severe TBI. We have discerned novel associations between age and various markers of injury-unrelated to AHT-that may lead to testable hypotheses in the future.	[Sarnaik, Ajit] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Ferguson, Nikki Miller; O'Meara, A. M. Iqbal] Virginia Commonwealth Univ, Dept Pediat, Richmond, VA USA; [Agrawal, Shruti] Addenbrookes Hosp, Dept Pediat, Cambridge, England; [Deep, Akash] Kings Coll Hosp London, Dept Pediat, London, England; [Buttram, Sandra] Phoenix Childrens Hosp, Dept Pediat, Phoenix, AZ USA; [Bell, Michael J.] Univ Pittsburgh, Crit Care Med Neurol Surg & Pediat, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.; Luther, James F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Pain Med, Seattle, WA 98195 USA; [Hartman, Adam L.] NINDS, Off Clin Res, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	Bell, MJ (corresponding author), Univ Pittsburgh, Crit Care Med Neurol Surg & Pediat, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Ferguson, Nikki Miller/AAA-4548-2020; Hartman, Adam/W-9782-2019	Hartman, Adam/0000-0001-5672-3409; Figaji, Anthony/0000-0002-3357-6490; , Alia Marie/0000-0003-3158-7943; Bennett, Tellen/0000-0003-1483-4236; Edwards, Richard/0000-0001-8415-2180; Kilbaugh, Todd/0000-0002-4959-3092	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS081041]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS081041] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number U01 NS081041. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CDC, TRAUMATIC BRAIN INJU; CDC, TRAUM BRAIN INJ US; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Davies FC, 2015, EMERG MED J, V32, P921, DOI 10.1136/emermed-2015-205285; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Moran LM, 2016, J INT NEUROPSYCH SOC, V22, P512, DOI 10.1017/S1355617716000175; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Treble-Barna A, 2016, DEV PSYCHOL, V52, P1777, DOI 10.1037/dev0000208; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Villablanca JR, 1998, DEV BRAIN RES, V105, P309, DOI 10.1016/S0165-3806(97)00187-9	37	17	17	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2018	28	3					302	313		10.1007/s12028-017-0480-x			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	GK8EB	WOS:000436449800007	29476389				2021-06-18	
J	Staerk, L; Fosbol, EL; Lamberts, M; Bonde, AN; Gadsboll, K; Sindet-Pedersen, C; Holm, EA; Gerds, TA; Ozenne, B; Lip, GYH; Torp-Pedersen, C; Gislason, GH; Olesen, JB				Staerk, Laila; Fosbol, Emil Loldrup; Lamberts, Morten; Bonde, Anders Nissen; Gadsboll, Kasper; Sindet-Pedersen, Caroline; Holm, Ellen A.; Gerds, Thomas Alexander; Ozenne, Brice; Lip, Gregory Y. H.; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar; Olesen, Jonas Bjerring			Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study	EUROPEAN HEART JOURNAL			English	Article						Atrial fibrillation; Traumatic injury; Oral anticoagulation; Warfarin; NOAC; Bleeding	MORTALITY; HEMORRHAGE; GUIDELINES; DABIGATRAN; VALIDITY; TRENDS; USAGE; FALL; AGE	Aims We examined the risks of all-cause mortality, stroke, major bleeding, and recurrent traumatic injury associated with resumption of vitamin K antagonists (VKAs) and non-VKAs oral anticoagulants (NOACs) following traumatic injury in atrial fibrillation (AF) patients. Methods and results This was a Danish nationwide registry-based study (2005-16), including 4541 oral anticoagulant (OAC)-treated AF patients experiencing traumatic injury (defined as traumatic brain injury, hip fracture, or traumatic torso or abdominal injury). Within 90 days following discharge from traumatic injury, 60.6% resumed VKA (median age = 80, CHA(2)DS(2)-VASc = 4, HAS-BLED = 2), 16.7% resumed NOAC (median age = 81, CHA(2)DS(2)-VASc = 4, HAS-BLED = 2), and 22.7% did not resume OAC treatment (median age = 81, CHA(2)DS(2)-VASc= 4, HAS-BLED = 3). Switch from VKA to NOAC occurred among 9.5%. Since 2009, the trend in OAC resumption increased (P-value <0.0001), in particular with NOACs (P-value <0.0001). Follow-up started 90 days after discharge, and time-varying multiple Cox regression analyses were used for comparisons. Compared with non-resumption, VKA and NOAC resumption were associated with lower hazard [95% confidence interval (CI)] of all-cause mortality [hazard ratio (HR) 0.48 (0.42-0.53) and HR 0.55 (0.47-0.66), respectively] and ischaemic stroke [HR 0.56 (0.43-0.72) and HR 0.54 (0.35-0.82), respectively], increased major bleeding hazard [HR 1.30 (1.03 1.64) and HR 1.15 (0.81 1.63), respectively], and similar hazard of recurrent traumatic injury [HR 0.93 (0.73-1.18) and HR 0.87 (0.60-1.27), respectively]. Conclusion AF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.	[Staerk, Laila; Lamberts, Morten; Bonde, Anders Nissen; Gadsboll, Kasper; Sindet-Pedersen, Caroline; Gislason, Gunnar Hilmar; Olesen, Jonas Bjerring] Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Kildegaardsvej 28, DK-2900 Hellerup, Denmark; [Fosbol, Emil Loldrup; Lamberts, Morten] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark; [Fosbol, Emil Loldrup; Gislason, Gunnar Hilmar] Danish Heart Assoc, Vognmagergade 7, DK-1120 Copenhagen K, Denmark; [Holm, Ellen A.] Nykobing F Hosp, Dept Internal Med, Fjordvej 15, DK-4800 Nykobing, Denmark; [Gerds, Thomas Alexander; Ozenne, Brice] Univ Copenhagen, Sect Biostat, Dept Publ Hlth, Oster Farimagsgade 5, DK-1353 Copenhagen K, Denmark; [Lip, Gregory Y. H.] Univ Birmingham, Inst Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; [Lip, Gregory Y. H.] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Fredrik Bajers Vej 5, DK-9100 Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ Hosp, Dept Cardiol & Clin Epidemiol, Hobrovej 18-22, DK-9100 Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ, Dept Hlth Sci & Technol, Fredrik Bajers Vej 5, DK-9100 Aalborg, Denmark; [Gislason, Gunnar Hilmar] Univ Copenhagen, Fac Hlth & Med Sci, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark; [Gislason, Gunnar Hilmar] Univ Southern Denmark, Natl Inst Publ Hlth, Oster Farimagsgade 5, DK-1353 Copenhagen K, Denmark	Staerk, L (corresponding author), Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Kildegaardsvej 28, DK-2900 Hellerup, Denmark.	lailastaerk@gmail.com	Gislason, Gunnar H/B-7561-2009	Gislason, Gunnar H/0000-0002-0548-402X; Holm, Ellen Astrid/0000-0002-7600-6025; Bonde, Anders Nissen/0000-0001-6794-8726; Lamberts, Morten/0000-0002-9827-440X; Gerds, Thomas Alexander/0000-0002-5955-816X; Fosbol, Emil/0000-0002-2048-4167	Velux Foundations; Boehringer-IngelheimBoehringer Ingelheim; Novo Nordisk FoundationNovo Nordisk Foundation	This work was supported by the Velux Foundations and Boehringer-Ingelheim. The sponsors had no influence on the study design, interpretation of results, or the decision to submit the manuscript for publication. G.H.G. is supported by an unrestricted clinical research scholarship from the Novo Nordisk Foundation.	AALEN OO, 1978, SCAND J STAT, V5, P141; Alamneh EA, 2016, AM J CARDIOVASC DRUG, V16, P183, DOI 10.1007/s40256-016-0161-8; Albrecht JS, 2014, JAMA INTERN MED, V174, P1244, DOI 10.1001/jamainternmed.2014.2534; BENICHOU J, 1990, BIOMETRICS, V46, P813, DOI 10.2307/2532098; de Vries OJ, 2013, AGE AGEING, V42, P764, DOI 10.1093/ageing/aft089; Frost L, 2007, AM J MED, V120, P47, DOI 10.1016/j.amjmed.2005.12.027; Hadjizacharia P, 2011, AM SURGEON, V77, P634; Healey JS, 2016, LANCET, V388, P1161, DOI 10.1016/S0140-6736(16)30968-0; Hundrup YA, 2004, SCAND J PUBLIC HEALT, V32, P136, DOI 10.1080/14034940310017490; Hylek EM, 2006, STROKE, V37, P1075, DOI 10.1161/01.STR.0000209239.71702.ce; Inui TS, 2014, J TRAUMA ACUTE CARE, V76, P642, DOI 10.1097/TA.0000000000000138; Jorgensen TSH, 2014, SCAND J PUBLIC HEALT, V42, P287, DOI 10.1177/1403494813516831; Kakkar AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063479; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Liu XG, 2015, J CLIN PHARMACOL, V55, P25, DOI 10.1002/jcph.375; Majdan M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008672; Olesen JB, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d124; Park YJ, 2016, AM J EMERG MED, V34, P515, DOI 10.1016/j.ajem.2015.12.024; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000; Sabouret P, 2015, ARCH CARDIOVASC DIS, V108, P544, DOI 10.1016/j.acvd.2015.05.005; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Staerk L, 2016, SCI REP-UK, V6, DOI 10.1038/srep31477; Staerk L, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5876; Stollberger C, 2016, NEUROL NEUROCHIR POL, V50, P200, DOI 10.1016/j.pjnns.2016.01.012; Stollberger C, 2015, J GERIATR CARDIOL, V12, P83, DOI 10.11909/j.issn.1671-5411.2015.01.010; Torstensson M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009522	31	17	17	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0195-668X	1522-9645		EUR HEART J	Eur. Heart J.	MAY 14	2018	39	19					1698	+		10.1093/eurheartj/ehx598			9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	GG4ST	WOS:000432687200010	29165556	Bronze			2021-06-18	
J	Takayama, W; Endo, A; Koguchi, H; Sugimoto, M; Murata, K; Otomo, Y				Takayama, Wataru; Endo, Akira; Koguchi, Hazuki; Sugimoto, Momoko; Murata, Kiyoshi; Otomo, Yasuhiro			The impact of blood type O on mortality of severe trauma patients: a retrospective observational study	CRITICAL CARE			English	Article						ABO blood type; Bleeding; Trauma; Exsanguination; Von Willebrand factor	VON-WILLEBRAND-FACTOR; METAANALYSIS; DISEASE; HEMOSTASIS; SCORE	Background: Recent studies have implicated the differences in the ABO blood system as a potential risk for various diseases, including hemostatic disorders and hemorrhage. In this study, we evaluated the impact of the difference in the ABO blood type on mortality in patients with severe trauma. Methods: A retrospective observational study was conducted in two tertiary emergency critical care medical centers in Japan. Patients with trauma with an Injury Severity Score (ISS) > 15 were included. The association between the different blood types (type O versus other blood types) and the outcomes of all-cause mortality, cause-specific mortalities (exsanguination, traumatic brain injury, and others), ventilator-free days (VFD), and total transfusion volume were evaluated using univariate and multivariate competing-risk regression models. Moreover, the impact of blood type O on the outcomes was assessed using regression coefficients in the multivariate analysis adjusted for age, ISS, and the Revised Trauma Score (RTS). Results: A total of 901 patients were included in this study. The study population was divided based on the ABO blood type: type O, 284 (32%); type A, 285 (32%); type B, 209 (23%); and type AB, 123 (13%). Blood type O was associated with high mortality (28% in patients with blood type O versus 11% in patients with other blood types; p < 0.001). Moreover, this association was observed in a multivariate model (adjusted odds ratio = 2.86, 95% confidence interval 1.84-4.46; p < 0.001). The impact of blood type O on all-cause in-hospital mortality was comparable to 12 increases in the ISS, 1.5 decreases in the RTS, and 26 increases in age. Furthermore, blood type O was significantly associated with higher cause-specific mortalities and shorter VFD compared with the other blood types; however, a significant difference was not observed in the transfusion volume between the two groups. Conclusions: Blood type O was significantly associated with high mortality in severe trauma patients and might have a great impact on outcomes. Further studies elucidating the mechanism underlying this association are warranted to develop the appropriate intervention.	[Takayama, Wataru; Endo, Akira; Otomo, Yasuhiro] Tokyo Med & Dent Univ Hosp Med, Trauma & Acute Crit Care Med Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1130034, Japan; [Koguchi, Hazuki; Sugimoto, Momoko; Murata, Kiyoshi] Matsudo City Hosp, Shock Trauma & Emergency Med Ctr, 4005 Kamihongo, Matsudo, Chiba, Japan	Takayama, W (corresponding author), Tokyo Med & Dent Univ Hosp Med, Trauma & Acute Crit Care Med Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1130034, Japan.	tak2accm@tmd.ac.jp	Endo, Akira/AAL-8535-2021		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K10969] Funding Source: KAKEN		[Anonymous], 1971, JAMA, V215, P277; Bayan K, 2009, DIGEST DIS SCI, V54, P1029, DOI 10.1007/s10620-008-0446-0; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chauleur C, 2008, J THROMB HAEMOST, V6, P2067, DOI 10.1111/j.1538-7836.2008.03168.x; Dentali F, 2013, SEMIN THROMB HEMOST, V39, P72, DOI 10.1055/s-0032-1329550; Dentali F, 2012, SEMIN THROMB HEMOST, V38, P535, DOI 10.1055/s-0032-1315758; GILL JC, 1987, BLOOD, V69, P1691; Jenkins PV, 2006, TRANSFUSION, V46, P1836, DOI 10.1111/j.1537-2995.2006.00975.x; Kruskall MS, 1997, TRANSFUS SCI, V18, P613, DOI 10.1016/S0955-3886(97)90148-X; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mazzeffi M, 2017, INTENS CARE MED, V43, P275, DOI 10.1007/s00134-016-4568-0; Moeller A, 2001, TRANSFUSION, V41, P56, DOI 10.1046/j.1537-2995.2001.41010056.x; O'Donnell J, 2001, TRANSFUSION MED, V11, P343, DOI 10.1046/j.1365-3148.2001.00315.x; Reilly JP, 2015, CLIN J AM SOC NEPHRO, V10, P1911, DOI 10.2215/CJN.12201214; RUGGERI ZM, 1987, BLOOD, V70, P895; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Sun WJ, 2015, CANCER EPIDEMIOL, V39, P150, DOI 10.1016/j.canep.2014.12.006; Wu O, 2008, J THROMB HAEMOST, V6, P62	19	17	18	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	MAY 2	2018	22								100	10.1186/s13054-018-2022-0			7	Critical Care Medicine	General & Internal Medicine	GE6QK	WOS:000431353900001	29716619	DOAJ Gold, Green Published			2021-06-18	
J	LoBue, C; Woon, FL; Rossetti, HC; Hynan, LS; Hart, J; Cullum, CM				LoBue, Christian; Woon, Fu L.; Rossetti, Heidi C.; Hynan, Linda S.; Hart, John, Jr.; Cullum, C. Munro			Traumatic Brain Injury History and Progression from Mild Cognitive Impairment to Alzheimer Disease	NEUROPSYCHOLOGY			English	Article						head injury; cognitive decline; mild cognitive impairment; dementia; risk	HEAD-INJURY; RISK-FACTOR; DEMENTIA; PATHOLOGY; ASSOCIATION; PREDICTION; DIAGNOSIS; AGE	Objective: To examine whether history of traumatic brain injury (TBI) is associated with more rapid progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Method: Data from 2,719 subjects with MCI were obtained from the National Alzheimer's Coordinating Center. TBI was categorized based on presence (TBI+) or absence (TBI-) of reported TBI with loss of consciousness (LOC) without chronic deficit occurring >1 year prior to diagnosis of MCI. Survival analyses were used to determine if a history of TBI predicted progression from MCI to AD up to 8 years. Random regression models were used to examine whether TBI history also predicted rate of decline on the Clinical Dementia Rating scale Sum of Boxes score (CDR-SB) among subjects who progress to AD. Results: Across 8 years, TBI history was not significantly associated with progression from MCI to a diagnosis of AD in unadjusted (HR = 0.80; 95% CI [0.63, 1.01]; p = .06) and adjusted (p = .15) models. Similarly, a history of TBI was a nonsignificant predictor for rate of decline on CDR-SB among subjects who progressed to AD (b = 0.15, p = .38). MCI was, however, diagnosed a mean of 2.6 years earlier (p < .001) in TBI+ subjects compared with the TBI-group. Conclusions: A history of TBI with LOC was not associated with progression from MCI to AD, but was linked to an earlier age of MCI diagnosis. These findings add to a growing literature suggesting that TBI might reduce the threshold for onset of MCI and certain neurodegenerative conditions, but appears unrelated to progression from MCI to AD.	[LoBue, Christian; Rossetti, Heidi C.; Hynan, Linda S.; Hart, John, Jr.] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75208 USA; [Woon, Fu L.] Univ Texas, Dell Med Sch, Seton Brain & Spine Inst, Dept Neurol, Austin, TX USA; [Hynan, Linda S.] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Richardson, TX 75083 USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dept Neurol & Neurotherapeut, Dallas, TX USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA	LoBue, C (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75208 USA.	christian.lobue@utsouthwestern.edu	Hynan, Linda S/P-6473-2016; Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P3012300-19]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG012300, U01AG016976] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health under grant number P3012300-19.	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Attems J, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0206-2; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Cedarbaum JM, 2013, ALZHEIMERS DEMENT, V9, pS45, DOI 10.1016/j.jalz.2011.11.002; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Exalto LG, 2014, ALZHEIMERS DEMENT, V10, P562, DOI 10.1016/j.jalz.2013.05.1772; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Farias ST, 2009, ARCH NEUROL-CHICAGO, V66, P1151, DOI 10.1001/archneurol.2009.106; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gilbert M, 2014, INT PSYCHOGERIATR, V26, P1593, DOI 10.1017/S1041610214000842; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Koepsell TD, 2012, NEUROLOGY, V79, P1591, DOI 10.1212/WNL.0b013e31826e26b7; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Petersen R C, 2000, Neurologia, V15, P93; Petersen RC, 2005, ARCH NEUROL-CHICAGO, V62, P1160, DOI 10.1001/archneur.62.7.1160; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rodrigue KM, 2012, NEUROLOGY, V78, P387, DOI 10.1212/WNL.0b013e318245d295; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tyas SL, 2007, AM J EPIDEMIOL, V165, P1231, DOI 10.1093/aje/kwm085; Vos SJB, 2013, NEUROLOGY, V80, P1124, DOI 10.1212/WNL.0b013e318288690c; Xu W, 2015, J NEUROL NEUROSUR PS, V86, P1299, DOI 10.1136/jnnp-2015-310548; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	37	17	18	0	16	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2018	32	4					401	409		10.1037/neu0000431			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	GH1GU	WOS:000433151900003	29809031	Bronze, Green Accepted			2021-06-18	
J	Vascak, M; Jin, XT; Jacobs, KM; Povlishock, JT				Vascak, Michal; Jin, Xiaotao; Jacobs, Kimberle M.; Povlishock, John T.			Mild Traumatic Brain Injury Induces Structural and Functional Disconnection of Local Neocortical Inhibitory Networks via Parvalbumin Interneuron Diffuse Axonal Injury	CEREBRAL CORTEX			English	Article						concussion; diffuse axonal injury; excitation/inhibition; fast-spiking; gray matter	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; WHITE-MATTER; CEREBRAL-CORTEX; CORTICAL INTERNEURONS; GAMMA-OSCILLATIONS; POSTTRAUMATIC EPILEPSY; COGNITIVE IMPAIRMENT; ANTIGEN RETRIEVAL; NEURONAL CIRCUITS	Diffuse axonal injury (DAI) plays a major role in cortical network dysfunction posited to cause excitatory/inhibitory imbalance after mild traumatic brain injury (mTBI). Current thought holds that white matter (WM) is uniquely vulnerable to DAI. However, clinically diagnosed mTBI is not always associated with WM DAI. This suggests an undetected neocortical pathophysiology, implicating GABAergic interneurons. To evaluate this possibility, we used mild central fluid percussion injury to generate DAI in mice with Cre-driven tdTomato labeling of parvalbumin (PV) intemeurons. We followed tdTomato+ profiles using confocal and electron microscopy, together with patch-clamp analysis to probe for DAI-mediated neocortical GABAergic interneuron disruption. Within 3 h post-mTBI tdTomato+ perisomatic axonal injury (PSAI) was found across somatosensory layers 2-6. The DAI marker amyloid precursor protein colocalized with GAD67 immunoreactivity within tdTomato+ PSAI, representing the majority of GABAergic intemeuron DAI. At 24 h post-mTBI, we used phospho-c-Jun, a surrogate DAI marker, for retrograde assessments of sustaining somas. Via this approach, we estimated DAI occurs in similar to 9% of total tdTomato+ interneurons, representing similar to 14% of pan-neuronal DAI. Patch-clamp recordings of tdTomato+ interneurons revealed decreased inhibitory transmission. Overall, these data show that PV interneuron DAI is a consistent and significant feature of experimental mTBI with important implications for cortical network dysfunction.	[Vascak, Michal; Jin, Xiaotao; Jacobs, Kimberle M.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	john.povlishock@vcuhealth.org	Jacobs, Kimberle/AAW-7526-2020	Vascak, Michal/0000-0001-8916-0796	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077675] Funding Source: NIH RePORTER	National Institutes of Health (grant NS077675).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Atallah BV, 2009, NEURON, V62, P566, DOI 10.1016/j.neuron.2009.04.027; BAHMANYAR S, 1987, SCIENCE, V237, P77, DOI 10.1126/science.3299701; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beamer M, 2016, EXP NEUROL, V283, P16, DOI 10.1016/j.expneurol.2016.05.025; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Buki A, 2000, J NEUROSCI, V20, P2825; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2007, NEURON, V56, P771, DOI 10.1016/j.neuron.2007.11.008; Buzsaki G, 2012, ANNU REV NEUROSCI, V35, P203, DOI 10.1146/annurev-neuro-062111-150444; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Cardin JA, 2009, NATURE, V459, P663, DOI 10.1038/nature08002; Carlo CN, 2013, P NATL ACAD SCI USA, V110, P1488, DOI 10.1073/pnas.1221398110; Carron SF, 2016, J COMP NEUROL, V524, P3530, DOI 10.1002/cne.24014; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CDC, 2003, C MILD TRAUM BRAIN I; Cesarovic N, 2010, LAB ANIM-UK, V44, P329, DOI 10.1258/la.2010.009085; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cole JT, 2010, P NATL ACAD SCI USA, V107, P2373, DOI 10.1073/pnas.1000184107; CRICK FHC, 1979, SCI AM, V241, P219, DOI 10.1038/scientificamerican0979-219; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DEFELIPE J, 1992, PROG NEUROBIOL, V39, P563, DOI 10.1016/0301-0082(92)90015-7; Delouche A, 2016, EUR J RADIOL, V85, P25, DOI 10.1016/j.ejrad.2015.11.004; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Doron G, 2014, NEURON, V81, P653, DOI 10.1016/j.neuron.2013.11.032; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; Douglas RJ, 2007, CURR BIOL, V17, pR496, DOI 10.1016/j.cub.2007.04.024; Egeblad M., 2011, COLD SPRING HARB PRO, V2011, P174; ERB DE, 1991, EXP BRAIN RES, V83, P253; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fish KN, 2011, CEREB CORTEX, V21, P2450, DOI 10.1093/cercor/bhr007; Fries P, 2009, ANNU REV NEUROSCI, V32, P209, DOI 10.1146/annurev.neuro.051508.135603; Gentet LJ, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00052; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Grimm KA., 2015, VET ANESTHESIA ANALG, V5th ed; Grubb MS, 2010, CURR OPIN NEUROBIOL, V20, P481, DOI 10.1016/j.conb.2010.04.012; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gulyas AI, 1999, J NEUROSCI, V19, P10082; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Haider B, 2009, NEURON, V62, P171, DOI 10.1016/j.neuron.2009.04.008; Hanell A, 2015, J NEUROTRAUM, V32, P1590, DOI 10.1089/neu.2014.3592; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Hangya B, 2014, CURR OPIN NEUROBIOL, V26, P117, DOI 10.1016/j.conb.2014.01.007; Hasenstaub A, 2005, NEURON, V47, P423, DOI 10.1016/j.neuron.2005.06.016; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; Howard MW, 2003, CEREB CORTEX, V13, P1369, DOI 10.1093/cercor/bhg084; Hsieh TH, 2017, CEREB CORTEX, V27, P5509, DOI 10.1093/cercor/bhw318; Hu H, 2014, SCIENCE, V345, P529, DOI 10.1126/science.1255263; Huang MX, 2017, J NEUROTRAUM, V34, P1412, DOI 10.1089/neu.2016.4581; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Isaacson JS, 2011, NEURON, V72, P231, DOI 10.1016/j.neuron.2011.09.027; Jiao Y, 1999, J NEUROSCI METH, V93, P149, DOI 10.1016/S0165-0270(99)00142-9; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kanaani J, 2010, J CELL BIOL, V190, P911, DOI 10.1083/jcb.200912101; Kann O, 2016, NEUROBIOL DIS, V90, P75, DOI 10.1016/j.nbd.2015.08.005; Kann O, 2014, J CEREBR BLOOD F MET, V34, P1270, DOI 10.1038/jcbfm.2014.104; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kepecs A, 2014, NATURE, V505, P318, DOI 10.1038/nature12983; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kole MHP, 2012, NEURON, V73, P235, DOI 10.1016/j.neuron.2012.01.007; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhlman SJ, 2013, NATURE, V501, P543, DOI 10.1038/nature12485; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lazarus MS, 2015, CEREB CORTEX, V25, P1290, DOI 10.1093/cercor/bht322; Lifshitz J, 2016, BRAIN INJURY, V30, P1; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Lorincz A, 2008, J NEUROSCI, V28, P9083, DOI 10.1523/JNEUROSCI.2494-08.2008; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Manning CF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038313; Mannix R, 2016, NAT REV NEUROL, V12, P486, DOI 10.1038/nrneurol.2016.99; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCormick DA, 2003, CEREB CORTEX, V13, P1219, DOI 10.1093/cercor/bhg104; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Packer AM, 2011, J NEUROSCI, V31, P13260, DOI 10.1523/JNEUROSCI.3131-11.2011; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Patel VC, 2017, EXP NEUROL, V289, P85, DOI 10.1016/j.expneurol.2016.12.012; Paterno R, 2016, J NEUROTRAUM, V33, P1645, DOI 10.1089/neu.2015.4107; Perrais D, 2000, EUR J NEUROSCI, V12, P400, DOI 10.1046/j.1460-9568.2000.00957.x; Pfeffer CK, 2013, NAT NEUROSCI, V16, P1068, DOI 10.1038/nn.3446; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 2001, HEAD TRAUMA, P281; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reichle ME, 2010, TRENDS COGN SCI, V14, P180, DOI 10.1016/j.tics.2010.01.008; Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scholl B, 2015, NEURON, V87, P424, DOI 10.1016/j.neuron.2015.06.030; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sohal VS, 2009, NATURE, V459, P698, DOI 10.1038/nature07991; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Sun JL, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00063, 10.3389/hsys.2015.00063]; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; Taniguchi H, 2011, NEURON, V71, P995, DOI 10.1016/j.neuron.2011.07.026; Trachtenberg JT, 2015, NEURON, V87, P247, DOI 10.1016/j.neuron.2015.06.041; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; van der Horn HJ, 2017, J NEUROTRAUM, V34, P1035, DOI 10.1089/neu.2016.4659; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Walhovd KB, 2014, NEUROSCIENCE, V276, P2, DOI 10.1016/j.neuroscience.2014.06.058; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Williams SR, 2008, NAT NEUROSCI, V11, P790, DOI 10.1038/nn.2137; Wolf JA, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00043; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Zhang DY, 2010, NAT REV NEUROL, V6, P15, DOI 10.1038/nrneurol.2009.198; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhou FW, 2009, J NEUROPHYSIOL, V102, P2514, DOI 10.1152/jn.00557.2009	161	17	17	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	MAY	2018	28	5					1625	1644		10.1093/cercor/bhx058			20	Neurosciences	Neurosciences & Neurology	GF3XH	WOS:000431890800006	28334184	Bronze, Green Published			2021-06-18	
J	Watanitanon, A; Lyons, VH; Lele, AV; Krishnamoorthy, V; Chaikittisilpa, N; Chandee, T; Vavilala, MS				Watanitanon, Arraya; Lyons, Vivian H.; Lele, Abhijit V.; Krishnamoorthy, Vijay; Chaikittisilpa, Nophanan; Chandee, Theerada; Vavilala, Monica S.			Clinical Epidemiology of Adults With Moderate Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						adult; facility; moderate; trauma designation; traumatic brain injury	HEAD-INJURY; DIAGNOSIS; OUTCOMES; CLASSIFICATION; TALK; AGE	Objectives: To characterize admission patterns, treatments, and outcomes among patients with moderate traumatic brain injury. Design: Retrospective cohort study. Setting: National Trauma Data Bank. Patients: Adults (age > 18 yr) with moderate traumatic brain injury (International Classification of Diseases, Ninth revision codes and admission Glasgow Coma Scale score of 9-13) in the National Trauma Data Bank between 2007 and 2014. Interventions: None. Measurement and Main Results: Demographics, mechanism of injury, hospital course, and facility characteristics were examined. Admission characteristics associated with discharge outcomes were analyzed using multivariable Poisson regression models. Of 114,066 patients, most were white (62%), male (69%), and had median admission Glasgow Coma Scale score of 12 (interquartile range, 10-13). Seventy-seven percent had isolated traumatic brain injury. Concussion, which accounted for 25% of moderate traumatic brain injury, was the most frequent traumatic brain injury diagnosis. Fourteen percent received mechanical ventilation, and 66% were admitted to ICU. Over 50% received care at a community hospital. Seven percent died, and 32% had a poor outcome, including those with Glasgow Coma Scale score of 13. Compared with patients 18-44 years, patients 45-64 years were twice as likely (adjusted relative risk, 1.97; 95% CI, 1.92-2.02) and patients over 80 years were five times as likely (adjusted relative risk, 4.66; 95% CI, 4.55-4.76) to have a poor outcome. Patients with a poor discharge outcome were more likely to have had hypotension at admission (adjusted relative risk, 1.10; 95% CI, 1.06-1.14), lower admission Glasgow Coma Scale (adjusted relative risk, 1.37; 95% CI, 1.34-1.40), higher Injury Severity Score (adjusted relative risk, 2.97; 95% CI, 2.86-3.09), and polytrauma (adjusted relative risk, 1.05; 95% CI, 1.02-1.07), compared with those without poor discharge outcomes. Conclusions: Many patients with moderate traumatic brain injury deteriorate, require neurocritical care, and experience poor outcomes. Optimization of care and outcomes for this vulnerable group of patients are urgently needed.	[Watanitanon, Arraya; Lele, Abhijit V.; Chaikittisilpa, Nophanan; Chandee, Theerada; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Watanitanon, Arraya; Lyons, Vivian H.; Krishnamoorthy, Vijay; Chaikittisilpa, Nophanan; Chandee, Theerada; Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Lyons, Vivian H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Krishnamoorthy, Vijay] Duke Univ, Dept Anesthesiol, Durham, NC USA	Watanitanon, A (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.; Watanitanon, A (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA.	arrayawat@gmail.com			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Dr. Lele's institution received funding from the National Institutes of Health (NIH). Dr. Vavilala received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Godoy DA, 2016, NEUROCRIT CARE, V25, P306, DOI 10.1007/s12028-016-0253-y; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cnossen MC, 2017, CRIT CARE MED, V45, P660, DOI 10.1097/CCM.0000000000002263; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P122, DOI 10.1097/HTR.0000000000000012; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Johnson WD, 2017, LANCET NEUROL, V16, P949, DOI 10.1016/S1474-4422(17)30362-9; Joseph B, 2017, J TRAUMA ACUTE CARE, V82, P575, DOI 10.1097/TA.0000000000001329; Leo P., 2016, TRANSLATIONAL RES TR; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lund SB, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0269-5; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Peterson EC, 2011, J TRAUMA, V71, P1588, DOI 10.1097/TA.0b013e31822b791d; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Savitsky B, 2016, BRAIN INJURY, V30, P1194, DOI 10.1080/02699052.2016.1187290; Scott MS, 2011, GUIDELINES FIELD TRI; Shafiei E, 2016, ARCH TRAUMA RES, V5, DOI 10.5812/atr.29729; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; TEASDALE G, 1974, LANCET, V2, P81; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1	28	17	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2018	46	5					781	787		10.1097/CCM.0000000000002991			7	Critical Care Medicine	General & Internal Medicine	GN9ZK	WOS:000439573700039	29369057	Green Accepted			2021-06-18	
J	Boutin, ME; Kramer, LL; Livi, LL; Brown, T; Moore, C; Hoffman-Kim, D				Boutin, Molly E.; Kramer, Liana L.; Livi, Liane L.; Brown, Tyler; Moore, Christopher; Hoffman-Kim, Diane			A three-dimensional neural spheroid model for capillary-like network formation	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Brain; Cortex; Vasculogenesis; in vitro; Spheroid; Neurovascular unit; Capillary-like network; Cellular self-assembly; Endothelial cells	BLOOD-BRAIN-BARRIER; MICROVASCULAR ENDOTHELIAL-CELLS; DEVELOPING RAT-BRAIN; IN-VITRO MODEL; LUMEN FORMATION; ANGIOGENESIS; EXPRESSION; TISSUE; ADHESION; CULTURE	Background: In vitro three-dimensional neural spheroid models have an in vivo-like cell density, and have the potential to reduce animal usage and increase experimental throughput. The aim of this study was to establish a spheroid model to study the formation of capillary-like networks in a three-dimensional environment that incorporates both neuronal and glial cell types, and does not require exogenous vasculogenic growth factors. New method: We created self-assembled, scaffold-free cellular spheroids using primary-derived postnatal rodent cortex as a cell source. The interactions between relevant neural cell types, basement membrane proteins, and endothelial cells were characterized by immunohistochemistry. Transmission electron microscopy was used to determine if endothelial network structures had lumens. Results: Endothelial cells within cortical spheroids assembled into capillary-like networks with lumens. Networks were surrounded by basement membrane proteins, including laminin, fibronectin and collagen IV, as well as key neurovascular cell types. Comparison with existing method(s): Existing in vitro models of the cortical neurovascular environment study monolayers of endothelial cells, either on transwell inserts or coating cellular spheroids. These models are not well suited to study vasculogenesis, a process hallmarked by endothelial cell cord formation and subsequent lumenization. Conclusions: The neural spheroid is a new model to study the formation of endothelial cell capillary-like structures in vitro within a high cell density three-dimensional environment that contains both neuronal and glial populations. This model can be applied to investigate vascular assembly in healthy or disease states, such as stroke, traumatic brain injury, or neurodegenerative disorders. (C) 2017 Elsevier B.V. All rights reserved.	[Boutin, Molly E.; Livi, Liane L.; Hoffman-Kim, Diane] Brown Univ, Ctr Biomed Engn, 175 Meeting St, Providence, RI 02912 USA; [Boutin, Molly E.; Kramer, Liana L.; Livi, Liane L.; Hoffman-Kim, Diane] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, 175 Meeting St, Providence, RI 02912 USA; [Brown, Tyler; Moore, Christopher] Brown Univ, Dept Neurosci, 175 Meeting St, Providence, RI 02912 USA; [Brown, Tyler; Moore, Christopher; Hoffman-Kim, Diane] Brown Univ, Brown Inst Brain Sci, 175 Meeting St, Providence, RI 02912 USA; [Boutin, Molly E.] NCATS, NIH, 9800 Med Ctr Dr, Rockville, MD 20850 USA; [Kramer, Liana L.] Brown Univ, Box G-B3, Providence, RI 02912 USA; [Livi, Liane L.] Brown Univ, Box GB3, Providence, RI 02912 USA; [Brown, Tyler] 10 Cornelius Way, Cambridge, MA 02141 USA; [Moore, Christopher] Brown Univ, Box GL-N, Providence, RI 02912 USA	Hoffman-Kim, D (corresponding author), Brown Univ, Box G B3, Providence, RI 02912 USA.	mollyboutin@gmail.com; Liana_Kramer@brown.edu; Liane_Livi@brown.edu; tylerclarkbrown@gmail.com; Christopher_Moore@brown.edu; Diane_Hoffman-Kim@brown.edu			National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); Brown University Seed Grant; Brown Institute for Brain Science Normal Prince Neurosciences Institute New Frontiers Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HL110791]; National Institutes of Health NRSA Postdoctoral Award [F32NS078895]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL110791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS078895] Funding Source: NIH RePORTER	The authors would like to thank Shai Shabbah for assistance with multiphoton imaging, Paula Weston for excellent technical assistance with TEM, Ken Miller and Justin Fallon for helpful consultations regarding TEM, and Timothy Bertram, Jason Machan, and Jeffrey Morgan for helpful scientific discussions. Financial support was provided to Molly Boutin from the National Science Foundation Graduate Research Fellowship, and to Diane Hoffman-Kim from the Brown University Seed Grant, Brown Institute for Brain Science Normal Prince Neurosciences Institute New Frontiers Program, and National Institutes of Health 5R01HL110791. Financial support was provided to Tyler Brown from the National Institutes of Health NRSA Postdoctoral Award (F32NS078895), and to Tyler Brown and Christopher Moore from the Association of Migraine Disorders. Support for this research was provided in part by a generous gift from Donna McGraw Weiss '89 and Jason Weiss. Funding sources had no involvement in the preparation of this article.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009; Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d; Boutin ME, 2015, TISSUE ENG PART C-ME, V21, P292, DOI [10.1089/ten.TEC.2014.0296, 10.1089/ten.tec.2014.0296]; BREIER G, 1992, DEVELOPMENT, V114, P521; Calabria AR, 2008, J CEREBR BLOOD F MET, V28, P135, DOI 10.1038/sj.jcbfm.9600518; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Cho HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15222; Crabtree B, 2007, IN VITRO CELL DEV-AN, V43, P87, DOI 10.1007/s11626-007-9012-x; Cucullo L, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-18; Dingle YTL, 2015, TISSUE ENG PART C-ME, V21, P1274, DOI [10.1089/ten.tec.2015.0135, 10.1089/ten.TEC.2015.0135]; Eckermann CW, 2011, CELL BIOL INT, V35, P1097, DOI 10.1042/CBI20100718; Egginton S, 2003, MICROCIRCULATION, V10, P45, DOI 10.1038/sj.mn.7800174; EICHMANN A, 2013, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A006551; ERIKSDOTTERNILSSON M, 1986, J NEUROSCI METH, V17, P275, DOI 10.1016/0165-0270(86)90128-7; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; Griep LM, 2013, BIOMED MICRODEVICES, V15, P145, DOI 10.1007/s10544-012-9699-7; Hagan N, 2015, SEMIN CELL DEV BIOL, V38, P7, DOI 10.1016/j.semcdb.2014.12.006; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hutter-Schmid B., 2015, FRONT CELL DEV BIOL, V3; Kamei M, 2006, NATURE, V442, P453, DOI 10.1038/nature04923; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Kunz-Schughart LA, 2006, AM J PHYSIOL-CELL PH, V290, pC1385, DOI 10.1152/ajpcell.00248.2005; Kuwajima T, 2013, DEVELOPMENT, V140, P1364, DOI 10.1242/dev.091844; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Li YSJ, 2005, J BIOMECH, V38, P1949, DOI 10.1016/j.jbiomech.2004.09.030; Mokry J, 1999, Gen Physiol Biophys, V18 Suppl 1, P25; Mokry Jaroslav, 2008, Acta Medica (Hradec Kralove), V51, P173; Moore CI, 2008, J NEUROPHYSIOL, V99, P2035, DOI 10.1152/jn.01366.2006; Moya ML, 2013, TISSUE ENG PART C-ME, V19, P730, DOI [10.1089/ten.TEC.2012.0430, 10.1089/ten.tec.2012.0430]; Nakagawa S, 2007, CELL MOL NEUROBIOL, V27, P687, DOI 10.1007/s10571-007-9195-4; Napolitano AP, 2007, TISSUE ENG, V13, P2087, DOI 10.1089/ten.2006.0190; Newman AC, 2011, MOL BIOL CELL, V22, P3791, DOI 10.1091/mbc.E11-05-0393; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Page H, 2013, CELL TISSUE RES, V352, P123, DOI 10.1007/s00441-012-1441-5; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Prabhakarpandian B, 2013, LAB CHIP, V13, P1093, DOI 10.1039/c2lc41208j; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; Sacharidou A, 2012, CELLS TISSUES ORGANS, V195, P122, DOI 10.1159/000331410; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stratman AN, 2009, BLOOD, V114, P5091, DOI 10.1182/blood-2009-05-222364; Urich E, 2013, SCI REP-UK, V3, DOI 10.1038/srep01500; Urich E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038149; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Vallon M, 2014, CELL MOL LIFE SCI, V71, P3489, DOI 10.1007/s00018-014-1625-0; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xu K, 2011, SEMIN CELL DEV BIOL, V22, P993, DOI 10.1016/j.semcdb.2011.05.001; Xue Q, 2013, INT J BIOL SCI, V9, P174, DOI 10.7150/ijbs.5115; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	56	17	17	1	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	APR 1	2018	299						55	63		10.1016/j.jneumeth.2017.01.014			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GG9IN	WOS:000433014300007	28143748				2021-06-18	
J	Chung, S; Fieremans, E; Wang, XY; Kucukboyaci, NE; Morton, CJ; Babb, J; Amorapanth, P; Foo, FYA; Novikov, DS; Flanagan, SR; Rath, JF; Lui, YW				Chung, Sohae; Fieremans, Els; Wang, Xiuyuan; Kucukboyaci, Nuri E.; Morton, Charles J.; Babb, James; Amorapanth, Prin; Foo, Farng-Yang A.; Novikov, Dmitry S.; Flanagan, Steven R.; Rath, Joseph F.; Lui, Yvonne W.			White Matter Tract Integrity: An Indicator of Axonal Pathology after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion; kurtosis; mild traumatic brain injury; MRI; white matter tract integrity	DIFFUSION TENSOR; CORPUS-CALLOSUM; KURTOSIS; CONCUSSION; METRICS; QUANTIFICATION; DEMYELINATION; PREDICTORS; MRI	We seek to elucidate the underlying pathophysiology of injury sustained after mild traumatic brain injury (mTBI) using multi-shell diffusion magnetic resonance imaging, deriving compartment-specific white matter tract integrity (WMTI) metrics. WMTI allows a more biophysical interpretation of white matter (WM) changes by describing microstructural characteristics in both intra- and extra-axonal environments. Thirty-two patients with mTBI within 30 days of injury and 21 age- and sex-matched controls were imaged on a 3 Tesla magnetic resonance scanner. Multi-shell diffusion acquisition was performed with five b-values (250-2500sec/mm(2)) along 6-60 diffusion encoding directions. Tract-based spatial statistics (TBSS) was used with family-wise error (FWE) correction for multiple comparisons. TBSS results demonstrated focally lower intra-axonal diffusivity (D-axon) in mTBI patients in the splenium of the corpus callosum (sCC; p < 0.05, FWE-corrected). The area under the curve value for D-axon was 0.76 with a low sensitivity of 46.9% but 100% specificity. These results indicate that D-axon may be a useful imaging biomarker highly specific for mTBI-related WM injury. The observed decrease in D-axon suggests restriction of the diffusion along the axons occurring shortly after injury.	[Chung, Sohae; Fieremans, Els; Wang, Xiuyuan; Morton, Charles J.; Babb, James; Novikov, Dmitry S.; Lui, Yvonne W.] NYU, Sch Med, Ctr Adv Imaging Innovat & Res, Dept Radiol, New York, NY 10016 USA; [Chung, Sohae; Fieremans, Els; Wang, Xiuyuan; Morton, Charles J.; Babb, James; Novikov, Dmitry S.; Lui, Yvonne W.] NYU, Sch Med, Bernard & Irene Schwartz Ctr Biomed Imaging, Dept Radiol, New York, NY USA; [Kucukboyaci, Nuri E.; Amorapanth, Prin; Flanagan, Steven R.; Rath, Joseph F.] NYU, Sch Med, Dept Rehabil Med, New York, NY USA; [Foo, Farng-Yang A.] New York Univ Langone Hlth, Dept Neurol, New York, NY USA	Lui, YW (corresponding author), NYU, Sch Med, Ctr Adv Imaging Innovat & Res, Dept Radiol, New York, NY 10016 USA.	yvonne.lui@nyumc.org	Chung, Sohae/S-9249-2019; Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Flanagan, Steven/0000-0001-9005-5897; Fieremans, Els/0000-0002-1384-8591; Babb, James/0000-0003-1798-1186; Amorapanth, Prin/0000-0002-4260-7826; Foo, Farng-Yang/0000-0002-5167-9442; Novikov, Dmitry/0000-0002-4213-3050	National Institutes of Health (NIH), National Institute for Neurological Disorders and Stroke (NINDS) [R01 NS039135-11, R21 NS090349]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG008051] Funding Source: NIH RePORTER	This work is supported in part by grant funding from the National Institutes of Health (NIH): R01 NS039135-11 and R21 NS090349, National Institute for Neurological Disorders and Stroke (NINDS). This work is also performed under the rubric of the Center for Advanced Imaging Innovation and Research (CAI<SUP>2</SUP>R, www.cai2r.net), a National Institute of Biomedical Imaging and Bioengineering Biomedical Technology Resource Center (NIH P41 EB017183).	Benitez A, 2014, NEUROIMAGE-CLIN, V4, P64, DOI 10.1016/j.nicl.2013.11.001; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; *CDCP NAT CTR INJ, 2003, REP C MILD TRAUM BRA; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Collier Q, 2015, MAGN RESON MED, V73, P2174, DOI 10.1002/mrm.25351; de Kouchkovsky I, 2016, J NEUROL, V263, P1146, DOI 10.1007/s00415-016-8118-z; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Falangola MF, 2014, NMR BIOMED, V27, P948, DOI 10.1002/nbm.3140; Fieremans E, 2013, AM J NEURORADIOL, V34, P2105, DOI 10.3174/ajnr.A3553; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2015, NEUROIMAGE, V118, P334, DOI 10.1016/j.neuroimage.2015.05.061; Guan XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117707; Guglielmetti C, 2016, NEUROIMAGE, V125, P363, DOI 10.1016/j.neuroimage.2015.10.052; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hui ES, 2012, STROKE, V43, P2968, DOI 10.1161/STROKEAHA.112.657742; Jelescu IO, 2016, NEUROIMAGE, V132, P104, DOI 10.1016/j.neuroimage.2016.02.004; Jelescu IO, 2015, NEUROIMAGE, V107, P242, DOI 10.1016/j.neuroimage.2014.12.009; Kellner E, 2016, MAGN RESON MED, V76, P1574, DOI 10.1002/mrm.26054; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Lazar M, 2014, NEUROIMAGE-CLIN, V4, P417, DOI 10.1016/j.nicl.2014.01.014; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Patton DA, 2015, J APPL BIOMECH, V31, P264, DOI 10.1123/jab.2014-0223; Reisert M, 2017, NEUROIMAGE, V147, P964, DOI 10.1016/j.neuroimage.2016.09.058; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	42	17	18	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	8					1015	1020		10.1089/neu.2017.5320			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0DM	WOS:000429447100004	29239261	Green Published			2021-06-18	
J	Dressler, D; Bhidayasiri, R; Bohlega, S; Chana, P; Chien, HF; Chung, TM; Colosimo, C; Ebke, M; Fedoroff, K; Frank, B; Kaji, R; Kanovsky, P; Kocer, S; Micheli, F; Orlova, O; Paus, S; Pirtosek, Z; Relja, M; Rosales, RL; Sagastegui-Rodriguez, JA; Schoenle, PW; Shahidi, GA; Timerbaeva, S; Walter, U; Saberi, FA				Dressler, Dirk; Bhidayasiri, Roongroj; Bohlega, Saeed; Chana, Pedro; Chien, Hsin Fen; Chung, Tae Mo; Colosimo, Carlo; Ebke, Markus; Fedoroff, Klemens; Frank, Bernd; Kaji, Ryuji; Kanovsky, Petr; Kocer, Serdar; Micheli, Federico; Orlova, Olga; Paus, Sebastian; Pirtosek, Zvezdan; Relja, Maja; Rosales, Raymond L.; Alberto Sagastegui-Rodriguez, Jose; Schoenle, Paul W.; Shahidi, Gholam Ali; Timerbaeva, Sofia; Walter, Uwe; Saberi, Fereshte Adib			Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy	JOURNAL OF NEUROLOGY			English	Article						Spasticity; Rigidity; Dystonia; Spasms; Contractures; Treatment; Botulinum toxin therapy	LIMB SPASTICITY	Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB-Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity-for the first time-based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.	[Dressler, Dirk] Hannover Med Sch, Dept Neurol, Movement Disorders Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Bhidayasiri, Roongroj] King Chulalongkorn Mem Hosp, Chulalongkorn Ctr Excellence Parkinsons Dis & Rel, Bangkok, Thailand; [Bohlega, Saeed] King Faisal Specialist Hosp & Res Ctr, Dept Neurol, Riyyad, Saudi Arabia; [Chana, Pedro] Univ Santiago de Chile, Dept Neurol, Santiago, Chile; [Chien, Hsin Fen] Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil; [Chung, Tae Mo] Univ Sao Paulo, Sao Paulo, Brazil; [Colosimo, Carlo] Azienda Osped Santa Maria Terni, Terni, Italy; [Ebke, Markus] Median Klin Bad Salzuflen, Bad Salzuflen, Germany; [Fedoroff, Klemens] Gailtal Klin, Hermagor, Austria; [Frank, Bernd] Helios Klin Leezen, Leezen, Germany; [Kaji, Ryuji] Univ Tokushima, Dept Neurol, Tokushima, Japan; [Kanovsky, Petr] Palacky Univ, Dept Neurol, Olomouc, Czech Republic; [Kocer, Serdar] Hop Jura, Ctr Reeducat & Med Phys, Porrentruy, Switzerland; [Micheli, Federico] Univ Buenos Aires, Hosp Clin Jose de San Martin, Dept Neurol, Buenos Aires, DF, Argentina; [Orlova, Olga] Clin Cecil Plus, Moscow, Russia; [Paus, Sebastian] Rhein Friedrich Wilhelms Univ, Dept Neurol, Bonn, Germany; [Pirtosek, Zvezdan] Univ Ljubljana, Dept Neurol, Med Ctr, Ljubljana, Slovenia; [Relja, Maja] Univ Zagreb, Dept Neurol, Zagreb, Croatia; [Rosales, Raymond L.] Univ Santo Tomas Hosp, Dept Neurol, Manila, Philippines; [Alberto Sagastegui-Rodriguez, Jose] Univ Monterrey, Dept Neurol, Monterrey, Nueva Leon, Mexico; [Schoenle, Paul W.] Maternus Klin Rehabil, Bad Oeynhausen, Germany; [Shahidi, Gholam Ali] Iran Univ Med Sci, Rasoul E Akram Hosp, Dept Neurol, Movement Disorders Clin, Tehran, Iran; [Timerbaeva, Sofia] Minist Hlth & Social Dev Russian Federat, Fed State Hosp Treatment & Rehabil, Moscow, Russia; [Walter, Uwe] Rostock Univ, Dept Neurol, Rostock, Germany; [Saberi, Fereshte Adib] IAB Interdisciplinary Working Grp Movement Disord, Hamburg, Germany	Dressler, D (corresponding author), Hannover Med Sch, Dept Neurol, Movement Disorders Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany.	dressler.dirk@mh-hannover.de	Colosimo, Carlo/AAY-8552-2020; Kocer, Serdar/AAG-2708-2019; Pirtosek, Zvezdan/AAB-4729-2020; Chana, Pedro/ABG-9944-2020; Walter, Uwe/O-4591-2017; Fheodoroff, Klemens/H-6406-2013	Colosimo, Carlo/0000-0002-2216-3973; Pirtosek, Zvezdan/0000-0002-5495-944X; Chana, Pedro/0000-0001-9946-3299; Walter, Uwe/0000-0002-6280-785X; Fheodoroff, Klemens/0000-0002-6508-5055; Shahidi, Gholam Ali/0000-0002-3889-4973	Newton Fund UK; Thailand research fundThailand Research Fund (TRF); Ratchadapisek sompot faculty grant; CU-CLUSTER fund of Chulalongkorn University; Ipsen PharmaIpsen; Merz Pharmaceuticals; AllerganAbbVieAllergan; Merz Pharma	Dressler D: DD received honoraria for services provided to Allergan, Ipsen, Merz, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. Bhidayasiri R: No conflict of interest to report. Stock Ownership in medically related fields: None. Consultancies: Ipsen Pharmaceuticals. Advisory Boards: Britannia Pharmaceuticals. Honoraria to speak: Novartis, BL Hua, Abbott. Partnerships: None. Grants: Newton Fund UK, Thailand research fund, Ratchadapisek sompot faculty grant and CU-CLUSTER fund of Chulalongkorn University. Intellectual Property Rights: Parkinson's disease laser cane, Tremor analysis algorithm, Nocturnal monitoring device (NIGHT-Recorder). Expert Testimony: None. Employment: Chulalongkorn University. Royalties: Blackwell-Wiley, Humana Publications. Others: None. Bohlega S: Nothing to declare. Chana P: Nothing to declare. Chien S: Nothing to declare. Chung TM: Honoraria from Ipsen, Allergan and Merz to lecture in Symposium, Training Couses and Advisory Board participation. Participation in clinical research from Ipsen. No research funding and no financial interest in Botulinum Toxin. Colosimo C: Consultancies with Zambon, Sunovion, Ipsen and Bial. Royalties from Cambridge University Press and Oxford University Press. Ebke M: Nothing to declare. Fedoroff K: Nothing to declare. Frank B: Nothing to declare. Kaji R: Nothing to declare. Kanovsky P: Nothing to declare. Kocer S: Nothing to declare. Micheli F: Nothing to declare. Orlova O: OO is scientific consultant for Ipsen, Allergan, Merz and Microgen. PausS: SP received research grants and lecturer fees from Ipsen Pharma and Merz Pharmaceuticals. Member of the Advisory Boards of Ipsen Pharma and Merz Pharmaceuticals. Pirtosek Z: Nothing to declare. Relja M: Northing to declare. Rosales RL: RR received advisory, research and travel grants from Ipsen Pharma and lecture and travel grants from Allergan and Merz Pharma. Sagastequi A: AS received honoraria for lecturing from Allergan and Ipsen. Schoenle PW: Nothing to declare. Shahidi G: Nothing to declare. Timerbaeva S: Nothing to declare. Walter U: UW received speaker honoraria and travel reimbursement from Merz Pharma, Ipsen Pharma, Allergan, Bristol-Myers Squibb, Daiichi Sankyo, Bayer Vital and Pfizer, and a research grant from Merz Pharma. Adib Saberi F: FAS received reimbursement from Abbot, Abbvie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB.	Barnes MP, 2008, UPPER MOTOR NEURONE SYNDROME AND SPASTICITY: CLINICAL MANAGEMENT AND NEUROPHYSIOLOGY, 2ND EDITION, P1, DOI 10.1017/CBO9780511544866.002; Brashear A, 2016, SPASTICITY: DIAGNOSIS AND MANAGEMENT, SECOND EDITION, P3; Dressler D, 2015, J NEURAL TRANSM, V122, P1573, DOI 10.1007/s00702-015-1425-1; Dressler D., 2000, BOTULINUM TOXIN THER; Dressler D, 2018, TREATMENT D IN PRESS; Dressler D, 2014, J NEURAL TRANSM, V121, P367, DOI 10.1007/s00702-013-1108-8; Dressler D, 2012, CURR OPIN MICROBIOL, V15, P325, DOI 10.1016/j.mib.2012.05.012; Egen-Lappe V, 2013, INT J GEN MED, V6, P135, DOI 10.2147/IJGM.S36030; Gracies JM, 2018, MUSCLE NERVE, V57, P245, DOI 10.1002/mus.25721; Horn LJ, 2016, SPASTICITY: DIAGNOSIS AND MANAGEMENT, SECOND EDITION, P111; Keating GM, 2017, DRUGS, V77, P563, DOI 10.1007/s40265-017-0720-6; Lance J. W., 1980, SPASTICITY DISORDERE, P485; McGuire JR, 2016, SPASTICITY: DIAGNOSIS AND MANAGEMENT, SECOND EDITION, P5; Nalysnyk L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-118; Nathan P W, 1965, J Neurol Sci, V2, P7, DOI 10.1016/0022-510X(65)90060-2; Puligopu AK, 2011, J PEDIATR NEUROSCI, V6, P118, DOI 10.4103/1817-1745.85730; Rosales RL, 2017, BOTULINUM TOXIN THER; Santamato A, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S86978; Sheean Geoffrey, 2003, Expert Rev Neurother, V3, P773, DOI 10.1586/14737175.3.6.773; Sherman SJ, 2000, J NEUROL SCI, V175, P145, DOI 10.1016/S0022-510X(00)00299-9; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; Wissel J, 2017, NEUROLOGY, V88, P1321, DOI 10.1212/WNL.0000000000003789	22	17	20	1	21	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	APR	2018	265	4					856	862		10.1007/s00415-018-8759-1			7	Clinical Neurology	Neurosciences & Neurology	GB3AV	WOS:000428928200013	29423615				2021-06-18	
J	Foley, KL; Hebela, N; Keenan, MA; Pignolo, RJ				Foley, Kristin L.; Hebela, Nader; Keenan, Mary Ann; Pignolo, Robert J.			Histopathology of periarticular non-hereditary heterotopic ossification	BONE			English	Article						Heterotopic ossification; Injury; Arthropathy; Traumatic brain injury; Cerebrovascular accident; Trauma; Spinal cord injury; Arthroplasty; Aging	TOTAL KNEE ARTHROPLASTY; ECTOPIC BONE-FORMATION; TOTAL HIP-ARTHROPLASTY; SPINAL-CORD-INJURY; HEAD-INJURIES; PROGRESSIVA; RECEPTOR; MICE; MANAGEMENT; INDUCTION	In the mature adult skeleton, new bone formation is normally restricted to regeneration of osseous tissue at sites of fracture. However, heterotopic ossification, or the formation of bone outside the normal skeleton, can occur within muscle, adipose, or fibrous connective tissue. Periarticular non-hereditary heterotopic ossification (NHHO) may occur after musculoskeletal trauma, following CNS injury, with certain arthropathies, or following injury or surgery that is often sustained in the context of age-related pathology. The histological mechanism of bone development in these forms of heterotopic ossification has thus far been uncharacterized. We performed a histological analysis of 90 bone specimens from 18 patients with NHHO secondary to defined precipitating conditions, including traumatic brain injury, spinal cord injury. cerebrovascular accident, trauma without neurologic injury, and total hip or knee arthroplasty. All bone specimens revealed normal endochondral osteogenesis at heterotopic sites. We defined the order of sequence progression in NHHO lesion formation as occurring through six distinct histological stages: (1) perivascular lymphocytic infiltration, (2) lymphocytic migration into soft tissue, (3) reactive fibroproliferation, (4) neovascularity, (5) cartilage formation, and (6) endochondral bone formation. This study provides the first systematic evaluation of the predominant histopathological findings associated with multiple forms of NHHO and shows that they share a common mechanism of lesion formation. (C) 2017 Elsevier Inc All rights reserved.	[Foley, Kristin L.] Boston Osteopath Hlth, Worcester, MA USA; [Foley, Kristin L.] Univ Massachusetts, Med Sch, Worcester, MA USA; [Foley, Kristin L.] Boston Osteopath Hlth, Newton, MA USA; [Foley, Kristin L.] Univ Massachusetts, Med Sch, Newton, MA USA; [Hebela, Nader] Cleveland Clin Abu Dhabi, Neurol Inst, Abu Dhabi, U Arab Emirates; [Keenan, Mary Ann] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA; [Pignolo, Robert J.] Mayo Clin, Sch Med, Dept Med, Rochester, MN USA	Pignolo, RJ (corresponding author), Mayo Clin, Coll Med, Div Geriatr Med & Gerontol, 200 First St SW, Rochester, MN 55905 USA.	klfoleydo@aol.com; Meekanm@comcast.net; Pignolo.Robert@mayo.edu	Keenan, Mary Ann/ABB-1551-2020		Ian Cali Distinguished Clinician-Scientist award at the University of Pennsylvania; Robert and Arlene Professorship in Geriatric Medicine at the Mayo Clinic; Radiant Hope Foundation	This work was supported by the Ian Cali Distinguished Clinician-Scientist award at the University of Pennsylvania, the Robert and Arlene Professorship in Geriatric Medicine at the Mayo Clinic, and the Radiant Hope Foundation.	ACKERMAN LV, 1958, J BONE JOINT SURG AM, V40, P279, DOI 10.2106/00004623-195840020-00004; AUSTIN KS, 1995, J ARTHROPLASTY, V10, P695, DOI 10.1016/S0883-5403(05)80219-0; Barrack RL, 2002, CLIN ORTHOP RELAT R, P208, DOI 10.1097/01.blo.0000030497.43495.3f; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Burd TA, 2001, J BONE JOINT SURG AM, V83A, P1783, DOI 10.2106/00004623-200112000-00003; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chakkalakal SA, 2016, J BONE MINER RES, V31, P1666, DOI 10.1002/jbmr.2820; Chua KSG, 2003, BRAIN INJURY, V17, P535, DOI 10.1080/0269905021000010104; Dalury DF, 2004, J ARTHROPLASTY, V19, P447, DOI 10.1016/j.arth.2003.12.064; DiCaprio MR, 2004, ORTHOPEDICS, V27, P41; Dua SG, 2011, CLIN NUCL MED, V36, P952, DOI 10.1097/RLU.0b013e31821a28b1; Fukuda T, 2006, GENESIS, V44, P159, DOI 10.1002/dvg.20201; FURIA JP, 1995, J ARTHROPLASTY, V10, P413, DOI 10.1016/S0883-5403(05)80139-1; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Glaser DL, 2003, J BONE JOINT SURG AM, V85A, P2332, DOI 10.2106/00004623-200312000-00010; Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358; Jamil F, 2002, SPINAL CORD, V40, P388, DOI 10.1038/sj.sc.3101305; JEE WSS, 1987, BONE, V8, P171, DOI 10.1016/8756-3282(87)90017-2; Joshi AB, 2002, J ARTHROPLASTY, V17, P427, DOI 10.1054/arth.2002.32170; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; Keenan MAE, 1996, J HEAD TRAUMA REHAB, V11, P8, DOI 10.1097/00001199-199608000-00004; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; Neal B, 2002, ANZ J SURG, V72, P808, DOI 10.1046/j.1445-2197.2002.02549.x; Nilsson Olle S., 1999, Current Opinion in Rheumatology, V11, P127, DOI 10.1097/00002281-199903000-00008; ORZEL JA, 1985, J NUCL MED, V26, P125; Pauli S, 2000, ANGIOLOGY, V51, P77, DOI 10.1177/000331970005100112; Pignolo RJ, 2005, CLIN REV BONE MINER, V3, P261, DOI 10.1385/BMM:3:3-4:261; Pignolo RJ, 2005, CLIN REV BONE MINER, V3, P195, DOI 10.1385/BMM:3:3-4:195; Pignolo RJ, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-80; Rader GP, 1997, ACTA ORTHOP SCAND, V68, P46, DOI 10.3109/17453679709003974; Ranganathan K, 2015, J BONE JOINT SURG AM, V97A, P1101, DOI 10.2106/JBJS.N.01056; Schurch B, 1997, ARCH PHYS MED REHAB, V78, P687, DOI 10.1016/S0003-9993(97)90074-5; SCUTT A, 1995, J BONE MINER RES, V10, P474; Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Sterner T, 2005, ARCH ORTHOP TRAUM SU, V125, P188, DOI 10.1007/s00402-005-0797-3; Stoeger T, 2002, GROWTH FACTORS, V20, P197, DOI 10.1080/0897719021000069579; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Webb L X, 1990, J Orthop Trauma, V4, P376, DOI 10.1097/00005131-199012000-00002	43	17	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	8756-3282	1873-2763		BONE	Bone	APR	2018	109				SI		65	70		10.1016/j.bone.2017.12.006			6	Endocrinology & Metabolism	Endocrinology & Metabolism	GB5DK	WOS:000429082400011	29225159				2021-06-18	
J	Mei, ZR; Qiu, JH; Alcon, S; Hashim, J; Rotenberg, A; Sun, Y; Meehan, WP; Mannix, R				Mei, Zhengrong; Qiu, Jianhua; Alcon, Sasha; Hashim, Jumana; Rotenberg, Alexander; Sun, Yan; Meehan, William P., III; Mannix, Rebekah			Memantine improves outcomes after repetitive traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Concussion; Repetitive concussion; NMDAR	D-ASPARTATE RECEPTORS; AMYLOID PRECURSOR PROTEIN; LONG-TERM POTENTIATION; CLOSED-HEAD-INJURY; NMDA-RECEPTOR; AXONAL INJURY; EXTRACELLULAR POTASSIUM; RECURRENT CONCUSSION; FOOTBALL PLAYERS; CELL-DEATH	Repetitive mild traumatic brain injury (rmTBI; e.g., sports concussions) is common and results in significant cognitive impairment. Targeted therapies for rmTBI are lacking, though evidence from other injury models indicates that targeting N-methyl-n-aspartate (NMDA) receptor (NMDAR)-mediated glutamatergic toxicity might mitigate rmTBI-induced neurologic deficits. However, there is a paucity of preclinical or clinical data regarding NMDAR antagonist efficacy in the rmTBI setting. To test whether NMDAR antagonist therapy improves outcomes after rmTBI, mice were subjected to rmTBI injury (4 injuries in 4 days) and randomized to treatment with the NMDA antagonist memantine or with vehicle. Functional outcomes were assessed by motor, anxiety/impulsivity and mnemonic behavioral tests. At the synaptic level, NMDAR-dependent long-term potentiation (LTP) was assessed in isolated neocortical slices. At the molecular level, the magnitude of gliosis and tau hyperphosphorylation was tested by Western blot and immunostaining, and NMDAR subunit expression was evaluated by Western blot and polymerase shain reaction (PCR). Compared to vehicle-treated mice, memantine-treated mice had reduced tau phosphorylation at acute time points after injury, and less glial activation and LTP deficit 1 month after injury. Treatment with memantine also corresponded to normal NMDAR expression after rmTBI. No corresponding protection in behavior outcomes was observed. Here we found NMDAR antagonist therapy may improve histopathological and functional outcomes after rmTBI, though without consistent corresponding improvement in behavioral outcomes. These data raise prospects for therapeutic post-concussive NMDAR antagonism, particularly in athletes and warriors, who suffer functional impairment and neurodegenerative sequelae after multiple concussions.	[Mei, Zhengrong] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pharm, Guangzhou 510150, Guangdong, Peoples R China; [Qiu, Jianhua; Alcon, Sasha; Hashim, Jumana; Meehan, William P., III; Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA; [Qiu, Jianhua; Rotenberg, Alexander; Meehan, William P., III; Mannix, Rebekah] Harvard Med Sch, Boston, MA USA; [Rotenberg, Alexander; Sun, Yan] Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100 Waltham, Suite Waltham, MA 02453 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA USA	Mannix, R (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	meizhengrong@126.com; Jianhua.Qiu@childrens.harvard.edu; Sasha.Alcon@childrens.harvard.edu; Jumana.Hashim@childrens.harvard.edu; Alexander.Rotenberg@childrens.harvard.edu; Yan.Sun@childrens.harvard.edu; William.Mehan@childrens.harvard.edu; Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		CHB IDDRC [1U54HD090255]; Harvard Catalyst (National Football League Players Association); National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; Guangzhou Education Bureau [1201421151];  [T32 HD40128-11A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD043034] Funding Source: NIH RePORTER	CHB IDDRC (1U54HD090255)supported all the behavior studies reported. Rebekah Mannix is supported by T32 HD40128-11A1 and by a grant from Harvard Catalyst (National Football League Players Association) and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. Zhengrong Mei is supported by the grant from Guangzhou Education Bureau 1201421151). Dr. Meehan receives royalties from ABC-Clio publishing for the sale of his book, Kids, Sports, and Concussion: A guide for coaches and parents, and royalties from Wolters Kluwer for working as an author for UpToDate. He is under contract with ABC-Clio publishing for a future book entitled, Concussions, and with Springer International publishing for a future book entitled, Head and Neck Injuries in Young Athletes. His research is funded, in part, by a grant from Harvard Catalyst (National Football League Players Association) and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Berberich S, 2005, J NEUROSCI, V25, P6907, DOI 10.1523/JNEUROSCI.1905-05.2005; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bortolotto ZA, 2001, CURR PROTOC NEUROSCI; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Montigny A, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/261593; Effgen GB, 2017, J NEUROTRAUM, V34, P934, DOI 10.1089/neu.2016.4528; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishikawa R, 2014, HIPPOCAMPUS, V24, P784, DOI 10.1002/hipo.22270; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Kamat PK, 2013, NEUROSCIENCE, V238, P97, DOI 10.1016/j.neuroscience.2013.01.075; Kanaan N.M., 2015, J NEUROPATHOL EXP NE; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lamprecht MR, 2015, J NEUROTRAUM, V32, P1361, DOI 10.1089/neu.2015.3912; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Ma JY, 2015, NEUROBIOL AGING, V36, P2544, DOI 10.1016/j.neurobiolaging.2015.05.017; Mancini M, 2016, NEUROPHARMACOLOGY, V101, P341, DOI 10.1016/j.neuropharm.2015.10.015; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martinez-Coria H, 2010, AM J PATHOL, V176, P870, DOI 10.2353/ajpath.2010.090452; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OLNEY JW, 1969, SCIENCE, V166, P386, DOI 10.1126/science.166.3903.386; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rao VLR, 2001, BRAIN RES, V911, P96; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Schuler T, 2008, J BIOL CHEM, V283, P37, DOI 10.1074/jbc.M703539200; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00222; Wesierska MJ, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00203; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Zhang JD, 2013, J NEUROSCI RES, V91, P240, DOI 10.1002/jnr.23150; Zhang XQ, 2013, J NEUROSCI, V33, P17737, DOI 10.1523/JNEUROSCI.2049-13.2013	48	17	17	0	45	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		195	204		10.1016/j.bbr.2017.04.017			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400023	28412305	Green Accepted			2021-06-18	
J	Baez-Jurado, E; Vega, GG; Aliev, G; Tarasov, VV; Esquinas, P; Echeverria, V; Barreto, GE				Baez-Jurado, Eliana; Guio Vega, Gina; Aliev, Gjumrakch; Tarasov, Vadim V.; Esquinas, Paula; Echeverria, Valentina; Barreto, George E.			Blockade of Neuroglobin Reduces Protection of Conditioned Medium from Human Mesenchymal Stem Cells in Human Astrocyte Model (T98G) Under a Scratch Assay	MOLECULAR NEUROBIOLOGY			English	Article						Astrocytes; Scratch assay; Mesenchymal stem cells; Conditioned medium; Adipose tissue; Neuroglobin	TRAUMATIC BRAIN-INJURY; HUMAN BONE-MARROW; IMPROVES SENSORIMOTOR OUTCOMES; OXYGEN-GLUCOSE DEPRIVATION; FIBRILLARY ACIDIC PROTEIN; ESTROGEN-RECEPTOR BETA; MOUSE MODEL; IN-VITRO; ADIPOSE-TISSUE; STROMAL CELLS	Previous studies have indicated that paracrine factors (conditioned medium) increase wound closure and reduce reactive oxygen species in a traumatic brain injury in vitro model. Although the beneficial effects of conditioned medium from human adipose tissue-derived mesenchymal stem cells (hMSCA-CM) have been previously suggested for various neurological diseases, their actions on astrocytic cells are not well understood. In this study, we have explored the effect of hMSCA-CM on human astrocyte model (T98G cells) subjected to scratch assay. Our results indicated that hMSCA-CM improved cell viability, reduced nuclear fragmentation, attenuated the production of reactive oxygen species, and preserved mitochondrial membrane potential and ultrastructural parameters. In addition, hMSCA-CM upregulated neuroglobin in T98G cells and the genetic silencing of this protein prevented the protective action of hMSCA-CM on damaged cells, suggesting that neuroglobin is mediating, at least in part, the protective effect of hMSCA-CM. Overall, this evidence suggests that the use of hMSCA-CM is a promising therapeutic strategy for the protection of astrocytic cells in central nervous system (CNS) pathologies.	[Baez-Jurado, Eliana; Guio Vega, Gina; Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia; [Aliev, Gjumrakch] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Russia; [Aliev, Gjumrakch] GALLY Int Biomed Res Consulting LLC, San Antonio, TX 78229 USA; [Aliev, Gjumrakch] Univ Atlanta, Sch Hlth Sci & Healthcare Adm, Johns Creek, GA 30097 USA; [Tarasov, Vadim V.] Sechenov First Moscow State Med Univ, Inst Pharm & Translat Med, 2-4 Bolshaya Pirogovskaya St, Moscow 119991, Russia; [Esquinas, Paula] Univ Nacl Colombia, Fac Med Vet & Zootecnia, Bogota, Colombia; [Echeverria, Valentina] Univ San Sebastian, Fac Ciencias Salud, Lientur 1457, Concepcion 4030000, Chile; [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile	Barreto, GE (corresponding author), Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia.; Barreto, GE (corresponding author), Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile.	gsampaio@javeriana.edu.co	Barreto, George E./AAD-7420-2020; Aliev, Gjumrakch/K-7302-2017; Aliev, Gjumrakch/AAE-7734-2020; Valentina Echeverria Moran, BCh/E-7765-2013	Barreto, George E./0000-0002-6644-1971; Aliev, Gjumrakch/0000-0001-7373-3182; Valentina Echeverria Moran, BCh/0000-0003-2393-5418; Tarasov, Vadim Vladimirovic/0000-0002-9394-7994	Vicerrectoria Academica of PUJ; PUJ [6260]	The authors thank Dr. Jorge Andres Afanador and the staff of the cosmetic surgery Clinic DHARA in Bogota - Colombia, for the adipose tissue samples. This work was supported by PUJ grant # 6260 to GEB and scholarship for doctoral studies awarded by the Vicerrectoria Academica of PUJ to Baez-Jurado E.	Acaz-Fonseca E., 2015, GLIA; Aizman I, 2013, STEM CELL TRANSL MED, V2, P223, DOI 10.5966/sctm.2012-0119; Allen JW, 1999, FASEB J, V13, P1875; Amri F, 2017, J NEUROCHEM, V140, P151, DOI 10.1111/jnc.13876; Rodriguez MA, 2014, J STEROID BIOCHEM, V144, P294, DOI 10.1016/j.jsbmb.2014.07.009; Avila-Rodriguez M, 2016, MOL CELL ENDOCRINOL, V433, P35, DOI 10.1016/j.mce.2016.05.024; Avivi A, 2010, P NATL ACAD SCI USA, V107, P21570, DOI 10.1073/pnas.1015379107; Baez E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00146; Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359; Banasr M, 2010, MOL PSYCHIATR, V15, P501, DOI 10.1038/mp.2008.106; Bankhead P., 2013, ANAL FLUORESCENCE MI; Bertheuil N, 2015, ANN CHIR PLAST ESTH, V60, P94, DOI 10.1016/j.anplas.2014.09.014; Birk AV, 2013, J AM SOC NEPHROL, V24, P1250, DOI 10.1681/ASN.2012121216; Bourguignon LYW, 2007, J NEUROCHEM, V101, P1002, DOI 10.1111/j.1471-4159.2007.04485.x; Cabezas R, 2015, NEUROTOX RES, V27, P355, DOI 10.1007/s12640-014-9509-5; Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515; Chen D, 2016, J NEUROSCI RES; Chen XM, 2015, NEUROSCI LETT, V606, P194, DOI 10.1016/j.neulet.2015.09.002; Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063; Cirillo G, 2011, NEUROBIOL DIS, V41, P630, DOI 10.1016/j.nbd.2010.11.012; Cogliati S, 2016, TRENDS BIOCHEM SCI, V41, P261, DOI 10.1016/j.tibs.2016.01.001; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; De Marinis E, 2013, J NEUROENDOCRINOL, V25, P260, DOI 10.1111/jne.12007; Deng LX, 2011, EXP NEUROL, V229, P238, DOI 10.1016/j.expneurol.2011.02.001; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033; Eirin A, 2014, GENE, V551, P55, DOI 10.1016/j.gene.2014.08.041; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Fiocchetti M, 2015, J STEROID BIOCHEM, V149, P128, DOI 10.1016/j.jsbmb.2015.02.005; George E, 2011, ROLE ASTROCYTES NEUR; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gnecchi Massimiliano, 2016, Methods Mol Biol, V1416, P123, DOI 10.1007/978-1-4939-3584-0_7; Gonzalez A, 2007, BRAIN RES, V1178, P28, DOI 10.1016/j.brainres.2007.08.040; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; GRIFFITHS CEM, 1990, J INVEST DERMATOL, V95, pS53, DOI 10.1111/1523-1747.ep12505786; Guerit D, 2014, STEM CELLS DEV, V23, P1195, DOI 10.1089/scd.2013.0463; Guo ZY, 2015, NEURAL REGEN RES, V10, P651, DOI 10.4103/1673-5374.155442; Habersetzer J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075429; Hao P, 2014, METAB BRAIN DIS, V29, P193, DOI 10.1007/s11011-014-9490-y; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Hu L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32993; Huang B, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0792-1; Huang WY, 2015, J CELL PHYSIOL, V230, P2461, DOI 10.1002/jcp.24981; HUE L, 1976, BIOCHEM SOC T, V4, P994, DOI 10.1042/bst0040994; Hwang B, 2016, J THORAC CARDIOV SUR, V151, P841, DOI 10.1016/j.jtcvs.2015.11.043; Janer A, 2016, EMBO MOL MED, V8, P1019, DOI 10.15252/emmm.201506159; Jeong SH, 2014, MAR DRUGS, V12, P4602, DOI 10.3390/md12084602; Jin KL, 2010, STROKE, V41, P557, DOI 10.1161/STROKEAHA.109.567149; Kaewsuya P, 2007, ANAL BIOANAL CHEM, V387, P2775, DOI 10.1007/s00216-007-1135-0; Kallakuri S, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.166354; Kemp K, 2010, J NEUROCHEM, V114, P1569, DOI 10.1111/j.1471-4159.2009.06553.x; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Kim WS, 2008, J DERMATOL SCI, V49, P133, DOI 10.1016/j.jdermsci.2007.08.004; Lattanzi W, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/468705; Lechauve C, 2013, BBA-PROTEINS PROTEOM, V1834, P1772, DOI 10.1016/j.bbapap.2013.04.014; Lee Hyun-Ho, 2015, Korean J Neurotrauma, V11, P44, DOI 10.13004/kjnt.2015.11.2.44; Lee JC, 2016, J PATHOL TRANSL MED, V50, P325, DOI 10.4132/jptm.2015.09.11.r; Li L, 2014, MOL NEUROBIOL, V49, P149, DOI 10.1007/s12035-013-8506-7; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Li Y, 2016, J MOL NEUROSCI, V58, P28, DOI 10.1007/s12031-015-0645-z; Liang CM, 2014, CYTOTHERAPY, V16, P1371, DOI 10.1016/j.jcyt.2014.05.015; Lin WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063444; Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001; Liu YC, 2015, BRAIN INJURY, V29, P651, DOI 10.3109/02699052.2014.1002004; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078514; Mimura J, 2011, J BIOCHEM, V150, P209, DOI 10.1093/jb/mvr065; Mirotsou M, 2011, J MOL CELL CARDIOL, V50, P280, DOI 10.1016/j.yjmcc.2010.08.005; Mita T, 2015, BEHAV BRAIN RES, V293, P189, DOI 10.1016/j.bbr.2015.07.043; Nakashima-Kamimura N, 2005, J CELL SCI, V118, P5357, DOI 10.1242/jcs.02645; Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035; Oliva CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024665; Oliveira K, 2015, METAB BRAIN DIS, V30, P1401, DOI 10.1007/s11011-015-9718-5; Ong WK, 2013, INT J BIOCHEM CELL B, V45, P1083, DOI 10.1016/j.biocel.2013.02.013; Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22-3-377; Ott C, 2012, MOL CELL BIOL, V32, P1173, DOI 10.1128/MCB.06388-11; Ouyang YB, 2011, MITOCHONDRION, V11, P279, DOI 10.1016/j.mito.2010.10.007; Park CM, 2016, IN VITRO CELL DEV-AN, V52, P68, DOI 10.1007/s11626-015-9948-1; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Picard M, 2013, AM J PHYSIOL-REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012; Pires AO, 2016, STEM CELLS DEV, V25, P1073, DOI 10.1089/scd.2016.0048; Pischiutta F, 2016, CRIT CARE MED, V44, pE1118, DOI 10.1097/CCM.0000000000001864; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Platas J, 2016, AGING-US, V8, P1703, DOI 10.18632/aging.101007; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809; Rampelt H, 2016, BIOCH BIOPHYS ACTA; Ren CH, 2015, RESTOR NEUROL NEUROS, V33, P369, DOI 10.3233/RNN-140413; Salgado AJ, 2010, STEM CELLS DEV, V19, P1067, DOI 10.1089/scd.2009.0279; Salgado AJ, 2010, CURR STEM CELL RES T, V5, P103; Sandhir R, 2014, NEUROSCI LETT, V577, P123, DOI 10.1016/j.neulet.2014.06.005; Sasaki S, 2015, J BIOL CHEM, V290, P2303, DOI 10.1074/jbc.M114.581892; Scheibe F, 2012, CELL MOL NEUROBIOL, V32, P567, DOI 10.1007/s10571-012-9798-2; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; Skalnikova HK, 2013, BIOCHIMIE, V95, P2196, DOI 10.1016/j.biochi.2013.07.015; Song M, 2015, J NEUROSCI RES, V93, P973, DOI 10.1002/jnr.23569; Stetler RA, 2013, J CEREBR BLOOD F MET, V33, P22, DOI 10.1038/jcbfm.2012.158; Sun H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072926; Taniguchi H, 2016, J VIS EXP; Taylor JM, 2014, NEUROSCI LETT, V577, P125, DOI 10.1016/j.neulet.2014.03.012; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Toro-Urrego N, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00152; Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659; van Koppen A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038746; Walter MNM, 2010, EXP CELL RES, V316, P1271, DOI 10.1016/j.yexcr.2010.02.026; Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Witte I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.91; Xie BC, 2016, AM J TRANSL RES, V8, P3241; Yalvac ME, 2013, BRAIN BEHAV IMMUN, V32, P122, DOI 10.1016/j.bbi.2013.03.007; Yamazaki H, 2015, NEUROSCI LETT, V609, P53, DOI 10.1016/j.neulet.2015.10.023; Yousefi F, 2016, IMMUNOL LETT, V172, P94, DOI 10.1016/j.imlet.2016.02.016; Yu Z, 2012, NEUROSCIENCE, V218, P235, DOI 10.1016/j.neuroscience.2012.05.054; Yu ZL, 2014, NEUROSCIENCE, V270, P158, DOI 10.1016/j.neuroscience.2014.04.013; Yu ZY, 2016, MOL NEUROBIOL, V53, P3249, DOI 10.1007/s12035-015-9273-4; Yu ZY, 2012, INT J MOL SCI, V13, P6995, DOI 10.3390/ijms13066995; Yuan H, 2016, CELL BIOL INT; Yuan YJ, 2016, CLIN SCI, V130, P2181, DOI 10.1042/CS20160235; Zhang JY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0417-0; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67; Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015; Zick M, 2009, BBA-MOL CELL RES, V1793, P5, DOI 10.1016/j.bbamcr.2008.06.013	125	17	17	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2285	2300		10.1007/s12035-017-0481-y			16	Neurosciences	Neurosciences & Neurology	FY5TG	WOS:000426897800038	28332151				2021-06-18	
J	Dang, S; Gomez-Orozco, CA; van Zuilen, MH; Levis, S				Dang, Stuti; Gomez-Orozco, Carlos A.; van Zuilen, Maria H.; Levis, Silvina			Providing Dementia Consultations to Veterans Using Clinical Video Telehealth: Results from a Clinical Demonstration Project	TELEMEDICINE AND E-HEALTH			English	Article						clinical video telehealth; dementia; technology; access to care	NURSING-HOME PLACEMENT; MINI-MENTAL-STATE; COGNITIVE IMPAIRMENT; PSYCHOSOCIAL INTERVENTIONS; CAREGIVER BURDEN; TELEMEDICINE; DEPRESSION; MANAGEMENT; PEOPLE; HEALTH	Purpose:Veterans with dementia and their caregivers in remote areas may not have access to specialists to provide diagnosis, treatment, and education. The purpose of this clinical demonstration project was to examine the feasibility, acceptability, and impact of a video consultations clinic for veterans with dementia or memory complaints and their caregivers.Methods:The dementia clinical video telehealth (CVT) consultation clinic was established to identify, diagnose, and treat dementia in veterans at sites distant from the main medical center. A geriatrician at the main facility provided video consultation to patients and caregivers at seven satellite facilities. Diagnoses made and services provided were recorded after the initial consultation. Patient and caregiver satisfaction with the CVT clinic were assessed.Findings:Ninety-four patients were evaluated in the CVT dementia clinic (average age=74.7; average Mini-Mental State Exam=24.4). Forty patients had a prior dementia diagnosis, 15 received a new dementia diagnosis, and 20 a new mild cognitive impairment diagnosis. Of the remaining patients evaluated for memory complaints, seven were found to have depression, three had hearing loss, and three had traumatic brain injury. After CVT consultation, common referrals included social work (n=43), neuropsychology (n=36), and brain imaging (n=26). Patients and caregivers expressed high satisfaction with the video consultation and 90% of caregivers indicated they would rather use CVT than travel to see the specialist in person.Conclusions:Video consultation was well accepted by both dementia patients and caregivers. CVT may facilitate timely diagnosis and management and provide support for rural dementia patients and caregivers.	[Dang, Stuti; van Zuilen, Maria H.; Levis, Silvina] Miami Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Miami, FL USA; [Dang, Stuti; van Zuilen, Maria H.; Levis, Silvina] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Gomez-Orozco, Carlos A.] South Florida Vet Affairs Fdn Res & Educ Inc, Miami, FL USA	Dang, S (corresponding author), Miami VA Geriatr Res Educ & Clin Ctr, Bruce W Carter Vet Affairs Med Ctr, 1201 NW 16th St,11GRC, Miami, FL 33125 USA.	stuti.dang@va.gov			VHA Office of Rural Health; Miami VA Geriatric Research, Education, and Clinical Center	Funding for this project was provided by the VHA Office of Rural Health. The project was also supported by the Miami VA Geriatric Research, Education, and Clinical Center. Findings in this article were presented, in part, at the Gerontological Society of America's 68th Annual Scientific Meeting (November 18, 2015) and the Geriatrics & Extended Care Leads Virtual Conference (April 26, 2016).	Azad N, 2012, CAN GERIATR J, V15, P96, DOI 10.5770/cgj.15.28; Barton C, 2011, TELEMED E-HEALTH, V17, P789, DOI 10.1089/tmj.2011.0083; Bass DM, 2013, J AM GERIATR SOC, V61, P1377, DOI 10.1111/jgs.12362; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Chodosh J, 2004, J AM GERIATR SOC, V52, P1051, DOI 10.1111/j.1532-5415.2004.52301.x; Chua R, 2001, J NEUROL NEUROSUR PS, V71, P63, DOI 10.1136/jnnp.71.1.63; Ciemins EL, 2009, TELEMED J E-HEALTH, V15, P476, DOI 10.1089/tmj.2008.0144; COLERICK EJ, 1986, J AM GERIATR SOC, V34, P493, DOI 10.1111/j.1532-5415.1986.tb04239.x; Cooke DD, 2001, AGING MENT HEALTH, V5, P120; Craig JJ, 1999, J TELEMED TELECARE, V5, P177, DOI 10.1258/1357633991933594; Cullum CM, 2006, ASSESSMENT, V13, P385, DOI 10.1177/1073191106289065; Dang S, 2008, J TELEMED TELECARE, V14, P443, DOI 10.1258/jtt.2008.080608; Dang S, 2008, SOUTH MED J, V101, P1246, DOI 10.1097/SMJ.0b013e318187cccc; DeKosky S, 2003, ALZ DIS ASSOC DIS, V17, pS99, DOI 10.1097/00002093-200307004-00004; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Dyer CB, 2000, J AM GERIATR SOC, V48, P205, DOI 10.1111/j.1532-5415.2000.tb03913.x; Easter Seals Disability Services, 2006, CAR RUR AM; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Harrell KM, 2014, J AM MED DIR ASSOC, V15, P600, DOI 10.1016/j.jamda.2014.04.015; Katz AE, 2006, INTERACTIVE DEMENTIA; KOENIG HG, 1988, INT J PSYCHIAT MED, V18, P17; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Loh PK, 2007, J TELEMED TELECARE, V13, P90, DOI 10.1258/135763307780096159; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin-Khan M, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.004; Morgan DG, 2009, AGING MENT HEALTH, V13, P17, DOI 10.1080/13607860802154432; Morgan DG, 2002, SOC SCI MED, V55, P1129, DOI 10.1016/S0277-9536(01)00255-6; Sclan S G, 1992, Int Psychogeriatr, V4 Suppl 1, P55; Shores MM, 2004, INT J GERIATR PSYCH, V19, P101, DOI 10.1002/gps.1029; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wackerbarth SB, 2002, PATIENT EDUC COUNS, V47, P95, DOI 10.1016/S0738-3991(01)00194-X; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	37	17	17	3	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627	1556-3669		TELEMED E-HEALTH	Telemed. e-Health	MAR	2018	24	3					203	209		10.1089/tmj.2017.0089			7	Health Care Sciences & Services	Health Care Sciences & Services	GA3IQ	WOS:000428222400005	28686082				2021-06-18	
J	De Kegel, D; Vastmans, J; Fehervary, H; Depreitere, B; Vander Sloten, J; Famaey, N				De Kegel, Dries; Vastmans, Julie; Fehervary, Heleen; Depreitere, Bart; Vander Sloten, Jos; Famaey, Nele			Biomechanical characterization of human dura mater	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Planar biaxial tensile tests; Dura mater; Constitutive modelling; Gasser-Ogden-Holzapfel model; Ogden model	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; FINITE-ELEMENT-ANALYSIS; INTRACRANIAL-PRESSURE; MECHANICAL-PROPERTIES; SPINAL-CORD; HUMAN HEAD; TISSUE; MENINGES; GLYCEROL	A reliable computational model of the human head is necessary for better understanding of the physical mechanisms of traumatic brain injury (TBI), car-crash investigation, development of protective head gear and advancement of dural replacement materials. The performance and biofidelity of these models depend largely on the material description of the different structures present in the head. One of these structures is the dura mater, the protective layer around the brain. We tested five human dura mater specimens, with samples at different locations, using planar biaxial tests. We describe the resulting stress-strain curves using both the anisotropic Gasser-Ogden-Holzapfel (GOH) model and the isotropic one-term Ogden model. The low-strain section of the curves is also described using a Neo-Hookean formulation. The obtained stress-strain curves reveal highly nonlinear but isotropic behaviour. A significant amount of inter- and intra-specimen variability is noticed, whereby the latter does not seem to be influenced by location. The GOH model achieves the best fit of the individual test data. A simple Neo-Hookean model can only be used with extreme caution, as it does not manage to capture the nonlinear effects present even at low strains.	[De Kegel, Dries; Vastmans, Julie; Fehervary, Heleen; Vander Sloten, Jos; Famaey, Nele] Katholieke Univ Leuven, Biomech Sect, Leuven, Belgium; [Depreitere, Bart] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Neurosurg, Leuven, Belgium	De Kegel, D (corresponding author), Katholieke Univ Leuven, Biomech Sect, Leuven, Belgium.	dries.dekegel@kuleuven.be	Vastmans, Julie/AAP-2906-2020; Depreitere, Bart/AAA-9846-2020; Fehervary, Heleen/AAG-6014-2019	Vastmans, Julie/0000-0001-5415-875X; Depreitere, Bart/0000-0002-7458-0648; Famaey, Nele/0000-0002-7374-8912	Research Foundation Flanders (FWO)FWO [G.0067.13, 1535316N, PDO-012]	This research was funded by a research project, a pre- and post-doctoral fellowship of the Research Foundation Flanders (FWO) (G.0067.13, 1535316N, PDO-012). The authors would like to express their sincerest gratitude to Gracia Umuhire Musigazi, MD, for her help with harvesting the cranial vault dura mater, and to Lotte Vanmol, MSc., for her help with the thickness measurements and the implementation of the filter.	Adeeb N, 2012, CHILD NERV SYST, V28, P827, DOI 10.1007/s00381-012-1744-6; Andersson J., 2013, THESIS, V10; Baeck K, 2013, THESIS; Bashkatov AN, 2003, BIOPHYS J, V85, P3310, DOI 10.1016/S0006-3495(03)74750-X; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Bylski D. I., 1983, J BIOMECH ENG, V105, P71; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chauvet D, 2010, NEUROSURG REV, V33, P287, DOI 10.1007/s10143-010-0261-x; Chen YL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/815981; Clarke A G, 1944, Postgrad Med J, V20, P74; Ellis H, 2012, SURGERY, V30, P99; Esopenko C, 2015, J NEUROTRAUM, V32, P209, DOI 10.1089/neu.2014.3506; Faul M., 2011, INJURY PREV, V16, P268; Fehervary H, 2016, J MECH BEHAV BIOMED, V61, P135, DOI 10.1016/j.jmbbm.2016.01.011; FUNG YC, 1993, BIOMECHANICS; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gillis J., 2017, OPTISTACK; Haimann MCJ, 1998, J ANAT, V192, P99; HOFFMAN AH, 1984, J BIOMECH, V17, P795, DOI 10.1016/0021-9290(84)90110-6; Holzapfel GA., 2001, HDB MAT BEHAV MODELS, P1057, DOI DOI 10.1016/13978-012443341-0/50107-1; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; Li ZG, 2011, ANN BIOMED ENG, V39, P2984, DOI 10.1007/s10439-011-0409-z; MacManus DB, 2017, ACTA BIOMATER, V57, P384, DOI 10.1016/j.actbio.2017.05.022; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Mao HJ, 2011, J NEUROTRAUM, V28, P2263, DOI 10.1089/neu.2010.1600; Mao HJ, 2011, INT J NUMER METH BIO, V27, P357, DOI 10.1002/cnm.1403; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Maxeiner H, 1997, FORENSIC SCI INT, V89, P103, DOI 10.1016/S0379-0738(97)00124-2; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; O'Leary SA, 2013, J BIOMECH, V46, P1955, DOI 10.1016/j.jbiomech.2013.05.003; OGDEN RW, 1972, J MECH PHYS SOLIDS, V20, P77, DOI 10.1016/0022-5096(72)90032-4; Patel N, 2009, SEMIN ULTRASOUND CT, V30, P559, DOI 10.1053/j.sult.2009.08.006; Protasoni M, 2011, J NEUROSURG, V114, P1723, DOI 10.3171/2010.12.JNS101732; Robertson D, 2014, J MECH BEHAV BIOMED, V40, P234, DOI 10.1016/j.jmbbm.2014.09.006; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Runza M, 1999, ANESTH ANALG, V88, P1317, DOI 10.1097/00000539-199906000-00022; Sacks M. S., 2000, BIAXIAL MECH EVALUAT; Salimi JM, 2014, COMPUT METHOD BIOMEC, V17, P1368, DOI [10.1080/10255842.2012.748755, DOI 10.1080/10255842.2012.748755]; Schafer RW, 2011, IEEE SIGNAL PROC MAG, V28, P111, DOI 10.1109/MSP.2011.941097; Shetye SS, 2014, J MECH BEHAV BIOMED, V34, P146, DOI 10.1016/j.jmbbm.2014.02.014; Standring S., 2008, GRAYS ANATOMY ANATOM; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; van Noort R, 1981, Clin Phys Physiol Meas, V2, P197, DOI 10.1088/0143-0815/2/3/003; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Wilcox Ruth K, 2003, J Orthop Sci, V8, P432, DOI 10.1007/s10776-003-0644-9; Yang King H, 2006, Stapp Car Crash J, V50, P429; Yang ZR, 2015, BRAIN RES, V1602, P160, DOI 10.1016/j.brainres.2014.11.038; Yue XF, 2008, AFR J BIOTECHNOL, V7, P689; Zhang L. Y., 2001, STAPP CAR CRASH J, V45, P1	55	17	17	1	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAR	2018	79						122	134		10.1016/j.jmbbm.2017.12.023			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	FW1PQ	WOS:000425072300015	29294435				2021-06-18	
J	Kerr, WT; Janio, EA; Braesch, CT; Le, JM; Hori, JM; Patel, AB; Gallardo, NL; Bauirjan, J; Chau, AM; Hwang, ES; Davis, EC; Buchard, A; Torres-Barba, D; D'Ambrosio, S; Al Banna, M; Cho, AY; Engel, J; Cohen, MS; Stern, JM				Kerr, Wesley T.; Janio, Emily A.; Braesch, Chelsea T.; Le, Justine M.; Hori, Jessica M.; Patel, Akash B.; Gallardo, Norma L.; Bauirjan, Janar; Chau, Andrea M.; Hwang, Eric S.; Davis, Emily C.; Buchard, Albert; Torres-Barba, David; D'Ambrosio, Shannon; Al Banna, Mona; Cho, Andrew Y.; Engel, Jerome, Jr.; Cohen, Mark S.; Stern, John M.			An objective score to identify psychogenic seizures based on age of onset and history	EPILEPSY & BEHAVIOR			English	Article						Dissociative seizures; Diagnostic score; Logistic regression; Multiple imputation	POSTTRAUMATIC-STRESS-DISORDER; TEMPORAL-LOBE EPILEPSY; NONEPILEPTIC SEIZURES; SYSTEMS QUESTIONNAIRE; TRAUMATIC EVENTS; DIAGNOSTIC DELAY; FOCAL EPILEPSY; BRAIN-INJURY; HEAD-INJURY; CHILDREN	Objective: Psychogenic nonepileptic seizure (PNES) is a common diagnosis after evaluation of medication resistant or atypical seizures with video-electroencephalographic monitoring (VEM), but usually follows a long delay after the development of seizures, during which patients are treated for epilepsy. Therefore, more readily available diagnostic tools are needed for earlier identification of patients at risk for PNES. A tool based on patient reported psychosocial history would be especially beneficial because it could be implemented in the outpatient clinic. Methods: Based on the data from 1375 patients with VEM-confirmed diagnoses, we used logistic regression to compare the frequency of specific patient-reported historical events, demographic information, age of onset, and delay from first seizure until VEM in five mutually exclusive groups of patients: epileptic seizures (ES), PNES, physiologic nonepileptic seizure-like events (PSLE), mixed PNES plus ES, and inconclusive monitoring. To determine the diagnostic utility of this information to differentiate PNES only from ES only, we used multivariate piecewise-linear logistic regression trained using retrospective data from chart review and validated based on data from 246 prospective standardized interviews. Results: The prospective area under the curve of our weighted multivariate piecewise-linear by-sex score was 73%, with the threshold that maximized overall retrospective accuracy resulting in a prospective sensitivity of 74% (95% CI: 70-79%) and prospective specificity of 71% (95% CI: 64-82%). The linear model and piecewise linear without an interaction term for sex had very similar performance statistics. In the multivariate piecewise-linear sex-split predictive model, the significant factors positively associated with ES were history of febrile seizures, current employment or active student status, history of traumatic brain injury (TBI), and longer delay from first seizure until VEM. The significant factors associated with PNES were female sex, older age of onset, mild TBI, and significant stressful events with sexual abuse, in particular, increasing the likelihood of PNES. Delays longer than 20 years, age of onset after 31 years for men, and age of onset after 40 years for women had no additional effect on the likelihood of PNES. Discussion: Our promising results suggest that an objective score has the potential to serve as an early outpatient screening tool to identify patients with greater likelihood of PNES when considered in combination with other factors. In addition, our analysis suggests that sexual abuse, more than other psychological stressors including physical abuse, is more associated with PNES. There was a trend of increasing frequency of PNES for women during childbearing years and plateauing outside those years that was not observed in men. (C) 2017 Elsevier Inc. All rights reserved.	[Kerr, Wesley T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; [Kerr, Wesley T.; Janio, Emily A.; Braesch, Chelsea T.; Le, Justine M.; Hori, Jessica M.; Patel, Akash B.; Gallardo, Norma L.; Bauirjan, Janar; Chau, Andrea M.; Hwang, Eric S.; Davis, Emily C.; Buchard, Albert; Torres-Barba, David; D'Ambrosio, Shannon; Al Banna, Mona; Cho, Andrew Y.; Engel, Jerome, Jr.; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Engel, Jerome, Jr.; Cohen, Mark S.; Stern, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Engel, Jerome, Jr.; Cohen, Mark S.; Stern, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Cohen, Mark S.] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA; [Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Cohen, Mark S.] Univ Calif Los Angeles, Dept Biomed Phys, Los Angeles, CA USA; [Cohen, Mark S.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA; [Cohen, Mark S.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA; [Kerr, Wesley T.] Eisenhower Med Ctr, Dept Internal Med, Rancho Mirage, CA USA	Kerr, WT (corresponding author), Univ Calif Los Angeles, Semel Inst, 760 Westwood Plaza,Room C9-420, Los Angeles, CA 90095 USA.	WesleyTK@UCLA.edu	Kerr, Wesley T/I-6301-2019; Cohen, Mark S/C-6610-2011	Kerr, Wesley T/0000-0002-5546-5951; Cohen, Mark S/0000-0001-6731-4053; Janio, Emily/0000-0002-2221-0805; Stern, John/0000-0002-3549-1642	UCLA-California Institute of Technology Medical Scientist Training Program [NIH T32 GM08042]; Neuroimaging Training Program [NIH T90 DA022768, R90 DA022768, R90 DA023422]; William M. Keck FoundationW.M. Keck Foundation [NS03310, NS080181]; UCLA Departments of Psychiatry & Biobehavioral Sciences and Biomathematics; Eisenhower Medical Center Department of Internal Medicine; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS002808, P20NS080181, R01NS033310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T90DA022768, R90DA023422, R21DA026109] Funding Source: NIH RePORTER	The authors thank Kirk Shattuck, Marc Nuwer, and Edward P. Lau for organization support, access to the data, and technical support. This work was supported by the UCLA-California Institute of Technology Medical Scientist Training Program (NIH T32 GM08042), the Neuroimaging Training Program (NIH T90 DA022768, R90 DA022768, & R90 DA023422 to MSC), the William M. Keck Foundation, research grants to JE (NS03310 & NS080181), the UCLA Departments of Psychiatry & Biobehavioral Sciences and Biomathematics, and the Eisenhower Medical Center Department of Internal Medicine.	Adams SJ, 2008, BRIT J PSYCHIAT, V192, P464, DOI 10.1192/bjp.bp.107.046664; Alessi R, 2014, SEIZURE-EUR J EPILEP, V23, P906, DOI 10.1016/j.seizure.2014.07.016; Alessi R, 2013, EPILEPSY BEHAV, V27, P292, DOI 10.1016/j.yebeh.2013.02.003; ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; Asadi-Pooya A, 2017, NEUROL SCI, V38, P935, DOI 10.1007/s10072-017-2887-8; Asadi-Pooya AA, 2016, J CLIN NEUROSCI, V34, P105, DOI 10.1016/j.jocn.2016.05.037; Badour CL, 2013, J ANXIETY DISORD, V27, P155, DOI 10.1016/j.janxdis.2012.11.002; Baroni G, 2016, SEIZURE-EUR J EPILEP, V37, P35, DOI 10.1016/j.seizure.2016.02.003; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Begley CE, 2000, EPILEPSIA, V41, P342, DOI 10.1111/j.1528-1157.2000.tb00166.x; Behrouz R, 2006, EPILEPSY BEHAV, V8, P649, DOI 10.1016/j.yebeh.2006.02.003; Bernasconi N, 2005, NEUROLOGY, V65, P223, DOI 10.1212/01.wnl.0000169066.46912.fa; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; Dickinson P, 2012, EPILEPSIA, V53, P1679, DOI 10.1111/j.1528-1167.2012.03606.x; Diseth TH, 2005, NORD J PSYCHIAT, V59, P79, DOI 10.1080/08039480510022963; Dixit R, 2013, EPILEPSY BEHAV, V28, P137, DOI 10.1016/j.yebeh.2013.05.004; Duncan R, 2006, EXPERT OPIN DRUG SAF, V5, P609, DOI 10.1517/14740338.5.5.609; Duncan R, 2006, NEUROLOGY, V66, P1644, DOI 10.1212/01.wnl.0000223320.94812.7a; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GATES JR, 1985, ARCH NEUROL-CHICAGO, V42, P1183, DOI 10.1001/archneur.1985.04060110065017; Gazzola DM, 2012, EPILEPSY BEHAV, V25, P662, DOI 10.1016/j.yebeh.2012.10.008; Gilbert DL, 2003, NEUROLOGY, V60, P564, DOI 10.1212/01.WNL.0000044152.79316.27; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Haneef Z, 2010, NEUROLOGY, V75, P699, DOI 10.1212/WNL.0b013e3181eee457; Hesdorffer DC, 2012, EPILEPSIA, V53, P1471, DOI 10.1111/j.1528-1167.2012.03567.x; Holmes MD, 2001, EPILEPSY BEHAV, V2, P568, DOI 10.1006/ebeh.2001.0268; Hubsch C, 2010, J NEUROL, V82, P955; Isaac M, 2006, CURR OPIN PSYCHIATR, V19, P61, DOI 10.1097/01.yco.0000194811.83720.69; JEFFERYS JGR, 1995, ITAL J NEUROL SCI, V16, P27, DOI 10.1007/BF02229071; Jones SG, 2010, PSYCHOSOM MED, V72, P487, DOI 10.1097/PSY.0b013e3181d96550; Kallen B, 2014, SEMIN FETAL NEONAT M, V19, P239, DOI 10.1016/j.siny.2014.04.002; Kellinghaus C, 2004, J NEUROL, V251, P704, DOI 10.1007/s00415-004-0406-3; Kerr WT, 2017, EPILEPSIA, V58, P1852, DOI 10.1111/epi.13888; Kerr WT, 2016, SEIZURE-EUR J EPILEP, V40, P123, DOI 10.1016/j.seizure.2016.06.015; Kerr WT, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00031; Kerr WT, 2012, EPILEPSIA, V53, pe189, DOI 10.1111/j.1528-1167.2012.03653.x; KRUMHOLZ A, 1983, NEUROLOGY, V33, P498, DOI 10.1212/WNL.33.4.498; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; LaFrance WC, 2013, EPILEPSIA, V54, P53, DOI 10.1111/epi.12106; LaFrance WC, 2006, NEUROLOGY, V66, P1620, DOI 10.1212/01.wnl.0000224953.94807.be; LaFrance WC, 2004, EPILEPSIA, V45, P15, DOI 10.1111/j.0013-9580.2004.452002.x; LANCMAN ME, 1994, J CHILD NEUROL, V9, P404, DOI 10.1177/088307389400900413; Lesser RP, 1996, NEUROLOGY, V46, P1499, DOI 10.1212/WNL.46.6.1499; Magee JA, 2014, EPILEPSY BEHAV, V33, P45, DOI 10.1016/j.yebeh.2014.02.010; Marin-Valencia I, 2014, EPILEPSIA, V55, P970, DOI 10.1111/epi.12650; McInnes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174847; MEIERKORD H, 1991, NEUROLOGY, V41, P1643, DOI 10.1212/WNL.41.10.1643; MILLER ME, 1991, STAT MED, V10, P1213, DOI 10.1002/sim.4780100805; Nagamitsu S, 2011, BRAIN DEV-JPN, V33, P601, DOI 10.1016/j.braindev.2010.10.001; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Oto M, 2005, SEIZURE-EUR J EPILEP, V14, P33, DOI 10.1016/j.seizure.2004.02.008; Pakalnis A, 2000, J CHILD NEUROL, V15, P78, DOI 10.1177/088307380001500202; Patel H, 2007, EPILEPSIA, V48, P2086, DOI 10.1111/j.1528-1167.2007.01200.x; Perez DL, 2016, CNS SPECTRUMS, V21, P239, DOI 10.1017/S109285291600002X; Pittau F, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.01969.x; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Razvi S, 2012, EPILEPSY BEHAV, V23, P7, DOI 10.1016/j.yebeh.2011.10.009; Reuber M, 2002, NEUROLOGY, V58, P493, DOI 10.1212/WNL.58.3.493; Ritter AC, 2016, EPILEPSIA, V57, P1503, DOI 10.1111/epi.13470; Robles L, 2015, EPILEPSY BEHAV, V45, P151, DOI 10.1016/j.yebeh.2015.02.003; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Rubin DB., 1987, MULTIPLE IMPUTATION; Scioli-Salter ER, 2016, PSYCHOL TRAUMA-US, V8, P585, DOI 10.1037/tra0000135; Scott DF, 1982, PSEUDOSEIZURES, P21; Seneviratne U, 2012, EPILEPSIA, V53, pe63, DOI 10.1111/j.1528-1167.2011.03382.x; Seneviratne U, 2010, EPILEPSIA, V51, P1159, DOI 10.1111/j.1528-1167.2010.02560.x; St Louis Erik K, 2016, Continuum (Minneap Minn), V22, P15, DOI 10.1212/CON.0000000000000284; Syed TU, 2008, EPILEPSIA, V49, P898, DOI 10.1111/j.1528-1167.2007.01456.x; Syed TU, 2011, ANN NEUROL, V69, P997, DOI 10.1002/ana.22345; Szabo L, 2012, EPILEPSIA, V53, P565, DOI 10.1111/j.1528-1167.2012.03404.x; Taylor BC, 2017, J NEUROTRAUM, V34, P2567, DOI 10.1089/neu.2016.4910; Tojek TM, 2000, PSYCHOSOMATICS, V41, P221, DOI 10.1176/appi.psy.41.3.221; Valente KD, 2017, PEDIATR NEUROL, V67, P71, DOI 10.1016/j.pediatrneurol.2016.10.021; vanMerode T, 1997, SEIZURE, V6, P311; Vezzaani A, 2015, COLD SPRING HARB PER, V6, DOI DOI 10.1101/CSHPERSPECT.A022699; Vincentiis S, 2006, EPILEPSY BEHAV, V8, P294, DOI 10.1016/j.yebeh.2005.08.014; WALCZAK TS, 1995, EPILEPSIA, V36, P1131, DOI 10.1111/j.1528-1157.1995.tb00472.x; Walczak TS, 2001, EPILEPSIA, V42, P804; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; WILKUS RJ, 1984, EPILEPSIA, V25, P100, DOI 10.1111/j.1528-1157.1984.tb04162.x; Wyllie E, 1999, ARCH PEDIAT ADOL MED, V153, P244	86	17	17	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	MAR	2018	80						75	83		10.1016/j.yebeh.2017.11.035			9	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	GA0PK	WOS:000428016400013	29414562	Green Accepted			2021-06-18	
J	Lippa, SM; Brickell, TA; Bailie, JM; French, LM; Kennedy, JE; Lange, RT				Lippa, Sara M.; Brickell, Tracey A.; Bailie, Jason M.; French, Louis M.; Kennedy, Jan E.; Lange, Rael T.			Postconcussion Symptom Reporting After Mild Traumatic Brain Injury in Female Service Members: Impact of Gender, Posttraumatic Stress Disorder, Severity of Injury, and Associated Bodily Injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						female; gender; mild traumatic brain injury; military; postconcussion symptoms; posttraumatic stress disorder; symptom reporting	IRAQI FREEDOM; OEF/OIF VETERANS; COMBAT STRESS; POLYTRAUMA; BLAST; AFGHANISTAN; PERSISTENT; DEPLOYMENT; TBI; CONCUSSION	Objective: Examine effects of diagnostically relevant posttraumatic stress disorder (PTSD) symptoms, mild traumatic brain injury (TBI) severity, and associated bodily injury severity on postconcussion symptom reporting in female service members (SM) compared with a matched sample of male SM. Setting: Six US military medical treatment facilities. Participants: A total of 158 SM (79 females, 79males) evaluated within 30months aftermild TBI. Men and women were matched by age, days postinjury, PTSD symptom status, mild TBI severity, and bodily injury severity. All passed a measure of symptom validity. Design: Compare reported postconcussion symptoms for men and women stratified by PTSD diagnostic symptoms (present/absent), mild TBI severity (alteration of consciousness/loss of consciousness), and bodily injury severity (mild/moderate-severe). Main Measures: Neurobehavioral Symptom Inventory, PTSD Checklist, Abbreviated Injury Scale. Results: Overall postconcussion symptom reporting increased with PTSD but did not significantly differ based on severity of mild TBI or associated bodily injury. Females reported more somatosensory and/or vestibular symptoms than males under some circumstances. Females in the PTSD-Present group, Alteration of Consciousness Only group, and Moderate-Severe Bodily Injury group reported more somatosensory symptoms than males in those groups. Females in the Alteration of Consciousness Only group and Minor Bodily Injury group reported more vestibular symptoms than males in those groups. Conclusion: Diagnostically relevant PTSD symptoms, mild TBI severity, and bodily injury severity differentially impact somatosensory and vestibular postconcussion symptom reporting for male and female SM after mild TBI. Controlling for PTSD and symptom validity resulted in fewer gender-based differences in postconcussive symptoms than previously demonstrated in the literature.	[Lippa, Sara M.; Brickell, Tracey A.; Bailie, Jason M.; French, Louis M.; Kennedy, Jan E.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Lippa, Sara M.; Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Lippa, Sara M.; Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Bailie, Jason M.] Naval Hosp Camp Pendleton, Oceanside, CA USA; [French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Kennedy, Jan E.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada	Lippa, SM (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 19 Room 6003,8901 Wisconsin Ave, Bethesda, MD 20889 USA.	saralippa@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This material is based upon work supported by the Defense and Veterans Brain Injury Center. The views, opinions, and/or findings contained in this article are those of the authors and should not be construed as an official Department of Defense position, policy, or decision unless so designated by other official documentation.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2017, J HEAD TRAUMA REHAB, V32, P46, DOI 10.1097/HTR.0000000000000208; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brickell TA, 2017, J NEUROTRAUM, V34, P300, DOI 10.1089/neu.2016.4403; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Defense Manpower Data Center, 2016, TABL ACT DUT FEM RAN; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; French LM, 2014, J NEUROTRAUM, V31, P1607, DOI 10.1089/neu.2014.3401; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Iverson KM, 2013, J WOMENS HEALTH, V22, P267, DOI 10.1089/jwh.2012.3755; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2011, NATO SCI PEACE SEC, V86, P171, DOI 10.3233/978-1-60750-797-0-171; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P265, DOI 10.1080/13803395.2015.1004303; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Secretary of Defense, IMPL GUID FULL INT W; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	51	17	17	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2018	33	2					101	112		10.1097/HTR.0000000000000353			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GN6AI	WOS:000439152200011	29084103				2021-06-18	
J	Moles, A; Heudes, PM; Amelot, A; Cristini, J; Salaud, C; Roualdes, V; Riem, T; Martin, SA; Raoul, S; Terreaux, L; Bord, E; Buffenoir, K				Moles, Alexis; Heudes, Pierre Marie; Amelot, Aymeric; Cristini, Joseph; Salaud, Celine; Roualdes, Vincent; Riem, Tanguy; Martin, Stephane Andre; Raoul, Sylvie; Terreaux, Luc; Bord, Eric; Buffenoir, Kevin			Long-Term Follow-Up Comparative Study of Hydroxyapatite and Autologous Cranioplasties: Complications, Cosmetic Results, Osseointegration	WORLD NEUROSURGERY			English	Article						Autologous; Complication; Cosmetics; Cranioplasty; Hydroxyapatite; Osseointegration	CUSTOM-MADE HYDROXYAPATITE; TRAUMATIC BRAIN-INJURY; LARGE SKULL DEFECT; DECOMPRESSIVE CRANIECTOMY; BONE FLAP; RECONSTRUCTION; IMPLANTATION; PROSTHESIS; EXPERIENCE; RESORPTION	OBJECTIVE: A three-dimensional reconstruction technique using the CustomBone (CB) prosthesis allows custom-made cranioplasty (CP) possessing osseointegration properties owing to its porous hydroxyapatite (HA) composition. This reconstruction technique has replaced less expensive techniques such as subcutaneously preserved autologous bone (SP). Our primary objective was to evaluate complications between CB and SP CP techniques. A secondary objective was to assess cosmetic results and osseointegration of CPs. METHODS: This single-center study comprised patients undergoing delayed CB or SP CP after craniectomy between 2007 and 2014. A prospective interview was conducted to collect all data, including 2-year follow-up clinical and radiologic data. Cosmetic results were assessed by a qualitative score, and osseointegration was assessed by measuring relative fusion at the CP margins. RESULTS: Of 100 patients undergoing CB or SP CP between 2007 and 2014, 92 (CB, n =44; SP, n =48) participated in the prospective interview. No significant difference in complication rates was observed between the 2 groups. The main complication specific to the CB group was fracture of the prosthesis observed in 20.8% patients. A higher rate of good cosmetic results was observed in the CB group (92.5% vs. 74.3%, P = 0.031). In the CB group, 51% of patients demonstrated no signs of bone fusion of the CP. CONCLUSIONS: Although the CB prosthesis is associated with cosmetic advantages, the porous hydroxyapatite composition makes it fragile in the short-term and long-term, and effective osseointegration remains uncertain.	[Moles, Alexis; Amelot, Aymeric; Cristini, Joseph; Salaud, Celine; Roualdes, Vincent; Riem, Tanguy; Martin, Stephane Andre; Raoul, Sylvie; Terreaux, Luc; Bord, Eric; Buffenoir, Kevin] Nantes Univ Hosp, Neurosurg & Neurotraumatol Dept, Nantes, France; [Heudes, Pierre Marie] Nantes Univ Hosp, Dept Neuroradiol, Nantes, France; [Amelot, Aymeric] Hop La Pitie Salpetriere, AP HP, Dept Neurosurg, Paris, France; [Raoul, Sylvie; Buffenoir, Kevin] INSERM, EA3826, Pain Neuromodulat & Qual Life, Nantes, France	Moles, A (corresponding author), Nantes Univ Hosp, Neurosurg & Neurotraumatol Dept, Nantes, France.	alexis.moles@neurochirurgie.fr	Buffenoir, Kevin/ABD-9003-2020				Adetchessi AT, 2012, NEUROCHIRURGIE, V58, P382, DOI 10.1016/j.neuchi.2012.06.001; Beuriat PA, 2016, NEUROCHIRURGIE, V62, P25, DOI 10.1016/j.neuchi.2016.04.003; Brommeland T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0155-6; Cheng Cheng-Hsin, 2014, Clin Neurol Neurosurg, V124, P85, DOI 10.1016/j.clineuro.2014.06.029; Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Frassanito P, 2013, CLIN NEUROL NEUROSUR, V115, P1496, DOI 10.1016/j.clineuro.2012.11.032; Fricia M, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.027; Hardy H, 2012, NEUROCHIRURGIE, V58, P25, DOI 10.1016/j.neuchi.2011.09.006; Haute Autorite de Sante, CUSTOMBONE 2014; Honeybul S, 2016, J NEUROSURG, V125, P775, DOI 10.3171/2016.3.JNS1683; Lemee JM, 2013, NEUROCHIRURGIE, V59, P60, DOI 10.1016/j.neuchi.2012.10.138; Lindner D, 2017, J NEUROSURG, V126, P175, DOI 10.3171/2015.10.JNS151245; Lovati AB, 2016, CALCIFIED TISSUE INT, V99, P209, DOI 10.1007/s00223-016-0140-8; Malcolm JG, 2016, J CLIN NEUROSCI, V33, P39, DOI 10.1016/j.jocn.2016.04.017; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Martini L, 2012, PLAST RECONSTR SURG, V129, p625E, DOI 10.1097/PRS.0b013e318244220d; Mastrogiacomo M, 2005, Orthod Craniofac Res, V8, P277, DOI 10.1111/j.1601-6343.2005.00350.x; Messina G, 2011, ACTA NEUROCHIR, V153, P1717, DOI 10.1007/s00701-011-1014-5; Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516; Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; Sprio S, 2016, J APPL BIOMATER FUNC, V14, pE470, DOI 10.5301/jabfm.5000293; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Staffa G, 2012, J CRANIO MAXILL SURG, V40, pE65, DOI 10.1016/j.jcms.2011.04.014; Stefini R, 2015, J APPL BIOMATER FUNC, V13, pE136, DOI 10.5301/jabfm.5000211; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Wen L, 2015, BRAIN INJURY, V29, P1654, DOI 10.3109/02699052.2015.1075248; Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021; Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025; Zanotti B, 2015, ACTA NEUROCHIR, V157, P517, DOI 10.1007/s00701-014-2319-y	31	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2018	111						E388	E395		10.1016/j.wneu.2017.12.082			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG7WI	WOS:000432908700048	29277595				2021-06-18	
J	Xiong, LL; Hu, Y; Zhang, P; Zhang, Z; Li, LH; Gao, GD; Zhou, XF; Wang, TH				Xiong, Liu-Lin; Hu, Yue; Zhang, Piao; Zhang, Zhuo; Li, Li-Hong; Gao, Guo-Dong; Zhou, Xin-Fu; Wang, Ting-Hua			Neural Stem Cell Transplantation Promotes Functional Recovery from Traumatic Brain Injury via Brain Derived Neurotrophic Factor-Mediated Neuroplasticity	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Neural stem cell transplantation; Synaptophysin; Brain-derived neurotrophic factor; RNA knockdown	SPINAL-CORD-INJURY; ADULT RATS; DOPAMINERGIC-NEURONS; TEMPORAL-CHANGES; BDNF; DIFFERENTIATION; HIPPOCAMPUS; EXPRESSION; DISEASES; MICE	Traumatic brain injury (TBI) induces cognitive impairments, motor and behavioral deficits. Previous evidences have suggested that neural stem cell (NSC) transplantation could facilitate functional recovery from brain insults, but their underlying mechanisms remains to be elucidated. Here, we established TBI model by an electromagnetic-controlled cortical impact device in the rats. Then, 5 mu l NSCs (5.0 x 10(5)/mu l), derived from green fluorescent protein (GFP) transgenic mouse, was transplanted into the traumatic brain regions of rats at 24 h after injury. After differentiation of the NSCs was determined using immunohistochemistry, neurological severity scores (NSS) and rotarod test were conducted to detect the neurological behavior. Western blot and RT-PCR as well as ELASA were used to evaluate the expression of synaptophysin and brain-derived neurotrophic factor (BDNF). In order to elucidate the role of BDNF on the neural recovery after NSC transplantation, BDNF knockdown in NSC was performed and transplanted into the rats with TBI, and potential mechanism for BDNF knockdown in the NSC was analyzed using microassay analysis. Meanwhile, BDNF antibody blockade was conducted to further confirm the effect of BDNF on neural activity. As a result, an increasing neurological function improvement was seen in NSC transplanted rats, which was associated with the upregulation of synaptophysin and BDNF expression. Moreover, transplantation of BDNF knockdown NSCs and BDNF antibody block reduced not only the level of synaptophysin but also exacerbated neurological function deficits. Microassay analysis showed that 14 genes such as Wnt and Gsk3-beta were downregulated after BDNF knockdown. The present data therefore showed that BDNF-mediated neuroplasticity underlie the mechanism of NSC transplantation for the treatment of TBI in adult rats.	[Xiong, Liu-Lin; Hu, Yue; Wang, Ting-Hua] Sichuan Univ, Inst Neurol Dis, West China Hosp, Translat Neurosci Ctr, Chengdu 610041, Sichuan, Peoples R China; [Xiong, Liu-Lin; Hu, Yue; Wang, Ting-Hua] Sichuan Univ, Dept Anesthesiol, West China Hosp, Translat Neurosci Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Piao; Wang, Ting-Hua] Kunming Med Univ, Inst Neurosci, Kunming 650500, Yunnan, Peoples R China; [Zhang, Piao; Wang, Ting-Hua] Kunming Med Univ, Anim Zool Dept, Kunming 650500, Yunnan, Peoples R China; [Zhang, Zhuo; Li, Li-Hong; Gao, Guo-Dong] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Zhou, Xin-Fu] Flinders Univ S Australia, Dept Human Physiol, GPO Box 2100, Adelaide, SA 5001, Australia	Wang, TH (corresponding author), Sichuan Univ, Inst Neurol Dis, West China Hosp, Translat Neurosci Ctr, Chengdu 610041, Sichuan, Peoples R China.; Wang, TH (corresponding author), Sichuan Univ, Dept Anesthesiol, West China Hosp, Translat Neurosci Ctr, Chengdu 610041, Sichuan, Peoples R China.; Wang, TH (corresponding author), Kunming Med Univ, Inst Neurosci, Kunming 650500, Yunnan, Peoples R China.; Wang, TH (corresponding author), Kunming Med Univ, Anim Zool Dept, Kunming 650500, Yunnan, Peoples R China.	tinghua_neuron@263.net	Zhou, Xiaofang/C-6169-2013; Zhou, Xin-Fu/F-4119-2013	Zhou, Xiaofang/0000-0001-6343-1455; Zhou, Xin-Fu/0000-0002-8687-0175	National Key Technology Research and Development Program of the Ministry of Science and Technology of China (CN) [2014BAI01B10]; Program of Innovative Research Team in Science and Technology in University of Yunnan (IRTSTYN); program Innovative Research Team in Science and Technology in Yunnan Province	This research was supported by a grant from the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (CN) (No. 2014BAI01B10) and supported by the Program of Innovative Research Team in Science and Technology in University of Yunnan (IRTSTYN), together with program Innovative Research Team in Science and Technology in Yunnan Province.	Ba YC, 2010, NEUROCHEM RES, V35, P273, DOI 10.1007/s11064-009-0052-3; Beliaeva Ia S, 2013, Ross Fiziol Zh Im I M Sechenova, V99, P976; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Chaturvedi RK, 2008, EXP NEUROL, V210, P608, DOI 10.1016/j.expneurol.2007.12.016; Chen J, 2007, NEUROSCI RES, V59, P399, DOI 10.1016/j.neures.2007.08.006; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Cheng XA, 2011, NEUROSCI LETT, V493, P18, DOI 10.1016/j.neulet.2011.02.006; Christophersen NS, 2006, BRAIN RES BULL, V70, P457, DOI 10.1016/j.brainresbull.2006.07.001; Conti L, 2006, BRAIN PATHOL, V16, P143, DOI 10.1111/j.1750-3639.2006.00009.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fu KY, 2011, ARTIF ORGANS, V35, P363, DOI 10.1111/j.1525-1594.2010.01105.x; Furman JL, 2016, J NEUROSCI, V36, P1502, DOI 10.1523/JNEUROSCI.1930-15.2016; Hasegawa K, 2005, EXP NEUROL, V193, P394, DOI 10.1016/j.expneurol.2004.12.024; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kim SU, 2007, BRAIN DEV-JPN, V29, P193, DOI 10.1016/j.braindev.2006.07.012; Leveque X, 2011, CURR OPIN ORGAN TRAN, V16, P190, DOI 10.1097/MOT.0b013e32834494b5; Li XL, 2007, NEUROPEPTIDES, V41, P135, DOI 10.1016/j.npep.2007.02.001; Li Y, 2011, CELL MOL NEUROBIOL, V31, P407, DOI 10.1007/s10571-010-9633-6; Maller JJ, 2014, MED HYPOTHESES, V83, P838, DOI 10.1016/j.mehy.2014.11.003; Martinez SA, 2001, CURR GENE THER, V1, P279; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Qin DX, 2006, NEUROSCI LETT, V410, P222, DOI 10.1016/j.neulet.2006.10.006; Ramage R, 1999, J PEPT SCI, V5, P195, DOI 10.1002/(SICI)1099-1387(199904)5:4<195::AID-PSC203>3.0.CO;2-G; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rong R, 2011, GROWTH FACTORS, V29, P263, DOI 10.3109/08977194.2011.606786; Shin MS, 2016, INT NEUROUROL J, V20, pS49, DOI 10.5213/inj.1632616.308; Solomon D, 2011, CYTOKINE, V54, P20, DOI 10.1016/j.cyto.2010.12.013; Sun S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083523; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Wang L, 2011, J NEUROSCI METH, V194, P274, DOI 10.1016/j.jneumeth.2010.10.025; Wang TTH, 2006, NEUROREPORT, V17, P1433, DOI 10.1097/01.wnr.0000227980.06013.31; Wei P, 2007, NEUROSCI LETT, V419, P49, DOI 10.1016/j.neulet.2007.03.046; Widera D, 2011, STEM CELLS DEV, V20, P2053, DOI 10.1089/scd.2010.0525; Xu CJ, 2011, NEUROPATH APPL NEURO, V37, P135, DOI 10.1111/j.1365-2990.2010.01117.x; Yan J, 2004, J COMP NEUROL, V480, P101, DOI 10.1002/cne.20344; Yang HJ, 2009, GROWTH FACTORS, V27, P237, DOI 10.1080/08977190903024298; Yang JW, 2015, NEUROPEPTIDES, V54, P35, DOI 10.1016/j.npep.2015.08.005; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Zeng X, 2011, CELL TRANSPLANT, V20, P1881, DOI 10.3727/096368911X566181; Zhang C, 2017, REDOX BIOL, V11, P1, DOI 10.1016/j.redox.2016.10.019; Zhang HT, 2008, J CHEM NEUROANAT, V36, P138, DOI 10.1016/j.jchemneu.2008.07.004; Zhang HT, 2007, J HISTOCHEM CYTOCHEM, V55, P1, DOI 10.1369/jhc.6A6952.2006; Zhang ZB, 2011, BRAIN INJURY, V25, P227, DOI 10.3109/02699052.2010.542430; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	47	17	19	0	26	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2696	2711		10.1007/s12035-017-0551-1			16	Neurosciences	Neurosciences & Neurology	FY5TG	WOS:000426897800070	28421542				2021-06-18	
J	Zhang, JY; Lee, JH; Gu, XH; Wei, ZZ; Harris, MJ; Yu, SP; Wei, L				Zhang, James Ya; Lee, Jin Hwan; Gu, Xiaohuan; Wei, Zheng Zachory; Harris, Mallory Jessica; Yu, Shan Ping; Wei, Ling			Intranasally Delivered Wnt3a Improves Functional Recovery after Traumatic Brain Injury by Modulating Autophagic, Apoptotic, and Regenerative Pathways in the Mouse Brain	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; autophagy; beta-catenin; functional recovery; regeneration; traumatic brain injury; Wnt	CONTROLLED CORTICAL IMPACT; STEM-CELLS; NEURONAL DIFFERENTIATION; SIGNALING PROMOTES; ISCHEMIC-STROKE; NERVOUS-SYSTEM; BETA-CATENIN; MICE; DEATH; PROLIFERATION	Traumatic brain injury (TBI) is a prevalent disorder, but no effective therapies currently exist. An underlying patho-physiology of TBI includes the pathological elevation of autophagy. beta-Catenin, a downstream mediator of the canonical Wnt pathway, is a repressor of autophagy. The Wnt/beta-catenin pathway plays a crucial role in cell proliferation and neuronal plasticity/repair in the adult brain. We hypothesized that activation of this pathway could promote neuroprotection and neural regeneration following TBI. In the controlled cortical impact (CCI) model of TBI in C57BL/6 mice (total n = 160), we examined intranasal application of recombinant Wnt3a (2 mu g/kg) in a short-term (1 dose/day for 2 days) and long-term (1 dose/day for 7 days) regimen. Immunohistochemistry was performed at 1 to 14 days post-TBI to assess cell death and neurovascular regeneration. Western blotting measured canonical Wnt3a activity, expression of growth factors, and cell death markers. Longitudinal behavior assays evaluated functional recovery. In short-term experiments, Wnt3a treatment with a 60-min delay post-TBI suppressed TBI-induced autophagic activity in neurons (44.3 +/- 6.98 and 4.25 +/- 2.53 LC3+/NeuN+ double positive cells in TBI+Saline and TBI+Wnt3a mice, respectively; p < 0.0001, n = 5/group), reduced autophagic markers light chain 3 (LC3)-II and Beclin-1, as well as injury markers caspase-3 and matrix metalloproteinase 9 (MMP-9). The Wnt3a treatment reduced cell death and contusion volume (0.72 +/- 0.07mm(2) and 0.26 +/- 0.04mm(2) in TBI+Saline and TBI+Wnt3a mice, respectively; p < 0.001, n = 5/group). The 7-day Wnt3a treatment increased levels of beta-catenin and growth factors glial-derived growth factor (GDNF) and vascular endothelial growth factor (VEGF). This chronic Wnt3a therapy augmented neurogenesis (0.52 +/- 0.09 and 1.25 +/- 0.13 BrdU+/NeuN+ co-labeled cells in TBI+Saline mice and TBI+Wnt3a mice, respectively; p < 0.01, n = 6/group) and angiogenesis (0.26 +/- 0.07 and 0.74 +/- 0.13 BrdU+/GLUT1+ co-labeled cells in TBI+Saline and TBI+Wnt3a mice, respectively; p = 0.014, n = 6/group). The treatment improved performance in the rotarod test and adhesive removal test. Targeting the Wnt pathway implements a unique combination of protective and regenerative approaches after TBI.	[Zhang, James Ya; Lee, Jin Hwan; Gu, Xiaohuan; Wei, Zheng Zachory; Harris, Mallory Jessica; Yu, Shan Ping; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Wei, L (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,WMB Suite 617, Atlanta, GA 30322 USA.	lwei7@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	VAUS Department of Veterans Affairs [1I01RX002473-01A1] Funding Source: Federal RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091585] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002473] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008169] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS091585] Funding Source: Medline; RRD VA [I01 RX002473] Funding Source: Medline		Andelic N, 2013, LANCET NEUROL, V12, P28, DOI 10.1016/S1474-4422(12)70294-6; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Bradbury MWB, 1985, EXPT BIOL LYMPHATIC, P355; Chauhan M. B., J NEUROL NEUROSURG, V2; Chen D., ASN NEURO, V7; Chen JL, 2012, SPR SER TRANSL STROK, P231, DOI 10.1007/978-1-4419-9530-8_11; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Clarkson ED, 1997, CELL TISSUE RES, V289, P207, DOI 10.1007/s004410050867; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Deretic V., 2008, AUTOPHAGOSOME PHAGOS, P9; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Dzietko M, 2013, TRANSL STROKE RES, V4, P189, DOI 10.1007/s12975-012-0221-6; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamm R. J., J NEUROTRAUMA, V11, P187; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Inoue T, 2006, STEM CELLS, V24, P95, DOI 10.1634/stemcells.2005-0124; Jia ZQ, 2014, CELL SIGNAL, V26, P2299, DOI 10.1016/j.cellsig.2014.07.028; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kaur N, 2013, MOL CELL NEUROSCI, V54, P44, DOI 10.1016/j.mcn.2013.01.001; Koch SBJ, 2014, PSYCHONEUROENDOCRINO, V40, P242, DOI 10.1016/j.psyneuen.2013.11.018; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kuhn K, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.31; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu S, 2012, CURR PHARM DESIGN, V18, P3653, DOI 10.2174/138161212802002706; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lochhead JJ, 2012, ADV DRUG DELIVER REV, V64, P614, DOI 10.1016/j.addr.2011.11.002; Lucivero V, 2007, NEUROL SCI, V28, P165, DOI 10.1007/s10072-007-0814-0; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Munji RN, 2011, J NEUROSCI, V31, P1676, DOI 10.1523/JNEUROSCI.5404-10.2011; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Qi LS, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0107-4; Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860; Sheng R, 2012, AUTOPHAGY, V8, P310, DOI 10.4161/auto.18673; Shruster A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040843; Thomsen GM, 2014, STEM CELL RES, V13, P48, DOI 10.1016/j.scr.2014.04.013; Thorne RG, 2008, NEUROSCIENCE, V152, P785, DOI 10.1016/j.neuroscience.2008.01.013; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Wang YZ, 2011, J CELL SCI, V124, P1553, DOI 10.1242/jcs.080580; Wei N, 2013, CELL TRANSPLANT, V22, P977, DOI 10.3727/096368912X657251; Wei ZZ, 2015, CELL TRANSPLANT, V24, P391, DOI 10.3727/096368915X686887; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whyte JL, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008078; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wood MD, 2012, MUSCLE NERVE, V46, P122, DOI 10.1002/mus.23295; Yi H, 2012, NEUROREPORT, V23, P189, DOI 10.1097/WNR.0b013e32834fab06; Yoshinaga Y, 2010, CELL MOL NEUROBIOL, V30, P1049, DOI 10.1007/s10571-010-9536-6; Young JE, 2009, J BIOL CHEM, V284, P2363, DOI 10.1074/jbc.M806088200; Yu JM, 2006, MOL CELL BIOCHEM, V288, P17, DOI 10.1007/s11010-005-9113-3	65	17	18	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2018	35	5					802	813		10.1089/neu.2016.4871			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FX4ZY	WOS:000426088600010	29108471	Green Published			2021-06-18	
J	Xiong, XX; Pan, F; Chen, RQ; Hu, DX; Qiu, XY; Li, CY; Xie, XQ; Tian, B; Chen, XQ				Xiong, Xin Xin; Pan, Feng; Chen, Ruo Qiao; Hu, Dian Xing; Qiu, Xin Yao; Li, Chun Yang; Xie, Xiao Qiang; Tian, Bo; Chen, Xiao Qian			Neuroglobin boosts axon regeneration during ischemic reperfusion via p38 binding and activation depending on oxygen signal	CELL DEATH & DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; HEPATOCELLULAR-CARCINOMA; INDUCED NEUROGENESIS; NEURONAL SURVIVAL; STROKE; RECOVERY; PROTEIN; PHOSPHORYLATION; PATHWAYS; GLOBIN	Cerebral ischemia causes severe cell death or injury including axon breakdown or retraction in the brain. Axon regeneration is crucial for the functional recovery of injured neurons or brains after ischemia/reperfusion (I/R); however, this process has been proved extremely difficult in adult brains and there is still no effective therapy for it. Here we reported that neuroglobin (Ngb), a novel oxygen-binding or sensor protein existing predominantly in neurons or brains, functions as a driving factor for axon regeneration during I/R. Ngb was upregulated and accumulated in growth cones of ischemic neurons in primary cultures, rat, and human brains, correlating positively to the elevation of axon-regeneration markers GAP43, neurofilament-200, and Tau-1. Ngb overexpression promoted while Ngb knockdown suppressed axon regeneration as well as GAP43 expression in neurons during oxygen-glucose deprivation/reoxygenation (OGD/Re). By using specific pharmacological inhibitors, we identified p38 MAPK as the major downstream player of Ngb-induced axon regeneration during OGD/Re. Mechanistically, Ngb directly bound to and activated p38 in neurons upon OGD/Re. Serial truncation and point mutation of Ngb revealed that the 7-105 aa fragment of Ngb was required and the oxygen-binding site (His(64)) of Ngb was the major regulatory site for its p38 interaction/activation. Finally, administration of exogenous TAT-Ngb peptides significantly enhanced axon regeneration in cultured neurons upon OGD/Re. Taken together, Ngb promotes axon regeneration via O-2-Ngb-p38-GAP43 signaling during I/R. This novel mechanism suggests potential therapeutic applications of Ngb for ischemic stroke and other related axonopathy.	[Xiong, Xin Xin; Chen, Ruo Qiao; Hu, Dian Xing; Qiu, Xin Yao; Li, Chun Yang; Chen, Xiao Qian] Huazhong Univ Sci & Technol, Dept Pathophysiol, Sch Basic Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Xiong, Xin Xin; Chen, Ruo Qiao; Hu, Dian Xing; Qiu, Xin Yao; Li, Chun Yang; Chen, Xiao Qian] Huazhong Univ Sci & Technol, Inst Brain Res, Wuhan, Hubei, Peoples R China; [Xiong, Xin Xin; Chen, Ruo Qiao; Hu, Dian Xing; Qiu, Xin Yao; Li, Chun Yang; Chen, Xiao Qian] Huazhong Univ Sci & Technol, Key Lab Neurol Dis, Minist Educ, Wuhan, Hubei, Peoples R China; [Xiong, Xin Xin; Chen, Ruo Qiao; Hu, Dian Xing; Qiu, Xin Yao; Li, Chun Yang; Chen, Xiao Qian] Huazhong Univ Sci & Technol, Hubei Prov Key Lab Neurol Dis, Wuhan, Hubei, Peoples R China; [Pan, Feng] Huazhong Univ Sci & Technol, Union Hosp, Dept Urol, Wuhan, Hubei, Peoples R China; [Xie, Xiao Qiang] Yangtze Univ, Jingzhou Cent Hosp, Dept Pathol, Clin Med Coll 2, Jingzhou, Peoples R China; [Tian, Bo] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Neurobiol, Tongji Med Coll, Wuhan, Hubei, Peoples R China	Chen, XQ (corresponding author), Huazhong Univ Sci & Technol, Dept Pathophysiol, Sch Basic Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Chen, XQ (corresponding author), Huazhong Univ Sci & Technol, Inst Brain Res, Wuhan, Hubei, Peoples R China.; Chen, XQ (corresponding author), Huazhong Univ Sci & Technol, Key Lab Neurol Dis, Minist Educ, Wuhan, Hubei, Peoples R China.; Chen, XQ (corresponding author), Huazhong Univ Sci & Technol, Hubei Prov Key Lab Neurol Dis, Wuhan, Hubei, Peoples R China.	chenxq@mails.tjmu.edu.cn	Chen, Xiaoqian/AAH-5831-2019; TIAN, BO/G-2354-2011	xiong, xin xin/0000-0001-9329-6370	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471386, 81672504, 31571044]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2017KFYXJJ048]; Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST; National Science Foundation of Hubei Province [2017 CFB639]; Science and Technology Planning Project of Wuhan [2017060201010202]	This work was supported by the National Nature Science Foundation of China (No. 81471386 and No. 81672504 to XQC, No. 31571044 to BT); the Fundamental Research Funds for the Central Universities (No. 2017KFYXJJ048) to XQC; the Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST; National Science Foundation of Hubei Province (No. 2017 CFB639) and Science and Technology Planning Project of Wuhan (No. 2017060201010202) to FP.	Baez E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00146; Baldauf K, 2005, BRAIN RES, V1056, P158, DOI 10.1016/j.brainres.2005.07.035; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Cai J, 2012, J PATHOL, V226, P495, DOI 10.1002/path.2980; Carmichael ST, 2017, EXP NEUROL, V287, P384, DOI 10.1016/j.expneurol.2016.02.007; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Dempsey RJ, 2007, NEUROSURG CLIN N AM, V18, P183, DOI 10.1016/j.nec.2006.10.011; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fink KL, 2017, CELL REP, V18, P2687, DOI 10.1016/j.celrep.2017.02.058; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hinman JD, 2014, CURR OPIN NEUROL, V27, P615, DOI 10.1097/WCO.0000000000000149; Jayaraman T, 2011, J BIOL CHEM, V286, P42679, DOI 10.1074/jbc.M111.271973; Jiang JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.239; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Jung KM, 2003, MOL PHARMACOL, V63, P607, DOI 10.1124/mol.63.3.607; Kim H, 2016, J PHARMACOL EXP THER, V359, P262, DOI 10.1124/jpet.116.235127; Kudo T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124024; Lan WB, 2014, BRAIN RES, V1562, P100, DOI 10.1016/j.brainres.2014.03.020; Li L, 2014, MOL NEUROBIOL, V49, P149, DOI 10.1007/s12035-013-8506-7; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; O'Donovan KJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00486; Pillai VB, 2011, MOL CELL BIOL, V31, P2349, DOI 10.1128/MCB.01205-10; Qiu Xin Yao, 2014, Biomol Concepts, V5, P195, DOI 10.1515/bmc-2014-0011; Raida Zindy, 2012, Exp Transl Stroke Med, V4, P15, DOI 10.1186/2040-7378-4-15; Sharma TP, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.22; Sommer CJ, 2017, STROKE, V48, P1112, DOI 10.1161/STROKEAHA.116.013324; Stankiewicz TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00314; Sun F, 2013, J ALZHEIMERS DIS, V36, P659, DOI 10.3233/JAD-130323; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Tobin MK, 2014, J CEREBR BLOOD F MET, V34, P1573, DOI 10.1038/jcbfm.2014.130; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wang YL, 2016, ONCOTARGET, V7, P11284, DOI 10.18632/oncotarget.7022; Zhang J, 2013, MOL PHARMACOL, V83, P1109, DOI 10.1124/mol.112.083634; Zhu WS, 2011, DRUG DELIV, V18, P338, DOI 10.3109/10717544.2011.557785	39	17	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB 7	2018	9								163	10.1038/s41419-017-0260-8			16	Cell Biology	Cell Biology	FZ2IN	WOS:000427401400005	29416029	DOAJ Gold, Green Published			2021-06-18	
J	Carrie, C; Bentejac, M; Cottenceau, V; Masson, F; Petit, L; Cochard, JF; Sztark, F				Carrie, Cedric; Bentejac, Merry; Cottenceau, Vincent; Masson, Francoise; Petit, Laurent; Cochard, Jean-Francois; Sztark, Francois			Association between augmented renal clearance and clinical failure of antibiotic treatment in brain-injured patients with ventilator-acquired pneumonia: A preliminary study	ANAESTHESIA CRITICAL CARE & PAIN MEDICINE			English	Article						Augmented renal clearance; Traumatic brain injury; Ventilator-acquired pneumonia; Therapeutic failure; beta-lactams	CRITICALLY-ILL PATIENTS; CREATININE CLEARANCE; INTENSIVE-CARE; INFUSION; THERAPY; HYDROCORTISONE; PIPERACILLIN; INTERMITTENT; SUFFICIENT; DURATION	Objectives: This preliminary study aimed to determine whether augmented renal clearance (ARC) impacts negatively on the clinical outcome in traumatic brain-injured patients (TBI) treated for a first episode of ventilator-acquired pneumonia (VAP). Methods: During a 5-year period, all TBI patients who had developed VAP were retrospectively reviewed to assess variables associated with clinical failure in multivariate analysis. Clinical failure was defined as an impaired clinical response with a need for escalating antibiotics during treatment and/or within 15 days after the end-of-treatment. Recurrence was considered if at least one of the initial causative bacterial strains was growing at a significant concentration from a second sample. Augmented renal clearance (ARC) was defined by an enhanced creatinine clearance exceeding 130 mL/min/1.73 m(2) calculated from a urinary sample during the first three days of antimicrobial therapy. Main results: During the study period, 223 TBI patients with VAP were included and 59 (26%) presented a clinical failure. Factors statistically associated with clinical failure were GSC <= 7 (OR = 2.2 [1.1-4.4], P = 0.03), early VAP (OR = 3.9 [1.9-7.8], P = 0.0001), bacteraemia (OR = 11 [2.2-54], P = 0.003) and antimicrobial therapy <= 7 days (OR = 3.7 [1.8-7.4], P = 0.0003). ARC was statistically associated with recurrent infections with an OR of 4.4 [1.2-16], P = 0.03. Conclusion: ARC was associated with recurrent infection after a first episode of VAP in TBI patients. The optimal administration and dosing of the antimicrobial agents in this context remain to be determined. (C) 2017 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.	[Carrie, Cedric; Bentejac, Merry; Cottenceau, Vincent; Masson, Francoise; Petit, Laurent; Cochard, Jean-Francois; Sztark, Francois] CHU Bordeaux, Anaesthesiol & Crit Care Dept 1, Surg Intens Care Unit, F-33000 Bordeaux, France; [Sztark, Francois] Univ Bordeaux Segalen, F-33000 Bordeaux, France	Carrie, C (corresponding author), CHU Bordeaux, Hop Pellegrin, Anaesthesiol & Crit Care Dept 1, Surg Intens Care Unit, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	cedric.carrie@chu-bordeaux.fr					Abdul-Aziz MH, 2016, INTENS CARE MED, V42, P1535, DOI 10.1007/s00134-015-4188-0; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Asehnoune K, 2014, LANCET RESP MED, V2, P706, DOI 10.1016/S2213-2600(14)70144-4; Asin-Prieto E, 2014, J ANTIMICROB CHEMOTH, V69, P180, DOI 10.1093/jac/dkt304; Barletta JF, 2016, J TRAUMA ACUTE CARE, V81, P1115, DOI 10.1097/TA.0000000000001211; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Claus BOM, 2013, J CRIT CARE, V28, P695, DOI 10.1016/j.jcrc.2013.03.003; Combes A, 2003, CRIT CARE MED, V31, P1102, DOI 10.1097/01.CCM.0000059313.31477.2C; Cotta MO, 2015, INFECT DIS-NOR, V47, P739, DOI 10.3109/23744235.2015.1021831; De Cock PAJG, 2015, ANTIMICROB AGENTS CH, V59, P7027, DOI [10.1128/AAC.01368-15, 10.1128/AAC.01368-]; Dimopoulos G, 2013, CHEST, V144, P1759, DOI 10.1378/chest.13-0076; Geeraerts T, 2016, ANESTH REANIM, V2, P431, DOI 10.1016/j.anrea.2016.09.007; Hobbs ALV, 2015, PHARMACOTHERAPY, V35, P1063, DOI 10.1002/phar.1653; Huttner A, 2015, INT J ANTIMICROB AG, V45, P385, DOI 10.1016/j.ijantimicag.2014.12.017; Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI 10.1093/cid/ciw504; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; KIM KE, 1972, BRIT MED J, V1, P379, DOI 10.1136/bmj.1.5796.379-b; Kollef MH, 2012, CRIT CARE, V16, DOI 10.1186/cc11862; May CC, 2015, NEUROCRIT CARE, V23, P374, DOI 10.1007/s12028-015-0127-8; Reese AM, 2005, INT J ANTIMICROB AG, V26, P114, DOI 10.1016/j.ijantimicag.2005.06.004; Roberts JA, 2007, J ANTIMICROB CHEMOTH, V59, P285, DOI [10.1093/jac/dk1478, 10.1093/jac/dkl478]; Roberts JA, 2016, AM J RESP CRIT CARE, V194, P681, DOI 10.1164/rccm.201601-0024OC; Roberts JA, 2014, CLIN INFECT DIS, V58, P1072, DOI 10.1093/cid/ciu027; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9091; Tsai D, 2015, CURR OPIN CRIT CARE, V21, P412, DOI 10.1097/MCC.0000000000000229; Udy A, 2010, ANESTH ANALG, V111, P1505, DOI 10.1213/ANE.0b013e3181f7107d; Udy AA, 2017, J NEUROTRAUM, V34, P137, DOI 10.1089/neu.2015.4328; Udy AA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0750-y; Udy AA, 2014, CRIT CARE MED, V42, P520, DOI 10.1097/CCM.0000000000000029; Udy AA, 2013, CRIT CARE, V17, DOI 10.1186/cc12544; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Wahl WL, 2009, J BURN CARE RES, V30, P801, DOI 10.1097/BCR.0b013e3181b47ef9; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	34	17	17	0	6	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	2352-5568			ANAESTH CRIT CARE PA	Anaesth. Crit. Care Pain Med.	FEB	2018	37	1					35	41		10.1016/j.accpm.2017.06.006			7	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	FU5DC	WOS:000423872100010	28756331				2021-06-18	
J	Motes, MA; Yezhuvath, US; Aslan, S; Spence, JS; Rypma, B; Chapman, SB				Motes, Michael A.; Yezhuvath, Uma S.; Aslan, Sina; Spence, Jeffrey S.; Rypma, Bart; Chapman, Sandra B.			Higher-order cognitive training effects on processing speed-related neural activity: a randomized trial	NEUROBIOLOGY OF AGING			English	Article						Aging; Cognitive training; Reasoning; Processing speed; Neuroplasticity; fMRI; DSVT; Exercise	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; PREFRONTAL CORTEX; WORKING-MEMORY; METAANALYSIS; EXERCISE; FITNESS; GAINS; TASK	Higher-order cognitive training has shown to enhance performance in older adults, but the neural mechanisms underlying performance enhancement have yet to be fully disambiguated. This randomized trial examined changes in processing speed and processing speed-related neural activity in older participants (57-71 years of age) who underwent cognitive training (CT, N = 12) compared with wait-listed (WLC, N = 15) or exercise-training active (AC, N = 14) controls. The cognitive training taught cognitive control functions of strategic attention, integrative reasoning, and innovation over 12 weeks. All 3 groups worked through a functional magnetic resonance imaging processing speed task during 3 sessions (baseline, mid-training, and post-training). Although all groups showed faster reaction times (RTs) across sessions, the CT group showed a significant increase, and the WLC and AC groups showed significant decreases across sessions in the association between RT and BOLD signal change within the left prefrontal cortex (PFC). Thus, cognitive training led to a change in processing speed-related neural activity where faster processing speed was associated with reduced PFC activation, fitting previously identified neural efficiency profiles. (C) 2017 The Authors. Published by Elsevier Inc.	[Motes, Michael A.; Aslan, Sina; Spence, Jeffrey S.; Rypma, Bart; Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA; [Yezhuvath, Uma S.; Aslan, Sina] Adv MRI LLC, Frisco, TX USA	Chapman, SB (corresponding author), Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA.	schapman@utdallas.edu		Motes, Michael/0000-0001-6635-6948	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC1-AG035954, R01-NS067015, R01-AG033106]; Lyda Hill Foundation; T. Boone Pickens Foundation; Dee Wyly Distinguished University Endowment; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RC1AG035954, R01AG033106] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health (RC1-AG035954, 2009; R01-NS067015, 2010; R01-AG033106; 2009) and by grants from the Lyda Hill Foundation, T. Boone Pickens Foundation, and the Dee Wyly Distinguished University Endowment.	Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Anand R, 2011, INT J GERIATR PSYCH, V26, P961, DOI 10.1002/gps.2633; Aslan S, 2010, MAGN RESON MED, V63, P765, DOI 10.1002/mrm.22245; Baltes PB, 1997, PSYCHOL AGING, V12, P12, DOI 10.1037/0882-7974.12.1.12; Baniqued PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142169; Basak C, 2008, PSYCHOL AGING, V23, P765, DOI 10.1037/a0013494; Biswal BB, 2010, CEREB CORTEX, V20, P2188, DOI 10.1093/cercor/bhp284; Brehmer Y, 2011, NEUROIMAGE, V58, P1110, DOI 10.1016/j.neuroimage.2011.06.079; Buchsbaum BR, 2005, HUM BRAIN MAPP, V25, P35, DOI 10.1002/hbm.20128; BUCKHALT JA, 1991, PERS INDIV DIFFER, V12, P683, DOI 10.1016/0191-8869(91)90223-X; Chapman S.B., 2014, MAKE YOUR BRAIN SMAR; Chapman SB, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00338; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chapman SB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00069; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cox RW, 2017, BRAIN CONNECT, V7, P152, DOI 10.1089/brain.2016.0475; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; EARLES JL, 1995, J GERONTOL B-PSYCHOL, V50, pP33, DOI 10.1093/geronb/50B.1.P33; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Ekstrom R.B., 1979, MULTIVARIATE BEHAV R, V79, P8; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Heinzel S, 2016, NEUROIMAGE, V134, P236, DOI 10.1016/j.neuroimage.2016.03.068; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; JENSEN AR, 1992, PERS INDIV DIFFER, V13, P869, DOI 10.1016/0191-8869(92)90004-9; KAIL R, 1991, PSYCHOL BULL, V109, P490, DOI 10.1037/0033-2909.109.3.490; Kannurpatti SS, 2011, HUM BRAIN MAPP, V32, P1125, DOI 10.1002/hbm.21097; Lu HZ, 2011, CEREB CORTEX, V21, P1426, DOI 10.1093/cercor/bhq224; Mackey AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137627; Motes MA, 2014, BRAIN COGNITION, V84, P44, DOI 10.1016/j.bandc.2013.10.007; Motes MA, 2011, COGN NEUROSCI-UK, V2, P1, DOI 10.1080/17588928.2010.512974; Motes MA, 2010, NEUROIMAGE, V49, P1933, DOI 10.1016/j.neuroimage.2009.08.054; Mudar RA, 2017, INT J GERIATR PSYCH, V32, P548, DOI 10.1002/gps.4492; Park DC, 2002, PSYCHOL AGING, V17, P299, DOI 10.1037//0882-7974.17.2.299; Park DC, 2009, ANNU REV PSYCHOL, V60, P173, DOI 10.1146/annurev.psych.59.103006.093656; Rao NK, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00840; Rosano C, 2010, J GERONTOL A-BIOL, V65, P639, DOI 10.1093/gerona/glq038; Rypma B, 2000, NAT NEUROSCI, V3, P509, DOI 10.1038/74889; Rypma B, 2006, NEUROIMAGE, V33, P969, DOI 10.1016/j.neuroimage.2006.05.065; Rypma B, 2009, INTELLIGENCE, V37, P207, DOI 10.1016/j.intell.2008.12.004; Salthouse T. A., 1991, THEORETICAL PERSPECT; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SALTHOUSE TA, 1992, J GERONTOL, V47, pP121, DOI 10.1093/geronj/47.3.P121; Salthouse TA, 2009, NEUROBIOL AGING, V30, P507, DOI 10.1016/j.neurobiolaging.2008.09.023; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Vas A, 2016, NEUROPSYCHOL REHABIL, V26, P502, DOI 10.1080/09602011.2015.1044013; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Venza EE, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01676; Voelcker-Rehage C, 2013, NEUROSCI BIOBEHAV R, V37, P2268, DOI 10.1016/j.neubiorev.2013.01.028; Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Young J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005381.pub4; Yuan P, 2014, NEUROSCI BIOBEHAV R, V42, P180, DOI 10.1016/j.neubiorev.2014.02.005	54	17	17	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	FEB	2018	62						72	81		10.1016/j.neurobiolaging.2017.10.003			10	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	FQ6MM	WOS:000418478600007	29121545	Green Accepted, Other Gold			2021-06-18	
J	Salehi, A; Jullienne, A; Baghchechi, M; Hamer, M; Walsworth, M; Donovan, V; Tang, JP; Zhang, JH; Pearce, WJ; Obenaus, A				Salehi, Arjang; Jullienne, Amandine; Baghchechi, Mohsen; Hamer, Mary; Walsworth, Mark; Donovan, Virginia; Tang, Jiping; Zhang, John H.; Pearce, William J.; Obenaus, Andre			Up-regulation of Wnt/beta-catenin expression is accompanied with vascular repair after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Angiogenesis; brain recovery; brain trauma; regeneration and recovery; vascular biology	ENDOTHELIAL GROWTH-FACTOR; BETA-CATENIN; PROGENITOR CELLS; CHRONIC HYPOXIA; ANGIOGENESIS; BARRIER; VEGF; MOUSE; RAT; PATHWAY	Recent data suggest that repairing the cerebral vasculature after traumatic brain injury (TBI) may help to improve functional recovery. The Wnt/beta-catenin signaling pathway promotes blood vessel formation during vascular development, but its role in vascular repair after TBI remains elusive. In this study, we examined how the cerebral vasculature responds to TBI and the role of Wnt/beta-catenin signaling in vascular repair. We induced a moderate controlled cortical impact in adult mice and performed vessel painting to visualize the vascular alterations in the brain. Brain tissue around the injury site was assessed for beta-catenin and vascular markers. A Wnt transgenic mouse line was utilized to evaluate Wnt gene expression. We report that TBI results in vascular loss followed by increases in vascular structure at seven days post injury (dpi). Immature, non-perfusing vessels were evident in the tissue around the injury site. beta-catenin protein expression was significantly reduced in the injury site at 7 dpi. However, there was an increase in beta-catenin expression in perilesional vessels at 1 and 7 dpi. Similarly, we found increased number of Wnt-GFP-positive vessels after TBI. Our findings suggest that Wnt/beta-catenin expression contributes to the vascular repair process after TBI.	[Salehi, Arjang; Obenaus, Andre] Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; [Salehi, Arjang; Jullienne, Amandine; Baghchechi, Mohsen; Hamer, Mary; Walsworth, Mark; Donovan, Virginia; Obenaus, Andre] Loma Linda Univ, Dept Pediat, Coleman Pavil,Room A-1120,11175 Campus St, Loma Linda, CA 92354 USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; [Tang, Jiping; Zhang, John H.; Pearce, William J.] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; [Pearce, William J.] Loma Linda Univ, Ctr Perinatal Biol, Loma Linda, CA 92354 USA	Obenaus, A (corresponding author), Loma Linda Univ, Dept Pediat, Coleman Pavil,Room A-1120,11175 Campus St, Loma Linda, CA 92354 USA.	aobenaus@llu.edu	Jullienne, Amandine/H-3081-2019	Jullienne, Amandine/0000-0001-9458-055X; , Andre/0000-0003-0081-6950; Pearce, William/0000-0002-5331-5677	NIH Program Project grant from National Institute of Neurological Disorders and Stroke [1P01NS082184]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD083132] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NIH Program Project grant from National Institute of Neurological Disorders and Stroke (1P01NS082184, Project 3).	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Bernard P, 2008, BIOL CELL, V100, P167, DOI 10.1042/BC20070072; Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Corada M, 2014, ARTERIOSCL THROM VAS, V34, P2372, DOI 10.1161/ATVBAHA.114.303218; Corada M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3609; Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Easwaran V, 2003, CANCER RES, V63, P3145; Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Gong D, 2011, J TRAUMA, V70, P1480, DOI 10.1097/TA.0b013e31821ac9e1; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hughes S, 2014, METHODS MOL BIOL, V1135, P127, DOI 10.1007/978-1-4939-0320-7_12; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kim KI, 2006, ARTERIOSCL THROM VAS, V26, P91, DOI 10.1161/01.ATV.0000193569.12490.4b; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Lambert C, 2016, MOL NEUROBIOL, V53, P2297, DOI 10.1007/s12035-015-9138-x; Lange C, 2016, EMBO J, V35, P924, DOI 10.15252/embj.201592372; Lengfeld JE, 2017, P NATL ACAD SCI USA, V114, pE1168, DOI 10.1073/pnas.1609905114; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Lim RG, 2017, CELL REP, V19, P1365, DOI 10.1016/j.celrep.2017.04.021; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Robertson RT, 2015, HISTOCHEM CELL BIOL, V143, P225, DOI 10.1007/s00418-014-1301-3; Sakata N, 2010, TRANSPLANTATION, V89, P686, DOI 10.1097/TP.0b013e3181cb3e8d; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Siddiq I, 2012, J NEUROTRAUM, V29, P2647, DOI 10.1089/neu.2012.2444; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002; Wang XH, 2002, CIRC RES, V90, P340, DOI 10.1161/hh0302.104466; Ward NL, 2007, J APPL PHYSIOL, V102, P1927, DOI 10.1152/japplphysiol.00909.2006; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xu K, 2006, J APPL PHYSIOL, V100, P725, DOI 10.1152/japplphysiol.00940.2005; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456; Zhang YM, 2016, ACUPUNCT MED, V34, P48, DOI 10.1136/acupmed-2014-010742; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	58	17	17	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2018	38	2					274	289		10.1177/0271678X17744124			16	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	FU7VJ	WOS:000424060500008	29160735	Green Published, Bronze			2021-06-18	
J	Slowik, A; Lammerding, L; Hoffmann, S; Beyer, C				Slowik, A.; Lammerding, L.; Hoffmann, S.; Beyer, C.			Brain inflammasomes in stroke and depressive disorders: Regulation by oestrogen	JOURNAL OF NEUROENDOCRINOLOGY			English	Article; Proceedings Paper	9th International Meeting on Steroids and Nervous System	FEB 11-15, 2017	Torino, ITALY			depressive disorder; oestrogen; inflammasome; ischaemia; neuroinflammation	POLYUNSATURATED FATTY-ACIDS; SPINAL-CORD-INJURY; FACTOR-KAPPA-B; NLRP3 INFLAMMASOME; CEREBRAL-ISCHEMIA; FRONTAL-CORTEX; RECEPTOR BETA; CELL-DEATH; MAJOR DEPRESSION; DORSAL RAPHE	Neuroinflammation is a devastating pathophysiological process that results in brain damage and neuronal death. Pathogens, cell fragments and cellular dysfunction trigger inflammatory responses. Irrespective of the cause, inflammasomes are key intracellular multiprotein signalling platforms that sense neuropathological conditions. The activation of inflammasomes leads to the auto-proteolytic cleavage of caspase-1, resulting in the proteolysis of the pro-inflammatory cytokines interleukin (IL)1 and IL18 into their bioactive forms. It also initiates pyroptosis, a type of cell death. The two cytokines contribute to the pathogenesis in acute and chronic brain diseases and also play a central role in human aging and psychiatric disorders. Sex steroids, in particular oestrogens, are well-described neuroprotective agents in the central nervous system. Oestrogens improve the functional outcome after ischaemia and traumatic brain injury, reduce neuronal death in Parkinsons and Alzheimers disease, as well as in amyotrophic lateral sclerosis, attenuate glutamate excitotoxicity and the formation of radical oxygen species, and lessen the spread of oedema after damage. Moreover, oestrogens alleviate menopause-related depressive symptoms and have a positive influence on depressive disorders probably by influencing growth factor production and serotonergic brain circuits. Recent evidence also suggests that inflammasome signalling affects anxiety- and depressive-like behaviour and that oestrogen ameliorates depression-like behaviour through the suppression of inflammasomes. In the present review, we highlight the most recent findings demonstrating that oestrogens selectively suppress the activation of the neuroinflammatory cascade in the brain in acute and chronic brain disease models. Furthermore, we aim to describe putative regulatory signalling pathways involved in the control of inflammasomes. Finally, we consider that psychiatric disorders such as depression also contain an inflammatory component that could be modulated by oestrogen.	[Slowik, A.; Lammerding, L.; Beyer, C.] Rhein Westfal TH Aachen, Med Fac, Inst Neuroanat, Aachen, Germany; [Hoffmann, S.] Rhein Westfal TH Aachen, Med Fac, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany; [Hoffmann, S.; Beyer, C.] JARA Translat Brain Med, Aachen, Germany	Beyer, C (corresponding author), Rhein Westfal TH Aachen, Inst Neuroanat, Aachen, Germany.	cbeyer@ukaachen.de		Dr. Slowik, Alexander/0000-0001-9907-2263	START grant of the Medical Faculty of the RWTH Aachen, Germany	START grant (A. Slowik) of the Medical Faculty of the RWTH Aachen, Germany	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Barrington J, 2017, BRAIN PATHOL, V27, P205, DOI 10.1111/bpa.12476; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bethea CL, 2006, J PSYCHIATR NEUROSCI, V31, P105; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Chakrabarti M, 2016, REV NEUROSCIENCE, V27, P271, DOI 10.1515/revneuro-2015-0032; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Choi AJS, 2014, MOL CELLS, V37, P441, DOI 10.14348/molcells.2014.0104; Chuang SY, 2013, P NATL ACAD SCI USA, V110, P16079, DOI 10.1073/pnas.1306556110; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Dambal S, 2015, NUCLEIC ACIDS RES, V43, P7173, DOI 10.1093/nar/gkv703; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; de Freitas GR, 2001, EUR J NEUROL, V8, P1, DOI 10.1046/j.1468-1331.2001.00150.x; De Nicola AF, 2013, J NEUROENDOCRINOL, V25, P1095, DOI 10.1111/jne.12043; Debye B, 2016, BRAIN PATHOL; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Elinav E, 2011, IMMUNITY, V34, P665, DOI 10.1016/j.immuni.2011.05.007; Fann D. Y., 2017, MOL NEUROBIOL; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Fann DYW, 2014, EXP NEUROL, V257, P114, DOI 10.1016/j.expneurol.2014.04.017; Farooq RK, 2017, BIOMED REP, V6, P15, DOI 10.3892/br.2016.807; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Gao L, 2017, INFLAMM RES, V66, P17, DOI 10.1007/s00011-016-0981-7; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414; Lopez MG, 2015, IMMUNOPHARM IMMUNOT, V37, P343, DOI 10.3109/08923973.2015.1059439; Gordon JL, 2015, AM J PSYCHIAT, V172, P227, DOI 10.1176/appi.ajp.2014.14070918; Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Han SJ, 2015, CELL, V163, P960, DOI 10.1016/j.cell.2015.10.034; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Heitzer M, 2016, MOL NEUROBIOL; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Herzog R, 2017, J STEROID BIOCHEM, V167, P126, DOI 10.1016/j.jsbmb.2016.11.018; Hodes GE, 2017, J NEUROSCI RES, V95, P692, DOI 10.1002/jnr.23876; Hu W, 2016, BRAIN BEHAV IMMUN, V52, P58, DOI 10.1016/j.bbi.2015.09.019; Ishrat T, 2015, MOL NEUROBIOL, V51, P766, DOI 10.1007/s12035-014-8766-x; Iwata M, 2013, BRAIN BEHAV IMMUN, V31, P105, DOI 10.1016/j.bbi.2012.12.008; Jeon SW, 2016, WORLD J PSYCHIATR, V6, P283, DOI 10.5498/wjp.v6.i3.283; Jin Y, 2015, J NUTR BIOCHEM, V26, P970, DOI 10.1016/j.jnutbio.2015.04.005; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Johnson AB, 2005, NEUROBIOL AGING, V26, P1365, DOI 10.1016/j.neurobiolaging.2004.12.006; Kajta M, 2006, BRAIN RES, V1116, P64, DOI 10.1016/j.brainres.2006.07.105; Kaufmann FN, 2017, BRAIN BEHAV IMMUN, V64, P367, DOI 10.1016/j.bbi.2017.03.002; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Kim HK, 2016, J PSYCHIATR RES, V72, P43, DOI 10.1016/j.jpsychires.2015.10.015; Kim MJ, 2016, BMB REP, V49, P529, DOI 10.5483/BMBRep.2016.49.10.115; Kipp M, 2016, NEUROSCI BIOBEHAV R, V67, P125, DOI 10.1016/j.neubiorev.2015.11.016; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kiss A, 2012, BEHAV BRAIN RES, V227, P100, DOI 10.1016/j.bbr.2011.10.047; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Kong X, 2016, J NEUROSCI RES; Koo JW, 2010, P NATL ACAD SCI USA, V107, P2669, DOI 10.1073/pnas.0910658107; Kuppers E, 2008, PSYCHONEUROENDOCRINO, V33, P832, DOI 10.1016/j.psyneuen.2008.03.007; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Li Y, 2015, TOXICOL APPL PHARM, V286, P53, DOI 10.1016/j.taap.2015.03.010; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lommatzsch M, 2006, PSYCHONEUROENDOCRINO, V31, P388, DOI 10.1016/j.psyneuen.2005.09.003; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu SJ, 2013, COMPR PSYCHIAT, V54, P953, DOI 10.1016/j.comppsych.2013.03.026; Lunov O, 2011, ACS NANO, V5, P9648, DOI 10.1021/nn203596e; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; May M, 2016, NAT MED, V22, P1370, DOI 10.1038/nm1216-1370; Michelsen KA, 2007, BRAIN RES REV, V55, P329, DOI 10.1016/j.brainresrev.2007.01.002; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Mohamed IN, 2015, ANTIOXID REDOX SIGN, V22, P1188, DOI 10.1089/ars.2014.6126; Munding C, 2006, CELL DEATH DIFFER, V13, P1938, DOI 10.1038/sj.cdd.4401896; Nishi Y, 2013, KIDNEY INT, V83, P662, DOI 10.1038/ki.2012.475; Numakawa T, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00136; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007; Panchanathan R, 2015, MOL CELL ENDOCRINOL, V415, P45, DOI 10.1016/j.mce.2015.08.003; Peeri M, 2015, MED HYPOTHESES, V85, P707, DOI 10.1016/j.mehy.2015.10.026; Peng H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030344; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rao YS, 2013, ENDOCRINOLOGY, V154, P2795, DOI 10.1210/en.2013-1230; Rim HK, 2013, INDIAN J MED RES, V137, P142; Sahin C, 2016, BASIC CLIN PHARMACOL, V119, P367, DOI 10.1111/bcpt.12604; Sarvari M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-82; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shelton RC, 2011, MOL PSYCHIATR, V16, P751, DOI 10.1038/mp.2010.52; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Slowik A, 2015, J STEROID BIOCHEM, V153, P135, DOI 10.1016/j.jsbmb.2015.02.013; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Thakkar R, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8309031; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Trendelenburg G, 2014, J CEREBR BLOOD F MET, V34, P1857, DOI 10.1038/jcbfm.2014.159; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Vaccari JPD, 2016, J NEUROCHEM, V136, P492, DOI 10.1111/jnc.13404; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Vinuesa CG, 2009, INT REV IMMUNOL, V28, P112, DOI 10.1080/08830180902934909; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang Y, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-77; Wang YJ, 2016, BEHAV BRAIN RES, V307, P18, DOI 10.1016/j.bbr.2016.03.044; Wei Q, 2015, LAB INVEST, V95, P804, DOI 10.1038/labinvest.2015.63; Wohleb ES, 2016, NAT REV NEUROSCI, V17, P497, DOI 10.1038/nrn.2016.69; Wu WF, 2013, P NATL ACAD SCI USA, V110, P3543, DOI 10.1073/pnas.1300313110; Xu YJ, 2016, BRAIN BEHAV IMMUN, V56, P175, DOI 10.1016/j.bbi.2016.02.022; Xu YJ, 2015, BEHAV BRAIN RES, V288, P71, DOI 10.1016/j.bbr.2015.04.017; Yao X, 2014, AM J PHYSIOL-HEART C, V306, pH882, DOI 10.1152/ajpheart.00475.2013; Yin Y, 2009, INT J IMMUNOPATH PH, V22, P311, DOI 10.1177/039463200902200208; Zendedel A, 2017, MOL NEUROBIOL; Zendedel A, 2016, MOL NEUROBIOL, V53, P3063, DOI 10.1007/s12035-015-9203-5; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhang Y, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv006; Zhang Y, 2014, CNS NEUROSCI THER, V20, P119, DOI 10.1111/cns.12170; Zhao QQ, 2017, CURR PHARM DESIGN, V23, P522, DOI 10.2174/1381612822666161208142617; Zhong Z, 2016, CLIN EXP RHEUMATOL, V34, pS12; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	133	17	17	3	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	FEB	2018	30	2			SI				e12482	10.1111/jne.12482			11	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	FW7RG	WOS:000425521300001	28477436				2021-06-18	
J	Uccella, L; Zoia, C; Bongetta, D; Gaetani, P; Martig, F; Candrian, C; Rosso, R				Uccella, Laura; Zoia, Cesare; Bongetta, Daniele; Gaetani, Paolo; Martig, Franz; Candrian, Christian; Rosso, Raffaele			Are Antiplatelet and Anticoagulants Drugs A Risk Factor for Bleeding in Mild Traumatic Brain Injury?	WORLD NEUROSURGERY			English	Article						Blood coagulation; Brain trauma; Clopidogrel; Head CT scan; Rivaroxaban	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; INTRACRANIAL HEMORRHAGE; PREINJURY CLOPIDOGREL; WARFARIN; OUTCOMES; THERAPY; MANAGEMENT; SCAN; RULE	OBJECTIVE: Facing mild traumatic brain injury, clinicians must decide whether to perform a computed tomography (CT) scan to detect a potential intracranial hemorrhage. Many useful guidelines have been developed for the general population, but there is no general consensus about the best practice to adopt when dealing with patients on antiplatelet or anticoagulation drugs. The relatively recent introduction of new anticoagulants and second-generation antiplatelet drugs poses new challenges in this field. There are no data in the literature about the relative risk of intracranial bleeding in such categories. METHODS: We enrolled 2773 consecutive patients presenting at our emergency department with mild traumatic brain injury as chief complaint and evaluated the results of their head CT scans, stratifying their anticoagulation and/or antiplatelet drug regime. RESULTS: Of these patients, 1608 matched the criteria for head CT scan and had a Glasgow Coma Scale (GCS) score of 15; 517 were on antiplatelet drugs, whereas 213 were on anticoagulants. The risk of developing intracranial bleeding was significantly higher for patients on antiplatelet drugs, whereas the risk of anticoagulated patients overlapped with that of the general population. The trend for second-generation drugs was of higher risk of bleeding only for antiplatelets. CONCLUSIONS: Patients with a GCS score of 15 on long-term anticoagulation therapy seem to be at no higher risk for intracranial hemorrhage than are nonanticoagulated patients. On the contrary, patients with a GCS score of 15 on antiplatelet therapy seem to be more prone to developing intracranial bleeding than are the general population, with a trend to be more at risk when it comes to second-generation drugs.	[Uccella, Laura; Martig, Franz; Candrian, Christian; Rosso, Raffaele] Civ Hosp, Dept Surg & Orthopaed, Lugano, Switzerland; [Zoia, Cesare; Bongetta, Daniele; Gaetani, Paolo] Fdn IRCCS Policlin S Matteo, Dept Neurosurg, Pavia, Italy; [Bongetta, Daniele] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy	Uccella, L (corresponding author), Civ Hosp, Dept Surg & Orthopaed, Lugano, Switzerland.	laura.uccella@eoc.ch	Zoia, Cesare/ABE-5286-2020; Zoia, Cesare/B-8463-2015	Zoia, Cesare/0000-0001-7304-6120; Zoia, Cesare/0000-0001-7304-6120; Candrian, Christian/0000-0002-3543-981X			Barratt H, 2010, EMERG MED J, V27, P173, DOI 10.1136/emj.2009.075382; Beynon C, 2015, CLIN NEUROL NEUROSUR, V136, P73, DOI 10.1016/j.clineuro.2015.05.035; Bouida W, 2013, ANN EMERG MED, V61, P521, DOI 10.1016/j.annemergmed.2012.07.016; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Centers for Disease Control and Prevention, 2014, REP C TRAUM BARIN IN; Cull JD, 2015, AM SURGEON, V81, P128; Ganetsky M, 2017, ACAD EMERG MED, V24, P1258, DOI 10.1111/acem.13217; Garcia DA, 2011, J FAM PRACTICE, V60, P70; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; Michelson AD, 2006, EUR HEART J SUPPL, V8, pG53, DOI 10.1093/eurheartj/sul056; NICEeNational Institute for Health and Care, EXC GUID; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Schoonman GG, 2014, EUR J NEUROL, V21, P1021, DOI 10.1111/ene.12429; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Uccella L, 2016, WORLD NEUROSURG, V93, P100, DOI 10.1016/j.wneu.2016.05.061; van den Brand CL, 2017, J NEUROTRAUM, V34, P1, DOI 10.1089/neu.2015.4393	24	17	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2018	110						E339	E345		10.1016/j.wneu.2017.10.173			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FX1ZT	WOS:000425856900047	29129761				2021-06-18	
J	Katsumoto, A; Miranda, AS; Butovsky, O; Teixeira, AL; Ransohoff, RM; Lamb, BT				Katsumoto, Atsuko; Miranda, Aline S.; Butovsky, Oleg; Teixeira, Antonio L.; Ransohoff, Richard M.; Lamb, Bruce T.			Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model	JOURNAL OF NEUROINFLAMMATION			English	Article						Laquinimod; Microglia; Peripherally derived monocytes; Traumatic brain injury	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PLACEBO-CONTROLLED TRIAL; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; ORAL LAQUINIMOD; MICE; DISEASE; CELLS; MILD; MICROGLIA	Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. Methods: To test our hypothesis, Ccr2(rfp/+) Cx3cr1(gfp/+) mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.	[Katsumoto, Atsuko; Miranda, Aline S.; Ransohoff, Richard M.; Lamb, Bruce T.] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Katsumoto, Atsuko; Lamb, Bruce T.] Indiana Univ Sch Med, Stark Neurosci Res Inst, 320 W 15th St, Indianapolis, IN 46202 USA; [Miranda, Aline S.] Univ Fed Minas Gerais, Dept Morphol, Lab Neurobiol, Belo Horizonte, MG, Brazil; [Butovsky, Oleg] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; [Teixeira, Antonio L.] Univ Fed Minas Gerais, Sch Med, Interdisciplinary Lab Med Invest, Belo Horizonte, MG, Brazil	Katsumoto, A; Lamb, BT (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chiwawan-atsuko@hotmail.co.jp; btlamb@iu.edu	Teixeira, Antonio L/N-3315-2014; Butovsky, Oleg/ABG-9086-2020	Teixeira, Antonio L/0000-0002-9621-5422; Butovsky, Oleg/0000-0003-0186-8867; Katsumoto, Atsuko/0000-0002-5582-3050	Teva Pharmaceuticals, Ltd. Netanya Israel; CNPq SWO scholar-ship	This work was supported by the Teva Pharmaceuticals, Ltd. Netanya Israel to BTL and OB. ASM was a CNPq SWO scholar-ship recipient.	Aharoni R, 2012, J NEUROIMMUNOL, V251, P14, DOI 10.1016/j.jneuroim.2012.06.005; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Comi G, 2012, NEW ENGL J MED, V366, P1000, DOI 10.1056/NEJMoa1104318; D'Haens G, 2015, GUT, V64, P1227, DOI 10.1136/gutjnl-2014-307118; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dobson L, 2016, J NEUROCHEM, V137, P782, DOI 10.1111/jnc.13553; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Filippi M, 2014, J NEUROL NEUROSUR PS, V85, P852, DOI 10.1136/jnnp-2013-306132; Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jolivel V, 2013, BRAIN, V136, P1048, DOI 10.1093/brain/awt023; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Lourenco EV, 2014, ARTHRITIS RHEUMATOL, V66, P674, DOI 10.1002/art.38259; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mishra MK, 2012, AM J PATHOL, V181, P642, DOI 10.1016/j.ajpath.2012.05.011; Mishra MK, 2014, ANN CLIN TRANSL NEUR, V1, P409, DOI 10.1002/acn3.67; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ono K, 2010, NEUROSCI LETT, V473, P146, DOI 10.1016/j.neulet.2010.02.041; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Vollmer TL, 2014, J NEUROL, V261, P773, DOI 10.1007/s00415-014-7264-4; Wegner C, 2010, J NEUROIMMUNOL, V227, P133, DOI 10.1016/j.jneuroim.2010.07.009; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yang HS, 2004, J NEUROIMMUNOL, V156, P3, DOI 10.1016/j.jneuroim.2004.02.016; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yousefzadeh-Chabok S, 2015, ARCH TRAUMA RES, V4, DOI 10.5812/atr.18357; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041	49	17	17	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 30	2018	15									10.1186/s12974-018-1075-y			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FU2XB	WOS:000423712200001	29382353	DOAJ Gold, Green Published			2021-06-18	
J	Johnson, RA; Albright, DL; Marzolf, JR; Bibbo, JL; Yaglom, HD; Crowder, SM; Carlisle, GK; Willard, A; Russell, CL; Grindler, K; Osterlind, S; Wassman, M; Harms, N				Johnson, Rebecca A.; Albright, David L.; Marzolf, James R.; Bibbo, Jessica L.; Yaglom, Hayley D.; Crowder, Sandra M.; Carlisle, Gretchen K.; Willard, Amy; Russell, Cynthia L.; Grindler, Karen; Osterlind, Steven; Wassman, Marita; Harms, Nathan			Effects of therapeutic horseback riding on post-traumatic stress disorder in military veterans	MILITARY MEDICAL RESEARCH			English	Article						Animal-assisted intervention; Coping self-efficacy; Emotion regulation; Military veterans; Post-traumatic stress disorder; Social engagement; Therapeutic horseback riding; Traumatic brain injury	SUBSTANCE USE DISORDERS; MENTAL-HEALTH PROBLEMS; SOLDIERS; PTSD; IRAQ; DEPLOYMENT; SYMPTOMS; CHILDREN; VALIDITY; BEHAVIOR	Background: Large numbers of post-deployment U.S. veterans are diagnosed with post-traumatic stress disorder (PTSD) and/or traumatic brain injury (TBI), leading to an urgent need for effective interventions to reduce symptoms and increase veterans' coping. PTSD includes anxiety, flashbacks, and emotional numbing. The symptoms increase health care costs for stress-related illnesses and can make veterans' civilian life difficult. Methods: We used a randomized wait-list controlled design with repeated measures of U.S. military veterans to address our specific aim to test the efficacy of a 6-week therapeutic horseback riding (THR) program for decreasing PTSD symptoms and increasing coping self-efficacy, emotion regulation, social and emotional loneliness. Fifty-seven participants were recruited and 29 enrolled in the randomized trial. They were randomly assigned to either the horse riding group (n = 15) or a wait-list control group (n = 14). The wait-list control group experienced a 6-week waiting period, while the horse riding group began THR. The wait-list control group began riding after 6 weeks of participating in the control group. Demographic and health history information was obtained from all the participants. PTSD symptoms were measured using the standardized PTSD Checklist-Military Version (PCL-M). The PCL-M as well as other instruments including, The Coping Self Efficacy Scale (CSES), The Difficulties in Emotion Regulation Scale (DERS) and The Social and Emotional Loneliness Scale for Adults-short version (SELSA) were used to access different aspects of individual well-being and the PTSD symptoms. Results: Participants had a statistically significant decrease in PTSD scores after 3 weeks of THR (P <= 0.01) as well as a statistically and clinically significant decrease after 6 weeks of THR (P <= 0.01). Logistic regression showed that participants had a 66.7% likelihood of having lower PTSD scores at 3 weeks and 87.5% likelihood at 6 weeks. Under the generalized linear model(GLM), our ANOVA findings for the coping self-efficacy, emotion regulation, and social and emotional loneliness did not reach statistical significance. The results for coping self-efficacy and emotion regulation trended in the predicted direction. Results for emotional loneliness were opposite the predicted direction. Logistic regression provided validation that outcome effects were caused by riding longer. Conclusion: The findings suggest that THR may be a clinically effective intervention for alleviating PTSD symptoms in military veterans.	[Johnson, Rebecca A.; Crowder, Sandra M.; Carlisle, Gretchen K.] Univ Missouri, Res Ctr Human Anim Interact, Coll Vet Med, Columbia, MO 65211 USA; [Johnson, Rebecca A.] Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65211 USA; [Albright, David L.] Univ Alabama, Sch Social Work, Tuscaloosa, AL 35487 USA; [Marzolf, James R.] Harry S Truman Mem Vet Hosp, Occupat Hlth Serv, Columbia, MO 65211 USA; [Bibbo, Jessica L.] Purdue Univ, Coll Vet Med, Ctr Human Anim Bond, W Lafayette, IN 47907 USA; [Yaglom, Hayley D.] Univ Missouri, Sch Hlth Profess, Columbia, MO 65211 USA; [Willard, Amy; Harms, Nathan] TREE House Greater St Louis, Wentzville, MO 63385 USA; [Russell, Cynthia L.] Univ Missouri, Sch Nursing & Hlth Studies, Kansas City, MO 64108 USA; [Grindler, Karen] Cedar Creek Therapeut Riding Ctr, Columbia, MO 65201 USA; [Osterlind, Steven] Univ Missouri, Sch & Counseling Psychol, Coll Educ, Columbia, MO 65211 USA; [Wassman, Marita] Ride On St Louis, Kimmswick, MO 63053 USA	Johnson, RA (corresponding author), Univ Missouri, Res Ctr Human Anim Interact, Coll Vet Med, Columbia, MO 65211 USA.; Johnson, RA (corresponding author), Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65211 USA.	rajohnson@missouri.edu	Crowder, Sandra/ABI-8336-2020		Horses and Humans Research Foundation [#00040568] Funding Source: Medline; University of Missouri Interdisciplinary Center on Aging [n/a] Funding Source: Medline		Araujo TB, 2011, BRAZ J PHYS THER, V15, P414, DOI 10.1590/S1413-35552011005000027; Asselin G, 2012, REHABIL NURS, V37, P270, DOI 10.1002/rnj.027; Bandura A., 2006, SELF EFFICACY BELIEF, P307; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bandura A., 1997, SELF EFFICACY EXERCI; Biery MJ, 1989, ADAPTED PHYSICAL ACT, V6, P221, DOI DOI 10.1123/apaq.6.3.221; Bizub AL, 2003, PSYCHIATR REHABIL J, V26, P377, DOI 10.2975/26.2003.377.384; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Cantin A, 2001, MENT HEALTH LEARN, V8, P51; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chesney MA, 2006, BRIT J HEALTH PSYCH, V11, P421, DOI 10.1348/135910705X53155; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; de Assis MA, 2008, CLINICS, V63, P473, DOI 10.1590/S1807-59322008000400010; Department of Veterans Affairs and Department of Defense, 2010, VA DOD CLIN PRACT GU; DiTommaso E, 2004, EDUC PSYCHOL MEAS, V64, P99, DOI 10.1177/0013164403258450; Duncan C., 2014, CANADIAN MILITARY J, V14, P64; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Farias-Tomaszewski S., 2001, Therapeutic Recreation Journal, V35, P250; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Gewirtz AH, 2010, J CONSULT CLIN PSYCH, V78, P599, DOI 10.1037/a0020571; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Hakanson M, 2009, J BODYW MOV THER, V13, P43, DOI 10.1016/j.jbmt.2007.06.002; Hammer Ann, 2005, Physiotherapy Theory and Practice, V21, P51, DOI 10.1080/09593980590911525; Henriksen J D, 1971, Arch Phys Med Rehabil, V52, P282; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; International Association of Human-Animal Interactions Organizations, 2014, IAHAIO WHIT PAP; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Johnson RA, 2003, AM BEHAV SCI, V47, P55, DOI 10.1177/0002764203255213; Johnson RA, 2008, ONCOL NURS FORUM, V35, P225, DOI 10.1188/08.ONF.225-232; Johnson RA, 2010, CLIN NURS RES, V19, P387, DOI 10.1177/1054773810373122; Kazdin AE., 2003, METHODOLOGICAL ISSUE; Kazdin AE., 2003, J CONSTR PSYCHOL, V49, P183; Keaveney SM, 2008, J BUS RES, V61, P444, DOI 10.1016/j.jbusres.2007.07.017; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Land Gary, 2002, Occup Ther Health Care, V14, P1, DOI 10.1080/J003v14n01_01; Lanning BA, 2013, J REHABIL RES DEV, V50, pXV, DOI 10.1682/JRRD.2013.07.0159; Lechner HE, 2003, SPINAL CORD, V41, P502, DOI 10.1038/sj.sc.3101492; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Libby DJ, 2012, PSYCHIAT SERV, V63, P1134, DOI 10.1176/appi.ps.201100456; MACKAY-LYONS M, 1988, Physiotherapy Canada, V40, P104; MacLean B, 2011, J REHABIL RES DEV, V48, pIX, DOI 10.1682/JRRD.2011.05.0085; MCLEOD JD, 1990, J HEALTH SOC BEHAV, V31, P162, DOI 10.2307/2137170; Meregillano Gary, 2004, Phys Med Rehabil Clin N Am, V15, P843; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; [National Center for PTSD U. S. Department of Veterans Affairs], 2011, PTSD CHECKL MIL VERS; Nazarian D, 2012, J TRAUMA STRESS, V25, P220, DOI 10.1002/jts.21690; Nesbit R, 2011, PUBLIC ADMIN REV, V71, P67, DOI 10.1111/j.1540-6210.2010.02307.x; Newman Caren L, 2007, Int J Emerg Ment Health, V9, P133; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Owens GP, 2012, PSYCHOL TRAUMA-US, V4, P221, DOI 10.1037/a0024251; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Panksepp J, 2005, CONSCIOUS COGN, V14, P30, DOI 10.1016/j.concog.2004.10.004; Payne E, 2016, BEHAV PROCESS, V125, P114, DOI 10.1016/j.beproc.2015.10.004; Pendry P, 2014, J PRIM PREV, V35, P281, DOI 10.1007/s10935-014-0350-7; Schell TL, 2008, NVISIBLE WOUNDS WAR, P93; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Seal KH, 2011, AM PUBLIC HLTH, V116, P93; Silkwood-Sherer D., 2003, PATH INT STRIDES, V9, P14; Stein JY, 2014, J CONSTR PSYCHOL, V7, P122; Strauss JL, 2012, PTSD RES Q, V23, P1; Streeter CC, 2012, MED HYPOTHESES, V78, P571, DOI 10.1016/j.mehy.2012.01.021; Taft CT, 2008, J CONSULT CLIN PSYCH, V76, P648, DOI 10.1037/a0012576; U. S. Census Bureau, 2012, VET 2012 STAT ABSTR; U.S. Department of Veterans Affairs, 2016, PTSD CHECKL DSM 5 PC; U. S. Dept. of Veterans Affairs, 2015, PTSD HIST OV; Ungermann CM, 2001, J ALTERN COMPLEM MED, V17, P1191; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Webster A, 1995, SCI J THERAPEUTIC RI, V1, P333; Wynn GH, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0600-2; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690	76	17	18	1	39	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2095-7467	2054-9369		MILITARY MED RES	MILITARY MED. RES.	JAN 19	2018	5								3	10.1186/s40779-018-0149-6			13	Medicine, General & Internal	General & Internal Medicine	FT1SI	WOS:000422916100001	29502529	DOAJ Gold, Green Published			2021-06-18	
J	Armistead-Jehle, P; Cooper, DB; Grills, CE; Cole, WR; Lippa, SM; Stegman, RL; Lange, RT				Armistead-Jehle, Patrick; Cooper, Douglas B.; Grills, Chad E.; Cole, Wesley R.; Lippa, Sara M.; Stegman, Robert L.; Lange, Rael T.			Clinical utility of the mBIAS and NSI validity-10 to detect symptom over-reporting following mild TBI: A multicenter investigation with military service members	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						mBIAS; MMPI-2-RF; NSI Validity-10; symptom over-reporting; military	TRAUMATIC BRAIN-INJURY; DEFINED MALINGERING GROUPS; BIAS SCALE RBS; POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; ANALOG SIMULATION; PTSD CHECKLIST; CUTOFF SCORES; SAMPLE; MMPI-2-RF	Self-report measures are commonly relied upon in military healthcare environments to assess service members following a mild traumatic brain injury (mTBI). However, such instruments are susceptible to over-reporting and rarely include validity scales. This study evaluated the utility of the mild Brain Injury Atypical Symptoms scale (mBIAS) and the Neurobehavioral Symptom Inventory Validity-10 scale to detect symptom over-reporting. A total of 359 service members with a reported history of mTBI were separated into two symptom reporting groups based on MMPI-2-RF validity scales (i.e., non-over-reporting versus symptom over-reporting). The clinical utility of the mBIAS and Validity-10 as diagnostic indicators and screens of symptom over-reporting were evaluated by calculating sensitivity, specificity, positive test rate, positive predictive power (PPP), and negative predictive power (NPP) values. An mBIAS cut score of 10 was optimal as a diagnostic indicator, which resulted in high specificity and PPP; however, sensitivity was low. The utility of the mBIAS as a screening instrument was limited. A Validity-10 cut score of 33 was optimal as a diagnostic indicator. This resulted in very high specificity and PPP, but low sensitivity. A Validity-10 cut score of 7 was considered optimal as a screener, which resulted in moderate sensitivity, specificity, NPP, but relatively low PPP. Owing to low sensitivity, the current data suggests that both the mBIAS and Validity-10 are insufficient as stand-alone measures of symptom over-reporting. However, Validity-10 scores above the identified cut-off of 7should be taken as an indication that further evaluation to rule out symptom over-reporting is necessary.	[Armistead-Jehle, Patrick] Munson Army Hlth Ctr, Concuss Clin, 550 Pope Ave, Ft Leavenworth, KS 66027 USA; [Cooper, Douglas B.] San Antonio Mil Med Ctr, Dept Neurol, San Antonio, TX USA; [Cooper, Douglas B.; Cole, Wesley R.; Lippa, Sara M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Grills, Chad E.] US Army Hlth Clin, Brain Injury Clin, Schofield Barracks, HI USA; [Cole, Wesley R.; Stegman, Robert L.] Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC USA; [Lippa, Sara M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD USA; [Lippa, Sara M.; Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA	Armistead-Jehle, P (corresponding author), Munson Army Hlth Ctr, Concuss Clin, 550 Pope Ave, Ft Leavenworth, KS 66027 USA.	patrick.j.armistead-jehle.civ@mail.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath Y. S., 2011, MANUAL ADM SCORING I; Ben-Porath YS, 2008, MANUAL ADM SCORING I; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Butcher J. N, 2001, MMPI 2 MINNESOTA MUL; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Grills CE, 2016, APPL NEUROPSYCH-ADUL, V23, P295, DOI 10.1080/23279095.2015.1079713; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ingram PB, 2016, CLIN NEUROPSYCHOL, V30, P473, DOI 10.1080/13854046.2016.1187769; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P786, DOI 10.1093/arclin/acw035; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P273, DOI 10.1093/arclin/acw006; Jones A, 2011, CLIN NEUROPSYCHOL, V25, P1207, DOI 10.1080/13854046.2011.600726; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lippa SM, 2016, J CLIN EXP NEUROPSYC, V38, P721, DOI 10.1080/13803395.2016.1161732; Lippa SM, 2016, J REHABIL RES DEV, V53, P379, DOI 10.1682/JRRD.2015.01.0009; Lippa SM, 2014, ARCH CLIN NEUROPSYCH, V29, P236, DOI 10.1093/arclin/acu002; McCrea M, 2008, MILD TRAUMATIC BRAIN; Morey L. C., 1991, PERSONALITY ASSESSME; Sullivan KA, 2016, APPL NEUROPSYCH-ADUL, V23, P353, DOI 10.1080/23279095.2015.1079714; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	39	17	17	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2018	40	3					213	223		10.1080/13803395.2017.1329406			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	FV7WV	WOS:000424797100001	28539077				2021-06-18	
J	Chesnut, RM; Temkin, N; Dikmen, S; Rondina, C; Videtta, W; Petroni, G; Lujan, S; Alanis, V; Falcao, A; de la Fuenta, G; Gonzalez, L; Jibaja, M; Lavarden, A; Sandi, F; Merida, R; Romero, R; Pridgeon, J; Barber, J; Machamer, J; Chaddock, K				Chesnut, Randall M.; Temkin, Nancy; Dikmen, Sureyya; Rondina, Carlos; Videtta, Walter; Petroni, Gustavo; Lujan, Silvia; Alanis, Victor; Falcao, Antonio; de la Fuenta, Gustavo; Gonzalez, Luis; Jibaja, Manuel; Lavarden, Arturo; Sandi, Freddy; Merida, Roberto; Romero, Ricardo; Pridgeon, Jim; Barber, Jason; Machamer, Joan; Chaddock, Kelley			A Method of Managing Severe Traumatic Brain Injury in the Absence of Intracranial Pressure Monitoring: The Imaging and Clinical Examination Protocol	JOURNAL OF NEUROTRAUMA			English	Article						global health; intracranial hypertension; intracranial pressure monitoring; neurocritical care; severe traumatic brain injury	SEVERE HEAD-INJURY; CARE MANAGEMENT; UNITED-STATES; TRIALS	The imaging and clinical examination (ICE) algorithm used in the Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure (BEST TRIP) randomized controlled trial is the only prospectively investigated clinical protocol for traumatic brain injury management without intracranial pressure (ICP) monitoring. As the default literature standard, it warrants careful evaluation. We present the ICE protocol in detail and analyze the demographics, outcome, treatment intensity, frequency of intervention usage, and related adverse events in the ICE-protocol cohort. The 167 ICE protocol patients were young (median 29 years) with a median Glasgow Coma Scale motor score of 4 but with anisocoria or abnormal pupillary reactivity in 40%. This protocol produced outcomes not significantly different from those randomized to the monitor-based protocol (favorable 6-month extended Glasgow Outcome Score in 39%; 41% mortality rate). Agents commonly employed to treat suspected intracranial hypertension included low-/moderate-dose hypertonic saline (72%) and mannitol (57%), mild hyperventilation (adjusted partial pressure of carbon dioxide 30-35mm Hg in 73%), and pressors to maintain cerebral perfusion (62%). High-dose hyperosmotics or barbiturates were uncommonly used. Adverse event incidence was low and comparable to the BEST TRIP monitored group. Although this protocol should produce similar/acceptable results under circumstances comparable to those in the trial, influences such as longer pre-hospital times and non-specialist transport personnel, plus an intensive care unit model of aggressive physician-intensive care by small groups of neurotrauma-focused intensivists, which differs from most high-resource models, support caution in expecting the same results in dissimilar settings. Finally, this protocol's ICP-titration approach to suspected intracranial hypertension (vs. crisis management for monitored ICP) warrants further study.	[Chesnut, Randall M.; Temkin, Nancy; Dikmen, Sureyya; Pridgeon, Jim; Barber, Jason; Machamer, Joan; Chaddock, Kelley] Univ Washington, Harborview Med Ctr, 325 9Th Ave, Seattle, WA 98104 USA; [Rondina, Carlos; Petroni, Gustavo; Lujan, Silvia] Hosp Emergencia Dr Clemente Alvarez, Rosario, Santa Fe, Argentina; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Buenos Aires, DF, Argentina; [Alanis, Victor] Hosp San Juan Dios, Santa Cruz, Bolivia; [Falcao, Antonio] Hosp Clin Unicamp, Campinas, SP, Brazil; [Petroni, Gustavo] Hosp Japones, Santa Cruz, Bolivia; [Gonzalez, Luis] Hosp Luis Vernaza, Guayaquil, Ecuador; [Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador; [Lavarden, Arturo] Hosp Viedma, Cochabamba, Bolivia; [Sandi, Freddy] Hosp Obrero 1 La Paz, La Paz, Bolivia; [Merida, Roberto] Hosp San Juan Dios, Tarija, Bolivia; [Romero, Ricardo] Fdn Clin Campbell, Barranquilla, Colombia	Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA.	chesnutr@u.washington.edu		Falcao, Antonio/0000-0002-1630-7889; Chesnut, Randall/0000-0001-6377-3666; ROMERO FIGUEROA, RICARDO LUIS/0000-0002-3124-8717	Integra LifeSciences; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080648] Funding Source: NIH RePORTER	Integra LifeSciences donated the ICP monitoring catheters and monitors and provided additional unrestricted support for the parent study. Integra had no role in study design or conduct, data analysis, or the writing of any manuscripts.	Arabi YM, 2010, J CRIT CARE, V25, P190, DOI 10.1016/j.jcrc.2009.05.004; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TEASDALE G, 1974, LANCET, V2, P81; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2	21	17	17	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					54	63		10.1089/neu.2016.4472			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700008	28726590	Green Published			2021-06-18	
J	Cui, HJ; Tao, L; Li, PF; Ali, Y; Zhou, HJ; Luo, JK; Yang, W; Tao, T				Cui Hanjin; Tao, Liu; Li Pengfei; Ali, Yang; Zhou Huajun; Luo Jiekun; Yang, Wang; Tao, Tang			Altered Long Noncoding RNA and Messenger RNA Expression in Experimental Intracerebral Hemorrhage - a Preliminary Study	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Intracerebral hemorrhage; Long non-coding RNA (lncRNA); Messenger RNA (mRNA); Expression profile	TRAUMATIC BRAIN-INJURY; CELL-DEATH; GROWTH-HORMONE; INFLAMMATORY MEDIATORS; CONSERVATIVE TREATMENT; CEREBRAL-ISCHEMIA; UP-REGULATION; RAT BRAINS; FACTOR-I; RECEPTOR	Background/Aims: Functional recovery in the chronic phase is a difficult problem in intracerebral hemorrhage (ICH) treatment. Long noncoding RNAs (lncRNAs) are demonstrated to be involved in central nervous system (CNS) disorders. However, the roles of lncRNAs in post-ICH injury and repair are poorly understood, especially those that may be attributed to long-term neurological deficit. The present study depicted the lncRNA and messenger RNA (mRNA) profile by microarray at late stage after an experimental ICH. Methods: LncRNA and mRNA microarray was used to first identify differentially expressed genes. Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to determine bio-functions and signaling pathways, with which differentially expressed genes are most closely related. Quantitative real-time polymerase chain reaction (PCR) was used to validate the results of microarray. Finally, the lncRNA-mRNA co-expression network was constructed to find the interaction of genes. Results: A total of 625 differentially expressed lncRNAs and 826 expressed mRNAs were identified. Altered genes were enriched in mitochondrial matrix, G-protein coupled receptor signaling pathway, and olfactory transduction, which may be associated with ICH-induced pathophysiologic changes in the long term. A co-expression network profile based on 5 validated differentially expressed lncRNAs and 205 interacted mRNAs was composed of 210 nodes and 298 connections. Conclusion: Mitochondrial matrix, reduced G-protein coupled receptor activity, and impaired olfactory transduction may be involved in the sequelae following ICH. Further, these dysregulated lncRNAs and mRNAs may be the promising therapeutic targets to overcome obstacles in functional recovery following ICH. (C) 2018 The Author(s) Published by S. Karger AG, Basel	[Cui Hanjin; Tao, Liu; Li Pengfei; Luo Jiekun; Yang, Wang; Tao, Tang] Cent S Univ, Xiangya Hosp, Inst Integrat Med, Changsha, Hunan, Peoples R China; [Tao, Liu] Xinjiang Med Univ, Tradit Chinese Med Hosp, Dept Gerontol, Urumqi, Peoples R China; [Ali, Yang] Cent S Univ, Xiangya Hosp, Inst Neurol, Changsha, Hunan, Peoples R China; [Ali, Yang] Henan Prov Peoples Hosp, Dept Neurol, Zhengzhou, Henan, Peoples R China; [Zhou Huajun] China Three Gorges Univ, Coll Clin Med Sci 1, Inst Neurol, Yichang, Hubei, Peoples R China	Yang, W; Tao, T (corresponding author), Cent S Univ, Xiangya Hosp, Inst Integrat Med, Changsha, Hunan, Peoples R China.	wangyang_xy87@csu.edu.cn; tangtaotay@csu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81473573, 81173175, 81202625, 81673719, 81603414]; Science Foundation for Young Scientists of Xiangya Hospital, Central South University [2016Q09]	This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81473573, 81173175, 81202625, 81673719 and 81603414), Science Foundation for Young Scientists of Xiangya Hospital, Central South University (Grant No. 2016Q09).	Al-Khaled M, 2014, J STROKE CEREBROVASC, V23, P230, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.018; Almeida DV, 2013, TRANSGENIC RES, V22, P75, DOI 10.1007/s11248-012-9627-x; Andersen Grethe, 2007, Ugeskr Laeger, V169, P3376; Arisi GM, 2012, BEHAV BRAIN RES, V227, P356, DOI 10.1016/j.bbr.2011.03.050; Baek H, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0280-9; Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P133, DOI 10.1097/MCC.0000000000000072; Cassidy JM, 2017, TRANSL STROKE RES, V8, P33, DOI 10.1007/s12975-016-0467-5; Castillo C, 2005, ENDOCRINE, V26, P11, DOI 10.1385/ENDO:26:1:011; Cavaliere F, 2001, NEUROCHEM INT, V38, P199, DOI 10.1016/S0197-0186(00)00087-5; Cavaliere F, 2001, NEUROCHEM INT, V38, P189, DOI 10.1016/S0197-0186(00)00088-7; Chen L, 2014, RESTOR NEUROL NEUROS, V32, P533, DOI 10.3233/RNN-140403; Chen Y, 2017, METAB BRAIN DIS, V32, P281, DOI 10.1007/s11011-017-9965-8; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Contreras-Garcia JI, 2012, NEUROSCI LETT, V522, P6, DOI 10.1016/j.neulet.2012.05.050; Cui HJ, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0605-8; Dharap A, 2012, STROKE, V43, P2800, DOI 10.1161/STROKEAHA.112.669465; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Gao YF, 2016, TUMOR BIOL, V37, P14403, DOI 10.1007/s13277-016-5307-4; Goya Y, 2014, EUR NEUROL, V71, P203, DOI 10.1159/000356198; Gudziol V, 2014, EUR ARCH OTO-RHINO-L, V271, P1533, DOI 10.1007/s00405-013-2687-6; Han Y, 2016, CELL MOL NEUROBIOL, V36, P1097, DOI 10.1007/s10571-015-0303-6; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Jaako-Movits K, 2005, EUR J NEUROSCI, V22, P2871, DOI 10.1111/j.1460-9568.2005.04481.x; Jeong H, 2010, PLOS ONE, V5; Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9; Kate MP, 2014, J CEREBR BLOOD F MET, V34, P81, DOI 10.1038/jcbfm.2013.164; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; Lan X, 2017, NAT REV NEUROL, V13, P420, DOI 10.1038/nrneurol.2017.69; Liu T, 2014, MOL MED REP, V10, P1275, DOI 10.3892/mmr.2014.2351; Majidi S, 2017, WORLD NEUROSURG, V101, P742, DOI 10.1016/j.wneu.2017.03.079; Martoncikova M, 2011, ACTA HISTOCHEM, V113, P326, DOI 10.1016/j.acthis.2010.01.002; Melani A, 2005, NEUROCHEM INT, V47, P442, DOI 10.1016/j.neuint.2005.05.014; Melani A, 2006, J CEREBR BLOOD F MET, V26, P974, DOI 10.1038/sj.jcbfm.9600250; Mendelow AD, 2005, LANCET, V365, P387; Mino M, 2003, NEUROL RES, V25, P839, DOI 10.1179/016164103771953934; Ng SY, 2013, TRENDS GENET, V29, P461, DOI 10.1016/j.tig.2013.03.002; Niimura M, 2006, NEUROSCI LETT, V407, P136, DOI 10.1016/j.neulet.2006.08.060; Park MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23015; Pope K, 2007, NEUROSCI LETT, V422, P13, DOI 10.1016/j.neulet.2007.05.041; Rettberg JR, 2014, FRONT NEUROENDOCRIN, V35, P8, DOI 10.1016/j.yfrne.2013.08.001; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Suzumura A, 2013, CURR PROTEIN PEPT SC, V14, P16, DOI 10.2174/1389203711314010004; Thal SC, 2014, CRIT CARE MED, V42, P129, DOI 10.1097/CCM.0b013e3182a639fd; Tveiten A, 2014, ACTA NEUROL SCAND, V129, P269, DOI 10.1111/ane.12185; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Wang CL, 2014, PEPTIDES, V54, P27, DOI 10.1016/j.peptides.2014.01.005; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang JP, 2014, BEHAV BRAIN RES, V265, P171, DOI 10.1016/j.bbr.2014.02.033; Wang MY, 2015, MAGN RESON MED, V74, P42, DOI 10.1002/mrm.25690; Wu H, 2010, NEUROCHEM INT, V57, P248, DOI 10.1016/j.neuint.2010.06.002; Xu Xi, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1437; Yin KJ, 2014, NEUROCHEM INT, V77, P9, DOI 10.1016/j.neuint.2014.03.013; You Y, 2016, BRAIN RES, V1646, P34, DOI 10.1016/j.brainres.2016.04.076; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang Z, 2017, MOL NEUROBIOL, V54, P1874, DOI 10.1007/s12035-016-9785-6; Zhao FY, 2015, SCI REP-UK, V5, DOI 10.1038/srep13850; Zhou HJ, 2010, J NEUROSURG, V113, P820, DOI 10.3171/2010.1.JNS09637; Zweifel C, 2011, BIOMARKERS, V16, P511, DOI 10.3109/1354750X.2011.599074	61	17	17	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2018	45	3					1284	1301		10.1159/000487464			18	Cell Biology; Physiology	Cell Biology; Physiology	FX4HN	WOS:000426033900034	29448258	DOAJ Gold			2021-06-18	
J	Filho, IT				Filho, Ivo Torres			Hemorrhagic Shock and the Microvasculature	COMPREHENSIVE PHYSIOLOGY			English	Article							NEAR-INFRARED SPECTROSCOPY; BODY NEGATIVE-PRESSURE; FRESH-FROZEN PLASMA; RED-BLOOD-CELLS; ENDOTHELIAL GLYCOCALYX DEGRADATION; HEMOGLOBIN OXYGEN-SATURATION; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; HYPERTONIC SALINE RESUSCITATION; INDUCED VASCULAR HYPOREACTIVITY	The microvasculature plays a central role in the pathophysiology of hemorrhagic shock and is also involved in arguably all therapeutic attempts to reverse or minimize the adverse consequences of shock. Microvascular studies specific to hemorrhagic shock were reviewed and broadly grouped depending on whether data were obtained on animal or human subjects. Dedicated sections were assigned to microcirculatory changes in specific organs, and major categories of pathophysiological alterations and mechanisms such as oxygen distribution, ischemia, inflammation, glycocalyx changes, vasomotion, endothelial dysfunction, and coagulopathy as well as biomarkers and some therapeutic strategies. Innovative experimental methods were also reviewed for quantitative microcirculatory assessment as it pertains to changes during hemorrhagic shock. The text and figures include representative quantitative microvascular data obtained in various organs and tissues such as skin, muscle, lung, liver, brain, heart, kidney, pancreas, intestines, and mesentery from various species including mice, rats, hamsters, sheep, swine, bats, and humans. Based on reviewed findings, a new integrative conceptual model is presented that includes about 100 systemic and local factors linked to microvessels in hemorrhagic shock. The combination of systemic measures with the understanding of these processes at the microvascular level is fundamental to further develop targeted and personalized interventions that will reduce tissue injury, organ dysfunction, and ultimately mortality due to hemorrhagic shock. Published 2018.	[Filho, Ivo Torres] US Army, Inst Surg Res, JBSA, Ft Sam Houston, TX 78234 USA	Filho, IT (corresponding author), US Army, Inst Surg Res, JBSA, Ft Sam Houston, TX 78234 USA.	ivo.p.torresfilho.civ@mail.mil		Torres Filho, Ivo/0000-0003-1797-519X	US Army Medical Research Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Brazilian National Council for Scientific and Technological DevelopmentConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Pew Charitable Trusts; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; US Department of DefenseUnited States Department of Defense	The opinions or assertions contained herein are the private views of the author and not to be construed as official or as reflecting the views of the Department of the Army or the US Department of Defense. This study was supported by the US Army Medical Research Materiel Command. The experimental studies by the author were conducted in compliance with the Animal Welfare Act, the implementing Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory Animals, using protocols approved by the Institutional Animal Care and Use Committee of the respective institutions, including the US Army ISR. The author thanks the wisdom, support, and collaboration of various colleagues, technicians, and students, mainly at the State and Federal Universities of Rio de Janeiro, University of Washington, University of Arizona, University of California, San Diego, Virginia Commonwealth University, and US Army Institute of Surgical Research. The support from the Brazilian National Council for Scientific and Technological Development, the Pew Charitable Trusts, National Institutes of Health, and the US Department of Defense is also acknowledged. The author declares no competing financial interests although has intellectual property on the use of resonance Raman spectroscopy for tissue oxygenation monitoring.	Aalkjaer C, 2005, BRIT J PHARMACOL, V144, P605, DOI 10.1038/sj.bjp.0706084; Aalkjaer C, 2011, ACTA PHYSIOL, V202, P253, DOI 10.1111/j.1748-1716.2011.02320.x; ACHAKRI H, 1995, J VASC RES, V32, P237, DOI 10.1159/000159098; Adolphs J, 2003, ANESTHESIOLOGY, V99, P685, DOI 10.1097/00000542-200309000-00025; Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Aksu U, 2012, RESUSCITATION, V83, P767, DOI 10.1016/j.resuscitation.2011.11.022; ALTURA BM, 1976, EUR J PHARMACOL, V37, P155, DOI 10.1016/0014-2999(76)90018-2; ALTURA BM, 1976, J PHARMACOL EXP THER, V198, P187; AMUNDSON B, 1980, ACTA PHYSIOL SCAND, V108, P147, DOI 10.1111/j.1748-1716.1980.tb06512.x; AMUNDSON B, 1982, SCAND J PLAST RECONS, P16; AMUNDSON B, 1980, ACTA PHYSIOL SCAND, V108, P139, DOI 10.1111/j.1748-1716.1980.tb06511.x; Angele MK, 2008, CRIT CARE, V12, DOI 10.1186/cc6919; Audonnet-Blaise S, 2006, RESUSCITATION, V70, P124, DOI 10.1016/j.resuscitation.2005.11.014; Ba ZF, 2005, AM J PHYSIOL-GASTR L, V288, pG860, DOI 10.1152/ajpgi.00437.2004; BADONNEL MC, 1983, J NEUROPATH EXP NEUR, V42, P561, DOI 10.1097/00005072-198309000-00008; BADR KF, 1988, NEW ENGL J MED, V319, P623; BAEZ S, 1964, Int Anesthesiol Clin, V2, P365, DOI 10.1097/00004311-196402000-00012; BAKER M, 1974, MICROVASC RES, V7, P131, DOI 10.1016/0026-2862(74)90043-0; Balaz D, 2016, UNDERSEA HYPERBAR M, V43, P123; Ban KC, 2015, SHOCK, V44, P452, DOI 10.1097/SHK.0000000000000452; Baron BJ, 2004, J TRAUMA, V57, P69, DOI 10.1097/01.TA.0000090754.94232.2C; BARROSOARANDA J, 1988, CIRC RES, V63, P437, DOI 10.1161/01.RES.63.2.437; BarrosoAranda J, 1995, J CARDIOVASC PHARM, V25, pS23, DOI 10.1097/00005344-199500252-00006; BARROSOARANDA J, 1989, AM J PHYSIOL, V257, pH846; Bartlett AH, 2007, MOL CELLS, V24, P153; Bauer C, 2004, SHOCK, V21, P165, DOI 10.1097/01.shk.0000107442.26299.fb; Bauer I, 1998, HEPATOLOGY, V27, P829, DOI 10.1002/hep.510270327; Becker BF, 2011, NUCLEOS NUCLEOT NUCL, V30, P1161, DOI 10.1080/15257770.2011.605089; Becker BF, 2015, BRIT J CLIN PHARMACO, V80, P389, DOI 10.1111/bcp.12629; BEHRMAN SW, 1991, J TRAUMA, V31, P589, DOI 10.1097/00005373-199105000-00001; Beilman GJ, 1999, SHOCK, V12, P196, DOI 10.1097/00024382-199909000-00005; Belizaire RM, 2012, J AM COLL SURGEONS, V214, P648, DOI 10.1016/j.jamcollsurg.2011.12.032; BELLAMY RF, 1984, CIRC SHOCK, V14, P113; BENNETT HS, 1959, AM J PHYSIOL, V196, P381; Bertuglia S, 1997, MICROVASC RES, V54, P233, DOI 10.1006/mvre.1997.2042; Bezemer R, 2010, MED BIOL ENG COMPUT, V48, P1233, DOI 10.1007/s11517-010-0698-7; Bezemer R, 2010, OPT EXPRESS, V18, P15054, DOI 10.1364/OE.18.015054; Bhattacharjee H, 2011, SHOCK, V35, P590, DOI 10.1097/SHK.0b013e3182150e80; BICHER HI, 1971, J PHYSIOL-LONDON, V217, P689, DOI 10.1113/jphysiol.1971.sp009594; Bjerkvig CK, 2016, TRANSFUSION, V56, pS182, DOI 10.1111/trf.13500; BLAHITKA J, 1977, CIRC SHOCK, V4, P79; Bliemel C, 2014, J TRAUMA ACUTE CARE, V76, P366, DOI [10.1097/TA.0000000000000088, 10.1097/TA.0b013e3182aafd7a]; BOHLEN HG, 1976, MICROVASC RES, V11, P103, DOI 10.1016/0026-2862(76)90081-9; Bojic S, 2015, TOHOKU J EXP MED, V237, P103, DOI 10.1620/tjem.237.103; Boldt J, 2010, INTENS CARE MED, V36, P1299, DOI 10.1007/s00134-010-1912-7; BORGSTROM P, 1992, CIRC SHOCK, V36, P57; BORGSTROM P, 1990, AM J PHYSIOL, V259, pH190; Bougle A, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-1; BOUSKELA E, 1989, BRAZ J MED BIOL RES, V22, P259; BOUSKELA E, 1979, AM J PHYSIOL, V237, pH59; BOUSKELA E, 1989, MICROVASC RES, V37, P339, DOI 10.1016/0026-2862(89)90051-4; BOUSKELA E, 1990, ACTA PHYSIOL SCAND, V140, P85, DOI 10.1111/j.1748-1716.1990.tb08978.x; Branemark P-I, 2006, J Tissue Viability, V16, P16; Branemark PI, 1968, MICROCIRCULATION REL, P161; BREDENBERG CE, 1980, ANN SURG, V192, P86, DOI 10.1097/00000658-198007000-00015; Breithaupt-Faloppa AC, 2013, SHOCK, V40, P203, DOI 10.1097/SHK.0b013e3182a01e24; Breslin JW, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003336; BREZIS M, 1994, AM J PHYSIOL-RENAL, V267, pF1063; Broekhuizen LN, 2010, DIABETOLOGIA, V53, P2646, DOI 10.1007/s00125-010-1910-x; Brookes ZLS, 2002, BRIT J ANAESTH, V88, P255, DOI 10.1093/bja/88.2.255; Bruegger D, 2005, AM J PHYSIOL-HEART C, V289, pH1993, DOI 10.1152/ajpheart.00218.2005; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2014, J TRAUMA ACUTE CARE, V76, P19; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Cabrales P, 2005, SHOCK, V24, P66, DOI 10.1097/01.shk.0000167111.80753.ef; Cabrales P, 2005, SHOCK, V23, P549, DOI 10.1097/01.shk.0000164187.38741.19; Cabrales P, 2004, AM J PHYSIOL-HEART C, V287, pH363, DOI 10.1152/ajpheart.01039.2003; Cabrales P, 2008, RESUSCITATION, V77, P379, DOI 10.1016/j.resuscitation.2008.01.008; Cabrales P, 2007, RESUSCITATION, V72, P306, DOI 10.1016/j.resuscitation.2006.06.021; Cabrales P, 2009, RESUSCITATION, V80, P1431, DOI 10.1016/j.resuscitation.2009.09.005; Cabrales P, 2009, RESUSCITATION, V80, P707, DOI 10.1016/j.resuscitation.2009.03.001; Cabrates P, 2007, RESUSCITATION, V75, P124, DOI 10.1016/j.resuscitation.2007.03.010; Cardenas JC, 2014, CURR OPIN HEMATOL, V21, P404, DOI 10.1097/MOH.0000000000000063; Carpentier P, 1981, CAPILLAROSCOPIE PERI; Cecconi M, 2014, INTENS CARE MED, V40, P1795, DOI 10.1007/s00134-014-3525-z; Chambers R, 1944, AM J ANAT, V75, P173, DOI 10.1002/aja.1000750204; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; Chappell D, 2007, ANESTHESIOLOGY, V107, P776, DOI 10.1097/01.anes.0000286984.39328.96; Chappell D, 2014, EUR J ANAESTH, V31, P474, DOI 10.1097/EJA.0000000000000085; Chappell D, 2011, ANESTHESIOLOGY, V115, P483, DOI 10.1097/ALN.0b013e3182289988; Chappell D, 2010, SHOCK, V34, P133, DOI 10.1097/SHK.0b013e3181cdc363; Chappell D, 2009, CARDIOVASC RES, V83, P388, DOI 10.1093/cvr/cvp097; Chappell D, 2009, CIRC RES, V104, P1313, DOI 10.1161/CIRCRESAHA.108.187831; Chappell D, 2009, BASIC RES CARDIOL, V104, P78, DOI 10.1007/s00395-008-0749-5; Chelazzi C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0741-z; Chen B, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-77; Chen CW, 1997, ACTA PHYSIOL SCAND, V161, P281, DOI 10.1046/j.1365-201X.1997.00216.x; Chen CW, 1999, SHOCK, V12, P69, DOI 10.1097/00024382-199907000-00010; Chen HZ, 2005, J SURG RES, V123, P235, DOI 10.1016/j.jss.2004.08.025; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cheung AT, 2006, CLIN HEMORHEOL MICRO, V34, P325; CHIEN S, 1967, PHYSIOL REV, V47, P214; Chignalia AZ, 2016, SHOCK, V45, P338, DOI 10.1097/SHK.0000000000000513; Childs EW, 2008, AM J PHYSIOL-HEART C, V294, pH2285, DOI 10.1152/ajpheart.01361.2007; Childs EW, 2008, SHOCK, V29, P636, DOI 10.1097/SHK.0b013e318157f524; Childs EW, 2007, AM J PHYSIOL-HEART C, V292, pH3179, DOI 10.1152/ajpheart.01337.2006; Childs EW, 2010, SHOCK, V34, P229, DOI 10.1097/SHK.0b013e3181d75b50; Childs EW, 2005, J TRAUMA, V58, P271, DOI 10.1097/01.TA.0000119203.24601.7E; Childs EW, 2002, SHOCK, V18, P423, DOI 10.1097/00024382-200211000-00006; Choi JY, 2012, SHOCK, V38, P635, DOI 10.1097/SHK.0b013e318273299f; Chong SP, 2015, BIOMED OPT EXPRESS, V6, P1429, DOI 10.1364/BOE.6.001429; Clavijo JA, 2008, MED SCI MONITOR, V14, pBR175; Coffey JC, 2016, LANCET GASTROENTEROL, V1, P238, DOI 10.1016/S2468-1253(16)30026-7; COLANTUONI A, 1985, MICROVASC RES, V30, P133, DOI 10.1016/0026-2862(85)90045-7; COLANTUONI A, 1994, INT J MICROCIRC, V14, P151, DOI 10.1159/000178823; Convertino VA, 2013, J APPL PHYSIOL, V115, P1196, DOI 10.1152/japplphysiol.00668.2013; Cooke WH, 2004, J APPL PHYSIOL, V96, P1249, DOI 10.1152/japplphysiol.01155.2003; Cooper ES, 2009, J TRAUMA, V66, P1365, DOI 10.1097/TA.0b013e3181919e43; Coyan GN, 2014, SHOCK, V42, P518, DOI 10.1097/SHK.0000000000000241; Crimi E, 2012, J CRIT CARE, V27, P108, DOI 10.1016/j.jcrc.2011.06.001; Crookes BA, 2005, J TRAUMA, V58, P806, DOI 10.1097/01.TA.0000158269.68409.1C; CRYER HM, 1985, J SURG RES, V39, P59, DOI 10.1016/0022-4804(85)90162-3; Curry FE, 2012, ANN BIOMED ENG, V40, P828, DOI 10.1007/s10439-011-0429-8; Czabanka M, 2007, CURR VASC PHARMACOL, V5, P266, DOI 10.2174/157016107782023389; Davenport RA, 2016, CURR OPIN ANESTHESIO, V29, P212, DOI 10.1097/ACO.0000000000000295; DAVIS MJ, 1985, AM J PHYSIOL, V248, pH143; DAVIS MJ, 1987, MICROVASC RES, V34, P223, DOI 10.1016/0026-2862(87)90055-0; Davis MJ, 2011, COMPREHENSIVE PHYSL, P161, DOI [10.1002/cphy.cp020406, DOI 10.1002/CPHY.CP020406]; De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; De Backer D, 2004, AM HEART J, V147, P91, DOI 10.1016/j.ahj.2003.07.006; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; De Backer D, 2014, BEST PRACT RES-CLIN, V28, P441, DOI 10.1016/j.bpa.2014.09.005; de Carvalho H, 1999, SHOCK, V12, P75, DOI 10.1097/00024382-199907000-00011; Deb S, 1999, J TRAUMA, V46, P582, DOI 10.1097/00005373-199904000-00005; Deitch EA, 2014, CRIT CARE MED, V42, pE200, DOI 10.1097/CCM.0000000000000119; Dekker SE, 2014, SURGERY, V156, P556, DOI 10.1016/j.surg.2014.04.016; DeLano FA, 2014, SHOCK, V41, P55, DOI 10.1097/SHK.0000000000000048; DeLano FA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005046; Delano MJ, 2015, SHOCK, V44, P25, DOI 10.1097/SHK.0000000000000368; DEMLING RH, 1980, SURGERY, V87, P552; DEMLING RH, 1980, CIRC SHOCK, V7, P149; DEMLING RH, 1980, J TRAUMA, V20, P856, DOI 10.1097/00005373-198010000-00006; Deng XY, 2016, SHOCK, V45, P50, DOI 10.1097/SHK.0000000000000458; deWerra I, 1997, CRIT CARE MED, V25, P607, DOI 10.1097/00003246-199704000-00009; Driessen B, 2007, CRIT CARE MED, V35, P2101, DOI 10.1097/01.CCM.0000277040.31978.3D; DRUCKER WR, 1975, ANN SURG, V181, P698, DOI 10.1097/00000658-197505000-00026; Dubin A, 2009, INTENS CARE MED, V35, P556, DOI 10.1007/s00134-008-1385-0; DULING BR, 1981, AM J PHYSIOL, V241, pH108; Dunphy I, 2002, ANAL BIOCHEM, V310, P191, DOI 10.1016/S0003-2697(02)00384-6; Duret J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0854-4; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Ekelund U, 1996, ACTA PHYSIOL SCAND, V157, P471, DOI 10.1046/j.1365-201X.1996.516275000.x; Ekelund U, 1998, ACTA PHYSIOL SCAND, V164, P285; ELLIS CG, 1990, AM J PHYSIOL, V258, pH1216; ERNI D, 1995, EUR J ANAESTH, V12, P423; Essayagh S, 2005, THROMB HAEMOSTASIS, V94, P853, DOI 10.1160/TH04-12-0786; Estrada AD, 2008, OPT LETT, V33, P1038, DOI 10.1364/OL.33.001038; FABER JE, 1982, AM J PHYSIOL, V243, pH837; Fang XS, 2006, CRIT CARE MED, V34, pS447, DOI 10.1097/01.CCM.0000246011.86907.3A; Fellahi JL, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.05.004; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Flusberg BA, 2008, NAT METHODS, V5, P935, DOI 10.1038/nmeth.1256; Fruchterman TM, 1998, SHOCK, V10, P417, DOI 10.1097/00024382-199812000-00007; Fulop A, 2013, EUR SURG RES, V50, P57, DOI 10.1159/000348808; Gagnon L, 2016, FRONT COMPUT NEUROSC, V10, DOI 10.3389/fncom.2016.00082; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; Goering J, 2016, SHOCK, V45, P33, DOI 10.1097/SHK.0000000000000477; Golub AS, 1997, BIOPHYS J, V73, P452, DOI 10.1016/S0006-3495(97)78084-6; Gomez H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135032; Gong WF, 2011, J TRAUMA, V71, P275, DOI 10.1097/TA.0b013e318226eb51; GORBUNOVA NA, 1991, GEMATOL TRANSFUZIOL, V36, P3; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gouverneur M, 2006, J INTERN MED, V259, P393, DOI 10.1111/j.1365-2796.2006.01625.x; GRAY SD, 1972, J TRAUM, V12, P147, DOI 10.1097/00005373-197202000-00008; GROSSLIGHT K, 1985, ANESTHESIOLOGY, V63, P533, DOI 10.1097/00000542-198511000-00011; Gruartmoner G, 2015, CURR OPIN CRIT CARE, V21, P276, DOI 10.1097/MCC.0000000000000220; Gulati A, 2016, CURR VASC PHARMACOL, V14, P187, DOI 10.2174/1570161114666151202210221; GUNNARSSON U, 1994, SHOCK, V2, P60, DOI 10.1097/00024382-199407000-00012; Gustafsson U, 1995, INT J MICROCIRC, V15, P163, DOI 10.1159/000178971; GUSTAFSSON U, 1991, MICROVASC RES, V42, P224, DOI 10.1016/0026-2862(91)90090-X; Gutierrez G, 2004, CRIT CARE, V8, P373, DOI 10.1186/cc2851; Hahnenkamp K, 2002, ANESTH ANALG, V94, P1441, DOI 10.1097/00000539-200206000-00011; HALDENBY KA, 1994, J VASC RES, V31, P2, DOI 10.1159/000159025; Haljamae H, 1984, Am J Emerg Med, V2, P100, DOI 10.1016/0735-6757(84)90117-7; HARRIS PD, 1970, AM J PHYSIOL, V218, P560; Harrois A, 2013, CRIT CARE MED, V41, pE376, DOI 10.1097/CCM.0b013e318292388d; Haugaa H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0903-z; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Helling TS, 2005, J AM COLL SURGEONS, V201, P774, DOI 10.1016/j.jamcollsurg.2005.05.035; Henry CBS, 2000, AM J PHYSIOL-HEART C, V279, pH2815; HERSHEY SG, 1950, ANESTHESIOLOGY, V11, P145, DOI 10.1097/00000542-195003000-00001; Hierholzer C, 2001, ARCH ORTHOP TRAUM SU, V121, P219, DOI 10.1007/s004020000211; Hildebrand F, 2006, J LEUKOCYTE BIOL, V79, P1173, DOI 10.1189/jlb.0106029; HILLEN GP, 1971, AM J SURG, V122, P639, DOI 10.1016/0002-9610(71)90292-3; Hinojosa-Laborde C, 2014, J APPL PHYSIOL, V116, P406, DOI 10.1152/japplphysiol.00640.2013; Hiratsuka M, 2009, INFLAMM RES, V58, P463, DOI 10.1007/s00011-009-0011-0; Hofmann-Kiefer KF, 2009, EUR J MED RES, V14, P526; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, ANN SURG, V254, P201, DOI 10.1097/SLA.0b013e318226483d; Holcroft JW, 1999, J TRAUMA, V46, P588; Horstick G, 2002, CRIT CARE MED, V30, P851, DOI 10.1097/00003246-200204000-00023; Hu Y, 2014, J TRAUMA ACUTE CARE, V76, P394, DOI 10.1097/TA.0b013e3182aa2d98; Hubbard W, 2015, J SURG RES, V193, P355, DOI 10.1016/j.jss.2014.06.047; HUGUET C, 1978, ARCH SURG-CHICAGO, V113, P1448; Hungerer S, 2006, ARTIF CELL BLOOD SUB, V34, P455, DOI 10.1080/10731190600769008; HUTCHINS PM, 1973, MICROVASC RES, V5, P131, DOI 10.1016/0026-2862(73)90064-2; Hyttel-Sorensen S, 2014, J CLIN MONIT COMPUT, V28, P149, DOI 10.1007/s10877-013-9507-9; Ince C, 2016, J APPL PHYSIOL, V120, P226, DOI 10.1152/japplphysiol.00298.2015; Ince C, 2015, CRIT CARE, V19, DOI 10.1186/cc14726; Inoue K, 2008, SHOCK, V29, P252, DOI 10.1097/shk.0b013e3180cab913; INTAGLIETTA M, 1991, BLOOD VESSELS, V28, P1; INTAGLIETTA M, 1972, J APPL PHYSIOL, V32, P546; INTAGLIETTA M, 1971, IEEE T BIO-MED ENG, VBM18, P376, DOI 10.1109/TBME.1971.4502869; INTAGLIETTA M, 1976, MED PROG TECHNOL, V4, P55; Israel A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158; Ivanov KP, 2006, B EXP BIOL MED+, V141, P666, DOI 10.1007/s10517-006-0247-4; Japee SA, 2005, MICROCIRCULATION, V12, P489, DOI 10.1080/10739680591003332; Japee SA, 2004, MICROCIRCULATION, V11, P39, DOI 10.1080/10739680490266171; Jia JM, 2017, NAT METHODS, V14, P160, DOI [10.1038/NMETH.4105, 10.1038/nmeth.4105]; Jiang H, 2014, SHOCK, V42, P271, DOI 10.1097/SHK.0000000000000212; Jin XH, 1998, J APPL PHYSIOL, V85, P2360; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johnson BD, 2014, J APPL PHYSIOL, V117, P131, DOI 10.1152/japplphysiol.00070.2014; JOHNSON PC, 1973, MICROVASC RES, V5, P292, DOI 10.1016/0026-2862(73)90040-X; Jones TW, 1852, PHILOS T R SOC LOND, V142, P131, DOI [10.1098/rstl.1852.0011, DOI 10.1098/RSTL.1852.0011]; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Kalogeris T, 2017, COMPR PHYSIOL, V7, P113, DOI 10.1002/cphy.c160006; Kamoun WS, 2010, NAT METHODS, V7, P655, DOI [10.1038/NMETH.1475, 10.1038/nmeth.1475]; Edul VSK, 2012, CRIT CARE MED, V40, P1443, DOI 10.1097/CCM.0b013e31823dae59; Kara A, 2016, CURR OPIN CRIT CARE, V22, P444, DOI 10.1097/MCC.0000000000000335; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kerger H, 1996, AM J PHYSIOL-HEART C, V270, pH827; Kerger H, 1997, ANESTHESIOLOGY, V86, P372, DOI 10.1097/00000542-199702000-00012; Kerger H, 1999, AM J PHYSIOL-HEART C, V276, pH2035; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802; Kerger H, 1997, AM J PHYSIOL-HEART C, V272, pH525; Kheirbek T, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-65; KITAJIMA T, 1995, DIGESTION, V56, P111, DOI 10.1159/000201230; KOO A, 1977, MICROVASC RES, V13, P315, DOI 10.1016/0026-2862(77)90097-8; Korzonek-Szlacheta I, 2007, PHARMACOL REP, V59, P98; Kottke MA, 2016, SHOCK, V46, P20, DOI 10.1097/SHK.0000000000000666; Koury J, 2004, SHOCK, V22, P270, DOI 10.1097/01.shk.0000135256.67441.3f; Kovach A G, 1988, Prog Clin Biol Res, V264, P147; KOVACH AGB, 1979, ACTA PHYSIOL HUNG, V54, P333; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; KOZIOL JM, 1988, J TRAUMA, V28, P10; Krejci V, 2000, BRIT J ANAESTH, V84, P468; Krizbai IA, 2005, SHOCK, V24, P428, DOI 10.1097/01.shk.0000183389.98519.d3; Kubulus D, 2008, SHOCK, V29, P583, DOI 10.1097/SHK.0b013e318157e526; Kubulus D, 2009, SHOCK, V32, P179, DOI 10.1097/SHK.0b013e318199352b; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lapi D, 2008, J VASC RES, V45, P89, DOI 10.1159/000109818; LAZARUS HM, 1984, CIRC SHOCK, V13, P171; Le Dorze M, 2009, CURR OPIN CRIT CARE, V15, P503, DOI 10.1097/MCC.0b013e328332f6cf; LEE RE, 1949, AM J PHYSIOL, V157, P259; Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706; Legrand M, 2010, ANESTHESIOLOGY, V112, P119, DOI 10.1097/ALN.0b013e3181c4a5e2; Leong B, 2011, RESUSCITATION, V82, P937, DOI 10.1016/j.resuscitation.2011.03.018; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Li RR, 2015, CRIT CARE MED, V43, pE567, DOI 10.1097/CCM.0000000000001203; Li T, 2011, J CARDIOVASC PHARM, V57, P656, DOI 10.1097/FJC.0b013e318215e21d; Li YH, 2009, AM J PHYSIOL-REG I, V297, pR1670, DOI 10.1152/ajpregu.00445.2009; Lima R, 2012, SHOCK, V38, P493, DOI 10.1097/SHK.0b013e31826b64e5; LINDBOM L, 1985, INT J MICROCIRC, V4, P19; Lipowsky HH, 2011, AM J PHYSIOL-HEART C, V301, pH2235, DOI 10.1152/ajpheart.00803.2011; Liu HZ, 2015, FRONT BIOSCI-LANDMRK, V20, P927, DOI 10.2741/4347; Liu Jie, 2000, Chin J Traumatol, V3, P39; Liu LM, 2005, J SURG RES, V125, P128, DOI 10.1016/j.jss.2004.12.008; Lomas-Neira JL, 2016, SHOCK, V45, P157, DOI 10.1097/SHK.0000000000000499; Lomas-Niera JL, 2005, SHOCK, V24, P33, DOI 10.1097/01.shk.0000191411.48719.ab; LONGNECKER DE, 1982, ANESTHESIOLOGY, V57, P177, DOI 10.1097/00000542-198209000-00006; LONGNECKER DE, 1980, FED PROC, V39, P1580; Looney MR, 2014, ANNU REV PHYSIOL, V76, P431, DOI 10.1146/annurev-physiol-021113-170331; Lu HZ, 2014, J SURG RES, V187, P262, DOI 10.1016/j.jss.2013.10.015; Lu XG, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-80; Lubbers DW, 1997, KIDNEY INT, V51, P372, DOI 10.1038/ki.1997.49; LUFT JH, 1966, FED PROC, V25, P1773; Luo ZC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116076; Maier M, 2003, SHOCK, V19, P457, DOI 10.1097/01.shk.0000056961.48384.f2; Maier S, 2009, J TRAUMA, V66, P337, DOI 10.1097/TA.0b013e31817dac66; Majde JA, 2003, J TRAUMA, V54, pS100, DOI 10.1097/01.TA.0000064503.24416.F4; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marki A, 2015, J LEUKOCYTE BIOL, V98, P503, DOI 10.1189/jlb.3MR0115-011R; Martini J, 2013, CRIT CARE MED, V41, pE301, DOI 10.1097/CCM.0b013e31828a4520; Martini J, 2008, CRIT CARE, V12, DOI 10.1186/cc6874; Massey MJ, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1213-9; Matheson PJ, 2005, MICROSURG, V25, P247, DOI 10.1002/micr.20120; Matsuki T, 2000, MICROCIRCULATION, V7, P411, DOI 10.1038/sj.mn.7300128; MAZZONI MC, 1989, CIRC SHOCK, V29, P27; MAZZONI MC, 1994, INT J MICROCIRC, V14, P144, DOI 10.1159/000178822; Mazzoni MC, 1995, INT J MICROCIRC, V15, P265, DOI 10.1159/000179028; MAZZONI MC, 1992, J APPL PHYSIOL, V73, P1467; MAZZONI MC, 1994, AM J PHYSIOL-HEART C, V267, pH1928; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; MELLANDER S, 1963, CIRC RES, V13, P105, DOI 10.1161/01.RES.13.2.105; MELLANDER S, 1987, ACTA PHYSIOL SCAND, V129, P325, DOI 10.1111/j.1748-1716.1987.tb08076.x; METZGER H, 1984, ADV EXP MED BIOL, V180, P599; MEYER JU, 1988, MICROVASC RES, V35, P193, DOI 10.1016/0026-2862(88)90062-3; Mik EG, 2004, J APPL PHYSIOL, V97, P1962, DOI 10.1152/japplphysiol.01399.2003; Miyabe M, 2002, ANESTH ANALG, V94, P296, DOI 10.1097/00000539-200202000-00012; Moochhala S, 2009, FRONT BIOSCI-LANDMRK, V14, P4631, DOI 10.2741/3555; Motaharinia J, 2015, DARU, V23, DOI 10.1186/s40199-015-0130-9; Moy AJ, 2011, MICROVASC RES, V82, P199, DOI 10.1016/j.mvr.2011.07.004; Muir WW, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/864237; Mulivor AW, 2004, AM J PHYSIOL-HEART C, V286, pH1672, DOI 10.1152/ajpheart.00832.2003; Mulivor AW, 2002, AM J PHYSIOL-HEART C, V283, pH1282, DOI 10.1152/ajpheart.00117.2002; Myburgh JA, 2013, NEW ENGL J MED, V369, P2462, DOI 10.1056/NEJMc1313345; MYERS BD, 1986, NEW ENGL J MED, V314, P97; NAGAKAWA B, 1976, SURG GYNECOL OBSTET, V142, P871; Nassour I, 2015, SHOCK, V43, P166, DOI 10.1097/SHK.0000000000000264; Naumann DN, 2016, SHOCK, V46, P609, DOI 10.1097/SHK.0000000000000687; Naumann DN, 2015, SYST REV-LONDON, V4, DOI 10.1186/s13643-015-0113-4; NERLICH M, 1983, CIRC SHOCK, V10, P179; NICOLL PA, 1946, ANN NY ACAD SCI, V46, P697, DOI 10.1111/j.1749-6632.1946.tb31698.x; Nilsson Holger, 2003, Mol Interv, V3, P79, DOI 10.1124/mi.3.2.79; NYSTROM SHM, 1968, ACTA NEUROPATHOL, V10, P209, DOI 10.1007/BF00687724; Ortiz D, 2014, AM J EMERG MED, V32, P248, DOI 10.1016/j.ajem.2013.11.045; Ostrowski SR, 2017, J TRAUMA ACUTE CARE, V82, P293, DOI 10.1097/TA.0000000000001304; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Paes-da-Silva F, 2003, SHOCK, V19, P55, DOI 10.1097/00024382-200301000-00011; Page AV, 2013, VIRULENCE, V4, P507, DOI 10.4161/viru.24530; Pajk W, 2002, AM J PHYSIOL-HEART C, V283, pH2511, DOI 10.1152/ajpheart.00222.2002; Palagyi P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/847152; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Paxian M, 2004, AM J PHYSIOL-GASTR L, V286, pG37, DOI 10.1152/ajpgi.00041.2003; Paxian M, 2003, FASEB J, V17, P993, DOI 10.1096/fj.02-0624com; Paxian M, 2003, SHOCK, V20, P449, DOI 10.1097/01.shk.0000090601.26659.87; Paxian M, 2003, ANESTHESIOLOGY, V98, P1391, DOI 10.1097/00000542-200306000-00014; Paxian M, 2001, SHOCK, V15, P438, DOI 10.1097/00024382-200115060-00005; Peiniger S, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-78; PEITZMAN AB, 1995, CURR PROB SURG, V32, P930; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Pennings FA, 2004, STROKE, V35, P1284, DOI 10.1161/01.STR.0000126039.91400.cb; Perez-Barcena J, 2015, J NEUROL SCI, V353, P38, DOI 10.1016/j.jns.2015.03.044; Peruski AM, 2014, AM J VET RES, V75, P77, DOI 10.2460/ajvr.75.1.77; Peruski AM, 2011, AM J VET RES, V72, P438, DOI 10.2460/ajvr.72.4.438; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Pittman RN, 2011, ACTA PHYSIOL, V202, P311, DOI 10.1111/j.1748-1716.2010.02232.x; Popel AS, 2005, ANNU REV FLUID MECH, V37, P43, DOI 10.1146/annurev.fluid.37.042604.133933; Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226; Potter DR, 2015, J TRAUMA ACUTE CARE, V78, pS7, DOI 10.1097/TA.0000000000000630; Pries A. R., 2006, V176, P1; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; PRIES AR, 1995, AM J PHYSIOL-HEART C, V269, pH1713; Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021; PROCTOR HJ, 1979, J TRAUMA, V19, P682, DOI 10.1097/00005373-197909000-00009; Pruefer D, 2003, ANN THORAC SURG, V75, P210, DOI 10.1016/S0003-4975(02)03932-2; Puyana JC, 1999, J TRAUMA, V46, P9, DOI 10.1097/00005373-199901000-00003; Rahbar E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0481-5; Rajnik M, 2002, SHOCK, V17, P322, DOI 10.1097/00024382-200204000-00015; RANA MW, 1992, J TRAUMA, V32, P420, DOI 10.1097/00005373-199204000-00003; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Reitsma S, 2011, THROMB HAEMOSTASIS, V106, P939, DOI 10.1160/TH11-02-0133; Rhee CJ, 2012, J APPL PHYSIOL, V113, P307, DOI 10.1152/japplphysiol.00024.2012; Rickards CA, 2015, COMPR PHYSIOL, V5, P1585, DOI 10.1002/cphy.c140058; Rickards CA, 2015, J APPL PHYSIOL, V119, P677, DOI 10.1152/japplphysiol.00127.2015; Rixen D, 2005, CRIT CARE, V9, P441, DOI 10.1186/cc3526; Rixen D, 2001, SHOCK, V16, P239, DOI 10.1097/00024382-200116030-00012; Roesner JP, 2006, INTENS CARE MED, V32, P1649, DOI 10.1007/s00134-006-0335-y; ROMANUS M, 1978, SCAND J PLAST RECONS, V12, P181, DOI 10.3109/02844317809012993; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Rowland MR, 2014, SURGERY, V156, P861, DOI 10.1016/j.surg.2014.06.019; RUMSEY WL, 1988, SCIENCE, V241, P1649, DOI 10.1126/science.3420417; RUSH BF, 1989, ANN SURG, V210, P342, DOI 10.1097/00000658-198909000-00010; RUSSELL DH, 1995, SHOCK, V4, P50, DOI 10.1097/00024382-199507000-00008; Sailhamer EA, 2010, CYTOKINE, V49, P303, DOI 10.1016/j.cyto.2009.11.013; Sakadzic S, 2010, NAT METHODS, V7, P755, DOI 10.1038/nmeth.1490; Sakai H, 1999, AM J PHYSIOL-HEART C, V276, pH563, DOI 10.1152/ajpheart.1999.276.2.H563; Sakai H, 2009, SHOCK, V31, P507, DOI 10.1097/SHK.0b013e318188f83d; Vazquez BYS, 2009, BIORHEOLOGY, V46, P167, DOI 10.3233/BIR-2009-0539; Samarska IV, 2009, ANESTHESIOLOGY, V111, P600, DOI 10.1097/ALN.0b013e3181b31c8e; Sarelius IH, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.985954; Sawant DA, 2014, J PHYSIOL BIOCHEM, V70, P971, DOI 10.1007/s13105-014-0366-8; Sawant DA, 2014, J CARDIOVASC TRANSL, V7, P711, DOI 10.1007/s12265-014-9589-x; Sawant DA, 2011, J TRAUMA, V70, P481, DOI 10.1097/TA.0b013e31820b3ed7; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; SCALIA SV, 1992, J TRAUMA, V33, P321, DOI 10.1097/00005373-199208000-00024; Schmid-Schonbein Geert W, 2011, Bol Soc Port Hemorreol Microcirc, V26, P6; Schmid-Schonbein GW, 2005, MICROCIRCULATION, V12, P71, DOI 10.1080/10739680590896009; Schmid-Schonbein GW, 2001, BIORHEOLOGY, V38, P185; SCHMIDSCHONBEIN GW, 1990, BIORHEOLOGY, V27, P859; Schumacher J, 2006, BRIT J ANAESTH, V96, P437, DOI 10.1093/bja/ael030; Schumacher J, 2003, SHOCK, V20, P565, DOI 10.1097/01.shk.0000093540.78705.71; Schwartz M, 2004, J CELL SCI, V117, P5457, DOI 10.1242/jcs.01582; SCHYWALSKY M, 1990, ADV EXP MED BIOL, V277, P697; Segal SS, 2005, MICROCIRCULATION, V12, P33, DOI 10.1080/10739680590895028; SEYDE WC, 1984, ANESTHESIOLOGY, V61, P686, DOI 10.1097/00000542-198412000-00010; Shen Q, 2017, PHYSL REP, V2; Shinohara H, 1996, HEPATOLOGY, V23, P137, DOI 10.1002/hep.510230119; Shires GT, 2005, AM J SURG, V189, P85, DOI 10.1016/j.amjsurg.2004.06.040; SHORR E, 1948, ANN NY ACAD SCI, V49, P571, DOI 10.1111/j.1749-6632.1948.tb30953.x; Sielenkamper AW, 2000, ANESTHESIOLOGY, V93, P844, DOI 10.1097/00000542-200009000-00036; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P998, DOI 10.1097/TA.0000000000000193; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P12, DOI 10.1097/TA.0b013e3182aaa675; Simoes C, 2002, J CARDIOVASC PHARM, V39, P340, DOI 10.1097/00005344-200203000-00004; Sinaasappel M, 1999, J PHYSIOL-LONDON, V514, P245, DOI 10.1111/j.1469-7793.1999.245af.x; SLAAF DW, 1988, AM J PHYSIOL, V255, pH1240; SLAAF DW, 1987, INT J MICROCIRC, V6, P391; SMITH M, 1986, J TRAUMA, V26, P217, DOI 10.1097/00005373-198603000-00002; Soller BR, 2012, J TRAUMA ACUTE CARE, V73, pS106, DOI 10.1097/TA.0b013e318260a928; Song D, 1998, ADV EXP MED BIOL, V454, P173; Sordi R, 2015, MOL MED, V21, P563, DOI 10.2119/molmed.2015.00049; Sordia T, 2004, CLIN HEMORHEOL MICRO, V30, P461; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; STEVENS PM, 1965, AM J CARDIOL, V16, P506, DOI 10.1016/0002-9149(65)90027-5; Stringham JR, 2014, J TRAUMA ACUTE CARE, V76, P1214, DOI 10.1097/TA.0000000000000231; Styp-Rekowska B, 2007, MICROCIRCULATION, V14, P207, DOI 10.1080/10739680601139302; Sun NN, 2014, ACAD RADIOL, V21, P175, DOI 10.1016/j.acra.2013.11.017; Szabo A, 2004, SHOCK, V21, P320, DOI 10.1097/00024382-200404000-00006; SZABO C, 1994, SHOCK, V2, P145, DOI 10.1097/00024382-199408000-00011; Szopinski J, 2011, J TRAUMA, V71, P1779, DOI 10.1097/TA.0b013e31823a05b5; Tachon G, 2014, CRIT CARE MED, V42, P1433, DOI 10.1097/CCM.0000000000000223; Takasu A, 1999, CRIT CARE MED, V27, P1557, DOI 10.1097/00003246-199908000-00025; Tanaka S, 2017, CRIT CARE MED, V45, pE154, DOI 10.1097/CCM.0000000000002064; Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x; Tarbell JM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.140pt8; Tharakan B, 2012, SHOCK, V37, P306, DOI 10.1097/SHK.0b013e318240b564; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; Torres IP, 2017, J THROMB HAEMOST, V15, P163, DOI 10.1111/jth.13556; Torres Filho IP, 2009, FASEB J, V23, P950; Torres I, 2016, J SURG RES, V201, P425, DOI 10.1016/j.jss.2015.12.001; Filho IT, 2013, MICROVASC RES, V85, P128, DOI 10.1016/j.mvr.2012.11.005; Torres IP, 2008, J APPL PHYSIOL, V104, P1809, DOI 10.1152/japplphysiol.00025.2008; Torres IP, 2016, AM J PHYSIOL-HEART C, V310, pH1468, DOI 10.1152/ajpheart.00006.2016; Torres IP, 2005, AM J PHYSIOL-HEART C, V289, pH488, DOI 10.1152/ajpheart.01171.2004; TORRES IP, 1994, P NATL ACAD SCI USA, V91, P2081, DOI 10.1073/pnas.91.6.2081; TORRES IP, 1993, AM J PHYSIOL, V265, pH1434; Torres IP, 1996, MICROVASC RES, V51, P202; Torres IP, 2001, SHOCK, V15, P353, DOI 10.1097/00024382-200115050-00004; Torres IP, 2001, LIFE SCI, V68, P1057; TORRES IP, 1994, INT J MICROCIRC, V14, P3; TORRES IP, 1989, AM J PHYSIOL, V257, pH1647; Torres LN, 2008, MICROVASC RES, V75, P217, DOI 10.1016/j.mvr.2007.07.003; Torres LN, 2014, J TRAUMA ACUTE CARE, V77, P716, DOI 10.1097/TA.0000000000000448; Torres LN, 2013, J TRAUMA ACUTE CARE, V75, P759, DOI 10.1097/TA.0b013e3182a92514; TSAI AG, 1993, INT J MICROCIRC, V12, P75; Tsai AG, 2004, TRANSFUSION, V44, P1626, DOI 10.1111/j.0041-1132.2004.04128.x; Tsai AG, 2004, EXPERT OPIN BIOL TH, V4, P1147, DOI 10.1517/14712598.4.7.1147; Tsai AG, 2001, BIORHEOLOGY, V38, P229; Tsai AG, 2010, TRANSFUS APHER SCI, V43, P69, DOI 10.1016/j.transci.2010.05.011; Tsukada K, 2004, J APPL PHYSIOL, V96, P1561, DOI 10.1152/japplphysiol.00764.2003; Turek Z, 2009, SEMIN CARDIOTHORAC V, V13, P249, DOI 10.1177/1089253209353134; Uhl E, 2003, NEUROSURGERY, V52, P1307, DOI 10.1227/01.NEU.0000065154.04824.9E; Vajda K, 2004, EUR SURG RES, V36, P338, DOI 10.1159/000081640; Vajda K, 2004, MICROCIRCULATION, V11, P307, DOI 10.1080/10739680490437469; Vallet B, 2011, ANESTH ANALG, V112, P258, DOI 10.1213/ANE.0b013e3182066299; van Bommel J, 1998, ADV EXP MED BIOL, V454, P189; van Bommel J, 2001, TRANSFUSION, V41, P1515, DOI 10.1046/j.1537-2995.2001.41121515.x; van Golen RF, 2012, FREE RADICAL BIO MED, V52, P1382, DOI 10.1016/j.freeradbiomed.2012.01.013; van Iterson M, 2003, J TRAUMA, V55, P1111, DOI 10.1097/01.TA.0000101391.58216.DD; van Iterson M, 1998, J LAB CLIN MED, V132, P421; van Iterson M, 2012, TRANSFUSION, V52, P1552, DOI 10.1111/j.1537-2995.2011.03471.x; van Meurs M, 2008, SHOCK, V29, P291, DOI 10.1097/shk.0b013e318145a7c1; van Meurs M, 2011, ANESTHESIOLOGY, V115, P474, DOI 10.1097/ALN.0b013e318229a640; van Meurs M, 2009, AM J PHYSIOL-RENAL, V297, pF272, DOI 10.1152/ajprenal.00137.2009; VANDERKLEIJ AJ, 1983, SURGERY, V93, P518; VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476; Vazquez BYS, 2008, BBA-PROTEINS PROTEOM, V1784, P1421, DOI 10.1016/j.bbapap.2008.04.020; Vazquez BYS, 2011, CRIT CARE MED, V39, P1461, DOI 10.1097/CCM.0b013e3182120cdb; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; Villela NR, 2011, J TRAUMA, V71, P418, DOI 10.1097/TA.0b013e3181fa2630; Villela NR, 2009, CURR OPIN ANESTHESIO, V22, P163, DOI 10.1097/ACO.0b013e328328d304; Vincent JL, 2013, NEW ENGL J MED, V369, P1726, DOI 10.1056/NEJMra1208943; Vink H, 1996, CIRC RES, V79, P581, DOI 10.1161/01.RES.79.3.581; Vlahu CA, 2012, J AM SOC NEPHROL, V23, P1900, DOI 10.1681/ASN.2011121181; Vollmar B, 1998, ADV EXP MED BIOL, V454, P95; VOLLMAR B, 1994, AM J PHYSIOL-HEART C, V267, pH1936; Vollmar B, 1997, MICROVASC RES, V54, P164, DOI 10.1006/mvre.1997.2028; Vollmar B, 1996, CRIT CARE MED, V24, P445, DOI 10.1097/00003246-199603000-00014; Vollmer C, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/589606; VRIELINK HHEO, 1990, AM J PHYSIOL, V258, pH29; VRIELINK HHEO, 1989, PFLUG ARCH EUR J PHY, V414, P571, DOI 10.1007/BF00580993; Wan Z, 2010, CRIT CARE MED, V38, P928, DOI 10.1097/CCM.0b013e3181cd100c; Wandall-Frostholm C, 2015, BRIT J PHARMACOL, V172, P4493, DOI 10.1111/bph.13234; Wang B, 2015, SHOCK, V44, P234, DOI 10.1097/SHK.0000000000000408; WANG P, 1993, AM J PHYSIOL, V265, pH973; WANG P, 1992, CAN J PHYSIOL PHARM, V70, P349, DOI 10.1139/y92-044; WANG P, 1990, CIRC SHOCK, V32, P307; WANG P, 1992, AM J PHYSIOL, V262, pG92; WANG P, 1991, J SURG RES, V50, P368, DOI 10.1016/0022-4804(91)90205-Z; WANG P, 1990, AM J PHYSIOL, V259, pR645; WANG P, 1993, J SURG RES, V54, P499, DOI 10.1006/jsre.1993.1077; Wang XM, 2012, AM J PHYSIOL-REG I, V302, pR805, DOI 10.1152/ajpregu.00350.2011; Wanner GA, 2000, CRIT CARE MED, V28, P950, DOI 10.1097/00003246-200004000-00007; WARD BJ, 1993, CARDIOVASC RES, V27, P384, DOI 10.1093/cvr/27.3.384; Ward KR, 2010, RESUSCITATION, V81, P987, DOI 10.1016/j.resuscitation.2010.03.027; Ward KR, 2006, CRIT CARE MED, V34, P792, DOI 10.1097/01.CCM.0000201898.43135.3F; Ward KR, 2006, RESUSCITATION, V68, P27, DOI 10.1016/j.resuscitation.2005.06.022; Waschke KF, 2004, J TRAUMA, V56, P591, DOI 10.1097/01.TA.0000075335.35705.E2; Waschke KF, 1996, INTENS CARE MED, V22, P1026, DOI 10.1007/s001340050208; WAYLAND H, 1967, J APPL PHYSIOL, V22, P333; WEIL MH, 1979, ANESTH ANALG, V58, P124; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wettstein R, 2004, SHOCK, V21, P235, DOI 10.1097/01.shk.0000114301.36496.ea; Wettstein R, 2003, CRIT CARE MED, V31, P1824, DOI 10.1097/01.CCM.0000069340.16319.F2; WHALEN WJ, 1967, J APPL PHYSIOL, V23, P798; White NJ, 2015, J THROMB HAEMOST, V13, P978, DOI 10.1111/jth.12919; Whitehouse T, 2006, AM J PHYSIOL-RENAL, V291, pF647, DOI 10.1152/ajprenal.00475.2005; Wichmann MW, 1998, CRIT CARE MED, V26, P1372, DOI 10.1097/00003246-199808000-00024; Zakaria ER, 2007, SURGERY, V142, P487, DOI 10.1016/j.surg.2007.08.007; Zakaria ER, 2006, SURGERY, V140, P579, DOI 10.1016/j.surg.2006.05.015; Zakaria ER, 2005, J TRAUMA, V58, P499, DOI 10.1097/01.TA.0000152892.24841.54; WIEDERHIELM CA, 1979, MICROVASC RES, V18, P124, DOI 10.1016/0026-2862(79)90022-0; WIEDERHIELM CA, 1964, AM J PHYSIOL, V207, P173; Wilson DF, 2013, ADV EXP MED BIOL, V789, P51, DOI 10.1007/978-1-4614-7411-1_8; Winslow RM, 2004, ARTIF ORGANS, V28, P800, DOI 10.1111/j.1525-1594.2004.07392.x; WU CH, 1989, INT J MICROCIRC, V8, P303; Wu CY, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1135-y; Wu CY, 2015, MICROVASC RES, V101, P55, DOI 10.1016/j.mvr.2015.06.003; Xiang M, 2011, J IMMUNOL, V187, P4809, DOI 10.4049/jimmunol.1102093; Xu JF, 2013, SHOCK, V39, P361, DOI 10.1097/SHK.0b013e31828936aa; Xu J, 2012, CARDIOVASC RES, V96, P308, DOI 10.1093/cvr/cvs254; Xu J, 2010, J TRAUMA, V69, P1274, DOI 10.1097/TA.0b013e3181d74abe; Yada-Langui MM, 2004, EXP BIOL MED, V229, P684; YAMASHITA M, 1977, CAN ANAESTH SOC J, V24, P695, DOI 10.1007/BF03006712; Yang GM, 2013, J TRAUMA ACUTE CARE, V74, P1033, DOI 10.1097/TA.0b013e31828586a2; Yang YM, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23494; Yu HP, 2006, J LEUKOCYTE BIOL, V79, P963, DOI 10.1189/jlb.1005596; Zaets SB, 2011, J SURG RES, V166, pE135, DOI 10.1016/j.jss.2010.12.001; Zakaria ER, 2007, SHOCK, V27, P436, DOI 10.1097/01.shk.0000245017.86117.4e; Zakaria ER, 2005, SURGERY, V138, P195, DOI 10.1016/j.surg.2005.06.009; Zhang GQ, 2010, AM J PHYSIOL-HEART C, V299, pH1494, DOI 10.1152/ajpheart.00462.2010; Zhang HY, 2011, J SURG RES, V171, P218, DOI 10.1016/j.jss.2010.01.024; ZHAO KS, 1985, MICROVASC RES, V30, P143, DOI 10.1016/0026-2862(85)90046-9; ZHAO KS, 1987, MICROVASC RES, V34, P84, DOI 10.1016/0026-2862(87)90081-1; Zhao KS, 2002, SHOCK, V18, P189, DOI 10.1097/00024382-200208000-00017; Zhao KS, 2000, CLIN HEMORHEOL MICRO, V23, P259; Zhu Y, 2013, J SURG RES, V184, P951, DOI 10.1016/j.jss.2013.03.039; Zuurbier CJ, 2005, J APPL PHYSIOL, V99, P1471, DOI 10.1152/japplphysiol.00436.2005; Zweifach Benjamin W., 1995, Microcirculation (New York), V2, P245, DOI 10.3109/10739689509146770; ZWEIFACH BW, 1957, J EXP MED, V106, P403, DOI 10.1084/jem.106.3.403; Zweifach BW, 1944, AM J PHYSIOL, V142, P80; ZWEIFACH BW, 1974, ANESTHESIOLOGY, V41, P157, DOI 10.1097/00000542-197408000-00006; ZWEIFACH BW, 1957, J EXP MED, V106, P385, DOI 10.1084/jem.106.3.385; ZWEIFACH BW, 1952, ANN NY ACAD SCI, V55, P370, DOI 10.1111/j.1749-6632.1952.tb26553.x; ZWEIFACH BW, 1949, SURG GYNECOL OBSTET, V89, P469; ZWEIFACH BW, 1948, ANN NY ACAD SCI, V49, P553, DOI 10.1111/j.1749-6632.1948.tb30952.x; ZWEIFACH BW, 1945, SURGERY, V18, P48; Zweifach BW, 1944, ANN SURG, V120, P232, DOI 10.1097/00000658-194408000-00011	537	17	20	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2040-4603			COMPR PHYSIOL	Compr. Physiol.	JAN	2018	8	1					61	101		10.1002/cphy.c170006			41	Physiology	Physiology	GB0VC	WOS:000428766500003	29357125				2021-06-18	
J	Johnson, J; Pajarillo, EAB; Taka, E; Reams, R; Son, DS; Aschner, M; Lee, E				Johnson, James, Jr.; Pajarillo, Edward Alain B.; Taka, Equar; Reams, Romonia; Son, Deok-Soo; Aschner, Michael; Lee, Eunsook			Valproate and sodium butyrate attenuate manganese-decreased locomotor activity and astrocytic glutamate transporters expression in mice	NEUROTOXICOLOGY			English	Article; Proceedings Paper	28th International Neurotoxicology Conference - Manganese Health Effects on Neurodevelopment and Neurodegenerative Diseases (MANGANESE)	SEP 25-28, 2016	Icahn Sch Med Mt Sinai, New York, NY	Icahn Sch Med Mt Sinai, Dept Environm Med & Publ Hlth, Int Manganese Inst, Charles River Labs, Int Commiss Occupat Hlth, Soc Toxicol, Elsevier	Icahn Sch Med Mt Sinai	Valproic acid; Sodium butyrate; Glutamate transporters; Manganese; Behavior	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; YIN YANG 1; TRANSCRIPTIONAL REGULATION; NEUROLOGICAL DISORDERS; MOLECULAR PERSPECTIVE; HISTONE DEACETYLASE; ANTIEPILEPTIC DRUGS; HDAC INHIBITORS; MOUSE MODEL	Manganese (Mn) is an essential trace element, but chronic overexposure to this metal, either environmentally or occupationally may cause manganism, a disease analogous to Parkinson's disease. Inhibitors of histone deacetylases, such as valproic acid (VPA) and sodium butyrate (NaB) exert neuroprotective effects in various animal models of neurological disorders. Thus, the present study investigated whether VPA or NaB prevent Mn-induced neurotoxicity by assessing locomotor activities and expression of astrocytic glutamate transporters, glutamate transporter 1 (GLT-1) and glutamate aspartate transporter (GLAST), in C57BL/6 mice. C57BL/6 mice were pretreated with VPA (200 mg/kg, i.p.) or NaB (1200 mg/kg, i.p.) prior to intranasal instillation of Mn (30 mg/kg) continually for 21 days, followed by open-field and rota-rod behavioral tests and analyses of astrocytic glutamate transporters GLT-1 and GLAST protein/mRNA levels. The results showed that Mn significantly decreased locomotor activity as determined by total distance travelled, stereotypic and ambulatory counts. Mn also significantly decreased rota -rod activity reflecting altered motor coordination. Pretreatment with VPA and NaB with Mn reversed the effects of Mn on the locomotor activity and motor coordination. VPA and NaB also attenuated the Mn-induced decrease in GLT-1 and GLAST mRNA and protein levels in the cerebral cortical and cerebellar regions of mice. These results suggest that VPA and NaB exert protective effects against Mn toxicity seem in vitro are also shown in vivo. VPA and NaB pretreatment in mice enhancing astrocytic glutamate transporter GLT-1 expression as well as locomotor activities. Future research endeavors are warranted to determine if the therapeutic potential of VPA and NaB is via common molecular mechanism, namely, inhibition of histone deacetylases. (C) 2017 Published by Elsevier B.V.	[Pajarillo, Edward Alain B.; Taka, Equar; Reams, Romonia; Lee, Eunsook] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32301 USA; [Johnson, James, Jr.] Meharry Med Coll, Dept Neurosci & Pharmacol, Nashville, TN 37208 USA; [Son, Deok-Soo] Meharry Med Coll, Dept Biochem & Canc Biol, Nashville, TN 37208 USA; [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Lee, E (corresponding author), Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32301 USA.	eunsook.lee@famu.edu			 [R01ES024756];  [SC1089630];  [SC1CA200519];  [R01 ES10563];  [1R03ES024849];  [1R21ES025415]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [SC1CA200519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R03ES024849, R01ES010563, R01ES024756, R21ES025415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [SC1GM089630, R25GM059994] Funding Source: NIH RePORTER	The present study has been supported in part by R01ES024756 (EL), SC1089630 (EL), SC1CA200519 (DS), R01 ES10563 (MA), 1R03ES024849 (MA) and 1R21ES025415 (MA).	Aguirre G, 2008, NEUROCHEM INT, V52, P1322, DOI 10.1016/j.neuint.2008.01.015; Belcastro V, 2013, EPILEPSY RES, V107, P1, DOI 10.1016/j.eplepsyres.2013.08.016; BROUILLET EP, 1993, EXP NEUROL, V120, P89, DOI 10.1006/exnr.1993.1042; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]; Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512; Chuang DM, 2009, TRENDS NEUROSCI, V32, P591, DOI 10.1016/j.tins.2009.06.002; Dauncey MJ, 2012, P NUTR SOC, V71, P581, DOI 10.1017/S0029665112000237; Campos MSD, 2016, PHARMACOTHERAPY, V36, P1255, DOI 10.1002/phar.1855; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Garner JP, 2002, BEHAV BRAIN RES, V136, P83, DOI 10.1016/S0166-4328(02)00111-0; Gianutsos G, 1997, FUND APPL TOXICOL, V37, P102, DOI 10.1006/faat.1997.2306; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Graff J, 2013, ANNU REV PHARMACOL, V53, P311, DOI 10.1146/annurev-pharmtox-011112-140216; Henriksson J, 2000, TOXICOL SCI, V55, P392, DOI 10.1093/toxsci/55.2.392; Jayakumar AR, 2016, ADV NEUROBIOL, V13, P327, DOI 10.1007/978-3-319-45096-4_13; Karki P, 2015, J BIOL CHEM, V290, P23725, DOI 10.1074/jbc.M115.649327; Karki P, 2014, MOL CELL BIOL, V34, P1280, DOI 10.1128/MCB.01176-13; Kim J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033533; Kimura A, 2015, NEUROSCI LETT, V588, P108, DOI 10.1016/j.neulet.2014.12.054; Kotz C, 2012, ANN NY ACAD SCI, V1264, P72, DOI 10.1111/j.1749-6632.2012.06585.x; Kratsman N, 2016, NEUROPHARMACOLOGY, V102, P136, DOI 10.1016/j.neuropharm.2015.11.003; Langley B, 2008, J NEUROSCI, V28, P163, DOI 10.1523/JNEUROSCI.3200-07.2008; Lason W, 2011, PHARMACOL REP, V63, P271, DOI 10.1016/S1734-1140(11)70497-2; Lee ESY, 2009, J NEUROCHEM, V110, P530, DOI 10.1111/j.1471-4159.2009.06105.x; Leke R, 2016, ADV NEUROBIOL, V13, P223, DOI 10.1007/978-3-319-45096-4_8; Li HX, 2016, BRAIN RES, V1642, P70, DOI 10.1016/j.brainres.2016.03.031; Li L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6469; LOSCHER W, 1993, EPILEPSY RES, V16, P183, DOI 10.1016/0920-1211(93)90079-M; Ximenes JCM, 2013, N-S ARCH PHARMACOL, V386, P575, DOI 10.1007/s00210-013-0853-4; Malago JJ, 2015, J ZHEJIANG UNIV-SC B, V16, P224, DOI 10.1631/jzus.B1400191; Maski KP, 2011, CURR OPIN PEDIATR, V23, P609, DOI 10.1097/MOP.0b013e32834c9282; Moberly AH, 2012, NEUROTOXICOLOGY, V33, P996, DOI 10.1016/j.neuro.2012.04.014; Monti Barbara, 2009, Curr Mol Pharmacol, V2, P95; Monti B, 2009, MINI-REV MED CHEM, V9, P769, DOI 10.2174/138955709788452621; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Normandin L, 2002, METAB BRAIN DIS, V17, P375, DOI 10.1023/A:1021970120965; Park MJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0765-6; Peres TV, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0099-0; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Qian YR, 2010, KOREAN J PHYSIOL PHA, V14, P435, DOI 10.4196/kjpp.2010.14.6.435; Rayavarapu S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012981; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Robison G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048899; Roth JA, 2006, BIOL RES, V39, P45, DOI 10.4067/S0716-97602006000100006; Rothstein JD, 1996, CLIN NEUROSCI, V3, P348; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Skidmore FM, 2008, J REHABIL RES DEV, V45, P1343, DOI 10.1682/JRRD.2008.01.0002; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Takuma K, 2014, PHARMACOL BIOCHEM BE, V126, P43, DOI 10.1016/j.pbb.2014.08.013; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Ximenes J.C., 2015, J NEURODEGENERATIVE; Yamawaki Y, 2012, WORLD J BIOL PSYCHIA, V13, P458, DOI 10.3109/15622975.2011.585663; Yu QF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059627; Zaky A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00337; Zhang LN, 2016, MOL NEUROBIOL, V53, P1124, DOI 10.1007/s12035-014-9071-4; Zhong T, 2014, BRIT J ANAESTH, V113, P634, DOI 10.1093/bja/aeu184	60	17	17	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	JAN	2018	64				SI		230	239		10.1016/j.neuro.2017.06.007			10	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	FV4HM	WOS:000424534200027	28610743	Green Accepted			2021-06-18	
S	Lucas, A; Yaron, JR; Zhang, LQ; Ambadapadi, S		Lucas, A		Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram			Overview of Serpins and Their Roles in Biological Systems	SERPINS: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Serpin; Serpinopathy; Peptides; Bacteria; Malaria; Virus; Phage; Kinetics; Crystallography; Thrombosis; Trypsin; Inflammation; Neurotrauma; Microbiome	PLASMINOGEN-ACTIVATOR; POLYMERIZATION; INHIBITION; PROTEINASE; MECHANISM; SURVIVAL	Serine protease inhibitors are ubiquitous regulators for a multitude of pathways in humans. The serpins represent an ancient pathway now known to be present in all kingdoms and often regulating central pathways for clotting, immunity, and even cancer in man. Serpins have been present from the time of the dinosaurs and can represent a large proportion of circulating blood proteins. With this introductory chapter, we present an overview of serpins as well as an introduction and overview of the chapters describing the methodology used in the new approaches to understanding their molecular mechanisms of action and their roles in health and disease.	[Lucas, Alexandra] Arizona State Univ, Biodesign Ctr Personalized Diagnost, Tempe, AZ 85281 USA; [Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram] Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85281 USA; [Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram] Arizona State Univ, Ctr Personalized Diagnost, Biodesign Inst, Tempe, AZ 85281 USA; [Lucas, Alexandra] St Josephs Hosp, Div Cardiol, Dign Hlth, Phoenix, AZ 85013 USA; [Lucas, Alexandra; Ambadapadi, Sriram] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL 32611 USA; [Lucas, Alexandra; Ambadapadi, Sriram] Univ Florida, Dept Med, Div Rheumatol, Gainesville, FL 32611 USA; [Ambadapadi, Sriram] Pharmacyclics LLC, Sunnyvale, CA USA	Lucas, A (corresponding author), Arizona State Univ, Biodesign Ctr Personalized Diagnost, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), Arizona State Univ, Ctr Personalized Diagnost, Biodesign Inst, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), St Josephs Hosp, Div Cardiol, Dign Hlth, Phoenix, AZ 85013 USA.; Lucas, A (corresponding author), Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL 32611 USA.; Lucas, A (corresponding author), Univ Florida, Dept Med, Div Rheumatol, Gainesville, FL 32611 USA.		Zhang, Liqiang/D-4987-2015; Yaron, Jordan R/S-1136-2019	Yaron, Jordan R/0000-0002-4133-474X			Bauman S.J, 2002, CURR PROTOC PROTEIN, V21, P7; Carrell RW, 2017, SEMIN CELL DEV BIOL, V62, P133, DOI 10.1016/j.semcdb.2016.12.007; Chan WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113402; Chen H, 2013, ANTIMICROB AGENTS CH, V57, P4114, DOI 10.1128/AAC.02594-12; Csuka D, 2017, MOL IMMUNOL, V89, P59, DOI 10.1016/j.molimm.2017.05.020; Dai EB, 2006, J BIOL CHEM, V281, P8041, DOI 10.1074/jbc.M509454200; Eappen AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062937; Foernvik K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183086; Gettins PGW, 2016, BIOCHEM J, V473, P2273, DOI 10.1042/BCJ20160014; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gooptu B, 2014, TRENDS MOL MED, V20, P116, DOI 10.1016/j.molmed.2013.10.007; Gupta KK, 2016, BIOCHEM BIOPH RES CO, V477, P503, DOI 10.1016/j.bbrc.2016.06.065; Hughes VA, 2017, PLOS ONE, V9; Huntington JA, 2011, J THROMB HAEMOST, V9, P26, DOI 10.1111/j.1538-7836.2011.04360.x; Irving JA, 2011, METHOD ENZYMOL, V501, P421, DOI 10.1016/B978-0-12-385950-1.00018-3; Ishikawa M, 2017, J SURG RES, V208, P140, DOI 10.1016/j.jss.2016.09.041; Kawabata S, 2010, J BIOCHEM, V147, P611, DOI 10.1093/jb/mvq026; Leisegang R, 2005, J I BREWING, V111, P112, DOI 10.1002/j.2050-0416.2005.tb00656.x; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Mazzoccoli G, 2012, J CANCER RES CLIN, V138, P501, DOI 10.1007/s00432-011-1126-6; Mejia P, 2016, PLOS ONE, V11; Mejia P, 2016, J INFECT DIS, V213, P80, DOI 10.1093/infdis/jiv439; Mulder R, 2017, BRIT J HAEMATOL, V178, P279, DOI 10.1111/bjh.14658; Rau JC, 2007, J THROMB HAEMOST, V5, P102, DOI 10.1111/j.1538-7836.2007.02516.x; Roussel BD, 2016, EPILEPTIC DISORD, V18, pS103, DOI 10.1684/epd.2016.0847; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simone TM, 2015, CELL SIGNAL, V27, P923, DOI 10.1016/j.cellsig.2015.01.009; Viswanathan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044694; Williams AR, 2013, INT J PARASITOL, V43, P869, DOI 10.1016/j.ijpara.2013.06.004	29	17	18	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-8645-3; 978-1-4939-8644-6	METHODS MOL BIOL	Methods Mol. Biol.		2018	1826						1	7		10.1007/978-1-4939-8645-3_1	10.1007/978-1-4939-8645-3		7	Biochemical Research Methods; Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	BM1XI	WOS:000460670300002	30194590				2021-06-18	
J	Ruet, A; Jourdan, C; Bayen, E; Darnoux, E; Sahridj, D; Ghout, I; Azerad, S; Diehl, PP; Aegerter, P; Charanton, J; Azouvi, CV; Azouvi, P				Ruet, Alexis; Jourdan, Claire; Bayen, Eleonore; Darnoux, Emmanuelle; Sahridj, Dalila; Ghout, Idir; Azerad, Sylvie; Diehl, Pascale Pradat; Aegerter, Philippe; Charanton, James; Azouvi, Claire Vallat; Azouvi, Philippe			Employment outcome four years after a severe traumatic brain injury: results of the Paris severe traumatic brain injury study	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; follow-up study; employment; return to work; disability	FOLLOW-UP; ACUTE PREDICTORS; BOTULINUM TOXIN; JOB STABILITY; RETURN; WORK; MODERATE; PRODUCTIVITY; COHORT	Objective: To describe employment outcome four years after a severe traumatic brain injury by the assessment of individual patients' preinjury sociodemographic data, injury-related and postinjury factors. Design: A prospective, multicenter inception cohort of 133 adult patients in the Paris area (France) who had received a severe traumatic brain injury were followed up postinjury at one and four years. Sociodemographic data, factors related to injury severity and one-year functional and cognitive outcomes were prospectively collected. Methods: The main outcome measure was employment status. Potential predictors of employment status were assessed by univariate and multivariate analysis. Results: At the four-year follow-up, 38% of patients were in paid employment. The following factors were independent predictors of unemployment: being unemployed or studying before traumatic brain injury, traumatic brain injury severity (i.e., a lower Glasgow Coma Scale score upon admission and a longer stay in intensive care) and a lower one-year Glasgow Outcome Scale-Extended score. Conclusion: This study confirmed the low rate of long-term employment amongst patients after a severe traumatic brain injury. The results illustrated the multiple determinants of employment outcome and suggested that students who had received a traumatic brain injury were particularly likely to be unemployed, thus we propose that they may require specific support to help them find work.	[Ruet, Alexis] CHU Caen, Serv Med Phys & Readaptat, Ave Cote Nacre, F-14000 Caen, France; [Ruet, Alexis] INSERM, U1077, Caen, France; [Jourdan, Claire; Sahridj, Dalila; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, Garches, France; [Jourdan, Claire; Azouvi, Claire Vallat; Azouvi, Philippe] Univ Versailles St Quentin, HANDIReSP, EA 4047, Versailles, France; [Bayen, Eleonore; Diehl, Pascale Pradat] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, Paris, France; [Bayen, Eleonore; Diehl, Pascale Pradat] Univ Paris 06, Paris, France; [Darnoux, Emmanuelle; Ghout, Idir; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, AP HP, Unite Rech Clin, Boulogne, France; [Darnoux, Emmanuelle; Charanton, James] CRFTC, Paris, France; [Azouvi, Claire Vallat] Hop Raymond Poincare, Antenne UEROS SAMSAH UGECAM IDF 92, Garches, France	Ruet, A (corresponding author), CHU Caen, Serv Med Phys & Readaptat, Ave Cote Nacre, F-14000 Caen, France.	ruet-a@chu-caen.fr	RUET, Alexis/L-8726-2015	RUET, Alexis/0000-0002-5080-5734; AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health [AOM04084]; Institut de Recherche en Sante Publique (IRESP); AP-HP (Departement de la Recherche Clinique et du Developpement)	This study was funded by grants from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004), grant number AOM04084; the Institut de Recherche en Sante Publique (IRESP). It was supported by AP-HP (Departement de la Recherche Clinique et du Developpement).	Azouvi P, 2015, NEUROPSYCHOL REHABIL, V25, P864, DOI 10.1080/09602011.2014.990907; Baert I, 2012, ARCH PHYS MED REHAB, V93, P669, DOI 10.1016/j.apmr.2011.09.022; Bayen E, 2014, J HEAD TRAUMA REHAB, V31, P59; CLAUS D, 1995, MOVEMENT DISORD, V10, P574, DOI 10.1002/mds.870100508; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Diaz AP, 2014, REV BRAS PSIQUIATR, V36, P213, DOI 10.1590/1516-4446-2013-1303; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fitzpatrick RC, 2004, J APPL PHYSIOL, V96, P2301, DOI 10.1152/japplphysiol.00008.2004; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Jourdan C, 2016, ANN PHYS REHABIL MED, V59, P100, DOI 10.1016/j.rehab.2015.10.009; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2016, J HEAD TRAUMA REHAB, V31, pE42, DOI 10.1097/HTR.0000000000000147; Jourdan C, 2015, BRAIN INJURY, V29, P701, DOI 10.3109/02699052.2015.1004646; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Meulenbroek P, 2016, DISABIL REHABIL, V38, P452, DOI 10.3109/09638288.2015.1044621; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; R Core Team, 2018, R LANG ENV STAT COMP; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Sarifakioglu N, 2004, ANN PLAS SURG, V53, P543, DOI 10.1097/01.sap.0000139563.51598.75; Scaratti C, 2017, DISABIL REHABIL, V39, P847, DOI 10.3109/09638288.2016.1162854; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Willmott C, 2015, BRAIN INJURY, V29, P929, DOI 10.3109/02699052.2015.1022882; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	47	17	18	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2018	40	18					2200	2207		10.1080/09638288.2017.1327992			8	Rehabilitation	Rehabilitation	GL6WK	WOS:000437334400012	28521527				2021-06-18	
J	Yang, Q; Zhang, DS; Li, Y; Li, YQ; Li, YP				Yang, Qiu; Zhang, Dongshan; Li, Ya; Li, Yongquan; Li, Yinpeng			Paclitaxel alleviated liver injury of septic mice by alleviating inflammatory response via microRNA-27a/TAB3/NF-kappa B signaling pathway	BIOMEDICINE & PHARMACOTHERAPY			English	Article						Sepsis; Paclitaxel; Inflammatory response; MicroRNA-27a; NF-kappa B signaling pathway	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; BREAST-CANCER; OXIDATIVE STRESS; DOWN-REGULATION; EXPRESSION; SEPSIS; ACTIVATION; MECHANISMS; INHIBITION	Excessive inflammatory response and apoptosis play an important role in the sepsis-induced liver injury. Paclitaxel, a diterpene alkaloid of Taxus brevifolia, is widely used as an anti-tumor drug and shows protective effects on acute lung and kidney injury. However, whether it has a protective effect against sepsis-induced liver injury has not been reported. The objective of this study was to investigate the protective effects of paclitaxel in septic liver injury in mice and associated molecular mechanisms. Our results showed that paclitaxel treatment improved LPS-induced liver injury, as evidenced by the reduced aminotransferase activity, histological scores and apoptosis in the liver tissues. This was accompanied by the alleviating of inflammation and oxidative stress, such as decreased levels of tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-6) interleukin-1 beta (IL-1 beta) and malondialdehyde (MDA) and increased levels of superoxide dismutase (SOD) and glutathione peroxidase (GSHpx) in serum and liver tissues. Subsequent microarray and qRT-PCR analysis further showed that miR-27a was significantly decreased in mice with sepsis, which was recovered by paclitaxel pretreatment. Antagomir-miR-27a suppressed the therapeutic effects of paclitaxel in mice liver injury model via promoting inflammatory response. Of note, TAB3, which participated in the activation of the NF-kappa B signaling pathway, was identified as a direct target of miR-27 by luciferase reporter gene assays. Then, we revealed a reverse relationship between miR-27a expression levels and TAB3 mRNA levels in liver tissues from septic mice. Furthermore, paclitaxel treatment significantly decreased the expression of NF-kappa B p65, but increased inhibitor of nuclear factor-kappa B-a (I.Ba) protein levels in septic mice, suggesting the inactivation of NF-kappa B signaling pathway. Notably, the inhibitory effects of paclitaxel on NF-kappa B signaling pathway were reversed by antagomir-miR-27a. Our data indicated that paclitaxel significantly attenuated septic induced liver injury through reducing inflammatory response via miR-27a/TAB3/NF-kappa B signaling pathway.	[Yang, Qiu; Li, Yinpeng] Jinan Univ, Clin Med Coll 2, Dept Gastroenterol, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518000, Peoples R China; [Zhang, Dongshan] Cent S Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha, Hunan, Peoples R China; [Zhang, Dongshan] Cent S Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Hunan, Peoples R China; [Li, Ya; Li, Yongquan] Jinan Univ, Clin Med Coll 2, Dept Nephrol, Shenzhen, Peoples R China	Li, YP (corresponding author), Jinan Univ, Clin Med Coll 2, Dept Gastroenterol, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518000, Peoples R China.	li_yinpeng65@163.com			Scientific Research Project of Shenzhen Health and Family Planning System [201507002]	This study was supported by the Scientific Research Project of Shenzhen Health and Family Planning System in 2015 (NO.: 201507002).	Ayyagari VN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185111; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bennett GJ, 2011, EUR J NEUROSCI, V33, P1667, DOI 10.1111/j.1460-9568.2011.07652.x; Cai Q, 2016, NEURAL REGEN RES, V11, P1285, DOI 10.4103/1673-5374.189194; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen WW, 2017, EXP CELL RES, V350, P318, DOI 10.1016/j.yexcr.2016.12.008; CHENG Y, 2015, BIOMED RES INT, V2015; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Chu X, 2012, J AGR FOOD CHEM, V60, P3947, DOI 10.1021/jf2051587; Du C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-869; Einzig Avi I., 1996, Am J Ther, V3, P750, DOI 10.1097/00045391-199611000-00003; El-Tanbouly DM, 2015, PHARMACOL REP, V67, P914, DOI 10.1016/j.pharep.2015.02.004; Fumoleau P, 1997, Expert Opin Investig Drugs, V6, P1853, DOI 10.1517/13543784.6.12.1853; Geng HH, 2016, BIOMED PHARMACOTHER, V81, P258, DOI 10.1016/j.biopha.2016.04.020; Gornstein E, 2014, NEUROPHARMACOLOGY, V76, P175, DOI 10.1016/j.neuropharm.2013.08.016; Hsiao Hung-Tsung, 2016, Acta Anaesthesiol Taiwan, V54, P6, DOI 10.1016/j.aat.2015.11.002; Huang HL, 2017, CELL PHYSIOL BIOCHEM, V42, P889, DOI 10.1159/000478644; Kamp DW, 2011, ONCOLOGY-NY, V25, P400; Kim KJ, 2015, INT J MOL SCI, V16, P27589, DOI 10.3390/ijms161126048; Kronski E, 2014, MOL ONCOL, V8, P581, DOI 10.1016/j.molonc.2014.01.005; Lee KS, 2006, MOL PHARMACOL, V69, P1829, DOI 10.1124/mol.106.022228; Li LN, 2017, ONCOL LETT, V13, P4837, DOI 10.3892/ol.2017.6041; Lin WC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178387; Lin Y, 2015, ORAL ONCOL, V51, P921, DOI 10.1016/j.oraloncology.2015.07.006; Liu XJ, 2017, INT IMMUNOPHARMACOL, V49, P50, DOI 10.1016/j.intimp.2017.05.022; Liu XP, 2015, ONCOTARGET, V6, P20070, DOI 10.18632/oncotarget.4039; Luo CF, 2015, MOL MED REP, V12, P1082, DOI 10.3892/mmr.2015.3527; Lv X, 2015, MOL MED REP, V12, P6013, DOI 10.3892/mmr.2015.4188; Lv YN, 2017, CELL MOL NEUROBIOL, V37, P195, DOI 10.1007/s10571-016-0361-4; Malacarne P, 2008, CRIT CARE MED, V36, P1105, DOI 10.1097/CCM.0b013e318169ed30; Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206; Oliva-Gonzalez C, 2017, TOXICOL LETT, V280, P92, DOI 10.1016/j.toxlet.2017.08.013; Panagiotou Anthi, 2013, J Intensive Care Med, V28, P281, DOI 10.1177/0885066611425759; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pfeiffer D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179850; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Shin JS, 2016, J CELL BIOCHEM, V117, P2327, DOI 10.1002/jcb.25530; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wang P, 2017, INT IMMUNOPHARMACOL, V51, P9, DOI 10.1016/j.intimp.2017.07.020; Wang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080547; Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018; Wu YM, 2016, BIOMED PHARMACOTHER, V84, P1126, DOI 10.1016/j.biopha.2016.10.024; Xue WL, 2015, BIOCHEM BIOPH RES CO, V464, P855, DOI 10.1016/j.bbrc.2015.07.051; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang BT, 2016, ONCOTARGET, V7, P5702, DOI 10.18632/oncotarget.6790; Zhang DS, 2013, J PHARMACOL EXP THER, V345, P69, DOI 10.1124/jpet.112.202481; Zhang DS, 2010, LAB INVEST, V90, P436, DOI 10.1038/labinvest.2009.149; Zhang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1080/10298436.2015.1019502; Zhao Y. N., 2013, BIOCH BIOPHYS RES CO, V435; Zheng D, 2016, J INFECT DIS, V213, P1661, DOI 10.1093/infdis/jiv760; Zhong WH, 2016, BIOMED PHARMACOTHER, V83, P302, DOI 10.1016/j.biopha.2016.06.036; Zhou LF, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-146; Zhu HG, 2017, BIOMED PHARMACOTHER, V92, P879, DOI 10.1016/j.biopha.2017.05.143	60	17	17	2	13	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0753-3322	1950-6007		BIOMED PHARMACOTHER	Biomed. Pharmacother.	JAN	2018	97						1424	1433		10.1016/j.biopha.2017.11.003			10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	FR4NC	WOS:000419041300171	29156532				2021-06-18	
J	Yang, YK; Wei, H; Zhou, XH; Zhang, F; Wang, CH				Yang, Yongkai; Wei, Hao; Zhou, Xiaohui; Zhang, Fan; Wang, Chunhua			Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury	NEUROREPORT			English	Article						extracellular signal-regulated kinase; hyperbaric oxygen; neural stem cells; traumatic brain injury; vascular endothelial growth factor	RAT MODEL; VEGF; DIFFERENTIATION; NEUROGENESIS; EXPRESSION; PATHWAY	Hyperbaric oxygen (HBO) therapy and neural stem cell (NSC) transplantation can improve traumatic brain injury (TBI) clinically. This study aimed to investigate the mechanism of HBO promoting NSC proliferation and neurological recovery after TBI. Twenty-four Sprague-Dawley rats were divided randomly into three groups: a sham group, a TBI group (constructed using Feeney's free-fall method), and an HBO-treated TBI group. Neurological function was evaluated by Neurological Severity Scores on days 1, 3, and 7, and we found that TBI-induced poor neurological function was improved by HBO. On day 7 after TBI, we observed that TBI promoted NSC proliferation, migration to the lesion area, and the levels of vascular endothelial growth factor (VEGF), VEGFR2, Raf-1, MEK1/2, and phospho-extracellular signal-regulated kinase (ERK) 1/2 protein, which were further boosted by HBO, from immunohistochemistry, immunofluorescence, and Western blot experiments. In vitro, cell injury was applied to NSCs isolated from neonatal Sprague-Dawley rats by the Cell Injury Controller II system. Moreover, data from the BrdU Kit and Western blot showed that in-vitro HBO significantly accelerated NSC proliferation and the levels of proteins related to cell cycle and the VEGF/ERK pathway after cell injury, which was suppressed by the VEGFR2 inhibitor. Taken together, this study indicated that HBO may promote NSC proliferation by activating VEGF/ERK signaling and play a crucial role in neuroprotection after TBI.	[Yang, Yongkai; Wei, Hao; Zhou, Xiaohui; Zhang, Fan] Fujian Med Univ, Hosp Fuzhou City Affiliated 1, Dept Neurosurg, Fuzhou 350009, Fujian, Peoples R China; [Wang, Chunhua] Res Inst Fujian Prov, Dept Neurosurg, Fuzhou, Fujian, Peoples R China	Zhang, F (corresponding author), Fujian Med Univ, Hosp Fuzhou City Affiliated 1, Dept Neurosurg, Fuzhou 350009, Fujian, Peoples R China.	fanzhangfj@163.com			Cultural Project of Innovative Research Team in Fuzhou Health and Family Planning System [2013-S-wt1]; Special Project on Research and Development of Non Affiliated Hospitals of Fujian Medical University [FZS13002Z]; Project of the Natural Science Foundation of Fujian Province [2015J01498]	This work was supported partially by grants from the Cultural Project of Innovative Research Team in Fuzhou Health and Family Planning System (2013-S-wt1); the Special Project on Research and Development of Non Affiliated Hospitals of Fujian Medical University (FZS13002Z); and the Project of the Natural Science Foundation of Fujian Province (2015J01498).	Alexiades NG, 2015, STEM CELL RES, V15, P598, DOI 10.1016/j.scr.2015.10.005; Covacu R., 2015, NEUROSCIENTIST; Du YB, 2016, MOL MED REP, V14, P2473, DOI 10.3892/mmr.2016.5582; Feng ZC, 2013, NEURAL REGEN RES, V8, P1220, DOI 10.3969/j.issn.1673-5374.2013.13.007; Haigh CL, 2016, CELL BIOCHEM BIOPHYS, V74, P297, DOI 10.1007/s12013-016-0747-4; Han W, 2017, EPILEPSY BEHAV, V68, P159, DOI 10.1016/j.yebeh.2016.12.007; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Kirby ED, 2015, P NATL ACAD SCI USA, V112, P4128, DOI 10.1073/pnas.1422448112; Kleiderman S, 2016, STEM CELLS, V34, P2861, DOI 10.1002/stem.2483; Li XR, 2016, GENE, V590, P201, DOI 10.1016/j.gene.2015.11.047; Liu CX, 2015, CELL MOL BIOL, V61, P75; Liu XH, 2014, SPINE J, V14, P119, DOI 10.1016/j.spinee.2013.06.084; Meng XE, 2016, MED SCI MONITOR, V22, P284, DOI 10.12659/MSM.894148; Oh JS, 2012, NEUROREPORT, V23, P174, DOI 10.1097/WNR.0b013e32834f4f3a; Peng ZR, 2014, J NEUROL SCI, V342, P114, DOI 10.1016/j.jns.2014.04.037; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Takahashi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116119; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Wee HY, 2015, J SURG RES, V197, P382, DOI 10.1016/j.jss.2015.04.052; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Zhang P, 2016, SCI REP-UK, V6, DOI 10.1038/srep26295; Zhang XY, 2011, CELL MOL NEUROBIOL, V31, P101, DOI 10.1007/s10571-010-9559-z; Zhou Y, 2013, CHINESE MED J-PEKING, V126, P3897, DOI 10.3760/cma.j.issn.0366-6999.20130571	24	17	22	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	DEC 13	2017	28	18					1232	1238		10.1097/WNR.0000000000000901			7	Neurosciences	Neurosciences & Neurology	FN4EV	WOS:000415958000008	28953090				2021-06-18	
J	Alosco, ML; Mez, J; Kowall, NW; Stein, TD; Goldstein, LE; Cantu, RC; Katz, DI; Solomon, TM; Kiernan, PT; Murphy, L; Abdolmohammadi, B; Daneshvar, D; Montenigro, PH; Nowinski, CJ; Stern, RA; Mckee, AC				Alosco, Michael L.; Mez, Jesse; Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Solomon, Todd M.; Kiernan, Patrick T.; Murphy, Lauren; Abdolmohammadi, Bobak; Daneshvar, Daniel; Montenigro, Philip H.; Nowinski, Christopher J.; Stern, Robert A.; Mckee, Ann C.			Cognitive Reserve as a Modifier of Clinical Expression in Chronic Traumatic Encephalopathy: A Preliminary Examination	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							21ST-CENTURY BRAIN BANKING; ALZHEIMERS-DISEASE; COLUMBIA-UNIVERSITY; EDUCATION; INJURY; PATHOLOGY; DEMENTIA; SPECTRUM; CRITERIA	This study conducted a preliminary examination on cognitive reserve (CR) as a modifier of symptom expression in subjects with autopsy-confirmed chronic traumatic encephalopathy (CTE). The sample included 25 former professional football players neuropathologically diagnosed with CTE stage III or IV. Next of kin interviews ascertained age at cognitive and behavioral/mood symptom onset and demographic/athletic characteristics. Years of education and occupational attainment defined CR. High occupational achievement predicted later age at cognitive (p=0.02) and behavioral/mood (p=0.02) onset. Education was not an individual predictor. These preliminary findings suggest that CR may forestall the clinical manifestation of CTE.	[Alosco, Michael L.; Mez, Jesse; Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; Cantu, Robert C.; Solomon, Todd M.; Kiernan, Patrick T.; Murphy, Lauren; Abdolmohammadi, Bobak; Daneshvar, Daniel; Montenigro, Philip H.; Nowinski, Christopher J.; Stern, Robert A.; Mckee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Alosco, Michael L.; Mez, Jesse; Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; Katz, Douglas I.; Solomon, Todd M.; Kiernan, Patrick T.; Murphy, Lauren; Abdolmohammadi, Bobak; Daneshvar, Daniel; Montenigro, Philip H.; Stern, Robert A.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel] North Shore Med Ctr, Dept Internal Med, Boston, MA USA; [Kowall, Neil W.; Stein, Thor D.; Mckee, Ann C.] VA Boston Healthcare Syst, US Dept Vet Affairs, Boston, MA 02130 USA; [Kowall, Neil W.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Biomed Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Elect & Comp Engn, Boston, MA 02215 USA; [Cantu, Robert C.; Nowinski, Christopher J.] Concuss Legacy Fdn, Boston, MA USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Mckee, AC (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA.; Mckee, AC (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.; Mckee, AC (corresponding author), VA Boston Healthcare Syst, US Dept Vet Affairs, Boston, MA 02130 USA.; Mckee, AC (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.; Mckee, AC (corresponding author), Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA.		Kowall, Neil/M-5378-2019; , Bob/ABA-8507-2020	Kowall, Neil/0000-0002-6624-0213; Stein, Thor/0000-0001-6954-4477; Daneshvar, Daniel/0000-0003-3691-9513	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1UO1NS086659-01, R01NS078337, R56NS078337]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP) [13267017]; National Institute of Aging Boston University Framingham Heart Study [R01AG1649]; National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation; Andlinger Foundation; WWE; NFL; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32NS096803-01]; Johnson & Johnson (New Brunswick, N.J.)/Janssen Research & Development, LLC (Raritan, N.J.); Rebiscan, Inc. (Cambridge, Mass.); Ivivi Health Sciences; Mackey-White Committee; NFL Players Association; Avid Radiopharmaceuticals, Inc. (Philadelphia); Athena Diagnostics/Quest Laboratories (Marlborough, Mass.); Amarantus BioScience Holdings, Inc. (San Francisco); Avanir Pharmaceuticals, Inc. (Aliso Viejo, Calif.); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337, R56NS078337, U01NS086659, U01NS093334, F32NS096803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, P30AG013846, P30AG019610] Funding Source: NIH RePORTER	Supported by the National Institute of Neurological Disorders and Stroke (1UO1NS086659-01, R01NS078337, R56NS078337), the Department of Defense (W81XWH-13-2-0064), the Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5), the Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017), the National Institute of Aging Boston University Framingham Heart Study (R01AG1649), and the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the WWE, and the NFL. Michael L. Alosco and research reported in this article are supported by the National Institutes of Health under grant 1F32NS096803-01.; Dr. Goldstein is a paid consultant to Johnson & Johnson (New Brunswick, N.J.)/Janssen Research & Development, LLC (Raritan, N.J.), and Rebiscan, Inc. (Cambridge, Mass.); and he has received funding from the WWE and Ivivi Health Sciences. Dr. Nowinski is a member of the Mackey-White Committee of the NFL Players Association and receives fees for speaking at educational programs. Dr. Stern has received research funding from the NFL, the NFL Players Association, and Avid Radiopharmaceuticals, Inc. (Philadelphia); he is a member of the Mackey-White Committee of the NFL Players Association; he is a paid consultant to Athena Diagnostics/Quest Laboratories (Marlborough, Mass.), Amarantus BioScience Holdings, Inc. (San Francisco), and Avanir Pharmaceuticals, Inc. (Aliso Viejo, Calif.); he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, Fla.), as well as compensation from expert legal opinion. Dr. McKee has received funding from the NFL, WWE, and is a member of the Mackey-White Committee of the NFL Players Association. All other authors report no financial relationships with commercial interests.	Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; BARBER R, 1995, J NEUROL NEUROSUR PS, V59, P61, DOI 10.1136/jnnp.59.1.61; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bennett DA, 2014, ACTA NEUROPATHOL, V127, P137, DOI 10.1007/s00401-013-1226-2; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; Ghaffar O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047206; Harrison SL, 2015, J CLIN EXP NEUROPSYC, V37, P253, DOI 10.1080/13803395.2014.1002759; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Linds AB, 2015, CAN J NEUROL SCI, V42, P389, DOI 10.1017/cjn.2015.266; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2016, CUMULATIVE HEAD IMPA; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; U.S. Department of Labor, 1991, DICT OCCUPATIONAL TI; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Wilson RS, 2013, NEUROLOGY, V80, P1202, DOI 10.1212/WNL.0b013e3182897103; Wright MJ, 2016, J CLIN EXP NEUROPSYC, V38, P561, DOI 10.1080/13803395.2016.1139057; Zahodne LB, 2015, NEUROPSYCHOLOGIA, V77, P260, DOI 10.1016/j.neuropsychologia.2015.09.009	30	17	17	1	89	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2017	29	1					6	12		10.1176/appi.neuropsych.16030043			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	EP0WO	WOS:000397107600002	27539377	Green Accepted, Bronze			2021-06-18	
J	Yilmaz, T; Roks, G; de Koning, M; Scheenen, M; van der Horn, H; Plas, G; Hageman, G; Schoonman, G; Spikman, J; van der Naalt, J				Yilmaz, Tansel; Roks, Gerwin; de Koning, Myrthe; Scheenen, Myrthe; van der Horn, Harm; Plas, Gerben; Hageman, Gerard; Schoonman, Guus; Spikman, Jacoba; van der Naalt, Joukje			Risk factors and outcomes associated with post-traumatic headache after mild traumatic brain injury	EMERGENCY MEDICINE JOURNAL			English	Article							SYMPTOMS FOLLOWING MILD; FOLLOW-UP; PREDICTION; COMPLAINTS; ANXIETY	Objectives To determine the prevalence and potential risk factors of acute and chronic post-traumatic headache (PTH) in patients with mild to moderate traumatic brain injury (TBI) in a prospective longitudinal observational multicentre study. Acute PTH (aPTH) is defined by new or worsening of pre-existing headache occurring within 7 days after trauma, whereas chronic PTH (cPTH) is defined as persisting aPTH >3 months after trauma. An additional goal was to study the impact of aPTH and cPTH in terms of return to work (RTW), anxiety and depression. Methods This was a prospective observational study conducted between January 2013 and February 2014 in three trauma centres in the Netherlands. Patients aged 16 years and older with a GCS score of 9-15 on admission to the ED, with loss of consciousness and/ or amnesia were prospectively enrolled. Follow-up questionnaires were completed at 2 weeks and 3 months after injury with the Head Injury Symptom Checklist, the Hospital Anxiety and Depression Scale and RTW scale. Results In total, 628 patients were enrolled in the study, 469 completed the 2-week questionnaire (75%) at 2 weeks and 409 (65%) at 3 months. At 2 weeks, 238 (51%) had developed aPTH and at 3 months 95 (23%) had developed cPTH. Female gender, younger age, headache immediately at the ED and CT scan abnormalities increased the risk for aPTH. Risk factors for cPTH were female gender and headache at the ED. Patients with cPTH were less likely to have returned to work than those without cPTH (35% vs 14%, P=0.001). Patients with aPTH and cPTH more often report anxiety (20% and 28%, P=0.001) and depression (19% and 28%, P=0.001) after trauma in comparison with the group without PTH (10% anxiety and 8% depression). Conclusions PTH is an important health problem with a significant impact on long-term outcome of TBI patients. Several risk factors were identified, which can aid in early identification of subjects at risk for PTH.	[Yilmaz, Tansel; Roks, Gerwin; Schoonman, Guus] St Elizabeth Hosp, Dept Neurol, Hilvarenbeekseweg 60, NL-5022 GC Tilburg, Netherlands; [de Koning, Myrthe; Scheenen, Myrthe; van der Horn, Harm; Spikman, Jacoba; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Plas, Gerben; Hageman, Gerard] MST, Dept Neurol, Enschede, Netherlands	Yilmaz, T (corresponding author), St Elizabeth Hosp, Dept Neurol, Hilvarenbeekseweg 60, NL-5022 GC Tilburg, Netherlands.	t.yilmaz@elisabeth.nl		Spikman, Jacoba/0000-0002-6477-0763			Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; D'Onofrio F, 2014, NEUROL SCI, V35, pS203, DOI 10.1007/s10072-014-1771-z; Erickson Jay C, 2010, Continuum (Minneap Minn), V16, P55, DOI 10.1212/01.CON.0000391453.37923.83; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; GANTI L, 2014, INT J EMERG MED, V7; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McMurtray AM, 2013, INT J PSYCHIAT MED, V45, P227, DOI 10.2190/PM.45.3.b; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	17	17	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	DEC	2017	34	12					800	805		10.1136/emermed-2015-205429			6	Emergency Medicine	Emergency Medicine	FN8UO	WOS:000416301200007	28689194				2021-06-18	
J	Zeiler, FA; Donnelly, J; Calviello, L; Menon, DK; Smielewski, P; Czosnyka, M				Zeiler, Frederick A.; Donnelly, Joseph; Calviello, Leanne; Menon, David K.; Smielewski, Peter; Czosnyka, Marek			Pressure Autoregulation Measurement Techniques in Adult Traumatic Brain Injury, Part I: A Scoping Review of Intermittent/Semi-Intermittent Methods	JOURNAL OF NEUROTRAUMA			English	Article						adult TBI; autoregulation measurement; intermittent techniques; systematic review	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; DOPPLER ULTRASONOGRAPHY TCD; INTRACRANIAL-PRESSURE; CEREBROVASCULAR AUTOREGULATION; DYNAMIC AUTOREGULATION; STATIC AUTOREGULATION; PERFUSION-PRESSURE; BEDSIDE ASSESSMENT; REACTIVITY	The purpose of this study was to perform a systematic, scoping review of commonly described intermittent/semiintermittent autoregulation measurement techniques in adult traumatic brain injury (TBI). Nine separate systematic reviews were conducted for each intermittent technique: computed tomographic perfusion (CTP)/Xenon-CT (Xe-CT), positron emission tomography (PET), magnetic resonance imaging (MRI), arteriovenous difference in oxygen (AVDO(2)) technique, thigh cuff deflation technique (TCDT), transient hyperemic response test (THRT), orthostatic hypotension test (OHT), mean flow index (Mx), and transfer function autoregulation index (TF-ARI). MEDLINE (R), BIOSIS, EMBASE, Global Health, Scopus, Cochrane Library (inception to December 2016), and reference lists of relevant articles were searched. A two tier filter of references was conducted. The total number of articles utilizing each of the nine searched techniques for intermittent/semi-intermittent autoregulation techniques in adult TBI were: CTP/Xe-CT (10), PET (6), MRI (0), AVDO2 (10), ARI-based TCDT (9), THRT (6), OHT (3), Mx (17), and TF-ARI (6). The premise behind all of the intermittent techniques is manipulation of systemic blood pressure/blood volume via either chemical (such as vasopressors) or mechanical (such as thigh cuffs or carotid compression) means. Exceptionally, Mx and TF-ARI are based on spontaneous fluctuations of cerebral perfusion pressure (CPP) or mean arterial pressure (MAP). The method for assessing the cerebral circulation during these manipulations varies, with both imaging-based techniques and TCD utilized. Despite the limited literature for intermittent/semi-intermittent techniques in adult TBI (minus Mx), it is important to acknowledge the availability of such tests. They have provided fundamental insight into human autoregulatory capacity, leading to the development of continuous and more commonly applied techniques in the intensive care unit (ICU). Numerous methods of intermittent/semi-intermittent pressure autoregulation assessment in adult TBI exist, including: CTP/Xe-CT, PET, AVDO(2) technique, TCDT-based ARI, THRT, OHT, Mx, and TF-ARI. MRI-based techniques in adult TBI are yet to be described, with the main focus of MRI techniques on metabolic-based cerebrovascular reactivity (CVR) and not pressure-based autoregulation.	[Zeiler, Frederick A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Donnelly, Joseph; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Sect Brain Phys, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Sect Neurosurg, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Clinician Investigator Program, Winnipeg, MB, Canada	Zeiler, FA (corresponding author), Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	umzeiler@myumanitoba.ca	Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Zeiler, Frederick/0000-0003-1737-0510	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada - Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; Woolf Fisher Scholarship (NZ); National Institute for Healthcare Research (NIHR), UK through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; European Union Framework Program 7 grant (CENTER-TBI) [602150]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada - Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund. J.D. is supported by a Woolf Fisher Scholarship (NZ). These studies were also supported by the National Institute for Healthcare Research (NIHR), UK through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to D.K.M. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150).	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Aslam AA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012040.pub2; Berre J. A., 2002, ANESTHESIOLOGY, V2000, pA350; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Budohoski KP, 2012, NEUROCRIT CARE, V17, P211, DOI 10.1007/s12028-011-9572-1; Carrera E, 2009, J NEUROL SCI, V285, P191, DOI 10.1016/j.jns.2009.06.041; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; Chieregato A, 2007, INTENS CARE MED, V33, P856, DOI 10.1007/s00134-007-0604-4; Christ M, 2007, INTENS CARE MED, V33, P246, DOI 10.1007/s00134-006-0451-8; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2000, ACT NEUR S, V76, P483; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; Czosnyka M., 2007, J CEREB BLOOD FLOW M, V27; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; da Costa L, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00070; DAFFERTSHOFER M, 1995, J CLIN ULTRASOUND, V23, P125, DOI 10.1002/jcu.1870230207; DAFFERTSHOFER M, 1991, J NEUROL SCI, V104, P32, DOI 10.1016/0022-510X(91)90212-P; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Hlatky R, 2006, NEUROCRIT CARE, V4, P127, DOI 10.1385/NCC:4:2:127; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Horsfield MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062588; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; Lewis Philip M, 2012, Acta Neurochir Suppl, V114, P147, DOI 10.1007/978-3-7091-0956-4_27; Liu XY, 2016, ACTA NEUROCHIR SUPPL, V122, P233, DOI 10.1007/978-3-319-22533-3_47; Liu XY, 2015, J CEREBR BLOOD F MET, V35, P248, DOI 10.1038/jcbfm.2014.192; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; McNair N, 2012, BRAIN INJURY, V26, P558; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Ng SCP, 2002, ACT NEUR S, V81, P125; Ng SCP, 2000, ACT NEUR S, V76, P479; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Peterson E, 2009, J TRAUMA, V67, P944, DOI 10.1097/TA.0b013e3181ae6e6d; Peterson EC, 2012, NEUROSURGERY, V71, pE560, DOI 10.1227/01.neu.0000417741.24547.1c; Puppo C, 2007, ACTA NEUROCHIR, V149, P139, DOI 10.1007/s00701-006-1074-0; Puppo C, 2002, ACTA NEUROCHIR SUPPL, V81, P129; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rangel-Castilla L, 2010, NEUROL RES, V32, P1033, DOI 10.1179/016164110X12767786356598; Riberholt CG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154831; Ingelmo AR, 2016, J INVEST ALLERG CLIN, V26, P144, DOI 10.18176/jiaci.0058; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sahuquillo J, 2000, ACTA NEUROCHIR SUPPL, V76, P485; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Schmidt EA, 2003, J NEUROIMAGING, V13, P248, DOI 10.1177/1051228403013003008; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steinmeier R, 2002, J NEUROTRAUM, V19, P1127, DOI 10.1089/08977150260337949; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699908540620; Varsos GV, 2014, NEUROCRIT CARE, V21, P266, DOI 10.1007/s12028-014-9971-1; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Zhang Y, 2016, ACTA NEUROCHIR SUPPL, V122, P205, DOI 10.1007/978-3-319-22533-3_41; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	77	17	17	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2017	34	23					3207	3223		10.1089/neu.2017.5085			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FN9HM	WOS:000416341700001	28648106				2021-06-18	
J	Cavanagh, JF; Napolitano, A; Wu, C; Mueen, A				Cavanagh, James F.; Napolitano, Arthur; Wu, Christopher; Mueen, Abdullah			The Patient Repository for EEG Data plus Computational Tools (PRED plus CT)	FRONTIERS IN NEUROINFORMATICS			English	Article						EEG; open data; pattern classification; databases as topic; clinical neuroscience	TRAUMATIC BRAIN-INJURY; QUANTITATIVE EEG; ELECTRICAL-ACTIVITY; NEUROIMAGING DATA; AMERICAN ACADEMY; IDENTIFICATION; PSYCHIATRY; ENDOPHENOTYPES; DIAGNOSIS; NEUROLOGY	Electroencephalographic (EEG) recordings are thought to reflect the network-wide operations of canonical neural computations, making them a uniquely insightful measure of brain function. As evidence of these virtues, numerous candidate biomarkers of different psychiatric and neurological diseases have been advanced. Presumably, we would only need to apply powerful machine-learning methods to validate these ideas and provide novel clinical tools. Yet, the reality of this advancement is more complex: the scale of data required for robust and reliable identification of a clinical biomarker transcends the ability of any single laboratory. To surmount this logistical hurdle, collective action and transparent methods are required. Here we introduce the Patient Repository of EEG Data + Computational Tools (PRED + CT: predictsite.com). The ultimate goal of this project is to host a multitude of available tasks, patient datasets, and analytic tools, facilitating large-scale data mining. We hope that successful completion of this aim will lead to the development of novel EEG biomarkers for differentiating populations of neurological and psychiatric disorders.	[Cavanagh, James F.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Napolitano, Arthur; Wu, Christopher; Mueen, Abdullah] Univ New Mexico, Dept Comp Sci, Albuquerque, NM 87131 USA	Cavanagh, JF (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	jcavanagh@unm.edu			University of New Mexico Office of the Vice President of Research; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [1P20GM109089-01A1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089] Funding Source: NIH RePORTER	This work was supported by a grant from the University of New Mexico Office of the Vice President of Research. JC and AM are also supported by NIGMS 1P20GM109089-01A1.	Allen JJB, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00232; Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Arns M, 2013, J ATTEN DISORD, V17, P374, DOI 10.1177/1087054712460087; Ayaz SI, 2015, AM J EMERG MED, V33, P493, DOI 10.1016/j.ajem.2014.11.015; Bigdely-Shamlo N, 2015, FRONT NEUROINFORM, V9, DOI 10.3389/fninf.2015.00016; Cavanagh JF, 2017, BIOL PSYCHIAT-COGN N, V2, P413, DOI 10.1016/j.bpsc.2017.01.004; Cavanagh JF, 2016, NEUROIMAGE, V133, P1, DOI 10.1016/j.neuroimage.2016.02.075; Cavanagh JF, 2015, J PHYSIOL-PARIS, V109, P3, DOI 10.1016/j.jphysparis.2014.04.003; Chaumon M, 2015, J NEUROSCI METH, V250, P47, DOI 10.1016/j.jneumeth.2015.02.025; Coburn KL, 2006, J NEUROPSYCH CLIN N, V18, P460, DOI 10.1176/appi.neuropsych.18.4.460; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Detre G., 2006, MULTIVOXEL PATTERN A; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Doshi-Velez F, 2017, RIGOROUS SCI INTERPR; Dyrholm Mads, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4249; Eickhoff S, 2016, NEUROIMAGE, V124, P1065, DOI 10.1016/j.neuroimage.2015.10.079; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Food and Drug Administration, 2013, DE NOV CLASS REQ NEU; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; Fries P, 2009, ANNU REV NEUROSCI, V32, P209, DOI 10.1146/annurev.neuro.051508.135603; Gillan CM, 2016, NEURON, V91, P19, DOI 10.1016/j.neuron.2016.06.002; Gloss D, 2016, NEUROLOGY, V87, P2375, DOI 10.1212/WNL.0000000000003265; Gorgolewski KJ, 2015, FRONT NEUROINFORM, V9, DOI 10.3389/fninf.2015.00008; Gould TD, 2006, GENES BRAIN BEHAV, V5, P113, DOI 10.1111/j.1601-183X.2005.00186.x; Hanke M, 2009, NEUROINFORMATICS, V7, P37, DOI 10.1007/s12021-008-9041-y; Hanley DF, 2013, J NEUROTRAUM, V30, P2051, DOI 10.1089/neu.2013.3062; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Iyengar S, 2016, P NATL ACAD SCI USA, V113, P7699, DOI 10.1073/pnas.1608146113; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kaiser DA, 2000, J NEUROTHERAPY, V1530-017X, P57, DOI DOI 10.1300/J184V04N02_07; Kappenman ES, 2012, SCHIZOPHRENIA BULL, V38, P92, DOI 10.1093/schbul/sbr147; Kennedy DN, 2004, NEUROINFORMATICS, V2, P367, DOI 10.1385/NI:2:4:367; Kieffaber PD, 2016, CLIN NEUROPHYSIOL, V127, P2192, DOI 10.1016/j.clinph.2016.01.023; Kraus N, 2016, SCI REP-UK, V6, DOI 10.1038/srep39009; Lainscsek C, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00200; Landis D, 2016, NEUROIMAGE, V124, P1084, DOI 10.1016/j.neuroimage.2015.05.049; Lemm S, 2011, NEUROIMAGE, V56, P387, DOI 10.1016/j.neuroimage.2010.11.004; Mognon A, 2011, PSYCHOPHYSIOLOGY, V48, P229, DOI 10.1111/j.1469-8986.2010.01061.x; Montague PR, 2012, TRENDS COGN SCI, V16, P72, DOI 10.1016/j.tics.2011.11.018; Moser JS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00466; Nair AK, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00001; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Nichols TE, 2017, NAT NEUROSCI, V20, P299, DOI 10.1038/nn.4500; Nolan H, 2010, J NEUROSCI METH, V192, P152, DOI 10.1016/j.jneumeth.2010.07.015; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Parra LC, 2005, NEUROIMAGE, V28, P326, DOI 10.1016/j.neuroimage.2005.05.032; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Plis SM, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00365; Poldrack RA, 2017, NAT REV NEUROSCI, V18, P115, DOI 10.1038/nrn.2016.167; Poldrack RA, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00012; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2014, COMPUT BIOL MED, V53, P125, DOI 10.1016/j.compbiomed.2014.07.011; Proudfit GH, 2015, PSYCHOPHYSIOLOGY, V52, P449, DOI 10.1111/psyp.12370; Robbins TW, 2012, TRENDS COGN SCI, V16, P81, DOI 10.1016/j.tics.2011.11.009; Saad JF, 2018, J ATTEN DISORD, V22, P815, DOI 10.1177/1087054715578270; Schirrmeister R T, 2017, DEEP LEARNING CONVOL; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Solis-Vivanco R, 2015, CLIN NEUROPHYSIOL, V126, P2142, DOI 10.1016/j.clinph.2014.12.024; Steele VR, 2014, BIOL PSYCHIAT, V76, P75, DOI 10.1016/j.biopsych.2013.09.030; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; Teeters JL, 2008, NEUROINFORMATICS, V6, P47, DOI 10.1007/s12021-008-9009-y; Thatcher RW, 2003, CLIN ELECTROENCEPHAL, V34, P39, DOI 10.1177/155005940303400203; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Wiener M, 2016, NEURON, V92, P617, DOI 10.1016/j.neuron.2016.10.037; Woo CW, 2017, NAT NEUROSCI, V20, P365, DOI 10.1038/nn.4478	68	17	17	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5196			FRONT NEUROINFORM	Front. Neuroinformatics	NOV 21	2017	11								67	10.3389/fninf.2017.00067			9	Mathematical & Computational Biology; Neurosciences	Mathematical & Computational Biology; Neurosciences & Neurology	FN2PN	WOS:000415835900002	29209195	DOAJ Gold, Green Published			2021-06-18	
J	Wicher, G; Wallenquist, U; Lei, Y; Enoksson, M; Li, XF; Fuchs, B; Abu Hamdeh, S; Marklund, N; Hillered, L; Nilsson, G; Forsberg-Nilsson, K				Wicher, Grzegorz; Wallenquist, Ulrika; Lei, Ying; Enoksson, Mattias; Li, Xiaofei; Fuchs, Barbara; Abu Hamdeh, Sami; Marklund, Niklas; Hillered, Lars; Nilsson, Gunnar; Forsberg-Nilsson, Karin			Interleukin-33 Promotes Recruitment of Microglia/Macrophages in Response to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						alarmin; glia; microglia; traumatic brain injury; neuroinflammation	INFLAMMATORY RESPONSE; NEUROINTENSIVE CARE; SPINAL-CORD; IL-33; MICRODIALYSIS; EXPRESSION; MACROPHAGES; ACTIVATION; CHEMOKINES; MICROGLIA	Traumatic brain injury (TBI) is a devastating condition, often leading to life-long consequences for patients. Even though modern neurointensive care has improved functional and cognitive outcomes, efficient pharmacological therapies are still lacking. Targeting peripherally derived, or resident inflammatory, cells that are rapid responders to brain injury is promising, but complex, given that the contribution of inflammation to exacerbation versus improved recovery varies with time post-injury. The injury-induced inflammatory response is triggered by release of alarmins, and in the present study we asked whether interleukin-33 (IL-33), an injury-associated nuclear alarmin, is involved in TBI. Here, we used samples from human TBI microdialysate, tissue sections from human TBI, and mouse models of central nervous system injury and found that expression of IL-33 in the brain was elevated from nondetectable levels, reaching a maximum after 72 h in both human samples and mouse models. Astrocytes and oligodendrocytes were the main producers of IL-33. Post-TBI, brains of mice deficient in the IL-33 receptor, ST2, contained fewer microglia/macrophages in the injured region than wild-type mice and had an altered cytokine/chemokine profile in response to injury. These observations indicate that IL-33 plays a role in neuroinflammation with microglia/macrophages being cellular targets for this interleukin post-TBI.	[Wicher, Grzegorz; Wallenquist, Ulrika; Li, Xiaofei; Forsberg-Nilsson, Karin] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, Box 256, S-75185 Uppsala, Sweden; [Lei, Ying; Enoksson, Mattias; Fuchs, Barbara; Nilsson, Gunnar] Karolinska Inst, Immunol & Allergy Unit, Dept Med, Stockholm, Sweden; [Lei, Ying; Enoksson, Mattias; Fuchs, Barbara; Nilsson, Gunnar] Karolinska Univ Hosp, Stockholm, Sweden; [Abu Hamdeh, Sami; Marklund, Niklas; Hillered, Lars] Uppsala Univ, Dept Neurosci, Neurosurg, Uppsala, Sweden; [Li, Xiaofei] Karolinska Inst, Dept Neurosci, Stockholm, Sweden	Wicher, G (corresponding author), Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, Box 256, S-75185 Uppsala, Sweden.	Grzegorz.Wicher@igp.uu.se	Forsberg-Nilsson, Karin/D-9604-2019	Forsberg-Nilsson, Karin/0000-0003-0692-6245; Marklund, Niklas/0000-0002-9797-5626	Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study was supported by grants from the Swedish Research Council.	Akimoto N, 2013, BIOCHEM BIOPH RES CO, V436, P455, DOI 10.1016/j.bbrc.2013.05.126; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen H, 2015, NEUROSCIENCE, V308, P157, DOI 10.1016/j.neuroscience.2015.09.019; Christophi GP, 2012, CLIN IMMUNOL, V142, P308, DOI 10.1016/j.clim.2011.11.007; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Espinassous Q, 2009, J IMMUNOL, V183, P1446, DOI 10.4049/jimmunol.0803067; Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hudson CA, 2008, J LEUKOCYTE BIOL, V84, P631, DOI 10.1189/jlb.1207830; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947; Jovanovic IP, 2012, ONCOIMMUNOLOGY, V1, P229, DOI 10.4161/onci.1.2.18131; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Murphy CA, 2002, J IMMUNOL, V169, P7054, DOI 10.4049/jimmunol.169.12.7054; Pomeshchik Y, 2015, BRAIN BEHAV IMMUN, V44, P68, DOI 10.1016/j.bbi.2014.08.002; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Wicher G, 2013, NEUROSCI LETT, V555, P171, DOI 10.1016/j.neulet.2013.09.046; Yasuoka S, 2011, BRAIN RES, V1385, P8, DOI 10.1016/j.brainres.2011.02.045	35	17	17	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3173	3182		10.1089/neu.2016.4900			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000013	28490277				2021-06-18	
J	Kingery, KM; Narad, ME; Taylor, HG; Yeates, KO; Stancin, T; Wade, SL				Kingery, Kathleen M.; Narad, Megan E.; Taylor, H. Gerry; Yeates, Keith Owen; Stancin, Terry; Wade, Shari L.			Do Children Who Sustain Traumatic Brain Injury in Early Childhood Need and Receive Academic Services 7 Years After Injury?	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						pediatric TBI; academic service; service utilization	TERM BEHAVIOR PROBLEMS; LONG-TERM; YOUNG-CHILDREN; EXECUTIVE FUNCTION; OUTCOMES; ADOLESCENTS; ADHD; ACHIEVEMENT; PREDICTORS; RECOVERY	Objective: To examine the prevalence of academic need, academic service utilization, and unmet need as well as factors associated with academic service utilization 6.8 years after traumatic brain injury (TBI) in early childhood. Methods: Fifty-eight (16 severe, 14 moderate, 28 complicated mild) children with TBI and 72 children with orthopedic injury (OI) completed the long-term follow-up 6.8 years after injury in early childhood (ages 3-7 years). Injury group differences in rates of need for academic services, academic service utilization, and unmet need as well as factors associated with service utilization and unmet need were examined. Results: Students with moderate and severe TBI had significantly greater rates of need than those with OI. A greater proportion of the severe TBI sample was receiving academic services at long-term follow-up than the OI and complicated mild groups however, among those with an identified need, injury group did not affect academic service utilization. Below average IQ/achievement scores was the only area of need predictive of academic service utilization. Rates of unmet need were high and similar across injury groups (46.2%-63.6%). Conclusion: The need for academic services among patients who sustained a TBI during early childhood remains high 6.8 years post injury. Findings underscore the importance of continued monitoring of behaviors and academic performance in students with a history of early childhood TBI. This may be especially true among children with less severe injuries who are at risk for being underserved.	[Kingery, Kathleen M.; Narad, Megan E.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 3015, Cincinnati, OH 45229 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp Res Inst, Hotchkiss Brain Inst, Dept Psychol, Calgary, AB, Canada; [Stancin, Terry] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA	Narad, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 3015, Cincinnati, OH 45229 USA.	megan.narad@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729 K02 HD44099]; United States Public Health Service National Institutes of HealthUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [8 UL1 TR000077-04, K12 HD001097-16]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097, R01HD042729, F32HD088011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	This project was supported by the National Institute of Child Health and Human Development (R01 HD42729 K02 HD44099), United States Public Health Service National Institutes of Health (M01 RR 08084), State of Ohio Emergency Medical Services trauma research grants, National Center for Research Resources and the National Center for Advancing Translational Sciences, and National Institutes of Health (8 UL1 TR000077-04 and K12 HD001097-16).	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Aldrich EM, 2012, CAN J SCH PSYCHOL, V27, P291, DOI 10.1177/0829573512455016; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bussing R, 2003, SOC PSYCH PSYCH EPID, V38, P563, DOI 10.1007/s00127-003-0674-8; Bussing R, 2003, J BEHAV HEALTH SER R, V30, P176, DOI 10.1007/BF02289806; Bussing R, 2001, HARVARD REV PSYCHIAT, V9, P223, DOI 10.1093/hrp/9.5.223; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; Glang A, 2008, NEUROREHABILITATION, V23, P477; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jensen PS, 2011, PEDIATRICS, V128, P970, DOI 10.1542/peds.2009-0367; Karver CL, 2014, ARCH PHYS MED REHAB, V95, P1556, DOI 10.1016/j.apmr.2014.03.030; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Papoutsis J, 2014, DEV NEUROPSYCHOL, V39, P638, DOI 10.1080/87565641.2014.979926; Prasad MR, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000218; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Scott MN, 2012, J DEV BEHAV PEDIATR, V33, P202, DOI 10.1097/DBP.0b013e3182475287; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wechsler D., 1999, WESCHLER ABBREVIATED; Wolraich ML, 2004, J DEV BEHAV PEDIATR, V25, P41, DOI 10.1097/00004703-200402000-00007; Woodcock RW, 2001, TECHNICAL MANUAL WOO; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	56	17	17	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	NOV-DEC	2017	38	9					728	735					8	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	FS5AX	WOS:000419806500007	28953005	Green Accepted			2021-06-18	
J	Gill, J; Cashion, A; Osier, N; Arcurio, L; Motamedi, V; Dell, KC; Carr, W; Kim, HS; Yun, SJ; Walker, P; Ahlers, S; LoPresti, M; Yarnell, A				Gill, Jessica; Cashion, Ann; Osier, Nicole; Arcurio, Lindsay; Motamedi, Vida; Dell, Kristine C.; Carr, Walter; Kim, Hyung-Suk; Yun, Sijung; Walker, Peter; Ahlers, Stephen; LoPresti, Matthew; Yarnell, Angela			Moderate blast exposure alters gene expression and levels of amyloid precursor protein	NEUROLOGY-GENETICS			English	Article							TRAUMATIC BRAIN-INJURY; AXONAL INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNA; NEUROPROTECTION; MARKER; MODEL	Objective: To explore gene expression after moderate blast exposure (vs baseline) and proteomic changes after moderate- (vs low-) blast exposure.& para;& para;Methods: Military personnel (N = 69) donated blood for quantification of protein level, and peak pressure exposures were detected by helmet sensors before and during a blast training program (10 days total). On day 7, some participants (n = 29) sustained a moderate blast (mean peak pressure = 7.9 psi) and were matched to participants with no/low-blast exposure during the training (n = 40). PAXgene tubes were collected from one training site at baseline and day 10; RNA-sequencing day 10 expression was compared with each participant's own baseline samples to identify genes and pathways differentially expressed in moderate blast-exposed participants. Changes in amyloid precursor protein (APP) from baseline to the day of blast and following 2 days were evaluated. Symptoms were assessed using a self-reported form.& para;& para;Results: We identified 1,803 differentially expressed genes after moderate blast exposure; the most altered network was APP. Significantly reduced levels of peripheral APP were detected the day after the moderate blast exposure and the following day. Protein concentrations correlated with the magnitude of the moderate blast exposure on days 8 and 9. APP concentrations returned to baseline levels 3 days following the blast, likely due to increases in the genetic expression of APP. Onset of concentration problems and headaches occurred after moderate blast.& para;& para;Conclusions: Moderate blast exposure results in a signature biological profile that includes acute APP reductions, followed by genetic expression increases and normalization of APP levels; these changes likely influence neuronal recovery.	[Gill, Jessica] Uniformed Serv Univ Hlth Sci, Intramural Res Program, CNRM Co Director Biomarkers Core, Bethesda, MD 20814 USA; [Cashion, Ann; Osier, Nicole; Arcurio, Lindsay; Motamedi, Vida; Kim, Hyung-Suk; Yun, Sijung] NINR, NIH, Bethesda, MD 20892 USA; [Dell, Kristine C.; LoPresti, Matthew; Yarnell, Angela] Walter Reed Army Inst Res, Silver Spring, MD USA; [Carr, Walter] Army Med Res & Mat Command, Ft Detrick, MD USA; [Walker, Peter; Ahlers, Stephen] Naval Med Res Ctr, Silver Spring, MD USA	Gill, J (corresponding author), Uniformed Serv Univ Hlth Sci, Intramural Res Program, CNRM Co Director Biomarkers Core, Bethesda, MD 20814 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017; Osier, Nicole/Q-7913-2017	Osier, Nicole/0000-0002-2903-6774	U.S. Navy Bureau of Medicine and Surgery [WUN 603115HP.2380.001.A1304]; National Institutes of Health, Intramural Department of ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000030, ZIANR000015] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health, Intramural Department of Research, and the U.S. Army Medical Research and Materiel Command and the U.S. Navy Bureau of Medicine and Surgery (WUN 603115HP.2380.001.A1304).	Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Carr W, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00049; Cartagena CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158576; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; del Mar N, 2015, EXP NEUROL, V271, P53, DOI 10.1016/j.expneurol.2015.04.023; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Jiang SD, 2003, AM J MED GENET B, V118B, P99, DOI 10.1002/ajmg.b.10067; Kallakuri S, 2015, J NEUROSCI RURAL PRA, V6, P481, DOI 10.4103/0976-3147.169767; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Livingston WS, 2017, J NEUROTRAUM, V34, P853, DOI 10.1089/neu.2016.4479; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Niederwolfsgruber E, 1998, J GERONTOL A-BIOL, V53, pB186, DOI 10.1093/gerona/53A.3.B186; Padovani A, 2001, NEUROLOGY, V57, P2243, DOI 10.1212/WNL.57.12.2243; Perez-Barcena J, 2008, EUR J ANAESTH, V25, P4; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plummer S, 2016, AGING DIS, V7, P163, DOI 10.14336/AD.2015.0907; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Shi C, 2014, J STEROID BIOCHEM, V144, P280, DOI 10.1016/j.jsbmb.2014.06.010; SMALL DH, 1994, J NEUROSCI, V14, P2117; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thelin EP, BEHAV BRAIN RES; Van den Heuvel C, 2000, J CLIN NEUROSCI, V7, P140; Verma SK, 2015, NMR BIOMED, V28, P1069, DOI 10.1002/nbm.3351; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	28	17	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2376-7839			NEUROL-GENET	Neurol.-Genet.	OCT	2017	3	5							e186	10.1212/NXG.0000000000000186			9	Genetics & Heredity; Clinical Neurology	Genetics & Heredity; Neurosciences & Neurology	FW1BY	WOS:000425031500010	28975156	DOAJ Gold, Green Published			2021-06-18	
J	Jiang, ZX; Zhang, JN; Cai, YH; Huang, JX; You, LT				Jiang, Zhixian; Zhang, Jinning; Cai, Yonghui; Huang, Jiaxin; You, Lingtong			Catechin attenuates traumatic brain injury-induced blood-brain barrier damage and improves longer-term neurological outcomes in rats	EXPERIMENTAL PHYSIOLOGY			English	Article						blood-brain barrier; catechin; inflammation; neuroprotection; traumatic brain injury	GREEN TEA CATECHINS; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; TIGHT JUNCTION; PROTECTS; INTEGRITY; OCCLUDIN	Traumatic brain injury (TBI) resulting from external force on the head usually leads to long-term deficits in motor and cognitive functions. Catechin has shown neuroprotective effects in neurodegenerative diseases and ischaemia models. We therefore investigated the potential neuroprotective effects of catechin after TBI and explored the underlying mechanisms. Male rats were subjected to controlled cortical impact injury and then treated with catechin. Brain damage, motor and cognitive functions, blood-brain barrier (BBB) integrity and neuro-inflammation were examined. Catechin treatment ameliorated brain damage and motor and cognitive deficits after TBI. Catechin was shown to protect BBB integrity, alleviate the TBI-induced loss of the junction proteins occludin and zonula occludens protein-1 and suppress local inflammatory reactions. Catechin treatment had neuroprotective effects in a rat model of TBI, and these effects might be mediated by intervention in the self-perpetuating process of BBB disruption and excessive inflammatory reaction.	[Jiang, Zhixian; Zhang, Jinning; Cai, Yonghui; Huang, Jiaxin; You, Lingtong] Fujian Med Univ, Quanzhou Hosp 1, Chendong Area, Inpatient Dept, 10th Floor Dist N13, Quanzhou 362000, Peoples R China	Zhang, JN (corresponding author), Fujian Med Univ, Quanzhou Hosp 1, Chendong Area, Inpatient Dept, 10th Floor Dist N13, Quanzhou 362000, Peoples R China.	zjn00131@sina.com					Abd El-Aziz TA, 2012, CLIN EXP MED, V12, P233, DOI 10.1007/s10238-011-0165-2; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Ashafaq M, 2012, NEUROCHEM RES, V37, P1747, DOI 10.1007/s11064-012-0786-1; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Haque AM, 2008, J NUTR BIOCHEM, V19, P619, DOI 10.1016/j.jnutbio.2007.08.008; Hirao K, 2010, LIFE SCI, V86, P654, DOI 10.1016/j.lfs.2010.02.017; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Kago T, 2006, BIOCHEM BIOPH RES CO, V339, P1197, DOI 10.1016/j.bbrc.2005.11.133; Li Q, 2009, NEUROSCIENCE, V163, P741, DOI 10.1016/j.neuroscience.2009.07.014; Liu WY, 2012, CNS NEUROSCI THER, V18, P609, DOI 10.1111/j.1755-5949.2012.00340.x; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mandel SA, 2005, NEUROSIGNALS, V14, P46, DOI 10.1159/000085385; Mandel SA, 2008, CNS NEUROSCI THER, V14, P352, DOI 10.1111/j.1755-5949.2008.00060.x; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Uzun FG, 2013, FOOD CHEM TOXICOL, V55, P549, DOI 10.1016/j.fct.2013.01.056; Wang YL, 2014, J NEUROCHEM, V129, P827, DOI 10.1111/jnc.12695; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010	25	17	17	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0670	1469-445X		EXP PHYSIOL	Exp. Physiol.	OCT 1	2017	102	10					1269	1277		10.1113/EP086520			9	Physiology	Physiology	FI5ZM	WOS:000412067400003	28678393	Bronze			2021-06-18	
J	Jin, X; Feng, ZY; Mika, V; Li, HY; Viano, DC; Yang, KH				Jin, Xin; Feng, Zhaoying; Mika, Valerie; Li, Haiyan; Viano, David C.; Yang, King H.			The Role of Neck Muscle Activities on the Risk of Mild Traumatic Brain Injury in American Football	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						active muscle response; concussion; neck strength; finite element method	SEGMENT DYNAMIC STABILIZATION; PROFESSIONAL FOOTBALL; HEAD; CONCUSSION; ACCELERATION; BIOMECHANICS; STRENGTH; PLAYERS	Concussion, or mild traumatic brain injury (mTBI), is frequently associated with sports activities. It has generally been accepted that neck strengthening exercises are effective as a preventive strategy for reducing sports-related concussion risks. However, the interpretation of the link between neck strength and concussion risks remains unclear. In this study, a typical helmeted head-to-head impact in American football was simulated using the head and neck complex finite element (FE) model. The impact scenario selected was previously reported in lab-controlled incident reconstructions from high-speed video footages of the National Football League using two head-neck complexes taken from Hybrid III dummies. Four different muscle activation strategies were designed to represent no muscle response, a reactive muscle response, a pre-activation response, and response due to stronger muscle strength. Head kinematics and various head/brain injury risk predictors were selected as response variables to compare the effects of neck muscles on the risk of sustaining the concussion. Simulation results indicated that active responses of neck muscles could effectively reduce the risk of brain injury. Also, anticipatory muscle activation played a dominant role on impact outcomes. Increased neck strength can decrease the time to compress the neck and its effects on reducing brain injury risks need to be further studied.	[Jin, Xin; Feng, Zhaoying; Mika, Valerie; Li, Haiyan; Viano, David C.; Yang, King H.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Li, Haiyan] Tianjin Univ Sci & Technol, Coll Mech Engn, Tianjin 300222, Peoples R China; [Viano, David C.] Probiomech LLC, Bloomfield Hills, MI 48304 USA	Jin, X (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA.		Mika, Valerie H./AAO-2816-2020		Bioengineering Center, Wayne State University	This study was funded in part by the Bioengineering Center, Wayne State University. The authors also like to show our great appreciation to the Global Human Body Modeling Consortium for providing the whole body model for use in the current study.	Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Conley MS, 1997, J APPL PHYSIOL, V83, P2105; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Delaney T., 2015, SOCIOLOGY SPORTS INT; Faul M., 2010, CTR DIS CONTR PREV; Fice J. B., 2010, THESIS; Fung Y., 1993, BIOMECHANICS MECH PR; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Holbourn AHS, 1943, LANCET, V2, P438; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Salmon DM, 2011, AVIAT SPACE ENVIR MD, V82, P978, DOI 10.3357/ASEM.2841.2011; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; van der Horst M, 1997, 973346 SAE; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang L., 2003, IRCOBI C LISB PORT S, P27	24	17	17	1	23	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	OCT	2017	139	10							101002	10.1115/1.4037399			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	FK3OU	WOS:000413396200002	28753688				2021-06-18	
J	Kochanek, PM; Wallisch, JS; Bayir, H; Clark, RSB				Kochanek, Patrick M.; Wallisch, Jessica S.; Bayir, Hulya; Clark, Robert S. B.			Pre-clinical models in pediatric traumatic brain injury-challenges and lessons learned	CHILDS NERVOUS SYSTEM			English	Article						Head trauma; Developmental; Immature; Abusive head trauma; Shaken baby syndrome	CONTROLLED CORTICAL IMPACT; SHAKEN BABY SYNDROME; CLOSED-HEAD INJURY; WHITE-MATTER INJURY; INFANT RAT MODEL; AXONAL INJURY; IMMATURE RATS; CALPAIN ACTIVATION; NEONATAL PIG; CHILDREN	Despite the enormity of the problem and the lack of new therapies, research in the pre-clinical arena specifically using pediatric traumatic brain injury (TBI) models is limited. In this review, some of the key models addressing both the age spectrum of pediatric TBI and its unique injury mechanisms will be highlighted. Four topics will be addressed, namely, (1) unique facets of the developing brain important to TBI model development, (2) a description of some of the most commonly used pre-clinical models of severe pediatric TBI including work in both rodents and large animals, (3) a description of the pediatric models of mild TBI and repetitive mild TBI that are relatively new, and finally (4) a discussion of challenges, gaps, and potential future directions to further advance work in pediatric TBI models. This narrative review on the topic of pediatric TBI models was based on review of PUBMED/Medline along with a synthesis of information on key factors in pre-clinical and clinical developmental brain injury that influence TBI modeling. In the contemporary literature, six types of models have been used in rats including weight drop, fluid percussion injury (FPI), impact acceleration, controlled cortical impact (CCI), mechanical shaking, and closed head modifications of CCI. In mice, studies are largely restricted to CCI. In large animals, FPI and rotational injury have been used in piglets and shake injury has also been used in lambs. Most of the studies have been in severe injury models, although more recently, studies have begun to explore mild and repetitive mild injuries to study concussion. Given the emerging importance of TBI in infants and children, the morbidity and mortality that is produced, along with its purported link to the development of chronic neurodegenerative diseases, studies in these models merit greater systematic investigations along with consortium-type approaches and long-term follow-up to translate new therapies to the bedside.	[Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Crit Care Med,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Anesthesiol,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Pediat,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Bioengn,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Clin & Translat Sci,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Wallisch, Jessica S.; Bayir, Hulya; Clark, Robert S. B.] UPMC, Safar Ctr Resuscitat Res, Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Wallisch, Jessica S.; Bayir, Hulya; Clark, Robert S. B.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, 3550 Terrace St,Scaife Hall, Pittsburgh, PA 15261 USA; [Bayir, Hulya; Clark, Robert S. B.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, UPMC,Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Bayir, Hulya] Univ Pittsburgh, Pittsburgh Ctr Free Rad & Antioxidant Hlth, Sch Med, 100 Technol Dr, Pittsburgh, PA 15219 USA	Kochanek, PM (corresponding author), UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Crit Care Med,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kochanek, PM (corresponding author), UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Anesthesiol,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kochanek, PM (corresponding author), UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Pediat,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kochanek, PM (corresponding author), UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Bioengn,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kochanek, PM (corresponding author), UPMC, Childrens Hosp Pittsburgh, John G Rangos Res Ctr, Dept Clin & Translat Sci,Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	kochanekpm@ccm.upmc.edu; jessica.wallisch@chp.edu; bayihx@ccm.upmc.edu; clarkrs@ccm.upmc.edu		Wallisch, Jessica/0000-0002-7908-9479	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	We thank NICHD T32 HD040686 for the support (JW).	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson RWG, 2014, J BIOMECH, V47, P2578, DOI 10.1016/j.jbiomech.2014.06.002; Armstead WM, 2016, PEDIATR CRIT CARE ME, V17, pe130, DOI 10.1097/PCC.0000000000000603; Armstead WM, 2013, PEDIATR CRIT CARE ME, V14, pE103, DOI 10.1097/PCC.0b013e3182712b44; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; Curvello V, 2017, PEDIATR RES, V82, P108, DOI 10.1038/pr.2017.83; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutschke JK, 2017, APPL IMMUNOHISTO M M, V25, P277, DOI 10.1097/PAI.0000000000000273; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferguson NM, 2017, CRIT CARE MED, V45, P1398, DOI 10.1097/CCM.0000000000002378; Fidan E, 2016, J NEUROTRAUM, V33, P641, DOI 10.1089/neu.2015.3958; Finnie JW, 2012, J CLIN NEUROSCI, V19, P1159, DOI 10.1016/j.jocn.2011.12.019; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hanlon LA, 2017, EXP NEUROL, V290, P1, DOI 10.1016/j.expneurol.2016.12.010; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hays SR, 2011, CURR NEUROL NEUROSCI, V11, P205, DOI 10.1007/s11910-010-0177-4; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jenkins LW, 2016, ROGERS TXB PEDIAT IN, P861; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Kochanek P.M., 2011, YOUMANS NEUROLOGICAL, P3300; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; Sandoz B, 2012, Comput Methods Biomech Biomed Engin, V15 Suppl 1, P293; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Smith SL, 1998, J NEUROTRAUM, V15, P707, DOI 10.1089/neu.1998.15.707; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Young C, 2005, NEUROBIOL DIS, V20, P608, DOI 10.1016/j.nbd.2005.04.014; Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814; Zou XJ, 2011, NEUROTOXICOL TERATOL, V33, P592, DOI 10.1016/j.ntt.2011.06.003	75	17	17	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2017	33	10					1693	1701		10.1007/s00381-017-3474-2			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	FG1LZ	WOS:000409558900012	29149385	Green Accepted			2021-06-18	
J	Qian, HH; Li, QH; Shi, WD				Qian, Huihui; Li, Qinghe; Shi, Woda			Hyperbaric oxygen alleviates the activation of NLRP-3-inflammasomes in traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury hyperbaric oxygen therapy; NLRP-3 inflammasome; microglia	NLRP3 INFLAMMASOME; THERAPY; NEUROPROTECTION; MECHANISMS; EXPRESSION; NEURONS; SYSTEM; FLUID; IL-18	Growing evidence has demonstrated that the nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP-3) inflammasome-mediated inflammatory pathways have been involved in the secondary injury of traumatic brain injury (TBI). In the present study, the authors investigated the effects of hyperbaric oxygen (HBO) therapy on the NLRP-3 inflammasome pathway following TBI. Following the evaluation of motor deficits and brain edema, the therapeutic effects of HBO on interleukin (IL)-1 beta and IL-18 expression were assessed, as well as NLRP-3 inflammasome activation following TBI. HBO may improve motor score and reduce brain edema, accompanied with the reduction of IL-1 beta and IL-18 during the 7-day observation period. Furthermore, HBO suppressed mRNA and protein expression of NLRP-3-inflammasome components, especially reducing NLRP-3 expression in microglia. Thus, these results suggested that HBO alleviates the inflammatory response in experimental TBI via modulating microglial NLRP-3-inflammasome signaling.	[Qian, Huihui] Southeast Univ, Med Coll, Affiliated Yancheng Hosp, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China; [Li, Qinghe] Southeast Univ, Med Coll, Affiliated Yancheng Hosp, Dept Nursing, Yancheng 224001, Jiangsu, Peoples R China; [Shi, Woda] Southeast Univ, Med Coll, Affiliated Yancheng Hosp, Dept Cardiothorac Surg, 2 West XIndu Rd, Yancheng 224001, Jiangsu, Peoples R China	Shi, WD (corresponding author), Southeast Univ, Med Coll, Affiliated Yancheng Hosp, Dept Cardiothorac Surg, 2 West XIndu Rd, Yancheng 224001, Jiangsu, Peoples R China.	yc3hpucheetah@aliyun.com					Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Camporesi EM, 2014, UNDERSEA HYPERBAR M, V41, P247; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Ciaramella A, 2014, NEUROIMMUNOMODULAT, V21, P8, DOI 10.1159/000354764; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; Figueroa XA, 2015, UNDERSEA HYPERBAR M, V42, P333; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maier NK, 2014, J IMMUNOL, V192, P763, DOI 10.4049/jimmunol.1301434; Matsunami T, 2011, INT J CLIN EXP PATHO, V4, P255; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Ralay R. H., 2011, J NEUROTRAUM, V28, P1757, DOI DOI 10.1089/NEU.2011.1799; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2016, TRANSL RES, V167, P35, DOI 10.1016/j.trsl.2015.05.003; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang Y, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-18; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002	28	17	19	0	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	OCT	2017	16	4					3922	3928		10.3892/mmr.2017.7079			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	FG9JA	WOS:000410753800028	29067455	Other Gold, Green Published			2021-06-18	
J	Tajiri, N; Quach, DM; Kaneko, Y; Wu, S; Lee, D; Lam, T; Hayama, KL; Hazel, TG; Johe, K; Wu, MC; Borlongan, CV				Tajiri, Naoki; Quach, David M.; Kaneko, Yuji; Wu, Stephanie; Lee, David; Lam, Tina; Hayama, Ken L.; Hazel, Thomas G.; Johe, Karl; Wu, Michael C.; Borlongan, Cesar V.			NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article						behavioral recovery; cerebral ischemia; neurite outgrowth; neurogenesis; pharmacotherapy; trophic factors	NEURAL STEM-CELLS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTORS; PRECURSOR CELLS; RECOVERY; NEUROPROTECTION; NEURONS; MODEL	Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI-189, an orally active, new molecular entity (mol. wt. 366) with enhanced neurogenic activity, and indicated as an anti-depressant drug in a clinical trial (Fava et al., 2015, Molecular Psychiatry, DOI: 10.1038/mp. 2015.178) and being tested in a Phase 2 efficacy trial (ClinicalTrials. gov, 2016, ClinicalTrials. gov Identifier: NCT02695472) for treatment of major depression. Oral administration of NSI-189 in adult Sprague-Dawley rats starting at 6 hr after middle cerebral artery occlusion, and daily thereafter over the next 12 weeks resulted in significant amelioration of stroke-induced motor and neurological deficits, which was maintained up to 24 weeks post-stroke. Histopathological assessment of stroke brains from NSI-189-treated animals revealed significant increments in neurite outgrowth as evidencedbyMAP2immunoreactivity that was prominently detected in the hippocampus and partially in the cortex. These results suggest NSI-189 actively stimulated remodeling of the stroke brain. Parallel in vitro studies further probed this remodeling process and demonstrated that oxygen glucose deprivation and reperfusion (OGD/R) initiated typical cell death processes, which were reversed by NSI-189 treatment characterized by significant attenuation of OGD/R-mediated hippocampal cell death and increased Ki67 and MAP2 expression, coupled with upregulation of neurogenic factors such as BDNF and SCF. These findings support the use of oral NSI-189 as a therapeutic agent well beyond the initial 6-hr time window to accelerate and enhance the overall functional improvement in the initial6months post stroke.	[Tajiri, Naoki; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL USA; [Quach, David M.; Wu, Stephanie; Lee, David; Lam, Tina; Hayama, Ken L.; Hazel, Thomas G.; Johe, Karl] Neuralstem Inc, Rockville, MD USA; [Wu, Michael C.] Neurodigitech LLC, San Diego, CA USA	Borlongan, CV (corresponding author), Univ S Florida, Res Dept Neurosurg & Brain Repair, Morsani Coll Med, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Wu, Michael/AAP-2829-2021		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956, 1R01NS090962, 1R21NS089851]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; James and Esther King Foundation for Biomedical Research Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS094087, R01NS071956, R21NS089851] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Neurological Disorders and Stroke, Grant numbers: 1R01NS071956, 1R01NS090962, 1R21NS089851; Department of Defense, Grant number: W81XWH-11-1-0634; James and Esther King Foundation for Biomedical Research Program	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005; Brill MS, 2009, NAT NEUROSCI, V12, P1524, DOI 10.1038/nn.2416; Chapman KZ, 2015, NEUROBIOL DIS, V83, P1, DOI 10.1016/j.nbd.2015.08.013; dela Pena I, 2015, TRANSL STROKE RES, V6, P421, DOI 10.1007/s12975-015-0430-x; Doeppner TR, 2009, NEUROBIOL DIS, V34, P87, DOI 10.1016/j.nbd.2008.12.013; Esposito E, 2015, STROKE, V46, P2691, DOI 10.1161/STROKEAHA.115.009070; Fava M, 2016, MOL PSYCHIATR, V21, P1372, DOI 10.1038/mp.2015.178; Hara K, 2007, J NEUROSCI RES, V85, P1240, DOI 10.1002/jnr.21234; Hermann DM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00291; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Hess David C, 2008, Expert Rev Neurother, V8, P1193, DOI 10.1586/14737175.8.8.1193; Hu X, 2013, CURR MOL MED, V13, P1465; Jablonska A, 2016, MOL NEUROBIOL, V53, P6413, DOI 10.1007/s12035-015-9530-6; Kaneko Y, 2012, INT J MOL SCI, V13, P7424, DOI 10.3390/ijms13067424; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kokaia Z, 2011, TRANSL STROKE RES, V2, P272, DOI 10.1007/s12975-011-0100-6; Kreuzberg M, 2010, EXP NEUROL, V226, P90, DOI 10.1016/j.expneurol.2010.08.006; Kuge A, 2009, NEUROL RES, V31, P969, DOI 10.1179/174313209X383312; Li Y, 2010, TRANSL STROKE RES, V1, P184, DOI 10.1007/s12975-010-0016-6; Lindvall O, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019034; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Matsukawa N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-126; Morimoto T, 2011, CELL TRANSPLANT, V20, P1049, DOI 10.3727/096368910X544915; Osman AM, 2011, STROKE, V42, P3559, DOI 10.1161/STROKEAHA.111.627802; Peron S, 2015, CURR OPIN GENET DEV, V34, P46, DOI 10.1016/j.gde.2015.07.004; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rosell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073244; Seo JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103174; Sieber-Blum M, 1998, BIOCHEM CELL BIOL, V76, P1039, DOI 10.1139/bcb-76-6-1039; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Sun XY, 2016, J MOL NEUROSCI, V58, P233, DOI 10.1007/s12031-015-0662-y; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tajiri N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043779; Venna VR, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.128; Wang LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087284; Watson N, 2015, CELL TRANSPLANT, V24, P591, DOI 10.3727/096368915X687723; Xia CF, 2006, HUM GENE THER, V17, P206, DOI 10.1089/hum.2006.17.206; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Zhang WT, 2015, EXP NEUROL, V272, P170, DOI 10.1016/j.expneurol.2015.03.005; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhang ZG, 2015, TRENDS MOL MED, V21, P543, DOI 10.1016/j.molmed.2015.07.005	47	17	18	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	OCT	2017	232	10					2731	2740		10.1002/jcp.25847			10	Cell Biology; Physiology	Cell Biology; Physiology	FC7KK	WOS:000407019900015	28181668	Green Published, Other Gold			2021-06-18	
J	Mulherkar, S; Firozi, K; Huang, W; Uddin, MD; Grill, RJ; Costa-Mattioli, M; Robertson, C; Tolias, KF				Mulherkar, Shalaka; Firozi, Karen; Huang, Wei; Uddin, Mohammad Danish; Grill, Raymond J.; Costa-Mattioli, Mauro; Robertson, Claudia; Tolias, Kimberley F.			RhoA-ROCK Inhibition Reverses Synaptic Remodeling and Motor and Cognitive Deficits Caused by Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; KINASE INHIBITOR; DENDRITIC SPINES; DORSAL HIPPOCAMPUS; CEREBRAL VASOSPASM; CONDITIONED FEAR; FASUDIL PROTECTS; RANDOMIZED-TRIAL; FAMILY GTPASES; MILD	Traumatic brain injury (TBI) causes extensive neural damage, often resulting in long-term cognitive impairments. Unfortunately, effective treatments for TBI remain elusive. The RhoA-ROCK signaling pathway is a potential therapeutic target since it is activated by TBI and can promote the retraction of dendritic spines/synapses, which are critical for information processing and memory storage. To test this hypothesis, RhoA-ROCK signaling was blocked by RhoA deletion from postnatal neurons or treatment with the ROCK inhibitor fasudil. We found that TBI impairs both motor and cognitive performance and inhibiting RhoA-ROCK signaling alleviates these deficits. Moreover, RhoA-ROCK inhibition prevents TBI-induced spine remodeling and mature spine loss. These data argue that TBI elicits pathological spine remodeling that contributes to behavioral deficits by altering synaptic connections, and RhoA-ROCK inhibition enhances functional recovery by blocking this detrimental effect. As fasudil has been safely used in humans, our results suggest that it could be repurposed to treat TBI.	[Mulherkar, Shalaka; Firozi, Karen; Huang, Wei; Uddin, Mohammad Danish; Costa-Mattioli, Mauro; Tolias, Kimberley F.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA; [Grill, Raymond J.] Univ Texas Houston, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Robertson, Claudia] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Tolias, Kimberley F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Huang, Wei] Johns Hopkins Univ, Sch Med, Solomon Snyder Dept Neurosci, 733N Broadway, Baltimore, MD 21205 USA; [Grill, Raymond J.] Univ Mississippi, Med Ctr, Dept Neurobiol & Anat Sci, Jackson, MS 39216 USA	Tolias, KF (corresponding author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; Tolias, KF (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	tolias@bcm.edu		Tolias, Kimberley/0000-0002-2092-920X	DoDUnited States Department of Defense [W81XWH0820148]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS062829, 1S10 OD016167, 1U54 HD083092, 5P30HD 024064]; Mission Connect-TIRR Foundation; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [096816]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [076708]; Department of DefenseUnited States Department of Defense [AR120254]; Angelman Syndrome Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024064, U54HD083092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062829] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016167] Funding Source: NIH RePORTER	This work was supported by grants from the DoD (W81XWH0820148), the NIH (R01NS062829), and the Mission Connect-TIRR Foundation (K.F.T.) and NIMH (096816), NINDS (076708) and the Department of Defense (AR120254) to M.C.-M. S.M. is supported by an Angelman Syndrome Foundation Postdoctoral fellowship. We received technical assistance from the BCM RNA In Situ Hybridization Core (funded by NIH grants 1S10 OD016167 and 1U54 HD083092), the BCM Pathology Core (funded by NIH grant 5P30HD 024064), and the Neurobehavioral Core (NICHD, U54HD083092). We thank F. Liu and Cheng-lin (Vivian) Shaw for technical help and S. Gaddam and S. Pillai for guidance with surgeries.	Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Antoniadis EA, 2000, BEHAV BRAIN RES, V108, P1, DOI 10.1016/S0166-4328(99)00121-7; Auer M, 2011, ANN ANAT, V193, P259, DOI 10.1016/j.aanat.2011.02.015; Avalos AM, 2004, J BIOL CHEM, V279, P39139, DOI 10.1074/jbc.M403439200; Barcia C, 2012, SCI REP-UK, V2, DOI 10.1038/srep00809; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bye N, 2016, EXP NEUROL, V279, P86, DOI 10.1016/j.expneurol.2016.02.012; Cappello S, 2012, NEURON, V73, P911, DOI 10.1016/j.neuron.2011.12.030; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Ding J, 2010, J NEUROCHEM, V114, P1619, DOI 10.1111/j.1471-4159.2010.06876.x; Ding J, 2009, BRAIN BEHAV IMMUN, V23, P1083, DOI 10.1016/j.bbi.2009.05.002; Dragatsis I, 2000, GENESIS, V26, P133, DOI 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Duman JG, 2015, NEUROSCI LETT, V601, P4, DOI 10.1016/j.neulet.2015.05.034; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Forgione N, 2014, WORLD NEUROSURG, V82, pE535, DOI 10.1016/j.wneu.2013.01.009; Fortin DA, 2012, NEUROSCIENTIST, V18, P326, DOI 10.1177/1073858411407206; Fournier AE, 2003, J NEUROSCI, V23, P1416; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Glenn DE, 2017, DEPRESS ANXIETY, V34, P723, DOI 10.1002/da.22642; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harris KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005587; Higley MJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005686; Holtje M, 2005, J NEUROCHEM, V95, P1237, DOI 10.1111/j.1471-4159.2005.03443.x; Huang W, 2013, NAT NEUROSCI, V16, P441, DOI 10.1038/nn.3351; Huentelman MJ, 2009, BEHAV NEUROSCI, V123, P218, DOI 10.1037/a0014260; Ibrahim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21793; Kaczkurkin AN, 2017, AM J PSYCHIAT, V174, P125, DOI 10.1176/appi.ajp.2016.15121549; Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lai KO, 2013, BBA-MOL BASIS DIS, V1832, P2257, DOI 10.1016/j.bbadis.2013.08.012; Lau CL, 2012, J CELL PHYSIOL, V227, P1199, DOI 10.1002/jcp.22838; Li Z, 2000, NAT NEUROSCI, V3, P217; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Maren S, 1997, NEUROBIOL LEARN MEM, V67, P142, DOI 10.1006/nlme.1996.3752; Maren S, 2013, NAT REV NEUROSCI, V14, P417, DOI 10.1038/nrn3492; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Mulherkar S, 2014, DEV BIOL, V394, P39, DOI 10.1016/j.ydbio.2014.08.004; Mulherkar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067015; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; O'Shea RD, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00050; Paterno R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0762-x; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Penzes P, 2011, NAT NEUROSCI, V14, P285, DOI 10.1038/nn.2741; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Sabirzhanova I, 2013, J NEUROTRAUM, V30, P1449, DOI 10.1089/neu.2012.2673; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Seal KH, 2016, J REHABIL RES DEV, V53, P185, DOI 10.1682/JRRD.2014.12.0301; Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003; SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571; Song Y, 2013, CNS NEUROSCI THER, V19, P603, DOI 10.1111/cns.12116; Stankiewicz TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00314; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tolias KF, 2011, PROG NEUROBIOL, V94, P133, DOI 10.1016/j.pneurobio.2011.04.011; Tonnesen J, 2014, NAT NEUROSCI, V17, P678, DOI 10.1038/nn.3682; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wehner Jeanne M, 2004, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0805cs27; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Wu XB, 2016, NEURAL REGEN RES, V11, P23, DOI 10.4103/1673-5374.169601; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; Yuste R, 2013, ANNU REV NEUROSCI, V36, P429, DOI 10.1146/annurev-neuro-062111-150455; Zhang HF, 2013, NEUROIMMUNOMODULAT, V20, P313, DOI 10.1159/000351221; Zhao JZ, 2006, NEUROL MED-CHIR, V46, P421, DOI 10.2176/nmc.46.421; Zhao JZ, 2011, NEUROL MED-CHIR, V51, P679, DOI 10.2176/nmc.51.679; Zhu PJ, 2011, CELL, V147, P1384, DOI 10.1016/j.cell.2011.11.029	79	17	17	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 6	2017	7								10689	10.1038/s41598-017-11113-3			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FG0MI	WOS:000409439900107	28878396	DOAJ Gold, Green Published			2021-06-18	
J	Bhattacharjee, S; Jun, B; Belayev, L; Heap, J; Kautzmann, MA; Obenaus, A; Menghani, H; Marcell, SJ; Khoutorova, L; Yang, R; Petasis, NA; Bazan, NG				Bhattacharjee, Surjyadipta; Jun, Bokkyoo; Belayev, Ludmila; Heap, Jessica; Kautzmann, Marie-Audrey; Obenaus, Andre; Menghani, Hemant; Marcell, Shawn J.; Khoutorova, Larissa; Yang, Rong; Petasis, Nicos A.; Bazan, Nicolas G.			Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury	SCIENCE ADVANCES			English	Article							OXYGEN-GLUCOSE DEPRIVATION; CEREBRAL ISCHEMIC-INJURY; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; STROKE; MECHANISMS; ELOVL4; NEUROPROTECTIN-D1; PERMEABILITY; TRANSLATION	We report the characterization of a novel class of lipid mediators termed elovanoids (ELVs) (ELV-N32 and ELV-N34), which are dihydroxylated derivatives of 32:6n3 and 34:6n3, respectively. The precursors of ELVs are made by elongation of a 22:6n3 fatty acid and catalyzed by ELOVL4 (elongation of very-long-chain fatty acids-4). The structure and stereochemistry of ELVs were established using synthetic compounds produced by stereocontrolled total synthesis. We report that ELV-mediated protection is induced in neuronal cultures undergoing either oxygen/glucose deprivation or N-methyl-D-aspartate receptor-mediated excitotoxicity, as well as in experimental ischemic stroke. The methyl ester or sodium salt of ELV-N32 and ELV-N34 resulted in reduced infarct volumes, promoted cell survival, and diminished neurovascular unit disruption when administered 1 hour following 2 hours of ischemia by middle cerebral artery occlusion. Together, our data reveal a novel prohomeostatic and neuroprotective lipid-signaling mechanism aiming to sustain neural cell integrity.	[Bhattacharjee, Surjyadipta; Jun, Bokkyoo; Belayev, Ludmila; Heap, Jessica; Kautzmann, Marie-Audrey; Menghani, Hemant; Marcell, Shawn J.; Khoutorova, Larissa; Bazan, Nicolas G.] Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA; [Menghani, Hemant] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Div Hematol Oncol, New Orleans, LA 70118 USA; [Menghani, Hemant] Childrens Hosp New Orleans, New Orleans, LA 70118 USA; [Yang, Rong; Petasis, Nicos A.] Univ Southern Calif, Loker Hydrocarbon Res Inst, Dept Chem, Los Angeles, CA 90033 USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	Bazan, NG (corresponding author), Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, New Orleans, LA 70112 USA.	nbazan@lsuhsc.edu	Petasis, Nicos/B-3162-2009; Bhattacharjee, Surjyadipta/I-5354-2016; Bhattacharjee, Surjyadipta/AAD-7586-2021; Bazan, Nicolas/AAN-4121-2020	Petasis, Nicos/0000-0002-8864-4446; Bhattacharjee, Surjyadipta/0000-0003-0185-553X; Bhattacharjee, Surjyadipta/0000-0003-0185-553X; Bazan, Nicolas/0000-0002-9243-5444; , Andre/0000-0003-0081-6950	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046741]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM103340]; Arthur C. Cope Scholar Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046741] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke (grant NS046741 to N.G.B.) and the National Institute of General Medical Sciences (grant GM103340 to N.G.B.). This work was also funded by the Arthur C. Cope Scholar Fund administered by the American Chemical Society (to N.A.P.).	Agbaga MP, 2016, ADV EXP MED BIOL, V854, P129, DOI 10.1007/978-3-319-17121-0_18; Aldahmesh MA, 2011, AM J HUM GENET, V89, P745, DOI 10.1016/j.ajhg.2011.10.011; Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Brouns R, 2011, EUR NEUROL, V65, P23, DOI 10.1159/000321965; Cameron DJ, 2007, INT J BIOL SCI, V3, P111; Chen HB, 2016, SCI REP-UK, V6, DOI 10.1038/srep30459; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Font MA, 2010, CURR CARDIOL REV, V6, P238, DOI 10.2174/157340310791658802; Haley MJ, 2017, J CEREBR BLOOD F MET, V37, P456, DOI 10.1177/0271678X16629976; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Obenaus A, 2011, ANN NEUROL, V69, P282, DOI 10.1002/ana.22168; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Petasis NA, 2012, TETRAHEDRON LETT, V53, P1695, DOI 10.1016/j.tetlet.2012.01.032; Ratan RR, 2010, TRANSL STROKE RES, V1, P71, DOI 10.1007/s12975-010-0024-6; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Shi SH, 2016, MED GAS RES, V6, P147, DOI 10.4103/2045-9912.191360; Stark DT, 2011, J NEUROSCI, V31, P13710, DOI 10.1523/JNEUROSCI.3544-11.2011; Takeshita K, 2016, GENES ENVIRON, V38, DOI 10.1186/s41021-016-0047-7; Tasca CI, 2015, METHODS MOL BIOL, V1254, P197, DOI 10.1007/978-1-4939-2152-2_15; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thrift AG, 2017, INT J STROKE, V12, P13, DOI 10.1177/1747493016676285	34	17	17	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	2375-2548			SCI ADV	Sci. Adv.	SEP	2017	3	9							e1700735	10.1126/sciadv.1700735			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FU6GH	WOS:000423949400006	28959727	DOAJ Gold, Green Published			2021-06-18	
J	Hansen, B; Khan, AR; Shemesh, N; Lund, TE; Sangill, R; Eskildsen, SF; Ostergaard, L; Jespersen, SN				Hansen, Brian; Khan, Ahmad R.; Shemesh, Noam; Lund, Torben E.; Sangill, Ryan; Eskildsen, Simon F.; Ostergaard, Leif; Jespersen, Sune N.			White matter biomarkers from fast protocols using axially symmetric diffusion kurtosis imaging	NMR IN BIOMEDICINE			English	Article						biophysics; diffusion; kurtosis; MRI; white matter; WMTI	MAGNETIC-RESONANCE MICROSCOPY; NON-GAUSSIAN DIFFUSION; TRAUMATIC BRAIN-INJURY; TRACT INTEGRITY; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; TENSOR MICROSCOPY; NERVOUS-TISSUE; METRICS; TIME	White matter tract integrity (WMTI) can characterize brain microstructure in areas with highly aligned fiber bundles. Several WMTI biomarkers have now been validated against microscopy and provided promising results in studies of brain development and aging, as well as in a number of brain disorders. Currently, WMTI is mostly used in dedicated animal studies and clinical studies of slowly progressing diseases, and has not yet emerged as a routine clinical tool. To this end, a less data intensive experimental method would be beneficial by enabling high resolution validation studies, and ease clinical applications by speeding up data acquisition compared with typical diffusion kurtosis imaging (DKI) protocols utilized as part of WMTI imaging. Here, we evaluate WMTI based on recently introduced axially symmetric DKI, which has lower data demand than conventional DKI. We compare WMTI parameters derived from conventional DKI with those calculated analytically from axially symmetric DKI. We employ numerical simulations, as well as data from fixed rat spinal cord (one sample) and in vivo human (three subjects) and rat brain (four animals). Our analysis shows that analytical WMTI based on axially symmetric DKI with sparse data sets (19 images) produces WMTI metrics that correlate strongly with estimates based on traditional DKI data sets (60 images or more). We demonstrate the preclinical potential of the proposed WMTI technique in in vivo rat brain (300m isotropic resolution with whole brain coverage in a 1h acquisition). WMTI parameter estimates are subject to a duality leading to two solution branches dependent on a sign choice, which is currently debated. Results from both of these branches are presented and discussed throughout our analysis. The proposed fast WMTI approach may be useful for preclinical research and e.g. clinical evaluation of patients with traumatic white matter injuries or symptoms of neurovascular or neuroinflammatory disorders.	[Hansen, Brian; Khan, Ahmad R.; Lund, Torben E.; Sangill, Ryan; Eskildsen, Simon F.; Ostergaard, Leif; Jespersen, Sune N.] Aarhus Univ, Dept Clin Med, CFIN, Aarhus, Denmark; [Hansen, Brian; Khan, Ahmad R.; Lund, Torben E.; Sangill, Ryan; Eskildsen, Simon F.; Ostergaard, Leif; Jespersen, Sune N.] Aarhus Univ, Dept Clin Med, MINDLab, Aarhus, Denmark; [Shemesh, Noam] Champalimaud Ctr Unknown, Champalimaud Neurosci Programme, Lisbon, Portugal; [Jespersen, Sune N.] Aarhus Univ, Dept Phys & Astron, Aarhus, Denmark	Hansen, B (corresponding author), Aarhus Univ, Dept Clin Med, CFIN, Aarhus, Denmark.; Hansen, B (corresponding author), Aarhus Univ, Dept Clin Med, MINDLab, Aarhus, Denmark.	brian@cfin.au.dk	Ostergaard, Leif/A-9281-2008; Khan, Ahmad Raza/L-1461-2019; Eskildsen, Simon/K-3934-2019; Lund, Torben E/B-1919-2008; Ostergaard, Lars/AAA-3020-2020; Jespersen, Sune Norhoj/B-1914-2008	Ostergaard, Leif/0000-0003-2930-6997; Khan, Ahmad Raza/0000-0002-7396-3073; Eskildsen, Simon/0000-0003-4242-9158; Lund, Torben E/0000-0002-9002-4676; Ostergaard, Lars/0000-0003-2459-0511; Jespersen, Sune Norhoj/0000-0003-3146-4329; Shemesh, Noam/0000-0001-6681-5876; Ostergaard, Lars/0000-0002-7619-605X	Danish Ministry of Science, Technology and Innovation's University Investment Grant [0601-01354B]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EB012874-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB012874] Funding Source: NIH RePORTER	Danish Ministry of Science, Technology and Innovation's University Investment Grant, Grant/Award Number: 0601-01354B; NIH, Grant/Award Number: 1R01EB012874-01	BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Benitez A, 2014, NEUROIMAGE-CLIN, V4, P64, DOI 10.1016/j.nicl.2013.11.001; Chuhutin A, 2016, ISMRM 24 ANN M EXH S; Chuhutin A, 2015, P 23 ANN M ISMRM BER, P2833; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; de Kouchkovsky I, 2016, J NEUROL, V263, P1146, DOI 10.1007/s00415-016-8118-z; Falangola MF, 2014, NMR BIOMED, V27, P948, DOI 10.1002/nbm.3140; Falangola MF, 2013, MAGN RESON IMAGING, V31, P840, DOI 10.1016/j.mri.2013.02.008; Falangola MF, 2008, J MAGN RESON IMAGING, V28, P1345, DOI 10.1002/jmri.21604; Fieremans E, 2013, AM J NEURORADIOL, V34, P2105, DOI 10.3174/ajnr.A3553; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Fieremans E, 2010, NMR BIOMED, V23, P711, DOI 10.1002/nbm.1577; Flint JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep18095; Flint JJ, 2012, NEUROIMAGE, V60, P1404, DOI 10.1016/j.neuroimage.2012.01.050; Flint JJ, 2010, NEUROIMAGE, V52, P556, DOI 10.1016/j.neuroimage.2010.04.031; Flint JJ, 2009, NEUROIMAGE, V46, P1037, DOI 10.1016/j.neuroimage.2009.03.009; Glenn GR, 2015, NMR BIOMED, V28, P448, DOI 10.1002/nbm.3271; Gong NJ, 2014, NEUROBIOL AGING, V35, P2203, DOI 10.1016/j.neurobiolaging.2014.03.011; Grinberg F, 2011, NEUROIMAGE, V57, P1087, DOI 10.1016/j.neuroimage.2011.04.050; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guglielmetti C, 2016, NEUROIMAGE, V125, P363, DOI 10.1016/j.neuroimage.2015.10.052; Hansen B, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.72; Hansen B, 2016, NEUROIMAGE, V142, P371, DOI 10.1016/j.neuroimage.2016.08.022; Hansen B, 2016, MAGN RESON MED, V76, P1455, DOI 10.1002/mrm.26055; Hansen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23999; Hansen B, 2014, MAGN RESON MED, V71, P2250, DOI 10.1002/mrm.25090; Hansen B, 2011, NEUROIMAGE, V57, P1458, DOI 10.1016/j.neuroimage.2011.04.052; Hansen MS, 2013, MAGN RESON MED, V69, P1768, DOI [10.1002/mrm.24389, 10.1002/mrm.24743]; Hardin RH, 1996, DISCRETE COMPUT GEOM, V15, P429, DOI 10.1007/BF02711518; Hui ES, 2015, NEUROIMAGE, V120, P371, DOI 10.1016/j.neuroimage.2015.07.013; Hui ES, 2012, STROKE, V43, P2968, DOI 10.1161/STROKEAHA.112.657742; Inglese M, 2010, NMR BIOMED, V23, P865, DOI 10.1002/nbm.1515; Jelescu IO, 2016, NEUROIMAGE, V132, P104, DOI 10.1016/j.neuroimage.2016.02.004; Jelescu IO, 2016, NMR BIOMED, V29, P33, DOI 10.1002/nbm.3450; Jelescu IO, 2015, NEUROIMAGE, V107, P242, DOI 10.1016/j.neuroimage.2014.12.009; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jensen JH, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3689; Jensen JH, 2014, NMR BIOMED, V27, P363, DOI [10.1002/nbm.3094, 10.1002/nbm.3030]; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jespersen SN, 2012, NMR BIOMED, V25, P813, DOI 10.1002/nbm.1808; Jespersen SN, 2012, IEEE T MED IMAGING, V31, P16, DOI 10.1109/TMI.2011.2162099; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kellner E, 2016, MAGN RESON MED, V76, P1574, DOI 10.1002/mrm.26054; Kelma ND, 2016, NEUROIMAGE, V124, P612, DOI 10.1016/j.neuroimage.2015.09.028; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; Koay CG, 2006, J MAGN RESON, V179, P317, DOI 10.1016/j.jmr.2006.01.016; Lazar M, 2014, NEUROIMAGE-CLIN, V4, P417, DOI 10.1016/j.nicl.2014.01.014; Lee CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11147; Leergaard TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008595; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Naess-Schmidt ET, 2017, BRAIN INJURY, V31, P230, DOI 10.1080/02699052.2016.1229034; Novikov DS, ARXIV1609091441PHYSI; Ong HH, 2010, NEUROIMAGE, V51, P1360, DOI 10.1016/j.neuroimage.2010.03.063; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Paydar A, 2014, AM J NEURORADIOL, V35, P808, DOI 10.3174/ajnr.A3764; Poot DHJ, 2010, IEEE T MED IMAGING, V29, P819, DOI 10.1109/TMI.2009.2037915; Pyatigorskaya N, 2014, MAGN RESON MED, V72, P492, DOI 10.1002/mrm.24921; Reisert M, 2017, NEUROIMAGE, V147, P964, DOI 10.1016/j.neuroimage.2016.09.058; Ronen I, 2014, BRAIN STRUCT FUNCT, V219, P1773, DOI 10.1007/s00429-013-0600-0; SCHOENIGER JS, 1994, J MAGN RESON SER B, V103, P261, DOI 10.1006/jmrb.1994.1039; Shemesh N, 2016, MAGN RESON MED, V75, P82, DOI 10.1002/mrm.25901; Skinner NP, 2017, MAGN RESON MED, V77, P1639, DOI 10.1002/mrm.26243; Torkildsen O, 2008, ACTA NEUROL SCAND, V117, P72, DOI 10.1111/j.1600-0404.2008.01036.x; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Weber RA, 2015, STROKE, V46, P545, DOI 10.1161/STROKEAHA.114.006782; Westin CF, 1999, LECT NOTES COMPUT SC, V1679, P441; Zhang H, 2011, NEUROIMAGE, V56, P1301, DOI 10.1016/j.neuroimage.2011.01.084	70	17	17	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	SEP	2017	30	9							e3741	10.1002/nbm.3741			17	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	FD6QV	WOS:000407653900007	28543843	Green Accepted			2021-06-18	
J	Roy, D; Vaishnavi, S; Han, DF; Rao, V				Roy, Durga; Vaishnavi, Sandeep; Han, Dingfen; Rao, Vani			Correlates and Prevalence of Aggression at Six Months and One Year After First-Time Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							PHYSICAL AGGRESSION; BEHAVIOR; SCALE; RELIABILITY; RESPONSES	Few studies have examined clinical correlates of aggression after first-time traumatic brain injury (TBI) within the first year after injury. The authors aimed to identify the rates of aggression at 6 and 12 months post-TBI and establish clinical and demographic correlates. A total of 103 subjects with first-time TBI were seen within 12 months postinjury and evaluated for aggression. Post-TBI social functioning and new-onset depression (within 3 months of the TBI) may serve as particularly important predictors for aggression within the first year of TBI, as these factors may afford intervention and subsequent decreased risk of aggression.	[Roy, Durga; Han, Dingfen; Rao, Vani] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Vaishnavi, Sandeep] Neuropsychiat Clin Carolina Partners, Durham, NC USA; [Vaishnavi, Sandeep] Duke Univ, Dept Community & Family Med, Sch Med, Durham, NC USA; [Vaishnavi, Sandeep] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA	Roy, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.	droy4@jhmi.edu			NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894]; Department of DefenseUnited States Department of Defense [W81XWH-13-1-0469]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER	Supported by NIMH grant K23 MH 066894 to Dr. Rao and in part by Department of Defense grant W81XWH-13-1-0469 to Dr. Rao.	Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Benedict R., 1997, BRIEF VISUOSPATIAL M; Brandt J., 2001, HOPKINS VERBAL LEARN; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; First M.B., 1997, COMMUNICATION; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Giles GM, 2007, BRAIN INJURY, V21, P505, DOI 10.1080/02699050701311729; Golden J. C., 1978, STROOP COLOR WORD TE; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2001, BRAIN INJURY, V15, P255; James AIW, 2013, BRAIN INJURY, V27, P1162, DOI 10.3109/02699052.2013.804200; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kafantaris V, 1996, J NEUROPSYCH CLIN N, V8, P186; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; MCNIEL DE, 1991, AM J PSYCHIAT, V148, P1317; Nelson HE, 1982, NATL ADULT READING T; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Schretlen D., 1996, BRIEF TEST ATTENTION; Silver J M, 1991, J Neuropsychiatry Clin Neurosci, V3, pS22; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Stefan A, 2016, ANN PHYS REHABIL MED, V59, P5, DOI 10.1016/j.rehab.2015.11.002; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; Wolfson D, 1985, HALSTEAD REITAN NEUR; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	30	17	17	0	5	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2017	29	4					334	342		10.1176/appi.neuropsych.16050088			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	FM9CH	WOS:000415390900005	28558481	Green Accepted, Bronze			2021-06-18	
J	Ryan, NP; Catroppa, C; Beare, R; Silk, TJ; Hearps, SJ; Beauchamp, MH; Yeates, KO; Anderson, VA				Ryan, Nicholas P.; Catroppa, Cathy; Beare, Richard; Silk, Timothy J.; Hearps, Stephen J.; Beauchamp, Miriam H.; Yeates, Keith O.; Anderson, Vicki A.			Uncovering the neuroanatomical correlates of cognitive, affective and conative theory of mind in paediatric traumatic brain injury: a neural systems perspective	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						childhood; brain injuries; Theory of Mind; social cognition; magnetic resonance imaging	SOCIAL COGNITION; MIRROR NEURON; EXECUTIVE FUNCTIONS; FRONTAL-CORTEX; CHILDREN; NETWORK; CONNECTIVITY; CHILDHOOD; MODERATE; OUTCOMES	Deficits in theory of mind (ToM) are common after neurological insult acquired in the first and second decade of life, however the contribution of large-scale neural networks to ToM deficits in children with brain injury is unclear. Using paediatric traumatic brain injury (TBI) as a model, this study investigated the sub-acute effect of paediatric traumatic brain injury on grey-matter volume of three large-scale, domain-general brain networks (the Default Mode Network, DMN; the Central Executive Network, CEN; and the Salience Network, SN), as well as two domain-specific neural networks implicated in social-affective processes (the Cerebro-Cerebellar Mentalizing Network, CCMN and the Mirror Neuron/Empathy Network, MNEN). We also evaluated prospective structure-function relationships between these large-scale neural networks and cognitive, affective and conative ToM. 3D T1- weighted magnetic resonance imaging sequences were acquired sub-acutely in 137 children [TBI: n = 103; typically developing (TD) children: n = 34]. All children were assessed on measures of ToM at 24-months post-injury. Children with severe TBI showed sub-acute volumetric reductions in the CCMN, SN, MNEN, CEN and DMN, as well as reduced grey-matter volumes of several hub regions of these neural networks. Volumetric reductions in the CCMN and several of its hub regions, including the cerebellum, predicted poorer cognitive ToM. In contrast, poorer affective and conative ToM were predicted by volumetric reductions in the SN and MNEN, respectively. Overall, results suggest that cognitive, affective and conative ToM may be prospectively predicted by individual differences in structure of different neural systems-the CCMN, SN and MNEN, respectively. The prospective relationship between cerebellar volume and cognitive ToM outcomes is a novel finding in our paediatric brain injury sample and suggests that the cerebellum may play a role in the neural networks important for ToM. These findings are discussed in relation to neurocognitive models of ToM. We conclude that detection of sub-acute volumetric abnormalities of large-scale neural networks and their hub regions may aid in the early identification of children at risk for chronic social-cognitive impairment.	[Ryan, Nicholas P.; Catroppa, Cathy; Hearps, Stephen J.; Anderson, Vicki A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Parkville, Vic 3052, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Parkville, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia; [Beare, Richard; Silk, Timothy J.] Murdoch Childrens Res Inst, Dev Imaging, Parkville, Vic, Australia; [Silk, Timothy J.; Anderson, Vicki A.] Univ Melbourne, Dept Pediat, Parkville, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Yeates, Keith O.] Univ Calgary, Hotchkiss Brain Inst, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Yeates, Keith O.] Univ Calgary, Dept Psychol, Calgary, AB, Canada	Ryan, NP (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019; Hearps, Stephen/L-6853-2016; Yeates, Keith/AAJ-4223-2020; Silk, Tim/K-4295-2019	Ryan, Nicholas/0000-0002-0878-8889; Yeates, Keith/0000-0001-7680-2892; Silk, Tim/0000-0002-7290-512X; Beare, Richard/0000-0002-7530-5664	Victoria Neurotrauma Initiative, Australia [CO6E1]; Victorian Government Operational Infrastructure Support Program; Australian Postgraduate AwardAustralian Government; MCRI PhD scholarship; NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed GrantNational Health and Medical Research Council of Australia; NHMRC Senior Practitioner FellowshipNational Health and Medical Research Council of Australia	This work was supported by a grant from the Victoria Neurotrauma Initiative, Australia (No. CO6E1); the Victorian Government Operational Infrastructure Support Program; an Australian Postgraduate Award, MCRI PhD scholarship, and NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed Grant to NR; and an NHMRC Senior Practitioner Fellowship to VA.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Ahmed RM, 2016, J NEUROL NEUROSUR PS, V87, P1234, DOI 10.1136/jnnp-2014-308350; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Apperly IA, 2005, TRENDS COGN SCI, V9, P572, DOI 10.1016/j.tics.2005.10.004; Backhausen LL, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00558; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blakemore SJ, 2007, SOC COGN AFFECT NEUR, V2, P130, DOI 10.1093/scan/nsm009; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Coffey C., 1991, Psychopathology and the Brain, V3, P243; Corradini A, 2013, CONSCIOUS COGN, V22, P1152, DOI 10.1016/j.concog.2013.03.003; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldman AI, 2009, MIND LANG, V24, P235, DOI 10.1111/j.1468-0017.2008.01361.x; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Herbet G, 2013, CORTEX, V49, P2711, DOI 10.1016/j.cortex.2013.08.003; Iacobini M., 2008, MIRRORING PEOPLE SCI; Iacoboni M., 2008, MIRRORING PEOPLE; Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kao HW, 2012, EUR RADIOL, V22, P1397, DOI 10.1007/s00330-012-2387-4; Keysers C, 2007, TRENDS COGN SCI, V11, P194, DOI 10.1016/j.tics.2007.02.002; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI 10.1016/j.tics.2007.04.005; Lawrence EJ, 2006, NEUROIMAGE, V29, P1173, DOI 10.1016/j.neuroimage.2005.09.001; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mitchell JP, 2005, NEUROIMAGE, V28, P757, DOI 10.1016/j.neuroimage.2005.03.011; Molenberghs P, 2016, NEUROSCI BIOBEHAV R, V65, P276, DOI 10.1016/j.neubiorev.2016.03.020; Molenberghs P, 2009, NEUROSCI BIOBEHAV R, V33, P975, DOI 10.1016/j.neubiorev.2009.03.010; Ochsner KN, 2005, NEUROIMAGE, V28, P797, DOI 10.1016/j.neuroimage.2005.06.069; Pfeifer JH, 2008, NEUROIMAGE, V39, P2076, DOI 10.1016/j.neuroimage.2007.10.032; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Samson D, 2004, NAT NEUROSCI, V7, P499, DOI 10.1038/nn1223; Saxe R, 2009, PHILOS STUD, V144, P447, DOI 10.1007/s11098-009-9353-2; Saxe RR, 2009, CHILD DEV, V80, P1197, DOI 10.1111/j.1467-8624.2009.01325.x; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schmitgen MM, 2016, NEUROIMAGE, V129, P450, DOI 10.1016/j.neuroimage.2016.01.029; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Sebastian CL, 2012, SOC COGN AFFECT NEUR, V7, P53, DOI 10.1093/scan/nsr023; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shaw P, 2004, BRAIN, V127, P1535, DOI 10.1093/brain/awh168; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Sodian B, 2011, CHILD DEV PERSPECT, V5, P39, DOI 10.1111/j.1750-8606.2010.00152.x; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stewart E, 2016, NEUROPSYCHOL REV, V26, P3, DOI 10.1007/s11065-015-9313-x; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Taylor H. G., 2010, PEDIAT TRAUMATIC BRA, P145; TEASDALE G, 1974, LANCET, V2, P81; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Van Overwalle F, 2015, HUM BRAIN MAPP, V36, P5137, DOI 10.1002/hbm.23002; Van Overwalle F, 2016, NEUROIMAGE, V124, P248, DOI 10.1016/j.neuroimage.2015.09.001; Van Overwalle F, 2015, SOC NEUROSCI-UK, V10, P337, DOI 10.1080/17470919.2015.1005666; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wang AT, 2006, SOC COGN AFFECT NEUR, V1, P107, DOI 10.1093/scan/nsl018; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wiech K, 2010, J NEUROSCI, V30, P16324, DOI 10.1523/JNEUROSCI.2087-10.2010; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wolfe KR, 2013, CHILD NEUROPSYCHOL, V19, P370, DOI 10.1080/09297049.2012.669470; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Young L, 2010, NEUROPSYCHOLOGIA, V48, P2658, DOI 10.1016/j.neuropsychologia.2010.05.012; Zaki J, 2010, J NEUROSCI, V30, P8481, DOI 10.1523/JNEUROSCI.0382-10.2010	104	17	18	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	SEP	2017	12	9					1414	1427		10.1093/scan/nsx066			14	Neurosciences; Psychology; Psychology, Experimental	Neurosciences & Neurology; Psychology	FJ3QI	WOS:000412646400005	28505355	DOAJ Gold, Green Published			2021-06-18	
J	Snook, ML; Henry, LC; Sanfilippo, JS; Zeleznik, AJ; Kontos, AP				Snook, Meredith L.; Henry, Luke C.; Sanfilippo, Joseph S.; Zeleznik, Anthony J.; Kontos, Anthony P.			Association of Concussion With Abnormal Menstrual Patterns in Adolescent and Young Women	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; FEMALE ATHLETE TRIAD; BONE-MINERAL DENSITY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; REPRODUCTIVE FUNCTION; CONSENSUS STATEMENT	IMPORTANCE Brain injurymay interrupt menstrual patterns by altering hypothalamic-pituitary-ovarian axis function. Investigators have yet to evaluate the association of concussion with menstrual patterns in young women. OBJECTIVE To compare abnormal menstrual patterns in adolescent and young women after a sport-related concussion with those after sport-related orthopedic injuries to areas other than the head (nonhead). DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study of adolescent and young women with a sport-related concussion (n = 68) or a nonhead sport-related orthopedic injury (n = 61) followed up participants for 120 days after injury. Patients aged 12 to 21 years who presented within 30 days after a sport-related injury to a concussion or sports medicine clinic at a single academic center were eligible. Menstrual patterns were assessed using a weekly text message link to an online survey inquiring about bleeding episodes each week. The first patient was enrolled on October 14, 2014, and follow-up was completed on January 24, 2016. Inclusion criteria required participants to be at least 2 years postmenarche, to report regular menses in the previous year, and to report no use of hormonal contraception. EXPOSURES Sport-related concussion or nonhead sport-related orthopedic injury. MAIN OUTCOMES AND MEASURES Abnormal menstrual patternswere defined by an intermenstrual interval of less than 21 days (short) or more than 35 days (long) or a bleeding duration of less than 3 days or more than 7 days. RESULTS A total of 1784 survey responses were completed of the 1888 text messages received by patients, yielding 487 menstrual patterns in 128 patients (mean [SD] age, 16.2 [2.0] years). Of the 68 patients who had a concussion, 16 (23.5%) experienced 2 or more abnormal menstrual patterns during the study period compared with 3 of 60 patients (5%) who had an orthopedic injury. Despite similar gynecologic age, body mass index, and type of sports participation between groups, the risk of 2 or more abnormal menstrual bleeding patterns after injury was significantly higher among patients with concussion than among those with an orthopedic injury (odds ratio, 5.85; 95% CI, 1.61-21.22). CONCLUSIONS AND RELEVANCE Adolescent and young women may have increased risk of multiple abnormal menstrual patterns after concussion. Because abnormal menstrual patterns can have important health implications, monitoring menstrual patterns after concussion may be warranted in this population. Additional research is needed to elucidate the relationship between long-term consequences of concussion and the function of the hypothalamic-pituitary-ovarian axis.	[Snook, Meredith L.; Sanfilippo, Joseph S.; Zeleznik, Anthony J.] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Henry, Luke C.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Sports Med Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA	Kontos, AP (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Sports Med Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; Magee-Women's Research Institute [CTRA-8064]	This research was supported in part by grant 1K01DC012332-01A1 from the National Institute on Deafness and Other Communication Disorders (Dr Kontos and University of Pittsburgh) and grant CTRA-8064 from the Magee-Women's Research Institute (Dr Snook).	Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Amer Soc Reproductive Med, 2008, FERTIL STERIL, V90, pS219, DOI 10.1016/j.fertnstert.2008.08.038; [Anonymous], 2016, PEDIATRICS, V137, P53; Austin Tricia M, 2009, Int J Adolesc Med Health, V21, P555; Barrack MT, 2014, AM J SPORT MED, V42, P949, DOI 10.1177/0363546513520295; Beals KA, 2002, INT J SPORT NUTR EXE, V12, P281, DOI 10.1123/ijsnem.12.3.281; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BERGA SL, 1995, ENDOCRINOLOGIST, V5, P416, DOI 10.1097/00019616-199511000-00005; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Centers for Disease Control and Prevention Injury Center, HEADS YOUTH SPORTS; Colantonio A, 2010, J WOMENS HEALTH, V19, P1109, DOI 10.1089/jwh.2009.1740; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; De Souza MJ, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2013-093218; Dusick JR, 2012, PITUITARY, V15, P2, DOI 10.1007/s11102-008-0130-6; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; FLUG D, 1984, ANN HUM BIOL, V11, P495, DOI 10.1080/03014468400007411; Fourman LT, 2015, J CLIN ENDOCR METAB, V100, P812, DOI 10.1210/jc.2014-3344; Gessel LM, 2007, J ATHL TRAINING, V42, P495; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Henry YM, 2004, OSTEOPOROSIS INT, V15, P263, DOI 10.1007/s00198-003-1542-9; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Klein JD, 2006, PEDIATRICS, V118, P2245, DOI 10.1542/peds.2006-2481; Legro RS, 2000, J CLIN ENDOCR METAB, V85, P1021, DOI 10.1210/jc.85.3.1021; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Menstruation in girls and adolescents: using the menstrual cycle as a vital sign, 2015, OBSTET GYNECOL, V126, pe143; Nichols JF, 2007, INT J SPORT NUTR EXE, V17, P364, DOI 10.1123/ijsnem.17.4.364; Nichols JF, 2007, BONE, V41, P371, DOI 10.1016/j.bone.2007.05.003; Nichols JF, 2006, ARCH PEDIAT ADOL MED, V160, P137, DOI 10.1001/archpedi.160.2.137; Popat VB, 2009, J CLIN ENDOCR METAB, V94, P2277, DOI 10.1210/jc.2008-1878; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Thein-Nissenbaum JM, 2012, J ATHL TRAINING, V47, P74; Williams NI, 2007, AM J PHYSIOL-ENDOC M, V293, pE270, DOI 10.1152/ajpendo.00108.2007; Williams NI, 2015, AM J PHYSIOL-ENDOC M, V308, pE29, DOI 10.1152/ajpendo.00386.2013; World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls, 1986, J ADOLESC HLTH CARE, V7, P229; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	49	17	17	3	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	SEP	2017	171	9					879	886		10.1001/jamapediatrics.2017.1140			8	Pediatrics	Pediatrics	FG3XL	WOS:000410140700015	28672284	Green Published			2021-06-18	
J	Westerhof-Evers, HJ; Visser-Keizer, AC; Fasotti, L; Schonherr, MC; Vink, M; van der Naalt, J; Spikman, JM				Westerhof-Evers, Herma J.; Visser-Keizer, Annemarie C.; Fasotti, Luciano; Schonherr, Marleen C.; Vink, Martie; van der Naalt, Joukje; Spikman, Jacoba M.			Effectiveness of a Treatment for Impairments in Social Cognition and Emotion Regulation (T-ScEmo) After Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect recognition; emotion perception; social behavior; social cognition; social skills; TBI; ToM	ECOLOGICALLY VALID TEST; PERCEPTION DEFICITS; RECOGNITION; LIFE; HEALTH; ADULTS; SKILLS; MIND; METAANALYSIS; MARRIAGE	Objective: To evaluate the effects of a multifaceted Treatment for Social cognition and Emotion regulation (T-ScEmo) in patients with a traumatic brain injury. Participants: Sixty-one patients with moderate to severe traumatic brain injury randomly assigned to an experimental T-ScEmo intervention or a Cogniplus control condition. Interventions: T-ScEmo is a compensatory strategy training for impairments in emotion recognition, theory of mind, and social behavioral skills. Cogniplus is a computerized cognitive function training. Both interventions were given in 16 to 20 weekly 1-hour sessions. Main Measures: Social cognition tests and questionnaires for social behavior (self-and proxy-rated) administered at baseline, immediately posttreatment, and at 3 to 5 months of follow-up. Results: Compared with the Cogniplus group, the T-ScEmo group improved significantly on facial affect recognition, theory of mind, proxy-rated empathic behavior, societal participation, and treatment goal attainment, which lasted up to 5 months after treatment. At follow-up, the T-ScEmo group also reported higher quality of life and their life partners rated relationship quality to be higher than the Cogniplus group. Conclusion: This study shows that impairments in social cognition can be effectively dealt with by using a comprehensive treatment protocol, leading to improvements in everyday life social functioning.	[Westerhof-Evers, Herma J.; Spikman, Jacoba M.] Univ Groningen, Dept Clin & Dev Neuropsychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands; [Westerhof-Evers, Herma J.; Schonherr, Marleen C.] Univ Groningen, Univ Med Ctr Groningen, Ctr Rehabil, Groningen, Netherlands; [Visser-Keizer, Annemarie C.; van der Naalt, Joukje; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Fasotti, Luciano] Klimmendaal Rehabil Ctr, Arnhem, Netherlands; [Vink, Martie] Reade Rehabil Ctr, Amsterdam, Netherlands	Westerhof-Evers, HJ (corresponding author), Univ Groningen, Dept Clin & Dev Neuropsychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.	h.j.evers@rug.nl		Spikman, Jacoba/0000-0002-6477-0763			Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Beck R, 1998, COGNITIVE THER RES, V22, P63, DOI 10.1023/A:1018763902991; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bookwala J, 2005, J AGING HEALTH, V17, P85, DOI 10.1177/0898264304272794; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Brooks N., 1984, HEAD INJURY FAMILY, P148; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Deelman B, 1980, NEUROPSYCHOLOGIE NED; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; DYWAN J, 1995, J INT NEUROPSYCH SOC, V1, P121; Emmanouel A, 2014, BRAIN INJURY, V28, P1581, DOI 10.3109/02699052.2014.942371; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Fallowfield L., 1990, QUALITY LIFE MISSING; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Godwin EE, 2011, J HEAD TRAUMA REHAB, V26, P43, DOI 10.1097/HTR.0b013e3182048f54; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Harwood MD, 2006, BRIT J DEV PSYCHOL, V24, P401, DOI 10.1348/026151005X50302; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Kiecolt-Glaser JK, 2001, PSYCHOL BULL, V127, P472, DOI 10.1037//0033-2909.127.4.472; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Neumann D, 2015, J HEAD TRAUMA REHAB, V30, pE12, DOI 10.1097/HTR.0000000000000054; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Saxton ME, 2013, NEUROREHABILITATION, V33, P263, DOI 10.3233/NRE-130954; Schmand B., 1992, NEDERLANDSE LEESTEST; Spikman JM, 2016, J NEUROTRAUM, V33, P22, DOI 10.1089/neu.2014.3788; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Struchen MA, 2014, HDB NEUROPSYCHOLOGY, P213, DOI DOI 10.1007/978; Sturm W, 2003, Z NEUROPSYCHOL, V14, P283, DOI [DOI 10.1024/1016-264X.14.4.283, 10.1024/1016-264X.14.4.283]; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Westerhof-Evers HJ, 2014, J CLIN EXP NEUROPSYC, V36, P1031, DOI 10.1080/13803395.2014.966661; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Winegardner J, 2016, NEUROREHABILITATION, V39, P153, DOI 10.3233/NRE-161347; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Young A., 2002, FACIAL EXPRESSIONS E	54	17	17	2	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					296	307		10.1097/HTR.0000000000000332			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800010	28786854				2021-06-18	
J	Stokum, JA; Keledjian, K; Hayman, E; Karimy, JK; Pampori, A; Imran, Z; Woo, SK; Gerzanich, V; Simard, JM				Stokum, Jesse A.; Keledjian, Kaspar; Hayman, Erik; Karimy, Jason K.; Pampori, Adam; Imran, Ziyan; Woo, Seung Kyoon; Gerzanich, Volodymyr; Simard, J. Marc			Glibenclamide pretreatment protects against chronic memory dysfunction and glial activation in rat cranial blast traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Blast-TBI; Glibenclamide; Memory dysfunction; Glial activation; Blood-brain barrier	SULFONYLUREA RECEPTOR 1; K-ATP-CHANNELS; CEREBRAL-ARTERIES; OXIDATIVE STRESS; DENTATE GYRUS; RODENT MODEL; MOUSE MODEL; TIME-COURSE; INFLAMMATION; GLYBURIDE	Blast traumatic brain injury (bTBI) affects both military and civilian populations, and often results in chronic deficits in cognition and memory. Chronic glial activation after bTBI has been linked with cognitive decline. Pharmacological inhibition of sulfonylurea receptor 1 (SUR1) with glibenclamide was shown previously to reduce glial activation and improve cognition in contusive models of CNS trauma, but has not been examined in bTBI. We postulated that glibenclamide would reduce chronic glial activation and improve long-term memory function after bTBI. Using a rat direct cranial model of bTBI (dc-bTBI), we evaluated the efficacy of two glibenclamide treatment paradigms: glibenclamide prophylaxis (pre-treatment), and treatment with glibenclamide starting after dc-bTBI (post-treatment). Our results show that dc-bTBI caused hippocampal astrocyte and microglial/macrophage activation that was associated with hippocampal memory dysfunction (rapid place learning paradigm) at 28 days, and that glibenclamide pre-treatment, but not post-treatment, effectively protected against glial activation and memory dysfunction. We also report that a brief transient time-window of blood brain barrier (BBB) disruption occurs after dc-bTBI, and we speculate that glibenclamide, which is mostly protein bound and does not normally traverse the intact BBB, can undergo CNS delivery only during this brief transient opening of the BBB. Together, our findings indicate that prophylactic glibenclamide treatment may help to protect against chronic cognitive sequelae of bTBI in warfighters and other at-risk populations.	[Stokum, Jesse A.; Keledjian, Kaspar; Hayman, Erik; Karimy, Jason K.; Pampori, Adam; Imran, Ziyan; Woo, Seung Kyoon; Gerzanich, Volodymyr] Univ Maryland, Sch Med, Dept Neurosurg, MSTF, 10 S Pine St,Room 634B, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, MSTF, 10 S Pine St,Room 634B, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, MSTF, 10 S Pine St,Room 634B, Baltimore, MD 21201 USA	Stokum, JA (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, MSTF, 10 S Pine St,Room 634B, Baltimore, MD 21201 USA.	jesse.stokum@som.umaryland.edu			Veterans AdministrationUS Department of Veterans Affairs [5I01BX001629]	Funding for this study was provided in part by a grant to JMS from the Veterans Administration (5I01BX001629).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adebiyi A, 2011, AM J PHYSIOL-HEART C, V301, pH1360, DOI 10.1152/ajpheart.00406.2011; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bast T, 2009, PLOS BIOL, V7, P730, DOI 10.1371/journal.pbio.1000089; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cemak I, 2011, NEUROBIOL DIS, V41, P538; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Gopalakrishnan M, 2000, BRIT J PHARMACOL, V129, P1323, DOI 10.1038/sj.bjp.0703181; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Heron-Milhavet L, 2004, MOL CELL NEUROSCI, V25, P585, DOI 10.1016/j.mcn.2003.10.012; Hosier H, 2015, J NEUROTRAUM, V32, P1633, DOI 10.1089/neu.2015.3892; Hue CD, 2016, J NEUROTRAUM, V33, P1202, DOI 10.1089/neu.2015.4067; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Ishizaki E, 2009, J PHYSIOL-LONDON, V587, P2233, DOI 10.1113/jphysiol.2009.169003; Jansen-Olesen I, 2005, EUR J PHARMACOL, V523, P109, DOI 10.1016/j.ejphar.2005.08.028; JONSSON A, 1994, DIABETES CARE, V17, P142, DOI 10.2337/diacare.17.2.142; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; Kawoos U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167510; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kilkenny C, 2012, VET CLIN PATH, V41, P27, DOI 10.1111/j.1939-165X.2012.00418.x; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurland DB, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0599-2; Kwon MS, 2015, INT J MOL SCI, V16, P5028, DOI 10.3390/ijms16035028; Lahmann C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134476; Lee I, 2004, NEURON, V42, P803, DOI 10.1016/j.neuron.2004.05.010; Lee JW, 2009, LEARN MEMORY, V16, P530, DOI 10.1101/lm.1483709; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Makar TK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0432-3; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Martin Y., 2010, PROT EXCHANGE, V10; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McHugh T.J., SCIENCE, V317; Mehta RI, 2015, J NEUROPATH EXP NEUR, V74, P835, DOI 10.1097/NEN.0000000000000223; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Mutalik S, 2004, J PHARM SCI-US, V93, P1577, DOI 10.1002/jps.20058; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nakashiba T, 2008, SCIENCE, V319, P1260, DOI 10.1126/science.1151120; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; O'Reilly RC, 2001, PSYCHOL REV, V108, P311, DOI 10.1037//0033-295X.108.2.311; OLSEN KM, 1995, J CLIN PHARMACOL, V35, P739, DOI 10.1002/j.1552-4604.1995.tb04115.x; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ranaivo HR, 2010, BRAIN RES, V1313, P222, DOI 10.1016/j.brainres.2009.11.063; Rawson RA, 1943, AM J PHYSIOL, V138, P0708; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Robel S, 2009, GLIA, V57, P1630, DOI 10.1002/glia.20876; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenfeld JV, 2005, MED J AUSTRALIA, V183, P567, DOI 10.5694/j.1326-5377.2005.tb00036.x; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RYDBERG T, 1994, DIABETES CARE, V17, P1026, DOI 10.2337/diacare.17.9.1026; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Simard J.M., 2017, BEHAV BRAIN RES, V333, P43; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Sola D, 2015, ARCH MED SCI, V11, P840, DOI 10.5114/aoms.2015.53304; Sun HS, 2015, EXP NEUROL, V263, P161, DOI 10.1016/j.expneurol.2014.10.003; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhuo JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136151; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	94	17	18	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	AUG 30	2017	333						43	53		10.1016/j.bbr.2017.06.038			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FE5ZK	WOS:000408289600006	28662892				2021-06-18	
J	Post, A; Hoshizaki, TB; Gilchrist, MD; Cusimano, MD				Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.; Cusimano, Michael D.			Peak linear and rotational acceleration magnitude and duration effects on maximum principal strain in the corpus callosum for sport impacts	JOURNAL OF BIOMECHANICS			English	Article						Finite element modelling; Strain; Brain injury; Acceleration; Duration	ACCIDENT RECONSTRUCTION; AXONAL DAMAGE; HEAD; ELEMENT; INJURY; BIOMECHANICS; TISSUE; MODEL	Concussion has been linked to the presence of injurious strains in the brain tissues. Research investigating severe brain injury has reported that strains in the brain may be affected by two parameters: magnitude of the acceleration, and duration of that acceleration. However, little is known how this relationship changes in terms of creating risk for brain injury for magnitudes and durations of acceleration common in sporting environments. This has particular implications for the understanding and prevention of concussive risk of injury in sporting environments. The purpose of this research was to examine the interaction between linear and rotational acceleration and duration on maximum principal strain in the brain tissues for loading conditions incurred in sporting environments. Linear and rotational acceleration loading curves of magnitudes and durations similar to those from impact in sport were used as input to the University College Brain Trauma Model and maximum principal strain (MPS) was measured for the different curves. The results demonstrated that magnitude and duration do have an effect on the strain incurred by the brain tissue. As the duration of the acceleration increases, the magnitude required to achieve strains reflecting a high risk of concussion decreases, with rotational acceleration becoming the dominant contributor. The magnitude required to attain a magnitude of MPS representing risk of brain injury was found to be as low as 2500 rad/s(2) for impacts of 10-15 ms; indicating that interventions to reduce the risk of concussion in sport must consider the duration of the event while reducing the magnitude of acceleration the head incurs. (C) 2017 Elsevier Ltd. All rights reserved.	[Post, Andrew; Cusimano, Michael D.] St Michaels Hosp, Toronto, ON, Canada; [Post, Andrew; Hoshizaki, T. Blaine] Univ Ottawa, Human Kinet, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland	Post, A (corresponding author), 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Cusimano, Michael/X-4059-2019				Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2007, THESIS; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hitosugi M, 2014, BIOMED RES-TOKYO, V35, P339, DOI 10.2220/biomedres.35.339; Ho J, 2008, THESIS; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki T.B., 2016, TRAUMA; Hoshizaki T.B., 2014, J NEUROL NEUROPHYSIO, V5, P181; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Kendall M., 2016, THESIS; Khong E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00156; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S., 2005, P IRCOBI C PRAG CZEC, P41; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lao Y, 2015, PROC SPIE, V9287, DOI 10.1117/12.2072600; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller R.T., 1998, STAPP CAR CRASH J, P155; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; Patton DA, 2013, J APPL BIOMECH, V29, P721, DOI 10.1123/jab.29.6.721; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A., 2016, SPORTS ENG; Post A, 2015, ACCIDENT ANAL PREV, V79, P33, DOI 10.1016/j.aap.2015.03.017; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Rousseau P., 2014, THESIS; Ruan J, 1994, THESIS; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Ting W.K., 2016, FRONT NEUROL, V6, P1; Van Lierde C, 2005, THESIS; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Willinger R, 1995, P IRCOBI C; Willinger R., 1992, P INT IRCOBI C BIOM, P179; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yang JK, 2011, COMPUTATIONAL BIOMECHANICS FOR MEDICINE: SOFT TISSUES AND THE MUSCULOSKELETAL SYSTEM, P5, DOI 10.1007/978-1-4419-9619-0_2; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310	53	17	17	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	AUG 16	2017	61						183	192		10.1016/j.jbiomech.2017.07.013			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	FH9QQ	WOS:000411547200024	28807524				2021-06-18	
J	Bickford, PC; Flowers, A; Grimmig, B				Bickford, Paula C.; Flowers, Antwoine; Grimmig, Bethany			Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases	EXPERIMENTAL GERONTOLOGY			English	Article; Proceedings Paper	13th International Symposium on the Neurobiology and Neuroendocrinology of Aging	JUL 17-22, 2016	Bregenz, AUSTRIA	Natl Inst Aging, Orentreich Fdn Advancement Sci, Co Morbid Relat AIDS, European Commiss, 7th Framework Program, Juniper & Pasquale Fdn, Land Vorarlberg & Landeshaupstadt, Univ N Dakota, Sch Med & Hlth Sci, Dept Biomed Sci		Microglia; Polyphenol	COGNITIVE FUNCTION; AGED RATS; PROINFLAMMATORY CYTOKINES; DIETARY SUPPLEMENTATION; PROGENITOR CELLS; STEM-CELLS; INFLAMMATION; NEUROGENESIS; REVERSES; MICE	Aging is the primary risk factor for many neurodegenerative diseases. Thus, understanding the basic biological changes that take place with aging that lead to the brain being less resilient to disease progression of neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease or insults to the brain such as stroke or traumatic brain injuries. Clearly this will not cure the disease per se, yet increasing the ability of the brain to respond to injury could improve long term outcomes. The focus of this review is examining changes in microglia with age and possible therapeutic interventions involving the use of polyphenol rich dietary supplements. Published by Elsevier Inc.	[Bickford, Paula C.] James A Haley Vet Adm Hosp, Res Serv, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA; [Bickford, Paula C.; Flowers, Antwoine; Grimmig, Bethany] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL USA	Bickford, PC (corresponding author), James A Haley Vet Adm Hosp, Res Serv, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	pbickfor@health.usf.edu	Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG044919]; VA grant [I01BX003421]; Veterans AdministrationUS Department of Veterans Affairs [I01BX003421]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044919, P01AG004418, R36AG051747] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003421] Funding Source: NIH RePORTER	This work was supported by NIH grants R01AG044919 (PCB), and VA grant I01BX003421 (PCB).; This work was supported by the Veterans Administration (I01BX003421). Content does not represent the views of the Department of Veterans Affairs nor the US Government.	Acosta S, 2010, REJUV RES, V13, P581, DOI 10.1089/rej.2009.1011; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Bhullar KS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/891748; Bickford PC, 2015, AGE, V37, DOI 10.1007/s11357-015-9840-7; Bickford PC, 2006, STEM CELLS DEV, V15, P118, DOI 10.1089/scd.2006.15.118; Cho SH, 2015, J NEUROSCI, V35, P807, DOI 10.1523/JNEUROSCI.2939-14.2015; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Flowers A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0395-4; Gemma C, 2005, EUR J NEUROSCI, V22, P1751, DOI 10.1111/j.1460-9568.2005.04334.x; Gemma C, 2002, J NEUROSCI, V22, P6114; GRANHOLM AC, 1987, BRAIN RES, V423, P71, DOI 10.1016/0006-8993(87)90826-2; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; L'Episcopo F, 2013, J NEUROSCI, V33, P1462, DOI 10.1523/JNEUROSCI.3206-12.2013; Lastres-Becker I, 2012, HUM MOL GENET, V21, P3173, DOI 10.1093/hmg/dds143; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749; Michaud M, 2013, J AM MED DIR ASSOC, V14, P877, DOI 10.1016/j.jamda.2013.05.009; Moll L, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13917; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Piccin D, 2014, NEUROBIOL AGING, V35, P1669, DOI 10.1016/j.neurobiolaging.2014.01.026; Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Small BJ, 2014, REJUV RES, V17, P27, DOI 10.1089/rej.2013.1477; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Turan B, 2012, J BIOENERG BIOMEMBR, V44, P281, DOI 10.1007/s10863-012-9429-0; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Wang Y, 2005, EXP NEUROL, V193, P75, DOI 10.1016/j.expneurol.2004.12.014; Wilcock D. M., 2012, INT J ALZHEIMERS DIS; Willis L, 2005, CELL TRANSPLANT, V14, P213, DOI 10.3727/000000005783983142; Willis LM, 2010, GLIA, V58, P679, DOI 10.1002/glia.20954; Yasuhara T, 2008, REJUV RES, V11, P201, DOI 10.1089/rej.2007.0608; Zhao X, 2014, J NEUROCHEM	40	17	17	3	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	AUG	2017	94				SI		4	8		10.1016/j.exger.2017.01.027			5	Geriatrics & Gerontology	Geriatrics & Gerontology	EZ1TS	WOS:000404494300002	28163132	Green Accepted			2021-06-18	
J	Glenn, DE; Acheson, DT; Geyer, MA; Nievergelt, CM; Bakermd, DG; Risbrough, VB				Glenn, Daniel E.; Acheson, Dean T.; Geyer, Mark A.; Nievergelt, Caroline M.; Bakermd, Dewleen G.; Risbrough, Victoria B.		MRS-II Team	Fear learning alterations after traumatic brain injury and their role in development of posttraumatic stress symptoms	DEPRESSION AND ANXIETY			English	Article						biological markers; posttraumatic stress disorder; startle; trauma; traumatic brain injury	CONDITIONED FEAR; SEX-DIFFERENCES; POSTCONCUSSIVE SYMPTOMS; ANXIETY DISORDERS; EXTINCTION; PTSD; CONCUSSION; SEQUELAE; RISK; ASSOCIATION	Background: It is unknown how traumatic brain injury (TBI) increases risk for posttraumatic stress disorder (PTSD). One potential mechanism is via alteration of fear-learning processes that could affect responses to trauma memories and cues. We utilized a prospective, longitudinal design to determine if TBI is associated with altered fear learning and extinction, and if fear processing mediates effects of TBI on PTSD symptom change. Methods: Eight hundred fifty two active-duty Marines and Navy Corpsmen were assessed before and after deployment. Assessments included TBI history, PTSD symptoms, combat trauma and deployment stress, and a fear-potentiated startle task of fear acquisition and extinction. Startle response and self-reported expectancy and anxiety served as measures of fear conditioning, and PTSD symptoms were measured with the Clinician-Administered PTSD Scale. Results: Individuals endorsing "multiple hit" exposure (both deployment TBI and a prior TBI) showed the strongest fear acquisition and highest fear expression compared to groups without multiple hits. Extinction did not differ across groups. Endorsing a deployment TBI was associated with higher anxiety to the fear cue compared to those without deployment TBI. The association of deployment TBI with increased postdeployment PTSD symptoms was mediated by postdeployment fear expression when recent prior-TBI exposure was included as a moderator. TBI associations with increased response to threat cues and PTSD symptoms remained when controlling for deployment trauma and postdeployment PTSD diagnosis. Conclusions: Deployment TBI, and multiple-hit TBI in particular, are associated with increases in conditioned fear learning and expression that may contribute to risk for developing PTSD symptoms.	[Glenn, Daniel E.; Acheson, Dean T.; Nievergelt, Caroline M.; Bakermd, Dewleen G.; Risbrough, Victoria B.] San Diego Vet Affairs Hlth Serv, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Glenn, Daniel E.; Acheson, Dean T.; Geyer, Mark A.; Nievergelt, Caroline M.; Bakermd, Dewleen G.; Risbrough, Victoria B.; MRS-II Team] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Geyer, Mark A.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA	Risbrough, VB (corresponding author), San Diego Vet Affairs Hlth Serv, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	vrisbrough@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; 	Navy Bureau of Medicine and Surgery [N62645-11-C-4037]; VA Center of Excellence for Stress and Mental Health; Veterans AffairsUS Department of Veterans Affairs [I01BX002558] Funding Source: NIH RePORTER	Grant sponsor: Navy Bureau of Medicine and Surgery; Contract grant number: N62645-11-C-4037; Grant sponsor: the VA Center of Excellence for Stress and Mental Health.	Acheson D, 2013, PSYCHOPHARMACOLOGY, V229, P199, DOI 10.1007/s00213-013-3099-4; Achesona DT, 2015, PSYCHONEUROENDOCRINO, V51, P495, DOI 10.1016/j.psyneuen.2014.09.030; Alosco M. L., 2015, J HEAD TRAUMA REHAB, V31, P1; Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1995, BEHAV RES THER, V33, P369, DOI 10.1016/0005-7967(94)00067-T; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Briscione MA, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00088; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Craske M, 2006, FEAR LEARNING BASIC, P217; Davies D. R., 2016, FRONT BEHAV NEUROSCI, V10, P1; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fidan E, 2016, J NEUROTRAUM, V33, P641, DOI 10.1089/neu.2015.3958; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Goshen I, 2009, FRONT NEUROENDOCRIN, V30, P30, DOI 10.1016/j.yfrne.2008.10.001; Grillon C, 2009, BIOL PSYCHIAT, V66, P47, DOI 10.1016/j.biopsych.2008.12.028; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Hermans D, 2006, BIOL PSYCHIAT, V60, P361, DOI 10.1016/j.biopsych.2005.10.006; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huang MX, 2017, J NEUROTRAUM, V34, P1412, DOI 10.1089/neu.2016.4581; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2016, PSYCHONEUROENDOCRINO, V63, P398, DOI 10.1016/j.psyneuen.2015.02.008; IBM Corporation, 2012, IBM SPSS STAT WIND V; Inslicht SS, 2013, J PSYCHIATR RES, V47, P64, DOI 10.1016/j.jpsychires.2012.08.027; Iverson G. L., 2012, REHABILITATION REP, V2012; Jones ME, 2015, NEUROPSYCHOPHARMACOL, V40, P1289, DOI 10.1038/npp.2014.317; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lissek S, 2015, INT J PSYCHOPHYSIOL, V98, P594, DOI 10.1016/j.ijpsycho.2014.11.006; Logue OC, 2016, EXP NEUROL, V277, P227, DOI 10.1016/j.expneurol.2015.12.019; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Maeng LY, 2015, HORM BEHAV, V76, P106, DOI 10.1016/j.yhbeh.2015.04.002; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mineka S, 2006, AM PSYCHOL, V61, P10, DOI 10.1037/0003-066X.61.1.10; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Pace TWW, 2011, BRAIN BEHAV IMMUN, V25, P6, DOI 10.1016/j.bbi.2010.10.003; Palmer CP, 2016, EXP NEUROL, V277, P215, DOI 10.1016/j.expneurol.2016.01.004; Passos IC, 2015, LANCET PSYCHIAT, V2, P1002, DOI 10.1016/S2215-0366(15)00309-0; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prasad KN, 2015, BRAIN RES, V1599, P103, DOI 10.1016/j.brainres.2014.12.038; Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Risbrough V. B., 2016, ELECTROPHYSIOLOGY PS, V28, P1, DOI DOI 10.1007/7854_; Schneider BL, 2016, J NEUROTRAUM, V33, P1614, DOI 10.1089/neu.2015.4190; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shvil E, 2014, NEUROBIOL LEARN MEM, V113, P101, DOI 10.1016/j.nlm.2014.02.003; Sierra-Mercado D, 2015, BRAIN RES, V1606, P133, DOI 10.1016/j.brainres.2015.02.031; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; VanElzakker MB, 2014, NEUROBIOL LEARN MEM, V113, P3, DOI 10.1016/j.nlm.2013.11.014; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vogt D, 2013, J TRAUMA STRESS, V26, P710, DOI 10.1002/jts.21868; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wessa M, 2007, AM J PSYCHIAT, V164, P1684, DOI 10.1176/appi.ajp.2007.07030525; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Wohleb ES, 2014, J NEUROSCI, V34, P2583, DOI 10.1523/JNEUROSCI.3723-13.2014; Yeh PH, 2017, HUM BRAIN MAPP, V38, P352, DOI 10.1002/hbm.23365; Yurgil KA, 2016, J HEAD TRAUMA REHAB, V31, P30, DOI 10.1097/HTR.0000000000000117; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593	89	17	17	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	AUG	2017	34	8					723	733		10.1002/da.22642			11	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	FC4TZ	WOS:000406835000007	28489272				2021-06-18	
J	Wade, SL; Narad, ME; Kingery, KM; Taylor, HG; Stancin, T; Kirkwood, MW; Yeates, KO				Wade, Shari L.; Narad, Megan E.; Kingery, Kathleen M.; Taylor, H. Gerry; Stancin, Terry; Kirkwood, Michael W.; Yeates, Keith O.			Teen Online Problem Solving for Teens With Traumatic Brain Injury: Rationale, Methods, and Preliminary Feasibility of a Teen Only Intervention	REHABILITATION PSYCHOLOGY			English	Article						problem solving intervention; traumatic brain injury; telehealth	COGNITIVE PREDICTORS; PRELIMINARY EFFICACY; FAMILY INTERVENTION; ADOLESCENTS; CHILDHOOD; CHILDREN; BEHAVIOR; OUTCOMES; THERAPY; SKILLS	Purpose/Objective: To describe the Teen Online Problem Solving-Teen Only (TOPS-TO) intervention relative to the original Teen Online Problem Solving-Family (TOPS-F) intervention, to describe a randomized controlled trial to assess intervention efficacy, and to report feasibility and acceptability of the TOPS-TO intervention. Research method and design: This is a multisite randomized controlled trial, including 152 teens (49 TOPS-F, 51 TOPS-TO, 52 IRC) between the ages of 11-18 who were hospitalized for a moderate to severe traumatic brain injury in the previous 18 months. Assessments were completed at baseline, 6-months post baseline, and 12-months post baseline. Data discussed include adherence and satisfaction data collected at the 6-month assessment (treatment completion) for TOPS-F and TOPS-TO. Results: Adherence measures (sessions completed, dropout rates, duration of treatment engagement, and rates of program completion) were similar across treatment groups. Overall, teen and parent reported satisfaction was high and similar across groups. Teens spent a similar amount of time on the TOPS website across groups, and parents in the TOPS-F spent more time on the TOPS website than those in the TOPS-TO group (p = .002). Parents in the TOPS-F group rated the TOPS website as more helpful than those in the TOPS-TO group (p = .05). Conclusions/Implications: TOPS-TO intervention is a feasible and acceptable intervention approach. Parents may perceive greater benefit from the family based intervention. Further examination is required to understand the comparative efficacy in improving child and family outcomes, and who is likely to benefit from each approach.	[Wade, Shari L.; Narad, Megan E.; Kingery, Kathleen M.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave MLC 3015, Cincinnati, OH 45229 USA; [Kingery, Kathleen M.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Dept Pediat, Div Pediat Psychol, Cleveland, OH 44106 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Boulder, CO 80309 USA; [Yeates, Keith O.] Univ Calgary, Alberta Childrens Hosp Res Inst, Hotchkiss Brain Inst, Dept Psychol, Calgary, AB, Canada	Narad, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave MLC 3015, Cincinnati, OH 45229 USA.	M@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133B090010]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD088011] Funding Source: NIH RePORTER	This project was supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (grant H133B090010).	Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; D'Zurilla TJ, 2010, HDB COGNITIVE BEHAV, V3, P197; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAZDIN AE, 1992, J CONSULT CLIN PSYCH, V60, P733, DOI 10.1037/0022-006X.60.5.733; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lazarus R.S., 1984, STRESS APPRAISAL COP; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; NEZU AM, 1986, J CONSULT CLIN PSYCH, V54, P196, DOI 10.1037/0022-006X.54.2.196; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Puskar Kathryn, 2003, J Child Adolesc Psychiatr Nurs, V16, P71, DOI 10.1111/j.1744-6171.2003.tb00350.x; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Spence SH, 2003, J CONSULT CLIN PSYCH, V71, P3, DOI 10.1037/0022-006X.71.1.3; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006	31	17	17	0	3	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2017	62	3					290	299		10.1037/rep0000160			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	FT3KV	WOS:000423046900008	28836809	Bronze, Green Accepted			2021-06-18	
J	Bertisch, H; Rivara, FP; Kisala, PA; Wang, J; Yeates, KO; Durbin, D; Zonfrillo, MR; Bell, MJ; Temkin, N; Tulsky, DS				Bertisch, Hilary; Rivara, Frederick P.; Kisala, Pamela A.; Wang, Jin; Yeates, Keith Owen; Durbin, Dennis; Zonfrillo, Mark R.; Bell, Michael J.; Temkin, Nancy; Tulsky, David S.			Psychometric evaluation of the pediatric and parent-proxy Patient-Reported Outcomes Measurement Information System and the Neurology and Traumatic Brain Injury Quality of Life measurement item banks in pediatric traumatic brain injury	QUALITY OF LIFE RESEARCH			English	Article						Brain Injuries; Child; Adolescent; Outcome assessment (Health Care); Patient-centered outcomes research	PROMISA(R) PHYSICAL FUNCTION; RESPONSE THEORY ANALYSIS; GENERIC CORE SCALES; DIFFICULTIES QUESTIONNAIRE; CHRONIC PAIN; SELF-REPORT; POSTCONCUSSIVE SYMPTOMS; SEDENTARY BEHAVIOR; ORTHOPEDIC FOOT; STRENGTH IMPACT	The primary objective is to provide evidence of convergent and discriminant validity for the pediatric and parent-proxy versions of the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety, Depression, Anger, Peer Relations, Mobility, Pain Interference, and Fatigue item banks, the Neurology Quality of Life measurement system (Neuro-QOL) Cognition-General Concerns and Stigma item banks, and the Traumatic Brain Injury Quality of Life (TBI-QOL) Executive Function and Headache item banks in a pediatric traumatic brain injury (TBI) sample. Participants were 134 parent-child (ages 8-18 years) days. Children all sustained TBI and the dyads completed outcome ratings 6 months after injury at one of six medical centers across the United States. Ratings included PROMIS, Neuro-QOL, and TBI-QOL item banks, as well as the Pediatric Quality of Life inventory (PedsQL), the Health Behavior Inventory (HBI), and the Strengths and Difficulties Questionnaire (SDQ) as legacy criterion measures against which these item banks were validated. The PROMIS, Neuro-QOL, and TBI-QOL item banks demonstrated good convergent validity, as evidenced by moderate to strong correlations with comparable scales on the legacy measures. PROMIS, Neuro-QOL, and TBI-QOL item banks showed weaker correlations with ratings of unrelated constructs on legacy measures, providing evidence of discriminant validity. Our results indicate that the constructs measured by the PROMIS, Neuro-QOL, and TBI-QOL item banks are valid in our pediatric TBI sample and that it is appropriate to use these standardized scores for our primary study analyses.	[Bertisch, Hilary] NYU, Sch Med, NYU Rusk Rehabil, 240 East 38th St,Suite 17-72, New York, NY 10016 USA; [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle Childrens Res Inst, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle Childrens Res Inst, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Kisala, Pamela A.] Univ Delaware, Dept Phys Therapy, Ctr Assessment Res & Translat, Newark, DE USA; [Wang, Jin] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Durbin, Dennis] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Brown Univ, Alpert Med Sch, Hasbro Childrens Hosp, Dept Emergency Med, Providence, RI 02912 USA; [Bell, Michael J.] Univ Pittsburgh, Crit Care Med, Neurol Surg & Pediat, Pittsburgh, PA USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Tulsky, David S.] Univ Delaware, Ctr Assessment Res & Translat, Dept Phys Therapy, Newark, DE USA; [Tulsky, David S.] Univ Delaware, Ctr Assessment Res & Translat, Dept Psychol & Brain Sci, Newark, DE USA; [Tulsky, David S.] Kessler Fdn, W Orange, NJ USA	Bertisch, H (corresponding author), NYU, Sch Med, NYU Rusk Rehabil, 240 East 38th St,Suite 17-72, New York, NY 10016 USA.	Hilary.bertisch@nyumc.org	Yeates, Keith/AAJ-4223-2020; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Tulsky, David/0000-0002-4335-4509; Yeates, Keith/0000-0001-7680-2892	United States Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002196]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002196] Funding Source: NIH RePORTER	This project was funded by the United States Centers for Disease Control and Prevention, Grant Number U01CE002196. The authors would like to thank Marni Levy and Natalie Jenkins for their dedicated efforts in acquiring the data described in this manuscript.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bevans KB, 2013, J PEDIATR PSYCHOL, V38, P173, DOI 10.1093/jpepsy/jss107; Broderick Joan E, 2013, EGEMS (Wash DC), V1, P1015, DOI 10.13063/2327-9214.1015; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carle AC, 2011, EXPERT REV PHARM OUT, V11, P677, DOI [10.1586/erp.11.74, 10.1586/ERP.11.74]; Carlsson M, 2008, DEV MED CHILD NEUROL, V50, P784, DOI 10.1111/j.1469-8749.2008.03090.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cella D, 2010, INVERSTIGATORS N Q; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Centers for Disease Control and Prevention, 2016, INJ PREV CONTR TRAUM; Centers for Disease Control and Prevention, 1999, TBI US REP C; Clover A., 2006, MBMC PUBLIC HLTH, V6, P105; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; de Kloet AJ, 2015, J DEV BEHAV PEDIATR, V36, P342, DOI 10.1097/DBP.0000000000000169; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; DeWalt DA, 2015, QUAL LIFE RES, V24, P2195, DOI 10.1007/s11136-015-0953-3; DeWalt DA, 2013, HEALTH PSYCHOL, V32, P1093, DOI 10.1037/a0032670; DeWitt EM, 2011, J CLIN EPIDEMIOL, V64, P794, DOI 10.1016/j.jclinepi.2010.10.012; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fries JF, 2005, CLIN EXP RHEUMATOL, V23, pS53; Gershon R, 2010, QUAL LIFE RES, V19, P677, DOI 10.1007/s11136-010-9634-4; Gershon Richard C, 2005, J Appl Meas, V6, P109; Gershon Richard C, 2010, J Appl Meas, V11, P304; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Gipson DS, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-30; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Green L, 2012, DEV NEUROREHABIL, V15, P105, DOI 10.3109/17518423.2011.638331; Hinds PS, 2013, PEDIATR BLOOD CANCER, V60, P402, DOI 10.1002/pbc.24233; Ho B, 2016, FOOT ANKLE INT, V37, P911, DOI 10.1177/1071100716665113; Howell CR, 2016, QUAL LIFE RES, V25, P1815, DOI 10.1007/s11136-016-1237-2; Hung M, 2014, FOOT ANKLE INT, V35, P592, DOI 10.1177/1071100714528492; Hung M, 2013, CLIN ORTHOP RELAT R, V471, P3466, DOI 10.1007/s11999-013-3097-1; Hunt KJ, 2014, FOOT ANKLE INT, V35, P847, DOI 10.1177/1071100714544157; Irwin DE, 2012, QUAL LIFE RES, V21, P697, DOI 10.1007/s11136-011-9969-5; Irwin DE, 2010, QUAL LIFE RES, V19, P595, DOI 10.1007/s11136-010-9619-3; Irwin DE, 2010, QUAL LIFE RES, V19, P585, DOI 10.1007/s11136-010-9618-4; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobson CJ, 2013, J PEDIATR PSYCHOL, V38, P82, DOI 10.1093/jpepsy/jss099; Jacobson CJ, 2015, J PAIN, V16, P1243, DOI 10.1016/j.jpain.2015.08.007; Johnson H, 2005, DEV MED CHILD NEUROL, V47, P237, DOI 10.1017/S0012162205000460; Kashikar-Zuck S, 2015, PAIN; Kratz AL, 2013, QUAL LIFE RES, V22, P2865, DOI 10.1007/s11136-013-0397-6; Lai JS, 2015, EPILEPSY BEHAV, V46, P209, DOI 10.1016/j.yebeh.2015.02.038; Lai JS, 2013, QUAL LIFE RES, V22, P2417, DOI 10.1007/s11136-013-0357-1; Lai JS, 2012, NEUROREHAB NEURAL RE, V26, P36, DOI 10.1177/1545968311412054; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Liu YY, 2015, QUAL LIFE RES, V24, P1491, DOI 10.1007/s11136-014-0870-x; Mano KEJ, 2011, J PEDIATR PSYCHOL, V36, P517, DOI 10.1093/jpepsy/jsp099; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Mulcahey MJ, 2016, J PEDIATR ORTHOPED, V36, P749, DOI 10.1097/BPO.0000000000000533; (NINDS) NIoNDaS, 2015, MAN QUAL LIF NEUR DI; Olsson GM, 2008, NORD J PSYCHIAT, V62, P66, DOI 10.1080/08039480801979586; Organization PH, PROMIS DOM FRAM; Papuga MO, 2016, SPINE, V41, P1153, DOI 10.1097/BRS.0000000000001518; Quinn H, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0160-x; Ravens-Sieberer U, 2014, J CLIN EPIDEMIOL, V67, P207, DOI 10.1016/j.jclinepi.2013.08.018; Reeve BB, 2015, QUALITY LIFE RES INT; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schalet BD, 2015, J GEN INTERN MED, V30, P1517, DOI 10.1007/s11606-015-3360-0; Selewski DT, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-29; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Stroke NIoNDa, 2014, NINDS COMM DAT EL PR; Swanson JO, 2012, PEDIATR RADIOL, V42, P974, DOI 10.1007/s00247-012-2372-8; Thissen D, 2016, QUAL LIFE RES, V25, P13, DOI 10.1007/s11136-015-1058-8; Thissen D, 2011, QUAL LIFE RES, V20, P1497, DOI 10.1007/s11136-011-9874-y; Tucker CA, 2014, PEDIATR PHYS THER, V26, P385, DOI 10.1097/PEP.0000000000000074; Tucker CA, 2014, PEDIATR PHYS THER, V26, P376, DOI 10.1097/PEP.0000000000000073; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; van de Looij-Jansen PM, 2011, BRIT J CLIN PSYCHOL, V50, P127, DOI 10.1348/014466510X498174; Varni James W, 2004, Health Qual Life Outcomes, V2, P55, DOI 10.1186/1477-7525-2-55; Varni JW, 2014, QUAL LIFE RES, V23, P1233, DOI 10.1007/s11136-013-0544-0; Varni JW, 2010, J PAIN, V11, P1109, DOI 10.1016/j.jpain.2010.02.005; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, J BEHAV MED, V25, P175, DOI 10.1023/A:1014836921812; Wagner LI, 2015, CANCER-AM CANCER SOC, V121, P927, DOI 10.1002/cncr.29104; Weaver B, 2013, BEHAV RES METHODS, V45, P880, DOI 10.3758/s13428-012-0289-7; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Yeatts KB, 2010, J ASTHMA, V47, P295, DOI 10.3109/02770900903426997; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	92	17	17	0	3	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0962-9343	1573-2649		QUAL LIFE RES	Qual. Life Res.	JUL	2017	26	7					1887	1899		10.1007/s11136-017-1524-6			13	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	EY4MS	WOS:000403952800023	28271316				2021-06-18	
J	Byom, L; Turkstra, LS				Byom, Lindsey; Turkstra, Lyn S.			Cognitive task demands and discourse performance after traumatic brain injury	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						traumatic brain injury; social communication; theory of mind; executive function; speech-language pathology	SOCIAL COMMUNICATION; EXECUTIVE FUNCTION; EMOTION RECOGNITION; STORY NARRATIVES; HEAD-INJURY; MIND; ADULTS; LANGUAGE; ADOLESCENTS; DEFICITS	BackgroundSocial communication problems are common in adults with traumatic brain injury (TBI), particularly problems in spoken discourse. Social communication problems are thought to reflect underlying cognitive impairments. AimsTo measure the contribution of two cognitive processes, executive functioning (EF) and theory of mind (ToM), to the communication of adults with TBI, and to investigate the relationships between discourse performance and potential communication partners' perceptions. Methods & ProceduresTwenty-one adults with moderate-to-severe TBI and 23 uninjured adults completed a discourse task in which EF and ToM demands were manipulated across three conditions: baseline, high-EF and high-ToM. Dependent variables were fluency (for EFs), number of mental state terms (MSTs; for ToM) and speech rate. Discourse from high-EF/ToM conditions was judged by naive raters for social acceptability. Outcomes & ResultsThe TBI group produced significantly fewer MSTs than the comparison group across conditions and also spoke at a slower rate, and there were significant effects of condition on both measures (MST: high-EF < baseline = high-ToM; speech rate: high-EF < high-ToM < baseline). There were no significant between-groups differences in fluency or interaction of fluency with condition. MST use and fluency were associated with social acceptability ratings. Conclusions & ImplicationsResults added further evidence of social communication problems in adults with TBI and demonstrated that discourse behaviours may negatively affect how a speaker is perceived. Results also indicated that task manipulations can affect discourse performance, suggesting that general cognitive demands may influence social communication after TBI.	[Byom, Lindsey; Turkstra, Lyn S.] William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA; [Byom, Lindsey] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA	Byom, L (corresponding author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA.	lindsey.byom@va.gov	Byom, Lindsey/AAC-5095-2019	Byom, Lindsey/0000-0002-2457-1735	Wisconsin Alumni Research Foundation; Walker Foundation; NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31DC012481]; University of Wisconsin-Madison Department of Communication Sciences and Disorders Interdisciplinary training grant NIDCD [T32DC005259]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R56DC005259, R01DC005259, F31DC012481] Funding Source: NIH RePORTER	This manuscript was prepared at the William S. Middleton Memorial Veteran Affairs Hospital in Madison, WI; GRECC manuscript #2015-014. The views and content expressed in this article are solely the responsibility of the authors and do not necessarily reflect the position, policy, or official views of the Department of Veteran Affairs or the U.S. government. This work was supported in part by funds from the Wisconsin Alumni Research Foundation and the Walker Foundation, as well as through fellowship support to the first author from NIDCD F31DC012481 and from the University of Wisconsin-Madison Department of Communication Sciences and Disorders Interdisciplinary training grant NIDCD T32DC005259. The authors thank Professor Skye McDonald for comments made on an earlier version of the manuscript; and Sarah Riedeman and Rachel Solomon for assistance with data analysis. The authors also thank the participants and their families for participation in this study.	Adrian JE, 2005, J CHILD LANG, V32, P673, DOI 10.1017/S0305000905006963; Ambady N, 2000, ADV EXP SOC PSYCHOL, V32, P201, DOI 10.1016/S0065-2601(00)80006-4; Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; BATES E, 1983, CAN J PSYCHOL, V37, P59, DOI 10.1037/h0080695; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Breau LM, 2015, J CHILD NEUROL, V30, P588, DOI 10.1177/0883073814528282; BRETHERTON I, 1982, DEV PSYCHOL, V18, P906, DOI 10.1037/0012-1649.18.6.906; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Byom Lindsey J, 2013, Front Hum Neurosci, V7, P413, DOI 10.3389/fnhum.2013.00413; Byom LJ, 2012, INT J LANG COMM DIS, V47, P310, DOI 10.1111/j.1460-6984.2011.00102.x; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DKEFS DELIS KAPLAN E; Despins EH, 2016, ARCH PHYS MED REHAB, V97, pS26, DOI 10.1016/j.apmr.2014.06.023; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); FAGAN WT, 1982, RES TEACH ENGL, V16, P85; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Ghayoumi Z, 2015, ARCH TRAUMA RES, V4, DOI 10.5812/atr.21473; IBM, 2013, SPSS STAT MAC VERS 2; Jones CA, 2011, BRAIN INJURY, V25, P844, DOI 10.3109/02699052.2011.585507; Kertesz A., 1982, W APHASIA BATTERY; KOWAL S, 1975, J PSYCHOLINGUIST RES, V4, P195, DOI 10.1007/BF01066926; Le K, 2014, AM J SPEECH-LANG PAT, V23, P271, DOI 10.1044/2014_AJSLP-13-0095; MacWhinney B., 2000, CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL; Marini A, 2014, NEUROPSYCHOLOGIA, V64, P282, DOI 10.1016/j.neuropsychologia.2014.09.042; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moran C, 2012, LANG SPEECH HEAR SER, V43, P264, DOI 10.1044/0161-1461(2011/10-0114); Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; QUALTRICS, 2013, QUALTR SURV SUIT VER; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Sainson C., 2014, Annals of Physical and Rehabilitation Medicine, V57, P664, DOI 10.1016/j.rehab.2014.08.011; Schmeichel BJ, 2007, J EXP PSYCHOL GEN, V136, P241, DOI 10.1037/0096-3445.136.2.241; Sedikides C., 1999, REPRESENT R SOC PSYC, V23, P1; Stronach ST, 2008, APHASIOLOGY, V22, P1054, DOI 10.1080/02687030701632187; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Turkstra Lyn S, 2004, Acta Neuropsychol, V2, P70; Wechsler D, 1997, WAIS 3 ADM SCORING M; Ybarra O, 2008, PERS SOC PSYCHOL B, V34, P248, DOI 10.1177/0146167207310454	55	17	17	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-2822	1460-6984		INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	JUL-AUG	2017	52	4					501	513		10.1111/1460-6984.12289			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	EZ7VK	WOS:000404933600011	27891725	Green Accepted			2021-06-18	
J	Gu, YZ; Jukkola, P; Wang, Q; Esparza, T; Zhao, Y; Brody, D; Gu, C				Gu, Yuanzheng; Jukkola, Peter; Wang, Qian; Esparza, Thomas; Zhao, Yi; Brody, David; Gu, Chen			Polarity of varicosity initiation in central neuron mechanosensation	JOURNAL OF CELL BIOLOGY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC AXONAL INJURY; BRAIN-INJURY; MOLECULAR-MECHANISMS; STRETCH INJURY; TRP CHANNELS; ION-CHANNEL; ANKYRIN-G; PROTEIN; MICE	Little is known about mechanical regulation of morphological and functional polarity of central neurons. In this study, we report that mechanical stress specifically induces varicosities in the axons but not the dendrites of central neurons by activating TRPV4, a Ca2+/Na+-permeable mechanosensitive channel. This process is unexpectedly rapid and reversible, consistent with the formation of axonal varicosities in vivo induced by mechanical impact in a mouse model of mild traumatic brain injury. In contrast, prolonged stimulation of glutamate receptors induces varicosities in dendrites but not in axons. We further show that axonal varicosities are induced by persistent Ca2+ increase, disassembled microtubules (MTs), and subsequently reversible disruption of axonal transport, and are regulated by stable tubulin-only polypeptide, an MT-associated protein. Finally, axonal varicosity initiation can trigger action potentials to antidromically propagate to the soma in retrograde signaling. Therefore, our study demonstrates a new feature of neuronal polarity: axons and dendrites preferentially respond to physical and chemical stresses, respectively.	[Gu, Yuanzheng; Gu, Chen] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Jukkola, Peter; Gu, Chen] Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA; [Wang, Qian; Zhao, Yi] Ohio State Univ, Biomed Engn Dept, Columbus, OH 43210 USA; [Esparza, Thomas; Brody, David] Washington Univ, Dept Neurol, St Louis, MO USA	Gu, C (corresponding author), Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA.; Gu, C (corresponding author), Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA.	gu.49@osu.edu	Jukkola, Peter/O-4982-2019; Wang, Qian/B-4282-2015	Wang, Qian/0000-0002-9706-2421; Jukkola, Peter/0000-0001-6076-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS062720, R01NS093073, R21AA024873]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062720, R01NS093073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA024873] Funding Source: NIH RePORTER	This work was supported in part by grants from National Institutes of Health (R01NS062720, R01NS093073, and R21AA024873) to C. Gu.	Akhmanova A, 2008, NAT REV MOL CELL BIO, V9, P309, DOI 10.1038/nrm2369; Amack JD, 2012, SCIENCE, V338, P212, DOI 10.1126/science.1223953; Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; Arnadottir J, 2010, ANNU REV BIOPHYS, V39, P111, DOI 10.1146/annurev.biophys.37.032807.125836; Baas PW, 2016, CYTOSKELETON, V73, P442, DOI 10.1002/cm.21286; Barry J, 2014, DEV CELL, V28, P117, DOI 10.1016/j.devcel.2013.11.023; Barry J, 2013, J CELL SCI, V126, P2027, DOI 10.1242/jcs.122234; Barsukova AG, 2012, J NEUROSCI, V32, P12028, DOI 10.1523/JNEUROSCI.0408-12.2012; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Bentley M, 2016, NAT REV NEUROSCI, V17, P611, DOI 10.1038/nrn.2016.100; Betz T, 2011, P NATL ACAD SCI USA, V108, P13420, DOI 10.1073/pnas.1106145108; Beyder A, 2010, J PHYSIOL-LONDON, V588, P4969, DOI 10.1113/jphysiol.2010.199034; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Campas O, 2014, NAT METHODS, V11, P183, DOI [10.1038/NMETH.2761, 10.1038/nmeth.2761]; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cho Y, 2013, CELL, V155, P894, DOI 10.1016/j.cell.2013.10.004; Christensen AP, 2007, NAT REV NEUROSCI, V8, P510, DOI 10.1038/nrn2149; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Couegnas A, 2007, J NEUROSCI RES, V85, P1515, DOI 10.1002/jnr.21278; Debanne D, 2004, NAT REV NEUROSCI, V5, P304, DOI 10.1038/nrn1397; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delmas P, 2011, NAT REV NEUROSCI, V12, P139, DOI 10.1038/nrn2993; Deloulme JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8246; Eastwood SL, 2007, J PSYCHOPHARMACOL, V21, P635, DOI 10.1177/0269881106068825; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fournet V, 2012, J NEUROCHEM, V121, P99, DOI 10.1111/j.1471-4159.2011.07615.x; Franze K, 2009, BIOPHYS J, V97, P1883, DOI 10.1016/j.bpj.2009.07.033; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardner A, 2012, NAT PROTOC, V7, P1774, DOI 10.1038/nprot.2012.100; Gibson HE, 2008, NEURON, V57, P746, DOI 10.1016/j.neuron.2007.12.027; Gilmour D, 2004, NAT NEUROSCI, V7, P491, DOI 10.1038/nn1235; Grevesse T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09475; Gu C, 2006, NEURON, V52, P803, DOI 10.1016/j.neuron.2006.10.022; Gu YZ, 2014, MOL NEUROBIOL, V50, P339, DOI 10.1007/s12035-014-8654-4; Gu YZ, 2013, J PHYSIOL-LONDON, V591, P2491, DOI 10.1113/jphysiol.2013.251983; Gu YZ, 2012, J BIOL CHEM, V287, P1755, DOI 10.1074/jbc.M111.299305; Gu YZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011931; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; Harrington AW, 2013, NAT REV NEUROSCI, V14, P177, DOI 10.1038/nrn3253; Hasbani MJ, 2001, J NEUROSCI, V21, P2393; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jukkola P, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-70; Jukkola PI, 2012, NEUROBIOL DIS, V47, P280, DOI 10.1016/j.nbd.2012.04.012; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kang JS, 2008, CELL, V132, P137, DOI 10.1016/j.cell.2007.11.024; Koleske AJ, 2013, NAT REV NEUROSCI, V14, P536, DOI 10.1038/nrn3486; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lefevre J, 2011, J BIOL CHEM, V286, P3065, DOI 10.1074/jbc.M110.144089; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; MARGOLIS RL, 1986, P NATL ACAD SCI USA, V83, P639, DOI 10.1073/pnas.83.3.639; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Morris CE, 2007, BIOPHYS J, V93, P822, DOI 10.1529/biophysj.106.101246; Namba T, 2015, PHYSIOL REV, V95, P995, DOI 10.1152/physrev.00025.2014; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Richard M, 2009, MOL CELL NEUROSCI, V41, P120, DOI 10.1016/j.mcn.2009.02.004; Rishal I, 2014, NAT REV NEUROSCI, V15, P32, DOI 10.1038/nrn3609; Ryskamp DA, 2011, J NEUROSCI, V31, P7089, DOI 10.1523/JNEUROSCI.0359-11.2011; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; SERRANO L, 1986, J BIOL CHEM, V261, P7076; Shepherd GMG, 1998, J NEUROSCI, V18, P8300; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tseng CY, 2011, J NEUROSCI, V31, P15468, DOI 10.1523/JNEUROSCI.2442-11.2011; van Beuningen SFB, 2016, CURR OPIN NEUROBIOL, V39, P1, DOI 10.1016/j.conb.2016.02.003; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; [王启睿 Wang Qirui], 2013, [空间结构, Spatial Structures], V19, P10; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Xu MX, 2007, J NEUROSCI, V27, P14158, DOI 10.1523/JNEUROSCI.3675-07.2007; Xu MX, 2010, J NEUROSCI, V30, P15987, DOI 10.1523/JNEUROSCI.3565-10.2010; Yang J, 2013, NEURON, V80, P1175, DOI 10.1016/j.neuron.2013.08.034; Zheng Y, 2008, NAT CELL BIOL, V10, P1172, DOI 10.1038/ncb1777; Ziv NE, 1995, J NEUROPHYSIOL, V74, P2625	87	17	17	0	15	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0021-9525	1540-8140		J CELL BIOL	J. Cell Biol.	JUL	2017	216	7					2179	2199		10.1083/jcb.201606065			21	Cell Biology	Cell Biology	EZ2TP	WOS:000404563700029	28606925	Bronze, Green Published			2021-06-18	
J	Keret, A; Bennett-Back, O; Rosenthal, G; Gilboa, T; Shweiki, M; Shoshan, Y; Benifla, M				Keret, Amit; Bennett-Back, Odeya; Rosenthal, Guy; Gilboa, Tal; Shweiki, Moatasim; Shoshan, Yigal; Benifla, Mony			Posttraumatic epilepsy: long-term follow-up of children with mild traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						posttraumatic epilepsy; mild traumatic brain injury; pediatric neurosurgery; trauma	HEAD-INJURY; YOUNG-ADULTS; SEIZURES; RISK; EPIDEMIOLOGY; COHORT; EPILEPTOGENESIS; PREVALENCE; PREDICTORS; MECHANISMS	OBJECTIVE Posttraumatic epilepsy (PTE) is a known complication of traumatic brain injury (TBI). The true incidence of PTE in children is still uncertain, because most research has been based primarily on adults. This study aimed to determine the true incidence of PTE in a pediatric population with mild TBI (MTBI) and to identify risk factors for the development of epileptic events. METHODS Data were collected from electronic medical records of children 0-17 years of age, who were admitted to a single medical center between 2007 and 2009 with a diagnosis of MTBI. This prospective research consisted of a telephone survey between 2015 and 2016 of children or their caregivers, querying for information about epileptic episodes and current seizure and neurological status. The primary outcome measure was the incidence of epilepsy following TBI, which was defined as 2 unprovoked seizure episodes. Posttraumatic seizure (PTS) was defined as a single, nonrecurrent convulsive episode that occurred > 24 hours following injury. Seizures within 24 hours of the injury were defined as immediate PTS. RESULTS Of 290 children eligible for this study, 191 of them or their caregivers were reached by telephone survey and were included in the analysis. Most injuries (80.6%) were due to falls. Six children had immediate PTS. All children underwent CT imaging; of them, 72.8% demonstrated fractures and 10.5% did not demonstrate acute findings. The mean follow-up was 7.4 years. Seven children (3.7%) experienced PTS; of them, 6 (85.7%) developed epilepsy and 3 (42.9%) developed intractable epilepsy. The overall incidence of epilepsy and intractable epilepsy in this cohort was 3.1% and 1.6%, respectively. None of the children who had immediate PTS developed epilepsy. Children who developed epilepsy spent an average of 2 extra days in the hospital at the time of the injury. The mean time between trauma and onset of seizures was 3.1 years. Immediate PTS was not correlated with PTE. CONCLUSIONS In this analysis of data from medical records and long-term follow-up, MTBI was found to confer increased risk for the development of PTE and intractable PTE, of 4.5 and 8 times higher, respectively. As has been established in adults, these findings confirm that MTBI increases the risk for PTE in the pediatric population.	[Keret, Amit; Shweiki, Moatasim; Benifla, Mony] Hadassah Ein Kerem Med Ctr, Pediat Neurosurg Unit, Jerusalem, Israel; [Rosenthal, Guy; Shweiki, Moatasim; Shoshan, Yigal; Benifla, Mony] Hadassah Ein Kerem Med Ctr, Neurosurg Dept, Jerusalem, Israel; [Bennett-Back, Odeya; Gilboa, Tal] Hadassah Ein Kerem Med Ctr, Pediat Neurol Dept, Jerusalem, Israel	Benifla, M (corresponding author), Hadassah Med Ctr, Dept Neurosurg, POB 12000, IL-91120 Jerusalem, Israel.	beniflam@yahoo.com		Keret, Amit/0000-0002-2242-3632			Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Ates O, 2006, CHILD NERV SYST, V22, P279, DOI 10.1007/s00381-005-1177-6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Del Felice A, 2010, EPILEPSIA, V51, P37, DOI 10.1111/j.1528-1167.2009.02141.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Huguenard AL, 2016, J NEUROSURG-PEDIATR, V17, P476, DOI 10.3171/2015.7.PEDS14723; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Iudice A, 2000, DRUGS, V59, P1091, DOI 10.2165/00003495-200059050-00005; Jabbari B, 2002, BRAIN INJURY, V16, P463, DOI 10.1080/02699050110102086; Jobst BC, 2015, JAMA-J AM MED ASSOC, V313, P285, DOI 10.1001/jama.2014.17426; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Matsumoto JH, 2013, EPILEPSY BEHAV, V27, P233, DOI 10.1016/j.yebeh.2013.01.024; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schmidt D, 2005, EPILEPSIA, V46, P858, DOI 10.1111/j.1528-1167.2005.54904.x; Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	42	17	18	1	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUL	2017	20	1					64	70		10.3171/2017.2.PEDS16585			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EY6IZ	WOS:000404087300009	28474982	Bronze			2021-06-18	
J	Lyons, VH; Moore, M; Guiney, R; Ayyagari, RC; Thompson, L; Rivara, FP; Fleming, R; Crawley, D; Harper, D; Vavilala, MS				Lyons, Vivian H.; Moore, Megan; Guiney, Roxanne; Ayyagari, Rajiv C.; Thompson, Leah; Rivara, Frederick P.; Fleming, Robin; Crawley, Deborah; Harper, Dawn; Vavilala, Monica S.			Strategies to Address Unmet Needs and Facilitate Return to Learn Guideline Adoption Following Concussion	JOURNAL OF SCHOOL HEALTH			English	Article						concussion; academic accommodations; traumatic brain injury (TBI); return to learn (RTL) services	QUALITATIVE CONTENT-ANALYSIS; TRAUMATIC BRAIN-INJURY; EDUCATIONAL-SERVICES; SUPPORT; SCHOOL; TBI; RECOMMENDATIONS; REHABILITATION; FRAMEWORK; SYMPTOMS	BACKGROUND: Many students do not receive return to learn (RTL) services upon return to academics following a concussion. METHODS: Using a mixed-methods approach, we conducted a survey of RTL practices and experiences in Washington State schools between January 2015 and June 2015. We then held a statewide summit of RTL stakeholders and used a modified Delphi process to develop a consensus-based RTL implementation model and process. RESULTS: Survey participants included 83 educators, 57 school nurses, 14 administrators, and 30 parents, representing 144 schools in rural and urban areas. Unmet need domains and recommendations identified were (1) a current lack of school policies; (2) barriers to providing or receiving accommodations; (3) wide variability in communication patterns; and (4) recommendations shared by all stakeholder groups (including desire for readily available best practices, development of a formal school RTL policy for easy adoption and more training). Using stakeholder input from RTL summit participants and survey responses, we developed an RTL implementation model and checklist for RTL guideline adoption. CONCLUSIONS: Washington State children have unmet needs upon returning to public schools after concussion. The student-centered RTL model and checklist for implementing RTL guidelines can help schools provide timely RTL services following concussion.	[Lyons, Vivian H.] Univ Washington, Dept Epidemiol, 1959 NE Pacific St,Hlth Sci Bldg,F-262,Box 357236, Seattle, WA 98195 USA; [Moore, Megan] Univ Washington, Sch Social Work, 4101 15th Ave NE, Seattle, WA 98105 USA; [Guiney, Roxanne] Harborview Med Ctr, Dept Psychiat & Behav Sci, 325 9th Ave,Box 359911, Seattle, WA 98104 USA; [Ayyagari, Rajiv C.] Johns Hopkins Univ, 3400 North Charles St, Baltimore, MD 21218 USA; [Thompson, Leah] Seattle Pediat Concuss Res Collaborat, 4800 Sand Point Way NE, Seattle, WA 98105 USA; [Rivara, Frederick P.] Univ Washington, Pediat, Sch Med, Box 359960,325 9th Ave, Seattle, WA 98104 USA; [Fleming, Robin] Off Superintendent Publ Instruct, Hlth Serv Program, 600 Washington St SE, Olympia, WA 98504 USA; [Crawley, Deborah] Brain Injury Alliance Washington, 316 Broadway Suite 305, Seattle, WA 98122 USA; [Harper, Dawn] Issaquah Valley Elementary Sch, 98927 555 Northwest Holly St, Issaquah, WA 98027 USA; [Vavilala, Monica S.] Harborview Injury Prevent & Res Ctr, Seattle, WA 98122 USA; [Vavilala, Monica S.] Univ Washington, Anesthesiol & Pain Med, Sch Med, 401 Broadway, Seattle, WA 98122 USA	Lyons, VH (corresponding author), Univ Washington, Dept Epidemiol, 1959 NE Pacific St,Hlth Sci Bldg,F-262,Box 357236, Seattle, WA 98195 USA.	vlyons@uw.edu; mm99@uw.edu; rmulvih@uw.edu; rayyaga3@jhu.edu; Leah.Thompson@seattlechildrens.org; fpr@uw.edu; Robin.Fleming@k12.wa.us; deborahc@biawa.org; harperd@issaquah.wednet.edu; vavilala@uw.edu			Washington State Department of Health and Human Services Traumatic Brain Injury Council; Seattle Children's Research Institute (SCRI); National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421] Funding Source: NIH RePORTER	This study was funded by the Washington State Department of Health and Human Services Traumatic Brain Injury Council (Award to Dr. M.S.V.), Seattle Children's Research Institute (SCRI) and the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR000421 to Dr. M.M.). The funding sources had no involvement in the study design, data collection, analysis and interpretation of data; in the writing of the report; or in our decision to submit the paper for publication. Special thanks to Molly Fuentes, MD, Christina Schwien, MN, MPH, Sharon Ashman, PhD, Brian Ross, MA, and Mark Gudmastad for their support of this project. We would also like to thank Bud Bannan, MEd, Laura Bienen, David Breiger, PhD, Sara Chrisman, MD, MPH, David Coppel, PhD, Nora Coronado, MSW, MPH, Julie Dawning, MSP, CBIS, Matt Gillingham, Jessica Giordano, MA, AnnGlang, PhD, Kris Harper, BSN, Stanley Herring, MD, Will Hitchcock, Jeanne Hoffman, PhD, Emily Kroshus, ScD, MPH, Cari McCarty, PhD, Anne Messerly, Kristin White, MD, Laura Ploudre, MEd, Benjamin Rogers, Karen Starr, MEd, Elizabeth Stein, BA and Laura Widdice, MN for their engagement in the Return to Learn Summit.	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517; Brown BE., BRAINSTEPS STUDENTS; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Dedoose, 2016, WEB APPL MAN AN PRES; Delahunty SE, 2015, J SCHOOL HEALTH, V85, P17, DOI 10.1111/josh.12219; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Glang A, 2004, NEUROREHABILITATION, V19, P219; Glang A, 1996, CHILDREN ACQUIRED BR; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hsu C-C., 2007, PRACT ASSESSMENT RES, V12, P1; Johnson R. B., 2004, AM ED RES ASS, V33, P14, DOI [10.3102/0013189X033007014, DOI 10.3102/0013189X033007014]; Johnson RB, 2007, J MIX METHOD RES, V1, P112, DOI 10.1177/1558689806298224; Kay MC, 2015, J SPORT REHABIL, V24, P210, DOI 10.1123/jsr.2013-0132; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Laxe S, 2015, NEUROCIRUGIA, V26, P84, DOI 10.1016/j.neucir.2014.09.008; Leonhard M.J., 2015, INJURY EPIDEMIOLOGY, V2, P32, DOI DOI 10.1186/s40621-015-0063-2; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McAvoy K., REAP BENEFITS GOOD C; ORCAS Inc, 2011, ORCAS INC POL RES HD; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Shaklai S, 2014, BRAIN INJURY, V28, P915, DOI 10.3109/02699052.2013.862739; StataCorp, 2015, STAT STAT SOFTW REL; Su Y. R. S., 2016, TRANSLATIONAL RES TR, P163; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	34	17	17	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	JUN	2017	87	6					416	426		10.1111/josh.12510			11	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	EW8ME	WOS:000402772000003	28463445				2021-06-18	
J	Meeuwisse, WH; Schneider, KJ; Dvorak, J; Omu, O; Finch, CF; Hayden, KA; McCrory, P				Meeuwisse, Willem H.; Schneider, Kathryn J.; Dvorak, Jiri; Omu, Onutobor (Tobi); Finch, Caroline F.; Hayden, K. Alix; McCrory, Paul			The Berlin 2016 process: a summary of methodology for the 5th International Consensus Conference on Concussion in Sport	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							STATEMENT; ZURICH	The purpose of this paper is to summarise the methodology for the 5th International Consensus Conference on Concussion in Sport. The 18 months of preparation included engagement of a scientific committee, an expert panel of 33 individuals in the field of concussion and a modified Delphi technique to determine the primary questions to be answered. The methodology also involved the writing of 12 systematic reviews to inform the consensus conference and submission and review of scientific abstracts. The meeting itself followed a 2-day open format, a 1-day closed expert panel meeting and two additional half day meetings to develop the Concussion Recognition Tool 5 (Pocket CRT5), Sport Concussion Assessment Tool 5 (SCAT5) and Child SCAT5.	[Meeuwisse, Willem H.; Schneider, Kathryn J.; Omu, Onutobor (Tobi)] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Dvorak, Jiri] Schulthess Clin Zurich, Swiss Concuss Ctr, Zurich, Switzerland; [Finch, Caroline F.] Federat Univ Australia, Australian Collaborat Res Injury Sport & Its Prev, SMB Campus, Ballarat, Vic, Australia; [Hayden, K. Alix] Univ Calgary, Lib & Cultural Resources, Calgary, AB, Canada; [McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia	Schneider, KJ (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada.	kjschnei@ucalgary.ca	McCrory, Paul/Q-8688-2019; Iriti, Marcello/Q-8580-2017	Iriti, Marcello/0000-0002-5063-1236; McCrory, Paul/0000-0003-4850-0568; Schneider, Kathryn/0000-0002-5951-5899	University of Calgary from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions; FIFA; Alberta Children's Hospital Research Institute; Hotchkiss Brain Institute; IOC; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Province of Alberta; Cogstate Inc.; Australian Football League; NFL	WHM is the medical director of the National Hockey League. He has received research grant support through the University of Calgary from the Canadian Institutes of Health Research, Alberta Innovates Health Solutions, the FIFA, Alberta Children's Hospital Research Institute and the Hotchkiss Brain Institute. He is the founding chair of the Sport Injury Prevention Research Centre, which is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the IOC. He has a clinical consulting practice in sport medicine at the University of Calgary Sport Medicine Centre. He is an expert group member of the IOC Medical Commission and has received travel funding in that capacity. KJS is a physiotherapy consultant at Evidence Sport and Spinal Therapy in Calgary, Alberta, Canada. She has received honoraria for speaking at various conferences. She has received research grant support through the University of Calgary from the Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute and the Canada Foundation for Innovation (including matching funds through the Province of Alberta). She is a faculty member at the Sport Injury Prevention Research Centre, within is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the IOC. CFF is a member of World Rugby's Independent Expert Panel on Concussion. She was not involved in any other aspects of the International Consensus Conference on Concussion in Sport except for the planning for the Delphi study and review and editing of the manuscript. PM is a coinvestigator, collaborator, or consultant on grants relating to mild TBI funded by several governmental organisations. He is directly employed by the National Health and Medical Research Council of Australia and is based at the Florey Institute of Neuroscience and Mental Health. He is co-chair of the Australian Centre for Research into Sports Injury and its Prevention (ACRISP), which is one of the International University Research Centres for Prevention of Injury and Protection of Athlete Health supported by the IOC. He is co-chair of the International Concussion in Sport Group. He has a clinical and consulting practise in general and sports neurology. He receives book royalties from McGraw-Hill and was employed in an editorial capacity by the British Medical Journal Publishing Group from 2001 to 2008. He has been reimbursed by the government, professional scientific bodies and sporting bodies for travel costs related to presenting research on mild TBI and sport-related concussion at meetings, scientific conferences and symposiums. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received research funding since 2001 from Cogstate Inc. He has not received any research funding, salary or other monies from the Australian Football League, FIFA or the NFL. The Australian Football League funds research at the Florey Institute under a legal memorandum and PM does not receive any money from this industry-funded research. PM is a cofounder and shareholder in two biomedical companies (involved in eHealth and Compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessment or technology.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGowan J, 2016, TABLE 10 PRESS GUIDE; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; White PE, 2014, BRIT J SPORT MED, V48, P130, DOI 10.1136/bjsports-2013-092720	7	17	17	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					873	876		10.1136/bjsports-2017-097569			4	Sport Sciences	Sport Sciences	EW3QP	WOS:000402416500007	28446449	Bronze			2021-06-18	
J	Mollayeva, T; Colantonio, A; Cassidy, JD; Vernich, L; Moineddin, R; Shapiro, CM				Mollayeva, Tatyana; Colantonio, Angela; Cassidy, J. David; Vernich, Lee; Moineddin, Rahim; Shapiro, Colin M.			Sleep stage distribution in persons with mild traumatic brain injury: a polysomnographic study according to American Academy of Sleep Medicine standards	SLEEP MEDICINE			English	Article						Nocturnal wakefulness; REM sleep; Non-REM sleep; Slow-wave sleep; Sex differences; Normative data	EYE-MOVEMENT SLEEP; HEAD TRAUMA; CONCUSSION; ARCHITECTURE; DEPRIVATION; DISTURBANCE; DISORDER; INSOMNIA; SYNCOPE; SPORT	Objective and background: Sleep stage disruption in persons with mild traumatic brain injury (mTBI) has received little research attention. We examined deviations in sleep stage distribution in persons with mTBI relative to population age- and sex-specific normative data and the relationships between such deviations and brain injury-related, medical/psychiatric, and extrinsic factors. Patients and methods: We conducted a cross-sectional polysomnographic investigation in 40 participants diagnosed with mTBI (mean age 47.54 11.30 years; 56% males). Measurements: At the time of investigation, participants underwent comprehensive clinical and neuroimaging examinations and one full-night polysomnographic study. We used the 2012 American Academy of Sleep Medicine recommendations for recording, scoring, and summarizing sleep stages. We compared participants' sleep stage data with normative data stratified by age and sex to yield z-scores for deviations from available population norms and then employed stepwise multiple regression analyses to determine the factors associated with the identified significant deviations. Results: In patients with mTBI, the mean duration of nocturnal wakefulness was higher and consolidated sleep stage N2 and REM were lower than normal (p < 0.0001, p = 0.018, and p = 0.010, respectively). In multivariate regression analysis, several covariates accounted for the variance in the relative changes in sleep stage duration. No sex differences were observed in the mean proportion of non-REM or REM sleep. Conclusions: We observed longer relative nocturnal wakefulness and shorter relative N2 and REM sleep in patients with mTBI, and these outcomes were associated with potentially modifiable variables. Addressing disruptions in sleep architecture in patients with mTBI could improve their health status. (C) 2017 Elsevier B.V.All rights reserved.	[Mollayeva, Tatyana; Colantonio, Angela] Univ Toronto, Fac Med, Rehabil Sci Inst, Toronto, ON, Canada; [Mollayeva, Tatyana] Univ Toronto, Collaborat Program Neurosci, Toronto, ON, Canada; [Mollayeva, Tatyana] Toronto Rehab Univ Hlth Network, Toronto, ON, Canada; [Shapiro, Colin M.] Univ Toronto, Fac Arts & Sci, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Acquired Brain Injury Res Lab, Toronto, ON, Canada; [Shapiro, Colin M.] Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada; [Shapiro, Colin M.] Youthdale Child & Adolescent Sleep Clin, Toronto, ON, Canada; [Cassidy, J. David] Univ Hlth Network, Krembil Res Inst, Div Hlth Care & Outcomes Res, Toronto, ON, Canada; [Cassidy, J. David; Vernich, Lee; Moineddin, Rahim] Univ Toronto, Dalla Lana Sch Publ Hlth, Inst Hlth Policy Management & Evaluat, Div Epidemiol, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Mollayeva, T (corresponding author), Univ Toronto, Toronto Rehabil Inst, Univ Hlth Network, Rehabil Sci Inst, 550 Univ Ave,Room 11-183, Toronto, ON MSG 2A2, Canada.	tatyana.mollayeva@utoronto.ca	, Mollayeva/A-4522-2018	Colantonio, Angela/0000-0003-2094-4765; Moineddin, Rahim/0000-0002-5506-084X; Mollayeva, Tatyana/0000-0002-2787-1848	Neurotrauma Foundation Summer Scholarship; Mitacs Accelerate Graduate Internship; Frederick Banting and Charles Best Doctoral Research Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [290950]; Alzheimer's AssociationAlzheimer's Association [AARF-16-442937]; Canadian Institutes for Health Research Grant Institute for Gender and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]; University of TorontoUniversity of Toronto	Our study had no external funding source. The first author was supported by the 2011 Neurotrauma Foundation Summer Scholarship, the 2011/2012 Mitacs Accelerate Graduate Internship, the 2013/2015 Frederick Banting and Charles Best Doctoral Research Award from the Canadian Institutes of Health Research (#290950), and the postdoctoral research fellowship from the University of Toronto and the Alzheimer's Association (AARF-16-442937). Angela Colantonio was supported by the Canadian Institutes for Health Research Grant Institute for Gender and Health (#CGW-126580). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Association of Workers' Compensation Boards of Canada (AWCBC), 2011, NAT RES WORK COMP; Austin PC, 2015, J CLIN EPIDEMIOL, V68, P627, DOI 10.1016/j.jclinepi.2014.12.014; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Berry R.B., 2012, AASM MANUAL SCORING; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; Bjurstrom MF, 2016, SLEEP MED REV, V26, P74, DOI 10.1016/j.smrv.2015.03.004; Borzage M, 2014, BRAIN STRUCT FUNCT, V219, P141, DOI 10.1007/s00429-012-0490-6; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chung F, 2012, BRIT J ANAESTH, V108, P768, DOI 10.1093/bja/aes022; Dang-Vu TT, 2008, P NATL ACAD SCI USA, V105, P15160, DOI 10.1073/pnas.0801819105; DeMartinis Nicholas A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P17, DOI 10.2174/187152707779940835; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dorffner G, 2015, ADV EXP MED BIOL, V821, P93, DOI 10.1007/978-3-319-08939-3_13; ETEVENON P, 1986, NEUROPSYCHOBIOLOGY, V16, P146, DOI 10.1159/000118316; Fogel SM, 2011, NEUROSCI BIOBEHAV R, V35, P1154, DOI 10.1016/j.neubiorev.2010.12.003; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Government of Ontario, 2016, AB ONT; HERSCOVITCH J, 1981, SLEEP, V4, P83, DOI 10.1093/sleep/4.1.83; Hughes SW, 2005, NEUROSCIENTIST, V11, P357, DOI 10.1177/1073858405277450; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; International Statistical Classification of Diseases and Related Health Problems, 2010, SYMPT SIGNS ABN CLIN; Jackson J, 2014, NAT NEUROSCI, V17, P1362, DOI 10.1038/nn.3803; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Lippel K, 2012, AM J IND MED, V55, P519, DOI 10.1002/ajim.22022; Lu W, 2015, BRAIN INJURY, V29, P1342, DOI 10.3109/02699052.2015.1043947; Madigan MF, 1997, PERCEPT MOTOR SKILL, V85, P1451, DOI 10.2466/pms.1997.85.3f.1451; Maestri M, 2015, SLEEP MED, V16, P1139, DOI 10.1016/j.sleep.2015.04.027; Mancebo-Sosa V, 2016, SLEEP SCI, V9, P84, DOI 10.1016/j.slsci.2016.06.002; Maquet P, 2000, J SLEEP RES, V9, P207; MAQUET P, 1992, BRAIN RES, V571, P149, DOI 10.1016/0006-8993(92)90522-B; Maroon JC, 2014, PROG NEUROL SURG, V28, P1, DOI 10.1159/000358746; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McEwen BS, 2006, METABOLISM, V55, pS20, DOI 10.1016/j.metabol.2006.07.008; Merica H, 2003, CEREB CORTEX, V13, P1044, DOI 10.1093/cercor/13.10.1044; Mitterling T, 2015, SLEEP, V38, P867, DOI 10.5665/sleep.4730; Mollayeva T, 2013, ENCY SLEEP; Mollayeva T, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0657-2; Mollayeva T, 2013, SLEEP MED, V14, P1235, DOI 10.1016/j.sleep.2013.07.009; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nofzinger EA, 2004, ARCH GEN PSYCHIAT, V61, P695, DOI 10.1001/archpsyc.61.7.695; Oosterhuis HEM, 2017, PSYCHOMETRIKA, V82, P559, DOI 10.1007/s11336-016-9535-8; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Popat RA, 2010, SLEEP MED, V11, P154, DOI 10.1016/j.sleep.2009.01.012; Puel V, 2013, INT J CARDIOL, V168, P1666, DOI 10.1016/j.ijcard.2013.03.061; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Sheehan A, 2012, EMERG MED J, V29, P899, DOI 10.1136/emermed-2011-200155; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Stone AA, 2002, ANN BEHAV MED, V24, P236, DOI 10.1207/S15324796ABM2403_09; Sturzenegger C, 2004, J SLEEP RES, V13, P395, DOI 10.1111/j.1365-2869.2004.00422.x; Thase Michael E, 2006, Dialogues Clin Neurosci, V8, P217; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; van der Helm E, 2011, CURR BIOL, V21, P2029, DOI 10.1016/j.cub.2011.10.052; Varga AW, 2016, SLEEP, V39, P2041, DOI 10.5665/sleep.6240; Vitiello M V, 1989, Clin Geriatr Med, V5, P289; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; WILLIAMS RL, 1974, ELECTROENCEPHALOGRAP, P49; Wolf H, 2014, J NEUROSURG, V120, P447, DOI 10.3171/2013.10.JNS13726; World Health Organization, 2010, NEUR DIS PUBL HLTH C; Xiong C, 2016, DISABIL HEALTH J, V9, P439, DOI 10.1016/j.dhjo.2015.12.002; Zysko D, 2014, CARDIOL J, V21, P674, DOI 10.5603/CJ.2014.0099	69	17	17	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	JUN	2017	34						179	192		10.1016/j.sleep.2017.02.021			14	Clinical Neurology	Neurosciences & Neurology	EW2VF	WOS:000402353400028	28522089				2021-06-18	
J	Sufrinko, AM; Kontos, AP; Apps, JN; McCrea, M; Hickey, RW; Collins, MW; Thomas, DG				Sufrinko, Alicia M.; Kontos, Anthony P.; Apps, Jennifer N.; McCrea, Michael; Hickey, Robert W.; Collins, Michael W.; Thomas, Danny G.			The Effectiveness of Prescribed Rest Depends on Initial Presentation After Concussion	JOURNAL OF PEDIATRICS			English	Article							SPORT-RELATED CONCUSSION; TEST-RETEST RELIABILITY; HIGH-SCHOOL; ACTIVITY LEVEL; SYMPTOMS; RECOVERY; DURATION; SPECIFICITY; SENSITIVITY; DEFICITS	Objective To evaluate if patients with signs of injury respond differently to prescribed rest after concussion compared with patients with symptoms only. Study design Secondary analysis was completed of a prospective randomized controlled trial (NCT01101724) of pediatric concussion patients aged 11-18 years. Patients completed computerized neurocognitive testing and standardized balance assessment at the emergency department within 24 hours of injury and on follow-up (3 and 10 days). Patients were randomized to rest or usual care and completed activity and symptom diaries for 10 days after injury. A series of 2 x 2 ANOVAs with grouping factors of patient group (symptoms, signs) and treatment arm (prescribed rest, standard of care) were used to examine differences on clinical measures. Univariate nonparametric test (ie, X-2 with ORs and 95% CIs) was used to examine the association between treatment arm and symptom status 1-9 days after injury. Results A 2 x 2 factorial ANOVA revealed a significant patient group x treatment arm interaction for symptom score at 3 days after injury (F = 6.31, P = .01, eta(2) = 0.07). Prescribed rest increased the likelihood of still being symptomatic at days 1-6 and 8 (P < .05) for the symptoms group. Rest was beneficial for patients in the signs group on verbal memory performance (t = -2.28, P = .029), but not for the symptoms group. Conclusion Compared with patients with signs of injury, patients with predominantly symptoms were more likely to remain symptomatic after injury if prescribed rest, whereas patients with signs of injury benefited from rest after a concussion. Individualized treatment planning after concussion should start in the emergency department.	[Sufrinko, Alicia M.; Kontos, Anthony P.; Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Sports Med Concuss Program, Pittsburgh, PA USA; [Apps, Jennifer N.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Hickey, Robert W.] Univ Pittsburgh, Pediat Emergency Med, Pittsburgh, PA USA; [Thomas, Danny G.] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Thomas, DG (corresponding author), Childrens Hosp Wisconsin, Corp Ctr, Dept Pediat, Emergency Med, 999 N 92nd St,Ste C550, Milwaukee, WI 53226 USA.	dthomas@mcw.edu		Kontos, Anthony/0000-0002-3749-4310; Thomas, Danny/0000-0002-7470-9835	Injury Research Center of the Medical College of Wisconsin	Funded by the Injury Research Center of the Medical College of Wisconsin. M.C. is a co-founder and 10% shareholder of ImPACT. The other authors declare no conflicts of interest.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bondi CO, 2014, J NEUROTRAUM, V31, P873, DOI 10.1089/neu.2014.3328; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Craton N, 2014, CLIN J SPORT MED, V24, P93, DOI 10.1097/JSM.0000000000000023; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dijk DJ, 2015, J SLEEP RES, V24, P475, DOI 10.1111/jsr.12352; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gibson SR, 2010, MED SCI SPORT EXER, V42, P752, DOI 10.1249/01.MSS.0000386182.12785.e9; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kirkwood MW, 2012, CLIN J SPORT MED, V22, P383, DOI 10.1097/JSM.0b013e31826396fc; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Lovati C, 2017, EXPERT REV NEUROTHER, V17, P239, DOI 10.1080/14737175.2016.1226133; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marshall S.W., 2015, INJURY EPIDEMIOLOGY, V2, P1, DOI [10.1186/s40621-015-0045-4, DOI 10.1186/S40621-015-0045-4]; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider KJ, 2013, BRIT J SPORT MED, V47, pe1; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Waldron-Perrine B, 2015, BRAIN INJURY, V29, P1051, DOI 10.3109/02699052.2015.1004742; Wells EM, 2016, J CHILD NEUROL, V31, P86, DOI 10.1177/0883073815570152	44	17	17	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUN	2017	185						167	172		10.1016/j.jpeds.2017.02.072			6	Pediatrics	Pediatrics	FB1JJ	WOS:000405899400033	28365025				2021-06-18	
J	Treble-Barna, A; Wade, SL; Martin, LJ; Pilipenko, V; Yeates, KO; Taylor, HG; Kurowski, BG				Treble-Barna, Amery; Wade, Shari L.; Martin, Lisa J.; Pilipenko, Valentina; Yeates, Keith Owen; Taylor, H. Gerry; Kurowski, Brad G.			Influence of Dopamine-Related Genes on Neurobehavioral Recovery after Traumatic Brain Injury during Early Childhood	JOURNAL OF NEUROTRAUMA			English	Article						behavior; genetic factors; neurotransmitters; pediatric brain injury; TBI	DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CATECHOL-O-METHYLTRANSFERASE; D2 RECEPTOR-BINDING; AGE-RELATED-CHANGES; EXECUTIVE FUNCTION; WORKING-MEMORY; SIGNIFICANT ASSOCIATION; COGNITIVE PERFORMANCE; FUNCTIONAL OUTCOMES	The present study examined the association of dopamine-related genes with short-and long-term neurobehavioral recovery, as well as neurobehavioral recovery trajectories over time, in children who had sustained early childhood traumatic brain injuries (TBI) relative to children who had sustained orthopedic injuries (OI). Participants were recruited from a prospective, longitudinal study evaluating outcomes of children who sustained a TBI (n = 68) or OI (n = 72) between the ages of 3 and 7 years. Parents completed ratings of child executive function and behavior at the immediate post-acute period (0-3 months after injury); 6, 12, and 18 months after injury; and an average of 3.5 and 7 years after injury. Thirty-two single nucleotide polymorphisms (SNPs) in dopamine-related genes (dopamine receptor D2 [DRD2], solute carrier family 6 member 3 [SLC6A3], solute carrier family 18 member A2 [SLC18A2], catechol-o-methyltransferase [COMT], and ankyrin repeat and kinase domain containing 1 [ANKK1]) were examined in association with short-and long-term executive function and behavioral adjustment, as well as their trajectories over time. After controlling for premorbid child functioning, genetic variation within the SLC6A3 (rs464049 and rs460000) gene was differentially associated with neurobehavioral recovery trajectories over time following TBI relative to OI, with rs464049 surviving multiple testing corrections. In addition, genetic variation within the ANKK1 (rs1800497 and rs2734849) and SLC6A3 (rs464049, rs460000, and rs1042098) genes was differentially associated with short-and long-term neurobehavioral recovery following TBI, with rs460000 and rs464049 surviving multiple testing corrections. The findings provide preliminary evidence that genetic variation in genes involved in DRD2 expression and density (ANKK1) and dopamine transport (SLC6A3) plays a role in neurobehavioral recovery following pediatric TBI.	[Treble-Barna, Amery] Univ Pittsburgh, Sch Med, Div Phys Med & Rehabil, Pittsburgh, PA USA; [Wade, Shari L.; Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Martin, Lisa J.; Pilipenko, Valentina] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Alberta Childrens Hosp Res Inst, Dept Psychol, Calgary, AB, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Martin, Lisa/E-2425-2016; Yeates, Keith/AAJ-4223-2020	Martin, Lisa/0000-0001-8702-9946; Yeates, Keith/0000-0001-7680-2892	Rehabilitation Medicine Scientist Training Program (RMSTP) [K-12 HD001097-16]; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683-01A1, R01 HD42729]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]	Funding for this study was supported in part by the Rehabilitation Medicine Scientist Training Program (RMSTP) K-12 HD001097-16, National Institute for Child Health and Human Development K23HD074683-01A1, R01 HD42729, and Grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other supporting agencies.	Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742; Abraham JE, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-19; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Albrecht B, 2014, J CHILD PSYCHOL PSYC, V55, P914, DOI 10.1111/jcpp.12212; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Backman L, 2011, SCIENCE, V333, P718, DOI 10.1126/science.1204978; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BANNON MJ, 1983, PHARMACOL REV, V35, P53; Barnett JH, 2009, AM J PSYCHIAT, V166, P909, DOI 10.1176/appi.ajp.2009.08081251; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Benes FM, 2001, DEV COGN NEUROSCI, P79; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x; Brehmer Y, 2009, NEUROSCI LETT, V467, P117, DOI 10.1016/j.neulet.2009.10.018; Brocki K, 2009, NEUROSCIENCE, V164, P241, DOI 10.1016/j.neuroscience.2009.01.029; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Conley YP, 2011, PM&R, V3, pS52, DOI 10.1016/j.pmrj.2011.04.004; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; Derogatis L., 1982, BRIEF SYMPTOM INVENT; Diamond A, 2011, PROG BRAIN RES, V189, P319, DOI 10.1016/B978-0-444-53884-0.00032-4; Failla MD, 2015, J HEAD TRAUMA REHAB, V30, pE54, DOI 10.1097/HTR.0000000000000118; Faraone SV, 2005, BIOL PSYCHIAT, V57, P1313, DOI 10.1016/j.biopsych.2004.11.024; Fasano C, 2008, EUR J NEUROSCI, V28, P1480, DOI 10.1111/j.1460-9568.2008.06450.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2008, NEUROCHEM RES, V33, P1940, DOI 10.1007/s11064-008-9693-x; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gizer IR, 2009, HUM GENET, V126, P51, DOI 10.1007/s00439-009-0694-x; Hawi Z, 2015, MOL PSYCHIATR, V20, P289, DOI 10.1038/mp.2014.183; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Haycock JW, 2003, J NEUROCHEM, V87, P574, DOI 10.1046/j.1471-4159.2003.02017.x; Huang WH, 2009, NEUROPSYCHOPHARMACOL, V34, P319, DOI 10.1038/npp.2008.37; Jeong SH, 2015, PSYCHIAT GENET, V25, P119, DOI 10.1097/YPG.0000000000000086; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Karabanov A, 2010, P NATL ACAD SCI USA, V107, P7574, DOI 10.1073/pnas.0911805107; Klingberg T, 2014, TRENDS COGN SCI, V18, P573, DOI 10.1016/j.tics.2014.06.007; Kurowski BG, 2016, J HEAD TRAUMA REHAB, V31, pE1, DOI 10.1097/HTR.0000000000000162; Laakso A, 2005, PHARMACOGENET GENOM, V15, P387, DOI 10.1097/01213011-200506000-00003; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Li DW, 2006, HUM MOL GENET, V15, P2276, DOI 10.1093/hmg/ddl152; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Luciana M, 2012, DEV PSYCHOL, V48, P844, DOI 10.1037/a0027432; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Markos S.M., 2016, J HEAD TRAUMA REHABI; Matthys W, 2013, DEV PSYCHOPATHOL, V25, P193, DOI 10.1017/S0954579412000272; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Myrga J.M., 2015, J HEAD TRAUMA REHAB, V31, pE15; Myrga JM, 2016, NEUROREHAB NEURAL RE, V30, P920, DOI 10.1177/1545968316648409; Narbad M.E., 2016, J HEAD TRAUMA REHABI; Pattij T, 2008, TRENDS PHARMACOL SCI, V29, P192, DOI 10.1016/j.tips.2008.01.002; Rieck M, 2012, PHARMACOGENOMICS, V13, P1701, DOI [10.2217/PGS.12.149, 10.2217/pgs.12.149]; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SEEMAN P, 1987, SYNAPSE, V1, P399, DOI 10.1002/syn.890010503; Sesack SR, 1998, J NEUROSCI, V18, P2697; Shang CY, 2014, INT J NEUROPSYCHOPH, V17, P9, DOI 10.1017/S1461145713000783; Shen W, 2007, NAT NEUROSCI, V10, P1458, DOI 10.1038/nn1972; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Smith HJ, 2013, DEVELOPMENTAL SCI, V16, P515, DOI 10.1111/desc.12046; Smith HJ, 2012, CHILD DEV, V83, P1932, DOI 10.1111/j.1467-8624.2012.01818.x; Soderqvist S, 2014, J COGNITIVE NEUROSCI, V26, P54, DOI 10.1162/jocn_a_00478; Soderqvist S, 2012, DEV PSYCHOL, V48, P836, DOI 10.1037/a0026179; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; TEASDALE G, 1974, LANCET, V2, P81; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Treble-Barna A., NEUROPSYCHO IN PRESS; Treble-Barna A, 2017, J NEUROTRAUM, V34, P353, DOI 10.1089/neu.2016.4476; Treble-Barna A, 2016, DEV PSYCHOL, V52, P1777, DOI 10.1037/dev0000208; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Willmott C, 2014, J NEUROTRAUM, V31, P1507, DOI 10.1089/neu.2013.3308; Willmott C, 2013, BRAIN INJURY, V27, P1281, DOI 10.3109/02699052.2013.809553; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yang LY, 2016, PEDIATR RES, V80, P356, DOI 10.1038/pr.2016.85; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1	87	17	18	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1919	1931		10.1089/neu.2016.4840			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500002	28323555	Green Published			2021-06-18	
J	Yang, DB; Yu, WH; Dong, XQ; Zhang, ZY; Du, Q; Zhu, Q; Che, ZH; Wang, H; Shen, YF; Jiang, L				Yang, Ding-Bo; Yu, Wen-Hua; Dong, Xiao-Qiao; Zhang, Zu-Yong; Du, Quan; Zhu, Qiang; Che, Zhi-Hao; Wang, Hao; Shen, Yong-Feng; Jiang, Li			Serum macrophage migration inhibitory factor concentrations correlate with prognosis of traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						Traumatic brain injury; Macrophage migration inhibitory factor; Prognosis	POSTTRAUMATIC CEREBRAL INFARCTION; FACTOR MIF; COAGULOPATHY; MODERATE; PATHOPHYSIOLOGY; PROGRESSION; HEMORRHAGE; EXPRESSION; REGULATOR; CT	Background: Macrophage migration inhibitory factor (MIF) is a well-known pro-inflammatory cytokine. Serum MIF concentrations are associated with the severity and prognosis of ischemic stroke. Methods: In this prospective, observational study, white blood cell (WBC) count and serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and MIF among 108 severe traumatic brain injury (TBI) patients and 108 controls were measured. We determined whether serum MIF concentrations are associated with inflammation, severity, in-hospital major adverse events (IMAEs) (i.e., in hospital mortality, acute lung injury, acute traumatic coagulopathy, progressive hemorrhagic injury and posttraumatic cerebral infarction) and long-term clinical outcome (i.e., 6-month functional outcome) after TBI. Results: As compared to the controls, serum CRP, IL-6, TNF-a and MIF concentrations were significantly increased. MIF concentrations correlated with WBC count, CRP, IL-6 and TNF-alpha concentrations and Glasgow coma scale (GCS) scores. MIF in serum was independently associated with IMAEs and long-term clinical outcome. Area under receiver operating characteristic curve of MIF concentrations was similar to GCS scores'. Moreover, MIF concentrations markedly improved the predictive value of GCS scores for 6-month unfavorable outcome. Conclusion: Increased serum MIF concentrations have close relation to inflammation, trauma severity and clinical outcomes, substantializing MIF as a good prognostic biomarker after TBI.	[Yang, Ding-Bo] Tumor Hosp Hangzhou City, Dept Neurosurg, 34 Yanguan Lane, Hangzhou 310002, Zhejiang, Peoples R China; [Yu, Wen-Hua; Dong, Xiao-Qiao; Du, Quan; Zhu, Qiang; Che, Zhi-Hao; Wang, Hao; Shen, Yong-Feng; Jiang, Li] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China; [Zhang, Zu-Yong] Hangzhou Hosp Tradit Chinese Med, Dept Neurosurg, 453 Tiyuchang Rd, Hangzhou 310007, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxqhyy@163.com			Zhejiang Province Medical and Health Project [2014KYA177, 2016RCB016]; Hangzhou Medical Research Fund Project [2014Z06, 2016Z10]	The authors thank the staffs in Department of Neurosurgery, The Hangzhou First People's Hospital (Hangzhou, China) for their technical support. This study was supported financially by Zhejiang Province Medical and Health Project (No. 2014KYA177, 2016RCB016) and Hangzhou Medical Research Fund Project (No. 2014Z06, 2016Z10).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Assis DN, 2014, HEPATOLOGY, V59, P580, DOI 10.1002/hep.26664; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Bernhagen Juergen, 1994, Trends in Microbiology, V2, P198, DOI 10.1016/0966-842X(94)90111-H; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Capone-Neto A, 2009, CURR OPIN CRIT CARE, V15, P290, DOI 10.1097/MCC.0b013e32832e383e; Chuang CC, 2004, CRIT CARE MED, V32, P734, DOI 10.1097/01.CCM.0000117170.13320.F4; Chuang TY, 2014, INT J INFECT DIS, V20, P13, DOI 10.1016/j.ijid.2013.12.006; Cohen MJ, 2014, THROMB RES, V133, pS25, DOI 10.1016/j.thromres.2014.03.013; Dong XQ, 2010, CRIT CARE, V14, DOI 10.1186/cc9307; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Frattalone AR, 2013, NEUROSURG CLIN N AM, V24, P309, DOI 10.1016/j.nec.2013.03.006; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harris T, 2012, POSTGRAD MED J, V88, P595, DOI 10.1136/postgradmedj-2011-130285; Hemmila MR, 2017, CRIT CARE CLIN, V33, P193, DOI 10.1016/j.ccc.2016.08.010; Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194; Kim KW, 2016, KOREAN J INTERN MED, V31, P634, DOI 10.3904/kjim.2016.098; Koda M, 2004, ACTA NEUROPATHOL, V108, P31, DOI 10.1007/s00401-004-0853-z; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Latronico N, 2009, J TRAUMA, V66, P1745, DOI 10.1097/TA.0b013e3181a56c8b; Li Y, 2016, ADV MATER TECHNOL-US, V1, DOI 10.1002/admt.201600102; Lolis E, 1996, P ASSOC AM PHYSICIAN, V108, P415; Lv W, 2016, CANCER LETT, V375, P245, DOI 10.1016/j.canlet.2016.02.005; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Shen YF, 2016, CLIN CHIM ACTA, V456, P75, DOI 10.1016/j.cca.2016.02.029; Sheriff FG, 2015, SEMIN NEUROL, V35, P42, DOI 10.1055/s-0035-1544238; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P12, DOI 10.1097/TA.0b013e3182aaa675; Su YH, 2016, ONCOTARGET; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Turtzo LC, 2013, NEUROBIOL DIS, V54, P421, DOI 10.1016/j.nbd.2013.01.016; Wang KY, 2012, CLIN CHIM ACTA, V413, P1737, DOI 10.1016/j.cca.2012.07.002; Wu GQ, 2016, CLIN CHIM ACTA, V458, P124, DOI 10.1016/j.cca.2016.05.001; Zammit Christopher, 2013, Emerg Med Pract, V15, P1; Zis O, 2015, MOL NEUROBIOL, V51, P155, DOI 10.1007/s12035-014-8727-4	38	17	19	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	JUN	2017	469						99	104		10.1016/j.cca.2017.03.030			6	Medical Laboratory Technology	Medical Laboratory Technology	EV6KU	WOS:000401879100016	28366792				2021-06-18	
J	Zhao, ZA; Zhao, Y; Ning, YL; Yang, N; Peng, Y; Li, P; Chen, XY; Liu, D; Wang, H; Chen, X; Bai, W; Chen, JF; Zhou, YG				Zhao, Z-A; Zhao, Y.; Ning, Y-L; Yang, N.; Peng, Y.; Li, P.; Chen, X-Y; Liu, D.; Wang, H.; Chen, X.; Bai, W.; Chen, J-F; Zhou, Y-G			Adenosine A(2A) receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation	TRANSLATIONAL PSYCHIATRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; MICROTUBULE INTERACTIONS; MILITARY PERSONNEL; ALZHEIMERS-DISEASE; PATTERN COMPLETION; IN-VIVO; PHOSPHORYLATION; CAFFEINE; MEMORY	Tau is a microtubule-associated protein, and the oligomeric and hyperphosphorylated forms of tau are increased significantly after neurotrauma and considered important factors in mediating cognitive dysfunction. Blockade of adenosine A(2A) receptors, either by caffeine or gene knockout (KO), alleviates cognitive dysfunction after traumatic brain injury (TBI). We postulated that A(2A)R activation exacerbates cognitive impairment via promoting tau hyperphosphorylation. Using a mouse model of moderate controlled cortical impact, we showed that TBI induced hyperphosphorylated tau (p-tau) in the hippocampal dentate gyrus and spatial memory deficiency in the Morris water maze test at 7 days and 4 weeks after TBI. Importantly, pharmacological blockade (A(2A)R antagonist ZM241385 or non-selective adenosine receptor antagonist caffeine) or genetic inactivation of A(2A)Rs reduced the level of tau phosphorylation at Ser404 and alleviated spatial memory dysfunction. The A(2A)R control of p-tau is further supported by the observations that a KO of A(2A)R decreased the activity of the tau phosphorylation kinases, glycogen synthase kinase-3 beta (GSK-3 beta) and protein kinase A (PKA) after TBI, and by that CGS21680 (A(2A)R agonist) exacerbated okadaic acid-induced tau hyperphosphorylation in cultured primary hippocampal neurons. Lastly, CGS21680-induced neuronal tau hyperphosphorylation and axonal injury were effectively alleviated by individual treatments with ZM241385 (A2AR antagonist), H89 (PKA antagonist) and SB216763 (GSK-3 beta antagonist), or by the combined treatment with H89 and SB216763. Our findings suggest a novel mechanism whereby A(2A)R activation triggers cognitive dysfunction by increasing the phosphorylation level of tau protein after TBI and suggest a promising therapeutic and prophylactic strategy by targeting aberrant A(2A)R signaling via tau phosphorylation.	[Zhao, Z-A; Zhao, Y.; Ning, Y-L; Yang, N.; Peng, Y.; Li, P.; Chen, X-Y; Liu, D.; Chen, X.; Bai, W.; Zhou, Y-G] Third Mil Med Univ, Res Inst Surg, State Key Lab Trauma Burn & Combined Injury, Mol Biol Ctr, Chongqing 400042, Peoples R China; [Zhao, Z-A; Zhao, Y.; Ning, Y-L; Yang, N.; Peng, Y.; Li, P.; Chen, X-Y; Liu, D.; Wang, H.; Chen, X.; Bai, W.; Zhou, Y-G] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Wang, H.] Third Mil Med Univ, Res Inst Surg, Dept Neurosurg, Chongqing, Peoples R China; [Chen, J-F] Boston Univ, Sch Med, Dept Neurol & Pharmacol, Boston, MA 02118 USA	Zhou, YG (corresponding author), Third Mil Med Univ, Res Inst Surg, State Key Lab Trauma Burn & Combined Injury, Mol Biol Ctr, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China.	yuanguo.zhou@gmail.com	Li, ping/J-6507-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471109, 81201461]	This work was supported by the National Natural Science Foundation of China (Nos. 81471109 and 81201461).	ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Batalha VL, 2013, MOL PSYCHIATR, V18, P320, DOI 10.1038/mp.2012.8; Bennett DA, 2004, ARCH NEUROL-CHICAGO, V61, P378, DOI 10.1001/archneur.61.3.378; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Canas PM, 2009, NEUROBIOL AGING, V30, P1877, DOI 10.1016/j.neurobiolaging.2008.01.003; Chakraborti A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040844; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2014, INT REV NEUROBIOL, V119, P1, DOI 10.1016/B978-0-12-801022-8.00001-5; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; Cowan CM, 2010, ACTA NEUROPATHOL, V120, P593, DOI 10.1007/s00401-010-0716-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Cunha RA, 2016, J NEUROCHEM, V139, P1019, DOI 10.1111/jnc.13724; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Ding HP, 2006, J BIOL CHEM, V281, P19107, DOI 10.1074/jbc.M511697200; Duarte JMN, 2006, NEUROCHEM INT, V48, P144, DOI 10.1016/j.neuint.2005.08.008; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gelber RP, 2011, J ALZHEIMERS DIS, V23, P607, DOI 10.3233/JAD-2010-101428; Giralt A, 2011, HUM MOL GENET, V20, P4232, DOI 10.1093/hmg/ddr351; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gruart A, 2012, J NEUROSCI, V32, P17431, DOI 10.1523/JNEUROSCI.4339-12.2012; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Jack CR, 2013, NEURON, V80, P1347, DOI 10.1016/j.neuron.2013.12.003; Jin JJ, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00170; Kaster MP, 2015, P NATL ACAD SCI USA, V112, P7833, DOI 10.1073/pnas.1423088112; Laurent C, 2016, MOL PSYCHIATR, V21, P97, DOI 10.1038/mp.2014.151; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li WZ, 2009, INT CON DISTR COMP S, P215, DOI 10.1109/ICDCS.2009.23; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; Liu F, 2007, EUR J NEUROSCI, V26, P3429, DOI 10.1111/j.1460-9568.2007.05955.x; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Lopes LV, 1999, J NEUROCHEM, V73, P1733, DOI 10.1046/j.1471-4159.1999.731733.x; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Moradi AR, 2012, BEHAV RES THER, V50, P435, DOI 10.1016/j.brat.2012.03.009; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Neunuebel JP, 2014, NEURON, V81, P416, DOI 10.1016/j.neuron.2013.11.017; Ning YL, 2015, CHIN J TRAUMATOL, V18, P204, DOI 10.1016/j.cjtee.2015.10.003; Ning YL, 2013, J CEREBR BLOOD F MET, V33, P1789, DOI 10.1038/jcbfm.2013.127; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Parnass Z, 2000, HIPPOCAMPUS, V10, P561, DOI 10.1002/1098-1063(2000)10:5<561::AID-HIPO6>3.3.CO;2-O; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Ritchie K, 2007, NEUROLOGY, V69, P536, DOI 10.1212/01.wnl.0000266670.35219.0c; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Steinhilb ML, 2007, MOL BIOL CELL, V18, P5060, DOI 10.1091/mbc.E07-04-0327; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; van Boxtel MPJ, 2003, PHARMACOL BIOCHEM BE, V75, P921, DOI 10.1016/S0091-3057(03)00171-0; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Whittington RA, 2013, PROG NEURO-PSYCHOPH, V47, P147, DOI 10.1016/j.pnpbp.2013.03.004; Xu L, 2015, BBA-MOL BASIS DIS, V1852, P1298, DOI 10.1016/j.bbadis.2015.03.009; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; Zhao Zi-Ai, 2014, Sheng Li Ke Xue Jin Zhan, V45, P213; Zhou SJ, 2009, BRAIN RES, V1303, P74, DOI 10.1016/j.brainres.2009.09.082	66	17	18	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	MAY 9	2017	7								e1123	10.1038/tp.2017.98			12	Psychiatry	Psychiatry	EW2MY	WOS:000402331900006	28485728	DOAJ Gold, Green Published			2021-06-18	
J	Finkel, AG; Yerry, JA; Klaric, JS; Ivins, BJ; Scher, A; Choi, YS				Finkel, Alan G.; Yerry, Juanita A.; Klaric, John S.; Ivins, Brian J.; Scher, Ann; Choi, Young S.			Headache in military service members with a history of mild traumatic brain injury: A cohort study of diagnosis and classification	CEPHALALGIA			English	Article						Traumatic brain injury; military; headache; migraine; chronic migraine; diagnosis	POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; POSTCONCUSSION SYNDROME; TERTIARY CARE; MIGRAINE PAIN; PREVALENCE; VETERANS; CRITERIA; IMPACT	Introduction: Headaches after concussion are highly prevalent, relatively persistent and are being treated like primary headaches, especially migraine. Methods: We studied all new patients seen between August 2008 and December 2009 assessed by a civilian headache specialist at the TBI Center at Womack Army Medical Center, Fort Bragg, NC. We report sample demographics, injuries and headache characteristics, including time from injury to headache onset, detailed descriptions and International Classification of Headache Disorders second edition primary headache diagnosis type. Results: A total of 95 soldiers reported 166 headaches. The most common injury cited was a blast (53.7%). Most subjects (76.8%) recalled the onset of any headache within 7 days of injury. The most commonly diagnosed headache was a continuous type with migraine features (n=31 (18.7%)), followed by chronic migraine (type 1.5.1, n=14 (8.4%)), migraine with aura (type 1.2.1, n=10 (6.0%)), hemicrania continua (type 4.7, n=12 (7.2%)), chronic cluster (type 3.1.2, n=6 (3.6%)) and headaches not otherwise classifiable (type 14.1, n=5 (3.0%)) also present. The most clinically important was a continuous headache with migraine features. Conclusion: We present a series of patients seen in a military treatment facility for headache diagnosis after concussion in whom we found migraine, as well as uncommon primary headache types, at frequencies that were much higher than expected.	[Finkel, Alan G.; Yerry, Juanita A.; Klaric, John S.; Choi, Young S.] WAMC, Ft Bragg, NC USA; [Finkel, Alan G.; Ivins, Brian J.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Finkel, Alan G.] Carolina Headache Inst, Chapel Hill, NC USA; [Scher, Ann] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA	Finkel, AG (corresponding author), 6114 Fayetteville Rd,Suite 109, Durham, NC 27713 USA.	finkela@chi09.com		Scher, Ann/0000-0003-4599-9834	Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Funding was received from the Defense and Veterans Brain Injury Center.	Armed Forces Health Surveillance Branch, 2013, MED SURV MONTHL REP; Baandrup L, 2005, CEPHALALGIA, V25, P240, DOI 10.1111/j.1468-2982.2004.00909.x; Bigal ME, 2004, HEADACHE, V44, P684, DOI 10.1111/j.1526-4610.2004.04128.x; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cohen SP, 2012, CEPHALALGIA, V32, P94, DOI 10.1177/0333102411422382; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; De Marco AP, 2016, J CHILD NEUROL, V31, P68, DOI 10.1177/0883073814559645; Defense and Veterans Brain Injury Center, 2014, PROGR RET ACT FOLL A; Defense and Veterans Brain Injury Center, 2009, MILD TRAUM BRAIN INJ; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Finkel AG, 2012, HEADACHE, V52, P957, DOI 10.1111/j.1526-4610.2012.02167.x; Friedman AP, 1962, CLASSIFICATION HEADA, V12, P378; Gallai V, 2002, HEADACHE, V42, P1016, DOI 10.1046/j.1526-4610.2002.02231.x; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hartmann JE, 2006, J NEUROL SCI, V241, P83, DOI 10.1016/j.jns.2005.11.002; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kelman L, 2007, CEPHALALGIA, V27, P394, DOI 10.1111/j.1468-2982.2007.01303.x; Kelman L, 2006, CEPHALALGIA, V26, P548, DOI 10.1111/j.1468-2982.2006.01075.x; Kelman L, 2005, HEADACHE, V45, P1038, DOI 10.1111/j.1526-4610.2005.05185.x; Kelman L, 2004, CEPHALALGIA, V24, P728, DOI 10.1111/j.1468-2982.2004.00748.x; Kelman L, 2006, HEADACHE, V46, P942, DOI 10.1111/j.1526-4610.2006.00443.x; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lambru G, 2012, CURR PAIN HEADACHE R, V16, P162, DOI 10.1007/s11916-012-0248-0; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Manzoni Gian Camillo, 2006, Curr Pain Headache Rep, V10, P130, DOI 10.1007/s11916-006-0024-0; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Nash JM, 2003, HEADACHE, V43, P2, DOI 10.1046/j.1526-4610.2003.03002.x; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Rapp PE, 2012, J TRAUMA ACUTE CARE, V73, pS13, DOI 10.1097/TA.0b013e318260604b; Rigg JL, 2011, PM R S2, V3, pS380; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Ruff RL, 2012, J REHABIL RES DEV, V49, P1305, DOI 10.1682/JRRD.2011.12.0251; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Shevel D, 2014, J BIOMED SCI ENG, V7, P112; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Solomon S, 1997, NEUROL CLIN, V15, P15, DOI 10.1016/S0733-8619(05)70292-9; SOLOMON S, 1993, CEPHALALGIA, V13, P63, DOI 10.1177/0333102493013S1213; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Sullivan KA, 2014, J HEAD TRAUMA REHAB, V29, P54, DOI 10.1097/HTR.0b013e31828c708a; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; TURKEWITZ LJ, 1992, HEADACHE, V32, P504, DOI 10.1111/j.1526-4610.1992.hed3210504.x; US Army, 2009, ARMY MED        0227; van Reekum R, 2013, BRAIN INJURY, V27, P1210, DOI 10.3109/02699052.2013.801515; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Walker Russell W, 2007, Curr Pain Headache Rep, V11, P137, DOI 10.1007/s11916-007-0011-0; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Ward Thomas N, 2012, Continuum (Minneap Minn), V18, P753, DOI 10.1212/01.CON.0000418640.07405.31; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Wheeler SD, 2009, NEUROLOGIST, V15, P59, DOI 10.1097/NRL.0b013e318165eb94; Yerry JA, 2015, HEADACHE, V55, P395, DOI 10.1111/head.12495	66	17	17	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	MAY	2017	37	6					548	559		10.1177/0333102416651285			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EU4UG	WOS:000401026600007	27206963				2021-06-18	
J	Vilcinis, R; Bunevicius, A; Tamasauskas, A				Vilcinis, Rimantas; Bunevicius, Adomas; Tamasauskas, Arimantas			The Association of Surgical Method with Outcomes of Acute Subdural Hematoma Patients: Experience with 643 Consecutive Patients	WORLD NEUROSURGERY			English	Article						Coma; Decompressive craniectomy; Outcome; Prognosis; Subdural hematoma	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; CLINICAL ARTICLE; CRANIOTOMY; MANAGEMENT; EVACUATION; TRIAL	OBJECTIVE: We investigated the association of decompressive craniectomy (DC) and osteoplastic craniotomy (OC) with outcomes in consecutive patients undergoing surgical evacuation of acute subdural hematoma (ASDH) and analyzed prognostic indicators to determine optimal surgical management strategy for patients with ASDH. METHODS: We performed a prospective review of all adult patients with ASDH operated on by craniotomy from January 2009 to January 2016. Mortality and discharge outcomes (Glasgow Outcome Scale) were analyzed as a function of surgical method adjusting for age, admission Glasgow Coma Scale score, ASDH thickness and midline shift. RESULTS: OC was performed in 394 (61%) patients, and DC was performed in 249 (39%) patients. Patients undergoing DC were younger, with lower Glasgow Coma Scale score, greater ASDH thickness, and greater midline shift (P < 0.001). Mortality rate (54% vs. 20%; P < 0.001) and proportion of patients with poor discharge outcomes (85% and 45%; P < 0.001) were greater in DC patients versus OC patients. Glasgow Outcome Scale score was lower and mortality rate was greater (P <= 0.048) in DC patients versus OC patients across all patient subgroups. Outcomes were similar between the 2 groups in patients with Glasgow Coma Scale score of 3 and midline shift of >= 2 cm. Adjusting for disease severity, DC remained associated with greater risk for in-hospital mortality (odds ratio = 3.442 [95% confidence interval 2.196-5.396], P < 0.001) and unfavorable discharge outcome (odds ratio [5.277 [95% confidence interval 3.030-9.191], P < 0.001). CONCLUSIONS: DC was performed more often in younger and more severely injured patients. DC is associated with greater mortality and handicap rates independent of disease severity. Clinical trials investigating optimal surgical management strategy of patients with ASDH are needed.	[Vilcinis, Rimantas; Bunevicius, Adomas; Tamasauskas, Arimantas] Hosp Lithuanian Univ Hlth Sci, Dept Neurosurg, Kaunas, Lithuania; [Bunevicius, Adomas; Tamasauskas, Arimantas] Lithuanian Univ Hlth Sci, Neurosci Inst, Kaunas, Lithuania	Bunevicius, A (corresponding author), Hosp Lithuanian Univ Hlth Sci, Dept Neurosurg, Kaunas, Lithuania.; Bunevicius, A (corresponding author), Lithuanian Univ Hlth Sci, Neurosci Inst, Kaunas, Lithuania.	a.bunevicius@yahoo.com	Bunevicius, Adomas/I-3394-2019	Bunevicius, Adomas/0000-0003-0446-6898			Bunevicius A, 2013, J NEUROSURG, V118, P1279, DOI 10.3171/2013.1.JNS121696; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Hanif S, 2009, Ir Med J, V102, P255; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Honeybul S, 2014, INJURY, V45, P1332, DOI 10.1016/j.injury.2014.03.007; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; JENNETT B, 1975, LANCET, V1, P480; Karibe H, 2014, NEUROL MED-CHIR, V54, P887, DOI 10.2176/nmc.cr.2014-0204; Kinoshita T, 2016, WORLD NEUROSURG, V89, P187, DOI 10.1016/j.wneu.2016.01.071; Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Li XG, 2013, J CLIN NEUROSCI, V20, P509, DOI 10.1016/j.jocn.2012.04.019; Lund-Johansen M, 2011, WORLD NEUROSURG, V75, P454, DOI 10.1016/j.wneu.2011.01.020; Nguyen R, 2016, CAN J NEUROL SCI, V27, P1; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Tanrikulu L, 2015, CLIN NEUROL NEUROSUR, V135, P15, DOI 10.1016/j.clineuro.2015.04.019; Walcott BP, 2013, WORLD NEUROSURG, V79, P80, DOI 10.1016/j.wneu.2012.11.014; Wang JW, 2016, J CLIN NEUROSCI, V27, P1, DOI 10.1016/j.jocn.2015.06.037	22	17	17	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2017	101						335	342		10.1016/j.wneu.2017.02.010			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EV7CR	WOS:000401932500044	28216211				2021-06-18	
J	Armstead, WM; Riley, J; Vavilala, MS				Armstead, William M.; Riley, John; Vavilala, Monica S.			Sex and Age Differences in Epinephrine Mechanisms and Outcomes after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						age; brain injury; cerebral autoregulation; histopathology; sex; signal transduction; vasopressor	ACTIVATED PROTEIN-KINASE; CEREBRAL AUTOREGULATION; UP-REGULATION; ERK MAPK; HIPPOCAMPAL NECROSIS; JUVENILE PIGS; INHIBITION; CEREBROVASODILATION; HYPOTENSION; JNK	Traumatic brain injury (TBI) is the leading cause of injury-related death in children, with boys and children < 4 years of age having particularly poor outcomes. Cerebral autoregulation is often impaired after TBI, contributing to poor outcome. Cerebral perfusion pressure can be normalized by use of vasoactive agents. The c-Jun-terminal kinase (JNK) isoform of mitogen activated protein kinase (MAPK) produces hemodynamic impairment after TBI, but less is known about its role in histopathology. We investigated whether epinephrine (EPI), age, and sex dependently protected cerebral autoregulation and limited histopathology after TBI, and sought to determine the role of JNK in that outcome. Lateral fluid percussion injury (FPI) was produced in anesthetized pigs. Pial artery reactivity was measured via a closed cranial window. Phosphorylated JNK MAPK was quantified by enzyme-linked immunosorbent assay (ELISA). Results show that EPI preserves autoregulation, prevents histopathology, and blocks phosphorylated JNK upregulation in newborn males and females and juvenile females but not juvenile males after TBI. These data indicate that EPI preserves cerebral autoregulation and limits histopathology after TBI through blockade of JNK in an age-and sex-dependent manner.	[Armstead, William M.; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS090998]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090998] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS090998.	Armstead WM, 2008, BRAIN RES, V1231, P121, DOI 10.1016/j.brainres.2008.06.115; Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2016, J NEUROTRAUM, V33, P1761, DOI 10.1089/neu.2015.4290; Armstead WM, 2016, PEDIATR CRIT CARE ME, V17, pe130, DOI 10.1097/PCC.0000000000000603; Armstead WM, 2013, PEDIATR CRIT CARE ME, V14, pE103, DOI 10.1097/PCC.0b013e3182712b44; Armstead WM, 2012, NEUROL RES, V34, P530, DOI 10.1179/1743132812Y.0000000039; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Dai YX, 2014, NEUROCHEM RES, V39, P1603, DOI 10.1007/s11064-014-1355-6; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Dobbing J, 1981, SCI F PAEDIATRICS, P744; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Ross J, 2005, BRAIN RES, V1054, P95, DOI 10.1016/j.brainres.2005.06.065; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed	28	17	17	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1666	1675		10.1089/neu.2016.4770			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500018	27912253	Green Published			2021-06-18	
J	Huang, MX; Harrington, DL; Swan, AR; Quinto, AA; Nichols, S; Drake, A; Song, T; Diwakar, M; Huang, CW; Risbrough, VB; Dale, A; Bartsch, H; Matthews, S; Huang, JW; Lee, RR; Baker, DG				Huang, Ming-Xiong; Harrington, Deborah L.; Swan, Ashley Robb; Quinto, Annemarie Angeles; Nichols, Sharon; Drake, Angela; Song, Tao; Diwakar, Mithun; Huang, Charles W.; Risbrough, Victoria B.; Dale, Anders; Bartsch, Hauke; Matthews, Scott; Huang, Jeffrey W.; Lee, Roland R.; Baker, Dewleen G.			Resting-State Magnetoencephalography Reveals Different Patterns of Aberrant Functional Connectivity in Combat-Related Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast brain injury; excitation; inhibition; FC; MEG; TBI	DEFAULT-MODE NETWORK; PERSISTENT POSTCONCUSSIVE SYMPTOMS; SIGNAL SPACE SEPARATION; SOURCE IMAGING APPROACH; MIDLINE THETA-RHYTHM; INDEPENDENT COMPONENT; ALZHEIMERS-DISEASE; COGNITIVE CONTROL; SERVICE MEMBERS; BLAST EXPOSURE	Blast mild traumatic brain injury (mTBI) is a leading cause of sustained impairment in military service members and veterans. However, the mechanism of persistent disability is not fully understood. The present study investigated disturbances in brain functioning in mTBI participants using a source-imaging-based approach to analyze functional connectivity (FC) from resting-state magnetoencephalography (rs-MEG). Study participants included 26 active-duty service members or veterans who had blast mTBI with persistent post-concussive symptoms, and 22 healthy control active-duty service members or veterans. The source time courses from regions of interest (ROIs) were used to compute ROI to whole-brain (ROI-global) FC for different frequency bands using two different measures: 1) time-lagged cross-correlation and 2) phase-lock synchrony. Compared with the controls, blast mTBI participants showed increased ROI-global FC in beta, gamma, and low-frequency bands, but not in the alpha band. Sources of abnormally increased FC included the: 1) prefrontal cortex (right ventromedial prefrontal cortex [vmPFC], right rostral anterior cingulate cortex [rACC]), and left ventrolateral and dorsolateral prefrontal cortex; 2) medial temporal lobe (bilateral parahippocampus, hippocampus, and amygdala); and 3) right putamen and cerebellum. In contrast, the blast mTBI group also showed decreased FC of the right frontal pole. Group differences were highly consistent across the two different FC measures. FC of the left ventrolateral prefrontal cortex correlated with executive functioning and processing speed in mTBI participants. Altogether, our findings of increased and decreased regionalpatterns of FC suggest that disturbances in intrinsic brain connectivity may be the result of multiple mechanisms, and are associated with cognitive sequelae of the injury.	[Huang, Ming-Xiong; Harrington, Deborah L.; Swan, Ashley Robb; Quinto, Annemarie Angeles; Matthews, Scott; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Harrington, Deborah L.; Swan, Ashley Robb; Quinto, Annemarie Angeles; Song, Tao; Diwakar, Mithun; Dale, Anders; Bartsch, Hauke; Matthews, Scott; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Harrington, Deborah L.; Swan, Ashley Robb; Quinto, Annemarie Angeles; Song, Tao; Diwakar, Mithun; Dale, Anders; Bartsch, Hauke; Matthews, Scott; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Huang, Ming-Xiong; Harrington, Deborah L.; Swan, Ashley Robb; Quinto, Annemarie Angeles; Song, Tao; Diwakar, Mithun; Dale, Anders; Bartsch, Hauke; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Nichols, Sharon] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Huang, Charles W.] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; [Risbrough, Victoria B.; Matthews, Scott; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Drake, Angela] Naval Med Ctr, San Diego, CA USA; [Risbrough, Victoria B.; Baker, Dewleen G.] VA Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Matthews, Scott] VASDHS Residential Rehabil Treatment Program, Aspire Ctr, San Diego, CA USA; [Huang, Jeffrey W.] Westview High Sch, San Diego, CA USA	Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; Bartsch, Hauke/0000-0003-1486-4128	Merit Review Grants from the Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX000499, MHBA-010-14F, NURC-022-10F, NEUC-044-06S, I01-CX000146]; Naval Medical Research Center's Advanced Medical Development program [N62645-11-C-4037]; Veterans AffairsUS Department of Veterans Affairs [I01CX000499, I01CX000146, I01BX002558] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Grants from the Department of Veterans Affairs to M.X. Huang (I01-CX000499, MHBA-010-14F, NURC-022-10F, NEUC-044-06S), R.R. Lee, and D.L. Harrington (I01-CX000146), and Naval Medical Research Center's Advanced Medical Development program (Naval Medical Logistics Command Contract #N62645-11-C-4037, for MRS-II (D.G. Baker, M.X. Huang, V.B. Risbrough). We acknowledge the MRS-II administrative core, Anjana Patel, Andrew De La Rosa, and members of the MRS-II Team, including logistic coordinators, clinician-interviewers, and data collection staff. We thank staff at the VA San Diego Healthcare System and the Veterans Medical Research Foundation (VRMF). We also thank the participating Marines and veteran volunteers for their military service and participation in this study.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Alhourani A, 2016, J NEUROPHYSIOL, V116, P1840, DOI 10.1152/jn.00513.2016; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Antonakakis M, 2016, INT J PSYCHOPHYSIOL, V102, P1, DOI 10.1016/j.ijpsycho.2016.02.002; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; Badre D, 2008, TRENDS COGN SCI, V12, P193, DOI 10.1016/j.tics.2008.02.004; Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Banks SD, 2016, ARCH PHYS MED REHAB, V97, P1254, DOI 10.1016/j.apmr.2016.03.013; Bharath RD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00513; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Braver TS, 2002, NEUROIMAGE, V15, P523, DOI 10.1006/nimg.2001.1019; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Chen Y, 2016, CURR ALZHEIMER RES, V13, P234, DOI 10.2174/156720501303160217113858; Cocchi L, 2013, TRENDS COGN SCI, V17, P493, DOI 10.1016/j.tics.2013.08.006; Cohen D., 2002, P 13 INT C BIOM, P919; Cole MW, 2013, NAT NEUROSCI, V16, P1348, DOI 10.1038/nn.3470; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; de Munck JC, 2009, NEUROIMAGE, V47, P69, DOI 10.1016/j.neuroimage.2009.04.029; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DePalma R.G., 2016, BEHAV BRAIN RES; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Douaud G, 2013, J NEUROSCI, V33, P2147, DOI 10.1523/JNEUROSCI.4437-12.2013; Douglas David B, 2015, Top Magn Reson Imaging, V24, P241, DOI 10.1097/RMR.0000000000000062; Dunkley BT, 2015, NEUROIMAGE-CLIN, V7, P611, DOI 10.1016/j.nicl.2015.02.020; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Ellison-Wright I, 2009, SCHIZOPHR RES, V108, P3, DOI 10.1016/j.schres.2008.11.021; Fitzsimmons J, 2013, CURR OPIN PSYCHIATR, V26, P172, DOI 10.1097/YCO.0b013e32835d9e6a; Forn C, 2013, BRAIN COGNITION, V82, P152, DOI 10.1016/j.bandc.2013.04.003; Fornito A, 2012, P NATL ACAD SCI USA, V109, P12788, DOI 10.1073/pnas.1204185109; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hannawi Y, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0642-9; Harrington Deborah L, 2014, Timing Time Percept, V2, P145, DOI 10.1163/22134468-00002025; Haufe S, 2011, NEUROIMAGE, V54, P851, DOI 10.1016/j.neuroimage.2010.09.003; He BYJ, 2008, P NATL ACAD SCI USA, V105, P16039, DOI 10.1073/pnas.0807010105; Hindriks R, 2013, NEUROIMAGE, V70, P150, DOI 10.1016/j.neuroimage.2012.12.018; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang CW, 2016, CLIN NEUROPHYSIOL, V127, P2308, DOI 10.1016/j.clinph.2016.02.007; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P408, DOI 10.1016/j.nicl.2014.08.004; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2016, PSYCHONEUROENDOCRINO, V63, P398, DOI 10.1016/j.psyneuen.2015.02.008; Hyafil A, 2015, TRENDS NEUROSCI, V38, P725, DOI 10.1016/j.tins.2015.09.001; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Hyvarinen A, 2000, NEURAL NETWORKS, V13, P411, DOI 10.1016/S0893-6080(00)00026-5; Iraji A, 2016, NEUROIMAGE-CLIN, V12, P100, DOI 10.1016/j.nicl.2016.06.012; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kandel E.R., 2013, PRINCIPLES NEURAL SC; Kantarci K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00316; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KNAPP CH, 1976, IEEE T ACOUST SPEECH, V24, P320, DOI 10.1109/TASSP.1976.1162830; Koechlin E, 2007, SCIENCE, V318, P594, DOI 10.1126/science.1142995; Koechlin E, 2006, NEURON, V50, P963, DOI 10.1016/j.neuron.2006.05.017; Kolb B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00377; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Lee KYK, 2011, NEUROIMAGE, V54, pS30, DOI 10.1016/j.neuroimage.2010.05.042; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; Lisman JE, 2013, NEURON, V77, P1002, DOI 10.1016/j.neuron.2013.03.007; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mielke MM, 2012, ALZHEIMERS DEMENT, V8, P105, DOI 10.1016/j.jalz.2011.05.2416; MIZUKI Y, 1980, ELECTROEN CLIN NEURO, V49, P345, DOI 10.1016/0013-4694(80)90229-1; MIZUKI Y, 1992, INT J PSYCHOPHYSIOL, V12, P169, DOI 10.1016/0167-8760(92)90008-Y; MIZUKI Y, 1984, FOLIA PSYCHIAT NEU J, V38, P451; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nir Y, 2008, NAT NEUROSCI, V11, P1100, DOI 10.1038/nn.2177; Orr JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124797; Ou W, 2008, LECT NOTES COMPUT SC, V5241, P26, DOI 10.1007/978-3-540-85988-8_4; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Scheeringa R, 2012, BRAIN CONNECT, V2, P254, DOI 10.1089/brain.2012.0088; Schilbach L, 2016, NEUROIMAGE-CLIN, V10, P326, DOI 10.1016/j.nicl.2015.11.021; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholvinck ML, 2013, NEUROIMAGE, V80, P297, DOI 10.1016/j.neuroimage.2013.04.010; Scholvinck ML, 2010, P NATL ACAD SCI USA, V107, P10238, DOI 10.1073/pnas.0913110107; Shen X, 2013, NEUROIMAGE, V82, P403, DOI 10.1016/j.neuroimage.2013.05.081; Shmuel A, 2008, HUM BRAIN MAPP, V29, P751, DOI 10.1002/hbm.20580; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song J, 2015, BRAIN CONNECT, V5, P276, DOI 10.1089/brain.2014.0308; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P550, DOI 10.1007/s11682-015-9424-2; Sours C, 2015, BRAIN CONNECT, V5, P442, DOI 10.1089/brain.2014.0333; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P190, DOI 10.1007/s11682-014-9295-y; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Swan AR, 2015, J NEUROTRAUM, V32, P1510, DOI 10.1089/neu.2014.3654; Takahashi N, 1997, CLIN ELECTROENCEPHAL, V28, P49, DOI 10.1177/155005949702800109; Tamnes CK, 2016, J AM ACAD CHILD PSY, V55, P269, DOI 10.1016/j.jaac.2016.01.004; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S, 2004, Neurol Clin Neurophysiol, V2004, P35; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Usui N, 2009, NEUROSCI LETT, V463, P1, DOI 10.1016/j.neulet.2009.07.048; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van der Horn HJ, 2016, HUM BRAIN MAPP, V37, P1645, DOI 10.1002/hbm.23126; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wechsler D., 2013, WAIS 4; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Xiong KL, 2016, NEURORADIOLOGY, V58, P733, DOI 10.1007/s00234-016-1675-0; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Young LA, 2015, SEMIN NEUROL, V35, P5, DOI 10.1055/s-0035-1544242; Zhan J, 2015, J NERV MENT DIS, V203, P786, DOI 10.1097/NMD.0000000000000368; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	143	17	17	2	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1412	1426		10.1089/neu.2016.4581			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600011	27762653				2021-06-18	
J	Sahn, JJ; Hodges, TR; Chan, JZ; Martin, SF				Sahn, James J.; Hodges, Timothy R.; Chan, Jessica Z.; Martin, Stephen F.			Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity	ACS MEDICINAL CHEMISTRY LETTERS			English	Article						Sigma receptor; norbenzomorphan; neuroprotection; Alzheimer's disease; traumatic brain injury	MEMBRANE COMPONENT 1; PGRMC1 PROTEIN; BINDING; ANTAGONISTS; LIGANDS; DIVERSE	Some norbenzomorphans exhibit high affinity for sigma 1 and sigma 2 receptors, and varying the position of substituents on the aromatic ring of this scaffold has a significant effect on subtype selectivity. In particular, compounds bearing several different substituents at C7 of the norbenzomorphan ring system exhibit a general preference for the sigma 1 receptor, whereas the corresponding C8-substituted analogues preferentially bind at the sigma 2 receptor. These findings suggest that the norbenzomorphan scaffold may be a unique chemical template that can be easily tuned to prepare small molecules for use as tool compounds to study the specific biological effects arising from preferential binding at either sigma receptor subtype. In the absence of structural characterization data for the sigma 2 receptor, such compounds will be useful toward refining the pharmacophore model of its binding site.	[Sahn, James J.; Hodges, Timothy R.; Chan, Jessica Z.; Martin, Stephen F.] Univ Texas Austin, Dept Chem, Austin, TX 78712 USA	Martin, SF (corresponding author), Univ Texas Austin, Dept Chem, Austin, TX 78712 USA.	sfrnartin@mail.utexas.edu	Martin, Stephen/U-4676-2019	Hodges, Timothy/0000-0003-1216-9551	The Robert A. Welch FoundationThe Welch Foundation [F-0652]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM 86192]; ADR; BrightFocus FoundationBrightFocus Foundation; Dell Medical School's Texas Health Catalyst program	Generous funding for this research was provided by The Robert A. Welch Foundation (F-0652), the National Institutes of Health (GM 86192), the donors of the ADR, a program of the BrightFocus Foundation, and the Dell Medical School's Texas Health Catalyst program.	Abate C, 2015, EUR J PHARMACOL, V758, P16, DOI 10.1016/j.ejphar.2015.03.067; Bai SP, 2014, J MED CHEM, V57, P4239, DOI 10.1021/jm5001453; Cahill MA, 2007, J STEROID BIOCHEM, V105, P16, DOI 10.1016/j.jsbmb.2007.02.002; CHEN YL, 1994, J MED CHEM, V37, P1996, DOI 10.1021/jm00039a013; Chu UB, 2015, EBIOMEDICINE, V2, P1806, DOI 10.1016/j.ebiom.2015.10.017; Cobos EJ, 2005, SYNAPSE, V55, P192, DOI 10.1002/syn.20103; Guo L, 2015, CURR MED CHEM, V22, P989, DOI 10.2174/0929867322666150114163607; Hayashi T., 2005, Current Neuropharmacology, V3, P267, DOI 10.2174/157015905774322516; Huang YS, 2014, MED RES REV, V34, P532, DOI 10.1002/med.21297; Izzo NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111898; Izzo NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111899; JACOBSON AE, 1970, J MED CHEM, V13, P7, DOI 10.1021/jm00295a002; Jasper A, 2009, EUR J MED CHEM, V44, P4306, DOI 10.1016/j.ejmech.2009.07.017; Kabe Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11030; Laurini E, 2010, BIOORG MED CHEM LETT, V20, P2954, DOI 10.1016/j.bmcl.2010.03.009; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Mach RH, 2013, J MED CHEM, V56, P7137, DOI 10.1021/jm301545c; Manohar M, 2015, AUST J CHEM, V68, P600, DOI 10.1071/CH14590; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Matsumoto Rae R., 2007, P1, DOI 10.1007/978-0-387-36514-5_1; Moller HJ, 2001, J CLIN PSYCHOPHARM, V21, P59, DOI 10.1097/00004714-200102000-00011; Narayanan S, 2011, FUTURE MED CHEM, V3, P79, DOI 10.4155/FMC.10.279; Narita N, 1996, EUR J PHARMACOL, V307, P117, DOI 10.1016/0014-2999(96)00254-3; Pati ML, 2017, PHARMACOL RES, V117, P67, DOI 10.1016/j.phrs.2016.12.023; Sahn J. J., 2016, TARGETING SIG2 RPGRM; Sahn JJ, 2016, CHEMMEDCHEM, V11, P556, DOI 10.1002/cmdc.201500551; Sahn JJ, 2014, ORG BIOMOL CHEM, V12, P7659, DOI 10.1039/c4ob00835a; Sahn JJ, 2012, ACS COMB SCI, V14, P496, DOI 10.1021/co300068a; Sahn JJ, 2011, ORG LETT, V13, P2590, DOI 10.1021/ol200709h; Schmidt HR, 2016, NATURE, V532, P527, DOI 10.1038/nature17391; Sun H, 2016, J MED CHEM, V59, P6329, DOI 10.1021/acs.jmedchem.6b00571; Sunderhaus JD, 2007, ORG LETT, V9, P4223, DOI 10.1021/ol7018357; Sunderhaus JD, 2009, TETRAHEDRON, V65, P6454, DOI 10.1016/j.tet.2009.05.009; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vela JM, 2015, EXPERT OPIN INV DRUG, V24, P883, DOI 10.1517/13543784.2015.1048334; Xu JB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1386; Yi BN, 2017, J NEUROCHEM, V140, P561, DOI 10.1111/jnc.13917; Zeng CB, 2016, MOL IMAGING BIOL, V18, P172, DOI 10.1007/s11307-015-0891-z; Zeng CB, 2014, ANAL BIOCHEM, V448, P68, DOI 10.1016/j.ab.2013.12.008	39	17	17	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-5875			ACS MED CHEM LETT	ACS Med. Chem. Lett.	APR	2017	8	4					455	460		10.1021/acsmedchemlett.7b00066			6	Chemistry, Medicinal	Pharmacology & Pharmacy	ES3NG	WOS:000399435700015	28435536	Green Published			2021-06-18	
J	Topolovec-Vranic, J; Schuler, A; Gozdzik, A; Somers, J; Bourque, PE; Frankish, CJ; Jbilou, J; Pakzad, S; Lazgare, LIP; Hwang, SW				Topolovec-Vranic, Jane; Schuler, Andree; Gozdzik, Agnes; Somers, Julian; Bourque, Paul-Emile; Frankish, C. James; Jbilou, Jalila; Pakzad, Sarah; Lazgare, Luis Ivan Palma; Hwang, Stephen W.			The high burden of traumatic brain injury and comorbidities amongst homeless adults with mental illness	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Brain injuries; Homeless persons; Mental disorders; Psychiatric diagnosis; Health care delivery; Comorbidity	POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; HEAD-INJURY; COMMUNITY; POPULATION; PREVALENCE; CHALLENGES; MANAGEMENT; SERVICES; SEIZURES	Objective: characterize the prevalence of self-reported head injury with loss of consciousness (LOC) and associated demographic, clinical and service use factors in a sample of homeless adults with mental illness. Method: Participants in the At Home/Chez Soi study were interviewed at the time of study enrollment regarding their history of head injuries, mental and physical health diagnoses and justice system and healthcare interactions. Sociodemographic and clinical data were also collected. Results: Over half of the 2088 study respondents (52.6%, n = 1098) reported a history of head injury with a LOC, which was associated with several demographic, clinical and service use variables in this population. With respect to specific mental health conditions, a history of head injury with LOC was associated with higher odds of current depression (OR = 2.18, CI: 1.83-2.60), manic episode or hypomanic episode (OR = 1.91, CI: 1.45-2.50), PTSD (OR = 2.98, CI: 2.44-3.65), panic disorder (OR = 2.37, CI:1.91-2.93), mood disorder (OR = 1.78, CI: 1.40-2.26) and alcohol (OR = 2.09, CI: 1.75-2.49) and drug (OR = 1.73, CI: 1.46-2.06) misuse disorders, but reduced odds of having diagnosis of a psychotic disorder (OR = 0.63, CI: 0.53-0.76). A history of head injury with LOC was also associated with increased use of variety of services, including family medicine (OR = 1.33, CI: 1.12-1.59), criminal justice system (OR = 1.50, CI: 1.25-1.80) and the emergency department (OR = 1.03, CI: 1.01-1.05). Conclusions: Amongst homeless adults with mental illness having a history of head injuries with LOC was independently associated with various adverse outcomes. These individuals constitute a high-risk group who may benefit from specialized services. (C) 2016 Elsevier Ltd. All rights reserved.	[Topolovec-Vranic, Jane] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON, Canada; [Topolovec-Vranic, Jane] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Topolovec-Vranic, Jane] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Schuler, Andree; Gozdzik, Agnes; Lazgare, Luis Ivan Palma; Hwang, Stephen W.] St Michaels Hosp, Ctr Urban Hlth Solut, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Somers, Julian] Simon Fraser Univ, Fac Hlth Sci, Somers Res Grp, Vancouver, BC, Canada; [Bourque, Paul-Emile; Jbilou, Jalila; Pakzad, Sarah] Univ Moncton, Sch Psychol, Moncton, NB, Canada; [Frankish, C. James] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Hwang, Stephen W.] Univ Toronto, Dalla Lana Sch Publ Hlth, Inst Hlth Policy,Management & Evaluat, Dept Med,Div Gen Internal Med, Toronto, ON, Canada	Hwang, SW (corresponding author), St Michaels Hosp, Ctr Urban Hlth Solut, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.	hwangs@smh.ca	Topolovec-Vranic, Jane/A-5293-2013; Hwang, Stephen/D-2297-2011	Topolovec-Vranic, Jane/0000-0001-7695-4212; Hwang, Stephen/0000-0002-1276-1101	Health Canada via the Mental Health Commission of Canada (MHCC)	This research has been made possible through a financial contribution from Health Canada via the Mental Health Commission of Canada (MHCC). The authors, writing for the At Home/Chez Soi investigators, thank Jayne Barker (2008-2011), PhD, Cameron Keller (2011-2012), and Catharine Hume (2012-present) MHCC At Home/Chez Soi National Project Leads, Paula Goering, PhD, the National Research Lead, the National Research Team, the five site research teams, the Site Coordinators, the numerous service and housing providers, as well as people with lived experience, who have contributed to this project and the research.	Amen DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129659; Andersen J, 2014, DISABIL REHABIL, V36, P2210, DOI 10.3109/09638288.2014.895870; Aubry T, 2016, PSYCHIAT SERV, V67, P275, DOI 10.1176/appi.ps.201400587; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Barnes SM, 2015, J HEALTH CARE POOR U, V26, P92, DOI 10.1353/hpu.2015.0010; Beghi M, 2013, NEUROPSYCH DIS TREAT, V9, P1725, DOI 10.2147/NDT.S40213; Blackmer J, 1999, BRAIN INJURY, V13, P627; Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Currie LB, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-404; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Farrer TJ, 2012, TRAUMA VIOLENCE ABUS, V13, P77, DOI 10.1177/1524838012440338; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gagnon A, 2016, DISABIL REHABIL, V38, P433, DOI 10.3109/09638288.2015.1044035; Goering PN, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000323; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-73; Hwang SW, 2008, CMAJ, V179, P179; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaycox L., 2008, INVISIBLE WOUNDS WAR; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kessler RC, 2004, BIOL PSYCHIAT, V56, P730, DOI 10.1016/j.biopsych.2004.06.034; Lasry Oliver, 2016, CMAJ Open, V4, pE249, DOI 10.9778/cmajo.20150105; Linton KF, 2014, BRAIN INJURY, V28, P1076, DOI 10.3109/02699052.2014.901558; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; McMillan TM, 2015, J NEUROTRAUM, V32, P116, DOI 10.1089/neu.2014.3387; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; NINDS Common Data Elements Team, 2012, TBI CDES V3 DEF TRAU; O'Callaghan A, 2012, BRAIN INJURY, V26, P1599, DOI 10.3109/02699052.2012.698788; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Russell LM, 2013, AM J PUBLIC HEALTH, V103, pS211, DOI 10.2105/AJPH.2013.301485; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Schofield PW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132558; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stergiopoulos V, 2015, JAMA-J AM MED ASSOC, V313, P905, DOI 10.1001/jama.2015.1163; Svoboda T, 2014, EMERG MED J, V31, P571, DOI 10.1136/emermed-2012-201761; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; To MJ, 2015, J HEAD TRAUMA REHAB, V30, P270, DOI 10.1097/HTR.0000000000000044; Topolovec-Vranic J., 2013, TRAUMATIC BRAIN INJU, P4; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; U.S. Department of Veterans Affairs, 2010, VA CONS C PRACT REC; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	58	17	17	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	APR	2017	87						53	60		10.1016/j.jpsychires.2016.12.004			8	Psychiatry	Psychiatry	EO8WK	WOS:000396971000008	28006664				2021-06-18	
J	Emmerich, T; Abdullah, L; Ojo, J; Mouzon, B; Nguyen, T; Laco, GS; Crynen, G; Evans, JE; Reed, J; Mullan, M; Crawford, F				Emmerich, Tanja; Abdullah, Laila; Ojo, Joseph; Mouzon, Benoit; Thinh Nguyen; Laco, Gary S.; Crynen, Gogce; Evans, James E.; Reed, Jon; Mullan, Michael; Crawford, Fiona			Mild TBI Results in a Long-Term Decrease in Circulating Phospholipids in a Mouse Model of Injury	NEUROMOLECULAR MEDICINE			English	Article						Mild traumatic brain injury (mTBI); Phospholipids (PL); Plasma biomarkers; Lipidomics; Mouse model	TRAUMATIC BRAIN-INJURY; FATTY-ACIDS; HIGH-SCHOOL; PROTEIN; LIPIDS; LIPOPROTEINS; CONCUSSION; MECHANISMS; BIOMARKERS; RECOVERY	Neurophysiological and neurological dysfunction is usually experienced for a short period of time in patients with mild traumatic brain injury (mTBI). However, around 15 % of patients exhibit symptoms months after TBI. Phospholipid (PL) changes have been observed in plasma from mTBI patients at chronic stages, suggesting a role in TBI pathology. We examined long-term plasma phospholipid profiles in a mouse model of mTBI to determine their translational value in reproducing PL changes observed in mTBI patients. Plasma samples were collected at an acute timepoint (24 h post-injury) and at several chronic stages (3, 6, 12 and 24 months post-injury) from injured mice and sham controls. Phospholipids were identified and quantified using liquid chromatography/mass spectrometry analysis. In accordance with human data, we observed significantly lower levels of several major PL classes in mTBI mice compared to controls at chronic timepoints. Saturated, monounsaturated and polyunsaturated fatty acids (PUFAs) were differently regulated over time. As PUFA levels were decreased at 3 months, we measured levels of malondialdehyde to assess lipid peroxidation, which we found to be elevated at this timepoint. Ether-containing PE species were elevated at 24 h post-injury and decreased relative to controls at chronic stages. Arachidonic acid and docosahexaenoic acid-containing species were significantly decreased within all PL classes at the chronic stages. Our findings are similar to changes in PL levels observed in human mTBI subjects. Chronic TBI biomarkers have received little attention, even though disabilities at this stage can be of major importance. Our study provides information on biochemical abnormalities that persist long after the initial injury; these abnormalities may provide useful insight into the continuing pathogenesis and serve as diagnostic biomarkers.	[Emmerich, Tanja; Abdullah, Laila; Ojo, Joseph; Mouzon, Benoit; Thinh Nguyen; Laco, Gary S.; Crynen, Gogce; Evans, James E.; Reed, Jon; Mullan, Michael; Crawford, Fiona] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Emmerich, Tanja; Abdullah, Laila; Ojo, Joseph; Mouzon, Benoit; Crynen, Gogce; Crawford, Fiona] Open Univ, Walton Hall, Milton Keynes MK7 6AA, Bucks, England; [Emmerich, Tanja; Abdullah, Laila; Mouzon, Benoit; Evans, James E.; Reed, Jon; Crawford, Fiona] James A Haley Vet Hosp, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA	Emmerich, T (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.; Emmerich, T (corresponding author), Open Univ, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.; Emmerich, T (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	temmerich@roskampinstitute.net; labdullah@roskampinsitute.net; bojo@roskampinstitute.net; bmouzon@rfdn.org; tnguyen@roskampinstitute.net; glaco@roskampinstitute.net; gkayihan@rfdn.org; jevans@roskampinstitute.net; jreed@rfdn.org; mmullan@rfdn.org; fcrawford@rfdn.org		Emmerich, Tanja/0000-0001-5064-7150	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759, W81XWH-13-1-0253]; VA Research Award [RX-16-007]; Roskamp Foundation	This research was funded by Department of Defense Awards (W81XWH-10-1-0759 and W81XWH-13-1-0253) and VA Research Award (RX-16-007) to VA Research Career scientist Dr. Fiona Crawford and by the Roskamp Foundation. The contents do not represent the views of the Department of Veterans Affairs, or the US Government.	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Begum H, 2016, SCI REP-UK, V6, DOI 10.1038/srep19139; Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Chaurio RA, 2009, MOLECULES, V14, P4892, DOI 10.3390/molecules14124892; Coronado V., 2009, EPIDEMIOLOGY; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138; Emmerich T., 2015, J NEUROTRAUMA; Fischer H., 2015, DOD NUMBERS TRAUMATI, P1; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fredman G, 2011, BIOCHEM J, V437, P185, DOI 10.1042/BJ20110327; Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Jackson Laboratories, 2007, PHYSL DAT SUMM C57BL, V6 J; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim Seungwoo, 2014, Osong Public Health Res Perspect, V5, P345, DOI 10.1016/j.phrp.2014.10.002; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kosicek M, 2013, INT J MOL SCI, V14, P1310, DOI 10.3390/ijms14011310; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Norman AB, 2011, SYNAPSE, V65, P404, DOI 10.1002/syn.20858; Ovsepian L M, 2012, Adv Gerontol, V25, P250; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Purdon AD, 2002, NEUROCHEM RES, V27, P1641, DOI 10.1023/A:1021635027211; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Reno F, 1998, HISTOCHEM CELL BIOL, V110, P467, DOI 10.1007/s004180050308; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Spector AA, 2001, J MOL NEUROSCI, V16, P159, DOI 10.1385/JMN:16:2-3:159; Vance DE, 2008, N COMP BIOC, P1; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442	46	17	17	1	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084	1559-1174		NEUROMOL MED	Neuromol. Med.	MAR	2017	19	1					122	135		10.1007/s12017-016-8436-4			14	Neurosciences	Neurosciences & Neurology	EN5EX	WOS:000396029500012	27540748				2021-06-18	
J	Ide, K; Uematsu, S; Tetsuhara, K; Yoshimura, S; Kato, T; Kobayashi, T				Ide, Kentaro; Uematsu, Satoko; Tetsuhara, Kenichi; Yoshimura, Satoshi; Kato, Takahiro; Kobayashi, Tohru			External Validation of the PECARN Head Trauma Prediction Rules in Japan	ACADEMIC EMERGENCY MEDICINE			English	Article							DECISION RULE; CHILDREN; INJURY	ObjectivesThe Pediatric Emergency Care Applied Research Network (PECARN) head trauma prediction rules are used to assist computed tomography (CT) decision-making for children with minor head trauma. Although the PECARN rules have been validated in North America and Europe, they have not yet been validated in Asia. In Japan, there are no clinical decision rules for children with minor head trauma. The rate of head CT for children with minor head trauma in Japan is high since CT is widely accessible across the country. The objective of this study was to evaluate the diagnostic accuracy of the PECARN rules for identifying clinically important traumatic brain injuries (ciTBI) in children with minor head trauma in Japan. MethodsWe conducted a retrospective cohort study at a tertiary care pediatric hospital in Japan (30,000 patients/year). We enrolled all children younger than 18 years with minor head trauma (Glasgow Coma Scale 14) who presented to the emergency department within 24 hours of their injury between January and December 2013. We retrospectively classified the children into three risk categories according to the PECARN rules. The PECARN rules were considered negative when children were classified into the very-low-risk category. The primary outcome was considered positive when a child had ciTBI defined as head injury resulting in death, neurosurgery, intubation for>24 hours, or hospital admission 2 nights with evidence of TBI on CT. ResultsAmong 2,208 children included in the study, 24 (1.1%) had ciTBI. Sensitivities and specificities of the PECARN rules to predict ciTBI were 85.7% (12/14; 95% confidence interval [CI]= 57.2 to 98.2) and 73.5% (572/778; 95% CI= 70.3 to 76.6), respectively, for children<2 years old, and 100% (10/10; 95% CI= 58.7 to 100) and 73.5% (1033/1406; 95% CI= 71.0 to 75.7) for children 2 years old, respectively. There were 10 cases of physically abused children<2 years old, and six (60%) of them had ciTBI. Also, two cases of physically abused children with ciTBI were classified as very low risk. If we did not include physically abused children, the sensitivity of the PECARN rule for children<2 years old improved from 85.7% to 100% (8/8). ConclusionsThe PECARN rules were less sensitive for physically abused children, although the rules showed excellent applicability for the cohort without physical abuse. Thoughtful consideration may be needed for cases of nonaccidental trauma. Further prospective studies are required to verify the applicability of the PECARN rules for children with minor head trauma in Japan.	[Ide, Kentaro] Natl Ctr Child Hlth & Dev, Div Crit Care Med, Tokyo, Japan; [Uematsu, Satoko; Tetsuhara, Kenichi; Kato, Takahiro] Natl Ctr Child Hlth & Dev, Div Pediat Emergency & Transport Serv, Tokyo, Japan; [Yoshimura, Satoshi] Natl Ctr Child Hlth & Dev, Dept Gen Pediat & Interdisciplinary Med, Tokyo, Japan; [Kobayashi, Tohru] Natl Ctr Child Hlth & Dev, Ctr Clin Res & Dev, Div Clin Res Planning, Dept Dev Strategy, Tokyo, Japan; [Ide, Kentaro] Hosp Sick Children, Dept Crit Care Med, Toronto, ON, Canada; [Ide, Kentaro] SickKids Res Inst, Neurosci & Mental Hlth Program, Toronto, ON, Canada	Ide, K (corresponding author), Natl Ctr Child Hlth & Dev, Div Crit Care Med, Tokyo, Japan.; Ide, K (corresponding author), Hosp Sick Children, Dept Crit Care Med, Toronto, ON, Canada.; Ide, K (corresponding author), SickKids Res Inst, Neurosci & Mental Hlth Program, Toronto, ON, Canada.	ide-k@ncchd.go.jp	Tetsuhara, Kenichi/AAD-2776-2019	Tetsuhara, Kenichi/0000-0001-6473-0326	Foundation for Growth Science [26-44]; Japanese Foundation for Pediatric Research; Marumo Science Research Foundation for Emergency Medicine	This work was supported in part by grants from the Foundation for Growth Science (26-44), the Japanese Foundation for Pediatric Research, and the Marumo Science Research Foundation for Emergency Medicine.	Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V10, P92; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Kemp AM, 2014, ARCH DIS CHILD, V99, P108, DOI 10.1136/archdischild-2013-304339; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lorton F, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0287-3; Ono K, 2011, HEALTH PHYS, V100, P491, DOI 10.1097/HP.0b013e3181f497ef; Ozaki M, 2010, JPN J NEUROSURG TOKY, V19, P474; Pierce MC, 2010, PEDIATRICS, V125, P67, DOI 10.1542/peds.2008-3632; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983	15	17	17	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAR	2017	24	3					308	314		10.1111/acem.13129			7	Emergency Medicine	Emergency Medicine	EP7LL	WOS:000397559200004	27862642	Bronze			2021-06-18	
J	Merz, ZC; Van Patten, R; Lace, J				Merz, Zachary C.; Van Patten, Ryan; Lace, John			Current Public Knowledge Pertaining to Traumatic Brain Injury: Influence of Demographic Factors, Social Trends, and Sport Concussion Experience on the Understanding of Traumatic Brain Injury Sequelae	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Sport concussion; Post-concussive syndrome	PROFESSIONAL FOOTBALL PLAYERS; HEAD-INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; HEALTH-PROFESSIONALS; LEAGUE PLAYER; ENCEPHALOPATHY; MISCONCEPTIONS; RISK; EPIDEMIOLOGY	Objective: The current study aimed to assess current broad traumatic brain injury (TBI)-related knowledge in the general public, as well as understanding regarding specific TBI-related conditions including post-concussive syndrome (PCS) and chronic traumatic encephalopathy (CTE). Methods: Data were collected from 307 domestic and 73 international individuals via online researcher-developed survey instrumentation utilizing the Amazon Mechanical Turk marketplace, a recently developed website that allows for a streamlined process of survey-based participant recruitment and data collection. Participants completed background demographics questions, a 31-item true/false questionnaire pertaining to TBI-related knowledge, and an inquiry related to willingness to allow (future) child(ren) to participate in several popular U.S. sports. Results: The overall accuracy rate of our U. S. sample was 61%. No accuracy differences were present for gender or geographic region (p's > .05). Participants who self-reported a prior concussion diagnosis, who reported receiving formal concussion training, and who endorsed participation in collegiate, semi-professional, or professional athletic competition, all exhibited lower accuracy rates than the respective comparison groups (p's < .001). Finally, individual item analysis revealed the presence of significant misconceptions pertaining to PCS and CTE. Conclusions: Misconceptions regarding TBI remain highly prevalent within the general public and may be explained, to some extent, by inefficiencies in current TBI-education practices. Moreover, misconceptions regarding PCS and CTE are also prevalent and likely reflect inconsistencies in the scientific literature, coupled with misleading media reports. To combat these trends, greater emphasis must be placed on construct definition within the field and streamlined, efficient communication with the general public.	[Merz, Zachary C.; Van Patten, Ryan; Lace, John] St Louis Univ, Dept Psychol, 3700 Lindell Blvd Suite 1200, St Louis, MO 63108 USA	Merz, ZC (corresponding author), St Louis Univ, Dept Psychol, 3700 Lindell Blvd Suite 1200, St Louis, MO 63108 USA.	merzz@slu.edu	Lace, John/AAF-7063-2020	Merz, Zachary/0000-0001-7268-6265; Lace, John/0000-0003-3628-0334			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Bradford LS, 2015, REHABIL PSYCHOL, V60, P344, DOI 10.1037/rep0000057; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980; Casler K, 2013, COMPUT HUM BEHAV, V29, P2156, DOI 10.1016/j.chb.2013.05.009; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Difallah DE, 2015, PROCEEDINGS OF THE 24TH INTERNATIONAL CONFERENCE ON WORLD WIDE WEB (WWW 2015), P238, DOI 10.1145/2736277.2741685; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dunning David, 2004, Psychol Sci Public Interest, V5, P69, DOI 10.1111/j.1529-1006.2004.00018.x; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Evans K, 2009, CONT ISSUES COMMUN S, V36, P166; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field A. P, 2009, DISCOVERING STAT USI; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Karantzoulis S, 2013, NEUROPSYCHOL REV, V23, P350, DOI 10.1007/s11065-013-9243-4; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M. D., 2012, NEUROPSYCHOLOGICAL A, P10; Linden MA, 2010, BRAIN INJURY, V24, P642, DOI 10.3109/02699051003601689; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Minton E., 2013, AMA WINT ED C P, V24; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; O'Jile J. R., 1997, INT J REHABILITATION, V3, P61, DOI DOI 10.1007/BF02766798; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sprouse J, 2011, BEHAV RES METHODS, V43, P155, DOI 10.3758/s13428-010-0039-7; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Vanderploeg RD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P279, DOI 10.1007/0-387-25610-5_16; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280	64	17	17	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2017	32	2					155	167		10.1093/arclin/acw092			13	Psychology, Clinical; Psychology	Psychology	EQ4EG	WOS:000398026400003	27765734	Bronze			2021-06-18	
J	Schiller, RM; van den Bosch, GE; Muetzel, RL; Smits, M; Dudink, J; Tibboel, D; Ijsselstijn, H; White, T				Schiller, Raisa M.; van den Bosch, Gerbrich E.; Muetzel, Ryan L.; Smits, Marion; Dudink, Jeroen; Tibboel, Dick; Ijsselstijn, Hanneke; White, Tonya			Neonatal critical illness and development: white matter and hippocampus alterations in school-age neonatal extracorporeal membrane oxygenation survivors	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POPULATION; NEPSY; ECMO	AIM To examine the neurobiology of long-term neuropsychological deficits after neonatal extracorporeal membrane oxygenation (ECMO). METHOD This cross-sectional study assessed white matter integrity and hippocampal volume of ECMO survivors (8-15y) and healthy children (8-17y) using diffusion tensor imaging (DTI) and structural magnetic resonance imaging (MRI) respectively. Neuropsychological outcome was evaluated in ECMO survivors. Included clinical predictors of white matter integrity: age start ECMO, ECMO duration, highest oxygenation index before ECMO, highest mean airway pressure, and mechanical ventilation duration. RESULTS ECMO survivors (n=23) had lower global fractional anisotropy than healthy children (n=54) (patients=0.368; comparison group=0.381; p=0.018), but similar global mean diffusivity (p=0.410). ECMO survivors had lower fractional anisotropy in the left cingulum bundle (ECMO survivors=0.345; comparison group=0.399; p<0.001) and higher mean diffusivity in a region of the left parahippocampal cingulum (patients=0.916; comparison group=0.871; p<0.001). Higher global mean diffusivity predicted worse verbal memory in ECMO survivors (n=17) (beta=-0.74, p=0.008). ECMO survivors (n= 23) had smaller bilateral hippocampal volume than healthy children (n= 43) (left, p<0.001; right, p<0.001) and this was related to worse verbal memory (left, beta=0.65, p=0.018; right, beta=0.71, p=0.006). INTERPRETATION Neonatal ECMO survivors are at risk for long-term brain alterations, which may partly explain long-term neuropsychological impairments. Neuroimaging may contribute to better risk stratification of long-term impairments.	[Schiller, Raisa M.; van den Bosch, Gerbrich E.; Tibboel, Dick; Ijsselstijn, Hanneke] Erasmus MC Sophia Childrens Hosp, Intens Care & Dept Pediat Surg, Rotterdam, Netherlands; [Schiller, Raisa M.; Muetzel, Ryan L.; White, Tonya] Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiatry Psychol, NL-3000 CB Rotterdam, Netherlands; [Smits, Marion; Dudink, Jeroen; White, Tonya] Erasmus MC, Dept Radiol, Rotterdam, Netherlands; [Dudink, Jeroen] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands	White, T (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiatry Psychol, NL-3000 CB Rotterdam, Netherlands.	t.white@erasmusmc.nl	van den Bosch, Gerbrich/AAP-4158-2020; Smits, Marion/E-4795-2011; Smits, Marion/AAB-3985-2019	Smits, Marion/0000-0001-5563-2871; Dudink, Jeroen/0000-0003-0446-3646; White, Tonya/0000-0003-0271-1896	Dutch Research Council: ZonMw Priority Medicines for Children [40-4150098.9020]; Sophia Stichting Wetenschappelijk Onderzoek (SSWO) [S14-21]; ZonMwNetherlands Organization for Health Research and Development [TOP 91211021]	This study was supported by the Dutch Research Council: ZonMw Priority Medicines for Children grant 40-4150098.9020 and the Sophia Stichting Wetenschappelijk Onderzoek (SSWO): S14-21. A component of the neuroimaging infrastructure was supported through a ZonMw TOP 91211021 to TW. We thank Joost van Rosmalen (PhD) from the department of Biostatistics (Erasmus MC, Rotterdam, the Netherlands) for statistical input and advice. The authors have stated that they had no interests which may be perceived as posing a conflict or bias.	Allison P., 1999, LOGISTIC REGRESSION; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brooks BL, 2010, CHILD NEUROPSYCHOL, V16, P80, DOI 10.1080/09297040903146966; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cooper JM, 2015, CEREB CORTEX, V25, P1469, DOI 10.1093/cercor/bht332; de Groot M, 2015, ALZHEIMERS DEMENT, V11, P321, DOI 10.1016/j.jalz.2014.06.011; Dubois J, 2014, NEUROSCIENCE, V276, P48, DOI 10.1016/j.neuroscience.2013.12.044; Eichenbaum H, 1997, SCIENCE, V277, P330, DOI 10.1126/science.277.5324.330; Extracorporeal Life Support Organization, 2016, ECLS REG REP INT SUM; Madderom MJ, 2016, CRIT CARE MED, V44, P1182, DOI 10.1097/CCM.0000000000001626; Madderom MJ, 2013, INTENS CARE MED, V39, P1584, DOI 10.1007/s00134-013-2973-1; McNally H, 2006, PEDIATRICS, V117, pE845, DOI 10.1542/peds.2005-1167; Muetzel RL, 2015, NEUROIMAGE, V119, P119, DOI 10.1016/j.neuroimage.2015.06.014; Polito A, 2013, INTENS CARE MED, V39, P1594, DOI 10.1007/s00134-013-2985-x; Raets MMA, 2013, PEDIATR CRIT CARE ME, V14, P884, DOI 10.1097/PCC.0b013e3182a555ac; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Stinnett TA, 2002, J PSYCHOEDUC ASSESS, V20, P66, DOI 10.1177/073428290202000105; STOLAR CJH, 1991, J PEDIATR SURG, V26, P563, DOI 10.1016/0022-3468(91)90708-2; van den Bosch GE, 2015, PEDIATR CRIT CARE ME, V16, P652, DOI 10.1097/PCC.0000000000000474; van Heijst AFJ, 2014, SEMIN PERINATOL, V38, P104, DOI 10.1053/j.semperi.2013.11.008; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; White T, 2013, EUR J EPIDEMIOL, V28, P99, DOI 10.1007/s10654-013-9768-0; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110	25	17	17	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	MAR	2017	59	3					304	310		10.1111/dmcn.13309			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	EP3ZM	WOS:000397320200016	27873310	Bronze			2021-06-18	
J	Singh, S; Mishra, A; Srivastava, N; Shukla, S				Singh, Sonu; Mishra, Akanksha; Srivastava, Neha; Shukla, Shubha			MK-801 (Dizocilpine) Regulates Multiple Steps of Adult Hippocampal Neurogenesis and Alters Psychological Symptoms via Wnt/beta-Catenin Signaling in Parkinsonian Rats	ACS CHEMICAL NEUROSCIENCE			English	Article						MK-801; neural stem cells; hippocampal neurogenesis; Parkinson's disease; nonmotor symptoms	MIDBRAIN DOPAMINERGIC-NEURONS; NMDA RECEPTOR ANTAGONISTS; NEURAL PROGENITOR CELLS; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; MOUSE HIPPOCAMPUS; SUBSTANTIA-NIGRA; PRECURSOR CELLS; SELF-RENEWAL; DISEASE	Adult hippocampal neurogenesis is directly involved in regulation of stress, anxiety, and depression that are commonly observed nonmotor symptoms in Parkinson's disease (PD). These symptoms do not respond to pharmacological dopamine replacement therapy. Excitotoxic damage to neuronal cells by N-methyl-D-aspartate (NMDA) receptor activation is also a major contributing factor in PD development, but whether it regulates hippocampal neurogenesis and nonmotor symptoms in PD is yet unexplored. Herein, for the first time, we studied the effect of MK-801, an NMDA receptor antagonist, on adult hippocampal neurogenesis and behavioral functions in 6-OHDA (6-hydroxydopamine) induced rat model of PD. MK-801 treatment (0.2 mg/kg, ip) increased neural stem cell (NSC) proliferation, self-renewal capacity, long-term survival, and neuronal differentiation in the hippocampus of rat model of PD. MK-801 potentially enhanced long-term survival, improved dendritic arborization of immature neurons, and reduced 6-01-IDA induced neurodegeneration via maintaining the NSC pool in hippocampus, leading to decreased anxiety and depression-like phenotypes in the PD model. MK-801 inhibited glycogen synthase kinase-3 beta (GSK-3/3) through up-regulation of Wnt-3a, which resulted in the activation of Wnt/beta-catenin signaling leading to enhanced hippocampal neurogenesis in PD model. Additionally, MK-801 treatment protected the dopaminergic (DAergic) neurons in the nigrostriatal pathway and improved motor functions by increasing the expression of Nurr-1 and Pitx-3 in the PD model. Therefore, MK-801 treatment serves as a valuable tool to enhance hippocampal neurogenesis in PD, but further studies are needed to revisit the role of MK-801 in the neurodegenerative disorder before proposing a potential therapeutic candidate.	[Singh, Sonu; Mishra, Akanksha; Srivastava, Neha; Shukla, Shubha] CSIR CDRI, Pharmacol Div, BS-10-1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India	Shukla, S (corresponding author), CSIR CDRI, Pharmacol Div, BS-10-1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.	shubha_shulda@cdri.res.in		Singh, Sonu/0000-0002-2389-6685	Council of Scientific and Industrial Research (CSIR) Network grant miND [BSC0115]; Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR); CSIR, New Delhi, IndiaCouncil of Scientific & Industrial Research (CSIR) - India	The authors thank Director of CSIR-Central Drug Research Institute (CDRI), Lucknow, India, for constant support and direction in the study. This research work is supported by Council of Scientific and Industrial Research (CSIR) Network grant miND (BSC0115) to Shubha Shukla. Sonu Singh and Akanksha Mishra are supported by a research fellowship from Indian Council of Medical Research (ICMR) and CSIR, New Delhi, India, respectively. The CSIR-CDRI manuscript communication number for this article is 9391.	Ahlander M, 1999, NEUROPSYCHOPHARMACOL, V21, P414, DOI 10.1016/S0893-133X(98)00116-X; Ahn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Baker SA, 2004, EUR J NEUROSCI, V20, P575, DOI 10.1111/j.1460-9568.2004.03486.x; Barkus C, 2010, EUR J PHARMACOL, V626, P49, DOI 10.1016/j.ejphar.2009.10.014; Bernabeu R, 2000, J CEREBR BLOOD F MET, V20, P1669, DOI 10.1097/00004647-200012000-00006; Bond AM, 2015, CELL STEM CELL, V17, P385, DOI 10.1016/j.stem.2015.09.003; Broussard JI, 2016, CELL REP, V14, P1930, DOI 10.1016/j.celrep.2016.01.070; CAMERON HA, 1995, J NEUROSCI, V15, P4687; Carvalho MM, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-14; Chen Y, 2005, J NEUROSCI, V25, P8209, DOI 10.1523/JNEUROSCI.1951-05.2005; Choi JH, 2011, CELL MOL NEUROBIOL, V31, P285, DOI 10.1007/s10571-010-9619-4; Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x; De Biase LM, 2011, J NEUROSCI, V31, P12650, DOI 10.1523/JNEUROSCI.2455-11.2011; Fong HL, 2008, STEM CELLS, V26, P1931, DOI 10.1634/stemcells.2007-1002; Gonera EG, 1997, MOVEMENT DISORD, V12, P871, DOI 10.1002/mds.870120607; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hack I, 2002, NAT NEUROSCI, V5, P939, DOI 10.1038/nn923; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Hegarty SV, 2013, DEV BIOL, V379, P123, DOI 10.1016/j.ydbio.2013.04.014; Hewett SJ, 2006, J PHARMACOL EXP THER, V319, P1219, DOI 10.1124/jpet.106.109876; Hill AS, 2015, NEUROPSYCHOPHARMACOL, V40, P2368, DOI 10.1038/npp.2015.85; Hoglinger GU, 2014, J COMP NEUROL, V522, P2336, DOI 10.1002/cne.23537; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Hsu KS, 1996, J NEUROPHYSIOL, V76, P1887; Joelving FC, 2006, HIPPOCAMPUS, V16, P826, DOI 10.1002/hipo.20212; Jonkers N, 2000, EUR J PHARMACOL, V407, P281, DOI 10.1016/S0014-2999(00)00753-6; Kaidanovich-Beilin O, 2004, BIOL PSYCHIAT, V55, P781, DOI 10.1016/j.biopsych.2004.01.008; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Kitayama T, 2004, J NEUROSCI RES, V76, P599, DOI 10.1002/jnr.20095; L'Episcopo F, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-49; Langen B, 2012, PSYCHOPHARMACOLOGY, V221, P249, DOI 10.1007/s00213-011-2567-y; Latysheva NV, 2003, PROG NEURO-PSYCHOPH, V27, P787, DOI 10.1016/S0278-5846(03)00110-6; Lazarini F, 2014, J NEUROSCI, V34, P14430, DOI 10.1523/JNEUROSCI.5366-13.2014; Le W, 1999, J NEUROCHEM, V73, P2218; Lemke MR, 2008, EUR J NEUROL, V15, P21, DOI 10.1111/j.1468-1331.2008.02058.x; Li C, 2013, GLIA, V61, P732, DOI 10.1002/glia.22469; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Maxwell SL, 2005, DEV BIOL, V282, P467, DOI 10.1016/j.ydbio.2005.03.028; Michetti C, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00095; MILNER TA, 1989, J COMP NEUROL, V281, P479, DOI 10.1002/cne.902810311; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Morales M, 2013, BEHAV BRAIN RES, V250, P18, DOI 10.1016/j.bbr.2013.04.050; MURASE S, 1993, J NEURAL TRANSM-GEN, V91, P13, DOI 10.1007/BF01244915; Nacher J, 2003, NEUROBIOL AGING, V24, P273, DOI 10.1016/S0197-4580(02)00096-9; Niu S, 2004, NEURON, V41, P71, DOI 10.1016/S0896-6273(03)00819-5; Okuyama N, 2004, J NEUROCHEM, V88, P717, DOI 10.1046/j.1471-4159.2003.02215.x; PAPP M, 1994, EUR J PHARMACOL, V263, P1, DOI 10.1016/0014-2999(94)90516-9; Paquette MA, 2010, NEUROPHARMACOLOGY, V58, P1002, DOI 10.1016/j.neuropharm.2010.01.003; Park D, 2010, STEM CELLS, V28, P2162, DOI 10.1002/stem.541; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Petrus DS, 2009, EUR J NEUROSCI, V29, P244, DOI 10.1111/j.1460-9568.2008.06579.x; Qiu JH, 2009, STEM CELLS, V27, P920, DOI 10.1002/stem.1; Racca C, 2000, J NEUROSCI, V20, P2512; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schaefer A, 2008, DEV NEUROBIOL, V68, P590, DOI 10.1002/dneu.20601; Schoenfeld TJ, 2015, NEUROPSYCHOPHARMACOL, V40, P113, DOI 10.1038/npp.2014.230; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shin JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050496; Shulman LM, 2001, MOVEMENT DISORD, V16, P507, DOI 10.1002/mds.1099; Singh S, 2016, MOL NEUROBIOL, V53, P4286, DOI 10.1007/s12035-015-9361-5; Sonmez A, 2015, NEUROSCI LETT, V597, P137, DOI 10.1016/j.neulet.2015.05.001; Suzuki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009260; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; van den Munckhof P, 2003, DEVELOPMENT, V130, P2535, DOI 10.1242/dev.00464; Varela-Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100; Wilkinson MB, 2011, J NEUROSCI, V31, P9084, DOI 10.1523/JNEUROSCI.0039-11.2011; Winner B, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a021287; Won SJ, 2006, EXP NEUROL, V198, P250, DOI 10.1016/j.expneurol.2005.12.008; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020945; Zarrindast MR, 2012, PHARMACOL BIOCHEM BE, V103, P102, DOI 10.1016/j.pbb.2012.07.016; Zou H, 2008, PHARMACOL BIOCHEM BE, V90, P753, DOI 10.1016/j.pbb.2008.06.002	76	17	17	0	9	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAR	2017	8	3					592	605		10.1021/acschemneuro.6b00354			14	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	EO6MT	WOS:000396807900020	27977132				2021-06-18	
J	Alosco, ML; Jarnagin, J; Tripodis, Y; Platt, M; Martin, B; Chaisson, CE; Baugh, CM; Fritts, NG; Cantu, RC; Stern, RA				Alosco, Michael L.; Jarnagin, Johnny; Tripodis, Yorghos; Platt, Michael; Martin, Brett; Chaisson, Christine E.; Baugh, Christine M.; Fritts, Nathan G.; Cantu, Robert C.; Stern, Robert A.			Olfactory Function and Associated Clinical Correlates in Former National Football League Players	JOURNAL OF NEUROTRAUMA			English	Article						American football; chronic traumatic encephalopathy; National Football League; olfaction; repetitive head impacts	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; HIGH-SCHOOL FOOTBALL; SMELL IDENTIFICATION TEST; ODOR IDENTIFICATION; ALZHEIMERS-DISEASE; OLDER-ADULTS; NFL PLAYERS; CONCUSSION; DYSFUNCTION	Professional American football players incur thousands of repetitive head impacts (RHIs) throughout their lifetime. The long-term consequences of RHI are not well characterized, but may include olfactory dysfunction. RHI has been associated with changes to brain regions involved in olfaction, and olfactory impairment is common after traumatic brain injury. Olfactory dysfunction is a frequent early sequelae of neurodegenerative diseases (e.g., Alzheimer's disease), and RHI is associated with the neurodegenerative disease, chronic traumatic encephalopathy (CTE). We examined olfaction, and its association with clinical measures, in former National Football League (NFL) players. Ninety-five former NFL players (ages 40-69) and 28 same-age controls completed a neuropsychological and neuropsychiatric evaluation as part of a National Institutes of Health-funded study. The Brief Smell Identification Test (B-SIT) assessed olfaction. Principal component analysis generated a four-factor structure of the clinical measures: behavioral/mood, psychomotor speed/executive function, and verbal and visual memory. Former NFL players had worse B-SIT scores relative to controls (p = 0.0096). A B-SIT cutoff of 11 had the greatest accuracy (c-statistic = 0.61) and specificity (79%) for discriminating former NFL players from controls. In the former NFL players, lower B-SIT scores correlated with greater behavioral/mood impairment (p = 0.0254) and worse psychomotor speed/executive functioning (p = 0.0464) after controlling for age and education. Former NFL players exhibited lower olfactory test scores relative to controls, and poorer olfactory test performance was associated with worse neuropsychological and neuropsychiatric functioning. Future work that uses more-comprehensive tests of olfaction and structural and functioning neuroimaging may improve understanding on the association between RHI and olfaction.	[Alosco, Michael L.; Baugh, Christine M.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Jarnagin, Johnny; Martin, Brett; Chaisson, Christine E.; Fritts, Nathan G.] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Platt, Michael] Boston Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA 02118 USA; [Martin, Brett] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [Chaisson, Christine E.] Boston Univ, Sch Publ Hlth, Dept Biostat, Data Coordinating Ctr, Boston, MA USA; [Baugh, Christine M.] Interfac Initiat Hlth Policy, Cambridge, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol & Neurosurg, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Stern, RA (corresponding author), Boston Univ, Alzheimers Dis & CTE Ctr, Dept Neurol, 72 East Concord St,Suite B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG13846, R01 NS 078337, R01 9500301152, R56 9500304025, U01 NS093334]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32NS096803-01]; National Institutes of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334, R01NS078337, F32NS096803, R56NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG019610, P30AG013846] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NIH; P30 AG13846, R01 NS 078337, R01 9500301152, R56 9500304025, and U01 NS093334). M.L.A. and research reported in this publication are supported by the NIH under grant number 1F32NS096803-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. C.B. is currently supported by the National Institutes of Mental Health under award number T32MH019733. There were no restrictions on the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication. There is no sponsor.	Albers MW, 2015, ALZHEIMERS DEMENT, V11, P70, DOI 10.1016/j.jalz.2014.04.514; Attems J, 2005, J ALZHEIMERS DIS, V7, P149; Attems J, 2006, CLIN NEUROPATHOL, V25, P265; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; Beck A., 1988, MANUAL BECK HOPELESS; Beck A., 1996, MANUAL BDI 2; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Charland-Verville V, 2012, AM J RHINOL ALLERGY, V26, P222, DOI 10.2500/ajra.2012.26.3769; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cross DJ, 2013, J NUCL MED, V54, P1278, DOI 10.2967/jnumed.112.116558; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; de Guise E, 2015, BRAIN INJURY, V29, P730, DOI 10.3109/02699052.2015.1004748; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Delank KW, 1996, LARYNGO RHINO OTOL, V75, P154, DOI 10.1055/s-2007-997554; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Devanand DP, 2015, NEUROLOGY, V84, P182, DOI 10.1212/WNL.0000000000001132; Doty R.L., 1983, SMELL IDENTIFICATION; Doty RL, 1995, CHEM SENSES, V20, P645, DOI 10.1093/chemse/20.6.645; DOTY RL, 1989, PERCEPT PSYCHOPHYS, V45, P381, DOI 10.3758/BF03210709; Coello AF, 2010, J NEUROSURG, V113, P547, DOI 10.3171/2010.6.JNS091620; Fortin A, 2010, BRAIN INJURY, V24, P27, DOI 10.3109/02699050903446815; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Growdon ME, 2015, NEUROLOGY, V84, P2153, DOI 10.1212/WNL.0000000000001614; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Heaton RK, 1993, WISCONSIN CARD SORT; Hedner M, 2010, J CLIN EXP NEUROPSYC, V32, P1062, DOI 10.1080/13803391003683070; HIRSCH AR, 1993, J NEUROL ORTH MED S, V14, P152; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lezak M. D., 2012, NEUROPSYCHOLOGICAL A, pxxv; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Luzzi S, 2007, NEUROPSYCHOLOGIA, V45, P1823, DOI 10.1016/j.neuropsychologia.2006.12.008; Magerova H, 2014, AM J ALZHEIMERS DIS, V29, P762, DOI 10.1177/1533317514539033; Makizako M, 2014, CHEM SENSES, V39, P39, DOI 10.1093/chemse/bjt052; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miller BL, 2007, HUMAN FRONTAL LOBES; MILLER IW, 1986, J CONSULT CLIN PSYCH, V54, P724, DOI 10.1037/0022-006X.54.5.724; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Patel ZM, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/675635; Pinto JM, 2014, J GERONTOL A-BIOL, V69, P323, DOI 10.1093/gerona/glt063; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts RO, 2016, JAMA NEUROL, V73, P93, DOI 10.1001/jamaneurol.2015.2952; Roth R.M., 2005, BRIEF BEHAV RATING I; Royet JP, 2001, NEUROIMAGE, V13, P506, DOI 10.1006/nimg.2000.0704; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Schofield PW, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00005; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sigurdardottir S, 2016, NEUROPSYCHOLOGY, V30, P98, DOI 10.1037/neu0000206; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Sohrabi HR, 2009, J ALZHEIMERS DIS, V17, P135, DOI 10.3233/JAD-2009-1020; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stanciu I, 2014, J INT NEUROPSYCH SOC, V20, P209, DOI 10.1017/S1355617713001409; Stern R. A., 1999, BQSS BOSTON QUALITAT; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Swan GE, 2002, NEUROEPIDEMIOLOGY, V21, P58, DOI 10.1159/000048618; Tabert MH, 2005, ANN NEUROL, V58, P155, DOI 10.1002/ana.20533; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Vent J, 2010, BRAIN RES, V1320, P1, DOI 10.1016/j.brainres.2010.01.007; Wechsler D., 1997, WAIS 3 ADM SCORING M; Westervelt HJ, 2008, J CLIN EXP NEUROPSYC, V30, P151, DOI 10.1080/13803390701287408; White T, 2003, NAB NEUROPSYCHOLOGIC; Wilson RS, 2007, J NEUROL NEUROSUR PS, V78, P30, DOI 10.1136/jnnp.2006.099721; Wilson RS, 2007, ARCH GEN PSYCHIAT, V64, P802, DOI 10.1001/archpsyc.64.7.802; Wilson RS, 2006, NEUROEPIDEMIOLOGY, V26, P61, DOI 10.1159/000090250; Wu AP, 2008, AM J RHINOL, V22, P606, DOI 10.2500/ajr.2008.22.3238; Xydakis MS, 2015, NEUROLOGY, V84, P1559, DOI 10.1212/WNL.0000000000001475; Yoon JH, 2015, J NEUROL SCI, V355, P174, DOI 10.1016/j.jns.2015.06.013; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171	91	17	17	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					772	780		10.1089/neu.2016.4536			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200003	27430424	Green Published			2021-06-18	
J	Urban, KJ; Riggs, L; Wells, GD; Keightley, M; Chen, JK; Ptito, A; Fait, P; Taha, T; Sinopoli, KJ				Urban, Karolina J.; Riggs, Lily; Wells, Greg D.; Keightley, Michelle; Chen, Jen-Kai; Ptito, Alain; Fait, Philippe; Taha, Tim; Sinopoli, Katia J.			Cortical Thickness Changes and Their Relationship to Dual-Task Performance following Mild Traumatic Brain Injury in Youth	JOURNAL OF NEUROTRAUMA			English	Article						concussion; cortical thickness; dual-task paradigm; mTBI; working memory	CHILDREN; CONCUSSION; MODERATE; MEMORY; MRI; REGISTRATION; CORTEX; SPORT; MAP	Mild traumatic brain injury (mTBI) is common in youth, especially in those who participate in sport. Recent investigations from our group have shown that asymptomatic children and adolescents with mTBI continue to exhibit alterations in neural activity and cognitive performance compared with those without a history of mTBI. This is an intriguing finding, given that current return-to-learn and return-to-play protocols rely predominately on subjective symptom reports, which may not be sensitive enough to detect subtle injury-related changes. As a result, youth may be at greater risk for re-injury and long-term consequences if they are cleared for activity while their brains continue to be compromised. It is currently unknown whether mTBI also affects brain microstructure in the developing brain, particularly cortical thickness, and whether such changes are also related to cognitive performance. The present study examined cortical thickness in 13 asymptomatic youth (10-14 years old) who had sustained an mTBI 3-8 months prior to testing compared with 14 age-matched typically developing controls. Cortical thickness was also examined in relation to working memory performance during single and dual task paradigms. The results show that youth who had sustained an mTBI had thinner cortices in the left dorsolateral prefrontal region and right anterior and posterior inferior parietal lobes. Additionally, cortical thinning was associated with slower reaction time during the dual-task condition in the injured youth only. The results also point to a possible relationship between functional and structural alterations as a result of mTBI in youth, and lend evidence for neural changes beyond symptom resolution.	[Urban, Karolina J.; Riggs, Lily; Keightley, Michelle] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Urban, Karolina J.; Keightley, Michelle] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Wells, Greg D.; Taha, Tim] Univ Toronto, Dept Kinesiol & Phys Educ, Toronto, ON, Canada; [Wells, Greg D.] Hosp Sick Children, Dept Physiol & Expt Med, Toronto, ON, Canada; [Sinopoli, Katia J.] Hosp Sick Children, Dept Psychol, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Chen, Jen-Kai; Ptito, Alain] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Chen, Jen-Kai; Ptito, Alain] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Fait, Philippe] Univ Quebec Trois Rivieres, Dept Human Kinet, Trois Rivieres, PQ, Canada; [Fait, Philippe] Univ Quebec Trois Rivieres, Res Grp Neuromusculoskeletal Dysfunct GRAN, Trois Rivieres, PQ, Canada	Sinopoli, KJ (corresponding author), Hosp Sick Children, Dept Psychol, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	katia.sinopoli@sickkids.ca	Sinopoli, Katia/AAO-7803-2020	Urban, Karolina/0000-0003-1301-7891	Ontario Neurotrauma Foundation [ONF 2009-ABI-IMAGING-750]; Rita G. Rudel Early Career Award	This project was funded by the Ontario Neurotrauma Foundation (ONF 2009-ABI-IMAGING-750) awarded to Drs. Keightley and Wells, and the Rita G. Rudel Early Career Award awarded to Dr. Sinopoli. We thank Dr. Elysa Widjaja (staff neuroradiologist, Hospital for Sick Children) for reviewing the clinical MRI scans, and Nick Reed, Sam Liu, and Sabrina Agnihotri for their assistance in the development of the imaging protocols.	Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Alexander-Bloch A, 2013, J NEUROSCI, V33, P2889, DOI 10.1523/JNEUROSCI.3554-12.2013; Baker S, 2014, BRAIN INJURY, V28, P686; Boucher M, 2009, MED IMAGE ANAL, V13, P203, DOI 10.1016/j.media.2008.09.001; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Cocosco CA, 2003, MED IMAGE ANAL, V7, P513, DOI 10.1016/S1361-8415(03)00037-9; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Croteau-Chonka EC, 2016, NEUROIMAGE, V125, P413, DOI 10.1016/j.neuroimage.2015.10.038; Dean PJ, 2015, BRAIN INJURY, P1; Einarson D., 2006, HUMAN BRAIN MAPPING; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giza C. C., 2014, NEUROSURGERY, V75, P24, DOI DOI 10.1227/NEU.0000000000000505; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Hartikainen P, 2012, J ALZHEIMERS DIS, V30, P857, DOI 10.3233/JAD-2012-112060; Jaeggi SM, 2007, COGN AFFECT BEHAV NE, V7, P75, DOI 10.3758/CABN.7.2.75; Jonkman LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129380; Keightley ML, 2012, CURR OPIN PEDIATR, V24, P709, DOI 10.1097/MOP.0b013e3283599a55; Khundrakpam BS, 2013, CEREB CORTEX, V23, P2072, DOI 10.1093/cercor/bhs187; Kim JS, 2005, NEUROIMAGE, V27, P210, DOI 10.1016/j.neuroimage.2005.03.036; Lerch JP, 2005, NEUROIMAGE, V24, P163, DOI 10.1016/j.neuroimage.2004.07.045; Levan A, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000040; List J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00228; Lyttelton O, 2007, NEUROIMAGE, V34, P1535, DOI 10.1016/j.neuroimage.2006.10.041; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Mutlu AK, 2013, NEUROIMAGE, V82, P200, DOI 10.1016/j.neuroimage.2013.05.076; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; PARENT A, 1995, HUMAN NEUROANATOMY; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Ptak R, 2012, NEUROSCIENTIST, V18, P502, DOI 10.1177/1073858411409051; Raznahan A, 2011, J NEUROSCI, V31, P7174, DOI 10.1523/JNEUROSCI.0054-11.2011; Richter J, 2015, PSYCHIAT RES-NEUROIM, V234, P15, DOI 10.1016/j.pscychresns.2015.06.011; Robbins S, 2004, MED IMAGE ANAL, V8, P311, DOI 10.1016/j.media.2004.06.009; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sun D, 2009, SCHIZOPHR RES, V108, P85, DOI 10.1016/j.schres.2008.11.026; Szameitat AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195; Tau GZ, 2010, NEUROPSYCHOPHARMACOL, V35, P147, DOI 10.1038/npp.2009.115; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Wierenga LM, 2014, NEUROIMAGE, V87, P120, DOI 10.1016/j.neuroimage.2013.11.010; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	65	17	17	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					816	823		10.1089/neu.2016.4502			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200008	27629883				2021-06-18	
J	Lynall, RC; Zukowski, LA; Plummer, P; Mihalik, JP				Lynall, Robert C.; Zukowski, Lisa A.; Plummer, Prudence; Mihalik, Jason P.			Reliability and validity of the protokinetics movement analysis software in measuring center of pressure during walking	GAIT & POSTURE			English	Article						Gait; Functional movement; Movement assessment; Dynamic balance	GAITRITE(R) WALKWAY SYSTEM; BALANCE CONTROL; GAIT; PARAMETERS; QUANTIFICATION; CONCUSSION	Our purpose was to determine the validity and test-retest reliability of the Protokinetics Movement Analysis Software (PKMAS) in measuring center of pressure (COP) during walking as compared to a force plate gold standard. Twenty-five healthy participants (14 females, 11 males; age 20.0 +/- 1.5 years) completed 2 testing sessions approximately 5 days apart (mean = 5.5 +/- 1.1 days). In each session, participants completed 16 total trials across a 6 m walkway: 8 trials walking on a ProtoKinetics Zeno Walkway using PKMAS and 8 trials walking over 2 force plates arranged in an offset tandem pattern. COP path length (cm) and speed (cm/s) were calculated from data averaged across the 8 trials on a given device for a given foot. Intraclass correlation coefficients (ICC 2, k) were computed to determine between session reliability. Pearson correlation coefficients (r) and Bland-Altman plots were produced between the PKMAS and force plate outcomes for session 1 to determine validity. The PKMAS demonstrated excellent reliability (ICC 2, k >= 0.962) for all COP measures. Pearson correlation coefficients between PKMAS and force plates were >= 0.75 for all outcome variables. Bland-Altman plots and 95% levels of agreement revealed a bias where the PKMAS appeared to underestimate COP path length and speed by approximately 4 cm and 6 cm/s, respectively. After correcting for bias, our findings suggest the PKMAS is a reliable tool to measure COP in healthy people during gait. Using the PKMAS with the ProtoKinetics Zeno Walkway may allow for more efficient investigation of dynamic balance variables during functional movement tasks. (C) 2016 Elsevier B.V. All rights reserved.	[Lynall, Robert C.; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Dept Exercise & Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Lynall, Robert C.; Plummer, Prudence; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Sch Med, Dept Allied Hlth Sci, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Zukowski, Lisa A.; Plummer, Prudence] Univ North Carolina Chapel Hill, Sch Med, Dept Allied Hlth Sci, Div Phys Therapy, Chapel Hill, NC USA; [Mihalik, Jason P.] Univ North Carolina Chapel Hill, Injury Prevent Res Ctr, Chapel Hill, NC USA	Lynall, RC (corresponding author), Univ Georgia, Dept Kinesiol, UGA Concuss Res Lab, 330 River Rd, Athens, GA 30602 USA.	rlynall@uga.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640			Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Brunnekreef JJ, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-17; Buesing C, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0062-0; Cho MK, 2015, GAIT POSTURE, V42, P73, DOI 10.1016/j.gaitpost.2015.04.009; Dames KD, 2015, GAIT POSTURE, V42, P122, DOI 10.1016/j.gaitpost.2015.04.017; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gribble PA, 2012, J ATHL TRAINING, V47, P339, DOI 10.4085/1062-6050-47.3.08; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Jian Y., 1993, GAIT POSTURE, V1, P9, DOI [10.1016/0966-6362(93)90038-3, DOI 10.1016/0966-6362(93)90038-3]; Menz HB, 2004, GAIT POSTURE, V20, P20, DOI 10.1016/S0966-6362(03)00068-7; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Roemmich RT, 2012, GAIT POSTURE, V36, P340, DOI 10.1016/j.gaitpost.2012.01.018; van der Krogt M.M., 2015, J BIOMECH; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Xu H, 2015, GAIT POSTURE, V42, P110, DOI 10.1016/j.gaitpost.2015.04.015	15	17	17	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	FEB	2017	52						308	311		10.1016/j.gaitpost.2016.12.023			4	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	EQ3XS	WOS:000398007900052	28033577				2021-06-18	
J	Xiong, M; Jones, OD; Peppercorn, K; Ohline, SM; Tate, WP; Abraham, WC				Xiong, Monica; Jones, Owen D.; Peppercorn, Katie; Ohline, Shane M.; Tate, Warren P.; Abraham, Wickliffe C.			Secreted amyloid precursor protein-alpha can restore novel object location memory and hippocampal LTP in aged rats	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Aging; Memory; Long-term potentiation; Hippocampus; Secreted amyloid precursor protein	LONG-TERM POTENTIATION; CEREBROSPINAL-FLUID LEVELS; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; SPATIAL MEMORY; APPS-ALPHA; IN-VITRO; SYNAPTIC PLASTICITY; LEARNING-CAPACITY	Secreted amyloid precursor protein-a (sAPP alpha) is a neurotrophic and neuroprotective molecule which can enhance learning and synaptic plasticity. Aging is associated with memory decline and impaired long-term potentiation (LTP). SAPP alpha therefore has potential as a nootropic agent which could be used to offset age-related cognitive decline. In this study we investigated the effects of sAPPa on spatial memory tasks and LTP in aged and young Long-Evans rats. Two hippocampus-dependent tasks were employed to measure spatial memory that is susceptible to impairments during aging. Aged rats showed a mild deficit in the novel object location task, but memory was significantly enhanced by bilateral intrahippocampal injections of sAPPa. There was no effect on the performance of young animals. In the watermaze task, however, sAPPa did not alleviate age-related decline in spatial memory. In subsequent electrophysiological experiments, LTP was impaired in slices from aged animals, but plasticity was rescued in a concentration-dependent manner by exogenous sAPPa administration. In contrast, LTP was impaired in young animals by sAPPa. Overall, these data support the hypothesis that sAPPa has therapeutic potential as a treatment for age-related cognitive decline. (C) 2016 Elsevier Inc. All rights reserved.	[Xiong, Monica; Jones, Owen D.; Ohline, Shane M.; Abraham, Wickliffe C.] Univ Otago, Brain Res New Zealand, Brain Hlth Res Ctr, Dept Psychol, Dunedin, New Zealand; [Peppercorn, Katie; Tate, Warren P.] Univ Otago, Brain Res New Zealand, Brain Hlth Res Ctr, Dept Biochem, Dunedin, New Zealand	Abraham, WC (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin 9054, New Zealand.	cabraham@psy.otago.ac.nz		Abraham, Wickliffe/0000-0001-9919-0622; Tate, Warren/0000-0002-6971-7734; Ohline, Shane/0000-0001-7716-5055	Health Research Council of New ZealandHealth Research Council of New Zealand; University of Otago Research Committee, New Zealand; Fulbright Foundation, U.S.A.	This research was supported by grants from the Health Research Council of New Zealand and the University of Otago Research Committee, New Zealand to W.C.A. and W.P.T, and by a Fulbright Foundation, U.S.A. scholarship to M.X. We thank Ms B. Logan for assistance with the surgical procedures.	Almkvist O, 1997, ARCH NEUROL-CHICAGO, V54, P641, DOI 10.1001/archneur.1997.00550170111022; Anderson JJ, 1999, NEUROSCIENCE, V93, P1409, DOI 10.1016/S0306-4522(99)00244-4; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Burke SN, 2010, BEHAV NEUROSCI, V124, P559, DOI 10.1037/a0020893; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Claasen AM, 2009, NEUROSCI LETT, V460, P92, DOI 10.1016/j.neulet.2009.05.040; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; DEUPREE DL, 1991, BRAIN RES, V554, P1, DOI 10.1016/0006-8993(91)90164-Q; Deyts C, 2016, TRENDS PHARMACOL SCI, V37, P390, DOI 10.1016/j.tips.2016.01.005; Eckert MJ, 2010, LEARN MEMORY, V17, P480, DOI 10.1101/lm.1822610; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fellgiebel A, 2009, J GERIATR PSYCH NEUR, V22, P3, DOI 10.1177/0891988708327810; Fol R, 2016, ACTA NEUROPATHOL, V131, P247, DOI 10.1007/s00401-015-1498-9; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; Greifzu F, 2014, P NATL ACAD SCI USA, V111, P1150, DOI 10.1073/pnas.1313385111; Hick M, 2015, ACTA NEUROPATHOL, V129, P21, DOI 10.1007/s00401-014-1368-x; Hu YS, 2010, FASEB J, V24, P1667, DOI 10.1096/fj.09-136945; Huber G, 1997, NEUROSCIENCE, V80, P313, DOI 10.1016/S0306-4522(97)00120-6; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Kobayashi S, 2002, J NEUROSCI RES, V70, P340, DOI 10.1002/jnr.10442; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Kumar A, 2004, J NEUROPHYSIOL, V91, P2437, DOI 10.1152/jn.01148.2003; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B; Maei HR, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.004.2009; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mileusnic R, 2004, EUR J NEUROSCI, V19, P1933, DOI 10.1111/j.1460-9568.2004.03276.x; MookJung I, 1997, NEUROSCI LETT, V235, P1, DOI 10.1016/S0304-3940(97)00631-9; Moreno L, 2015, J ALZHEIMERS DIS, V48, P927, DOI 10.3233/JAD-150297; Okamoto M, 2001, NEUROSCIENCE, V104, P653, DOI 10.1016/S0306-4522(01)00124-5; Olsson A, 2003, EXP NEUROL, V183, P74, DOI 10.1016/S0014-4886(03)00027-X; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; Ray B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020405; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Ryan MM, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-376; Sokol DK, 2011, NEUROLOGY, V76, P1344, DOI 10.1212/WNL.0b013e3182166dc7; Speisman RB, 2013, NEUROBIOL AGING, V34, P263, DOI 10.1016/j.neurobiolaging.2012.05.023; SQUIRE LR, 1980, SCIENCE, V209, P836, DOI 10.1126/science.7190729; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; TONKISS J, 1992, DEV PSYCHOBIOL, V25, P567, DOI 10.1002/dev.420250804; Turner PR, 2007, J NEUROSCI METH, V164, P68, DOI 10.1016/j.jneumeth.2007.04.001; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Wallace WC, 1997, MOL BRAIN RES, V52, P213, DOI 10.1016/S0169-328X(97)00259-3	56	17	18	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	FEB	2017	138				SI		291	299		10.1016/j.nlm.2016.08.002			9	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	EN4HU	WOS:000395969400028	27521248				2021-06-18	
J	Tao, XG; Shi, JH; Hao, SY; Chen, XT; Liu, BY				Tao, Xiao-Gang; Shi, Jing-Hua; Hao, Shu-Yu; Chen, Xue-Tao; Liu, Bai-Yun			Protective Effects of Calpain Inhibition on Neurovascular Unit Injury through Downregulating Nuclear Factor-kappa B-related Inflammation during Traumatic Brain Injury in Mice	CHINESE MEDICAL JOURNAL			English	Article						Calpain; Inflammation; Neurovascular Unit; Nuclear Factor-kappa B; Traumatic Brain Injury	IN-VIVO MODEL; BARRIER DISRUPTION; PHARMACOLOGICAL ANALYSIS; CEREBRAL-ISCHEMIA; AXONAL-TRANSPORT; RAT MODEL; MDL-28170; IMPACT; INVOLVEMENT; DYSFUNCTION	Background: In addition to neurons, all components of the neurovascular unit (NVU), such as glial, endothelial, and basal membranes, are destroyed during traumatic brain injury (TBI). Previous studies have shown that excessive stimulation of calpain is crucial for cerebral injury after traumatic insult. The objective of this study was to investigate whether calpain activation participated in NVU disruption and edema formation in a mouse model of controlled cortical impact (CCI). Methods: One hundred and eight mice were divided into three groups: the sham group, the control group, and the MDL28170 group. MDL28170 (20 mg/ kg), an efficient calpain inhibitor, was administered intraperitoneally at 5 min, 3 h, and 6 h after experimental CCI. We then measured neurobehavioral deficits, calpain activity, inflammatory mediator levels, blood-brain barrier (BBB) disruption, and NVU deficits using electron microscopy and histopathological analysis at 6 h and 24 h after CCI. Results: The MDL28170 treatment significantly reduced the extent of both cerebral contusion (MDL28170 vs. vehicle group, 16.90 +/- 1.01 mm(3) and 17.20 +/- 1.17 mm(3) vs. 9.30 +/- 1.05 mm(3) and 9.90 +/- 1.17 mm(3), both P < 0.001) and edema (MDL28170 vs. vehicle group, 80.76 +/- 1.25% and 82.00 +/- 1.84% vs. 82.55 +/- 1.32% and 83.64 +/- 1.25%, both P < 0.05), improved neurological scores (MDL28170 vs. vehicle group, 7.50 +/- 0.45 and 6.33 +/- 0.38 vs. 12.33 +/- 0.48 and 11.67 +/- 0.48, both P < 0.001), and attenuated NVU damage resulting (including tight junction (TJ), basement membrane, BBB, and neuron) from CCI at 6 h and 24 h. Moreover, MDL28170 markedly downregulated nuclear factor-kappa B-related inflammation (tumor necrosis factor-alpha [ TNF-alpha]: MDL28170 vs. vehicle group, 1.15 +/- 0.07 and 1.62 +/- 0.08 vs. 1.59 +/- 0.10 and 2.18 +/- 0.10, both P < 0.001; inducible nitric oxide synthase: MDL28170 vs. vehicle group, 4.51 +/- 0.23 vs. 6.23 +/- 0.12, P < 0.001 at 24 h; intracellular adhesion molecule-l: MDL28170 vs. vehicle group, 1.45 +/- 0.13 vs. 1.70 +/- 0.12, P < 0.01 at 24 h) and lessened both myeloperoxidase activity (MDL28170 vs. vehicle group, 0.016 +/- 0.001 and 0.016 +/- 0.001 vs. 0.024 +/- 0.001 and 0.023 +/- 0.001, P < 0.001 and 0.01, respectively) and matrix metalloproteinase-9 (MMP-9) levels (MDL28170 vs. vehicle group, 0.87 +/- 0.13 and 1.10 +/- 0.10 vs. 1.17 +/- 0.13 and 1.25 +/- 0.12, P < 0.001 and 0.05, respectively) at 6 h and 24 h after CCI. Conclusions: These findings demonstrate that MDL28170 can protect the structure of the NVU by inhibiting the inflammatory cascade, reducing the expression of MMP-9, and supporting the integrity of TJ during acute TBI.	[Tao, Xiao-Gang; Hao, Shu-Yu; Chen, Xue-Tao; Liu, Bai-Yun] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Shi, Jing-Hua] Capital Med Univ, Beijing Tian Tan Hosp, Dept Otolaryngol, Beijing 100050, Peoples R China; [Liu, Bai-Yun] Capital Med Univ, Beijing Neurosurg Inst, Dept Neurotrauma, Beijing 100050, Peoples R China	Liu, BY (corresponding author), Capital Med Univ, Beijing Neurosurg Inst, Dept Neurotrauma, Beijing 100050, Peoples R China.	liubaiyun1963@163.com					Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Bains M, 2013, J NEUROCHEM, V125, P125, DOI 10.1111/jnc.12118; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Banks WA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0434-1; Barakat R, 2016, MED PRIN PRACT, V25, P3, DOI 10.1159/000435858; Blanc F, 2016, AM J PHYSIOL-LUNG C, V310, pL689, DOI 10.1152/ajplung.00314.2015; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Calderon-Garciduenas L, 2016, ENVIRON RES, V146, P404, DOI 10.1016/j.envres.2015.12.031; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Cuzzocrea S, 2001, GUT, V48, P478, DOI 10.1136/gut.48.4.478; Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Fontana ACK, 2016, J NEUROTRAUM, V33, P1073, DOI 10.1089/neu.2015.4079; Gao M, 2010, J ASIAN NAT PROD RES, V12, P407, DOI 10.1080/10286020.2010.485129; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Guo SZ, 2009, STROKE, V40, pS4, DOI 10.1161/STROKEAHA.108.534388; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Jasinska M, 2006, ACTA NEUROBIOL EXP, V66, P99; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Lacoste B, 2015, MECH DEVELOP, V138, P43, DOI 10.1016/j.mod.2015.06.003; Li PY, 2014, STROKE, V45, P857, DOI 10.1161/STROKEAHA.113.004100; Lin MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124558; Liu Y, 2016, J MOL NEUROSCI, V58, P254, DOI 10.1007/s12031-015-0670-y; Liu YQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0177-4; Lo EH, 2009, STROKE, V40, pS2, DOI 10.1161/STROKEAHA.108.534404; Ma M, 2012, J NEUROTRAUM, V29, P2555, DOI 10.1089/neu.2012.2473; Ma MR, 2012, J NEUROTRAUM, V29, P445, DOI 10.1089/neu.2011.2060; Marzocco S, 2004, SHOCK, V21, P38, DOI 10.1097/01.shk.0000095056.62263.b2; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; Pan JH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0808-z; Ponnappan Subramaniam, 2005, Immun Ageing, V2, P15, DOI 10.1186/1742-4933-2-15; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Robertson CS, 2011, J NEUROTRAUM, V28, P727, DOI 10.1089/neu.2010.1476; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Simard M, 2003, J NEUROSCI, V23, P9254; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Sun M, 2008, CELL MOL NEUROBIOL, V28, P593, DOI 10.1007/s10571-007-9183-8; Tao X, 2015, NEUROSCIENCE, V291, P26, DOI 10.1016/j.neuroscience.2015.01.070; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Trager N, 2014, J NEUROCHEM, V130, P268, DOI 10.1111/jnc.12659; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vosler PS, 2009, EXP NEUROL, V218, P213, DOI 10.1016/j.expneurol.2009.04.032; Won S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122821; Wu CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16151; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	58	17	17	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	JAN 20	2017	130	2					187	198		10.4103/0366-6999.198001			12	Medicine, General & Internal	General & Internal Medicine	EK5MV	WOS:000393971400011	28091411	DOAJ Gold			2021-06-18	
J	Chiaretti, A; Conti, G; Falsini, B; Buonsenso, D; Crasti, M; Manni, L; Soligo, M; Fantacci, C; Genovese, O; Calcagni, ML; Di Giuda, D; Mattoli, MV; Cocciolillo, F; Ferrara, P; Ruggiero, A; Staccioli, S; Colafati, GS; Riccardi, R				Chiaretti, Antonio; Conti, Giorgio; Falsini, Benedetto; Buonsenso, Danilo; Crasti, Matteo; Manni, Luigi; Soligo, Marzia; Fantacci, Claudia; Genovese, Orazio; Calcagni, Maria Lucia; Di Giuda, Daniela; Mattoli, Maria Vittoria; Cocciolillo, Fabrizio; Ferrara, Pietro; Ruggiero, Antonio; Staccioli, Susanna; Colafati, Giovanna Stefania; Riccardi, Riccardo			Intranasal Nerve Growth Factor administration improves cerebral functions in a child with severe traumatic brain injury: A case report	BRAIN INJURY			English	Article						Nerve Growth Factor; Doublecortin; traumatic brain injury; intranasal administration	DOUBLECORTIN EXPRESSION; ENDOTHELIAL-CELLS; FACTOR INFUSION; CARDIAC-ARREST; NGF; DELIVERY; RATS; RESUSCITATION; DEFICITS; INFANTS	Background: Nerve growth factor (NGF) promotes neural recovery after experimental traumatic brain injury (TBI) supporting neuronal growth, differentiation and survival of brain cells and up-regulating the neurogenesis-associated protein Doublecortin (DCX). Only a few studies reported NGF administration in paediatric patients with severe TBI.Methods: A four-year-old boy in a persistent unresponsive wakefulness syndrome (UWS) was treated with intranasal murine NGF administration 6months after severe TBI. The patient received four cycles of intranasal NGF (0.1mg/kg, twice a day for 10 consecutive days).Results: NGF administration improved functional [Positron Emission Tomography/Computed Tomography (PET/CT); Single photon emission/Computed Tomography (SPECT/CT) and Magnetic Resonance Imaging (MRI)] assessment, electrophysiological [Electroencephalogram (EEG) and Visual Evoked Potential (VEP)] studies and clinical conditions. He showed improvements in voluntary movements, facial mimicry, phonation, attention and verbal comprehension, ability to cry, cough reflex, oral motility, feeding capacity, and bowel and urinary functions. After NGF administration, raised levels of both NGF and DCX were found in the cerebrospinal fluid of the patient. No side effects were reported.Conclusions: Although further studies are needed for better understanding the neuroprotective role of this neurotrophin, intranasal NGF administration appears to be a promising and safe rescuing strategy treatment in children with neurological impairment after TBI.	[Chiaretti, Antonio; Buonsenso, Danilo; Crasti, Matteo; Fantacci, Claudia; Ferrara, Pietro] Univ Cattolica Sacro Cuore, Inst Pediat, Rome, Italy; [Conti, Giorgio; Genovese, Orazio] Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, Rome, Italy; [Falsini, Benedetto; Calcagni, Maria Lucia; Di Giuda, Daniela; Mattoli, Maria Vittoria] Univ Cattolica Sacro Cuore, Inst Ophthalmol, Rome, Italy; [Manni, Luigi; Soligo, Marzia] CNR, Inst Translat Pharmacol, Rome, Italy; [Cocciolillo, Fabrizio] Univ Cattolica Sacro Cuore, Inst Nucl Med, Rome, Italy; [Ruggiero, Antonio; Riccardi, Riccardo] Univ Cattolica Sacro Cuore, Pediat Oncol, Rome, Italy; [Staccioli, Susanna] Bambino Gesu Pediat Hosp, Dept Neurosci & Neurorehabil, Rome, Italy; [Colafati, Giovanna Stefania] Bambino Gesu Pediat Hosp, Neuroradiol Unit, Dept Imaging, Rome, Italy	Chiaretti, A (corresponding author), Univ Cattolica Sacro Cuore, Inst Pediat, Rome, Italy.	achiaretti@yahoo.it	Falsini, Benedetto/V-1070-2019; Colafati, Giovanna Stefania/J-8937-2018; Soligo, Marzia/AAC-1543-2019; Di Giuda, Daniela/U-1975-2017; Ruggiero, Antonio/M-7849-2018; Manni, Luigi/J-5637-2018; Buonsenso, Danilo/I-8910-2018	Falsini, Benedetto/0000-0002-1694-1062; Colafati, Giovanna Stefania/0000-0002-1142-4904; Di Giuda, Daniela/0000-0002-5758-3986; Ruggiero, Antonio/0000-0002-6052-3511; FERRARA, Pietro/0000-0001-9449-3464; GENOVESE, Orazio/0000-0002-1989-1363; Falsini, Benedetto/0000-0002-3569-4968; Buonsenso, Danilo/0000-0001-8567-2639			ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Catz A, 2007, SPINAL CORD, V45, P275, DOI 10.1038/sj.sc.3101960; Centers for Disease Control and Prevention, 2010, REP C TRAUM BRAIN IN; Centers for Disease Control and Prevention, 2001, RAT TBI REL EM DEP V; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, NEUROL RES, V30, P223, DOI 10.1179/016164107X247948; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158, DOI 10.2174/156720509787602870; Cramer Steven C., 2000, Molecular Medicine Today, V6, P301, DOI 10.1016/S1357-4310(00)01744-5; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Dolle JP, 2005, J PHARMACOL EXP THER, V315, P1220, DOI 10.1124/jpet.105.093252; Falsini B, 2008, J NEURO-ONCOL, V88, P87, DOI 10.1007/s11060-008-9537-1; Frey WH, 1997, DRUG DELIV, V4, P87, DOI 10.3109/10717549709051878; FUJIOKA M, 1994, STROKE, V25, P2091, DOI 10.1161/01.STR.25.10.2091; GAROFALO L, 1994, EXP NEUROL, V125, P195, DOI 10.1006/exnr.1994.1024; Geocadin RG, 2008, NEUROL CLIN, V26, P487, DOI 10.1016/j.ncl.2008.03.015; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guidelines E, 2000, CIRCULATION, V102, P1; Hanson LR, 2013, JOVE-J VIS EXP, V8, P212; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lv QS, 2014, J NEUROL SCI, V345, P48, DOI 10.1016/j.jns.2014.06.037; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Manni L, 2013, GROWTH FACTORS, V31, P115, DOI 10.3109/08977194.2013.804073; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Moser KV, 2004, BRAIN RES, V1017, P53, DOI 10.1016/j.brainres.2004.05.013; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; Pan WH, 1998, BRAIN RES, V788, P87, DOI 10.1016/S0006-8993(97)01525-4; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRADIER P, 1994, J PHYSIOLOGY-PARIS, V88, P273, DOI 10.1016/0928-4257(94)90008-6; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Takase H, 2016, BEHAV BRAIN RES, DOI [10.1016/j.bbr.2016.10.042., DOI 10.1016/J.BBR.2016.10.042.]; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; van Middendorp JJ, 2011, GLOB SPINE J, V1, P1, DOI 10.1055/s-0031-1296049; Wake H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8844; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Young J, 2015, BRAIN RES BULL, V115, P17, DOI 10.1016/j.brainresbull.2015.04.003; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	47	17	17	1	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	11					1538	1547		10.1080/02699052.2017.1376760			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FN4GB	WOS:000415961200019	28972396	Green Published			2021-06-18	
J	Cui, CM; Song, SX; Cui, JZ; Feng, Y; Gao, JL; Jiang, P				Cui, Changmeng; Song, Sixin; Cui, Jianzhong; Feng, Yan; Gao, Junling; Jiang, Pei			Vitamin D Receptor Activation Influences NADPH Oxidase (NOX2) Activity and Protects against Neurological Deficits and Apoptosis in a Rat Model of Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							1,25-DIHYDROXYVITAMIN D-3; BCL-2 FAMILY; D HORMONE; CALCITRIOL; PROTEINS; INVOLVEMENT; PREVALENCE; EXPRESSION; PREVENTION; CALCIUM	Traumatic brain injury (TBI) is a worldwide phenomenon which results in significant neurological and cognitive deficits in humans. Vitamin D (VD) is implicated as a therapeutic strategy for various neurological diseases now. Recently, inhibition of the NADPH oxidase (NOX2) was reported to protect against oxidative stress (ROS) production. However, whether alterations in NOX2 expression and NOX activity are associated with calcitriol (active metabolite of VD) treatment following TBI remains unclear. In the present study, rats were randomly assigned to the sham, TBI, and calcitriol-treated groups. Calcitriol was administered intraperitoneally (2 mu g/kg) at 30 min, 24 h, and 48 h after TBI insult. We observed that calcitriol treatment alleviated neurobehavioral deficits and brain edema following TBI. At the molecular levels, administration of calcitriol activated the expression of VDR and downregulated NOX2 as well as suppressed apoptosis cell rate in the hippocampus CA1 region of TBI rats. In conclusion, our findings indicate that the protective effects of calcitriol may be related to the modulation of NADPH oxidase and thereby ultimately inhibited the progression of apoptosis. Calcitriol may be promising as a protective intervention following TBI, and more study is warranted for its clinical testing in the future.	[Cui, Changmeng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining 272000, Shandong, Peoples R China; [Cui, Changmeng; Gao, Junling] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Changmeng; Cui, Jianzhong] Tangshan Gongren Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China; [Song, Sixin] Taishan Med Univ, Affiliated Hosp, Dept Neurosurg, Tai An 271000, Shandong, Peoples R China; [Feng, Yan] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China; [Jiang, Pei] Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China	Gao, JL (corresponding author), North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China.; Jiang, P (corresponding author), Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China.	jlgaodr2001@163.com; jiangpeicsu@sina.com		Jiang, Pei/0000-0002-8360-7427	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81602846]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	This work was supported by the National Natural Science Foundation of China (Grant no. 81602846) and the Natural Science Foundation of Hebei Province (Grant no. H2014105079).	Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Baroni E, 2008, REGUL TOXICOL PHARM, V52, P332, DOI 10.1016/j.yrtph.2008.09.002; Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chabas JF, 2008, J NEUROTRAUM, V25, P1247, DOI 10.1089/neu.2008.0593; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dang RL, 2015, EUR NEUROPSYCHOPHARM, V25, P1239, DOI 10.1016/j.euroneuro.2015.04.028; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dong JH, 2012, EUR HEART J, V33, P2980, DOI 10.1093/eurheartj/ehr459; Evatt ML, 2008, ARCH NEUROL-CHICAGO, V65, P1348, DOI 10.1001/archneur.65.10.1348; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Finnie J. W., VET RES COMMUNICATIO, V38, P297; Fu J, 2013, MOL MED REP, V8, P1708, DOI 10.3892/mmr.2013.1734; Hellman P, 1999, INT J MOL MED, V3, P355; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hwang JH, 2013, INT J MOL MED, V32, P1394, DOI 10.3892/ijmm.2013.1506; Imazeki I, 2006, BIOMED RES-TOKYO, V27, P1, DOI 10.2220/biomedres.27.1; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jia J, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/893516; Jiang P, 2014, NUTRIENTS, V6, P6048, DOI 10.3390/nu6126048; Jiang P, 2014, PSYCHOPHARMACOLOGY, V231, P3445, DOI 10.1007/s00213-014-3440-6; Jorde R, 2015, J NEUROL SCI, V355, P155, DOI 10.1016/j.jns.2015.06.009; Kalueff AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P738, DOI 10.1023/B:BIRY.0000040196.65686.2f; Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814; Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004; Liu J., 2009, BMC BIOINFORMATICS, V10, P9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Oshima Y, 2008, J BIOL CHEM, V283, P26499, DOI 10.1074/jbc.M800933200; Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Segaert S, 2000, BIOCHEM BIOPH RES CO, V279, P89, DOI 10.1006/bbrc.2000.3892; Shinpo K, 2000, J NEUROSCI RES, V62, P374, DOI 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Thakkar R, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8309031; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wang P., 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/1020357; Wirrell E, 2010, PEDIATR NEUROL, V42, P394, DOI 10.1016/j.pediatrneurol.2010.02.001; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	52	17	18	0	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2017	2017								9245702	10.1155/2017/9245702			13	Cell Biology	Cell Biology	FR4SN	WOS:000419056100001	29410737	DOAJ Gold, Green Published			2021-06-18	
J	Ellis, MJ; Ritchie, LJ; McDonald, PJ; Cordingley, D; Reimer, K; Nijjar, S; Koltek, M; Hosain, S; Johnston, J; Mansouri, B; Sawyer, S; Silver, N; Girardin, R; Larkins, S; Vis, S; Selci, E; Davidson, M; Gregoire, S; Sam, A; Black, B; Bunge, M; Essig, M; MacDonald, P; Leiter, J; Russell, K				Ellis, Michael J.; Ritchie, Lesley J.; McDonald, Patrick J.; Cordingley, Dean; Reimer, Karen; Nijjar, Satnam; Koltek, Mark; Hosain, Shahid; Johnston, Janine; Mansouri, Behzad; Sawyer, Scott; Silver, Norm; Girardin, Richard; Larkins, Shannon; Vis, Sara; Selci, Erin; Davidson, Michael; Gregoire, Scott; Sam, Angela; Black, Brian; Bunge, Martin; Essig, Marco; MacDonald, Peter; Leiter, Jeff; Russell, Kelly			Multidisciplinary Management of Pediatric Sports-Related Concussion	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article						Sports-related concussion; traumatic brain injury; pediatric; healthcare utilization; multidisciplinary; concussion program	TRAUMATIC BRAIN-INJURY; CERVICAL-SPINE; POSITION STATEMENT; PSYCHIATRIC-DISORDERS; SYMPTOM SEVERITY; CHILDREN; RECOVERY; ADOLESCENTS; ASSOCIATION; MODIFIERS	Objectives: To summarize the clinical characteristics and outcomes of pediatric sports-related concussion (SRC) patients who were evaluated and managed at a multidisciplinary pediatric concussion program and examine the healthcare resources and personnel required to meet the needs of this patient population. Methods: We conducted a retrospective review of all pediatric SRC patients referred to the Pan Am Concussion Program from September 1(st), 2013 to May 25(th), 2015. Initial assessments and diagnoses were carried out by a single neurosurgeon. Return-to-Play decision-making was carried out by the multidisciplinary team. Results: 604 patients, including 423 pediatric SRC patients were evaluated at the Pan Am Concussion Program during the study period. The mean age of study patients was 14.30 years (SD: 2.32, range 7-19 years); 252 (59.57%) were males. Hockey (182; 43.03%) and soccer (60; 14.18%) were the most commonly played sports at the time of injury. Overall, 294 (69.50%) of SRC patients met the clinical criteria for concussion recovery, while 75 (17.73%) were lost to follow-up, and 53 (12.53%) remained in active treatment at the end of the study period. The median duration of symptoms among the 261 acute SRC patients with complete follow-up was 23 days (IQR: 15, 36). Overall, 25.30% of pediatric SRC patients underwent at least one diagnostic imaging test and 32.62% received referral to another member of our multidisciplinary clinical team. Conclusion: Comprehensive care of pediatric SRC patients requires access to appropriate diagnostic resources and the multidisciplinary collaboration of experts with national and provincially-recognized training in TBI.	[Ellis, Michael J.; McDonald, Patrick J.; Black, Brian; MacDonald, Peter; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; McDonald, Patrick J.; Sawyer, Scott; Silver, Norm; Selci, Erin; Black, Brian; Bunge, Martin; Russell, Kelly] Univ Manitoba, Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Ritchie, Lesley J.] Univ Manitoba, Clin Hlth Psychol, Winnipeg, MB R3T 2N2, Canada; [Reimer, Karen; Larkins, Shannon] Univ Manitoba, Rehabil Sci, Winnipeg, MB R3T 2N2, Canada; [Nijjar, Satnam; Johnston, Janine; Mansouri, Behzad] Univ Manitoba, Neurol, Winnipeg, MB R3T 2N2, Canada; [Koltek, Mark; Hosain, Shahid] Univ Manitoba, Psychiat, Winnipeg, MB R3T 2N2, Canada; [Davidson, Michael; Gregoire, Scott; Sam, Angela; Bunge, Martin; Essig, Marco] Univ Manitoba, Diagnost Imaging, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; McDonald, Patrick J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB R3T 2N2, Canada; [Black, Brian; MacDonald, Peter] Univ Manitoba, Orthoped, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; McDonald, Patrick J.; Cordingley, Dean; Reimer, Karen; Nijjar, Satnam; Koltek, Mark; Hosain, Shahid; Johnston, Janine; Mansouri, Behzad; Sawyer, Scott; Silver, Norm; Girardin, Richard; Larkins, Shannon; Vis, Sara; Davidson, Michael; Gregoire, Scott; Sam, Angela; Black, Brian; Bunge, Martin; Essig, Marco; MacDonald, Peter; Leiter, Jeff] Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; McDonald, Patrick J.; Cordingley, Dean; Reimer, Karen; Nijjar, Satnam; Koltek, Mark; Hosain, Shahid; Johnston, Janine; Mansouri, Behzad; Sawyer, Scott; Silver, Norm; Girardin, Richard; Larkins, Shannon; Vis, Sara; Davidson, Michael; Gregoire, Scott; Sam, Angela; Black, Brian; Bunge, Martin; Essig, Marco; MacDonald, Peter; Leiter, Jeff] Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.; McDonald, Patrick J.; Reimer, Karen] Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; McDonald, Patrick J.; Cordingley, Dean; Reimer, Karen; Nijjar, Satnam; Koltek, Mark; Hosain, Shahid; Johnston, Janine; Mansouri, Behzad; Sawyer, Scott; Silver, Norm; Girardin, Richard; Larkins, Shannon; Vis, Sara; Davidson, Michael; Gregoire, Scott; Sam, Angela; Black, Brian; Bunge, Martin; Essig, Marco; MacDonald, Peter; Leiter, Jeff] Canada North Concuss Network, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis@panamclinic.com		essig, marco/0000-0002-7964-2297; Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation; Winnipeg Jets True North Foundation	This study was supported by funding provided by the Pan Am Clinic Foundation, the Winnipeg Jets True North Foundation, and a generous donation by Leonard and Susan Asper.	Anderson RC, 2016, NEUROSURG FOCUS, V20, pE3; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Boutis K, 2015, J PEDIATR-US, V166, P1214, DOI 10.1016/j.jpeds.2015.02.013; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chung S, 2011, J TRAUMA, V70, P873, DOI 10.1097/TA.0b013e3182108823; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058868; Echemendia RJ, 2012, ARCH CLIN NEUROPSYCH, V27, P119, DOI 10.1093/arclin/acr077; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Ellis MJ, 2015, CURR SPORT MED REP, V14, P20, DOI 10.1249/JSR.0000000000000108; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ellis MJ, CLIN J SPOR IN PRESS; Ellis MJ, CURRENT SPO IN PRESS; Ellis MJ, 2015, J NEUROSURG PEDIAT, P1; Ellis MJ, CANADIAN MED ASS J; Eubanks Jason David, 2006, J Am Acad Orthop Surg, V14, P552; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry M, 2013, CHILD NERV SYST, V29, P1333, DOI 10.1007/s00381-013-2092-x; Henry M, 2013, J NEUROSURG-PEDIATR, V12, P30, DOI 10.3171/2013.4.PEDS12477; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leong DF, 2015, J OPTOM; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P272, DOI 10.1176/appi.neuropsych.12040078; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moreau WJ, 2013, J CHIROPR MED, V12, P269, DOI 10.1016/j.jcm.2013.07.002; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORTS MED; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Reynolds E, 2014, NEUROSURGERY S4, V75, P71; Ritchie LJ, 2015, CURR RES CONCUSSION, V2, P8; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Seeger TA, 2015, J CHILD NEUROL, V30, P1142, DOI 10.1177/0883073814553973; Seifert T, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0448-x; Slack SE, 2004, EMERG MED J, V21, P189, DOI 10.1136/emj.2003.012310; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Stiell IG, 2010, CAN MED ASSOC J, V182, P1173, DOI 10.1503/cmaj.091430; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	64	17	17	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	JAN	2017	44	1					24	34		10.1017/cjn.2016.312			11	Clinical Neurology	Neurosciences & Neurology	EK3VP	WOS:000393856800005	27772532	Bronze			2021-06-18	
J	Fuller, CW; Fuller, GW; Kemp, SPT; Raftery, M				Fuller, Colin W.; Fuller, Gordon W.; Kemp, Simon P. T.; Raftery, Martin			Evaluation of World Rugby's concussion management process: results from Rugby World Cup 2015	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONSENSUS STATEMENT; OPERATIONAL DEFINITION; POSITION STATEMENT; BRAIN-INJURY; SPORT; PATHOPHYSIOLOGY; ZURICH	Objective To evaluate World Rugby's concussion management process during Rugby World Cup (RWC) 2015. Design A prospective, whole population study. Population 639 international rugby players representing 20 countries. Method The concussion management process consisted of 3 time-based, multifaceted stages: an initial on-pitch and/or pitch-side assessment of the injury, a follow-up assessment within 3 hours and an assessment at 36-48 hours. The initial on-pitch assessment targeted obvious signs of concussion, which, if identified, lead to a 'permanent removal from play' decision and a diagnosis of concussion. If the on-pitch diagnosis was unclear, a 10-min off-pitch assessment was undertaken for signs and symptoms of concussion leading to a 'suspected concussion with permanent removal from play' or a 'no indication of concussion with return to play' decision. Evaluations at 3 and 36-48 hours postmatch lead to diagnoses of 'confirmed concussion' or 'no concussion'. Medical staff's decision-making was supported during each stage by real-time video review of events. Players diagnosed with confirmed concussion followed a 5-stage graduated-return-to-play protocol before being allowed to return to training and/or competition. Results Players were evaluated for concussion on 49 occasions, of which 24 resulted in diagnoses of concussion. Fourteen players showing on-pitch signs of concussion were permanently removed from play: 4 of the 5 players removed from play following off-pitch medical room evaluation were later diagnosed with a confirmed concussion. Five players not exhibiting in-match signs or symptoms of concussion were later diagnosed with concussion. The overall incidence of concussion during RWC 2015 was 12.5 concussions/1000 player-match-hours. Conclusions This study supports the implementation of a multimodal, multitime-based concussion evaluation process to ensure that immediate and late developing concussions are captured.	[Fuller, Colin W.] Colin Fuller Consultancy Ltd, Loughborough, England; [Fuller, Gordon W.] Univ Sheffield, Sch Hlth & Related Res, Emergency Med Res Sheffield Grp, Sheffield, S Yorkshire, England; [Kemp, Simon P. T.] Rugby Football Union, London, England; [Raftery, Martin] World Rugby, Dublin, Ireland	Fuller, CW (corresponding author), Colin Fuller Consultancy Ltd, Loughborough, England.	ColinFullerConsultancy@gmail.com	Ball, James E/G-1734-2011	Ball, James E/0000-0001-8342-1916; Kemp, Simon/0000-0002-3250-2713; Fuller, Gordon Ward/0000-0001-8532-3500	World Rugby; England Rugby; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish	The study was funded by World Rugby and supported by England Rugby 2015.	Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2017, BRIT J SPORT MED, V51, P51, DOI 10.1136/bjsports-2016-096275; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller GW, 2015, BRIT J SPORT MED, V49, P529, DOI 10.1136/bjsports-2014-093498; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Helmy A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5748; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kirkwood B., 2003, ESSENTIAL MED STAT, V2nd; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Patricios JS, 2014, BRIT J SPORT MED, V48, P76, DOI 10.1136/bjsports-2013-093031; Quarrie KL, 2014, BRIT J SPORT MED, V48, P1589, DOI 10.1136/bjsports-2014-094112; Raftery M, 2016, BRIT J SPORT MED, V50, P642, DOI 10.1136/bjsports-2016-095959; Raftery M, 2014, BRIT J SPORT MED, V48, P79, DOI 10.1136/bjsports-2013-093051; Rugby Football Union, 2016, ENGL PROF RUGB INJ S; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018	23	17	17	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2017	51	1					64	+		10.1136/bjsports-2016-096461			7	Sport Sciences	Sport Sciences	EH0EK	WOS:000391435400014	27587799	Green Accepted			2021-06-18	
J	Gallun, FJ; Papesh, MA; Lewis, MS				Gallun, Frederick J.; Papesh, Melissa A.; Lewis, M. Samantha			Hearing complaints among veterans following traumatic brain injury	BRAIN INJURY			English	Article						Hearing; TBI; auditory; Veteran; auditory processing	HIGH-INTENSITY BLASTS; CLOSED-HEAD INJURY; AUDITORY DYSFUNCTION; EXPOSURE; PERFORMANCE; SEQUELAE; SYSTEM; TESTS; TBI	It has been shown that there is an increased risk for impaired auditory function following traumatic brain injury (TBI) in Veterans. Evidence is strongest in the area of self-report, but behavioural and electrophysiological data have been obtained that, are consistent,with these complaints. Peripheral and central dysfunction have both been observed. Historically, studies have focused on penetrating head injuries where central injury is more easily documented than in mild closed head injuries, but several recent reports have expanded the literature to include closed head injuries as well. The lack of imaging technology that can identify which closed head injuries are likely to impact auditory function is a significant barrier to accurate diagnosis and rehabilitation. Current behavioural and electrophysiological measures are effective in substantiating the auditory complaints of these patients but leave many questions unanswered. One significant limitation of current approaches is the lack of clear data regarding the potential influence of those mental health comorbidities that are very likely to be present in the Veteran population. In the area of rehabilitation, there are indications that hearing aids and other assistive listening devices may provide benefit, as can auditory training programmes, yet more research needs to be done.	[Gallun, Frederick J.; Papesh, Melissa A.; Lewis, M. Samantha] VA Portland Hlth Care Syst, VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Gallun, Frederick J.; Lewis, M. Samantha] Oregon Hlth & Sci Univ, Dept Otolaryngol H&NS, Portland, OR 97201 USA; [Gallun, Frederick J.] Oregon Hlth & Sci Univ, Neurosci Grad Program, Portland, OR 97201 USA	Gallun, FJ (corresponding author), VA Portland Hlth Care Syst, VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Frederick.Gallun@va.gov	Gallun, Frederick J./G-3792-2012	Gallun, Frederick J./0000-0002-4145-2199	Veterans AffairsUS Department of Veterans Affairs [I01RX000536] Funding Source: NIH RePORTER; VAUS Department of Veterans Affairs [5I01RX000536-02] Funding Source: Federal RePORTER; RRD VA [I01 RX000536] Funding Source: Medline		Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Bergemalm PO, 2005, INT J AUDIOL, V44, P39, DOI 10.1080/14992020400022546; Bressler S, 2016, HEAR RES; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Gallun FJ, 2016, J REHABIL RES DEV, V53, P705, DOI 10.1682/JRRD.2014.12.0313; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Hoover EC, 2015, SIG 6 PERSPECT HEAR, V19, P12; Hoover EC, J AM ACAD AU I PRESS; JABBARI B, 1987, Seminars in Hearing, V8, P261, DOI 10.1055/s-0028-1091376; Jabbari B, SEMIN HEAR, V8, P240; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kokx-Ryan M, 2016, INT HEAR AID RES C; Krause MO, 2014, BRAIN INJURY, V28, P1473, DOI 10.3109/02699052.2014.920520; Mueller H, 1987, SEMINAR HEARING, V8, P279, DOI DOI 10.1055/S-0028-1091378; Mueller HG, SEMIN HEAR, V8, P223; Mueller HG, SEMIN HEAR, V8, P267; Mueller HG, SEMIN HEAR, V8, P253; Munjal SK, 2010, BRAIN INJURY, V24, P525, DOI 10.3109/02699050903516872; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Saunders GH, 2015, J REHABIL RES DEV, V52, P343, DOI 10.1682/JRRD.2014.11.0275; Saunders Gabrielle H., 2014, Seminars in Hearing, V35, P227, DOI 10.1055/s-0034-1383507; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; Vance SC, SEMIN HEAR, V8, P215; Weihing Jeffrey, 2015, Seminars in Hearing, V36, P199, DOI 10.1055/s-0035-1564458	32	17	17	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1183	1187		10.1080/02699052.2016.1274781			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600004	28981349	Green Accepted, Other Gold			2021-06-18	
J	Khan, RS; Dine, K; Geisler, JG; Shindler, KS				Khan, Reas S.; Dine, Kimberly; Geisler, John G.; Shindler, Kenneth S.			Mitochondrial Uncoupler Prodrug of 2,4-Dinitrophenol, MP201, Prevents Neuronal Damage and Preserves Vision in Experimental Optic Neuritis	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							BROWN ADIPOSE-TISSUE; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; MULTIPLE-SCLEROSIS; MOUSE MODEL; AXONAL LOSS; PROTEIN-2; DYSFUNCTION; UCP2; NEURODEGENERATION	The ability of novel mitochondrial uncoupler prodrug of 2,4-dinitrophenol (DNP), MP201, to prevent neuronal damage and preserve visual function in an experimental autoimmune encephalomyelitis (EAE) model of optic neuritis was evaluated. Optic nerve inflammation, demyelination, and axonal loss are prominent features of optic neuritis, an inflammatory optic neuropathy often associated with the central nervous system demyelinating disease multiple sclerosis. Currently, optic neuritis is frequently treated with high-dose corticosteroids, but treatment fails to prevent permanent neuronal damage and associated vision changes that occur as optic neuritis resolves, thus suggesting that additional therapies are required. MP201 administered orally, once per day, attenuated visual dysfunction, preserved retinal ganglion cells (RGCs), and reduced RGC axonal loss and demyelination in the optic nerves of EAE mice, with limited effects on inflammation. The prominent mild mitochondrial uncoupling properties of MP201, with slow elimination of DNP, may contribute to the neuroprotective effect by modulating the entire mitochondria's physiology directly. Results suggest that MP201 is a potential novel treatment for optic neuritis.	[Khan, Reas S.; Dine, Kimberly; Shindler, Kenneth S.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; [Khan, Reas S.; Dine, Kimberly; Shindler, Kenneth S.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA; [Geisler, John G.] Mitochon Pharmaceut Inc, 970 Cross Lane, Blue Bell, PA USA	Shindler, KS (corresponding author), Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.; Shindler, KS (corresponding author), Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.	kenneth.shindler@uphs.upenn.edu		Dine, Kimberly/0000-0001-5569-7261	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY019014]; Research to Prevent Blindness Physician Scientist AwardResearch to Prevent Blindness (RPB); F. M. Kirby Foundation	This work was supported by the National Institutes of Health grant EY019014; Research to Prevent Blindness Physician Scientist Award; and the F. M. Kirby Foundation. The authors thank Mitochon Pharmaceuticals, Inc. for providing MP201 for the studies reported in this manuscript.	Alemzadeh R, 2008, METABOLISM, V57, P1597, DOI 10.1016/j.metabol.2008.06.017; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Arnold AC, 2005, AM J OPHTHALMOL, V139, P1101, DOI 10.1016/j.ajo.2005.01.031; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barnstable CJ, 2016, J MOL NEUROSCI, V58, P461, DOI 10.1007/s12031-016-0728-5; Beck RW, 2008, ARCH OPHTHALMOL-CHIC, V126, P994, DOI 10.1001/archopht.126.7.994; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; Beck RW, 2004, AM J OPHTHALMOL, V137, P77, DOI 10.1016/S0002-9394(02)00862-6; Brodsky M, 2008, ARCH NEUROL-CHICAGO, V65, P727, DOI 10.1001/archneur.65.6.727; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Calvo-Rodriguez M, 2015, NEURAL REGEN RES, V10, P1371, DOI 10.4103/1673-5374.165219; Christensen CR, 2006, CLIN NUCL MED, V31, P193, DOI 10.1097/01.rlu.0000204199.33136.05; Chu ACY, 2009, FREE RADICAL BIO MED, V46, P810, DOI 10.1016/j.freeradbiomed.2008.12.015; Costello F, 2006, ANN NEUROL, V59, P963, DOI 10.1002/ana.20851; Cutting WC, 1933, J AMER MED ASSOC, V101, P193, DOI 10.1001/jama.1933.02740280013006; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; da Silva CCC, 2008, AGING CELL, V7, P552, DOI 10.1111/j.1474-9726.2008.00407.x; De Felice FG, 2006, IUBMB LIFE, V58, P185, DOI 10.1080/15216540600702198; Deierborg T, 2008, J CEREBR BLOOD F MET, V28, P1186, DOI 10.1038/jcbfm.2008.8; Diano S, 2003, ENDOCRINOLOGY, V144, P5014, DOI 10.1210/en.2003-0667; Federico A., 2012, J NEUROL SCI, V15, P1; Fonseca-Kelly Zoe, 2012, Front Neurol, V3, P84, DOI 10.3389/fneur.2012.00084; GEHRING PJ, 1969, TOXICOL APPL PHARM, V15, P574, DOI 10.1016/0041-008X(69)90060-X; Geisler JG, 2011, DIABETOLOGIA, V54, P237, DOI 10.1007/s00125-010-1932-4; Geisler J. G., 2016, ALZHEIMERS DEMENT, V16, pS1552; Geisler J. G., 2017, DIS MODIFYING EFFECT; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Guy J, 1998, P NATL ACAD SCI USA, V95, P13847, DOI 10.1073/pnas.95.23.13847; HARRIS M, 1995, APERTURE, P1; Horner W D, 1941, Trans Am Ophthalmol Soc, V39, P405; Khan RS, 2017, SCI REP-UK, V7, DOI 10.1038/srep41768; Khan RS, 2014, INVEST OPHTH VIS SCI, V55, P5744, DOI 10.1167/iovs.14-14672; Khan RS, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-3; Khan RS, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00063; Korde AS, 2005, J NEUROCHEM, V94, P1676, DOI 10.1111/j.1471-4159.2005.03328.x; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kwok KHH, 2010, FREE RADICAL BIO MED, V49, P1023, DOI 10.1016/j.freeradbiomed.2010.06.017; Lee V., 2010, INVEST OPHTHALMOL, V52, P639; Lieven CJ, 2006, INVEST OPHTH VIS SCI, V47, P1477, DOI 10.1167/iovs.05-0921; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu D, 2015, J NEUROCHEM, V134, P677, DOI 10.1111/jnc.13176; Liu D, 2010, J ALZHEIMERS DIS, V22, P443, DOI 10.3233/JAD-2010-101017; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; da Costa RFM, 2010, J NEUROTRAUM, V27, P829, DOI 10.1089/neu.2009.1189; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 2012, CELL METAB, V16, P706, DOI 10.1016/j.cmet.2012.08.012; Mookerjee SA, 2010, MECH AGEING DEV, V131, P463, DOI 10.1016/j.mad.2010.03.010; Nedergaard J, 1999, J BIOENERG BIOMEMBR, V31, P475, DOI 10.1023/A:1005400507802; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; PARASCANDOLA J, 1974, MOL CELL BIOCHEM, V5, P69, DOI 10.1007/BF01874175; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Perry RJ, 2015, SCIENCE, V347, P1253, DOI 10.1126/science.aaa0672; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; Qi L, 2014, ANN SURG, V260, P169, DOI 10.1097/SLA.0000000000000328; Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P681, DOI 10.1167/iovs.06-0553; Shindler KS, 2010, J NEURO-OPHTHALMOL, V30, P328, DOI 10.1097/WNO.0b013e3181f7f833; SKULACHEV VP, 1967, NATURE, V216, P718, DOI 10.1038/216718a0; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Su K, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00169; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Tainter ML, 1935, J AMER MED ASSOC, V105, P0332, DOI 10.1001/jama.1935.02760310006002; Trip SA, 2005, ANN NEUROL, V58, P383, DOI 10.1002/ana.20575; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Vogler S, 2006, AM J PATHOL, V168, P1570, DOI 10.2353/ajpath.2006.051069; Voss Elke, 2011, Ther Adv Neurol Disord, V4, P123, DOI 10.1177/1756285611398702; Wasilewska-Sampaio AP, 2005, FASEB J, V19, P1627, DOI 10.1096/fj.05-3812com; Witte ME, 2014, TRENDS MOL MED, V20, P179, DOI 10.1016/j.molmed.2013.11.007; Wu B, 2017, EXP NEUROL, V293, P83, DOI 10.1016/j.expneurol.2017.03.020; Wu ZF, 2010, J CLIN BIOCHEM NUTR, V46, P187, DOI 10.3164/jcbn.09-104-2; Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157	70	17	17	0	10	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2017	2017								7180632	10.1155/2017/7180632			10	Cell Biology	Cell Biology	EX4JV	WOS:000403201700001		DOAJ Gold, Green Published			2021-06-18	
J	Main, KL; Soman, S; Pestilli, F; Furst, A; Noda, A; Hernandez, B; Kong, J; Cheng, JT; Fairchild, JK; Taylor, J; Yesavage, J; Ashford, JW; Kraemer, H; Adamson, MM				Main, Keith L.; Soman, Salil; Pestilli, Franco; Furst, Ansgar; Noda, Art; Hernandez, Beatriz; Kong, Jennifer; Cheng, Jauhtai; Fairchild, Jennifer K.; Taylor, Joy; Yesavage, Jerome; Ashford, J. Wesson; Kraemer, Helena; Adamson, Maheen M.			DTI measures identify mild and moderate TBI cases among patients with complex health problems: A receiver operating characteristic analysis of US veterans	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Concussion; Imaging; Axon degeneration; Neurodegeneration	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSE AXONAL INJURY; WHITE-MATTER INTEGRITY; POST-CONCUSSION SYNDROME; TENSOR IMAGING FINDINGS; HEAD-INJURY; FIBER TRACTOGRAPHY; POSTCONCUSSION SYNDROME; EXTERNAL VALIDATION	Standard MRI methods are often inadequate for identifying mild traumatic brain injury (TBI). Advances in diffusion tensor imaging now provide potential biomarkers of TBI among white matter fascicles (tracts). However, it is still unclear which tracts are most pertinent to TBI diagnosis. This study ranked fiber tracts on their ability to discriminate patients with and without TBI. We acquired diffusion tensor imaging data from military veterans admitted to a polytrauma clinic (Overall n = 109; Age: M = 47.2, SD= 11.3; Male: 88%; TBI: 67%). TBI diagnosis was based on self-report and neurological examination. Fiber tractography analysis produced 20 fiber tracts per patient. Each tract yielded four clinically relevant measures (fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity). We applied receiver operating characteristic (ROC) analyses to identify the most diagnostic tract for each measure. The analyses produced an optimal cutpoint for each tract. We then used kappa coefficients to rate the agreement of each cutpoint with the neurologist's diagnosis. The tract with the highest kappa was most diagnostic. As a check on the ROC results, we performed a stepwise logistic regression on each measure using all 20 tracts as predictors. We also bootstrapped the ROC analyses to compute the 95% confidence intervals for sensitivity, specificity, and the highest kappa coefficients. The ROC analyses identified two fiber tracts as most diagnostic of TBI: the left cingulum (LCG) and the left inferior fronto-occipital fasciculus (LIF). Like ROC, logistic regression identified LCG as most predictive for the FA measure but identified the right anterior thalamic tract (RAT) for the MD, RD, and AD measures. These findings are potentially relevant to the development of TBI biomarkers. Our methods also demonstrate how ROC analysis may be used to identify clinically relevant variables in the TBI population.	[Main, Keith L.; Soman, Salil; Furst, Ansgar; Kong, Jennifer; Cheng, Jauhtai; Yesavage, Jerome; Ashford, J. Wesson] VAPAHCS, War Related Illness & Injury Study Ctr, Palo Alto, CA USA; [Main, Keith L.] DVBIC, 1335 East West Highway,Suite 4-100, Silver Spring, MD 20910 USA; [Main, Keith L.] GDHS, Fairfax, VA USA; [Soman, Salil; Furst, Ansgar; Noda, Art; Hernandez, Beatriz; Fairchild, Jennifer K.; Taylor, Joy; Yesavage, Jerome; Ashford, J. Wesson; Kraemer, Helena; Adamson, Maheen M.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Soman, Salil] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA USA; [Pestilli, Franco] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Furst, Ansgar] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Adamson, Maheen M.] Stanford Sch Med, Dept Neurosurg, Stanford, CA USA; [Adamson, Maheen M.] VAPAHCS, DVBIC, Palo Alto, CA USA	Main, KL (corresponding author), VAPAHCS, War Related Illness & Injury Study Ctr, Palo Alto, CA USA.; Main, KL (corresponding author), DVBIC, 1335 East West Highway,Suite 4-100, Silver Spring, MD 20910 USA.	keith.l.main3.ctr@mail.mil	Ashford, J. Wesson/D-3929-2009	Adamson, Maheen/0000-0002-1534-4063; Soman, Salil/0000-0002-5887-0717	ar Related Illness and Injury Study Center; NSFNational Science Foundation (NSF) [IIS 1636893]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ULTTR001108]	This research was funded by the ar Related Illness and Injury Study Center. F.P. is supported by NSF IIS 1636893 and NIH ULTTR001108.	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alemayehu D, 2012, ACAD RADIOL, V19, P1457, DOI 10.1016/j.acra.2012.09.006; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bozzali M, 2005, BRAIN, V128, P1595, DOI 10.1093/brain/awh493; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; BROWN JW, 1975, NEUROPSYCHOLOGIA, V13, P107, DOI 10.1016/0028-3932(75)90054-8; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Catani M, 2007, BRAIN, V130, P602, DOI 10.1093/brain/awm008; Centers for Disease Control and Prevention, 2013, REP C TRAUM BRAIN IN; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daniels JK, 2016, EBIOMEDICINE, V4, P20, DOI 10.1016/j.ebiom.2016.02.002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Defense and Veterans Brain Injury Center, 2012, DOD WORLDW NUMB TBI; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dong Q, 2004, J MAGN RESON IMAGING, V19, P6, DOI 10.1002/jmri.10424; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fairchild JK, 2013, INT PSYCHOGERIATR, V25, P607, DOI 10.1017/S1041610212002049; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; Fernandez-Miranda JC, 2012, NEUROSURGERY, V71, P430, DOI 10.1227/NEU.0b013e3182592faa; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; Gong GL, 2005, HUM BRAIN MAPP, V24, P92, DOI 10.1002/hbm.20072; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Gwet K.L, 2014, HDB INTERRATER RELIA; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Han ZZ, 2013, BRAIN, V136, P2952, DOI 10.1093/brain/awt205; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hoblyn J, 2006, J PSYCHIATR RES, V40, P160, DOI 10.1016/j.jpsychires.2005.06.004; HODGSON VR, 1983, P 27 STAPP CAR CRASH; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Honeybul S, 2014, J NEUROSURG, V120, P1131, DOI 10.3171/2014.1.JNS131559; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Huster RJ, 2009, HUM BRAIN MAPP, V30, P383, DOI 10.1002/hbm.20509; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kiernan M, 2001, PSYCHOL METHODS, V6, P35, DOI 10.1037//1082-989X.6.1.35; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinoshita LM, 2012, SLEEP BREATH, V16, P1201, DOI 10.1007/s11325-011-0632-8; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraemer H. C., 2005, TUTORIALS BIOSTATIST, V1; Kraemer H.C., 1992, EVALUATING MED TESTS; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lange G, 2013, MIL MED, V178, P705, DOI 10.7205/MILMED-D-13-00053; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macmillan N. A., 2005, DETECTION THEORY USE; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Matsuo K, 2008, NEURORADIOLOGY, V50, P605, DOI 10.1007/s00234-008-0379-5; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; Mirnezami R, 2012, NEW ENGL J MED, V366, P489, DOI 10.1056/NEJMp1114866; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nelles M, 2008, AM J NEURORADIOL, V29, P488, DOI 10.3174/ajnr.A0855; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Noda A, 2006, AM J GERIAT PSYCHIAT, V14, P931, DOI 10.1097/01.JGP.0000230660.39635.68; O'Hara R, 2002, J GERIATR PSYCH NEUR, V15, P233, DOI 10.1177/089198870201500409; O'Hara Ruth, 2002, Ann Gen Hosp Psychiatry, V1, P1, DOI 10.1186/1475-2832-1-1; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Periyakoil VS, 2005, INT J METH PSYCH RES, V14, P202, DOI 10.1002/mpr.8; Periyakoil VS, 2012, J PALLIAT MED, V15, P1350, DOI 10.1089/jpm.2012.0280; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pestilli F, 2014, NAT METHODS, V11, P1058, DOI 10.1038/nmeth.3098; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Porto L, 2011, EUR J PAEDIATR NEURO, V15, P493, DOI 10.1016/j.ejpn.2011.06.004; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Povlishock JT, 1996, ACT NEUR S, V66, P81; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Rayhan RU, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058493, 10.1371/journal.pone.0063903]; Ressel V., 2016, BRAIN IMAGING BEHAV; Rodrigo S, 2007, AM J NEURORADIOL, V28, P1526, DOI 10.3174/ajnr.A0584; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sanjuan PM, 2013, PSYCHIAT RES-NEUROIM, V214, P260, DOI 10.1016/j.pscychresns.2013.09.002; Sekiguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083967; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shen C., 2008, J DATA SCI, V6, P189; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHULTZ EK, 1995, CLIN CHEM, V41, P1248; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Sorg SF, 2016, J HEAD TRAUMA REHAB, V31, P297, DOI 10.1097/HTR.0000000000000189; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SU JQ, 1993, J AM STAT ASSOC, V88, P1350; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tanielian T., 2008, INVISIBLE WOUNDS OF; Taoka T, 2006, AM J NEURORADIOL, V27, P1040; TEASDALE G, 1974, LANCET, V2, P81; Thanassi W, 2012, PULM MED, V2012, DOI 10.1155/2012/291294; Thiebaut de Schotten M, 2011, NEUROIMAGE, V54, P49, DOI 10.1016/j.neuroimage.2010.07.055; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Tinklenberg JR, 2015, AM J GERIAT PSYCHIAT, V23, P384, DOI 10.1016/j.jagp.2014.09.007; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tyszka JM, 2006, NEUROIMAGE, V29, P1058, DOI 10.1016/j.neuroimage.2005.08.037; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu X, 2013, IEEE ACM T COMPUT BI, V10, P173, DOI 10.1109/TCBB.2012.141; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yamada K, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085827.54986.89; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yeatman JD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5932; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yesavage JA, 2003, J PSYCHIAT RES, V37, P535, DOI 10.1016/S0022-3956(03)00053-0; Yesavage JA, 2011, J GERONTOL B-PSYCHOL, V66, P444, DOI 10.1093/geronb/gbr031; Yin XT, 2013, HUM BRAIN MAPP, V34, P796, DOI 10.1002/hbm.21477; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zhang WH, 2008, NEUROIMAGE, V42, P771, DOI 10.1016/j.neuroimage.2008.04.241; ZWEIG MH, 1993, CLIN CHEM, V39, P561	213	17	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	16						1	16		10.1016/j.nicl.2017.06.031			16	Neuroimaging	Neurosciences & Neurology	FK1IU	WOS:000413235100001	28725550	DOAJ Gold, Green Published			2021-06-18	
J	Poulin, V; Korner-Bitensky, N; Bherer, L; Lussier, M; Dawson, DR				Poulin, Valerie; Korner-Bitensky, Nicol; Bherer, Louis; Lussier, Maxime; Dawson, Deirdre R.			Comparison of two cognitive interventions for adults experiencing executive dysfunction post-stroke: a pilot study	DISABILITY AND REHABILITATION			English	Article						Cognitive rehabilitation; computerised training; executive function; strategy training; stroke	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ACUTE STROKE; WORKING-MEMORY; REHABILITATION; PERFORMANCE; FEASIBILITY; MANAGEMENT; DEFICITS; PROGRAM	Purpose This pilot partially randomised controlled trial compared the feasibility and preliminary efficacy of two promising interventions for persons with executive dysfunction post-stroke: (1) occupation-based strategy training using an adapted version of the Cognitive Orientation to daily Occupational Performance (CO-OP) approach; and (2) Computer-based EF training (COMPUTER training). Method Participants received 16h of either CO-OP or COMPUTER training. We assessed feasibility and acceptability of each intervention, and change in intervention outcomes at baseline, post-intervention and one-month follow-up. Performance and satisfaction with performance in self-selected everyday life goals were measured by the participant and the significant other-rated Canadian Occupational Performance Measure (COPM). Other intervention outcomes included changes in EF impairment, participation in daily life and self-efficacy. Results Six participants received CO-OP and five received COMPUTER training: one in each group discontinued the intervention for medical reasons unrelated to the intervention. The remaining nine participants completed all 16 sessions. Participants expressed high levels of satisfaction with both interventions. Both treatment groups showed large improvements in self and significant other-rated performance and satisfaction with performance on their goals immediately post-intervention and at follow-up (CO-OP: effect sizes (ES)=1.6-3.5; COMPUTER: ES=0.9-4.0), with statistically significant within-group differences in CO-OP (p<0.05). The COMPUTER group also showed large improvements in some areas of EF impairment targeted by the computerised tasks (ES=0.9-1.6); the CO-OP group demonstrated large improvements in self-efficacy for performing everyday activities (ES=1.5). Conclusions Our findings provide preliminary evidence supporting the feasibility of using both CO-OP and COMPUTER training with patients with executive dysfunction post-stroke.	[Poulin, Valerie] Univ Quebec Trois Rivieres, Dept Occupat Therapy, CP 500,3351 Boul Forges, Trois Rivieres, PQ G9A 5H7, Canada; [Poulin, Valerie] Ctr Interdisciplinaire Rech Readaptat & Integrat, Quebec City, PQ, Canada; [Korner-Bitensky, Nicol] McGill Univ, Sch Phys & Occupat Therapy, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [Bherer, Louis] Concordia Univ, Dept Psychol, Montreal, PQ, Canada; [Bherer, Louis] Concordia Univ, PERFORM Ctr, Montreal, PQ, Canada; [Lussier, Maxime] Univ Quebec, Dept Psychol, Montreal, PQ, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada; [Dawson, Deirdre R.] Baycrest, Rotman Res Inst, Toronto, ON, Canada	Poulin, V (corresponding author), Univ Quebec Trois Rivieres, Dept Occupat Therapy, CP 500,3351 Boul Forges, Trois Rivieres, PQ G9A 5H7, Canada.	valerie.poulin@uqtr.ca	Dawson, Deirdre/I-8882-2014	Dawson, Deirdre/0000-0001-7517-6121	Richard and Edith Strauss Canada Foundation; Fonds de recherche du Quebec - SanteFonds de la Recherche en Sante du Quebec; Canadian Stroke Network; Canadian Research Chair programCanada Research Chairs	This study was carried out with financial support from the Richard and Edith Strauss Canada Foundation. Valerie Poulin was also supported by a PhD fellowship award from the Fonds de recherche du Quebec - Sante at the time of the study. Nicol Korner-Bitensky was supported by the Canadian Stroke Network. Louis Bherer was supported by the Canadian Research Chair program. The authors report no declarations of interest.	Anderson PJ, 2010, STUD NEUROPSYCHOL NE, P3; Army Individual Test Battery, 1944, MAN DIR SCOR; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Dawson D, 2014, CLIN REHABIL, V28, P118, DOI 10.1177/0269215513492541; Dawson DR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-306; Dawson DR, 2013, ARCH PHYS MED REHAB, V94, P1959, DOI 10.1016/j.apmr.2013.05.021; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Field A.P., 2005, DISCOVERING STAT USI; Figueiredo S, 2013, DISABIL REHABIL, V35, P968, DOI 10.3109/09638288.2012.717580; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fougeyrollas P, 2002, LIFE HABITS MEASURE; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Glass G.V., 1976, EDUC RES, P3, DOI DOI 10.3102/0013189X005010003; Godefroy O, 2007, BEHAVIORAL AND COGNITIVE NEUROLOGY OF STROKE, P369, DOI 10.1017/CBO9780511544880.020; Honda Tetsumi, 1999, Top Stroke Rehabil, V6, P15, DOI 10.1310/CN46-B2WU-NGVN-37YJ; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; Lesniak M, 2008, DEMENT GERIATR COGN, V26, P356, DOI 10.1159/000162262; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Lussier M, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00129; Lyrette J, 2009, THESIS; Machin DCM., 2009, SAMPLE SIZE TABLES C; Man DWK, 2006, NEUROREHABILITATION, V21, P205; McDowd JM, 2003, J GERONTOL B-PSYCHOL, V58, pP45, DOI 10.1093/geronb/58.1.P45; McEwen S, 2015, NEUROREHAB NEURAL RE, V29, P526, DOI 10.1177/1545968314558602; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; McEwen SE, 2009, BRAIN INJURY, V23, P1041, DOI 10.3109/02699050903421107; National Institute for Health Research Evaluation Trials and Studies Coordinating Centre, 2015, EV TRIALS STUD GLOSS; Ng EMW, 2013, BRAIN INJURY, V27, P548, DOI 10.3109/02699052.2013.766927; Ownsworth T, 2008, DISABIL REHABIL, V30, P531, DOI 10.1080/09638280701355694; Polatajko H. J., 2004, ENABLING OCCUPATION; Poulin V, 2012, TOP STROKE REHABIL, V19, P158, DOI 10.1310/tsr1902-158; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rand D, 2010, NEUROREHAB NEURAL RE, V24, P722, DOI 10.1177/1545968310368684; Rand D, 2009, AM J OCCUP THER, V63, P535, DOI 10.5014/ajot.63.5.535; Riepe MW, 2004, DEMENT GERIATR COGN, V17, P49, DOI 10.1159/000074082; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; SCHOENFELD D, 1980, INT J RADIAT ONCOL, V6, P371, DOI 10.1016/0360-3016(80)90153-4; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; Skidmore E. R., 2014, NEUROREHABILITATION, V29, P668; Skidmore ER, 2015, PM&R, V7, P562, DOI 10.1016/j.pmrj.2014.12.010; Skidmore ER, 2014, CLIN REHABIL, V28, P378, DOI 10.1177/0269215513502799; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss D. T., 2009, REHABILITATION EXECU, P3; Sugavanam T, 2013, DISABIL REHABIL, V35, P177, DOI 10.3109/09638288.2012.690501; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Torkia C, 2012, CAN STROK C 2012 SEP, pe27; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI DOI 10.1080/110381299443771; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015	60	17	20	4	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2017	39	1					1	13		10.3109/09638288.2015.1123303			13	Rehabilitation	Rehabilitation	EC9WG	WOS:000388494400001	26750772				2021-06-18	
J	Salat, DH; Robinson, ME; Miller, DR; Clark, DC; McGlinchey, RE				Salat, David H.; Robinson, Meghan E.; Miller, Danielle R.; Clark, Dustin C.; McGlinchey, Regina E.			Neuroimaging of deployment-associated traumatic brain injury (TBI) with a focus on mild TBI (mTBI) since 2009	BRAIN INJURY			English	Article						Cortical thickness; diffusion tensor imaging; DTI; EEG; ERP: positron emission tomography; FA tractography; fcMRI; FDG; fMRI; fractional anisotropy; functional connectivity; functional magnetic resonance imaging; Glasgow Coma Scale: concussion; magnetic resonance imaging; MEG; MRI; neuroimaging; PET; TBI; Traumatic brain injury	WHITE-MATTER ABNORMALITIES; POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; FUNCTIONAL CONNECTIVITY; BLAST EXPOSURE; MILITARY PERSONNEL; CORTICAL THICKNESS; COMBAT VETERANS; ALZHEIMERS-DISEASE; ENDURING FREEDOM	Objectives:, A substantial body of recent research has aimed to better understand the clinical sequelae,of military trauma through the application of advanced brain imaging procedures in Veteran populations. The primary objective of this review was to highlight:a portion of these recent studies to demonstrate how imaging tools can be used to understand millitary-associated brain injury; Methods: We focus here on the phenomenon Of mild traumatic brain injury (mTBI) given its high prevalence in the Veteran population and,current recognition of the need to better understand, the clinical implications. of this trauma. ThiS is intended to provide readers with an initial exposure to the field of neuroimaging of. mTBI with A brief introduction to the concept of traumatic brain injury, followed by a summary-of the major imaging techniques that have been applied to the study of mTBI. Results: Taken together, the collection of studies reviewed demonstrates a clear role.-for neuroimaging towards understanding the various neural consequences of mTBI as well as the clinical complications of such brain changes. Conclusions This information must be considered-in the-larger context of research into mTBI, including the potentially unique nature of blast exposure and the long-term consequences of mTBI.	[Salat, David H.; Robinson, Meghan E.; Clark, Dustin C.] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, 150 South Huntington Ave, Boston, MA 02130 USA; [Salat, David H.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Salat, David H.; Robinson, Meghan E.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA; [Robinson, Meghan E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Miller, Danielle R.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Miller, Danielle R.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [McGlinchey, Regina E.] Geriatr Res Educ & Clin Ctr, Boston, MA USA; [McGlinchey, Regina E.] Harvard Med Sch, Dept Psychiat, Boston, MA USA	Salat, DH (corresponding author), VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, 150 South Huntington Ave, Boston, MA 02130 USA.	salat@nmh.mgh.harvard.edu		Sullivan, Danielle R./0000-0002-0141-5887	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019836] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: NIH RePORTER		Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Alexander MP, 1995, NEUROLOGY; Alosco ML, 2016, J HEAD TRAUMA REHAB, V31, P360, DOI 10.1097/HTR.0000000000000201; Andre Jalal B, 2015, Top Magn Reson Imaging, V24, P275, DOI 10.1097/RMR.0000000000000065; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Catafau AM, 2015, CLIN TRANSL IMAGING, V3, P39, DOI 10.1007/s40336-014-0098-3; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cifu DX, 2016, BRAIN INJURY, V30, P1397, DOI 10.1080/02699052.2016.1219065; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Farmer CM, 2016, UNDERSTANDING TREATM; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Franke LM, 2016, INT J PSYCHOPHYSIOL, V106, P21, DOI 10.1016/j.ijpsycho.2016.05.010; French L., 2008, J SPEC OPER MED, V8, P68; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Ibarra S., 2011, ENCY CLIN NEUROPSYCH, P325; Johnson VE, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2014.241; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kallakuri S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169239; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu J, 2016, J NEUROTRAUM, V33, P10, DOI 10.1089/neu.2014.3856; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2017, NEUROIMAGE-CLIN, V14, P371, DOI 10.1016/j.nicl.2017.02.005; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Michael AP, 2015, J NEUROTRAUM, V32, P1751, DOI 10.1089/neu.2015.3918; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Miller DR, 2016, BRAIN IMAGING BEHAV, V11, P1; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; Newsome MR, 2016, J INT NEUROPSYCH SOC, V22, P631, DOI 10.1017/S1355617716000448; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Pun PB, 2011, TRAUMAT INJUR NERV S, V29; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shu IW, 2014, PSYCHIAT RES-NEUROIM, V224, P58, DOI 10.1016/j.pscychresns.2014.07.010; Shu IW, 2014, J AFFECT DISORDERS, V155, P234, DOI 10.1016/j.jad.2013.06.057; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tatel DF, 2016, J NEUROL, V263, P2065, DOI 10.1007/s00415-016-8236-7; TEASDALE G, 1974, LANCET, V2, P81; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Villemagne VL, 2015, LANCET NEUROL, V14, P114, DOI 10.1016/S1474-4422(14)70252-2; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Walker WC, 2016, BRAIN INJURY, V30, P1469, DOI 10.1080/02699052.2016.1219061; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeh PH, 2016, HUM BRAIN MAPP	113	17	17	1	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1204	1219		10.1080/02699052.2017.1327672			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600007	28981347	Other Gold			2021-06-18	
J	Ziegler, D; Cravens, G; Poche, G; Gandhi, R; Tellez, M				Ziegler, Daniel; Cravens, George; Poche, Gerard; Gandhi, Raj; Tellez, Mark			Use of Transcranial Doppler in Patients with Severe Traumatic Brain Injuries	JOURNAL OF NEUROTRAUMA			English	Article						hypoperfusion; TBI; TCD; vasospasm	CEREBRAL BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; VASOSPASM; NIMODIPINE; ULTRASOUND; DIAGNOSIS; VELOCITY; SPASM	Severe traumatic brain injuries (TBI) are associated with a high rate of mortality and disability. Transcranial Doppler (TCD) sonography permits a noninvasive measurement of cerebral blood flow. The purpose of this study is to determine the usefulness of TCD in patients with severe TBI. TCD was performed, from April 2008 to April 2013, on 255 patients with severe TBI, defined as a Glasgow Coma Scale score of <= 8 on admission. TCD was performed on hospital days 1, 2, 3, and 7. Hypoperfusion was defined by having two out of three of the following: 1) mean velocity (Vm) of the middle cerebral artery <35cm/sec, 2) diastolic velocity (Vd) of the middle cerebral artery <20cm/sec, or 3) pulsatility index (PI) of >1.4. Vasospasm was defined by the following: Vm of the middle cerebral artery > 120 cm/sec and/or a Lindegaard index (LI) >3. One hundred fourteen (45%) had normal measurements. Of these, 92 (80.7%) had a good outcome, 6 (5.3%) had moderate disability, and 16 (14%) died, 4 from brain death. Seventy-two patients (28%) had hypoperfusion and 71 (98.6%) died, 65 from brain death, and 1 patient survived with moderate disability. Sixty-nine patients (27%) had vasospasm, 31 (44.9%) had a good outcome, 16 (23.2%) had severe disability, and 22 (31.9%) died, 13 from brain death. The vasospasm was detected on hospital day 1 in 8 patients, on day 2 in 23 patients, on day 3 in 22 patients, and on day 7 in 16 patients. Patients with normal measurements can be expected to survive. Patients with hypoperfusion have a poor prognosis. Patients with vasospasm have a high incidence of mortality and severe disability. TCD is useful in determining early prognosis.	[Ziegler, Daniel; Gandhi, Raj; Tellez, Mark] John Peter Smith Hosp, Dept Surg, 1500 South Main St, Ft Worth, TX 76104 USA; [Cravens, George; Poche, Gerard] John Peter Smith Hosp, Dept Neurosurg, Ft Worth, TX 76104 USA	Ziegler, D (corresponding author), John Peter Smith Hosp, Dept Surg, 1500 South Main St, Ft Worth, TX 76104 USA.	dziegler@jpshealth.org					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bouzat P, 2011, NEUROSURGERY, V68, P1603, DOI 10.1227/NEU.0b013e31820cd43e; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; CHAN KH, 1992, NEUROSURGERY, V30, P697; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JENNETT B, 1975, LANCET, V1, P480; Kosty T, 2005, CRIT CARE NURS Q, V28, P122, DOI 10.1097/00002727-200504000-00005; Langham J., 2008, COCHRANE DB SYST REV, V4, P1; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; Moreno J, 2000, NEUROSURG FOCUS, V8, P8; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Sahuquillo J, 2000, REV NEUROLOGIA, V30, P401, DOI 10.33588/rn.3005.99063; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shroder M., 1995, J NEUROSURG, V82, P212; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; White R P, 1990, Neurosurg Clin N Am, V1, P401; WHITE RP, 1982, PHARMACOL THERAPEUT, V18, P313, DOI 10.1016/0163-7258(82)90035-3; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zubkov ZY, 2000, SURG NEUROL, V53, P126	40	17	17	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					121	127		10.1089/neu.2015.3967			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100015	26913374				2021-06-18	
J	Daley, M; Dekaban, G; Bartha, R; Brown, A; Stewart, TC; Doherty, T; Fischer, L; Holmes, J; Menon, RS; Rupar, CA; Shoemaker, JK; Fraser, DD				Daley, Mark; Dekaban, Greg; Bartha, Robert; Brown, Arthur; Stewart, Tanya Charyk; Doherty, Timothy; Fischer, Lisa; Holmes, Jeff; Menon, Ravi S.; Rupar, C. Anthony; Shoemaker, J. Kevin; Fraser, Douglas D.			Metabolomics profiling of concussion in adolescent male hockey players: a novel diagnostic method	METABOLOMICS			English	Article						Concussion; Diagnosis; Biomarker; Metabolomics; Adolescents; Ice hockey	SPORTS-RELATED CONCUSSION; TRANSLATIONAL RESEARCH; BRAIN-INJURY; METABOLISM; STATEMENT; CHILDREN	Introduction Concussions are a major health concern as they cause significant acute symptoms and in some athletes, long-term neurologic dysfunction. Diagnosis of concussion can be difficult, as are the decisions to stop play. Objective To determine if concussions in adolescent male hockey players could be diagnosed using plasma metabolomics profiling. Methods Plasma was obtained from 12 concussed and 17 non-concussed athletes, and assayed for 174 metabolites with proton nuclear magnetic resonance and direct injection liquid chromatography tandem mass spectrometry. Data were analysed with multivariate statistical analysis and machine learning. Results The estimated time from concussion occurrence to blood draw at the first clinic visit was 2.3 +/- 0.7 days. Using principal component analysis, the leading 10 components, each containing 9 metabolites, were shown to account for 82 % of the variance between cohorts, and relied heavily on changes in glycerophospholipids. Cross-validation of the classifier using a leave-one out approach demonstrated a 92 % accuracy rate in diagnosing a concussion (P < 0.0001). The number of metabolites required to achieve the 92 % diagnostic accuracy was minimized from 174 to as few as 17 metabolites. Receiver operating characteristic analyses generated an area under the curve of 0.91, indicating excellent concussion diagnostic potential. Conclusion Metabolomics profiling, together with multivariate statistical analysis and machine learning, identified concussed athletes with >90 % certainty. Metabolomics profiling represents a novel diagnostic method for concussion, and may be amenable to point-of-care testing.	[Daley, Mark] Univ Western Ontario, Dept Comp Sci, London, ON, Canada; [Dekaban, Greg] Univ Western Ontario, Mol Med, Robarts Res Inst, London, ON, Canada; [Bartha, Robert; Menon, Ravi S.] Univ Western Ontario, Dept Med Biophys, London, ON, Canada; [Brown, Arthur; Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON, Canada; [Doherty, Timothy] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; [Fischer, Lisa] Univ Western Ontario, Dept Family Med, London, ON, Canada; [Holmes, Jeff] Univ Western Ontario, Dept Occupat Therapy, London, ON, Canada; [Rupar, C. Anthony] Univ Western Ontario, Dept Biochem, London, ON, Canada; [Rupar, C. Anthony] Univ Western Ontario, Dept Pathol & Lab Med, London, ON, Canada; [Shoemaker, J. Kevin] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Paediat Crit Care Med, Childrens Hosp, London Hlth Sci Ctr, Room C2-846,800 Commissioners Rd East, London, ON N6A 5W9, Canada	Fraser, DD (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Dept Pediat, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Paediat Crit Care Med, Childrens Hosp, London Hlth Sci Ctr, Room C2-846,800 Commissioners Rd East, London, ON N6A 5W9, Canada.	douglas.fraser@lhsc.on.ca	Daley, Mark/AAS-7366-2020; Fischer, Lisa K/H-3999-2015; Menon, Ravi/ABA-8654-2020; Dekaban, Gregory/L-1987-2013; Menon, Ravi S/K-5500-2013; Shoemaker, Joel Kevin/L-2682-2013; Brown, Arthur/K-8328-2013; Bartha, Robert/K-3611-2013	Daley, Mark/0000-0002-6939-9772; Fischer, Lisa K/0000-0001-5992-0176; Menon, Ravi/0000-0002-7916-0263; Menon, Ravi S/0000-0002-7916-0263; Shoemaker, Joel Kevin/0000-0002-6794-5979; Brown, Arthur/0000-0002-8725-3195; Bartha, Robert/0000-0002-7118-9096	Children's Health Foundation	We thank Ms. Christy Barreira and Ms. Sandra Shaw for excellent technical support, and Ms. Kathryn Manning and Mr. Kevin Blackney for assistance with data. We graciously acknowledge analytic support from The Metabolomics Innovation Centre at the University of Alberta, Edmonton, AB (Ms. Rupasri Mandal, Ms. Jennifer D. Reid and Dr. David Wishart). This study was supported by the Children's Health Foundation (http://childhealth.ca/) grant to DDF.	Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Brisson AR, 2012, PEDIATRICS, V129, P153, DOI 10.1542/peds.2011-0134; Bujak R, 2015, J PHARMACEUT BIOMED, V113, P108, DOI 10.1016/j.jpba.2014.12.017; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Gillio-Meina C, 2013, PEDIATRICS, V131, P754, DOI 10.1542/peds.2012-1181; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Lehmann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011519; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; OBRIEN JS, 1965, J LIPID RES, V6, P537; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Shouval R, 2014, BONE MARROW TRANSPL, V49, P332, DOI 10.1038/bmt.2013.146; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vitali C, 2014, CARDIOVASC RES, V103, P405, DOI 10.1093/cvr/cvu148; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Zhu W., 2010, NE SAS US GROUP P	32	17	17	1	30	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1573-3882	1573-3890		METABOLOMICS	Metabolomics	DEC	2016	12	12							185	10.1007/s11306-016-1131-5			9	Endocrinology & Metabolism	Endocrinology & Metabolism	EE4VS	WOS:000389604300010					2021-06-18	
J	Haring, RS; Sheffield, ID; Canner, JK; Schneider, EB				Haring, R. Sterling; Sheffield, Isaac D.; Canner, Joseph K.; Schneider, Eric B.			Epidemiology of Sports-Related Eye Injuries in the United States	JAMA OPHTHALMOLOGY			English	Article							US EMERGENCY-DEPARTMENTS; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; VISUAL IMPAIRMENT; PROTECTIVE EYEWEAR; VISION; RISK; SEVERITY; CASUALTY; TRENDS	IMPORTANCE Ocular trauma can lead to lifelong sequelae, and sports-related ocular injuries have been shown to disproportionately affect the young. Studies quantifying and characterizing the incidence and type of injuries seen with sports-related ocular trauma may be useful for resource utilization, training, and prevention efforts. OBJECTIVE To examine the emergency department (ED) burden of sports-related ocular trauma in the United States. DESIGN, SETTING, AND PARTICIPANTS This retrospective, cross-sectional study examined the Nationwide Emergency Department Sample, containing data from approximately 30 million ED visits annually at more than 900 hospitals nationwide, from January 1, 2010, to December 31, 2013, to determine factors associated with sports-related ocular trauma. MAIN OUTCOMES AND MEASURES Annual incidence of sports-related ocular trauma, broken down by age, sex, mechanism of injury, and related activity, as well as factors associated with short-term impaired vision. RESULTS During the study period, 120 847 individuals (mean age, 22.3 years [95% CI, 21.9-22.7]; 96 872 males, 23 963 females, and 12 with missing data) presented with sports-related ocular trauma, which was the primary diagnosis in 85 961 patients. Injuries occurred most commonly among males (69 849 [81.3%]; 95% CI, 80.6%-81.9%) and occurred most frequently as a result of playing basketball (22.6%; 95% CI, 21.7%-23.6%), playing baseball or softball (14.3%; 95% CI, 13.7%-14.9%), and shooting an air gun (11.8%; 95% CI, 10.8%-12.8%). Odds of presentation to the ED with impaired vision were greatest for paintball and air gun injuries relative to football-related injuries (odds ratio, 4.75; 95% CI, 2.21-10.19 and 3.71; 95% CI, 2.34-5.88, respectively; P < .001). CONCLUSIONS AND RELEVANCE In our study, approximately 30 000 individuals presented annually to EDs in the United States with sports-related eye injuries; in more than 70% of these cases, eye injuries were the primary diagnosis. Activities involving projectiles pose the greatest risk for visual impairment in the short term, although long-term outcomes were unavailable.	[Haring, R. Sterling] Univ Lugano, Ctr Healthcare Qual & Patient Safety, Via G Buffi 13, CH-6900 Lugano, Switzerland; [Haring, R. Sterling; Sheffield, Isaac D.; Schneider, Eric B.] Harvard Med Sch, Ctr Surg & Publ Hlth, Boston, MA USA; [Haring, R. Sterling; Schneider, Eric B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Haring, R. Sterling; Canner, Joseph K.; Schneider, Eric B.] Johns Hopkins Sch Med, Johns Hopkins Surg Ctr Outcomes Res, Baltimore, MD USA; [Sheffield, Isaac D.] Univ Iowa, Carver Coll Med, Iowa City, IA USA	Haring, RS (corresponding author), Univ Lugano, Ctr Healthcare Qual & Patient Safety, Via G Buffi 13, CH-6900 Lugano, Switzerland.	sterling.haring@jhmi.edu					[Anonymous], 2007, AV ANN RAT EY REL EM; Black AA, 2016, OPTOMETRY VISION SCI, V93, P560, DOI 10.1097/OPX.0000000000000831; Bro T, SCAND J MED SCI SPOR; Channa R, 2016, JAMA OPHTHALMOL, V134, P312, DOI 10.1001/jamaophthalmol.2015.5778; Chen Allison J, 2014, R I Med J (2013), V97, P44; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Court H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0181-7; Crews JE, 2006, J VISUAL IMPAIR BLIN, V100, P824; Esquivel AO, 2015, SPORTS HEALTH, V7, P366, DOI 10.1177/1941738115579854; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FONG LP, 1994, MED J AUSTRALIA, V160, P743, DOI 10.5694/j.1326-5377.1994.tb125941.x; Frick KD, 2012, INDIAN J OPHTHALMOL, V60, P406, DOI 10.4103/0301-4738.100535; Gardner EC, 2015, AM J SPORT MED, V43, P2027, DOI 10.1177/0363546515588175; Goldstein MH, 2011, EYE CONTACT LENS, V37, P160, DOI 10.1097/ICL.0b013e31821790db; Green D, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4691276; Haring RS, 2016, INJURY, V47, P104, DOI 10.1016/j.injury.2015.07.020; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; Haut ER, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6626; Hayes A, 2016, VALUE HEALTH, V19, P36, DOI 10.1016/j.jval.2015.10.010; Horowitz A, 2003, GENERATIONS, V27, P32; Hoskin AK, 2016, ACTA OPHTHALMOL, V94, pE407, DOI 10.1111/aos.12911; Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633; JONES NP, 1989, SPORTS MED, V7, P163, DOI 10.2165/00007256-198907030-00003; JONES NP, 1988, EYE, V2, P484, DOI 10.1038/eye.1988.97; Karpman S, 2016, CLIN J SPORT MED, V26, P332, DOI 10.1097/JSM.0000000000000235; Kim T, 2011, GRAEF ARCH CLIN EXP, V249, P1743, DOI 10.1007/s00417-010-1556-x; Kriz PK, 2015, PEDIATRICS, V136, P521, DOI 10.1542/peds.2015-0216; Kriz PK, 2012, PEDIATRICS, V130, P1069, DOI 10.1542/peds.2012-1492; Kuhn F, 2006, OPHTHAL EPIDEMIOL, V13, P209, DOI 10.1080/09286580600665886; Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544; Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155; Leivo T, 2007, SCAND J MED SCI SPOR, V17, P556, DOI 10.1111/j.1600-0838.2006.00607.x; Leivo T, 2015, ACTA OPHTHALMOL, V93, P224, DOI 10.1111/aos.12633; Lincoln AE, 2012, AM J SPORT MED, V40, P611, DOI 10.1177/0363546511428873; MACEWEN CJ, 1987, BRIT J OPHTHALMOL, V71, P701, DOI 10.1136/bjo.71.9.701; Micieli JA, 2014, CAN J OPHTHALMOL, V49, P243, DOI 10.1016/j.jcjo.2014.03.008; Ong HS, 2012, CONTACT LENS ANTERIO, V35, P285, DOI 10.1016/j.clae.2012.07.007; Pardhan S, 1995, EYE, V9, P50; Park HY, 2015, ASIA-PAC J PUBLIC HE, V27, P631, DOI 10.1177/1010539515588944; Park SJ, 2014, EYE, V28, P312, DOI 10.1038/eye.2013.283; Pineles SL, 2015, JAMA OPHTHALMOL, V133, P60, DOI 10.1001/jamaophthalmol.2014.3941; Pollard KA, 2012, CLIN PEDIATR, V51, P374, DOI 10.1177/0009922811427583; Popchak A, 2015, AM J PHYS MED REHAB, V94, P395, DOI 10.1097/PHM.0000000000000184; Press VG, 2015, J HOSP MED, V10, P311, DOI 10.1002/jhm.2342; Radic B, 2014, ACTA CLIN CROAT, V53, P430; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Taylor CA, 2015, J HEAD TRAUMA REHAB, V30, P150, DOI 10.1097/HTR.0000000000000105; Wilson P, 2014, J R Nav Med Serv, V100, P56; Yuksel H, 2014, ARQ BRAS OFTALMOL, V77, P95, DOI 10.5935/0004-2749.20140024	49	17	18	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	DEC 1	2016	134	12					1382	1390		10.1001/jamaophthalmol.2016.4253			9	Ophthalmology	Ophthalmology	EF8SR	WOS:000390600300014	27812702				2021-06-18	
J	Hossfeld, B; Bein, B; Boettiger, BW; Bohn, A; Fischer, M; Graesner, JT; Hinkelbein, J; Kill, C; Lott, C; Popp, E; Roessler, M; Schaumberg, A; Wenzel, V; Bernhard, M				Hossfeld, Bjoern; Bein, Bertold; Boettiger, Bernd W.; Bohn, Andreas; Fischer, Matthias; Graesner, Jan-Thorsten; Hinkelbein, Jochen; Kill, Clemens; Lott, Carsten; Popp, Erik; Roessler, Markus; Schaumberg, Alin; Wenzel, Volker; Bernhard, Michael			Recommended practice for out-of-hospital emergency anaesthesia in adults: Statement from the Out-of-Hospital Emergency Anaesthesia Working Group of the Emergency Medicine Research Group of the German Society of Anaesthesiology and Intensive Care	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							RAPID-SEQUENCE INTUBATION; PREHOSPITAL AIRWAY-MANAGEMENT; TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; VIDEO LARYNGOSCOPES; TRACHEAL INTUBATION; SUCCESS RATES; ETOMIDATE; INDUCTION; MULTICENTER	Emergency anaesthesia is an important therapeutic measure in out-of-hospital emergency medicine. The associated risks are considerably higher than those of in-hospital anaesthesia. The primary objectives of emergency anaesthesia are hypnosis, analgesia, oxygenation and ventilation through airway management. The secondary objectives of emergency anaesthesia are amnesia, anxiolysis, the reduction of oxygen consumption and respiratory work, the protection of vital organs and the avoidance of secondary myocardial and cerebral damage. A critical evaluation of the indications for outof- hospital emergency anaesthesia must take into consideration patient, case and provider-related factors. Rapid sequence induction of emergency anaesthesia includes standard monitoring, preoxygenation, standardised preparation of emergency anaesthesia, drug administration, manual in-line stabilisation during intubation (if necessary), airway management and checking of correct tube placement. Spontaneously breathing casualties should receive preoxygenation for at least 3 to 4 min with a tight-fitting facemask with reservoir using 12 to 15 l min_1 of oxygen or with a demand valve providing 100% oxygen. As an alternative, preoxygenation may be performed as noninvasive ventilation with 100% oxygen. Standardised anaesthesia preparation comprises filling drugs into syringes and labelling them, checking ventilation equipment, preparing endotracheal tube and syringe for inflating the cuff and the introducer, stethoscope and fixation material, preparing alternative instruments for airway management as well as checking suction, ventilation and standard monitoring devices, including capnography. Standard monitoring for out-of-hospital emergency anaesthesia comprises ECG, blood pressure measurement and pulse oximetry. Continuous capnography is always and exclusively performed to check the placement of airway devices, as well as to indirectly monitor haemodynamics.	[Hossfeld, Bjoern] Armed Forces Hosp, Sect Emergency Med, Dept Anaesthesiol & Intens Care Med, Oberer Eselsberg 40, D-89081 Ulm, Germany; [Bein, Bertold] ASKLEPIOS Hosp St Georg, Dept Anaesthesiol, Intens Care Med, Emergency Med,Pain Serv, Hamburg, Germany; [Boettiger, Bernd W.; Hinkelbein, Jochen] Univ Hosp Cologne, Dept Anaesthesiol & Intens Care Med, Cologne, Germany; [Bohn, Andreas] City Munster Fire Dept, Munster, Germany; [Fischer, Matthias] Hosp Eichert, Dept Anaesthesiol, Intens Care Med, Emergency Med,Pain Serv, Goeppingen, Germany; [Graesner, Jan-Thorsten] Univ Schleswig Holstein, Dept Emergency Med, Kiel, Germany; [Kill, Clemens] Univ Giessen & Marburg, Dept Emergency Med, Campus Marburg, Marburg, Germany; [Lott, Carsten] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Popp, Erik] Heidelberg Univ, Dept Anesthesiol, Heidelberg, Germany; [Roessler, Markus] Univ Med Ctr Gottingen, Dept Anesthesiol, Gottingen, Germany; [Schaumberg, Alin] Univ Giessen & Marburg, Dept Anaesthesiol & Intens Care Med, Campus Giessen, Giessen, Germany; [Wenzel, Volker] Med Univ Innsbruck, Dept Anesthesiol & Crit Care Med, Innsbruck, Austria; [Bernhard, Michael] Univ Leipzig, Emergency Dept, Leipzig, Germany	Hossfeld, B (corresponding author), Armed Forces Hosp, Sect Emergency Med, Dept Anaesthesiol & Intens Care Med, Oberer Eselsberg 40, D-89081 Ulm, Germany.	bjoern.hossfeld@extern.uni-ulm.de	Hinkelbein, Jochen/AAA-8801-2021; Roessler, Markus Soeren/I-7834-2013				Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Barnard EBG, 2015, EMERG MED J, V32, P449, DOI 10.1136/emermed-2014-203740; Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034; Bernhard M, 2006, ANAESTHESIST, V55, P1157, DOI 10.1007/s00101-006-1106-4; Bernhard M, 2014, ANAESTHESIST, V63, P589, DOI 10.1007/s00101-014-2348-1; Bernhard M, 2011, NOTFALL RETTUNGSMED, V14, P554, DOI 10.1007/s10049-010-1402-z; Bernhard M, 2010, ANASTH INTENSIVMED, V51, pS615; Braun P, 2010, CURR OPIN ANESTHESIO, V23, P500, DOI 10.1097/ACO.0b013e32833bc135; Breckwoldt J, 2012, RESUSCITATION, V83, P434, DOI 10.1016/j.resuscitation.2011.10.011; Bretschneider I, 2011, NOTARZT, V27, P270, DOI 10.1055/s-0031-1276960; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Christ M., 2010, Intensivmedizin und Notfallmedizin, V47, P83, DOI 10.1007/s00390-009-0140-2; Connor CW, 2014, ANESTH ANALG, V118, P419, DOI 10.1213/ANE.0000000000000012; Cook T, 2012, CURR OPIN ANESTHESIO, V25, P461, DOI 10.1097/ACO.0b013e32835528b1; Cotton BA, 2008, ARCH SURG-CHICAGO, V143, P62, DOI 10.1001/archsurg.143.1.62; Cowan GM, 2012, EMERG MED J, V29, P136, DOI 10.1136/emj.2010.105304; Easby J, 2004, J TRAUMA, V6, P217; Edlow JA, 2014, LANCET, V384, P2064, DOI 10.1016/S0140-6736(13)62184-4; Eich C, 2009, RESUSCITATION, V80, P1371, DOI 10.1016/j.resuscitation.2009.09.004; El-Orbany M, 2010, ANESTH ANALG, V110, P1318, DOI 10.1213/ANE.0b013e3181d5ae47; ELBEHEIRY H, 1995, CAN J ANAESTH, V42, P875, DOI 10.1007/BF03011034; Grasner JT, 2007, NOTFALLMEDIZIN UP2DA, V2, P197; Gries A, 2006, ANAESTHESIST, V55, P1080, DOI 10.1007/s00101-006-1051-2; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hedenstierna G, 2005, INTENS CARE MED, V31, P1327, DOI 10.1007/s00134-005-2761-7; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Helm M, 2013, ACTA ANAESTH SCAND, V57, P199, DOI 10.1111/aas.12032; Helm M, 2010, ANAESTHESIST, V59, P896, DOI 10.1007/s00101-010-1759-x; Helm M, 2005, BEST PRACT RES-CLIN, V19, P623, DOI 10.1016/j.bpa.2005.06.002; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Herff H, 2009, ANESTH ANALG, V109, P303, DOI 10.1213/ane.0b013e3181ad8a1e; Heuer JF, 2012, ANAESTH INTENS CARE, V40, P120, DOI 10.1177/0310057X1204000113; Hossfeld B, 2011, NOTFALL RETTUNGSMED, V14, P15, DOI 10.1007/s10049-010-1355-2; Hossfeld B, 2011, NOTFALL RETTUNGSMED, V14, P10, DOI 10.1007/s10049-010-1354-3; HUGG CJ, 1993, ANESTH ANALG       S, V25, P77; Innerklinische Akutversorgung des Patienten mit Schadel-Hirn-Trauma, 2009, ANASTH INTENSIVMED, V50, pS489; Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1; Jacoby J, 2006, ANN EMERG MED, V47, P525, DOI 10.1016/j.annemergmed.2005.12.009; Kheterpal S, 2013, ANESTHESIOLOGY, V119, P1360, DOI 10.1097/ALN.0000435832.39353.20; Koenig SJ, 2015, J INTENSIVE CARE MED, V30, P499, DOI 10.1177/0885066614523100; Liccardi G, 2009, CURR MED RES OPIN, V25, P1621, DOI 10.1185/03007990903010474; Lockey D, 2009, 2009 AAGBI SAFETY GU; Luxen J, 2014, ANAESTHESIST, V63, P331, DOI 10.1007/s00101-014-2303-1; Mayglothling J, 2012, J TRAUMA ACUTE CARE, V73, pS333, DOI 10.1097/TA.0b013e31827018a5; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; MRUGALLA H, 2003, NOTFALL RETTUNGSMED, V6, P233; Neumayr A, 2014, NOTFALL RETTUNGSMED, V17, P25, DOI 10.1007/s10049-013-1816-5; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; Niven AS, 2013, CURR OPIN CRIT CARE, V19, P9, DOI 10.1097/MCC.0b013e32835c6014; Paal P, 2010, RESUSCITATION, V81, P148, DOI 10.1016/j.resuscitation.2009.10.023; Patanwala AE, 2014, ACAD EMERG MED, V21, P87, DOI 10.1111/acem.12292; Pehbock D, 2010, ANESTHESIOLOGY, V113, P593, DOI 10.1097/ALN.0b013e3181e73f07; Perry JJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002788.pub2; Reinhart K, 2010, ANAESTHESIST, V59, P347, DOI 10.1007/s00101-010-1719-5; Rortgen D, 2011, ANAESTHESIST, V60, P312, DOI 10.1007/s00101-010-1812-9; Rognas L, 2014, EUR J EMERG MED, V21, P418, DOI 10.1097/MEJ.0000000000000103; Rognas L, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-58; Sakles JC, 2013, ACAD EMERG MED, V20, P71, DOI 10.1111/acem.12055; Schlechtriemen T, 2004, NOTFALL RETTUNGSMED, V7, P231; Schmidt J, 2007, ANASTH INTENSIVMED, V48, pS88; Sefrin P, 2014, NOTARZT, V30, P73, DOI 10.1055/s-0034-1369910; Sitzwohl C, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5943; Sorensen MK, 2012, BRIT J ANAESTH, V108, P682, DOI 10.1093/bja/aer503; Springer Zollinger A, 2012, ANASTHESIOLOGIE; Steinmann D, 2009, ANAESTHESIST, V58, P695, DOI 10.1007/s00101-009-1548-6; Stollings JL, 2014, ANN PHARMACOTHER, V48, P62, DOI 10.1177/1060028013510488; Swanson Eric R, 2004, Prehosp Emerg Care, V8, P273; Thierbach A, 2004, ANAESTHESIST, V53, P543, DOI 10.1007/s00101-004-0679-z; Timmermann A, 2012, ANASTH INTENSIVMED, V53, P294; Timmermann A, 2009, ANAESTHESIST, V58, P663, DOI 10.1007/s00101-009-1570-8; van den Heuvel I, 2013, CURR OPIN ANESTHESIO, V26, P404, DOI 10.1097/ACO.0b013e328362a84c; VANDERWALT J, 1995, PAEDIATR ANAESTH, V5, P257; Voelckel WG, 2004, ANAESTHESIST, V53, P1151, DOI 10.1007/s00101-004-0771-4; von Goedecke A, 2007, ANESTH ANALG, V104, P481, DOI 10.1213/01.ane.0000255964.86086.63; Weingart SD, 2012, ANN EMERG MED, V59, P165, DOI 10.1016/j.annemergmed.2011.10.002; WELLER D, 2006, AKTUEL NEUROL, V33, P532; Werdan K, 2011, KARDIOLOGE, V5, P166, DOI 10.1007/s12181-011-0349-8; Wetsch WA, 2013, EUR J ANAESTH, V30, P537, DOI 10.1097/EJA.0b013e3283614119; Wetsch WA, 2011, EUR J ANAESTH, V28, P849, DOI 10.1097/EJA.0b013e32834c7c7f; Wilbur K, 2001, CJEM, V3, P302; WILLIAMS PL, 1994, J ADV NURS, V19, P180, DOI 10.1111/j.1365-2648.1994.tb01066.x	83	17	18	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	DEC	2016	33	12					881	897		10.1097/EJA.0000000000000533			17	Anesthesiology	Anesthesiology	EB3OR	WOS:000387275500003	27635954				2021-06-18	
J	Karout, M; Miesch, M; Geoffroy, P; Kraft, S; Hofmann, HD; Mensah-Nyagan, AG; Kirsch, M				Karout, Mona; Miesch, Michel; Geoffroy, Philippe; Kraft, Stephanie; Hofmann, Hans-Dieter; Mensah-Nyagan, Ayikoe Guy; Kirsch, Matthias			Novel analogs of allopregnanolone show improved efficiency and specificity in neuroprotection and stimulation of proliferation	JOURNAL OF NEUROCHEMISTRY			English	Article						allopregnanolone; hippocampus; neural stem cells; neurogenesis; neuroprotection; -amyloid	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEURAL STEM; 3-ALPHA-HYDROXYSTEROID OXIDOREDUCTASE; PROGESTERONE-RECEPTORS; NEUROPATHIC PAIN; PROGENITOR CELLS; GABA-RECEPTOR; NERVE INJURY; MOUSE MODEL	The natural neurosteroid allopregnanolone exerts beneficial effects in animal models of neurodegenerative diseases, nervous system injury and peripheral neuropathies. It not only has anti-apoptotic activity, but also promotes proliferation of progenitor cells. With respect to using it as a therapeutic tool, such pleiotropic actions might create unwanted side effects. Therefore, we have synthesized allopregnanolone analogs and analyzed their neuroprotective and proliferative effects to identify compounds with higher efficiency and less ambiguous biological actions. Proliferation-promoting effects of 3 and 3 isomers of 3-O-allyl-allopregnanolone and 12 oxo-allopregnanolone were studied in adult subventricular zone stem cell cultures and in primary hippocampal cultures by measuring 5-ethynyl-2-deoxyuridine incorporation. Neuroprotective activity against amyloid beta 42-induced cell death was determined by quantifying caspase 3/7 activity. The 3 isomers significantly stimulated proliferation in all culture systems, whereas the 3 isomers were ineffective. The stimulatory effect of 3-O-allyl-allopregnanolone was significantly higher than that of allopregnanolone. In neural stem cell cultures, 3-O-allyl-allopregnanolone specifically enhanced proliferation of Nestin-positive progenitors. In addition, it promoted the differentiation of doublecortin-positive neurons. In neural stem cell cultures treated with amyloid beta 42, both the and isomers of O-allyl- allopregnanolone showed increased neuroprotective activity as compared to allopregnanolone, completely preventing amyloid-induced caspase 3/7 activation. The 12 oxo-allopregnanolone analogs were ineffective. These results identify structural allopregnanolone analogs with higher anti-apoptotic and proliferation-promoting activity than the natural neurosteroid. Interestingly, stereoisomers of the analogs were found to have distinct profiles of activity raising the possibility of exploiting the neuroprotective properties of neurosteroids with or without simultaneously stimulating neurogenesis.	[Karout, Mona; Kraft, Stephanie; Hofmann, Hans-Dieter; Kirsch, Matthias] Univ Freiburg, Inst Anat & Cell Biol, Fac Med, Dept Neuroanat,ZfN, Albertstr 23, D-79104 Freiburg, Germany; [Karout, Mona; Mensah-Nyagan, Ayikoe Guy] Univ Strasbourg, FMTS, INSERM U1119, Biopathol Myeline Neuroprotect & Strategies Thera, Strasbourg, France; [Miesch, Michel; Geoffroy, Philippe] Univ Strasbourg, Inst Chim, UMR 7177, Lab Chim Organ Synth, Strasbourg, France	Kirsch, M (corresponding author), Univ Freiburg, Inst Anat & Cell Biol, Fac Med, Dept Neuroanat,ZfN, Albertstr 23, D-79104 Freiburg, Germany.; Mensah-Nyagan, AG (corresponding author), Univ Strasbourg, INSERM U1119, Fac Med, Batiment 3,11 Rue Humann, F-67000 Strasbourg, France.	gmensah@unistra.fr; matthias.kirsch@zfn.uni-freiburg.de	Mensah-Nyagan, Ayikoe G/D-5951-2011; Kirsch, Matthias/G-7227-2015	Mensah-Nyagan, Ayikoe G/0000-0003-4454-511X; Kirsch, Matthias/0000-0002-2090-8556; Karout, Mona/0000-0002-5087-3673	INTERREG IV Program (European Fund for Regional Development) in the Upper Rhine Region; Offensive Science Call	This work was funded by INTERREG IV Program (European Fund for Regional Development) in the Upper Rhine Region and the Offensive Science Call 2012. We thank Gaby Kaiser and Birgit Egle for excellent technical support. Authors declare that AGMN, PG and MM are the owners of Patent number WO 2012127176 A1 and US 2014/0058079 A1.	Afrazi S, 2014, J STEROID BIOCHEM, V139, P98, DOI 10.1016/j.jsbmb.2013.10.010; Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103; AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Antoine JC, 2007, LANCET NEUROL, V6, P75, DOI 10.1016/S1474-4422(06)70679-2; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Chen SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024293; Deleyrolle Loic P., 2009, V549, P91, DOI 10.1007/978-1-60327-931-4_7; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Eckert A, 2008, NEURODEGENER DIS, V5, P157, DOI 10.1159/000113689; Faroni Alessandro, 2011, Front Endocrinol (Lausanne), V2, P103, DOI 10.3389/fendo.2011.00103; Gotz J, 2011, CELL MOL LIFE SCI, V68, P3359, DOI 10.1007/s00018-011-0750-2; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grimm A, 2014, BBA-MOL BASIS DIS, V1842, P2427, DOI 10.1016/j.bbadis.2014.09.013; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Heinitz K, 2006, J NEUROCHEM, V98, P1930, DOI 10.1111/j.1471-4159.2006.04015.x; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Irwin RW, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00203; Irwin RW, 2014, PROG NEUROBIOL, V113, P40, DOI 10.1016/j.pneurobio.2013.08.004; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Larson ME, 2012, J NEUROCHEM, V120, P125, DOI 10.1111/j.1471-4159.2011.07478.x; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Meyer L, 2008, NEUROBIOL DIS, V30, P30, DOI 10.1016/j.nbd.2007.12.001; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Moore A, 2009, PEDIATR BLOOD CANCER, V53, P1180, DOI 10.1002/pbc.22161; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Pang YF, 2013, ENDOCRINOLOGY, V154, P283, DOI 10.1210/en.2012-1772; Patte-Mensah C, 2005, P NATL ACAD SCI USA, V102, P9044, DOI 10.1073/pnas.0502968102; Patte-Mensah C, 2014, PROG NEUROBIOL, V113, P70, DOI 10.1016/j.pneurobio.2013.07.004; Patte-Mensah C, 2003, J NEUROCHEM, V86, P1233, DOI 10.1046/j.1471-4159.2003.01935.x; Patte-Mensah C, 2010, PAIN, V150, P522, DOI 10.1016/j.pain.2010.06.004; Pelletier G, 2010, PROG BRAIN RES, V181, P193, DOI 10.1016/S0079-6123(08)81011-4; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Reddy D S, 2000, Prog Med Chem, V37, P135, DOI 10.1016/S0079-6468(08)70059-6; Reddy Doodipala Samba, 2003, Critical Reviews in Neurobiology, V15, P197; Reddy DS, 2010, PROG BRAIN RES, V186, P113, DOI 10.1016/B978-0-444-53630-3.00008-7; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Singh C, 2012, NEUROBIOL AGING, V33, P1493, DOI 10.1016/j.neurobiolaging.2011.06.008; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wang JM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S11; Wang Mingde, 2011, Front Endocrinol (Lausanne), V2, P44, DOI 10.3389/fendo.2011.00044; Young SZ, 2009, PHYSIOLOGY, V24, P171, DOI 10.1152/physiol.00002.2009; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	55	17	17	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2016	139	5					782	794		10.1111/jnc.13693			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ED8QA	WOS:000389134800010	27256158	Bronze			2021-06-18	
J	Nagakannan, P; Iqbal, MA; Yeung, A; Thliveris, JA; Rastegar, M; Ghavami, S; Eftekharpour, E				Nagakannan, Pandian; Iqbal, Mohamed Ariff; Yeung, Albert; Thliveris, James A.; Rastegar, Mojgan; Ghavami, Saeid; Eftekharpour, Eftekhar			Perturbation of redox balance after thioredoxin reductase deficiency interrupts autophagy-lysosomal degradation pathway and enhances cell death in nutritionally stressed SH-SY5Y cells	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Neurodegenerative disease; Redox Regulation; Lysosome; Autophagy-Apotosis Interplay; Ubiquitination; Proteasome	AURANOFIN INDUCES APOPTOSIS; SPINAL-CORD-INJURY; OXIDATIVE STRESS; GLUTATHIONE; INHIBITION; ANTIOXIDANTS; MITOCHONDRIA; MODULATION; ACTIVATION; EXPRESSION	Oxidative damage and aggregation of cellular proteins is a hallmark of neuronal cell death after neurotrauma and chronic neurodegenerative conditions. Autophagy and ubiquitin protease system are involved in degradation of protein aggregates, and interruption of their function is linked to apoptotic cell death in these diseases. Oxidative modification of cysteine groups in key molecular proteins has been linked to modification of cellular systems and cell death in these conditions. Glutathione and thioredoxin systems provide reducing protons that can effectively reverse protein modifications and promote cell survival. The central role of Thioredoxin in inhibition of apoptosis is well identified. Additionally, its involvement in initiation of autophagy has been suggested recently. We therefore aimed to investigate the involvement of Thioredoxin system in autophagy-apoptosis processes. A model of serum deprivation in SH-SY5Y was used that is associated with autophagy and apoptosis. Using pharmacological and RNA-editing technology we show that Thioredoxin reductase deficiency in this model enhances oxidative stress and interrupts the early protective autophagy and promotes apoptosis. This was associated with decreased protein-degradation in lysosomes due to altered lysosomal acidification and accumulation of autophagosomes as well as impairment in proteasome pathway. We further confirmed that the extent of oxidative stress is a determining factor in autophagy-apoptosis interplay, as upregulation of cellular reducing capacity by N-acetylcysteine prevented impairment in autophagy and proteasome systems thus promoted cell viability. Our study provides evidence that excessive oxidative stress inhibits protein degradation systems and affects the final stages of autophagy by inhibiting autolysosome maturation: a novel mechanistic link between protein aggregation and conversion of autophagy to apoptosis that can be applicable to neurodegenerative diseases.	[Nagakannan, Pandian; Iqbal, Mohamed Ariff; Yeung, Albert; Eftekharpour, Eftekhar] Univ Manitoba, Rady Fac Hlth Sci, Dept Physiol & Pathophysiol, Spinal Cord Res Ctr, Winnipeg, MB, Canada; [Rastegar, Mojgan] Univ Manitoba, Rady Fac Hlth Sci, Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Thliveris, James A.; Ghavami, Saeid] Univ Manitoba, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada; [Nagakannan, Pandian; Iqbal, Mohamed Ariff; Yeung, Albert; Rastegar, Mojgan; Eftekharpour, Eftekhar] Univ Manitoba, Rady Fac Hlth Sci, Regenerat Med Program, Winnipeg, MB, Canada	Eftekharpour, E (corresponding author), Univ Manitoba, Dept Physiol & Pathophysiol, Spinal Cord Res Ctr, 631 BMSB,745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada.		Ghavami, Saeid/Q-8918-2016; Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Pandian, Nagakannan/0000-0002-6791-0661; Iqbal, Mohamed Ariff/0000-0002-5094-0717; Ghavami, Saeid/0000-0001-5948-508X; Eftekharpour, Eftekhar/0000-0002-2849-3754			Ahsan MK, 2009, ANTIOXID REDOX SIGN, V11, P2741, DOI [10.1089/ars.2009.2683, 10.1089/ARS.2009.2683]; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Arodin L, 2014, FREE RADICAL BIO MED, V73, P328, DOI 10.1016/j.freeradbiomed.2014.05.011; Bai J, 2007, ANTIOXID REDOX SIGN, V9, P603, DOI 10.1089/ars.2006.1513; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Bar-Am O, 2005, FASEB J, V19, P1899, DOI 10.1096/fj.05-3794fje; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; Brigelius-Flohe Regina, 2012, Int J Cell Biol, V2012, P486147, DOI 10.1155/2012/486147; Cabet E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137009; Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10-07-0616; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Cox AG, 2008, BIOCHEM PHARMACOL, V76, P1097, DOI 10.1016/j.bcp.2008.08.021; Desideri E, 2012, AUTOPHAGY, V8, P1769, DOI 10.4161/auto.22037; Du YT, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.392225; Eftekharpour E, 2000, GLIA, V31, P241, DOI 10.1002/1098-1136(200009)31:3<241::AID-GLIA50>3.0.CO;2-9; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Ghavami S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.36; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Gu Z, 2005, CELL DEATH DIFFER, V12, P1202, DOI 10.1038/sj.cdd.4401705; Haga S, 2014, ANTIOXID REDOX SIGN, V21, P2515, DOI 10.1089/ars.2013.5391; Hanschmann EM, 2013, ANTIOXID REDOX SIGN, V19, P1539, DOI 10.1089/ars.2012.4599; Hintze KJ, 2003, J NUTR, V133, P2721; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kiermayer C, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002153; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008; Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025; Li L, 2013, EVID-BASED COMPL ALT, V2013, P1, DOI DOI 10.1155/2013/467245; Lin YX, 2015, MOL PHARMACEUT, V12, P2869, DOI 10.1021/acs.molpharmaceut.5b00060; Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu ZH, 2013, NEURAL REGEN RES, V8, P3275, DOI 10.3969/j.issn.1673-5374.2013.35.002; Lovell MA, 2000, FREE RADICAL BIO MED, V28, P418, DOI 10.1016/S0891-5849(99)00258-0; Lu J., 2007, P NATL ACAD SCI US, V104; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998; Marzano C, 2007, FREE RADICAL BIO MED, V42, P872, DOI 10.1016/j.freeradbiomed.2006.12.021; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Oslowski CM, 2012, CELL METAB, V16, P265, DOI 10.1016/j.cmet.2012.07.005; Pandey S, 2003, APOPTOSIS, V8, P497, DOI 10.1023/A:1025542424986; Perez-Perez ME, 2014, AUTOPHAGY, V10, P1953, DOI 10.4161/auto.34396; Pirkmajer S, 2011, AM J PHYSIOL-CELL PH, V301, pC272, DOI 10.1152/ajpcell.00091.2011; Rastegar M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006810; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Shao FY, 2015, ONCOTARGET, V6, P30939, DOI 10.18632/oncotarget.5132; Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Underwood BR, 2010, HUM MOL GENET, V19, P3413, DOI 10.1093/hmg/ddq253; Walter C., 2016, NEUROPHARMACOLOGY; [王增林 Wang Zenglin], 2014, [油气地质与采收率, Petroleum Geology and Recovery Efficiency], V21, P5; Xu HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063232; You BR, 2015, MOL MED REP, V11, P1428, DOI 10.3892/mmr.2014.2830; Zeldich E, 2014, J BIOL CHEM, V289, P24700, DOI 10.1074/jbc.M114.567321; Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11; Zhou KL, 2015, SCI REP-UK, V5, DOI 10.1038/srep17130	61	17	17	3	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2016	101						53	70		10.1016/j.freeradbiomed.2016.09.026			18	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	EG0DN	WOS:000390701300006	27693380				2021-06-18	
J	Shah, S; Kimberly, WT				Shah, Shreyansh; Kimberly, W. Taylor			Today's Approach to Treating Brain Swelling in the Neuro Intensive Care Unit	SEMINARS IN NEUROLOGY			English	Article						brain swelling; cerebral edema; diagnosis; treatment	MIDDLE CEREBRAL-ARTERY; SEVERE HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; MALIGNANT EDEMA; INFARCTION; STROKE; MANAGEMENT; OCCLUSION	Brain swelling is an urgent clinical problem that frequently accompanies ischemic stroke, brain hemorrhage; and traumatic brain injury; it increases morbidity and mortality associated with them. It occurs due to failure of membrane transporters and leakage of the blood brain barrier (BBB), resulting in combination of cytotoxic, ionic, and vasogenic edema. Currently, decompressive craniectomy and osmotherapy are the mainstays of management, but these therapies do not halt the underlying molecular cascade leading to brain swelling. Recent advances in the molecular underpinnings of cerebral edema have opened up possibilities of newer targeted therapeutic options. Here the authors outline the current approach for rapid diagnosis and intervention to reduce mortality and morbidity associated with brain swelling.	[Shah, Shreyansh; Kimberly, W. Taylor] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Lunder 644,55 Fruit St, Boston, MA 02114 USA	Kimberly, WT (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Lunder 644,55 Fruit St, Boston, MA 02114 USA.	wtkimberly@mgh.harvard.edu	Shah, Shreyansh/V-8581-2019	Shah, Shreyansh/0000-0001-8441-6326	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS076597]; AHAAmerican Heart Association [14GRNT19060044]; Remedy Pharmaceuticals, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099209, K23NS076597] Funding Source: NIH RePORTER	Dr. Kimberly has received research grants from NIH K23NS076597, AHA 14GRNT19060044, and Remedy Pharmaceuticals, Inc.	Asuzu D, 2016, NEUROCRIT CARE, V24, P381, DOI 10.1007/s12028-015-0198-6; Battey TWK, 2014, STROKE, V45, P3643, DOI 10.1161/STROKEAHA.114.006884; Broderick JP, 2007, STROKE, V38, P1072, DOI 10.1161/01.STR.0000258078.35316.30; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai XM, 2015, SEMIN NEUROL, V35, P638, DOI 10.1055/s-0035-1564687; Carhuapoma JR, 2003, J NEUROSURG ANESTH, V15, P230, DOI 10.1097/00008506-200307000-00010; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Damian MS, 2007, NEUROCRIT CARE, V6, P165, DOI 10.1007/s12028-007-0010-3; Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8; Dey M, 2014, NEUROSURGERY, V74, pS142, DOI 10.1227/NEU.0000000000000221; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Ditillo M, 2011, J TRAUMA, V71, P373; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Geeganage C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000323.pub2; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hauer EM, 2011, CRIT CARE MED, V39, P1766, DOI 10.1097/CCM.0b013e318218a390; Hom J, 2011, AM J NEURORADIOL, V32, P41, DOI 10.3174/ajnr.A2244; Jayakumar AR, 2011, J HEPATOL, V54, P272, DOI 10.1016/j.jhep.2010.06.041; jtittler E, 2014, NEW ENGL J MED, V370, P1091; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kasner SE, 2001, STROKE, V32, P2117, DOI 10.1161/hs0901.095719; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kelly AG, 2012, NEUROLOGY, V79, P941, DOI 10.1212/WNL.0b013e318266fc40; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Node Y, 1990, Adv Neurol, V52, P359; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Olm-Shipman C, 2015, STROKE, V46; Olson DaiWai M, 2003, Crit Care Nurse, V23, P45; Oppenheim C, 2000, STROKE, V31, P2175, DOI 10.1161/01.STR.31.9.2175; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Sansing LH, 2003, J NEUROSURG, V98, P985, DOI 10.3171/jns.2003.98.5.0985; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sheth KN, 2016, NEUROCRIT CARE, V24, P132, DOI 10.1007/s12028-015-0189-7; Sheth KN, 2014, STROKE, V45, P3748, DOI 10.1161/STROKEAHA.114.005804; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2014, NEUROCRIT CARE, V20, P319, DOI 10.1007/s12028-013-9923-1; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Stokum JA, 2015, NEUROCHEM RES, V40, P317, DOI 10.1007/s11064-014-1374-3; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Takeuchi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12424; Thomalla G, 2010, ANN NEUROL, V68, P435, DOI 10.1002/ana.22125; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vemmos KN, 2003, J HYPERTENS, V21, P2167, DOI 10.1097/00004872-200311000-00027; Venkatasubramanian C, 2011, STROKE, V42, P73, DOI 10.1161/STROKEAHA.110.590646; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; Wang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058838; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021; ZWECKBERGER K, 2014, REV CEREBROVASC DIS, V38, P313, DOI DOI 10.1159/000365864	66	17	20	0	3	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	DEC	2016	36	6					502	507		10.1055/s-0036-1592109			6	Clinical Neurology	Neurosciences & Neurology	EE0PT	WOS:000389282100005	27907954	Green Accepted			2021-06-18	
J	Skovira, JW; Wu, JF; Matyas, JJ; Kumar, A; Hanscom, M; Kabadi, SV; Fang, R; Faden, AI				Skovira, Jacob W.; Wu, Junfang; Matyas, Jessica J.; Kumar, Alok; Hanscom, Marie; Kabadi, Shruti V.; Fang, Raymond; Faden, Alan I.			Cell cycle inhibition reduces inflammatory responses, neuronal loss, and cognitive deficits induced by hypobaria exposure following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Inflammation; Neuronal cell death; Aeromedical evacuation; Hypobaria	SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; PROVIDES NEUROPROTECTION; AEROMEDICAL EVACUATION; THERAPEUTIC TARGET; DEPENDENT KINASES; SCAR FORMATION; CDK INHIBITOR; CNS INJURY	Background: Traumatic brain injury (TBI) patients in military settings can be exposed to prolonged periods of hypobaria (HB) during aeromedical evacuation. Hypobaric exposure, even with supplemental oxygen to prevent hypoxia, worsens outcome after experimental TBI, in part by increasing neuroinflammation. Cell cycle activation (CCA) after TBI has been implicated as a mechanism contributing to both post-traumatic cell death and neuroinflammation. Here, we examined whether hypobaric exposure in rats subjected to TBI increases CCA and microglial activation in the brain, as compared to TBI alone, and to evaluate the ability of a cyclin-dependent kinase (CDK) inhibitor (CR8) to reduce such changes and improve behavioral outcomes. Methods: Adult male Sprague Dawley rats were subjected to fluid percussion-induced injury, and HB exposure was performed at 6 h after TBI. Western blot and immunohistochemistry (IHC) were used to assess cell cycle-related protein expression and inflammation at 1 and 30 days after injury. CR8 was administered intraperitoneally at 3 h post-injury; chronic functional recovery and histological changes were assessed. Results: Post-traumatic hypobaric exposure increased upregulation of cell cycle-related proteins (cyclin D1, proliferating cell nuclear antigen, and CDK4) and microglial/macrophage activation in the ipsilateral cortex at day 1 post-injury as compared to TBI alone. Increased immunoreactivity of cell cycle proteins, as well as numbers of Iba-1(+) and GFAP(+) cells in both the ipsilateral cortex and hippocampus were found at day 30 post-injury. TBI/HB significantly increased the numbers of NADPH oxidase 2 (gp91(phox)) enzyme-expressing cells that were co-localized with Iba-1(+). Each of these changes was significantly reduced by the administration of CR8. Unbiased stereological assessment showed significantly decreased numbers of microglia displaying the highly activated phenotype in the ipsilateral cortex of TBI/HB/CR8 rats compared with TBI/HB/Veh rats. Moreover, treatment with this CDK inhibitor also significantly improved spatial and retention memory and reduced lesion volume and hippocampal neuronal cell loss. Conclusions: HB exposure following TBI increases CCA, neuroinflammation, and associated neuronal cell loss. These changes and post-traumatic cognitive deficits are reduced by CDK inhibition; such drugs may therefore serve to protect TBI patients requiring aeromedical evacuation.	[Skovira, Jacob W.; Wu, Junfang; Matyas, Jessica J.; Kumar, Alok; Hanscom, Marie; Kabadi, Shruti V.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Skovira, Jacob W.; Wu, Junfang; Matyas, Jessica J.; Kumar, Alok; Hanscom, Marie; Kabadi, Shruti V.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Skovira, Jacob W.] US Army Med Res Inst Chem Def, Div Res, Pharmacol Branch, Aberdeen, MD 21010 USA; [Fang, Raymond] Univ Maryland, Sch Med, Program Trauma, Ctr Sustainment Trauma & Readiness Skills C STARS, Baltimore, MD 21201 USA	Wu, JF (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Wu, JF (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA.	jwu@anes.umm.edu; afaden@anes.umm.edu		Hanscom, Marie/0000-0001-8308-135X; Faden, Alan I./0000-0003-0128-2348	711 HPW/XPT [FA8650-11-2-6D04]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007698] Funding Source: NIH RePORTER	This study was supported by the 711 HPW/XPT under Cooperative Agreement number FA8650-11-2-6D04. The funder had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Arendt T, 2012, MOL NEUROBIOL, V46, P125, DOI 10.1007/s12035-012-8262-0; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dardiotis E, 2012, BRAIN INJURY PATHOGE, P2446, DOI [10.4161/cc.29420, DOI 10.4161/CC.29420]; Defense and Veterans Brain Injury Center DVBIC, 2016, DOD TBI WORLDW NUMB; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Fang R, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1043; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Katsel P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068361; Kim H, 2016, PSYCHIAT INVEST, V13, P127, DOI 10.4306/pi.2016.13.1.127; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Liu S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.527; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Neve RL, 2006, PHARMACOL THERAPEUT, V111, P99, DOI 10.1016/j.pharmthera.2005.09.005; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rashidian J, 2007, BBA-MOL BASIS DIS, V1772, P484, DOI 10.1016/j.bbadis.2006.11.009; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Reno J, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1023; Sanphui P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078842; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Seward ME, 2013, J CELL SCI, V126, P1278, DOI 10.1242/jcs.1125880; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Skovira JW, 2016, J NEUROTRAUM, V33, P1292, DOI 10.1089/neu.2015.4189; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Wu J, 2014, CELL CYCLE, V13, P15; Wu JF, 2016, PAIN, V157, P488, DOI 10.1097/j.pain.0000000000000393; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153	43	17	17	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	DEC 1	2016	13								299	10.1186/s12974-016-0769-2			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EG0IF	WOS:000390714500001	27903275	DOAJ Gold, Green Published			2021-06-18	
J	Thompson, LL; Lyons, VH; McCart, M; Herring, SA; Rivara, FP; Vavilala, MS				Thompson, Leah L.; Lyons, Vivian H.; McCart, Melissa; Herring, Stanley A.; Rivara, Frederick P.; Vavilala, Monica S.			Variations in State Laws Governing School Reintegration Following Concussion	PEDIATRICS			English	Article							RECOMMENDATIONS; SYMPTOMS; CHILDREN; PREVALENCE; MANAGEMENT; KNOWLEDGE; STUDENT; SUPPORT; RETURN	OBJECTIVE: We sought to examine the prevalence, scope, and specificity of provisions abstract governing school reintegration in current state concussion laws. METHODS: State concussion laws as of May 2016 were independently assessed and classified by 2 trained coders. Statutes were classified as "Return-to-Learn" (RTL) laws if they contained language mandating institutional action at the state, district, or school level related to academic reintegration of youth who have sustained a concussion. All statutes classified as RTL laws were further analyzed to determine scope, required actions, and delineation of responsibility. RESULTS: RTL laws were uncommon, present in only 8 states. Most (75%) of these laws held schools responsible for RTL management but mandated RTL education for school personnel was less frequent, present in only one-quarter of the laws. None of the RTL laws provided guidance on support of students with persistent postconcussive symptoms, and only 1 recommended an evidence-based standard for RTL guidelines. CONCLUSIONS: Our review of state concussion laws indicates scant and vague legal guidance regarding RTL. These findings suggest an opportunity for legislative action on the issue of RTL, and reveal the need for better integration of laws and research, so that laws reflect existing best-practice recommendations and remain current as the evidence base develops.	[Thompson, Leah L.; Rivara, Frederick P.] Seattle Childrens Res Inst, Seattle, WA USA; [Lyons, Vivian H.; Rivara, Frederick P.; Vavilala, Monica S.] Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA; [Lyons, Vivian H.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Med Sports Hlth & Safety Inst, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Med Sports Concuss Program, Seattle, WA 98195 USA; [McCart, Melissa] Ctr Brain Injury Res & Training, Eugene, OR USA	Vavilala, MS (corresponding author), Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA.	vavilala@uw.edu	McCart, Melissa/AAN-1506-2020		Washington State Department of Health and Human Services Traumatic Brain Injury Council; Harborview Injury Prevention and Research Center; Seattle Children's Research Institute	This study was funded by the Washington State Department of Health and Human Services Traumatic Brain Injury Council, Harborview Injury Prevention and Research Center, and Seattle Children's Research Institute.	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Blank NR, 2013, HEALTH AFFAIR, V32, P1282, DOI 10.1377/hlthaff.2013.0239; Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Dreer LE, 2017, HEALTH PROMOT PRACT, V18, P428, DOI 10.1177/1524839916650865; Echemendia RJ, 2015, BRAIN INJURY, V29, P185, DOI 10.3109/02699052.2014.965212; Gioia GA, 2016, J HEAD TRAUMA REHAB, V31, P397, DOI 10.1097/HTR.0000000000000205; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Graham R., 2014, SPORTS RELATED CONCU; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harvey HH, 2015, J LAW MED ETHICS, V43, P87, DOI 10.1111/jlme.12225; Hatzenbuehler ML, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.2411; Heyer GL, 2015, J PEDIATR-US, V166, P594, DOI 10.1016/j.jpeds.2014.09.038; Jones SE, 2008, J SCHOOL HEALTH, V78, P69, DOI 10.1111/j.1746-1561.2007.00272_1.x; Kasamatsu T, 2016, J ATHL TRAINING, V51, P153, DOI 10.4085/1062-6050-51.4.02; Lowrey KM, 2014, J BUSINESS TECH L, V10, P61; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Olympia RP, 2016, CLIN J SPORT MED, V26, P115, DOI 10.1097/JSM.0000000000000208; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Rocky Mountain Hospital for Children, CONC MAN REAP; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Taber DR, 2015, J SCHOOL HEALTH, V85, P578, DOI 10.1111/josh.12288; The Center on Brain Injury Research and Training, OR CONC AW MAN PROGR; Wing R, 2016, CLIN PEDIATR, V55, P228, DOI 10.1177/0009922815592879; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zirkel PA, 2015, J SCH NURS, V31, P99, DOI 10.1177/1059840514521465; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	34	17	17	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2016	138	6							e20162151	10.1542/peds.2016-2151			7	Pediatrics	Pediatrics	ED5WX	WOS:000388924800047		Bronze			2021-06-18	
J	Thomsen, GM; Ma, AM; Ko, A; Harada, MY; Wyss, L; Haro, PS; Vit, JP; Shelest, O; Rhee, P; Svendsen, CN; Ley, EJ				Thomsen, Gretchen M.; Ma, Annie M.; Ko, Ara; Harada, Megan Y.; Wyss, Livia; Haro, Patricia S.; Vit, Jean-Philippe; Shelest, Oksana; Rhee, Peter; Svendsen, Clive N.; Ley, Eric J.			A model of recurrent concussion that leads to long-term motor deficits, CTE-like tauopathy and exacerbation of an ALS phenotype	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	46th Annual Meeting of the Western-Trauma-Association	FEB 28-MAR 04, 2016	CA	Western Trauma Assoc		Traumatic brain injury; concussion; rat model; amyotrophic lateral sclerosis	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT MODEL; HEAD-INJURY; NEURON DEGENERATION; ALZHEIMERS-DISEASE; MUTANT SOD1; MOUSE MODEL; IN-VIVO; ENCEPHALOPATHY	BACKGROUND: Concussion injury is the most common form of traumatic brain injury (TBI). How recurrent concussions alter long-term outcomes is poorly understood, especially as related to the development of neurodegenerative disease. We evaluated the functional and pathological consequences of repeated TBI over time in wild type (WT) rats as well as rats harboring the human SOD1(G93A) mutation ("SOD1"), a model of familial amyotrophic lateral sclerosis (ALS). METHODS: A total of 42 rats, 26 WT and 16 SOD1, were examined over a study period of 25 weeks (or endpoint). At postnatal day 60, 20 WT and 7 SOD1 rats were exposed to mild, bilateral TBI once per week for either 2 weeks (2 x TBI) or 5 weeks (5 x TBI) using a controlled cortical impact device. Six WT and nine SOD1 rats underwent sham injury with anesthesia alone. Twenty WT rats were euthanized at 12 weeks after first injury and six WT rats were euthanized at 25 weeks after first injury. SOD1 rats were euthanized when they reached ALS disease endpoint. Weekly body weights and behavioral assessments were performed. Tauopathy in brain tissue was analyzed using immunohistochemistry. RESULTS: 2XTBI injured rats initially demonstrated recovery of motor function but failed to recover to baseline within the 12-week study period. Relative to both 2XTBI and sham controls, 5XTBI rats demonstrated significant deficits that persisted over the 12-week period. SOD1 5XTBI rats reached a peak body weight earlier than sham SOD1 rats, indicating earlier onset of the ALS phenotype. Histologic examination of brain tissue revealed that, in contrast with sham controls, SOD1 and WT TBI rats demonstrated cortical and corpus collosum thinning and tauopathy, which increased over time. CONCLUSIONS: Unlike previous models of repeat brain injury, which demonstrate only transient deficits in motor function, our concussion model of repeat, mild, bilateral TBI induced long-lasting deficits in motor function, decreased cortical thickness, shrinkage of the corpus callosum, increased brain tauopathy, and earlier onset of ALS symptoms in SOD1 rats. This model may allow for a greater understanding of the complex relationship between TBI and neurodegenerative diseases and provides a potential method for testing novel therapeutic strategies. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Thomsen, Gretchen M.; Ma, Annie M.; Wyss, Livia; Haro, Patricia S.; Shelest, Oksana; Svendsen, Clive N.] Cedars Sinai Med Ctr, Regenerat Med Inst, Los Angeles, CA 90048 USA; [Vit, Jean-Philippe; Svendsen, Clive N.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Vit, Jean-Philippe] Cedars Sinai Med Ctr, Biobehav Res Core, Los Angeles, CA 90048 USA; [Ko, Ara; Harada, Megan Y.; Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Rhee, Peter] Univ Arizona, Med Ctr, Div Trauma Crit Care Burn & Emergency Surg, Tucson, AZ USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215 N, Los Angeles, CA 90048 USA.	Eric.Ley@cshs.org	vit, jean-philippe/Q-7286-2019	Vit, Jean-Philippe/0000-0001-5057-8554			Bae JS, 2013, J CLIN NEUROL, V9, P65, DOI 10.3988/jcn.2013.9.2.65; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buchele F, 2016, J NEUROTRAUM, V33, P1171, DOI 10.1089/neu.2015.4001; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gerson J. E., 2016, J NEUROTRAUMA; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham R., 2014, SPORTS RELATED CONCU; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Przekwas A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00002; Sabbagh JJ, 2016, J NEUROTRAUMA; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Suzuki M, 2010, EXP NEUROL, V221, P346, DOI 10.1016/j.expneurol.2009.12.004; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomsen GM, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0059-14.2015; Thomsen GM, 2014, J NEUROSCI, V34, P15587, DOI 10.1523/JNEUROSCI.2037-14.2014; Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001; Vucic S, 2008, BRAIN, V131, P1540, DOI 10.1093/brain/awn071; Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	49	17	17	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2016	81	6					1070	1079		10.1097/TA.0000000000001248			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EE0BH	WOS:000389237900011	27602892				2021-06-18	
J	Vakorin, VA; Doesburg, SM; da Costa, L; Jetly, R; Pang, EW; Taylor, MJ				Vakorin, Vasily A.; Doesburg, Sam M.; da Costa, Leodante; Jetly, Rakesh; Pang, Elizabeth W.; Taylor, Margot J.			Detecting Mild Traumatic Brain Injury Using Resting State Magnetoencephalographic Connectivity	PLOS COMPUTATIONAL BIOLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PARTIAL LEAST-SQUARES; FUNCTIONAL CONNECTIVITY; IMAGING APPROACH; PHASE SYNCHRONIZATION; CLINICAL MANAGEMENT; SYMPTOM SEVERITY; HEAD TRAUMA; MEG; CONCUSSION	Accurate means to detect mild traumatic brain injury (mTBI) using objective and quantitative measures remain elusive. Conventional imaging typically detects no abnormalities despite post-concussive symptoms. In the present study, we recorded resting state magnetoencephalograms (MEG) from adults with mTBI and controls. Atlas-guided reconstruction of resting state activity was performed for 90 cortical and subcortical regions, and calculation of inter-regional oscillatory phase synchrony at various frequencies was performed. We demonstrate that mTBI is associated with reduced network connectivity in the delta and gamma frequency range (>30 Hz), together with increased connectivity in the slower alpha band (8-12 Hz). A similar temporal pattern was associated with correlations between network connectivity and the length of time between the injury and the MEG scan. Using such resting state MEG network synchrony we were able to detect mTBI with 88% accuracy. Classification confidence was also correlated with clinical symptom severity scores. These results provide the first evidence that imaging of MEG network connectivity, in combination with machine learning, has the potential to accurately detect and determine the severity of mTBI.	[Vakorin, Vasily A.; Doesburg, Sam M.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC, Canada; [Vakorin, Vasily A.; Doesburg, Sam M.] Simon Fraser Univ, Behav & Cognit Neurosci Inst, Burnaby, BC, Canada; [Doesburg, Sam M.; Taylor, Margot J.] Hosp Sick Children Res Inst, Dept Diagnost Imaging, Toronto, ON, Canada; [Doesburg, Sam M.; Pang, Elizabeth W.; Taylor, Margot J.] Hosp Sick Children Res Inst, Neurosci & Mental Hlth, Toronto, ON, Canada; [da Costa, Leodante] Univ Toronto, Sunnybrook Hosp, Div Neurosurg, Dept Surg, Toronto, ON, Canada; [da Costa, Leodante] Sunnybrook Med Ctr, Dept Med Imaging, Toronto, ON, Canada; [Jetly, Rakesh] Directorate Mental Hlth, Canadian Forces Hlth Serv, Ottawa, ON, Canada; [Pang, Elizabeth W.; Taylor, Margot J.] Hosp Sick Children, Dept Neurol, Toronto, ON, Canada; [Taylor, Margot J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Taylor, Margot J.] Univ Toronto, Dept Psychol, Toronto, ON, Canada	Vakorin, VA (corresponding author), Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC, Canada.; Vakorin, VA (corresponding author), Simon Fraser Univ, Behav & Cognit Neurosci Inst, Burnaby, BC, Canada.	vasily_vakorin@sfu.ca			Canadian Forces Health Services; Defence Research and Development Canada (DRDC) [W7719-135182/001/TOR]	This work was supported by the Canadian Forces Health Services and funding from Defence Research and Development Canada (DRDC) (contract # W7719-135182/001/TOR) to MJT and EWP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Avants B.B., 2011, ADV NORMALIZATION TO; Avants BB, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00044; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Boser BE, 1992, P 5 ANN WORKSH COMP, V152, P144; Bosl W, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-18; Cao C, 2014, IEEE T NEUR SYS REH, V18, P11; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Chavez M, 2003, IEEE T BIO-MED ENG, V50, P571, DOI 10.1109/TBME.2003.810696; Dosenbach NUF, 2010, SCIENCE, V329, P1358, DOI 10.1126/science.1194144; Dunkley BT, 2014, NEUROIMAGE-CLIN, V5, P377, DOI 10.1016/j.nicl.2014.07.017; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Fonov V, 2011, NEUROIMAGE, V54, P313, DOI 10.1016/j.neuroimage.2010.07.033; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; Heisz JJ, 2014, J COGNITIVE NEUROSCI, V26, P41, DOI 10.1162/jocn_a_00466; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hosken JWJ, 1998, 1 BREAK, V6, P24; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; James LM, 2015, PSYCHIAT RES-NEUROIM, V231, P1, DOI 10.1016/j.pscychresns.2014.11.007; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kecman V., 2001, LEARNING SOFT COMPUT; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lalancette M, 2011, PHYS MED BIOL, V56, P5621, DOI 10.1088/0031-9155/56/17/010; Lemoine, 1996, TIME FREQUENCY TOOLB; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Lobaugh NJ, 2001, PSYCHOPHYSIOLOGY, V38, P517, DOI 10.1017/S0048577201991681; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McIntosh AR, 2013, ANNU REV PSYCHOL, V64, P499, DOI 10.1146/annurev-psych-113011-143804; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Mormann F, 2000, PHYSICA D, V144, P358, DOI 10.1016/S0167-2789(00)00087-7; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Quraan MA, 2011, HUM BRAIN MAPP, V32, P812, DOI 10.1002/hbm.21068; Rosenblum MG, 1996, PHYS REV LETT, V76, P1804, DOI 10.1103/PhysRevLett.76.1804; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tass P, 1998, PHYS REV LETT, V81, P3291, DOI 10.1103/PhysRevLett.81.3291; Theodoridis S, 2009, PATTERN RECOGNITION, 4RTH EDITION, P1; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Uddin LQ, 2013, JAMA PSYCHIAT, V70, P869, DOI 10.1001/jamapsychiatry.2013.104; Uhlhaas PJ, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.017.2009; Vakorin VA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057217; Vakorin VA, 2011, J NEUROSCI, V31, P6405, DOI 10.1523/JNEUROSCI.3153-10.2011; Ward LM, 2003, TRENDS COGN SCI, V7, P553, DOI 10.1016/j.tics.2003.10.012; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	60	17	17	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA		1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	DEC	2016	12	12							e1004914	10.1371/journal.pcbi.1004914			24	Biochemical Research Methods; Mathematical & Computational Biology	Biochemistry & Molecular Biology; Mathematical & Computational Biology	EH9XT	WOS:000392126000002	27906973	DOAJ Gold, Green Published			2021-06-18	
J	Briggs, DI; Angoa-Perez, M; Kuhn, DM				Briggs, Denise I.; Angoa-Perez, Mariana; Kuhn, Donald M.			Prolonged Repetitive Head Trauma Induces a Singular Chronic Traumatic Encephalopathy-Like Pathology in White Matter Despite Transient Behavioral Abnormalities	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PROFESSIONAL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; MILD STRESS MODEL; BRAIN-INJURY; MOUSE MODEL; RECURRENT CONCUSSION; MEMORY DEFICITS; OPTIC-NERVE; GRAY-MATTER; IMPACT	Repetitive mild traumatic brain injury (rmTBI), resulting from insults caused by an external mechanical force that disrupts normal brain function, has been linked to the development of neurodegenerative diseases, such as chronic traumatic encephalopathy and Alzheimer disease; however, neither the severity nor frequency of head injury required to trigger adverse behavioral outcomes is well understood. In this study, the administration of 30 head impacts using two different weights to tightly anesthetized, completely unrestrained mice established a paradigm that simulates the highly repetitive nature of sports- and military-related head injury. As the number of head impacts increases, the time to recover consciousness diminishes; however, both the sensorimotor function and behavioral outcomes of impacted mice evolve during the ensuing weeks. Postmortem analyses reveal robust Alzheimer disease and chronic traumatic encephalopathy like conditions that manifest in a singular manner throughout the white matter concomitant with evidence of chronic oligoden-drogenesis. Our data suggest that latency to recover the righting reflex may be an inadequate measure of injury severity and imply that exposure to repeated head impacts may mask the severity of an underlying and developing neuropathologic condition that does not manifest itself until long after head collisions cease. In addition, our data indicate that there is a cumulative and dose-dependent effect of repetitive head impacts that induces the neurobehavioral and neuropathologic outcomes seen in humans with a history of rmTBI.	[Briggs, Denise I.; Angoa-Perez, Mariana; Kuhn, Donald M.] John D Dingell VA Med Ctr, Res & Dev Serv, 4646 John R St, Detroit, MI 48201 USA; [Briggs, Denise I.; Angoa-Perez, Mariana; Kuhn, Donald M.] Wayne State Univ, Dept Psychiat & Behav Neurosci, Sch Med, Detroit, MI 48207 USA	Briggs, DI (corresponding author), John D Dingell VA Med Ctr, Res & Dev Serv, 4646 John R St, Detroit, MI 48201 USA.	dbriggs@med.wayne.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Briggs, Denise/0000-0002-4824-3947	Department of Veterans Affairs grantUS Department of Veterans Affairs [5IO1RX000375]; New Investigator grant from the Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine; Veterans AffairsUS Department of Veterans Affairs [I01RX000375, IK6RX002419] Funding Source: NIH RePORTER	Supported by Department of Veterans Affairs grant 5IO1RX000375 (D.M.K.); and a New Investigator grant from the Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine (D.I.B.).	Alsalaheen B, 2016, J HEAD TRAUMA REHAB, V31, P242, DOI 10.1097/HTR.0000000000000175; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Deacon R. M. J., 2013, JOVE-J VIS EXP, V76, P2610, DOI [10.3791/2610, DOI 10.3791/2610]; Denny-Brown Russell WR, 1940, J PHYSL, V99, P153; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Holbourn AHS, 1943, LANCET, V2, P438; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Maxwell WL, 2015, J NEUROTRAUM, V32, P780, DOI 10.1089/neu.2014.3369; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; O'Leary TP, 2009, BEHAV BRAIN RES, V201, P120, DOI 10.1016/j.bbr.2009.01.039; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Perunovic B, 2001, J NEUROL SCI, V185, P55, DOI 10.1016/S0022-510X(01)00463-4; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Piato AL, 2008, J ETHNOPHARMACOL, V118, P300, DOI 10.1016/j.jep.2008.04.018; Reith FCM, 2016, J NEUROTRAUM, V33, P89, DOI 10.1089/neu.2014.3843; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szabo AJ, 2013, J ATHL TRAINING, V48, P851, DOI 10.4085/1062-6050-48.6.20; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomas DM, 2008, J NEUROCHEM, V105, P605, DOI 10.1111/j.1471-4159.2007.05155.x; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walker AK, 2014, J NEUROSCI, V34, P6448, DOI 10.1523/JNEUROSCI.0248-14.2014; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Xu LY, 2015, EXP NEUROL, V273, P168, DOI 10.1016/j.expneurol.2015.08.014; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yalcin I, 2005, EUR J PHARMACOL, V514, P165, DOI 10.1016/j.ejphar.2005.03.029; Yalcin I, 2007, BEHAV PHARMACOL, V18, P623, DOI 10.1097/FBP.0b013e3282eff109	84	17	17	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2016	186	11					2869	2886		10.1016/j.ajpath.2016.07.013			18	Pathology	Pathology	EA9TG	WOS:000386987000010	27662795	Bronze			2021-06-18	
J	Hansen, C; Cushman, D; Anderson, N; Chen, W; Cheng, C; Hon, SD; Hung, M				Hansen, Colby; Cushman, Dan; Anderson, Nicholas; Chen, Wei; Cheng, Christine; Hon, Shirley D.; Hung, Man			A Normative Dataset of the Balance Error Scoring System in Children Aged Between 5 and 14	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain concussion; sports; pediatrics; child; reference values	SPORTS-RELATED CONCUSSION; 2ND IMPACT SYNDROME; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; POSTURAL STABILITY; FOOTBALL PLAYERS; UNITED-STATES; INJURY; MANAGEMENT	Objective: Pediatric head injuries occur commonly and are being reported in increasing numbers. Balance testing is a key component in the evaluation of suspected concussion, and the balance error scoring system (BESS) is likely the most well-known and widely used measure. To date, normative BESS scores for adults have been reported but not for children. Design: Normative data for BESS scores and modified BESS scores were created in a cohort of healthy children. Potential variables were analyzed as predictors of BESS performance. Setting: Local elementary and junior high schools. Participants: A total of 373 healthy children between the ages of 5 and 14. Interventions: The BESS was performed on all children. Assessment of Risk Factors: Gender, body mass index percentile, previous concussions, athletic participation, age, and the parental opinion of child's balance ability were examined as factors associated with the BESS score. Main Outcome Measures: BESS scores. Results: Normative data are reported, stratified by age groups of 5 to 7 years, 8 to 10 years, and 11 to 14 years of age, for both BESS and modified BESS. Median BESS scores are 23 for children aged 5 to 7, 18 for children aged 8 to 10, and 16 for children aged 11 to 14. Median modified BESS scores are 8 for children age 5 to 7, 5 for children age 8 to 10, and 4 for children age 11 to 14. Increasing age and positive parental opinion regarding their child's balance ability were independently correlated with decreasing BESS scores (P < 0.01). Conclusions: The normative data on BESS scores for healthy children reported here provide age-stratified reference values for suspected balance alterations.	[Hansen, Colby; Cushman, Dan; Anderson, Nicholas] Univ Utah, Div Phys Med & Rehabil, 590 Wakara Way, Salt Lake City, UT 84108 USA; [Chen, Wei] Univ Utah, Div Epidemiol, Salt Lake City, UT USA; [Cheng, Christine] Roseman Univ, Coll Pharm, South Jordan, UT USA; [Hon, Shirley D.] Univ Utah, Dept Elect & Comp Engn, Salt Lake City, UT USA; [Hung, Man] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA	Cushman, D (corresponding author), Univ Utah, Div Phys Med & Rehabil, 590 Wakara Way, Salt Lake City, UT 84108 USA.	dan.cushman.work@gmail.com	Hansen, Colby/AAP-7680-2021	Hansen, Colby/0000-0002-8012-2483; Cushman, Daniel/0000-0002-4580-1173	University of Utah, Division of PM&R pilot research grant fund; University of Utah Department of Orthopaedics; Center for Outcomes Research and Assessment; Study Design and Biostatistics Center; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000105]	Supported by the University of Utah, Division of PM&R pilot research grant fund, the University of Utah Department of Orthopaedics, the Center for Outcomes Research and Assessment and the Study Design and Biostatistics Center, with funding in part from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8UL1TR000105.	[Anonymous], 2013, Br J Sports Med, V47, P259; [Anonymous], 2013, Br J Sports Med, V47, P263; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Franjoine Mary Rose, 2003, Pediatr Phys Ther, V15, P114, DOI 10.1097/01.PEP.0000068117.48023.18; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham R., 2014, SPORTS RELATED CONCU; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; May KH, 2014, INT J SPORTS PHYS TH, V9, P242; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Stuart E, 2015, CURR RES, V2, P22; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	33	17	17	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2016	26	6					497	501		10.1097/JSM.0000000000000285			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EB6DO	WOS:000387471600010	27783573				2021-06-18	
J	Kurowski, BG; Wade, SL; Dexheimer, JW; Dyas, J; Zhang, NH; Babcock, L				Kurowski, Brad G.; Wade, Shari L.; Dexheimer, Judith W.; Dyas, Jenna; Zhang, Nanhua; Babcock, Lynn			Feasibility and Potential Benefits of a Web-Based Intervention Delivered Acutely After Mild Traumatic Brain Injury in Adolescents: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescents; concussion; intervention; mild traumatic brain injury; Web-based	COGNITIVE-BEHAVIORAL THERAPY; SPORT-RELATED CONCUSSION; PROBLEM-SOLVING THERAPY; POSTCONCUSSION SYNDROME; EXECUTIVE DYSFUNCTION; RANDOMIZED-TRIAL; CHILDREN; SYMPTOMS; RECOVERY; EFFICACY	Background: There is a paucity of evidence-based interventions for mild traumatic brain injury (mTBI). Objective: To evaluate the feasibility and potential benefits of an interactive, Web-based intervention for mTBI. Setting: Emergency department and outpatient settings. Participants: Of the 21 adolescents aged 11 to 18 years with mTBI recruited from November 2013 to June 2014 within 96 hours of injury, 13 completed the program. Design: Prospective, open pilot. Intervention: The Web-based Self-Management Activity-restriction and Relaxation Training (SMART) program incorporates anticipatory guidance and psychoeducation, self-management and pacing of cognitive and physical activities, and cognitive-behavioral principles for early management of mTBI in adolescents. Main Measures: Primary: Daily Post-Concussion Symptom Scale (PCSS). Secondary: Daily self-reported ratings of activities and satisfaction survey. Results: Average time from injury to baseline testing was 14.0 (standard deviation = 16.7) hours. Baseline PCSS was 23.6 (range: 0-46), and daily activity was 1.8 (range: 0-5.75) hours. Repeated-measures, generalized linear mixed-effects model analysis demonstrated a significant decrease of PCSS at a rate of 2.0 points per day that stabilized after about 2 weeks. Daily activities, screen time, and physical activity increased by 0.06 (standard error [SE] = 0.04, P = .09), 0.04 (SE = 0.02, P = .15), and 0.03 (SE = 0.02, P = .05) hours per day, respectively, over the 4-week follow-up. Satisfaction was rated highly by parents and youth. Conclusions: Self-Management Activity-restriction and Relaxation Training is feasible and reported to be helpful and enjoyable by participants. Future research will need to determine the comparative benefits of SMART and ideal target population.	[Kurowski, Brad G.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Dexheimer, Judith W.; Dyas, Jenna; Babcock, Lynn] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Emergency Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Dexheimer, Judith W.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biomed Informat, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Kurowski, BG (corresponding author), Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org		Zhang, Nanhua/0000-0001-5796-3404; Babcock, Lynn/0000-0002-2658-6893	Ohio Department of Public Safety; Cincinnati Children's Research Foundation Place Outcomes Grant; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683-01A1]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425, UL1TR000077] Funding Source: NIH RePORTER	Funding for this study was supported in part by the Ohio Department of Public Safety, Cincinnati Children's Research Foundation Place Outcomes Grant, National Institute for Child Health and Human Development K23HD074683-01A1, and Grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other supporting agencies.	Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; CASEY R, 1987, PEDIATRICS, V80, P159; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Dexheimer JW, 2014, PED AC SOC ANN C VAN; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hofmann SG, 2012, COGNITIVE THER RES, V36, P427, DOI 10.1007/s10608-012-9476-1; ImPACT Applications Inc, 2011, IMM POSTC ASS TEST I; Institute of Medicine and National Research Council Committee on Sports Related Concussion in Youth, 2014, SPORTS RELATED CONCU; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lukens EP, 2004, BRIEF TREATMENT CRIS, V4, P205, DOI [10.1093/brief-treatment/mhh019, DOI 10.1093/BRIEF-TREATMENT/MHH019]; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, NAT REV NEUROL, V9, P361, DOI 10.1038/nrneurol.2013.88; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2015, PEDIATRICS, V135, pE487, DOI 10.1542/peds.2014-1386; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	49	17	17	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					369	378		10.1097/HTR.0000000000000180			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800008	26360000	Green Accepted			2021-06-18	
J	Zhang, H; Zhang, XN; Zhang, HL; Huang, L; Chi, QQ; Zhang, X; Yun, XP				Zhang, Hao; Zhang, Xiao-Nian; Zhang, Hui-Li; Huang, Liang; Chi, Qian-Qian; Zhang, Xin; Yun, Xiao-Ping			Differences in cognitive profiles between traumatic brain injury and stroke: A comparison of the Montreal Cognitive Assessment and Mini-Mental State Examination	CHINESE JOURNAL OF TRAUMATOLOGY			English	Article						Montreal Cognitive Assessment; Mini-Mental State Examination; Cognitive impairment; Cognitive assessment; Brain injuries; Stroke		Purpose: To investigate the profiles of cognitive impairment through Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in patients with chronic traumatic brain injury (TBI) or stroke and to evaluate the sensitivity of the two scales in patients with TBI. Methods: In this cohort study, a total of 230 patients were evaluated, including TBI group (n = 103) and stroke group (n = 127). The cognitive functions of two groups were evaluated by designated specialists using MoCA (Beijing version) and MMSE (Chinese version). Results: Compared with the patients with stroke, the patients with TBI received significantly lower score in orientation subtest and recall subtest in both tests. MoCA abnormal rates in the TBI group and stroke group were 94.17% and 86.61% respectively, while MMSE abnormal rates were 69.90% and 57.48%, respectively. In the TBI group, 87.10% patients with normal MMSE score had abnormal MoCA score and in the stroke group, about 70.37% patients with normal MMSE score had abnormal MoCA score. The diagnostic consistency of two scales in the TBI group and the stroke group were 72% and 69%, respectively. Conclusion: In our rehabilitation center, patients with TBI may have more extensive and severe cognitive impairments than patients with stroke, prominently in orientation and recall domain. In screening postTBI cognitive impairment, MoCA tends to be more sensitive than MMSE. (C) 2016 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.	[Zhang, Hao; Zhang, Xiao-Nian; Chi, Qian-Qian; Zhang, Xin] Capital Med Univ, Beijing Boai Hosp, Sch Rehabil, Neurorehabil Dept,China Rehabil Res Ctr, Beijing 100068, Peoples R China; [Zhang, Hui-Li; Yun, Xiao-Ping] Capital Med Univ, Beijing Boai Hosp, Sch Rehabil, Rehabil Evaluat Dept,China Rehabil Res Ctr, Beijing 100068, Peoples R China; [Huang, Liang] Huabei Oil Field Huayuan Hosp, Rehabil Dept, Hejian 062450, Hebei, Peoples R China	Yun, XP (corresponding author), Capital Med Univ, Beijing Boai Hosp, Sch Rehabil, Rehabil Evaluat Dept,China Rehabil Res Ctr, Beijing 100068, Peoples R China.	crrck3@sina.com			special basic research fund for Chinese central public research institutes [2013CZ-30, 2013CZ-41]	This study was supported by the special basic research fund for Chinese central public research institutes (No. 2013CZ-30, 2013CZ-41).	Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Damian AM, 2011, DEMENT GERIATR COGN, V31, P126, DOI 10.1159/000323867; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grau-Olivares M, 2010, CEREBROVASC DIS, V30, P157, DOI 10.1159/000316059; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Li SZ, 1989, CHIN J NEUROSURG, V5, P2; Lonie JA, 2009, INT J GERIATR PSYCH, V24, P902, DOI 10.1002/gps.2208; Mitchell AJ, 2009, J PSYCHIATR RES, V43, P411, DOI 10.1016/j.jpsychires.2008.04.014; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nazem S, 2009, J AM GERIATR SOC, V57, P304, DOI 10.1111/j.1532-5415.2008.02096.x; Passier PECA, 2010, CEREBROVASC DIS, V29, P557, DOI 10.1159/000306642; Pendlebury ST, 2012, CEREBROVASC DIS, V34, P48, DOI 10.1159/000338905; Pendlebury ST, 2012, STROKE, V43, P464, DOI 10.1161/STROKEAHA.111.633586; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Sachdev PS, 2004, NEUROLOGY, V62, P912, DOI 10.1212/01.WNL.0000115108.65264.4B; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Wang Z, 1989, SHANGHAI ARCH PSYCHI, V7, P108; Wen Hong-Bo, 2008, Zhonghua Nei Ke Za Zhi, V47, P36; Xie SP, 1999, CHIN J EPIDEMIOL, V20, P299; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23	28	17	20	0	2	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	1008-1275			CHIN J TRAUMATOL	Chin. J. Traumatol.	OCT	2016	19	5					271	274		10.1016/j.cjtee.2015.03.007			4	Orthopedics	Orthopedics	VF1PV	WOS:000442111000006	27780506	DOAJ Gold, Green Published			2021-06-18	
J	Goriely, A; Weickenmeier, J; Kuhl, E				Goriely, Alain; Weickenmeier, Johannes; Kuhl, Ellen			Stress Singularities in Swelling Soft Solids	PHYSICAL REVIEW LETTERS			English	Article							TRAUMATIC BRAIN-INJURY	When a swelling soft solid is rigidly constrained on all sides except for a circular opening, it will bulge out to expand as observed during decompressive craniectomy, a surgical procedure used to reduce stresses in swollen brains. While the elastic energy of the solid decreases throughout this process, large stresses develop close to the opening. At the point of contact, the stresses exhibit a singularity similar to the ones found in the classic punch indentation problem. Here, we study the stresses generated by swelling and the evolution of the bulging shape associated with this process. We also consider the possibility of damage triggered by zones of either high shear stresses or high fiber stretches.	[Goriely, Alain] Univ Oxford, Math Inst, Oxford OX2 6GG, England; [Weickenmeier, Johannes; Kuhl, Ellen] Stanford Univ, Living Matter Lab, Stanford, CA 94305 USA	Goriely, A (corresponding author), Univ Oxford, Math Inst, Oxford OX2 6GG, England.		Kuhl, Ellen/G-4444-2011	Kuhl, Ellen/0000-0002-6283-935X; Weickenmeier, Johannes/0000-0003-1889-5976	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54GM072970]	This work was supported by the NIH Grant No. U54GM072970 to E. K. The authors are grateful to Michael Sutcliffe for sharing data and an earlier version of a manuscript and to Michel Destrade for discussions on Rivlin's work.	Ambrosi D, 2011, J MECH PHYS SOLIDS, V59, P863, DOI 10.1016/j.jmps.2010.12.011; [Anonymous], 2014, AB 6 14 AN US MAN; Barber J.R., 1992, ELASTICITY; Ben Amar M., 2011, NEW TRENDS PHYS MECH; Cerruti V, 1882, REND ACCAD LINCEI, V3, P81; Collins WD, 1963, P EDINBURGH MATH SOC, V13, P235, DOI [10.1017/s0013091500010889, DOI 10.1017/S0013091500010889]; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Destrade M, 2015, INT J NONLIN MECH, V75, P54, DOI 10.1016/j.ijnonlinmec.2015.02.014; Fletcher T. L., 2016, ANN BIOMED ENG, V1; Fletcher TL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102131; Gladwell G.M.L., 1980, CONTACT PROBLEMS CLA; Goriely A, 2015, ADV APPL MECH, V48, P79, DOI 10.1016/bs.aams.2015.10.002; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Johnson K., 1987, CONTACT MECH; Lang GE, 2015, BIOMECH MODEL MECHAN, V14, P1197, DOI 10.1007/s10237-015-0665-1; Lang GE, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0123; Mihai LA, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0486; Muskhelishvili N.I, 1977, SOME BASIC PROBLEMS; RIVLIN RS, 1947, J APPL PHYS, V18, P444, DOI 10.1063/1.1697674; Roitman A.B., 1973, INT APPL MECH+, V9, P725; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Walberer M, 2008, J NEUROSURG, V109, P287, DOI 10.3171/JNS/2008/109/8/0287; Weickenmeier J, 2016, ACTA BIOMATER, V42, P265, DOI 10.1016/j.actbio.2016.07.040; Weickenmeier J., 2016, COMP METH APPL MECH; Weickenmeier J., J MECH PHYS SOLIDS; Weickenmeier J., ARXIV160903129	26	17	17	0	16	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	0031-9007	1079-7114		PHYS REV LETT	Phys. Rev. Lett.	SEP 21	2016	117	13							138001	10.1103/PhysRevLett.117.138001			5	Physics, Multidisciplinary	Physics	DW7SF	WOS:000383851000021	27715096	Bronze			2021-06-18	
J	Sturdivant, NM; Smith, SG; Ali, SF; Wolchok, JC; Balachandran, K				Sturdivant, Nasya M.; Smith, Sean G.; Ali, Syed F.; Wolchok, Jeffrey C.; Balachandran, Kartik			Acetazolamide Mitigates Astrocyte Cellular Edema Following Mild Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							IN-VITRO; VOLUME REGULATION; AQUAPORIN 4; CULTURES; STRAIN; TISSUE; MICE; PATHOPHYSIOLOGY; MECHANISMS; ISCHEMIA	Non-penetrating or mild traumatic brain injury (mTBI) is commonly experienced in accidents, the battlefield and in full-contact sports. Astrocyte cellular edema is one of the major factors that leads to high morbidity post-mTBI. Various studies have reported an upregulation of aquaporin-4 (AQP4), a water channel protein, following brain injury. AZA is an antiepileptic drug that has been shown to inhibit AQP4 expression and in this study we investigate the drug as a therapeutic to mitigate the extent of mTBI induced cellular edema. We hypothesized that mTBI-mediated astrocyte dysfunction, initiated by increased intracellular volume, could be reduced when treated with AZA. We tested our hypothesis in a three-dimensional in vitro astrocyte model of mTBI. Samples were subject to no stretch (control) or one high-speed stretch (mTBI) injury. AQP4 expression was significantly increased 24 hours after mTBI. mTBI resulted in a significant increase in the cell swelling within 30 min of mTBI, which was significantly reduced in the presence of AZA. Cell death and expression of S100B was significantly reduced when AZA was added shortly before mTBI stretch. Overall, our data point to occurrence of astrocyte swelling immediately following mTBI, and AZA as a promising treatment to mitigate downstream cellular mortality.	[Sturdivant, Nasya M.; Smith, Sean G.; Wolchok, Jeffrey C.; Balachandran, Kartik] Univ Arkansas, Dept Biomed Engn, Fayetteville, AR 72701 USA; [Ali, Syed F.] US FDA, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	Balachandran, K (corresponding author), Univ Arkansas, Dept Biomed Engn, Fayetteville, AR 72701 USA.	kbalacha@uark.edu			National Science FoundationNational Science Foundation (NSF) [CMMI-1404716]; NSF Graduate Research FellowshipNational Science Foundation (NSF) [DGE-1450079]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA008748] Funding Source: NIH RePORTER	This work was supported by the National Science Foundation under grant no. CMMI-1404716 and by the NSF Graduate Research Fellowship Program under grant no. DGE-1450079. We would like to acknowledge Dr. Timothy Muldoon for the use of the multiphoton microscope in his laboratory. We also acknowledge Addison Walker for his assistance with the neonatal rat astrocyte harvest.	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/782424; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Danny Liang M. D., 2009, NEUROSURG FOCUS, V22; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; Guo FY, 2012, TRANSL STROKE RES, V3, P130, DOI 10.1007/s12975-011-0106-0; HANSON MA, 1981, J PHYSIOL-LONDON, V320, P113, DOI 10.1113/jphysiol.1981.sp013938; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Hubbard JA, 2015, ASN NEURO, V7, DOI 10.1177/1759091415605486; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038; Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165; Kamegawa A, 2016, MICROSCOPY-JPN, V65, P177, DOI 10.1093/jmicro/dfv368; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Katada R., 2012, AMERIAN J PATHOLOGY, P17; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kerr Zachary Y, 2014, N C Med J, V75, P8; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lan Y.-L., 2015, ACTA NEUROLOGICA BEL, P1; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Magou GC, 2015, BRAIN RES, V1624, P525, DOI 10.1016/j.brainres.2015.07.056; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Marmarou A, 2003, ACT NEUR S, V86, P7; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mendizabal A, 2015, J MECH BEHAV BIOMED, V45, P1, DOI 10.1016/j.jmbbm.2015.01.016; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; NINDS, 2015, TRAUM BRAIN INJ HOP; Pasantes-Morales H, 2006, AM J MED, V119, pS4, DOI 10.1016/j.amjmed.2006.05.002; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Thrane A. S., 2011, PNAS, P86; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Vappou J, 2007, MAGN RESON MATER PHY, V20, P273, DOI 10.1007/s10334-007-0098-7; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Xiao M, 2014, CNS NEUROSCI THER, V20, P385, DOI 10.1111/cns.12267; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7	60	17	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 14	2016	6								33330	10.1038/srep33330			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DV8QE	WOS:000383200700001	27623738	DOAJ Gold, Green Published			2021-06-18	
J	Llompart-Pou, JA; Chico-Fernandez, M; Sanchez-Casado, M; Alberdi-Odriozola, F; Guerrero-Lopez, F; Mayor-Garcia, MD; Gonzalez-Robledo, J; Ballesteros-Sanz, MA; Herran-Mongei, R; Leon-Lopez, R; Lopez-Amork, L; Bueno-Gonzalez, A				Antonio Llompart-Pou, Juan; Chico-Fernandez, Mario; Sanchez-Casado, Marcelino; Alberdi-Odriozola, Fermin; Guerrero-Lopez, Francisco; Dolores Mayor-Garcia, Maria; Gonzalez-Robledo, Javier; Angeles Ballesteros-Sanz, Maria; Herran-Mongei, Ruben; Leon-Lopez, Rafael; Lopez-Amork, Lucia; Bueno-Gonzalez, Ana		Trauma & Neurointensive Care	Age-related injury patterns in Spanish trauma ICU patients. Results from the RETRAUCI	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Intensive care unit; Elderly; Injury patterns; Trauma registry	BRAIN-INJURY; GERIATRIC TRAUMA; MORTALITY; CARE; EPIDEMIOLOGY; MANAGEMENT; REGISTRIES; COMPLICATIONS; PREDICTORS; OUTCOMES	Background: Injury patterns may differ in trauma patients when age is considered. This information is relevant in the management of trauma patients and for planning preventive measures. Methods: We included in the study all patients admitted for traumatic disease in the participating ICUs from November 23rd, 2012 to July 31st, 2015 with complete records. Data on epidemiology, injury patterns, severity scores, acute management, resources utilisation and outcome were recorded and compared in the following groups of age: <= 55 years (young adults), 56-65 years (adults), 66-75 years (elderly), > 75 years (very elderly). Quantitative datawere reported as median (Interquartile Range (IQR) 25-75) and categorical data as number and percentage. Comparison between groups of age with quantitative variables was performed using the analysis of variance (ANOVA) test. Differences between groups with categorical variables were compared using the chi-square test. A value of p < 0.05 was considered significant. Results: We included 2700 patients (78.9% male). Median age was 46 (31-62) years. Blunt trauma was present in 93.7% of the patients. Median RTS was 7.55 (5.97-7.84). Median ISS was 20 (13-26). High-energy trauma secondary to motor-vehicle accident with rhabdomyolysis and drugs abuse showed an inverse linear association with ageing, whilst pedestrian falls with isolated brain injury, being run-over and pre-injury antiplatelets or anticoagulant treatment increased with age (in all cases p < 0.001). Multiple injurieswere more common in young adults (p < 0.001). Acute kidney injury prevalence was higher in elderly and very elderly patients (p < 0.001). ICU Mortality increased with age in spite of similar severity scores in all groups (p < 0.001). The main cause of death in all groups was intracranial hypertension. Conclusions: Different injury patterns exist in relation with ageing in trauma ICU patients. Adult patients were more likely to present high-energy trauma with significant injuries in different areas whilst elderly patients were prone to low-energy falls, complicated by antiplatelets or anticoagulants use, resulting in severe brain injury and increased mortality. (C) 2016 Elsevier Ltd. All rights reserved.	[Antonio Llompart-Pou, Juan] Hosp Univ Son Espases, Serv Med Intens, Palma De Mallorca, Spain; [Chico-Fernandez, Mario] Hosp Univ 12 Octubre, Serv Med Intens, UCI Trauma & Emergencias, Ave Andalucia S-N, Madrid 28041, Spain; [Sanchez-Casado, Marcelino] Hosp Virgen Salud, Serv Med Intens, Toledo, Spain; [Alberdi-Odriozola, Fermin] Hosp Univ Donostia, Serv Med Intens, San Sebastian, Spain; [Guerrero-Lopez, Francisco] Hosp Univ Virgen Nieves, Serv Med Intens, Granada, Spain; [Dolores Mayor-Garcia, Maria] Complejo Hosp Torrecardenas, Serv Med Intens, Almeria, Spain; [Gonzalez-Robledo, Javier] Complejo Asistencial Univ Salamanca, Serv Med Intens, Salamanca, Spain; [Angeles Ballesteros-Sanz, Maria] Hosp Univ Marques de Valdecilla, Serv Med Intens, Santander, Spain; [Herran-Mongei, Ruben] Hosp Univ Rio Hortega, Serv Med Intens, Valladolid, Spain; [Leon-Lopez, Rafael] Ciudad Sanitaria Reina Sofia, Serv Med Intens, Cordoba, Spain; [Lopez-Amork, Lucia] Hosp Univ Cent Asturias, Serv Med Intens, Asturias, Spain; [Bueno-Gonzalez, Ana] Hosp Gen Univ Ciudad Real, Serv Med Intens, Ciudad Real, Spain	Chico-Fernandez, M (corresponding author), Hosp Univ 12 Octubre, Serv Med Intens, UCI Trauma & Emergencias, Ave Andalucia S-N, Madrid 28041, Spain.	murgchico@yahoo.es		Ballesteros, Maria A/0000-0002-4032-9973	Fundacion Mutua Madrilena, Trauma and Neurointensive Care Working Group of the Spanish Society of Intensive Care Medicine (SEMICYUC) [AP117892013]	RETRAUCI received funding from the Fundacion Mutua Madrilena during 3 years for the development of a web-based database granted to Dr. Chico-Fernandez (reference AP117892013), on behalf of Trauma and Neurointensive Care Working Group of the Spanish Society of Intensive Care Medicine (SEMICYUC)	Adams SD, 2012, J TRAUMA ACUTE CARE, V72, P112, DOI 10.1097/TA.0b013e318241f073; Alberdi F, 2014, MED INTENSIVA, V38, P580, DOI 10.1016/j.medin.2014.06.012; Beynon C, 2015, CLIN NEUROL NEUROSUR, V136, P73, DOI 10.1016/j.clineuro.2015.05.035; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Fernandez MC, 2013, MED INTENSIVA, V37, P284, DOI 10.1016/j.medin.2013.01.010; Chico-Fernandez M, 2015, MED INTENSIVA; Clement ND, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-26; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Egea-Guerrero JJ, 2015, MED INTENSIVA, V39, P167, DOI 10.1016/j.medin.2014.09.008; Gibson AA, 2014, INJURY, V45, P1066, DOI 10.1016/j.injury.2014.02.037; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; Harr JN, 2013, CRIT CARE MED, V41, P399, DOI 10.1097/CCM.0b013e31826ab38b; Hashmi A, 2014, J TRAUMA ACUTE CARE, V76, P894, DOI 10.1097/TA.0b013e3182ab0763; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Lee H, 2015, ANZ J SURG, V85, P230, DOI 10.1111/ans.12676; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Min LL, 2013, J TRAUMA ACUTE CARE, V74, P1125, DOI 10.1097/TA.0b013e31828273a0; Moore L, 2008, INJURY, V39, P686, DOI 10.1016/j.injury.2008.02.023; Oliver M, 2012, INJURY, V43, P1296, DOI 10.1016/j.injury.2012.04.021; Sanchez FIP, 2015, MED INTENSIVA, V39, P114, DOI 10.1016/j.medin.2014.06.008; Schaefer JH, 2014, J CEREBR BLOOD F MET, V34, P870, DOI 10.1038/jcbfm.2014.31; Skinner DL, 2014, INJURY, V45, P259, DOI 10.1016/j.injury.2013.07.013; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Willis CD, 2007, INJURY, V38, P527, DOI 10.1016/j.injury.2006.06.018	25	17	17	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2016	47			3			S61	S65		10.1016/S0020-1383(16)30608-8			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	EF7VW	WOS:000390538400011	27692109				2021-06-18	
J	Desai, B; Hsu, Y; Schneller, B; Hobbs, JG; Mehta, AI; Linninger, A				Desai, Bhargav; Hsu, Ying; Schneller, Benjamin; Hobbs, Jonathan G.; Mehta, Ankit I.; Linninger, Andreas			Hydrocephalus: the role of cerebral aquaporin-4 channels and modeling considerations of cerebrospinal fluid	NEUROSURGICAL FOCUS			English	Article						hydrocephalus; aquaporin-4; AQP4; computational modeling; reconstruction; pharmaceutical; therapy; treatment; diagnosis	NORMAL-PRESSURE HYDROCEPHALUS; INDUCED SALIVARY HYPOFUNCTION; OSMOTIC WATER PERMEABILITY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; INTRAVENTRICULAR HEMORRHAGE; RAT-BRAIN; NEUROLOGICAL DISORDERS; ACCELERATED RESOLUTION	Aquaporin-4 (AQP4) channels play an important role in brain water homeostasis. Water transport across plasma membranes has a critical role in brain water exchange of the normal and the diseased brain. AQP4 channels are implicated in the pathophysiology of hydrocephalus, a disease of water imbalance that leads to CSF accumulation in the ventricular system. Many molecular aspects of fluid exchange during hydrocephalus have yet to be firmly elucidated, but review of the literature suggests that modulation of AQP4 channel activity is a potentially attractive future pharmaceutical therapy. Drug therapy targeting AQP channels may enable control over water exchange to remove excess CSF through a molecular intervention instead of by mechanical shunting. This article is a review of a vast body of literature on the current understanding of AQP4 channels in relation to hydrocephalus, details regarding molecular aspects of AQP4 channels, possible drug development strategies, and limitations. Advances in medical imaging and computational modeling of CSF dynamics in the setting of hydrocephalus are summarized. Algorithmic developments in computational modeling continue to deepen the understanding of the hydrocephalus disease process and display promising potential benefit as a tool for physicians to evaluate patients with hydrocephalus.	[Desai, Bhargav; Mehta, Ankit I.; Linninger, Andreas] Univ Illinois, Dept Neurosurg, Chicago, IL USA; [Hsu, Ying; Schneller, Benjamin; Linninger, Andreas] Univ Illinois, Dept Bioengn, Chicago, IL USA; [Hobbs, Jonathan G.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA	Linninger, A (corresponding author), Univ Illinois, 912 South Wood St,M-C 799 4N NPI, Chicago, IL 60612 USA.	linninge@uic.edu	Mehta, Ankit/AAL-3851-2020		Hydrocephalus Association	Partial support through an Innovator Award (P.I. Andreas Linninger) by the Hydrocephalus Association (directed by Dr. J. Koschnitzky) is gratefully acknowledged.	Abe Y, 2012, J NEUROCHEM, V120, P899, DOI 10.1111/j.1471-4159.2012.07652.x; Aghayev K, 2012, ACTA NEUROCHIR, V154, P753, DOI 10.1007/s00701-011-1241-9; Agre P, 2004, NEUROSCIENCE, V129, P849, DOI 10.1016/j.neuroscience.2004.10.001; AIMARD G, 1990, REV NEUROL, V146, P437; Alikina TY, 2002, P 3 INT C BIOINF GEN; Ambarki K, 2012, AM J NEURORADIOL, V33, P1951, DOI 10.3174/ajnr.A3067; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, NEUROSCIENCE, V129, P999, DOI 10.1016/j.neuroscience.2004.08.049; Assentoft M, 2013, GLIA, V61, P1101, DOI 10.1002/glia.22498; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baum BJ, 2006, BBA-BIOMEMBRANES, V1758, P1071, DOI 10.1016/j.bbamem.2005.11.006; Baum BJ, 2012, P NATL ACAD SCI USA, V109, P19403, DOI 10.1073/pnas.1210662109; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Bloch O, 2006, J CEREBR BLOOD F MET, V26, P1527, DOI 10.1038/sj.jcbfm.9600306; BROWN PN, 1985, PHYS MED BIOL, V30, P1113, DOI 10.1088/0031-9155/30/10/010; Buishas J, 2014, CROAT MED J, V55, P481, DOI 10.3325/cmj.2014.55.481; CABANES J, 1983, J NEUROSURG, V59, P311, DOI 10.3171/jns.1983.59.2.0311; CACABELOS R, 1991, METHOD FIND EXP CLIN, V13, P455; Carmosino M, 2007, BIOL CELL, V99, P25, DOI 10.1042/BC200600068; Castaneyra-Ruiz L, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-18; Cheng S., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P151, DOI 10.1080/10255840601124753; Clarke Michelle J, 2007, Neurosurg Focus, V22, pE3, DOI 10.3171/foc.2007.22.4.4; CUTLER RWP, 1968, BRAIN, V91, P707, DOI 10.1093/brain/91.4.707; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; De Bellis M, 2014, MOL BIOL CELL, V25, P470, DOI 10.1091/mbc.E13-06-0331; Del Bigio MR, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-12; Del Bigio MR, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0025-2; Del Bigio MR, 2010, DEV DISABIL RES REV, V16, P16, DOI 10.1002/ddrr.94; Dey M, 2015, NEUROSURGERY, V76, P291, DOI 10.1227/NEU.0000000000000624; Diringer MN, 1998, STROKE, V29, P1352, DOI 10.1161/01.STR.29.7.1352; Dombrowski SM, 2006, J CEREBR BLOOD F MET, V26, P1298, DOI 10.1038/sj.jcbfm.9600282; Engel A, 2008, CURR OPIN STRUC BIOL, V18, P229, DOI 10.1016/j.sbi.2007.11.003; Feng XC, 2009, J NEUROSCI RES, V87, P1150, DOI 10.1002/jnr.21927; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; Ferreira Cesar Biselli, 2015, Rev Bras Ter Intensiva, V27, P315, DOI 10.5935/0103-507X.20150055; Filippidis AS, 2011, CHILD NERV SYST, V27, P27, DOI 10.1007/s00381-010-1227-6; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Galarza M, 2014, CHILD NERV SYST, V30, P105, DOI 10.1007/s00381-013-2226-1; Gao F, 2016, ACTA NEUROCHIR SUPPL, V121, P373, DOI 10.1007/978-3-319-18497-5_64; Gao F, 2014, J CEREBR BLOOD F MET, V34, P489, DOI 10.1038/jcbfm.2013.225; Gao R, 2011, GENE THER, V18, P38, DOI 10.1038/gt.2010.128; GOMEZ DG, 1981, ACTA ANAT, V111, P247; Gunnarson E, 2005, NEUROSCIENCE, V136, P105, DOI 10.1016/j.neuroscience.2005.07.027; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; HAYDEN PW, 1968, PEDIATRICS, V41, P955; Hiroaki Y, 2006, J MOL BIOL, V355, P628, DOI 10.1016/j.jmb.2005.10.081; Hodel J, 2014, EUR RADIOL, V24, P136, DOI 10.1007/s00330-013-2990-z; Hodel J, 2013, EUR RADIOL, V23, P1450, DOI 10.1007/s00330-012-2732-7; Hsu C.-Y., 2016, MAGN RESON MED; Hsu MS, 2011, NEUROSCIENCE, V178, P21, DOI 10.1016/j.neuroscience.2011.01.020; Hsu Y, 2015, CROAT MED J, V56, P401, DOI 10.3325/cmj.2015.56.401; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038; Igarashi H, 2014, NEUROREPORT, V25, P39, DOI 10.1097/WNR.0000000000000042; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ishii K, 2013, DEMENT GER COGN D EX, V3, P489, DOI 10.1159/000357329; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ivkovic M, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0004-z; Kadohira I, 2008, BIOCHEM BIOPH RES CO, V377, P463, DOI 10.1016/j.bbrc.2008.09.155; Kamali-Zare P, 2013, BASIC CLIN NEUROSCI, V4, P282; Kato J, 2013, BIOCHEM J, V454, P275, DOI 10.1042/BJ20130046; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kitchen P, 2015, J BIOL CHEM, V290, P16873, DOI 10.1074/jbc.M115.646034; Klarica M, 2013, NEUROSCIENCE, V248, P278, DOI 10.1016/j.neuroscience.2013.06.022; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Kong H, 2008, J CELL SCI, V121, P4029, DOI 10.1242/jcs.035758; Krishnamurthy S, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-13; Krishnamurthy S, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-16; Kuwahara-Otani S, 2013, J VET MED SCI, V75, P1081, DOI 10.1292/jvms.13-0083; Lee P, 2013, NEUROSURGERY, V73, pN13, DOI 10.1227/01.neu.0000438332.72566.f5; Li X, 2009, NEUROSCIENCE, V162, P67, DOI 10.1016/j.neuroscience.2009.04.044; Linninger AA, 2016, ANNU REV FLUID MECH, V48, P219, DOI 10.1146/annurev-fluid-122414-034321; Linninger AA, 2009, J MATH BIOL, V59, P729, DOI 10.1007/s00285-009-0250-2; Linninger AA, 2009, ANN BIOMED ENG, V37, P1434, DOI 10.1007/s10439-009-9691-4; Luciano Mark, 2007, Cleve Clin J Med, V74 Suppl 1, pS128; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Mao XY, 2006, EUR J NEUROSCI, V23, P2929, DOI 10.1111/j.1460-9568.2006.04829.x; MEALEY J, 1968, J PEDIATR-US, V72, P257, DOI 10.1016/S0022-3476(68)80319-1; MERCURI E, 1994, ACTA PAEDIATR, V83, P1319, DOI 10.1111/j.1651-2227.1994.tb13028.x; Migliati E, 2009, MOL PHARMACOL, V76, P105, DOI 10.1124/mol.108.053744; MINER ME, 1986, CHILD NERV SYST, V2, P105; Mobasheri A, 2007, CHANNELS, V1; Moe SE, 2008, GENOMICS, V91, P367, DOI 10.1016/j.ygeno.2007.12.003; Moeller HB, 2009, NEUROSCIENCE, V164, P1674, DOI 10.1016/j.neuroscience.2009.09.072; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nielsen S, 1997, J NEUROSCI, V17, P171; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; Oku H, 2015, OPHTHALMIC RES, V54, P212, DOI 10.1159/000440846; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Oshio K, 2003, ACT NEUR S, V86, P525; Pan CF, 2010, CHINESE MED J-PEKING, V123, P1888, DOI 10.3760/cma.j.issn.0366-6999.2010.14.011; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Park EH, 2010, J NEUROSURG-PEDIATR, V6, P159, DOI 10.3171/2010.5.PEDS09142; Paul L, 2011, NEUROSURGERY, V68, P462, DOI 10.1227/NEU.0b013e3182011860; Penn RD, 2011, J NEUROSURG, V115, P159, DOI 10.3171/2010.12.JNS10926; Piper RJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003434.pub3; Pisani F, 2011, GLIA, V59, P1923, DOI 10.1002/glia.21234; Poca MA, 2005, EXPERT OPIN PHARMACO, V6, P1525, DOI 10.1517/14656566.6.9.1525; Qi LL, 2011, LIFE SCI, V88, P50, DOI 10.1016/j.lfs.2010.10.025; Ramakrishna R, 2010, NEUROSURGERY, V67, P110, DOI 10.1227/01.NEU.0000370920.44359.91; Rash JE, 2004, NEUROSCIENCE, V129, P915, DOI 10.1016/j.neuroscience.2004.06.076; Ratelade J, 2012, INT J BIOCHEM CELL B, V44, P1519, DOI 10.1016/j.biocel.2012.06.013; Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rossi A, 2012, TRAFFIC, V13, P43, DOI 10.1111/j.1600-0854.2011.01299.x; Rossi A, 2011, GLIA, V59, P1056, DOI 10.1002/glia.21177; Sadlish H, 2005, NAT STRUCT MOL BIOL, V12, P870, DOI 10.1038/nsmb994; Saehle T, 2015, J NEUROSURG, V122, P1076, DOI 10.3171/2014.12.JNS141029; Salminen LE, 2016, TECHNOL INNOV, V18, P5, DOI 10.21300/18.1.2016.5; Shen XQ, 2006, J NEUROSURG, V105, P459, DOI 10.3171/ped.2006.105.6.459; Shoesmith CL, 2000, NEUROL RES, V22, P111; Silberstein C, 2004, AM J PHYSIOL-RENAL, V287, pF501, DOI 10.1152/ajprenal.00439.2003; Skjolding AD, 2010, FLUIDS BARRIERS CNS, V7, DOI 10.1186/1743-8454-7-20; SMITH QR, 1980, J PHARMACOL EXP THER, V215, P673; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Spector R, 2015, EXP NEUROL, V267, P78, DOI 10.1016/j.expneurol.2015.02.032; Supuran CT, 2015, EXPERT REV NEUROTHER, V15, P851, DOI 10.1586/14737175.2015.1066675; Suzuki H, 2008, BBA-BIOMEMBRANES, V1778, P1181, DOI 10.1016/j.bbamem.2007.12.007; Swenson ER, 2016, J APPL PHYSIOL, V120, P204, DOI 10.1152/japplphysiol.00443.2015; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tarkowski E, 2003, NEUROBIOL AGING, V24, P707, DOI 10.1016/S0197-4580(02)00187-2; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Tomas-Camardiel M, 2005, J NEUROSCI RES, V80, P235, DOI 10.1002/jnr.20443; Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; van Meer G, 2005, EMBO REP, V6, P418, DOI 10.1038/sj.embor.7400410; Venero JL, 2004, CURR PHARM DESIGN, V10, P2153, DOI 10.2174/1381612043384150; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF; Yool AJ, 2007, NEUROSCIENTIST, V13, P470, DOI 10.1177/1073858407303081; Zelenin S, 2000, PEDIATR RES, V48, P335, DOI 10.1203/00006450-200009000-00012; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhang H, 2008, J MOL BIOL, V382, P1136, DOI 10.1016/j.jmb.2008.07.089; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zheng GQ, 2010, NEUROCHEM INT, V56, P651, DOI 10.1016/j.neuint.2010.01.014; Ziai WC, 2014, INT J STROKE, V9, P536, DOI 10.1111/ijs.12097	145	17	19	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	SEP	2016	41	3							E8	10.3171/2016.7.FOCUS16191			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DW1ZK	WOS:000383442500008	27581320	Bronze			2021-06-18	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Predicting long-term neurological outcomes after severe traumatic brain injury requiring decompressive craniectomy: A comparison of the CRASH and IMPACT prognostic models	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Decompressive craniectomy; CRASH prediction model; IMPACT prediction model	MIDDLE CEREBRAL-ARTERY; EXTERNAL VALIDATION; HEAD-INJURY; INTRACRANIAL HYPERTENSION; SURGICAL DECOMPRESSION; BIFRONTAL CRANIECTOMY; MALIGNANT INFARCTION; HEMICRANIECTOMY; MULTICENTER; MODERATE	Background: Predicting long-term neurological outcomes after severe traumatic brain (TBI) is important, but which prognostic model in the context of decompressive craniectomy has the best performance remains uncertain. Methods: This prospective observational cohort study included all patients who had severe TBI requiring decompressive craniectomy between 2004 and 2014, in the two neurosurgical centres in Perth, Western Australia. Severe disability, vegetative state, or death were defined as unfavourable neurological outcomes. Area under the receiver-operating-characteristic curve (AUROC) and slope and intercept of the calibration curve were used to assess discrimination and calibration of the CRASH (Corticosteroid-Randomisation-After-Significant-Head injury) and IMPACT (International-Mission-For-Prognosis-And-Clinical-Trial) models, respectively. Results: Of the 319 patients included in the study, 119 (37%) had unfavourable neurological outcomes at 18-month after decompressive craniectomy for severe TBI. Both CRASH (AUROC 0.86, 95% confidence interval 0.81-0.90) and IMPACT full-model (AUROC 0.85, 95% CI 0.80-0.89) were similar in discriminating between favourable and unfavourable neurological outcome at 18-month after surgery (p = 0.690 for the difference in AUROC derived from the two models). Although both models tended to over-predict the risks of long-term unfavourable outcome, the IMPACT model had a slightly better calibration than the CRASH model (intercept of the calibration curve = -4.1 vs. -5.7, and log likelihoods -159 vs. -360, respectively), especially when the predicted risks of unfavourable outcome were <80%. Conclusions: Both CRASH and IMPACT prognostic models were good in discriminating between favourable and unfavourable long-term neurological outcome for patients with severe TBI requiring decompressive craniectomy, but the calibration of the IMPACT full-model was better than the CRASH model. Crown Copyright (C) 2016 Published by Elsevier Ltd. All rights reserved.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia; [Honeybul, Stephen] Royal Perth Hosp, Dept Neurosurg, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bayram N, 2008, EUR J PEDIATR, V167, P821, DOI 10.1007/s00431-007-0566-0; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Dombrowski KE, 2011, BRIT J NEUROSURG, V25, P249, DOI 10.3109/02688697.2010.544784; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Ho KM, 2007, J CLIN EPIDEMIOL, V60, P746, DOI 10.1016/j.jclinepi.2006.10.017; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2016, J NEUROSURG IN PRESS; Honeybul S, 2015, STROKE, V46, P2695, DOI 10.1161/STROKEAHA.115.010078; Honeybul S, 2014, J NEUROSURG, V120, P1131, DOI 10.3171/2014.1.JNS131559; Honeybul S, 2012, J MED ETHICS, V38, P657, DOI 10.1136/medethics-2012-100672; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoppe DJ, 2009, J BONE JOINT SURG AM, V91A, P2, DOI 10.2106/JBJS.H.01571; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Keller E, 2005, ACTA NEUROCHIR SUPPL, V94, P177; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Majdan M, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0068-9; Nguyen Ha Son, 2011, Childs Nerv Syst, V27, P657, DOI 10.1007/s00381-010-1285-9; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Scozzafava J, 2007, NEUROCRIT CARE, V6, P49, DOI 10.1385/NCC:6:1:49; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Song JW, 2010, PLAST RECONSTR SURG, V126, P2234, DOI 10.1097/PRS.0b013e3181f44abc; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Weber J, 2004, ZBL NEUROCHIR, V65, P135, DOI 10.1055/s-2004-816239; Wendell LC, 2010, NEUROCRIT CARE, V13, P113, DOI 10.1007/s12028-010-9361-2; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd	49	17	17	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2016	47	9					1886	1892		10.1016/j.injury.2016.04.017			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	DU5QG	WOS:000382265800004	27157985				2021-06-18	
J	Wolfe, PL; Lehockey, KA				Wolfe, Penny L.; Lehockey, Katie A.			Neuropsychological Assessment of Driving Capacity	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Disability; handicaps; Elderly; geriatrics; aging; Head injury; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINI-MENTAL-STATE; MONTREAL COGNITIVE ASSESSMENT; CLOSED-HEAD-INJURY; OLDER DRIVERS; DIVIDED ATTENTION; AWARENESS QUESTIONNAIRE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HUNTINGTON DISEASE	Clinicians are increasingly requested to make determinations regarding patients' driving capacity in the context of neurological injury/conditions and a growing cohort of older drivers. The capability to drive safely involves a number of cognitive, physical, and sensorimotor abilities that may be impacted by injury, illness, or substances that influence alertness. Neuropsychological measures are an important component of a multidisciplinary approach for evaluation of driving capacity. Clinicians should become familiar with measures that have the best predictive validity so they may incorporate a patient's neurocognitive strengths and weaknesses in decisions about driving ability.	[Wolfe, Penny L.; Lehockey, Katie A.] MedStar Natl Rehabil Hosp, 102 Irving St NW, Washington, DC 20010 USA	Wolfe, PL (corresponding author), MedStar Natl Rehabil Hosp, 102 Irving St NW, Washington, DC 20010 USA.	penny.wolfe@medstar.net					Adler G, 2005, J SAFETY RES, V36, P399, DOI 10.1016/j.jsr.2005.07.005; Akinwuntan AE, 2006, NEUROREHAB NEURAL RE, V20, P417, DOI 10.1177/1545968306287157; Akinwuntan AE, 2013, TOP STROKE REHABIL, V20, P87, DOI 10.1310/tsr2001-87; Aksan N, 2015, ACCIDENT ANAL PREV, V75, P236, DOI 10.1016/j.aap.2014.12.007; Al Banna M, 2016, J NEUROL NEUROSUR PS, V87, P161, DOI 10.1136/jnnp-2015-310305; American Bar Association Commission on Law and Aging & American Psychological Association, 2008, ASS OLD AD DIM CAP H, P91; Amick MM, 2007, ARCH CLIN NEUROPSYCH, V22, P957, DOI 10.1016/j.acn.2007.07.004; [Anonymous], 2012, TRAFF SAF FACTS 2012; Anstey KJ, 2012, ACCIDENT ANAL PREV, V45, P766, DOI 10.1016/j.aap.2011.10.006; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Ball K., 1998, USEFUL FIELD OF VIEW; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Bowers AR, 2013, ACCIDENT ANAL PREV, V59, P537, DOI 10.1016/j.aap.2013.06.037; Brouwer W H, 1994, Disabil Rehabil, V16, P149; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Colarusso R., 2003, MOTOR FREE VISUAL PE, V3rd edn; Crizzle AM, 2012, ACCIDENT ANAL PREV, V49, P287, DOI 10.1016/j.aap.2012.02.003; Cuenen A, 2015, ACCIDENT ANAL PREV, V77, P12, DOI 10.1016/j.aap.2015.01.011; Cullen N, 2014, BRAIN INJURY, V28, P38, DOI 10.3109/02699052.2013.849005; Cyr AA, 2009, J CLIN EXP NEUROPSYC, V31, P472, DOI 10.1080/13803390802255627; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Devos H, 2014, NEUROLOGY, V82, P956, DOI 10.1212/WNL.0000000000000220; Devos H, 2012, NEUROLOGY, V79, P1975, DOI 10.1212/WNL.0b013e3182735d11; Dobbs B. M., 2005, MED CONDITIONS DRIVI; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; FINKELMAN JM, 1977, J APPL PSYCHOL, V62, P713, DOI 10.1037/0021-9010.62.6.713; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fleming JM, 1996, BRAIN INJURY, V10, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Galski T, 2009, HANDBOOK FOR THE ASSESSMENT OF DRIVING CAPACITY, P187, DOI 10.1016/B978-0-12-631255-3.00010-2; Gfeller JD, 1996, J CLIN PSYCHOL, V52, P191, DOI 10.1002/(SICI)1097-4679(199603)52:2<191::AID-JCLP10>3.0.CO;2-F; GOLPER LAC, 1980, ARCH PHYS MED REHAB, V61, P34; Gorman AA, 2009, NEUROPSYCHOL REV, V19, P186, DOI 10.1007/s11065-009-9095-0; Grace J, 2005, J INT NEUROPSYCH SOC, V11, P766, DOI 10.1017/S135561770505848; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hargrave DD, 2012, NEUROPSYCHOL REHABIL, V22, P489, DOI 10.1080/09602011.2012.662333; Hartje W, 1991, NEUROPSYCHOL REHABIL, V3, P161; Hollis AM, 2015, J AM GERIATR SOC, V63, P988, DOI 10.1111/jgs.13384; Hooper H.E., 1958, HOOPER VISUAL ORG TE; Iverson DJ, 2010, NEUROLOGY, V74, P1316, DOI 10.1212/WNL.0b013e3181da3b0f; Joseph PG, 2014, J AM GERIATR SOC, V62, P1419, DOI 10.1111/jgs.12936; KAWAS C, 1994, ARCH NEUROL-CHICAGO, V51, P901, DOI 10.1001/archneur.1994.00540210073015; Kay LG, 2009, DISABIL REHABIL, V31, P1074, DOI 10.1080/09638280802509553; Kelly E, 2004, DRUG ALCOHOL REV, V23, P319, DOI 10.1080/09595230412331289482; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lundqvist A., 2011, SCIRES, V2, P615, DOI [10.4236/psych.2011.26094, DOI 10.4236/PSYCH.2011.26094]; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; Mathias JL, 2009, INT PSYCHOGERIATR, V21, P637, DOI 10.1017/S1041610209009119; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Mazer BL, 2001, AM J OCCUP THER, V55, P552, DOI 10.5014/ajot.55.5.552; McInerney K, 2016, J INT NEUROPSYCH SOC, V22, P332, DOI 10.1017/S1355617715001253; McKenna P, 2004, BRIT J CLIN PSYCHOL, V43, P325, DOI 10.1348/0144665031752952; McKenna P., 2009, ROOKWOOD DRIVING BAT; McKenna P, 2007, J NEUROPSYCHOL, V1, P85, DOI 10.1348/174866407X180837; Mizenko A.J., 2014, OLDER AM DRIVERS TRA; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Motta K, 2014, J SAFETY RES, V49, P33, DOI 10.1016/j.jsr.2014.02.005; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Mrazik M, 2010, ARCH CLIN NEUROPSYCH, V25, P236, DOI 10.1093/arclin/acq006; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; National Highway Traffic Safety Administration, 2015, TRAFF SAF FACTS 2014; National Highway Traffic Safety Administration, 2016, CLEAR OLD ROAD US SA; National Highway Traffic Safety Administration and American Medical Association, 2010, PHYS GUIDE ASSESSING; Neavyn MJ, 2014, J MED TOXICOL, V10, P269, DOI 10.1007/s13181-014-0393-4; Nouri F M, 1987, Int Disabil Stud, V9, P110; NOURI FM, 1994, STROKE DRIVER SCREEN; Ortoleva C, 2012, J HEAD TRAUMA REHAB, V27, P302, DOI 10.1097/HTR.0b013e3182236299; Oswanski MF, 2007, AM J PHYS MED REHAB, V86, P190, DOI 10.1097/PHM.0b013e31802b7de5; Owens DA, 2007, HUM FACTORS, V49, P1115, DOI 10.1518/001872007X249974; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rapoport MJ, 2013, ACCIDENT ANAL PREV, V61, P288, DOI 10.1016/j.aap.2013.03.030; Regan MA, 2011, ACCIDENT ANAL PREV, V43, P1771, DOI 10.1016/j.aap.2011.04.008; Reger M. A., 2004, NEUROPSYCHOLOGY, P85; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schultheis Maria T, 2014, Curr Phys Med Rehabil Rep, V2, P176; Schultheis MT, 2009, HANDBOOK FOR THE ASSESSMENT OF DRIVING CAPACITY, P117, DOI 10.1016/B978-0-12-631255-3.00007-2; Schultheis MT, 2010, ARCH PHYS MED REHAB, V91, P465, DOI 10.1016/j.apmr.2009.09.026; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sivan AB., 1992, BENTON VISUAL RETENT; Smith A., 1982, SYMBOL DIGIT MODALIT; STERN RA, 1999, BOSTON QUALITATIVE S; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stolwyk RJ, 2006, J CLIN EXP NEUROPSYC, V28, P898, DOI 10.1080/13803390591000909; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Vaughan L, 2015, J AM GERIATR SOC, V63, P1774, DOI 10.1111/jgs.13634; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vrkljan BH, 2011, CAN J OCCUP THER, V78, P80, DOI 10.2182/cjot.2011.78.2.3; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wolfe P. L., 2012, CIVIL CAPACITIES CLI, P121; Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P577, DOI 10.1167/iovs.08-2506; Yale Steven H, 2003, Clin Med Res, V1, P177; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; Zuin D, 2002, EUR J NEUROL, V9, P29, DOI 10.1046/j.1468-1331.2002.00296.x	105	17	17	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2016	31	6					517	529		10.1093/arclin/acw050			13	Psychology, Clinical; Psychology	Psychology	DZ7AU	WOS:000386016000005	27474026	Bronze			2021-06-18	
J	Zhang, MK; Cui, ZW; Cui, H; Cao, Y; Wang, Y; Zhong, CL				Zhang, Mingkun; Cui, Zhenwen; Cui, Hua; Cao, Yang; Wang, Yong; Zhong, Chunlong			Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice	BMC NEUROSCIENCE			English	Article						Astaxanthin; Traumatic brain injury; Aquaporin-4; Na+-K+-2Cl(-) co-transporter-1; Cerebral edema	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; FLUID PERCUSSION INJURY; CULTURED ASTROCYTES; OXIDATIVE STRESS; VASOGENIC EDEMA; RATS; AQUAPORIN-4; COTRANSPORTER-1; MANAGEMENT; APOPTOSIS	Background: Astaxanthin is a carotenoid pigment that possesses potent antioxidative, anti-inflammatory, antitumor, and immunomodulatory activities. Previous studies have demonstrated that astaxanthin displays potential neuroprotective properties for the treatment of central nervous system diseases, such as ischemic brain injury and subarachnoid hemorrhage. This study explored whether astaxanthin is neuroprotective and ameliorates neurological deficits following traumatic brain injury (TBI). Results: Our results showed that, following CCI, treatment with astaxanthin compared to vehicle ameliorated neurologic dysfunctions after day 3 and alleviated cerebral edema and Evans blue extravasation at 24 h (p < 0.05). Astaxanthin treatment decreased AQP4 and NKCC1 mRNA levels in a dose-dependent manner at 24 h. AQP4 and NKCC1 protein expressions in the peri-contusional cortex were significantly reduced by astaxanthin at 24 h (p < 0.05). Furthermore, we also found that bumetanide (BU), an inhibitor of NKCC1, inhibited trauma-induced AQP4 upregulation (p < 0.05). Conclusions: Our data suggest that astaxanthin reduces TBI-related injury in brain tissue by ameliorating AQP4/NKCC1-mediated cerebral edema and that NKCC1 contributes to the upregulation of AQP4 after TBI.	[Zhang, Mingkun; Cui, Hua; Cao, Yang; Wang, Yong; Zhong, Chunlong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Cui, Zhenwen] Qingdao Univ, Affiliated Hosp, Dept Neurosurg, Qingdao 266005, Peoples R China	Wang, Y; Zhong, CL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	wangyong68@163.com; drchunlongzhong@126.com			basic research program of project 973 by the Ministry of Science and Technology of China [2011CB013304]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571184, 81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15140902100, 10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	This research was supported by a basic research program of project 973 by the Ministry of Science and Technology of China (2011CB013304), and by Grants from the National Natural Science Foundation of China (Nos. 81571184, 81070990, 30670719, 30500525), the Shanghai Science and Technology Commission (Nos. 15140902100, 10QH1401700, 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20).	Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Cabrera S, 2012, Q REV BIOL, V87, P89; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chan KC, 2009, J FOOD SCI, V74, pH225, DOI 10.1111/j.1750-3841.2009.01274.x; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Eghwrudjakpor PO, 2010, LIBYAN J MED, V5, DOI [10.4176/091104, 10.3402/ljm.v5i0.4620]; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Gao Y, 2015, J NEUROCHEM, V134, P340, DOI 10.1111/jnc.13123; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Hui H, 2016, NEUROCHEM INT, V94, P23, DOI 10.1016/j.neuint.2016.02.002; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Khan SK, 2010, THROMB RES, V126, P299, DOI 10.1016/j.thromres.2010.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Liu XB, 2009, FORUM NUTR, V61, P129, DOI 10.1159/000212745; Lopez-Rodriguez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128782; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Pasantes-Morales H, 2010, NEUROSCIENCE, V168, P871, DOI 10.1016/j.neuroscience.2009.11.074; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Stewart JS, 2008, FOOD CHEM TOXICOL, V46, P3030, DOI 10.1016/j.fct.2008.05.038; Tollner K, 2015, EUR J PHARMACOL, V746, P167, DOI 10.1016/j.ejphar.2014.11.019; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730; Zheng D, 2014, NEUROPHARMACOLOGY, V84, P13, DOI 10.1016/j.neuropharm.2014.04.013; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	36	17	19	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	AUG 31	2016	17								60	10.1186/s12868-016-0295-2			9	Neurosciences	Neurosciences & Neurology	DW0PD	WOS:000383341900002	27581370	DOAJ Gold, Green Published			2021-06-18	
J	Shishido, H; Kishimoto, Y; Kawai, N; Toyota, Y; Ueno, M; Kubota, T; Kirino, Y; Tamiya, T				Shishido, Hajime; Kishimoto, Yasushi; Kawai, Nobuyuki; Toyota, Yasunori; Ueno, Masaki; Kubota, Takashi; Kirino, Yutaka; Tamiya, Takashi			Traumatic brain injury accelerates amyloid-beta deposition and impairs spatial learning in the triple-transgenic mouse model of Alzheimer's disease	NEUROSCIENCE LETTERS			English	Article						Alzheimer's disease; Amyloid-beta protein; Cognitive impairment; Traumatic brain injury; Triple-transgenic AD-model mouse	CLOSED-HEAD INJURY; MICE; PROTEIN; RISK; ENCEPHALOPATHY; ACCUMULATION; DEMENTIA; RATS	Several pathological and epidemiological studies have demonstrated a possible relationship between traumatic brain injury (TBI) and Alzheimer's disease (AD). However, the exact contribution of TBI to AD onset and progression is unclear. Hence, we examined AD-related histopathological changes and cognitive impairment after TBI in triple transgenic (3 xTg)-AD model mice. Five- to seven-month-old 3 xTg-AD model mice were subjected to either TBI by the weight-drop method or a sham treatment. In the 3 xTg-AD mice subjected to TBI, the spatial learning was not significantly different 7 days after TBI compared to that of the sham-treated 3xTg-AD mice. However, 28 days after TBI, the 3 xTg-AD mice exhibited significantly lower spatial learning than the sham-treated 3xTg-AD mice. Correspondingly, while a few amyloid-beta (A beta) plaques were observed in both sham-treated and TBI-treated 3 xTg-AD mouse hippocampus 7 days after TBI, the A beta deposition was significantly greater in 3 xTg-AD mice 28 days after TBI. Thus, we demonstrated that TBI induced a significant increase in hippocampal A beta deposition 28 days after TBI compared to that of the control animals, which was associated with worse spatial learning ability in 3 xTg-AD mice. The present study suggests that TBI could be a risk factor for accelerated AD progression, particularly when genetic and hereditary predispositions are involved. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Shishido, Hajime; Toyota, Yasunori; Tamiya, Takashi] Kagawa Univ, Fac Med, Dept Neurol Surg, Takamatsu, Kagawa, Japan; [Kishimoto, Yasushi; Kubota, Takashi; Kirino, Yutaka] Tokushima Bunri Univ, Kagawa Sch Pharmaceut Sci, Biophys Lab, Tokushima, Japan; [Kawai, Nobuyuki] Kagawa Gen Rehabil Hosp, Dept Neurol Surg, 1114 Tamura Cho, Takamatsu, Kagawa 7618057, Japan; [Ueno, Masaki] Kagawa Univ, Fac Med, Dept Inflammat Pathol, Takamatsu, Kagawa, Japan	Kawai, N (corresponding author), Kagawa Gen Rehabil Hosp, Dept Neurol Surg, 1114 Tamura Cho, Takamatsu, Kagawa 7618057, Japan.; Kishimoto, Y (corresponding author), Tokushima Bunri Univ, Kagawa Sch Pharmaceut Sci, Dept Biophys, 1314-1 Shido, Sanuki, Kagawa 7612193, Japan.	kishimot@kph.bunri-u.ac.jp; nobu@kagawa-reha.net	Kishimoto, Yasushi/AAH-4923-2021	Kishimoto, Yasushi/0000-0002-4828-1249	Tokushima Bunri University for Educational Reform and Collaborative Research [TBU2012-2-2];  [24590133];  [15K07910];  [26462161]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26462161] Funding Source: KAKEN	This work was supported by Grants-in-Aid for Scientific Research (C) (grant No. 24590133, 15K07910 to Y Kishimoto and grant No. 26462161 to N Kawai), and a grant from Tokushima Bunri University for Educational Reform and Collaborative Research (No. TBU2012-2-2 to Y Kishimoto).	Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gimenez-Llort L, 2007, NEUROSCI BIOBEHAV R, V31, P125, DOI 10.1016/j.neubiorev.2006.07.007; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kishimoto Y., 2016, DATA BRIEF; Kishimoto Y, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00134; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mastrangelo MA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-81; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Su DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050172; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	29	17	17	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 26	2016	629						62	67		10.1016/j.neulet.2016.06.066			6	Neurosciences	Neurosciences & Neurology	DU7QF	WOS:000382409000012	27373531				2021-06-18	
J	Leung, A; Shukla, S; Yang, E; Canlas, B; Kadokana, M; Heald, J; Davani, A; Song, D; Lin, L; Polston, G; Tsai, A; Lee, R				Leung, Albert; Shukla, Shivshil; Yang, Eric; Canlas, Bryan; Kadokana, Mawj; Heald, Jason; Davani, Ariea; Song, David; Lin, Lisa; Polston, Greg; Tsai, Alice; Lee, Roland			Diminished supraspinal pain modulation in patients with mild traumatic brain injury	MOLECULAR PAIN			English	Article						Traumatic brain injury; chronic posttraumatic headaches; pain; functional magnetic resonance imaging; supraspinal pain processing; mild traumatic brain injury; resting state functional connectivity	TRANSCRANIAL MAGNETIC STIMULATION; POSTTRAUMATIC-STRESS-DISORDER; NEEDLE COMBINATION; THERMAL PAIN; MILITARY; HEADACHE; BLAST; MECHANISMS; VETERANS; ELECTROACUPUNCTURE	Background: Chronic pain conditions are highly prevalent in patients with mild traumatic brain injury. Supraspinal diffuse axonal injury is known to dissociate brain functional connectivity in these patients. The effect of this dissociated state on supraspinal pain network is largely unknown. A functional magnetic resonance imaging study was conducted to compare the supraspinal pain network in patients with mild traumatic brain injury to the gender and age-matched healthy controls with the hypothesis that the functional connectivities of the medial prefrontal cortices, a supraspinal pain modulatory region to other pain-related sensory discriminatory and affective regions in the mild traumatic brain injury subjects are significantly reduced in comparison to healthy controls. Results: The mild traumatic brain injury group (N = 15) demonstrated significantly (P < 0.01, cluster threshold > 150 voxels) less activities in the thalamus, pons, anterior cingulate cortex, insula, dorsolateral prefrontal cortex, and medial prefrontal cortices than the healthy control group (N = 15). Granger Causality Analyses (GCA) indicated while the left medial prefrontal cortices of the healthy control group cast a noticeable degree of outward (to affect) causality inference to multiple pain processing related regions, this outward inference pattern was not observed in the mild traumatic brain injury group. On the other hand, only patients' bilateral anterior cingulate cortex received multiple inward (to be affected) causality inferences from regions including the primary and secondary somatosensory cortices and the inferior parietal lobe. Resting state functional connectivity analyses indicated that the medial prefrontal cortices of the mild traumatic brain injury group demonstrated a significantly (P < 0.01, F = 3.6, cluster size > 150 voxels) higher degree of functional connectivity to the inferior parietal lobe, premotor and secondary somatosensory cortex than the controls. Conversely, the anterior cingulate cortex of the healthy group demonstrated significantly (P < 0.01, F = 3.84, cluster size > 150 voxels) less degree of functional connectivities to the inferior parietal lobe and secondary somatosensory cortex than their mild traumatic brain injury counterparts. Conclusions: In short, the current study demonstrates that patients with mild traumatic brain injury and headaches appear to have an altered state of supraspinal modulatory and affective functions related to pain perception.	[Leung, Albert; Shukla, Shivshil; Polston, Greg] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92161 USA; [Leung, Albert; Shukla, Shivshil; Song, David; Lin, Lisa; Polston, Greg; Tsai, Alice; Lee, Roland] Veteran Adm San Diego Healthcare Syst, San Diego, CA USA; [Yang, Eric; Canlas, Bryan; Kadokana, Mawj] Univ Calif San Diego, San Diego, CA 92103 USA; [Heald, Jason] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Davani, Ariea] St Louis Sch Med, St Louis, MO USA; [Song, David] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Lee, Roland] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA	Leung, A (corresponding author), Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92161 USA.	ayleung@ucsd.edu			VA Rehabilitation and Research Development Award	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors thank the funding support of VA Rehabilitation and Research Development Award.	Abler B, 2006, MAGN RESON IMAGING, V24, P181, DOI 10.1016/j.mri.2005.10.022; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Borsook D, 2012, BRAIN, V135, P320, DOI 10.1093/brain/awr271; Bouwense SAW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055460; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Esposito F, 2005, NEUROIMAGE, V25, P193, DOI 10.1016/j.neuroimage.2004.10.042; Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; Goebel R, 2006, HUM BRAIN MAPP, V27, P392, DOI 10.1002/hbm.20249; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Hehar H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139842; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Joubert Jacques, 2005, Aust Fam Physician, V34, P621; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Kriegeskorte N, 2001, NEUROIMAGE, V14, P329, DOI 10.1006/nimg.2001.0831; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Leung A, 2005, J ALTERN COMPLEM MED, V11, P653, DOI 10.1089/acm.2005.11.653; Leung A, 2014, HEADACHE, V54, P57; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; Leung A, 2006, NEUROIMAGE, V31, P504; Leung A, 2016, NEUROMODULATION, V19, P133, DOI 10.1111/ner.12364; Leung A, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-23; Leung A, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-18; Leung A, 2007, MED ACUPUNCT, V19, P191, DOI 10.1089/acu.2007.0564; Leung AY, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-18; Leung AY, 2005, PAIN, V116, P26, DOI 10.1016/j.pain.2005.03.026; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Matos SC, 2015, J NEUROSCI, V35, P13244, DOI 10.1523/JNEUROSCI.0799-15.2015; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Moulton EA, 2012, J NEUROSCI, V32, P6024, DOI 10.1523/JNEUROSCI.0006-12.2012; Neugebauer V, 2009, BRAIN RES REV, V60, P226, DOI 10.1016/j.brainresrev.2008.12.014; Oshiro Y, 2007, J NEUROSCI, V27, P3388, DOI 10.1523/JNEUROSCI.5128-06.2007; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schmidt-Wilcke T, 2014, NEUROIMAGE-CLIN, V6, P252, DOI 10.1016/j.nicl.2014.09.007; Schmidt-Wilcke T, 2014, PAIN MED, V15, P1346, DOI 10.1111/pme.12460; Seifert F, 2010, NEUROSCIENCE, V170, P670, DOI 10.1016/j.neuroscience.2010.07.024; Shukla S, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-45; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Tracey I, 2005, CURR OPIN NEUROBIOL, V15, P478, DOI 10.1016/j.conb.2005.06.010; Tracey Irene, 2007, Curr Opin Support Palliat Care, V1, P109, DOI 10.1097/SPC.0b013e3282efc58b; Wang S., 2012, NONGCUN JISHU JINGJI, V6, P4, DOI DOI 10.1186/1752-1505-6-4; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	65	17	17	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		1744-8069		MOL PAIN	Mol. Pain	AUG 16	2016	12								1744806916662661	10.1177/1744806916662661			13	Neurosciences	Neurosciences & Neurology	EA2SJ	WOS:000386444700001	27531671	DOAJ Gold, Green Published			2021-06-18	
J	Gooijers, J; Chalavi, S; Beeckmans, K; Michiels, K; Lafosse, C; Sunaert, S; Swinnen, SP				Gooijers, Jolien; Chalavi, Sima; Beeckmans, Kurt; Michiels, Karla; Lafosse, Christophe; Sunaert, Stefan; Swinnen, Stephan P.			Subcortical Volume Loss in the Thalamus, Putamen, and Pallidum, Induced by Traumatic Brain Injury, Is Associated With Motor Performance Deficits	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; gray matter; cortical and subcortical volume; global volume; bimanual motor performance	WHITE-MATTER INTEGRITY; BIMANUAL COORDINATION; LONGITUDINAL CHANGES; BEHAVIOR RELATIONSHIPS; CORTICAL THICKNESS; DIFFUSION-TENSOR; POSTURAL CONTROL; QUANTIFIED MRI; ATROPHY; NETWORK	Background. Traumatic brain injury (TBI) has been associated with altered microstructural organization of white matter (WM) and reduced gray matter (GM). Although disrupted WM organization has been linked to poorer motor performance, the predictive value of GM atrophy for motor impairments in TBI remains unclear. Objective. Here, we investigated TBI-induced GM volumetric abnormalities and uniquely examined their relationship with bimanual motor impairments. Methods. 22 moderate to severe TBI patients (mean age = 25.9 years, standard deviation [SD] = 4.9 years; time since injury = 4.7 years, SD = 3.7 years) and 27 age- and gender-matched controls (mean age = 23.4 years; SD = 3.8 years) completed bimanual tasks and a structural magnetic resonance imaging scan. Cortical and subcortical GM volumes were extracted and compared between groups using FreeSurfer. The association between bimanual performance and GM volumetric measures was investigated using partial correlations. Results. Relative to controls, patients performed significantly poorer on the bimanual tasks and demonstrated significantly smaller total GM as well as overall and regional subcortical GM. However, the groups did not show significant differences in regional cortical GM volume. The majority of the results remained significant even after excluding TBI patients with focal lesions, suggesting that TBI-induced volume reductions were predominantly caused by diffuse injury. Importantly, atrophy of the thalamus, putamen, and pallidum correlated significantly with poorer bimanual performance within the TBI group. Conclusions. Our results reveal that GM atrophy is associated with motor impairments in TBI, providing new insights into the etiology of motor control impairments following brain trauma.	[Gooijers, Jolien; Chalavi, Sima; Swinnen, Stephan P.] Katholieke Univ Leuven, Movement Control & Neuroplast Res Grp, Biomed Sci Grp, Tervuursevest 101, B-3001 Leuven, Belgium; [Beeckmans, Kurt] Ctr Epilepsy & Acquired Brain Injury CEPOS, Duffel, Belgium; [Michiels, Karla] Katholieke Univ Leuven Hosp, Dept Phys Med & Rehabil, Campus Pellenberg, Leuven, Belgium; [Lafosse, Christophe] Rehabil Hosp RevArte, Edegem, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Grp Biomed Sci, Med Imaging Ctr, Leuven, Belgium; [Swinnen, Stephan P.] Leuven Res Inst Neurosci & Dis LIND, Leuven, Belgium	Gooijers, J (corresponding author), Katholieke Univ Leuven, Movement Control & Neuroplast Res Grp, Biomed Sci Grp, Tervuursevest 101, B-3001 Leuven, Belgium.	Jolien.gooijers@faber.kuleuven.be	Gooijers, Jolien/AAH-9202-2020	Chalavi, Sima/0000-0002-2339-8168; Gooijers, Jolien/0000-0002-7569-7223	Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P7/11]; Research Fund KU LeuvenKU Leuven [OT/11/071]; FWO VlaanderenFWO [G.0721.12, G.A114.11]; KU Leuven Research FundKU Leuven [PDMK/14/165]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Interuniversity Attraction Poles program of the Belgian federal government (P7/11). Additional support was provided by the Research Fund KU Leuven (OT/11/071) and FWO Vlaanderen (G.0721.12, G.A114.11). JG is funded by the KU Leuven Research Fund (PDMK/14/165).	Aramaki Y, 2006, CEREB CORTEX, V16, P1338, DOI 10.1093/cercor/bhj075; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Debaere F, 2004, NEUROPSYCHOLOGIA, V42, P855, DOI 10.1016/j.neuropsychologia.2003.12.010; DESROSIERS J, 1995, DISABIL REHABIL, V17, P217, DOI 10.3109/09638289509166638; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gooijers J, 2014, NEUROSCI BIOBEHAV R, V43, P1, DOI 10.1016/j.neubiorev.2014.03.008; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Merkley TL, 2013, J INT NEUROPSYCH SOC, V19, P899, DOI 10.1017/S135561771300074X; Nedelec B, 2011, J HAND THER, V24, P31, DOI 10.1016/j.jht.2010.09.001; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; Ng THB, 2013, BEHAV BRAIN RES, V247, P182, DOI 10.1016/j.bbr.2013.03.020; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Penta M, 1998, ARCH PHYS MED REHAB, V79, P1038, DOI 10.1016/S0003-9993(98)90167-8; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Serbruyns L, 2015, CORTEX, V65, P128, DOI 10.1016/j.cortex.2015.01.003; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wannier T, 2002, NEUROREPORT, V13, P143, DOI 10.1097/00001756-200201210-00033; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wenderoth N, 2006, NEUROIMAGE, V31, P264, DOI 10.1016/j.neuroimage.2005.11.033; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wonderlick JS, 2009, NEUROIMAGE, V44, P1324, DOI 10.1016/j.neuroimage.2008.10.037; Wu T, 2010, BRAIN, V133, P2394, DOI 10.1093/brain/awq151; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	51	17	17	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	AUG	2016	30	7					603	614		10.1177/1545968315613448			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DS7BN	WOS:000380937600001	26498433	Bronze			2021-06-18	
J	Reyes-Mendoza, J; Morales, T				Reyes-Mendoza, Julio; Morales, Teresa			POST-TREATMENT WITH PROLACTIN PROTECTS HIPPOCAMPAL CA1 NEURONS OF THE OVARIECTOMIZED FEMALE RAT AGAINST KAINIC ACID-INDUCED NEURODEGENERATION	NEUROSCIENCE			English	Article						hippocampus; excitotoxicity; prolactin; females; memory; neurogenesis	ENDOTHELIAL GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; INDUCED EXPRESSION; MOLECULAR-MECHANISMS; OBJECT RECOGNITION; DORSAL HIPPOCAMPUS; GLIAL RESPONSES; DENTATE GYRUS; NEUROGENESIS	Kainic acid (KA) is a glutamate agonist widely used in studies of neurodegeneration due to its ability to induce excitotoxic damage in the rodent brain. Previously, we reported that pre-treatment with prolactin (PRL) prevents the neuron loss induced by KA administration in CA1, CA3 and CA4 of the hippocampus of the female rat. Here, we investigated if PRL has a neuroprotective effect in the dorsal hippocampus when it is administered after KA. For this, 100 ng of KA or 0.9% saline was administered intracere-broventricularly (ICV) to ovariectomized female rats. One hour later, they received subcutaneous PRL (103 mu g/day for 7 days) or saline through an osmotic minipump. Also, to determine the hippocampal neurogenesis rate, the rats were administered bromodeoxyuridine along with the PRL treatment. Immunostaining for NeuN revealed that neuronal loss is lower in the CA1 of PRL-treated rats compared with the untreated group, but PRL did not confer any protection in the CA3 and CA4 subfields. Furthermore, PRL prevented the KA-induced cognitive deficit measured as a better performance in the novel object recognition test. The PRL treatment did not modify the neurogenesis rate. These data indicate that post-treatment with PRL confers differential neuroprotection against KA-induced neuronal loss in hippocampal subfield CA1, which correlates with a more mild cognitive deficit compared with the untreated control group. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Reyes-Mendoza, Julio; Morales, Teresa] Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Celular & Mol, Queretaro 76230, Qro, Mexico	Morales, T (corresponding author), Univ Nacl Autonoma Mexico, Inst Neurobiol, Blvd Juriquilla 3001, Queretaro 76230, Qro, Mexico.	marter@unam.mx	Morales, Teresa/I-2941-2019	Morales, Teresa/0000-0003-1539-2070	UNAM-DGAPA-PAPIITPrograma de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IN202812, 202315]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [128090, 298998]	This study was supported by funds from UNAM-DGAPA-PAPIIT IN202812 and 202315, and CONACYT 128090 grants. We thank Dr. Dorothy Pless for grammatical review, and Nydia Hernandez (digital imaging), Eugenia Ramos, and Martin Garcia, and Alejandra Castilla (Animal Care) for technical assistance. JRM received CONACYT scholarship No. 298998 as part of his master studies (Maestria en Ciencias Neurobiologia, UNAM).	Alipanahzadeh H, 2014, CELL J, V16, P315; Arnold E, 2014, J NEUROSCI, V34, P1868, DOI 10.1523/JNEUROSCI.2452-13.2014; Bakowska JC, 1997, J COMP NEUROL, V386, P161, DOI 10.1002/(SICI)1096-9861(19970922)386:2<161::AID-CNE1>3.0.CO;2-#; BOLZAN AD, 1995, EXP GERONTOL, V30, P169, DOI 10.1016/0531-5565(94)00053-0; Bolzan AD, 1997, EXP GERONTOL, V32, P297, DOI 10.1016/S0531-5565(96)00101-5; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Cabrera V, 2009, NEUROSCI LETT, V461, P136, DOI 10.1016/j.neulet.2009.06.017; Chen ZG, 2005, J NEUROBIOL, V62, P207, DOI 10.1002/neu.20099; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; de Lima MN, 2005, EXP GERONTOL, V40, P506, DOI 10.1016/j.exger.2005.03.004; DEVITO WJ, 1992, ENDOCRINOLOGY, V130, P2549, DOI 10.1210/en.130.5.2549; DEVITO WJ, 1995, J CELL BIOCHEM, V57, P290, DOI 10.1002/jcb.240570213; DEVITO WJ, 1995, MOL CELL ENDOCRINOL, V108, P125, DOI 10.1016/0303-7207(94)03465-6; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Franssen RA, 2012, BRAIN RES, V1454, P80, DOI 10.1016/j.brainres.2012.03.028; Freeman ME, 2000, PHYSIOL REV, V80, P1523; Frye CA, 2011, DEV NEUROBIOL, V71, P142, DOI 10.1002/dneu.20832; Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P949, DOI 10.1097/01.WCB.0000077641.41248.EA; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kinoshita Y, 2012, EPILEPSIA, V53, P125, DOI 10.1111/j.1528-1167.2012.03483.x; Kochendoerfer SK, 2003, J ENDOCRINOL, V178, P265, DOI 10.1677/joe.0.1780265; LEFF M, 1996, ENDOCRINOLOGY, V144, P2102; Levesque M, 2013, NEUROSCI BIOBEHAV R, V37, P2887, DOI 10.1016/j.neubiorev.2013.10.011; Mala G, 2014, PLOS ONE, V9; Matsuzaki H, 2001, FASEB J, V15, P1218; Moderscheim TAE, 2007, NEUROSCIENCE, V145, P963, DOI 10.1016/j.neuroscience.2006.12.053; Morales T, 2014, NEUROSCIENCE, V258, P211, DOI 10.1016/j.neuroscience.2013.11.015; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; Olney J W, 1986, Adv Neurol, V44, P857; Palomero-Gallagher N, 2003, J COMP NEUROL, V459, P468, DOI 10.1002/cne.10638; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; Pearson JN, 2014, EPILEPSY RES, V108, P1032, DOI 10.1016/j.eplepsyres.2014.04.003; Ploszaj T, 1998, APOPTOSIS, V3, P295, DOI 10.1023/A:1009669427662; Rampon C, 2000, NAT NEUROSCI, V3, P238; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; SIGNORELLA AP, 1984, ANAL BIOCHEM, V136, P372, DOI 10.1016/0003-2697(84)90232-X; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; Sugino N, 1998, BIOL REPROD, V59, P599, DOI 10.1095/biolreprod59.3.599; SWANSON LW, 1998, BRAIN MAPS STRUCTURE; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Tejadilla D, 2010, NEUROSCIENCE, V169, P1178, DOI 10.1016/j.neuroscience.2010.05.074; Too CKL, 1998, MOL CELL ENDOCRINOL, V137, P187, DOI 10.1016/S0303-7207(97)00240-2; Torner L, 2013, BEHAV BRAIN RES, V252, P32, DOI 10.1016/j.bbr.2013.05.031; Torner L, 2009, J NEUROSCI, V29, P1826, DOI 10.1523/JNEUROSCI.3178-08.2009; Vanoye-Carlo A, 2008, HORM BEHAV, V53, P112, DOI 10.1016/j.yhbeh.2007.09.004; Veliskova J, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb01553.x; Walker TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044371; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang XM, 2011, CURR NEUROPHARMACOL, V9, P388, DOI 10.2174/157015911795596540; Zheng X, 2010, J BIOMED BIOTECHNOL, V2011, P1	60	17	17	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 22	2016	328						58	68		10.1016/j.neuroscience.2016.04.030			11	Neurosciences	Neurosciences & Neurology	DM5JP	WOS:000376385100007	27126559				2021-06-18	
J	Hong, CT; Huang, YH; Liu, HY; Chiou, HY; Chan, L; Chien, LN				Hong, Chien Tai; Huang, Yao Hsien; Liu, Hung Yi; Chiou, Hung-Yi; Chan, Lung; Chien, Li-Nien			Newly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort Study	SCIENTIFIC REPORTS			English	Article							RED-BLOOD-CELLS; PROPENSITY-SCORE; IRON CONTENT; POTENTIAL BIOMARKER; ALPHA-SYNUCLEIN; BRAIN; ERYTHROCYTE; NEUROPROTECTION; SYMPTOMS; PREMOTOR	Anemia and low hemoglobin have been identified to increase Parkinson's disease (PD) risk. This population-based cohort study investigated PD risk in newly diagnosed anemic patients by using data from the Taiwan National Health Insurance Research Database. All newly diagnosed anemic patients (n = 86,334) without a history of stroke, neurodegenerative diseases, traumatic brain injury, major operations, or blood loss diseases were enrolled. A cohort of nonanemic controls, 1: 1 matched with anemic patients on the basis of the demographics and pre-existing medical conditions, was also included. Competing risk analysis was used to evaluate PD risk in anemic patients compared with that in their matched controls. The adjusted hazard ratio (aHR) of PD risk in the anemic patients was 1.36 (95% confidence interval [CI]: 1.22-1.52, p < 0.001). Iron deficiency anemia (IDA) patients tended to exhibit a higher PD risk (aHR: 1.49; 95% CI: 1.24-1.79, p < 0.001). Furthermore, Iron supplement did not significantly affect the PD risk: the aHRs for PD risk were 1.32 (95% CI: 1.07-1.63, p < 0.01) and 1.86 (95% CI: 1.46-2.35, p < 0.001) in IDA patients with and without iron supplementation, respectively. The population-based cohort study indicated newly diagnosed anemia increases PD risk.	[Hong, Chien Tai; Huang, Yao Hsien; Chan, Lung] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, Taipei, Taiwan; [Hong, Chien Tai; Huang, Yao Hsien; Chan, Lung] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan; [Liu, Hung Yi; Chiou, Hung-Yi] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Publ Hlth, Taipei, Taiwan; [Chien, Li-Nien] Taipei Med Univ, Coll Management, Sch Hlth Care Adm, Taipei, Taiwan	Chan, L (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, Taipei, Taiwan.; Chan, L (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan.; Chien, LN (corresponding author), Taipei Med Univ, Coll Management, Sch Hlth Care Adm, Taipei, Taiwan.	cjustinmd@gmail.com; lnchien@tmu.edu.tw	Chan, Lung/AAI-6349-2020; Chan, Lung/AAM-3231-2021	Chan, Lung/0000-0001-5795-4460; Chiou, Hung Yi/0000-0002-4545-9697	Health and Clinical Data Research Center, Taipei Medical University; Ministry of Health and WelfareMinistry of Health, Labour and Welfare, Japan [MOHW104-TDU-B-212-113001]; Taipei Medical University [TMU101-AE1-B57]	We appreciate the support from the Health and Clinical Data Research Center, Taipei Medical University. This study was also supported by grants from the Ministry of Health and Welfare (MOHW104-TDU-B-212-113001) and Taipei Medical University (TMU101-AE1-B57).	Adler CH, 2011, INT J NEUROSCI, V121, P3, DOI 10.3109/00207454.2011.620192; Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Barbour R, 2008, NEURODEGENER DIS, V5, P55, DOI 10.1159/000112832; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2007, ACTA NEUROPATHOL, V113, P421, DOI 10.1007/s00401-007-0193-x; Cabantchik ZI, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00167; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fraser, 2010, PROPENSITY SCORE ANA; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Goldman JG, 2014, CURR OPIN NEUROL, V27, P434, DOI 10.1097/WCO.0000000000000112; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; JOHANNSEN P, 1991, J NEUROL NEUROSUR PS, V54, P679, DOI 10.1136/jnnp.54.8.679; Kalia LV, 2015, MOVEMENT DISORD, V30, P1442, DOI 10.1002/mds.26354; KANEKO JJ, 1980, CLIN BIOCH DOMESTIC; Kieburtz K, 2013, MOVEMENT DISORD, V28, P8, DOI 10.1002/mds.25150; KILINC A, 1988, NEUROSCI LETT, V87, P307, DOI 10.1016/0304-3940(88)90467-3; Lang F, 2014, ANTIOXID REDOX SIGN, V21, P138, DOI 10.1089/ars.2013.5747; Lee YC, 2013, NEUROLOGY, V81, P410, DOI 10.1212/WNL.0b013e31829d873c; Martin WRW, 2008, NEUROLOGY, V70, P1411, DOI 10.1212/01.wnl.0000286384.31050.b5; Miyake Y, 2011, J NEUROL SCI, V306, P98, DOI 10.1016/j.jns.2011.03.035; Nelson C, 1997, J NUTR, V127, P2282; Noyce AJ, 2016, J NEUROL NEUROSUR PS, V87, P871, DOI 10.1136/jnnp-2015-311890; Olanow CW, 2008, ANN NEUROL, V64, pS101, DOI 10.1002/ana.21461; Pearce N, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i969; Pichler I, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001462; Pont-Sunyer C, 2015, MOVEMENT DISORD, V30, P229, DOI 10.1002/mds.26077; Pretorius E, 2014, AGING-US, V6, P788, DOI 10.18632/aging.100695; Rees K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008454.pub2; Roberts KM, 2013, IUBMB LIFE, V65, P350, DOI 10.1002/iub.1144; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Savica R, 2009, NEUROLOGY, V73, P1381, DOI 10.1212/WNL.0b013e3181bd80c1; Savica R, 2010, ARCH NEUROL-CHICAGO, V67, P798, DOI 10.1001/archneurol.2010.135; Schapira AHV, 2008, EUR J NEUROL, V15, P5, DOI 10.1111/j.1468-1331.2008.02055.x; Schapira AHV, 2014, LANCET, V384, P545, DOI 10.1016/S0140-6736(14)61010-2; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; URAKAMI K, 1992, JPN J PSYCHIAT NEUR, V46, P933; Wang XM, 2015, NEUROSCI LETT, V599, P115, DOI 10.1016/j.neulet.2015.05.030; Zhou BQ, 2011, BIOMETRICS, V67, P661, DOI 10.1111/j.1541-0420.2010.01493.x	42	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 14	2016	6								29651	10.1038/srep29651			7	Multidisciplinary Sciences	Science & Technology - Other Topics	DR0CX	WOS:000379576700001	27412825	DOAJ Gold, Green Published			2021-06-18	
J	Marceau, EM; Lunn, J; Berry, J; Kelly, PJ; Solowij, N				Marceau, Ely M.; Lunn, Jo; Berry, Jamie; Kelly, Peter J.; Solowij, Nadia			The Montreal Cognitive Assessment (MoCA) is Sensitive to Head Injury and Cognitive Impairment in a Residential Alcohol and Other Drug Therapeutic Community	JOURNAL OF SUBSTANCE ABUSE TREATMENT			English	Article						Substance misuse; Cognitive impairment; Therapeutic community; Residential treatment; Cognitive screening; Head injury	TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSE TREATMENT; PSYCHOLOGICAL DISTRESS; USE DISORDERS; NEUROPSYCHOLOGICAL CONSEQUENCES; EXECUTIVE FUNCTIONS; DEPENDENCE SCALE; ADDICTION; USERS; REHABILITATION	Introduction: Retaining clients in residential alcohol and other drug (AOD) treatment is difficult and cognitive impairment has been identified as a significant predictor of treatment dropout. The application of extensive screening for cognitive impairment is cost-prohibitive for most AOD treatment services. The current study aimed to explore cognitive functioning and impairment-associated factors in a typical sample of residential AOD clients using a free brief screening tool that could be utilised by front-line AOD services. Methods: Residents of an AOD therapeutic community (n = 128) and a non-substance using control group (n = 37) were administered a brief cognitive screening measure, the Montreal Cognitive Assessment (MoCA). MoCA total and domain scores were compared between these groups and within the AOD group examined in association with primary substance of misuse, severity of dependence, gender, psychological distress, and history of head injury. Results: Almost half (43.8%) of the AOD sample were identified as cognitively impaired, compared to 162% of the control group. Furthermore, 67.2% of the AOD sample had sustained head injuries and 50% of the sample required hospitalization for head injury. History of head injury was a significant determinant of cognitive impairment, and associated with greater levels of psychological distress. Conclusions: There are high rates of inter-related cognitive impairment, head injuries, and psychological distress among clients in residential AOD treatment Routine screening of clients at intake for cognitive impairment by means of a brief screening measure such as the MoCA, in combination with the assessment of history of head injuries and comorbid psychological disorders, could inform treatment modifications or adjunct interventions to increase retention and improve long-term outcomes. (C) 2016 Elsevier Inc. All rights reserved.	[Marceau, Ely M.; Kelly, Peter J.; Solowij, Nadia] Univ Wollongong, Sch Psychol, Ctr Hlth Initiat, Northfields Ave, Wollongong, NSW 2522, Australia; [Marceau, Ely M.; Kelly, Peter J.; Solowij, Nadia] Univ Wollongong, Illawarra Hlth & Med Res Inst, Northfields Ave, Wollongong, NSW 2522, Australia; [Lunn, Jo] We Help Ourselves WHOs, Bldg 128,Church St, Lilyfield, NSW 2040, Australia; [Berry, Jamie] Adv Neuropsychol Treatment Serv, POB 4070, Strathfield South, NSW 2136, Australia	Solowij, N (corresponding author), Univ Wollongong, Sch Psychol, Northfields Ave, Wollongong, NSW 2522, Australia.	nadia@uow.edu.au	Marceau, Ely/AAG-2399-2019	Solowij, Nadia/0000-0002-5222-5637; Kelly, Peter/0000-0003-0500-1865; Berry, Jamie/0000-0001-6560-2457			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; *AUSTR I HLTH WELF, 2005, NAT DRUG STRAT HOUS; Bates ME, 2013, NEUROPSYCHOL REV, V23, P27, DOI 10.1007/s11065-013-9228-3; Bernstein IH, 2011, CLIN NEUROPSYCHOL, V25, P119, DOI 10.1080/13854046.2010.533196; Brorson HH, 2013, CLIN PSYCHOL REV, V33, P1010, DOI 10.1016/j.cpr.2013.07.007; Broyd SJ, 2016, BIOL PSYCHIAT, V79, P557, DOI 10.1016/j.biopsych.2015.12.002; Caplan JP, 2007, NEUROPSYCHOL REV, V17, P363, DOI 10.1007/s11065-007-9037-7; Copersino ML, 2012, AM J DRUG ALCOHOL AB, V38, P246, DOI 10.3109/00952990.2012.670866; Copersino ML, 2009, EXP CLIN PSYCHOPHARM, V17, P337, DOI 10.1037/a0017260; Darke S, 2012, DRUG ALCOHOL REV, V31, P64, DOI 10.1111/j.1465-3362.2011.00298.x; Deane FP, 2012, J STUD ALCOHOL DRUGS, V73, P216, DOI 10.15288/jsad.2012.73.216; Duro D, 2010, J NEUROL, V257, P728, DOI 10.1007/s00415-009-5399-5; Ersche KD, 2007, NEUROPSYCHOL REV, V17, P317, DOI 10.1007/s11065-007-9033-y; Fals-Stewart W, 2010, EXP CLIN PSYCHOPHARM, V18, P87, DOI 10.1037/a0018058; FALSSTEWART W, 1992, J CLIN PSYCHOL, V48, P539, DOI 10.1002/1097-4679(199207)48:4<539::AID-JCLP2270480416>3.0.CO;2-I; FALSSTEWART W, 1994, PSYCHOL ADDICT BEHAV, V8, P179, DOI 10.1037/0893-164X.8.3.179; Freitas S, 2012, J INT NEUROPSYCH SOC, V18, P242, DOI 10.1017/S1355617711001573; George J, 2010, DRUG ALCOHOL REV, V29, P243, DOI 10.1111/j.1465-3362.2009.00159.x; Gierski F, 2013, ALCOHOL CLIN EXP RES, V37, pE356, DOI 10.1111/j.1530-0277.2012.01903.x; Goncalves PD, 2014, DRUG ALCOHOL DEPEN, V141, P79, DOI 10.1016/j.drugalcdep.2014.05.006; Gonzalez R, 2007, NEUROPSYCHOL REV, V17, P347, DOI 10.1007/s11065-007-9036-8; GOSSOP M, 1995, ADDICTION, V90, P607, DOI 10.1046/j.1360-0443.1995.9056072.x; Gossop M, 1997, ADDICTION, V92, P353, DOI 10.1111/j.1360-0443.1997.tb03205.x; Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y; Hester R, 2010, CURR TOP BEHAV NEURO, V3, P301, DOI 10.1007/7854_2009_28; Hides L, 2007, AUST NZ J PSYCHIAT, V41, P166, DOI 10.1080/00048670601109949; IBM Corp, 2010, IBM SPSS STAT WIND V; Fernandez-Serrano MJ, 2010, J PSYCHOPHARMACOL, V24, P1317, DOI 10.1177/0269881109349841; Fernandez-Serrano MJ, 2010, EUR J PHARMACOL, V626, P104, DOI 10.1016/j.ejphar.2009.10.019; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lorenzetti V, 2016, BIOL PSYCHIAT, V79, pE17, DOI 10.1016/j.biopsych.2015.11.013; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Nasreddine Z., 2015, MONTREAL COGNITIVE A; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; OLEJNIK SF, 1985, EVALUATION REV, V9, P51, DOI 10.1177/0193841X8500900104; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Perry JL, 2011, BRAIN RES REV, V65, P124, DOI 10.1016/j.brainresrev.2010.09.001; QUADE D, 1967, J AM STAT ASSOC, V62, P1187, DOI 10.2307/2283769; Rupp CI, 2012, J STUD ALCOHOL DRUGS, V73, P625, DOI 10.15288/jsad.2012.73.625; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sunderland M, 2012, J PSYCHOPATHOL BEHAV, V34, P253, DOI 10.1007/s10862-012-9276-7; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Verdejo-Garcia A., 2011, PSYCHIAT TIMES, V28, P46; Vergara-Moragues E, 2013, J STUD ALCOHOL DRUGS, V74, P452, DOI 10.15288/jsad.2013.74.452; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Wexler BE, 2011, BIOL PSYCHIAT, V69, P197, DOI 10.1016/j.biopsych.2010.11.016; Yucel M, 2007, DRUG ALCOHOL REV, V26, P33, DOI 10.1080/09595230601036978; Yucel M, 2007, AUST NZ J PSYCHIAT, V41, P957, DOI 10.1080/00048670701689444	53	17	18	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0740-5472			J SUBST ABUSE TREAT	J. Subst. Abus. Treat.	JUL	2016	66						30	36		10.1016/j.jsat.2016.03.002			7	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	DN1GO	WOS:000376814500005	27211994				2021-06-18	
J	Salter, KL; McClure, JA; Foley, NC; Sequeira, K; Teasell, RW				Salter, Katherine L.; McClure, J. Andrew; Foley, Norine C.; Sequeira, Keith; Teasell, Robert W.			Pharmacotherapy for Depression Posttraumatic Brain Injury: A Meta-analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; meta-analysis; pharmacotherapy; traumatic brain injury	PSYCHIATRIC-DISORDERS; HEAD-INJURY; ANTIDEPRESSANTS; SERTRALINE; REHABILITATION; DISABILITY; SEQUELAE; QUALITY; TRIALS	Objective: To examine the effectiveness of pharmacotherapy for the treatment of depression following traumatic brain injury (TBI). Design: Systematic review and meta-analysis. Multiple electronic databases were searched to identify relevant studies examining effectiveness of pharmacotherapy for depression post-TBI. Clinical trials evaluating the use of pharmacotherapy in individuals with depression at baseline and using standardized assessments of depression were included. Data abstracted included sample size, antidepressant used, treatment timing/duration, method of assessment, and results pertaining to impact of treatment. Study quality was assessed using a modified Jadad scale. Results: Nine studies met criteria for inclusion. Pooled analyses based on reported means (standard deviations) from repeated assessments of depression showed that, over time, antidepressant treatment was associated with a significant effect in favor of treatment (Hedges g = 1.169; 95% confidence interval, 0.849-1.489; P < .001). Similarly, when limited to placebo-controlled trials, treatment was associated with a significant reduction in symptoms (standardized mean difference = 0.84; 95% confidence interval, 0.314-1.366; P = .002). Conclusion: Pharmacotherapy after TBI may be associated with a reduction in depressive symptomatology. Given limitations within the available literature, further well-powered, placebo-controlled trials should be conducted to confirm the effectiveness of antidepressant therapy in this population.	[Salter, Katherine L.; McClure, J. Andrew; Foley, Norine C.; Sequeira, Keith; Teasell, Robert W.] Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care Program, Parkwood Hosp Site, London, ON, Canada; [Salter, Katherine L.] Western Univ, Grad Program, Hlth & Rehabil Sci, London, ON, Canada; [Sequeira, Keith; Teasell, Robert W.] Univ Western Ontario, Schulich Sch Med, Dept Phys Med & Rehabil, London, ON, Canada	Salter, KL (corresponding author), Western Univ, Fac Hlth Sci, Lab Knowledge Translat & Exchange, Room HSB 403,Hlth Sci Bldg, London, ON N6A 5B9, Canada.	katesalt1@gmail.com		McClure, Andrew/0000-0001-5595-730X			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Arroll B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007954; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bae KY, 2011, PSYCHIAT INVEST, V8, P234, DOI 10.4306/pi.2011.8.3.234; Biostat Inc, 2005, COMPREHENSIVE METAAN; Borenstein M., 2009, INTRO METAANALYSIS; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chen Y, 2006, ANN PHARMACOTHER, V40, P2115, DOI 10.1345/aph.1H389; Cohen J., 1977, STAT POWER ANAL BEHA, P1; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Gill D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001312.pub2; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Guaiana G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004186.pub2; Hackett ML, 2008, COCHRANE DB SYST REV; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huggins JM, 2011, AM J HEALTH-SYST PH, V68, P254, DOI 10.2146/ajhp090629; Hurley Robin A., 2002, Curr Treat Options Neurol, V4, P59, DOI 10.1007/s11940-002-0005-5; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lipsey M.W., 2001, PRACTICAL META ANAL; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; McDowell I, 1996, MEASURING HLTH GUIDE; Newburn G, 1999, BRAIN INJURY, V13, P637; Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147; Price A, 2011, J NEUROL NEUROSUR PS, V82, P914, DOI 10.1136/jnnp.2010.230862; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rayner L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007503.pub2; Salter K, 2007, TOP STROKE REHABIL, V14, P1, DOI 10.1310/tsr1403-1; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206	47	17	17	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2016	31	4					E21	E32		10.1097/HTR.0000000000000193			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FW	WOS:000379789000003	26479398				2021-06-18	
J	Scultetus, AH; Haque, A; Chun, SJ; Hazzard, B; Mahon, RT; Harssema, MJ; Auker, CR; Moon-Massat, P; Malone, DL; McCarron, RM				Scultetus, Anke H.; Haque, Ashraful; Chun, Steve J.; Hazzard, Brittany; Mahon, Richard T.; Harssema, Martin J.; Auker, Charles R.; Moon-Massat, Paula; Malone, Debra L.; McCarron, Richard M.			Brain hypoxia is exacerbated in hypobaria during aeromedical evacuation in swine with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Aeromedical evacuation; altitude; hypobaria; cerebral oxygenation; traumatic brain injury; swine	DECOMPRESSION-SICKNESS; HIGH-ALTITUDE; MODEL	BACKGROUND: There is inadequate information on the physiologic effects of aeromedical evacuation on wounded war fighters with traumatic brain injury (TBI). At altitudes of 8,000 ft, the inspired oxygen is lower than standard sea level values. In troops experiencing TBI, this reduced oxygen may worsen or cause secondary brain injury. We tested the hypothesis that the effects of prolonged aeromedical evacuation on critical neurophysiologic parameters (i.e., brain oxygenation [PbtO2]) of swine with a fluid percussion injury/TBI would be detrimental compared with ground (normobaric) transport. METHODS: Yorkshire swine underwent fluid percussion injury/TBI with pretransport stabilization before being randomized to a 4-hour aeromedical transport at simulated flight altitude of 8,000 ft (HYPO, n = 8) or normobaric ground transport (NORMO, n = 8). Physiologic measurements (i.e., PbtO2], cerebral perfusion pressure, intracranial pressure, regional cerebral blood flow, mean arterial blood pressure, and oxygen transport variables) were analyzed. RESULTS: Survival was equivalent between groups. Measurements were similar in both groups at all phases up to and including onset of flight. During the flight, PbtO2], cerebral perfusion pressure, and mean arterial blood pressure were significantly lower in the HYPO than in the NORMO group. At the end of flight, regional cerebral blood flow was lower in the HYPO than in the NORMO group. Other parameters such as intracranial pressure, cardiac output, and mean pulmonary artery pressure were not significantly different between the two groups. CONCLUSION: A 4-hour aeromedical evacuation at a simulated flight altitude of 8,000 ft caused a notable reduction in neurophysiologic parameters compared with normobaric conditions in this TBI swine model. Results suggest that hypobaric conditions exacerbate cerebral hypoxia and may worsen TBI in casualties already in critical condition. (J Trauma Acute Care Surg. 2016; 81: 101-107. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Scultetus, Anke H.; Haque, Ashraful; Chun, Steve J.; Hazzard, Brittany; Mahon, Richard T.; Auker, Charles R.; Moon-Massat, Paula; McCarron, Richard M.] NMRC, Silver Spring, MD 20910 USA; [Scultetus, Anke H.; Malone, Debra L.; McCarron, Richard M.] USU, Dept Surg, Bethesda, MD USA; [Chun, Steve J.; Malone, Debra L.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Harssema, Martin J.] Joint Base Andrews, Crit Care Air Transport Team, Med Grp 79, Bethesda, MD USA	Scultetus, AH (corresponding author), Naval Med Res Ctr, NeuroTrauma Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	anke.h.scultetus2.ctr@mail.mil					Auten JD, 2010, AVIAT SPACE ENVIR MD, V81, P427, DOI 10.3357/ASEM.2406.2010; Chesnut RM, 2004, CRIT CARE CLIN, V20, P25, DOI 10.1016/S0749-0704(03)00090-3; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Dukes SF, 2013, MIL MED, V178, P11, DOI 10.7205/MILMED-D-12-00177; Fang R, 2010, J TRAUMA, V69, pS140, DOI 10.1097/TA.0b013e3181e452a2; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Hu SL, 2010, NEUROL RES, V32, P173, DOI 10.1179/174313209X414524; Hurd WW, 2003, AEROMEDICAL EVACUATI; Johannigman Jay, 2015, J Trauma Acute Care Surg, V79, pS216, DOI 10.1097/TA.0000000000000736; Joshi M C, 2010, Med J Armed Forces India, V66, P63, DOI 10.1016/S0377-1237(10)80097-8; Kannan N, 1998, AVIAT SPACE ENVIR MD, V69, P965; Kragh John F Jr, 2011, US Army Med Dep J, P38; MAROTTE H, 1990, AVIAT SPACE ENVIR MD, V61, P690; Mongan PD, 2009, J TRAUMA, V67, P51, DOI 10.1097/TA.0b013e3181838030; Pilmanis AA, 1996, AVIAT SPACE ENVIR MD, V67, P1092; Ran Y, 2011, MIL MED, V176, P647, DOI 10.7205/MILMED-D-10-00390; Skovira JW, 2016, J NEUROTRAUMA; STAPP JP, 1986, AVIAT SPACE ENVIR MD, V57, pA32; Yu AY, 2014, NEUROREPORT, V25, P1272, DOI 10.1097/WNR.0000000000000259	19	17	17	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2016	81	1					101	107		10.1097/TA.0000000000001048			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DS5BV	WOS:000380796400016	26998778				2021-06-18	
J	Wang, JF; Zarbin, M; Sugino, I; Whitehead, I; Townes-Anderson, E				Wang, Jianfeng; Zarbin, Marco; Sugino, Ilene; Whitehead, Ian; Townes-Anderson, Ellen			RhoA Signaling and Synaptic Damage Occur Within Hours in a Live Pig Model of CNS Injury, Retinal Detachment	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						photoreceptor; retinal detachment; RhoA; ROCK; synaptic plasticity	SCLERAL BUCKLING SURGERY; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; VISUAL RECOVERY; LYSOPHOSPHATIDIC ACID; LESIONAL EXPRESSION; AXON RETRACTION; PROTEIN-KINASE; SMOOTH-MUSCLE; IN-VITRO	PURPOSE. The RhoA pathway is activated after retinal injury. However, the time of onset and consequences of activation are unknown in vivo. Based on in vitro studies we focused on a period 2 hours after retinal detachment, in pig, an animal whose retina is holangiotic and contains cones. METHODS. Under anesthesia, retinal detachments were created by subretinal injection of a balanced salt solution. Two hours later, animals were sacrificed and enucleated for GTPase activity assays and quantitative Western blot and confocal microscopy analyses. RESULTS. RhoA activity with detachment was increased 1.5-fold compared to that in normal eyes or in eyes that had undergone vitrectomy only. Increased phosphorylation of myosin light chain, a RhoA effector, also occurred. By 2 hours, rod cells had retracted their terminals toward their cell bodies, disrupting the photoreceptor-to-bipolar synapse and producing significant numbers of spherules with SV2 immunolabel in the outer nuclear layer of the retina. In eyes with detachment, distant retina that remained attached also showed significant increases in RhoA activity and synaptic disjunction. Increases in RAC1 activity and glial fibrillary acidic protein (GFAP) were not specific for detachment, and sprouting of bipolar dendrites, reported for longer detachments, was not seen. The RhoA kinase inhibitor Y27632 significantly reduced axonal retraction by rod cells. CONCLUSIONS. Activation of the RhoA pathway occurs quickly after injury and promotes synaptic damage that can be controlled by RhoA kinase inhibition. We suggest that retinal detachment joins the list of central nervous system injuries, such as stroke and spinal cord injury, that should be considered for rapid therapeutic intervention.	[Wang, Jianfeng; Townes-Anderson, Ellen] Rutgers State Univ, Rutgers Biomed Hlth Sci, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, 185 South Orange Ave, Newark, NJ 07103 USA; [Zarbin, Marco; Sugino, Ilene] Rutgers State Univ, Rutgers Biomed Hlth Sci, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA; [Whitehead, Ian] Rutgers State Univ, Rutgers Biomed Hlth Sci, New Jersey Med Sch, Dept Microbiol Biochem & Med Genet, Newark, NJ USA	Townes-Anderson, E (corresponding author), Rutgers State Univ, Rutgers Biomed Hlth Sci, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, 185 South Orange Ave, Newark, NJ 07103 USA.	andersel@njms.rutgers.edu			NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY021542] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY021542] Funding Source: Medline		Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Auer M, 2011, ANN ANAT, V193, P259, DOI 10.1016/j.aanat.2011.02.015; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Brabeck C, 2003, ARCH NEUROL-CHICAGO, V60, P1245, DOI 10.1001/archneur.60.9.1245; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Burton T C, 1982, Trans Am Ophthalmol Soc, V80, P475; Chan D, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.234005; CHISHOLM IA, 1975, T OPHTHAL SOC UK, V95, P167; Conrad S, 2005, J COMP NEUROL, V487, P166, DOI 10.1002/cne.20561; Degasperi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087293; Dergham P, 2002, J NEUROSCI, V22, P6570; Diederen RMH, 2007, OPHTHALMOLOGY, V114, P705, DOI 10.1016/j.ophtha.2006.09.004; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; ERICKSON PA, 1983, INVEST OPHTH VIS SCI, V24, P927; Faure J, 2001, BIOCHIMIE, V83, P409, DOI 10.1016/S0300-9084(01)01263-9; Fisher SK, 2003, VISION RES, V43, P887, DOI 10.1016/S0042-6989(02)00680-6; Fontainhas AM, 2008, INVEST OPHTH VIS SCI, V49, P4177, DOI 10.1167/iovs.07-1580; Fontainhas AM, 2011, INVEST OPHTH VIS SCI, V52, P579, DOI 10.1167/iovs.10-5744; Francke M, 2001, INVEST OPHTH VIS SCI, V42, P1072; Gallo G, 2004, EXP NEUROL, V189, P112, DOI 10.1016/j.expneurol.2004.05.019; Garnock-Jones K, 2014, DRUGS, V74, P2211, DOI 10.1007/s40265-014-0333-2; Gerke C. G. Jr., 1995, Hong Kong Medical Journal, V1, P302; GIRARD P, 1995, OPHTHALMOLOGICA, V209, P323, DOI 10.1159/000310651; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; GUERIN CJ, 1993, INVEST OPHTH VIS SCI, V34, P175; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107; Henrich PB, 2009, KLIN MONATSBL AUGENH, V226, P289, DOI 10.1055/s-0028-1109330; Hou Y, 2012, NEUROSCIENCE, V200, P120, DOI 10.1016/j.neuroscience.2011.10.030; Iandiev I, 2006, INVEST OPHTH VIS SCI, V47, P2161, DOI 10.1167/iovs.05-0595; Joo EE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4510; Khodair MA, 2003, INVEST OPHTH VIS SCI, V44, P4976, DOI 10.1167/iovs.03-0036; Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LEWIS GP, 1995, INVEST OPHTH VIS SCI, V36, P2404; Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424; Lewis GP, 2003, MOL NEUROBIOL, V28, P159, DOI 10.1385/MN:28:2:159; Lewis GP, 2002, EYE, V16, P375, DOI 10.1038/sj.eye.6700202; Lin-Jones J, 2009, J COMP NEUROL, V513, P209, DOI 10.1002/cne.21958; Linberg KA, 2009, MOL VIS, V15, P10; Liu F, 2006, OPHTHALMOLOGICA, V220, P174, DOI 10.1159/000091761; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Mervin K, 1999, AM J OPHTHALMOL, V128, P155, DOI 10.1016/S0002-9394(99)00104-X; Mowatt L, 2005, EUR J OPHTHALMOL, V15, P109; Murthy KS, 2003, BIOCHEM J, V374, P145, DOI 10.1042/BJ20021274; NachmanClewner M, 1996, J NEUROCYTOL, V25, P597, DOI 10.1007/BF02284827; Ozgur S, 2007, RETINA-J RET VIT DIS, V27, P358; Petratos S, 2008, BRAIN, V131, P90, DOI 10.1093/brain/awm260; PRINCE JH, 1960, AM J OPHTHALMOL, V49, P1202; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Ross W, 2005, OPHTHALMOLOGY, V112, P1213, DOI 10.1016/j.ophtha.2005.01.040; Ross W H, 2000, Curr Opin Ophthalmol, V11, P191, DOI 10.1097/00055735-200006000-00007; Ross WH, 1998, OPHTHALMOLOGY, V105, P2149, DOI 10.1016/S0161-6420(98)91142-3; Ryan SJ, 2006, RETINA; Salicone A, 2006, OPHTHALMOLOGY, V113, P1734, DOI 10.1016/j.ophtha.2006.03.064; Santos-Bredariol AS, 2002, J NEUROCYTOL, V31, P149, DOI 10.1023/A:1023997506760; Sasoh M, 1997, DOC OPHTHALMOL, V94, P239, DOI 10.1007/BF02582982; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3; Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518; Sherry DM, 2000, INVEST OPHTH VIS SCI, V41, P2779; SIMOENS P, 1992, EXP EYE RES, V54, P965, DOI 10.1016/0014-4835(92)90161-K; Song Y, 2013, CNS NEUROSCI THER, V19, P603, DOI 10.1111/cns.12116; STEINBERG RH, 1986, EXP EYE RES, V43, P695, DOI 10.1016/S0014-4835(86)80001-X; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; TANI P, 1981, AM J OPHTHALMOL, V92, P611, DOI 10.1016/S0002-9394(14)74651-3; Tonges L, 2012, BRAIN, V135, P3355, DOI 10.1093/brain/aws254; Tura A, 2009, INVEST OPHTH VIS SCI, V50, P452, DOI 10.1167/iovs.08-1973; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Bussel EM, 2014, RETINA-J RET VIT DIS, V34, P1917, DOI 10.1097/IAE.0000000000000296; Wang Jianfeng, 2011, J Vis Exp, DOI 10.3791/2655; Wang WW, 2015, INVEST OPHTH VIS SCI, V56, P7847, DOI 10.1167/iovs.15-17278; Yamashita K, 2007, BRAIN RES, V1154, P215, DOI 10.1016/j.brainres.2007.04.013; Zhang JY, 2014, REPRODUCTION, V148, P99, DOI 10.1530/REP-13-0556	78	17	17	0	2	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	JUL	2016	57	8					3892	3906		10.1167/iovs.16-19447			15	Ophthalmology	Ophthalmology	DT8GW	WOS:000381729000044	27472075	DOAJ Gold, Green Published			2021-06-18	
J	Sherman, M; Liu, MM; Birnbaum, S; Wolf, SE; Minei, JP; Gatson, JW				Sherman, Matthew; Liu, Ming-Mei; Birnbaum, Shari; Wolf, Steven E.; Minei, Joseph P.; Gatson, Joshua W.			Adult obese mice suffer from chronic secondary brain injury after mild TBI	JOURNAL OF NEUROINFLAMMATION			English	Article						TBI; Inflammation; Obesity	ADIPOSE-TISSUE; INFLAMMATION; SEX; COMORBIDITIES; ACCUMULATION; RESISTANCE; CORTISOL; OUTCOMES	Background: A traumatic brain injury (TBI) event is a devastating injury to the brain that may result in heightened inflammation, neurodegeneration, and subsequent cognitive and mood deficits. TBI victims with co-morbidities such as heart disease, diabetes, or obesity may be more vulnerable to the secondary brain injury that follows the initial insult. Compared to lean individuals, obese subjects tend to have worse clinical outcomes and higher mortality rates after trauma. Methods: To elucidate whether obesity predisposes individuals to worse outcomes after TBI, we subjected adult lean and obese male/female mice to a mild TBI. The injury was administered using a controlled skull impact (CSI) device. Lean or obese 6-month-old C57 BL/6 mice were subjected once to a mild TBI. Additionally, at day 30 after injury, both the lean and obese mice were tested for increased anxiety using the open field test. Results: At day 30 after TBI, compared to the lean mice, we found heightened microglial (MG) activation in the cerebral cortex, corpus callosum, and hypothalamus. Another compelling finding was that, compared to the non-injured obese male control mice, the obese TBI mice had a decrease in the rate of weight gain and serum corticosterone levels at day 30 after injury. Additionally, the injured obese mice displayed higher levels of anxiety as determined by a significant decrease in time spent in the non-peripheral zones in the open field test. In contrast to the obese males, the obese female mice did not exhibit increases in the number of active MG in the brain, changes in weight gain/corticosterone levels, or increased anxiety at day 30 after TBI. Conclusions: The data presented here suggests that obese mice have worse outcomes compared to lean mice after mild TBI. Also, the obese males have worse outcomes than the injured female mice. This data may explain the sequela of chronic secondary brain injury in obese adults after a single mild TBI. Also, this report may help shape how the overweight/obese populations are monitored over the days and months following a TBI.	[Sherman, Matthew; Liu, Ming-Mei; Wolf, Steven E.; Minei, Joseph P.; Gatson, Joshua W.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Gatson, Joshua W.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Birnbaum, Shari] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX USA	Gatson, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.; Gatson, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joshua.gatson@utsouthwestern.edu		Wolf, Steven/0000-0003-2972-3440	Department of Surgery at the University of Texas Southwestern Medical Center	Funds were provided by the Department of Surgery at the University of Texas Southwestern Medical Center to complete the research studies.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Aguilar-Valles A, 2015, NEUROPHARMACOLOGY, V96, P124, DOI 10.1016/j.neuropharm.2014.12.023; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; Bousquet M, 2012, NEUROBIOL DIS, V45, P529, DOI 10.1016/j.nbd.2011.09.009; Brown LM, 2010, BRAIN RES, V1350, P77, DOI 10.1016/j.brainres.2010.04.056; Bruce-Keller AJ, 2009, BBA-MOL BASIS DIS, V1792, P395, DOI 10.1016/j.bbadis.2008.10.004; Buga AM, 2013, BIOGERONTOLOGY, V14, P651, DOI 10.1007/s10522-013-9465-0; Castanon N, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00074; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chan V, 2016, ARCH PHYS MED REHAB, V97, P772, DOI 10.1016/j.apmr.2016.01.011; Choi JY, 2005, FREE RADICAL BIO MED, V38, P806, DOI 10.1016/j.freeradbiomed.2004.12.008; Di Napoli M, 2012, NEUROLOGY, V79, P690, DOI 10.1212/WNL.0b013e318264e3be; Ditillo M, 2014, J TRAUMA ACUTE CARE, V76, P176, DOI 10.1097/TA.0b013e3182ab0d7c; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedor A, 2013, OBESITY FACTS, V6, P185, DOI 10.1159/000351138; GOLD RM, 1973, SCIENCE, V182, P488, DOI 10.1126/science.182.4111.488; Greenberg AS, 2006, AM J CLIN NUTR, V83, p461S, DOI DOI 10.1093/ajcn/83.2.461S; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Kalmijn S, 2000, J Nutr Health Aging, V4, P202; Karelina K, 2016, EUR J NEUROSCI, V43, P1034, DOI 10.1111/ejn.13194; King BA, 2006, PHYSIOL BEHAV, V87, P221, DOI 10.1016/j.physbeh.2005.10.007; MOLITCH ME, 1983, CLIN ENDOCRINOL META, V12, P825, DOI 10.1016/S0300-595X(83)80066-8; Morris JK, 2010, AM J PHYSIOL-REG I, V299, pR1082, DOI 10.1152/ajpregu.00449.2010; Nguyen JCD, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00375; Palmer BF, 2015, MOL CELL ENDOCRINOL, V402, P113, DOI 10.1016/j.mce.2014.11.029; Pasquali R, 2002, J CLIN ENDOCR METAB, V87, P166, DOI 10.1210/jc.87.1.166; Pasquali R, 2006, ANN NY ACAD SCI, V1083, P111, DOI 10.1196/annals.1367.009; Popa-Wagner A, 2014, BIOGERONTOLOGY, V15, P439, DOI 10.1007/s10522-014-9516-1; Posey KA, 2009, AM J PHYSIOL-ENDOC M, V296, pE1003, DOI 10.1152/ajpendo.90377.2008; Puig KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030378; Purkayastha S, 2013, MOL METAB, V2, P356, DOI 10.1016/j.molmet.2013.09.005; Rodriguez ACI, 2015, PSYCHONEUROENDOCRINO, V62, P301, DOI 10.1016/j.psyneuen.2015.08.014; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sandu RE, 2015, NEURAL REGEN RES, V10, P1349, DOI 10.4103/1673-5374.165208; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Singhal G, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00097; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Spielman LJ, 2014, J NEUROIMMUNOL, V273, P8, DOI 10.1016/j.jneuroim.2014.06.004; Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P117, DOI 10.2174/156720507780362065; Willeumier K, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.67; Woods SC, 2003, EXP BIOL MED, V228, P1175; Yehuda S, 2005, NUTR NEUROSCI, V8, P309, DOI 10.1080/00268970500509972	50	17	19	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUN 30	2016	13								171	10.1186/s12974-016-0641-4			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DQ0CE	WOS:000378864800001	27357503	DOAJ Gold, Green Published			2021-06-18	
J	Wang, JY; Huang, YN; Chiu, CC; Tweedie, D; Luo, WM; Pick, CG; Chou, SY; Luo, Y; Hoffer, BJ; Greig, NH; Wang, JY				Wang, Jin-Ya; Huang, Ya-Ni; Chiu, Chong-Chi; Tweedie, David; Luo, Weiming; Pick, Chaim G.; Chou, Szu-Yi; Luo, Yu; Hoffer, Barry J.; Greig, Nigel H.; Wang, Jia-Yi			Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat	JOURNAL OF NEUROINFLAMMATION			English	Article						Pomalidomide; Thalidomide; Traumatic brain injury; Controlled cortical impact; Tumor necrosis factor-alpha; Interleukin-1 beta; Interleukin-6; Glutamate excitotoxicity; Neuronal apoptosis; Neuroinflammation	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; ALPHA SYNTHESIS INHIBITOR; TNF-ALPHA; IN-VITRO; INFLAMMATORY CYTOKINES; FUNCTIONAL OUTCOMES; COGNITIVE DEFICITS	Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6). Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial activation, and the induction of TNF-alpha were assessed in mixed cortical cultures following a glutamate challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and reduced microglial cell activation, significantly attenuating the induction of TNF-alpha. Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom for potential use in clinical TBI.	[Tweedie, David; Luo, Weiming; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jin-Ya; Huang, Ya-Ni; Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan; [Huang, Ya-Ni] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Chiu, Chong-Chi] Chi Mei Med Ctr, Dept Gen Surg, Tainan, Taiwan; [Chiu, Chong-Chi] Chi Mei Med Ctr, Dept Gen Surg, Liouying, Taiwan; [Pick, Chaim G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Sch Med, Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel; [Chou, Szu-Yi] Taipei Med Univ, Coll Med Sci & Technol, Grad Program Neuroregenerat, Taipei, Taiwan; [Luo, Yu; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Dept Physiol, 250 Wu Hsing St, Taipei 110, Taiwan	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.; Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.; Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Dept Physiol, 250 Wu Hsing St, Taipei 110, Taiwan.	greign@mail.NIH.gov; jywang2010@tmu.edu.tw		Luo, Yu/0000-0002-7939-5505; Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST104-2923-B-038-001-MY3]; Ari and Regine Aprijaskis Fund at Tel-Aviv University, Tel-Aviv, Israel; National Institute of Neurological Disorders and Stroke, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS094152]; Intramural Research Program of the National Institute on Aging, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 000311-16]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000311] Funding Source: NIH RePORTER	This study was supported in part by (i) a grant from the Ministry of Science and Technology, Taiwan (MOST104-2923-B-038-001-MY3); (ii) the Ari and Regine Aprijaskis Fund at Tel-Aviv University, Tel-Aviv, Israel; (iii) the National Institute of Neurological Disorders and Stroke, NIH (grant RO1NS094152); and (iv) the Intramural Research Program of the National Institute on Aging, NIH (AG 000311-16). These funding organizations had no role in the design of the study or the collection, analysis, and interpretation of data and in writing the manuscript.	Aizawa M, 2011, NEUROSCI RES, V69, P343, DOI 10.1016/j.neures.2010.12.019; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Calabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chanan-Khan AA, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.38; Chang Xiu-Bao, 2011, Int J Biochem Mol Biol, V2, P287; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Choudhery MS, 2012, CELL BIOL INT, V36, P747, DOI 10.1042/CBI20110183; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EGER K, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1073; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feng Y., 2016, CELL MOL NEUROBIOL; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabbita SP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-99; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hanaizi Z, 2015, ONCOLOGIST, V20, P329, DOI 10.1634/theoncologist.2014-0073; Hernandez-Ilizaliturri FJ, 2005, CLIN CANCER RES, V11, P5984, DOI 10.1158/1078-0432.CCR-05-0577; Huang YN, 2009, TOXICOL APPL PHARM, V240, P315, DOI 10.1016/j.taap.2009.06.021; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jo S, 2005, J NEUROCHEM, V94, P1212, DOI 10.1111/j.1471-4159.2005.03344.x; KLING J, 2000, MODERN DRUG DISCOVER, V3, P35; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lee KM, 2015, BIOCHEM BIOPH RES CO, V458, P34, DOI 10.1016/j.bbrc.2015.01.054; Li ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071754; Liu WM, 2009, BRIT J CANCER, V101, P803, DOI 10.1038/sj.bjc.6605206; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mahony C, 2013, P NATL ACAD SCI USA, V110, P12703, DOI 10.1073/pnas.1307684110; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Millrine D, 2016, INT IMMUNOL; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Niwayama S, 1996, J MED CHEM, V39, P3044, DOI 10.1021/jm960284r; Ocio EM, 2015, LEUKEMIA, V29, P705, DOI 10.1038/leu.2014.238; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sampaio EP, 2002, BIOMED PHARMACOTHER, V56, P13, DOI 10.1016/S0753-3322(01)00147-0; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/S1074-7613(04)00234-1; Shalapour S, 2006, CLIN CANCER RES, V12, P5526, DOI 10.1158/1078-0432.CCR-06-0719; SHESKIN J, 1965, CLIN PHARMACOL THER, V6, P303; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shortt J, 2013, ONCOGENE, V32, P4191, DOI 10.1038/onc.2012.599; SMITH RL, 1995, J NEUROSCI, V15, P4057; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teo SK, 2002, MICROBES INFECT, V4, P1193, DOI 10.1016/S1286-4579(02)01645-3; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; US Food and Drug Administration (FDA), 2005, GUID IND EST MAX SAF; Vargesson N, 2015, BIRTH DEFECTS RES C, V105, P140, DOI 10.1002/bdrc.21096; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Weingartner S, 2012, ANN RHEUM DIS, V71, P1895, DOI 10.1136/annrheumdis-2012-201784; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yoon JS, 2013, J NEUROSCI RES, V91, P671, DOI 10.1002/jnr.23190; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhu YX, 2013, LEUKEMIA LYMPHOMA, V54, P683, DOI 10.3109/10428194.2012.728597; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	89	17	18	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 28	2016	13								168	10.1186/s12974-016-0631-6			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DQ0BZ	WOS:000378864100002	27353053	DOAJ Gold, Green Published			2021-06-18	
J	Delic, J; Alhilali, LM; Hughes, MA; Gumus, S; Fakhran, S				Delic, Joseph; Alhilali, Lea M.; Hughes, Marion A.; Gumus, Serter; Fakhran, Saeed			White Matter Injuries in Mild Traumatic Brain Injury and Posttraumatic Migraines: Diffusion Entropy Analysis	RADIOLOGY			English	Article							ABNORMALITIES	Purpose: To determine the performance of Shannon entropy (SE) as a diagnostic tool in patients with mild traumatic brain injury (mTBI) with posttraumatic migraines (PTMs) and those without PTMs on the basis of analysis of fractional anisotropy (FA) maps. Materials and Methods: The institutional review board approved this retrospective study, with waiver of informed consent. FA maps were obtained and neurocognitive testing was performed in 74 patients with mTBI (57 with PTM, 17 without PTM). FA maps were obtained in 22 healthy control subjects and in 20 control patients with migraine headaches. Mean FA and SE were extracted from total brain FA histograms and were compared between patients with mTBI and control subjects and between patients with and those without PTM. Mean FA and SE were correlated with clinical variables and were used to determine the areas under the receiver operating characteristic curve (AUCs) and likelihood ratios for mTBI and development of PTM. Results: Patients with mTBI had significantly lower SE (P < .001) and trended toward lower mean FA (P = .07) compared with control subjects. SE inversely correlated with time to recovery (TTR) (r = -0.272, P = .02). Patients with mTBI with PTM had significantly lower SE (P < .001) but not mean FA (P = .15) than did other patients with mTBI. SE provided better discrimination between patients with mTBI and control subjects than mean FA (AUC = 0.92; P = .01), as well as better discrimination between patients with mTBI with PTM and those without PTM (AUC = 0.85; P < .001). SE of less than 0.751 resulted in a 16.1 increased likelihood of having experienced mTBI and a 3.2 increased likelihood of developing PTM. Conclusion: SE more accurately reveals mTBI than mean FA, more accurately reveals those patients with mTBI who develop PTM, and inversely correlates with TTR.	[Delic, Joseph; Alhilali, Lea M.; Hughes, Marion A.; Gumus, Serter; Fakhran, Saeed] Univ Pittsburgh, Med Ctr, Div Neuroradiol, Dept Radiol, 200 Lothrop St,PUH 2nd Floor,Suite 201 East Wing, Pittsburgh, PA 15213 USA; [Alhilali, Lea M.] Barrow Neurol Inst, Div Neuroradiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA	Alhilali, LM (corresponding author), Univ Pittsburgh, Med Ctr, Div Neuroradiol, Dept Radiol, 200 Lothrop St,PUH 2nd Floor,Suite 201 East Wing, Pittsburgh, PA 15213 USA.	lalhilali@sniweb.net					Alcaraz R, 2008, PHYSIOL MEAS, V29, P65, DOI 10.1088/0967-3334/29/1/005; Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Altman DG, 1990, PRACTICAL STAT MED R, p[268, 352, 354, 417]; Baron EM, 2007, NEUROSURGERY, V60, P35, DOI 10.1227/01.NEU.0000215383.64386.82; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Cui JL, 2011, NEUROIMAGE, V54, P2125, DOI 10.1016/j.neuroimage.2010.10.018; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fozouni N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076343; Guan XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117707; HOSMER DW, 2000, WILEY PS TX, P1; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Metwalli Nader S, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2260; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Shannon CE, 1997, M D COMPUT, V14, P306; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Yu DH, 2013, CEPHALALGIA, V33, P34, DOI 10.1177/0333102412466964; Zhou T, 2009, IEEE ENG MED BIO, P3470, DOI 10.1109/IEMBS.2009.5334608	29	17	17	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	JUN	2016	279	3					859	866		10.1148/radiol.2015151388			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DP8AG	WOS:000378719700024	26829524	Bronze			2021-06-18	
J	Kleffelgaard, I; Soberg, HL; Bruusgaard, KA; Tamber, AL; Langhammer, B				Kleffelgaard, Ingerid; Soberg, Helene Lundgaard; Bruusgaard, Kari A.; Tamber, Anne L.; Langhammer, Birgitta			Vestibular Rehabilitation After Traumatic Brain Injury: Case Series	PHYSICAL THERAPY			English	Article							POST-CONCUSSION SYMPTOMS; POSTTRAUMATIC VERTIGO; LEVEL MOBILITY; DIZZINESS; DISORDERS	Background and Purpose. There has been an increasing focus on vestibular rehabilitation (VR) after traumatic brain injury (TBI) in recent years. However, detailed descriptions of the content of and patient responses to VR after TBI are limited. The purposes of this case series are (1) to describe a modified, group-based VR intervention and (2) to examine changes in self-reported and performance-based outcome measures. Case Description. Two women and 2 men (aged 24-45 years) with mild TBI, dizziness, and balance problems participated in an 8-week intervention consisting of group sessions with guidance, individually modified VR exercises, a home exercise program, and an exercise diary. Self-reported and performance-based outcome measures were applied to assess the impact of dizziness and balance problems on functions related to activity and participation. Outcomes. The intervention caused no adverse effects. Three of the 4 patients reported reduced self-perceived disability because of dizziness, diminished frequency and severity of dizziness, improved health-related quality of life, reduced psychological distress, and improved performance-based balance. The change scores exceeded the minimal detectable change, indicating a clinically significant change or improvement in the direction of age-related norms. The fourth patient did not change or improve in most outcome measures. Discussion. A modified, group-based VR intervention was safe and appeared to be viable and beneficial when addressing dizziness and balance problems after TBI. However, concurrent physical and psychological symptoms, other neurological deficits, and musculoskeletal problems might influence the course of central nervous system compensation and recovery. The present case series may be useful for tailoring VR interventions to patients with TBI. Future randomized controlled trials are warranted to evaluate the short- and longterm effects of VR after TBI.	[Kleffelgaard, Ingerid; Soberg, Helene Lundgaard] Oslo Univ Hosp, Dept Phys Med & Rehabil, POB 4956, N-0424 Oslo, Oslo, Norway; [Kleffelgaard, Ingerid; Soberg, Helene Lundgaard; Bruusgaard, Kari A.; Tamber, Anne L.; Langhammer, Birgitta] Oslo & Akershus Univ Coll, Fac Hlth Sci, Inst Physiotherapy, Oslo, Norway	Kleffelgaard, I (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, POB 4956, N-0424 Oslo, Oslo, Norway.; Kleffelgaard, I (corresponding author), Oslo & Akershus Univ Coll, Fac Hlth Sci, Inst Physiotherapy, Oslo, Norway.	ingerid.kleffelgard@hioa.no	Langhammer, Birgitta/P-1765-2019	Langhammer, Birgitta/0000-0002-9639-0570			Ahn SK, 2011, J TRAUMA, V70, P442, DOI 10.1097/TA.0b013e3181d0c3d9; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fife TD, 2013, SEMIN NEUROL, V33, P238, DOI 10.1055/s-0033-1354599; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Hassett LM, 2008, COCHRANE DB SYST REV, V2; Herdman SJ., 2014, VESTIBULAR REHABILIT, V4th edn; Kleffelgaard I, 2013, PHYS THER, V93, P900, DOI 10.2522/ptj.20120381; Kleffelgaard I, 2012, DISABIL REHABIL, V34, P788, DOI 10.3109/09638288.2011.619624; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Peterson MD, 2010, J HEAD TRAUMA REHAB, V25, P193, DOI 10.1097/HTR.0b013e3181dc82fa; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Shumway-Cook A, 2007, VESTIBULAR REHABILIT, P444; Shumway-Cook A., 2012, MOTOR CONTROL TRANSL; Tamber AL, 2014, EUR J PHYSIOTHER, V16, P93, DOI 10.3109/21679169.2014.886721; Tamber AL, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-101; von SN, 2010, J NEUROTRAUM, V27, P1167; von SN, 2010, J NEUROTRAUM, V27, P1157; Wilhelmsen K, 2008, BMC EAR NOSE THROAT, V8, DOI 10.1186/1472-6815-8-2; Yardley L, 2004, ANN INTERN MED, V141, P598, DOI 10.7326/0003-4819-141-8-200410190-00007; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	17	18	0	17	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	JUN	2016	96	6					839	849		10.2522/ptj.20150095			11	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	DN1CT	WOS:000376804600011	26586860	Bronze, Green Published			2021-06-18	
J	Valko, PO; Gavrilov, YV; Yamamoto, M; Noain, D; Reddy, H; Haybaeck, J; Weis, S; Baumann, CR; Scammell, TE				Valko, Philipp O.; Gavrilov, Yuri V.; Yamamoto, Mihoko; Noain, Daniela; Reddy, Hasini; Haybaeck, Johannes; Weis, Serge; Baumann, Christian R.; Scammell, Thomas E.			Damage to Arousal-Promoting Brainstem Neurons with Traumatic Brain Injury	SLEEP			English	Article						traumatic brain injury; arousal; coma; locus coeruleus; raphe nucleus	DIFFUSE AXONAL INJURY; HEAD-INJURY; DAYTIME SLEEPINESS; STATE; COMA	Study Objectives: Coma and chronic sleepiness are common after traumatic brain injury (TBI). Here, we explored whether injury to arousal-promoting brainstem neurons occurs in patients with fatal TBI. Methods: Postmortem examination of 8 TBI patients and 10 controls. Results: Compared to controls, TBI patients had 17% fewer serotonergic neurons in the dorsal raphe nucleus (effect size: 1.25), but the number of serotonergic neurons did not differ in the median raphe nucleus. TBI patients also had 29% fewer noradrenergic neurons in the locus coeruleus (effect size: 0.96). The number of cholinergic neurons in the pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT) was similar in TBI patients and controls. Conclusions: TBI injures arousal-promoting neurons of the mesopontine tegmentum, but this injury is less severe than previously observed in hypothalamic arousal-promoting neurons. Most likely, posttraumatic arousal disturbances are not primarily caused by damage to these brainstem neurons, but arise from an aggregate of injuries, including damage to hypothalamic arousal nuclei and disruption of other arousal-related circuitries.	[Valko, Philipp O.; Gavrilov, Yuri V.; Yamamoto, Mihoko; Baumann, Christian R.; Scammell, Thomas E.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Valko, Philipp O.; Gavrilov, Yuri V.; Noain, Daniela; Baumann, Christian R.] Univ Zurich, Univ Zurich Hosp, Dept Neurol, CH-8006 Zurich, Switzerland; [Gavrilov, Yuri V.] Russian Acad Med Sci, Inst Expt Med, Dept Gen Pathol & Pathol Physiol, St Petersburg P-22, Russia; [Reddy, Hasini] Beth Israel Deaconess Med Ctr, Dept Neuropathol, Boston, MA 02215 USA; [Haybaeck, Johannes] Med Univ Graz, Dept Neuropathol, Inst Pathol, Graz, Austria; [Haybaeck, Johannes] Johannes Kepler Univ Linz, Dept Neuropathol, State Neuropsychiat Hosp Wagner, Jauregg Kepler Univ Hosp, Linz, Austria	Valko, PO (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.; Valko, PO (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	philipp.valko@usz.ch	Gavrilov, Yury/AAA-2915-2019	Baumann, Christian/0000-0003-3417-1978; Gavrilov, Yury/0000-0003-1409-7686	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32003B-125504]; Clinical Research Priority Program "Sleep and Health" of the University of Zurich; EisaiEisai Co Ltd	This was not an industry supported study. This study was supported by the Swiss National Science Foundation (grant No. 32003B-125504) and the Clinical Research Priority Program "Sleep and Health" of the University of Zurich. Dr. Scammell has received research support from Eisai and has consulted for Merck, Symphony, Prexa, Jazz, Cereve, Purdue Pharma, Ferrer, Heptares, and Synageva. The other authors have indicated no financial conflicts of interest.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Carter ME, 2012, P NATL ACAD SCI USA, V109, pE2635, DOI 10.1073/pnas.1202526109; CROMPTON MR, 1971, LANCET, V1, P669; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Sara SJ, 2012, NEURON, V76, P130, DOI 10.1016/j.neuron.2012.09.011; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Valko PO, 2013, ANN NEUROL, V74, P794, DOI 10.1002/ana.24019	17	17	17	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	JUN 1	2016	39	6					1249	1252	PII sp-00640-15	10.5665/sleep.5844			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DP7JO	WOS:000378675200012	27091531	Green Published, Bronze			2021-06-18	
J	Ackland, HM; Pilcher, DV; Roodenburg, OS; McLellan, SA; Cameron, PA; Cooper, DJ				Ackland, Helen M.; Pilcher, David V.; Roodenburg, Owen S.; McLellan, Susan A.; Cameron, Peter A.; Cooper, D. James			Danger at every rung: Epidemiology and outcomes of ICU-admitted ladder-related trauma	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Ladder; Ladder falls; Ladder-related trauma; Ladder injuries; High falls; Traumatic brain injury; Intensive care	FALL INJURIES; BRAIN-INJURY; ACCIDENTS; PATTERNS; SCALE; RISK	Introduction: The incidence of ladder-related falls is increasing, and this represents a disturbing trend, particularly in the context of increased life expectancy and the impending retirement of the populous 'baby-boomer' generation. To date, there have been no critical illness-focused studies reporting on the incidence, severity and outcomes of severe ladder-related injuries requiring ICU management. Methods: Major trauma patients admitted to ICU over a 5 year period to June 2011 after ladder falls > 1 m were identified from prospectively collected trauma data at a Level 1 trauma service. Demographic and ICU clinical management data were collected and non-parametric statistical analyses were used to explore the relationships between variables in hospital mortality/survival. Results: There were 584 ladder fall admissions, including 194 major trauma cases, of whom 29.9% (n = 58) fell > 1 m and were admitted to ICU. Hospital mortality was 26%, and fatal cases were almost entirely older males in domestic falls of <= 3 m who died as a result of traumatic brain injury. Non-survivors had lower GCS at the scene (p = 0.02), higher AIS head code (p = 0.01), higher heart rate and lower mean arterial pressure (p < 0.01) in the initial 24 h period in ICU, and were >= 55 years of age (p = 0.05). Only 46% of patients available for follow-up were living at home at 12 months without requiring additional care. Conclusions: The incidence of ladder falls requiring ICU management is increasing, and severe traumatic brain injury was responsible for the majority of deaths and for poor outcomes in survivors. In-hospital costs attributable to the care of these patients are high, and fewer than half were living independently at home at 12 months post-fall. A concerted public health campaign is required to alert the community to the potential consequences of this mechanism of injury. The use of helmets for ladder users in domestic settings, where occupational health and safety regulations are less likely to be applied, is strongly recommended to mitigate the risk of severe brain injury. The benefits of this simple strategy far outweigh any mild inconvenience for the wearer, and may prevent catastrophic injury. Crown Copyright (C) 2016 Published by Elsevier Ltd. All rights reserved.	[Ackland, Helen M.; Pilcher, David V.; Roodenburg, Owen S.; Cooper, D. James] Alfred Hosp, Dept Intens Care, Melbourne, Vic 3004, Australia; [Ackland, Helen M.; Pilcher, David V.; McLellan, Susan A.; Cameron, Peter A.; Cooper, D. James] Monash Univ, Crit Care Res Div, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Ackland, Helen M.] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic 3004, Australia	Ackland, HM (corresponding author), Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia.	h.ackland@alfred.org.au	Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Pilcher, David/0000-0002-8939-7985; Cameron, Peter/0000-0002-1443-557X	Department of Health and Human Services; State Government of Victoria and Transport Accident Commission	The Victorian State Trauma Registry (VSTR) is jointly funded by the Department of Health and Human Services, State Government of Victoria and Transport Accident Commission - we also gratefully acknowledge the Victorian State Trauma Outcome Registry and Monitoring (VSTORM) group for the provision of VSTR data.	American Academy of Orthopedic Surgeons, 2012, LADD SAF GUID; Australian and New Zealand Intensive Care Society, 2013, ANZICS CTR OUTC RES; Australian and New Zealand Intensive Care Society, 2014, 201213 ANZICS CORE; Australian Competition and Consumer Commission, 2015, PROD SAF AUSTR LADD; Australian Government Department of Health and Ageing, 2011, AUSTR HOSP PAT COST; Bedi HS, 2008, J TRAUMA, V64, P1608, DOI 10.1097/TA.0b013e31804aa444; BJORNSTIG U, 1992, J SAFETY RES, V23, P9, DOI 10.1016/0022-4375(92)90035-8; Bradley C., 2007, LADDER RELATED FALL; Lopez MAC, 2011, J SAFETY RES, V42, P391, DOI 10.1016/j.jsr.2011.08.003; Cassell E, 2006, INJURY RELATED USE L, P1; Con J, 2014, J SURG RES, V191, P262, DOI 10.1016/j.jss.2014.05.072; D'Souza AL, 2007, AM J PREV MED, V32, P413, DOI 10.1016/j.amepre.2007.01.012; Department of Health Victoria, 2014, VICT STAT TRAUM REG; Diggs BS, 2005, ACAD EMERG MED, V12, P267, DOI 10.1197/j.aem.2004.10.028; Faergemann C, 2000, ACCIDENT ANAL PREV, V32, P745, DOI 10.1016/S0001-4575(99)00124-4; Inui TS, 2014, J TRAUMA ACUTE CARE, V76, P642, DOI 10.1097/TA.0000000000000138; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Kent Alison, 2006, Emerg Med Australas, V18, P23, DOI 10.1111/j.1742-6723.2006.00800.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mitra B, 2007, MED J AUSTRALIA, V186, P31, DOI 10.5694/j.1326-5377.2007.tb00785.x; MUIR L, 1993, INJURY, V24, P485, DOI 10.1016/0020-1383(93)90156-Z; O'Sullivan J, 2004, INJURY, V35, P429, DOI 10.1016/S0020-1383(03)00265-1; Oxley J, 2014, REPORT REDUCTION MAJ; Partridge RA, 1998, ACAD EMERG MED, V5, P31, DOI 10.1111/j.1553-2712.1998.tb02571.x; Pliner EM, 2014, ERGONOMICS, P1; Safe Work Australia, 2013, WORK REL INJ FAT INV; Seluga Kristopher J, 2007, Int J Inj Contr Saf Promot, V14, P215, DOI 10.1080/17457300701722601; Simeonov P, 2013, APPL ERGON, V44, P496, DOI 10.1016/j.apergo.2012.10.017; Smith GS, 2006, ACCIDENT ANAL PREV, V38, P973, DOI 10.1016/j.aap.2006.04.008; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tsipouras S, 2001, MED J AUSTRALIA, V174, P516, DOI 10.5694/j.1326-5377.2001.tb143403.x; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Warren LR, 2015, ANZ J SURG S1, V85, P132; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; WorkSafe Victoria, 2005, PREV FALLS LADD	35	17	17	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2016	47	5					1109	1117		10.1016/j.injury.2015.12.016			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	DK6TA	WOS:000375057000023	26783012				2021-06-18	
J	Bick, SKB; Eskandar, EN				Bick, Sarah K. B.; Eskandar, Emad N.			Neuromodulation for restoring memory	NEUROSURGICAL FOCUS			English	Article						deep brain stimulation; memory; Alzheimer disease; traumatic brain injury	DEEP-BRAIN-STIMULATION; INTRACRANIAL SELF-STIMULATION; NUCLEUS BASALIS MAGNOCELLULARIS; TRANSCRANIAL MAGNETIC STIMULATION; ACTIVE-AVOIDANCE RETENTION; HIGH-FREQUENCY STIMULATION; VAGUS NERVE-STIMULATION; TEMPORAL-LOBE EPILEPSY; ALZHEIMERS-DISEASE; ELECTRICAL-STIMULATION	Disorders of learning and memory have a large social and economic impact in today's society. Unfortunately, existing medical treatments have shown limited clinical efficacy or potential for modification of the disease course. Deep brain stimulation is a successful treatment for movement disorders and has shown promise in a variety of other diseases including psychiatric disorders. The authors review the potential of neuromodulation for the treatment of disorders of learning and memory. They briefly discuss learning circuitry and its involvement in Alzheimer disease and traumatic brain injury. They then review the literature supporting various targets for neuromodulation to improve memory in animals and humans. Multiple targets including entorhinal cortex, fornix, nucleus basalis of Meynert, basal ganglia, and pedunculopontine nucleus have shown a promising potential for improving dysfunctional memory by mechanisms such as altering firing patterns in neuronal networks underlying memory and increasing synaptic plasticity and neurogenesis. Significant work remains to be done to translate these findings into durable clinical therapies.	[Bick, Sarah K. B.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St, Boston, MA 02114 USA	Bick, SKB (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St, Boston, MA 02114 USA.	sbick@partners.org					Aldavert-Vera L, 2013, BEHAV BRAIN RES, V250, P46, DOI 10.1016/j.bbr.2013.04.025; Arrieta-Cruz I, 2010, TRANSL NEUROSCI, V1, P188, DOI 10.2478/v10134-010-0023-x; Bari A, 2014, NEUROSURG CLIN N AM, V25, P137, DOI 10.1016/j.nec.2013.08.004; Berger TW, 2012, IEEE PULSE, V3, P17, DOI 10.1109/MPUL.2012.2205775; Berger TW, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046017; Boggio PS, 2012, BRAIN STIMUL, V5, P223, DOI 10.1016/j.brs.2011.06.006; Boix-Trelis N, 2006, LEARN MEMORY, V13, P783, DOI 10.1101/lm.305306; Chen N, 2014, CHINESE MED J-PEKING, V127, P125, DOI 10.3760/cma.j.issn.0366-6999.20131025; Costa A, 2010, PARKINSONISM RELAT D, V16, P64, DOI 10.1016/j.parkreldis.2009.05.009; Cotelli M, 2012, NEUROCASE, V18, P217, DOI 10.1080/13554794.2011.588176; Custodio JCD, 2013, BRAIN STIMUL, V6, P261, DOI 10.1016/j.brs.2012.07.004; Dhaliwal SK, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00119; Encinas JM, 2011, J COMP NEUROL, V519, P6, DOI 10.1002/cne.22503; Fell J, 2001, NAT NEUROSCI, V4, P1259, DOI 10.1038/nn759; Fell J, 2013, BRAIN STIMUL, V6, P270, DOI 10.1016/j.brs.2012.08.001; Fell J, 2011, NAT REV NEUROSCI, V12, P105, DOI 10.1038/nrn2979; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Fontaine D, 2013, J ALZHEIMERS DIS, V34, P315, DOI 10.3233/JAD-121579; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Freund HJ, 2009, ARCH NEUROL-CHICAGO, V66, P781, DOI 10.1001/archneurol.2009.102; Gondard E, 2015, BRAIN STIMUL, V8, P1058, DOI 10.1016/j.brs.2015.07.044; Gonzalez MMC, 2013, J NEUROTRAUM, V30, P119, DOI 10.1089/neu.2012.2499; Gratwicke J, 2013, NEUROSCI BIOBEHAV R, V37, P2676, DOI 10.1016/j.neubiorev.2013.09.003; Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165; Guo Yi, 2002, Frontiers of Medical and Biological Engineering, V11, P237, DOI 10.1163/156855701321138905; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; Hamani C, 2011, EXP NEUROL, V232, P100, DOI 10.1016/j.expneurol.2011.08.023; Hamani C, 2010, EXP NEUROL, V225, P154, DOI 10.1016/j.expneurol.2010.06.007; Hanell A, 2015, J NEUROTRAUM, V32, P1590, DOI 10.1089/neu.2014.3592; Hansen N, 2014, FRONT NEUROL, V5, DOI [10.3389/fneur.2014.00080, 10.3389/fpsyg.2014.01052]; Hao S, 2015, NATURE, V526, P430, DOI 10.1038/nature15694; Hardenacke Katja, 2013, Front Psychiatry, V4, P159, DOI 10.3389/fpsyt.2013.00159; Hardenacke K, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.12.005; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Hescham S, 2015, BEHAV BRAIN RES, V292, P353, DOI 10.1016/j.bbr.2015.06.032; Hescham S, 2013, NEUROSCI BIOBEHAV R, V37, P2666, DOI 10.1016/j.neubiorev.2013.09.002; Hescham S, 2013, BRAIN STIMUL, V6, P72, DOI 10.1016/j.brs.2012.01.008; Hotta H, 2007, J PHYSIOL SCI, V57, P383, DOI 10.2170/physiolsci.SC008107; Hotta H, 2009, NEUROSCI RES, V63, P122, DOI 10.1016/j.neures.2008.11.004; Houeto JL, 2005, J NEUROL NEUROSUR PS, V76, P992, DOI 10.1136/jnnp.2004.043273; Hu R, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.4.FOCUS0975; Huguet G, 2009, NEUROSCIENCE, V162, P359, DOI 10.1016/j.neuroscience.2009.04.074; Jausovec N, 2014, BIOL PSYCHOL, V96, P42, DOI 10.1016/j.biopsycho.2013.11.006; Javadi AH, 2012, BRAIN STIMUL, V5, P231, DOI 10.1016/j.brs.2011.06.007; Jeong DU, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/568587; Kadar E, 2011, GENES BRAIN BEHAV, V10, P69, DOI 10.1111/j.1601-183X.2010.00609.x; Kadar E, 2014, BEHAV BRAIN RES, V274, P43, DOI 10.1016/j.bbr.2014.07.050; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Knowlton B, 2012, NEW ENGL J MED, V366, P502; Kohler S, 2004, J COGNITIVE NEUROSCI, V16, P178, DOI 10.1162/089892904322984490; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Koubeissi MZ, 2013, ANN NEUROL, V74, P223, DOI 10.1002/ana.23915; Lacruz ME, 2010, NEUROSCIENCE, V170, P623, DOI 10.1016/j.neuroscience.2010.06.042; Laxton Adrian W, 2013, Handb Clin Neurol, V116, P307, DOI 10.1016/B978-0-444-53497-2.00025-5; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2015, J NEUROTRAUM, V32, P1822, DOI 10.1089/neu.2014.3744; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Lee H, 2013, TRENDS COGN SCI, V17, P574, DOI 10.1016/j.tics.2013.09.002; Liu A, 2015, ELIFE, V4, DOI 10.7554/eLife.04803; Liu X, 2012, NATURE, V484, P381, DOI 10.1038/nature11028; Lyketsos Constantine G, 2012, Innov Clin Neurosci, V9, P10; Mair RG, 2008, J NEUROSCI, V28, P14293, DOI 10.1523/JNEUROSCI.3301-08.2008; Mannu P, 2011, CLIN INTERV AGING, V6, P207, DOI 10.2147/CIA.S23394; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McLachlan RS, 2010, EPILEPSIA, V51, P304, DOI 10.1111/j.1528-1167.2009.02332.x; McLin DE, 2002, P NATL ACAD SCI USA, V99, P4002, DOI 10.1073/pnas.062057099; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Merrill CA, 2006, J CLIN PSYCHIAT, V67, P1171, DOI 10.4088/JCP.v67n0801; Miatton M, 2011, EPILEPSY BEHAV, V22, P759, DOI 10.1016/j.yebeh.2011.09.016; Miller JP, 2015, BRAIN, V138, P1833, DOI 10.1093/brain/awv095; Mollion H, 2011, MOVEMENT DISORD, V26, P2019, DOI 10.1002/mds.23769; Montero-Pastor A, 2004, BEHAV BRAIN RES, V154, P41, DOI 10.1016/j.bbr.2004.01.017; Montero-Pastor A, 2001, BRAIN RES, V900, P337, DOI 10.1016/S0006-8993(01)02325-3; Mure H, 2012, J NEUROSCI, V32, P2804, DOI 10.1523/JNEUROSCI.4331-11.2012; Neren D, 2015, NEUROCRIT CARE; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Oh YS, 2012, SEIZURE-EUR J EPILEP, V21, P183, DOI 10.1016/j.seizure.2011.12.003; OJEMANN GA, 1971, BRAIN, V94, P225, DOI 10.1093/brain/94.2.225; Pachalska M, 2011, MED SCI MONITOR, V17, pCS120, DOI 10.12659/MSM.881970; PAPEZ JW, 1995, J NEUROPSYCH CLIN N, V7, P103; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Paterno R, 2016, J NEUROTRAUMA; Pereira Julio Leonardo Barbosa, 2014, Surg Neurol Int, V5, pS385, DOI 10.4103/2152-7806.140191; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; RASMUSSON DD, 1992, BRAIN RES, V594, P150, DOI 10.1016/0006-8993(92)91041-C; Ruiz-Medina J, 2008, NEUROBIOL LEARN MEM, V89, P574, DOI 10.1016/j.nlm.2007.11.005; Salviati M, 2014, BRAIN STIMUL, V7, P492, DOI 10.1016/j.brs.2014.02.005; Sankar T, 2015, BRAIN STIMUL, V8, P645, DOI 10.1016/j.brs.2014.11.020; Scherder EJA, 1998, BIOL PSYCHIAT, V43, P417, DOI 10.1016/S0006-3223(97)00208-4; Schumacher A, 2011, BEHAV BRAIN RES, V222, P368, DOI 10.1016/j.bbr.2011.04.001; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Sharma Mayur, 2015, J Clin Med Res, V7, P501, DOI 10.14740/jocmr2127w; Shirvalkar P, 2006, P NATL ACAD SCI USA, V103, P17007, DOI 10.1073/pnas.0604811103; Sjogren MJC, 2002, J CLIN PSYCHIAT, V63, P972, DOI 10.4088/JCP.v63n1103; Smith GS, 2012, ARCH NEUROL-CHICAGO, V69, P1141, DOI 10.1001/archneurol.2012.590; Sole-Padulles C, 2006, CEREB CORTEX, V16, P1487, DOI 10.1093/cercor/bhj083; Soriano-Mas C, 2005, BEHAV BRAIN RES, V160, P141, DOI 10.1016/j.bbr.2004.11.025; Soriano-Mas C, 2007, BRAIN RES BULL, V74, P51, DOI 10.1016/j.brainresbull.2007.05.003; Stefani A, 2010, CLIN EEG NEUROSCI, V41, P82, DOI 10.1177/155005941004100207; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Stone SSD, 2011, HIPPOCAMPUS, V21, P1348, DOI 10.1002/hipo.20845; Suthana N, 2014, NEUROIMAGE, V85, P996, DOI 10.1016/j.neuroimage.2013.07.066; Sweeney-Reed CM, 2014, ELIFE, V3, DOI 10.7554/eLife.05352; Sweet JA, 2014, HIPPOCAMPUS, V24, P1592, DOI 10.1002/hipo.22338; Toda H, 2008, J NEUROSURG, V108, P132, DOI 10.3171/JNS/2008/108/01/0132; TURNBULL IM, 1985, APPL NEUROPHYSIOL, V48, P216; Ulam F, 2015, CLIN NEUROPHYSIOL, V126, P486, DOI 10.1016/j.clinph.2014.05.015; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; Vignal JP, 2007, BRAIN, V130, P88, DOI 10.1093/brain/awl329; Wang XJ, 2002, J NEUROPHYSIOL, V87, P889, DOI 10.1152/jn.00135.2001; Williams ZM, 2006, NAT NEUROSCI, V9, P562, DOI 10.1038/nn1662; Zhang C, 2015, CHINESE MED J-PEKING, V128, P1190, DOI 10.4103/0366-6999.156114	113	17	18	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2016	40	5							E5	10.3171/2016.3.FOCUS162			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DK7PX	WOS:000375119300007	27132526	Bronze			2021-06-18	
J	Cunha, MP; Lieberknecht, V; Ramos-Hryb, AB; Olescowicz, G; Ludka, FK; Tasca, CI; Gabilan, NH; Rodrigues, ALS				Cunha, Mauricio P.; Lieberknecht, Vicente; Ramos-Hryb, Ana Belen; Olescowicz, Gislaine; Ludka, Fabiana K.; Tasca, Carla I.; Gabilan, Nelson H.; Rodrigues, Ana Lucia S.			Creatine affords protection against glutamate-induced nitrosative and oxidative stress	NEUROCHEMISTRY INTERNATIONAL			English	Article						Cellular viability; Creatine; Glutamate; Hydrogen peroxide; Nitric oxide	CENTRAL-NERVOUS-SYSTEM; PENTYLENETETRAZOL-INDUCED SEIZURES; NEUROBLASTOMA SH-SY5Y CELLS; NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; REACTIVE OXYGEN; IN-VITRO; ANTIOXIDANT PROPERTIES; NEURONAL CELLS	Creatine has been reported to exert beneficial effects in several neurodegenerative diseases in which glutamatergic excitotoxicity and oxidative stress play an etiological role. The purpose of this study was to investigate the protective effects of creatine, as compared to the N-Methyl-D-Aspartate (NMDA) receptor antagonist dizocilpine (MK-801), against glutamate or hydrogen peroxide (H2O2)-induced injury in human neuroblastoma SH-SY5Y cells. Exposure of cells to glutamate (60-80 mM) or H2O2 (200-300 mu M) for 24 h decreased cellular viability and increased dichlorofluorescein (DCF) fluorescence (indicative of increased reactive oxygen species, ROS) and nitric oxide (NO) production (assessed by mono-nitrogen oxides, NOx, levels). Creatine (1-10 mM) or MK-801 (0.1-10 mu M) reduced glutamate- and H2O2-induced toxicity. The protective effect of creatine against glutamate-induced toxicity involves its antioxidant effect, since creatine, similar to MK-801, prevented the increase on DCF fluorescence induced by glutamate or H2O2. Furthermore, creatine or MK-801 blocked gltitamate- and H2O2-induced increases in NOx levels. In another set of experiments, the repeated, but not acute, administration of creatine (300 mg/kg, po) in mice prevented the decreases on cellular viability and mitochondrial membrane potential (assessed by tetramethylrhodamine ethyl ester, TMRE, probe) of hippocampal slices incubated with glutaihate (10 mM). Creatine concentration-dependent decreased the amount of nitrite formed in the reaction of oxygen with NO produced from sodium nitroprusside solution, suggesting that its protective effect against glutamate or H2O2-induced toxicity might be due to its scavenger activity. Overall, the results suggest that creatine may be useful as adjuvant therapy for neurodegenerative disease treatments. (C) 2016 Elsevier Ltd. All rights reserved.	[Cunha, Mauricio P.; Lieberknecht, Vicente; Ramos-Hryb, Ana Belen; Olescowicz, Gislaine; Ludka, Fabiana K.; Tasca, Carla I.; Gabilan, Nelson H.; Rodrigues, Ana Lucia S.] Univ Fed Santa Catarina, Ctr Biol Sci, Dept Biochem, Campus Univ, BR-88040900 Florianopolis, SC, Brazil	Cunha, MP (corresponding author), Univ Fed Santa Catarina, Ctr Biol Sci, Dept Biochem, Campus Univ, BR-88040900 Florianopolis, SC, Brazil.	mauricio.personal@gmail.com	Rodrigues, Ana Lucia/P-6869-2015; Tasca, Carla Ines/AAB-8287-2019; Cunha, Mauricio/J-7135-2013; Lieberknecht, Vicente/AAC-6952-2019; Lieberknecht, Vicente/L-2121-2017; Hryb, Ana Belen B R-H Ramos/P-3615-2014	Rodrigues, Ana Lucia/0000-0001-6285-8780; Tasca, Carla Ines/0000-0002-3414-6150; Cunha, Mauricio/0000-0002-0269-7521; Lieberknecht, Vicente/0000-0002-8418-2352; Lieberknecht, Vicente/0000-0002-8418-2352; Hryb, Ana Belen B R-H Ramos/0000-0003-3376-5977; Olescowicz, Gislaine/0000-0002-7462-3150	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [308723/2013-9, 449436/2014-4]; Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Apoio a Pesquisa Cientifica e Tecnologica do Estado de Santa Catarina (FAPESC)Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FA; Rede Instituto Brasileiro de Neurociencia (IBN-Net/CNPq); Nucleo de Excelencia em Neurociencias Aplicadas de Santa Catarina (NENASC) Project/PRONEX Program (CNPq/FAPESC) [1262/2012-9]	This study was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, #308723/2013-9, #449436/2014-4), Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES), Fundacao de Apoio a Pesquisa Cientifica e Tecnologica do Estado de Santa Catarina (FAPESC), Rede Instituto Brasileiro de Neurociencia (IBN-Net/CNPq), Nucleo de Excelencia em Neurociencias Aplicadas de Santa Catarina (NENASC) Project/PRONEX Program (CNPq/FAPESC, # 1262/2012-9).	Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Ballaz S, 2013, J NEUROSCI RES, V91, P1609, DOI 10.1002/jnr.23276; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Beister A, 2004, J NEURAL TRANSM-SUPP, P117; Blandini F, 1996, MOL NEUROBIOL, V12, P73, DOI 10.1007/BF02740748; Blandini F, 1996, FUNCT NEUROL, V11, P3; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Cacabelos R, 1999, INT J GERIATR PSYCH, V14, P3, DOI 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Capone C, 2013, FREE RADICAL BIO MED, V63, P99, DOI 10.1016/j.freeradbiomed.2013.05.007; CARTER AJ, 1995, J NEUROCHEM, V64, P2691; Cheng AW, 2003, DEV BIOL, V258, P319, DOI 10.1016/S0012-1606(03)00120-9; Cheng YH, 2014, BIOTECHNOL LETT, V36, P1615, DOI 10.1007/s10529-014-1521-6; Coco M, 2012, J SPORT MED PHYS FIT, V52, P165; Colle D, 2012, PHARM BIOL, V50, P883, DOI 10.3109/13880209.2011.641981; Colle D, 2012, J MED FOOD, V15, P549, DOI 10.1089/jmf.2011.0282; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; Contestabile A, 2003, CURR MED CHEM, V10, P2147, DOI 10.2174/0929867033456792; Cooper R, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-33; Cunha MP, 2013, NEUROSCIENCE, V238, P185, DOI 10.1016/j.neuroscience.2013.02.030; Cunha MP, 2015, AMINO ACIDS, V47, P795, DOI 10.1007/s00726-014-1910-0; Cunha MP, 2012, J PSYCHOPHARMACOL, V26, P1489, DOI 10.1177/0269881112447989; Deminice R, 2014, EUR J NUTR, V53, P1355, DOI 10.1007/s00394-013-0636-1; Deminice R, 2009, BRIT J NUTR, V102, P110, DOI 10.1017/S0007114508162985; DIGUISEPPI J, 1984, CRC CR REV TOXICOL, V12, P315, DOI 10.3109/10408448409044213; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Fimognari C, 2009, MUTAT RES-FUND MOL M, V670, P59, DOI 10.1016/j.mrfmmm.2009.07.005; Forman HJ, 2015, FREE RADICAL BIO MED, V78, P233, DOI 10.1016/j.freeradbiomed.2014.10.504; Royes LF, 2008, NEUROCHEM INT, V53, P33, DOI 10.1016/j.neuint.2008.04.008; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Genius J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030554; Gualano B, 2012, AMINO ACIDS, V43, P519, DOI 10.1007/s00726-011-1132-7; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Guidi C, 2008, BBA-GEN SUBJECTS, V1780, P16, DOI 10.1016/j.bbagen.2007.09.018; Hosamani R, 2010, NEUROCHEM RES, V35, P1402, DOI 10.1007/s11064-010-0198-z; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu Y, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/728342; Hu Y, 2014, J MOL NEUROSCI, V53, P600, DOI 10.1007/s12031-013-0226-y; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Iadarola ND, 2015, THER ADV CHRONIC DIS, V6, P97, DOI 10.1177/2040622315579059; Juravleva E, 2005, J NEUROSCI RES, V79, P224, DOI 10.1002/jnr.20291; Juravleva E, 2003, NATO SCI SERIES LIFE, V343, P113; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; Kingsley MIC, 2009, OXID MED CELL LONGEV, V2, P247, DOI 10.4161/oxim.2.4.9415; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lin Y, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P1928; Saraiva ALL, 2012, BRAIN RES BULL, V87, P180, DOI 10.1016/j.brainresbull.2011.10.010; Lorrio S, 2013, NEUROPHARMACOLOGY, V67, P403, DOI 10.1016/j.neuropharm.2012.12.001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; Malcon C, 2000, BRAIN RES, V860, P195, DOI 10.1016/S0006-8993(00)02038-2; Manosso LM, 2013, FOOD FUNCT, V4, P1776, DOI 10.1039/c3fo60246j; MARCOCCI L, 1994, BIOCHEM MOL BIOL INT, V34, P531; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Mikati MA, 2004, BRAIN INJURY, V18, P1229, DOI 10.1080/02699050410001719880; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; NATHAN C, 1992, FASEB J, V6, P3051; Nciri R, 2013, INT J NEUROPSYCHOPH, V16, P365, DOI 10.1017/S1461145712000132; Neukirchen M, 2012, BRIT J ANAESTH, V109, P887, DOI 10.1093/bja/aes303; Parada E, 2010, FREE RADICAL BIO MED, V49, P1815, DOI 10.1016/j.freeradbiomed.2010.09.017; Parodi M, 2003, BRAIN RES, V963, P197, DOI 10.1016/S0006-8993(02)03976-8; Cunha MP, 2014, ASN NEURO, V6, DOI 10.1177/1759091414554945; Pereira CF, 2000, NEUROSCI RES, V37, P227, DOI 10.1016/S0168-0102(00)00124-3; Pereira CMF, 1997, FREE RADICAL BIO MED, V23, P637, DOI 10.1016/S0891-5849(97)00020-8; Persky AM, 2001, PHARMACOL REV, V53, P161; Petroni D, 2013, ENVIRON TOXICOL, V28, P700, DOI 10.1002/tox.20765; Platt SR, 2007, VET J, V173, P278, DOI 10.1016/j.tvjl.2005.11.007; Quincozes-Santos A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064372; Rae CD, 2015, NEUROCHEM INT, V89, P249, DOI 10.1016/j.neuint.2015.08.010; Rahimi R, 2011, J STRENGTH COND RES, V25, P3448, DOI 10.1519/JSC.0b013e3182162f2b; Rambo LM, 2013, AMINO ACIDS, V44, P857, DOI 10.1007/s00726-012-1408-6; Rambo LM, 2009, NEUROCHEM INT, V55, P333, DOI 10.1016/j.neuint.2009.04.007; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Royes LFF, 2006, PHARMACOL BIOCHEM BE, V83, P136, DOI 10.1016/j.pbb.2005.12.017; Sanacora G, 2012, NEUROPHARMACOLOGY, V62, P63, DOI 10.1016/j.neuropharm.2011.07.036; Sartini S, 2012, J NEUROSCI RES, V90, P435, DOI 10.1002/jnr.22762; Schubert D, 2001, J NEUROSCI, V21, P7455; Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035; Sestili P, 2011, AMINO ACIDS, V40, P1385, DOI 10.1007/s00726-011-0875-5; Sestili P, 2009, MOL NUTR FOOD RES, V53, P1187, DOI 10.1002/mnfr.200800504; Siegel S, 2012, PHARMACOL BIOCHEM BE, V100, P653, DOI 10.1016/j.pbb.2011.11.002; Sonsalla PK, 1998, AMINO ACIDS, V14, P69, DOI 10.1007/BF01345245; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Sulkowski G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113954; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772; Sun HZ, 2010, CHINESE MED J-PEKING, V123, P1052, DOI 10.3760/cma.j.issn.0366-6999.2010.08.014; Sun ZW, 2010, NEUROSCI BULL, V26, P8, DOI 10.1007/s12264-010-0813-7; Swaminathan A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00282; Taveira M, 2014, J STEROID BIOCHEM, V140, P106, DOI 10.1016/j.jsbmb.2013.12.013; Tian JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095777; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Tzschentke TM, 2002, AMINO ACIDS, V23, P147, DOI 10.1007/s00726-001-0120-8; van Marum RJ, 2009, NEUROPSYCH DIS TREAT, V5, P237; Vielhaber S, 2001, EXP NEUROL, V172, P377, DOI 10.1006/exnr.2001.7797; Wei TT, 2000, BBA-MOL CELL RES, V1498, P72, DOI 10.1016/S0167-4889(00)00078-1; Wyss M, 2002, NEUROSCIENCE, V112, P243, DOI 10.1016/S0306-4522(02)00088-X; Xu MF, 2012, ACTA PHARMACOL SIN, V33, P578, DOI 10.1038/aps.2012.3; Yamamoto M, 2004, NEUROSCIENCE, V128, P163, DOI 10.1016/j.neuroscience.2004.06.026; Young JF, 2010, J INT SOC SPORT NUTR, V7, DOI 10.1186/1550-2783-7-9; Zhang AY, 2007, NEW PHYTOL, V175, P36, DOI 10.1111/j.1469-8137.2007.02071.x; Zhu XH, 2009, TOXICOL APPL PHARM, V240, P286, DOI 10.1016/j.taap.2009.06.020	117	17	18	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	MAY	2016	95						4	14		10.1016/j.neuint.2016.01.002			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DL3EB	WOS:000375515900002	26804444	Bronze			2021-06-18	
J	Jourdan, C; Bayen, E; Bahrami, S; Ghout, I; Darnoux, E; Azerad, S; Ruet, A; Vallat-Azouvi, C; Weiss, JJ; Aegerter, P; Mateo, J; Vigue, B; Tazarourte, K; Pradat-Diehl, P; Azouvi, P				Jourdan, Claire; Bayen, Eleonore; Bahrami, Stephane; Ghout, Idir; Darnoux, Emmanuelle; Azerad, Sylvie; Ruet, Alexis; Vallat-Azouvi, Claire; Weiss, Jean-Jacques; Aegerter, Philippe; Mateo, Joaquim; Vigue, Bernard; Tazarourte, Karim; Pradat-Diehl, Pascale; Azouvi, Philippe			Loss to Follow-Up and Social Background in an Inception Cohort of Patients With Severe Traumatic Brain Injury: Results From the PariS-TBI Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol-related disorders; bias (epidemiology); brain injuries; cohort studies; craniocerebral trauma; lost to follow-up; patient outcome assessment; socioeconomic factors	NATIONAL INSTITUTE; SYSTEMATIC BIAS; REHABILITATION; MODEL; EPIDEMIOLOGY; OUTCOMES; PRODUCTIVITY; PREDICTORS; DISABILITY; DATABASE	Objectives: To assess determinants of loss to follow-up (FU) at 2 time points of an inception traumatic brain injury (TBI) cohort. Design and Participants: The PariS-TBI study consecutively included 504 adults with severe TBI on the accident scene (76% male, mean age 42 years, mean Glasgow Coma Scale 5). No exclusion criteria were used. Main Measure: Loss to FU at 1 and 4 years was defined among survivors as having no outcome data other than survival status. Results: Among 257 1-year survivors, 118 (47%) were lost to FU at 1 year and 98 (40%) at 4 years. Main reasons for loss to FU were impossibility to achieve contact (109 at 1 year, 52 at 4 years) and refusal to participate (respectively 5 and 24). At 1 year, individuals not working preinjury or with nonaccidental traumas were more often lost to FU in univariate and multivariable analyses. At 4 years, loss to FU was significantly associated with preinjury alcohol abuse and unemployment. Relationship with injury severity was not significant. Conclusions: Socially disadvantaged persons are underrepresented in TBI outcome research. It could result in overestimation of outcome and biased estimates of sociodemographic characteristics' effects. These persons, particularly unemployed individuals, require special attention in clinical practice.	[Jourdan, Claire; Ruet, Alexis; Vallat-Azouvi, Claire; Azouvi, Philippe] Hop Raymond Poincare, APHP, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France; [Jourdan, Claire; Bahrami, Stephane; Ruet, Alexis; Azouvi, Philippe] Univ Versailles St Quentin, EA ECIPSY 4047, St Quentin en Yvelines, France; [Bayen, Eleonore] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Univ Paris 06, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Hop Univ Pitie Salpetriere Charles Foix, APHP, Serv Med Phys & Readaptat, Paris, France; [Bahrami, Stephane] Hop Raymond Poincare, APHP, Unite Sante Publ, F-92380 Garches, France; [Bahrami, Stephane] INSERM, CIC IT 805, F-92380 Garches, France; [Ghout, Idir; Darnoux, Emmanuelle; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, APHP, URC, Boulogne, France; [Darnoux, Emmanuelle; Azerad, Sylvie; Weiss, Jean-Jacques] CRFTC, Paris, France; [Vallat-Azouvi, Claire] Hop Raymond Poincare, UGECAM IDF, Antenne UEROS SAMSAH92, F-92380 Garches, France; [Mateo, Joaquim] Hop Lariboisiere, APHP, Dept Anesthesiol, Soins Intensifs & SAMU, Paris, France; [Vigue, Bernard] Hop Bicetre, APHP, Dept Anesthesiol & Soins Intensifs, Le Kremlin Bicetre, France; [Tazarourte, Karim] Hop Marc Jacquet, Mobile Care Unit, SAMU 77, Melun, France	Jourdan, C (corresponding author), Hop Raymond Poincare, APHP, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	claire.jourdan@rpc.aphp.fr	RUET, Alexis/L-8726-2015	RUET, Alexis/0000-0002-5080-5734; AEGERTER, Philippe/0000-0002-9156-5028; tazarourte, karim/0000-0002-3376-1258			Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P814, DOI 10.3109/02699052.2012.655360; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Collie A, 2013, INJURY, V44, P1514, DOI 10.1016/j.injury.2013.03.006; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CRIQUI MH, 1979, AM J EPIDEMIOL, V109, P394, DOI 10.1093/oxfordjournals.aje.a112695; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; INSEE, POP POP AG 2007 2040; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Krellman JW, 2014, ARCH PHYS MED REHAB, V95, P633, DOI 10.1016/j.apmr.2013.10.016; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2478, DOI 10.1016/j.apmr.2013.06.019; R Core Team, 2013, R LANG ENV STAT COMP; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Traumatic Brain Injury Model Systems National Data and Statistical Center, GUID STRAT MAX FOLL; Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	34	17	17	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					E42	E48		10.1097/HTR.0000000000000147			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800005	26098257				2021-06-18	
J	Leeper, CM; Nasr, I; McKenna, C; Berger, RP; Gaines, BA				Leeper, Christine M.; Nasr, Isam; McKenna, Christine; Berger, Rachel P.; Gaines, Barbara A.			Elevated admission international normalized ratio strongly predicts mortality in victims of abusive head trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Abusive head trauma; international normalized ratio; acute traumatic coagulopathy; mortality	BRAIN-INJURY; RAPID THROMBELASTOGRAPHY; BLEEDING DISORDERS; EARLY COAGULOPATHY; YOUNG-CHILDREN; ORGAN FAILURE; INFANTS; SHOCK; DEFINITION; OUTCOMES	BACKGROUND: Victims of abusive head trauma have poor outcomes compared with other injured children. There is often a delay in diagnosis because these young patients are unable to communicate with health care providers. These critically injured patients would benefit from early identification and therapy. METHODS: We performed a retrospective review of our single hospital trauma registry from 2005 to 2014. All Level 1 pediatric (age 0-17 years) trauma patients who sustained abusive head trauma were included. Exclusion criteria included no admission coagulation studies, prehospital product transfusion, preexisting coagulation disorder, or death upon arrival. Primary outcome was mortality; secondary outcomes were early blood transfusion and neurosurgical intervention. Univariate analysis included Fisher's exact and Wilcoxon rank-sum testing; we then performed logistic regression modeling and calculated adjusted odds ratios (AORs) to control for known predictors of poor outcome including hypotension, hypothermia, acidosis, Injury Severity Score (ISS), and head Abbreviated Injury Scale (AIS) score. RESULTS: In 101 total subjects, 35% (n = 35) had international normalized ratio (INR) of 1.3 or greater at admission. On univariate analysis, patients with coagulation dysregulation were more likely to have hypothermia, hypotension, acidosis, high ISS, and low Glasgow Coma Scale (GCS) score (all p < 0.05). Therewas no difference in age, anemia, and incidence of polytrauma. Overallmortalitywas 24.8% (n = 25), which varied significantly based at admission INR (60% INR = 1.3 vs. 6% INR > 1.3, p < 0.001). Patients with elevated INR were also more likely to have early packed red blood cell transfusion (p = 0.003) and neurosurgical intervention (p = 0.011). In logistic regression analysis, admission INR was the strongest independent predictor of mortality, with increased odds of 3.65 (p = 0.045). AOR after controlling specifically for hypotension, hypothermia, and acidosis was 6.25 (p = 0.006), and after controlling for head AIS score and admission GCS score, the AOR was 5.27 (p = 0.007). CONCLUSION: Admission INR of 1.3 or greater strongly predicts mortality in abusive head trauma. These patients should be targeted for early aggressive interventions and monitoring with the goal of improving patient outcomes. Further study is warranted to investigate potential therapeutic targets in trauma-induced coagulation dysregulation. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Leeper, Christine M.; McKenna, Christine; Berger, Rachel P.; Gaines, Barbara A.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15224 USA; [Leeper, Christine M.] Univ Pittsburgh, Dept Surg, Div Gen Surg & Trauma, Dept Surg, Pittsburgh, PA 15224 USA; [Nasr, Isam] Johns Hopkins Univ Hosp, Div Pediat Surg, Baltimore, MD 21287 USA	Gaines, BA (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, UPMC, 7th Floor,Fac Pavilion,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	Barbara.Gaines@chp.edu					Acker SN, 2015, J PEDIATR SURG, V50, P331, DOI 10.1016/j.jpedsurg.2014.08.009; Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; Anderst JD, 2013, PEDIATRICS, V131, pE1314, DOI 10.1542/peds.2013-0195; Attard C, 2013, J THROMB HAEMOST, V11, P1850, DOI 10.1111/jth.12372; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brousseau TJ, 2005, J EMERG MED, V29, P283, DOI 10.1016/j.jemermed.2005.02.009; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Eswald MB, 2010, TXB PEDIAT EMERGENCY, V6; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Falcone RA, 2007, J PEDIATR SURG, V42, P1031, DOI 10.1016/j.jpedsurg.2007.01.038; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Frith D, 2010, SURG-J R COLL SURG E, V8, P159, DOI 10.1016/j.surge.2009.10.022; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gonzalez E, 2014, SCAND J SURG, V103, P89, DOI 10.1177/1457496914531927; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jackson J, 2012, CHILD ABUSE NEGLECT, V36, P127, DOI 10.1016/j.chiabu.2011.09.009; Janus J, 2010, AM FAM PHYSICIAN, V81, P1462; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kleinman ME, 2010, PEDIATRICS, V126, pE1361, DOI 10.1542/peds.2010-2972D; Kutcher ME, 2015, J TRAUMA ACUTE CARE, V78, P516, DOI 10.1097/TA.0000000000000545; Lecky FE, 2010, DAMAGE CONTROL MANAGEMENT IN THE POLYTRAUMA PATIENT, P13, DOI 10.1007/978-0-387-89508-6_2; Lind K, 2015, CHILD ABUSE NEGL; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Matschke J, 2015, INT J LEGAL MED, V129, P105, DOI 10.1007/s00414-014-1060-7; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Niederkrotenthaler T, 2013, CHILD ABUSE NEGLECT, V37, P446, DOI 10.1016/j.chiabu.2013.02.002; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peltan ID, 2015, CRIT CARE MED, V43, P1429, DOI 10.1097/CCM.0000000000000981; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Roaten JB, 2006, J PEDIATR SURG, V41, P2013, DOI 10.1016/j.jpedsurg.2006.08.028; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Shein SL, 2012, J PEDIATR-US, V161, P716, DOI 10.1016/j.jpeds.2012.03.046; Stewart CL, 2013, J PEDIATR SURG, V48, P2106, DOI 10.1016/j.jpedsurg.2013.05.009; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Vogel AM, 2013, J PEDIATR SURG, V48, P1371, DOI 10.1016/j.jpedsurg.2013.03.036; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb	50	17	17	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2016	80	5					711	716		10.1097/TA.0000000000000954			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DM9ZB	WOS:000376723100005	27100929				2021-06-18	
J	Moran, LM; Babikian, T; Del Piero, L; Ellis, MU; Kernan, CL; Newman, N; Giza, CC; Mink, R; Johnson, J; Babbitt, C; Asarnow, R				Moran, Lisa M.; Babikian, Talin; Del Piero, Larissa; Ellis, Monica U.; Kernan, Claudia L.; Newman, Nina; Giza, Christopher C.; Mink, Richard; Johnson, Jeffrey; Babbitt, Christopher; Asarnow, Robert			The UCLA study of Predictors of Cognitive Functioning Following Moderate/Severe Pediatric Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive Symptoms; Longitudinal Studies; Neuropsychological Tests; Psychometrics; Children; Adolescents; Brain Injury	OF-THE-LITERATURE; YOUNG-CHILDREN; UNITED-STATES; RECOVERY; OUTCOMES; TERM; VARIABLES; SEVERITY; AGE	Objectives: Following pediatric moderate-to-severe traumatic brain injury (msTBI), few predictors have been identified that can reliably identify which individuals are at risk for long-term cognitive difficulties. This study sought to determine the relative contribution of detailed descriptors of injury severity as well as demographic and psychosocial factors to long-term cognitive outcomes after pediatric msTBI. Methods: Participants included 8- to 19-year-olds, 46 with msTBI and 53 uninjured healthy controls (HC). Assessments were conducted in the post-acute and chronic stages of recovery. Medical record review provided details regarding acute injury severity. Parents also completed a measure of premorbid functioning and behavioral problems. The outcome of interest was four neurocognitive measures sensitive to msTBI combined to create an index of cognitive performance. Results: Results indicated that none of the detailed descriptors of acute injury severity predicted cognitive performance. Only the occurrence of injury, parental education, and premorbid academic competence predicted post-acute cognitive functioning. Long-term cognitive outcomes were best predicted by post-acute cognitive functioning. Conclusions: The findings suggest that premorbid factors influence cognitive outcomes nearly as much as the occurrence of a msTBI. Furthermore, of youth with msTBI who initially recover to a level of moderate disability or better, a brief cognitive battery administered within several months after injury can best predict which individuals will experience poor long-term cognitive outcomes and require additional services.	[Moran, Lisa M.; Babikian, Talin; Ellis, Monica U.; Kernan, Claudia L.; Newman, Nina; Asarnow, Robert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Hlth, Los Angeles, CA USA; [Babikian, Talin; Giza, Christopher C.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Del Piero, Larissa] Univ Southern Calif, Dept Psychol, Los Angeles, CA 90089 USA; [Ellis, Monica U.] Fuller Theol Seminary, Dept Psychol, Pasadena, CA 91101 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA USA; [Mink, Richard; Johnson, Jeffrey] Los Angeles Cty, Dept Pediat, Los Angeles, CA USA; [Mink, Richard] Harbor Univ Calif, Los Angeles, CA USA; [Johnson, Jeffrey] Univ Southern Calif, Med Ctr, Los Angeles, CA USA; [Babbitt, Christopher] Miller Childrens Hosp, Dept Pediat, Long Beach, CA USA; [Asarnow, Robert] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Asarnow, Robert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	Babikian, T (corresponding author), Univ Calif Los Angeles, Div Child & Adolescent Psychiat, 760 Westwood Plaza, Los Angeles, CA 90095 USA.	tbabikian@mednet.ucla.edu		Del Piero, Larissa/0000-0002-4407-5472	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061504]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER	No competing financial interests exist. The authors declare no conflict of interest. This work was supported by grant R01 HD061504 from the National Institute of Child Health and Human Development to Robert Asarnow, Ph.D.	Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Howard I., 2005, ETHN DIS S5, V15; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; McCabe DP, 2010, NEUROPSYCHOLOGY, V24, P222, DOI 10.1037/a0017619; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	27	17	17	1	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2016	22	5					512	519		10.1017/S1355617716000175			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DU8SJ	WOS:000382484300003	27019212				2021-06-18	
J	Shen, YF; Yu, WH; Dong, XQ; Du, Q; Yang, DB; Wu, GQ; Zhang, ZY; Wang, H; Jiang, L				Shen, Yong-Feng; Yu, Wen-Hua; Dong, Xiao-Qiao; Du, Quan; Yang, Ding-Bo; Wu, Gang-Qun; Zhang, Zu-Yong; Wang, Hao; Jiang, Li			The change of plasma galectin-3 concentrations after traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						Traumatic brain injury; Galectin-3; Acute traumatic coagulopathy; Progressive hemorrhagic injury; Posttraumatic cerebral infarction; Mortality	POSTTRAUMATIC CEREBRAL INFARCTION; RISK-FACTORS; HEAD TRAUMA; COAGULOPATHY; HEMORRHAGE; MICROGLIA; MODERATE; PATHOPHYSIOLOGY; INFLAMMATION; PROGRESSION	Background: Galectin-3 plays a significant role in microglia activation. Its increased circulating concentration has been associated with some inflammatory diseases. In-hospital major adverse events (IMAEs), including acute traumatic coagulopathy, progressive hemorrhagic injury and posttraumatic cerebral infarction, have high prevalence and are strong predictors of mortality after severe traumatic brain injury (STBI). The present study was designed to investigate the relationships between plasma galectin-3 concentrations and trauma severity, in-hospital mortality and IMAEs following STBI. Methods: Plasma galectin-3 concentrations of 100 STBI patients and 100 controls were determined. Diagnosis of progressive hemorrhagic injury and posttraumatic cerebral infarction was made on the follow-up computerized tomography scan. Acute traumatic coagulopathy was defined based on coagulation test. Results: Plasma galectin-3 concentrations were significantly higher in patients as compared to controls and also associated highly with Glasgow Coma Scale scores and plasma C-reactive protein concentrations. Galectin-3 emerged as an independent predictor for in-hospital mortality and IMAEs. Areas under receiver operating characteristic curve of plasma galectin-3 concentrations were similar to those of Glasgow Coma Scale scores for prediction of in-hospital morality and IMAEs. Conclusions: Plasma galectin-3 concentrations have close relation to inflammation, trauma severity and clinical outcome, suggesting that galectin-3 should have the potential to be a good prognostic biomarker after STBI. (C) 2016 Elsevier B.V. All rights reserved.	[Shen, Yong-Feng; Yang, Ding-Bo] Tumor Hosp Hangzhou City, Dept Neurosurg, 34 Yanguan Lane, Hangzhou 310002, Zhejiang, Peoples R China; [Yu, Wen-Hua; Dong, Xiao-Qiao; Du, Quan; Wang, Hao; Jiang, Li] Nanjing Med Univ, Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China; [Wu, Gang-Qun] Tonglu TCM Hosp, Dept Neurosurg, 25 Guangchang Rd, Tonglu 311500, Peoples R China; [Zhang, Zu-Yong] Hangzhou Hosp Tradit Chinese Med, Dept Neurosurg, 453 Tiyuchang Rd, Hangzhou 310007, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxghyy@163.com			Zhejiang Province Medical and Health Project [2014KYA177, 2016RCB016]; Hangzhou Medical Research Fund Project [2014Z06]	The authors thank all staffs in the Department of Neurosurgery, The Hangzhou First People's Hospital (Hangzhou, China) for their technical support. This study was supported financially by the Zhejiang Province Medical and Health Project (No. 2014KYA177, 2016RCB016) and the Hangzhou Medical Research Fund Project (No. 2014Z06).	Ahmed H, 2015, CLIN MED INSIGHTS-ON, V9, P113, DOI [10.4137/CMO.S29462., 10.4137/CMO.S29462]; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Arad U, 2015, CYTOKINE, V73, P30, DOI 10.1016/j.cyto.2015.01.016; Boza-Serrano A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0156-0; Burguillos MA, 2015, CELL REP, V10, P1626, DOI 10.1016/j.celrep.2015.02.012; Chen Hung-Lin, 2014, Adv Neurobiol, V9, P517, DOI 10.1007/978-1-4939-1154-7_24; Chiariotti L, 1999, BIOCHIMIE, V81, P381, DOI 10.1016/S0300-9084(99)80085-6; Cohen MJ, 2014, THROMB RES, V133, pS25, DOI 10.1016/j.thromres.2014.03.013; de Oliveira FL, 2015, EXP BIOL MED, V240, P1019, DOI 10.1177/1535370215593826; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Edsfeldt A, 2016, CEREBROVASC DIS, V41, P199, DOI 10.1159/000443022; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Frattalone AR, 2013, NEUROSURG CLIN N AM, V24, P309, DOI 10.1016/j.nec.2013.03.006; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Koca SS, 2014, CLIN RHEUMATOL, V33, P215, DOI 10.1007/s10067-013-2346-8; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lalancette-Hebert M, 2012, J NEUROSCI, V32, P10383, DOI 10.1523/JNEUROSCI.1498-12.2012; Latronico N, 2009, J TRAUMA, V66, P1745, DOI 10.1097/TA.0b013e3181a56c8b; Li LC, 2014, J PHARMACOL EXP THER, V351, P336, DOI 10.1124/jpet.114.218370; Li Y, 2008, J IMMUNOL, V181, P2781, DOI 10.4049/jimmunol.181.4.2781; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Nielsen C. T., 2014, SCI MED, V1; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ohshima S, 2003, ARTHRITIS RHEUM-US, V48, P2788, DOI 10.1002/art.11287; Peacock William Frank, 2014, Crit Pathw Cardiol, V13, P73, DOI 10.1097/HPC.0000000000000012; Piper SE, 2016, INT J CARDIOL, V207, P279, DOI 10.1016/j.ijcard.2016.01.179; Satoh K, 2011, NEUROSCI LETT, V504, P199, DOI 10.1016/j.neulet.2011.09.015; Sheriff FG, 2015, SEMIN NEUROL, V35, P42, DOI 10.1055/s-0035-1544238; Shin T, 2013, ACTA HISTOCHEM, V115, P407, DOI 10.1016/j.acthis.2012.11.010; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P12, DOI 10.1097/TA.0b013e3182aaa675; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Zammit Christopher, 2013, Emerg Med Pract, V15, P1; Zhang WL, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001993; Zhou JY, 2010, J PROTEOME RES, V9, P5133, DOI 10.1021/pr100409r	40	17	17	0	144	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	MAY 1	2016	456						75	80		10.1016/j.cca.2016.02.029			6	Medical Laboratory Technology	Medical Laboratory Technology	DL0YG	WOS:000375357900014	26944570				2021-06-18	
J	Shin, MS; Park, HK; Kim, TW; Ji, ES; Lee, JM; Choi, HS; Kim, MY; Kim, YP				Shin, Mal Soon; Park, Hun Kyung; Kim, Tae Woon; Ji, Eun Sang; Lee, Jae Min; Choi, Han Sung; Kim, Mi Ye; Kim, Young Pyo			Neuroprotective Effects of Bone Marrow Stromal Cell Transplantation in Combination With Treadmill Exercise Following Traumatic Brain Injury	INTERNATIONAL NEUROUROLOGY JOURNAL			English	Article						Brain Injuries; Mesenchymal Stromal Cells; Exercise Test; Neurogenesis; Apoptosis	STEM-CELLS; APOPTOSIS; NEUROGENESIS; HIPPOCAMPUS; RAT; MITOCHONDRIA; PLASTICITY; RECOVERY; MODEL; LTP	Purpose: Traumatic brain injury (TBI) causes cognitive impairments, motor deficits, and neuropsychiatric/behavioral deficits problems. Transplantation of bone marrow stromal cells (BMSCs) facilitates functional recovery from brain insults. Treadmill exercise increases neurogenesis and inhibits apoptosis. In this study, we investigated the effects of BMSC transplantation in combination with treadmill exercise on memory function, by evaluating its effect on neurogenesis and apoptosis in the hippocampus following TBI. Methods: TBI was induced using an electromagnetic-controlled cortical impact device. BMSCs were transplanted into both sides of traumatic scar region 1 week after TBI induction. One week after transplantation of BMSCs, the rats in the exercise groups were trained to run on a treadmill for 30 minutes once daily for 28 days. Step-down avoidance task and radial 8-arm maze test were conducted. Levels of 5-bromo-2'-deoxyuridine and caspase-3 were evaluated using immunohistochemistry. Western blot was used to evaluate the expression of brain-derived neurotrophic factor (BDNF), tyrosine kinase B (TrkB), total-extracellular signal-regulated kinase 1 and 2 (t-ERK1/2), phosphorylated-ERK1/2 (p-ERK1/2), Bcl-2, and Bax. Results: TBI deteriorated memory function, suppressed neurogenesis, and accelerated apoptosis in the hippocampus. Treadmill exercise and BMSC transplantation independently improved memory function by increasing neurogenesis with suppression of apoptosis through the BDNF-ERK pathway in the TBI-induced rats. Combination of BMSC transplantation with treadmill exercise showed additional enhancement of neurogenesis and suppression of apoptosis in the hippocampus. Conclusions: The present study shows that treadmill exercise may aid the therapeutic effect of BMSC transplantation on TBI in rats.	[Shin, Mal Soon] Korea Univ, Sch Global Sport Studies, Sejong, South Korea; [Park, Hun Kyung; Kim, Tae Woon; Ji, Eun Sang; Lee, Jae Min] Kyung Hee Univ, Dept Physiol, Coll Med, Seoul, South Korea; [Choi, Han Sung] Kyung Hee Univ, Dept Emergency Med, Coll Med, Seoul, South Korea; [Kim, Mi Ye; Kim, Young Pyo] Jeju Natl Univ, Dept Kinesiol, Coll Nat Sci, 102 Jejudaehak Ro, Jeju 63243, South Korea	Kim, YP (corresponding author), Jeju Natl Univ, Dept Kinesiol, Coll Nat Sci, 102 Jejudaehak Ro, Jeju 63243, South Korea.	kimyp@jejunu.ac.kr			Korea Institute of Sport Science, Seoul Olympic Sports Promotion Foundation [KISS-14-A05005]	This work was done with the sports promotion fund from Korea Institute of Sport Science, Seoul Olympic Sports Promotion Foundation (KISS-14-A05005).	Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Chae CH, 2009, NEUROCHEM INT, V55, P208, DOI 10.1016/j.neuint.2009.02.024; Cho YS, 2015, MOL MED REP, V12, P1796, DOI 10.3892/mmr.2015.3612; Cullen SP, 2009, CELL DEATH DIFFER, V16, P935, DOI 10.1038/cdd.2009.59; De Feo D, 2012, CURR OPIN NEUROL, V25, P322, DOI 10.1097/WCO.0b013e328352ec45; Ernfors P, 2003, TRENDS NEUROSCI, V26, P171, DOI 10.1016/S0166-2236(03)00064-X; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Javazon EH, 2001, STEM CELLS, V19, P219, DOI 10.1634/stemcells.19-3-219; Ji ES, 2015, J EXERC REHABIL, V11, P133, DOI 10.12965/jer.150212; Jiang YF, 2011, NEUROL RES, V33, P331, DOI 10.1179/016164110X12816242542571; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kim K, 2015, J EXERC REHABIL, V11, P296, DOI 10.12965/jer.150264; Kim SE, 2013, NEUROSCI LETT, V538, P54, DOI 10.1016/j.neulet.2013.01.039; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Neirinckx V, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0202-2; O'Callaghan RM, 2007, BEHAV BRAIN RES, V176, P362, DOI 10.1016/j.bbr.2006.10.018; Park MS, 2014, J EXERC REHABIL, V10, P148, DOI 10.12965/jer.140109; Shen Q, 2016, CELL PHYSIOL BIOCHEM, V38, P748, DOI 10.1159/000443031; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423; Song HW, 2011, LIFE SCI, V89, P439, DOI 10.1016/j.lfs.2011.07.003; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	26	17	19	0	11	KOREAN CONTINENCE SOC	YEONGOTONG-GU	DEPT UROLOGY, AJOU UNIV COLL MEDICINE, SAN 5 WONCHEN-DONG, YEONGOTONG-GU, SUWON 443-721, SOUTH KOREA	2093-4777	2093-6931		INT NEUROUROL J	Int. Neurourol. J.	MAY	2016	20			1			S49	S56		10.5213/inj.1632616.308			8	Urology & Nephrology	Urology & Nephrology	DN3ZN	WOS:000377002900008	27230460	DOAJ Gold, Green Published			2021-06-18	
J	Wu, LM; Tanenbaum, ML; Dijkers, MPJM; Amidi, A; Hall, SJ; Penedo, FJ; Diefenbach, MA				Wu, Lisa M.; Tanenbaum, Molly L.; Dijkers, Marcel P. J. M.; Amidi, Ali; Hall, Simon J.; Penedo, Frank J.; Diefenbach, Michael A.			Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study	SOCIAL SCIENCE & MEDICINE			English	Article						Prostate cancer; Oncology; Cognitive functioning; Neurobehavioral functioning; Androgen deprivation therapy; Attributions; Quality of life	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; STEM-CELL TRANSPLANT; MEN; IMPAIRMENT; APATHY; CHEMOTHERAPY; METAANALYSIS; MANAGEMENT; CIRCUITS	BACKGROUND: Few studies have investigated prostate cancer patients' experiences of cognitive functioning or neurobehavioral symptoms (i.e., behavioral changes associated with neurological dysfunction) following androgen deprivation therapy (ADT). METHODS: Semi-structured interviews conducted from the US by phone and in-person were used to explore and characterize the: 1) experience of cognitive and neurobehavioral functioning in non metastatic prostate cancer patients undergoing ADT (n = 19) compared with patients who had not undergone ADT (n = 20); 2) perceived causes of cognitive and neurobehavioral symptoms; 3) impact of these symptoms on quality of life; and 4) strategies used to cope with or compensate for these symptoms. Neuropsychological performance was assessed to characterize the sample. RESULTS: Overall, ADT patients experienced marginally more cognitive problems than non-ADT (nADT) patients even though there were no significant differences between groups in neuropsychological performance. ADT patients also experienced more declines in prospective memory and multi-tasking than nADT patients. Significant proportions of participants in both groups also experienced retrospective memory, attention and concentration, and information processing difficulties. With respect to neurobehavioral symptoms, more ADT patients experienced emotional lability and impulsivity (both aspects of disinhibition) than nADT patients. Among the causes to which participants attributed declines, both groups attributed them primarily to aging. A majority of ADT patients also attributed declines to ADT. For both groups, increased cognitive and neurobehavioral symptoms negatively impacted quality of life, and most participants developed strategies to ameliorate these problems. CONCLUSION: ADT patients are more vulnerable to experiencing specific cognitive and neurobehavioral symptoms than nADT patients. This study highlights the importance of capturing: a) cognitive symptoms not easily detected using neuropsychological tests; b) neurobehavioral symptoms that can be confused with psychological symptoms, and c) causal beliefs that may affect how people cope with these symptoms. Effective interventions are needed to assist prostate cancer patients in managing these symptoms. (C) 2016 Elsevier Ltd. All rights reserved.	[Wu, Lisa M.; Penedo, Frank J.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 633 North St Clair,Suite 19-073, Chicago, IL 60611 USA; [Tanenbaum, Molly L.] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; [Dijkers, Marcel P. J. M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Amidi, Ali] Aarhus Univ Hosp, Dept Oncol, Unit Psychooncol & Hlth Psychol, Aarhus C, Denmark; [Amidi, Ali] Aarhus Univ Hosp, Dept Psychol & Behav Sci, Aarhus C, Denmark; [Amidi, Ali] Aarhus Univ, Aarhus C, Denmark; [Diefenbach, Michael A.] Northwell Hlth, Dept Med, Great Neck, NY USA; [Diefenbach, Michael A.] Northwell Hlth, Dept Urol, Great Neck, NY USA	Wu, LM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 633 North St Clair,Suite 19-073, Chicago, IL 60611 USA.	lisa.wu1@northwestern.edu; mollyt@stanford.edu; Marcel.Dijkers@mountsinai.org; ali@psy.au.dk; Shall12@Northwell.edu; fpenedo@northwestern.edu; MDiefenbach@Northwell.edu	; Wu, Lisa/P-1202-2018	Tanenbaum, Molly/0000-0003-4222-4224; Wu, Lisa/0000-0003-2241-9905; Dijkers, Marcel/0000-0002-8362-5596; Amidi, Ali/0000-0003-2921-9797	National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5R03CA165827-02, 7K07CA184145-02]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07CA184145, P30CA060553, R03CA165827] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers #5R03CA165827-02 and #7K07CA184145-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also thank Krista Herbert, M.A. for her assistance with data management.	Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Anderson M. C., 2009, MEMORY; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Batrinos ML, 2012, INT J ENDOCRINOL MET, V10, P563, DOI 10.5812/ijem.3661; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Butler C, 2005, J NEUROL NEUROSUR PS, V76, pI31, DOI 10.1136/jnnp.2004.060459; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chambers R, 2009, CLIN PSYCHOL REV, V29, P560, DOI 10.1016/j.cpr.2009.06.005; Cherner MM, 2009, PSYCHO-ONCOLOGY, V18, P237, DOI 10.1002/pon.1401; Cherrier MM, 2015, AM J ALZHEIMERS DIS, V30, P421, DOI 10.1177/1533317514556874; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dauncey MJ, 2014, EUR J CLIN NUTR, V68, P1179, DOI 10.1038/ejcn.2014.173; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; Garcia JGD, 2007, SOC SCI MED, V64, P2223, DOI 10.1016/j.socscimed.2007.02.001; Donovan KA, 2015, CANCER-AM CANCER SOC, V121, P4286, DOI 10.1002/cncr.29672; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Glaser B. G., 1967, DISCOVERY GROUNDED T; Gomella LG, 2007, BJU INT, V99, P25, DOI 10.1111/j.1464-410X.2007.06598.x; Gonzalez B. D., 2015, J CLIN ONCOL OFF J A, DOI JC0.2014.60.1963[pii]; Gualtieri C.T., 2004, 32 INT NEUR SOC ANN; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hutchinson AD, 2012, CANCER TREAT REV, V38, P926, DOI 10.1016/j.ctrv.2012.05.002; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Jansen CE, 2007, ONCOL NURS FORUM, V34, P997, DOI 10.1188/07.ONF.997-1005; Joly F, 2006, J UROLOGY, V176, P2443, DOI 10.1016/j.juro.2006.07.151; Kocka A, 2014, BEHAV SCI, V4, P352, DOI 10.3390/bs4040352; Kryscio RJ, 2014, NEUROLOGY, V83, P1359, DOI 10.1212/WNL.0000000000000856; Kumar Ravi J, 2005, Rev Urol, V7 Suppl 5, pS37; Lane-Brown A, 2010, J HEAD TRAUMA REHAB, V25, P459, DOI 10.1097/HTR.0b013e3181d98e1d; Larner A. J., 2010, DICT NEUROLOGICAL SI; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Maggio M, 2006, J ANDROL, V27, P725, DOI 10.2164/jandrol.106.000141; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mandelblatt JS, 2013, SEMIN ONCOL, V40, P709, DOI 10.1053/j.seminoncol.2013.09.006; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McGinty HL, 2014, SUPPORT CARE CANCER, V22, P2271, DOI 10.1007/s00520-014-2285-1; Miller S.M., 2008, HDB EMOTIONS, P645; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Ollendick TH, 2003, ENCY CLIN CHILD PEDI; Reisberg B, 2010, ALZHEIMERS DEMENT, V6, P11, DOI 10.1016/j.jalz.2009.10.002; Richards L, 2005, HANDLING QUALITATIVE; Salman H, 2012, BIOMED PHARMACOTHER, V66, P330, DOI 10.1016/j.biopha.2012.03.004; Sangha O, 2003, ARTHRIT RHEUM-ARTHR, V49, P156, DOI 10.1002/art.10993; Singh J, 2010, CLIN INTERV AGING, V5, P187; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; VERMEULEN A, 1991, J CLIN ENDOCR METAB, V73, P221, DOI 10.1210/jcem-73-2-221; Voerman B, 2006, J PSYCHOSOC ONCOL, V24, P49, DOI 10.1300/J077v24n02_04; Von Ah D, 2014, CLIN J ONCOL NURS, V18, P17, DOI 10.1188/14.CJON.S3.17-25; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Wechsler D., 2001, WECHSLER TEST ADULT; Wefel JS, 2015, CA-CANCER J CLIN, V65, P123, DOI 10.3322/caac.21258; Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1; Wu LM, 2014, PSYCHO-ONCOLOGY, V23, P1406, DOI 10.1002/pon.3554; Wu LM, 2013, UROL ONCOL-SEMIN ORI, V31, P1533, DOI 10.1016/j.urolonc.2012.07.003; Wu LM, 2012, PSYCHO-ONCOLOGY, V21, P1175, DOI 10.1002/pon.2012; Yang J, 2015, EUR J CANCER CARE, V24, P198, DOI 10.1111/ecc.12299	60	17	17	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	MAY	2016	156						80	89		10.1016/j.socscimed.2016.03.016			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	DL3ET	WOS:000375517700010	27019142	Green Accepted			2021-06-18	
J	DeMar, J; Sharrow, K; Hill, M; Berman, J; Oliver, T; Long, J				DeMar, James; Sharrow, Keith; Hill, Miya; Berman, Jonathan; Oliver, Thomas; Long, Joseph			Effects of Primary Blast Overpressure on Retina and Optic Tract in Rats	FRONTIERS IN NEUROLOGY			English	Article						blast; neurotrauma; retina; optic tract; rat	TRAUMATIC BRAIN-INJURY; INDUCED OCULAR TRAUMA; MOUSE MODEL; AFGHANISTAN WARS; DEGENERATION; TBI; DAMAGE; EYE; PATHOPHYSIOLOGY; MECHANISMS	Blast has been the leading cause of injury, particularly traumatic brain injury and visual system injury, in combat operations in Iraq and Afghanistan. We determined the effect of shock tube-generated primary blast on retinal electrophysiology and on retinal and brain optic tract histopathology in a rat model. The amplitude of a- and b-waves on the electroretinogram (ERG) for both right and left eyes were measured prior to a battlefield simulation Friedlander-type blast wave and on 1, 7, and 14 days thereafter. Histopathologic findings of the right and left retina and the right and left optic tracts (2.8 mm postoptic chiasm) were evaluated 14 days after the blast. For two experiments in which the right eye was oriented to the blast, the amplitude of ERG a- and b-waves at 7 days post blast on the right side but not on the left side was diminished compared to that of sham animals (P = 0.005-0.01) Histopathologic injury scores at 14 days post blast for the right retina but not the left retina were higher than for sham animals (P = 0.01), and histopathologic injury scores at 14 days for both optic tracts were markedly higher than for shams (P < 0.0001). Exposure of one eye to a blast wave, comparable to that causing human injury, produced injury to the retina as determined by ERG and histopathology, and to both postchiasmatic optic tracts as determined by histopathology. This model may be useful for analyzing the effect of therapeutic interventions on retinal damage due to primary blast waves.	[DeMar, James; Hill, Miya; Long, Joseph] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Sharrow, Keith] Med Countermeasures Syst, Frederick, MD USA; [Berman, Jonathan] Walter Reed Army Inst Res, Dept Clin Pharmacol, Silver Spring, MD USA; [Oliver, Thomas] Uniformed Serv Univ Hlth Sci, Clin Res Unit, Bethesda, MD 20814 USA	DeMar, J (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA.	james.c.demar.ctr@mail.mil			USAMRMC/TATRC Vision Research Program [W81XWH-12-2-0082]	This work was supported in part by a USAMRMC/TATRC Vision Research Program grant award, #: W81XWH-12-2-0082.	Aviles-Trigueros M, 2003, EXP NEUROL, V184, P767, DOI 10.1016/S0014-4886(03)00298-X; Banihani SM, 2010, MED HYPOTHESES, V74, P741, DOI 10.1016/j.mehy.2009.10.037; Bricker-Anthony C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131921; Bricker-Anthony C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0192-5; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Choi JH, 2015, CLIN EXP OPHTHALMOL, V43, P239, DOI 10.1111/ceo.12407; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Jiang YD, 2014, CYTOKINE, V70, P115, DOI 10.1016/j.cyto.2014.07.004; Jiang YD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-96; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Rossi T, 2012, INVEST OPHTH VIS SCI, V53, P8057, DOI 10.1167/iovs.12-10591; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; THANOS S, 1991, J CELL SCI, P125; Wang HCH, 2014, MIL MED, V179, P34, DOI 10.7205/MILMED-D-13-00504; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; You YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052061; Zou YY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-79	32	17	17	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	APR 25	2016	7								59	10.3389/fneur.2016.00059			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DK0WV	WOS:000374633800001	27199884	DOAJ Gold, Green Published			2021-06-18	
J	Davies, DR; Olson, D; Meyer, DL; Scholl, JL; Watt, MJ; Manzerra, P; Renner, KJ; Forster, GL				Davies, Daniel R.; Olson, Dawne; Meyer, Danielle L.; Scholl, Jamie L.; Watt, Michael J.; Manzerra, Pasquale; Renner, Kenneth J.; Forster, Gina L.			Mild Traumatic Brain Injury with Social Defeat Stress Alters Anxiety, Contextual Fear Extinction, and Limbic Monoamines in Adult Rats	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						mild traumatic brain injury; social stress; posttraumatic stress disorder; anxiety; fear conditioning; monoamine	CORTICOTROPIN-RELEASING-FACTOR; PREFRONTAL CORTEX; CONDITIONED FEAR; VENTRAL HIPPOCAMPUS; AMYGDALA RESPONSE; WORKING-MEMORY; CUED FEAR; DISORDER; PTSD; BEHAVIOR	Mild traumatic brain injury (mTBI) produces symptoms similar to those typifying posttraumatic stress disorder (PTSD) in humans. We sought to determine whether a rodent model of stress concurrent with mTBI produces characteristics of PTSD such as impaired contextual fear extinction, while also examining concurrent alterations to limbic monoamine activity in brain regions relevant to fear and anxiety states. Male rats were exposed to social stress or control conditions immediately prior to mTBI induction, and 6 days later were tested either for anxiety-like behavior using the elevated plus maze (EPM), or for contextual fear conditioning and extinction. Brains were collected 24 h after EPM testing, and tissue from various limbic regions analyzed for content of monoamines, their precursors and metabolites using HPLC with electrochemical detection. Either social defeat or mTBI alone decreased time spent in open arms of the EPM, indicating greater anxiety-like behavior. However, this effect was enhanced by the combination of treatments. Further, rats exposed to both social defeat and mTBI exhibited greater freezing within extinction sessions compared to all other groups, suggesting impaired contextual fear extinction. Social defeat combined with mTBI also had greater effects on limbic monoamines than either insult alone, particularly with respect to serotonergic effects associated with anxiety and fear learning. The results suggest social stress concurrent with mTBI produces provides a relevant animal model for studying the prevention and treatment of post-concussive psychobiological outcomes.	[Davies, Daniel R.; Olson, Dawne; Meyer, Danielle L.; Scholl, Jamie L.; Watt, Michael J.; Manzerra, Pasquale; Forster, Gina L.] Univ S Dakota, Sanford Sch Med, Div Basic Biomed Sci, Ctr Brain & Behav Res, Vermillion, SD 57069 USA; [Renner, Kenneth J.] Univ S Dakota, Dept Biol, Ctr Brain & Behav Res, Vermillion, SD 57069 USA	Forster, GL (corresponding author), Univ S Dakota, Sanford Sch Med, Div Basic Biomed Sci, Ctr Brain & Behav Res, Vermillion, SD 57069 USA.	gforster@usd.edu		Watt, Michael/0000-0003-1164-1367	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0578]; USD U. Discover fellowship	This work was funded by Department of Defense Grant W81XWH-10-1-0578, and DD was funded by an USD U. Discover fellowship.	Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Armony JL, 2005, AM J PSYCHIAT, V162, P1961, DOI 10.1176/appi.ajp.162.10.1961; Attar CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042397; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barr JL, 2013, EUR J NEUROSCI, V37, P479, DOI 10.1111/ejn.12050; Bauer EP, 2015, BEHAV BRAIN RES, V277, P68, DOI 10.1016/j.bbr.2014.07.028; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Berton O, 1999, NEUROSCIENCE, V92, P327, DOI 10.1016/S0306-4522(98)00742-8; Bjorkqvist K, 2001, PHYSIOL BEHAV, V73, P435, DOI 10.1016/S0031-9384(01)00490-5; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Calfa G, 2006, BEHAV BRAIN RES, V172, P324, DOI 10.1016/j.bbr.2006.05.022; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CLEMENT HW, 1992, EUR J PHARMACOL, V217, P43, DOI 10.1016/0014-2999(92)90509-3; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Forster GL, 2006, NEUROSCIENCE, V141, P1047, DOI 10.1016/j.neuroscience.2006.04.006; Forster GL, 2012, AMYGDALA - A DISCRETE MULTITASKING MANAGER, P61, DOI 10.5772/50323; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Grillon C, 1999, J ABNORM PSYCHOL, V108, P134, DOI 10.1037/0021-843X.108.1.134; GUBITS RM, 1991, J NEUROSCI RES, V30, P625, DOI 10.1002/jnr.490300405; Hammels C, 2015, NEUROSCI BIOBEHAV R, V59, P111, DOI 10.1016/j.neubiorev.2015.10.006; Hendler T, 2003, NEUROIMAGE, V19, P587, DOI 10.1016/S1053-8119(03)00141-1; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hitora-Imamura N, 2015, ELIFE, V4, DOI 10.7554/eLife.08274; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huhman KL, 2006, HORM BEHAV, V50, P640, DOI 10.1016/j.yhbeh.2006.06.022; Hunsaker MR, 2008, NEUROBIOL LEARN MEM, V89, P61, DOI 10.1016/j.nlm.2007.08.016; Jovanovic Tanja, 2011, Front Behav Neurosci, V5, P44, DOI 10.3389/fnbeh.2011.00044; Jovanovic T, 2009, PSYCHIAT RES, V167, P151, DOI 10.1016/j.psychres.2007.12.014; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim MJ, 2008, J PSYCHIATR RES, V42, P268, DOI 10.1016/j.jpsychires.2007.02.003; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lehner M, 2008, BEHAV BRAIN RES, V192, P203, DOI 10.1016/j.bbr.2008.04.003; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; MacBeth AH, 2008, BRAIN RES, V1241, P136, DOI 10.1016/j.brainres.2008.09.006; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011; Milad MR, 2014, BEHAV RES THER, V62, P17, DOI 10.1016/j.brat.2014.08.006; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Millan MJ, 2003, PROG NEUROBIOL, V70, P83, DOI 10.1016/s0301-0082(03)00087-X; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Morey RA, 2009, J PSYCHIATR RES, V43, P809, DOI 10.1016/j.jpsychires.2008.10.014; Novick AM, 2011, BRAIN RES BULL, V86, P123, DOI 10.1016/j.brainresbull.2011.06.009; Ohmura Y, 2010, NEUROPSYCHOPHARMACOL, V35, P1271, DOI 10.1038/npp.2009.229; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Quirk GJ, 2006, BIOL PSYCHIAT, V60, P337, DOI 10.1016/j.biopsych.2006.03.010; Radwanska K, 2015, NEUROBIOL LEARN MEM, V125, P106, DOI 10.1016/j.nlm.2015.08.007; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rod AMK, 2012, STRESS, V15, P658, DOI 10.3109/10253890.2012.663836; Scholl JL, 2009, PHYSIOL BEHAV, V96, P493, DOI 10.1016/j.physbeh.2008.12.001; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 2004, HIPPOCAMPUS, V14, P292, DOI 10.1002/hipo.10183; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Sierra-Mercado D, 2015, BRAIN RES, V1606, P133, DOI 10.1016/j.brainres.2015.02.031; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Steiger F, 2015, INT J PSYCHOPHYSIOL, V98, P584, DOI 10.1016/j.ijpsycho.2015.06.009; Stockhorst U, 2016, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00359; Toth I, 2013, CELL TISSUE RES, V354, P107, DOI 10.1007/s00441-013-1636-4; TRULSON ME, 1984, LIFE SCI, V35, P511, DOI 10.1016/0024-3205(84)90244-3; Watt MJ, 2009, BEHAV NEUROSCI, V123, P564, DOI 10.1037/a0015752; Williams LM, 2006, NEUROIMAGE, V29, P347, DOI 10.1016/j.neuroimage.2005.03.047; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907	78	17	17	0	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	APR 19	2016	10								71	10.3339/fnbeh.2015.00071			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DJ8EM	WOS:000374445300001	27147992	DOAJ Gold			2021-06-18	
J	Ong, QX; Guo, SL; Duan, LT; Zhang, K; Collier, EA; Cui, BX				Ong, Qunxiang; Guo, Shunling; Duan, Liting; Zhang, Kai; Collier, Eleanor Ann; Cui, Bianxiao			The Timing of Raf/ERK and AKT Activation in Protecting PC12 Cells against Oxidative Stress	PLOS ONE			English	Article							OPTOGENETIC CONTROL; ISCHEMIC-INJURY; BRAIN-INJURY; OXYGEN; MECHANISMS; DYNAMICS; TIME; REQUIREMENT; EXPRESSION; INDUCTION	Acute brain injuries such as ischemic stroke or traumatic brain injury often cause massive neural death and irreversible brain damage with grave consequences. Previous studies have established that a key participant in the events leading to neural death is the excessive production of reactive oxygen species. Protecting neuronal cells by activating their endogenous defense mechanisms is an attractive treatment strategy for acute brain injuries. In this work, we investigate how the precise timing of the Raf/ERK and the AKT pathway activation affects their protective effects against oxidative stress. For this purpose, we employed optogenetic systems that use light to precisely and reversibly activate either the Raf/ERK or the AKT pathway. We find that preconditioning activation of the Raf/ERK or the AKT pathway immediately before oxidant exposure provides significant protection to cells. Notably, a 15-minute transient activation of the Raf/ERK pathway is able to protect PC12 cells against oxidant strike that is applied 12 hours later, while the transient activation of the AKT pathway fails to protect PC12 cells in such a scenario. On the other hand, if the pathways are activated after the oxidative insult, i.e. postconditioning, the AKT pathway conveys greater protective effect than the Raf/ERK pathway. We find that postconditioning AKT activation has an optimal delay period of 2 hours. When the AKT pathway is activated 30min after the oxidative insult, it exhibits very little protective effect. Therefore, the precise timing of the pathway activation is crucial in determining its protective effect against oxidative injury. The optogenetic platform, with its precise temporal control and its ability to activate specific pathways, is ideal for the mechanistic dissection of intracellular pathways in protection against oxidative stress.	[Ong, Qunxiang; Guo, Shunling; Duan, Liting; Collier, Eleanor Ann; Cui, Bianxiao] Stanford Univ, Dept Chem, Stanford, CA 94305 USA; [Zhang, Kai] Univ Illinois, Sch Mol & Cellular Biol, Dept Biochem, Urbana, IL 61801 USA	Cui, BX (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	bcui@stanford.edu	Zhang, Kai/G-6437-2010	Zhang, Kai/0000-0002-6687-4558	US National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP2-NS082125]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [DP2NS082125] Funding Source: NIH RePORTER	This work was supported by US National Institute of Health (www.nih.gov) DP2-NS082125 to BC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALKHULAIFI AM, 1993, CARDIOSCIENCE, V4, P163; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bugaj LJ, 2013, NAT METHODS, V10, P249, DOI 10.1038/nmeth.2360; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Choi YS, 2007, EXP MOL MED, V39, P556, DOI 10.1038/emm.2007.61; Cohen MV, 2015, BRIT J PHARMACOL, V172, P1913, DOI 10.1111/bph.12903; DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6; Dijkmans TF, 2008, J NEUROCHEM, V105, P2388, DOI 10.1111/j.1471-4159.2008.05338.x; Duan LT, 2015, CHEM BIOL, V22, P671, DOI 10.1016/j.chembiol.2015.04.014; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FOOTE CS, 1968, ACCOUNTS CHEM RES, V1, P104, DOI 10.1021/ar50004a002; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Hausenloy DJ, 2016, NAT REV CARDIOL, V13, P193, DOI 10.1038/nrcardio.2016.5; Idevall-Hagren O, 2012, P NATL ACAD SCI USA, V109, pE2316, DOI 10.1073/pnas.1211305109; Jiang H, 2005, J MOL NEUROSCI, V25, P133, DOI 10.1385/JMN:25:2:133; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Katsura Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14589; Kennedy MJ, 2010, NAT METHODS, V7, P973, DOI [10.1038/nmeth.1524, 10.1038/NMETH.1524]; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; Kim SY, 2011, ONCOL REP, V26, P1561, DOI 10.3892/or.2011.1439; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kokona D, 2015, EXP EYE RES, V136, P45, DOI 10.1016/j.exer.2015.05.007; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Loukogeorgakis SP, 2006, CIRCULATION, V113, P1015, DOI 10.1161/CIRCULATIONAHA.105.590398; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marinho HS, 2013, METHOD ENZYMOL, V526, P159, DOI 10.1016/B978-0-12-405883-5.00010-7; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Moreira JBN, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0444-x; Muller K, 2013, MOL BIOSYST, V9, P596, DOI 10.1039/c3mb25590e; Neumann JT, 2015, J CEREBR BLOOD F MET, V35, P121, DOI 10.1038/jcbfm.2014.185; Noh MY, 2013, MOL NEUROBIOL, V47, P757, DOI 10.1007/s12035-012-8382-6; Ong Q, 2015, OPTOGENETIC CO UNPUB; Ong QX, 2015, ACS CHEM NEUROSCI, V6, P130, DOI 10.1021/cn500288n; Perez-Pinzon MA, 2005, ANTIOXID REDOX SIGN, V7, P1150, DOI 10.1089/ars.2005.7.1150; SACK S, 1993, CARDIOVASC RES, V27, P551, DOI 10.1093/cvr/27.4.551; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Shahzad T, 2013, J MOL CELL CARDIOL, V58, P209, DOI 10.1016/j.yjmcc.2013.01.003; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; STEEVES G, 1994, ANN NY ACAD SCI, V723, P116, DOI 10.1111/j.1749-6632.1994.tb36721.x; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8; Tischer D, 2014, NAT REV MOL CELL BIO, V15, P551, DOI 10.1038/nrm3837; Toettcher JE, 2013, CELL, V155, P1422, DOI 10.1016/j.cell.2013.11.004; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wauson EM, 2013, BIOCHEMISTRY-US, V52, P5164, DOI 10.1021/bi4007644; Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A; Weitzman M, 2014, CURR OPIN CELL BIOL, V30, P112, DOI 10.1016/j.ceb.2014.08.004; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YOUNGMAN RJ, 1981, FEBS LETT, V129, P265, DOI 10.1016/0014-5793(81)80180-9; Zhang K, 2015, TRENDS BIOTECHNOL, V33, P92, DOI 10.1016/j.tibtech.2014.11.007; Zhang KW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098215; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	61	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2016	11	4							e0153487	10.1371/journal.pone.0153487			20	Multidisciplinary Sciences	Science & Technology - Other Topics	DJ6AH	WOS:000374291800022	27082641	DOAJ Gold, Green Published			2021-06-18	
J	Ban, VS; Madden, CJ; Bailes, JE; Batjer, HH; Lonser, RR				Ban, Vin Shen; Madden, Christopher J.; Bailes, Julian E.; Batjer, H. Hunt; Lonser, Russell R.			The science and questions surrounding chronic traumatic encephalopathy	NEUROSURGICAL FOCUS			English	Article						chronic traumatic encephalopathy; concussion; subconcussion; diagnosis; treatment; research directions; controversies	LIFE COGNITIVE IMPAIRMENT; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; HEAD IMPACTS; RECURRENT CONCUSSION; 1ST EXPOSURE; BRAIN-INJURY; IN-VIVO; AGE	Recently, the pathobiology, causes, associated factors, incidence and prevalence, and natural history of chronic traumatic encephalopathy (CTE) have been debated. Data from retrospective case series and high-profile media reports have fueled public fear and affected the medical community's understanding of the role of sports-related traumatic brain injury (TBI) in the development of CTE. There are a number of limitations posed by the current evidence that can lead to confusion within the public and scientific community. In this paper, the authors address common questions surrounding the science of CTE and propose future research directions.	[Ban, Vin Shen; Madden, Christopher J.; Batjer, H. Hunt] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75235 USA; [Bailes, Julian E.] Univ Chicago, Pritzker Sch Med, Dept Neurol Surg, NorthShore Univ HealthSyst, Evanston, IL USA; [Lonser, Russell R.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA	Ban, VS (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	vinshen.ban@cantab.net		Ban, Vin Shen/0000-0002-4532-8101			Anthony IC, 2010, BRAIN, V133, P3685, DOI 10.1093/brain/awq263; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Belson K, 2015, NY TIMES; Belson K., 2014, NY TIMES; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Breslow J., 2015, NEW 87 DECEASED NFL; Breslow JM, 76 79 DEC NFL PLAYER; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Cairns NJ, 1 NIH CONS C DEF NEU; Carroll L, 2015, NBC NEWS        0318; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; CTE Awareness Foundation, WHAT CAUS CTE; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hanna J, 2015, CNN             1011; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2015, NEUROLOGY, V85, P1007, DOI 10.1212/WNL.0000000000001942; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Neporent L., 2013, ABC NEWS; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shen H, 2015, NATURE, V518, P466, DOI 10.1038/518466a; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Solomon G, 2015, PHYSICIAN SPORTSMED, V43, P247, DOI 10.1080/00913847.2015.1024582; Solomon GS, 2014, PHYSICIAN SPORTSMED, V42, P26, DOI 10.3810/psm.2014.09.2072; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040	51	17	17	0	57	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E15	10.3171/2016.2.FOCUS15609			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500015	27032918	Bronze			2021-06-18	
J	Fogerson, SM; van Brummen, AJ; Busch, DJ; Allen, SR; Roychaudhuri, R; Banks, SML; Klarner, FG; Schrader, T; Bitan, G; Morgan, JR				Fogerson, Stephanie M.; van Brummen, Alexandra J.; Busch, David J.; Allen, Scott R.; Roychaudhuri, Robin; Banks, Susan M. L.; Klaerner, Frank-Gerrit; Schrader, Thomas; Bitan, Gal; Morgan, Jennifer R.			Reducing synuclein accumulation improves neuronal survival after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						CLR01; Lamprey; Molecular tweezer; Neurodegeneration; Parkinson's disease; Synaptotagmin	TRAUMATIC BRAIN-INJURY; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; AXON REGENERATION; IN-VIVO; PATHOLOGY; DEMENTIA; REPAIR; BETA; NEURODEGENERATION	Spinal cord injury causes neuronal death, limiting subsequent regeneration and recovery. Thus, there is a need to develop strategies for improving neuronal survival after injury. Relative to our understanding of axon regeneration, comparatively little is known about the mechanisms that promote the survival of damaged neurons. To address this, we took advantage of lamprey giant reticulospinal neurons whose large size permits detailed examination of post-injury molecular responses at the level of individual, identified cells. We report here that spinal cord injury caused a select subset of giant reticulospinal neurons to accumulate synuclein, a synaptic veside-associated protein best known for its atypical aggregation and causal role in neurodegeneration in Parkinson's and other diseases. Post-injury synuclein accumulation took the form of punctate aggregates throughout the somata and occurred selectively in dying neurons, but not in those that survived. In contrast, another synaptic vesicle protein, synaptotagmin, did not accumulate in response to injury. We further show that the post-injury synuclein accumulation was greatly attenuated after single dose application of either the "molecular tweezer" inhibitor, CLR01, or a translation-blocking synuclein morpholino. Consequently, reduction of synuclein accumulation not only improved neuronal survival, but also increased the number of axons in the spinal cord proximal and distal to the lesion. This study is the first to reveal that reducing synuclein accumulation is a novel strategy for improving neuronal survival after spinal cord injury. (C) 2016 Elsevier Inc. All rights reserved.	[Fogerson, Stephanie M.; van Brummen, Alexandra J.; Allen, Scott R.; Banks, Susan M. L.; Morgan, Jennifer R.] Marine Biol Lab, Eugene Bell Ctr Regenerat Biol & Tissue Engn, 7 MBL St, Woods Hole, MA 02543 USA; [van Brummen, Alexandra J.; Busch, David J.] Univ Texas Austin, Sect Mol Cell & Dev Biol, Austin, TX 78712 USA; [Roychaudhuri, Robin; Bitan, Gal] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Klaerner, Frank-Gerrit; Schrader, Thomas] Univ Duisburg Essen, Inst Organ Chem, D-45117 Essen, Germany; [Bitan, Gal] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; [Bitan, Gal] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Fogerson, Stephanie M.] Duke Univ, Dept Biol, Durham, NC 27708 USA; [Busch, David J.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA; [Roychaudhuri, Robin] Johns Hopkins Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA	Morgan, JR (corresponding author), Marine Biol Lab, Eugene Bell Ctr Regenerat Biol & Tissue Engn, 7 MBL St, Woods Hole, MA 02543 USA.	jmorgan@mbl.edu	Bitan, Gal/U-2204-2019	Bitan, Gal/0000-0001-7046-3754; Roychaudhuri, Robin/0000-0003-3851-4181	Morton Cure Paralysis Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS078165]; Parkinson's Disease Foundation [PDF-SFW-1214]; University of California-Los Angeles Jim Easton Consortium; Team Parkinson/Parkinson Alliance; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078165] Funding Source: NIH RePORTER	This work was supported by research grants from the Morton Cure Paralysis Fund and the NIH (RO1 NS078165 to JRM), a Parkinson's Disease Foundation summer student fellowship (PDF-SFW-1214 to AJVB), University of California-Los Angeles Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development (GB), and Team Parkinson/Parkinson Alliance (GB). The authors would like to thank Michele Nsianya and the 2013 Brown-MBL NeuroPracticum Course students for the technical assistance with immunofluorescence experiments, and Paul Oliphint for the histological image of the lamprey spinal cord.	Acharya S, 2014, J BIOL CHEM, V289, P10727, DOI 10.1074/jbc.M113.524520; Attar A, 2012, BRAIN, V135, P3735, DOI 10.1093/brain/aws289; Barreiro-Iglesias Anton, 2012, Enzyme Res, V2012, P835731, DOI 10.1155/2012/835731; Becker CG, 2004, J NEUROSCI, V24, P7837, DOI 10.1523/JNEUROSCI.2420-04.2004; Bendor JT, 2013, NEURON, V79, P1044, DOI 10.1016/j.neuron.2013.09.004; Beyer K, 2008, CURR MED CHEM, V15, P2748, DOI 10.2174/092986708786242868; Blesch A, 2009, TRENDS NEUROSCI, V32, P41, DOI 10.1016/j.tins.2008.09.008; Bloom OE, 2011, MOL CELL NEUROSCI, V48, P339, DOI 10.1016/j.mcn.2011.04.003; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Busch DJ, 2014, MOL BIOL CELL, V25, P3926, DOI 10.1091/mbc.E14-02-0708; Busch DJ, 2012, J COMP NEUROL, V520, P1751, DOI 10.1002/cne.23011; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Cookson MR, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-9; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Ebrahimi-Fakhari D, 2011, J NEUROSCI, V31, P14508, DOI 10.1523/JNEUROSCI.1560-11.2011; Emmanouilidou E, 2010, NEUROBIOL AGING, V31, P953, DOI 10.1016/j.neurobiolaging.2008.07.008; Ferrucci Michela, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS180, DOI 10.1016/j.parkreldis.2008.04.025; Fujita M, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1101; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Giorgi FS, 2006, J NEURAL TRANSM-SUPP, P105; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Hu JL, 2013, J NEUROSCI METH, V220, P92, DOI 10.1016/j.jneumeth.2013.08.016; Jacobs AJ, 1997, J NEUROSCI, V17, P5206; Jin LQ, 2009, J COMP NEUROL, V515, P295, DOI 10.1002/cne.22057; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Lau BYB, 2013, EXP NEUROL, V250, P31, DOI 10.1016/j.expneurol.2013.09.004; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Lulla A., 2016, NEUROTOXICITY UNPUB; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Ninkina N, 2009, HUM MOL GENET, V18, P1779, DOI 10.1093/hmg/ddp090; Oliphint PA, 2010, J COMP NEUROL, V518, P2854, DOI 10.1002/cne.22368; Prabhudesai S, 2012, NEUROTHERAPEUTICS, V9, P464, DOI 10.1007/s13311-012-0105-1; ROVAINEN CM, 1967, J NEUROPHYSIOL, V30, P1000; Roychaudhuri R, 2014, J MOL BIOL, V426, P2422, DOI 10.1016/j.jmb.2014.04.004; Sakurai M, 2009, J CEREBR BLOOD F MET, V29, P752, DOI 10.1038/jcbfm.2008.167; Shifman MI, 2008, J COMP NEUROL, V510, P269, DOI 10.1002/cne.21789; Sinha S, 2011, J AM CHEM SOC, V133, P16958, DOI 10.1021/ja206279b; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Surgucheva I, 2014, MOL CELL NEUROSCI, V63, P114, DOI 10.1016/j.mcn.2014.10.005; Surguchov A, 2008, INT REV CEL MOL BIO, V270, P225, DOI 10.1016/S1937-6448(08)01406-8; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vargas KJ, 2014, J NEUROSCI, V34, P9364, DOI 10.1523/JNEUROSCI.4787-13.2014; Viscomi M. T., 2014, MOL NEUROBIOL; Wang LN, 2014, CURR BIOL, V24, P2319, DOI 10.1016/j.cub.2014.08.027; Wang Y.C., 2016, APOPTOSIS; Williams RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118918; YIN HS, 1983, J NEUROSCI, V3, P1135; Zhang GX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137670	50	17	17	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2016	278						105	115		10.1016/j.expneurol.2016.02.004			11	Neurosciences	Neurosciences & Neurology	DH3EX	WOS:000372671400011	26854933	Green Accepted, Green Published			2021-06-18	
J	Sung, CW; Lee, HC; Chiang, YH; Chiu, WT; Chu, SF; Ou, JC; Tsai, SH; Liao, KH; Lin, CM; Lin, JW; Chen, GS; Li, WJ; Wang, JY				Sung, Chih-Wei; Lee, Hsin-Chien; Chiang, Yung-Hsiao; Chiu, Wen-Ta; Chu, Shu-Fen; Ou, Ju-Chi; Tsai, Shin-Han; Liao, Kuo-Hsing; Lin, Chien-Min; Lin, Jia-Wei; Chen, Gunng-Shinng; Li, Wei-Jiun; Wang, Jia-Yi			Early dysautonomia detected by heart rate variability predicts late depression in female patients following mild traumatic brain injury	PSYCHOPHYSIOLOGY			English	Article						mTBI; Depression; Heart rate variability; Dysautonomia; Autonomic dysfunction	PROFESSIONAL FOOTBALL PLAYERS; CORONARY-ARTERY-DISEASE; MAJOR DEPRESSION; PSYCHIATRIC OUTPATIENTS; RECURRENT CONCUSSION; GENDER DIFFERENCES; SPECTRAL-ANALYSIS; INVENTORY-II; RISK FACTOR; SYMPTOMS	Depression is one of the frequent complications following a mild traumatic brain injury (mTBI). Recent research indicated that abnormalities in the autonomic nervous system (ANS) can be evaluated by a noninvasive power spectral analysis of the heart rate variability (HRV). In this study, we investigated whether a frequency-domain analysis of HRV was correlated with late depression in mTBI patients. In total, 181 patients diagnosed with mTBI and 83 volunteers as healthy controls were recruited in 2010-2014. Beck Depression Inventory (BDI) scores were used to evaluate depression in the 1st week of assessment and at 1.5-, 3-, 6-, 12-, and 18-month follow-ups. Correlation and logistic regression analyses of the 1st week HRV parameters with BDI scores at 18 months were performed in individual female mTBI patients. Female mTBI patients were more vulnerable to depression accompanied by reduced HRV compared to healthy controls. Over time, depression was aggravated in female mTBI patients but was alleviated in male mTBI patients. A significantly lower parasympathetic proportion of the ANS was noted at 18 months with respect to the 1st week in female mTBI patients. In addition, depression in female mTBI patients at 18 months after injury was significantly correlated with a decrease in the parasympathetic proportion of the ANS in the 1st week (=-0.411; p<.05). Dysautonomia resulted in higher risks of depression in female mTBI patients. We concluded that early dysautonomia following an mTBI contributes to late depression in female mTBI patients.	[Sung, Chih-Wei; Chen, Gunng-Shinng; Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan; [Sung, Chih-Wei; Li, Wei-Jiun] Taipei Med Univ, Coll Med, Sch Med, Taipei 110, Taiwan; [Lee, Hsin-Chien] Taipei Med Univ, Shuang Ho Hosp, Dept Psychiat, New Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Taipei Med Univ Hosp, Dept Neurosurg, Taipei 110, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Grad Program Neuroregenerat, Taipei 110, Taiwan; [Chiu, Wen-Ta; Chu, Shu-Fen; Tsai, Shin-Han] Taipei Med Univ, Coll Publ Hlth, Grad Inst Injury & Prevent, Taipei 110, Taiwan; [Ou, Ju-Chi] Taipei Med Univ, Shuang Ho Hosp, Dept Emergency, New Taipei, Taiwan; [Liao, Kuo-Hsing] Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei 110, Taiwan; [Lin, Chien-Min; Lin, Jia-Wei] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, New Taipei, Taiwan; [Chen, Gunng-Shinng] Tri Serv Gen Hosp, Dept Dent, Div Orthodont & Dentofacial Orthoped & Pedodont, Taipei, Taiwan; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Sch Med, Dept Physiol, Taipei 110, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw		Wang, Jia-Yi/0000-0002-9106-3351; lee, hsin-chien/0000-0002-7557-8259; Sung, Chih-Wei/0000-0003-3312-2752	Ministry of Science and Technology [MOST-103-2321-B-038-002, MOST-104-2320-B-038-057-MY3, MOST-103-2815-C-038-016-B]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC 98-2321-B-038-003-MY3, NSC102-2632-B-038-001-MY3]	This work was supported in part by grants from the Ministry of Science and Technology (MOST-103-2321-B-038-002 and MOST-104-2320-B-038-057-MY3) to JYW, from the National Science Council (NSC 98-2321-B-038-003-MY3) to WTC and NSC102-2632-B-038-001-MY3 to HCL, and from the Ministry of Science and Technology (MOST-103-2815-C-038-016-B) to CWS.	Akdemir A, 2001, COMPR PSYCHIAT, V42, P161, DOI 10.1053/comp.2001.19756; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Barton DA, 2008, ARCH GEN PSYCHIAT, V65, P38, DOI 10.1001/archgenpsychiatry.2007.11; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Bjornelv S, 2011, SOC PSYCH PSYCH EPID, V46, P353, DOI 10.1007/s00127-010-0197-z; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BRYER JB, 1992, J NEUROPSYCH CLIN N, V4, P440; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Cameron O, 1996, PSYCHOSOM MED, V58, P111, DOI 10.1097/00006842-199603000-00002; Carney RM, 2005, PSYCHOSOM MED, V67, pS29, DOI 10.1097/01.psy.0000162254.61556.d5; Carney RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2; CARNEY RM, 1995, ANN BEHAV MED, V17, P142, DOI 10.1007/BF02895063; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hou CL, 2006, BRAIN RES, V1095, P154, DOI 10.1016/j.brainres.2006.04.026; Hughes JW, 2000, PSYCHOSOM MED, V62, P796, DOI 10.1097/00006842-200011000-00009; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kendler KS, 2001, PSYCHOL MED, V31, P605, DOI 10.1017/S0033291701003907; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; KLIKS BR, 1975, AM J CARDIOL, V36, P45, DOI 10.1016/0002-9149(75)90866-8; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mancilla-Diaz JM, 2009, EAT WEIGHT DISORD-ST, V14, pE169, DOI 10.1007/BF03325113; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Nestler EJ, 2014, JAMA PSYCHIAT, V71, P454, DOI 10.1001/jamapsychiatry.2013.4291; Nishizawa S, 1997, P NATL ACAD SCI USA, V94, P5308, DOI 10.1073/pnas.94.10.5308; Nolen-Hoeksema S, 1999, J PERS SOC PSYCHOL, V77, P1061, DOI 10.1037/0022-3514.77.5.1061; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; PODRID PJ, 1990, CIRCULATION, V82, P103; RABINS PV, 1985, J AFFECT DISORDERS, V9, P165, DOI 10.1016/0165-0327(85)90096-5; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; del Paso GAR, 2013, PSYCHOPHYSIOLOGY, V50, P477, DOI 10.1111/psyp.12027; Rhee H, 2000, HEADACHE, V40, P528, DOI 10.1046/j.1526-4610.2000.00084.x; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; RUTHERFORD WH, 1977, LANCET, V1, P1; SANTORELLI G, 1964, Osp Psichiatr, V32, P69; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SCHWARTZ PJ, 1981, J CARDIOVASC PHARM, V3, P1251, DOI 10.1097/00005344-198111000-00012; Sheffield D, 1998, INT J BEHAV MED, V5, P31, DOI 10.1207/s15327558ijbm0501_3; Sosin DM, 1996, BRAIN INJURY, V10, P47; Steer RA, 1997, PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Sund AM, 2011, SOC PSYCH PSYCH EPID, V46, P431, DOI 10.1007/s00127-010-0208-0; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; TEASDALE G, 1974, LANCET, V2, P81; Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilhelm K, 2002, ACTA PSYCHIAT SCAND, V106, P45, DOI 10.1034/j.1600-0447.2002.02094.x; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011; Zheng A, 2008, J NUTR SCI VITAMINOL, V54, P148, DOI 10.3177/jnsv.54.148	70	17	17	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	APR	2016	53	4					455	464		10.1111/psyp.12575			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	DH6GN	WOS:000372889100004	26560198				2021-06-18	
J	Tajiri, N; De La Pena, I; Acosta, SA; Kaneko, Y; Tamir, S; Landesman, Y; Carlson, R; Shacham, S; Borlongan, CV				Tajiri, Naoki; De La Pena, Ike; Acosta, Sandra A.; Kaneko, Yuji; Tamir, Sharon; Landesman, Yosef; Carlson, Robert; Shacham, Sharon; Borlongan, Cesar V.			A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						Cell death protein trafficking; Neuroinflammation; Nuclear export inhibitor; Secondary cell death	SELECTIVE INHIBITORS; PRECLINICAL MODELS; EXPORT INHIBITORS; DRUG-RESISTANCE; CRM1; RATS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEINS	BackgroundExportin 1 (XPO1/CRM1) plays prominent roles in the regulation of nuclear protein export. Selective inhibitors of nuclear export (SINE) are small orally bioavailable molecules that serve as drug-like inhibitors of XPO1, with potent anti-cancer properties. Traumatic brain injury (TBI) presents with a secondary cell death characterized by neuroinflammation that is putatively regulated by nuclear receptors. Aims and ResultsHere, we report that the SINE compounds (KPT-350 or KPT-335) sequestered TBI-induced neuroinflammation-related proteins (NF-B-k, AKT, FOXP1) within the nucleus of cultured primary rat cortical neurons, which coincided with protection against TNF- (20ng/mL)-induced neurotoxicity as shown by at least 50% and 100% increments in preservation of cell viability and cellular enzymatic activity, respectively, compared to non-treated neuronal cells (P's<0.05). In parallel, using an invivo controlled cortical impact (CCI) model of TBI, we demonstrate that adult Sprague-Dawley rats treated post-injury with SINE compounds exhibited significant reductions in TBI-induced behavioral and histological deficits. Animals that received KPT-350 orally starting at 2h post-TBI and once a day thereafter over the next 4days exhibited significantly better motor coordination, and balance in the rotorod test and motor asymmetry test by 100-200% improvements, as early as 4h after initial SINE compound injection that was sustained during subsequent KPT-350 dosing, and throughout the 18-day post-TBI study period compared to vehicle treatment (P's<0.05). Moreover, KPT-350 reduced cortical core impact area and peri-impact cell death compared to vehicle treatment (P's<0.05). ConclusionsBoth invitro and invivo experiments revealed that KPT-350 increased XPO1, AKT, and FOXP1 nuclear expression and relegated NF-B-k expression within the neuronal nuclei. Altogether, these findings advance the utility of SINE compounds to stop trafficking of cell death proteins within the nucleus as an efficacious treatment for TBI.	[Tajiri, Naoki; De La Pena, Ike; Acosta, Sandra A.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL USA; [Tamir, Sharon; Landesman, Yosef; Carlson, Robert; Shacham, Sharon] Karyopharm Therapeut Inc, Newton, MA USA	Borlongan, CV (corresponding author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Kaneko, Yuji/J-6447-2012		Karyopharm Inc	This study was funded by Karyopharm Inc. The authors thank the excellent technical assistance of Mr. Quinn Colburn in final preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Azmi AS, 2013, GASTROENTEROLOGY, V144, P447, DOI 10.1053/j.gastro.2012.10.036; Bachstetter AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010496; Bell E, 2003, DIABETES, V52, P2731, DOI 10.2337/diabetes.52.11.2731; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Cheng Y, 2014, MOL CANCER THER, V13, P675, DOI 10.1158/1535-7163.MCT-13-0416; Cooper G. M., 2000, CELL MOL APPROACH, P1; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Draetta GF, 2011, J CLIN ONCOL, V29; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Fang YS, 2012, ANNU REV CELL DEV BI, V28, P575, DOI 10.1146/annurev-cellbio-101011-155836; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Guttler T, 2011, EMBO J, V30, P3457, DOI 10.1038/emboj.2011.287; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Haines JD, 2015, NAT NEUROSCI, V18, P511, DOI 10.1038/nn.3953; Kaneko Y, 2016, MOL NEUROBIOL, V53, P1874, DOI 10.1007/s12035-015-9126-1; Kaneko Y, 2014, CNS NEUROSCI THER, V20, P275, DOI 10.1111/cns.12208; Kim JY, 2010, NAT NEUROSCI, V13, P180, DOI 10.1038/nn.2471; Kojima K, 2013, BLOOD, V121, P4166, DOI 10.1182/blood-2012-08-447581; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Landesman Y, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3775; Lapalombella R, 2012, BLOOD, V120, P4621, DOI 10.1182/blood-2012-05-429506; Li AH, 2013, J MOL NEUROSCI, V51, P208, DOI 10.1007/s12031-013-9994-7; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; London CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087585; McCauley D, 2012, J CLIN ONCOL S, V30; Mendonca J, 2014, ONCOTARGET, V5, P6102, DOI 10.18632/oncotarget.2174; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; Nguyen Kevin T, 2012, Int J Biochem Mol Biol, V3, P137; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Owen T, 2012, ARTHRITIS RHEUM S, V64; Owen T, 2013, 13 ACR ARHP ANN M OC; Perwitasari O, 2014, J VIROL, V88, P10228, DOI 10.1128/JVI.01774-14; Ranganathan P, 2012, BLOOD, V120, P1765, DOI 10.1182/blood-2012-04-423160; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Tai YT, 2014, LEUKEMIA, V28, P155, DOI 10.1038/leu.2013.115; Tajiri N, 2014, CELL TRANSPLANT, V23, P785; Tajiri N, 2014, 10 WORLD C BRAIN INJ; Tajiri N, 2014, BRAIN RES, V1559, P65, DOI 10.1016/j.brainres.2014.02.041; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Turner JG, 2008, CURR MED CHEM, V15, P2648, DOI 10.2174/092986708786242859; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Xu DR, 2010, CURR OPIN STRUC BIOL, V20, P782, DOI 10.1016/j.sbi.2010.09.008; Zhang K, 2013, EXP HEMATOL, V41	55	17	17	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	APR	2016	22	4			SI		306	315		10.1111/cns.12501			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DH7QO	WOS:000372989100009	26842647	Green Published, Other Gold			2021-06-18	
J	Wang, YN; Liu, Z; Li, Z; Shi, HN; Kang, YJ; Wang, JF; Huang, JQ; Jiang, L				Wang, Yanni; Liu, Zhe; Li, Zhen; Shi, Haina; Kang, Yujun; Wang, Jianfu; Huang, Jinqiang; Jiang, Li			Effects of heat stress on respiratory burst, oxidative damage and SERPINH1 (HSP47) mRNA expression in rainbow trout Oncorhynchus mykiss	FISH PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Heat stress; Respiratory burst; Oxidative stress; SERPINH1 (HSP47) expression; Oncorhynchus mykiss	SHOCK-PROTEIN EXPRESSION; HSP70 GENE-EXPRESSION; THERMAL TOLERANCE; ACCLIMATION TEMPERATURE; SUPEROXIDE-DISMUTASE; MOLECULAR CHAPERONE; OXYGEN LIMITATION; WATER TEMPERATURE; CLIMATE-CHANGE; TISSUE	For rainbow trout Oncorhynchus mykiss, high temperature is a major abiotic stress that limits its growth and productivity. In this study, spleen macrophage respiratory burst (RB), serum superoxide dismutase (SOD), serum malondialdehyde (MDA) and mRNA expression of the SERPINH1 (HSP47) gene in different tissues (liver, spleen, head kidney and heart) were measured in unstressed (18 A degrees C) and heat-stressed (25 A degrees C) fish. Spleen macrophage RB activity, serum SOD activity and MDA content all increased significantly (P < 0.05) during heat shock, and peaked at 8, 12 and 4 h, respectively. SERPINH1 mRNA expression responded in a time- and tissue-specific manner to heat stress, which was mainly reflected in the significant up-regulation in all tissues (P < 0.05) and greater expression in the liver than the other tissues (P < 0.05). During the heat-shock recovery period, the MDA content returned to the unstressed level. These results indicate that heat shock causes cell injury, induces oxidative damage and promotes SERPINH1 mRNA expression, which plays an important protective function during heat stress in O. mykiss. In practice, close attention should be given to temperature changes in O. mykiss production to reduce the effects of high temperature.	[Wang, Yanni; Liu, Zhe; Li, Zhen; Shi, Haina; Kang, Yujun; Wang, Jianfu; Huang, Jinqiang] Gansu Agr Univ, Coll Anim Sci & Technol, 1 Yingmencun, Lanzhou 730070, Gansu, Peoples R China; [Jiang, Li] Chinese Acad Fishery Sci, 150 Nanqingtacun, Beijing 100039, Peoples R China	Liu, Z (corresponding author), Gansu Agr Univ, Coll Anim Sci & Technol, 1 Yingmencun, Lanzhou 730070, Gansu, Peoples R China.	liuz@gsau.edu.cn	Kang, Yujun/F-2708-2010	Kang, Yujun/0000-0001-9696-5242	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31460687]; Fundamental Research Funds for the University of Gansu Province	This research was supported by the National Natural Science Foundation of China (No. 31460687) and the Fundamental Research Funds for the University of Gansu Province. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.	Amenomori M, 2010, RESP MED, V104, P895, DOI 10.1016/j.rmed.2010.01.011; Bagnyukova TV, 2007, J THERM BIOL, V32, P255, DOI 10.1016/j.jtherbio.2007.01.014; Bahrndorff S, 2009, FUNCT ECOL, V23, P233, DOI 10.1111/j.1365-2435.2009.01541.x; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591; Burrells C, 1999, VET IMMUNOL IMMUNOP, V72, P277, DOI 10.1016/S0165-2427(99)00143-9; Cui YT, 2014, FISH PHYSIOL BIOCHEM, V40, P721, DOI 10.1007/s10695-013-9879-2; Currie S, 2000, J FISH BIOL, V56, P398, DOI 10.1111/j.1095-8649.2000.tb02114.x; DYER SD, 1991, CAN J ZOOL, V69, P2021, DOI 10.1139/z91-282; Fangue NA, 2006, J EXP BIOL, V209, P2859, DOI 10.1242/jeb.02260; Hamdoun AM, 2003, BIOL BULL-US, V205, P160, DOI 10.2307/1543236; Hidalgo MC, 2002, INT J BIOCHEM CELL B, V34, P183, DOI 10.1016/S1357-2725(01)00105-4; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hochachka P. W., 2002, BIOCH ADAPTATION MEC; Hofmann GE, 1999, AM ZOOL, V39, P889; HOKANSON KEF, 1977, J FISH RES BOARD CAN, V34, P639, DOI 10.1139/f77-100; Hori TS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-72; Huber K, 2006, PROTOPLASMA, V229, P221, DOI 10.1007/s00709-006-0206-y; Kassahn KS, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-358; Keefer ML, 2009, CAN J FISH AQUAT SCI, V66, P1734, DOI 10.1139/F09-131; Lele Z, 1997, DEV GENET, V21, P123, DOI 10.1002/(SICI)1520-6408(1997)21:2<123::AID-DVG2>3.3.CO;2-K; Lesser MP, 2004, COMP BIOCHEM PHYS A, V137, P495, DOI 10.1016/j.cbpb.2003.10.022; Li Da-Peng, 2008, Acta Hydrobiologica Sinica, V32, P327, DOI 10.3724/SP.J.1035.2008.00327; Lushchak VI, 2006, COMP BIOCHEM PHYS C, V143, P36, DOI 10.1016/j.cbpc.2005.11.018; Manchado M, 2008, GENE, V416, P77, DOI 10.1016/j.gene.2008.03.007; Mancino R, 2011, MOL VIS, V17, P1298; Matthews KR, 1997, J FISH BIOL, V50, P50, DOI 10.1111/j.1095-8649.1997.tb01339.x; Ming JH, 2010, FISH SHELLFISH IMMUN, V28, P407, DOI 10.1016/j.fsi.2009.11.018; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/S0968-0004(06)80023-X; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; Nielsen F, 1997, CLIN CHEM, V43, P1209; Nikoskelainen S, 2004, DEV COMP IMMUNOL, V28, P581, DOI 10.1016/j.dci.2003.10.003; Ojima N, 2005, BIOCHEM BIOPH RES CO, V329, P51, DOI 10.1016/j.bbrc.2005.01.097; Parihar MS, 1997, J THERM BIOL, V22, P151, DOI 10.1016/S0306-4565(97)00006-5; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Patel S, 2009, FISH SHELLFISH IMMUN, V26, P385, DOI 10.1016/j.fsi.2008.11.018; Pearson DS, 1996, DNA CELL BIOL, V15, P263, DOI 10.1089/dna.1996.15.263; Portner HO, 2007, SCIENCE, V315, P95, DOI 10.1126/science.1135471; Portner HO, 2001, NATURWISSENSCHAFTEN, V88, P137; Ranford J C, 2000, Expert Rev Mol Med, V2, P1, DOI 10.1017/S1462399400002015; Rebl A, 2013, MAR BIOTECHNOL, V15, P445, DOI 10.1007/s10126-013-9501-8; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Schmidt H, 1998, BIOL CHEM, V379, P1227, DOI 10.1515/bchm.1998.379.10.1227; Secombes C.J., 1990, TECHNIQUES FISH IMMU, P137; Shi HN, 2015, GENET MOL RES, V14, P5280, DOI 10.4238/2015.May.18.20; Smith TR, 1999, FISH PHYSIOL BIOCHEM, V20, P279, DOI 10.1023/A:1007743329892; Tang Y, 2010, SHONG YI YAO, V50, P117, DOI DOI 10.3969/J.ISSN.1002-266X.2010.49.078; Taylor JF, 2007, GEN COMP ENDOCR, V152, P314, DOI 10.1016/j.ygcen.2007.02.029; Tian ZhaoHui, 2013, Acta Hydrobiologica Sinica, V37, P344; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Varfolomeeva EY, 2010, B EXP BIOL MED+, V149, P485, DOI 10.1007/s10517-010-0976-2; Wang YB, 2007, COMP BIOCHEM PHYS A, V148, P821, DOI 10.1016/j.cbpa.2007.08.009; Wood LA, 1999, COMP BIOCHEM PHYS A, V123, P35, DOI 10.1016/S1095-6433(99)00035-5; YU BP, 1994, PHYSIOL REV, V74, P139; Zhang ChongYing, 2012, Journal of Fisheries of China, V36, P336	55	17	23	2	34	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-1742	1573-5168		FISH PHYSIOL BIOCHEM	Fish Physiol. Biochem.	APR	2016	42	2					701	710		10.1007/s10695-015-0170-6			10	Biochemistry & Molecular Biology; Fisheries; Physiology	Biochemistry & Molecular Biology; Fisheries; Physiology	DH7GU	WOS:000372961400025	26614500				2021-06-18	
J	Holcomb, EM; Towns, S; Kamper, JE; Barnett, SD; Sherer, M; Evans, C; Nakase-Richardson, R				Holcomb, Erin M.; Towns, Stephanie; Kamper, Joel E.; Barnett, Scott D.; Sherer, Mark; Evans, Clea; Nakase-Richardson, Risa			The Relationship Between Sleep-Wake Cycle Disturbance and Trajectory of Cognitive Recovery During Acute Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; brain injury; cognition; sleep	DEPRIVATION; PERFORMANCE; DISORDERS; DELIRIUM; CONSEQUENCES; PREVALENCE; VALIDATION; STATE	Objective: Following traumatic brain injury, both sleep dysfunction and cognitive impairment are common. Unfortunately, little is known regarding the potential associations between these 2 symptoms during acute recovery. This study sought to prospectively examine the relationship between ratings of sleep dysfunction and serial cognitive assessments among traumatic brain injury acute neurorehabilitation admissions. Methods: Participants were consecutive admissions to a free-standing rehabilitation hospital following moderate to severe traumatic brain injury (Median Emergency Department Glasgow Coma Scale = 7). Participants were assessed for sleep-wake cycle disturbance (SWCD) and cognitive functioning at admission and with subsequent weekly examinations. Participants were grouped on the basis of presence (SWCD+) or absence (SWCD-) of sleep dysfunction for each examination; groups were equivalent on demographic and injury variables. Individual Growth Curve modeling was used to examine course of Cognitive Test for Delirium performance across examinations. Results: Individual Growth Curve modeling revealed a significant interaction between examination number (ie, time) and SWCD group (beta = -4.03, P < .001) on total Cognitive Test for Delirium score. The SWCD+ ratings on later examinations were predicted to result in lower Cognitive Test for Delirium scores and greater cognitive impairment over time. Conclusions: This study has implications for improving neurorehabilitation treatment, as targeting sleep dysfunction for early intervention may facilitate cognitive recovery.	[Holcomb, Erin M.; Sherer, Mark] TIRR Mem Hermann, 1333 Moursund St, Houston, TX 77030 USA; [Kamper, Joel E.; Nakase-Richardson, Risa] James A Haley Vet Hosp, Mental Hlth & Behav Sci, Tampa, FL USA; [Barnett, Scott D.; Nakase-Richardson, Risa] James A Haley Vet Hosp, Ctr Innovat Disabil Rehabil & Res CINDRR, Tampa, FL USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Def & Vet Brain Injury Ctr, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Dept Med, Tampa, FL USA; [Towns, Stephanie] Geisel Sch Med Dartmouth, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA; [Evans, Clea] Methodist Rehabil Ctr, Jackson, MS USA	Holcomb, EM (corresponding author), TIRR Mem Hermann, 1333 Moursund St, Houston, TX 77030 USA.	holcomberin@gmail.com	Towns, Stephanie/AAF-2035-2020; Kamper, Joel/V-2450-2019	Kamper, Joel/0000-0001-5098-5176	Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research; VHA Central Office VA TBI Model System Program of Research; General Dynamics Health Solutions from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U. S. Department of Veterans Affairs [W91YTZ-13-C-0015, 1 I50 HX001233-01, W81XWH-13-2-0095]; General Dynamics Health Solutions from the U. S. Department of Defense Congressionally Directed Medical Research Programs	The Polytrauma Rehabilitation Center Traumatic Brain Injury (TBI) Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research. This research is sponsored by VHA Central Office VA TBI Model System Program of Research, and Subcontract from General Dynamics Health Solutions (W91YTZ-13-C-0015) from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U. S. Department of Veterans Affairs grants (1 I50 HX001233-01, W81XWH-13-2-0095), and U. S. Department of Defense Congressionally Directed Medical Research Programs. The contents of this article were developed under grants from the National Institute on Disability and Rehabilitation Research, Department of Education H133A120020 (Texas TBIModel System of TIRR). The views, opinions, and/ or findings contained in this article are those of the authors and should not be construed as an official Department of Defense, Department of Veterans Affairs, or Department of Education position or any other federal agency, policy, or decision unless so designated by other official documentation.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bourne RS, 2007, CRIT CARE, V11, DOI 10.1186/cc5966; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chuah YML, 2006, J NEUROSCI, V26, P7156, DOI 10.1523/JNEUROSCI.0906-06.2006; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dash MB, 2009, J NEUROSCI, V29, P580, DOI 10.1523/JNEUROSCI.5486-08.2009; Dinges DF, 1997, SLEEP, V20, P267; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Grover S, 2011, J PSYCHOSOM RES, V70, P473, DOI 10.1016/j.jpsychores.2010.11.007; Hairston IS, 2004, NATURE, V430, P27, DOI 10.1038/430027a; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HORNE JA, 1985, ANN CLIN RES, V17, P199; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; KESSLER RC, 1991, LINEAR PANEL ANAL MO; Longordo F, 2009, EUR J NEUROSCI, V29, P1810, DOI 10.1111/j.1460-9568.2009.06719.x; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McDermott CM, 2003, J NEUROSCI, V23, P9687; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; ROGOSA D, 1982, PSYCHOL BULL, V92, P726, DOI 10.1037/0033-2909.92.3.726; ROGOSA DR, 1985, PSYCHOMETRIKA, V50, P203, DOI 10.1007/BF02294247; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Silva MA, 2012, AM J PHYS MED REHAB, V91, P890, DOI 10.1097/PHM.0b013e31825a1648; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Van Someren EJW, 2007, SLEEP MED REV, V11, P465, DOI 10.1016/j.smrv.2007.07.003; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Ware, 2012, APPL LONGITUDINAL AN, V998; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Zepelin H., 2005, PRINCIPLES PRACT SLE, V4, P91, DOI [10.1016/b0-72-160797-7/50015-x, DOI 10.1016/B0-72-160797-7/50015-X]; Zohar D, 2005, SLEEP, V28, P47, DOI 10.1093/sleep/28.1.47; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	40	17	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2016	31	2			SI		108	116		10.1097/HTR.0000000000000206			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DH7NO	WOS:000372981100004	26709584				2021-06-18	
J	Logue, OC; Cramer, NP; Xu, XF; Perl, DP; Galdzicki, Z				Logue, Omar C.; Cramer, Nathan P.; Xu, Xiufen; Perl, Daniel P.; Galdzicki, Zygmunt			Alterations of functional properties of hippocampal networks following repetitive closed-head injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Hippocampus; Long-term potentiation; Neuroplasticity; Electrophysiology; Spontaneous excitatory currents; Spontaneous inhibitory currents, fear-conditioning context and cued	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; TS65DN MOUSE MODEL; SYNAPTIC PLASTICITY; AMPA RECEPTOR; DOWN-SYNDROME; CORTICAL-NEURONS; GLUR2 ENDOCYTOSIS; CELL SYNAPSES; CA1 AREA	Traumatic brain injury (TBI) is the leading cause of death for persons under the age of 45. Military service members who have served on multiple combat deployments and contact-sport athletes are at particular risk of sustaining repetitive TBI (rTBI). Cognitive and behavioral deficits resulting from rTBI are well documented. Optimal associative LTP, occurring in the CA1 hippocampal Schaffer collateral pathway, is required for both memory formation and retrieval. Surprisingly, ipsilateral Schaffer collateral CA1 LIP evoked by 100 Hz tetanus was enhanced in mice from the 3 x closed head injury (3 x CHI) treatment group in comparison to LTP in contralateral or 3 x Sham CA1 area, and in spite of reduced freezing during contextual fear conditioning at one week following 3 x CHI. Electrophysiological activity of CA1 neurons was evaluated with whole-cell patch-clamp recordings. 3 x CHI ipsilateral CA1 neurons exhibited significant increases in action potential amplitude and maximum rise and decay slope while the action potential duration was decreased. Recordings of CA1 neuron postsynaptic currents were conducted to detect spontaneous excitatory and inhibitory postsynaptic currents (sEPSCs/sIPSCs) and respective miniature currents (mEPSCs and mIPSCs). In the 3 x CHI mice, sEPSCs and sIPSCs in ipsilateral CA1 neurons had an increased frequency of events but decreased amplitudes. In addition, 3 x CHI altered the action potential-independent miniature postsynaptic currents. The mEPSCs of ipsilateral CA1 neurons exhibited both an increased frequency of events and larger amplitudes. Moreover, the effect of 3 x CHI on mIPSCs was opposite to that of the sIPSCs. Specifically, the frequency of the mIPSCs was decreased while the amplitudes were increased. These results are consistent with a mechanism in which repetitive closed-head injury affects CA1 hippocampal function by promoting a remodeling of excitatory and inhibitory synaptic inputs leading to impairment in hippocampal-dependent tasks. Published by Elsevier Inc.	[Logue, Omar C.] Uniformed Serv Univ Hlth Sci, Sch Med, Grad Program Neurosci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Logue, Omar C.; Cramer, Nathan P.; Xu, Xiufen; Galdzicki, Zygmunt] Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Neurosci & Regenerat Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Neurosci & Regenerat Med, Dept Pathol, Bethesda, MD 20814 USA	Galdzicki, Z (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Neurosci & Regenerat Med, Dept Anat Physiol & Genet,Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Galdzicki, Z (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Neurosci & Regenerat Med, MCB Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	zygmunt.galdzicki@usuhs.edu		Cramer, Nathan/0000-0001-6146-3664; Logue, Omar/0000-0002-9919-7688	USUHS [T070B013]; CNRMUnited States Department of Defense [PAT-74-2333, G17030, G1702577]; DMRDP [D61_I_10_J6_214]	This research was supported by USUHS grant T070B013 (OL), CNRM grants PAT-74-2333 (DP), G17030 and G1702577 (ZG) and DMRDP grant D61_I_10_J6_214 (ZG).	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Almeida-Suhett CP, 2015, EXP NEUROL, V273, P11, DOI 10.1016/j.expneurol.2015.07.028; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Bang S.A., 2015, J NEUROTRAUMA; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2015, J HEAD TRAUMA REHABI; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BERBERIAN BJ, 1990, CUTIS, V46, P46; Best TK, 2012, EXP NEUROL, V233, P749, DOI 10.1016/j.expneurol.2011.11.033; Bourtchouladze R, 2006, LEARN MEMORY, V13, P745, DOI 10.1101/lm.354106; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chakrabarti L, 2010, NAT NEUROSCI, V13, P927, DOI 10.1038/nn.2600; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Di Filippo M, 2008, TRENDS PHARMACOL SCI, V29, P402, DOI 10.1016/j.tips.2008.06.005; Di Filippo M, 2013, NEUROBIOL DIS, V52, P229, DOI 10.1016/j.nbd.2012.12.009; Drexel M, 2015, NEUROPHARMACOLOGY, V88, P122, DOI 10.1016/j.neuropharm.2014.08.023; Drummond JB, 2012, NEUROREPORT, V23, P1031, DOI 10.1097/WNR.0b013e32835ad229; Dutra RC, 2013, BRAIN BEHAV IMMUN, V33, P90, DOI 10.1016/j.bbi.2013.06.002; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; FORSCHER P, 1985, J GEN PHYSIOL, V85, P743, DOI 10.1085/jgp.85.5.743; Gardner SM, 2005, NEURON, V45, P903, DOI 10.1016/j.neuron.2005.02.026; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graves LA, 2003, LEARN MEMORY, V10, P168, DOI 10.1101/lm.48803; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; He SJ, 2014, NEUROPHARMACOLOGY, V77, P379, DOI 10.1016/j.neuropharm.2013.10.016; Hoge CW, 2010, ARCH PHYS MED REHAB, V91, P963, DOI 10.1016/j.apmr.2010.02.005; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holopainen IE, 2003, NEUROSCIENCE, V118, P967, DOI 10.1016/S0306-4522(03)00046-0; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Imbrosci B, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/614329; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Kandel ER, 2014, CELL, V157, P163, DOI 10.1016/j.cell.2014.03.001; Kato AS, 2010, TRENDS NEUROSCI, V33, P241, DOI 10.1016/j.tins.2010.02.004; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kirischuk S, 2000, NEUROREPORT, V11, P3709, DOI 10.1097/00001756-200011270-00024; Klausberger T, 2009, EUR J NEUROSCI, V30, P947, DOI 10.1111/j.1460-9568.2009.06913.x; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lu W, 2009, NEURON, V62, P254, DOI 10.1016/j.neuron.2009.02.027; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Martin LJ, 2010, J NEUROSCI, V30, P5269, DOI 10.1523/JNEUROSCI.4209-09.2010; McMillan R, 1990, Transfus Med Rev, V4, P136, DOI 10.1016/S0887-7963(90)70258-1; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Min SS, 2009, NEUROSCI LETT, V456, P20, DOI 10.1016/j.neulet.2009.03.079; Mitterdorfer J, 2002, J NEUROSCI, V22, P10106; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Nistico R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0162; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Penn AC, 2012, NEURON, V76, P503, DOI 10.1016/j.neuron.2012.08.010; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Plant K, 2006, NAT NEUROSCI, V9, P602, DOI 10.1038/nn1678; Raible DJ, 2015, EXP NEUROL, V271, P445, DOI 10.1016/j.expneurol.2015.07.001; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Rozov Andrei, 2012, Front Synaptic Neurosci, V4, P4, DOI 10.3389/fnsyn.2012.00004; Rozov A, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00022; Sara Y, 2005, NEURON, V45, P563, DOI 10.1016/j.neuron.2004.12.056; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Shen H, 2007, NAT NEUROSCI, V10, P469, DOI 10.1038/nn1868; Siarey RJ, 2006, J NEUROCHEM, V98, P1266, DOI 10.1111/j.1471-4159.2006.03971.x; Siarey RJ, 1999, NEUROPHARMACOLOGY, V38, P1917, DOI 10.1016/S0028-3908(99)00083-0; Siarey RJ, 2005, NEUROPHARMACOLOGY, V49, P122, DOI 10.1016/j.neuropharm.2005.02.012; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Soares C, 2013, J NEUROSCI, V33, P13547, DOI 10.1523/JNEUROSCI.1873-13.2013; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terashima A, 2008, NEURON, V57, P872, DOI 10.1016/j.neuron.2008.01.028; Tsuzuki K, 2001, J NEUROCHEM, V77, P1650, DOI 10.1046/j.1471-4159.2001.00388.x; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Vargas-Caballero M, 2010, NEUROPHARMACOLOGY, V58, P668, DOI 10.1016/j.neuropharm.2009.11.005; Viosca J, 2009, LEARN MEMORY, V16, P198, DOI 10.1101/lm.1220309; Vithlani M, 2011, PHYSIOL REV, V91, P1009, DOI 10.1152/physrev.00015.2010; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Warren KM, 2012, J NEUROTRAUM, V29, P1922, DOI 10.1089/neu.2012.2383; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Whitehead G, 2013, BRAIN, V136, P3753, DOI 10.1093/brain/awt293; Wiltgen BJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012818; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yokoi N, 2012, INT REV CEL MOL BIO, V297, P1, DOI 10.1016/B978-0-12-394308-8.00001-7; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Yurdakoc A, 2008, ACTA ANAESTH SCAND, V52, P658, DOI 10.1111/j.1399-6576.2008.01635.x; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	123	17	18	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2016	277						227	243		10.1016/j.expneurol.2015.12.019			17	Neurosciences	Neurosciences & Neurology	DF2ST	WOS:000371194800023	26730521	Other Gold			2021-06-18	
J	Williams, DSB; Murray, NG; Powell, DW				Williams, D. S. Blaise, III; Murray, Nicholas G.; Powell, Douglas W.			Athletes who train on unstable compared to stable surfaces exhibit unique postural control strategies in response to balance perturbations	JOURNAL OF SPORT AND HEALTH SCIENCE			English	Article						Athletes; Balance; Negative feedback; Postural stability; Training	DYNAMIC BALANCE; CEREBRAL CONCUSSION; APPROXIMATE ENTROPY; RHYTHMIC GYMNASTICS; HEALTHY-YOUNG; BODY SWAY; ADULTS; EQUILIBRIUM; DIRECTIONS; BASKETBALL	Background: Athletes have been shown to exhibit better balance compared to non-athletes (NON). However, few studies have investigated how the surface on which athletes train affects the strategies adopted to maintain balance. Two distinct athlete groups who experience different types of sport-specific balance training are stable surface athletes (SSA) such as basketball players and those who train on unstable surfaces (USA) such as surfers. The purpose of this study was to investigate the effects of training surface on dynamic balance in athletes compared to NON. Methods: Eight NON, eight SSA, and eight USA performed five 20-s trials in each of five experimental conditions including a static condition and four dynamic conditions in which the support surface translated in the anteroposterior (AP) or mediolateral (ML) planes using positive or negative feedback paradigms. Approximate entropy (ApEn) and root mean square distance (RMS) of the center of pressure (CoP) were calculated for the AP and ML directions. Four 3 x 5 (group x condition) repeated measures ANOVAs were used to determine significant effects of group and condition on variables of interest. Results: USA exhibited smaller ApEn values than SSA in the AP signals while no significant differences were observed in the ML CoP signals. Generally, the negative feedback conditions were associated with significantly greater RMS values than the positive feedback conditions. Conclusion: USA exhibit unique postural strategies compared to SSA. These unique strategies seemingly exhibit a direction-specific attribute and may be associated with divergent motor control strategies. (C) 2016 Production and hosting by Elsevier B.V. on behalf of Shanghai University of Sport.	[Williams, D. S. Blaise, III] Virginia Commonwealth Univ, Dept Phys Therapy, Med Coll Virginia Campus, Richmond, VA 23284 USA; [Murray, Nicholas G.] Georgia So Univ, Dept Hlth Sci & Kinesiol, Statesboro, GA 30458 USA; [Powell, Douglas W.] Campbell Univ, Coll Pharm & Hlth Sci, Dept Phys Therapy, Buies Creek, NC 27506 USA; [Powell, Douglas W.] Campbell Univ, Sch Osteopath Med, Dept Physiol, Buies Creek, NC 27506 USA	Powell, DW (corresponding author), Campbell Univ, Coll Pharm & Hlth Sci, Dept Phys Therapy, Buies Creek, NC 27506 USA.; Powell, DW (corresponding author), Campbell Univ, Sch Osteopath Med, Dept Physiol, Buies Creek, NC 27506 USA.	dwp0817@gmail.com					Bressel E, 2007, J ATHL TRAINING, V42, P42; Calavalle AR, 2008, EUR J APPL PHYSIOL, V104, P643, DOI 10.1007/s00421-008-0815-6; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chen Wei-ting, 2006, J Zhejiang Univ Sci B, V7, P844, DOI 10.1631/jzus.2006.B0844; Davlin CD, 2004, PERCEPT MOTOR SKILL, V98, P1171, DOI 10.2466/PMS.98.4.1171-1176; Demura SI, 2008, PERCEPT MOTOR SKILL, V107, P89, DOI 10.2466/PMS.107.1.89-98; Gerbino PG, 2007, GAIT POSTURE, V26, P501, DOI 10.1016/j.gaitpost.2006.11.205; Golomer E, 1999, NEUROSCI LETT, V267, P189, DOI 10.1016/S0304-3940(99)00356-0; Guillou E, 2007, CLIN NEUROPHYSIOL, V118, P317, DOI 10.1016/j.clinph.2006.10.001; Hansen MS, 2000, KNEE SURG SPORT TR A, V8, P180, DOI 10.1007/s001670050211; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; Kiers H, 2013, SPORTS MED, V43, P1171, DOI 10.1007/s40279-013-0082-5; Kioumourtzoglou E, 1998, PERCEPT MOTOR SKILL, V86, P771, DOI 10.2466/pms.1998.86.3.771; Kioumourtzoglou E, 1997, PERCEPT MOTOR SKILL, V84, P1363, DOI 10.2466/pms.1997.84.3c.1363; Klous M, 2011, J NEUROPHYSIOL, V105, P2275, DOI 10.1152/jn.00665.2010; Lamoth CJC, 2009, GAIT POSTURE, V29, P546, DOI 10.1016/j.gaitpost.2008.12.006; McKeon PO, 2008, J ATHL TRAINING, V43, P293, DOI 10.4085/1062-6050-43.3.293; Perrin P, 2002, GAIT POSTURE, V15, P187, DOI 10.1016/S0966-6362(01)00149-7; Powell DW, 2015, HUM MOVEMENT SCI, V44, P73, DOI 10.1016/j.humov.2015.08.013; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; RILEY PO, 1990, J BIOMECH, V23, P503, DOI 10.1016/0021-9290(90)90306-N; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; Sforza C, 2003, PERCEPT MOTOR SKILL, V96, P127, DOI 10.2466/PMS.96.1.127-136; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; Thompson WR., 2010, ACSMS GUIDELINES EXE; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; Yamamoto S, 2001, NAT NEUROSCI, V4, P759, DOI 10.1038/89559	31	17	17	0	22	SHANGHAI UNIV SPORT	SHANGHAI	EDITORIAL BOARD, 650 QINGYUANHUAN RD, SHANGHAI, 200438, PEOPLES R CHINA	2095-2546	2213-2961		J SPORT HEALTH SCI	J. Sport Health Sci.	MAR	2016	5	1					70	76		10.1016/j.jshs.2016.01.010			7	Hospitality, Leisure, Sport & Tourism; Sport Sciences	Social Sciences - Other Topics; Sport Sciences	DI8AH	WOS:000373722600009	30356520	DOAJ Gold, Green Published			2021-06-18	
J	Dziewas, R; Glahn, J; Helfer, C; Ickenstein, G; Keller, J; Ledl, C; Lindner-Pfleghar, B; Nabavi, DG; Prosiegel, M; Riecker, A; Lapa, S; Stanschus, S; Warnecke, T; Busse, O				Dziewas, Rainer; Glahn, Joerg; Helfer, Christine; Ickenstein, Guntram; Keller, Jochen; Ledl, Christian; Lindner-Pfleghar, Beate; Nabavi, Darius G.; Prosiegel, Mario; Riecker, Axel; Lapa, Sriramya; Stanschus, Soenke; Warnecke, Tobias; Busse, Otto			Flexible endoscopic evaluation of swallowing (FEES) for neurogenic dysphagia: training curriculum of the German Society of Neurology and the German stroke society	BMC MEDICAL EDUCATION			English	Article						Nervous system diseases; Flexible Endoscopic Evaluation of Swallowing; Muscular diseases; Stroke; Clinical competence	TRAUMATIC BRAIN-INJURY; LATERAL-SCLEROSIS; COMPLICATIONS; ASPIRATION; DISORDERS; SAFETY; VIDEOFLUOROSCOPY; DIAGNOSIS; DEMENTIA; DISEASE	Background: Neurogenic dysphagia is one of the most frequent and prognostically relevant neurological deficits in a variety of disorders, such as stroke, parkinsonism and advanced neuromuscular diseases. Flexible endoscopic evaluation of swallowing (FEES) is now probably the most frequently used tool for objective dysphagia assessment in Germany. It allows evaluation of the efficacy and safety of swallowing, determination of appropriate feeding strategies and assessment of the efficacy of different swallowing manoeuvres. The literature furthermore indicates that FEES is a safe and well-tolerated procedure. In spite of the huge demand for qualified dysphagia diagnostics in neurology, a systematic FEES education has not yet been established. Results: The structured training curriculum presented in this article aims to close this gap and intends to enforce a robust and qualified FEES service. As management of neurogenic dysphagia is not confined to neurologists, this educational programme is applicable to other clinicians and speech-language therapists with expertise in dysphagia as well. Conclusion: The systematic education in carrying out FEES across a variety of different professions proposed by this curriculum will help to spread this instrumental approach and to improve dysphagia management.	[Dziewas, Rainer; Warnecke, Tobias] Univ Hosp Munster, Dept Neurol, Albert Schweitzer Campus 1, D-48149 Munster, Germany; [Glahn, Joerg] Johannes Wesling Klinikum Minden, Dept Neurol, Minden, Germany; [Helfer, Christine] Vivantes Klinikum Neukolln, ENT Dept, Berlin, Germany; [Helfer, Christine; Nabavi, Darius G.] Vivantes Klinikum Neukolln, Dept Neurol, Berlin, Germany; [Ickenstein, Guntram] HELIOS Klinikum Aue, Dept Neurol, Aue, Germany; [Ickenstein, Guntram] HELIOS Klinikum Aue, Stroke Unit, Aue, Germany; [Keller, Jochen] St Martinus Hosp, Clin Acute Geriatr, Dusseldorf, Germany; [Ledl, Christian] Schon Klin Bad Aibling, Bad Aibling, Germany; [Lindner-Pfleghar, Beate; Riecker, Axel] Univ Ulm, Dept Neurol, D-89069 Ulm, Germany; [Prosiegel, Mario] German Soc Dysphagia, Munich, Germany; [Riecker, Axel] Reha Nova, Clin Neurol & Neurosurg Rehabil, Cologne, Germany; [Lapa, Sriramya] Goethe Univ Frankfurt, Dept Neurol, ZNN, D-60054 Frankfurt, Germany; [Stanschus, Soenke] Hosp Zum Heiligen Geist, Kempen, Germany; [Busse, Otto] DSG & DGN Off, D-10117 Berlin, Germany	Dziewas, R (corresponding author), Univ Hosp Munster, Dept Neurol, Albert Schweitzer Campus 1, D-48149 Munster, Germany.	dziewas@uni-muenster.de	Dziewas, Rainer/AAX-9505-2020	Dziewas, Rainer/0000-0003-1592-8461	DSG; DGN	Travel expenses of the meetings of the FEES task force were covered by the DGN and DSG.	[Anonymous], FIBR END EV SWALL FE; Aviv JE, 2000, DYSPHAGIA, V15, P39, DOI 10.1007/s004559910008; Aviv JE., 2001, ENDOSCOPIC EVALUATIO, P235; Carnaby-Mann G, 2008, PHYS MED REH CLIN N, V19, P747, DOI 10.1016/j.pmr.2008.05.008; Cohen MA, 2003, LARYNGOSCOPE, V113, P21, DOI 10.1097/00005537-200301000-00004; Deutschmann MW, 2013, HEAD NECK-J SCI SPEC, V35, P974, DOI 10.1002/hed.23066; Dziewas R, 2003, J NEUROL NEUROSUR PS, V74, P1429, DOI 10.1136/jnnp.74.10.1429; Dziewas R, 2008, CEREBROVASC DIS, V26, P41, DOI 10.1159/000135652; GROB D, 1987, ANN NY ACAD SCI, V505, P472; Hafner G, 2008, EUR ARCH OTO-RHINO-L, V265, P441, DOI 10.1007/s00405-007-0507-6; Hoffmann S, 2012, STROKE, V43, P2617, DOI 10.1161/STROKEAHA.112.653055; HORNER J, 1994, ALZ DIS ASSOC DIS, V8, P177; Kelly AM, 2006, CLIN OTOLARYNGOL, V31, P425, DOI 10.1111/j.1749-4486.2006.01292.x; Kelly AM, 2007, LARYNGOSCOPE, V117, P1723, DOI 10.1097/MLG.0b013e318123ee6a; Kuhnlein P, 2008, NAT CLIN PRACT NEURO, V4, P366, DOI 10.1038/ncpneuro0853; Langmore S E, 1988, Dysphagia, V2, P216, DOI 10.1007/BF02414429; Langmore SE, 2001, ENDOSCOPIC EVALUATIO; Langmore SE, 2007, ARCH NEUROL-CHICAGO, V64, P58, DOI 10.1001/archneur.64.1.58; Langmore Susan E, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P485, DOI 10.1097/00020840-200312000-00014; Leder SB, 2004, DYSPHAGIA, V19, P177, DOI 10.1007/s00455-004-0009-2; Leder SB, 1999, J HEAD TRAUMA REHAB, V14, P448, DOI 10.1097/00001199-199910000-00005; Leder SB, 1998, DYSPHAGIA, V13, P19, DOI 10.1007/PL00009544; Leder SB, 1997, DYSPHAGIA, V12, P52; Macht M, 2011, CRIT CARE, V15, DOI 10.1186/cc10472; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Martino R, 2005, STROKE, V36, P2756, DOI 10.1161/01.STR.0000190056.76543.eb; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); Miller N, 2006, AGE AGEING, V35, P614, DOI 10.1093/ageing/afl105; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; Mulcahy KP, 2012, DYSPHAGIA, V27, P64, DOI 10.1007/s00455-011-9338-0; Muller J, 2001, ARCH NEUROL-CHICAGO, V58, P259, DOI 10.1001/archneur.58.2.259; O'Donoghue S, 1999, FOLIA PHONIATR LOGO, V51, P158, DOI 10.1159/000021494; Scheel R, 2016, ANN OTO RHINOL LARYN, V125, P43, DOI 10.1177/0003489415596755; Suh MK, 2009, ALZ DIS ASSOC DIS, V23, P178, DOI 10.1097/WAD.0b013e318192a539; Suntrup S, 2012, NERVENARZT, V83, P1619, DOI 10.1007/s00115-012-3611-9; Suntrup S, 2012, J NEUROL, V259, P93, DOI 10.1007/s00415-011-6129-3; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; Warnecke T., 2013, NEUROGENE DYSPHAGIEN; Warnecke T, 2010, MOVEMENT DISORD, V25, P1239, DOI 10.1002/mds.23060; Warnecke T, 2009, NEUROMUSCULAR DISORD, V19, P704, DOI 10.1016/j.nmd.2009.06.371; Warnecke T, 2009, STROKE, V40, P482, DOI 10.1161/STROKEAHA.108.520775; Willging J Paul, 2005, Curr Gastroenterol Rep, V7, P240, DOI 10.1007/s11894-005-0041-x; Wu CH, 1997, LARYNGOSCOPE, V107, P396	43	17	19	4	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1472-6920			BMC MED EDUC	BMC Med. Educ.	FEB 25	2016	16								70	10.1186/s12909-016-0587-3			9	Education & Educational Research; Education, Scientific Disciplines	Education & Educational Research	DF1VE	WOS:000371126500001	26911194	DOAJ Gold, Green Published			2021-06-18	
J	Wang, C; Wang, P; Zeng, W; Li, WX				Wang, Chao; Wang, Peng; Zeng, Wen; Li, Weixin			Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Spinal cord injury; Tetramethylpyrazine; Akt; Nrf2; HO-1	OXIDATIVE STRESS; HEME OXYGENASE-1; BRAIN; NRF2; NEUROPROTECTION; SULFORAPHANE; INFLAMMATION; BARRIER; MODEL; RATS	Spinal cord injury (SCI) is one of the most severe traumatic conditions, resulting in postoperative complications. Our results and other reports have shown that tetramethylpyrazine (TMP) is able to exhibit neuro-protective effects after SCI. In the current study, we aimed to examine the possible mechanism underlying the neuro-protective effect of TMP in rat model of SCI. TMP improved locomotor functions and decreased permeability of blood-spinal cord barrier in rats with SCI, as evidenced by increase of Basso-Beattie-Bresnahan scores and decrease of Evans blue leakage. In addition, TMP decreased the expression of several proinflammatory cytokines, including IL-1 beta, TNF alpha and IL-18, reduced TUNEL-positive cells and caspase 3 and 9 activities, decreased thiobarbituric acid reactive substances content and increased glutathione level and superoxide dismutase activity in rats. All these effects were inhibited by zinc protoporphyrin IX (ZnPP), an inhibitor of HO-1, and LY294002, an inhibitor of Akt. Moreover, TMP inhibited the decrease of mRNA expression of HO-1 which was suppressed by ZnPP and LY294002. TMP inhibited the decrease of Akt phosphorylation in rats after SCI, which was suppressed by LY294002, but not ZnPP. Furthermore, LY294002, but not ZnPP, significantly inhibited TMP-induced increase of mRNA expression of Nrf2 and DNA binding activity of Nrf2 in HO-1 promoters in rat model of SCI. The data suggested that TMP induced neuro-protective effects against injury of spinal cord through the activation of Akt/ Nrf2/HO-1 signaling pathway. These results have appointed a new path toward the understanding of pathogenesis and TMP-related therapy of SCI and associated neurodegenerative diseases. (C) 2016 Elsevier Ltd. All rights reserved.	[Wang, Chao; Wang, Peng; Zeng, Wen; Li, Weixin] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian 710038, Peoples R China	Li, WX (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian 710038, Peoples R China.	weixin_li111@163.com					Alkabie S, 2015, WORLD NEUROSURG; Au ALS, 2003, EUR J PHARMACOL, V468, P199, DOI 10.1016/S0014-2999(03)01691-1; Benedict AL, 2012, J NEUROTRAUM, V29, P2576, DOI 10.1089/neu.2012.2474; Bijjem KRV, 2013, N-S ARCH PHARMACOL, V386, P79, DOI 10.1007/s00210-012-0816-1; Cheaib B, 2015, CHIN J CANCER, V34, P4, DOI 10.5732/cjc.014.10289; Chen SY, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-1; Cheng XR, 2007, CELL BIOL INT, V31, P438, DOI 10.1016/j.cellbi.2006.10.001; Dionyssiotis Yannis, 2014, Folia Med (Plovdiv), V56, P237, DOI 10.1515/folmed-2015-0002; Edwards WB, 2014, OSTEOPOROSIS INT, V25, P1005, DOI 10.1007/s00198-013-2557-5; Giuliano F, 1999, ANN NEUROL, V46, P15, DOI 10.1002/1531-8249(199907)46:1<15::AID-ANA5>3.0.CO;2-U; Guan DS, 2015, J NEUROCHEM, V134, P551, DOI 10.1111/jnc.13161; Hagg T., 2015, J NEUROTRAUMA; Henke D., 2015, SPINE J; HO WKK, 1989, STROKE, V20, P96, DOI 10.1161/01.STR.20.1.96; Hu JZ, 2013, J NEUROL SCI, V324, P94, DOI 10.1016/j.jns.2012.10.009; Kieseier B, 2015, ACTA NEUROPATHOL, V130, P297, DOI 10.1007/s00401-015-1457-5; Koushki D, 2015, J SPINAL CORD MED, V38, P13, DOI 10.1179/2045772314Y.0000000215; KWAN CY, 1994, STEM CELLS, V12, P64, DOI 10.1002/stem.5530120111; KWAN CY, 1990, J CARDIOVASC PHARM, V15, P157, DOI 10.1097/00005344-199001000-00025; Lin Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI 10.1038/sj.jcbfm.9600412; LIU SF, 1990, EUR J PHARMACOL, V191, P345, DOI 10.1016/0014-2999(90)94167-V; Luo Y., 2015, MOL MED REP; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Sothmann J, 2015, SAMJ, S. Afr. med. j., V105, P835, DOI [10.7196/SAMJnew.8072, 10.7196/SAMJNEW.8072]; Vargas MR, 2005, J BIOL CHEM, V280, P25571, DOI 10.1074/jbc.M501920200; Wang W, 2015, INT J CLIN EXP MED, V8, P3514; Wang XQ, 2014, J NEUROSCI, V34, P8585, DOI 10.1523/JNEUROSCI.2935-13.2014; Winkler EA, 2014, P NATL ACAD SCI USA, V111, pE1035, DOI 10.1073/pnas.1401595111; Wu W, 2013, BEHAV BRAIN RES, V253, P212, DOI 10.1016/j.bbr.2013.07.052; Xia B., 2015, INT J MOL MED; Xiao XL, 2010, NEUROL RES, V32, P547, DOI 10.1179/174313209X414533; Yip PY, 2015, TRANSL LUNG CANCER R, V4, P165, DOI 10.3978/j.issn.2218-6751.2015.01.04; Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041; Zhao TF, 2012, MOL BIOL REP, V39, P3541, DOI 10.1007/s11033-011-1127-1	35	17	20	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	FEB 15	2016	26	4					1287	1291		10.1016/j.bmcl.2016.01.015			5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	DC7CZ	WOS:000369377700038	26786697				2021-06-18	
J	Chi, YC; Wu, HL; Chu, CP; Huang, MC; Lee, PC; Chen, YY				Chi, Ying-Chen; Wu, Hyun-Ling; Chu, Chih-Pang; Huang, Ming-Chyi; Lee, Pei-Chen; Chen, Ying-Yeh			Traumatic brain injury and affective disorder: A nationwide cohort study in Taiwan, 2000-2010	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Traumatic brain injury; Affective disorders; Bipolar disorder; Major depression; Taiwan	MAJOR DEPRESSIVE DISORDER; PSYCHIATRIC-DISORDERS; MOOD DISORDERS; HEAD-INJURY; RISK-FACTOR; EPIDEMIOLOGY; ASSOCIATION; ADOLESCENTS; PREVALENCE; ADULTS	Background: Studies investigating the relationship between head injury and the subsequent onset of affective disorders often show conflicting results. Aims: To investigate the risk of affective disorders following traumatic brain injury in a large Taiwanese cohort. Method: This retrospective cohort study makes use of the National Health Insurance Research Database. A cohort containing 68,376 individuals who experienced traumatic brain injury (TBI) during 2000-2010 and had no prior history of mental disorders before the injury was identified. Using Cox Proportional Hazards regression, the subsequent risk of affective disorders was determined. Results: TBI was associated with a higher risk of both bipolar disorder (Hazard Ratio [HR] =1.42, 95% Confidence Interval [CI] = [1.26, 1.59]) and major depression (HR=1.41, 95% Cl= [1.28, 1.54]). More severe injury was associated with greater risk. The first year following the injury was the highest risk period for major depression, while the highest risk period for bipolar disorder was delayed until two to four years following the injury. Limitations: Using a claims database, we were unable to assess confounding variables that were not contained in the data set. Conclusions: The elevated risks of affective disorders after TBI speak to the psychiatric need of individuals who suffer from brain injury. Early detection and timely intervention may help prevent secondary and tertiary disability associated with head trauma. (c) 2015 Published by Elsevier By.	[Chi, Ying-Chen] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan; [Chi, Ying-Chen] Univ Kang Ning, Dept Informat Management, Taipei, Taiwan; [Wu, Hyun-Ling; Lee, Pei-Chen] Natl Taipei Univ Nursing & Hlth Sci, Taipei, Taiwan; [Chu, Chih-Pang; Huang, Ming-Chyi; Chen, Ying-Yeh] Taipei City Hosp, Taipei City Psychiat Ctr, Taipei, Taiwan; [Huang, Ming-Chyi] Taipei Med Univ, Sch Med, Dept Psychiat, Taipei, Taiwan; [Chen, Ying-Yeh] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Chen, Ying-Yeh] Natl Yang Ming Univ, Dept Publ Hlth, Taipei 112, Taiwan	Lee, PC (corresponding author), Taipei City Psychiat Ctr, Dept Gen Psychiat, 309 Songde Rd, Taipei 110, Taiwan.	pcl0807@gmail.com; ychen@tpech.gov.tw	Huang, Ming-Chyi/W-9515-2019	Chen, Ying-Yeh/0000-0001-5543-5704; , Pei-Chen/0000-0001-7813-0823	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST 103-2314-B-532-003-MY2, MOST 103-2314-B-227-002-MY2]; Department of Health Taipei City Government [10401-62-011]	Y.-Y.C. was supported by the Ministry of Science and Technology (Grant number: MOST 103-2314-B-532-003-MY2) and the Department of Health Taipei City Government (Grant number: 10401-62-011). P.-C.L. was supported by the Ministry of Science and Technology (Grant number: MOST 103-2314-B-227-002-MY2).	Blumberg HP, 2004, ANN NY ACAD SCI, V1021, P376, DOI 10.1196/annals.1308.048; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Diamond B, 2009, NAT REV IMMUNOL, V9, P449, DOI 10.1038/nri2529; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lam C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/487985; Liao SC, 2012, PSYCHOL MED, V42, P1227, DOI 10.1017/S0033291711002364; Lin JW, 2008, ACT NEUR S, V101, P113; Liu CY, 2006, J HLTH MANAGEMENT, V4, P1, DOI DOI 10.29805/JHM.200606.0001; Ma J, 2000, AM J HEALTH PROMOT, V15, P107, DOI 10.4278/0890-1171-15.2.107; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mortensen PB, 2003, J AFFECT DISORDERS, V76, P79, DOI 10.1016/S0165-0327(02)00073-3; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Patino-Alonso M. C., 2015, BR J NUTR, V114, P1; Patton GC, 2007, LANCET, V369, P1130, DOI 10.1016/S0140-6736(07)60366-3; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Shen HN, 2012, PANCREAS, V41, P696, DOI 10.1097/MPA.0b013e31823db941; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Tsai MC, 2014, J PEDIATR-US, V164, P136, DOI 10.1016/j.jpeds.2013.08.042; *US SURG GEN, 1984, HLTH CONS SMOK CHRON; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Zhang Y, 2011, DISCOV MED, V11, P395	35	17	17	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	FEB	2016	191						56	61		10.1016/j.jad.2015.11.035			6	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	DB1FL	WOS:000368253400009	26650968				2021-06-18	
J	Ahuja, P; Cantrelle, FX; Huvent, I; Hanoulle, X; Lopez, J; Smet, C; Wieruszeski, JM; Landrieu, I; Lippens, G				Ahuja, Puneet; Cantrelle, Francois-Xavier; Huvent, Isabelle; Hanoulle, Xavier; Lopez, Juan; Smet, Caroline; Wieruszeski, Jean-Michel; Landrieu, Isabelle; Lippens, G.			Proline Conformation in a Functional Tau Fragment	JOURNAL OF MOLECULAR BIOLOGY			English	Article						Tau protein; proline conformation; cis/trans isomerisation; exchange spectroscopy; nuclear magnetic resonance spectroscopy	NUCLEAR-MAGNETIC-RESONANCE; CIS-TRANS ISOMERIZATION; I PROCOLLAGEN INCELLULO; TRIPLE-HELIX; PROLYL ISOMERIZATION; PROTEIN; PHOSPHORYLATION; PEPTIDE; ASSIGNMENT; SPECTROSCOPY	The conformational state of distinct prolines can determine the folding of a protein but equally other biological processes when coupled to a conformation-sensitive secondary reaction. For the neuronal tau protein, the importance of proline conformation is underscored by its interaction with different prolyl cis/trans isomerases. The proline conformation would gain even further importance after phosphorylation of the preceding residue by various proline-directed kinases. A number of molecular diseases including Alzheimer's disease and traumatic brain injury were thereby recently qualified as "cistauosis", as they would imply a cis conformation for the pThr231-Pro232 prolyl bond. We here investigate by NMR spectroscopy the conformation of all prolines in a functional Tau fragment, Tau[208-324]. Although we can detect and identify some minor conformers in the cis form, we show that all prolines are for over 90% in the trans conformation. Phosphorylation by CDK2/CycA3, which notably leads to complete modification of the Thr231 residue, does not change this conclusion. Our data hence disagree with the notion that specific prolyl bonds in tau would adopt preferentially the cis conformation. (C) 2015 Elsevier Ltd. All rights reserved.	[Ahuja, Puneet; Cantrelle, Francois-Xavier; Huvent, Isabelle; Hanoulle, Xavier; Lopez, Juan; Smet, Caroline; Wieruszeski, Jean-Michel; Landrieu, Isabelle; Lippens, G.] Univ Lille, CNRS, UMR8576, F-59658 Villeneuve Dascq, France	Lippens, G (corresponding author), Univ Lille, CNRS, UMR8576, F-59658 Villeneuve Dascq, France.	Guy.Lippens@univ-lille1.fr	Hanoulle, Xavier/AAK-7236-2021; Landrieu, Isabelle/AAF-8495-2019; Smet-Nocca, Caroline/U-3427-2019; Smet-Nocca, Caroline/G-2868-2012	Hanoulle, Xavier/0000-0002-3755-2680; Smet-Nocca, Caroline/0000-0002-9793-0882; Landrieu, Isabelle/0000-0002-4883-2637; Huvent, Isabelle/0000-0002-7241-0290; lopez, juan/0000-0002-5390-6610; Lippens, Guy/0000-0002-8236-0901; cantrelle, francois-xavier/0000-0002-3413-5443	Complix (Ghent, Belgium); Region Nord-Pas de CalaisRegion Hauts-de-FranceEuropean Commission; CNRSCentre National de la Recherche Scientifique (CNRS)European Commission; Pasteur Institute of Lille; European Community (FEDER)European Commission; French Research MinistryMinistry of Research, France; University of Sciences and Technologies of Lille I; TGE RMN THC (France) [FR-3050]; Laboratory of Excellence, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's disease	P.A. was supported by a grant from Complix (Ghent, Belgium). The NMR facilities were funded by the Region Nord-Pas de Calais, CNRS, Pasteur Institute of Lille, European Community (FEDER), French Research Ministry and the University of Sciences and Technologies of Lille I. We acknowledge support from the TGE RMN THC (FR-3050, France). This study was supported by the Laboratory of Excellence, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's disease.	Amniai L, 2011, BIOCHEM BIOPH RES CO, V412, P743, DOI 10.1016/j.bbrc.2011.08.046; Amniai L, 2009, FASEB J, V23, P1146, DOI 10.1096/fj.08-121590; Bibow S, 2011, J AM CHEM SOC, V133, P15842, DOI 10.1021/ja205836j; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DORMAN DE, 1973, J ORG CHEM, V38, P2379, DOI 10.1021/jo00953a021; Eckert B, 2005, NAT STRUCT MOL BIOL, V12, P619, DOI 10.1038/nsmb946; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Fauquant C, 2011, J BIOL CHEM, V286, P33358, DOI 10.1074/jbc.M111.223545; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; HANGER DP, 2011, INT J ALZHEIMERS DIS, V2011, P1; HOWARTH OW, 1978, PROG NUCL MAG RES SP, V12, P1, DOI 10.1016/0079-6565(78)80001-6; Huvent I, 2014, BIOCHEM BIOPH RES CO, V445, P299, DOI 10.1016/j.bbrc.2014.01.161; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jinwal UK, 2010, J NEUROSCI, V30, P591, DOI 10.1523/JNEUROSCI.4815-09.2010; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; KERN D, 1995, BIOCHEMISTRY-US, V34, P13594, DOI 10.1021/bi00041a039; Kimura T, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00065; Kjaergaard M, 2011, J BIOMOL NMR, V49, P139, DOI 10.1007/s10858-011-9472-x; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Landrieu I, 2006, J AM CHEM SOC, V128, P3575, DOI 10.1021/ja054656+; Landrieu I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021521; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Lee KK, 2008, J PHYS CHEM B, V112, P16782, DOI 10.1021/jp803285x; Leroy A, 2010, J BIOL CHEM, V285, P33435, DOI 10.1074/jbc.M110.149419; LIN LN, 1983, BIOCHEMISTRY-US, V22, P559, DOI 10.1021/bi00272a006; Lu PJ, 1999, NATURE, V399, P784; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Peterson DW, 2010, P NATL ACAD SCI USA, V107, P2884, DOI 10.1073/pnas.0912718107; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Shen Y, 2010, J BIOMOL NMR, V46, P199, DOI 10.1007/s10858-009-9395-y; Shih HH, 2012, J BIOL CHEM, V287, P44425, DOI 10.1074/jbc.M112.415935; Sibille N, 2012, PROTEINS, V80, P454, DOI 10.1002/prot.23210; SIEMION IZ, 1975, ANGEW CHEM INT EDIT, V14, P702, DOI 10.1002/anie.197507021; Smet C, 2005, FEBS LETT, V579, P4159, DOI 10.1016/j.febslet.2005.06.048; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Smet C, 2004, CHEMBIOCHEM, V5, P1639, DOI 10.1002/cbic.200400145; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Tomlinson JH, 2012, J BIOMOL NMR, V52, P57, DOI 10.1007/s10858-011-9583-4; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887; VANHOOF G, 1995, FASEB J, V9, P736; WANG AC, 1995, J BIOMOL NMR, V5, P376; Weiwad M, 2004, J MOL BIOL, V339, P635, DOI 10.1016/j.jmb.2004.02.021; Werner-Allen JW, 2011, J BIOL CHEM, V286, P5717, DOI 10.1074/jbc.M110.197129; Wieruszeski JM, 2006, J MAGN RESON, V181, P199, DOI 10.1016/j.jmr.2006.04.007; WISHART DS, 1995, J BIOMOL NMR, V5, P332, DOI 10.1007/BF00211764; Xiang KH, 2010, NATURE, V467, P729, DOI 10.1038/nature09391; Yu Y, 2009, J NEUROCHEM, V108, P1480, DOI 10.1111/j.1471-4159.2009.05882.x; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	58	17	17	0	19	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0022-2836	1089-8638		J MOL BIOL	J. Mol. Biol.	JAN 16	2016	428	1					79	91		10.1016/j.jmb.2015.11.023			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DE5NC	WOS:000370676700008	26655856				2021-06-18	
J	Andelic, N; Arango-Lasprilla, JC; Perrin, PB; Sigurdardottir, S; Lu, J; Landa, LO; Forslund, MV; Roe, C				Andelic, Nada; Carlos Arango-Lasprilla, Juan; Perrin, Paul B.; Sigurdardottir, Solrun; Lu, Juan; Landa, Laiene Olabarrieta; Forslund, Marit V.; Roe, Cecilie			Modeling of Community Integration Trajectories in the First Five Years after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; recovery; rehabilitation; traumatic brain injury	QUALITY-OF-LIFE; MINORITY STATUS; OUTCOMES; REHABILITATION; PARTICIPATION; MODERATE; IMPACT; INDIVIDUALS; PREDICTION; BEHAVIOR	The aims of this study were to assess the trajectories of community integration in individuals with traumatic brain injury (TBI) through one, two, and five years post-injury and to examine whether those trajectories could be predicted by demographic and injury characteristics. A longitudinal cohort study was conducted with 105 individuals with moderate-to-severe TBI admitted to a trauma referral center in 2005-2007. Demographics and injury-related factors were extracted from medical records. At the one-, two- and five-year follow-ups, community integration was measured by the Community Integration Questionnaire (CIQ). A hierarchical linear model (HLM) examined whether longitudinal trajectories of community integration could be predicted by: time, sex, age, relationship status, education, employment status, occupation, acute Glasgow Coma Scale score, cause of injury, days in post-traumatic amnesia (PTA), computed tomography Marshall Score, and Injury Severity Score. CIQ scores improved across the three time-points (p<0.001). Additionally, higher trajectories of community integration were predicted by being single at the time of injury (p<.001), higher level of education (p=0.006), employment (p<0.001), and a shorter length of PTA (p<0.001). In a follow-up HLM with interaction terms, time*PTA was statistically significant (p<0.001), suggesting that participants with longer PTA increased in community integration more rapidly than those with shorter PTA. The longitudinal course of community integration described in this study may help rehabilitation professionals to plan more extensive follow-ups and targeted rehabilitation programs in the early stage of recovery for patients with specific demographic and injury characteristics.	[Andelic, Nada; Forslund, Marit V.; Roe, Cecilie] Oslo Univ Hosp Ulleval, Dept Phys Med & Rehabil, Oslo, Norway; [Andelic, Nada; Sigurdardottir, Solrun] Univ Oslo, Fac Med, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv, Oslo, Norway; [Carlos Arango-Lasprilla, Juan] Univ Deusto, Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Sigurdardottir, Solrun] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA USA; [Lu, Juan] Sunnaas Rehabil Hosp Trust, Akershus, Norway; [Landa, Laiene Olabarrieta] Univ Deusto, Dept Psychol, Bilbao, Spain; [Forslund, Marit V.; Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway.	nadand@ous-hf.no	Arango-Lasprilla, Juan Carlos/AAB-5407-2019; Landa, Laiene Olabarrieta/V-6207-2017; Perrin, Paul/L-5373-2015	Arango-Lasprilla, Juan Carlos/0000-0002-7184-8311; Landa, Laiene Olabarrieta/0000-0002-8305-8720; Andelic, Nada/0000-0002-3719-4406; Perrin, Paul/0000-0003-2070-215X; Lu, Juan/0000-0002-5389-7603	Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo	The authors would like to thank all the patients for their participation. Special thanks to Nini Hammergren for assistance with patient registrations during the first two years post-injury. This study was funded by grant from The Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2014, PM&R, V6, P1013, DOI 10.1016/j.pmrj.2014.05.005; Andelic N, 2013, J REHABIL MED, V45, P708, DOI [10.2340/16501977-1216, 10.2340/16501977-1224]; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Fleming J, 1999, BRAIN INJURY, V13, P417; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Rike PO, 2014, BRAIN INJURY, V28, P1687, DOI 10.3109/02699052.2014.947632; Romoren TI, 2011, INT J INTEGR CARE, V11; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sherer M, 2014, ARCH PHYS MED REHAB, V95, P1162, DOI [10.1016/j.apmr.2014.02.006, 10.1016/j.apmr.2013.06.004]; Sigurdardottir S, 2014, BRAIN INJURY, V28, P1542, DOI 10.3109/02699052.2014.934285; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Truelle JL, 2010, CURR OPIN NEUROL, V23, P688, DOI 10.1097/WCO.0b013e3283404258; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002	45	17	17	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					95	100		10.1089/neu.2014.3844			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200012	25897980				2021-06-18	
J	Block, CK; West, SE; Goldin, Y				Block, Cady K.; West, Sarah E.; Goldin, Yelena			Misconceptions and Misattributions About Traumatic Brain Injury: An Integrated Conceptual Framework	PM&R			English	Article							MILD HEAD-INJURY; GOOD OLD DAYS; POSTCONCUSSION-SYNDROME; SYMPTOM REPORT; INFORMATIONAL CASCADES; COMMON MISCONCEPTIONS; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CONCUSSION; KNOWLEDGE	The objective of the present narrative review was to provide a conceptual framework to address common misconceptions in the field of traumatic brain injury (TBI) and enhance clinical and research practices. This framework is based on review of the literature on TBI knowledge and beliefs. The comprehensive search of the literature included seminal and current texts as well as relevant articles on TBI knowledge and education, misconceptions, and misattributions. Reviewed materials ranged from 1970 to 2013 and were obtained from PubMed and PubMed Central online research databases. Research findings from the reviewed literature were integrated with existing social and cognitive psychological concepts to develop a framework that includes: (1) the identification antecedents of TBI-related misconceptions and misattribution; (2) understanding of how inaccurate beliefs form and persist as the result of pre-and postinjury cognitive operations such as informational cascades and attribution biases; and (3) a discussion of ways in which these beliefs can result in consequences in all domains of a survivor's life, including physical and mental health, stigma, and discrimination. This framework is intended to serve as a first stage of development of a model that will improve treatment endeavors and service delivery to individuals with TBI and their families.	[Block, Cady K.] Mem Hermann, TIRR, Houston, TX 77030 USA; [West, Sarah E.; Goldin, Yelena] JKF Johnson Rehabil Inst, Edison, NJ USA	Block, CK (corresponding author), Mem Hermann, TIRR, 1333 Moursund Ave, Houston, TX 77030 USA.	cady.block@memorialhermann.org	Block, Cady/I-3078-2014	Block, Cady/0000-0001-7168-6116			Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson LR, 1997, AM ECON REV, V87, P847; AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; Baxendale S, 2004, BMJ-BRIT MED J, V329, P1480, DOI 10.1136/bmj.329.7480.1480; BIKHCHANDANI S, 1992, J POLIT ECON, V100, P992, DOI 10.1086/261849; Bikhchandani S, 1998, J ECON PERSPECT, V12, P151, DOI 10.1257/jep.12.3.151; Block C, 2014, J HEAD TRAUMA REHAB, V29, P76, DOI 10.1097/HTR.0b013e3182886d78; Browndyke JN, 1997, ANN M NAT AC NEUR LA; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deidan C, 2002, STUD NEUROPSYCHOL DE, P281; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Evans K, 2009, CONT ISSUES COMMUN S, V36, P166; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Finch CF, 2012, INJURY RES THEORIES, P619; Fraas MR, 2007, DISABIL REHABIL, V29, P1449, DOI 10.1080/09638280601102311; Gordon KE, 2010, PEDIATR NEUROL, V43, P253, DOI 10.1016/j.pediatrneurol.2010.05.012; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Gouvier W Drew, 2002, Appl Neuropsychol, V9, P48, DOI 10.1207/S15324826AN0901_6; GOUVIER WD, 1991, REHABIL PSYCHOL, V36, P121, DOI 10.1037/0090-5550.36.2.121; Greenberg J., 2003, BEHAV ORG UNDERSTAND; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Heider, 1958, PSYCHOL INTERPERSONA; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hooper S., 2006, EXCEPTIONALITY, V14, P171, DOI DOI 10.1207/s15327035ex1403_5; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jackson H, 2001, NEUROREHABILITATION, V16, P27; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; Kempe CB, 2013, CLIN NEUROPSYCHOL, V27, P762, DOI 10.1080/13854046.2013.795245; Kozak G S, 1989, J Emerg Nurs, V15, P18; Kuran T, 1999, STANFORD LAW REV, V51, P683, DOI 10.2307/1229439; Linden MA, 2006, ARCH CLIN NEUROPSYCH, V21, P763, DOI 10.1016/j.acn.2006.08.010; Linden MA, 2010, BRAIN INJURY, V24, P642, DOI 10.3109/02699051003601689; Linden MA, 2005, BRAIN INJURY, V19, P1011, DOI 10.1080/02699050500110314; Linden MA, 2011, INT J NURS STUD, V48, P62, DOI 10.1016/j.ijnurstu.2010.05.011; Livneh H., 2001, J VOCATIONAL REHABIL, V16, P227; Major B, 2005, ANNU REV PSYCHOL, V56, P393, DOI 10.1146/annurev.psych.56.091103.070137; McClure J, 2008, BRAIN INJURY, V22, P639, DOI 10.1080/02699050802255585; McClure J, 2006, BRAIN INJURY, V20, P1029, DOI 10.1080/02699050600909870; McClure J, 2011, REHABIL PSYCHOL, V56, P85, DOI 10.1037/a0023354; McClure J, 2011, J HEAD TRAUMA REHAB, V26, P392, DOI 10.1097/HTR.0b013e3181f8fd34; McClure J, 2009, BRAIN IMPAIR, V10, P180, DOI 10.1375/brim.10.2.180; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLellan TL, 2011, BRIT J SPORT MED, V45, P993, DOI 10.1136/bjsm.2011.083618; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Miller P, 2004, DISABILISM TACKLE TA; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Morris Paul Graham, 2005, BMC Fam Pract, V6, P30, DOI 10.1186/1471-2296-6-30; MORROW KA, 1992, J COUNS DEV, V70, P571, DOI 10.1002/j.1556-6676.1992.tb01663.x; Noonan BM, 2004, J COUNS PSYCHOL, V51, P68, DOI 10.1037/0022-0167.51.1.68; O'Jile J. R., 1997, INT J REHABILITATION, V3, P61, DOI DOI 10.1007/BF02766798; Obsorn C., 2000, MY HEAD DOCTORS OWN; Ono MY, 2011, BRAIN INJURY, V25, P237, DOI 10.3109/02699052.2010.541893; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Pappadis MR, 2011, J HEAD TRAUMA REHAB, V26, P301, DOI 10.1097/HTR.0b013e3181e7832b; Pavalko EK, 2003, J HEALTH SOC BEHAV, V44, P18, DOI 10.2307/1519813; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Redpath SJ, 2010, BRAIN INJURY, V24, P802, DOI 10.3109/02699051003709623; REID JC, 1994, HEALTH COMMUN, V6, P327, DOI 10.1207/s15327027hc0604_7; Risher P, 2000, 11681 HARR INT INC B; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; RYAN GA, 1992, WORLD J SURG, V16, P398, DOI 10.1007/BF02104438; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; *US DEP HHS, HEADS FACTS PHYS MIL; Watts DD, 2011, J NEUROSCI NURS, V43, P122, DOI 10.1097/JNN.0b013e3182135af6; Weber M, 2010, BRAIN INJURY, V24, P1364, DOI 10.3109/02699052.2010.507110; Wei HG, 2000, ACAD EMERG MED, V7, P710, DOI 10.1111/j.1553-2712.2000.tb02052.x; WEINER B, 1980, J PERS SOC PSYCHOL, V39, P186, DOI 10.1037/0022-3514.39.2.186; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Widjicks EFM, 2006, J NEUROL NEUROSUR PS, V78, P644; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Woodruff L, 2008, INSTANT FAMILYS JOUR	91	17	17	2	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	JAN	2016	8	1					58	+		10.1016/j.pmrj.2015.05.022			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DB1KQ	WOS:000368267500008	26054960				2021-06-18	
J	Brodsky, JR; Cusick, BA; Zhou, GW				Brodsky, Jacob R.; Cusick, Brandon A.; Zhou, Guangwei			Evaluation and management of vestibular migraine in children: Experience from a pediatric vestibular clinic	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						Vestibular migraine; Migrainous vertigo; Migraine associated vertigo; Pediatric vertigo; Benign paroxysmal vertigo of childhood	BENIGN PAROXYSMAL VERTIGO; FOLLOW-UP; CHILDHOOD; DIZZINESS; THERAPY; MODULATION; NEURONS; IMPACT; RAT	Objective: Epidemiologic studies have shown Vestibular migraine (VM) to be the most common cause of vertigo in children, but little is known about the typical presentation and response to treatment of this disorder in the pediatric population. The aim of this study was to evaluate the diagnostic features and response to therapy of VM in children managed at a pediatric vestibular clinic. Methods: Twenty-eight patients <= 18 years old with a diagnosis of VM were identified from 208 patients seen at the Balance and Vestibular Program at Boston Children's Hospital from July 2012 July 2014, after excluding 12 patients with a history of major otologic or neurologic surgery, recent concussion, or additional vestibular disorders. Patients' electronic medical records and testing results were retrospectively reviewed. Results: Patients ranged in age from 9 to 18 years old (mean 14.48). All included patients met criteria for definite (n = 25) or probable (n = 3) VM as defined by the International Classification of Headache Disorders. Rotary chair (n = 17), caloric (n = 8), cervical vestibular evoked myogenic potential (n = 16), and video head impulse (n = 3) tests were normal. Medications effectively reduced reported vestibular symptoms in 88% of those treated with tricyclics (n = 8), 86% of those treated with cyprohepatadine (n = 7), 80% of those treated with topiramate (n = 5), 80% of those treated with triptans (n = 10), and 25% of those treated with gabapentin (n = 4). Conclusions: Vestibular migraine is a common cause of vertigo in the pediatric population that is frequently responsive to medical therapy. (C) 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Brodsky, Jacob R.; Cusick, Brandon A.; Zhou, Guangwei] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA USA; [Brodsky, Jacob R.; Zhou, Guangwei] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA	Brodsky, JR (corresponding author), Dept Otolaryngol & Commun Enhancement, 300 Longwood Ave, Boston, MA 02115 USA.	jacob.brodsky@childrens.harvard.edu		Brodsky, Jacob/0000-0001-9656-5855	Department of Otolaryngology and Communication Enhancement at Boston Children's Hospital	All financial support for this study was provided by the Department of Otolaryngology and Communication Enhancement at Boston Children's Hospital.	Afridi SK, 2005, ARCH NEUROL-CHICAGO, V62, P1270, DOI 10.1001/archneur.62.8.1270; Akerman S, 2005, NEUROREPORT, V16, P1383, DOI 10.1097/01.wnr.0000175250.33159.a9; Baier B, 2009, J NEUROL, V256, P1447, DOI 10.1007/s00415-009-5132-4; Balaban CD, 2011, J VESTIBUL RES-EQUIL, V21, P315, DOI 10.3233/VES-2011-0428; BASSER LS, 1964, BRAIN, V87, P141, DOI 10.1093/brain/87.1.141; Batson Glenna, 2004, Paediatr Child Health, V9, P31; Batuecas-Caletrio A, 2013, EUR J PAEDIATR NEURO, V17, P397, DOI 10.1016/j.ejpn.2013.01.006; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; BOWER CM, 1995, ARCH OTOLARYNGOL, V121, P911; Burstein R, 2000, BRAIN, V123, P1703, DOI 10.1093/brain/123.8.1703; Burstein R, 2011, J VESTIBUL RES-EQUIL, V21, P305, DOI 10.3233/VES-2012-0433; Carmona Sergio, 2009, Ther Clin Risk Manag, V5, P661; Celebisoy N, 2008, CEPHALALGIA, V28, P72, DOI 10.1111/j.1468-2982.2007.01474.x; Choung YH, 2003, INT J PEDIATR OTORHI, V67, P889, DOI 10.1016/S0165-5876(03)00136-8; DAgostino R, 1997, INT J PEDIATR OTORHI, V40, P133, DOI 10.1016/S0165-5876(97)00032-3; Dieterich M, 1999, J NEUROL, V246, P883, DOI 10.1007/s004150050478; Drigo P, 2001, BRAIN DEV-JPN, V23, P38, DOI 10.1016/S0387-7604(01)00175-9; Erbek SH, 2006, INT J PEDIATR OTORHI, V70, P1547, DOI 10.1016/j.ijporl.2006.04.001; Furman JM, 2005, J VESTIBUL RES-EQUIL, V15, P327; Furman JM, 2013, LANCET NEUROL, V12, P706, DOI 10.1016/S1474-4422(13)70107-8; Gelfand AA, 2013, CURR OPIN NEUROL, V26, P262, DOI 10.1097/WCO.0b013e32836085c7; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Gode S, 2010, HEADACHE, V50, P77, DOI 10.1111/j.1526-4610.2009.01496.x; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Halberstadt AL, 2006, NEUROSCIENCE, V140, P1067, DOI 10.1016/j.neuroscience.2006.02.053; Hamilton SS, 2015, INT J PEDIATR OTORHI, V79, P1283, DOI 10.1016/j.ijporl.2015.05.033; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holland PR, 2009, CEPHALALGIA, V29, P1, DOI 10.1111/j.1468-2982.2009.02027.x; Hong SM, 2011, OTOLARYNG HEAD NECK, V144, P284, DOI 10.1177/0194599810391755; Johnson A, 2014, PEDIATR NEUROL, V51, P706, DOI 10.1016/j.pediatrneurol.2014.06.018; KAYAN A, 1984, BRAIN, V107, P1123, DOI 10.1093/brain/107.4.1123; Khalmuratova R, 2010, J VESTIBUL RES-EQUIL, V20, P401, DOI 10.3233/VES-2010-0390; Koo JW, 2006, CEPHALALGIA, V26, P1310, DOI 10.1111/j.1468-2982.2006.01208.x; Krams B, 2011, CEPHALALGIA, V31, P439, DOI 10.1177/0333102410382797; Langhagen T, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00292; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Linde M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010610; Lindskog U, 1999, HEADACHE, V39, P33, DOI 10.1046/j.1526-4610.1999.3901033.x; Marano E, 2005, HEADACHE, V45, P325, DOI 10.1111/j.1526-4610.2005.05069.x; Marcelli V, 2006, BRAIN DEV-JPN, V28, P80, DOI 10.1016/j.braindev.2005.05.003; Marcelli V, 2010, HEADACHE, V50, P71, DOI 10.1111/j.1526-4610.2009.01454.x; Marcus DA, 2006, MED SCI MONITOR, V12, pPI1; Mikulec AA, 2012, AM J OTOLARYNG, V33, P121, DOI 10.1016/j.amjoto.2011.04.010; MIRA E, 1984, ACTA OTO-LARYNGOL, P271; Neuhauser H, 2003, NEUROLOGY, V60, P882, DOI 10.1212/01.WNL.0000049476.40047.A3; Neuhauser H, 2001, NEUROLOGY, V56, P436, DOI 10.1212/WNL.56.4.436; Neuhauser HK, 2006, NEUROLOGY, V67, P1028, DOI 10.1212/01.wnl.0000237539.09942.06; O'Reilly R, 2012, LARYNGOSCOPE, V122, pS93, DOI 10.1002/lary.23809; O'Reilly RC, 2011, OTOLARYNG HEAD NECK, V144, P142, DOI 10.1177/0194599810393679; Obermann M, 2014, CEPHALALGIA, V34, P1053, DOI 10.1177/0333102414527650; Radtke A, 2012, NEUROLOGY, V79, P1607, DOI 10.1212/WNL.0b013e31826e264f; Ralli G, 2009, INT J PEDIATR OTORHI, V73, pS16, DOI 10.1016/S0165-5876(09)70004-7; Reploeg MD, 2002, OTOL NEUROTOL, V23, P364, DOI 10.1097/00129492-200205000-00024; Rosman NP, 2009, J CHILD NEUROL, V24, P155, DOI 10.1177/0883073808322338; Russell G, 1999, INT J PEDIATR OTORHI, V49, pS105, DOI 10.1016/S0165-5876(99)00143-3; Sari Y, 2004, NEUROSCI BIOBEHAV R, V28, P565, DOI 10.1016/j.neubiorev.2004.08.008; Stolte B, 2015, CEPHALALGIA, V35, P262, DOI 10.1177/0333102414535113; Vitkovic J, 2013, J NEUROL, V260, P3039, DOI 10.1007/s00415-013-7116-7; von Brevern M, 2005, BRAIN, V128, P365, DOI 10.1093/brain/awh351; Whitney SL, 2000, LARYNGOSCOPE, V110, P1528, DOI 10.1097/00005537-200009000-00022; Wiener-Vacher SR, 2008, INT J AUDIOL, V47, P578, DOI 10.1080/14992020802334358; Zaleski A, 2015, OTOL NEUROTOL, V36, P295, DOI 10.1097/MAO.0000000000000665; Zhang DG, 2012, INT J PEDIATR OTORHI, V76, P107, DOI 10.1016/j.ijporl.2011.10.013; Zhou GW, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000037	64	17	17	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	JAN	2016	20	1					85	92		10.1016/j.ejpn.2015.09.011			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	DB5QQ	WOS:000368569100012	26521123				2021-06-18	
J	Hadanny, A; Meir, O; Bechor, Y; Fishlev, G; Bergan, J; Efrati, S				Hadanny, A.; Meir, O.; Bechor, Y.; Fishlev, G.; Bergan, J.; Efrati, S.			Seizures during hyperbaric oxygen therapy: retrospective analysis of 62,614 treatment sessions	UNDERSEA AND HYPERBARIC MEDICINE			English	Article						hyperbaric oxygenation; hyperbaric oxygen therapy; central nervous system oxygen toxicity; complications; adverse effects; side effects	TOXICITY SEIZURES; PRESSURE; TRIAL	Introduction: Hyperbaric oxygen (HBO2) therapy is considered to be a generally safe therapy. However, data regarding seizure incidence during HBO2 therapy as a clinical presentation of central nervous system(CNS) related oxygen toxicity are conflicting (ranging from 1:10,000 to 1:600 seizures:hyperbaric sessions). The risk for seizures is of significant importance for the growing population of patients suffering from chronic neurological disorders such as traumatic brain injury and stroke who are treated with HBO2. The aim of this study was to evaluate the incidence of seizures during HBO2 therapy in a large cohort of patients and determine whether patients with known chronic neurological disorders are at increased risk. Methods: Retrospective analysis of 2,334 patients treated at the Sagol Center of Hyperbaric Medicine and Research, Assaf Harofeh Medical Center, Israel, between June 2010 and December 2014. Patients were grouped into one of three categories according to indication for HBO2 therapy: Category A- non neurological indications; Category B- neurological indications; and Category C- acute indications. Results: A total of 62,614 hyperbaric sessions, administered to 2,334 patients, were included in the analysis. The overall incidence of seizures during hyperbaric sessions was 0.011% (1:8,945), occurring in seven (0.3%) patients. Only one patient had a clear oxygen toxicity-induced seizure, with an overall incidence of 1:62,614. Conclusions: Seizures induced by oxygen toxicity during HBO2 therapy are extremely rare. Moreover, in relation to oxygen-induced seizures, HBO2 therapy can be considered safe for patients suffering with chronic neurological disorders except for uncontrolled epilepsy.	[Hadanny, A.; Meir, O.; Bechor, Y.; Fishlev, G.; Bergan, J.; Efrati, S.] Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-70300 Zerifin, Israel; [Hadanny, A.; Efrati, S.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Hadanny, A.; Efrati, S.] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Efrati, S.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Hadanny, A; Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-70300 Zerifin, Israel.; Hadanny, A; Efrati, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.; Hadanny, A; Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel.; Efrati, S (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.	amir.had@gmail.com; efratishai@013.net					Banham NDG, 2011, DIVING HYPERB MED, V41, P202; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Chavko M, 2003, NITRIC OXIDE-BIOL CH, V9, P18, DOI 10.1016/S1089-8603(03)00045-4; CLARK JM, 1971, PHARMACOL REV, V23, P37; Clark JM, 1982, OXYGEN TOXICITY PHYS, P200; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Hampson N, 2003, UNDERSEA HYPERBAR M, V30, P147; Hampson NB, 2006, UNDERSEA HYPERBAR M, V33, P27; Hampson NB, 2014, UNDERSEA HYPERBAR M, V41, P605; Heyboer M, 2014, UNDERSEA HYPERBAR M, V41, P379; Jain KK, 1999, OXYGEN TOXICITY TXB, P47; KELLOGG RH, 1978, RESP PHYSIOL, V34, P1, DOI 10.1016/0034-5687(78)90046-4; Peleg RK, 2013, DIVING HYPERB MED, V43, P218; Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119; Sanders Robert W, 2012, J Emerg Med, V42, pe69, DOI 10.1016/j.jemermed.2008.12.017; Seidel R, 2013, UNDERSEA HYPERBAR M, V40, P515; Smerz RW, 2004, UNDERSEA HYPERBAR M, V31, P199; TORBATI D, 1992, FREE RADICAL BIO MED, V13, P101, DOI 10.1016/0891-5849(92)90070-W; WASSMANN W, 1980, EEG-EMG-Z ELEK ELEKT, V11, P97; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Yildiz S, 2004, AVIAT SPACE ENVIR MD, V75, P992	22	17	18	0	6	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	JAN-FEB	2016	43	1					21	28					8	Marine & Freshwater Biology; Medicine, Research & Experimental	Marine & Freshwater Biology; Research & Experimental Medicine	DD4GK	WOS:000369880300003	27000010				2021-06-18	
S	Kalish, BT; Whalen, MJ		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Kalish, Brian T.; Whalen, Michael J.			Weight Drop Models in Traumatic Brain Injury	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Mice; Closed head injury; Weight drop; Concussion; Cognitive deficits; Morris water maze; Diffuse injury; Mild traumatic brain injury	CLOSED-HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; TNF-ALPHA; ACETYLCHOLINESTERASE INHIBITOR; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; CEREBRAL CONCUSSION; MOUSE MODEL	Weight drop models in rodents have been used for several decades to advance our understanding of the pathophysiology of traumatic brain injury. Weight drop models have been used to replicate focal cerebral contusion as well as diffuse brain injury characterized by axonal damage. More recently, closed head injury models with free head rotation have been developed to model sports concussions, which feature functional disturbances in the absence of overt brain damage assessed by conventional imaging techniques. Here, we describe the history of development of closed head injury models in the first part of the chapter. In the second part, we describe the development of our own weight drop closed head injury model that features impact plus rapid downward head rotation, no structural brain injury, and long-term cognitive deficits in the case of multiple injuries. This rodent model was developed to reproduce key aspects of sports concussion so that a mechanistic understanding of how long-term cognitive deficits might develop will eventually follow. Such knowledge is hoped to impact athletes and war fighters and others who suffer concussive head injuries by leading to targeted therapies aimed at preventing cognitive and other neurological sequelae in these high-risk groups.	[Kalish, Brian T.] Boston Childrens Hosp, Dept Newborn Med, Boston, MA 02115 USA; [Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Boston, MA 02114 USA	Kalish, BT (corresponding author), Boston Childrens Hosp, Dept Newborn Med, Boston, MA 02115 USA.						Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Chen Y, 1998, BRAIN RES, V784, P18, DOI 10.1016/S0006-8993(97)00982-7; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	65	17	18	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						193	209		10.1007/978-1-4939-3816-2_12	10.1007/978-1-4939-3816-2		17	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500014	27604720				2021-06-18	
J	Kilbaugh, TJ; Karlsson, M; Duhaime, AC; Hansson, MJ; Elmer, E; Margulies, SS				Kilbaugh, Todd J.; Karlsson, Michael; Duhaime, Ann-Christine; Hansson, Magnus J.; Elmer, Eskil; Margulies, Susan S.			Mitochondrial response in a toddler-aged swine model following diffuse non-impact traumatic brain injury	MITOCHONDRION			English	Article						Pediatric brain injury; Traumatic brain injury; Mitochondria; In vivo studies; Large animal model of injury	MATURATION-DEPENDENT RESPONSE; IMMATURE BRAIN; HEAD-INJURY; RAT-BRAIN; AXONAL INJURY; DYSFUNCTION; PIGLETS; METABOLISM; SEVERITY; NEUROPROTECTION	Traumatic brain injury (TBI) is an important health problem, and a leading cause of death in children worldwide. Mitochondrial dysfunction is a critical component of the secondary TBI cascades. Mitochondrial response in the pediatric brain has limited investigation, despite evidence that the developing brain's response differs from that of the adult, especially in diffuse non-impact TBI. We performed a detailed evaluation of mitochondrial bioenergetics using high-resolution respirometry in a swine model of diffuse TBI (rapid non-impact rotational injury: RNR), and examined the cortex and hippocampus. A substrate-uncoupler-inhibitor-titration protocol examined the role of the individual complexes as well as the uncoupled maximal respiration. Respiration per mg of tissue was also related to citrate synthase activity (CS) as an attempt to control for variability in mitochondrial content following injury. Diffuse RNR stimulated increased complex II-driven respiration relative to mitochondrial content in the hippocampus compared to shams. LEAK (State 40) respiration increased in both regions, with decreased respiratory ratios of convergent oxidative phosphorylation through complex I and II, compared to sham animals, indicating uncoupling of oxidative phosphorylation at 24 h. The study suggests that proportionately, complex I contribution to convergent mitochondrial respiration was reduced in the hippocampus after RNR, with a simultaneous increase in complex-II driven respiration. Mitochondrial respiration 24 h after diffuse TBI varies by location within the brain. We concluded that significant uncoupling of oxidative phosphorylation and alterations in convergent respiration through complex I- and complex II-driven respiration reveals therapeutic opportunities for the injured at-risk pediatric brain. (C) 2015 Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Kilbaugh, Todd J.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Karlsson, Michael; Hansson, Magnus J.; Elmer, Eskil] Lund Univ, Dept Clin Sci, Mitochondrial Med, BMC A13, SE-22184 Lund, Sweden; [Duhaime, Ann-Christine] Univ Penn, Dept Bioengn, 210 South 33rd St, Philadelphia, PA 19104 USA; [Margulies, Susan S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St, Boston, MA 02114 USA; [Duhaime, Ann-Christine] 15 Parkman St, Boston, MA 02114 USA; [Margulies, Susan S.] 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA	Kilbaugh, TJ (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	kilbaugh@chop.edu; michael.karlsson@med.lu.se; aduhaime@partners.org; magnus.hansson@med.lu.se; eskil.elmer@med.lu.se; margulie@seas.upenn.edu	Karlsson, Michael/AAL-8743-2020; Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Karlsson, Michael/0000-0002-7247-2133; Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638; Kilbaugh, Todd/0000-0002-4959-3092	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS069545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545] Funding Source: NIH RePORTER	The authors would like to thank Melissa Byro, Ashley Bebee, Jill Ralston, Sarah Sullivan, Albana Shahini, and Saori Morota for their invaluable technical support. The Oroboros Oxygraph used in the study was a loan from NeuroVive Pharmaceutical AB, Lund Sweden. Studies were supported by the NIH UO1 NS069545.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DELMAESTRO R, 1987, MECH AGEING DEV, V41, P29, DOI 10.1016/0047-6374(87)90051-0; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Jaber SM, 2015, DEV NEUROPSYCHOL, V40, P34, DOI 10.1080/87565641.2014.969733; Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Miller AC, 2012, COMMON DATA ELEMENTS; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Perez-Pinzon MA, 2012, J CEREBR BLOOD F MET, V32, P1362, DOI 10.1038/jcbfm.2012.32; Ragan DK, 2013, J CEREBR BLOOD F MET, V33, P48, DOI 10.1038/jcbfm.2012.130; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SIMS NR, 1986, J NEUROCHEM, V47, P496; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Sullivan S, 2013, J NEUROTRAUM, V30, P1770, DOI 10.1089/neu.2013.2913; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	47	17	17	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	JAN	2016	26						19	25		10.1016/j.mito.2015.11.001			7	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	DE6UC	WOS:000370768100003	26549476	Green Accepted			2021-06-18	
J	LeVaillant, CJ; Sharma, A; Muhling, J; Wheeler, LPG; Cozens, GS; Hellstrom, M; Rodger, J; Harvey, AR				LeVaillant, Chrisna J.; Sharma, Anil; Muhling, Jill; Wheeler, Lachlan P. G.; Cozens, Greg S.; Hellstroem, Mats; Rodger, Jennifer; Harvey, Alan R.			Significant changes in endogenous retinal gene expression assessed 1 year after a single intraocular injection of AAV-CNTF or AAV-BDNF	MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; AXONAL REGENERATION; MEDIATED EXPRESSION; CLINICAL-TRIAL; MESSENGER-RNA; ADULT RATS; THERAPY; VECTOR; SYSTEM	Use of viral vectors to deliver therapeutic genes to the central nervous system holds promise for the treatment of neurodegenerative diseases and neurotrauma. Adeno-associated viral (AAV) vectors encoding brain-derived neurotrophic factor (BDNF) or ciliary derived neurotrophic factor (CNTF) promote the viability and regeneration of injured adult rat retinal ganglion cells. However, these growth-inducing transgenes are driven by a constitutively active promoter, thus we examined whether long-term AAV-mediated secretion of BDNF or CNTF affected endogenous retinal gene expression. One year after the intravitreal injection of AAV-green fluorescent protein (GFP), bi-cistronic AAV-BDNF-GFP or AAV-CNTF-GFP, mRNA was extracted and analyzed using custom 96 well polymerase chain reaction arrays. Of 93 test genes, 56% showed significantly altered expression in AAV-BDNF-GFP and/or AAVCNTF-GFP retinas compared with AAV-GFP controls. Of these genes, 73% showed differential expression in AAV-BDNF versus AAVCNTF injected eyes. To focus on retinal ganglion cell changes, quantitative polymerase chain reaction was undertaken on mRNA (16 genes) obtained from fixed retinal sections in which the ganglion cell layer was enriched. The sign and extent of fold changes in ganglion cell layer gene expression differed markedly from whole retinal samples. Sustained and global alteration in endogenous mRNA expression after gene therapy should be factored into any interpretation of experimental/clinical outcomes, particularly when introducing factors into the central nervous system that require secretion to evoke functionality.	[LeVaillant, Chrisna J.; Sharma, Anil; Muhling, Jill; Wheeler, Lachlan P. G.; Cozens, Greg S.; Hellstroem, Mats; Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Nedlands, WA, Australia; [Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Nedlands, WA, Australia; [Sharma, Anil] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Muhling, Jill] Childrens Med Res Inst, Westmead, NSW, Australia; [Hellstroem, Mats] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, Lab Transplantat & Regenerat Med, Gothenburg, Sweden; [Rodger, Jennifer; Harvey, Alan R.] Western Australian Neurosci Res Inst, Nedlands, WA, Australia	Harvey, AR (corresponding author), Univ Western Australia, Sch Anat Physiol & Human Biol, Nedlands, WA, Australia.; Harvey, AR (corresponding author), Western Australian Neurosci Res Inst, Nedlands, WA, Australia.	alan.harvey@uwa.edu.au	Rodger, Jennifer/H-5735-2014	Rodger, Jennifer/0000-0003-3413-4229; , Alan/0000-0002-2590-831X	WA Neurotrauma Research Program	This work was supported a grant from the WA Neurotrauma Research Program. We thank Marissa Penrose for assistance with preparation of the figures.	Bartus RT, 2014, MOL THER, V22, P487, DOI 10.1038/mt.2013.281; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019; Chen H, 2004, BRAIN RES, V1011, P99, DOI 10.1016/j.brainres.2004.03.024; de Winter F, 2013, EUR J PHARMACOL, V719, P145, DOI 10.1016/j.ejphar.2013.04.057; Douglas MR, 2009, BRAIN, V132, P3102, DOI 10.1093/brain/awp240; Godinho MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069987; Harvey AR, 2012, INT REV NEUROBIOL, V106, P1, DOI 10.1016/B978-0-12-407178-0.00002-8; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2011, J NEUROTRAUM, V28, P2475, DOI 10.1089/neu.2011.1928; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Hellstrom M, 2009, GENE THER, V16, P521, DOI 10.1038/gt.2008.178; Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5; Koilkonda RD, 2014, JAMA OPHTHALMOL, V132, P409, DOI 10.1001/jamaophthalmol.2013.7630; Kurimoto T, 2010, J NEUROSCI, V30, P15654, DOI 10.1523/JNEUROSCI.4340-10.2010; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Leaver SG, 2006, EUR J NEUROSCI, V24, P3323, DOI 10.1111/j.1460-9568.2006.05230.x; Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001; Maguire C, 2014, NEUROTHERAPEUTICS, V11, P817, DOI 10.1007/s13311-014-0299-5; Marks WJ, 2016, HUM GENE THER, V27, P522, DOI 10.1089/hum.2015.134; McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P5756, DOI 10.1167/iovs.07-0054; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Moore DL, 2011, MOL CELL NEUROSCI, V47, P233, DOI 10.1016/j.mcn.2011.05.005; Nagai J, 2015, SCI REP-UK, V5, DOI 10.1038/srep08269; Navarro-Yepes J, 2014, PHARMACOL THERAPEUT, V142, P206, DOI 10.1016/j.pharmthera.2013.12.007; O'Connor DM, 2015, TRENDS MOL MED, V21, P504, DOI 10.1016/j.molmed.2015.06.001; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rodger J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031061; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Scarrott JM, 2015, EXPERT OPIN BIOL TH, V15, P935, DOI 10.1517/14712598.2015.1044894; Sharma A, 2012, INVEST OPHTH VIS SCI, V53, P8367, DOI 10.1167/iovs.12-10799; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Sun Y, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa8695; Trapani I, 2015, HUM GENE THER, V26, P193, DOI 10.1089/hum.2015.030; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Uchida K, 2014, THER DELIV, V5, P591, DOI [10.4155/tde.14.20, 10.4155/TDE.14.20]; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wen R, 2006, J NEUROSCI, V26, P13523, DOI 10.1523/JNEUROSCI.4021-06.2006; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9; Wu K, 2003, HUM GENE THER, V14, P1463, DOI 10.1089/104303403769211673; You SW, 2016, EXP NEUROL, V279, P197, DOI 10.1016/j.expneurol.2016.03.006; Zein WM, 2014, INVEST OPHTH VIS SCI, V55, P6301, DOI 10.1167/iovs.14-14860	46	17	17	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA		2329-0501		MOL THER-METH CLIN D	Mol.Ther.-Methods Clin. Dev.		2016	3								16078	10.1038/mtm.2016.78			10	Medicine, Research & Experimental	Research & Experimental Medicine	VI6FQ	WOS:000503191500025	27933306	DOAJ Gold, Green Published			2021-06-18	
J	Madura, SA; McDevitt, JK; Tierney, RT; Mansell, JL; Hayes, DJ; Gaughan, JP; Krynetskiy, E				Madura, Stephanie A.; McDevitt, Jane K.; Tierney, Ryan T.; Mansell, Jamie L.; Hayes, David J.; Gaughan, John P.; Krynetskiy, Evgeny			Genetic variation in SLC17A7 promoter associated with response to sport-related concussions	BRAIN INJURY			English	Article						Polymorphism; VGLUT1; vesicular transporters; rs74174284; prolonged recovery; head impact; mild traumatic brain injury; athletes	VESICULAR GLUTAMATE TRANSPORTER-1; STATES HIGH-SCHOOL; RISK-FACTORS; RECOVERY; PATHOPHYSIOLOGY; EPIDEMIOLOGY; SENSITIVITY; COLLEGIATE; VGLUT1	Objective: To determine the association of the single nucleotide polymorphism (SNP) rs74174284 within SLC17A7 promoter with concussion severity or duration. Design: A between-subjects design was utilized. Methods: Saliva samples and concussion severity and duration data were collected from 40 athletes diagnosed with a sport-related concussion by a physician, utilizing a standardized concussion assessment protocol. DNA was extracted, estimated and genotyped. Results: An association was found between the dominant genetic model (CC vs GG + GC; p = 0.0179) and recovery, where those carrying the minor allele were 6.33-times more likely to experience prolonged recovery rates. Within the ImPACT assessment, those carrying the CC genotype (33.38 +/- 10.15, p = 0.01) had worse motor speed scores upon initial assessment compared to both heterozygous (CG) and homozygous (GG) genotypes (41.59 +/- 7.39). Conclusions: This study was the first to demonstrate an association between genetic polymorphism at rs7417284 SNP in the promoter region of the SLC17A7 gene and concussion severity and duration. Based upon these findings, rs74174284 is a potential predictive genetic marker for identifying athletes who are more susceptible for altered recovery times and worse motor speed ImPACT scores after sport-related concussion.	[Madura, Stephanie A.; McDevitt, Jane K.; Tierney, Ryan T.; Mansell, Jamie L.; Hayes, David J.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Gaughan, John P.] Biostat Consulting Ctr, Philadelphia, PA USA; [Krynetskiy, Evgeny] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA	Madura, SA (corresponding author), 18 Fox Run, Glen Gardner, NJ 08826 USA.	steph.madura@gmail.com					Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Beneyto M, 2006, CURRENT PSYCHOSIS TH, V4, P27; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; Fremeau RT, 2004, SCIENCE, V304, P1815, DOI 10.1126/science.1097468; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Liguz-Lecznar M, 2007, INT J DEV NEUROSCI, V25, P107, DOI 10.1016/j.ijdevneu.2006.12.005; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDevitt JK, 2011, BRAIN INJURY, V25, P1108, DOI 10.3109/02699052.2011.607790; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Silverthorn D, 2007, HUMAN PHYSL INTEGRAT, pA34; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674; Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101	32	17	17	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	7					908	913		10.3109/02699052.2016.1146958			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DP2MI	WOS:000378322400010	27029226				2021-06-18	
J	Sigurdardottir, S; Andelic, N; Skandsen, T; Anke, A; Roe, C; Holthe, OO; Wehling, E				Sigurdardottir, Solrun; Andelic, Nada; Skandsen, Toril; Anke, Audny; Roe, Cecilie; Holthe, Oyvor Oistensen; Wehling, Eike			Olfactory Identification and Its Relationship to Executive Functions, Memory, and Disability One Year After Severe Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						anosmia; olfaction; executive functions; memory; disability	MILD COGNITIVE IMPAIRMENT; ODOR IDENTIFICATION; ALZHEIMERS-DISEASE; HEAD-INJURY; APOLIPOPROTEIN-E; SMELL; DYSFUNCTION; PERFORMANCE; DEFICITS; ANOSMIA	Objective: To explore the frequency of posttraumatic olfactory (dys) function 1 year after severe traumatic brain injury (TBI) and determine whether there is a relationship between olfactory identification and neuropsychological test performance, injury severity and TBI-related disability. Method: A population-based multicenter study including 129 individuals with severe TBI (99 males; 16 to 85 years of age) that could accomplish neuropsychological examinations. Olfactory (dys) function (anosmia, hyposmia, normosmia) was assessed by the University of Pennsylvania Smell Identification Test (UPSIT) or the Brief Smell Identification Test (B-SIT). Three tests of the Delis-Kaplan Executive Function System (D-KEFS) were used to assess processing speed, verbal fluency, inhibition and set-shifting, and the California Verbal Learning Test-II was used to examine verbal memory. The Glasgow Outcome Scale-Extended (GOSE) was used to measure disability level. Results: Employing 2 different smell tests in 2 equal-sized subsamples, the UPSIT sample (n = 65) classified 34% with anosmia and 52% with hyposmia, while the B-SIT sample (n = 64) classified 20% with anosmia and 9% with hyposmia. Individuals classified with anosmia by the B-SIT showed significantly lower scores for set-shifting, category switching fluency and delayed verbal memory compared to hyposmia and normosmia groups. Only the B-SIT scores were significantly correlated with neuropsychological performance and GOSE scores. Brain injury severity (Rotterdam CT score) and subarachnoid hemorrhage were related to anosmia. Individuals classified with anosmia demonstrated similar disability as those with hyposmia/normosmia. Conclusions: Different measures of olfaction may yield different estimates of anosmia. Nevertheless, around 1 third of individuals with severe TBI suffered from anosmia, which may also indicate poorer cognitive outcome.	[Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, N-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Fac Med, N-0316 Oslo, Norway; [Andelic, Nada; Roe, Cecilie; Holthe, Oyvor Oistensen] Oslo Univ Hosp, Div Surg & Clin Neurosci, Dept Phys Med & Rehabil, Oslo, Norway; [Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, Trondheim, Norway; [Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Anke, Audny] Univ Tromso, Dept Clin Med, N-9001 Tromso, Norway; [Anke, Audny] Arctic Univ Norway, Tromso, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Inst Clin Med, N-0316 Oslo, Norway; [Wehling, Eike] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Wehling, Eike] Univ Bergen, Dept Biol & Med Psychol, N-5020 Bergen, Norway	Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@medisin.uio.no		Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406	Research Council of NorwayResearch Council of Norway; Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo	We thank all the individuals for their participation. Our special thanks to all the neuropsychologists who were involved in collecting neuropsychological data. Our warm thanks to Tone Jerstad, neuroradiologist, and other neuroradiologists at the trauma hospitals for the classification of the CT scans. We thank the reviewers for their valuable comments that substantially improved the manuscript. This study was funded by grants from the Research Council of Norway and the Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo.	Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Anke A, 2014, J HEAD TRAUMA REHABI; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; Bacon AW, 1998, ANN NY ACAD SCI, V855, P723, DOI 10.1111/j.1749-6632.1998.tb10651.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barresi M, 2012, J NEUROL SCI, V323, P16, DOI 10.1016/j.jns.2012.08.028; Bitter T, 2010, CHEM SENSES, V35, P407, DOI 10.1093/chemse/bjq028; Bramerson A, 2004, LARYNGOSCOPE, V114, P733; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Crowe SF, 2013, J CLIN EXP NEUROPSYC, V35, P298, DOI 10.1080/13803395.2013.771616; Croy I, 2014, CHEM SENSES, V39, P185, DOI 10.1093/chemse/bjt072; Dade LA, 2002, BRAIN, V125, P86, DOI 10.1093/brain/awf003; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Djordjevic J, 2008, NEUROBIOL AGING, V29, P693, DOI 10.1016/j.neurobiolaging.2006.11.014; Doty R.L., 2001, BRIEF SMELL IDENTIFI; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION; Driscoll I, 2009, NEUROLOGY, V72, P1906, DOI 10.1212/WNL.0b013e3181a82634; Drummond M, 2013, BRAIN INJURY, V27, P332, DOI 10.3109/02699052.2012.750743; Duraski SA, 2014, REHABIL NURS, V39, P140, DOI 10.1002/rnj.138; Fornazieri MA, 2015, CHEM SENSES, V40, P141, DOI 10.1093/chemse/bju068; Fortin A, 2010, BRAIN INJURY, V24, P27, DOI 10.3109/02699050903446815; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; Greiffenstein MF, 2002, J CLIN EXP NEUROPSYC, V24, P705, DOI 10.1076/jcen.24.5.705.1011; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Hedner M, 2010, J CLIN EXP NEUROPSYC, V32, P1062, DOI 10.1080/13803391003683070; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; Larsson M, 2000, J GERONTOL B-PSYCHOL, V55, pP304, DOI 10.1093/geronb/55.5.P304; Larsson M, 1997, CHEM SENSES, V22, P623, DOI 10.1093/chemse/22.6.623; Larsson M, 2004, CHEM SENSES, V29, P547, DOI 10.1093/chemse/bjh059; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Merkley TL, 2013, J INT NEUROPSYCH SOC, V19, P899, DOI 10.1017/S135561771300074X; Murphy C, 1998, ANN NY ACAD SCI, V855, P744, DOI 10.1111/j.1749-6632.1998.tb10654.x; Myers CS, 1915, LANCET, V1, P316; Neumann D, 2012, ARCH PHYS MED REHAB, V93, P1414, DOI 10.1016/j.apmr.2012.03.009; Ogle W, 1870, Med Chir Trans, V53, P263; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Robinson G, 2012, BRAIN, V135, P2202, DOI 10.1093/brain/aws142; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Rombaux P, 2006, LARYNGOSCOPE, V116, P901, DOI 10.1097/01.mlg.0000217533.60311.e7; Schiffman SS, 2000, EUR J CLIN NUTR, V54, pS54, DOI 10.1038/sj.ejcn.1601026; Schiffman SS, 2002, NEUROBIOL AGING, V23, P397, DOI 10.1016/S0197-4580(01)00337-2; Schofield PW, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00005; Serby M, 1996, BIOL PSYCHIAT, V39, P375, DOI 10.1016/0006-3223(95)00472-6; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Streiner DL, 2011, CHEST, V140, P16, DOI 10.1378/chest.11-0523; Stuss D. T., 2009, REHABILITATION EXECU, P3; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Weddell RA, 2010, ARCH PHYS MED REHAB, V91, P897, DOI 10.1016/j.apmr.2010.01.020; Wehling EI, 2010, AGING NEUROPSYCHOL C, V17, P205, DOI 10.1080/13825580903042684; Westervelt HJ, 2008, J CLIN EXP NEUROPSYC, V30, P151, DOI 10.1080/13803390701287408; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson RS, 2007, J NEUROL NEUROSUR PS, V78, P30, DOI 10.1136/jnnp.2006.099721; Wilson RS, 2006, NEUROEPIDEMIOLOGY, V26, P61, DOI 10.1159/000090250; Yochim B, 2007, J INT NEUROPSYCH SOC, V13, P704, DOI 10.1017/S1355617707070907; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	76	17	17	1	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2016	30	1					98	108		10.1037/neu0000206			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	CZ8CC	WOS:000367326600010	26076319				2021-06-18	
J	Smitherman, E; Hernandez, A; Stavinoha, PL; Huang, R; Kernie, SG; Diaz-Arrastia, R; Miles, DK				Smitherman, Emily; Hernandez, Ana; Stavinoha, Peter L.; Huang, Rong; Kernie, Steven G.; Diaz-Arrastia, Ramon; Miles, Darryl K.			Predicting Outcome after Pediatric Traumatic Brain Injury by Early Magnetic Resonance Imaging Lesion Location and Volume	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; cognitive function; MRI; outcome measures; pediatric brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; FUNCTIONAL RECOVERY; PROGNOSTIC VALUE; INTENSIVE-CARE; YOUNG-CHILDREN; MRI; STEM; CT; CLASSIFICATION	Brain lesions after traumatic brain injury (TBI) are heterogeneous, rendering outcome prognostication difficult. The aim of this study is to investigate whether early magnetic resonance imaging (MRI) of lesion location and lesion volume within discrete brain anatomical zones can accurately predict long-term neurological outcome in children post-TBI. Fluid-attenuated inversion recovery (FLAIR) MRI hyperintense lesions in 63 children obtained 6.2 +/- 5.6 days postinjury were correlated with the Glasgow Outcome Scale Extended-Pediatrics (GOS-E Peds) score at 13.5 +/- 8.6 months. FLAIR lesion volume was expressed as hyperintensity lesion volume index (HLVI)=(hyperintensity lesion volume / whole brain volume)x100 measured within three brain zones: zone A (cortical structures); zone B (basal ganglia, corpus callosum, internal capsule, and thalamus); and zone C (brainstem). HLVI-total and HLVI-zone C predicted good and poor outcome groups (p<0.05). GOS-E Peds correlated with HLVI-total (r=0.39; p=0.002) and HLVI in all three zones: zone A (r=0.31; p<0.02); zone B (r=0.35; p=0.004); and zone C (r=0.37; p=0.003). In adolescents ages 13-17 years, HLVI-total correlated best with outcome (r=0.5; p=0.007), whereas in younger children under the age of 13, HLVI-zone B correlated best (r=0.52; p=0.001). Compared to patients with lesions in zone A alone or in zones A and B, patients with lesions in all three zones had a significantly higher odds ratio (4.38; 95% confidence interval, 1.19-16.0) for developing an unfavorable outcome.	[Smitherman, Emily] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Kernie, Steven G.; Miles, Darryl K.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Stavinoha, Peter L.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hernandez, Ana; Stavinoha, Peter L.] Childrens Med Ctr, Dept Neuropsychol, Dallas, TX 75235 USA; [Huang, Rong] Childrens Med Ctr, Clin Res, Dallas, TX 75235 USA	Miles, DK (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	darryl.miles@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Diaz-Arrastia, Ramon/0000-0001-6051-3594; Stavinoha, Peter L/0000-0002-3955-9579; Kernie, Steven/0000-0003-1371-0549	Perot Brain and Nerve Injury Center at Children's Medical Center Dallas	The authors thank Dr. Michael Morriss for his assistance in the interpretation of neuroradiology results and Evin Shirley for her research coordinator support. This article was made possible through generous funding that supported the Perot Brain and Nerve Injury Center at Children's Medical Center Dallas.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson PD, 2013, LANCET NEUROL, V12, P849, DOI 10.1016/S1474-4422(13)70205-9; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bakshi R, 1999, AM J NEURORADIOL, V20, P629; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Carmelli D, 1998, STROKE, V29, P1177, DOI 10.1161/01.STR.29.6.1177; Carmichael O, 2010, ARCH NEUROL-CHICAGO, V67, P1370, DOI 10.1001/archneurol.2010.284; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Deng WB, 2010, NAT REV NEUROL, V6, P328, DOI 10.1038/nrneurol.2010.53; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Filippi M, 1997, NEUROLOGY, V49, P371, DOI 10.1212/WNL.49.2.371; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Manolakaki D, 2009, J TRAUMA, V66, P1008, DOI 10.1097/TA.0b013e31819adba2; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Mullen E. M., 1995, MULLEN SCALES EARLY; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pagni C A, 1975, J Neurosurg Sci, V19, P120; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Patrick PD, 2007, BRAIN INJURY, V21, P63, DOI 10.1080/02699050601111401; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Sigurta A, 2013, INTENS CARE MED, V39, P129, DOI 10.1007/s00134-012-2748-0; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Wechsler D., 2003, WECHLER INTELLIGENCE; Wechsler D., 2002, WPPSI 3 WECHSLER PRE; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Wright J., 2010, DEV NEUROSCI, V32; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	83	17	17	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					35	48		10.1089/neu.2014.3801			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200005	25808802	Green Published			2021-06-18	
J	Eslami, M; Sayyah, M; Soleimani, M; Alizadeh, L; Hadjighassem, M				Eslami, Mansoureh; Sayyah, Mohammad; Soleimani, Mansoureh; Alizadeh, Leila; Hadjighassem, Mahmoudreza			Lipopolysaccharide preconditioning prevents acceleration of kindling epileptogenesis induced by traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Controlled cortical impact; Epileptogenesis; LPS preconditioning; PTZ kindling	TEMPORAL-LOBE EPILEPSY; SELECTIVE VULNERABILITY; POSTTRAUMATIC EPILEPSY; ISCHEMIC TOLERANCE; NERVOUS-SYSTEM; MOUSE-BRAIN; SPINAL-CORD; RAT-BRAIN; NEUROPROTECTION; SEIZURES	10-20% of symptomatic epilepsies are post-traumatic. We examined effect of LPS preconditioning on epileptogenesis after controlled cortical impact (CCI). LPS (0.01, 0.1 and 0.5 mg/kg) was injected i.p. to rats 5 days before induction of CCI to parieto-temporal cortex. Kindling started 24 h after CCI by i.p. injection of 30 mg/kg of pentylenetetrazole every other day until manifestation of 3 consecutive generalized seizures. CCI injury accelerated the rate of kindled seizures acquisition. LPS (0.1 and 0.5 mg/kg) prevented the acceleration of kindling. LPS preconditioning significantly decreased IL-1 beta and TNF-alpha over-expression and the number of damaged neurons in the hippocampus of traumatic rats. (C) 2015 Elsevier B.V. All rights reserved.	[Eslami, Mansoureh; Soleimani, Mansoureh] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran; [Eslami, Mansoureh] Iran Univ Med Sci, Fac Adv Technol Med, Dept Neurosci, Tehran, Iran; [Eslami, Mansoureh; Sayyah, Mohammad] Pasteur Inst Iran, Dept Physiol & Pharmacol, Tehran 1316943551, Iran; [Eslami, Mansoureh] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Basic Sci, Tehran, Iran; [Alizadeh, Leila] Shefa Neurosci Res Ctr, Tehran, Iran; [Hadjighassem, Mahmoudreza] Univ Tehran Med Sci, Neurosci Inst, Imam Khomeini Hosp, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran; [Hadjighassem, Mahmoudreza] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Neurosci, Tehran, Iran	Sayyah, M (corresponding author), Pasteur Inst Iran, Dept Physiol & Pharmacol, Tehran 1316943551, Iran.	sayyahm2@pasteur.ac.ir; mhadjighassem@tums.ac.ir	Hadjighassem, Mahmoudreza/R-7811-2019; Sayyah, Mohammad/K-4871-2017; Hadjighassem, Mahmoudreza/AAD-8498-2019	Sayyah, Mohammad/0000-0003-0603-2444; 	Pasteur Institute of Iran [634]; Iran University of Medical Sciences. [15734]	This work is supported by grant no. 634 from the Pasteur Institute of Iran and grant no. 15734 from the Iran University of Medical Sciences.	Abdallah DM, 2010, BRAIN RES, V1351, P246, DOI 10.1016/j.brainres.2010.06.034; Ahmadi A, 2013, EXP BRAIN RES, V226, P107, DOI 10.1007/s00221-013-3415-6; Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Annegers J.F., 2000, SEIZURE, V1, P453; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Bingham D, 2013, J NEUROIMMUNOL, V256, P28, DOI 10.1016/j.jneuroim.2012.12.009; Bingham D, 2011, BRAIN RES BULL, V85, P403, DOI 10.1016/j.brainresbull.2011.04.007; Bordet R, 2000, J CEREBR BLOOD F MET, V20, P1190, DOI 10.1097/00004647-200008000-00004; Briggs R, 2015, DEV MED CHILD NEUROL, V57, P618, DOI 10.1111/dmcn.12674; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cristofori Irene, 2015, Handb Clin Neurol, V128, P579, DOI 10.1016/B978-0-444-63521-1.00037-6; D'Ambrosio R, 2013, EXPERT REV NEUROTHER, V13, P615, DOI [10.1586/ERN.13.54, 10.1586/ern.13.54]; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Davis AEM, 2005, EUR J NEUROSCI, V22, P2441, DOI 10.1111/j.1460-9568.2005.04447.x; Dmowska M, 2010, NEUROCHEM RES, V35, P262, DOI 10.1007/s11064-009-0050-5; Eslami M., 2015, NEUROL RES; Fukuda M, 2015, METAB BRAIN DIS, V30, P813, DOI 10.1007/s11011-014-9648-7; Furuya K, 2005, J NEUROSURG, V103, P715, DOI 10.3171/jns.2005.103.4.0715; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Hayakawa K, 2014, J NEUROSCI RES, V92, P1647, DOI 10.1002/jnr.23448; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Jayaram B, 2013, J MOL NEUROSCI, V49, P523, DOI 10.1007/s12031-012-9924-0; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Larochelle A, 2015, BRAIN BEHAV IMMUN, V46, P221, DOI 10.1016/j.bbi.2015.02.019; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Li G, 2011, SEIZURE-EUR J EPILEP, V20, P249, DOI 10.1016/j.seizure.2010.12.005; Lin HY, 2009, PEDIATR RES, V66, P254, DOI 10.1203/PDR.0b013e3181b0d336; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; MELDRUM BS, 1993, BRAIN PATHOL, V3, P405, DOI 10.1111/j.1750-3639.1993.tb00768.x; Mirrione MM, 2010, NEUROBIOL DIS, V39, P85, DOI 10.1016/j.nbd.2010.04.001; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Noe FM, 2013, NEUROBIOL DIS, V59, P183, DOI 10.1016/j.nbd.2013.07.015; Noh H, 2014, NEUROCHEM INT, V69, P35, DOI 10.1016/j.neuint.2014.02.008; Ooigawa H, 2006, ACTA NEUROPATHOL, V112, P471, DOI 10.1007/s00401-006-0108-2; Parsons MP, 2014, NEURON, V82, P279, DOI 10.1016/j.neuron.2014.03.030; Pitkanen A, 2012, JASPERS BASIC MECH E; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ravizza T, 2011, NEUROSCI LETT, V497, P223, DOI 10.1016/j.neulet.2011.02.040; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rosenzweig HL, 2007, J CEREBR BLOOD F MET, V27, P1663, DOI 10.1038/sj.jcbfm.9600464; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Savin C, 2009, J R SOC INTERFACE, V6, P655, DOI 10.1098/rsif.2008.0387; Sayyah M, 2003, EPILEPSY RES, V57, P175, DOI 10.1016/j.eplepsyres.2003.11.002; Schaafsma W, 2015, BRAIN BEHAV IMMUN, V48, P205, DOI 10.1016/j.bbi.2015.03.013; Song MY, 2014, CLIN LAB, V60, P233, DOI 10.7754/Clin.Lab.2013.130207; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Turrigiano GG, 2006, TRENDS MOL MED, V12, P458, DOI 10.1016/j.molmed.2006.08.002; Vandresen S, 2013, NEUROTOX RES, V24, P55, DOI 10.1007/s12640-012-9359-y; Vezzani A, 2015, NEUROPHARMACOLOGY, V96, P70, DOI 10.1016/j.neuropharm.2014.10.027; Vezzani A, 2013, NEUROPHARMACOLOGY, V69, P16, DOI 10.1016/j.neuropharm.2012.04.004; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiao ZH, 2015, J NEUROIMMUNOL, V282, P110, DOI 10.1016/j.jneuroim.2015.04.003; Zhang F., 2012, ANIM MODEL ACUTE NEU, V9, P93, DOI [10.1007/978-1-61779-782-8_9, DOI 10.1007/978-1-61779-782-8_9]	66	17	17	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	DEC 15	2015	289						143	151		10.1016/j.jneuroim.2015.11.003			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CZ0HA	WOS:000366784500020	26616884				2021-06-18	
J	Hamada, SR; Gauss, T; Pann, J; Dunser, M; Leone, M; Duranteau, J				Hamada, Sophie Rym; Gauss, Tobias; Pann, Jakob; Duenser, Martin; Leone, Marc; Duranteau, Jacques			European trauma guideline compliance assessment: the ETRAUSS study	CRITICAL CARE			English	Article							DECISION-MAKING; CARE; MORTALITY; MANAGEMENT; VOLUME; COAGULOPATHY; TRANSFUSION; VENTILATION; THERAPY; SEPSIS	Introduction: Haemorrhagic shock is the leading cause of preventable death in trauma patients. The 2013 European trauma guidelines emphasise a comprehensive, multidisciplinary, protocol-based approach to trauma care. The aim of the present Europe-wide survey was to compare 2015 practice with the 2013 guidelines. Methods: A group of members of the Trauma and Emergency Medicine section of the European Society of Intensive Care Medicine developed a 50-item questionnaire based upon the core recommendations of the 2013 guidelines, employing a multistep approach. The questionnaire covered five fields: care structure and organisation, haemodynamic resuscitation targets, fluid management, transfusion and coagulopathy, and haemorrhage control. The sampling used a two-step approach comprising initial purposive sampling of eminent trauma care providers in each European country, followed by snowball sampling of a maximum number of trauma care providers. Results: A total of 296 responses were collected, 243 (81 %) from European countries. Those from outside the European Union were excluded from the analysis. Approximately three-fourths (74 %) of responders were working in a designated trauma centre. Blunt trauma predominated, accounting for more than 90 % of trauma cases. Considerable heterogeneity was observed in all five core aspects of trauma care, along with frequent deviations from the 2013 guidelines. Only 92 (38 %) of responders claimed to comply with the recommended systolic blood pressure target, and only 81 (33 %) responded that they complied with the target pressure in patients with traumatic brain injury. Crystalloid use was predominant (n = 209; 86 %), and vasopressor use was frequent (n = 171, 76 %) but remained controversial. Only 160 respondents (66 %) declared that they used tranexamic acid always or often. Conclusions: This is the first European trauma survey, to our knowledge. Heterogeneity is significant across centres with regard to the clinical protocols for trauma patients and as to locally available resources. Deviations from guidelines are frequent, differ from region to region and are dependent upon specialty training. Further efforts are required to provide consensus guidelines and to improve their implementation across European countries.	[Hamada, Sophie Rym; Duranteau, Jacques] Hop Univ Paris Sud, Hop Bicetre, AP HP, Dept Anaesthesiol & Crit Care, F-94275 Le Kremlin Bicetre, France; [Gauss, Tobias] Hop Univ Paris Nord Val de Seine, Hop Beaujon, AP HP, Dept Anaesthesiol & Crit Care, F-92110 Clichy, France; [Pann, Jakob; Duenser, Martin] Salzburg Univ Hosp, Dept Anaesthesiol Perioperat & Gen Intens Care Me, A-5020 Salzburg, Austria; [Pann, Jakob; Duenser, Martin] Paracelsus Private Med Univ, A-5020 Salzburg, Austria; [Leone, Marc] Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Dept Anaesthesiol & Crit Care, Marseille, France	Hamada, SR (corresponding author), Hop Univ Paris Sud, Hop Bicetre, AP HP, Dept Anaesthesiol & Crit Care, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	sophiehamada@hotmail.com	Leone, Marc/P-4835-2016; Tobias, Gauss/AAT-4949-2020	Leone, Marc/0000-0002-3097-758X; 			Brunkhorst FM, 2008, CRIT CARE MED, V36, P2719, DOI 10.1097/CCM.0b013e318186b6f3; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Cassell J, 2003, CRIT CARE MED, V31, P1263, DOI 10.1097/01.CCM.0000059318.96393.14; Chittawatanarat Kaweesak, 2014, Journal of the Medical Association of Thailand, V97, pS108; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; deMattos PC, 2012, MANAGE DECIS, V50, P1549, DOI 10.1108/00251741211266688; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Dennison CR, 2007, CRIT CARE MED, V35, P2747, DOI 10.1097/01.CCM.0000287591.09487.70; European Society of Intensive Care Medicine (ESICM), 2015, NEW SURV ONL EUR TRA; Gigerenzer G, 2011, ANNU REV PSYCHOL, V62, P451, DOI 10.1146/annurev-psych-120709-145346; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Kalhan R, 2006, CRIT CARE MED, V34, P300, DOI 10.1097/01.CCM.0000198328.83571.4A; Khan S, 2015, INTENS CARE MED, V41, P239, DOI 10.1007/s00134-014-3584-1; Leone M, 2004, INTENS CARE MED, V30, P984, DOI 10.1007/s00134-004-2172-1; Leone M, 2012, CRIT CARE MED, V40, P3189, DOI 10.1097/CCM.0b013e31826571f2; Levy MM, 2010, INTENS CARE MED, V36, P222, DOI 10.1007/s00134-009-1738-3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mohan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105445; Mohan D, 2010, CRIT CARE MED, V38, pS637, DOI 10.1097/CCM.0b013e3181f202c3; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Nunez TC, 2010, J TRAUMA, V68, P1498, DOI 10.1097/TA.0b013e3181d3cc25; Rice TW, 2012, CRIT CARE MED, V40, P778, DOI 10.1097/CCM.0b013e318236f168; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae	25	17	20	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	DEC 8	2015	19								423	10.1186/s13054-015-1092-5			8	Critical Care Medicine	General & Internal Medicine	CY0NI	WOS:000366102400001	26643471	DOAJ Gold, Green Published			2021-06-18	
J	Jang, SH; Kwon, HG				Jang, Sung Ho; Kwon, Hyeok Gyu			Injury of the dentato- rubro- thalamic tract in a patient with mild traumatic brain injury	BRAIN INJURY			English	Article							INDUCED AXONAL INJURY; MOVEMENT-DISORDERS; STIMULATION; TRACKING; TREMOR; SCALE		[Jang, Sung Ho; Kwon, Hyeok Gyu] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Daegu 705717, South Korea	Kwon, HG (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyung Dong, Daegu 705717, South Korea.	khg0715@hanmail.net			DGIST R&D Program of the Ministry of Science, ICT and Future Planning [15-BD-0401]	The authors report no conflicts of interest. This work was supported by the DGIST R&D Program of the Ministry of Science, ICT and Future Planning (15-BD-0401).	Afifi A, 2005, FUNCTIONAL NEUROANAT; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Coenen VA, 2014, NEUROSURGERY, V75, P657, DOI 10.1227/NEU.0000000000000540; Coenen VA, 2011, ACTA NEUROCHIR, V153, P1579, DOI 10.1007/s00701-011-1036-z; Coenen VA, 2011, NEUROSURGERY, V68, P1069, DOI 10.1227/NEU.0b013e31820a1a20; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Krauss JK, 1997, MOVEMENT DISORD, V12, P428, DOI 10.1002/mds.870120326; Kwon HG, 2014, BRAIN INJURY, V28, P511, DOI 10.3109/02699052.2014.887228; Kwon HG, 2011, NEURORADIOLOGY, V53, P787, DOI 10.1007/s00234-011-0878-7; Lee HD, 2014, BRAIN INJURY, V28, P1485, DOI 10.3109/02699052.2014.930178; Lehericy S, 2001, NEUROLOGY, V57, P1055, DOI 10.1212/WNL.57.6.1055; Marek M, 2015, J NEUROL, V262, P54, DOI 10.1007/s00415-014-7503-8; Marx JJ, 2008, NEUROIMAGE, V39, P1625, DOI 10.1016/j.neuroimage.2007.10.006; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schlaier J, 2015, NEUROMODULATION, V18, P105, DOI 10.1111/ner.12238; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Weyer A, 2007, MOVEMENT DISORD, V22, P1633, DOI 10.1002/mds.21544; Yamada K, 2009, P NATL ACAD SCI USA, V106, pE14, DOI 10.1073/pnas.0812352106; Zasler ND, 2013, BRAIN INJURY MED PRI, p[1480, xxxii]	26	17	17	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC 6	2015	29	13-14					1725	1728		10.3109/02699052.2015.1075170			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CY8LL	WOS:000366659800026	26479208				2021-06-18	
J	Wen, L; Lou, HY; Xu, J; Wang, H; Huang, X; Gong, JB; Xiong, B; Yang, XF				Wen, Liang; Lou, Hai-Yan; Xu, Jun; Wang, Hao; Huang, Xin; Gong, Jiang-Biao; Xiong, Bin; Yang, Xiao-Feng			The impact of cranioplasty on cerebral blood perfusion in patients treated with decompressive craniectomy for severe traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; SINKING SKIN FLAP; PROSPECTIVE MULTICENTER; FLOW; CT; HEMODYNAMICS; MANAGEMENT		[Wen, Liang; Xu, Jun; Wang, Hao; Huang, Xin; Gong, Jiang-Biao; Yang, Xiao-Feng] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China; [Lou, Hai-Yan; Xiong, Bin] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Radiol, Hangzhou 310003, Zhejiang, Peoples R China	Yang, XF (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.	jediwen@163.com			Science Technology Department of Zhejiang Province [2014C33201]	The authors have reported no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This work was supported by the Science Technology Department of Zhejiang Province (2014C33201).	Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Erdogan E, 2003, NEUROL INDIA, V51, P479; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sarubbo S, 2014, NEURORADIOLOGY, V56, P237, DOI 10.1007/s00234-014-1318-2; Song J, 2014, ACTA NEUROCHIR, V156, P193, DOI 10.1007/s00701-013-1908-5; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Won YD, 2008, ACTA NEUROCHIR SUPPL, V102, P15, DOI 10.1007/978-3-211-85578-2_3; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	20	17	22	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC 6	2015	29	13-14					1654	1660		10.3109/02699052.2015.1075248			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CY8LL	WOS:000366659800017	26513495				2021-06-18	
J	Ruestow, PS; Duke, TJ; Finley, BL; Pierce, JS				Ruestow, Peter S.; Duke, Tina J.; Finley, Brent L.; Pierce, Jennifer S.			Effects of the NFL's Amendments to the Free Kick Rule on Injuries during the 2010 and 2011 Seasons	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE			English	Article						injury prevention; National Football League; occupational injuries	NATIONAL FOOTBALL LEAGUE; LOWER-EXTREMITY INJURY; RISK-FACTORS; PROFESSIONAL FOOTBALL; PLAYING SURFACE; CONCUSSION; SPORTS; ASSOCIATION; PREVENTION	Recognizing the chronic health effects associated with playing football, the National Football League (NFL) has enacted policies and rules aimed at improving player health and safety. Prior to the 2011 season, amendments to the Free Kick rule were implemented, whereby the restraining line was moved from the 30- to the 35-yard line and all kicking team players other than the kicker were required to line up no more than 5 yards behind their restraining line. The objective of this analysis was to evaluate the effects of these rule changes on injury rates.Data for injuries occurring on special teams plays during the 2010 and 2011 NFL seasons were obtained from publically available NFL gamebooks and injury reports. Injury rates for kickoff plays across seasons were statistically compared using incidence rate ratios (RR) and 95% confidence intervals. To evaluate whether injury rate changes could be attributable to the rule amendments, comparisons were made with punt injury rates (presumably unaffected by the Free Kick rule changes) and distributions of potential confounders were assessed across seasons.Incidence of injuries occurring on kickoff plays fell from 2010 to 2011 (RR: 0.45, 95% CI: 0.28-0.73), although on kickoff plays where the ball was returned, this decrease became non-significant (RR: 0.67, 95% CI: 0.41-1.08). While the incidence of head injuries decreased by approximately 3-fold during kickoff plays, this change was not statistically significant (RR: 0.33, 95% CI: 0.09-1.21). No difference was observed in injury incidence during punts between the two seasons, and the distribution of confounding factors was largely uniform across seasons.The observed decrease in injuries occurring during kickoffs was likely directly attributable to the Free Kick rule amendments, principally from the increased frequency of touchbacks. The absence of a significant change in head injuries during kickoffs was unexpected, but may be attributable to small sample size. Despite the injury rate reductions, the rule changes likely had little effect on player safety during active gameplay.	[Ruestow, Peter S.; Duke, Tina J.; Pierce, Jennifer S.] Cardno ChemRisk, Chicago, IL 60612 USA; [Finley, Brent L.] Cardno ChemRisk, New York, NY USA	Ruestow, PS (corresponding author), Cardno ChemRisk, 30 North LaSalle St,Suite 3910, Chicago, IL 60612 USA.	peter.ruestow@cardno.com					Albergotti R., 2011, WALL STREET J; Alentorn-Geli E, 2014, KNEE SURG SPORT TR A, V22, P3, DOI 10.1007/s00167-013-2725-3; Andrews Wilson, 2013, WASHINGTON POST; Baron S. L., 1994, HLTH HAZARD EVALUATI; Battista J., 2011, NY TIMES; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Domb BG, 2014, AM J SPORT MED, V42, P1704, DOI 10.1177/0363546514531551; Dragoo JL, 2013, KNEE, V20, P191, DOI 10.1016/j.knee.2012.07.006; Dragoo JL, 2010, SPORTS MED, V40, P981, DOI 10.2165/11535910-000000000-00000; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Golightly YM, 2009, J PHYS ACT HEALTH, V6, P638, DOI 10.1123/jpah.6.5.638; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mechelen E. V. A. W. V., 2009, SPORTS INJURY RES; Murphy DF, 2003, BRIT J SPORT MED, V37, P13, DOI 10.1136/bjsm.37.1.13; NFL E. A. T., 2013, OFF 2013 NFL REC FAC; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; POWELL J W, 1987, Athletic Training, V22, P202; Powell JW, 1999, J ATHL TRAINING, V34, P277; Robeson R, 2014, J LAW MED ETHICS, V42, P334, DOI 10.1111/jlme.12150; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Tyler TF, 2006, AM J SPORT MED, V34, P471, DOI 10.1177/0363546505280429	29	17	17	1	30	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1545-9624	1545-9632		J OCCUP ENVIRON HYG	J. Occup. Environ. Hyg.	DEC 2	2015	12	12					875	882		10.1080/15459624.2015.1072632			8	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	CV1SZ	WOS:000364039700003	26267168				2021-06-18	
J	Greenwald, BD; Hammond, FM; Harrison-Felix, C; Nakase-Richardson, R; Howe, LLS; Kreider, S				Greenwald, Brian D.; Hammond, Flora M.; Harrison-Felix, Cynthia; Nakase-Richardson, Risa; Howe, Laura L. S.; Kreider, Scott			Mortality following Traumatic Brain Injury among Individuals Unable to Follow Commands at the Time of Rehabilitation Admission: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; brain injury; chronic; disorder of consciousness; epidemiology; life expectancy; mortality; rehabilitation	LONG-TERM SURVIVAL; REPRESENTATIVENESS; CONSCIOUSNESS; DATABASE; OUTCOMES; COMA; CARE; TBI	Severe traumatic brain injury (TBI) has been associated with increased mortality. This study characterizes long-term mortality, life expectancy, causes of death, and risk factors for death among patients admitted within the National Institute on Disability and Rehabilitation Research (NIDRR) TBI Model Systems Programs (TBIMS) who lack command following at the time of admission for inpatient TBI rehabilitation. Of the 8084 persons enrolled from 1988 and 2009, 387 from 20 centers met study criteria. Individuals with moderate to severe TBI who received inpatient rehabilitation were 2.2 times more likely to die than individuals in the U.S. general population of similar age, gender, and race, with an average life expectancy (LE) reduction of 6.6 years. The subset of individuals who were unable to follow commands on admission to rehabilitation was 6.9 times more likely to die, with an average LE reduction of 12.2 years. Relative to the U.S. general population matched for age, gender, and race/ethnicity, these non-command following individuals were more than four times more likely to die of circulatory conditions, 44 times more likely to die of pneumonia, and 38 times more likely to die of aspiration pneumonia. The subset of individuals with TBI who are unable to follow commands upon admission to inpatient rehabilitation are at a significantly increased risk of death when compared with the U.S. general population and compared with all individuals with moderate to severe TBI receiving inpatient rehabilitation. Respiratory causes of death predominate, compared with the general population.	[Greenwald, Brian D.] Rutgers Robert Wood Johnson Med Sch, JFK Johnson Rehabil Ctr Head Injuries, Edison, NJ USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Harrison-Felix, Cynthia] Craig Hosp, Englewood, CO USA; [Harrison-Felix, Cynthia] Univ Colorado Denver, Dept Phys Med & Rehabil, Aurora, CO USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Howe, Laura L. S.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Kreider, Scott] Univ No Colorado, Dept Educ & Behav Sci, Greeley, CO 80639 USA	Greenwald, BD (corresponding author), JFK Johnson Rehabil Inst, 65 James St, Edison, NJ 08818 USA.	bgreenwald@jfkhealth.org			National Institute on Disability and Rehabilitation Research, Office of Special Education Services, Department of Education [H133A110006]; Indiana University School of Medicine [H133A120085]; Mount Sinai School of Medicine [H133A100284]; Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability and Rehabilitation Research; VA HSRD; Department of EducationUS Department of Education;  [1 I50 HX001233-01];  [SDR 13-228]	This work was supported, in part, by grants from the National Institute on Disability and Rehabilitation Research, Office of Special Education Services, Department of Education to the Traumatic Brain Injury Model Systems National Data and Statistical Center at Craig Hospital (H133A110006); Indiana University School of Medicine (H133A120085) and Mount Sinai School of Medicine (H133A100284). The Polytrauma Rehabilitation Center Traumatic Brain Injury Model System Collaboration was funded through an interagency agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability and Rehabilitation Research, and VA HSRD; 1 I50 HX001233-01 & SDR 13-228. Although the contents of this manuscript were developed under a grant from the Department of Education, the manuscript contents do not necessarily represent the policy of the Department of Education and should not assume endorsement by the federal government.	[Anonymous], 1997, GUIDE UNIFORM DATA S; Baguley I, 2000, BRAIN INJURY, V14, P505; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Coronado V. G., 2012, EPIDEMIOLOG IN PRESS; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Griffin GD, 2011, MIL MED, V176, P364, DOI 10.7205/MILMED-D-10-00021; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Injury Prevention and Control, INJ PREV CONTR TRAUM; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1884, DOI 10.1016/j.apmr.2012.11.054; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Shavelle R, 2000, J Insur Med, V32, P163; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Traumatic Brain Injury Model Systems National Data and Statistical Center, 2014, TRAUM BRAIN INJ MOD; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041	32	17	17	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1883	1892		10.1089/neu.2014.3454			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200005	25518731				2021-06-18	
J	Masel, BE; Urban, R				Masel, Brent E.; Urban, Randy			Chronic Endocrinopathies in Traumatic Brain Injury Disease	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; hypopituitarism; medical; rehabilitation	GROWTH-HORMONE GH; ANTERIOR-PITUITARY FUNCTION; ANEURYSMAL SUBARACHNOID HEMORRHAGE; PROFESSIONAL FOOTBALL PLAYERS; QUALITY-OF-LIFE; REPLACEMENT THERAPY; COGNITIVE IMPAIRMENT; PREMATURE MORTALITY; DEFICIENT PATIENTS; ADULT PATIENTS	The aim of this review was to explain the role played by pituitary hormonal deficiencies in the traumatic brain injury (TBI) disease process. Chronic dysfunction of the pituitary axis is observed in approximately 35% of individuals who sustain a moderate-to-severe TBI. The most common deficiency is that of growth hormone, followed by gonadotropin, cortisol, and thyroid. The medical, psychological, and psychiatric consequences of untreated hypopituitarism are extensive and can be devastating. Many of the consequences of a chronic symptomatic TBI have, in the past, been solely attributed to the brain injury per se. Analysis of the signs and symptoms of pituitary axis dysfunction suggests that many of these consequences can be attributed to post-traumatic hypopituitarism (PTH). PTH may well play a significant role in the progressive signs and symptoms that follow a chronic TBI.	[Masel, Brent E.] Transit Learning Ctr Galveston, Galveston, TX 77550 USA; [Urban, Randy] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA	Masel, BE (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.	bmasel@tlc-galveston.org					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bengtsson BA, 1999, J CLIN ENDOCR METAB, V84, P3929, DOI 10.1210/jc.84.11.3929; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Briscoe VJ, 2007, APPL PHYSIOL NUTR ME, V32, P576, DOI 10.1139/H07-025; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Centers for Disease Control and Prevention, 2007, TBI US CHILDR 0 14 Y; Cherrier MM, 2005, NEUROLOGY, V64, P290, DOI 10.1212/01.WNL.0000149639.25136.CA; Cherrier MM, 2003, J ANDROL, V24, P568; Cleare AJ, 2001, AM J PSYCHIAT, V158, P641, DOI 10.1176/appi.ajp.158.4.641; Colao A, 2004, J CLIN ENDOCR METAB, V89, P5998, DOI 10.1210/jc.2004-1042; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1277, DOI 10.1210/jc.84.4.1277; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DANIEL PM, 1959, LANCET, V2, P927; Davis J D, 2007, Minerva Endocrinol, V32, P49; Davis Jennifer Duncan, 2003, Curr Psychiatry Rep, V5, P384, DOI 10.1007/s11920-003-0073-6; DENICOFF KD, 1990, AM J PSYCHIAT, V147, P94; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Garber JR, 2012, ENDOCR PRACT, V18, P989, DOI 10.4158/EP12280.GL; Genazzani AR, 2007, HUM REPROD UPDATE, V13, P175, DOI 10.1093/humupd/dml042; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Grais IM, 2014, AM J MED, V127, P691, DOI 10.1016/j.amjmed.2014.03.009; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HAGGERTY JJ, 1993, AM J PSYCHIAT, V150, P508; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hatton J, 2006, J NEUROSURG, V105, P843, DOI 10.3171/jns.2006.105.6.843; Heather NL, 2012, J CLIN ENDOCR METAB, V97, P599, DOI 10.1210/jc.2011-2284; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Hohl A., 2014, OPEN J ENDOCR METAB, V4, P13; Ives JC, 2007, J ATHL TRAINING, V42, P431; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Lauzier F, 2014, CRIT CARE MED, V42, P712, DOI 10.1097/CCM.0000000000000046; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mitchell JL, 2003, ARCH INTERN MED, V163, P2485, DOI 10.1001/archinte.163.20.2485; Moreau OK, 2013, J NEUROTRAUM, V30, P998, DOI 10.1089/neu.2012.2705; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Muller M, 2005, NEUROLOGY, V64, P866, DOI 10.1212/01.WNL.0000153072.54068.E3; National Research Council, 2008, GULF WAR AND HLTH, V7; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Cenci MCP, 2009, PITUITARY, V12, P322, DOI 10.1007/s11102-009-0182-2; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Samuels MH, 2007, THYROID, V17, P249, DOI 10.1089/thy.2006.0252; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2013, J NEUROTRAUM, V30, P1426, DOI 10.1089/neu.2012.2752; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Ulutabanca H, 2014, CHILD NERV SYST, V30, P1021, DOI 10.1007/s00381-013-2334-y; Wekking EM, 2005, EUR J ENDOCRINOL, V153, P747, DOI 10.1530/eje.1.02025; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011	86	17	17	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1902	1910		10.1089/neu.2014.3526			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200007	25325517				2021-06-18	
J	Nemer, SN; Caldeira, JB; Santos, RG; Guimaraes, BL; Garcia, JM; Prado, D; Silva, RT; Azeredo, LM; Faria, ER; Souza, PCP				Nemer, Sergio Nogueira; Caldeira, Jefferson B.; Santos, Ricardo G.; Guimaraes, Bruno L.; Garcia, Joao Marcio; Prado, Darwin; Silva, Ricardo T.; Azeredo, Leandro M.; Faria, Eduardo R.; Souza, Paulo Cesar P.			Effects of positive end-expiratory pressure on brain tissue oxygen pressure of severe traumatic brain injury patients with acute respiratory distress syndrome: A pilot study	JOURNAL OF CRITICAL CARE			English	Article						Mechanical ventilation; Acute respiratory distress syndrome; Brain injury	INTRACRANIAL-PRESSURE; CARE	Purpose: To verify whether high positive end-expiratory pressure levels can increase brain tissue oxygen pressure, and also their effects on pulse oxygen saturation, intracranial pressure, and cerebral perfusion pressure. Material and Methods: Twenty traumatic brain injury patients with acute respiratory distress syndrome were submitted to positive end-expiratory pressure levels of 5, 10, and 15 cm H2O progressively. The 3 positive end-expiratory pressure levels were used during 20 minutes for each one, whereas brain tissue oxygen pressure, oxygen saturation, intracranial pressure, and cerebral perfusion pressure were recorded. Results: Brain tissue oxygen pressure and oxygen saturation increased significantly with increasing positive end-expiratory pressure from 5 to 10 and from 10 to 15 cm H2O (P = .0001 and P = .0001 respectively). Intracranial pressure and cerebral perfusion pressure did not differ significantly with increasing positive end-expiratory pressure from 5 to 10 and from 10 to 15 cm H2O (P = .16 and P = .79 respectively). Conclusions: High positive end-expiratory pressure levels increased brain tissue oxygen pressure and oxygen saturation, without increase in intracranial pressure or decrease in cerebral perfusion pressure. High positive end-expiratory pressure levels can be used in severe traumatic brain injury patients with acute respiratory distress syndrome as a safe alternative to improve brain oxygenation. (C) 2015 Elsevier Inc. All rights reserved.	[Nemer, Sergio Nogueira; Caldeira, Jefferson B.; Santos, Ricardo G.; Guimaraes, Bruno L.; Garcia, Joao Marcio; Prado, Darwin; Silva, Ricardo T.; Faria, Eduardo R.; Souza, Paulo Cesar P.] Complexo Hosp Niteroi, BR-24020090 Niteroi, RJ, Brazil; [Nemer, Sergio Nogueira; Azeredo, Leandro M.] Hosp Policia Militar Niteroi, BR-24240705 Niteroi, RJ, Brazil; [Nemer, Sergio Nogueira; Caldeira, Jefferson B.] Univ UNIGRANRIO, BR-25071202 Duque de Caxias, Brazil	Nemer, SN (corresponding author), Complexo Hosp Niteroi, Rua La Salle 12, BR-24020090 Niteroi, RJ, Brazil.	snnemer@gmail.com					Barbas CSV, 2014, CURR OPIN CRIT CARE, V20, P10, DOI 10.1097/MCC.0000000000000058; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2007, SURG CLIN N AM, V87, P119, DOI 10.1016/j.suc.2006.09.018; COOPER KR, 1985, J NEUROSURG, V63, P552, DOI 10.3171/jns.1985.63.4.0552; Crotti S, 2001, AM J RESP CRIT CARE, V164, P131, DOI 10.1164/ajrccm.164.1.2007011; Gelabert-Gonzalez M, 2003, REV NEUROLOGIA, V36, P744, DOI 10.33588/rn.3608.2002361; Georgiadis D, 2001, STROKE, V32, P2088, DOI 10.1161/hs0901.095406; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kalanuria AA, 2013, CURR OPIN CRIT CARE, V19, P113, DOI 10.1097/MCC.0b013e32835eba56; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Muench E, 2005, CRIT CARE MED, V33, P2367, DOI 10.1097/01.CCM.0000181732.37319.DF; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Nemer SN, 2011, J CRIT CARE, V26, P22, DOI 10.1016/j.jcrc.2010.04.015; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Videtta W, 2002, ACT NEUR S, V81, P93; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wolf S, 2005, ACTA NEUROCHIR SUPPL, V95, P103	22	17	18	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2015	30	6					1263	1266		10.1016/j.jcrc.2015.07.019			4	Critical Care Medicine	General & Internal Medicine	CV0MX	WOS:000363945900021	26307004				2021-06-18	
J	Song, Z; Zhao, X; Liu, M; Jin, HX; Wang, L; Hou, MX; Gao, Y				Song, Zhi; Zhao, Xiu; Liu, Martin; Jin, Hongxu; Wang, Ling; Hou, Mingxiao; Gao, Yan			Recombinant human brain natriuretic peptide attenuates trauma-/haemorrhagic shock-induced acute lung injury through inhibiting oxidative stress and the NF-B-dependent inflammatory/MMP-9 pathway	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						acute lung injury; antioxidative enzymes; brain natriuretic peptide; NF-B; trauma; haemorrhagic shock	KAPPA-B; HEMORRHAGIC-SHOCK; SEPSIS; MODEL; RATS; ISCHEMIA/REPERFUSION; SUPPRESSION; DYSFUNCTION; ENDOTOXIN; PROBNP	Acute lung injury (ALI) is one of the most serious complications in traumatic patients and is an important part of multiple organ dysfunction syndrome (MODS). Recombinant human brain natriuretic peptide (rhBNP) is a peptide with a wide range of biological activity. In this study, we investigated local changes in oxidative stress and the NF-B-dependent matrix metalloproteinase-9 (MMP-9) pathway in rats with trauma/haemorrhagic shock (TH/S)-induced ALI and evaluated the effects of pretreatment with rhBNP. Forty-eight rats were randomly divided into four groups: sham operation group, model group, low-dosage rhBNP group and high-dosage rhBNP group (n=12 for each group). Oxidative stress and MPO activity were measured by ELISA kits. MMP-9 activity was detected by zymography analysis. NF-B activity was determined using Western blot assay. With rhBNP pretreatment, TH/S-induced protein leakage, increased MPO activity, lipid peroxidation and metalloproteinase (MMP)-9 activity were inhibited. Activation of antioxidative enzymes was reversed. The phosphorylation of NF-B and the degradation of its inhibitor IB were suppressed. The results suggested that the protection mechanism of rhBNP is possibly mediated through upregulation of anti-oxidative enzymes and inhibition of NF-B activation. More studies are needed to further evaluate whether rhBNP is a suitable candidate as an effective inhaling drug to reduce the incidence of TH/S-induced ALI.	[Song, Zhi; Jin, Hongxu; Wang, Ling; Hou, Mingxiao; Gao, Yan] Gen Hosp Shenyang Mil Dist, Dept Emergency & Crit Care Med, 83 Wenhua Rd, Shenyang 110016, Peoples R China; [Zhao, Xiu] Shenyang Med Coll, Sch Stomatol, Centralab, Shenyang, Peoples R China; [Liu, Martin] Univ Nebraska Med Ctr, Dept Internal Med, Pulm Crit Care Sleep & Allergy Med, Omaha, NE USA	Gao, Y (corresponding author), Gen Hosp Shenyang Mil Dist, Dept Emergency & Crit Care Med, 83 Wenhua Rd, Shenyang 110016, Peoples R China.	gaoyan7879@163.com			Chinese Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M552693]; Science and Technology Project of Liaoning, China [2013225089]	This work was supported by Chinese Postdoctoral Science Foundation (2014M552693, to Z.S.) and Science and Technology Project of Liaoning, China (2013225089, to Z.S.).	Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Azoulay E, 2002, CRIT CARE MED, V30, P781, DOI 10.1097/00003246-200204000-00010; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Burger M R, 2001, Curr Opin Investig Drugs, V2, P929; Chiang CH, 2011, TRANSL RES, V158, P17, DOI 10.1016/j.trsl.2011.02.002; Ci XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034634; Corbel M, 2000, BRAZ J MED BIOL RES, V33, P749, DOI 10.1590/S0100-879X2000000700004; Deitch EA, 2004, SHOCK, V22, P221, DOI 10.1097/01.shk.0000133592.55400.83; Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083; El-Benna J, 2005, ARCH IMMUNOL THER EX, V53, P199; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Hellermann G, 2004, J ALLERGY CLIN IMMUN, V113, P79, DOI 10.1016/j.jaci.2003.10.009; Irwin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL849, DOI 10.1152/ajplung.00294.2004; Jarrar D, 1999, INT J MOL MED, V4, P575; Jin XN, 2014, LIFE SCI, V117, P40, DOI 10.1016/j.lfs.2014.09.023; Kang JL, 2001, AM J RESP CRIT CARE, V164, P2206, DOI 10.1164/ajrccm.164.12.2104017; Kher A, 2005, SHOCK, V23, P1, DOI 10.1097/01.shk.0000148055.12387.15; Kuo MY, 2011, FOOD CHEM TOXICOL, V49, P2660, DOI 10.1016/j.fct.2011.07.012; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; Li N, 2014, CELL BIOCHEM BIOPHYS, V70, P1317, DOI 10.1007/s12013-014-0057-7; Li N, 2013, FRONT BIOSCI-LANDMRK, V18, P1237, DOI 10.2741/4175; Li XL, 2007, AM J PHYSIOL-LUNG C, V292, pL1193, DOI 10.1152/ajplung.00408.2006; Lv X, 2011, INT J MED SCI, V8, P353, DOI 10.7150/ijms.8.353; MAEKAWA K, 1988, BIOCHEM BIOPH RES CO, V157, P410, DOI 10.1016/S0006-291X(88)80062-7; MANCA D, 1991, TOXICOLOGY, V67, P303, DOI 10.1016/0300-483X(91)90030-5; Mueller C, 2004, NEW ENGL J MED, V350, P647, DOI 10.1056/NEJMoa031681; Murphy TJ, 2004, J LEUKOCYTE BIOL, V75, P400, DOI 10.1189/jlb.0503233; Pandit Kaushik, 2011, Indian J Endocrinol Metab, V15 Suppl 4, pS345, DOI 10.4103/2230-8210.86978; Parthasarathy A, 2013, MOL CELL BIOCHEM, V378, P217, DOI 10.1007/s11010-013-1612-z; Romero M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071992; Roy SK, 2013, SHOCK, V40, P210, DOI 10.1097/SHK.0b013e31829efb06; Santry HP, 2010, SHOCK, V33, P229, DOI 10.1097/SHK.0b013e3181c30f0c; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Song Z, 2013, INT IMMUNOPHARMACOL, V17, P508, DOI 10.1016/j.intimp.2013.05.028; Subramanian V, 2014, EUR J PHARMACOL, V740, P388, DOI 10.1016/j.ejphar.2014.07.024; Teng L, 2012, MOL CELL BIOCHEM, V360, P271, DOI 10.1007/s11010-011-1066-0; Trocha M, 2014, ARCH MED SCI, V10, P817, DOI 10.5114/aoms.2013.38087; Wang F, 2012, CRIT CARE, V16, DOI 10.1186/cc11331; Ward PA, 2010, ANN NY ACAD SCI, V1203, P53, DOI 10.1111/j.1749-6632.2010.05552.x; Xia XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077823; Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006; Yamanouchi S, 2010, TOHOKU J EXP MED, V221, P175, DOI 10.1620/tjem.221.175; Yang HS, 2014, INT IMMUNOPHARMACOL, V19, P262, DOI 10.1016/j.intimp.2014.01.023; Yang SF, 2008, ARCH ORAL BIOL, V53, P287, DOI 10.1016/j.archoralbio.2007.09.001	44	17	19	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2015	96	6					406	413		10.1111/iep.12160			8	Pathology	Pathology	DD6UH	WOS:000370059500007	26852688	Green Published			2021-06-18	
J	Barbierato, M; Facci, L; Marinelli, C; Zusso, M; Argentini, C; Skaper, SD; Giusti, P				Barbierato, Massimo; Facci, Laura; Marinelli, Carla; Zusso, Morena; Argentini, Carla; Skaper, Stephen D.; Giusti, Pietro			Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells	SCIENTIFIC REPORTS			English	Article							CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; MAMMALIAN TARGET; CNS MYELINATION; OXIDATIVE STRESS; RAPAMYCIN MTOR; MAST-CELLS; DIFFERENTIATION; LUTEOLIN; NEUROINFLAMMATION	Oligodendrocytes have limited ability to repair the damage to themselves or to other nerve cells, as seen in demyelinating diseases like multiple sclerosis. An important strategy may be to replace the lost oligodendrocytes and/or promote the maturation of undifferentiated oligodendrocyte precursor cells (OPCs). Recent studies show that a composite of co-ultramicronized N-palmitoylethanolamine (PEA) and luteolin (co-ultramicronized PEA/luteolin, 10: 1 by mass) is efficacious in improving outcome in experimental models of spinal cord and traumatic brain injuries. Here, we examined the ability of co-ultramicronized PEA/luteolin to promote progression of OPCs into a more differentiated phenotype. OPCs derived from newborn rat cortex were placed in culture and treated the following day with 10 mu M co-ultramicronized PEA/luteolin. Cells were collected 1, 4 and 8 days later and analyzed for expression of myelin basic protein (MBP). qPCR and Western blot analyses revealed a time-dependent increase in expression of both mRNA for MBP and MBP content, along with an increased expression of genes involved in lipid biogenesis. Ultramicronized PEA or luteolin, either singly or in simple combination, were ineffective. Further, co-ultramicronized PEA/luteolin promoted morphological development of OPCs and total protein content without affecting proliferation. Co-ultramicronized PEA/luteolin may represent a novel pharmacological strategy to promote OPC maturation.	[Barbierato, Massimo; Facci, Laura; Marinelli, Carla; Zusso, Morena; Argentini, Carla; Skaper, Stephen D.; Giusti, Pietro] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy	Skaper, SD (corresponding author), Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy.	stephen.skaper@unipd.it		GIUSTi, Pietro/0000-0001-9352-4046	MIUR, PON 'Ricerca e Competitivita projectMinistry of Education, Universities and Research (MIUR); Regione Veneto project [103173COF/14/LR52001C2/000051]	This study was supported in part by MIUR, PON 'Ricerca e Competitivita 2007-2013' project PON01_02512, and by Regione Veneto project protocol 103173COF/14/LR52001C2/000051.	Alhouayek M, 2014, DRUG DISCOV TODAY, V19, P1632, DOI 10.1016/j.drudis.2014.06.007; BARBARESE E, 1988, J NEUROCHEM, V51, P1737, DOI 10.1111/j.1471-4159.1988.tb01153.x; Barbierato M, 2013, CNS NEUROL DISORD-DR, V12, P608; Baumann N, 2001, PHYSIOL REV, V81, P871; Brown MA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00147; Bsibsi M, 2014, ACTA NEUROPATHOL, V128, P215, DOI 10.1007/s00401-014-1317-8; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Butts BD, 2008, CELL DEATH DIFFER, V15, P1178, DOI 10.1038/cdd.2008.70; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Coleta M, 2008, BEHAV BRAIN RES, V189, P75, DOI 10.1016/j.bbr.2007.12.010; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Crupi R, 2013, CNS NEUROL DISORD-DR, V12, P989, DOI 10.2174/18715273113129990084; Damasceno A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096193; DEROSBO NK, 1993, J CLIN INVEST, V92, P2602, DOI 10.1172/JCI116875; Deshmukh VA, 2013, NATURE, V502, P327, DOI 10.1038/nature12647; Dugas JC, 2006, J NEUROSCI, V26, P10967, DOI 10.1523/JNEUROSCI.2572-06.2006; Filippini G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008933.pub2; Finkelsztejn A, 2014, PERSPECT MED CHEM, V6, P65, DOI 10.4137/PMC.S13213; Fraussen J, 2014, AUTOIMMUN REV, V13, P1126, DOI 10.1016/j.autrev.2014.07.002; Gomez O, 2011, BRIT J PHARMACOL, V163, P1520, DOI 10.1111/j.1476-5381.2011.01414.x; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; GRIFFITHS IR, 1995, NEUROPATH APPL NEURO, V21, P85, DOI 10.1111/j.1365-2990.1995.tb01034.x; Grosso C, 2013, CURR MED CHEM, V20, P4694, DOI 10.2174/09298673113209990155; Guardiola-Diaz HM, 2012, GLIA, V60, P476, DOI 10.1002/glia.22281; Hammond E, 2015, J NEUROSCI, V35, P5007, DOI 10.1523/JNEUROSCI.4787-14.2015; Hartline DK, 2007, CURR BIOL, V17, pR29, DOI 10.1016/j.cub.2006.11.042; Kamm CP, 2014, EUR NEUROL, V72, P132, DOI 10.1159/000360528; Kidd D, 1999, BRAIN, V122, P17, DOI 10.1093/brain/122.1.17; Kipp M, 2012, CNS NEUROL DISORD-DR, V11, P506, DOI 10.2174/187152712801661248; KOUL O, 1980, BIOCHEM J, V186, P959, DOI 10.1042/bj1860959; Kremer D, 2015, MULT SCLER J, V21, P541, DOI 10.1177/1352458514566419; Lebrun-Julien F, 2014, J NEUROSCI, V34, P8432, DOI 10.1523/JNEUROSCI.1105-14.2014; Lee J, 2005, J CELL BIOL, V170, P661, DOI 10.1083/jcb.200411047; Luessi F, 2014, EXPERT REV NEUROTHER, V14, P1315, DOI 10.1586/14737175.2014.969241; Michailidou I, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00454; MODELL JG, 1989, J CLIN PSYCHOPHARM, V9, P347; Najm FJ, 2015, NATURE, V522, P216, DOI 10.1038/nature14335; Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009; NOBLE PG, 1994, BRAIN RES, V633, P83, DOI 10.1016/0006-8993(94)91525-3; Norrmen C, 2013, BIOCHEM SOC T, V41, P944, DOI 10.1042/BST20130046; Olsen JA, 2015, J NEUROSCI RES, V93, P687, DOI 10.1002/jnr.23493; Paterniti I, 2014, CNS NEUROL DISORD-DR, V13, P1530, DOI 10.2174/1871527313666140806124322; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Peferoen L, 2014, IMMUNOLOGY, V141, P302, DOI 10.1111/imm.12163; Petrosino S, 2010, BIOCHIMIE, V92, P724, DOI 10.1016/j.biochi.2010.01.006; Ransohoff RM, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.14; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Schmitt S, 2015, BBA-MOL CELL BIOL L, V1851, P999, DOI 10.1016/j.bbalip.2014.12.016; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Skaper SD, 2014, INFLAMMOPHARMACOLOGY, V22, P79, DOI 10.1007/s10787-013-0191-7; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Skaper SD, 2012, PHILOS T R SOC B, V367, P3312, DOI 10.1098/rstb.2011.0391; Skaper Stephen D, 2012, Methods Mol Biol, V846, P67, DOI 10.1007/978-1-61779-536-7_7; Smith KJ, 1999, BRAIN PATHOL, V9, P69; Stahnke T, 2007, J MOL NEUROSCI, V32, P25, DOI 10.1007/s12031-007-0005-8; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Theoharides TC, 2012, INT J IMMUNOPATH PH, V25, P317, DOI 10.1177/039463201202500201; Thone J, 2013, DRUG HEALTHC PATIENT, V5, P37, DOI 10.2147/DHPS.S28822; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009; Wahl SE, 2014, J NEUROSCI, V34, P4453, DOI 10.1523/JNEUROSCI.4311-13.2014; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Winking H, 2004, CYTOGENET GENOME RES, V105, P251, DOI 10.1159/000078196; Xu B, 2010, EUR J PHARMACOL, V627, P99, DOI 10.1016/j.ejphar.2009.10.038	66	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 18	2015	5								16676	10.1038/srep16676			13	Multidisciplinary Sciences	Science & Technology - Other Topics	CW2UC	WOS:000364847400001	26578323	DOAJ Gold, Green Published			2021-06-18	
J	Buonora, JE; Mousseau, M; Jacobowitz, DM; Lazarus, RC; Yarnell, AM; Olsen, CH; Pollard, HB; Diaz-Arrastia, R; Latour, L; Mueller, GP				Buonora, John E.; Mousseau, Michael; Jacobowitz, David M.; Lazarus, Rachel C.; Yarnell, Angela M.; Olsen, Cara H.; Pollard, Harvey B.; Diaz-Arrastia, Ramon; Latour, Lawrence; Mueller, Gregory P.			Autoimmune Profiling Reveals Peroxiredoxin 6 as a Candidate Traumatic Brain Injury Biomarker	JOURNAL OF NEUROTRAUMA			English	Article						autoantibodies; autoimmune profiling; biomarker; peroxiredoxin 6; traumatic brain injury	C-TERMINAL HYDROLASE; CENTRAL-NERVOUS-SYSTEM; HUMAN PLATELETS; 2-DIMENSIONAL ELECTROPHORESIS; RHEUMATOID-ARTHRITIS; GEL-ELECTROPHORESIS; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; SERUM-LEVELS; PROTEIN	Autoimmune profiling in rats revealed the antioxidant enzyme, peroxiredoxin 6 (PRDX6), as a target for autoantibodies evoked in response to traumatic brain injury (TBI). Consistent with this proposal, immunohistochemical analysis of rat cerebral cortex demonstrated that PRDX6 is highly expressed in the perivascular space, presumably contained within astrocytic foot processes. Accordingly, an immunosorbent electrochemiluminescence assay was developed for investigating PRDX6 in human samples. PRDX6 was found to be measurable in human blood and highly expressed in human cerebral cortex and platelets. Circulating levels of PRDX6 were elevated fourfold over control values 4 to 24h following mild-to-moderate TBI. These findings suggest that PRDX6 may serve as a biomarker for TBI and that autoimmune profiling is a viable strategy for the discovery of novel TBI biomarkers.	[Buonora, John E.; Mousseau, Michael; Pollard, Harvey B.; Diaz-Arrastia, Ramon; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Buonora, John E.; Jacobowitz, David M.; Lazarus, Rachel C.; Yarnell, Angela M.; Pollard, Harvey B.; Diaz-Arrastia, Ramon; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [Mousseau, Michael; Jacobowitz, David M.; Pollard, Harvey B.; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Olsen, Cara H.] Uniformed Serv Univ Hlth Sci, Biostat Consulting Ctr, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Latour, Lawrence] NINDS, Sect Stroke Diagnost & Therapeut, Bethesda, MD 20892 USA	Mueller, GP (corresponding author), USUHS, C2117,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gregory.mueller@usuhs.edu	Latour, Larry/AAH-5663-2021	Latour, Larry/0000-0001-6160-5263; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1703D]; Defense Medical Research and Development Command [D61_I_10_J6_152]; TriService Nursing Research Program [N12-P12]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120] Funding Source: NIH RePORTER	The authors would like to acknowledge the expert technical assistance of Ms. Tinghua Chen and Mr. James Freedy. Support for this work included funding from: Department of Defense in the Center for Neuroscience and Regenerative Medicine (G1703D), Defense Medical Research and Development Command (D61_I_10_J6_152) and TriService Nursing Research Program (N12-P12).	Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Chen AS, 2010, J NEUROTRAUM, V27, P263, DOI 10.1089/neu.2009.1051; Chowdhury I, 2009, FREE RADICAL BIO MED, V46, P146, DOI 10.1016/j.freeradbiomed.2008.09.027; Cirillo C, 2011, WORLD J GASTROENTERO, V17, P1261, DOI 10.3748/wjg.v17.i10.1261; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; Driscoll WJ, 1999, MOL PHARMACOL, V55, P1067; Escartin C, 2008, MOL NEUROBIOL, V38, P231, DOI 10.1007/s12035-008-8043-y; Fujii T, 2001, HISTOCHEM J, V33, P267, DOI 10.1023/A:1017972906570; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Hattori Fumiyuki, 2007, V44, P357; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Heydorn W.E., 1988, NEURONAL GLIAL PROTE, P25; HEYDORN WE, 1983, J NEUROSCI, V3, P2597; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jin MH, 2005, NEUROSCI LETT, V381, P252, DOI 10.1016/j.neulet.2005.02.048; KENT C, 1992, DEV BRAIN RES, V68, P241, DOI 10.1016/0165-3806(92)90066-6; Khan F, 2006, J BIOCHEM MOL BIOL, V39, P189; Klareskog L, 2008, CURR OPIN RHEUMATOL, V20, P300, DOI 10.1097/BOR.0b013e3282fbd22a; Kumin A, 2006, AM J PATHOL, V169, P1194, DOI 10.2353/ajpath.2006.060119; Liu G, 2010, FREE RADICAL BIO MED, V49, P1172, DOI 10.1016/j.freeradbiomed.2010.07.002; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Massabki PS, 2003, J RHEUMATOL, V30, P2606; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Muth E, 2004, BBA-PROTEINS PROTEOM, V1699, P263, DOI 10.1016/j.bbapap.2004.03.007; Newman TA, 2013, HUM REPROD, V28, P2502, DOI 10.1093/humrep/det274; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Ousman SS, 2012, NAT NEUROSCI, V15, P1096, DOI 10.1038/nn.3161; Pan J, 2014, CURR MOL MED, V14, P1186, DOI 10.2174/1566524014666141021143333; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Routsias JG, 2011, RHEUMATOLOGY, V50, P1189, DOI 10.1093/rheumatology/ker090; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Scofield RH, 2005, FREE RADICAL BIO MED, V38, P719, DOI 10.1016/j.freeradbiomed.2004.11.001; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Strey CW, 2004, AM J PATHOL, V165, P1701, DOI 10.1016/S0002-9440(10)63426-8; Sung JH, 2009, J PINEAL RES, V46, P300, DOI 10.1111/j.1600-079X.2008.00661.x; Szodoray P, 2010, AUTOIMMUN REV, V9, P140, DOI 10.1016/j.autrev.2009.04.006; Tamura S, 2011, THROMB RES, V128, pE55, DOI 10.1016/j.thromres.2011.06.002; Tulsawani R, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-125; Wang Y, 2008, J CELL BIOCHEM, V104, P1274, DOI 10.1002/jcb.21703; Xu Y, 2014, EXP ANIM TOKYO, V63, P247, DOI 10.1538/expanim.63.247; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698	57	17	17	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1805	1814		10.1089/neu.2014.3736			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500011	25938937	Bronze, Green Published			2021-06-18	
J	Timaru-Kast, R; Herbig, EL; Luh, C; Engelhard, K; Thal, SC				Timaru-Kast, Ralph; Herbig, Elina L.; Luh, Clara; Engelhard, Kristin; Thal, Serge C.			Influence of Age on Cerebral Housekeeping Gene Expression for Normalization of Quantitative Polymerase Chain Reaction after Acute Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						aging; control genes; housekeeping; normalization; quantitative real-time RT-PCR; reference genes; traumatic brain injury	MESSENGER-RNA EXPRESSION; TIME RT-PCR; REAL-TIME; MOUSE HIPPOCAMPUS; RIBOSOMAL-RNA; QUANTIFICATION; VALIDATION; SELECTION; MODEL; EPIDEMIOLOGY	To prevent methodological errors of quantitative PCR (qPCR) normalization with reference genes is obligatory. Although known to influence gene expression, impact of age on housekeeping gene expression has not been determined after acute brain lesions such as traumatic brain injury (TBI). Therefore, expression of eight common control genes was investigated at 15min, 24h, and 72h after experimental TBI in 2- and 21-month-old C57Bl6 mice. Expression of (2)-microglobulin (B2M), -actin (ActB), and porphobilinogen deaminase (PBGD) increased after TBI in both ages. 2M demonstrated age-dependent differences and highest inter- and intragroup variations. Expression of cyclophilin A, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine ribosyltransferase (HPRT), S100B, and 18SrRNA remained stable. Cyclophilin A and HPRT demonstrated strongest inter- and intragroup stability. The data indicate that the expression of most but not all control genes is stable during aging. The correct choice of housekeeping genes is of key importance to ensure adequate normalization of qPCR data. With respect to insult and age, normalization strategies should consider cyclophilin A as a single normalizer. Normalization with two reference genes is recommended with cyclophilin A and HPRT in young mice and in mixed age studies and with cyclophilin A and GAPDH in old mice. In addition, the present study suggests not to use (2)-microglobulin, -actin or PBGD as single control genes because of strong regulation after CCI in 2- and 21-month-old mice.	[Timaru-Kast, Ralph; Herbig, Elina L.; Luh, Clara; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55131 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729	German Research FoundationGerman Research Foundation (DFG) [DFG TH1430/3-1, CRC1080/A9]; Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01EO1003]	This work was financially supported by a grant from the German Research Foundation (DFG TH1430/3-1) to SCT and to KE (CRC1080/A9) and to KE (CRC1080/A9) and by the Federal Ministry of Education and Research (BMBF 01EO1003) to SCT.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005; Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Boda E, 2009, J MOL NEUROSCI, V37, P238, DOI 10.1007/s12031-008-9128-9; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Harris JL, 2009, J NEUROTRAUM, V26, P1669, DOI [10.1089/neu.2009.0875, 10.1089/neu.2009-0875]; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; Krohn M, 2015, J NEUROTRAUM, V32, P430, DOI 10.1089/neu.2014.3524; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee CK, 2000, NAT GENET, V25, P294; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nishida Y, 2006, J PHARMACOL SCI, V101, P52, DOI 10.1254/jphs.FP0050881; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Ohl F, 2005, J MOL MED, V83, P1014, DOI 10.1007/s00109-005-0703-z; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Peters IR, 2007, VET IMMUNOL IMMUNOP, V117, P55, DOI 10.1016/j.vetimm.2007.01.011; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rhinn H, 2008, ANAL BIOCHEM, V372, P116, DOI 10.1016/j.ab.2007.08.023; Rhinn H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-62; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sieber MW, 2010, NEUROBIOL AGING, V31, P654, DOI 10.1016/j.neurobiolaging.2008.05.023; Somel M, 2006, CURR BIOL, V16, pR359, DOI 10.1016/j.cub.2006.04.024; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; Staib-Lasarzik I, 2014, J NEUROTRAUM, V31, P1664, DOI 10.1089/neu.2013.3243; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Talaat AM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf103; Tanic N, 2007, J MOL NEUROSCI, V32, P38, DOI 10.1007/s12031-007-0006-7; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Touchberry Chad D, 2006, J Biomol Tech, V17, P157; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; van den Berg GJ, 2015, J HEALTH ECON, V40, P141, DOI 10.1016/j.jhealeco.2014.02.004; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143; Weiss J., 2014, VERSUCHSTIERKUNDE TI; Zampieri M, 2010, MECH AGEING DEV, V131, P89, DOI 10.1016/j.mad.2009.12.005	57	17	17	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1777	1788		10.1089/neu.2014.3784			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500008	26102571				2021-06-18	
J	Hwang, HF; Cheng, CH; Chien, DK; Yu, WY; Lin, MR				Hwang, Hei-Fen; Cheng, Chui-Hsuan; Chien, Ding-Kuo; Yu, Wen-Yu; Lin, Mau-Roung			Risk Factors for Traumatic Brain Injuries During Falls in Older Persons	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fall mechanism; falls; older people; risk factor; traumatic brain injury	UNITED-STATES; IMPACT SEVERITY; HIP-FRACTURES; ADULTS; PEOPLE; MORTALITY; POPULATION; DISCHARGE; DESCENT; DEATHS	Objective: To identify risk factors for traumatic brain injuries (TBIs) during falls in older Taiwanese people. Participants: Case patients consisted of 113 patients aged 60 years or older with a moderate/severe TBI due to a fall. Two control groups: (1) 339 older patients with a soft-tissue injury; and (2) 113 with a mild-TBI due to a fall. Proxies were required to provide information for a considerable number of patients. Design: Matched case-control study. Settings: The emergency departments of 3 general hospitals. Measures: Sociodemographic, lifestyle behavior, chronic condition, medication use, functional abilities, and fall-related characteristics. Results: When patients with a soft-tissue injury were assigned to the control group, men were 2.06-fold more likely to have a moderate/severe TBI than women. Subjects who took antiarrhythmics within 4 hours of a fall were 2.59-fold more likely to have a moderate/severe TBI than those who took none. Subjects who were negotiating stairs and getting in/out of the bed/chair were 3.12-fold and 2.97-fold, respectively, more likely to have a moderate/severe TBI than those who fell while walking. Falling backward and sideways was 4.07-fold and 2.30-fold, respectively, more likely to cause a moderate/severe TBI than falling forward. When patients with a mild-TBI were assigned to the control group, results were similar, with the exception that the effect of antiarrhythmic use became nonsignificant and subjects who took 2 or more medications were 3.07-fold more likely to have a moderate/severe TBI than those who took none. Conclusion: Avoiding a head impact during a backward or sideways fall, reducing unnecessary use of polypharmacy and antiarrhythmics, and maintaining safety during stair negotiation and bed/chair transfer may protect an elderly person from a severe brain injury.	[Hwang, Hei-Fen] Natl Taipei Univ Nursing & Hlth Sci, Dept Nursing, Taipei, Taiwan; [Hwang, Hei-Fen; Lin, Mau-Roung] Taipei Med Univ, Coll Publ Hlth & Nutr, Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 110, Taiwan; [Cheng, Chui-Hsuan] Tzu Chi Gen Hosp, Taichung Branch, Dept Emergency Med, Taichung, Taiwan; [Chien, Ding-Kuo] Mackay Memorial Hosp, Dept Emergency Med, Taipei, Taiwan; [Yu, Wen-Yu] Taipei Med Univ Hosp, Dept Emergency Med, Taipei, Taiwan	Lin, MR (corresponding author), Taipei Med Univ, Coll Publ Hlth & Nutr, Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 110, Taiwan.	mrlin@tmu.edu.tw	Cheng, Chui-Hsuan/AAY-4057-2020	Chien, Ding-Kuo/0000-0001-5283-9850	National Health Research InstituteNational Health Research Institutes - Taiwan [NHRI-EX103-10317PI]; National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC102-2314-B-038-033]	This work was funded by the National Health Research Institute (NHRI-EX103-10317PI) and National Science Council (NSC102-2314-B-038-033), Taiwan.	*CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; Chiou HC, 1997, CHINESE J PUBLIC HLT, V16, P119, DOI DOI 10.6288/CJPH1997-16-02-02; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CUMMING RG, 1994, J AM GERIATR SOC, V42, P774, DOI 10.1111/j.1532-5415.1994.tb06540.x; CUMMING RG, 1991, AGE AGEING, V20, P455, DOI 10.1093/ageing/20.6.455; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; Davies AJ, 1996, AGE AGEING, V25, P362, DOI 10.1093/ageing/25.5.362; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Guo N.W., 1988, TAIWAN J PHYS MED RE, V16, P52, DOI DOI 10.1007/978-94-011-7973-7_3; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Leipzig RM, 1999, J AM GERIATR SOC, V47, P40, DOI 10.1111/j.1532-5415.1999.tb01899.x; Liao Y. C., 1995, MED J CHANGHUA CHRIS, V1, P11; LUUKINEN H, 1995, J AM GERIATR SOC, V43, P871, DOI 10.1111/j.1532-5415.1995.tb05529.x; MARCUS FI, 1983, AM HEART J, V106, P924, DOI 10.1016/0002-8703(83)90017-0; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Nagata H, 2007, IND HEALTH, V45, P462, DOI 10.2486/indhealth.45.462; Nagurney J T, 1998, J Emerg Med, V16, P709, DOI 10.1016/S0736-4679(98)00083-3; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; O'Mahony D, 1998, J GERONTOL A-BIOL, V53, pM435, DOI 10.1093/gerona/53A.6.M435; Ojha HA, 2009, PHYS THER, V89, P1080, DOI 10.2522/ptj.20080187; Palvanen M, 2000, OSTEOPOROSIS INT, V11, P822, DOI 10.1007/s001980070040; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Reid SM, 2011, GAIT POSTURE, V34, P529, DOI 10.1016/j.gaitpost.2011.07.008; Robinovitch SN, 2000, J BIOMECH, V33, P863, DOI 10.1016/S0021-9290(00)00025-7; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandler R, 2001, J BIOMECH ENG-T ASME, V123, P590, DOI 10.1115/1.1408940; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Srivastava A, 2006, BRAIN INJURY, V20, P1377, DOI 10.1080/02699050601111385; Startzell JK, 2000, J AM GERIATR SOC, V48, P567, DOI 10.1111/j.1532-5415.2000.tb05006.x; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Tinetti M, 1988, NEW ENGL J MED, V319, P927; TOPPER AK, 1993, J AM GERIATR SOC, V41, P479, DOI 10.1111/j.1532-5415.1993.tb01881.x; US Census Bureau, 2008, AM DIS 2005; Verghese J, 2008, ARCH PHYS MED REHAB, V89, P100, DOI 10.1016/j.apmr.2007.08.129; WHO/IASO/IOTF, 2000, AS PAC PERSP RED OB; Yu WY, 2013, ACCIDENT ANAL PREV, V50, P887, DOI 10.1016/j.aap.2012.07.015	49	17	17	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E9	E17		10.1097/HTR.0000000000000093			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300002	25629257				2021-06-18	
J	Jak, AJ; Aupperle, R; Rodgers, CS; Lang, AJ; Schiehser, DM; Norman, SB; Twamley, EW				Jak, Amy J.; Aupperle, Robin; Rodgers, Carie S.; Lang, Ariel J.; Schiehser, Dawn M.; Norman, Sonya B.; Twamley, Elizabeth W.			Evaluation of a hybrid treatment for Veterans with comorbid traumatic brain injury and posttraumatic stress disorder: Study protocol for a randomized controlled trial	CONTEMPORARY CLINICAL TRIALS			English	Article						PTSD; TBI; Cognitive processing therapy; Cognitive rehabilitation; Veterans; Treatment	COGNITIVE-PROCESSING THERAPY; PERSISTENT POSTCONCUSSION SYNDROME; HISTORY; PTSD; REHABILITATION; PERFORMANCE; COMPLAINTS; ADHERENCE; SYMPTOMS; OUTCOMES	Comorbidity of posttraumatic stress disorder (PTSD) and history of traumatic brain injury (TBI) is high among Veterans of Operation Iraqi Freedom/Enduring Freedom/New Dawn (OIF/OEF/OND). Cognitive processing therapy (CPT) is empirically supported for the treatment of PTSD, but it is not specifically designed to accommodate the memory, attention, or problem solving deficits that are experienced by many Veterans with comorbid PTSD and TBI. Compensatory cognitive rehabilitation, including cognitive symptom management and rehabilitation therapy (CogSMART), is effective for cognitive deficits stemming from a variety of etiologies, including TBI. We have integrated components of CogSMART into CPT in order to address the unique challenges faced by Veterans with ongoing cognitive complaints related to PTSD and a history of mild TBI. Here we describe an ongoing randomized controlled trial investigating the efficacy of our novel hybrid treatment, SMART-CPT, as compared to standard CPT, for OIF/OEF/OND Veterans with PTSD and a history of mild to moderate TBI. We describe the development of this hybrid treatment as well as implementation of the randomized controlled trial. Published by Elsevier Inc.	[Jak, Amy J.; Norman, Sonya B.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA; [Jak, Amy J.; Rodgers, Carie S.; Lang, Ariel J.; Schiehser, Dawn M.; Norman, Sonya B.; Twamley, Elizabeth W.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Schiehser, Dawn M.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Jak, Amy J.; Rodgers, Carie S.; Lang, Ariel J.; Schiehser, Dawn M.; Norman, Sonya B.; Twamley, Elizabeth W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Aupperle, Robin] Univ Tulsa, Laureate Inst Brain Res, Tulsa, OK 74104 USA; [Norman, Sonya B.] Natl Ctr PTSD, White River Jct, VT USA	Jak, AJ (corresponding author), 3350 La Jolla Village Dr,151B, San Diego, CA 92161 USA.	ajak@ucsd.edu; raupperle@laureateinstitute.org; cariesodgers@va.gov; ajlang@ucsd.edu; dschiehser@ucsd.edu; snorman@ucsd.edu; etwamley@ucsd.edu	Aupperle, Robin/AAU-8550-2020		U.S. Department of DefenseUnited States Department of Defense [W81XWH-11-1-0641]	Funding was provided by U.S. Department of Defense award W81XWH-11-1-0641.	Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2012, PTSD TRAUMATIC BRAIN; Bryant RA, 2012, PTSD MILD TRAUMATIC; Budget D.C., 2012, VETERANS HLTH ADM TR; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cook JM, 2015, ADM POLICY MENT HLTH, V42, P147, DOI 10.1007/s10488-014-0555-3; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Erbes CR, 2009, PSYCHOL SERV, V6, P175, DOI 10.1037/a0016662; Foa E.B., 2008, EFFECTIVE TREATMENTS; Forbes D, 2012, J ANXIETY DISORD, V26, P442, DOI 10.1016/j.janxdis.2012.01.006; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; GIBBONS RD, 1988, PSYCHOPHARMACOL BULL, V24, P438; Gupta SK, 2011, J PLANT PATHOL MICRO, V2, P2; Heaton RK, 2004, REVISED COMPREHENSIV; Hedeker D., 1999, J EDUC BEHAV STAT, V24, P70, DOI DOI 10.3102/10769986024001070]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; Keane TM, 1997, ANN NY ACAD SCI, V821, P24, DOI 10.1111/j.1749-6632.1997.tb48266.x; Kennedy C M, 2001, CNS Spectr, V6, P787; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lehman A, 1994, TOOLKIT EVALUATING Q; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meyers J., 1995, MEYERS SCORING SYSTE; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Resick PA, 2008, COGNITIVE PROCESSING; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Suris A, 2013, J TRAUMA STRESS, V26, P28, DOI 10.1002/jts.21765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Twamley E. W., 2015, J HEAD TRAU IN PRESS; Twamley E. W., 2014, J HEAD TRAUMA REHABI; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; UDDO M, 1993, J PSYCHOPATHOL BEHAV, V15, P43, DOI 10.1007/BF00964322; VA/DoD, 2010, VA DOD CLIN PRACT GU; Vasterling J., 2005, NEUROPSYCHOLOGY PTSD; Vasterling JJ, 2012, PTSD MILD TRAUMATIC; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Walter KH, 2014, J TRAUMA STRESS, V27, P438, DOI 10.1002/jts.21934; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D, 2008, WAIS 4 ADM SCORING M; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Wisco BE, 2014, J CLIN PSYCHIAT, V75, P1338, DOI 10.4088/JCP.14m09328	63	17	17	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1551-7144	1559-2030		CONTEMP CLIN TRIALS	Contemp. Clin. Trials	NOV	2015	45		B				210	216		10.1016/j.cct.2015.10.009			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	DA4FJ	WOS:000367755200011	26500169	Bronze			2021-06-18	
J	Maiti, TK; Konar, S; Bir, S; Kalakoti, P; Bollam, P; Nanda, A				Maiti, Tanmoy Kumar; Konar, Subhas; Bir, Shyamal; Kalakoti, Piyush; Bollam, Papireddy; Nanda, Anil			Role of apolipoprotein E polymorphism as a prognostic marker in traumatic brain injury and neurodegenerative disease: a critical review	NEUROSURGICAL FOCUS			English	Article						apolipoprotein E; Alzheimer's disease; traumatic brain injury; neurodegenerative disease	AMYOTROPHIC-LATERAL-SCLEROSIS; EPSILON 4 ALLELE; CEREBRAL AMYLOID ANGIOPATHY; ONSET ALZHEIMERS-DISEASE; APOE GENE POLYMORPHISMS; E GENOTYPE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; PROMOTER POLYMORPHISMS	OBJECT The difference in course and outcome of several neurodegenerative conditions and traumatic injuries of the nervous system points toward a possible role of genetic and environmental factors as prognostic markers. Apolipoprotein E (Apo-E), a key player in lipid metabolism, is recognized as one of the most powerful genetic risk factors for dementia and other neurodegenerative diseases. In this article, the current understanding of APOE polymorphism in various neurological disorders is discussed. METHODS The English literature was searched for various studies describing the role of APOE polymorphism as a prognostic marker in neurodegenerative diseases and traumatic brain injury. The wide ethnic distribution of APOE polymorphism was discussed, and the recent meta-analyses of role of APOE polymorphism in multiple diseases were analyzed and summarized in tabular form. RESULTS Results from the review of literature revealed that the distribution of APOE is varied in different ethnic populations. APOE polymorphism plays a significant role in pathogenesis of neurodegeneration, particularly in Alzheimer's disease. APOE epsilon 4 is considered a marker for poor prognosis in various diseases, but APOE epsilon 2 rather than APOE e4 has been associated with cerebral amyloid angiopathy-related bleeding and sporadic Parkinson's disease. The role of APOE polymorphism in various neurological diseases has not been conclusively elucidated. CONCLUSIONS Apo-E is a biomarker for various neurological and systemic diseases. Therefore, while analyzing the role of APOE polymorphism in neurological diseases, the interpretation should be done after adjusting all the confounding factors. A continuous quest to look for associations with various neurological diseases and wide knowledge of available literature are required to improve the understanding of the role of APOE polymorphism in these conditions and identify potential therapeutic targets.	[Maiti, Tanmoy Kumar; Konar, Subhas; Bir, Shyamal; Kalakoti, Piyush; Bollam, Papireddy; Nanda, Anil] LSU Hlth Shreveport, Dept Neurosurg, Shreveport, LA 71130 USA	Nanda, A (corresponding author), LSU Hlth Shreveport, Dept Neurosurg, 1501 Kings Hwy, Shreveport, LA 71130 USA.	ananda@lsuhsc.edu	Kalakoti, Piyush/J-5269-2015	Kalakoti, Piyush/0000-0002-9169-7418			AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AlChalabi A, 1996, LANCET, V347, P159, DOI 10.1016/S0140-6736(96)90343-8; Arendt T, 1997, J NEUROSCI, V17, P516; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Brat DJ, 2001, NEUROPATH APPL NEURO, V27, P197, DOI 10.1046/j.1365-2990.2001.00311.x; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Caselli RJ, 2001, J NEUROL SCI, V189, P93, DOI 10.1016/S0022-510X(01)00577-9; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Egensperger R, 1996, BIOCHEM BIOPH RES CO, V224, P484, DOI 10.1006/bbrc.1996.1053; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Galasko D, 2007, NEUROLOGY, V68, P1772, DOI 10.1212/01.wnl.0000262028.16738.64; Galasko D, 1998, ARCH NEUROL-CHICAGO, V55, P937, DOI 10.1001/archneur.55.7.937; Govone F, 2014, AMYOTROPH LAT SCL FR, V15, P551, DOI 10.3109/21678421.2014.918149; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; HARDY J, 1994, NEUROSCI LETT, V182, P1, DOI 10.1016/0304-3940(94)90190-2; HARRINGTON CR, 1995, NEUROSCI LETT, V183, P35, DOI 10.1016/0304-3940(94)11108-U; Huang XM, 2004, NEUROLOGY, V62, P2198, DOI 10.1212/01.WNL.0000130159.28215.6A; Itzhaki RF, 2004, ANN NY ACAD SCI, V1019, P15, DOI 10.1196/annals.1297.003; Jha A, 2008, J SPINAL CORD MED, V31, P171, DOI 10.1080/10790268.2008.11760708; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kehoe P, 1999, J MED GENET, V36, P108; Kokubo Y, 2000, STROKE, V31, P1299, DOI 10.1161/01.STR.31.6.1299; Lanterna LA, 2005, NEUROLOGY, V64, P1238, DOI 10.1212/01.WNL.0000156523.77347.B4; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Liu Y, 2015, J NEUROL NEUROSUR PS, V86, P127, DOI 10.1136/jnnp-2014-307719; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Mahley RW, 2006, ACTA NEUROL SCAND, V114, P8, DOI 10.1111/j.1600-0404.2006.00679.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; McCarron MO, 1999, STROKE, V30, P1643, DOI 10.1161/01.STR.30.8.1643; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Morris CM, 1996, J NEURAL TRANSM-SUPP, P205; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Niino M, 2003, MULT SCLER J, V9, P382, DOI 10.1191/1352458503ms934oa; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Poirier J, 1999, MOL DIAGN, V4, P335, DOI 10.1016/S1084-8592(99)80010-1; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Praline J, 2011, EUR J NEUROL, V18, P1046, DOI 10.1111/j.1468-1331.2010.03330.x; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Sadigh-Eteghad S, 2012, NEUROSCIENCES, V17, P321; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; Savettieri G, 2003, J NEUROL, V250, P1094, DOI 10.1007/s00415-003-0163-8; Schilling S, 2013, NEUROLOGY, V81, P292, DOI 10.1212/WNL.0b013e31829bfda4; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schurhoff F, 2003, AM J MED GENET B, V119B, P18, DOI 10.1002/ajmg.b.20007; Seet WT, 2004, CLIN CHIM ACTA, V340, P201, DOI 10.1016/j.cccn.2003.11.001; Setzer M, 2008, SPINE, V33, P497, DOI 10.1097/BRS.0b013e3181657cf7; Setzer M, 2009, J NEUROSURG-SPINE, V11, P659, DOI 10.3171/2009.7.SPINE08667; Siddique T, 1998, NEUROGENETICS, V1, P213, DOI 10.1007/s100480050031; SIEST G, 1995, CLIN CHEM, V41, P1068; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sudlow C, 2006, STROKE, V37, P364, DOI 10.1161/01.STR.0000199065.12908.62; Takeda M, 2010, PSYCHIAT CLIN NEUROS, V64, P592, DOI 10.1111/j.1440-1819.2010.02148.x; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Tsuzuki S, 1998, Rinsho Byori, V46, P829; Verpillat P, 2002, EUR J HUM GENET, V10, P399, DOI 10.1038/sj.ejhg.5200820; WARING SC, 1994, LANCET, V343, P611, DOI 10.1016/S0140-6736(94)91568-7; Wei YF, 2014, J CLIN NEUROSCI, V21, P390, DOI 10.1016/j.jocn.2013.07.019; WEST HL, 1994, NEUROSCI LETT, V175, P46, DOI 10.1016/0304-3940(94)91074-X; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; Xin XY, 2010, J ALZHEIMERS DIS, V19, P1283, DOI 10.3233/JAD-2010-1329; YAMANOUCHI Y, 1994, JPN J HUM GENET, V39, P315, DOI 10.1007/BF01874050; Yang DS, 1997, J NEUROCHEM, V68, P721; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zetterberg H, 2008, J NEUROL SCI, V273, P67, DOI 10.1016/j.jns.2008.06.025; Zhang RJ, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-47; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	87	17	17	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2015	39	5							E3	10.3171/2015.8.FOCUS15329			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CV8DM	WOS:000364508000003	26646927	Bronze			2021-06-18	
J	Sviri, GE				Sviri, Gill E.			Massive cerebral swelling immediately after cranioplasty, a fatal and unpredictable complication: report of 4 cases	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; traumatic brain injury; decompressive craniectomy; complication; cerebral edema; death	DEATH FOLLOWING CRANIOPLASTY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY	Cranioplasty after decompressive craniectomy (DC) is associated with increased morbidity, but the reported mortality rate is low. Recently, some authors have reported a rare unexplained complication of sudden death in association with massive cerebral edema immediately after cranioplasty. The author reports on 4 patients who underwent cranioplasty after DC between January 2005 and August 2010 at his department and died because of massive cerebral edema immediately after uneventful surgery and anesthesia. All 4 of the new cases reported involved young male patients who underwent decompressive hemicraniectomy after traumatic brain injury. They developed massive cerebral swelling immediately after uneventful cranioplasty (3 patients) or after removal of an epidural hematoma several hours after surgery (1 patient). All 4 patients had a large skull defect and significantly sunken craniotomy site, and all were treated with a closed vacuum suction system that was placed under the scalp and kept open at the end of the cranioplasty procedure. After surgery, the patients' pupils became fixed and dilated, and brain CT scans showed massive brain edema. Despite emergency DC, the patients did not recover, and all 4 died. A MEDLINE search showed 8 similar cases that were reported previously. Fatal cerebral swelling after uneventful cranioplasty is a distinct clinical entity, although it is unpredictable. It is postulated that a negative pressure difference from the elimination of atmospheric pressure that had been chronically applied on the injured sinking brain in combination with the negative pressure applied by the closed subgaleal suction drain may lead to a massive brain shift toward the cranioplasty site and initiate a fatal vasomotor reaction.	[Sviri, Gill E.] Rambam Maimonides Med Ctr, Dept Neurosurg, Haifa, Israel	Sviri, GE (corresponding author), Dept Neurosurg, Rambam Maimonides Hlth Care Campus, Haifa, Israel.	g_sviri@rambam.health.gov.il					Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chitale R, 2013, NEUROLOGIST, V19, P17, DOI 10.1097/NRL.0b013e31827c6bb6; Eom KS, 2010, CLIN NEUROL NEUROSUR, V112, P336, DOI 10.1016/j.clineuro.2009.10.010; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Mukherjee S, 2014, ACTA NEUROCHIR, V156, P989, DOI 10.1007/s00701-014-2024-x; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Santana-Cabrera Luciano, 2012, Int J Crit Illn Inj Sci, V2, P107, DOI 10.4103/2229-5151.97277; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Van Roost D, 2003, NEUROSURGERY, V53, P1315, DOI 10.1227/01.NEU.0000093498.08913.9E; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	12	17	17	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1188	1193		10.3171/2014.11.JNS141152			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800012	26090828	Bronze			2021-06-18	
J	Wang, HH; Wang, XK; Qu, J; Yue, Q; Hu, YN; Zhang, HX				Wang, Huihui; Wang, Xingkai; Qu, Jing; Yue, Qing; Hu, Ya'nan; Zhang, Huanxiang			VEGF Enhances the Migration of MSCs in Neural Differentiation by Regulating Focal Adhesion Turnover	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							MESENCHYMAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; FUNCTIONAL RECOVERY; TYROSINE KINASE; STROKE RATS; BETA-PIX; PHOSPHORYLATION; ACTIN	Mesenchymal stem cells (MSCs) hold great promise in neural regeneration, due to their intrinsic neuronal potential and migratory tropism to damaged nervous tissues. However, the chemotactic signals mediating the migration of MSCs remain poorly understood. Here, we investigated the regulatory roles for focal adhesion kinase (FAK) and Rac1 in vascular endothelial growth factor (VEGF)-stimulated migration of MSCs in neural differentiation. We found that MSCs in various differentiation states show significant different chemotactic responses to VEGF and cells in 24-h preinduction state possess the highest migration speed and efficiency. FAK, as the downstream signaling molecule, is involved in the VEGF-induced migration by regulating the assembly and distribution of focal adhesions (FAs) and reorganization of F-actin. The features of FAs and cytoskeletons and the ability of lamellipodia formation are closely related to the neural differentiation states of MSCs. VEGF promotes FA formation with an asymmetric distribution of FAs and induces the activation of Y397-FAK and Y31/118-paxillin of undifferentiated and 24-h preinduced MSCs in a time-dependent manner. Inhibition of FAK by PF-228 or expressing FAK-Y397F mutant impairs the dynamics of FAs in MSCs during VEGF-induced migration. Furthermore, Rac1 regulates FA formation in a FAK-dependent manner. Overexpression of constitutive activated mutants of Rac1 increases the number of FAs in undifferentiated and 24-h preinduced MSCs, while VEGF-induced increase of FA formation is decreased by inhibiting FAK by PF-228. Collectively, these results demonstrate that FAK and Rac1 signalings coordinately regulate the dynamics of FAs during VEGF-induced migration of MSCs in varying neural differentiation states. J. Cell. Physiol. 9999: 2728-2742, 2015. (c) 2015 Wiley Periodicals, Inc.	[Wang, Huihui; Wang, Xingkai; Qu, Jing; Yue, Qing; Hu, Ya'nan; Zhang, Huanxiang] Soochow Univ, Coll Med, Jiangsu Key Lab Stem Cell Res, Dept Cell Biol, Suzhou 215123, Peoples R China	Zhang, HX (corresponding author), Soochow Univ, Coll Med, Jiangsu Key Lab Stem Cell Res, Dept Cell Biol, Ren Ai Rd 199,Suzhou Ind Pk, Suzhou 215123, Peoples R China.	hzhang@suda.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31371407, 31071220]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20141198]	Contract grant sponsor: National Natural Science Foundation of China;; Contract grant numbers: 31371407, 31071220.; Contract grant sponsor: Natural Science Foundation of Jiangsu Province;; Contract grant number: BK20141198.	Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212; Angelucci A, 2007, CURR PHARM DESIGN, V13, P2129; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; Bae KS, 2011, YONSEI MED J, V52, P401, DOI 10.3349/ymj.2011.52.3.401; Berginski ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022025; Birnbaum T, 2007, J NEURO-ONCOL, V83, P241, DOI 10.1007/s11060-007-9332-4; Chang FM, 2007, MOL BIOL CELL, V18, P253, DOI 10.1091/mbc.E06-03-0207; Choi CK, 2011, BIOPHYS J, V100, P583, DOI 10.1016/j.bpj.2010.12.3719; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Doucette T, 2011, NEOPLASIA, V13, P716, DOI 10.1593/neo.101680; Glavaski-Joksimovic A, 2013, EXP NEUROL, V247, P25, DOI 10.1016/j.expneurol.2013.03.016; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hayakawa K, 2011, J NEUROSCI, V31, P10666, DOI 10.1523/JNEUROSCI.1944-11.2011; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Kao AP, 2011, FERTIL STERIL, V95, P1308, DOI 10.1016/j.fertnstert.2010.09.064; Kawakami K, 2001, J CELL SCI, V114, P3125; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028; Liao WX, 2010, ENDOCRINOLOGY, V151, P3432, DOI 10.1210/en.2009-1305; Lyu JY, 2013, J CELL BIOCHEM, V114, P1744, DOI 10.1002/jcb.24517; Matsuura S, 2011, J HISTOCHEM CYTOCHEM, V59, P864, DOI 10.1369/0022155411413929; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Nethe M, 2010, J CELL SCI, V123, P1948, DOI 10.1242/jcs.062919; Oh JY, 2012, MOL THER, V20, P2143, DOI 10.1038/mt.2012.165; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Pullar CE, 2006, MOL BIOL CELL, V17, P4925, DOI 10.1091/mbc.E06-05-0433; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Romanova LY, 2004, J CELL SCI, V117, P3759, DOI 10.1242/jcs.01206; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Schichor C, 2006, EXP NEUROL, V199, P301, DOI 10.1016/j.expneurol.2005.11.027; Shyu WC, 2007, STROKE, V38, P367, DOI 10.1161/01.STR.0000254463.24655.14; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005-0636; Uccelli A, 2011, CURR STEM CELL RES T, V6, P69, DOI 10.2174/157488811794480744; van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb SE, 1996, J CELL SCI, V109, P793; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xu XY, 2011, CELL TRANSPLANT, V20, P1065, DOI 10.3727/096368910X544906; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zheng B, 2013, J CELL PHYSIOL, V228, P149, DOI 10.1002/jcp.24114; Zhu XH, 2013, GASTRIC CANCER, V16, P155, DOI 10.1007/s10120-012-0166-1; ZICHA D, 1991, J CELL SCI, V99, P769	56	17	18	0	26	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	NOV	2015	230	11					2728	2742		10.1002/jcp.24997			15	Cell Biology; Physiology	Cell Biology; Physiology	CN8LS	WOS:000358692700017	25820249				2021-06-18	
J	Magou, GC; Pfister, BJ; Berlin, JR				Magou, George C.; Pfister, Bryan J.; Berlin, Joshua R.			Effect of acute stretch injury on action potential and network activity of rat neocortical neurons in culture	BRAIN RESEARCH			English	Article						Traumatic brain injury; Hyperexcitability; Hypoexcitability; Action potential; Bursting activity; Current clamp technique	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; IN-VITRO MODEL; MECHANICAL INJURY; CORTICAL-NEURONS; EARLY SEIZURES; CALCIUM; HYPEREXCITABILITY; TETRODOTOXIN; EXCITABILITY	The basis for acute seizures following traumatic brain injury (TBI) remains unclear. Animal models of TBI have revealed acute hyperexcitablility in cortical neurons that could underlie seizure activity, but studying initiating events causing hyperexcitability is difficult in these models. In vitro models of stretch injury with cultured cortical neurons, a surrogate for TBI, allow facile investigation of cellular changes after injury but they have only demonstrated post-injury hypoexcitability. The goal of this study was to determine if neuronal hyperexcitability could be triggered by in vitro stretch injury. Controlled uniaxial stretch injury was delivered to a spatially delimited region of a spontaneously active network of cultured rat cortical neurons, yielding a region of stretch-injured neurons and adjacent regions of non-stretched neurons that did not directly experience stretch injury. Spontaneous electrical activity was measured in non-stretched and stretch-injured neurons, and in control neuronal networks not subjected to stretch injury. Non-stretched neurons in stretch-injured cultures displayed a three-fold increase in action potential firing rate and bursting activity 30-60 min post-injury. Stretch-injured neurons, however, displayed dramatically lower rates of action potential firing and bursting. These results demonstrate that acute hyperexcitability can be observed in non-stretched neurons located in regions adjacent to the site of stretch injury, consistent with reports that seizure activity can arise from regions surrounding the site of localized brain injury. Thus, this in vitro procedure for localized neuronal stretch injury may provide a model to study the earliest cellular changes in neuronal function associated with acute post-traumatic seizures. (c) 2015 Published by Elsevier B.V.	[Magou, George C.; Pfister, Bryan J.] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med, Newark, NJ 07102 USA; [Magou, George C.; Berlin, Joshua R.] Rutgers State Univ, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07102 USA	Pfister, BJ (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med, Newark, NJ 07102 USA.	pfister@njit.edu			New Jersey Commission on Brain Injury Research [CBIR11PJT003]	The authors wish to thank Dr. Farzan Nadim for advice on analysis of spontaneous network activity, and Dr. Vijayalakshmi Santhakumar for technical advice and comments on the manuscript. Funding was provided by the New Jersey Commission on Brain Injury Research (CBIR11PJT003).	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Aungst S, 2013, J NEUROPHYSIOL, V109, P813, DOI 10.1152/jn.00869.2012; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; DeLima AD, 1997, J COMP NEUROL, V388, P526; Faul F., 2010, TRAUMATIC BRAIN INJU; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Gurkoff GG, 2012, EPILEPSIA, V53, P53, DOI 10.1111/j.1528-1167.2012.03475.x; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Lea PM, 2003, J NEUROTRAUM, V20, P1233, DOI 10.1089/089771503770802907; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Magou GC, 2011, J NEUROTRAUM, V28, P2203, DOI 10.1089/neu.2010.1596; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Patel TP, 2014, J NEUROSCI, V34, P4200, DOI 10.1523/JNEUROSCI.4172-13.2014; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prince DA, 2012, JASPERS BASIC MECH E; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Shahlaie K, 2010, J NEUROTRAUM, V27, P175, DOI 10.1089/neu.2009.1003; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STICHEL CC, 1991, DEV BRAIN RES, V64, P145, DOI 10.1016/0165-3806(91)90218-8; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wang WW, 2008, GLIA, V56, P241, DOI 10.1002/glia.20609; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	48	17	17	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 22	2015	1624						525	535		10.1016/j.brainres.2015.07.056			11	Neurosciences	Neurosciences & Neurology	CW5PY	WOS:000365050100053	26296661				2021-06-18	
J	Doulames, VM; Vilcans, M; Lee, S; Shea, TB				Doulames, Vanessa M.; Vilcans, Meghan; Lee, Sangmook; Shea, Thomas B.			Social interaction attenuates the extent of secondary neuronal damage following closed head injury in mice	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						Traumatic Brain Injury; neurodegeneration; cognitive impairment; oxidative damage; socialization; secondary injury	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; RISK-FACTOR; ENVIRONMENTAL ENRICHMENT; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; COGNITIVE DECLINE; AMYLOID-BETA	Recovery following Traumatic Brain Injury (TBI) can vary tremendously among individuals. Lifestyle following injury, including differential social interactions, may modulate the extent of secondary injury following TBI. To examine this possibility under controlled conditions, closed head injury (CHI) was induced in C57BI6 mice using a standardized weight drop device after which mice were either housed in isolation or with their original cagemates ("socially housed") for 4 weeks. CHI transiently impaired novel object recognition (NOR) in both isolated and social mice, confirming physical and functional injury. By contrast, Y maze navigation was impaired in isolated but not social mice at 1-4 weeks post CHI. CHI increased excitotoxic signaling in hippocampal slices from all mice, which was transiently exacerbated by isolation at 2 weeks post CHI. CHI slightly increased reactive oxygen species and did not alter levels of amyloid beta (Abeta), total or phosphotau, total or phosphorylated neurofilaments. CHI increased serum corticosterone in both groups, which was exacerbated by isolation. These findings support the hypothesis that socialization may attenuate secondary damage following TBI. In addition, a dominance hierarchy was noted among socially-housed mice, in which the most submissive mouse displayed indices of stress in the above analyses that were statistically identical to those observed for isolated mice. This latter finding underscores that the nature and extent of social interaction may need to vary among individuals to provide therapeutic benefit.	[Doulames, Vanessa M.; Vilcans, Meghan; Lee, Sangmook; Shea, Thomas B.] UMass Lowell, Ctr Neurobiol & Neurodegenerat Res, Lowell, MA 01854 USA; [Doulames, Vanessa M.; Shea, Thomas B.] Univ Massachusetts, Biomed & Biotechnol Program, Lowell, MA USA; [Vilcans, Meghan; Lee, Sangmook; Shea, Thomas B.] Univ Massachusetts, Dept Biol Sci, Lowell, MA USA	Shea, TB (corresponding author), UMass Lowell, Ctr Neurobiol & Neurodegenerat Res, Lowell, MA 01854 USA.	Thomas_shea@uml.edu	Doulames, Vanessa/AAG-8828-2021		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH091147, R21 MH086805] Funding Source: Medline		Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bowen A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007039.pub2; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Cacioppo JT, 2009, TRENDS COGN SCI, V13, P447, DOI 10.1016/j.tics.2009.06.005; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Daulatzai MA, 2013, NEUROTOX RES, V24, P216, DOI 10.1007/s12640-013-9379-2; Doulames V, 2014, INT J NEUROSCI, V124, P369, DOI 10.3109/00207454.2013.848441; Eluvathingal TJ, 2006, PEDIATRICS, V117, P2093, DOI 10.1542/peds.2005-1727; Ertel KA, 2008, AM J PUBLIC HEALTH, V98, P1215, DOI 10.2105/AJPH.2007.113654; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gilbert Frederic, 2011, AM J BIOTH NEUROSCI, p[48, 54], DOI DOI 10.1080/21507740.2011.611125; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Hellweg S, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/768456; Huang HJ, 2011, BRAIN RES, V1371, P150, DOI 10.1016/j.brainres.2010.11.043; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Huong NTT, 2005, BIOL PHARM BULL, V28, P1389, DOI 10.1248/bpb.28.1389; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lee S, 2012, J ALZHEIMERS DIS, V28, P497, DOI 10.3233/JAD-2011-111562; LEVINE S, 1964, ENDOCRINOLOGY, V75, P142, DOI 10.1210/endo-75-1-142; LOUCH CD, 1967, GEN COMP ENDOCR, V8, P441, DOI 10.1016/S0016-6480(67)80006-6; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer MJ, 2010, BRAIN INJURY, V24, P694, DOI 10.3109/02699051003692118; Miura H, 2002, SYNAPSE, V46, P116, DOI 10.1002/syn.10133; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Moller M, 2011, EUR NEUROPSYCHOPHARM, V21, P471, DOI 10.1016/j.euroneuro.2010.09.006; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NELSON W, 1975, J NUTR, V105, P171; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAVLIDES C, 1993, HIPPOCAMPUS, V3, P183, DOI 10.1002/hipo.450030210; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Salim S, 2011, BRAIN RES, V1404, P63, DOI 10.1016/j.brainres.2011.06.024; Sapolsky R.M., 2011, COMPR PHYSL, P517, DOI [DOI 10.1002/CPHY.CP070423, 10.1002/cphy.cp070423.]; Sapolsky RM, 1997, ARCH GEN PSYCHIAT, V54, P1137; Sapolsky RM, 2005, SCIENCE, V308, P648, DOI 10.1126/science.1106477; SAPOLSKY RM, 1992, PSYCHONEUROENDOCRINO, V17, P701, DOI 10.1016/0306-4530(92)90029-7; SCHUHR B, 1987, PHYSIOL BEHAV, V40, P689, DOI 10.1016/0031-9384(87)90269-1; Serra M, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/2/026009; Shea TB, 2014, DIET NUTR DEMENTIA C, P837; Shea TB, 2014, J ALZHEIMERS DIS, V41, P667, DOI 10.3233/JAD-132675; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van der Ploeg ES, 2013, INT PSYCHOGERIATR, V25, P565, DOI 10.1017/S1041610212002128; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YARNELL PR, 1970, LANCET, V1, P863; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zemianek JM, 2013, INT J DEV NEUROSCI, V31, P308, DOI 10.1016/j.ijdevneu.2013.03.011; Zemianek JM, 2013, INT J DEV NEUROSCI, V31, P131, DOI 10.1016/j.ijdevneu.2012.11.003; Zemianek JM, 2012, INT J DEV NEUROSCI, V30, P602, DOI 10.1016/j.ijdevneu.2012.08.001; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	72	17	17	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	OCT 15	2015	9								275	10.3389/fnbeh.2015.00275			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CT5GT	WOS:000362837700001	26834596	DOAJ Gold, Green Published			2021-06-18	
J	Hernandez, F; Shull, PB; Camarillo, DB				Hernandez, Fidel; Shull, Peter B.; Camarillo, David B.			Evaluation of a laboratory model of human head impact biomechanics	JOURNAL OF BIOMECHANICS			English	Article						Mild traumatic brain injury (mTBI); Six degree of freedom (6DOF) kinematics; Twin-wire drop testing; Head impact model; Rotational acceleration and velocity	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; HIGH-SCHOOL; CEREBRAL CONCUSSION; FOOTBALL PLAYERS; ACCELERATION; PERFORMANCE; KINEMATICS; FORM	This work describes methodology for evaluating laboratory models of head impact biomechanics. Using this methodology, we investigated: how closely does twin-wire drop testing model head rotation in American football impacts? Head rotation is believed to cause mild traumatic brain injury (mTBI) but helmet safety standards only model head translations believed to cause severe TBI. It is unknown whether laboratory head impact models in safety standards, like twin-wire drop testing, reproduce six degree-of-freedom (6DOF) head impact biomechanics that may cause mTBI. We compared 6DOF measurements of 421 American football head impacts to twin-wire drop tests at impact sites and velocities weighted to represent typical field exposure. The highest rotational velocities produced by drop testing were the 74th percentile of non-injury field impacts. For a given translational acceleration level, drop testing underestimated field rotational acceleration by 46% and rotational velocity by 72%. Primary rotational acceleration frequencies were much larger in drop tests (similar to 100 Hz) than field impacts (similar to 10 Hz). Drop testing was physically unable to produce acceleration directions common in field impacts. Initial conditions of a single field impact were highly resolved in stereo high-speed video and reconstructed in a drop test. Reconstruction results reflected aggregate trends of lower amplitude rotational velocity and higher frequency rotational acceleration in drop testing, apparently due to twin-wire constraints and the absence of a neck. These results suggest twin-wire drop testing is limited in modeling head rotation during impact, and motivate continued evaluation of head impact models to ensure helmets are tested under conditions that may cause mTBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Hernandez, Fidel; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Shull, Peter B.; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Shull, Peter B.] Shanghai Jiao Tong Univ, Sch Mech Engn, State Key Lab Mech Syst & Vibrat, Shanghai 200240, Peoples R China	Camarillo, DB (corresponding author), Stanford Univ, Dept Bioengn, 443 Via Ortega,Room 205, Stanford, CA 94305 USA.	dcamarillo@stanford.edu		Hernandez, Fidel/0000-0002-6078-0518	National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; NIH Clinical and Translational Science AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1 RR025744]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB017611] Funding Source: NIH RePORTER	We thank the Stanford Department of Athletics (Palo Alto, CA) for enabling this research, notably Scott Anderson, Director of Athletic Training, and Mike Gleeson, Video Director. We thank Rebecca Shultz and James Mattson for collecting high speed video data. We thank X2 Biosystems (Seattle, WA) for sharing mouthguard architecture and the twin-wire system. The study was supported by the National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, David and Lucile Packard Foundation 38454, and by the NIH Clinical and Translational Science Award 1UL1 RR025744 for the Stanford Center for Clinical and Translational Education and Research (Spectrum).	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bartsch A., 2013, P SPIE SENS TECHNOL, V8723, P1; Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cantu R, 2012, J NEUROSURG, V117, P187, DOI 10.3171/2011.12.JNS112108; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Forbes JA, 2013, PEDIATR NEUROSURG, V49, P43, DOI 10.1159/000355121; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Heikkila J, 1997, PROC CVPR IEEE, P1106, DOI 10.1109/CVPR.1997.609468; Hernandez E, 2013, P 2013 ASME SUMM BIO, P1; Hernandez F., 2014, ANN BIOMED ENG, V43, P1; Holbourn AHS, 1943, LANCET, V2, P438; HORN BKP, 1988, J OPT SOC AM A, V5, P1127, DOI 10.1364/JOSAA.5.001127; Ji S., 2014, ANN BIOMED ENG, P1; Johnson JR, 2014, SPACE SCI REV, V184, P1, DOI 10.1007/s11214-014-0085-z; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; King AI, 2012, ANN BIOMED ENG, V40, P2510, DOI 10.1007/s10439-012-0659-4; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; National Committee on Standards for Athletic Equipment, 2006, 08104M04 NOCSAE DOC, P1; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2012, ND00111M12 NOCSAE, P1; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson B., 2015, ANN BIOMED IN PRESS, P1; Rowson S, 2013, J NEUROSURG, V119, P805, DOI 10.3171/2013.3.JNS121735; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhengyou Zhang, 1999, Proceedings of the Seventh IEEE International Conference on Computer Vision, P666, DOI 10.1109/ICCV.1999.791289	56	17	18	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2015	48	12					3469	3477		10.1016/j.jbiomech.2015.05.034			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CT8ME	WOS:000363069900073	26117075	Green Accepted			2021-06-18	
J	Kriz, PK; Zurakowski, RD; Almquist, JL; Reynolds, J; Ruggieri, D; Collins, CL; d'Hemecourt, PA; Comstock, RD				Kriz, Peter K.; Zurakowski, R. David; Almquist, Jon L.; Reynolds, John; Ruggieri, Danielle; Collins, Christy L.; d'Hemecourt, Pierre A.; Comstock, R. Dawn			Eye Protection and Risk of Eye Injuries in High School Field Hockey	PEDIATRICS			English	Article							LACROSSE; EYEWEAR; HEAD; FACE	OBJECTIVE: To determine if injury rates among female field hockey players differ before and after implementation of a national mandate for protective eyewear (MPE). METHODS: We analyzed girls' field hockey exposure and injury data collected from national (High School Reporting Information Online [RIO]) and regional (Fairfax County Public Schools) high school sports injury databases in 2 seasons before (2009/10 and 2010/11) and 2 seasons after (2011/12 and 2012/13) a national MPE. RESULTS: The incidence of eye/orbital injuries was significantly higher in states without MPE (0.080 injuries per 1000 athletic exposures [AEs]) than in states with MPE (before the 2011/12 mandate) and the postmandate group (0.025 injuries per 1000 AEs) (odds ratio 3.20, 95% confidence interval 1.47-6.99, P = .003). There was no significant difference in concussion rates for the 2 groups (odds ratio 0.77, 95% confidence interval 0.58-1.02, P = .068). After the 2011/12 MPE, severe eye/orbital injuries (time loss >21 days) were reduced by 67%, and severe/medical disqualification head/face injuries were reduced by 70%. Concussion rates for field hockey (0.335 per 1000 AEs) rank third among girls' sports included in the High School RIO surveillance program. CONCLUSIONS: Among female high school field hockey players, MPE is associated with a reduced incidence of eye/orbital injuries and fewer severe eye/orbital and head/face injuries. Concussion rates did not change as a result of the national MPE. Concussion remains the most common injury involving the head and face among female field hockey players, prompting further inquiry into potential effects of adopting protective headgear/helmets.	[Kriz, Peter K.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Sports Med,Dept Orthoped,Hasbro Childrens Hos, Providence, RI 02903 USA; [Kriz, Peter K.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Sports Med,Dept Pediat,Hasbro Childrens Hosp, Providence, RI 02903 USA; [Zurakowski, R. David] Harvard Univ, Sch Med, Dept Anesthesia, Boston Childrens Hosp, Boston, MA 02115 USA; [Zurakowski, R. David] Harvard Univ, Sch Med, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA; [d'Hemecourt, Pierre A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Almquist, Jon L.; Reynolds, John] Fairfax Cty Publ Sch, Falls Church, VA USA; [Ruggieri, Danielle] Providence Coll, Providence, RI 02918 USA; [Collins, Christy L.] OhioHlth Res & Innovat Inst, Columbus, OH USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Aurora, CO USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Aurora, CO USA	Kriz, PK (corresponding author), 2 Dudley St,Ste 200, Providence, RI 02905 USA.	peter_kriz@brown.edu			Prevent Blindness America grant [701-5215]; Centers for Disease Control and Prevention grantUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001172-01]; National Operating Committee on Standards for Athletic Equipment; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172] Funding Source: NIH RePORTER	Funded in part by Prevent Blindness America grant 701-5215 and Centers for Disease Control and Prevention grant R49/CE001172-01. The authors also acknowledge the generous research funding contributions of the National Operating Committee on Standards for Athletic Equipment.	American Medical Society for Sports Medicine, 2014, SPORTS MED FELL US C; Dick R, 2007, J ATHL TRAINING, V42, P211; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; ELLIOTT AJ, 1984, BRIT MED J, V289, P21, DOI 10.1136/bmj.289.6436.21-a; Field Hockey NCAA, NCAA FIELD HOCK RUL; Field Hockey USA, US WOM NAT TEAM ROST; Hendrickson CD, 2008, CLIN J SPORT MED, V18, P399, DOI 10.1097/JSM.0b013e318188b89d; Kriz PK, 2012, PEDIATRICS, V130, P1069, DOI 10.1542/peds.2012-1492; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2012, AM J SPORT MED, V40, P611, DOI 10.1177/0363546511428873; Loh S, GOING DEEP OPINIONS; McCullagh P., 1989, GEN LINEAR MODELS, P193, DOI DOI 10.1007/978-1-4899-3242-6; Micieli JA, 2014, CAN J OPHTHALMOL, V49, P243, DOI 10.1016/j.jcjo.2014.03.008; Micieli R, 2014, OPEN ACCESS J SPORTS, V5, P43, DOI 10.2147/OAJSM.S61010; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; National Collegiate Athletic Association, 1981 82 2012 13 NCAA; National Federation of State High School Associations, PART STAT; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091	19	17	17	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2015	136	3					521	527		10.1542/peds.2015-0216			7	Pediatrics	Pediatrics	CQ6IN	WOS:000360708100040	26283783	Bronze			2021-06-18	
J	McIntosh, AS; Patton, DA				McIntosh, Andrew S.; Patton, Declan A.			Boxing headguard performance in punch machine tests	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL; HEAD IMPACTS; CONCUSSION; BIOMECHANICS; INJURY; FACE	Background The paper presents a novel laboratory method for assessing boxing headguard impact performance. The method is applied to examine the effects of headguards on head impact dynamics and injury risk. Methods A linear impactor was developed, and a range of impacts was delivered to an instrumented Hybrid III head and neck system both with and without an AIBA (Association Internationale de Boxe Amateur)approved headguard. Impacts at selected speeds between 4.1 and 8.3 m/s were undertaken. The impactor mass was approximately 4 kg and an interface comprising a semirigid 'fist' with a glove was used. Results The peak contact forces were in the range 1.9-5.9 kN. Differences in head impact responses between the Top Ten AIBA-approved headguard and bare headform in the lateral and forehead tests were large and/or significant. In the 8.3 m/s fist-glove impacts, the mean peak resultant headform accelerations for bare headform tests was approximately 130 g compared with approximately 85 g in the forehead impacts. In the 6.85 m/s bare headform impacts, mean peak resultant angular head accelerations were in the range of 5200-5600 rad/s(2) and almost halved by the headguard. Linear and angular accelerations in 45 degrees forehead and 60 degrees jaw impacts were reduced by the headguard. Conclusions The data support the opinion that current AIBA headguards can play an important role in reducing the risk of concussion and superficial injury in boxing competition and training.	[McIntosh, Andrew S.; Patton, Declan A.] Federat Univ Australia, ACRISP, Ballarat, Vic 3353, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res, Sydney, NSW, Australia	McIntosh, AS (corresponding author), Federat Univ Australia, ACRISP, POB 663, Ballarat, Vic 3353, Australia.	as.mcintosh@bigpond.com			IOC	The authors would like to thank the IOC for funding these projects, in particular Dr Torbjorn Soligard, who has been our point of contact; Cherine Fahmy and Professor Lars Engebretsen; RMS Crashlab staff, in particular-Drew Sherry, Colin Jackson, David Corless and Bruce Parker; and David Felice from Zoe's martial arts and boxing supplies in Sydney. Their assistance is gratefully acknowledged.	AIBA, 2013, AIBA OP BOX AOB COMP; Amateur International Boxing Association, 2013, REM HEADG EL MEN COM; American Society for Testing and Materials, 2012, F239709 ASTM; American Society for Testing and Materials, 2011, F144608 ASTM; Bartsch A, 2012, ACCIDENT ANAL PREV, V48, P285, DOI 10.1016/j.aap.2012.01.032; Bartsch AJ, 2012, J NEUROSURG, V116, P1070, DOI 10.3171/2011.12.JNS111478; Dau N, 2006, AM SOC BIOM ANN M BL; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; McIntosh AS, 2015, BRIT J SPORT MED, V49, P1113, DOI 10.1136/bjsports-2015-095093; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; Nyquist GW, 1986, 30TH P STAPP CAR CRA, V30, P379; O'Sullivan DM, 2013, BRIT J SPORT MED, V47, P447, DOI 10.1136/bjsports-2012-091416; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pierce JD, 2006, J QUANT ANAL SPORTS, V2, DOI [10.2202/1559-0410.1030, 10.2202/1559-0410.1004]; PLANATH I, 1991, ACCIDENT ANAL PREV, V23, P95, DOI 10.1016/0001-4575(91)90039-8; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SAE International, 1995, INSTR IMP TEST 1; Schneider DC, 1972, P 16 STAPP CAR CRASH, P186; Smith MS, 2006, J SPORT SCI MED, V5, P74; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; UNTERHARNSCHEID.FJ, 1970, MED SPORT, V10, P111; Unterharnscheidt F, 2003, IMPACT MECH NEUROPAT, P1; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Yoganandan N, 1988, 32 STAPP CAR CRASH C, P45; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	29	17	17	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2015	49	17					1108	1112		10.1136/bjsports-2015-095094			5	Sport Sciences	Sport Sciences	CP3AW	WOS:000359750200005	26175022	Bronze			2021-06-18	
J	Raj, SP; Antonini, TN; Oberjohn, KS; Cassedy, A; Makoroff, KL; Wade, SL				Raj, Stacey P.; Antonini, Tanya N.; Oberjohn, Karen S.; Cassedy, Amy; Makoroff, Kathi L.; Wade, Shari L.			Web-Based Parenting Skills Program for Pediatric Traumatic Brain Injury Reduces Psychological Distress Among Lower-Income Parents	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed head injury; parent-child relations; pediatrics; psychological well-being; socioeconomic factors; treatment outcomes	CHILD INTERACTION THERAPY; FAMILY OUTCOMES; INITIAL YEAR; BURDEN; INTERVENTIONS; ADAPTATION; PREDICTORS; EFFICACY	Objective: To examine changes in parent depression, psychological distress, parenting stress, and self-efficacy among participants in a randomized trial of a Web-based parent training program for pediatric traumatic brain injury (TBI). Methods: Primary caregivers of 37 children aged 3 to 9 years who sustained a moderate/complicated mild to severe TBI were randomly assigned to the intervention or control group, and both groups were equipped with home Internet access. The online parent training program was designed to increase positive parenting skills and improve caregiver stress management. It consisted of 10 core sessions and up to 4 supplemental sessions. Each session included self-guided Web content, followed by a videoconference call with a therapist to discuss content and practice parenting skills with live feedback. Families in the control group received links to TBI Web resources. Results: Parent income moderated treatment effects on parent functioning. Specifically, lower-income parents in the parenting skills group reported significant reductions in psychological distress compared with lower-income parents in the control group. No differences were found among higher-income parents for depression, parenting stress, or caregiver efficacy. Conclusions: Parent training interventions post-TBI may be particularly valuable for lower-income parents who are vulnerable to both environmental and injury-related stresses.	[Raj, Stacey P.; Antonini, Tanya N.; Oberjohn, Karen S.; Cassedy, Amy; Makoroff, Kathi L.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,ML 4009, Cincinnati, OH 45229 USA; [Raj, Stacey P.] Miami Univ, Dept Psychol, Oxford, OH 45056 USA; [Antonini, Tanya N.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,ML 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			National Institute on Disability and Rehabilitation Research, Department of Education [H133G060167, H133B090010]	This work was supported by the National Institute on Disability and Rehabilitation Research, Department of Education (grant nos. H133G060167 and H133B090010 to S.L.W.).	Abidin RR., 1995, PARENTING STRESS IND; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Bothroyd R, 1997, PRELIMINARY MANUAL C; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Lyons AM, 2010, J CHILD FAM STUD, V19, P516, DOI 10.1007/s10826-009-9323-5; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; New Freedom Commission on Mental Health, 2004, NEW FREED COMM MENT; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritterband LM, 2003, PROF PSYCHOL-RES PR, V34, P527, DOI 10.1037/0735-7028.34.5.527; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Webster-Stratton C, 2008, J CHILD PSYCHOL PSYC, V49, P471, DOI 10.1111/j.1469-7610.2007.01861.x; Werba BE, 2006, BEHAV MODIF, V30, P618, DOI 10.1177/0145445504272977; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	28	17	17	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					347	356		10.1097/HTR.0000000000000052			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400012	24842588				2021-06-18	
J	Zander, NE; Piehler, T; Boggs, ME; Banton, R; Benjamin, R				Zander, Nicole E.; Piehler, Thuvan; Boggs, Mary E.; Banton, Rohan; Benjamin, Richard			In vitro studies of primary explosive blast loading on neurons	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						primary blast; traumatic brain injury; in vitro model; dissociated cultures; explosives	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; MODEL; DYSFUNCTION; RECOVERY; DAMAGE	In a military setting, traumatic brain injury (TBI) is frequently caused by blast waves that can trigger a series of neuronal biochemical changes. Although many animal models have been used to study the effects of primary blast waves, elucidating the mechanisms of damage in a whole-animal model is extremely complex. In vitro models of primary blast, which allow for the deconvolution of mechanisms, are relatively scarce. It is largely unknown how structural damage at the cellular level impacts the functional activity at variable time scales after the TBI event. A novel in vitro system was developed to probe the effects of explosive blast (ranging from approximate to 25 to 40 psi) on dissociated neurons. PC12 neurons were cultured on laminin-coated substrates, submerged underwater, and subjected to single and multiple blasts in a controlled environment. Changes in cell membrane permeability, viability, and cell morphology were evaluated. Significant increases in axonal beading were observed in the injured cells. In addition, although cell death was minimal after a single insult, cell viability decreased significantly following repeated blast exposure. (c) 2015 Wiley Periodicals, Inc.	[Zander, Nicole E.; Piehler, Thuvan; Banton, Rohan; Benjamin, Richard] US Army Res Lab, Weap & Mat Res Directorate, Aberdeen Proving Ground, MD USA; [Boggs, Mary E.] Univ Delaware, Dept Biol, Newark, DE USA	Zander, NE (corresponding author), US Army Res Lab, Dept Army, RDRL WMM G, Bldg 4600, Aberdeen, MD 21005 USA.	nicole.e.zander.civ@mail.mil			United States Army Research Laboratory's Director's Science Initiative	Contract grant sponsor: United States Army Research Laboratory's Director's Science Initiative.	Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; Barthel J, 2008, 26 ARM SCI C ORL FL; Bernal R, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.018301; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chen Y, 2013, FRONT NEUROL, V4, P1; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chew SY, 2005, BIOMACROMOLECULES, V6, P2017, DOI 10.1021/bm0501149; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Department of the Army, 1984, DEP ARM TECHN MAN TM; Edwards MA, 2007, NEUROTOXICOLOGY, V28, P876, DOI 10.1016/j.neuro.2007.04.006; Effgen G. B., 2012, FRONT NEUROL, V3, P1; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fernandez P, 2010, BIOPHYS J, V99, P3571, DOI 10.1016/j.bpj.2010.10.027; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HINSHAW DB, 1993, BRAIN RES, V615, P13, DOI 10.1016/0006-8993(93)91110-E; Howard D, 1997, ULTRASOUND MED BIOL, V23, P1107, DOI 10.1016/S0301-5629(97)00081-1; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lee JY, 2009, BIOMATERIALS, V30, P4325, DOI 10.1016/j.biomaterials.2009.04.042; Liu Y, 2003, J CELL MOL MED, V7, P49, DOI 10.1111/j.1582-4934.2003.tb00202.x; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Pera M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074344; Ravin R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039421; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Williamson V., 2009, INVISIBLE WOUNDS PSY	42	17	18	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP	2015	93	9					1353	1363		10.1002/jnr.23594			11	Neurosciences	Neurosciences & Neurology	CM9HP	WOS:000358019100005	25914380				2021-06-18	
J	Yamal, JM; Rubin, ML; Benoit, JS; Tilley, BC; Gopinath, S; Hannay, HJ; Doshi, P; Aisiku, IP; Robertson, CS				Yamal, Jose-Miguel; Rubin, M. Laura; Benoit, Julia S.; Tilley, Barbara C.; Gopinath, Shankar; Hannay, H. Julia; Doshi, Pratik; Aisiku, Imoigele P.; Robertson, Claudia S.			Effect of Hemoglobin Transfusion Threshold on Cerebral Hemodynamics and Oxygenation	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; clinical trial; intracranial pressure; prospective study; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; CELL TRANSFUSION; HEMATOCRIT; INFORMATION; MODEL	Cerebral dysfunction caused by traumatic brain injury may adversely affect cerebral hemodynamics and oxygenation leading to worse outcomes if oxygen capacity is decreased due to anemia. In a randomized clinical trial of 200 patients comparing transfusion thresholds <7g/dl versus 10g/dl, where transfusion of leukoreduced packed red blood cells was used to maintain the assigned hemoglobin threshold, no long-term neurological difference was detected. The current study examines secondary outcome measures of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and brain tissue oxygenation (PbtO(2)) in patients enrolled in this randomized clinical trial. We observed a lower hazard for death (hazard ratio [HR]=0.12, 95% confidence interval [CI]=0.02-0.99) during the first 3 days post-injury, and a higher hazard for death after three days (HR=2.55, 95% CI=1.00-6.53) in the 10g/dl threshold group as compared to the 7g/dL threshold group. No significant differences were observed for ICP and CPP but MAP was slightly lower in the 7g/dL group, although the decreased MAP did not result in increased hypotension. Overall brain tissue hypoxia events were not significantly different in the two transfusion threshold groups. When the PbtO(2) catheter was placed in normal brain, however, tissue hypoxia occurred in 25% of patients in the 7g/dL threshold group, compared to 10.2% of patients in the 10g/dL threshold group (p=0.04). Although we observed a few differences in hemodynamic outcomes between the transfusion threshold groups, none were of major clinical significance and did not affect long-term neurological outcome and mortality.	[Yamal, Jose-Miguel; Rubin, M. Laura; Tilley, Barbara C.] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX 77005 USA; [Benoit, Julia S.] Univ Texas Houston, Coll Optometry, Dept Basic Vis Sci, Houston, TX 77005 USA; [Benoit, Julia S.] Univ Texas Houston, Texas Inst Measurement Evaluat & Stat, Houston, TX 77005 USA; [Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Hannay, H. Julia] Univ Texas Houston, Dept Psychol, Houston, TX 77005 USA; [Doshi, Pratik] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med & Internal Med, Houston, TX 77030 USA; [Aisiku, Imoigele P.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA	Yamal, JM (corresponding author), Univ Texas Houston, Sch Publ Hlth, Div Biostat, 1200 Pressler St,RAS W928, Houston, TX 77005 USA.	Jose-Miguel.Yamal@uth.tmc.edu		Hannay, H. Julia/0000-0001-7023-912X; Benoit, Julia/0000-0002-2734-5477	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM074902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study was supported by National Institute of Neurological Disorders and Stroke (grant #P01-NS38660).	BROWN MM, 1985, BRAIN, V108, P81, DOI 10.1093/brain/108.1.81; BROWN MM, 1985, LANCET, V1, P604; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Figaji AA, 2010, PEDIATR CRIT CARE ME, V11, P325, DOI 10.1097/PCC.0b013e3181b80a8e; HENRIKSEN L, 1981, ANN NEUROL, V9, P454, DOI 10.1002/ana.410090507; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; KUSUNOKI M, 1981, J CEREBR BLOOD F MET, V1, P413, DOI 10.1038/jcbfm.1981.45; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Ponce LL, 2012, NEUROSURGERY, V70, P1492, DOI 10.1227/NEU.0b013e31824ce933; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubin DB., 2004, MULTIPLE IMPUTATION; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Tango HK, 2009, J TRAUMA, V66, P720, DOI 10.1097/TA.0b013e3181719b35; THOMAS DJ, 1977, LANCET, V2, P161; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; VORSTRUP S, 1992, J CEREBR BLOOD F MET, V12, P745, DOI 10.1038/jcbfm.1992.105; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	19	17	17	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1239	1245		10.1089/neu.2014.3752			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400008	25566694	Green Published			2021-06-18	
J	Tan, AM; Waxman, SG				Tan, Andrew M.; Waxman, Stephen G.			Dendritic spine dysgenesis in neuropathic pain	NEUROSCIENCE LETTERS			English	Article						Neuropathic pain; Dendritic spine; SCI; Rac1; Diabetes; Nerve injury; Plasticity; Nociception; Spinal cord	LONG-TERM POTENTIATION; PERIPHERAL-NERVE INJURY; SODIUM-CHANNEL EXPRESSION; SUPERFICIAL DORSAL-HORN; CORD-INJURY; BURN INJURY; REMODELING CONTRIBUTES; MECHANICAL ALLODYNIA; DIABETIC-NEUROPATHY; SIGNALING PATHWAYS	Neuropathic pain is a significant unmet medical need in patients with variety of injury or disease insults to the nervous system. Neuropathic pain often presents as a painful sensation described as electrical, burning, or tingling. Currently available treatments have limited effectiveness and narrow therapeutic windows for safety. More powerful analgesics, e.g., opioids, carry a high risk for chemical dependence. Thus, a major challenge for pain research is the elucidation of the mechanisms that underlie neuropathic pain and developing targeted strategies to alleviate pathological pain. The mechanistic link between dendritic spine structure and circuit function could explain why neuropathic pain is difficult to treat, since nociceptive processing pathways are adversely "hard-wired" through the reorganization of dendritic spines. Several studies in animal models of neuropathic pain have begun to reveal the functional contribution of dendritic spine dysgenesis in neuropathic pain. Previous reports have demonstrated three primary changes in dendritic spine structure on nociceptive dorsal horn neurons following injury or disease, which accompany chronic intractable pain: (I) increased density of dendritic spines, particularly mature mushroom-spine spines, (II) redistribution of spines toward dendritic branch locations close to the cell body, and (III) enlargement of the spine head diameter, which generally presents as a mushroom-shaped spine. Given the important functional implications of spine distribution, density, and shape for synaptic and neuronal function, the study of dendritic spine abnormality may provide a new perspective for investigating pain, and the identification of specific molecular players that regulate spine morphology may guide the development of more effective and long-lasting therapies. Published by Elsevier Ireland Ltd.	[Tan, Andrew M.; Waxman, Stephen G.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Tan, Andrew M.; Waxman, Stephen G.] Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA; [Tan, Andrew M.; Waxman, Stephen G.] Vet Affairs Connecticut Healthcare Syst, Dept Neurol, New Haven, CT 06516 USA; [Tan, Andrew M.; Waxman, Stephen G.] Vet Affairs Connecticut Healthcare Syst, Rehabil Res Ctr, New Haven, CT 06516 USA	Tan, AM (corresponding author), Ctr Neurosci & Regenerat Res 127A, 950 Campbell Ave,Bldg 34, West Haven, CT 06516 USA.	andrew.tan@yale.edu	Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; Tan, Andrew/0000-0002-0099-8814	Paralyzed Veterans of America (PVA); Department of Veterans Affairs (VA) Medical Research Service and Rehabilitation Research Service; PVA Research Foundation; VA Career Development Award [1 IK2 RX001123-01A2]; Veterans AffairsUS Department of Veterans Affairs [I01BX000605, IK2RX001123] Funding Source: NIH RePORTER	The work presented is supported by grants from the Paralyzed Veterans of America (PVA) and the Department of Veterans Affairs (VA) Medical Research Service and Rehabilitation Research Service. Andrew M. Tan is funded by the PVA Research Foundation and a VA Career Development Award (1 IK2 RX001123-01A2). We thank Lakshmi Bangalore for her excellent editorial and intellectual contribution.	Ackermann M, 2003, NAT NEUROSCI, V6, P1194, DOI 10.1038/nn1135; Allen JW, 2004, METH MOLEC MED, P25; Alvarez VA, 2007, ANNU REV NEUROSCI, V30, P79, DOI 10.1146/annurev.neuro.30.051606.094222; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Baron R, 2000, CLIN J PAIN, V16, pS12, DOI 10.1097/00002508-200006001-00004; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; Bramham CR, 2008, CURR OPIN NEUROBIOL, V18, P524, DOI 10.1016/j.conb.2008.09.013; Carp JS, 2006, J NEUROPHYSIOL, V96, P1718, DOI 10.1152/jn.00470.2006; Chang YW, 2010, J PAIN, V11, P1146, DOI 10.1016/j.jpain.2010.02.010; Chang YW, 2010, J PAIN, V11, P119, DOI 10.1016/j.jpain.2009.06.009; Corbetta S, 2009, FASEB J, V23, P1347, DOI 10.1096/fj.08-121574; Cramer SW, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-36; Craner MJ, 2002, ANN NEUROL, V52, P786, DOI 10.1002/ana.10364; Deumens R, 2013, NEUROSCIENCE, V229, P155, DOI 10.1016/j.neuroscience.2012.10.036; Drdla R, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-18; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Erschbamer MK, 2005, J COMP NEUROL, V484, P224, DOI 10.1002/cne.20471; FIFKOVA E, 1985, CELL MOL NEUROBIOL, V5, P47, DOI 10.1007/BF00711085; Fischer TZ, 2012, J REHABIL RES DEV, V49, P515, DOI 10.1682/JRRD.2011.04.0071; Fischer TZ, 2010, NAT REV NEUROL, V6, P462, DOI 10.1038/nrneurol.2010.90; Francis JT, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/310737; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gazzaley A, 2002, NEUROSCIENCE, V111, P853, DOI 10.1016/S0306-4522(02)00021-0; Haber M, 2006, J NEUROSCI, V26, P8881, DOI 10.1523/JNEUROSCI.1302-06.2006; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2004, J NEUROSCI, V24, P4832, DOI 10.1523/JNEUROSCI.0300-04.2004; Hasbargen T, 2010, ANN NY ACAD SCI, V1198, P168, DOI 10.1111/j.1749-6632.2010.05462.x; Heppenstall P A, 2000, Curr Opin Anaesthesiol, V13, P573, DOI 10.1097/00001503-200010000-00015; Ikeda H, 2006, SCIENCE, V312, P1659, DOI 10.1126/science.1127233; Ikeda H, 2009, NEUROSCI RES, V64, P133, DOI 10.1016/j.neures.2009.03.004; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Kim SK, 2011, J NEUROSCI, V31, P5477, DOI 10.1523/JNEUROSCI.0328-11.2011; Knerlich-Lukoschus F, 2008, J NEUROTRAUM, V25, P427, DOI 10.1089/neu.2007.0431; LATARJET J, 1995, BURNS, V21, P344, DOI 10.1016/0305-4179(95)00003-8; Lee-Kubli CAG, 2014, PAIN, V155, P250, DOI 10.1016/j.pain.2013.10.001; Li YR, 2003, J NEUROPHYSIOL, V90, P857, DOI 10.1152/jn.00236.2003; Li YR, 2004, J NEUROPHYSIOL, V91, P767, DOI 10.1152/jn.00788.2003; Lu VB, 2009, J PHYSIOL-LONDON, V587, P1013, DOI 10.1113/jphysiol.2008.166306; Malenka RC, 2003, NAT REV NEUROSCI, V4, P923, DOI 10.1038/nrn1258; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Meisner JG, 2010, J NEUROTRAUM, V27, P729, DOI 10.1089/neu.2009.1166; Melemedjian OK, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-12; MENDELL LM, 1966, EXP NEUROL, V16, P316, DOI 10.1016/0014-4886(66)90068-9; Morrow T.J., 2004, CURR PROTOC NEUROSCI, V18; Nakayama AY, 2000, HIPPOCAMPUS, V10, P582, DOI 10.1002/1098-1063(2000)10:5<582::AID-HIPO8>3.0.CO;2-K; Nishida H, 2007, J NEUROSCI, V27, P331, DOI 10.1523/JNEUROSCI.4466-06.2007; O'Callaghan JP, 2010, METABOLISM, V59, pS21, DOI 10.1016/j.metabol.2010.07.011; Ohsawa K, 2000, J CELL SCI, V113, P3073; Ohsawa M, 2011, PAIN, V152, P114, DOI 10.1016/j.pain.2010.10.005; Pabreja K, 2011, EUR J PHARMACOL, V661, P15, DOI 10.1016/j.ejphar.2011.04.014; PONGRACZ F, 1985, NEUROSCIENCE, V15, P933, DOI 10.1016/0306-4522(85)90244-1; Price TJ, 2009, BRAIN RES REV, V60, P149, DOI 10.1016/j.brainresrev.2008.12.015; Rail W., 1967, J NEUROPHYSIOL, V30, P1169; Rex CS, 2009, J CELL BIOL, V186, P85, DOI 10.1083/jcb.200901084; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Saab CY, 2009, TRENDS NEUROSCI, V32, P110, DOI 10.1016/j.tins.2008.11.004; Sandkuhler J, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-9; Sandkuhler J, 1998, EUR J NEUROSCI, V10, P2476, DOI 10.1046/j.1460-9568.1998.00278.x; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Schwechter Brandon, 2013, Commun Integr Biol, V6, pe27343, DOI 10.4161/cib.27343; Segev I, 1998, TRENDS NEUROSCI, V21, P453, DOI 10.1016/S0166-2236(98)01327-7; Smith BH, 2012, CURR PAIN HEADACHE R, V16, P191, DOI 10.1007/s11916-012-0256-0; Svendsen F, 1997, NEUROREPORT, V8, P3427, DOI 10.1097/00001756-199711100-00002; Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001; Talbot S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-36; Tan AM, 2013, EXP NEUROL, V248, P509, DOI 10.1016/j.expneurol.2013.07.017; Tan AM, 2012, J NEUROSCI, V32, P6795, DOI 10.1523/JNEUROSCI.1017-12.2012; Tan AM, 2012, EXP NEUROL, V235, P142, DOI 10.1016/j.expneurol.2011.08.026; Tan AM, 2011, EXP NEUROL, V232, P222, DOI 10.1016/j.expneurol.2011.08.028; Tan AM, 2009, J NEUROPHYSIOL, V102, P2396, DOI 10.1152/jn.00095.2009; Tan AM, 2009, J REHABIL RES DEV, V46, P123, DOI 10.1682/JRRD.2008.03.0048; Tan AM, 2008, J NEUROSCI, V28, P13173, DOI 10.1523/JNEUROSCI.3142-08.2008; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Tashiro A, 2004, MOL CELL NEUROSCI, V26, P429, DOI 10.1016/j.mcn.2004.04.001; Tashiro A, 2008, METHOD ENZYMOL, V439, P285, DOI 10.1016/S0076-6879(07)00421-1; Tesfaye S, 2012, DIABETES-METAB RES, V28, P8, DOI 10.1002/dmrr.2239; Thacker MA, 2009, EUR J PAIN, V13, P263, DOI 10.1016/j.ejpain.2008.04.017; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Tsay D, 2004, TRENDS NEUROSCI, V27, P77, DOI 10.1016/j.tins.2003.11.008; Vinay L, 2008, BRAIN RES REV, V57, P103, DOI 10.1016/j.brainresrev.2007.09.003; von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008; Wang SX, 2011, PAIN MED, V12, P87, DOI 10.1111/j.1526-4637.2010.01021.x; Wang XL, 2007, J PHYSIOL-LONDON, V579, P849, DOI 10.1113/jphysiol.2006.126102; Wang Y, 2006, EUR J NEUROSCI, V23, P141, DOI 10.1111/j.1460-9568.2005.04547.x; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; Wolpaw JR, 1997, TRENDS NEUROSCI, V20, P588, DOI 10.1016/S0166-2236(97)01133-8; WOOLF CJ, 1991, TRENDS NEUROSCI, V14, P74, DOI 10.1016/0166-2236(91)90024-O; WOOLF CJ, 1986, J COMP NEUROL, V251, P517, DOI 10.1002/cne.902510407; WOOLF CJ, 1987, J COMP NEUROL, V261, P105, DOI 10.1002/cne.902610109; Yang YL, 2009, NEUROSCIENTIST, V15, P464, DOI 10.1177/1073858409340800; Yowtak J, 2013, PAIN, V154, P2469, DOI 10.1016/j.pain.2013.07.024; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zeilhofer HU, 2008, NEUROSCI LETT, V437, P170, DOI 10.1016/j.neulet.2008.03.056; Zeilhofer HU, 2008, INT IMMUNOPHARMACOL, V8, P182, DOI 10.1016/j.intimp.2007.07.009; Zhao P, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-27; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	102	17	18	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 5	2015	601						54	60		10.1016/j.neulet.2014.11.024			7	Neurosciences	Neurosciences & Neurology	CN5HR	WOS:000358460900008	25445354				2021-06-18	
J	Baldassarre, M; Smith, B; Harp, J; Herrold, A; High, WM; Babcock-Parziale, J; Pape, TLB				Baldassarre, Megan; Smith, Bridget; Harp, Jordan; Herrold, Amy; High, Walter M., Jr.; Babcock-Parziale, Judith; Pape, Theresa Louise-Bender			Exploring the Relationship Between Mild Traumatic Brain Injury Exposure and the Presence and Severity of Postconcussive Symptoms Among Veterans Deployed to Iraq and Afghanistan	PM&R			English	Article							POSTTRAUMATIC-STRESS-DISORDER; IDENTIFICATION TEST; ENDURING FREEDOM; HEALTH; SPECIFICITY; PREVALENCE; VALIDATION; DEPRESSION; COMPLAINTS; SEQUELAE	Objective: The aim of this study was to describe the association between mild traumatic brain injury (mTBI) and persisting postconcussive symptoms according to symptom category, number, and severity. Design: The study design was observational. Participants: The study sample comprised veterans (>= 18 years of age) deployed in Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) conflicts who had not received any treatment for mTBI in the 30 days preceding study enrollment. Methods: Veterans were interviewed and completed testing in a single day. The Standard TBI Diagnostic Interview and the Clinician-Administered PTSD Scale were used. Testing included the Neurobehavioral Symptom Inventory and a full neuropsychological battery. Gold standard classification methods were utilized to determine presence/absence of mTBI. For each of the 5 symptom outcomes, an adjusted multiple linear regression model (negative binomial count models) accounting for effects of socio-demographic variables and behavioral health conditions was used. Main Outcome Measures: Self-report of neurobehavioral symptoms categorized as affective, cognitive, somatic, and vestibular symptoms, in addition to the instruments specified above. Results: OEF/OIF veterans with mTBI, relative to veterans with no mTBI, were observed to have 30% more symptoms overall (P < .001), 34% more somatic symptoms (P < .001), 22% more cognitive symptoms (P = .008), 15% more affective symptoms (P = .017), and 59% more vestibular symptoms (P < .001). For adjusted models, variables significantly related to number of symptoms across all 4 symptom categories were anxiety (all P < .001) and insomnia (all P < .001). For the adjusted models, variables significantly related to symptom severity across all 4 symptom categories were insomnia (all P < .001), depression (P < .001-.05) and anxiety (all, P < .001). Conclusions: OEF/OIF veterans with mTBI, relative to veterans with no mTBI, have significantly more and significantly more severe persisting symptoms, with vestibular symptoms reported with the greatest frequency. After accounting for behavioral health conditions and socio-demographic factors, OEF/OIF veterans with mTBI compared to veterans without mTBI had significantly more cognitive, affective, vestibular, and somatic symptoms persisting 4.8 years after the mTBI event(s).	[Baldassarre, Megan; Smith, Bridget; Herrold, Amy; Pape, Theresa Louise-Bender] Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Management Complex Chron Care, Ctr Excellence, Hines, IL 60141 USA; [Baldassarre, Megan; Herrold, Amy; Pape, Theresa Louise-Bender] Edward Hines Jr VA Hosp, Res Serv, Hines, IL USA; [Baldassarre, Megan] Dartmouth Hitchcock Med Ctr, Dept Psychiat, Neuropsychol Serv, Lebanon, NH 03756 USA; [Smith, Bridget] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL 60611 USA; [Smith, Bridget] Edward Hines Jr VA Hosp, Spinal Cord Injury QUERI, Dept Vet Affairs VA, Hines, IL USA; [Harp, Jordan; High, Walter M., Jr.] Univ Kentucky, Dept Psychol, Coll Med, Lexington, KY 40506 USA; [Herrold, Amy] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [High, Walter M., Jr.] Northwestern Univ, Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [High, Walter M., Jr.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [High, Walter M., Jr.] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY USA; [High, Walter M., Jr.] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY USA; [Babcock-Parziale, Judith] Southern Arizona VA Hlth Care Syst 3 124, Tucson, AZ USA; [Pape, Theresa Louise-Bender] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Off Med Educ, Chicago, IL 60611 USA	Baldassarre, M (corresponding author), Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Management Complex Chron Care, Ctr Excellence, Hines, IL 60141 USA.	megan.baldassarre@gmail.com		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs (VA), Office of Research and Development, Health services Research and Development (HSR&D) Service, Service Directed Research ProjectUS Department of Veterans Affairs [08-377]; Department of Veterans Affairs DisclosuresUS Department of Veterans Affairs; Department of Veterans AffairsUS Department of Veterans Affairs; VA HSRD; Veterans AffairsUS Department of Veterans Affairs [IK2RX000949] Funding Source: NIH RePORTER	Disclosures related to this publication: grant, Department of Veterans Affairs (VA), Office of Research and Development, Health services Research and Development (HSR&D) Service, Service Directed Research Project #08-377; Disclosures related to this publication: grant, Department of Veterans Affairs; Disclosures related to this publication: grant, VA HSR&D	Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1987, J ABNORM PSYCHOL, V96, P179, DOI 10.1037/0021-843X.96.3.179; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beck AT, 1988, MANUAL BECK ANXIETY; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bradley KA, 2003, ARCH INTERN MED, V163, P821, DOI 10.1001/archinte.163.7.821; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Franke LM, 2012, J REHABIL RES DEV, V49, P985, DOI 10.1682/JRRD.2011.12.0250; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King PR, 2012, J CLIN PSYCHOL MED S, V19, P376, DOI 10.1007/s10880-012-9345-9; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Long S, 1997, ADV QUANTATIVE TECHN; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; National Center for Injury Prevention and Control Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Pape TLB, 2013, PM&R, V5, P856, DOI 10.1016/j.pmrj.2013.06.007; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	55	17	18	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	AUG	2015	7	8					845	858		10.1016/j.pmrj.2015.03.003			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CQ1LU	WOS:000360360000006	25758529				2021-06-18	
J	Luo, CL; Li, QQ; Gao, Y; Shen, X; Ma, L; Wu, Q; Wang, ZF; Zhang, MY; Zhao, ZQ; Chen, XP; Tao, LY				Luo, Chengliang; Li, Qianqian; Gao, Yuan; Shen, Xi; Ma, Lu; Wu, Qiong; Wang, Zufeng; Zhang, Mingyang; Zhao, Ziqin; Chen, Xiping; Tao, Luyang			Poloxamer 188 Attenuates Cerebral Hypoxia/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Oxygen-glucose deprivation; Primary cortical neurons; Middle cerebral artery occlusion; Apoptosis; Autophagy	TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM STRESS; CONTROLLED CORTICAL IMPACT; INDUCED CELL-DEATH; MAMMALIAN TARGET; IN-VITRO; RAPAMYCIN PROTECTS; ARTERY OCCLUSION; NEURONAL INJURY; ISCHEMIA	While the previous studies have shown poloxamer 188 (P188)'s neuroprotection in cultured HT22 cells under oxygen-glucose deprivation (OGD) insults, we investigated whether P188 is a potential neuroprotective agent in primary cortical neurons (PCNs) and in cerebral ischemia in vivo and whether the possible underlying mechanisms correlate with regulating mitochondrial membrane permeability (MMP) and autophagy. The protective effects of P188 were tested in PCNs in vitro exposed to OGD, as well as in cerebral ischemia in vivo. Cell death and viability were detected with LDH and MTT assay, and mitochondrial membrane potential was assessed using fluorescence microscopy. The apoptosis and autophagy of PCNs were investigated by expressions of cytc, caspase-3, light chain 3 (LC3), and Beclin-1. In addition, a mouse middle cerebral artery occlusion (MCAO) model was used to produce focal ischemia, and mice were treated with P188 and rapamycin after MCAO 10 min. The infarct volume, neurological scores, and phosphorylation of mammalian target of rapamycin (mTOR) were evaluated. The in vitro results showed that P188 prevented OGD-induced primary cerebrocortical neuron death and inhibited loss of mitochondrial membrane potential, the release of mitochondrial apoptogenic factor cytochrome c from mitochondria to the cytoplasm, and activation of caspase-3. P188 suppressed the activation of autophagy by decreasing LC3-II and Beclin-1 levels under OGD accordingly. Moreover, the in vivo results showed that P188 and rapamycin remarkably reduced the infarct volume and neurological deficits in the MCAO mouse model of cerebral ischemia, respectively. Both P188 and rapamycin induced phosphorylation of mTOR and reversed the decreased level upon MCAO. These data indicate that P188 prevents neuronal cell death resulting from ischemic brain injury and that its neuroprotective effects are mediated by preventing mitochondrial membrane integrity damage and autophagic activation. Given that it has low toxicity, P188 might become a potential novel therapy for ischemic injury.	[Luo, Chengliang; Gao, Yuan; Shen, Xi; Ma, Lu; Wu, Qiong; Wang, Zufeng; Zhang, Mingyang; Chen, Xiping; Tao, Luyang] Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China; [Li, Qianqian] Wannan Med Coll, Dept Forens Med, Wuhu 241002, Peoples R China; [Zhao, Ziqin] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China.	xipingchen@suda.edu.cn; taoluyang@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Zhang, Mingyang/0000-0003-1612-0763; Shen, Xi/0000-0001-7568-7335	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400999, 81172911, 81373251, 81301039]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M551660]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2015AA020503]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Science Foundation of China (No.81400999, No.81172911, No.81373251, No.81301039), China Postdoctoral Science Foundation (No.2014M551660), National High Technology Research and Development Program of China (863 Program, No.2015AA020503), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Carloni S, 2014, EXP NEUROL, V255, P103, DOI 10.1016/j.expneurol.2014.03.002; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; Chauhan A, 2011, BEHAV BRAIN RES, V225, P603, DOI 10.1016/j.bbr.2011.08.035; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; Cui DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035324; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Gera J, 2011, LEUKEMIA LYMPHOMA, V52, P1857, DOI 10.3109/10428194.2011.580478; Gu JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061641; Gu LJ, 2012, STROKE, V43, P1941, DOI 10.1161/STROKEAHA.112.656611; Gupta YK, 2011, INDIAN J MED RES, V133, P15; Hu ZP, 2015, MOL NEUROBIOL, V52, P1190, DOI 10.1007/s12035-014-8921-4; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Sheng R, 2012, AUTOPHAGY, V8, P310, DOI 10.4161/auto.18673; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang JY, 2011, J NEUROPATH EXP NEUR, V70, P314, DOI 10.1097/NEN.0b013e31821352bd; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhang WH, 2008, STROKE, V39, P455, DOI 10.1161/STROKEAHA.107.496810	39	17	18	0	19	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	AUG	2015	56	4					988	998		10.1007/s12031-015-0568-8			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CP7MU	WOS:000360073100028	25966641				2021-06-18	
J	Olsen, A; Brunner, JF; Evensen, KAI; Finnanger, TG; Vik, A; Skandsen, T; Landro, NI; Haberg, AK				Olsen, Alexander; Brunner, Jan Ferenc; Evensen, Kari Anne Indredavik; Finnanger, Torun Gangaune; Vik, Anne; Skandsen, Toril; Landro, Nils Inge; Haberg, Asta Kristine			Altered Cognitive Control Activations after Moderate-to-Severe Traumatic Brain Injury and Their Relationship to Injury Severity and Everyday-Life Function	CEREBRAL CORTEX			English	Article						cognitive control; compensation; continuous performance test; executive function; fMRI; time-on-task	WORKING-MEMORY; ATTENTION DEFICITS; EXECUTIVE FUNCTION; TEST-PERFORMANCE; TASK CONTROL; FATIGUE; FMRI; NETWORKS; ROBUST; TBI	This study investigated how the neuronal underpinnings of both adaptive and stable cognitive control processes are affected by traumatic brain injury (TBI). Functional magnetic resonance imaging (fMRI) was undertaken in 62 survivors of moderate-to-severe TBI (> 1 year after injury) and 68 healthy controls during performance of a continuous performance test adapted for use in a mixed block- and event-related design. Survivors of TBI demonstrated increased reliance on adaptive task control processes within an a priori core region for cognitive control in the medial frontal cortex. TBI survivors also had increased activations related to time-on-task effects during stable task-set maintenance in right inferior parietal and prefrontal cortices. Increased brain activations in TBI survivors had a dose-dependent linear positive relationship to injury severity and were negatively correlated with self-reported cognitive control problems in everyday-life situations. Results were adjusted for age, education, and fMRI task performance. In conclusion, evidence was provided that the neural underpinnings of adaptive and stable control processes are differently affected by TBI. Moreover, it was demonstrated that increased brain activations typically observed in survivors of TBI might represent injury-specific compensatory adaptations also utilized in everyday-life situations.	[Olsen, Alexander] Norwegian Univ Sci & Technol, MI Lab, N-7491 Trondheim, Norway; [Olsen, Alexander] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Brunner, Jan Ferenc; Vik, Anne; Skandsen, Toril; Haberg, Asta Kristine] Norwegian Univ Sci & Technol, Dept Neurosci, N-7491 Trondheim, Norway; [Evensen, Kari Anne Indredavik] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7491 Trondheim, Norway; [Evensen, Kari Anne Indredavik] Norwegian Univ Sci & Technol, Dept Lab Med, Childrens & Womens Hlth, N-7491 Trondheim, Norway; [Finnanger, Torun Gangaune] Norwegian Univ Sci & Technol, Reg Ctr Child & Youth Mental Hlth & Child Welf RK, N-7491 Trondheim, Norway; [Olsen, Alexander; Brunner, Jan Ferenc; Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Finnanger, Torun Gangaune] Univ Trondheim Hosp, St Olavs Hosp, Childrens Clin, Trondheim, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Landro, Nils Inge] Univ Trondheim Hosp, St Olavs Hosp, Natl Competence Ctr Complex Symptom Disorders, Trondheim, Norway; [Haberg, Asta Kristine] Univ Trondheim Hosp, St Olavs Hosp, Dept Radiol, Trondheim, Norway; [Evensen, Kari Anne Indredavik] Trondheim Municipal, Dept Physiotherapy, Trondheim, Norway; [Landro, Nils Inge] Univ Oslo, Dept Psychol, Clin Neurosci Res Grp, Oslo, Norway	Olsen, A (corresponding author), Norwegian Univ Sci & Technol, MI Lab, Postboks 8905, N-7491 Trondheim, Norway.	alexander.olsen@ntnu.no	Olsen, Alexander/P-5235-2019	Olsen, Alexander/0000-0001-8691-3860; Brunner, Jan Ferenc/0000-0002-8576-678X	Norwegian Research Council through Medical Imaging Laboratory (MI-LAB) at the Norwegian University of Science and Technology	This study was supported by the Norwegian Research Council through Medical Imaging Laboratory (MI-LAB) at the Norwegian University of Science and Technology. Funding to pay the Open Access publication charges for this article was provided by the Norwegian Research Council through Medical Imaging Laboratory (MI-Lab) at the Norwegian University of Science and Technology.	Altmann EM, 2002, PSYCHOL SCI, V13, P27, DOI 10.1111/1467-9280.00405; Anderson J, 2007, NONLINEAR REGISTRATI; Anderson JLR, 2007, NONLINEAR OPTIMISATI; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Braver TS, 2012, TRENDS COGN SCI, V16, P106, DOI 10.1016/j.tics.2011.12.010; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cazalis Fabienne, 2011, Front Neurol, V1, P158, DOI 10.3389/fneur.2010.00158; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Conners CK, 2003, J ABNORM CHILD PSYCH, V31, P555, DOI 10.1023/A:1025457300409; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Desmet C, 2011, J NEUROSCI, V31, P1366, DOI 10.1523/JNEUROSCI.5371-10.2011; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Edwards BG, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00032; Forstmann BU, 2008, P NATL ACAD SCI USA, V105, P17538, DOI 10.1073/pnas.0805903105; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00024; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Holland D, 2010, NEUROIMAGE, V50, P175, DOI 10.1016/j.neuroimage.2009.11.044; Jahfari S, 2012, J NEUROSCI, V32, P10870, DOI 10.1523/JNEUROSCI.0902-12.2012; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Leunissen I, 2014, HUM BRAIN MAPP, V35, P2459, DOI 10.1002/hbm.22341; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Majid DSA, 2013, J NEUROSCI, V33, P13259, DOI 10.1523/JNEUROSCI.5651-12.2013; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Miezin FM, 2000, NEUROIMAGE, V11, P735, DOI 10.1006/nimg.2000.0568; Nee DE, 2011, NEUROIMAGE, V54, P528, DOI 10.1016/j.neuroimage.2010.08.027; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Ogg RJ, 2008, MAGN RESON IMAGING, V26, P504, DOI 10.1016/j.mri.2007.09.004; Olsen A, 2013, J COGNITIVE NEUROSCI, V25, P903, DOI 10.1162/jocn_a_00358; Paxton JL, 2008, CEREB CORTEX, V18, P1010, DOI 10.1093/cercor/bhm135; Petersen SE, 2012, NEUROIMAGE, V62, P1177, DOI 10.1016/j.neuroimage.2011.09.084; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Roth R.M., 2005, BEHAV RATING INVENTO; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sozda CN, 2011, INT J PSYCHOPHYSIOL, V82, P97, DOI 10.1016/j.ijpsycho.2011.06.019; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Tana MG, 2010, COMPUT INTELL NEUROS; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Waid-Ebbs JK, 2012, BRAIN INJURY, V26, P1646, DOI 10.3109/02699052.2012.700087; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727	65	17	18	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	AUG	2015	25	8					2170	2180		10.1093/cercor/bhu023			11	Neurosciences	Neurosciences & Neurology	CO7DU	WOS:000359320000015	24557637	Green Published, Bronze			2021-06-18	
J	Sajja, VSSS; Hubbard, WB; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Hubbard, William B.; VandeVord, Pamela J.			SUBACUTE OXIDATIVE STRESS AND GLIAL REACTIVITY IN THE AMYGDALA ARE ASSOCIATED WITH INCREASED ANXIETY FOLLOWING BLAST NEUROTRAUMA	SHOCK			English	Article						Blast; inflammation; apoptosis; oxidative stress; trauma; anxiety; amygdala	TRAUMATIC BRAIN-INJURY; RAT MODEL; MICROGLIAL ACTIVATION; EXPRESSION; CONCUSSION; CONTUSION; VETERANS; PROTEINS; EXPOSURE; MICE	Behavioral symptoms, such as anxiety, are widely reported after blast overpressure (BOP) exposure. Amygdalar vulnerability to increasing magnitudes of BOP has not been investigated, and single exposures to blast have been limited to acute (<72 h) assessment. Rats were exposed to a single low, moderate, or high BOP (10, 14, or 24 psi) with an advanced blast simulator to test the susceptibility of the amygdala. Anxiety-like behavior was observed in the low-and moderate-pressure groups when subjected to the light/dark box assessment 7 days after the blast but not in high-pressure group. Immunohistochemistry was performed to measure apoptosis (cleaved caspase-3), neuronal loss (NeuN), reactive astrocytes (glial fibrillary acidic protein), microglia (Iba-1), and oxidative stress (CuZn superoxide dismutase). Slower progression of injury cascades was associated with a significant increase in anxiety, apoptosis, and astrogliosis in the low pressure group compared with others. A significant increase of CuZn superoxide dismutase in the low pressure group could be associated with neuroprotection from cell death caused by oxidative stress because neuronal loss was significant in the moderate-and high-but not the low-pressure group. Overall, this study demonstrated that overpressure as low as 10 psi can induce subacute anxiety, in addition to neuropathologic changes in the amygdala.	[Sajja, Venkata Siva Sai Sujith; Hubbard, William B.; VandeVord, Pamela J.] Virginia Polytech Inst & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [VandeVord, Pamela J.] Salem VA Med Ctr, Res & Dev Serv, Salem, VA USA	VandeVord, PJ (corresponding author), 447 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	pvord@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0207]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B1104-P]; Veterans AffairsUS Department of Veterans Affairs [I21RX001104] Funding Source: NIH RePORTER	This research was supported in part by the US Army Medical Research and Materiel Command (grant no. W81XWH-08-2-0207 to P.J.V.) and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (grant no. B1104-P to P.J.V.).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chaouloff F, 1997, BEHAV BRAIN RES, V85, P27, DOI 10.1016/S0166-4328(96)00160-X; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Franke LM, 2012, J REHABIL RES DEV, V49, P985, DOI 10.1682/JRRD.2011.12.0250; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kliethermes CL, 2004, ALCOHOL CLIN EXP RES, V28, P1012, DOI 10.1097/01.ALC.0000131976.40428.8F; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kochanek PM, 2009, J NEUROTRAUM, V26, P813, DOI 10.1089/neu.2008.0893; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	35	17	17	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2015	44			1			71	78		10.1097/SHK.0000000000000311			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	DO3NA	WOS:000377687100012	25521536				2021-06-18	
J	Brigo, F; Igwe, SC; Nardone, R; Lochner, P; Tezzon, F; Otte, WM				Brigo, Francesco; Igwe, Stanley C.; Nardone, Raffaele; Lochner, Piergiorgio; Tezzon, Frediano; Otte, Willem M.			Wikipedia and neurological disorders	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Epidemiology; Google; Infodemiology; Internet; Neurological disorders; Wikipedia	BREAST-CANCER; GOOGLE; BEHAVIOR; SEARCH; WEB; CELEBRITY; EPILEPSY; IMPACT; MEDIA; UK	Our aim was to evaluate Wikipedia page visits in relation to the most common neurological disorders by determining which factors are related to peaks in Wikipedia searches for these conditions. Millions of people worldwide use the internet daily as a source of health information. Wikipedia is a popular free online encyclopedia used by patients and physicians to search for health-related information. The following Wikipedia articles were considered: Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Epilepsy; Epileptic seizure; Migraine; Multiple sclerosis; Parkinson's disease; Stroke; Traumatic brain injury. We analyzed information regarding the total article views for 90 days and the rank of these articles among all those available in Wikipedia. We determined the highest search volume peaks to identify possible relation with online news headlines. No relation between incidence or prevalence of neurological disorders and the search volume for the related articles was found. Seven out of 10 neurological conditions showed relations in search volume peaks and news headlines. Six out of these seven peaks were related to news about famous people suffering from neurological disorders, especially those from showbusiness. Identification of discrepancies between disease burden and health seeking behavior on Wikipedia is useful in the planning of public health campaigns. Celebrities who publicly announce their neurological diagnosis might effectively promote awareness programs, increase public knowledge and reduce stigma related to diagnoses of neurological disorders. (C) 2015 Elsevier Ltd. All rights reserved.	[Brigo, Francesco] Univ Verona, Sect Clin Neurol, Dept Neurol & Movement Sci, I-37134 Verona, Italy; [Brigo, Francesco; Nardone, Raffaele; Lochner, Piergiorgio; Tezzon, Frediano] Franz Tappeiner Hosp, Dept Neurol, Merano, Italy; [Igwe, Stanley C.] Fed Teaching Hosp, Dept Neuropsychiat, Abakaliki, Abakaliki Ebony, Nigeria; [Nardone, Raffaele] Paracelsus Med Univ, Christian Doppler Clin, Dept Neurol, Salzburg, Austria; [Lochner, Piergiorgio] Univ Piemonte Orientale Amedeo Avogadro, Dept Translat Med, Novara, Italy; [Otte, Willem M.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Pediat Neurol, Utrecht, Netherlands; [Otte, Willem M.] Univ Med Ctr Utrecht, Image Sci Inst, Biomed MR Imaging & Spect Grp, Utrecht, Netherlands	Brigo, F (corresponding author), Univ Verona, Sect Clin Neurol, Dept Neurol & Movement Sci, Piazzale LA Scuro 10, I-37134 Verona, Italy.	dr.francescobrigo@gmail.com	Otte, Willem M/I-1228-2013; Lochner, Piergiorgio/AAB-6784-2020; Otte, Willem M./J-6140-2019; Brigo, Francesco/H-6513-2013	Otte, Willem M/0000-0003-1511-6834; Lochner, Piergiorgio/0000-0002-2101-6066; Otte, Willem M./0000-0003-1511-6834; Brigo, Francesco/0000-0003-0928-1577; Nardone, Raffaele/0000-0001-5243-6760			Bragazzi NL, 2013, MULT SCLER INT, V2013, DOI DOI 10.1155/2013/924029; Brigo F, 2014, MULT SCLER RELAT DIS, V3, P440, DOI 10.1016/j.msard.2014.02.005; Brigo F, 2014, CAN J NEUROL SCI, V41, P542, DOI 10.1017/S0317167100018692; Brigo F, 2014, EPILEPSY BEHAV, V31, P67, DOI 10.1016/j.yebeh.2013.11.020; Brigo F, 2014, SEIZURE-EUR J EPILEP, V23, P86, DOI 10.1016/j.seizure.2013.09.015; Butler D, 2013, NATURE, V494, P155, DOI 10.1038/494155a; Carneiro HA, 2009, CLIN INFECT DIS, V49, P1557, DOI 10.1086/630200; Chapman S, 2005, MED J AUSTRALIA, V183, P247, DOI 10.5694/j.1326-5377.2005.tb07029.x; Chataway Jeremy, 2010, Pract Neurol, V10, P271, DOI 10.1136/jnnp.2010.224931; Corley CD, 2010, ADV EXP MED BIOL, V680, P559, DOI 10.1007/978-1-4419-5913-3_61; Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Lazer D, 2014, SCIENCE, V343, P1203, DOI 10.1126/science.1248506; MacArthur GJ, 2011, J MED SCREEN, V18, P204, DOI 10.1258/jms.2011.011092; McIver DJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003581; Otte WM, 2013, EPILEPSY BEHAV, V29, P571, DOI 10.1016/j.yebeh.2013.10.013; Twine C, 2006, BREAST, V15, P667, DOI 10.1016/j.breast.2006.03.006	17	17	17	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	JUL	2015	22	7					1170	1172		10.1016/j.jocn.2015.02.006			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CK9KE	WOS:000356558200019	25890773				2021-06-18	
J	Hwang, H; Jeong, HS; Oh, PS; Na, KS; Kwon, J; Kim, J; Lim, S; Sohn, MH; Jeong, HJ				Hwang, Hyosook; Jeong, Hwan-Seok; Oh, Phil-Sun; Na, Kyung-Suk; Kwon, JeongIl; Kim, Jeonghun; Lim, SeokTae; Sohn, Myung-Hee; Jeong, Hwan-Jeong			Improving Cerebral Blood Flow Through Liposomal Delivery of Angiogenic Peptides: Potential of F-18-FDG PET Imaging in Ischemic Stroke Treatment	JOURNAL OF NUCLEAR MEDICINE			English	Article						liposomes; angiogenic peptides; therapy; F-18-FDG PET imaging	TRAUMATIC BRAIN INJURY; GLUCOSE-UTILIZATION; NEUROPROTECTION; EXPRESSION	Strategies to promote angiogenesis can benefit cerebral ischemia. We determined whether liposomal delivery of angiogenic peptides with a known biologic activity of vascular endothelial growth factor benefitted cerebral ischemia. Also, the study examined the potential of F-18-FDG PET imaging in ischemic stroke treatment. Methods: Male Sprague Dawley rats (n = 40) underwent 40 min of middle cerebral artery occlusion. After 15 min of reperfusion, the rats (n = 10) received angiogenic peptides incorporated into liposomes. Animals receiving phosphate-buffered solution or liposomes without peptides served as controls. One week later, F-18-FDG PET imaging was performed to examine regional changes in glucose utilization in response to the angiogenic, therapy. The following day, Tc-99m-hexamethylpropyleneamine oxime autoradiography was performed to determine changes in cerebral perfusion after angiogenic therapy. Corresponding changes in angiogenic markers, including von Willebrand factor and angiopoietin-1 and -2, were determined by immunostaining and polymerase chain reaction analysis, respectively. Results: A 40-min period of middle cerebral artery occlusion decreased blood perfusion in the ipsilateral ischemic cortex of the brain, compared with that in the contralateral cortex, as measured by Tc-99m-hexamethylpropyleneamine oxime autoradiography. Liposomal delivery of angiogenic peptides to the ischemic hemisphere of the brain attenuated the cerebral perfusion defect compared with controls. Similarly, vascular density evidenced by von Willebrand factor positive staining was increased in response to angiogenic therapy, compared with that of controls. This increase was accompanied by an early increase in angiopoietin-2 expression, a gene participating in angiogenesis. F-18-FDG PET imaging measured at 7 d after treatment revealed that liposomal delivery of angiogenic peptides facilitated glucose utilization in the ipsilateral ischemic cortex of the brain, compared with that in the controls. Furthermore, the change in regional glucose utilization was correlated with the extent of improvement in cerebral perfusion (r = 0.742, P = 0.035). Conclusion: Liposomal delivery of angiogenic peptides benefits cerebral ischemia. F-18-FDG PET imaging holds promise as an indicator of the effectiveness of angiogenic therapy in cerebral ischemia.	[Hwang, Hyosook; Jeong, Hwan-Seok; Oh, Phil-Sun; Na, Kyung-Suk; Kwon, JeongIl; Kim, Jeonghun; Lim, SeokTae; Sohn, Myung-Hee; Jeong, Hwan-Jeong] Chonbuk Natl Univ, Mol Imaging & Therapeut Med Res Ctr, Med Sch & Hosp, Cyclotron Res Ctr,Inst Med Sci,Biomed Res Inst,De, Jeonju 561756, Jeonbuk, South Korea	Jeong, HJ (corresponding author), Chonbuk Natl Univ, Med Sch & Hosp, Mol Imaging & Therapeut Med Res Ctr, Jeonbuk Reg Cyclotron Res Ctr, 634-18 GeumAm Dong, Jeonju Si, Jeollabuk Do, South Korea.	jayjeong@jbnu.ac.kr			Radiation Technology RD program [2012M2A2A7035779]; Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science ICT and Future Planning [2014R1A1A2008959]	The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This research was funded by Radiation Technology R&D program 2012M2A2A7035779 and Basic Science Research Program 2014R1A1A2008959 through the National Research Foundation of Korea grant funded by the Ministry of Science ICT and Future Planning. No other potential conflict of interest relevant to this article was reported.	ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BARON JC, 1984, J CEREBR BLOOD F MET, V4, P140, DOI 10.1038/jcbfm.1984.22; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; Bunevicius A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/634598; Finetti F, 2012, BIOCHEM PHARMACOL, V84, P303, DOI 10.1016/j.bcp.2012.04.011; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; Giordano RJ, 2010, P NATL ACAD SCI USA, V107, P5112, DOI 10.1073/pnas.0915141107; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hwang H, 2014, RADIOLOGY, V273, P160, DOI 10.1148/radiol.14132942; Garcia-Aranda MI, 2011, BIOORGAN MED CHEM, V19, P7526, DOI 10.1016/j.bmc.2011.10.032; Ishii T, 2013, FASEB J, V27, P1362, DOI 10.1096/fj.12-221325; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Lee TK, 2014, NUCL MED MOLEC IMAG, V48, P225, DOI 10.1007/s13139-014-0273-5; Liu Shimin, 2011, J Exp Stroke Transl Med, V4, P16; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; PASCHEN W, 1992, EXP NEUROL, V117, P325, DOI 10.1016/0014-4886(92)90142-D; Schmidt R, 2000, J NEUROL, V247, P81, DOI 10.1007/s004150050021; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Szpak GM, 1999, FOLIA NEUROPATHOL, V37, P264; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; WISE RJS, 1983, ANN NEUROL, V14, P627, DOI 10.1002/ana.410140605	23	17	17	0	12	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JUL	2015	56	7					1106	1111		10.2967/jnumed.115.154443			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM5UN	WOS:000357754600045	25977466	Bronze			2021-06-18	
J	LaVela, SL; Landers, K; Etingen, B; Karalius, VP; Miskevics, S				LaVela, Sherri L.; Landers, Kelsie; Etingen, Bella; Karalius, Vytas P.; Miskevics, Scott			Factors related to caregiving for individuals with spinal cord injury compared to caregiving for individuals with other neurologic conditions	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Caregiving; Spinal cord injury; Sleep; Coronary heart disease; Obesity	QUALITY-OF-LIFE; CORONARY-HEART-DISEASE; TRAUMATIC BRAIN-INJURY; SHORT-SLEEP DURATION; FAMILY CAREGIVERS; DEMENTIA CAREGIVERS; SPOUSAL CAREGIVERS; HEALTH; DEPRESSION; PEOPLE	Context/objective: To compare outcomes among caregivers of adults with spinal cord injuries (SCIs) to caregivers of adults with other neurological conditions, and determine if caregiving for SCI is associated with poor health status and chronic conditions. Design: Secondary data analysis of 2009/2010 Behavioral Risk Factor Surveillance System survey. Participants: Informal caregivers of adults with neurological conditions. Outcome measures: Sociodemographics, caregiving factors (e.g. role, emotional support, life satisfaction), lifestyle behaviors, chronic conditions, and health status. Results: Demographics and lifestyle behaviors did not differ in caregivers of adults with SCI vs. caregivers of adults with other neurological conditions (except younger age of SCI caregivers). Greater proportions of caregivers of adults with SCI had coronary heart disease (CHD) (12% vs. 6%, P = 0.06) and were obese (43% vs. 28%, P = 0.03). Frequent physical distress was reported by 20% of caregivers of persons with SCI (vs. 12% of other caregivers, P = 0.09), but mental health did not differ between caregiver groups. A greater proportion of caregivers of adults with SCI experienced insufficient sleep (47% vs. 30%, P = 0.008) and more days without enough sleep (13 vs. 9 days, P = 0.008). Odds of being younger, caregiver of a spouse, having CHD, and being obese were associated with being a caregiver of an adult with SCI. Conclusion: Caregivers of adults with SCI report similar mental health status, but more poor sleep, and have increased odds of CHD and obesity. Interventions to address physical distress, improve sleep, and address CHD and obesity are needed in this cohort.	[LaVela, Sherri L.; Landers, Kelsie; Etingen, Bella; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res & Dev, Hines, IL 60141 USA; [LaVela, Sherri L.; Etingen, Bella; Karalius, Vytas P.; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat S, Hines, IL 60141 USA; [LaVela, Sherri L.; Landers, Kelsie; Etingen, Bella; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Evaluat Practices & Experiences Patient Ctr C, Hines, IL 60141 USA; [LaVela, Sherri L.] Northwestern Univ, Ctr Healthcare Studies, Inst Publ Hlth & Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Karalius, Vytas P.] Loyola Univ, Dept Publ Hlth Sci, Stritch Sch Med, Maywood, IL 60153 USA	Etingen, B (corresponding author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res & Dev, 151-H,Bldg 1,Off D 322,5th Ave & Roosevelt Rd, Hines, IL 60141 USA.	Bella.Etingen@va.gov		LaVela, Sherri/0000-0001-9900-0120	Veterans Health Administration, Health Services Research and Development (HSRD) Service [LIP 42-125]	This work was supported by the Veterans Health Administration, Health Services Research and Development (HSR&D) Service (LIP 42-125).	Andresen EM, 2003, J EPIDEMIOL COMMUN H, V57, P339, DOI 10.1136/jech.57.5.339; Arango-Lasprilla JC, 2010, NEUROREHABILITATION, V27, P83, DOI 10.3233/NRE-2010-0583; Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Beccuti G, 2011, CURR OPIN CLIN NUTR, V14, P402, DOI 10.1097/MCO.0b013e3283479109; Blanes L, 2007, SPINAL CORD, V45, P399, DOI 10.1038/sj.sc.3102038; Buchanan Robert J, 2011, Int J MS Care, V13, P76, DOI 10.7224/1537-2073-13.2.76; Cappuccio FP, 2008, SLEEP, V31, P619, DOI 10.1093/sleep/31.5.619; Carter PA, 2000, CANCER NURS, V23, P410, DOI 10.1097/00002820-200012000-00002; Carter PA, 2003, CANCER NURS, V26, P253, DOI 10.1097/00002820-200308000-00001; Castro CM, 2009, BEHAV SLEEP MED, V7, P164, DOI 10.1080/15402000902976713; Chandola T, 2010, SLEEP, V33, P739, DOI 10.1093/sleep/33.6.739; Chang EWC, 2007, PSYCHO-ONCOLOGY, V16, P950, DOI 10.1002/pon.1167; Chang HY, 2010, ARCH GERONTOL GERIAT, V50, P267, DOI 10.1016/j.archger.2009.04.006; Cho MH, 2006, J CANCER EDUC, V21, pS37, DOI 10.1207/s15430154jce2101s_8; Dreer LE, 2007, REHABIL PSYCHOL, V52, P351, DOI 10.1037/0090-5550.52.3.351; Ebrahimzadeh MH, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-48; Eisenberg MG, 2010, FINAL REPORT INQUIRY; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Faraut B, 2012, J HYPERTENS, V30, P1354, DOI 10.1097/HJH.0b013e32835465e5; GERHART KA, 1993, ARCH PHYS MED REHAB, V74, P1030, DOI 10.1016/0003-9993(93)90057-H; Gibbins J, 2009, J PAIN SYMPTOM MANAG, V38, P860, DOI 10.1016/j.jpainsymman.2009.04.025; Godwin KM, 2013, J NEUROSCI NURS, V45, P147, DOI 10.1097/JNN.0b013e31828a410b; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hung Jen-Wen, 2012, Chang Gung Med J, V35, P392; Kim H, 2012, J ADV NURS, V68, P846, DOI 10.1111/j.1365-2648.2011.05787.x; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; Kotronoulas G, 2013, J PAIN SYMPTOM MANAG, V45, P579, DOI 10.1016/j.jpainsymman.2012.03.013; LaVela SL, 2012, SPINAL CORD, V50, P682, DOI 10.1038/sc.2012.31; Lavela SL, 2010, CHRONIC ILLN, V6, P67, DOI 10.1177/1742395309356943; Leproult R, 2010, ENDOCR DEV, V17, P11, DOI 10.1159/000262524; Lira FS, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-113; Manigandan C, 2000, SPINAL CORD, V38, P559, DOI 10.1038/sj.sc.3101035; McKibbin CL, 2005, SLEEP, V28, P1245, DOI 10.1093/sleep/28.10.1245; National Alliance for Caregiving, 2009, CAR US EX SUMM; National Alliance for Caregiving, 2010, CAR VET SERV HOM REP; Navaie-Waliser M, 2002, MED CARE, V40, P1249, DOI 10.1097/00005650-200212000-00012; Nogueira PC, 2012, REV LAT-AM ENFERM, V20, P1048, DOI 10.1590/S0104-11692012000600006; Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118; Post MWM, 2005, SPINAL CORD, V43, P311, DOI 10.1038/sj.sc.3101704; Raj JT, 2006, SPINAL CORD, V44, P676, DOI 10.1038/sj.sc.3101899; Rittman M, 2009, J NEUROSCI NURS, V41, P39, DOI 10.1097/JNN.0b013e318193459a; Rowe MA, 2008, J CLIN SLEEP MED, V4, P362; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Schulz R, 2009, REHABIL PSYCHOL, V54, P1, DOI 10.1037/a0014932; Shankar A, 2008, AM J EPIDEMIOL, V168, P1367, DOI 10.1093/aje/kwn281; Simpson C, 2013, J CLIN NURS, V22, P3042, DOI 10.1111/jocn.12127; Simpson G, 2013, CLIN REHABIL, V27, P367, DOI 10.1177/0269215512457961; Van Cauter E, 2008, EUR J ENDOCRINOL, V159, pS59, DOI 10.1530/EJE-08-0298; von Kanel R, 2008, GERONTOLOGY, V54, P131, DOI 10.1159/000113649; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; Wheaton AG, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-295; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Zahran H. S., 2004, Morbidity and Mortality Weekly Report, V53, P963	54	17	18	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUL	2015	38	4					505	514		10.1179/2045772314Y.0000000240			10	Clinical Neurology	Neurosciences & Neurology	CL4RS	WOS:000356941800013	24993244	Green Published			2021-06-18	
J	Mautner, K; Sussman, WI; Axtman, M; Al-Farsi, Y; Al-Adawi, S				Mautner, Kenneth; Sussman, Walter I.; Axtman, Matthew; Al-Farsi, Yahya; Al-Adawi, Samir			Relationship of Attention Deficit Hyperactivity Disorder and Postconcussion Recovery in Youth Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport-related concussion; mild traumatic brain injury; computerized neurocognitive testing; immediate postconcussion assessment and cognitive testing; attention deficit hyperactivity disorder	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; AMERICAN MEDICAL SOCIETY; STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; FOOTBALL PLAYERS; ON-FIELD; COLLEGIATE; IMPACT; SENSITIVITY	Objective:To investigate whether attention deficit hyperactivity disorder (ADHD) influences postconcussion recovery, as measured by computerized neurocognitive testing.Design:This is a retrospective case control study.Setting:Computer laboratories across 10 high schools in the greater Atlanta, Georgia area.Participants:Immediate postconcussion assessment and cognitive testing (ImPACT) scores of 70 athletes with a self-reported diagnosis of ADHD and who sustained a sport-related concussion were compared with a randomly selected age-matched control group. Immediate postconcussion assessment and cognitive testing scores over a 5-year interval were reviewed for inclusion.Main Outcome Measures:Postconcussion recovery was defined as a return to equivalent baseline neurocognitive score on the ImPACT battery, and a concussion symptom score of 7.Results:Athletes with ADHD had on average a longer time to recovery when compared with the control group (16.5 days compared with 13.5 days), although not statistically significant. The number of previous concussions did not have any effect on the rate of recovery in the ADHD or the control group. In addition, baseline neurocognitive testing did not statistically differ between the 2 groups, except in verbal memory.Conclusions:Although not statistically significant, youth athletes with ADHD took on average 3 days longer to return to baseline neurocognitive testing compared with a control group without ADHD.Clinical Relevance:Youth athletes with ADHD may have a marginally prolonged recovery as indexed by neurocognitive testing and should be considered when prognosticating time to recovery in this subset of student athletes.	[Mautner, Kenneth] Emory Univ, Emory Sports Med Ctr, Dept Orthopaed, Atlanta, GA 30322 USA; [Mautner, Kenneth] Emory Univ, Emory Sports Med Ctr, Dept Rehabil, Atlanta, GA 30322 USA; [Sussman, Walter I.] Emory Univ, Dept Rehabil, Atlanta, GA 30322 USA; [Axtman, Matthew] Spectrum Hlth Med Grp, Orthopaed & Sports Med, Grand Rapids, MI USA; [Al-Farsi, Yahya] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Family Med & Publ Hlth, Muscat, Oman; [Al-Adawi, Samir] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Med, Muscat, Oman	Mautner, K (corresponding author), Emory Orthopaed & Spine Ctr, Dept Orthopaed & Rehabil, 59 Execut Pk South, Atlanta, GA 30329 USA.	kmautne@emory.edu	Al-Farsi, Yahya/AAM-2181-2020; sussman, walter/V-5191-2019; Al-Adawi, Samir/A-9663-2016; Meijer, Anna/K-5118-2016	Al-Farsi, Yahya/0000-0002-0302-7132; sussman, walter/0000-0002-3279-6029; Al-Adawi, Samir/0000-0002-9858-5582; 			Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bonfield CM, 2013, J NEUROSURG-PEDIATR, V12, P97, DOI 10.3171/2013.5.PEDS12424; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; *CDCP, 2007, MORTALITY MORBIDITY, V0056; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coppel DB, 2011, PHYS MED REH CLIN N, V22, P653, DOI 10.1016/j.pmr.2011.08.006; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grindel Scott H, 2006, Curr Sports Med Rep, V5, P9; Guskiewicz KM, 2011, PHYS MED REH CLIN N, V22, P603, DOI 10.1016/j.pmr.2011.08.003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Monaghan S, HIGH SCH SPORTS PART; Owens JS, 2007, CLIN CHILD FAM PSYCH, V10, P335, DOI 10.1007/s10567-007-0027-3; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2011, CLIN J SPORT MED, V21, P392, DOI 10.1097/JSM.0b013e3182262eb1; Randolph C, 2001, J ATHL TRAINING, V36, P288; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seidman LJ, 1995, J CHILD PSYCHOL PSYC, V36, P1459, DOI 10.1111/j.1469-7610.1995.tb01675.x; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wolraich ML, 2005, PEDIATRICS, V115, P1734, DOI 10.1542/peds.2004-1959; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	53	17	17	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2015	25	4					355	360		10.1097/JSM.0000000000000151			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CM2EK	WOS:000357492400008	25353721				2021-06-18	
J	Nemes, O; Kovacs, N; Czeiter, E; Kenyeres, P; Tarjanyi, Z; Bajnok, L; Buki, A; Doczi, T; Mezosi, E				Nemes, Orsolya; Kovacs, Noemi; Czeiter, Endre; Kenyeres, Peter; Tarjanyi, Zita; Bajnok, Laszlo; Buki, Andras; Doczi, Tamas; Mezosi, Emese			Predictors of post-traumatic pituitary failure during long-term follow-up	HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM			English	Article						Traumatic brain injury; Hypopituitarism; GCS; Growth hormone deficiency	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE DEFICIENCY; ANTIPITUITARY ANTIBODIES; NATURAL-HISTORY; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; ADULTS	OBJECTIVE: There is increasing awareness among physicians of the risks of traumatic brain injury (TBI)-induced hypopituitarism. We have assessed the prevalence and risk factors of post-traumatic hypopituitarism by analyzing the TBI database of the University of Pecs. DESIGN: This consecutive analysis of 126 TBI survivors (mean age: 42.4 years, average follow-up time: 48 months) revealed that 60.3% had severe and 39.7% moderately severe trauma based on GCS score. Subdural hemorrhage (29.3%) and diffuse injury (27%) were the most common types of injury; 17.5% of patients suffered basal skull fractures. RESULTS: The prevalence of major anterior pituitary failure was 57.1%. Occurrence of total and partial growth hormone deficiency (GHD/GHI) was 39.7%, while LH/FSH, TSH and ACTH deficiencies were less frequent, namely 23.0%, 16.7% and 10.3%, respectively. Of the 82 patients with multiple endocrine evaluations, 31.7% presented significant changes in hormonal deficiencies during the follow-up period: new hormone deficiencies developed in 16 patients, while hormonal disturbances resolved in 10 subjects. Looking for factors influencing the prevalence of pituitary dysfunction, endocrine results were analyzed in relation to age, gender, GCS scores, injury types, basal skull fracture, ventricular drain insertion and necessity of neurosurgical intervention. All hormonal disturbances were more prevalent after severe trauma (OR: 3.25, p=0.002), while the need for surgery proved to be an independent determinant of multiple and GH deficits (OR: 3.72 (p=0.004) and 9.33 (p=0.001)). CONCLUSION: Post-traumatic hypopituitarism is common and may evolve or resolve over time. Victims of severe TBI and/or patients who have undergone neurosurgical intervention for head injury are the most prone to post-traumatic hypopituitarism.	[Nemes, Orsolya; Kenyeres, Peter; Tarjanyi, Zita; Bajnok, Laszlo; Mezosi, Emese] Univ Pecs, Dept Internal Med 1, H-7624 Pecs, Hungary; [Kovacs, Noemi; Czeiter, Endre; Buki, Andras; Doczi, Tamas] Univ Pecs, Dept Neurosurg, H-7624 Pecs, Hungary	Mezosi, E (corresponding author), Univ Pecs, Dept Internal Med 1, 13 Ifjusag, H-7624 Pecs, Hungary.	emese.mezosi@aok.pte.hu	Schernhammer, Eva S/L-7898-2018; Czeiter, Endre/B-1404-2009	Schernhammer, Eva S/0000-0002-4337-9415; Czeiter, Endre/0000-0002-9578-6944			Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; Ghigo E, 2008, GROWTH HORM IGF RES, V18, P1, DOI 10.1016/j.ghir.2007.07.004; Glynn N, 2013, CLIN ENDOCRINOL, V78, P17, DOI 10.1111/cen.12010; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Murray RD, 2004, J CLIN ENDOCR METAB, V89, P1586, DOI 10.1210/jc.2003-030761; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4195, DOI 10.1210/jc.2009-0602; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2008, J NEUROTRAUM, V25, P1071; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Ulfarsson T, 2013, J NEUROTRAUM, V30, P271, DOI 10.1089/neu.2012.2494; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430	38	17	18	1	5	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1109-3099	2520-8721		HORM-INT J ENDOCRINO	Horm.-Int. J. Endocrinol. Metab.	JUL-SEP	2015	14	3					383	391		10.14310/horm.2002.1564			9	Endocrinology & Metabolism	Endocrinology & Metabolism	CW6FG	WOS:000365092400006	25553764	Bronze, Green Accepted			2021-06-18	
J	Ramanathan, R; Gu, ZR; Limkemann, AJ; Chandrasekhar, S; Rensing, E; Mays, C; Duane, TM				Ramanathan, Rajesh; Gu, Zirui; Limkemann, Ashley J.; Chandrasekhar, Shillika; Rensing, Edna; Mays, Cathy; Duane, Therese M.			Association between Interruptions in Chemical Prophylaxis and VTE Formation	AMERICAN SURGEON			English	Article							DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM PROPHYLAXIS; TRAUMATIC BRAIN-INJURY; MAJOR TRAUMA; SURGERY; PREVENTION; PATIENT; HEPARIN; RISK; MECHANISMS	Venous thromboembolisms (VTE) are considered preventable events with appropriate mechanical or chemical prophylaxis. However, chemical prophylaxis is frequently delayed or interrupted during hospitalization. We investigated the impact of delayed initiation and interruption of chemical prophylaxis on VTE rates. The incidence of VTE at an urban academic medical center was measured in patients hospitalized for >2 days between November 2013 and May 2014. Patients receiving prophylaxis were grouped as complete (started within 24 hours of admission and no interruptions), delayed (started >24 hours and no interruptions), and interrupted (interruption for >24 hours with or without delay). There were 9961 hospital admissions and 33 VTE (3.3 per 1000 admissions). 25.2 per cent had complete, 16.4 per cent had delayed, and 11.8 per cent had interrupted prophylaxis. 36.8 per cent received no prophylaxis. Interrupted prophylaxis was associated with more VTE than complete (10.2 vs 2.0 per 1000, P < 0.01) and 5.2 greater odds. Admission to a surgical service and prolonged hospital stay were independently associated with increased likelihood of VTE. There was a lower likelihood of getting complete prophylaxis among patients admitted to orthopedic, transplant, cardiac, plastic, and vascular surgery. Surgical patients are at higher risk for VTE and interruptions in VTE prophylaxis significantly increase the risk of VTE.	[Ramanathan, Rajesh; Limkemann, Ashley J.] VCU Med Ctr, Dept Surg, Richmond, VA USA; [Gu, Zirui; Rensing, Edna; Mays, Cathy] VCU Med Ctr, Performance Improvement, Richmond, VA USA; [Chandrasekhar, Shillika] Virginia Commonwealth Univ, Richmond, VA USA; [Duane, Therese M.] JPS Hlth Network, Dept Surg, Ft Worth, TX USA	Duane, TM (corresponding author), 1500 S Main St Suite 303, Ft Worth, TX 76104 USA.	tduane@jpshealth.org					Agency for Healthcare Research and Quality, 2003, AHRQ QUAL IND GUID P; Barrera LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008303.pub2; Bick RL, 2005, HEMATOL ONCOL CLIN N, V19, P1, DOI 10.1016/j.hoc.2004.09.003; BOISCLAIR MD, 1993, BLOOD, V82, P3350; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; Falck-Ytter Y, 2012, CHEST, V141, pE278S, DOI 10.1378/chest.11-2404; Francis CW, 2013, J THROMB THROMBOLYS, V35, P359, DOI 10.1007/s11239-013-0889-9; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Guyatt GH, 2012, CHEST, V141, p48S, DOI 10.1378/chest.11-2286; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hill J, 2007, BMJ-BRIT MED J, V334, P1053, DOI 10.1136/bmj.39174.678032.AD; KAKKAR VV, 1972, LANCET, V2, P101; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Leonardi MJ, 2006, ARCH SURG-CHICAGO, V141, P790, DOI 10.1001/archsurg.141.8.790; Louis SG, 2014, JAMA SURG, V149, P365, DOI 10.1001/jamasurg.2013.3963; Lyman GH, 2013, J CLIN ONCOL, V31, P2189, DOI 10.1200/JCO.2013.49.1118; Mahan CE, 2011, THROMB HAEMOSTASIS, V106, P405, DOI 10.1160/TH11-02-0132; Malhotra AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106793; Muntz JE, 2010, AM J SURG, V199, pS11, DOI 10.1016/j.amjsurg.2009.10.007; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Ramanathan R, 2013, AM SURGEON, V79, P578; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers SO, 2007, J TRAUMA, V62, P562; Salottolo K, 2011, J TRAUMA, V70, P19, DOI 10.1097/TA.0b013e318207c54d	24	17	17	0	7	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JUL	2015	81	7					732	737					6	Surgery	Surgery	CN2FN	WOS:000358236300025	26140896				2021-06-18	
J	Scott, GG; Coats, B				Scott, Gregory G.; Coats, Brittany			Microstructural Characterization of the Pia-Arachnoid Complex Using Optical Coherence Tomography	IEEE TRANSACTIONS ON MEDICAL IMAGING			English	Article						Arachnoid; biomedical image processing; in situ imaging; manual image segmentation; meninges; optical coherence tomography (OCT); pig animal model; traumatic brain injury	BRAIN-INJURY; HEAD ROTATIONS; ANATOMY; MICROSCOPY; MORPHOLOGY; RESPONSES; NERVE	Traumatic brain injury (TBI) is one of the leading causes of death and disability in the world, and is often identified by the presence of subdural and/or subarachnoid hemorrhages that develop from ruptured cortical vessels during brain-skull displacement. The pia-arachnoid complex (PAC), also known as the leptomeninges, is the major mechanical connection between the brain and skull, and influences cortical vessel deformation and rupture following brain trauma. This complex consists of cerebrospinal fluid, arachnoid trabeculae, and subarachnoid vasculature sandwiched between the arachnoid and pia mater membranes. Remarkably, studies of the tissues in the PAC are largely qualitative and do not provide numerical metrics of population density and variability of the arachnoid trabeculae and subarachnoid vasculature. In this study, microstructural imaging was performed on the PAC to numerically quantify these metrics. Five porcine brains were perfusion-fixed and imaged in situ using optical coherence tomography with micrometer resolution. Image processing was performed to estimate the volume fraction (VF) of the arachnoid trabeculae and subarachnoid vasculature in 12 regions of the brain. High regional variability was found within each brain, with individual brains exhibiting up to a 38.4 percentage-point range in VF. Regions with high VF were often next to regions with low VF. This suggests that some areas of the brain may be mechanically weaker, increasing their susceptibility to hemorrhage during TBI events. This study provides the first quantifiable data of arachnoid trabeculae and subarachnoid vasculature distribution within the PAC and will be valuable to understanding brain biomechanics during head trauma.	[Scott, Gregory G.; Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA	Coats, B (corresponding author), Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA.	greg.scott.me@gmail.com; bcoats@mech.utah.edu			Primary Children's Medical Center Foundation Early Career Grant	This work was supported in part by the Primary Children's Medical Center Foundation Early Career Grant.	ALCOLADO R, 1988, NEUROPATH APPL NEURO, V14, P1, DOI 10.1111/j.1365-2990.1988.tb00862.x; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Assayag O, 2013, NEUROIMAGE-CLIN, V2, P549, DOI 10.1016/j.nicl.2013.04.005; Bizheva K, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1851513; Bizheva K, 2004, J BIOMED OPT, V9, P719, DOI 10.1117/1.1756920; Boppart SA, 2003, PSYCHOPHYSIOLOGY, V40, P529, DOI 10.1111/1469-8986.00055; Brezinski ME, 1997, HEART, V77, P397, DOI 10.1136/hrt.77.5.397; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Damestani Y, 2013, NANOMED-NANOTECHNOL, V9, P1135, DOI 10.1016/j.nano.2013.08.002; Dickerson J. W. T., 1966, Proceedings of the Royal Society, V166B, P384; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Eucker S. A., 2009, THESIS U PENNSYLVANI; Finke M, 2012, INT J MED ROBOT COMP, V8, P327, DOI 10.1002/rcs.1425; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Girard MJA, 2011, INVEST OPHTH VIS SCI, V52, P7738, DOI 10.1167/iovs.10-6925; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Izatt JA, 1996, IEEE J SEL TOP QUANT, V2, P1017, DOI 10.1109/2944.577331; Jeon SW, 2006, J NEUROSCI METH, V154, P96, DOI 10.1016/j.jneumeth.2005.12.008; Killer HE, 2003, BRIT J OPHTHALMOL, V87, P777, DOI 10.1136/bjo.87.6.777; Lee SJ, 2014, J MECH BEHAV BIOMED, V29, P213, DOI 10.1016/j.jmbbm.2013.08.026; Nahas A, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.121514; NICHOLAS DS, 1988, J NEUROSURG, V69, P276, DOI 10.3171/jns.1988.69.2.0276; OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003; Petroni S, 2003, CELLS TISSUES ORGANS, V173, P122, DOI 10.1159/000068943; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; SCHMITT JM, 1995, DERMATOLOGY, V191, P93, DOI 10.1159/000246523; Sci. Comput. Imag. Inst, SEG3D VOL IM SEGM VI; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Srinivasan VJ, 2011, J CEREBR BLOOD F MET, V31, P1339, DOI 10.1038/jcbfm.2011.19; Srinivasan VJ, 2010, OPT LETT, V35, P43, DOI 10.1364/OL.35.000043; Szu JI, 2012, JOVE-J VIS EXP, DOI 10.3791/50053; Wang H, 2011, NEUROIMAGE, V58, P984, DOI 10.1016/j.neuroimage.2011.07.005; Weller R. O., 2005, Morphologie, V89, P22, DOI 10.1016/S1286-0115(05)83235-7	40	17	17	0	6	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0062	1558-254X		IEEE T MED IMAGING	IEEE Trans. Med. Imaging	JUL	2015	34	7					1452	1459		10.1109/TMI.2015.2396527			8	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	CM3VX	WOS:000357614300004	25643401				2021-06-18	
J	Watts, LT; Shen, Q; Deng, SW; Chemello, J; Duong, TQ				Watts, Lora Talley; Shen, Qiang; Deng, Shengwen; Chemello, Jonathan; Duong, Timothy Q.			Manganese-Enhanced Magnetic Resonance Imaging of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						calcium activity; controlled cortical impact; cortical spreading depolarization; gliosis; MEMRI; TBI	REACTIVE GLIOSIS; MRI; CALCIUM; ACTIVATION; VISUALIZATION; CONNECTIVITY; PERFUSION; MICE	Calcium dysfunction is involved in secondary traumatic brain injury (TBI). Manganese-enhanced MRI (MEMRI), in which the manganese ion acts as a calcium analog and a MRI contrast agent, was used to study rats subjected to a controlled cortical impact. Comparisons were made with conventional T2 MRI, sensorimotor behavior, and immunohistology. The major findings were: (1) Low-dose manganese (29mg/kg) yielded excellent contrast with no negative effects on behavior scores relative to vehicle; (2) T1-weighted MEMRI was hyperintense in the impact area at 1-3h, hypointense on day 2, and markedly hypointense with a hyperintense area surrounding the core on days 7 and/or 14, in contrast to the vehicle group, which did not show a biphasic profile; (3) in the hyperacute phase, the area of hyperintense T1-weighted MEMRI was larger than that of T2 MRI; (4) glial fibrillary acidic protein staining revealed that the MEMRI signal void in the impact core and the hyperintense area surrounding the core on day 7 and/or 14 corresponded to tissue cavitation and reactive gliosis, respectively; (5) T2 MRI showed little contrast in the impact core at 2h, hyperintense on day 2 (indicative of vasogenic edema), hyperintense in some animals but pseudonormalized in others on day 7 and/or 14; (6) behavioral deficit peaked on day 2. We concluded that MEMRI detected early excitotoxic injury in the hyperacute phase, preceding vasogenic edema. In the subacute phase, MEMRI detected contrast consistent with tissue cavitation and reactive gliosis. MEMRI offers novel contrasts of biological processes that complement conventional MRI in TBI.	[Watts, Lora Talley; Shen, Qiang; Deng, Shengwen; Chemello, Jonathan; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA	Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	duongt@uthscsa.edu	Shen, Qiang/B-8784-2008; Duong, Tim/AAL-8357-2021	Shen, Qiang/0000-0002-4287-3403; Duong, Tim/0000-0001-6403-2827	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001120, KL2TR001118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001118, UL1 TR001120] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045879] Funding Source: Medline		Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; De La Garza BH, 2012, INVEST OPHTH VIS SCI, V53, P4352, DOI 10.1167/iovs.11-8826; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Duong TQ, 2000, MAGN RESON MED, V43, P383, DOI 10.1002/(SICI)1522-2594(200003)43:3<383::AID-MRM10>3.0.CO;2-Q; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Henning EC, 2005, MAGN RESON MED, V53, P851, DOI 10.1002/mrm.20438; Kawai Y, 2010, NEUROIMAGE, V49, P3122, DOI 10.1016/j.neuroimage.2009.11.005; Kivity S, 2010, ANN NY ACAD SCI, V1193, P70, DOI 10.1111/j.1749-6632.2009.05302.x; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Lin YJ, 1997, MAGN RESON MED, V38, P378, DOI 10.1002/mrm.1910380305; Long J. A., 2014, J NEUROTRAUMA; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Meng XJ, 2004, ANN NEUROL, V55, P207, DOI 10.1002/ana.10803; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Pautler RG, 2002, NEUROIMAGE, V16, P441, DOI 10.1006/nimg.2002.1075; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Silva AC, 2004, NMR BIOMED, V17, P532, DOI 10.1002/nbm.945; Smith KDB, 2007, NEUROIMAGE, V35, P1401, DOI 10.1016/j.neuroimage.2007.01.046; TRUMP BF, 1995, FASEB J, V9, P219; Tucciarone J, 2009, NEUROIMAGE, V44, P923, DOI 10.1016/j.neuroimage.2008.07.036; van der Zijden JP, 2007, NEUROIMAGE, V34, P1650, DOI 10.1016/j.neuroimage.2006.11.001; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	28	17	18	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					1001	1010		10.1089/neu.2014.3737			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200009	25531419	Green Published			2021-06-18	
J	Wolf, EG; Baugh, LM; Kabban, CMS; Richards, MF; Prye, J				Wolf, E. George; Baugh, Laura M.; Kabban, Christine M. Schubert; Richards, Michael F.; Prye, Jennifer			Cognitive function in a traumatic brain injury hyperbaric oxygen randomized trial	UNDERSEA AND HYPERBARIC MEDICINE			English	Article						traumatic brain injury; hyperbaric oxygen; cognitive function; TBI; HBO; HBO2; HBOT; hydrostatic pressure; PTSD; post-traumatic stress disorder; PCL; PCL-M; PCL-C	TEST-RETEST RELIABILITY; DELAYED NEUROPSYCHIATRIC SYNDROME; GENE-EXPRESSION; SYMPTOMS; CHECKLIST; VALIDITY; THERAPY; PTSD	Objective: Determine changes in cognition and post traumatic stress disorder (PTSD) symptoms in subjects with traumatic brain injury (TBI) exposed to 2.4 atmospheres absolute (atm abs) breathing 100% oxygen vs. sham (1.3 atm-abs air). Methods: Fifty randomized subjects completed a total of 30 exposures. A concussion history was taken, then baseline, post-series, and six-week follow-up immediate post-concussion assessment and cognitive testing, Brain checkers and PTSD Checklist for Military (PCL-M) tests were administered. Results: No statistically significant differences between groups were noted, but both groups improved. Subgroups analyses, based on concussion history and individual test components, showed improvement in the treatment group vs. the sham. These subgroups included the number of concussive events, time from event to consent, loss of consciousness, visual memory, processing, go no go, and simple reaction time. Conclusion: There was no statistically significant difference between a sham and 2.4 atm abs hyperbaric oxygen (HBO2) in cognitive scores from ImPACT and Brain checkers or composite scores in the PCL-M; however both groups showed improvement. Subgroups with favorable response to treatment are identified. Future studies evaluating HBO2 should consider concussion histories or focus on validating subgroup response to determine HBO2 as a potential adjunctive treatment for persistent symptoms following TBI.	[Wolf, E. George; Richards, Michael F.; Prye, Jennifer] US Air Force, Sch Aerosp Med, Hyperbar Med Dept, 59th Med Wing, Lackland AFB, TX USA; [Baugh, Laura M.] US Air Force Acad, Dept Neurol, Med Grp 10, Colorado Springs, CO 80840 USA; [Kabban, Christine M. Schubert] ENC Air Force Inst Technol, Dept Math & Stat, Wright Patterson AFB, OH USA	Wolf, EG (corresponding author), US Air Force, Sch Aerosp Med, Hyperbar Med Dept, 59th Med Wing, Lackland AFB, TX USA.	earl.wolf.ctr@us.af.mil			Air Force Medical Service; U.S. Navy Bureau of Medicine and Surgery; U.S. Army Medical Materiel Development Activity; Injured Marine Semper Fi Fund	The authors would like to recognize and thank the Air Force Medical Service for funding this research project; the U.S. Navy Bureau of Medicine and Surgery for funding temporary duty requirements; the U.S. Army Medical Materiel Development Activity for end of study funding; Ms. Sheila Galvin, Traumatic Brain Injury Program Coordinator for the Wounded Warrior Regiment USMC for her superb service in coordinating subject requirements; Ms. Karen Guenther and the Injured Marine Semper Fi Fund for transportation support for subjects; and Dr. Jason Cromar, while at USAFSAM, for coordinating the protocol.	[Anonymous], ANN REP, P29; [Anonymous], 2008, DOD HBOT TBI CONS C; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Chang DC, 2010, UNDERSEA HYPERBAR M, V37, P23; Chen Y, 2009, NEUROCHEM RES, V34, P1047, DOI 10.1007/s11064-008-9873-8; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; de Vet HCW, 2006, J RHEUMATOL, V33, P434; Dean JB, 2003, J APPL PHYSIOL, V95, P883, DOI 10.1152/japplphysiol.00920.2002; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN PRACT GU, p[6, 16, 57]; Department of Veterans Affairs Department of Defense, 2010, VA DOD CLIN PRACT GU, p[91, 177]; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Eggum TJ, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2979864; Elsmore TF, 2006, COGNITIVE STATUS REP; Elsmore TF, 2007, ARCH CLIN NEUROPSYCH, V22, pS135, DOI 10.1016/j.acn.2006.10.009; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0; Gore KL, 2013, PSYCHOL ASSESSMENT, V25, P1032, DOI 10.1037/a0033325; [郭紫芬 Guo Zifen], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P9353; Harch PG, 2013, J NEUROTRAUM, V30, P1995, DOI 10.1089/neu.2012.2799; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Kendall AC, 2013, UNDERSEA HYPERBAR M, V40, P115; Khusid M, 2013, PSYCHIAT ANN, V43, P340, DOI 10.3928/00485713-20130703-11; King EG, 2013, REHABIL PSYCHOL, V58, P272, DOI 10.1037/a0033116; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo CP, 2007, EUR J NEUROL, V14, P777, DOI 10.1111/j.1468-1331.2007.01854.x; Lovell M, 2012, MANAGEMENT SPORTS CO; Ma M, 2013, NEUROBIOL DIS, V60, P61, DOI 10.1016/j.nbd.2013.08.010; Macdonald AG, 1999, COMP BIOCHEM PHYS A, V122, P13, DOI 10.1016/S1095-6433(98)10173-3; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; McDonagh MS, 2003, AHRQ PUBLICATION, V03-E050; MedCalc Software, 2013, MEDCALC US FRIENDL S; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Mulkey DK, 2003, J APPL PHYSIOL, V95, P922, DOI 10.1152/japplphysiol.00865.2002; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Proponency Office for Rehabilitation & Reintegration, 2009, AUT NEUR ASS METR AN; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Scorza KA, 2013, UNDERSEA HYPERBAR M, V40, P548; Tofighi R, 2006, BRAIN RES, V1098, P1, DOI 10.1016/j.brainres.2006.04.095; U. S. Department of Veterans Affairs, 2014, US PTSD CHECKL DSM 4; Walker WC, 2013, NEUROREHABILITATION; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Wolf EG, 2012, UNDERSEA HYPERBAR M, V39, P1075; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698	54	17	19	0	6	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	JUL-AUG	2015	42	4					313	332					20	Marine & Freshwater Biology; Medicine, Research & Experimental	Marine & Freshwater Biology; Research & Experimental Medicine	DB5RM	WOS:000368571300004	26403017				2021-06-18	
J	Pilipovic, K; Zupan, Z; Dolenec, P; Mrsic-Pelcic, J; Zupan, G				Pilipovic, Kristina; Zupan, Zeljko; Dolenec, Petra; Mrsic-Pelcic, Jasenka; Zupan, Gordana			A single dose of PPAR gamma agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Inflammation; Oxidative stress; Pioglitazone; Rat; Traumatic brain injury	PROLIFERATOR-ACTIVATED RECEPTORS; TRANSIENT FOCAL ISCHEMIA; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INDUCED STATUS EPILEPTICUS; NF-KAPPA-B; GLUTATHIONE-PEROXIDASE; NEURONAL INJURY; HEAD-INJURY; PROVIDES NEUROPROTECTION	Neuroprotective actions of the peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists have been observed in various animal models of the brain injuries. In this study we examined the effects of a single dose of pioglitazone on oxidative and inflammatory parameters as well as on neurodegeneration and the edema formation in the rat parietal cortex following traumatic brain injury (TBI) induced by the lateral fluid percussion injury (LFPI) method. Pioglitazone was administered in a dose of 1 mg/kg at 10 min after the brain trauma. The animals of the control group were sham-operated and injected by vehicle. The rats were decapitated 24 h after LFPI and their parietal cortices were analyzed by biochemical and histological methods. Cortical edema was evaluated in rats sacrificed 48 h following TBI. Brain trauma caused statistically significant oxidative damage of lipids and proteins, an increase of glutathione peroxidase (GSH-Px) activity, the cyclooxygenase-2 (COX-2) overexpression, reactive astrocytosis, the microglia activation, neurodegeneration, and edema, but it did not influence the superoxide dismutase activity and the expressions of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in the rat parietal cortex. Pioglitazone significantly decreased the cortical lipid and protein oxidative damage, increased the GSH-Px activity and reduced microglial reaction. Although a certain degree of the TBI-induced COX-2 overexpression, neurodegeneration and edema decrease was detected in pioglitazone treated rats, it was not significant. In the injured animals, cortical reactive astrocytosis was unchanged by the tested PPAR gamma agonist. These findings demonstrate that pioglitazone, administered only in a single dose, early following LFPI, reduced cortical oxidative damage, increased antioxidant defense and had limited anti-inflammatory effect, suggesting the need for further studies of this drug in the treatment of TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Pilipovic, Kristina; Dolenec, Petra; Mrsic-Pelcic, Jasenka; Zupan, Gordana] Univ Rijeka, Sch Med, Dept Pharmacol, Rijeka 51000, Croatia; [Zupan, Zeljko] Univ Rijeka, Sch Med, Dept Anesthesiol Reanimatol & Intens Care Med, Rijeka 51000, Croatia; [Zupan, Zeljko] Clin Hosp Ctr Rijeka, Anesthesiol Clin, Rijeka, Croatia; [Zupan, Zeljko] Clin Hosp Ctr Rijeka, Clin Intens Care Med, Rijeka, Croatia	Zupan, G (corresponding author), Univ Rijeka, Sch Med, Dept Pharmacol, Brace Branchetta 20, Rijeka 51000, Croatia.	gordana.zupan@medri.uniri.hr	Zupan, Gordana/AAO-7020-2021; Zupan, Gordana/R-4927-2018; Zupan, Zeljko/AAO-1749-2021; Zupan, Gordana/AAO-7057-2021; Dolenec, Petra/S-3997-2018; Pilipovic, Kristina/Q-5974-2018; Mrsic-Pelcic, Jasenka/R-2972-2018; Zupan, Zeljko/S-2786-2018	Zupan, Gordana/0000-0002-4422-9021; Zupan, Zeljko/0000-0003-4576-7961; Zupan, Gordana/0000-0002-4422-9021; Dolenec, Petra/0000-0002-9960-0385; Pilipovic, Kristina/0000-0002-7129-1621; Mrsic-Pelcic, Jasenka/0000-0002-6313-9232; Zupan, Zeljko/0000-0003-4576-7961	Ministry of Science, Education and Sports of the Republic of CroatiaMinistry of Science, Education and Sports, Republic of Croatia [062-0620529-0519]; University of Rijeka [13.06.1.1.09]	The authors thank Marina Jakovac, eng.med.lab.diagn., and Maja Rukavina, univ.bacc.biotech et pharm.inv. from the Department of Pharmacology, School of Medicine, University of Rijeka, Rijeka, Croatia for then much appreciated technical assistance. This work has been supported in parts by Grant 062-0620529-0519 to G.Z. from The Ministry of Science, Education and Sports of the Republic of Croatia and by the University of Rijeka under the project number 13.06.1.1.09 to G.Z.	Abdallah DM, 2010, BRAIN RES, V1351, P246, DOI 10.1016/j.brainres.2010.06.034; Abdelrahman M, 2005, CARDIOVASC RES, V65, P772, DOI 10.1016/j.cardiores.2004.12.008; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Aoun P, 2003, EUR J PHARMACOL, V472, P65, DOI 10.1016/S0014-2999(03)01867-3; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; Bernardo A, 2006, CURR PHARM DESIGN, V12, P93, DOI 10.2174/138161206780574579; Bordt EA, 2014, FREE RADICAL BIO MED, V76, P34, DOI 10.1016/j.freeradbiomed.2014.07.033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Callaway JK, 1998, J PHARMACOL TOXICOL, V39, P155, DOI 10.1016/S1056-8719(98)00022-7; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chatzipanteli K, 2012, THER HYPOTHERMIA TEM, V2, P167, DOI 10.1089/ther.2012.0016; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; Cuzzocrea S, 2004, VASC PHARMACOL, V41, P187, DOI 10.1016/j.vph.2004.10.004; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Davis DS, 2013, NEURAL IMMUNE INTERA, P3, DOI DOI 10.1007/978-1-4614-4729-0_; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Dehmer T, 2004, J NEUROCHEM, V88, P494, DOI 10.1046/j.1471-4159.2003.02210.x; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Freire MAM, 2012, W INDIAN MED J, V61, P751; Gamboa J, 2010, NEUROSCIENCE, V170, P846, DOI 10.1016/j.neuroscience.2010.07.063; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Gurley C, 2008, PPAR RES, V2008, DOI 10.1155/2008/453120; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Heneka MT, 2007, BBA-MOL CELL BIOL L, V1771, P1031, DOI 10.1016/j.bbalip.2007.04.016; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kiaei M, 2005, NEURODEGENER DIS, V2, P246, DOI 10.1159/000090364; Kielian T, 2004, J NEUROCHEM, V90, P1163, DOI 10.1111/j.1471-4159.2004.02579.x; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; Kolker S, 2001, EUR J NEUROSCI, V13, P2115, DOI 10.1046/j.0953-816x.2001.01595.x; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V294, P1093, DOI 10.1016/S0006-291X(02)00602-2; Lee KJ, 2008, EUR J NEUROSCI, V27, P334, DOI 10.1111/j.1460-9568.2007.06007.x; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Liu F, 2014, MOL MED REP, V9, P1225, DOI 10.3892/mmr.2014.1967; Liu GW, 2007, AUTOIMMUNITY, V40, P95, DOI 10.1080/08916930601083946; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Moraga-Amaro R, 2014, J PHYSIOL-PARIS, V108, P240, DOI 10.1016/j.jphysparis.2014.08.005; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Okada K, 2006, BRAIN RES, V1102, P175, DOI 10.1016/j.brainres.2006.04.108; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; Ooigawa H, 2006, ACTA NEUROPATHOL, V112, P471, DOI 10.1007/s00401-006-0108-2; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Phulwani NK, 2006, J NEUROCHEM, V99, P1389, DOI 10.1111/j.1471-4159.2006.04183.x; Pilipovic K, 2011, NEUROCHEM RES, V36, P913, DOI 10.1007/s11064-011-0424-3; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Sakamoto J, 2000, BIOCHEM BIOPH RES CO, V278, P704, DOI 10.1006/bbrc.2000.3868; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schmerbach K, 2008, BRAIN RES, V1208, P225, DOI 10.1016/j.brainres.2008.02.032; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Shimazu T, 2005, STROKE, V36, P353, DOI 10.1161/01.STR.0000152271.21943.a2; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P103; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Storer PD, 2005, J NEUROIMMUNOL, V161, P113, DOI 10.1016/j.jneuroim.2004.12.015; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sun H, 2008, INT J DEV NEUROSCI, V26, P505, DOI 10.1016/j.ijdevneu.2008.01.009; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Sundararajan S, 2006, NEUROCHEM INT, V49, P136, DOI 10.1016/j.neuint.2006.03.020; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yu X, 2008, BRAIN RES, V1200, P146, DOI 10.1016/j.brainres.2008.01.047; Zhang DQ, 1999, NEUROSCI LETT, V272, P57, DOI 10.1016/S0304-3940(99)00455-3; Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x; Zhu Tao, 2004, Chin J Traumatol, V7, P32; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zupan Z, 2011, PROG NEURO-PSYCHOPH, V35, P1846, DOI 10.1016/j.pnpbp.2011.08.005	140	17	18	0	44	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	JUN 3	2015	59						8	20		10.1016/j.pnpbp.2015.01.003			13	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CB9WP	WOS:000349984900002	25579788				2021-06-18	
J	Liu, HZ; Xiao, XF; Sun, CZ; Sun, D; Li, YY; Yang, MS				Liu, Huaizheng; Xiao, Xuefei; Sun, Chuanzheng; Sun, Dao; Li, Yayong; Yang, Mingshi			Systemic inflammation and multiple organ injury in traumatic hemorrhagic shock	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						Systemic Inflammation; Multiple Organ Injury; Hemorrhagic Shock; Review	TOLL-LIKE RECEPTORS; FRESH WHOLE-BLOOD; BRAIN-INJURY; NA+/H+ EXCHANGER; HEPATIC-DYSFUNCTION; RURAL STATE; RESUSCITATION; MODEL; FAILURE; DEATHS	Traumatic hemorrhagic shock (HS) is a severe outcome of traumatic injury that accounts for numerous traumatic deaths. In the process of traumatic HS, both hemorrhage and trauma can trigger a complex cascade of posttraumatic events that are related to inflammatory and immune responses, which may lead to multiple organ injury or even death. From a mechanistic perspective, systemic inflammation and organ injury are involved coagulation, the complement system, impaired microcirculation and inflammatory signaling pathways. In this review, we discuss the systemic inflammation and multiple organ injury in post-traumatic HS.	[Liu, Huaizheng; Xiao, Xuefei; Sun, Chuanzheng; Sun, Dao; Li, Yayong; Yang, Mingshi] Cent S Univ, Xiangya Hosp 3, Emergency & Intens Care Ctr, Changsha 410013, Hunan, Peoples R China	Yang, MS (corresponding author), Cent S Univ, Xiangya Hosp 3, Emergency & Intens Care Ctr, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	lhz3385@yeah.net			Science and Technology Program from Hunan Science and Technology Burea [2012FJ4313]	This work was supported by Science and Technology Program from Hunan Science and Technology Burea (2012FJ4313).	Avkiran M, 2008, CURR OPIN PHARMACOL, V8, P133, DOI 10.1016/j.coph.2007.12.007; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Bogren LK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094225; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Catania R. A., 1999, Annals Academy of Medicine Singapore, V28, P120; Chai W, 2012, J SURG RES, V176, P210, DOI 10.1016/j.jss.2011.07.016; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeLong WG, 2004, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000130840.64528.1e; Esposito TJ, 2003, J TRAUMA, V54, P663, DOI 10.1097/01.TA.0000058124.78958.6B; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Fliegel L, 2009, EXPERT OPIN THER TAR, V13, P55, DOI 10.1517/14728220802600707 ; Frink M, 2007, ANN SURG, V246, P836, DOI 10.1097/SLA.0b013e318158fca0; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; Harbrecht BG, 2002, J TRAUMA, V53, P517, DOI 10.1097/00005373-200209000-00020; Harbrecht BG, 2001, AM SURGEON, V67, P122; Hawksworth JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034224; Hostmann A, 2008, CRIT CARE, V12, DOI 10.1186/cc6772; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; Kusumoto K, 2001, AM J PHYSIOL-HEART C, V280, pH738; Lee TH, 2013, TRANSFUSION, V53, p72S, DOI 10.1111/trf.12039; Lu Jian, 2012, Zhonghua Wai Ke Za Zhi, V50, P655; Makley AT, 2010, J TRAUMA, V68, P305, DOI 10.1097/TA.0b013e3181cb4472; Marcu AC, 2007, J TRAUMA, V63, P662, DOI 10.1097/TA.0b013e31802e70d9; Matheson PJ, 2009, SURGERY, V146, P739, DOI 10.1016/j.surg.2009.06.037; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mollen KP, 2008, J LEUKOCYTE BIOL, V83, P80, DOI 10.1189/jlb.0407201; Moore FA, 1999, POSTINJURY MULTIPLE, P1427; Nattie E. E., 1995, REGULATION BREATHING, P473; Neal MD, 2009, J TRAUMA, V67, P476, DOI 10.1097/TA.0b013e3181ad66bb; Park KH, 2010, J KOREAN MED SCI, V25, P128, DOI 10.3346/jkms.2010.25.1.128; PEITZMAN AB, 1995, CURR PROB SURG, V32, P930; Pfeifer R, 2013, CYTOKINE, V61, P585, DOI 10.1016/j.cyto.2012.10.022; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P12, DOI 10.1097/TA.0b013e3182aaa675; Sperry JL, 2008, J TRAUMA, V64, P572, DOI 10.1097/TA.0b013e3181650fdf; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; Tachon G, 2014, CRIT CARE MED, V42, P1433, DOI 10.1097/CCM.0000000000000223; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; Vincenzi R, 2009, AM J SURG, V198, P407, DOI 10.1016/j.amjsurg.2009.01.017; Wu DM, 2012, RESUSCITATION, V83, P774, DOI 10.1016/j.resuscitation.2011.11.025; Wu DM, 2009, CRIT CARE MED, V37, P1994, DOI 10.1097/CCM.0b013e3181a0052e	49	17	19	1	15	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JUN 1	2015	20						927	933		10.2741/4347			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CH9LA	WOS:000354355900003	25961533				2021-06-18	
J	Marina, D; Klose, M; Nordenbo, A; Liebach, A; Feldt-Rasmussen, U				Marina, Djordje; Klose, Marianne; Nordenbo, Annette; Liebach, Annette; Feldt-Rasmussen, Ulla			Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE DEFICIENCY; HYPOTHALAMOPITUITARY DYSFUNCTION; SUBARACHNOID HEMORRHAGE; BODY-COMPOSITION; CRITICAL ILLNESS; FREE CORTISOL; ACUTE-PHASE; HIGH-RISK; HYPOPITUITARISM	Objective: Severe brain injury may increase the risk of developing acute and chronic hypopituitarism. Pituitary hormone alterations developed in the early recovery phase after brain injury may have implications for long-term functional recovery. The objective of the present study was to assess the pattern and prevalence of pituitary hormone alterations 3 months after a severe brain injury with relation to functional outcome at a 1-year follow-up. Design: Prospective study at a tertiary university referral centre. Methods: A total of 163 patients admitted to neurorehabilitation after severe traumatic brain injury (TBI, n=111) or non-TBI (n=52) were included. The main outcome measures were endocrine alterations 3.3 months (median) after the brain injury and their relationship to the functioning and ability of the patients at a 1-year follow-up, as measured by the Functional Independence Measure and the Glasgow Outcome Scale-Extended. Results: Three months after the injury, elevated stress hormones (i.e. 30 min stimulated cortisol, prolactin and/or IGF1) and/or suppressed gonadal or thyroid hormones were recorded in 68 and 32% of the patients respectively. At 1 year after the injury, lower functioning level (Functional Independence Measure) and lower capability of performing normal life activities (Glasgow Outcome Scale-Extended) were related to both the elevated stress hormones (P <= 0.01) and the reduced gonadal and/or thyroid hormones (P <= 0.01) measured at 3 months. Conclusion: The present study suggests that brain injury-related endocrine alterations that mimic secondary hypogonadism and hypothyroidism and that occur with elevated stress hormones most probably reflect a prolonged stress response 2-5 months after severe brain injury, rather than pituitary insufficiency per se. These endocrine alterations thus seem to reflect a more severe disease state and relate to 1-year functional outcome.	[Marina, Djordje; Klose, Marianne; Feldt-Rasmussen, Ulla] Copenhagen Univ Hosp, Rigshosp, Dept Med Endocrinol PE2131, Copenhagen, Denmark; Copenhagen Univ Hosp, Glostrup Hosp, Dept Neurorehabil, Traumat Brain Injury Unit, Glostrup, Denmark	Feldt-Rasmussen, U (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Med Endocrinol PE2131, Copenhagen, Denmark.	ufeldt@rh.dk	Feldt-Rasmussen, Ulla/AAB-9218-2021	Feldt-Rasmussen, Ulla/0000-0002-5903-3355; Marina, Djordje/0000-0002-0367-9114	Arvid Nilsson's fund; Novo Nordisk FondenNovo Nordisk Foundation [NNF15OC0014622] Funding Source: researchfish	U Feldt-Rasmussen's research salary was supported by a grant from Arvid Nilsson's fund. We thank Lars Westergaard for his assistance in collecting data and constructing the patient database used in the present study.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bondanelli M, 2010, J CLIN ENDOCR METAB, V95, P4660, DOI 10.1210/jc.2010-0611; Boonen E, 2014, J CLIN ENDOCR METAB, V99, P1569, DOI 10.1210/jc.2013-4115; Boonen E, 2013, NEW ENGL J MED, V368, P1477, DOI 10.1056/NEJMoa1214969; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; Carroll TB, 2010, REV ENDOCR METAB DIS, V11, P147, DOI 10.1007/s11154-010-9143-3; Gardner CJ, 2013, EUR J ENDOCRINOL, V168, P473, DOI 10.1530/EJE-12-0849; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Hana V, 2012, PHYSIOL RES, V61, P161, DOI 10.33549/physiolres.932290; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P1326, DOI 10.1210/jc.2006-1791; Klose M, 2014, J CLIN ENDOCR METAB, V99, P101, DOI 10.1210/jc.2013-2397; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kopczak A, 2014, J NEUROTRAUM, V31, P99, DOI 10.1089/neu.2013.3002; Kronvall E, 2014, WORLD NEUROSURG, V81, P529, DOI 10.1016/j.wneu.2013.10.038; Mesotten D, 2006, ENDOCRIN METAB CLIN, V35, P793, DOI 10.1016/j.ecl.2006.09.010; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P699, DOI 10.1530/eje.1.02131; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Spratt DI, 2001, BEST PRACT RES CL EN, V15, P479, DOI 10.1053/beem.2001.0165; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Ulfarsson T, 2013, J NEUROTRAUM, V30, P271, DOI 10.1089/neu.2012.2494; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; Young TP, 2007, BRAIN INJURY, V21, P645, DOI 10.1080/02699050701210426	41	17	19	0	0	BIOSCIENTIFICA LTD	BRISTOL	STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JUN	2015	172	6					813	822		10.1530/EJE-14-1152			10	Endocrinology & Metabolism	Endocrinology & Metabolism	CL8GR	WOS:000357212600025	25825347	Bronze			2021-06-18	
